<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="brief-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Aging Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Aging Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">1239</journal-id><journal-id journal-id-type="pmc-domain">frontagineuro</journal-id><journal-id journal-id-type="publisher-id">Front. Aging Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Aging Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1663-4365</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12488688</article-id><article-id pub-id-type="pmcid-ver">PMC12488688.1</article-id><article-id pub-id-type="pmcaid">12488688</article-id><article-id pub-id-type="pmcaiid">12488688</article-id><article-id pub-id-type="pmid">41049537</article-id><article-id pub-id-type="doi">10.3389/fnagi.2025.1600798</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Aging Neuroscience</subject><subj-group><subject>Brief Research Report</subject></subj-group></subj-group></article-categories><title-group><article-title>Beyond traditional proxies: the contribution of leisure to cognitive reserve and dementia</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ottaviani</surname><given-names initials="S">Silvia</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3157763/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tagliafico</surname><given-names initials="L">Luca</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1422816/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Peruzzo</surname><given-names initials="S">Stefania</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ponzano</surname><given-names initials="M">Marta</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1247035/overview"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Signori</surname><given-names initials="A">Alessio</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nencioni</surname><given-names initials="A">Alessio</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Monacelli</surname><given-names initials="F">Fiammetta</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/966316/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Section of Geriatrics, Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa</institution>, <addr-line>Genoa</addr-line>, <country>Italy</country></aff><aff id="aff2"><sup>2</sup><institution>IRCCS Ospedale Policlinico San Martino</institution>, <addr-line>Genoa</addr-line>, <country>Italy</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Health Sciences - Section of Biostatistics, University of Genoa</institution>, <addr-line>Genoa</addr-line>, <country>Italy</country></aff><author-notes><fn fn-type="edited-by" id="fn0001"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/44248/overview" ext-link-type="uri">Thalia Fernandez</ext-link>, National Autonomous University of Mexico, Mexico</p></fn><fn fn-type="edited-by" id="fn0002"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1933699/overview" ext-link-type="uri">Cecilia Boccalini</ext-link>, University of Geneva, Switzerland</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2210102/overview" ext-link-type="uri">Yiru Yang</ext-link>, Shandong University, China</p></fn><corresp id="c001">*Correspondence: Silvia Ottaviani, <email>silvia.ottaviani96@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">481075</issue-id><elocation-id>1600798</elocation-id><history><date date-type="received"><day>26</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Ottaviani, Tagliafico, Peruzzo, Ponzano, Signori, Nencioni and Monacelli.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Ottaviani, Tagliafico, Peruzzo, Ponzano, Signori, Nencioni and Monacelli</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fnagi-17-1600798.pdf"/><abstract><sec id="sec1"><title>Introduction</title><p>Cognitive reserve (CR) is a multidimensional construct based on lifelong engagement in cognitively stimulating domains, including education, occupation and leisure activities, that plays a crucial role in mitigating the presentation of dementia. To date, the contribution of each CR subdomain in the development of dementia is under-investigated. This study is aimed at assessing the association of CR subdomains with cognitive status, accounting for sex and age in an old-age population.</p></sec><sec id="sec2"><title>Methods</title><p>317 older adults were recruited with a diagnosis of subjective cognitive impairment, mild cognitive impairment, and dementia due to Alzheimer&#8217;s disease or mixed-type dementia. Cognitive Reserve Index questionnaire (CRIq) was used to assess CR. Patients were stratified based on sex and dementia staging (CDR). Significant variables from univariate analysis entered a multivariate ordinal regression model, using CDR as the dependent variable.</p></sec><sec id="sec3"><title>Results</title><p>The results showed that the leisure activities subdomain was the main determinant of cognitive status (OR 0.90, 95%CI 0.82&#8211;1.00, <italic toggle="yes">p</italic>&#8239;=&#8239;0.003); CR and sex did not show any interaction.</p></sec><sec id="sec4"><title>Discussion</title><p>Unlike education and occupation, leisure activities may be considered a lifelong, dynamic contributor to CR. These findings highlight the importance of refining CR assessment, with particular attention to leisure activities as a potentially modifiable target for dementia prevention.</p></sec></abstract><kwd-group><kwd>gender medicine</kwd><kwd>leisure acitivites</kwd><kwd>cognitive resilience</kwd><kwd>CRI</kwd><kwd>sex difference</kwd><kwd>Alzheimer&#8217;s disease</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="3"/><equation-count count="0"/><ref-count count="40"/><page-count count="6"/><word-count count="4518"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Neurocognitive Aging and Behavior</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec5"><title>Introduction</title><p>Ageing involves significant changes in an individual&#8217;s physiological reserve that may account for a decline in physical, social and cognitive function. In this context, dementia is a key relevant medical and social challenge, influenced by intrinsic and environmental-based factors and leading to highly individualized variation in disease clinical expression between individuals. So far, the implementation of preventative approaches, based on the systematic prevention of modifiable risk factors, is largely emphasized, accounting for 40% of preventable worldwide cases (<xref rid="ref17" ref-type="bibr">Livingston et al., 2024</xref>).</p><p>Namely, Cognitive Reserve (CR) is a cumulative construct shaped by lifelong engagement in cognitively stimulating activities, including education, work, and leisure activities (<xref rid="ref33" ref-type="bibr">Stern, 2009</xref>). CR can be defined as &#8220;<italic toggle="yes">adaptability that helps explain the differential susceptibility of cognitive abilities or daily functioning to brain ageing&#8221;</italic> (<xref rid="ref35" ref-type="bibr">Stern et al., 2020</xref>). The impact of CR on cognitive aging displays a threshold model (<xref rid="ref18" ref-type="bibr">L&#246;vd&#233;n et al., 2020</xref>), where higher educational and occupational attainment, as well as intellectual engagement, contribute to cognitive skills that persist into later life, delaying the onset of dementia symptoms (<xref rid="ref32" ref-type="bibr">Soldan et al., 2017</xref>; <xref rid="ref13" ref-type="bibr">Kato et al., 2022</xref>). This aligns with findings that individuals with higher CR can better tolerate neurodegenerative burden before exhibiting cognitive impairment or dementia (<xref rid="ref38" ref-type="bibr">Van Loenhoud et al., 2022</xref>; <xref rid="ref34" ref-type="bibr">Stern, 2012</xref>). Recent advancements in CR analysis, including EEG, eye tracking, and neuroimaging techniques, hold the promise to unveil neural mechanisms of resilience (<xref rid="ref22" ref-type="bibr">Menardi et al., 2018</xref>), providing a non-invasive real-time assessment of brain activity (<xref rid="ref21" ref-type="bibr">Medeiros et al., 2024</xref>), enhancing emotional recognition and the timely detection of cognitive impairment (<xref rid="ref11" ref-type="bibr">Jiang et al., 2019</xref>; <xref rid="ref37" ref-type="bibr">Tokushige et al., 2023</xref>).</p><p>Dementia is a leading cause of mortality in women in high-income countries with a faster and more severe clinical progression compared to men (<xref rid="ref33" ref-type="bibr">Stern, 2009</xref>; <xref rid="ref35" ref-type="bibr">Stern et al., 2020</xref>). Emerging evidence underscores that both biological and social determinants may shape sex differences in cognitive resilience and in the development of dementia (<xref rid="ref6" ref-type="bibr">Emrani and Sundermann, 2025</xref>). Understanding such differences may allow for addressing peculiarities in terms of pathophysiological biomarkers, disease progression, treatment response, and targeted lines of prevention.</p><p>Recently, Arenaza-Urquijo et al. suggested that women tend to experience a more rapid cognitive decline as dementia progresses, potentially due to faster rates of amyloid and tau accumulation (<xref rid="ref3" ref-type="bibr">Arenaza-Urquijo et al., 2024</xref>), as reported in prior studies, addressing the need for further investigation on the role of sex differences in modulating CR.</p><p>In the context of the operationalization of CR, there is no established gold standard (<xref rid="ref12" ref-type="bibr">Kartschmit et al., 2019</xref>; <xref rid="ref24" ref-type="bibr">Nogueira et al., 2022</xref>). While education is commonly used as a proxy, other indicators such as occupational attainment (<xref rid="ref9" ref-type="bibr">Hakiki et al., 2021</xref>), reading ability (<xref rid="ref26" ref-type="bibr">O'Shea et al., 2015</xref>), intelligence quotient (<xref rid="ref1" ref-type="bibr">Alty et al., 2023</xref>), and composite measures have also been proposed (<xref rid="ref25" ref-type="bibr">Nucci et al., 2012</xref>) to reflect the individual CR. The multidimensional Cognitive Reserve Index Questionnaire (CRIq) (<xref rid="ref25" ref-type="bibr">Nucci et al., 2012</xref>) has been developed to integrate three distinct CR subdomains&#8212;education, occupational activity, and leisure time&#8212;and has been cross-culturally validated in multiple languages and different populations, including older adults (<xref rid="ref12" ref-type="bibr">Kartschmit et al., 2019</xref>; <xref rid="ref24" ref-type="bibr">Nogueira et al., 2022</xref>; <xref rid="ref27" ref-type="bibr">Ottaviani et al., 2024</xref>).</p><p>To date, studies investigating sex differences applied to the construct of CR are suboptimal and, similarly, there are no in-depth analyses on which subdomain of the multidimensional construct of CR might play a key relevant role in predicting the risk of dementia (<xref rid="ref30" ref-type="bibr">Rouillard et al., 2017</xref>).</p><p>Drawing upon available scientific background, the present study is aimed at assessing the association of CR subdomains with cognitive status, while accounting for sex and age, in an old-age outpatient population.</p></sec><sec sec-type="materials|methods" id="sec6"><title>Materials and methods</title><p>This cross-sectional study included 317 consecutive patients attending the outpatient geriatric memory clinic of the IRCCS San Martino Polyclinic Hospital (Genoa, Italy), from September 2022 to March 2023. The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of the University of Genoa (protocol code 54, 2024-06-12).</p><p>Inclusion criteria were: age 65&#8239;years and older, diagnosis of Subjective Cognitive Impairment [SCI (<xref rid="ref10" ref-type="bibr">Jessen et al., 2014</xref>)], Mild Cognitive Impairment [MCI (<xref rid="ref2" ref-type="bibr">American Psychiatric Association, 2013</xref>)] or dementia of Alzheimer&#8217;s type, and mixed dementia, according to DSM-V diagnostic criteria (<xref rid="ref2" ref-type="bibr">American Psychiatric Association, 2013</xref>).</p><p>Exclusion criteria were: diagnosis of major psychiatric disorders or psychosis; diagnosis of dementia of other neurodegenerative types (e.g., dementia with Lewy bodies, vascular dementia); diagnosis of major depression (<xref rid="ref2" ref-type="bibr">American Psychiatric Association, 2013</xref>); diagnosis of incident delirium (<xref rid="ref2" ref-type="bibr">American Psychiatric Association, 2013</xref>).</p><p>Cognitive status was evaluated at baseline using the Mini-Mental State Examination [MMSE (<xref rid="ref8" ref-type="bibr">Frisoni et al., 1993</xref>)], and the Clinical Dementia Rating Scale [CDR (<xref rid="ref23" ref-type="bibr">Morris, 1993</xref>)] was used to stage dementia severity. CR was measured using CRIq (<xref rid="ref25" ref-type="bibr">Nucci et al., 2012</xref>). <xref rid="SM1" ref-type="supplementary-material">Supplementary material S1</xref> contains the full details of the CRIq.</p><p>Throughout this study, we will use the term &#8220;<italic toggle="yes">sex</italic>,&#8221; while acknowledging that many disease-related differences arise from a complex interplay of biological and sociocultural factors that are difficult to disentangle; it is crucial to recognize that this binary framework does not fully capture the complexity of sex and gender (<xref rid="ref6" ref-type="bibr">Emrani and Sundermann, 2025</xref>).</p><sec id="sec7"><title>Statistical analysis</title><p>A descriptive analysis of patients&#8217; clinical phenotype was conducted and the stratification based on sex and cognitive status was performed. Namely, based on CDR staging, patients who scored zero were categorized as cognitively intact; patients who scored 0.5, 1, 2, and 3, were staged as having MCI, mild stage dementia, moderate stage dementia and advanced stage dementia, respectively. The appropriate Mann&#8211;Whitney test was applied.</p><p>All variables with <italic toggle="yes">p</italic>-value &lt;0.10 at the univariate analysis were selected to enter a multivariate ordinal regression model (<xref rid="ref29" ref-type="bibr">Ranganathan et al., 2017</xref>) with CDR score (categorized as follows: 0 vs. 0.5 vs. 1&#8211;4) as the dependent variable. The independent variables included age, CRIq subitems, and disease duration, with sex added as an adjustment variable. To explore the relationship between sex and CR, all interaction terms between CRIq subitems and sex were also tested.</p><p>An additional sex-adjusted univariate and multivariate linear regression model using the MMSE score as the dependent variable, and a logistic regression model with binary CDR (0 vs. 0.5&#8211;4) as the dependent variable were performed as part of the sensitivity analyses, as well as a non-sex-adjusted ordinal regression model.</p><p>All reported analyses were run by RStudio (Version 2022.07) and a two-sided <italic toggle="yes">&#945;</italic> less than 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec8"><title>Results</title><p>Patients had a mean age of 84&#8239;years (IQR 7, range 67&#8211;95), with a higher prevalence of females (67%)(<xref rid="tab1" ref-type="table">Table 1</xref>). The median MMSE score was 23.3, with no sex differences. Namely, 80 patients had a diagnosis of SCD (25.2%), 77 patients had a diagnosis of MCI (24.3%), and 160 patients received a diagnosis of dementia (50.5%). The median disease duration was 1.18&#8239;years.</p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Patients&#8217; clinical phenotype.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Total sample <italic toggle="yes">N</italic> =&#8239;317</th><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">N</italic> (%), median (IQR)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" rowspan="1" colspan="1">84 (7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Females</td><td align="center" valign="middle" rowspan="1" colspan="1">213 (67%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CDR</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">80 (25%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">77 (24%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">1&#8211;4</td><td align="center" valign="middle" rowspan="1" colspan="1">160 (51%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MMSE</td><td align="center" valign="middle" rowspan="1" colspan="1">23.3 (8.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Disease duration (years)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.18 (2.69)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRIq</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" rowspan="1" colspan="1">97 (27)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Education</td><td align="center" valign="middle" rowspan="1" colspan="1">100 (19)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Occupation</td><td align="center" valign="middle" rowspan="1" colspan="1">92 (29)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Leisure</td><td rowspan="1" colspan="1">103 (35)</td></tr></tbody></table><table-wrap-foot><p>CDR, Clinical Dementia Rating scale; MMSE, Mini Mental State Examination; CRIq, Cognitive Reserve Index questionnaire.</p></table-wrap-foot></table-wrap><p>Women showed lower scores across all CRIq subdomains (education, work, leisure) (<xref rid="tab2" ref-type="table">Table 2</xref>), indicating a sex difference.</p><table-wrap position="float" id="tab2" orientation="portrait"><label>Table 2</label><caption><p>Patients&#8217; clinical phenotype as for cognitive status (CDR 0 vs. 0.5&#8211;4) and as for sex.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Variables</th><th align="center" valign="top" rowspan="1" colspan="1">CDR&#8239;=&#8239;0 (median)</th><th align="center" valign="top" rowspan="1" colspan="1">CDR&#8239;=&#8239;0.5&#8211;4 (median)</th><th align="center" valign="top" rowspan="2" colspan="1"><italic toggle="yes">p</italic> value</th><th align="center" valign="top" rowspan="1" colspan="1">Female (median)</th><th align="center" valign="top" rowspan="1" colspan="1">Male (median)</th><th align="center" valign="top" rowspan="2" colspan="1"><italic toggle="yes">p</italic> value</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">N</italic> =&#8239;80</th><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">N</italic> =&#8239;237</th><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">N</italic> =&#8239;213</th><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">N</italic> =&#8239;104</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" rowspan="1" colspan="1">83</td><td align="center" valign="middle" rowspan="1" colspan="1">83.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.471</td><td align="center" valign="middle" rowspan="1" colspan="1">83.2</td><td align="center" valign="middle" rowspan="1" colspan="1">83.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MMSE</td><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">21.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">23.2</td><td align="center" valign="middle" rowspan="1" colspan="1">23.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.747</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRIq</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" rowspan="1" colspan="1">99</td><td align="center" valign="middle" rowspan="1" colspan="1">96</td><td align="center" valign="middle" rowspan="1" colspan="1">0.084</td><td align="center" valign="middle" rowspan="1" colspan="1">94</td><td align="center" valign="middle" rowspan="1" colspan="1">106</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Education</td><td align="center" valign="middle" rowspan="1" colspan="1">102</td><td align="center" valign="middle" rowspan="1" colspan="1">99</td><td align="center" valign="middle" rowspan="1" colspan="1">0.125</td><td align="center" valign="middle" rowspan="1" colspan="1">98</td><td align="center" valign="middle" rowspan="1" colspan="1">103</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Occupation</td><td align="center" valign="middle" rowspan="1" colspan="1">93.5</td><td align="center" valign="middle" rowspan="1" colspan="1">92</td><td align="center" valign="middle" rowspan="1" colspan="1">0.711</td><td align="center" valign="middle" rowspan="1" colspan="1">84</td><td align="center" valign="middle" rowspan="1" colspan="1">97</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Leisure</td><td align="center" valign="middle" rowspan="1" colspan="1">107</td><td align="center" valign="middle" rowspan="1" colspan="1">101</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">98</td><td align="center" valign="middle" rowspan="1" colspan="1">107</td><td align="center" valign="middle" rowspan="1" colspan="1">0.019</td></tr></tbody></table><table-wrap-foot><p>CDR: Clinical Dementia Rating scale; MMSE: Mini Mental State Examination; CRIq: Cognitive Reserve Index questionnaire.</p></table-wrap-foot></table-wrap><p>Based on CDR staging, patients with MCI or dementia (CDR score of 0.5 or higher) were more likely to exhibit lower CRIq leisure subdomain scores compared to cognitively intact individuals (CDR score of 0), suggesting a lower lifetime engagement in leisure activities.</p><p>After adjusting for age, disease duration, and sex, the ordinal regression model showed an association between the CRIq leisure score and cognitive status (OR = 0.90, 95%CI: 0.82&#8211;1.00, <italic toggle="yes">p</italic>&#8239;=&#8239;0.003). No statistically significant interactions were found between sex and any of the CRIq domains (<xref rid="tab3" ref-type="table">Table 3</xref>). Results were consistent in a sensitivity analysis performed without adjusting for sex (<xref rid="SM1" ref-type="supplementary-material">Supplementary material S2</xref>).</p><table-wrap position="float" id="tab3" orientation="portrait"><label>Table 3</label><caption><p>Multivariate ordinal regression model with CDR score (0 vs. 0.5 vs. 1&#8211;4) as the dependent variable, including interaction terms between sex and CR subdomains.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Variables</th><th align="center" valign="top" colspan="2" rowspan="1">Univariate model</th><th align="center" valign="top" colspan="2" rowspan="1">Multivariate model</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value</th><th align="center" valign="top" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1">1.07 (1.03&#8211;1.11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.011</td><td align="center" valign="top" rowspan="1" colspan="1">1.05 (1.01&#8211;1.10)</td><td align="center" valign="top" rowspan="1" colspan="1">0.018</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (ref: female)</td><td align="center" valign="top" rowspan="1" colspan="1">0.82 (0.52&#8211;1.27)</td><td align="center" valign="top" rowspan="1" colspan="1">0.371</td><td align="center" valign="top" rowspan="1" colspan="1">0.64 (0.38&#8211;1.07)</td><td align="center" valign="top" rowspan="1" colspan="1">0.089</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Disease duration (+ 1&#8239;year)</td><td align="center" valign="top" rowspan="1" colspan="1">1.21 (1.09&#8211;1.36)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">1.19 (1.06&#8211;1.34)</td><td align="center" valign="top" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRIq education (+10&#8239;pt)</td><td align="center" valign="top" rowspan="1" colspan="1">0.90 (0.74&#8211;1.00)</td><td align="center" valign="top" rowspan="1" colspan="1">0.054</td><td align="center" valign="top" rowspan="1" colspan="1">1.00 (0.98&#8211;1.10)</td><td align="center" valign="top" rowspan="1" colspan="1">0.997</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRIq occupation (+10&#8239;pt)</td><td align="center" valign="top" rowspan="1" colspan="1">0.90 (0.82&#8211;1.00)</td><td align="center" valign="top" rowspan="1" colspan="1">0.020</td><td align="center" valign="top" rowspan="1" colspan="1">1.00 (0.90&#8211;1.10)</td><td align="center" valign="top" rowspan="1" colspan="1">0.371</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRIq leisure (+10&#8239;pt)</td><td align="center" valign="top" rowspan="1" colspan="1">0.82 (0.74&#8211;0.91)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.90 (0.82&#8211;1.00)</td><td align="center" valign="top" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex*CRIq education</td><td align="center" valign="top" rowspan="1" colspan="1">1.00 (0.97&#8211;1.04)</td><td align="center" valign="top" rowspan="1" colspan="1">0.810</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex*CRIq occupation</td><td align="center" valign="top" rowspan="1" colspan="1">1.01 (0.99&#8211;1.04)</td><td align="center" valign="top" rowspan="1" colspan="1">0.360</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex*CRIq leisure</td><td align="center" valign="top" rowspan="1" colspan="1">0.99 (0.97&#8211;1.01)</td><td align="center" valign="top" rowspan="1" colspan="1">0.438</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>CRIq, Cognitive Reserve Index questionnaire.</p></table-wrap-foot></table-wrap><p>The linear regression model (MMSE score as the dependent variable) supported the association of CRIq leisure and cognitive status (<italic toggle="yes">&#946;</italic> = 0.08, 95%CI: 0.02&#8211;0.14, <italic toggle="yes">p</italic>&#8239;=&#8239;0.006), as did the multivariate logistic regression model with the binarized CDR score as outcome (OR = 0.91, 95%CI: 0.82&#8211;1.00, <italic toggle="yes">p</italic>&#8239;=&#8239;0.046) (see <xref rid="SM1" ref-type="supplementary-material">Supplementary materials S3 and S4</xref>, respectively).</p></sec><sec sec-type="discussion" id="sec9"><title>Discussion</title><p>In the last decades, growing evidence has investigated the role of CR in older adults with different types of cognitive decline, mainly pertaining to education and occupation. However, to the best of our knowledge, this is among the few studies to investigate the role of CR subdomains in mediating the association with cognitive status in older adults. We sought to analyze differences in CR subdomains and their influence on cognitive status in a real-world cohort of older adults.</p><p>Based on our results, women exhibited lower overall CRIq scores, indicating a sex-related disadvantage in the accumulation of CR, supporting existing literature (<xref rid="ref25" ref-type="bibr">Nucci et al., 2012</xref>; <xref rid="ref19" ref-type="bibr">Maiovis et al., 2016</xref>; <xref rid="ref31" ref-type="bibr">Slavi&#263; et al., 2022</xref>). Such findings might be attributed to the fact that women have historically had fewer opportunities to build CR due to limited access to education and fewer opportunities for employment complexity (<xref rid="ref36" ref-type="bibr">Subramaniapillai et al., 2021</xref>). Previous research has shown that older women show relatively better cognitive performance in countries with more egalitarian gender-role attitudes, an effect that is partially mediated by differences in education and labor force participation (<xref rid="ref4" ref-type="bibr">Bonsang et al., 2017</xref>).</p><p>Our results also showed that leisure time is a crucial component of CR and it is associated with dementia staging, even after adjusting for age, disease duration and sex. In line with that, Del Ser et al. showed that leisure activities were significantly associated with cognitive function, accounting for more than 20% of the variance (<xref rid="ref5" ref-type="bibr">Del Ser et al., 2023</xref>). Similarly, Leung et al. found that higher leisure activity levels were associated with a lower risk of MCI (<xref rid="ref16" ref-type="bibr">Leung et al., 2024</xref>), and Verghese et al. underscored that leisure activities showed the main protective role on the risk of developing dementia compared to physical activity (<xref rid="ref39" ref-type="bibr">Verghese et al., 2003</xref>), although reverse causality was not excluded.</p><p>Notably, <xref rid="ref28" ref-type="bibr">Pa et al. (2022)</xref> demonstrated that leisure activities contributed to the maintenance of cognitive processing speed in both men and women, while the contribution of CR to sustaining memory may be subject to sex-specific differences.</p><p>It could be hypothesized that, unlike education and occupation, which may be considered static constructs, as they are typically established earlier in life and are no longer modifiable in old age, leisure activities could be promoted throughout life, offering a dynamic enhancement of CR and cumulating until late life. Moreover, leisure time includes several activities and also takes into account years of practice. Social engagement and social participation&#8212;such as maintaining interpersonal relationships, participating in community activities, and engaging in group-based learning or recreational programs&#8212;may offer a dual benefit in shaping CR. On one hand, it promotes cognitive functioning by stimulating communication, problem-solving, and cognitive flexibility (<xref rid="ref7" ref-type="bibr">Evans et al., 2019</xref>; <xref rid="ref14" ref-type="bibr">Krueger et al., 2009</xref>). On the other hand, it mitigates loneliness and social vulnerability, ascertained risk factors for dementia.</p><p>No significant interaction was found between CR and sex, suggesting that sex does not intervene to mediate the relationship between CR and cognitive status. In other words, once CR is accumulated, its protective effects on cognitive status appear to be similar for both sexes. This could imply that, despite differences in CRIq scores, men and women benefit from CR in comparable ways; what makes a difference is the accumulation of such baggage, which appears strongly genderized. Alternatively, the lack of interaction may be the result of limited statistical power or unmeasured factors (e.g., social support, genetic predisposition) that warrant further investigation.</p><p>Limitations include the monocentric setting and the cross-sectional nature of the study design, which may reduce the generalizability of the findings.</p><p>Strengths include the analysis of the CR construct in a real-world old-age population using a validated CR multidimensional instrument such as the CRIq.</p><p>Longitudinal studies are warranted to investigate interaction or causation terms and to integrate biomarkers from neuroimaging, plasma/cerebrospinal fluid, and functional imaging, as well as APOE4 status, to refine our understanding of the biological basis of CR. For instance, recent advances in neuroimaging have underscored the value of multimodal approaches in exploring the neural basis of CR. Mart&#237;nez et al. demonstrated through magnetoencephalography that individuals with higher CR exhibited more efficient functional network configurations during memory tasks, requiring fewer and more optimally distributed connections (<xref rid="ref20" ref-type="bibr">Mart&#237;nez et al., 2018</xref>). Other studies have identified specific brain network features related to CR using PET and fMRI (<xref rid="ref15" ref-type="bibr">Lee et al., 2019</xref>), while dynamic network models based on spatio-temporal graph theory offer promising tools for detecting topological biomarkers of CR (<xref rid="ref40" ref-type="bibr">Zhu et al., 2024</xref>).</p><p>Moreover, since CRIq categorizes activities based on their frequency (daily, monthly, yearly) rather than their nature (e.g., intellectual, social, or physical), more structured analysis may help establish whether particular types of activity, such as social leisure, contribute in a different manner to CR.</p><p>In conclusion, this study may be a platform for developing future research aimed at integrating biological, clinical, and socio-cultural factors to provide a more comprehensive understanding of CR and its role in shaping cognitive status in older age. Our data may support adopting a dementia care approach that emphasizes the role of CR&#8212;particularly through leisure activities&#8212;which should be considered a lifelong modifiable risk factor.</p></sec></body><back><sec sec-type="data-availability" id="sec10"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="sec11"><title>Ethics statement</title><p>The studies involving humans were approved by Committee for Ethical Review of Research at the University of Genoa. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was obtained either directly from participants or, when necessary, from their legal guardians/next of kin.</p></sec><sec sec-type="author-contributions" id="sec12"><title>Author contributions</title><p>SO: Data curation, Formal analysis, Investigation, Writing &#8211; original draft. LT: Writing &#8211; review &amp; editing, Methodology. SP: Writing &#8211; review &amp; editing, Data curation, Formal analysis. MP: Formal analysis, Methodology, Writing &#8211; review &amp; editing. AS: Formal analysis, Methodology, Writing &#8211; review &amp; editing. AN: Project administration, Supervision, Writing &#8211; review &amp; editing. FM: Conceptualization, Methodology, Supervision, Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="sec14"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></sec><sec sec-type="ai-statement" id="sec15"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="sec16"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="sec17"><title>Supplementary material</title><p>The Supplementary material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fnagi.2025.1600798/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fnagi.2025.1600798/full#supplementary-material</ext-link></p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Supplementary_file_1.docx" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alty</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Bindoff</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Roccati</surname><given-names>E.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>King</surname><given-names>A. E.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Sex-specific protective effects of cognitive reserve on age-related cognitive decline: a 5-year prospective cohort study</article-title>. <source>Neurology</source><volume>100</volume>, <fpage>e211</fpage>&#8211;<lpage>e219</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000201369</pub-id><pub-id pub-id-type="pmid">36302670</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="book"><person-group person-group-type="author"><collab id="coll1">American Psychiatric Association</collab></person-group> (<year>2013</year>). <source>Diagnostic and statistical manual of mental disorders: DSM-5</source>. <edition>5th</edition> Edn. <publisher-loc>Washington, D.C.</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name>.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arenaza-Urquijo</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Casaletto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Anstey</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Vila-Castelar</surname><given-names>C.</given-names></name><name name-style="western"><surname>Colverson</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Sex and gender differences in cognitive resilience to aging and Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement.</source><volume>20</volume>, <fpage>5695</fpage>&#8211;<lpage>5719</lpage>. doi: <pub-id pub-id-type="doi">10.1002/alz.13844</pub-id>, PMID: <pub-id pub-id-type="pmid">38967222</pub-id><pub-id pub-id-type="pmcid">PMC11350140</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonsang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Skirbekk</surname><given-names>V.</given-names></name><name name-style="western"><surname>Staudinger</surname><given-names>U. M.</given-names></name></person-group> (<year>2017</year>). <article-title>As you sow, so shall you reap: gender-role attitudes and late-life cognition</article-title>. <source>Psychol. Sci.</source><volume>28</volume>, <fpage>1201</fpage>&#8211;<lpage>1213</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0956797617708634</pub-id>, PMID: <pub-id pub-id-type="pmid">28737096</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Ser</surname><given-names>T.</given-names></name><name name-style="western"><surname>Valeriano-Lorenzo</surname><given-names>E.</given-names></name><name name-style="western"><surname>J&#225;&#241;ez-Escalada</surname><given-names>L.</given-names></name><name name-style="western"><surname>&#193;vila-Villanueva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frades</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zea</surname><given-names>M. A.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Dimensions of cognitive reserve and their predictive power of cognitive performance and decline in the elderly</article-title>. <source>Front. Dement.</source><volume>2</volume>:<fpage>1099059</fpage>. doi: <pub-id pub-id-type="doi">10.3389/frdem.2023.1099059</pub-id>, PMID: <pub-id pub-id-type="pmid">39081990</pub-id><pub-id pub-id-type="pmcid">PMC11285562</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emrani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sundermann</surname><given-names>E. E.</given-names></name></person-group> (<year>2025</year>). <article-title>Sex/gender differences in the clinical trajectory of Alzheimer&#8217;s disease: insights into diagnosis and cognitive reserve</article-title>. <source>Front. Neuroendocrinol.</source><volume>77</volume>:<fpage>101184</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.yfrne.2025.101184</pub-id>, PMID: <pub-id pub-id-type="pmid">39951912</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>I. E. M.</given-names></name><name name-style="western"><surname>Martyr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brayne</surname><given-names>C.</given-names></name><name name-style="western"><surname>Clare</surname><given-names>L.</given-names></name></person-group> (<year>2019</year>). <article-title>Social isolation and cognitive function in later life: a systematic review and Meta-analysis</article-title>. <source>J Alzheimer's Dis</source><volume>70</volume>, <fpage>S119</fpage>&#8211;<lpage>S144</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-180501</pub-id>, PMID: <pub-id pub-id-type="pmid">30372678</pub-id><pub-id pub-id-type="pmcid">PMC6700717</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frisoni</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Rozzini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bianchetti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trabucchi</surname><given-names>M.</given-names></name></person-group> (<year>1993</year>). <article-title>Principal lifetime occupation and MMSE score in elderly persons</article-title>. <source>J. Gerontol.</source><volume>48</volume>, <fpage>S310</fpage>&#8211;<lpage>S314</lpage>. doi: <pub-id pub-id-type="doi">10.1093/geronj/48.6.S310</pub-id>, PMID: <pub-id pub-id-type="pmid">8228005</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hakiki</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pancani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Portaccio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Molino-Lova</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sofi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Macchi</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Impact of occupational complexity on cognitive decline in the oldest-old</article-title>. <source>Aging Ment. Health</source><volume>25</volume>, <fpage>1630</fpage>&#8211;<lpage>1635</lpage>. doi: <pub-id pub-id-type="doi">10.1080/13607863.2020.1746739</pub-id>, PMID: <pub-id pub-id-type="pmid">32252551</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jessen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Amariglio</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Van Boxtel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Breteler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ceccaldi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ch&#233;telat</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer&#8217;s disease</article-title>. <source>Alzheimers Dement.</source><volume>10</volume>, <fpage>844</fpage>&#8211;<lpage>852</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jalz.2014.01.001</pub-id>, PMID: <pub-id pub-id-type="pmid">24798886</pub-id><pub-id pub-id-type="pmcid">PMC4317324</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>A novel detection tool for mild cognitive impairment patients based on eye movement and electroencephalogram</article-title>. <source>J. Alzheimers Dis.</source><volume>72</volume>, <fpage>389</fpage>&#8211;<lpage>399</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-190628</pub-id>, PMID: <pub-id pub-id-type="pmid">31594231</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kartschmit</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mikolajczyk</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lacruz</surname><given-names>M. E.</given-names></name></person-group> (<year>2019</year>). <article-title>Measuring cognitive reserve (CR) &#8211; a systematic review of measurement properties of CR questionnaires for the adult population</article-title>. <source>PLoS One</source><volume>14</volume>:<fpage>e0219851</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0219851</pub-id>, PMID: <pub-id pub-id-type="pmid">31390344</pub-id><pub-id pub-id-type="pmcid">PMC6685632</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nishita</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Otsuka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Inui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Effect of cognitive reserve on amnestic mild cognitive impairment due to Alzheimer&#8217;s disease defined by fluorodeoxyglucose-positron emission tomography</article-title>. <source>Front. Aging Neurosci.</source><volume>14</volume>:<fpage>932906</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2022.932906</pub-id>, PMID: <pub-id pub-id-type="pmid">36034127</pub-id><pub-id pub-id-type="pmcid">PMC9399434</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krueger</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Kamenetsky</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Bienias</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Social engagement and cognitive function in old age</article-title>. <source>Exp. Aging Res.</source><volume>35</volume>, <fpage>45</fpage>&#8211;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1080/03610730802545028</pub-id>, PMID: <pub-id pub-id-type="pmid">19173101</pub-id><pub-id pub-id-type="pmcid">PMC2758920</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Roh</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>J. S.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Neural substrates of cognitive reserve in Alzheimer&#8217;s disease spectrum and normal aging</article-title>. <source>NeuroImage</source><volume>186</volume>, <fpage>690</fpage>&#8211;<lpage>702</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2018.11.053</pub-id>, PMID: <pub-id pub-id-type="pmid">30503934</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Eramudugolla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cherbuin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mortby</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Kiely</surname><given-names>K. M.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Estimating gender differences in the association between cognitive resilience and mild cognitive impairment incidence</article-title>. <source>Gerontology</source><volume>70</volume>, <fpage>776</fpage>&#8211;<lpage>784</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000538615</pub-id>, PMID: <pub-id pub-id-type="pmid">38697040</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Livingston</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K. Y.</given-names></name><name name-style="western"><surname>Costafreda</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Selb&#230;k</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alladi</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Dementia prevention, intervention, and care: 2024 report of the lancet standing commission</article-title>. <source>Lancet</source><volume>404</volume>, <fpage>572</fpage>&#8211;<lpage>628</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(24)01296-0</pub-id>, PMID: <pub-id pub-id-type="pmid">39096926</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#246;vd&#233;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fratiglioni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Glymour</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Lindenberger</surname><given-names>U.</given-names></name><name name-style="western"><surname>Tucker-Drob</surname><given-names>E. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Education and cognitive functioning across the life span</article-title>. <source>Psychol. Sci. Public Interest</source><volume>21</volume>, <fpage>6</fpage>&#8211;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1529100620920576</pub-id>, PMID: <pub-id pub-id-type="pmid">32772803</pub-id><pub-id pub-id-type="pmcid">PMC7425377</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maiovis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ioannidis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nucci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gotzamani-Psarrakou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karacostas</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>Adaptation of the cognitive reserve index questionnaire (CRIq) for the Greek population</article-title>. <source>Neurol. Sci.</source><volume>37</volume>, <fpage>633</fpage>&#8211;<lpage>636</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10072-015-2457-x</pub-id>, PMID: <pub-id pub-id-type="pmid">26712603</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Ariza</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chavez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pineda-Pardo</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>L&#243;pez-Sanz</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Functional brain networks reveal the existence of cognitive reserve and the interplay between network topology and dynamics</article-title>. <source>Sci. Rep.</source><volume>8</volume>:<fpage>10525</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-018-28747-6</pub-id>, PMID: <pub-id pub-id-type="pmid">30002460</pub-id><pub-id pub-id-type="pmcid">PMC6043549</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medeiros</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sim&#245;es</surname><given-names>M.</given-names></name><name name-style="western"><surname>Castelhano</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abreu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Couceiro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Henriques</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>EEG as a potential ground truth for the assessment of cognitive state in software development activities: a multimodal imaging study</article-title>. <source>PLoS One</source><volume>19</volume>:<fpage>e0299108</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0299108</pub-id>, PMID: <pub-id pub-id-type="pmid">38452019</pub-id><pub-id pub-id-type="pmcid">PMC10919648</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menardi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pascual-Leone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fried</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Santarnecchi</surname><given-names>E.</given-names></name></person-group> (<year>2018</year>). <article-title>The role of cognitive Reserve in Alzheimer&#8217;s disease and aging: a multi-modal imaging review</article-title>. <source>J. Alzheimers Dis.</source><volume>66</volume>, <fpage>1341</fpage>&#8211;<lpage>1362</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-180549</pub-id>, PMID: <pub-id pub-id-type="pmid">30507572</pub-id><pub-id pub-id-type="pmcid">PMC8972845</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>J. C.</given-names></name></person-group> (<year>1993</year>). <article-title>The clinical dementia rating (CDR): current version and scoring rules</article-title>. <source>Neurology</source><volume>43</volume>:<fpage>2412</fpage>. doi: <pub-id pub-id-type="doi">10.1212/wnl.43.11.2412-a</pub-id>, PMID: <pub-id pub-id-type="pmid">8232972</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nogueira</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gerardo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Santana</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sim&#245;es</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>S.</given-names></name></person-group> (<year>2022</year>). <article-title>The assessment of cognitive reserve: a systematic review of the Most used quantitative measurement methods of cognitive reserve for aging</article-title>. <source>Front. Psychol.</source><volume>13</volume>:<fpage>847186</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fpsyg.2022.847186</pub-id>, PMID: <pub-id pub-id-type="pmid">35465541</pub-id><pub-id pub-id-type="pmcid">PMC9023121</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nucci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mapelli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mondini</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Cognitive reserve index questionnaire (CRIq): a new instrument for measuring cognitive reserve</article-title>. <source>Aging Clin. Exp. Res.</source><volume>24</volume>, <fpage>218</fpage>&#8211;<lpage>226</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF03654795</pub-id>, PMID: <pub-id pub-id-type="pmid">21691143</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'Shea</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Fieo</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Zahodne</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>Manly</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Examining the association between late-life depressive symptoms, cognitive function, and brain volumes in the context of cognitive reserve</article-title>. <source>Int. J. Geriatr. Psychiatry</source><volume>30</volume>, <fpage>614</fpage>&#8211;<lpage>622</lpage>. doi: <pub-id pub-id-type="doi">10.1002/gps.4192</pub-id><pub-id pub-id-type="pmid">25145832</pub-id><pub-id pub-id-type="pmcid">PMC4336836</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ottaviani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tagliafico</surname><given-names>L.</given-names></name><name name-style="western"><surname>Muzyka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Page</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ottaviani</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ponzano</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Tipping the balance between cognitive reserve, frailty, and dementia in the very old?</article-title><source>J Alzheimer's Dis</source><volume>101</volume>, <fpage>1227</fpage>&#8211;<lpage>1235</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-231121</pub-id>, PMID: <pub-id pub-id-type="pmid">39331100</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aslanyan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Casaletto</surname><given-names>K. B.</given-names></name><name name-style="western"><surname>Renter&#237;a</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Harrati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tom</surname><given-names>S. E.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Effects of sex, APOE4, and lifestyle activities on cognitive reserve in older adults</article-title>. <source>Neurology</source><volume>99</volume>, <fpage>e789</fpage>&#8211;<lpage>e798</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000200675</pub-id>, PMID: <pub-id pub-id-type="pmid">35858818</pub-id><pub-id pub-id-type="pmcid">PMC9484731</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ranganathan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pramesh</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>R.</given-names></name></person-group> (<year>2017</year>). <article-title>Common pitfalls in statistical analysis: logistic regression</article-title>. <source>Perspect. Clin. Res.</source><volume>8</volume>, <fpage>148</fpage>&#8211;<lpage>151</lpage>. doi: <pub-id pub-id-type="doi">10.4103/picr.PICR_87_17</pub-id>, PMID: <pub-id pub-id-type="pmid">28828311</pub-id><pub-id pub-id-type="pmcid">PMC5543767</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rouillard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Audiffren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Albinet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ali Bahri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garraux</surname><given-names>G.</given-names></name><name name-style="western"><surname>Collette</surname><given-names>F.</given-names></name></person-group> (<year>2017</year>). <article-title>Contribution of four lifelong factors of cognitive reserve on late cognition in normal aging and Parkinson&#8217;s disease</article-title>. <source>J. Clin. Exp. Neuropsychol.</source><volume>39</volume>, <fpage>142</fpage>&#8211;<lpage>162</lpage>. doi: <pub-id pub-id-type="doi">10.1080/13803395.2016.1207755</pub-id>, PMID: <pub-id pub-id-type="pmid">27686164</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slavi&#263;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tomi&#263;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nikola&#353;evi&#263;</surname><given-names>&#381;.</given-names></name><name name-style="western"><surname>Djurdjevi&#263;</surname><given-names>N.</given-names></name><name name-style="western"><surname>Naumovi&#263;</surname><given-names>N.</given-names></name></person-group> (<year>2022</year>). <article-title>Age and gender differences in the cognitive reserve index</article-title>. <source>Ann. Indian Acad. Neurol.</source><volume>25</volume>, <fpage>767</fpage>&#8211;<lpage>770</lpage>. doi: <pub-id pub-id-type="doi">10.4103/aian.aian_1106_21</pub-id><pub-id pub-id-type="pmid">36211135</pub-id><pub-id pub-id-type="pmcid">PMC9540925</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soldan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pettigrew</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Moghekar</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Cognitive reserve and long-term change in cognition in aging and preclinical Alzheimer&#8217;s disease</article-title>. <source>Neurobiol. Aging</source><volume>60</volume>, <fpage>164</fpage>&#8211;<lpage>172</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2017.09.002</pub-id>, PMID: <pub-id pub-id-type="pmid">28968586</pub-id><pub-id pub-id-type="pmcid">PMC5679465</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stern</surname><given-names>Y.</given-names></name></person-group> (<year>2009</year>). <article-title>Cognitive reserve</article-title>. <source>Neuropsychologia</source><volume>47</volume>, <fpage>2015</fpage>&#8211;<lpage>2028</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuropsychologia.2009.03.004</pub-id>, PMID: <pub-id pub-id-type="pmid">19467352</pub-id><pub-id pub-id-type="pmcid">PMC2739591</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stern</surname><given-names>Y.</given-names></name></person-group> (<year>2012</year>). <article-title>Cognitive reserve in ageing and Alzheimer&#8217;s disease</article-title>. <source>Lancet Neurol.</source><volume>11</volume>, <fpage>1006</fpage>&#8211;<lpage>1012</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(12)70191-6</pub-id>, PMID: <pub-id pub-id-type="pmid">23079557</pub-id><pub-id pub-id-type="pmcid">PMC3507991</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stern</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Arenaza-Urquijo</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Bartr&#233;s-Faz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Belleville</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cantilon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chetelat</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance</article-title>. <source>Alzheimers Dement.</source><volume>16</volume>, <fpage>1305</fpage>&#8211;<lpage>1311</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jalz.2018.07.219</pub-id>, PMID: <pub-id pub-id-type="pmid">30222945</pub-id><pub-id pub-id-type="pmcid">PMC6417987</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subramaniapillai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Almey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Natasha Rajah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Einstein</surname><given-names>G.</given-names></name></person-group> (<year>2021</year>). <article-title>Sex and gender differences in cognitive and brain reserve: implications for Alzheimer&#8217;s disease in women</article-title>. <source>Front. Neuroendocrinol.</source><volume>60</volume>:<fpage>100879</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.yfrne.2020.100879</pub-id>, PMID: <pub-id pub-id-type="pmid">33137359</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tokushige</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Inomata-Terada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kotsuki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hamada</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Early detection of cognitive decline in Alzheimer&#8217;s disease using eye tracking</article-title>. <source>Front. Aging Neurosci.</source><volume>15</volume>:<fpage>1123456</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2023.1123456</pub-id>, PMID: <pub-id pub-id-type="pmid">37025964</pub-id><pub-id pub-id-type="pmcid">PMC10070704</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Loenhoud</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Groot</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bocancea</surname><given-names>D. I.</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F.</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Association of education and intracranial volume with cognitive trajectories and mortality rates across the Alzheimer disease continuum</article-title>. <source>Neurology</source><volume>98</volume>, <fpage>e1679</fpage>&#8211;<lpage>e1691</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000200116</pub-id><pub-id pub-id-type="pmid">35314498</pub-id><pub-id pub-id-type="pmcid">PMC9052567</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verghese</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lipton</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Derby</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Kuslansky</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Leisure activities and the risk of dementia in the elderly</article-title>. <source>N. Engl. J. Med.</source><volume>348</volume>, <fpage>2508</fpage>&#8211;<lpage>2516</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa022252</pub-id>, PMID: <pub-id pub-id-type="pmid">12815136</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Spatio-temporal graph Hubness propagation model for dynamic brain network classification</article-title>. <source>IEEE Trans. Med. Imaging</source><volume>43</volume>, <fpage>2381</fpage>&#8211;<lpage>2394</lpage>. doi: <pub-id pub-id-type="doi">10.1109/TMI.2024.3363014</pub-id>, PMID: <pub-id pub-id-type="pmid">38319754</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12488914</article-id><article-id pub-id-type="pmcid-ver">PMC12488914.1</article-id><article-id pub-id-type="pmcaid">12488914</article-id><article-id pub-id-type="pmcaiid">12488914</article-id><article-id pub-id-type="pmid">41034302</article-id><article-id pub-id-type="doi">10.1038/s41598-025-16267-z</article-id><article-id pub-id-type="publisher-id">16267</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Morphological and metabolic alterations in different stages of Alzheimer&#8217;s diseases: a study using surface-based morphometry (SBM) and amide proton transfer (APT) imaging</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhong</surname><given-names initials="M">Meimeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Song</surname><given-names initials="Q">Qingwei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="S">Shuo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Z">Zhewei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yuan</surname><given-names initials="C">Chang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="P">Peixue</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="N">Nan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="D">Dan</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="K">Kewei</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dong</surname><given-names initials="C">Chunbo</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="J">Jie</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Liu</surname><given-names initials="J">Jing</given-names></name><address><email>lj_18@163.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="C">Chao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/055w74b96</institution-id><institution-id institution-id-type="GRID">grid.452435.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 9070</institution-id><institution>Department of Radiology, </institution><institution>First Affiliated Hospital of Dalian Medical University, </institution></institution-wrap>Dalian, 116011 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/055w74b96</institution-id><institution-id institution-id-type="GRID">grid.452435.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 9070</institution-id><institution>Department of Nuclear Medicine, </institution><institution>First Affiliated Hospital of Dalian Medical University, </institution></institution-wrap>Dalian, 116011 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/055w74b96</institution-id><institution-id institution-id-type="GRID">grid.452435.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 9070</institution-id><institution>Department of Neurology, </institution><institution>First Affiliated Hospital of Dalian Medical University, </institution></institution-wrap>Dalian, 116011 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04c8eg608</institution-id><institution-id institution-id-type="GRID">grid.411971.b</institution-id><institution-id institution-id-type="ISNI">0000 0000 9558 1426</institution-id><institution>Dalian Medical University, </institution></institution-wrap>Dalian, 116044 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qqw3m37</institution-id><institution-id institution-id-type="GRID">grid.497849.f</institution-id><institution>United Imaging Healthcare, </institution></institution-wrap>Shanghai, 201815 China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04c8eg608</institution-id><institution-id institution-id-type="GRID">grid.411971.b</institution-id><institution-id institution-id-type="ISNI">0000 0000 9558 1426</institution-id><institution>National-Local Joint Engineering Research Center for Drug-Research and Development (R&amp;D) of Neurodegenerative Diseases, </institution><institution>Dalian Medical University, </institution></institution-wrap>Dalian, 116044 China </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>34245</elocation-id><history><date date-type="received"><day>10</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-03 00:25:14.440"><day>03</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_16267.pdf"/><abstract id="Abs1"><p id="Par1">Early diagnosis of Alzheimer&#8217;s disease (AD) remains a significant challenge due to the lack of objective biomarkers. Accurate identification of morphological and metabolic alterations during the different stages of AD is crucial for timely intervention and effective management of the disease. Surface-based morphometry (SBM) and amide proton transfer (APT) imaging are innovative techniques that offer the potential to visualize these changes in the brain. By leveraging these advanced imaging modalities, this study aims to investigate the specific alterations that occur in AD, thereby exploring potential imaging biomarkers that could facilitate early and precise diagnosis of the condition. The identification of such biomarkers is essential for improving the diagnostic accuracy and efficacy of therapeutic strategies for Alzheimer&#8217;s disease. In this prospective study, we enrolled 26 patients with AD, thirty-six patients with amnestic mild cognitive impairment (aMCI), and 32 healthy controls (HCs). All participants underwent 3D T1-weighted imaging (T1WI) and 3D-APT imaging. Morphological parameters, including cortical thickness (CTh), sulcal depth (SD), fractal dimension (FD), and gyrification index (GI), were calculated using the SBM algorithm. Magnetization transfer ratio asymmetry (MTR<sub>asym</sub>) values were computed for 106 brain regions utilizing the vendor&#8217;s post-processing workstation. AD Patients exhibited cortical thinning in the frontal, temporal, parietal lobes, and cingulate gyrus, along with a decrease in GI in the left parietal lobe. MCI patients showed a reduction in GI in the left parietal and temporal lobes. Multivariate logistic regression analysis identified widespread increased MTR<sub>asym</sub> values in AD patients, affecting the frontal, temporal, parietal, occipital, cingulate, basal ganglia regions, and white matter. The right amygdala shows the highest diagnostic performance. Additionally, a negative correlation was observed between MTR<sub>asym</sub> values and clinical assessments. SBM analysis revealed morphological changes in the brain across different stages of AD, while APT imaging identified metabolic alterations in AD patients. These findings suggest that the combination of SBM and APT imaging may hold potential as a non-invasive diagnostic and monitoring approach for AD.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-16267-z.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#8217;s disease</kwd><kwd>Amnestic mild cognitive impairment</kwd><kwd>Magnetic resonance imaging</kwd><kwd>Amide proton transfer</kwd><kwd>Surface-based morphometry</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Biomarkers</kwd><kwd>Diseases</kwd><kwd>Neurology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Alzheimer&#8217;s disease (AD) represents a significant public health challenge, with its prevalence increasing alongside the aging global population. Projections indicate that the number of AD patients worldwide will exceed 115&#160;million by 2050, imposing a substantial economic burden on society<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Mild cognitive impairment (MCI), recognized as a prodromal stage of AD, is characterized by cognitive decline beyond what is the expected level for an individual&#8217;s age and education, yet without significant impairment in daily activities. Epidemiological studies have reported an MCI a prevalence ranging from 3 to 19% among adults aged 65 and above. Notably, approximately 50% of individuals with amnestic MCI progress to AD, underscoring the importance of early identification and intervention during the MCI stage<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>.</p><p id="Par6">Current AD diagnostic and efficacy evaluations rely heavily on clinical manifestations and rating scales, which are often subjective, prone to inter-rater variability, and dependent on patient cooperation. Consequently, objective, accurate, and feasible diagnostic tools are urgently required. In 2011, the National Institute on Aging and the Alzheimer&#8217;s Association updated diagnostic guidelines that incorporated AD-related biomarker detection in the clinical diagnostic criteria for MCI for the first time<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Within the ATN (amyloidosis [A]/pathological tau [T]/neurodegeneration or neuronal injury [N]) framework, established AD imaging biomarkers include hypometabolism in the posterior cingulate and temporoparietal regions on positron emission tomography (PET), cortical &#946;-amyloid deposition, tau protein burden, and medial temporal lobe atrophy observed on structural magnetic resonance imaging (sMRI)<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>.</p><p id="Par7">Traditional structural MRI-based methods used to characterize AD-related brain changes include voxel-based morphometry and regional measure-based volumetric measurements. However, these methods do not capture the full complexity of human brain morphology, which extends beyond cortical volume to include cortical surface architecture and shape (e.g., gyri and sulci). Surface-based morphometry (SBM) has been successfully applied in AD studies to quantify subtle morphological features of cortical surface structures<sup><xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref></sup>. Thereby enabling a more precise assessment of whole brain surface patterns, including cortical thickness, sulcal depth, fractal dimension, and gyrification index.</p><p id="Par8">Extracellular plaques and intracellular neurofibrillary tangles (NFT) are considered the core pathological features of AD<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. The notion that the pathological processes underlying AD already start decades before symptoms appear is well-established<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. This predictable progression is exemplified by the patterns of beta-amyloid (A&#946;) plaque pathology, which advances from the neocortex, through limbic structures, diencephalon, and basal ganglia, to the brainstem and cerebellum&#8211;a staging described by Thal and colleagues<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. Similarly, the progression of neurofibrillary tangles (NFT) pathology, moving from the transentorhinal region to the limbic system and and ultimately the neocortex is described in stages proposed by Braak and colleagues<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Although PET imaging can detect abnormal protein accumulation and metabolic alterations in AD patients, its high cost and associated radiation exposure limit its broad clinical application. Amide proton transfer imaging (APT), a novel molecular MRI technique, non-invasively quantifies free proteins and peptides in tissue, indirectly reflecting intracellular metabolic changes and physiopathological information<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Previous APT studies in AD, however, have reported inconsistent findings. Some researches indicate significantly higher APT signal in the bilateral hippocampus and amygdala of MCI and AD patients compared to healthy control (HC)<sup><xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref></sup>, others have found no significant differences<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. These conflicting results may be attributed to limitations in data acquisition protocols and resolution of APT imaging, which may hamper accurate region of interest (ROI) delineation and the assessment of global APT signal changes. Implementing 3D APT imaging combined with automated segmentation techniques can reduce ROI profiling errors and provide comprehensive metabolic change information across the whole brain. Although multimodal MRI approaches have been explored in AD, synergistic analyses combining APT and SBM remain an emerging area. Current understanding reveals two important research needs: (1) Stage-specific metabolic signatures of APT across the AD continuum require further characterization, particularly during the MCI transition phase; (2) The relationship between protein aggregation-driven metabolic shifts and microstructural degeneration warrants systematic investigation. To address these needs, our study introduces the first simultaneous application of SBM and 3D APT imaging for cross-stage AD profiling. This study aimed to investigate the metabolic and morphological alterations at different stages of AD using APT imaging and SBM. By comparing APT and SBM indices among AD patients, MCI patients, and HCs, we aim to identify potential imaging biomarkers for early AD diagnosis.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Participant</title><p id="Par9">All procedures performed in this study complied with the Declaration of Helsinki. This prospective study was approved by the institutional review board of the First Affiliated Hospital of Dalian Medical University (registration number: PJ-KS-KY-2024-315). Written informed consent was obtained from all subjects in this study. From August 2023 to October 2024, patients meeting the National Institute of Neurological and Communicative Disorders and Stroke/AD and Related Disorders Association criteria for &#8220;Probable AD&#8221; or &#8220;Possible AD&#8221; were enrolled from the department of neurology and memory outpatient clinic. Participants with amnestic mild cognitive impairment (aMCI) were also included based on the Petersen criteria and National Institute on Aging and Alzheimer&#8217;s Association guidelines. Additionally, HCs were recruited from neighboring communities. All participants underwent the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) tests. Further inclusion criteria for all participants were: (1) age&#8201;&#8805;&#8201;50 years, (2) Fazekas scale score&#8201;&#8804;&#8201;2, and (3) right-handedness. Exclusion criteria were: (1)a history of other neurological, psychiatric, or systemic illnesses; (2) incomplete cognitive assessment data or missing MRI sequences; (3) head movement with maximum displacement&#8201;&gt;&#8201;1.5&#160;mm or rotation&#8201;&gt;&#8201;1.5&#176; in any direction. (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par10">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Flow diagram of participant selection. AD: Alzheimer&#8217;s disease; MCI: mild cognitive impairment; HC: healthy controls.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e376" position="float" orientation="portrait" xlink:href="41598_2025_16267_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec4"><title>MRI acquisition</title><p id="Par11">All MRI examinations were performed on a 3.0T scanner (uMR Omega, United Imaging Healthcare, China) equipped with a 32-channel head coil. A 3D T1-weighted image was acquired using a fast spoiled gradient-echo (GRE_FSP) sequence with the following parameters: repetition time (TR)&#8201;=&#8201;8.1 ms, echo time (TE)&#8201;=&#8201;3.1 ms, inversion time (TI)&#8201;=&#8201;750 ms, flip angle (FA)&#8201;=&#8201;9&#176;, field of view (FOV)&#8201;=&#8201;256&#8201;&#215;&#8201;256 mm<sup>2</sup>, voxel size&#8201;=&#8201;1&#8201;&#215;&#8201;1&#8201;&#215;&#8201;1 mm<sup>3</sup>, and acquisition time&#8201;=&#8201;2 min 28&#160;s. The amide proton transfer images were acquired using a fast spin echo sequence with the following parameters: block pulse radiofrequency saturation duration&#8201;=&#8201;2000 ms, saturation power&#8201;=&#8201;2 &#181;T, TR&#8201;=&#8201;5000 ms, TE&#8201;=&#8201;10.8 ms, FA&#8201;=&#8201;120&#176;, FOV&#8201;=&#8201;200&#8201;&#215;&#8201;240 mm<sup>2</sup>, voxel size&#8201;=&#8201;2&#8201;&#215;&#8201;2&#8201;&#215;&#8201;6 mm<sup>3</sup>, turbo spin-echo factor&#8201;=&#8201;184, and acquisition time&#8201;=&#8201;5&#160;min and 43&#160;s. Saturation offsets were unsaturated (S0) and &#177;&#8201;3.1 ppm, &#177;&#8201;3.5 ppm, and &#177;&#8201;3.9 ppm. A routine MRI protocol (T1WI, T2WI, FLAIR) was also performed in all subjects to exclude visible abnormalitie.</p></sec><sec id="Sec5"><title>Image processing</title><sec id="Sec6"><title>Surface-based morphometry</title><p id="Par12">Structural MRI data were processed using the Computational Anatomical Toolbox (CAT12.8.2 (r2170); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.neuro.uni-jena.de/cat/">http://www.neuro.uni-jena.de/cat/</ext-link>) and Statistical Parametric Mapping (SPM12 (7771); <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fil.ion.ucl.ac.uk/spm/software/spm12/">http://www.fil.ion.ucl.ac.uk/spm/software/spm12/</ext-link>) within the MATLAB environment (R2020a; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.mathworks.com">https://www.mathworks.com</ext-link>) for SBM analysis. The SBM preprocessing pipeline involved the following steps: &#9312; Format Conversion: T1-weighted data were converted from DICOM format to NIfTI format for subsequent analysis; &#9313; Spatial Normalization: Images were normalized to the ICBM space template to ensure anatomical alignment across subjects; &#9314; Inhomogeneity Correction: moderate intensity spatial inhomogeneity correction was conducted using SPM12 to minimize signal biases; &#9315; Brain Segmentation: The center of mass algorithm defined the image origin, and the APRG (adaptive probability region-growing) method was used for skull stripping; &#9316; Spatial Registration: Optimized shooting method was employed for spatial registration, aligning individual brain images to the standardized template;</p><p id="Par13">The SBM indices calculating steps were as follows: (&#8544;) Surface Parameter Extraction: CAT12 was used to extract brain surface parameters, including cortical thickness (CTh), sulcal depth (SD), fractal dimension (FD), and gyrification index (GI); (&#8545;) Data Resampling and Smoothing: Cortical thickness data were resampled and smoothed with a 15&#160;mm FWHM Gaussian kernel, while other indices were resampled and smoothed with a 20&#160;mm FWHM Gaussian kernel to reduce noise and enhance data readability<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>; (&#8546;) Surface value extraction: Desikan-Killiany 40 brain atlas labels, which comprehensively cover cortical areas implicated in AD pathogenesis, were used to obtain surface values from the cerebral cortex.</p></sec><sec id="Sec7"><title>APT data</title><p id="Par14">All APT image processing was performed on United Imaging post-processing workstation. &#9312; B0 Map Generation: A dual gradient-echo sequence was used to generate a voxelwise B0 map. &#9313; Motion correction: All CEST offset images and the B0 map were rigidly aligned to each other within the same APT acquisition space. &#9314; B0 inhomogeneity correction: The aligned B0 map was used to shift each voxel&#8217;s Z-spectrum to 0 ppm, eliminating local magnetic field offsets. &#9315; Registration to 3D-T1WI: The corrected CEST data were then co-registered to the 3D T1-weighted images, which were automatically segmented into 106 regions based on Desikan-Killiany atlas that comprehensively covers cortical and subcortical areas implicated in AD pathogenesis. &#9316; APT Parameter Calculation: the APT parameter&#8212;magnetization transfer ratio asymmetry (MTR<sub>asym</sub>)&#8212;was calculated for each of the 106 ROIs.<disp-formula id="Equa"><alternatives><tex-math id="d33e420">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:{\text{M}\text{T}\text{R}}_{\text{a}\text{s}\text{y}\text{m}}=\frac{{\text{S}}_{-3.5\:\text{p}\text{p}\text{m}}-{\text{S}}_{3.5\:\text{p}\text{p}\text{m}}}{{\text{S}}_{0}}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_16267_Article_Equa.gif"/></alternatives></disp-formula></p><p id="Par16">Where S<sub>&#8722;&#8201;3.5 ppm</sub> and S<sub>3.5 ppm</sub> represent the saturated signal intensities at &#8211; 3.5 ppm and +&#8201;3.5 ppm, respectively, while S<sub>0</sub> denotes the unsaturated signal intensity.</p></sec></sec><sec id="Sec8"><title>Statistical analysis</title><p id="Par17">Statistical analyses were conducted using SPSS software (version 25) and MedCalc (version 20.217). Continuous variables were assessed for normality using the Shapiro-Wilk test. Normally distributed data are presented as mean&#8201;&#177;&#8201;standard deviation (SD) and compared across three groups using one-way ANOVA. Non-normally distributed data are expressed as median (interquartile range, IQR) with group comparisons conducted using the Kruskal-Wallis H test. Categorical variables are reported as frequencies and analyzed by chi-square test. Bonferroni correction was applied for post-hoc analyses, with statistical significance defined as <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05. Initially, binary logistic regression was conducted for the MTR<sub>asym</sub> values, with age, sex, and education level as covariates. Subsequently, the area under the curve (AUC) of receiver operating characteristic (ROC) analysis was used to assess the accuracy of MTR<sub>asym</sub> in group classification. Spearman correlation was performed for the MTR<sub>asym</sub> and clinical assessment, including the MMSE and MoCA scores.</p><p id="Par18">For SBM indices, age, sex, and education level were included as covariates. Factorial design analysis was conducted using SPM12 software, followed by two-sample <italic toggle="yes">t</italic>-tests. Multiple comparison corrections were performed using the cluster-based correction method. Family-wise error (FWE) correction was applied across the entire brain. a corrected <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Participants characteristics</title><p id="Par19">A total of 94 participants were included in this study, comprising 26 AD patients (mean age 75.5&#8201;&#177;&#8201;8.9 years; 17 women), 36 MCI patients (median age: 68.5 years [IQR: 62.0&#8211;72.8]; 23 women), and 32 HCs (mean age 64.2&#8201;&#177;&#8201;5.3 years; 17 women) in this study. No significant differences were observed in sex or education level among the three groups. However, the mean age of participants in the AD group was higher than that of the MCI and HC groups (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). The MMSE and MoCA scores of the MCI group were lower than those of the HC group (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05), while the MMSE and MoCA scores of the AD group were lower than those of both the MCI and HC groups (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). The demographic and clinical characteristics of all participants are summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par20">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographic and clinical characteristics of the study cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="left" colspan="1" rowspan="1">HC (<italic toggle="yes">n</italic>&#8201;=&#8201;32)</th><th align="left" colspan="1" rowspan="1">MCI (<italic toggle="yes">n</italic>&#8201;=&#8201;36)</th><th align="left" colspan="1" rowspan="1">AD (<italic toggle="yes">n</italic>&#8201;=&#8201;26)</th><th align="left" colspan="1" rowspan="1">( &#967;<sup>2</sup>/H )</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Gender (male/female)</td><td align="left" colspan="1" rowspan="1">15/17</td><td align="left" colspan="1" rowspan="1">13/23</td><td align="left" colspan="1" rowspan="1">9/17</td><td char="." align="char" colspan="1" rowspan="1">1.16</td><td align="left" colspan="1" rowspan="1">0.559<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1">64.2&#8201;&#177;&#8201;5.3</td><td align="left" colspan="1" rowspan="1">68.5 (62.0, 72.8)</td><td align="left" colspan="1" rowspan="1">75.5&#8201;&#177;&#8201;8.9<sup>*#</sup></td><td char="." align="char" colspan="1" rowspan="1">26.37</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>b</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Educational level (years)</td><td align="left" colspan="1" rowspan="1">9.0 (9.0, 12.0)</td><td align="left" colspan="1" rowspan="1">12.0 (9.0, 15.0)</td><td align="left" colspan="1" rowspan="1">10.5 (9.0, 12.8)</td><td char="." align="char" colspan="1" rowspan="1">4.86</td><td align="left" colspan="1" rowspan="1">0.088<sup>b</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">MMSE score</td><td align="left" colspan="1" rowspan="1">29.0 (28.0, 29.0)</td><td align="left" colspan="1" rowspan="1">24.0 (22.0, 26.8)<sup>*</sup></td><td align="left" colspan="1" rowspan="1">14.1&#8201;&#177;&#8201;5.9<sup>*#</sup></td><td char="." align="char" colspan="1" rowspan="1">65.43</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>b</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">MoCA score</td><td align="left" colspan="1" rowspan="1">28.0 (26.3, 29.0)</td><td align="left" colspan="1" rowspan="1">19.1&#8201;&#177;&#8201;3.9<sup>*</sup></td><td align="left" colspan="1" rowspan="1">9.7&#8201;&#177;&#8201;4.3<sup>*#</sup></td><td char="." align="char" colspan="1" rowspan="1">77.34</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p><sup>*</sup> Indicates a statistically significant difference when compared to the HC group in post-hoc multiple comparisons, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05. <sup>#</sup>Indicates a statistically significant difference when compared to the MCI group in post-hoc multiple comparisons, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; <sup>a</sup> Chi-square test; <sup>b</sup> Kruskal-Wallis H test; HC&#8201;=&#8201;Healthy Control; MCI&#8201;=&#8201;Mild Cognitive Impairment; AD&#8201;=&#8201;Alzheimer&#8217;s Disease MMSE&#8201;=&#8201;Mini-Mental State Examination; MoCA&#8201;=&#8201;Montreal Cognitive Assessment.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>SBM analysis</title><p id="Par22">SBM analysis revealed significant CTh reductions in the AD group compared to the HC group across multiple brain regions, including the bilateral parahippocampal, fusiform, entorhinal, superior temporal, middle temporal, inferior temporal, temporal poles, bankssts, insula, left lateral orbitofrontal, bilateral precuneus, right superior parietal, right inferior parietal, right supramarginal, left posterior cingulate, and bilateral isthmus cingulate cortices (FWE corrected, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). No regions showed increased CTh in the AD group.</p><p id="Par23">Compared to the MCI group, the AD group exhibited decreased CTh in the left parahippocampal, entorhinal, superior temporal, temporal pole, transverse temporal, insula, right superior frontal, right medial orbitofrontal, left lateral orbitofrontal, supramarginal, bilateral precuneus, right anterior cingulate, bilateral posterior cingulate, and bilateral isthmus cingulate cortices (FWE corrected, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). No regions with enhanced CTh were detected in AD vs. MCI. No statistically significant CTh differences were identified between the HC and MCI groups.</p><p id="Par24">Regarding GI, the MCI group demonstrated a decrease in the left supramarginal, inferior parietal, bankssts, and superior temporal regions compared with the HC group (FWE corrected, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05), with no observed increases. Similarly, the AD group showed a decrease in the GI in the left superior parietal and postcentral regions compared with the HC group (FWE corrected, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05), with no observed increases. There were no statistically significant differences in SD and FD among the three groups (refer to Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>; Tables&#160;<xref rid="Tab2" ref-type="table">2</xref>, <xref rid="Tab3" ref-type="table">3</xref>, <xref rid="Tab4" ref-type="table">4</xref> and <xref rid="Tab5" ref-type="table">5</xref> for detailed data).</p><p id="Par25">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>(<bold>A</bold>) Regions with decreased cortical thickness in AD vs. HC; (<bold>B</bold>) Regions with decreased cortical thickness in AD vs. MCI; (<bold>C</bold>) Regions with decreased gyrification index in MCI vs. HC; (<bold>D</bold>) Regions with decreased gyrification index in AD vs. HC. The left side of the image corresponds to the left hemisphere. Colored areas (FWE corrected, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) indicate statistically significant differences. The color bar shows the range of <italic toggle="yes">P</italic> values.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e685" position="float" orientation="portrait" xlink:href="41598_2025_16267_Fig2_HTML.jpg"/></fig>
</p><p id="Par27">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Brain regions with decreased cortical thickness in the AD group compared to the HC Group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Encephalic region</th><th align="left" colspan="1" rowspan="1">Percentage</th><th align="left" colspan="1" rowspan="1">Cluster size (mm<sup>2</sup>)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value (FWE)</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">
<italic toggle="yes">Left</italic>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Superior temporal</td><td align="left" colspan="1" rowspan="1">21%</td><td char="." align="char" colspan="1" rowspan="1">1007</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Entorhinal</td><td align="left" colspan="1" rowspan="1">18%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Parahippocampal</td><td align="left" colspan="1" rowspan="1">18%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Middle temporal</td><td align="left" colspan="1" rowspan="1">14%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Temporal pole</td><td align="left" colspan="1" rowspan="1">12%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Insula</td><td align="left" colspan="1" rowspan="1">9%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Fusiform</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Lateral orbitofrontal</td><td align="left" colspan="1" rowspan="1">2%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Precuneus</td><td align="left" colspan="1" rowspan="1">42%</td><td char="." align="char" colspan="1" rowspan="1">551</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Posterior cingulate</td><td align="left" colspan="1" rowspan="1">37%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Isthmus cingulate</td><td align="left" colspan="1" rowspan="1">20%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Middle temporal</td><td align="left" colspan="1" rowspan="1">66%</td><td char="." align="char" colspan="1" rowspan="1">282</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Bankssts</td><td align="left" colspan="1" rowspan="1">26%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Inferior temporal</td><td align="left" colspan="1" rowspan="1">9%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">
<italic toggle="yes">Right</italic>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Inferior parietal</td><td align="left" colspan="1" rowspan="1">34%</td><td char="." align="char" colspan="1" rowspan="1">2255</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Middle temporal</td><td align="left" colspan="1" rowspan="1">25%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Bankssts</td><td align="left" colspan="1" rowspan="1">16%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Superior temporal</td><td align="left" colspan="1" rowspan="1">10%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Supramarginal</td><td align="left" colspan="1" rowspan="1">8%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Inferior temporal</td><td align="left" colspan="1" rowspan="1">6%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Precuneus</td><td align="left" colspan="1" rowspan="1">78%</td><td char="." align="char" colspan="1" rowspan="1">904</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Isthmus cingulate</td><td align="left" colspan="1" rowspan="1">19%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Superior parietal</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">parahippocampal</td><td align="left" colspan="1" rowspan="1">29%</td><td char="." align="char" colspan="1" rowspan="1">727</td><td char="." align="char" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Superior temporal</td><td align="left" colspan="1" rowspan="1">21%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Temporal pole</td><td align="left" colspan="1" rowspan="1">20%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Entorhinal</td><td align="left" colspan="1" rowspan="1">20%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Insula</td><td align="left" colspan="1" rowspan="1">6%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Fusiform</td><td align="left" colspan="1" rowspan="1">1%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Middle temporal</td><td align="left" colspan="1" rowspan="1">1%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Note: The percentage indicates the proportion of each brain region within the cluster.</p></table-wrap-foot></table-wrap>
</p><p id="Par29">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Brain regions with decreased cortical thickness in the AD group compared to the MCI Group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Encephalic region</th><th align="left" colspan="1" rowspan="1">Percentage</th><th align="left" colspan="1" rowspan="1">Cluster size (mm<sup>2</sup>)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value<break/>(FWE)</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">
<italic toggle="yes">Left</italic>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Insula</td><td align="left" colspan="1" rowspan="1">34%</td><td align="left" colspan="1" rowspan="1">916</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Superior temporal</td><td align="left" colspan="1" rowspan="1">27%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Entorhinal</td><td align="left" colspan="1" rowspan="1">17%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Temporal pole</td><td align="left" colspan="1" rowspan="1">13%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Parahippocampal</td><td align="left" colspan="1" rowspan="1">6%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Lateral orbitofrontal</td><td align="left" colspan="1" rowspan="1">2%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Superior temporal</td><td align="left" colspan="1" rowspan="1">45%</td><td align="left" colspan="1" rowspan="1">475</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Supramarginal</td><td align="left" colspan="1" rowspan="1">42%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Transverse temporal</td><td align="left" colspan="1" rowspan="1">13%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Precuneus</td><td align="left" colspan="1" rowspan="1">63%</td><td align="left" colspan="1" rowspan="1">468</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Posterior cingulate</td><td align="left" colspan="1" rowspan="1">35%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Isthmus cingulate</td><td align="left" colspan="1" rowspan="1">2%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">
<italic toggle="yes">Right</italic>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Posterior cingulate</td><td align="left" colspan="1" rowspan="1">37%</td><td align="left" colspan="1" rowspan="1">558</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Isthmus cingulate</td><td align="left" colspan="1" rowspan="1">33%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Precuneus</td><td align="left" colspan="1" rowspan="1">30%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Anterior cingulate</td><td align="left" colspan="1" rowspan="1">39%</td><td align="left" colspan="1" rowspan="1">484</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Superior frontal</td><td align="left" colspan="1" rowspan="1">31%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Medial orbitofrontal</td><td align="left" colspan="1" rowspan="1">29%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Note: The percentage indicates the proportion of each brain region within the cluster.</p></table-wrap-foot></table-wrap>
</p><p id="Par30">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Brain regions with reduced gyrification index in the MCI group compared to the HC group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Encephalic region</th><th align="left" colspan="1" rowspan="1">Percentage</th><th align="left" colspan="1" rowspan="1">Cluster size (mm<sup>2</sup>)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value<break/>(FWE)</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">
<italic toggle="yes">Left</italic>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Inferior parietal</td><td align="left" colspan="1" rowspan="1">36%</td><td align="left" colspan="1" rowspan="1">261</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Supramarginal</td><td align="left" colspan="1" rowspan="1">33%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Bankssts</td><td align="left" colspan="1" rowspan="1">30%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Superior temporal</td><td align="left" colspan="1" rowspan="1">2%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Note: The percentage indicates the proportion of each brain region within the cluster.</p></table-wrap-foot></table-wrap>
</p><p id="Par31">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Brain regions with reduced gyrification index in the AD group compared to the HC group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Encephalic region</th><th align="left" colspan="1" rowspan="1">Percentage</th><th align="left" colspan="1" rowspan="1">Cluster size (mm<sup>2</sup>)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value<break/>(FWE)</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">
<italic toggle="yes">Left</italic>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Superior parietal</td><td align="left" colspan="1" rowspan="1">60%</td><td align="left" colspan="1" rowspan="1">252</td><td align="left" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">postcentral</td><td align="left" colspan="1" rowspan="1">40%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Note: The percentage indicates the proportion of each brain region within the cluster.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec12"><title>APT analysis</title><sec id="Sec13"><title>Comparison of MTR<sub>asym</sub> values between groups</title><p id="Par32">The comparison of MTR<sub>asym</sub> values among the three groups is shown in Supplementary Table 1. After Bonferroni correction, the AD group showed significantly higher MTR<sub>asym</sub> values than the MCI group in the right insula, left middle cingulate, left posterior cingulate, bilateral hippocampus, bilateral amygdala, bilateral putamen, bilateral globus pallidus, left cuneus, right fusiform, right superior temporal gyrus slope, right white matter, and middle corpus callosum (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). Compared to the HC group, the AD group exhibited increased MTR<sub>asym</sub> values in the right precentral, right postcentral, bilateral paracentral, right lateral orbitofrontal, right operculum, bilateral insula, left middle cingulate, bilateral posterior cingulate, bilateral hippocampus, bilateral amygdala, right caudate nucleus, bilateral putamen, bilateral globus pallidus, bilateral superior parietal, right inferior parietal, left cuneus, right fusiform, left lingual, left pericalcarine, bilateral precuneus, right supramarginal right superior temporal, right middle temporal, right superior temporal gyrus slope, bilateral transverse temporal, and bilateral white matter(<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05).</p></sec><sec id="Sec14"><title>Multivariate binary logistic regression analysis</title><p id="Par33">Multivariate logistic was conducted with age, gender, and years of education included as covariates. MTR<sub>asym</sub> values in the right lateral orbitofrontal, right insula, left posterior cingulate, right hippocampus, right amygdala, bilateral putamen, bilateral superior parietal, left cuneus, left lingual, left pericalcarine, bilateral precuneus, right supramarginal, and bilateral white matter were identified as statistically significant predictors of AD vs. HC (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05), as detailed in Table&#160;<xref rid="Tab5" ref-type="table">6</xref>.</p><p id="Par34">
<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Binary multivariate logistic regression analysis between the AD and HC groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Encephalic region</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th><th align="left" colspan="1" rowspan="1">OR</th><th align="left" colspan="1" rowspan="1">OR (95%CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Right lateral orbitofrontal</td><td align="left" colspan="1" rowspan="1">0.048</td><td align="left" colspan="1" rowspan="1">0.237</td><td align="left" colspan="1" rowspan="1">(0.057, 0.985)</td></tr><tr><td align="left" colspan="1" rowspan="1">Right insula</td><td align="left" colspan="1" rowspan="1">0.032</td><td align="left" colspan="1" rowspan="1">0.044</td><td align="left" colspan="1" rowspan="1">(0.003, 0.768)</td></tr><tr><td align="left" colspan="1" rowspan="1">Left posterior cingulate</td><td align="left" colspan="1" rowspan="1">0.015</td><td align="left" colspan="1" rowspan="1">0.053</td><td align="left" colspan="1" rowspan="1">(0.005, 0.562)</td></tr><tr><td align="left" colspan="1" rowspan="1">Right hippocampus</td><td align="left" colspan="1" rowspan="1">0.032</td><td align="left" colspan="1" rowspan="1">0.103</td><td align="left" colspan="1" rowspan="1">(0.013, 0.823)</td></tr><tr><td align="left" colspan="1" rowspan="1">Right amygdala</td><td align="left" colspan="1" rowspan="1">0.016</td><td align="left" colspan="1" rowspan="1">0.082</td><td align="left" colspan="1" rowspan="1">(0.011, 0.631)</td></tr><tr><td align="left" colspan="1" rowspan="1">Left putamen</td><td align="left" colspan="1" rowspan="1">0.042</td><td align="left" colspan="1" rowspan="1">0.111</td><td align="left" colspan="1" rowspan="1">(0.013, 0.922)</td></tr><tr><td align="left" colspan="1" rowspan="1">Right putamen</td><td align="left" colspan="1" rowspan="1">0.015</td><td align="left" colspan="1" rowspan="1">0.033</td><td align="left" colspan="1" rowspan="1">(0.002, 0.510)</td></tr><tr><td align="left" colspan="1" rowspan="1">Left superior parietal</td><td align="left" colspan="1" rowspan="1">0.015</td><td align="left" colspan="1" rowspan="1">0.148</td><td align="left" colspan="1" rowspan="1">(0.032, 0.688)</td></tr><tr><td align="left" colspan="1" rowspan="1">Right superior parietal</td><td align="left" colspan="1" rowspan="1">0.014</td><td align="left" colspan="1" rowspan="1">0.186</td><td align="left" colspan="1" rowspan="1">(0.049, 0.708)</td></tr><tr><td align="left" colspan="1" rowspan="1">Left cuneus</td><td align="left" colspan="1" rowspan="1">0.005</td><td align="left" colspan="1" rowspan="1">0.002</td><td align="left" colspan="1" rowspan="1">(0.000, 0.158)</td></tr><tr><td align="left" colspan="1" rowspan="1">Left lingual</td><td align="left" colspan="1" rowspan="1">0.029</td><td align="left" colspan="1" rowspan="1">0.094</td><td align="left" colspan="1" rowspan="1">(0.011, 0.781)</td></tr><tr><td align="left" colspan="1" rowspan="1">pericalcarine</td><td align="left" colspan="1" rowspan="1">0.025</td><td align="left" colspan="1" rowspan="1">0.043</td><td align="left" colspan="1" rowspan="1">(0.003, 0.672)</td></tr><tr><td align="left" colspan="1" rowspan="1">Left precuneus</td><td align="left" colspan="1" rowspan="1">0.024</td><td align="left" colspan="1" rowspan="1">0.068</td><td align="left" colspan="1" rowspan="1">(0.007, 0.697)</td></tr><tr><td align="left" colspan="1" rowspan="1">Right precuneus</td><td align="left" colspan="1" rowspan="1">0.037</td><td align="left" colspan="1" rowspan="1">0.107</td><td align="left" colspan="1" rowspan="1">(0.013, 0.877)</td></tr><tr><td align="left" colspan="1" rowspan="1">Right supramarginal</td><td align="left" colspan="1" rowspan="1">0.035</td><td align="left" colspan="1" rowspan="1">0.191</td><td align="left" colspan="1" rowspan="1">(0.041, 0.891)</td></tr><tr><td align="left" colspan="1" rowspan="1">Left white matter</td><td align="left" colspan="1" rowspan="1">0.042</td><td align="left" colspan="1" rowspan="1">0.065</td><td align="left" colspan="1" rowspan="1">(0.005, 0.910)</td></tr><tr><td align="left" colspan="1" rowspan="1">Right white matter</td><td align="left" colspan="1" rowspan="1">0.011</td><td align="left" colspan="1" rowspan="1">0.010</td><td align="left" colspan="1" rowspan="1">(0.000, 0.353)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec15"><title>ROC analysis</title><p id="Par35">The ROC analysis revealed that the right amygdala had the highest diagnostic performance with the highest AUC of 0.840. The optimal diagnostic cut-off point was 0.8, with a sensitivity of 76.92% and a specificity of 78.12%. The AUC values for the remaining regions, ranked in descending order, were 0.826, 0.823, 0.822, 0.796, 0.791, 0.789, 0.769, 0.766, 0.758, 0.738, 0.731, 0.727, 0.718, 0.703, 0.698, and 0.692 (see Table&#160;<xref rid="Tab7" ref-type="table">7</xref>; Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref> for details). Figure&#160;<xref rid="Fig4" ref-type="fig">4</xref> demonstrates increased MTR<sub>asym</sub> values in the hippocampal region of AD patients compared to HC.</p><p id="Par36">
<table-wrap id="Tab7" position="float" orientation="portrait"><label>Table 7</label><caption><p>Analysis of ROC curves for distinguishing AD and HC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Encephalic region</th><th align="left" colspan="1" rowspan="1">Cut-off</th><th align="left" colspan="1" rowspan="1">AUC (95% CI)</th><th align="left" colspan="1" rowspan="1">Sensitivity (%)</th><th align="left" colspan="1" rowspan="1">specificity (%)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Right lateral orbitofrontal</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">0.738 (0.606&#8211;0.845)</td><td align="left" colspan="1" rowspan="1">88.46</td><td align="left" colspan="1" rowspan="1">50.00</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Right insula</td><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">0.822 (0.699&#8211;0.910)</td><td align="left" colspan="1" rowspan="1">88.46</td><td align="left" colspan="1" rowspan="1">65.62</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Left posterior cingulate</td><td align="left" colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">0.758 (0.627&#8211;0.861)</td><td align="left" colspan="1" rowspan="1">57.69</td><td align="left" colspan="1" rowspan="1">90.62</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Right hippocampus</td><td align="left" colspan="1" rowspan="1">1.4</td><td align="left" colspan="1" rowspan="1">0.796 (0.669&#8211;0.890)</td><td align="left" colspan="1" rowspan="1">69.23</td><td align="left" colspan="1" rowspan="1">84.37</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Right amygdala</td><td align="left" colspan="1" rowspan="1">0.8</td><td align="left" colspan="1" rowspan="1">0.840 (0.720&#8211;0.923)</td><td align="left" colspan="1" rowspan="1">76.92</td><td align="left" colspan="1" rowspan="1">78.12</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Left putamen</td><td align="left" colspan="1" rowspan="1">0.9</td><td align="left" colspan="1" rowspan="1">0.791 (0.665&#8211;0.887)</td><td align="left" colspan="1" rowspan="1">57.69</td><td align="left" colspan="1" rowspan="1">93.75</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Right putamen</td><td align="left" colspan="1" rowspan="1">1.0</td><td align="left" colspan="1" rowspan="1">0.826 (0.704&#8211;0.913)</td><td align="left" colspan="1" rowspan="1">65.38</td><td align="left" colspan="1" rowspan="1">90.62</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Left superior parietal</td><td align="left" colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">0.769 (0.640&#8211;0.870)</td><td align="left" colspan="1" rowspan="1">92.31</td><td align="left" colspan="1" rowspan="1">56.25</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Right superior parietal</td><td align="left" colspan="1" rowspan="1">1.3</td><td align="left" colspan="1" rowspan="1">0.731 (0.598&#8211;0.839)</td><td align="left" colspan="1" rowspan="1">84.62</td><td align="left" colspan="1" rowspan="1">56.25</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Left cuneus</td><td align="left" colspan="1" rowspan="1">1.6</td><td align="left" colspan="1" rowspan="1">0.823 (0.700&#8211;0.911)</td><td align="left" colspan="1" rowspan="1">61.54</td><td align="left" colspan="1" rowspan="1">93.75</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Left lingual</td><td align="left" colspan="1" rowspan="1">1.5</td><td align="left" colspan="1" rowspan="1">0.698 (0.563&#8211;0.811)</td><td align="left" colspan="1" rowspan="1">61.54</td><td align="left" colspan="1" rowspan="1">68.75</td><td align="left" colspan="1" rowspan="1">0.004</td></tr><tr><td align="left" colspan="1" rowspan="1">Left pericalcarine</td><td align="left" colspan="1" rowspan="1">1.0</td><td align="left" colspan="1" rowspan="1">0.703 (0.569&#8211;0.816)</td><td align="left" colspan="1" rowspan="1">88.46</td><td align="left" colspan="1" rowspan="1">43.75</td><td align="left" colspan="1" rowspan="1">0.003</td></tr><tr><td align="left" colspan="1" rowspan="1">Left precuneus</td><td align="left" colspan="1" rowspan="1">1.2</td><td align="left" colspan="1" rowspan="1">0.727 (0.594&#8211;0.835)</td><td align="left" colspan="1" rowspan="1">46.15</td><td align="left" colspan="1" rowspan="1">93.75</td><td align="left" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Right precuneus</td><td align="left" colspan="1" rowspan="1">1.3</td><td align="left" colspan="1" rowspan="1">0.692 (0.557&#8211;0.806)</td><td align="left" colspan="1" rowspan="1">61.54</td><td align="left" colspan="1" rowspan="1">78.12</td><td align="left" colspan="1" rowspan="1">0.008</td></tr><tr><td align="left" colspan="1" rowspan="1">Right supramarginal</td><td align="left" colspan="1" rowspan="1">1.6</td><td align="left" colspan="1" rowspan="1">0.766 (0.637&#8211;0.867)</td><td align="left" colspan="1" rowspan="1">61.54</td><td align="left" colspan="1" rowspan="1">84.37</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Left white matter</td><td align="left" colspan="1" rowspan="1">0.8</td><td align="left" colspan="1" rowspan="1">0.718 (0.585&#8211;0.828)</td><td align="left" colspan="1" rowspan="1">50.00</td><td align="left" colspan="1" rowspan="1">90.62</td><td align="left" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">Right white matter</td><td align="left" colspan="1" rowspan="1">0.7</td><td align="left" colspan="1" rowspan="1">0.789 (0.662&#8211;0.885)</td><td align="left" colspan="1" rowspan="1">69.23</td><td align="left" colspan="1" rowspan="1">75.00</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table></table-wrap>
</p><p id="Par37">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>ROC curve plot for MTR<sub>asym</sub> values in the encephalic regions with significant differences.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1762" position="float" orientation="portrait" xlink:href="41598_2025_16267_Fig3_HTML.jpg"/></fig>
</p><p id="Par38">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>(<bold>a</bold>, <bold>b</bold>) APT image of a 76-year-old male, healthy control (MMSE score: 29; MoCA score: 29); (<bold>c</bold>, <bold>d</bold>) APT image of a 73-year-old female with Alzheimer&#8217;s disease (MMSE score: 15; MoCA score: 9); In the hippocampal region (white arrow), Alzheimer&#8217;s disease patients exhibit elevated APT signal intensity compared to normal controls.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1785" position="float" orientation="portrait" xlink:href="41598_2025_16267_Fig4_HTML.jpg"/></fig>
</p></sec><sec id="Sec16"><title>Correlation between MTR<sub>asym</sub> values and MMSE and MoCA scores</title><p id="Par39">Spearman correlation revealed negative correlations between MMSE and MTR<sub>asym</sub> values in the right insula, right hippocampus, right amygdala, bilateral putamen, left cuneus, and right white matter. Similarly, MTR<sub>asym</sub> values in the right lateral orbitofrontal, right insula, left posterior cingulate, right hippocampus, right amygdala, bilateral putamen, bilateral superior parietal, left cuneus, left pericalcarine, left precuneus, right supramarginal, and bilateral white matter were negatively correlated with MoCA scores (Figs.&#160;<xref rid="Fig5" ref-type="fig">5</xref> and <xref rid="Fig6" ref-type="fig">6</xref>).</p><p id="Par40">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Correlations between MTR<sub>asym</sub> values and MMSE scores.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1815" position="float" orientation="portrait" xlink:href="41598_2025_16267_Fig5_HTML.jpg"/></fig>
</p><p id="Par41">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Correlations between MTR<sub>asym</sub> values and MoCA scores.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1828" position="float" orientation="portrait" xlink:href="41598_2025_16267_Fig6_HTML.jpg"/></fig>
</p></sec></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par42">Accurate and non-invasive diagnostic biomarkers are crucial for identifying AD in its early stages. Traditional diagnostic approaches, including cognitive assessments and structural imaging, often lack the sensitivity to detect the subtle changes that occur during the prodromal stages of AD. By employing SBM and APT imaging, this study investigated morphological and metabolic alterations in AD and MCI patients compared with HC. The findings revealed significant differences in both cortical structure and metabolic activity across the three groups, offering valuable insights into the pathophysiological changes associated with AD progression. Specifically, SBM detected subtle structural modifications, such as cortical thinning and reduced GI, while APT imaging provided a molecular perspective by revealing metabolic abnormalities linked to protein deposition. These results underscore the complementary value of combining SBM and APT imaging in elucidating the complex interplay between structural and metabolic disruptions during the prodromal stages of AD.</p><p id="Par43">Consistent with previous research<sup><xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref></sup>, this study observed widespread cortical thinning in AD patients, particularly in the frontal, temporal, parietal lobes, and cingulate gyrus. These patterns likely reflect progressive neuronal loss underlying cognitive decline in AD. Although no statistically significant differences in CTh were detected between MCI and HC groups, a reduced GI in the left parietal and temporal lobes among MCI patients relative to HC was observed, potentially associated with early neurodegenerative processes. The reduced parietal-temporal GI may serve as a potential biomarker for the early diagnosis of AD. We also found a reduced GI in the parietal lobes of AD patients, the parietal lobe is prone to early atrophy in AD and linked to multiple cognitive functions<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>. However, unlike the decrease in GI in the temporal lobe of MCI patients, our study did not detect similar changes in AD patients. This observation might speculatively align with reports of compensatory neural adaptations in early AD<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, though cross-sectional data preclude causal attribution to cognitive preservation.</p><p id="Par44">APT imaging revealed increased MTR<sub>asym</sub> values in multiple brain regions of AD patients, including the right lateral orbitofrontal, right insula, left posterior cingulate, right hippocampus, right amygdala, bilateral putamen, bilateral superior parietal, left cuneus, left lingual gyrus, left pericalcarine, bilateral precuneus, right supramarginal gyrus, and bilateral white matter. Notably, the right amygdala exhibited the highest AUC value (0.84) among these regions. The Braak staging scheme identifies the amygdala as an early site of NFT pathology in AD<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Consistent with this, multiple tau-PET imaging studies have consistently highlighted the amygdala as a key region for NFT accumulation in Alzheimer&#8217;s disease<sup><xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref></sup>, noting that this accumulation occurs very early, potentially even before the onset of cognitive symptoms and the appearance of NFT in the entorhinal cortex<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>. This underscores the amygdala&#8217;s early and significant role in the pathological progression of AD. Recent advancements in imaging and analytical techniques have further illuminated the amygdala&#8217;s substantial involvement in AD. For instance, research by Hari et al. suggests that amygdala volume reduction could serve as a significant MRI biomarker for early disease detection<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Our APT imaging results provide additional support for the amygdala&#8217;s importance in AD. The high AUC value observed in the right amygdala among all analyzed brain regions suggests its strong potential as an early diagnostic biomarker for AD. Furthermore, we observed that the elevations in MTR<sub>asym</sub> values were negatively correlated with cognitive performance, as measured by MMSE or MoCA scores. This indicates that higher MTR<sub>asym</sub> values were associated with more pronounced cognitive impairment. Consistent with previous studies<sup><xref ref-type="bibr" rid="CR30">30</xref>&#8211;<xref ref-type="bibr" rid="CR32">32</xref></sup>, we also found increased APT signals in the hippocampus of AD patients, and these hippocampal APT values in the hippocampus were negatively correlated with cognitive scores. However, unlike the findings reported by Zhang et al.<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, we did not observe statistically significant differences in APT values between the MCI and HC groups in our dataset. Nevertheless, a trend towards elevated APT signals was noted in certain regions, including the hippocampus and amygdala, in MCI patients compared to HC individuals. This discrepancy may potentially be attributed to variations in sample size or differences in the data acquisition protocols between studies.</p><p id="Par45">Although increased MTR<sub>asym</sub> was more widespread than cortical atrophy, six regions in AD patients&#8212;namely the right insula, superior parietal lobule, supramarginal gyrus, left posterior cingulate gyrus, and bilateral precuneus&#8212;exhibited both reduced cortical thickness and elevated MTR<sub>asym</sub>. Notably, the left superior parietal lobule showed both reduced gyrification and increased MTR<sub>asym</sub>. Previous studies indicate that cortical thinning correlates with A&#946; and tau accumulation, particularly in vulnerable regions such as temporal, parietal lobes, and cingulate gyrus<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. Our overlapping regions fall within these areas of known susceptibility. The strong association between tau pathology and atrophy, independent of significant amyloid deposits in some cases<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>, further supports the idea that protein aggregation, particularly tau, drives neurodegeneration. This is corroborated by findings such as the negative correlation between neuron count and neurofibrillary tangle density in the supramarginal gyrus<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>, directly linking protein accumulation to neuron loss. Therefore, while we refrain from asserting a definitive causal link based solely on these imaging correlations, the co-localization of cortical thinning and elevated MTR<sub>asym</sub> in these specific regions provides compelling in vivo evidence consistent with the hypothesis that protein accumulation is integral to the neurodegenerative process. These overlapping regions, particularly those within the Default Mode Network (DMN) such as the posterior cingulate cortex and precuneus, are known to be early and heavily affected by AD pathology<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref></sup>. Disruptions in DMN connectivity have been identified as promising early biomarkers, and alterations in regions like the supramarginal gyrus and precuneus have been linked to cognitive deficits<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup>. While both SBM and APT identified alterations in certain brain regions, they demonstrated differential sensitivity to distinct pathological processes. Specifically, SBM primarily detects macroscopic structural changes, such as cortical thinning, which are typically associated with neuronal loss<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. In contrast, APT provides information on microstructural alterations, potentially reflecting the presence of protein aggregation, such as A&#946; deposits. This differential sensitivity is illustrated by our findings, where the occipital lobe exhibited significant APT signal changes without corresponding SBM-detected atrophy. This interpretation aligns with the established temporal sequence of AD pathology. A&#946; deposition typically precedes tau protein aggregation and subsequent neurodegeneration<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Therefore, the observed partial non-overlap between SBM and APT findings can be plausibly attributed to different brain regions progressing through various stages of the disease process. However, this hypothesis requires further validation through longitudinal studies designed to track the evolution of these imaging biomarkers over time in individual patients.</p><p id="Par46">Several limitations of this study should be acknowledged. Firstly, APT imaging inherently possesses relatively coarse spatial resolution, a complicated contrast mechanism with multiple contributions, and the possibility for B0/B1 inhomogeneity artifacts and lipid artifacts, which may influence the interpretation of our findings. Secondly, the relatively small sample size may limit the generalizability of the results. Additionally, the cross-sectional design of the study precludes longitudinal assessment of APT and SBM indices. Thirdly, participants&#8217; cerebrospinal fluid (CSF) biomarkers (e.g., A&#946;42, p-tau) were not acquired. Future research should explore the utility of APT and SBM in larger, longitudinal studies to further validate their potential as diagnostic and prognostic tools for AD. Moreover, integrating APT and SBM with other imaging modalities (e.g., PET) and CSF biomarkers may provide a more comprehensive understanding of AD pathophysiology.</p></sec><sec id="Sec18"><title>Conclusions</title><p id="Par47">This study provides evidence for the utility of SBM and APT imaging in characterizing the metabolic and morphological alterations associated with AD and MCI. These imaging techniques offer meaningful insights into the pathophysiology of AD and may provide valuable tools for the early diagnosis and monitoring of AD progression.</p></sec><sec id="Sec19" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_16267_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors reviewed the manuscript. M.Z. contributed to formal analysis, visualization, and writing the original draft and editing the manuscript. Q.S., S.Z., Z.L., C.Y., P.L. and N.W. contributed to conceptualization, data curation, formal analysis, investigation, methodology, writing and revising the manuscript. D.Y. and K.W. contributed to software support. J.L. contributed to statistical analysis. J.Z. and C.D. contributed to data curation, project administration, and project integrity. C.Y. contributed to conceptualization, formal analysis, investigation, supervision, editing the manuscript, and project integrity.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par51">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer&#8217;s disease</article-title><source>Mol. Neurodegener.</source><year>2020</year><volume>15</volume><issue>1</issue><fpage>55</fpage><pub-id pub-id-type="doi">10.1186/s13024-020-00395-3</pub-id><pub-id pub-id-type="pmid">32962744</pub-id><pub-id pub-id-type="pmcid">PMC7507636</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Wang, X. et al. Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer&#8217;s disease. <italic toggle="yes">Mol. Neurodegener.</italic><bold>15</bold> (1), 55. 10.1186/s13024-020-00395-3 (2020).<pub-id pub-id-type="pmid">32962744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-020-00395-3</pub-id><pub-id pub-id-type="pmcid">PMC7507636</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gauthier</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mild cognitive impairment</article-title><source>Lancet (London England)</source><year>2006</year><volume>367</volume><issue>9518</issue><fpage>1262</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)68542-5</pub-id><pub-id pub-id-type="pmid">16631882</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Gauthier, S. et al. Mild cognitive impairment. <italic toggle="yes">Lancet (London England)</italic>. <bold>367</bold> (9518), 1262&#8211;1270. 10.1016/S0140-6736(06)68542-5 (2006).<pub-id pub-id-type="pmid">16631882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(06)68542-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mckhann</surname><given-names>GM</given-names></name><etal/></person-group><article-title>The diagnosis of dementia due to Alzheimer&#8217;s disease: recommendations from the National Institute on aging-Alzheimer&#8217;s association workgroups on diagnostic guidelines for Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dement. J. Alzheimer&#8217;s Assoc.</source><year>2011</year><volume>7</volume><issue>3</issue><fpage>263</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.005</pub-id><pub-id pub-id-type="pmcid">PMC3312024</pub-id><pub-id pub-id-type="pmid">21514250</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Mckhann, G. M., et al. The diagnosis of dementia due to Alzheimer&#8217;s disease: recommendations from the National Institute on aging-Alzheimer&#8217;s association workgroups on diagnostic guidelines for Alzheimer&#8217;s disease. <italic toggle="yes">Alzheimer&#8217;s Dement. J. Alzheimer&#8217;s Assoc.</italic><bold>7</bold> (3), 263&#8211;269. 10.1016/j.jalz.2011.03.005 (2011).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.03.005</pub-id><pub-id pub-id-type="pmcid">PMC3312024</pub-id><pub-id pub-id-type="pmid">21514250</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name><etal/></person-group><article-title>Alzheimer&#8217;s disease</article-title><source>Lancet (London England)</source><year>2021</year><volume>397</volume><issue>10284</issue><fpage>1577</fpage><lpage>1590</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32205-4</pub-id><pub-id pub-id-type="pmid">33667416</pub-id><pub-id pub-id-type="pmcid">PMC8354300</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Scheltens, P. et al. Alzheimer&#8217;s disease. <italic toggle="yes">Lancet (London England)</italic>. <bold>397</bold> (10284), 1577&#8211;1590. 10.1016/S0140-6736(20)32205-4 (2021).<pub-id pub-id-type="pmid">33667416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32205-4</pub-id><pub-id pub-id-type="pmcid">PMC8354300</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicastro</surname><given-names>N</given-names></name><etal/></person-group><article-title>Cortical complexity analyses and their cognitive correlate in Alzheimer&#8217;s disease and frontotemporal dementia</article-title><source>J. Alzheimer&#8217;s Disease: JAD</source><year>2020</year><volume>76</volume><issue>1</issue><fpage>331</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.3233/JAD-200246</pub-id><pub-id pub-id-type="pmid">32444550</pub-id><pub-id pub-id-type="pmcid">PMC7338220</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Nicastro, N. et al. Cortical complexity analyses and their cognitive correlate in Alzheimer&#8217;s disease and frontotemporal dementia. <italic toggle="yes">J. Alzheimer&#8217;s Disease: JAD</italic>. <bold>76</bold> (1), 331&#8211;340. 10.3233/JAD-200246 (2020).<pub-id pub-id-type="pmid">32444550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-200246</pub-id><pub-id pub-id-type="pmcid">PMC7338220</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><etal/></person-group><article-title>Correlation between brain structure atrophy and plasma Amyloid-&#946; and phosphorylated Tau in patients with Alzheimer&#8217;s disease and amnestic mild cognitive impairment explored by surface-based morphometry</article-title><source>Front. Aging Neurosci.</source><year>2022</year><volume>14</volume><fpage>816043</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2022.816043</pub-id><pub-id pub-id-type="pmid">35547625</pub-id><pub-id pub-id-type="pmcid">PMC9083065</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Li, K. et al. Correlation between brain structure atrophy and plasma Amyloid-&#946; and phosphorylated Tau in patients with Alzheimer&#8217;s disease and amnestic mild cognitive impairment explored by surface-based morphometry. <italic toggle="yes">Front. Aging Neurosci.</italic><bold>14</bold>, 816043. 10.3389/fnagi.2022.816043 (2022).<pub-id pub-id-type="pmid">35547625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.816043</pub-id><pub-id pub-id-type="pmcid">PMC9083065</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Gray matter deterioration pattern during Alzheimer&#8217;s disease progression: a regions-of-Interest based surface morphometry study</article-title><source>Front. Aging Neurosci.</source><year>2021</year><volume>13</volume><fpage>593898</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2021.593898</pub-id><pub-id pub-id-type="pmid">33613265</pub-id><pub-id pub-id-type="pmcid">PMC7886803</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Wu, Z. et al. Gray matter deterioration pattern during Alzheimer&#8217;s disease progression: a regions-of-Interest based surface morphometry study. <italic toggle="yes">Front. Aging Neurosci.</italic><bold>13</bold>, 593898. 10.3389/fnagi.2021.593898 (2021).<pub-id pub-id-type="pmid">33613265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2021.593898</pub-id><pub-id pub-id-type="pmcid">PMC7886803</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hyman</surname><given-names>BT</given-names></name><etal/></person-group><article-title>National institute on aging-Alzheimer&#8217;s association guidelines for the neuropathologic assessment of Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dement. J. Alzheimer&#8217;s Assoc.</source><year>2012</year><volume>8</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.10.007</pub-id><pub-id pub-id-type="pmcid">PMC3266529</pub-id><pub-id pub-id-type="pmid">22265587</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Hyman, B. T. et al. National institute on aging-Alzheimer&#8217;s association guidelines for the neuropathologic assessment of Alzheimer&#8217;s disease. <italic toggle="yes">Alzheimer&#8217;s Dement. J. Alzheimer&#8217;s Assoc.</italic><bold>8</bold> (1), 1&#8211;13. 10.1016/j.jalz.2011.10.007 (2012).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.10.007</pub-id><pub-id pub-id-type="pmcid">PMC3266529</pub-id><pub-id pub-id-type="pmid">22265587</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montine</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>National institute on aging-Alzheimer&#8217;s association guidelines for the neuropathologic assessment of Alzheimer&#8217;s disease: a practical approach</article-title><source>Acta Neuropathol.</source><year>2012</year><volume>123</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1007/s00401-011-0910-3</pub-id><pub-id pub-id-type="pmid">22101365</pub-id><pub-id pub-id-type="pmcid">PMC3268003</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Montine, T. J. et al. National institute on aging-Alzheimer&#8217;s association guidelines for the neuropathologic assessment of Alzheimer&#8217;s disease: a practical approach. <italic toggle="yes">Acta Neuropathol.</italic><bold>123</bold> (1), 1&#8211;11. 10.1007/s00401-011-0910-3 (2012).<pub-id pub-id-type="pmid">22101365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-011-0910-3</pub-id><pub-id pub-id-type="pmcid">PMC3268003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thal</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Phases of A beta-deposition in the human brain and its relevance for the development of AD</article-title><source>Neurology</source><year>2002</year><volume>58</volume><issue>12</issue><fpage>1791</fpage><lpage>1800</lpage><pub-id pub-id-type="doi">10.1212/wnl.58.12.1791</pub-id><pub-id pub-id-type="pmid">12084879</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Thal, D. R. et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. <italic toggle="yes">Neurology</italic><bold>58</bold> (12), 1791&#8211;1800. 10.1212/wnl.58.12.1791 (2002).<pub-id pub-id-type="pmid">12084879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.58.12.1791</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braak</surname><given-names>H</given-names></name><name name-style="western"><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Neuropathological stageing of Alzheimer-related changes</article-title><source>Acta Neuropathol.</source><year>1991</year><volume>82</volume><issue>4</issue><fpage>239</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1007/BF00308809</pub-id><pub-id pub-id-type="pmid">1759558</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Braak, H. &amp; Braak, E. Neuropathological stageing of Alzheimer-related changes. <italic toggle="yes">Acta Neuropathol.</italic><bold>82</bold> (4), 239&#8211;259. 10.1007/BF00308809 (1991).<pub-id pub-id-type="pmid">1759558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00308809</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><etal/></person-group><article-title>APT-weighted MRI: techniques, current neuro applications, and challenging issues</article-title><source>J. Magn. Reson. Imaging: JMRI</source><year>2019</year><volume>50</volume><issue>2</issue><fpage>347</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1002/jmri.26645</pub-id><pub-id pub-id-type="pmid">30663162</pub-id><pub-id pub-id-type="pmcid">PMC6625919</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Zhou, J. et al. APT-weighted MRI: techniques, current neuro applications, and challenging issues. <italic toggle="yes">J. Magn. Reson. Imaging: JMRI</italic>. <bold>50</bold> (2), 347&#8211;364. 10.1002/jmri.26645 (2019).<pub-id pub-id-type="pmid">30663162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmri.26645</pub-id><pub-id pub-id-type="pmcid">PMC6625919</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Amide proton transfer magnetic resonance imaging of Alzheimer&#8217;s disease at 3.0 tesla: a preliminary study</article-title><source>Chin. Med. J.</source><year>2015</year><volume>128</volume><issue>5</issue><fpage>615</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.4103/0366-6999.151658</pub-id><pub-id pub-id-type="pmid">25698192</pub-id><pub-id pub-id-type="pmcid">PMC4834771</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Wang, R. et al. Amide proton transfer magnetic resonance imaging of Alzheimer&#8217;s disease at 3.0 tesla: a preliminary study. <italic toggle="yes">Chin. Med. J.</italic><bold>128</bold> (5), 615&#8211;619. 10.4103/0366-6999.151658 (2015).<pub-id pub-id-type="pmid">25698192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0366-6999.151658</pub-id><pub-id pub-id-type="pmcid">PMC4834771</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="data"><name name-style="western"><surname>Guo</surname><given-names>Z</given-names></name><etal/><year>2021</year><data-title>Amide Proton Transfer-Weighted MRI Might Help Distinguish Amnestic Mild Cognitive Impairment From a Normal Elderly Population</data-title><pub-id pub-id-type="doi">10.3389/fneur.2021.707030</pub-id><pub-id pub-id-type="pmcid">PMC8545995</pub-id><pub-id pub-id-type="pmid">34712196</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="data">Guo, Z. et al. Amide Proton Transfer-Weighted MRI Might Help Distinguish Amnestic Mild Cognitive Impairment From a Normal Elderly Population. <italic toggle="yes">Front. Neurol.</italic>, <bold>12</bold>: 707030. doi: 10.3389/fneur.2021.707030. (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2021.707030</pub-id><pub-id pub-id-type="pmcid">PMC8545995</pub-id><pub-id pub-id-type="pmid">34712196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>H</given-names></name><etal/></person-group><article-title>Application of amide proton transfer imaging in amnestic mild cognitive impairment[J]</article-title><source>J. Mol. Imaging</source><year>2022</year><volume>45</volume><issue>2</issue><fpage>199</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.12122/j.issn.1674-4500.2022.02.07</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Han, H. et al. Application of amide proton transfer imaging in amnestic mild cognitive impairment[J]. <italic toggle="yes">J. Mol. Imaging</italic>. <bold>45</bold> (2), 199&#8211;203. 10.12122/j.issn.1674-4500.2022.02.07 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Application of amide proton transfer magnetic resonance imaging in Alzheimer&#8217;s disease and mild cognitive Impairment[J]</article-title><source>Chin. J. Med. Imaging</source><year>2022</year><volume>30</volume><issue>5</issue><fpage>430</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.3969/j.issn.1005-5185.2022.05.003</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Wang, D. et al. Application of amide proton transfer magnetic resonance imaging in Alzheimer&#8217;s disease and mild cognitive Impairment[J]. <italic toggle="yes">Chin. J. Med. Imaging</italic>. <bold>30</bold> (5), 430&#8211;434. 10.3969/j.issn.1005-5185.2022.05.003 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Alterations of peripheral cytokines, BDNF, and surface-based morphometry indices in T2DM patients without cognitive impairment</article-title><source>Front. NeuroSci.</source><year>2023</year><volume>17</volume><fpage>1141261</fpage><pub-id pub-id-type="doi">10.3389/fnins.2023.1141261</pub-id><pub-id pub-id-type="pmid">37113152</pub-id><pub-id pub-id-type="pmcid">PMC10126356</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Lyu, W. et al. Alterations of peripheral cytokines, BDNF, and surface-based morphometry indices in T2DM patients without cognitive impairment. <italic toggle="yes">Front. NeuroSci.</italic><bold>17</bold>, 1141261. 10.3389/fnins.2023.1141261 (2023).<pub-id pub-id-type="pmid">37113152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2023.1141261</pub-id><pub-id pub-id-type="pmcid">PMC10126356</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachmann</surname><given-names>T</given-names></name><etal/></person-group><article-title>Longitudinal changes in surface based brain morphometry measures in amnestic mild cognitive impairment and Alzheimer&#8217;s disease</article-title><source>NeuroImage Clin.</source><year>2023</year><volume>38</volume><fpage>103371</fpage><pub-id pub-id-type="doi">10.1016/j.nicl.2023.103371</pub-id><pub-id pub-id-type="pmid">36924681</pub-id><pub-id pub-id-type="pmcid">PMC10025277</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Bachmann, T. et al. Longitudinal changes in surface based brain morphometry measures in amnestic mild cognitive impairment and Alzheimer&#8217;s disease. <italic toggle="yes">NeuroImage Clin.</italic><bold>38</bold>, 103371. 10.1016/j.nicl.2023.103371 (2023).<pub-id pub-id-type="pmid">36924681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2023.103371</pub-id><pub-id pub-id-type="pmcid">PMC10025277</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>A</given-names></name><etal/></person-group><article-title>Associations of cortical iron accumulation with cognition and cerebral atrophy in Alzheimer&#8217;s disease</article-title><source>Quant. Imaging Med. Surg.</source><year>2022</year><volume>12</volume><issue>9</issue><fpage>4570</fpage><lpage>4586</lpage><pub-id pub-id-type="doi">10.21037/qims-22-7</pub-id><pub-id pub-id-type="pmid">36060596</pub-id><pub-id pub-id-type="pmcid">PMC9403583</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Yang, A. et al. Associations of cortical iron accumulation with cognition and cerebral atrophy in Alzheimer&#8217;s disease. <italic toggle="yes">Quant. Imaging Med. Surg.</italic><bold>12</bold> (9), 4570&#8211;4586. 10.21037/qims-22-7 (2022).<pub-id pub-id-type="pmid">36060596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/qims-22-7</pub-id><pub-id pub-id-type="pmcid">PMC9403583</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Associations of quantitative susceptibility mapping with cortical atrophy and brain connectome in Alzheimer&#8217;s disease: a multi-parametric study</article-title><source>NeuroImage</source><year>2024</year><volume>290</volume><fpage>120555</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2024.120555</pub-id><pub-id pub-id-type="pmid">38447683</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Chen, H. et al. Associations of quantitative susceptibility mapping with cortical atrophy and brain connectome in Alzheimer&#8217;s disease: a multi-parametric study. <italic toggle="yes">NeuroImage</italic><bold>290</bold>, 120555. 10.1016/j.neuroimage.2024.120555 (2024).<pub-id pub-id-type="pmid">38447683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2024.120555</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Surface-based correlates of cognition along the Alzheimer&#8217;s continuum in a memory clinic population</article-title><source>Front. Neurol.</source><year>2023</year><volume>14</volume><fpage>1214083</fpage><pub-id pub-id-type="doi">10.3389/fneur.2023.1214083</pub-id><pub-id pub-id-type="pmid">37731852</pub-id><pub-id pub-id-type="pmcid">PMC10508059</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Coleman, M. M. et al. Surface-based correlates of cognition along the Alzheimer&#8217;s continuum in a memory clinic population. <italic toggle="yes">Front. Neurol.</italic><bold>14</bold>, 1214083. 10.3389/fneur.2023.1214083 (2023).<pub-id pub-id-type="pmid">37731852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2023.1214083</pub-id><pub-id pub-id-type="pmcid">PMC10508059</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Dickerson, B. C. et al. The cortical signature of Alzheimer&#8217;s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. <italic toggle="yes">Cerebral cortex (New York, NY 1991).</italic> 19(3), 497&#8211;510 (2009). 10.1093/cercor/bhn113<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhn113</pub-id><pub-id pub-id-type="pmcid">PMC2638813</pub-id><pub-id pub-id-type="pmid">18632739</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>N&#250;&#241;ez</surname><given-names>C</given-names></name><etal/></person-group><article-title>Different cortical gyrification patterns in Alzheimer&#8217;s disease and impact on memory performance</article-title><source>Ann. Neurol.</source><year>2020</year><volume>88</volume><issue>1</issue><fpage>67</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1002/ana.25741</pub-id><pub-id pub-id-type="pmid">32277502</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">N&#250;&#241;ez, C. et al. Different cortical gyrification patterns in Alzheimer&#8217;s disease and impact on memory performance. <italic toggle="yes">Ann. Neurol.</italic><bold>88</bold> (1), 67&#8211;80. 10.1002/ana.25741 (2020).<pub-id pub-id-type="pmid">32277502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25741</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berron</surname><given-names>D</given-names></name><etal/></person-group><article-title>Early stages of Tau pathology and its associations with functional connectivity, atrophy and memory</article-title><source>Brain: J. Neurol.</source><year>2021</year><volume>144</volume><issue>9</issue><fpage>2771</fpage><lpage>2783</lpage><pub-id pub-id-type="doi">10.1093/brain/awab114</pub-id><pub-id pub-id-type="pmcid">PMC8557349</pub-id><pub-id pub-id-type="pmid">33725124</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Berron, D. et al. Early stages of Tau pathology and its associations with functional connectivity, atrophy and memory. <italic toggle="yes">Brain: J. Neurol.</italic><bold>144</bold> (9), 2771&#8211;2783. 10.1093/brain/awab114 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awab114</pub-id><pub-id pub-id-type="pmcid">PMC8557349</pub-id><pub-id pub-id-type="pmid">33725124</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>B</given-names></name><etal/></person-group><article-title>Abnormal Tau in amyloid PET negative individuals</article-title><source>Neurobiol. Aging</source><year>2022</year><volume>109</volume><fpage>125</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2021.09.019</pub-id><pub-id pub-id-type="pmid">34715443</pub-id><pub-id pub-id-type="pmcid">PMC9695003</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Yoon, B. et al. Abnormal Tau in amyloid PET negative individuals. <italic toggle="yes">Neurobiol. Aging</italic>. <bold>109</bold>, 125&#8211;134. 10.1016/j.neurobiolaging.2021.09.019 (2022).<pub-id pub-id-type="pmid">34715443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2021.09.019</pub-id><pub-id pub-id-type="pmcid">PMC9695003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leuzy</surname><given-names>A</given-names></name><etal/></person-group><article-title>Biomarker-based prediction of longitudinal Tau positron emission tomography in Alzheimer disease</article-title><source>JAMA Neurol.</source><year>2022</year><volume>79</volume><issue>2</issue><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2021.4654</pub-id><pub-id pub-id-type="pmid">34928318</pub-id><pub-id pub-id-type="pmcid">PMC8689441</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Leuzy, A. et al. Biomarker-based prediction of longitudinal Tau positron emission tomography in Alzheimer disease. <italic toggle="yes">JAMA Neurol.</italic><bold>79</bold> (2), 149&#8211;158. 10.1001/jamaneurol.2021.4654 (2022).<pub-id pub-id-type="pmid">34928318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2021.4654</pub-id><pub-id pub-id-type="pmcid">PMC8689441</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schultz</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Widespread distribution of tauopathy in preclinical Alzheimer&#8217;s disease</article-title><source>Neurobiol. Aging</source><year>2018</year><volume>72</volume><fpage>177</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.08.022</pub-id><pub-id pub-id-type="pmid">30292840</pub-id><pub-id pub-id-type="pmcid">PMC6422832</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Schultz, S. A. et al. Widespread distribution of tauopathy in preclinical Alzheimer&#8217;s disease. <italic toggle="yes">Neurobiol. Aging</italic>. <bold>72</bold>, 177&#8211;185. 10.1016/j.neurobiolaging.2018.08.022 (2018).<pub-id pub-id-type="pmid">30292840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2018.08.022</pub-id><pub-id pub-id-type="pmcid">PMC6422832</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Insel</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Neuroanatomical spread of amyloid &#946; and Tau in Alzheimer&#8217;s disease: implications for primary prevention</article-title><source>Brain Commun.</source><year>2020</year><volume>2</volume><issue>1</issue><fpage>fcaa007</fpage><pub-id pub-id-type="doi">10.1093/braincomms/fcaa007</pub-id><pub-id pub-id-type="pmid">32140682</pub-id><pub-id pub-id-type="pmcid">PMC7048875</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Insel, P. S. et al. Neuroanatomical spread of amyloid &#946; and Tau in Alzheimer&#8217;s disease: implications for primary prevention. <italic toggle="yes">Brain Commun.</italic><bold>2</bold> (1), fcaa007. 10.1093/braincomms/fcaa007 (2020).<pub-id pub-id-type="pmid">32140682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcaa007</pub-id><pub-id pub-id-type="pmcid">PMC7048875</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hari</surname><given-names>E</given-names></name><etal/></person-group><article-title>Morphometric analysis of medial temporal lobe subregions in Alzheimer&#8217;s disease using high-resolution MRI</article-title><source>Brain Struct. Function</source><year>2023</year><volume>228</volume><issue>8</issue><fpage>1885</fpage><lpage>1899</lpage><pub-id pub-id-type="doi">10.1007/s00429-023-02683-2</pub-id><pub-id pub-id-type="pmid">37486408</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Hari, E. et al. Morphometric analysis of medial temporal lobe subregions in Alzheimer&#8217;s disease using high-resolution MRI. <italic toggle="yes">Brain Struct. Function</italic>. <bold>228</bold> (8), 1885&#8211;1899. 10.1007/s00429-023-02683-2 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00429-023-02683-2</pub-id><pub-id pub-id-type="pmid">37486408</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><etal/></person-group><article-title>The correlation between brain MR amide proton imaging and scores of clinical psychometric scales in patients with Alzheimer&#8217;s disease[J]</article-title><source>Chin. J. Magn. Reson. Imaging</source><year>2018</year><volume>9</volume><issue>3</issue><fpage>161</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.12015/issn.1674-8034.2018.03.001</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Wang, R. et al. The correlation between brain MR amide proton imaging and scores of clinical psychometric scales in patients with Alzheimer&#8217;s disease[J]. <italic toggle="yes">Chin. J. Magn. Reson. Imaging</italic>. <bold>9</bold> (3), 161&#8211;165. 10.12015/issn.1674-8034.2018.03.001 (2018).</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Correlation between MMSE and amide proton transfer, susceptibility-weighted imaging in Alzheimer&#8217;s disease[J]</article-title><source>Chin. J. Magn. Reson. Imaging</source><year>2020</year><volume>11</volume><issue>6</issue><fpage>406</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.12015/issn.1674-8034.2020.06.002</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Zhang, C., Zheng, Y. &amp; Wang, X. Correlation between MMSE and amide proton transfer, susceptibility-weighted imaging in Alzheimer&#8217;s disease[J]. <italic toggle="yes">Chin. J. Magn. Reson. Imaging</italic>. <bold>11</bold> (6), 406&#8211;410. 10.12015/issn.1674-8034.2020.06.002 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Amide proton transfer-weighted imaging of patients with Alzheimer&#8217;s disease[J]</article-title><source>Chin. Gen. Pract.</source><year>2022</year><volume>25</volume><issue>24</issue><fpage>3005</fpage><lpage>3012</lpage><pub-id pub-id-type="doi">10.12114/j.issn.1007-9572.2022.0093</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Li, J. et al. Amide proton transfer-weighted imaging of patients with Alzheimer&#8217;s disease[J]. <italic toggle="yes">Chin. Gen. Pract.</italic><bold>25</bold> (24), 3005&#8211;3012. 10.12114/j.issn.1007-9572.2022.0093 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Protein-based amide proton transfer-weighted MR imaging of amnestic mild cognitive impairment</article-title><source>NeuroImage Clin.</source><year>2020</year><volume>25</volume><fpage>102153</fpage><pub-id pub-id-type="doi">10.1016/j.nicl.2019.102153</pub-id><pub-id pub-id-type="pmid">31901792</pub-id><pub-id pub-id-type="pmcid">PMC6948365</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Zhang, Z. et al. Protein-based amide proton transfer-weighted MR imaging of amnestic mild cognitive impairment. <italic toggle="yes">NeuroImage Clin.</italic><bold>25</bold>, 102153. 10.1016/j.nicl.2019.102153 (2020).<pub-id pub-id-type="pmid">31901792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2019.102153</pub-id><pub-id pub-id-type="pmcid">PMC6948365</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Chang, H. I. et al. Impact of amyloid pathology in mild cognitive impairment subjects: the longitudinal cognition and surface morphometry data. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>23</bold> (23). 10.3390/ijms232314635 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms232314635</pub-id><pub-id pub-id-type="pmcid">PMC9738566</pub-id><pub-id pub-id-type="pmid">36498962</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>HI</given-names></name><etal/></person-group><article-title>Distinct biological property of Tau in Tau-first cognitive proteinopathy: evidence by longitudinal clinical neuroimaging profiles and compared with late-onset Alzheimer disease</article-title><source>J. Neuropsychiatry Clin. Neurosci.</source><year>2024</year><volume>78</volume><issue>8</issue><fpage>446</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1111/pcn.13680</pub-id><pub-id pub-id-type="pmcid">PMC11488611</pub-id><pub-id pub-id-type="pmid">38864501</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Chang, H. I. et al. Distinct biological property of Tau in Tau-first cognitive proteinopathy: evidence by longitudinal clinical neuroimaging profiles and compared with late-onset Alzheimer disease. <italic toggle="yes">J. Neuropsychiatry Clin. Neurosci.</italic><bold>78</bold> (8), 446&#8211;455. 10.1111/pcn.13680 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pcn.13680</pub-id><pub-id pub-id-type="pmcid">PMC11488611</pub-id><pub-id pub-id-type="pmid">38864501</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Mak, E. et al. In vivo coupling of tau pathology and cortical thinning in Alzheimer&#8217;s disease. <italic toggle="yes">Alzheimer&#8217;s Dementia (Amsterdam, Netherlands)</italic><bold>10</bold>: 678&#8211;687. (2018). 10.1016/j.dadm.2018.08.005<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadm.2018.08.005</pub-id><pub-id pub-id-type="pmcid">PMC6222030</pub-id><pub-id pub-id-type="pmid">30426064</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grignon</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cytoarchitectonic alterations in the supramarginal gyrus of late onset Alzheimer&#8217;s disease</article-title><source>Acta Neuropathol.</source><year>1998</year><volume>95</volume><issue>4</issue><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1007/s004010050816</pub-id><pub-id pub-id-type="pmid">9560018</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Grignon, Y. et al. Cytoarchitectonic alterations in the supramarginal gyrus of late onset Alzheimer&#8217;s disease. <italic toggle="yes">Acta Neuropathol.</italic><bold>95</bold> (4), 395&#8211;406. 10.1007/s004010050816 (1998).<pub-id pub-id-type="pmid">9560018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s004010050816</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dennis</surname><given-names>EL</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>PM</given-names></name></person-group><article-title>Functional brain connectivity using fMRI in aging and Alzheimer&#8217;s disease</article-title><source>Neuropsychol. Rev.</source><year>2014</year><volume>24</volume><issue>1</issue><fpage>49</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1007/s11065-014-9249-6</pub-id><pub-id pub-id-type="pmid">24562737</pub-id><pub-id pub-id-type="pmcid">PMC4109887</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Dennis, E. L., Thompson, P. M. Functional brain connectivity using fMRI in aging and Alzheimer&#8217;s disease. <italic toggle="yes">Neuropsychol. Rev.</italic><bold>24</bold> (1), 49&#8211;62. 10.1007/s11065-014-9249-6 (2014).<pub-id pub-id-type="pmid">24562737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11065-014-9249-6</pub-id><pub-id pub-id-type="pmcid">PMC4109887</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Zhao, Q. et al. Functional segregation of executive control network and frontoparietal network in Alzheimer&#8217;s disease. Cortex; a journal devoted to the study of the nervous system and behavior, <bold>120</bold>: 36&#8211;48. (2019). 10.1016/j.cortex.2019.04.026<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cortex.2019.04.026</pub-id><pub-id pub-id-type="pmid">31228791</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prawiroharjo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Disconnection of the right superior parietal lobule from the precuneus is associated with memory impairment in oldest-old Alzheimer&#8217;s disease patients</article-title><source>Heliyon</source><year>2020</year><volume>6</volume><issue>7</issue><fpage>e04516</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2020.e04516</pub-id><pub-id pub-id-type="pmid">32728647</pub-id><pub-id pub-id-type="pmcid">PMC7381702</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Prawiroharjo, P. et al. Disconnection of the right superior parietal lobule from the precuneus is associated with memory impairment in oldest-old Alzheimer&#8217;s disease patients. <italic toggle="yes">Heliyon</italic><bold>6</bold> (7), e04516. 10.1016/j.heliyon.2020.e04516 (2020).<pub-id pub-id-type="pmid">32728647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2020.e04516</pub-id><pub-id pub-id-type="pmcid">PMC7381702</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maleki Balajoo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Decoupling of regional neural activity and inter-regional functional connectivity in Alzheimer&#8217;s disease: a simultaneous PET/MR study</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2022</year><volume>49</volume><issue>9</issue><fpage>3173</fpage><lpage>3185</lpage><pub-id pub-id-type="doi">10.1007/s00259-022-05692-1</pub-id><pub-id pub-id-type="pmid">35199225</pub-id><pub-id pub-id-type="pmcid">PMC9250470</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Maleki Balajoo, S. et al. Decoupling of regional neural activity and inter-regional functional connectivity in Alzheimer&#8217;s disease: a simultaneous PET/MR study. <italic toggle="yes">Eur. J. Nucl. Med. Mol. Imaging</italic>. <bold>49</bold> (9), 3173&#8211;3185. 10.1007/s00259-022-05692-1 (2022).<pub-id pub-id-type="pmid">35199225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-022-05692-1</pub-id><pub-id pub-id-type="pmcid">PMC9250470</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lapoint</surname><given-names>MR</given-names></name><etal/></person-group><article-title>The association between Tau PET and retrospective cortical thinning in clinically normal elderly</article-title><source>NeuroImage</source><year>2017</year><volume>157</volume><fpage>612</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.05.049</pub-id><pub-id pub-id-type="pmid">28545932</pub-id><pub-id pub-id-type="pmcid">PMC5772972</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Lapoint, et al. The association between Tau PET and retrospective cortical thinning in clinically normal elderly. <italic toggle="yes">NeuroImage</italic><bold>157</bold>, 612&#8211;622. 10.1016/j.neuroimage.2017.05.049 (2017).<pub-id pub-id-type="pmid">28545932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2017.05.049</pub-id><pub-id pub-id-type="pmcid">PMC5772972</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Tracking pathophysiological processes in Alzheimer&#8217;s disease: an updated hypothetical model of dynamic biomarkers</article-title><source>Lancet Neurol.</source><year>2013</year><volume>12</volume><issue>2</issue><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(12)70291-0</pub-id><pub-id pub-id-type="pmid">23332364</pub-id><pub-id pub-id-type="pmcid">PMC3622225</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Jack, C. R. et al. Tracking pathophysiological processes in Alzheimer&#8217;s disease: an updated hypothetical model of dynamic biomarkers. <italic toggle="yes">Lancet Neurol.</italic><bold>12</bold> (2), 207&#8211;216. 10.1016/S1474-4422(12)70291-0 (2013).<pub-id pub-id-type="pmid">23332364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(12)70291-0</pub-id><pub-id pub-id-type="pmcid">PMC3622225</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurotherapeutics</journal-id><journal-id journal-id-type="iso-abbrev">Neurotherapeutics</journal-id><journal-id journal-id-type="pmc-domain-id">1472</journal-id><journal-id journal-id-type="pmc-domain">neurother</journal-id><journal-title-group><journal-title>Neurotherapeutics</journal-title></journal-title-group><issn pub-type="ppub">1933-7213</issn><issn pub-type="epub">1878-7479</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12491808</article-id><article-id pub-id-type="pmcid-ver">PMC12491808.1</article-id><article-id pub-id-type="pmcaid">12491808</article-id><article-id pub-id-type="pmcaiid">12491808</article-id><article-id pub-id-type="pmid">40701909</article-id><article-id pub-id-type="doi">10.1016/j.neurot.2025.e00706</article-id><article-id pub-id-type="pii">S1878-7479(25)00184-9</article-id><article-id pub-id-type="publisher-id">e00706</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of efavirenz in Niemann-Pick disease type C</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Gasc&#243;n-Bayarri</surname><given-names initials="J">Jordi</given-names></name><email>jordigneuro@bellvitgehospital.cat</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Rico</surname><given-names initials="I">Inmaculada</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>S&#225;nchez-Casta&#241;eda</surname><given-names initials="C">Cristina</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Ledesma</surname><given-names initials="MD">Mar&#237;a Dolores</given-names></name><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Carnaval</surname><given-names initials="T">Thiago</given-names></name><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Bejr-Kasem</surname><given-names initials="H">Helena</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Campdelacreu</surname><given-names initials="J">Jaume</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Ferrer</surname><given-names initials="A">Anna</given-names></name><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Rodr&#237;guez-Bel</surname><given-names initials="L">Laura</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Cos</surname><given-names initials="M">M&#243;nica</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>de Lama</surname><given-names initials="E">Eugenia</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff11" ref-type="aff">k</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>L&#243;pez de Munain</surname><given-names initials="A">Adolfo</given-names></name><xref rid="aff12" ref-type="aff">l</xref></contrib><contrib contrib-type="author" id="au13"><name name-style="western"><surname>Rouco</surname><given-names initials="I">Idoia</given-names></name><xref rid="aff13" ref-type="aff">m</xref></contrib><contrib contrib-type="author" id="au14"><name name-style="western"><surname>P&#233;rez-Sousa</surname><given-names initials="C">Celia</given-names></name><xref rid="aff14" ref-type="aff">n</xref></contrib><contrib contrib-type="author" id="au15"><name name-style="western"><surname>Cerd&#225;n</surname><given-names initials="M">Mar&#237;a</given-names></name><xref rid="aff15" ref-type="aff">o</xref></contrib><contrib contrib-type="author" id="au16"><name name-style="western"><surname>Muelas</surname><given-names initials="N">Nuria</given-names></name><xref rid="aff16" ref-type="aff">p</xref></contrib><contrib contrib-type="author" id="au17"><name name-style="western"><surname>Sevillano</surname><given-names initials="MD">Mar&#237;a Dolores</given-names></name><xref rid="aff17" ref-type="aff">q</xref></contrib><contrib contrib-type="author" id="au18"><name name-style="western"><surname>Mir</surname><given-names initials="P">Pablo</given-names></name><xref rid="aff18" ref-type="aff">r</xref></contrib><contrib contrib-type="author" id="au19"><name name-style="western"><surname>Villoria</surname><given-names initials="J">Jes&#250;s</given-names></name><xref rid="aff19" ref-type="aff">s</xref></contrib><contrib contrib-type="author" id="au20"><name name-style="western"><surname>Videla</surname><given-names initials="S">Sebasti&#225;n</given-names></name><xref rid="aff20" ref-type="aff">t</xref><xref rid="aff21" ref-type="aff">u</xref><xref rid="aff22" ref-type="aff">v</xref></contrib><aff id="aff1"><label>a</label>Neurology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain</aff><aff id="aff2"><label>b</label>Adult Lysosomal Diseases Clinical Expertise Unit, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain</aff><aff id="aff3"><label>c</label>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain</aff><aff id="aff4"><label>d</label>Department of Morphological Sciences, School of Medicine, Autonomous University of Barcelona, Bellaterra, Barcelona, Spain</aff><aff id="aff5"><label>e</label>Department of Clinical Psychology and Psychobiology, Neurosciencies Institute, University of Barcelona, Barcelona, Spain</aff><aff id="aff6"><label>f</label>Severo Ochoa Molecular Biology Center (CSIC-UAM), Madrid, Spain</aff><aff id="aff7"><label>g</label>Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, IDIBELL, University of Barcelona, Spain</aff><aff id="aff8"><label>h</label>Pharmacy Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain</aff><aff id="aff9"><label>i</label>Nuclear Medicine-PET/CT Department (IDI), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain</aff><aff id="aff10"><label>j</label>Neuroradiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain</aff><aff id="aff11"><label>k</label>Radiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain</aff><aff id="aff12"><label>l</label>Neurology Department, Donostia-Osakidetza University Hospital, San Sebastian, Spain</aff><aff id="aff13"><label>m</label>Neurology Department, Cruces University Hospital, Bilbao, Spain</aff><aff id="aff14"><label>n</label>Neurology Department, A Coru&#241;a University Hospital Complex, A Coru&#241;a, Spain</aff><aff id="aff15"><label>o</label>Neurology Department, Santa Luc&#237;a-Santa Mar&#237;a Rosell University Hospital, Cartagena, Spain</aff><aff id="aff16"><label>p</label>Neurology Department, La Fe University and Polytechnical Hospital, Valencia, Spain</aff><aff id="aff17"><label>q</label>Neurology Department, Salamanca University Hospital, Salamanca, Spain</aff><aff id="aff18"><label>r</label>Neurology and Clinical Neurophysiology Department, Seville Biomedical Institute, Virgen del Rocio University Hospital/CSIC/University of Seville, Seville, Spain</aff><aff id="aff19"><label>s</label>Design and Biometrics Department, Medicxact, S.L., Alpedrete, Spain</aff><aff id="aff20"><label>t</label>Clinical Research Support Unit, Clinical Pharmacology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain</aff><aff id="aff21"><label>u</label>Clinical Research Support Area, Clinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain</aff><aff id="aff22"><label>v</label>Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, Bellaterra, Spain</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>jordigneuro@bellvitgehospital.cat</email></corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>22</day><month>7</month><year>2025</year></pub-date><volume>22</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">498231</issue-id><elocation-id>e00706</elocation-id><history><date date-type="received"><day>16</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>27</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-04 13:25:42.290"><day>04</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Introduction</title><p>In search of disease-modifying treatments for the Niemann-Pick disease type C (NPC), this Phase II single-arm clinical trial evaluated the safety and efficacy of efavirenz, a reverse transcriptase inhibitor that potentially ameliorates neuronal cholesterol turnover, typically impaired in this rare lysosomal storage disorder.</p></sec><sec><title>Material and methods</title><p>Patients 14 years of age or older with genetically confirmed NPC received efavirenz 25 mg/day (Weeks 1&#8211;26) or 100 mg/day (Weeks 27&#8211;52) orally on top of standard care including miglustat. The primary endpoint was the proportion of response, defined as lack of deterioration in a composite outcome of cognitive performance. Secondary endpoints included the quantitative scores of several clinical neuropsychological assessment tools, some relevant neurological signs and symptoms, and imaging and biological specimen-based biomarkers. Measures were taken repeatedly over time and were analyzed using generalized linear mixed models.</p></sec><sec><title>Results</title><p>Sixteen patients 15&#8211;60 years of age were enrolled. All (100.0 %, 95 % exact confidence interval: 79.4&#8211;100.0 %) met the primary endpoint response criterion at Week 52. Quantitative neuropsychological assessments yielded more nuanced results, with relative preservation of learning, memory and executive control, and subtle impairments of verbal fluency, selective and divided attention, and cognitive inhibition. Some patients had better responses than others, allowing us to set two well-differentiated subgroups that differed essentially in the time since symptoms onset. No efavirenz-related or serious adverse events were reported.</p></sec><sec><title>Conclusion</title><p>Efavirenz appears to be a safe, easy-to-use, new targeted therapeutic option which slows the rate of NPC progression. The benefits of efavirenz are greater if started earlier.</p></sec><sec><title>Trial Registration</title><p>Registered on the European Union Clinical Trials Register (EurdraCT) on December 20th, 2019 under the number: 2019-004498-18 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004498-18/ES/" id="intref0010">https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004498-18/ES/</ext-link>). The first patient was enrolled on May 25th, 2022.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Clinical trial</kwd><kwd>Dementia</kwd><kwd>Lipid metabolism disorders</kwd><kwd>Lysosomal storage diseases</kwd><kwd>Neurodegenerative diseases</kwd><kwd>Neuropsychological tests</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Niemann-Pick disease type C (NPC) is a rare autosomal recessive lysosomal storage disorder linked to abnormal intracellular lipid trafficking [<xref rid="bib1" ref-type="bibr">1</xref>]. It is caused by mutations in either the <italic toggle="yes">Npc1</italic> or <italic toggle="yes">Npc2</italic> genes&#8212;the latter being mutated in only 5 &#8203;% of patients [<xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>]. NPC1 and NPC2 are ubiquitous lysosomal membrane and luminal proteins involved in intracellular cholesterol transportation [<xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>]. Therefore, the endgame of defective NPC1/NPC2 proteins is the intracellular accumulation of unesterified cholesterol and glycosphingolipids within the late endolysosomal compartment, a biochemical hallmark of NPC (Supplemental Material, <xref rid="appsec1" ref-type="sec">Fig. S1</xref>) [<xref rid="bib7" ref-type="bibr">7</xref>,<xref rid="bib8" ref-type="bibr">8</xref>].</p><p id="p0015">NPC has an overall estimated incidence of 1:100,000 live births, although late-onset phenotypes may have higher incidence [<xref rid="bib9" ref-type="bibr">9</xref>]. Disease onset can occur anywhere throughout the lifespan [<xref rid="bib3" ref-type="bibr">3</xref>], and features a highly heterogeneous phenotypic spectrum. Although classically described as a neurovisceral condition (each component following independent clinical courses) [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib10" ref-type="bibr">10</xref>], the systemic component (liver, spleen, and sometimes lungs) is often less clinically significant&#8212;except in a small subset of newborns dying within the first 6 months after birth from hepatic or respiratory failure [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib11" ref-type="bibr">11</xref>]. In turn, neurodegenerative involvement&#8212;with vertical supranuclear saccadic palsy, progressive cerebellar ataxia, dysarthria, dysphagia and dementia, is the main feature in 90 &#8203;% of cases, aside from this subset of neonatal patients and a few anecdotal adult cases [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib11" ref-type="bibr">11</xref>].</p><p id="p0020">Although current pathophysiological knowledge of lipid dynamics within the central nervous system (CNS) in NPC disease is limited, we already have important insights. The abundance of NPC1 in axon terminals and synaptosomes [<xref rid="bib12" ref-type="bibr">12</xref>,<xref rid="bib13" ref-type="bibr">13</xref>], where appropriate cholesterol distribution and elimination is essential for the correct development of long-term potentiation (LTP)&#8212;a major event in synaptic plasticity [<xref rid="bib14" ref-type="bibr">14</xref>], suggests that neurons may be particularly vulnerable to NPC1/NPC2 loss-of-function. Furthermore, since neurons have high cholesterol requirements to keep membrane and synaptic functions, defective NPC1/NPC2 proteins may ultimately lead to neurodegeneration by undermining the ability of the late endosome/lysosome system to supply cholesterol [<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib16" ref-type="bibr">16</xref>].</p><p id="p0025">Notably, although NPC occurs throughout the CNS, certain regions are more prone to early and severe injury and give rise to some disease hallmarks [<xref rid="bib1" ref-type="bibr">1</xref>], particularly ataxia, dysarthria, and dysphagia (due to cerebellar Purkinje cell loss) [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib17" ref-type="bibr">17</xref>], dementia and seizures (caused by brain cortical lesions) [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib17" ref-type="bibr">17</xref>], and the characteristic vertical supranuclear gaze palsy (VSGP, resulting from severe cell loss in the rostral interstitial nucleus of the medial longitudinal fasciculus) [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib18" ref-type="bibr">18</xref>]. Although the basis for this selective neuronal vulnerability remains unclear, the absence of redundant neural circuitry might be a partial explanation [<xref rid="bib17" ref-type="bibr">17</xref>,<xref rid="bib19" ref-type="bibr">19</xref>].</p><p id="p0030">Although a number of molecules have been investigated over the last decades as potential treatments for NPC [<xref rid="bib20" ref-type="bibr">20</xref>], the inhibitor of glucosylceramide synthase miglustat is the only drug registered for clinical use [<xref rid="bib21" ref-type="bibr">21</xref>]. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) holding a market authorization for anti-human immunodeficiency virus (HIV) therapy for up to 25 years [<xref rid="bib22" ref-type="bibr">22</xref>]. Efavirenz is known to interact with different components of the cytochrome P450 enzyme system [<xref rid="bib23" ref-type="bibr">23</xref>], including the CYP46A1 (<italic toggle="yes">i.e.</italic>, cholesterol 24-hydroxylase), a CNS- specialized enzyme responsible for neuronal cholesterol turnover [<xref rid="bib24" ref-type="bibr">24</xref>]. Disturbances in levels of 24-hydroxycholesterol have been detected in NPC mice and human patients [<xref rid="bib25" ref-type="bibr">25</xref>]. Interestingly, animal studies have suggested that 24-hydroxycholesterol cerebrospinal fluid (CSF) and plasma levels are potential biomarkers of several neurodegenerative diseases [<xref rid="bib26" ref-type="bibr">26</xref>], which improve after potentiating CYP46A1 activity [<xref rid="bib27" ref-type="bibr">[27]</xref>, <xref rid="bib28" ref-type="bibr">[28]</xref>, <xref rid="bib29" ref-type="bibr">[29]</xref>, <xref rid="bib30" ref-type="bibr">[30]</xref>, <xref rid="bib31" ref-type="bibr">[31]</xref>]. Efavirenz was shown to enhance CYP46A1 activity at typically low-doses [<xref rid="bib32" ref-type="bibr">32</xref>], which normalized the <italic toggle="yes">in vivo</italic> synaptic cholesterol levels, LTP, and cognitive abilities in <italic toggle="yes">NPC1</italic><sup>nmf164</sup> mice (a late-onset NPC disease model), while extending their lifespan by 30 &#8203;% [<xref rid="bib33" ref-type="bibr">33</xref>]. In turn, a recently published pilot clinical trial demonstrated the ability of repeated low doses of efavirenz to enhance CYP46A1 activity in patients with early Alzheimer's disease [<xref rid="bib34" ref-type="bibr">34</xref>].</p><p id="p0035">Considering this pathophysiological knowledge and the promising results, we hypothesized that efavirenz's potentiation of CYP46A1 activity could compensate for NPC1 deficiency and improve synaptic function, therefore counteracting or even ameliorating the characteristic cognitive and psychiatric alterations of the CNS disease of NPC patients. The present clinical trial was conducted to assess the efficacy and safety of efavirenz in late-juvenile/adult-onset NPC patients over 52 weeks of treatment, in addition to standard care treatment, using a complete set of neuropsychological, neurological and biological outcomes.</p></sec><sec id="sec2"><title>Materials and Methods</title><sec id="sec2.1"><title>Trial design and oversight</title><p id="p0040">The study consisted of a single-center, phase II, single-arm clinical trial of efavirenz on top of standard care treatment over 52 (&#177;2) weeks for late-juvenile/adult-onset NPC patients (EudraCT: 2019-004498-18). The trial was performed at the Bellvitge University Hospital and was sponsored by the Bellvitge University Hospital and the Severo Ochoa Molecular Biology Center, both non-commercial. Patients were recruited in 2022, between May 25th and December 14th. Funding was provided by the not-for-profit Spanish Niemann-Pick Foundation. All investigators and the trial site were bound by confidentiality agreements according to current Spanish and European legislations.</p><p id="p0045">The study protocol, available in the Supplemental Material, received Institutional Review Board approval, and all patients and/or their legal representatives provided written informed consent before enrollment. This trial was conducted in accordance with the terms of the Declaration of Helsinki, Good Clinical Practice guidelines, and all applicable regulatory requirements. All authors had access to the trial data and vouch for its accuracy and completeness and for the fidelity of the trial to the protocol&#8212;the full text can be found at the Supplemental Material, and a dedicated publication is available elsewhere [<xref rid="bib35" ref-type="bibr">35</xref>].</p></sec><sec id="sec2.2"><title>Patients</title><p id="p0050">Eligible patients had to be 14 years of age or older, of either sex, with a genetically confirmed diagnosis of late-juvenile/adult-onset (onset of symptoms&#8212;see below&#8212; at or after 14 years of age) NPC and a global Clinical Dementia Rating (CDR) score of between 0.5 and 2 or a CDR-Sum of Boxes (SB) &#8804;12 (<italic toggle="yes">i.e.</italic>, mild to moderate cognitive impairment), at least 8 years of schooling, and under treatment with miglustat. Patients with chronic liver disease or unstable epilepsy were excluded. See the Supplemental Material (<xref rid="appsec1" ref-type="sec">Table S1</xref>) for the full list of eligibility criteria and prohibited concomitant medications during the trial.</p></sec><sec id="sec2.3"><title>Trial procedures</title><p id="p0055">All included participants started receiving efavirenz 25 &#8203;mg/day orally for 52 weeks in addition to standard care treatment, including miglustat. The trial featured a baseline screening visit (V1), conducted 30&#8211;60 days before treatment start (V2). Participants' sociodemographic characteristics and medical history were collected at this visit. These included the time since the onset of symptoms, which was mostly based on patients' or patient relatives' recall of the moment when first difficulties arose. A first follow-up visit (V2.1) was performed at 4 weeks (&#177;3 days), and subsequent follow-up visits (V3, V4, V5, and V6) were performed at 13-week intervals after V2. The study's main procedures are summarized and displayed in the Supplemental Material (<xref rid="appsec1" ref-type="sec">Fig. S2</xref>); lumbar punctures were not mandatory for trial participation and an additional written informed consent was required for this procedure.</p><p id="p0060">Efavirenz dose selection was based on preclinical studies [<xref rid="bib32" ref-type="bibr">32</xref>,<xref rid="bib33" ref-type="bibr">33</xref>] and on an ongoing (at the time of writing the protocol) clinical trial with efavirenz for Alzheimer's dementia (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03706885">NCT03706885</ext-link>). Of note, the starting dose of efavirenz is 6-fold lower than that recommended for anti-HIV therapy, and was increased to 100 &#8203;mg/day at V4, approximately 6 months from the start, to maximize efficacy. Additional details on the trial design, methods, rationale for dose selection, and objectives can be found elsewhere [<xref rid="bib35" ref-type="bibr">35</xref>].</p></sec><sec id="sec2.4"><title>Outcomes</title><p id="p0065">Given the relevance of cognitive disturbances in adult-onset NPC, we based the primary efficacy outcome on cognitive performance. We used a composite qualitative measure to assess the change from baseline in 3 domains (<italic toggle="yes">i.e.</italic>, dementia severity, verbal memory, and executive functioning). Patients were considered responders if they lacked deterioration in at least 2 of these domains.</p><p id="p0070">Dementia severity was quantified by the CDR-SB (scores range from 0 to 18, with higher scores indicating greater impairment); dementia progression was defined as a &#8805;2-point CDR-SB increase. Verbal memory assessment was carried out with the Free and Cued Selective Reminding Test (FCSRT), and a decrease &#8805;1 standard deviation (SD) was used to define verbal memory deterioration.</p><p id="p0075">Because of the complexity and multidimensionality of executive functioning assessment, different test components were used: (i) the digit span subtests of the revised Barcelona Test (r-BT); (ii) the mental control subtests of the r-BT; (iii) the semantic and phonemic tasks of the Verbal Fluency Test (VFT); (iv) the Trail Making Test (TMT) A and B; and (v) the Stroop Color-Word Interference Test (SCWT). They together provide a comprehensive functional assessment including selective (mainly via the TMT A and r-BT) and divided attention (TMT B), working memory (r-BT and VFT), executive control (Phonemic VFT), mental flexibility (TMT), information processing speed, cognitive flexibility, and cognitive inhibition (TMT B, SCWT). Executive functioning deterioration was assessed using both, a soft criterion&#8212;a &#8805;1-SD worsening in 2 or more of these five executive functioning component tests&#8212;and a strict criterion&#8212;a &#8805;1-SD reduction in 2 or more individual executive functioning tests scores (<italic toggle="yes">i.e</italic>., r-BT, semantic task, TMT A, TMT B, SCWT). Detailed descriptions of each neuropsychological assessment can be found in the Supplemental Material (<xref rid="appsec1" ref-type="sec">Supplemental Methods</xref>).</p><p id="p0080">Secondary efficacy outcomes were divided in neuropsychological, neurological, and biological. Secondary neuropsychological outcomes included the individual scores of each neuropsychological instrument used in the composite primary outcome and the following scores: (i) global CDR; (ii) Boston naming test (BNT); (iii) judgment of line orientation (JLO) test; (iv) dysexecutive questionnaire (DEX); (v) neuropsychiatric inventory questionnaire (NPI); (vi) apathy evaluation scale (AES); (vii) Beck depression inventory (BDI).</p><p id="p0085">Secondary neurological outcomes consisted of changes from baseline through week 52 in the total score on 4 different scales: (i) the Scale for the Assessment and Rating of Ataxia (SARA); (ii) the Eating Assessment Tool for dysphagia (EAT-10); (iii) the Pineda Disability Scale (PDS); and (iv) the block design and symbol search subtests of the Wechsler Adult Intelligence Scale III (WAIS-III). Higher scores in these scales indicate greater ataxia, dysphagia, disability, and higher cognitive abilities, respectively.</p><p id="p0090">Secondary biological outcomes included, among others, brain imaging, CSF proteins, and plasma 24-hydroxycholesterol levels.</p><p id="p0095">Safety outcomes included the cumulative incidence and seriousness of adverse events.</p></sec><sec id="sec2.5"><title>Statistical analysis</title><p id="p0100">All collected data were described using appropriate descriptive statistics, including means (SD) and medians (ranges) for continuous variables, as well as numbers and frequencies for categorical variables. Except for the global CDR and the CDR-SB, all neuropsychological tests had their scores mapped into norms-based scaled scores (mean &#8203;= &#8203;10, SD &#8203;= &#8203;3) for the healthy Spanish population, with higher scores invariably reflecting better clinical states (see the references provided in the Supplemental Material).</p><p id="p0105">Notably, some patients had better responses to efavirenz than others, allowing us to set 2 well-differentiated subgroups of patients, namely a favorable response (FR) subgroup featuring improvements in most of the assessments and an unfavorable response (UR) one (<italic toggle="yes">i.e.</italic>, with worsening/unchanged results despite efavirenz). For that purpose, we used a semi-automated discriminant analysis to classify patients into these two subgroups before proceeding with the remaining analyses (Supplemental Material, <xref rid="appsec1" ref-type="sec">Fig. S3</xref>).</p><p id="p0110">The primary outcome was analyzed as a Binomial proportion, for which exact Binomial 95 &#8203;% confidence intervals (CI) were calculated. Adjusted means of scale scores and their 95 &#8203;% CI were calculated at each study visit using generalized linear mixed models for repeated measures with a Gamma distribution for errors and a logarithmic link function. Note that these models are a general case of the analyses of covariance foreseen in the study protocol [<xref rid="bib35" ref-type="bibr">35</xref>], and may be a valid framework for imputing missing data. These models were also used to explore factors associated with response, including the SARA and PDS scores as dynamic (<italic toggle="yes">i.e.</italic>, changing over time) fixed factors, and age, subgroup, and time from symptom onset as static (baseline) fixed factors. We also performed a <italic toggle="yes">post-hoc</italic> analysis of the sensitivity to change of the component tests of the primary efficacy outcome by calculating some effect size measures (Cohen's <italic toggle="yes">d</italic> and Guyatt indices, and standardized mean responses) to ascertain those most sensitive to changes in disease status throughout treatment.</p><p id="p0115">Since NPC is quite an uncommon condition, we were able to recruit most subjects from the target population since the study site is a reference center of the Spanish National Health System for NPC adult patients. For this reason, we did not perform formal sample size calculations, but rather based the planned number of 14 participants on pragmatic grounds. Because this sample exceeds half the size of the target population (to date, only 27 adult patients have been diagnosed with NPC in Spain), uncertainty measures (such as confidence intervals) do not have the inferential role emanating from sampling theory but should rather be viewed as credibility margins. Although Bayesian credible intervals would fit such a role more appropriately, their calculation was outside the scope of this study, and we deem that the confidence intervals are a conservative (<italic toggle="yes">i.e.</italic>, wider) replacement.</p><p id="p0120">All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>Patients</title><p id="p0125">In total, 17 patients were screened for eligibility. One (5.9 &#8203;%) patient failed NPC diagnosis confirmation based on genetic testing and was excluded; ultimately, a total of 16 (94.1 &#8203;%), who attended all study visits, were analyzed (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). The median (range) age was 41.5 (15.0&#8211;60.0) years and 11 (68.8 &#8203;%) of them were males. The median (range) age at diagnosis was 29.5 (8.0&#8211;41.0) years, which was similar in both subgroups. The time since symptom onset (median: 21 years, range: 5&#8211;54 years) was shorter in the FR subgroup than in the UR subgroup (<xref rid="tbl1" ref-type="table">Table 1</xref>). Noteworthy, most patients of the FR subgroup had disease durations of under 10 years (third quartile: 12 years), but these were considerably longer in patients of the UR subgroup (first quartile: 24 years). All patients completed the trial; their demographic and baseline characteristics are shown in <xref rid="tbl1" ref-type="table">Table 1</xref>.<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>STROBE flow diagram.</p></caption><alt-text id="alttext0020">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Demographics and baseline characteristics.</p></caption><alt-text id="alttext0040">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Characteristic</th><th colspan="1" rowspan="1">Favorable Response<hr/></th><th colspan="1" rowspan="1">Unfavorable Response<hr/></th><th colspan="1" rowspan="1">Total<hr/></th></tr><tr><th colspan="1" rowspan="1">n &#8203;= &#8203;7</th><th colspan="1" rowspan="1">n &#8203;= &#8203;9</th><th colspan="1" rowspan="1">n &#8203;= &#8203;16</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age (years), median (range)</td><td colspan="1" rowspan="1">40 (22&#8211;48)</td><td colspan="1" rowspan="1">43 (15&#8211;60)</td><td colspan="1" rowspan="1">41.5 (15&#8211;60)</td></tr><tr><td colspan="4" rowspan="1">Sex, n (%)</td></tr><tr><td colspan="1" rowspan="1">&#160;Male</td><td align="char" colspan="1" rowspan="1">4 (57.1)</td><td align="char" colspan="1" rowspan="1">7 (77.8)</td><td align="char" colspan="1" rowspan="1">11 (68.9)</td></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td align="char" colspan="1" rowspan="1">3 (42.9)</td><td align="char" colspan="1" rowspan="1">2 (22.2)</td><td align="char" colspan="1" rowspan="1">5 (31.3)</td></tr><tr><td colspan="1" rowspan="1">Age at diagnosis (years), median (range)</td><td colspan="1" rowspan="1">30.0 (17.0&#8211;41.0)</td><td colspan="1" rowspan="1">29.0 (8.0&#8211;39.0)</td><td colspan="1" rowspan="1">29.5 (8.0&#8211;41.0)</td></tr><tr><td colspan="1" rowspan="1">Time since symptom onset (years), median (range)<xref rid="tbl1fnb" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1">8 (6&#8211;34)</td><td colspan="1" rowspan="1">27 (5&#8211;54)</td><td colspan="1" rowspan="1">21 (5&#8211;54)</td></tr><tr><td colspan="1" rowspan="1">Education (years completed), median (range)</td><td colspan="1" rowspan="1">12 (9&#8211;20)</td><td colspan="1" rowspan="1">11 (8&#8211;14)</td><td colspan="1" rowspan="1">11.5 (8&#8211;20)</td></tr><tr><td colspan="1" rowspan="1">Body weight (Kg), median (range)</td><td colspan="1" rowspan="1">62.0 (56.0&#8211;72.3)</td><td colspan="1" rowspan="1">66.0 (53.0&#8211;80.0)</td><td colspan="1" rowspan="1">65.0 (53.0&#8211;80.0)</td></tr><tr><td colspan="1" rowspan="1">Height (cm), median (range)</td><td colspan="1" rowspan="1">170 (158&#8211;180)</td><td colspan="1" rowspan="1">171 (156&#8211;178)</td><td colspan="1" rowspan="1">171 (156&#8211;180)</td></tr><tr><td colspan="1" rowspan="1">Right brain dominance, n (%)</td><td align="char" colspan="1" rowspan="1">0 (0)<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td align="char" colspan="1" rowspan="1">6 (75.0)<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td align="char" colspan="1" rowspan="1">6 (46.2)</td></tr><tr><td colspan="4" rowspan="1">Harmful habits, n (%)</td></tr><tr><td colspan="1" rowspan="1">&#160;Smoking (active)</td><td align="char" colspan="1" rowspan="1">2 (28.6)</td><td align="char" colspan="1" rowspan="1">0 (0)</td><td align="char" colspan="1" rowspan="1">2 (12.5)</td></tr><tr><td colspan="1" rowspan="1">&#160;Alcohol intake</td><td align="char" colspan="1" rowspan="1">0 (0)</td><td align="char" colspan="1" rowspan="1">0 (0)</td><td align="char" colspan="1" rowspan="1">0 (0)</td></tr><tr><td colspan="4" rowspan="1">Past medical history, n (%)</td></tr><tr><td colspan="1" rowspan="1">&#160;Dyslipidemia</td><td align="char" colspan="1" rowspan="1">0 (0)</td><td align="char" colspan="1" rowspan="1">1 (11.1)</td><td align="char" colspan="1" rowspan="1">1 (6.3)</td></tr><tr><td colspan="1" rowspan="1">&#160;Psychiatric disorders</td><td align="char" colspan="1" rowspan="1">0 (0)</td><td align="char" colspan="1" rowspan="1">1 (11.1)</td><td align="char" colspan="1" rowspan="1">1 (6.3)</td></tr><tr><td colspan="1" rowspan="1">&#160;Neonatal jaundice</td><td align="char" colspan="1" rowspan="1">0 (0)</td><td align="char" colspan="1" rowspan="1">4 (44.4)</td><td align="char" colspan="1" rowspan="1">4 (25.0)</td></tr><tr><td colspan="1" rowspan="1">Family history of neurodegenerative disorders, n (%)</td><td align="char" colspan="1" rowspan="1">4 (57.1)</td><td align="char" colspan="1" rowspan="1">3 (33.3)</td><td align="char" colspan="1" rowspan="1">7 (43.8)</td></tr><tr><td colspan="1" rowspan="1">Family history of metabolic disorders, n (%)</td><td align="char" colspan="1" rowspan="1">2 (28.6)</td><td align="char" colspan="1" rowspan="1">1 (11.1)</td><td align="char" colspan="1" rowspan="1">3 (18.8)</td></tr><tr><td colspan="1" rowspan="1">Motor delay, n (%)</td><td align="char" colspan="1" rowspan="1">4 (57.1)</td><td align="char" colspan="1" rowspan="1">7 (77.8)</td><td align="char" colspan="1" rowspan="1">11 (68.8)</td></tr><tr><td colspan="1" rowspan="1">Cognitive impairment, n (%)</td><td align="char" colspan="1" rowspan="1">5 (71.4)</td><td align="char" colspan="1" rowspan="1">9 (100.0)</td><td align="char" colspan="1" rowspan="1">14 (87.5)</td></tr></tbody></table><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0010">Two patients (28.6 &#8203;%) in the Favorable Response and one (11.1 &#8203;%) in the Unfavorable Response group had missing values. Percentages in the table are calculated over the total number of patients with available results.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0015">Based on patients' or patient relatives' recall of the moment when first difficulties arose.</p></fn></table-wrap-foot></table-wrap></p><p id="p0130">Overall, they had mild cognitive impairment at baseline, poor memory performance and moderate executive functioning deficits. All patients met the most restrictive genetic inclusion criterion of showing at least 2 NPC-related mutations; all but one (93.8 &#8203;%) had cerebral and thalamic hypometabolism, and all had cerebellar hypometabolism at baseline; however, only 4 (25.0 &#8203;%) and 6 (37.5 &#8203;%) showed brain and cerebellar atrophy, respectively. Splenomegaly was evidenced in 11 (68.8 &#8203;%) patients.</p></sec><sec id="sec3.2"><title>Primary efficacy outcome</title><p id="p0135">All 16 (100.0 &#8203;%, exact 95 &#8203;% CI: 79.4&#8211;100.0 &#8203;%) patients responded to efavirenz at week 52 (V6), meeting both strict and soft response criteria (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). Of these, 15 (93.7 &#8203;%, exact 95 &#8203;% CI: 69.8&#8211;99.8 &#8203;%) had already responded at V4, sustaining such a response at V6 for both criteria. The remaining patient presented deterioration of all cognitive performance domains at V4; however, these improved at V6 and, herewith, became a responder.<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Proportion of patients presenting deterioration in each neuropsychological milestone and proportion of responders to efavirenz. CDR-SB, Clinical Dementia Rating scale &#8211; Sum of Boxes; FCSRT, Free and Cued Selective Reminding Test; r-BT, revised Barcelona Test; TMT, Trail Making Test; SCWT, Stroop Color-Word Interference Test. (A) Percentage (exact 95 &#8203;% CI) of patients presenting deterioration in each cognitive performance domain at visits 4 (lighter colors) and 6 (darker colors). (B) Percentage (exact 95 &#8203;% CI) of responders at visits 4 (lighter colors) and 6 (darker colors).</p></caption><alt-text id="alttext0025">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec3.3"><title>Secondary efficacy outcomes</title><p id="p0140">Results for the secondary efficacy outcomes are presented for the whole sample and for the FR and UR subgroups.</p><sec id="sec3.3.1"><title>Secondary neuropsychological outcomes</title><p id="p0145">The FR subgroup featured a downward trend (toward improvement) in the global CDR score (<xref rid="fig3" ref-type="fig">Fig. 3</xref>A), while the CDR-SB showed no apparent changes (<xref rid="fig3" ref-type="fig">Fig. 3</xref>B). Conversely, the UR subgroup had upward (worsening) trends in both the CRD and CDR-SB scores. There were significant differences between subgroups that persisted even after adjusting for the time since symptom onset.<fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Evolution of adjusted (least square) mean scores (95 &#8203;% CI) of the components of the composite primary outcome throughout the trial. CDR, Clinical Dementia Rating scale; CDR-SB, Clinical Dementia Rating scale &#8211; Sum of Boxes; FCSRT, Free and Cued Selective Reminding Test; r-BT, revised Barcelona Test; TMT, Trail Making Test; SCWT, Stroop Color-Word Interference Test; V4, visit 4; V6, visit 6. The blue band within each scaled score indicates the mean and &#177;1 standard deviation for the scaled scores (mean &#8203;= &#8203;10, SD &#8203;= &#8203;3). Of note, due to the non-proportional relationship between raw and scaled scores, the 95 &#8203;% CI limits do not necessarily reflect the actual (sample) distribution of the scaled scores; however, this distortion does not affect the adjusted means (point estimates). P values come from adjusted analyses (for age, time from symptom onset, ataxia and disability scores) and reflect the effects of changes over time in both subgroups combined (visit factor), sustained differences between subgroups (group factor), and differences in time trajectories between subgroups (visit &#8203;&#215; &#8203;group factor).</p></caption><alt-text id="alttext0030">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0150">Verbal memory improved in the FR subgroup; both the free recall (<xref rid="fig3" ref-type="fig">Fig. 3</xref>C) and cued recall (<xref rid="fig3" ref-type="fig">Fig. 3</xref>D) adjusted mean scores reached the reference band contained within &#177;1 SD of the mean population scaled score. On the other hand, the UR subgroup showed a mild free recall improvement at V6 while presenting a slight progressive decline in its cued recall. There were significant differences between subgroups that persisted even after adjusting for the time since symptom onset.</p><p id="p0155">Results varied among the different components making up the executive functioning assessment. The FR subgroup presented better adjusted mean scores at V6 on both r-BT digit span components (<xref rid="fig3" ref-type="fig">Fig. 3</xref>E and F); however, it remained unchanged for the r-BT mental control component&#8212;despite the remarkable improvement at V4 that produced an inverted V-shaped curve (<xref rid="fig3" ref-type="fig">Fig. 3</xref>G)&#8212;and progressively deteriorated for the time to complete the mental control component (<xref rid="fig3" ref-type="fig">Fig. 3</xref>H). In turn, the UR subgroup presented progressive declines in both r-BT digit span subtests, whilst the time component of the mental control subtest showed a V-shaped curve (<xref rid="fig3" ref-type="fig">Fig. 3</xref>G). The differences between subgroups were not significant, except for the time trajectories of the latter (<xref rid="fig3" ref-type="fig">Fig. 3</xref>G).</p><p id="p0160">All components of the VFT (<xref rid="fig3" ref-type="fig">Fig. 3</xref>I and J), TMT A (<xref rid="fig3" ref-type="fig">Fig. 3</xref>K), and TMT B (<xref rid="fig3" ref-type="fig">Fig. 3</xref>L) showed poor scores at baseline and worsening trends during the study. Notably, both subgroups presented improvements in the semantic task of the VFT and the TMT A at V4. Still, they had subsequent declines at V6, thus presenting similar trajectories in both tests (<xref rid="fig3" ref-type="fig">Fig. 3</xref>I and K). There were significant differences between subgroups in verbal fluency scores that persisted after adjusting for the time since symptom onset.</p><p id="p0165">Except for the Interference scores (<xref rid="fig3" ref-type="fig">Fig. 3</xref>P) SCWT scores were in general poor at all study assessments (<xref rid="fig3" ref-type="fig">Fig. 3</xref>M&#8211;P). The FR subgroup had slightly better scores at the Word-Color and Interference components than the UR subgroup, and this difference even increased a little during the study. Conversely, Interference scores worsened between V4 and V6 in the UR subgroup. Word-Color and Interference scores differed significantly between subgroups even after adjusting for the time since symptom onset.</p><p id="p0170">As a corollary, improvements and deteriorations were observed in 5 and 7 patients, respectively, for dementia scores, 7 and 3 patients, respectively, for verbal memory scores, and 5 and 8 patients, respectively, for executive functioning scores (Supplemental Material, <xref rid="appsec1" ref-type="sec">Fig. S3</xref>), all constituting the primary efficacy outcome.</p><p id="p0175">Last, the FR subgroup presented slight improvements in all remaining neuropsychological tests performed, with higher BNT (naming and fluency components) and JLO mean scores and lower DEX (particularly in the self-assessed version), NPI, AES, and BDI mean scores at V6 (Supplemental Material, <xref rid="appsec1" ref-type="sec">Fig. S4</xref>). On the other hand, the UR subgroup presented improvements in the BNT naming component, NPI and AES, but not in the remaining tests.</p><p id="p0180">Individual trajectories are available in the Supplemental Material (<xref rid="appsec1" ref-type="sec">Fig. S5</xref>).</p></sec><sec id="sec3.3.2"><title><italic toggle="yes">Post hoc</italic> analysis</title><p id="p0185">The effect size measures showed that both r-BT digit span subtests (forward and backward, measuring selective attention and working memory) are particularly sensitive to deterioration while the TMT B and the SCWT Interference subtest (measuring cognitive flexibility and inhibition) are more sensitive to both improvement and deterioration (<xref rid="tbl2" ref-type="table">Table 2</xref> and <xref rid="appsec1" ref-type="sec">Table S2</xref>).<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Effect size measures (Cohen's <italic toggle="yes">d</italic> index) of the primary outcome components.</p></caption><alt-text id="alttext0045">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Neuropsychological Assessment</th><th colspan="1" rowspan="1">Favorable Response</th><th colspan="1" rowspan="1">Unfavorable Response</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">CDR</td><td align="char" colspan="1" rowspan="1">&#8722;0.21<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td align="char" colspan="1" rowspan="1">0.08</td></tr><tr><td colspan="1" rowspan="1">CDR-SB</td><td align="char" colspan="1" rowspan="1">&#8722;0.06</td><td align="char" colspan="1" rowspan="1">0.08</td></tr><tr><td colspan="1" rowspan="1">FCSRT (free recall)</td><td align="char" colspan="1" rowspan="1">0.28<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td align="char" colspan="1" rowspan="1">0.13</td></tr><tr><td colspan="1" rowspan="1">FCSRT (cued recall)</td><td align="char" colspan="1" rowspan="1">0.25<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td align="char" colspan="1" rowspan="1">&#8722;0.08</td></tr><tr><td colspan="1" rowspan="1">r-BT (digit span &#8211; forward)</td><td align="char" colspan="1" rowspan="1">0.13</td><td align="char" colspan="1" rowspan="1">&#8722;0.82<xref rid="tbl2fnc" ref-type="table-fn">c</xref></td></tr><tr><td colspan="1" rowspan="1">r-BT (digit span &#8211; backward)</td><td align="char" colspan="1" rowspan="1">0.00</td><td align="char" colspan="1" rowspan="1">&#8722;0.65<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td></tr><tr><td colspan="1" rowspan="1">r-BT (mental control)</td><td align="char" colspan="1" rowspan="1">&#8722;0.24<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td colspan="1" rowspan="1">r-BT (mental control &#8211; time)</td><td align="char" colspan="1" rowspan="1">&#8722;0.29<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td align="char" colspan="1" rowspan="1">&#8722;0.37<xref rid="tbl2fna" ref-type="table-fn">a</xref></td></tr><tr><td colspan="1" rowspan="1">Verbal fluency (semantic task)</td><td align="char" colspan="1" rowspan="1">&#8722;0.53<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td align="char" colspan="1" rowspan="1">&#8722;0.03</td></tr><tr><td colspan="1" rowspan="1">Verbal fluency (phonemic task)</td><td align="char" colspan="1" rowspan="1">&#8722;0.08</td><td align="char" colspan="1" rowspan="1">0.09</td></tr><tr><td colspan="1" rowspan="1">TMT A</td><td align="char" colspan="1" rowspan="1">0.11</td><td align="char" colspan="1" rowspan="1">&#8722;0.57<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td></tr><tr><td colspan="1" rowspan="1">TMT B</td><td align="char" colspan="1" rowspan="1">&#8722;0.40<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td align="char" colspan="1" rowspan="1">0.91<xref rid="tbl2fnc" ref-type="table-fn">c</xref></td></tr><tr><td colspan="1" rowspan="1">SCWT (word)</td><td align="char" colspan="1" rowspan="1">&#8722;0.33<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td align="char" colspan="1" rowspan="1">&#8722;0.10</td></tr><tr><td colspan="1" rowspan="1">SCWT (color)</td><td align="char" colspan="1" rowspan="1">&#8722;0.10</td><td align="char" colspan="1" rowspan="1">0.17</td></tr><tr><td colspan="1" rowspan="1">SCWT (word-color)</td><td align="char" colspan="1" rowspan="1">0.26<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td align="char" colspan="1" rowspan="1">&#8722;0.19</td></tr><tr><td colspan="1" rowspan="1">SCWT (interference)</td><td align="char" colspan="1" rowspan="1">0.60<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td align="char" colspan="1" rowspan="1">&#8722;0.34<xref rid="tbl2fna" ref-type="table-fn">a</xref></td></tr></tbody></table><table-wrap-foot><fn id="tspara0020"><p>CDR, Clinical Dementia Rating scale; CDR-SB, Clinical Dementia Rating scale &#8211; Sum of Boxes; FCSRT, Free and Cued Selective Reminding Test; r-BT, revised Barcelona Test; TMT, Trail Making Test; SCWT, Stroop Color-Word Interference Test.</p></fn><fn id="tspara0025"><p>Relationship with recommended cutoff values for Cohen's <italic toggle="yes">d</italic> [<xref rid="bib50" ref-type="bibr">50</xref>] have been marked with superscripts.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fna"><label>a</label><p id="ntpara0020">Small absolute values 0.20 &#8203;&#8804; &#8203;|d| &#8203;&lt; &#8203;0.50.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnb"><label>b</label><p id="ntpara0025">Moderate absolute values: 0.50 &#8804; |d| &lt; 0.80.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnc"><label>c</label><p id="ntpara0030">Large absolute values: |d| &#8805; 0.80.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.3.3"><title>Secondary neurological outcomes</title><p id="p0190">Ataxia and disability scores remained quite stable throughout the study (<xref rid="fig4" ref-type="fig">Fig. 4</xref>A and C); yet, they were better in the FR subgroup than in the UR subgroup. On the other hand, dysphagia improved in both subgroups (<xref rid="fig4" ref-type="fig">Fig. 4</xref>B); however, this improvement was remarkably more pronounced in the UR subgroup. Both WAIS-III subtests (symbol search and block design) improved in both subgroups (<xref rid="fig4" ref-type="fig">Fig. 4</xref>D and E). Individual trajectories are available in the Supplemental Material (<xref rid="appsec1" ref-type="sec">Fig. S5</xref>).<fig id="fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Evolution of the means (95 &#8203;% CI) of the neurological outcomes. SARA, Scale for the Assessment and Rating of Ataxia; EAT-10, Eating Assessment Tool &#8211; 10; PDS, Pineda Disability Scale; WAIS, Wechsler Adult Intelligence Scale; V4, visit 4; V6, visit 6.</p></caption><alt-text id="alttext0035">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="sec3.3.4"><title>Secondary biological outcomes</title><p id="p0195">At V6, all patients had evidence of brain and cerebellar hypometabolism, and all but one in the UR subgroup (88.9 &#8203;%), thalamic hypometabolism. Brain atrophy was found in 6 (100.0 &#8203;%) and cerebellar atrophy in 5 (83.3 &#8203;%) patients of the FR subgroup; one patient had missing values for these outcomes. In turn, in the UR subgroup, brain and cerebellar atrophy were evidenced in 3 (33.3 &#8203;%) and 5 (55.6 &#8203;%) patients, respectively (<xref rid="appsec1" ref-type="sec">Supplemental Fig. S6</xref>).</p><p id="p0200">As for splenomegaly, 4 (57.1 &#8203;%) patients in the FR and 6 (66.7 &#8203;%) in the UR subgroup had sonography-evidenced splenomegaly at V6.</p><p id="p0205">Both subgroups had upsurges in their mean CSF levels of amyloid beta protein at V6; however, the relative change was less pronounced in the UR subgroup (<xref rid="appsec1" ref-type="sec">Supplemental Fig. S7A</xref>). Mean CSF tau protein levels remained stable (<xref rid="appsec1" ref-type="sec">Supplemental Fig. S7B and S7C</xref>).</p></sec></sec><sec id="sec3.4"><title>Safety outcomes</title><p id="p0210">Only 3 adverse events occurred during the trial&#8212;all in the same patient&#8212;and consisted of traumatic brain injury and grade IV (American Association for the Surgery of Trauma) splenic laceration, both due to an accidental fall related to his/her ataxia, and stage IV myelocytic leukemia; the cumulative incidence of adverse events was 6.3 &#8203;%. All adverse events were deemed unrelated to efavirenz.</p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0215">In this phase II single-arm trial, all included NPC patients responded to efavirenz on top of standard care treatment at 52 weeks&#8212;that is, lacked deterioration in at least 2 out of 3 cognitive performance domains. Remarkably, some patients even showed slight improvements in some neuropsychological and neurological outcomes. Beyond this encouraging general picture, some nuances deserve attention. First, although no patient met the criteria for progression (simultaneous deterioration of several outcomes) the trajectories of individual scores allowed us to distinguish two distinct subgroups in which improvements and decays predominated. Second, these two subgroups differed essentially in the duration of the disease, which somewhat contradicts the reported linear rate of progression of adult-onset NPC once the neurological disease appears [<xref rid="bib36" ref-type="bibr">36</xref>,<xref rid="bib37" ref-type="bibr">37</xref>]. Third, in line with this, despite the baseline status of neurological endpoints such as ataxia, dysphagia or disability scores being consistently worse among those with longer diseases, the neuropsychological outcomes differed more from each other within subgroups than between subgroups. The onset of efavirenz therapy at the beginning of follow-up could partially explain the deviation from linear progression (first and second issues), but not the differences of neuropsychological outcomes at baseline (third issue).</p><p id="p0220">Although results from previous research efforts are somewhat contradictory regarding the cognitive correlates of neurological disease stages, with some reports stating that motor deficits precede cognitive deficits, and others the opposite [<xref rid="bib38" ref-type="bibr">[38]</xref>, <xref rid="bib39" ref-type="bibr">[39]</xref>, <xref rid="bib40" ref-type="bibr">[40]</xref>, <xref rid="bib41" ref-type="bibr">[41]</xref>, <xref rid="bib42" ref-type="bibr">[42]</xref>], they can shed light on the results of the present study. Regardless of the time since symptom onset, verbal fluency, selective and divided attention, and cognitive inhibition were clearly impaired at baseline, whilst learning, memory and executive control were relatively preserved. In turn, memory tests (r-BT digit span) detected worsening courses particularly well, whilst divided attention (TMT B) and cognitive inhibition (SCWT interference) were particularly sensitive to changes in either direction (worsening or improvement). Within the context of the aforementioned research, these findings suggest that the patients from this study were still at an early, albeit not initial, stage of the disease, in which impairments of verbal fluency, coordination and divided attention predominate, and memory, constructional praxis and visuospatial organizational abilities are relatively preserved [<xref rid="bib39" ref-type="bibr">39</xref>,<xref rid="bib40" ref-type="bibr">40</xref>,<xref rid="bib42" ref-type="bibr">42</xref>]. In this vein, we did not observe the particular sensitivity of VFTs for detecting early difficulties that others have reported [<xref rid="bib39" ref-type="bibr">39</xref>], probably because the patients had already passed this point in their disease stages.</p><p id="p0225">Efavirenz, which allegedly potentiates synaptic function by activating CYP46A1 to compensate for NPC1 deficiency, appeared to be beneficial in this setting of not very advanced disease. Because LTP is a major event for synaptic plasticity, involved in processes like memory, learning, and emotional responses, it seems reasonable to speculate that efavirenz could also help patients in more advanced stages. In fact, the statistical models showed benefits even when adjusted for the time since symptom onset, suggesting that efavirenz effects were relatively independent of disease duration. However, the clear divergence between the FR and UR subgroups, mainly differentiated by disease duration (with a cut-off point around 12 years), recommends caution at this point, since patients with shorter diseases were those most benefited. Taking together previous and current results into account, it seems reasonable to recommend starting efavirenz early, preferably within the first decade after the onset of neurological involvement. Moreover, with the exception of dysphagia, which improved particularly in the UR subgroup (<italic toggle="yes">i.e.</italic>, patients with longer diseases, in whom dysphagia is more probable), ataxia and disability barely changed, and were consistently better in the FR subgroup than in the UR subgroup. Thus, these &#8216;hard&#8217; neurological outcomes seemed to be more resistant to efavirenz. Effects on dysphagia of course are worth highlighting, since this condition can lead to malnutrition and aspiration issues, characteristic of NPC and with important repercussions on quality of life [<xref rid="bib37" ref-type="bibr">37</xref>], but it remains to be determined whether it was primarily a cognitive or motor effect, and whether ataxia and disability would have improved if efavirenz had started earlier or been given for a longer period. This could also be extended to brain and cerebellar atrophy, whose course seemed particularly untoward. Of note, beneficial effects of miglustat therapy in clinical studies were also greater the sooner this treatment was started [<xref rid="bib43" ref-type="bibr">43</xref>].</p><p id="p0230">The issue of when disease-modifying treatments (<italic toggle="yes">e.g.</italic>, enhancement of cholesterol turnover by efavirenz or reduction of sphingolipid synthesis by miglustat) may provide optimum benefits is not trivial from a pharmacodynamic perspective. The ascending pattern of beta amyloid CSF levels, which was more pronounced in the FR subgroup, may be proof of this. Increased CSF beta amyloid is a unique feature of NPC that is not shared with other neurodegenerative diseases that cause amyloid deposits [<xref rid="bib44" ref-type="bibr">44</xref>,<xref rid="bib45" ref-type="bibr">45</xref>]. But despite the inverse relationship that has been described with NPC severity and which may explain why increases were particularly evident in the FR subgroup [<xref rid="bib44" ref-type="bibr">44</xref>], our findings no do not match the reductions or the absence of changes reported previously with miglustat [<xref rid="bib44" ref-type="bibr">44</xref>,<xref rid="bib45" ref-type="bibr">45</xref>]. Although preclinical data indicates that efavirenz may potentiate synaptic efficiency [<xref rid="bib33" ref-type="bibr">33</xref>], an inflection point might exist when this effect cannot compensate for the loss of synapses, which could explain the differences in therapeutic effects observed between the two subgroups. In this vein, the level of brain atrophy might serve to anticipate treatment responses, and its predictive validity should be evaluated in further studies. Preliminary clinical studies with other agents have not provided details on this or other potential biomarkers of therapeutic response [<xref rid="bib46" ref-type="bibr">[46]</xref>, <xref rid="bib47" ref-type="bibr">[47]</xref>, <xref rid="bib48" ref-type="bibr">[48]</xref>].</p><p id="p0235">No efavirenz-related or serious adverse events were reported. Thus, this study does not raise any safety concern related to its continued use at low doses for the treatment of NPC, even when combined with miglustat. Since these two drugs have complementary mechanisms of action, this result suggests that efavirenz may be a suitable agent for combinatorial therapy with miglustat, a strategy recently postulated as key for therapeutic success [<xref rid="bib49" ref-type="bibr">49</xref>].</p><p id="p0240">The main limitation of this study relates to the fact that it was not controlled. Since patients with progressive neurodegenerative disorders such as NPC might show apparent improvement or stabilization with symptomatic treatments, we could not discount such effects by comparing treated patients with a control group receiving standard care alone. Our hypothesis related to synaptic functions, and not to neurodegeneration that may ultimately ensue in NPC. Studying effects on neurodegeneration, or other important aspects such as when the maximum benefit may be obtained or whether efavirenz can effectively modify the course of the disease, would have required longer follow-up times. The study may even have been too short to evaluate long-term cognitive effects. Lastly, since blood 24-hydroxycholesterol levels showed considerable variability, we were unable to personalize efavirenz doses accordingly, as initially planned [<xref rid="bib35" ref-type="bibr">35</xref>], which could have resulted in greater effects on neurological endpoints.</p><p id="p0245">In conclusion, this study shows, in line with previous research, that despite the NPC prognosis being bad in general, it is possible to slow the rate of progression after the onset of CNS involvement. In particular, efavirenz may be a safe, easy-to-use, new targeted therapeutic option to address NPC patients&#8217; unmet medical needs in the future. Benefits appear to be greater the earlier the treatment is started. The present findings will have to be confirmed in future extension or phase III clinical trials with longer follow-ups.</p></sec><sec id="sec5"><title>Author contributions</title><p id="p0250">Conceptualization, Jordi Gasc&#243;n-Bayarri, Mar&#237;a Dolores Ledesma, Helena Bejr-Kasem, Jaume Campdelacreu, Anna Ferrer and Sebasti&#225;n Videla; methodology, Jordi Gasc&#243;n-Bayarri and Sebasti&#225;n Videla; software, Jes&#250;s Villoria; validation, Jordi Gasc&#243;n-Bayarri and Sebasti&#225;n Videla; formal analysis, Jes&#250;s Villoria; investigation, Jordi Gasc&#243;n-Bayarri, Inmaculada Rico, Cristina S&#225;nchez-Casta&#241;eda, Laura Rodr&#237;gez-Bel, M&#243;nica Cos, Eugenia de Lama, Adolfo L&#243;pez de Munain, Idoia Rouco, Celia P&#233;rez-Sousa, Mar&#237;a Cerd&#225;n, Nuria Muelas, Mar&#237;a Dolores Sevillano and Pablo Mir; resources, Jordi Gasc&#243;n-Bayarri and Sebasti&#225;n Videla; data curation, Jordi Gasc&#243;n-Bayarri, Thiago Carnaval and Jes&#250;s Villoria; writing&#8212;original draft preparation, Thiago Carnaval and Jes&#250;s Villoria; writing&#8212;review and editing, Jordi Gasc&#243;n Bayarri and Sebasti&#225;n Videla; visualization, Thiago Carnaval and Jes&#250;s Villoria; supervision, Jordi Gasc&#243;n Bayarri and Sebasti&#225;n Videla; project administration, Jordi Gasc&#243;n-Bayarri; funding acquisition, Jordi Gasc&#243;n-Bayarri and Sebasti&#225;n Videla. All authors have read and agreed to the published version of the manuscript.</p></sec><sec id="sec6"><title>Data access and availability statements</title><p id="p0255">Jordi Gasc&#243;n-Bayarri, will oversee the dataset. Granting access to this information will be evaluated on a case-by-case basis, upon reasonable request by the interested party.</p></sec><sec id="sec7"><title>Additional contributions</title><p id="p0260">
<list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#8226;</label><p id="p0265">The relatives association, Niemann-PicK Foundation Espa&#241;a.</p></list-item><list-item id="u0015"><label>&#8226;</label><p id="p0270">Dr. Fina Casas, Lipidomic Service of the Institut for Advenced Chemistry of Catalonia (IQAC-CSIC).</p></list-item></list>
</p></sec><sec id="sec8"><title>Funding/Support</title><p id="p0275">Funding from the Niemann-Pick Foundation Espa&#241;a, a relatives association and we thank CERCA Programme/Generalitat de Catalunya for institutional support.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of Competing Interest</title><p id="p0280">None declared.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Patterson</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Vecchio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Prady</surname><given-names>H.</given-names></name><name name-style="western"><surname>Abel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wraith</surname><given-names>J.E.</given-names></name></person-group><article-title>Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study</article-title><source>Lancet Neurol</source><volume>6</volume><year>2007</year><fpage>765</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">17689147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(07)70194-1</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Vanier</surname><given-names>M.T.</given-names></name></person-group><article-title>Niemann-Pick disease type C</article-title><source>Orphanet J Rare Dis</source><volume>5</volume><year>2010</year><fpage>16</fpage><pub-id pub-id-type="pmid">20525256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1750-1172-5-16</pub-id><pub-id pub-id-type="pmcid">PMC2902432</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Geberhiwot</surname><given-names>T.</given-names></name><name name-style="western"><surname>Moro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dardis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramaswami</surname><given-names>U.</given-names></name><name name-style="western"><surname>Sirrs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marfa</surname><given-names>M.P.</given-names></name><etal/></person-group><article-title>Consensus clinical management guidelines for Niemann-Pick disease type C</article-title><source>Orphanet J Rare Dis</source><volume>13</volume><year>2018</year><fpage>50</fpage><pub-id pub-id-type="pmid">29625568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13023-018-0785-7</pub-id><pub-id pub-id-type="pmcid">PMC5889539</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Vanier</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Duthel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rodriguez-Lafrasse</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pentchev</surname><given-names>P.</given-names></name><name name-style="western"><surname>Carstea</surname><given-names>E.D.</given-names></name></person-group><article-title>Genetic heterogeneity in Niemann-Pick C disease: a study using somatic cell hybridization and linkage analysis</article-title><source>Am J Hum Genet</source><volume>58</volume><year>1996</year><fpage>118</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">8554047</pub-id><pub-id pub-id-type="pmcid">PMC1914948</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Ioannou</surname><given-names>Y.A.</given-names></name></person-group><article-title>Niemann-Pick C1 is a late endosome-resident protein that transiently associates with lysosomes and the trans-Golgi network</article-title><source>Mol Genet Metab</source><volume>68</volume><year>1999</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">10479477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/mgme.1999.2882</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Watari</surname><given-names>H.</given-names></name><name name-style="western"><surname>Blanchette-Mackie</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Dwyer</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Glick</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Neufeld</surname><given-names>E.B.</given-names></name><etal/></person-group><article-title>Niemann-Pick C1 protein: obligatory roles for N-terminal domains and lysosomal targeting in cholesterol mobilization</article-title><source>Proc Natl Acad Sci U S A</source><volume>96</volume><year>1999</year><fpage>805</fpage><lpage>810</lpage><pub-id pub-id-type="pmid">9927649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.96.3.805</pub-id><pub-id pub-id-type="pmcid">PMC15306</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Vance</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Karten</surname><given-names>B.</given-names></name></person-group><article-title>Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin</article-title><source>J Lipid Res</source><volume>55</volume><year>2014</year><fpage>1609</fpage><lpage>1621</lpage><pub-id pub-id-type="pmid">24664998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1194/jlr.R047837</pub-id><pub-id pub-id-type="pmcid">PMC4109756</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>D'Arcangelo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grossi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Racaniello</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cardinale</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zaratti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rufini</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Miglustat reverts the impairment of synaptic plasticity in a mouse model of NPC disease</article-title><source>Neural Plast</source><volume>2016</volume><year>2016</year><object-id pub-id-type="publisher-id">3830424</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2016/3830424</pub-id><pub-id pub-id-type="pmcid">PMC4738957</pub-id><pub-id pub-id-type="pmid">26885401</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Wassif</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Cross</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Iben</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sanchez-Pulido</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cougnoux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Platt</surname><given-names>F.M.</given-names></name><etal/></person-group><article-title>High incidence of unrecognized visceral/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets</article-title><source>Genet Med</source><volume>18</volume><year>2016</year><fpage>41</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">25764212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2015.25</pub-id><pub-id pub-id-type="pmcid">PMC4486368</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Vanier</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Millat</surname><given-names>G.</given-names></name></person-group><article-title>Niemann-Pick disease type C</article-title><source>Clin Genet</source><volume>64</volume><year>2003</year><fpage>269</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">12974729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1034/j.1399-0004.2003.00147.x</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Vanier</surname><given-names>M.T.</given-names></name></person-group><article-title>Complex lipid trafficking in Niemann-Pick disease type C</article-title><source>J Inherit Metab Dis</source><volume>38</volume><year>2015</year><fpage>187</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">25425283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10545-014-9794-4</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Karten</surname><given-names>B.</given-names></name><name name-style="western"><surname>Campenot</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Vance</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Vance</surname><given-names>J.E.</given-names></name></person-group><article-title>The Niemann-Pick C1 protein in recycling endosomes of presynaptic nerve terminals</article-title><source>J Lipid Res</source><volume>47</volume><year>2006</year><fpage>504</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">16340014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1194/jlr.M500482-JLR200</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Karten</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vance</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Campenot</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Vance</surname><given-names>J.E.</given-names></name></person-group><article-title>Trafficking of cholesterol from cell bodies to distal axons in Niemann Pick C1-deficient neurons</article-title><source>J Biol Chem</source><volume>278</volume><year>2003</year><fpage>4168</fpage><lpage>4175</lpage><pub-id pub-id-type="pmid">12458210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M205406200</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Brachet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Norwood</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brouwers</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Palomer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Helms</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Dotti</surname><given-names>C.G.</given-names></name><etal/></person-group><article-title>LTP-triggered cholesterol redistribution activates Cdc42 and drives AMPA receptor synaptic delivery</article-title><source>J Cell Biol</source><volume>208</volume><year>2015</year><fpage>791</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">25753037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.201407122</pub-id><pub-id pub-id-type="pmcid">PMC4362467</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Elrick</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lieberman</surname><given-names>A.P.</given-names></name></person-group><article-title>Impaired proteolysis underlies autophagic dysfunction in Niemann&#8211;Pick type C disease</article-title><source>Hum Mol Genet</source><volume>21</volume><year>2012</year><fpage>4876</fpage><lpage>4887</lpage><pub-id pub-id-type="pmid">22872701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/dds324</pub-id><pub-id pub-id-type="pmcid">PMC3607480</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Cariati</surname><given-names>I.</given-names></name><name name-style="western"><surname>Masuelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tancredi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>C.</given-names></name><name name-style="western"><surname>D'Arcangelo</surname><given-names>G.</given-names></name></person-group><article-title>Neurodegeneration in niemann-pick type C disease: an updated review on pharmacological and non-pharmacological approaches to counteract brain and cognitive impairment</article-title><source>Int J Mol Sci</source><volume>22</volume><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22126600</pub-id><pub-id pub-id-type="pmcid">PMC8234817</pub-id><pub-id pub-id-type="pmid">34202978</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Walkley</surname><given-names>S.U.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K.</given-names></name></person-group><article-title>Consequences of NPC1 and NPC2 loss of function in mammalian neurons</article-title><source>Biochim Biophys Acta</source><volume>1685</volume><year>2004</year><fpage>48</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15465426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbalip.2004.08.011</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Solomon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Winkelman</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Zee</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>L.</given-names></name><name name-style="western"><surname>B&#252;ttner-Ennever</surname><given-names>J.</given-names></name></person-group><article-title>Niemann-Pick type C disease in two affected sisters: ocular motor recordings and brain-stem neuropathology</article-title><source>Ann N Y Acad Sci</source><volume>1039</volume><year>2005</year><fpage>436</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">15826996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1196/annals.1325.041</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Sedel</surname><given-names>F.</given-names></name></person-group><article-title>[Clinical diagnosis of the adult form of Niemann-Pick type C disease]</article-title><source>Arch Pediatr</source><volume>17</volume><issue>Suppl 2</issue><year>2010</year><fpage>S50</fpage><lpage>S53</lpage><pub-id pub-id-type="pmid">20620896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0929-693X(10)70012-9</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Helquist</surname><given-names>P.</given-names></name><name name-style="western"><surname>Maxfield</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Wiech</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Wiest</surname><given-names>O.</given-names></name></person-group><article-title>Treatment of Niemann--Pick type C disease by histone deacetylase inhibitors</article-title><source>Neurotherapeutics</source><volume>10</volume><year>2013</year><fpage>688</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">24048860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13311-013-0217-2</pub-id><pub-id pub-id-type="pmcid">PMC3805865</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Sitarska</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tylki-Szymanska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lugowska</surname><given-names>A.</given-names></name></person-group><article-title>Treatment trials in Niemann-Pick type C disease</article-title><source>Metab Brain Dis</source><volume>36</volume><year>2021</year><fpage>2215</fpage><lpage>2221</lpage><pub-id pub-id-type="pmid">34596813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-021-00842-0</pub-id><pub-id pub-id-type="pmcid">PMC8580890</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><article-title>Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV</article-title><source>Int J Antimicrob Agents</source><volume>33</volume><year>2009</year><fpage>307</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">19108994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2008.10.010</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Gorski</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Flockhart</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Desta</surname><given-names>Z.</given-names></name></person-group><article-title>The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity</article-title><source>J Pharmacol Exp Ther</source><volume>306</volume><year>2003</year><fpage>287</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">12676886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.103.049601</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Mast</surname><given-names>N.</given-names></name><name name-style="western"><surname>Verwilst</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wilkey</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Guengerich</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Pikuleva</surname><given-names>I.A.</given-names></name></person-group><article-title>In vitro activation of cytochrome P450 46A1 (CYP46A1) by efavirenz-related compounds</article-title><source>J Med Chem</source><volume>63</volume><year>2020</year><fpage>6477</fpage><lpage>6488</lpage><pub-id pub-id-type="pmid">31617715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.9b01383</pub-id><pub-id pub-id-type="pmcid">PMC7226586</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Tortelli</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bagel</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sidhu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Cholesterol homeostatic responses provide biomarkers for monitoring treatment for the neurodegenerative disease Niemann-Pick C1 (NPC1)</article-title><source>Hum Mol Genet</source><volume>23</volume><year>2014</year><fpage>6022</fpage><lpage>6033</lpage><pub-id pub-id-type="pmid">24964810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddu331</pub-id><pub-id pub-id-type="pmcid">PMC4204776</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Pikuleva</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Cartier</surname><given-names>N.</given-names></name></person-group><article-title>Cholesterol hydroxylating cytochrome P450 46A1: from mechanisms of action to clinical applications</article-title><source>Front Aging Neurosci</source><volume>13</volume><year>2021</year><object-id pub-id-type="publisher-id">696778</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2021.696778</pub-id><pub-id pub-id-type="pmcid">PMC8297829</pub-id><pub-id pub-id-type="pmid">34305573</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Boussicault</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lamazi&#232;re</surname><given-names>A.</given-names></name><name name-style="western"><surname>Planques</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heck</surname><given-names>N.</given-names></name><name name-style="western"><surname>Moumn&#233;</surname><given-names>L.</given-names></name><etal/></person-group><article-title>CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease</article-title><source>Brain</source><volume>139</volume><year>2016</year><fpage>953</fpage><lpage>970</lpage><pub-id pub-id-type="pmid">26912634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awv384</pub-id><pub-id pub-id-type="pmcid">PMC4766376</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Burlot</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Braudeau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Michaelsen-Preusse</surname><given-names>K.</given-names></name><name name-style="western"><surname>Potier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ayciriex</surname><given-names>S.</given-names></name><name name-style="western"><surname>Varin</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology</article-title><source>Hum Mol Genet</source><volume>24</volume><year>2015</year><fpage>5965</fpage><lpage>5976</lpage><pub-id pub-id-type="pmid">26358780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddv268</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Chali</surname><given-names>F.</given-names></name><name name-style="western"><surname>Djelti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Eugene</surname><given-names>E.</given-names></name><name name-style="western"><surname>Valderrama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marquer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aubourg</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Inhibiting cholesterol degradation induces neuronal sclerosis and epileptic activity in mouse hippocampus</article-title><source>Eur J Neurosci</source><volume>41</volume><year>2015</year><fpage>1345</fpage><lpage>1355</lpage><pub-id pub-id-type="pmid">25847620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ejn.12911</pub-id><pub-id pub-id-type="pmcid">PMC4439180</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Djelti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Braudeau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hudry</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dhenain</surname><given-names>M.</given-names></name><name name-style="western"><surname>Varin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bi&#232;che</surname><given-names>I.</given-names></name><etal/></person-group><article-title>CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease</article-title><source>Brain</source><volume>138</volume><year>2015</year><fpage>2383</fpage><lpage>2398</lpage><pub-id pub-id-type="pmid">26141492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awv166</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Hudry</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van Dam</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kulik</surname><given-names>W.</given-names></name><name name-style="western"><surname>De Deyn</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Stet</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Ahouansou</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease</article-title><source>Mol Ther</source><volume>18</volume><year>2010</year><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">19654569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2009.175</pub-id><pub-id pub-id-type="pmcid">PMC2839219</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Mast</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Linger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pikuleva</surname><given-names>I.A.</given-names></name></person-group><article-title>Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice</article-title><source>J Biol Chem</source><volume>289</volume><year>2014</year><fpage>3529</fpage><lpage>3538</lpage><pub-id pub-id-type="pmid">24352658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M113.532846</pub-id><pub-id pub-id-type="pmcid">PMC3916554</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Mitroi</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Pereyra-Gomez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Soto-Huelin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Senovilla</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>NPC1 enables cholesterol mobilization during long-term potentiation that can be restored in Niemann-Pick disease type C by CYP46A1 activation</article-title><source>EMBO Rep</source><volume>20</volume><year>2019</year><object-id pub-id-type="publisher-id">e48143</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embr.201948143</pub-id><pub-id pub-id-type="pmcid">PMC6832102</pub-id><pub-id pub-id-type="pmid">31535451</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Lerner</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Maxfield</surname><given-names>E.</given-names></name><name name-style="western"><surname>Koenig</surname><given-names>A.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Fortin</surname><given-names>B.</given-names></name><etal/></person-group><article-title>CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer's disease</article-title><source>Alzheimers Res Ther</source><volume>14</volume><year>2022</year><fpage>198</fpage><pub-id pub-id-type="pmid">36581878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-022-01151-z</pub-id><pub-id pub-id-type="pmcid">PMC9797897</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Gasc&#243;n-Bayarri</surname><given-names>J.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Llop</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carnaval</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ledesma</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Rico</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Efficacy and safety clinical trial with efavirenz in patients diagnosed with adult Niemann-pick type C with cognitive impairment</article-title><source>Medicine (Baltim)</source><volume>101</volume><year>2022</year><object-id pub-id-type="publisher-id">e31471</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000031471</pub-id><pub-id pub-id-type="pmcid">PMC9726274</pub-id><pub-id pub-id-type="pmid">36482560</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Yanjanin</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Velez</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Gropman</surname><given-names>A.</given-names></name><name name-style="western"><surname>King</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bianconi</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Conley</surname><given-names>S.K.</given-names></name><etal/></person-group><article-title>Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><volume>153B</volume><year>2010</year><fpage>132</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">19415691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajmg.b.30969</pub-id><pub-id pub-id-type="pmcid">PMC2798912</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Imrie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dasgupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Besley</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>C.</given-names></name><name name-style="western"><surname>Heptinstall</surname><given-names>L.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The natural history of Niemann-Pick disease type C in the UK</article-title><source>J Inherit Metab Dis</source><volume>30</volume><year>2007</year><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">17160617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10545-006-0384-7</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Dambrosia</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pikus</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Pentchev</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A clinical staging classification for type C Niemann-Pick disease</article-title><source>Neurology</source><volume>42</volume><year>1992</year><fpage>2286</fpage><lpage>2290</lpage><pub-id pub-id-type="pmid">1461380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.42.12.2286</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Klarner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Klunemann</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Lurding</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aslanidis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R.</given-names></name></person-group><article-title>Neuropsychological profile of adult patients with Niemann-Pick C1 (NPC1) mutations</article-title><source>J Inherit Metab Dis</source><volume>30</volume><year>2007</year><fpage>60</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">17160616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10545-006-0417-6</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Heitz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Epelbaum</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nadjar</surname><given-names>Y.</given-names></name></person-group><article-title>Cognitive impairment profile in adult patients with Niemann pick type C disease</article-title><source>Orphanet J Rare Dis</source><volume>12</volume><year>2017</year><fpage>166</fpage><pub-id pub-id-type="pmid">29047377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13023-017-0714-1</pub-id><pub-id pub-id-type="pmcid">PMC5648435</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Wraith</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Guffon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rohrbach</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hwu</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Korenke</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Bembi</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study</article-title><source>Mol Genet Metab</source><volume>98</volume><year>2009</year><fpage>250</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">19616462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymgme.2009.06.009</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Maresca</surname><given-names>G.</given-names></name><name name-style="western"><surname>Formica</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nocito</surname><given-names>V.</given-names></name><name name-style="western"><surname>Latella</surname><given-names>D.</given-names></name><name name-style="western"><surname>Leonardi</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Cola</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Neuropsychological assessment in Niemann-Pick disease type C: a systematic review</article-title><source>Neurol Sci</source><volume>42</volume><year>2021</year><fpage>3167</fpage><lpage>3175</lpage><pub-id pub-id-type="pmid">34021815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10072-021-05337-5</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Pineda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walterfang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>M.C.</given-names></name></person-group><article-title>Miglustat in Niemann-Pick disease type C patients: a review</article-title><source>Orphanet J Rare Dis</source><volume>13</volume><year>2018</year><fpage>140</fpage><pub-id pub-id-type="pmid">30111334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13023-018-0844-0</pub-id><pub-id pub-id-type="pmcid">PMC6094874</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Mattsson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bianconi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yanjanin</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mansson</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study</article-title><source>Neurology</source><volume>76</volume><year>2011</year><fpage>366</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">21205675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e318208f4ab</pub-id><pub-id pub-id-type="pmcid">PMC3034414</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Mattsson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bianconi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yanjanin</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mansson</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in niemann-pick type C</article-title><source>JIMD Rep</source><volume>3</volume><year>2012</year><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">23430872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/8904_2011_47</pub-id><pub-id pub-id-type="pmcid">PMC3509856</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Bremova-Ertl</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ramaswami</surname><given-names>U.</given-names></name><name name-style="western"><surname>Brands</surname><given-names>M.</given-names></name><name name-style="western"><surname>Foltan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gautschi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gissen</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Trial of N-Acetyl-l-Leucine in niemann-pick disease type C</article-title><source>N Engl J Med</source><volume>390</volume><year>2024</year><fpage>421</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">38294974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2310151</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Mengel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Da Riol</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Del Toro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deodato</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gautschi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Efficacy and safety of arimoclomol in Niemann-Pick disease type C: results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment</article-title><source>J Inherit Metab Dis</source><volume>44</volume><year>2021</year><fpage>1463</fpage><lpage>1480</lpage><pub-id pub-id-type="pmid">34418116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jimd.12428</pub-id><pub-id pub-id-type="pmcid">PMC9293014</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Farmer</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Thurm</surname><given-names>A.</given-names></name><name name-style="western"><surname>Farhat</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bianconi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Keener</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>F.D.</given-names></name></person-group><article-title>Long-term neuropsychological outcomes from an open-label phase I/IIa trial of 2-Hydroxypropyl-beta-Cyclodextrins (VTS-270) in niemann-pick disease, type C1</article-title><source>CNS Drugs</source><volume>33</volume><year>2019</year><fpage>677</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">31187454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40263-019-00642-2</pub-id><pub-id pub-id-type="pmcid">PMC7448545</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Malara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prestel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tahirovic</surname><given-names>S.</given-names></name></person-group><article-title>Endo-lysosomal dysfunction and neuronal-glial crosstalk in Niemann-Pick type C disease</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><volume>379</volume><year>2024</year><object-id pub-id-type="publisher-id">20220388</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rstb.2022.0388</pub-id><pub-id pub-id-type="pmcid">PMC10874755</pub-id><pub-id pub-id-type="pmid">38368932</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Husted</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Farewell</surname><given-names>V.T.</given-names></name><name name-style="western"><surname>Gladman</surname><given-names>D.D.</given-names></name></person-group><article-title>Methods for assessing responsiveness: a critical review and recommendations</article-title><source>J Clin Epidemiol</source><volume>53</volume><year>2000</year><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">10812317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0895-4356(99)00206-1</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0285">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc2" position="float" orientation="portrait"><caption><title>Multimedia component 2</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc2.docx" position="float" orientation="portrait"><alt-text>Multimedia component 2</alt-text></media></supplementary-material></p></sec><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0290">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.neurot.2025.e00706" id="intref0015">https://doi.org/10.1016/j.neurot.2025.e00706</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12488692</article-id><article-id pub-id-type="pmcid-ver">PMC12488692.1</article-id><article-id pub-id-type="pmcaid">12488692</article-id><article-id pub-id-type="pmcaiid">12488692</article-id><article-id pub-id-type="pmid">41050416</article-id><article-id pub-id-type="doi">10.3389/fphar.2025.1670397</article-id><article-id pub-id-type="publisher-id">1670397</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Multifunctional PLGA nanosystems: enabling integrated diagnostic and therapeutic strategies</article-title><alt-title alt-title-type="left-running-head">Li et al.</alt-title><alt-title alt-title-type="right-running-head"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fphar.2025.1670397" ext-link-type="uri">10.3389/fphar.2025.1670397</ext-link></alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yue</given-names></name><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tao</surname><given-names initials="T">Tao</given-names></name><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiong</surname><given-names initials="Y">Yao</given-names></name><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="W">Weiyu</given-names></name><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Liang</surname><given-names initials="Y">Yangbiao</given-names></name><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2837375/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib></contrib-group><aff>
<institution>Ultrasound Medical Center, Zhujiang Hospital of Southern Medical University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/120646/overview" ext-link-type="uri">Jianxiang Zhang</ext-link>, Army Medical University, China</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/114517/overview" ext-link-type="uri">David Gonz&#225;lez Calatayud</ext-link>, Autonomous University of Madrid, Spain</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1186891/overview" ext-link-type="uri">Abdullahi Aborode</ext-link>, Florida International University, United States</p></fn><corresp id="c001">*Correspondence: Yangbiao Liang, <email>1821947399@qq.com</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">480654</issue-id><elocation-id>1670397</elocation-id><history><date date-type="received"><day>21</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>08</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Li, Tao, Xiong, Guo and Liang.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Li, Tao, Xiong, Guo and Liang</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphar-16-1670397.pdf"/><abstract><p>In the past decades, biodegradable polymers have been widely used in pharmaceutical and medical engineering materials. Poly (lactic-co-glycolic acid) (PLGA) copolymer, renowned for its exceptional biocompatibility, inherent non-toxicity, and superior encapsulation and film-forming capabilities, has been widely acknowledged as one of the foremost candidate materials among next-generation biodegradable polymers with remarkable application potential. PLGA nanoparticles exhibit demonstrated versatility in accommodating hydrophobic or hydrophilic substances, which can be either encapsulated within their core matrix or adsorbed onto the surface. This includes chemical drugs, nucleic acids, peptides, and proteins. Upon entering the systemic circulation, the size-tunable characteristics of PLGA nanoparticles synergize with surface ligand-receptor interactions to confer dual-targeting capabilities: passive targeting through enhanced permeability and retention (EPR) effects, and active targeting <italic toggle="yes">via</italic> specific molecular recognition at pathological sites. Moreover, the integration of multimodal imaging capabilities into PLGA-based nanoparticles enables <italic toggle="yes">in vivo</italic> imaging-guided drug delivery, which paves the way for more precise and enhanced approaches to disease diagnosis and therapeutic intervention. This review systematically examines the fabrication strategies, structural variants of PLGA-based nanostructures, and their applications in both diagnostic and therapeutic domains of biomedicine.</p></abstract><kwd-group><kwd>PLGA</kwd><kwd>theranostics</kwd><kwd>nanosystems</kwd><kwd>application</kwd><kwd>biocompatibility</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><counts><page-count count="20"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Translational Pharmacology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>The efficacy of a drug is not only related to pharmacokinetics, but more importantly depends on its bioavailability at the intended site of action, which in turn is determined by the drug delivery method (<xref rid="B5" ref-type="bibr">Agnihotri et al., 2004</xref>; <xref rid="B8" ref-type="bibr">Allen and Cullis, 2004</xref>; <xref rid="B6" ref-type="bibr">Alavi et al., 2024</xref>). Medical nanotechnology is an emerging multifunctional platform, which may greatly affect the delivery of multiple therapeutic drugs, including small molecule chemicals, peptides, genes and diagnostic imaging agents (<xref rid="B57" ref-type="bibr">Farokhzad and Langer, 2006</xref>; <xref rid="B144" ref-type="bibr">Shi et al., 2016</xref>; <xref rid="B95" ref-type="bibr">Li et al., 2021</xref>). Nanostructure based carriers can change the treatment mode of diseases through drug delivery controlled by time and space. These therapeutic agents are encapsulated in the nanocarrier or covalently grafted on the surface of the nanocarrier. After intravenous injection, Their release is affected by carrier composition, pH of microenvironment, temperature, external regulation and other factors (<xref rid="B77" ref-type="bibr">Kamaly et al., 2012</xref>; <xref rid="B78" ref-type="bibr">Kamaly et al., 2016</xref>; <xref rid="B181" ref-type="bibr">Zheng et al., 2017</xref>; <xref rid="B172" ref-type="bibr">Yang et al., 2024a</xref>). A diverse array of materials encompassing synthetic polymers (e.g., PLGA and polyamides), natural polymers (including hyaluronic acid, chitosan, and albumin), phospholipids, along with inorganic substrates (gold, copper, silver, and zinc) have been extensively employed in the fabrication of nanocarriers (<xref rid="B52" ref-type="bibr">Dykman and Khlebtsov, 2016</xref>; <xref rid="B92" ref-type="bibr">Lee et al., 2016</xref>; <xref rid="B70" ref-type="bibr">Hong and Choi, 2017</xref>; <xref rid="B93" ref-type="bibr">Lee et al., 2017</xref>; <xref rid="B125" ref-type="bibr">Oberli et al., 2017</xref>; <xref rid="B48" ref-type="bibr">De Matteis et al., 2018</xref>; <xref rid="B91" ref-type="bibr">Lee and Cho, 2018</xref>; <xref rid="B85" ref-type="bibr">Koo et al., 2019</xref>; <xref rid="B20" ref-type="bibr">Beach et al., 2024</xref>). Among these different materials, PLGA is the most promising material and the preferred material for preparing drug delivery nanoparticles (<xref rid="B45" ref-type="bibr">Danhier et al., 2012</xref>; <xref rid="B112" ref-type="bibr">Martins et al., 2017</xref>; <xref rid="B153" ref-type="bibr">Swider et al., 2018</xref>). <xref rid="T1" ref-type="table">Table 1</xref> presents a comparative analysis of PLGA and other nanocarriers for drug delivery. PLGA has a long history in medicine as a biodegradable suture material. PLGA can be degraded into lactic acid (LA) and Glycolic acid (GA), thus entering the metabolic pathway, and finally into water and carbon dioxide. The U.S. Food and Drug Administration (FDA) has granted regulatory approval for PLGA as a matrix material in parenteral dosage forms, solidifying its status as a pharmaceutically validated excipient for injectable formulations (<xref rid="B117" ref-type="bibr">Mir et al., 2017</xref>). Surface chemical modification of PLGA nanoparticles can confer biological targeting functionality and prolong their systemic circulation time. Pharmaceuticals, peptides, and nucleic acids with distinct physicochemical properties can be either encapsulated within the PLGA nanoparticle core or adsorbed onto their outer surface. Furthermore, imaging agents may be incorporated into PLGA nanoparticles to endow them with diagnostic imaging capabilities for precise localization of pathological lesions (<xref rid="B44" ref-type="bibr">Danhier et al., 2010</xref>; <xref rid="B133" ref-type="bibr">Ratzinger et al., 2010</xref>; <xref rid="B3" ref-type="bibr">Acharya and Sahoo, 2011</xref>; <xref rid="B108" ref-type="bibr">Maeda et al., 2013</xref>; <xref rid="B138" ref-type="bibr">Sah et al., 2013</xref>; <xref rid="B124" ref-type="bibr">Nottelet et al., 2015</xref>; <xref rid="B130" ref-type="bibr">Peres et al., 2017</xref>; <xref rid="B67" ref-type="bibr">Hamdallah et al., 2024</xref>). The historical progression of PLGA-based nanosystems represents a remarkable evolution in drug delivery technology. Research on biodegradable polymers for drug delivery has been ongoing since they were first used as bioresorbable surgical devices in the 1980s. The progression from conventional drug delivery to multifunctional diagnostic-therapeutic applications represents a significant advancement in PLGA nanotechnology. Recent developments have demonstrated innovative approaches such as the anti-VEGFR2 antibody-coated PLGA nanoparticles for ocular delivery combine photothermal and chemotherapy to treat corneal neovascularization, and PLGA-PEG nanoparticles encapsulating DOX, SPIONs exhibit superior cytotoxicity, reduced cardiotoxicity, dual-mode MRI-fluorescence imaging (<xref rid="B139" ref-type="bibr">Salmasi et al., 2024</xref>; <xref rid="B175" ref-type="bibr">Ye et al., 2024</xref>). These advancements highlight the evolution of PLGA nanosystems from simple drug carriers to sophisticated theranostic platforms that combine targeted therapy with diagnostic capabilities. The simplicity and reliability of the PLGA nanoparticles fabrication techniques, coupled with their excellent biocompatibility, have significantly enhanced the feasibility of PLGA-based nanoparticles in clinical applications. This paper elucidates the fundamental principles of employing PLGA as a drug delivery vehicle, outlines fabrication methodologies for PLGA-based nanostructures, and examines the versatile applications of these nanopolymeric systems across diverse pathologies including cardiovascular disorders, neurodegenerative diseases, infectious conditions, inflammatory ailments, with particular emphasis on their implementation in the diagnosis and treatment of malignancies.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Comparative analysis of PLGA vs other nanocarriers in drug delivery.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Feature</th><th align="center" rowspan="1" colspan="1">PLGA</th><th align="center" rowspan="1" colspan="1">Liposomes</th><th align="center" rowspan="1" colspan="1">Dendrimers</th><th align="center" rowspan="1" colspan="1">Inorganic nanoparticles</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">Material Composition</td><td align="center" rowspan="1" colspan="1">Synthetic biodegradable polymer (lactic/glycolic acid)</td><td align="center" rowspan="1" colspan="1">Phospholipid bilayers (often with cholesterol/PEG lipids)</td><td align="center" rowspan="1" colspan="1">Highly branched synthetic macromolecules (e.g., PAMAM)</td><td align="center" rowspan="1" colspan="1">Gold, silver, mesoporous silica<italic toggle="yes">etc.</italic>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Size Range</td><td align="center" rowspan="1" colspan="1">Nano- to micro-scale (often 100&#8211;300&#160;nm)</td><td align="center" rowspan="1" colspan="1">Typically 50&#8211;200&#160;nm</td><td align="center" rowspan="1" colspan="1">Molecularly precise (1&#8211;10&#160;nm)</td><td align="center" rowspan="1" colspan="1">Variable (e.g., gold: 10&#8211;100&#160;nm; silica: up to hundreds of nm)</td></tr><tr><td align="center" rowspan="1" colspan="1">Drug Loading</td><td align="center" rowspan="1" colspan="1">High&#160;for hydrophobic/hydrophilic drugs (<xref rid="B173" ref-type="bibr">Yang et al., 2024b</xref>)</td><td align="center" rowspan="1" colspan="1">High for hydrophilic (core) and hydrophobic (lipid bilayer) drugs</td><td align="center" rowspan="1" colspan="1">Moderate, limited by generation and internal cavities</td><td align="center" rowspan="1" colspan="1">Variable (mesoporous silica: high; gold: low, often surface-conjugated)</td></tr><tr><td align="center" rowspan="1" colspan="1">Release Profile</td><td align="center" rowspan="1" colspan="1">Sustained release (days to weeks) <italic toggle="yes">via</italic> diffusion/degradation</td><td align="center" rowspan="1" colspan="1">Biphasic (initial burst + sustained release)</td><td align="center" rowspan="1" colspan="1">Rapid release, modifiable <italic toggle="yes">via</italic> surface functionalization</td><td align="center" rowspan="1" colspan="1">Stimuli-responsive (e.g., light, heat, magnetic)</td></tr><tr><td align="center" rowspan="1" colspan="1">Targeting Ability</td><td align="center" rowspan="1" colspan="1">Requires surface functionalization for active targeting</td><td align="center" rowspan="1" colspan="1">Easily functionalized for active targeting</td><td align="center" rowspan="1" colspan="1">Excellent for active targeting due to multifunctional surface groups</td><td align="center" rowspan="1" colspan="1">Easily functionalized; strong active targeting potential</td></tr><tr><td align="center" rowspan="1" colspan="1">Biocompatibility</td><td align="center" rowspan="1" colspan="1">Excellent; biodegradable (FDA-approved); metabolites are safe (<xref rid="B76" ref-type="bibr">Kakavandi et al., 2025</xref>)</td><td align="center" rowspan="1" colspan="1">High (membrane-like); but some cationic lipids may show toxicity</td><td align="center" rowspan="1" colspan="1">Generation-dependent; high generations may cause membrane toxicity</td><td align="center" rowspan="1" colspan="1">Poor biodegradation; potential long-term toxicity (e.g., metal accumulation)</td></tr><tr><td align="center" rowspan="1" colspan="1">Clinical Progress</td><td align="center" rowspan="1" colspan="1">Widely used; multiple FDA-approved products (e.g., implants, microspheres)</td><td align="center" rowspan="1" colspan="1">Several clinical products&#160;(e.g., Doxil<sup>&#174;</sup> for chemotherapy) (<xref rid="B62" ref-type="bibr">Gabizon et al., 2025</xref>)</td><td align="center" rowspan="1" colspan="1">Mostly preclinical; some early-phase clinical trials</td><td align="center" rowspan="1" colspan="1">Few clinical applications&#160;(e.g., AuroShell<sup>&#174;</sup> for photothermal therapy) (<xref rid="B34" ref-type="bibr">Chen et al., 2023</xref>)</td></tr><tr><td align="center" rowspan="1" colspan="1">Key Advantages</td><td align="center" rowspan="1" colspan="1">Proven safety, tunable degradation, sustained release, versatile delivery routes</td><td align="center" rowspan="1" colspan="1">High biocompatibility, dual drug loading, mature technology</td><td align="center" rowspan="1" colspan="1">Precise structure, monodispersity, high surface functionality</td><td align="center" rowspan="1" colspan="1">Unique properties (optical, magnetic, electronic) for theranostics</td></tr><tr><td align="center" rowspan="1" colspan="1">Major Limitations</td><td align="center" rowspan="1" colspan="1">Burst release, organic solvent use in preparation, batch-to-batch variability</td><td align="center" rowspan="1" colspan="1">Stability issues (leakage), complement activation (CARPA)</td><td align="center" rowspan="1" colspan="1">Complex synthesis, high cost, scalability challenges</td><td align="center" rowspan="1" colspan="1">Poor biodegradability, potential long-term toxicity</td></tr></tbody></table></table-wrap></sec><sec id="s2"><title>2 The principle and preparation method of PLGA as a drug nanocarrier</title><p>Modern medicine asserts that pathological conditions originate from aberrant cells within bodily organs, and effective therapeutic intervention fundamentally relies on precise delivery of pharmacological agents. To achieve successful localization at diseased cells, these therapeutic compounds must overcome multiple physiological barriers including inadequate solubility, suboptimal membrane permeability, and rapid metabolic degradation. Implementation of advanced drug delivery systems designed for targeted transport to pathological cellular sites can simultaneously enhance therapeutic safety profiles, improve clinical efficacy, and mitigate intrinsic pharmaceutical limitations such as systemic toxicity, compromised hydrophilicity, molecular instability, and insufficient tissue specificity. Medical nanotechnology innovations have significantly advanced the engineering of nanoscale therapeutic delivery platforms. The polymer PLGA, certified by the FDA for its biodegradability, has become a cornerstone material in fabricating these precision-targeted nanocarriers, enabling enhanced pharmacological agent localization and temporally regulated payload release. At present, PLGA nanoparticles carrying various hydrophilic and hydrophobic drugs are being studied to solve various thorny diseases. In addition, many studies are exploring various synthesis techniques to improve the targeting ability of PLGA nanoparticles and enable them to be highly specific in transporting to target organs (<xref rid="B113" ref-type="bibr">Matoba and Egashira, 2014</xref>). The preparation method of PLGA nanoparticles may affect their physical and chemical properties, such as particle size, particle shape, particle size distribution, suspension stability, and drug encapsulation efficiency (<xref rid="B7" ref-type="bibr">Allahyari and Mohit, 2015</xref>). The methods for preparing PLGA nanoparticles include the following: (1) Emulsion evaporation method, which is the most commonly used method, divided into single emulsion method and double/multiple emulsion method. The single emulsion method begins by solubilizing PLGA and hydrophobic drugs in organic media (e.g., chloroform). This organic phase is subsequently combined with a surfactant-stabilized aqueous solution (typically containing polyvinyl alcohol) to generate an oil-in-water dispersion. Mechanical homogenization or ultrasonic energy is then applied to achieve nanoemulsion formation. PLGA nanoparticles can be obtained through centrifugation, washing, and freeze-drying (<xref rid="B117" ref-type="bibr">Mir et al., 2017</xref>; <xref rid="B153" ref-type="bibr">Swider et al., 2018</xref>). The double/multiple emulsion approach initiates by incorporating an aqueous suspension of hydrophilic therapeutic agents into a PLGA-containing matrix, creating a primary water-in-oil dispersion. This intermediate emulsion is subsequently dispersed into a secondary surfactant-rich aqueous medium, establishing a stabilized multi-compartmental emulsion system. Through precisely controlled solvent elimination, structurally consolidated nanoparticles are obtained. This versatile methodology enables simultaneous encapsulation of both lipophilic and hydrophilic pharmaceutical compounds. Furthermore, colloidal stabilization and dimensional characteristics can be modulated by optimizing mechanical agitation parameters such as rotational velocity and energy input during the emulsification process (<xref rid="B135" ref-type="bibr">Rezvantalab et al., 2018</xref>). (2) Microfluid method, microfluidic systems represent an emerging approach for precise control of minute fluid quantities. This methodology operates on the fundamental concept where two immiscible fluids converge within micron-sized channels. Through the application of external forces or hydrodynamic shear stress, these fluids fragment into nanoscale emulsion droplets. Subsequent solvent evaporation induces particle solidification, ultimately yielding uniform nanoparticles. The advantages of microfluidic methods are uniform particle size distribution, high repeatability, and easy surface modification. Its limitation is that the production scale is small and microchannels are prone to blockage (<xref rid="B152" ref-type="bibr">Sun et al., 2014</xref>; <xref rid="B58" ref-type="bibr">Feng et al., 2015</xref>). (3) Nanoprecipitation method, PLGA polymers and hydrophobic therapeutic agents demonstrate mutual solubility in water-miscible organic solvents. The resultant homogeneous organic phase undergoes controlled-rate infusion into a surfactant-stabilized aqueous phase <italic toggle="yes">via</italic> precision syringe pumping. Subsequent rapid solvent diffusion initiates interfacial phase separation, driving the spontaneous self-assembly of PLGA-drug complexes into monodisperse nanoparticles. This nanoprecipitation methodology exhibits exceptional reproducibility and operational simplicity, while its inherent hydrophobicity-driven assembly mechanism inherently limits encapsulation efficacy for hydrophilic pharmaceutical compounds (<xref rid="B64" ref-type="bibr">Ghaly et al., 2025</xref>; <xref rid="B104" ref-type="bibr">Long et al., 2025</xref>). (4) Spray-drying method, hydrophilic drug-loaded aqueous phases can be homogenized with PLGA-containing organic phases under high-shear conditions to generate stable water-in-oil emulsions, which may subsequently be engineered into complex multiple emulsion architectures. Particulate matrices are obtained through subsequent implementation of thermally assisted aerodynamic atomization, where controlled pneumatic dispersion of the emulsion systems is coupled with rapid solvent evaporation under optimized thermal conditions (<xref rid="B25" ref-type="bibr">Booysen et al., 2013</xref>). Despite its demonstrated versatility in hydrophobic drug encapsulation, spray-drying techniques exhibit critical operational constraints primarily stemming from wall deposition phenomena. Particulate adhesion to internal reactor surfaces during the aerodynamic atomization process substantially compromises production yields, necessitating systematic process parameter optimization to mitigate interfacial interactions between nascent nanoparticles and containment substrates (<xref rid="B49" ref-type="bibr">Ding and Zhu, 2018</xref>). A critical comparison of PLGA nanoparticle fabrication techniques, focusing on scalability, reproducibility, cost, and clinical suitability, is summarized in <xref rid="T2" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Critical comparison of PLGA nanoparticle fabrication techniques.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr style="background-color:#A4A4A4"><th align="center" rowspan="1" colspan="1">Fabrication method</th><th align="center" rowspan="1" colspan="1">Scalabi-lity</th><th align="center" rowspan="1" colspan="1">Reprodu-cibility</th><th align="center" rowspan="1" colspan="1">Cost-effective-ness</th><th align="center" rowspan="1" colspan="1">Suitability for clinical translation</th><th align="center" rowspan="1" colspan="1">Advantages</th><th align="center" rowspan="1" colspan="1">Limitations</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">Emulsion Evaporation (<xref rid="B153" ref-type="bibr">Swider et al., 2018</xref>)</td><td align="center" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">Moderate (solvent removal adds cost)</td><td align="center" rowspan="1" colspan="1">High (well-established, scalable)</td><td align="center" rowspan="1" colspan="1">Versatility for hydrophobic/hydrophilic drugs</td><td align="center" rowspan="1" colspan="1">Broad size distribution; use of hazardous solvents</td></tr><tr><td align="center" rowspan="1" colspan="1">Microfluidics (<xref rid="B58" ref-type="bibr">Feng et al., 2015</xref>)</td><td align="center" rowspan="1" colspan="1">Low</td><td align="center" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">Low (low throughput, high equipment cost)</td><td align="center" rowspan="1" colspan="1">Low (currently limited to pre-clinical scale)</td><td align="center" rowspan="1" colspan="1">Excellent size control, high monodispersity</td><td align="center" rowspan="1" colspan="1">Low production scale; channel clogging</td></tr><tr><td align="center" rowspan="1" colspan="1">Nanoprecipitation (<xref rid="B64" ref-type="bibr">Ghaly et al., 2025</xref>)</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">High (simple, low energy input)</td><td align="center" rowspan="1" colspan="1">Moderate to High (simple process, good for lipophilic drugs)</td><td align="center" rowspan="1" colspan="1">Operational simplicity, high reproducibility</td><td align="center" rowspan="1" colspan="1">Unsuitable for hydrophilic drugs</td></tr><tr><td align="center" rowspan="1" colspan="1">Spray-Drying (<xref rid="B25" ref-type="bibr">Booysen et al., 2013</xref>)</td><td align="center" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">Moderate (yield loss from wall deposition increases cost)</td><td align="center" rowspan="1" colspan="1">High (continuous production potential)</td><td align="center" rowspan="1" colspan="1">Rapid, single-step, continuous process</td><td align="center" rowspan="1" colspan="1">Particle adhesion to reactor walls, reducing yield</td></tr></tbody></table></table-wrap></sec><sec id="s3"><title>3 The application of PLGA in cardiovascular diseases</title><p>Cardiovascular disease is the main cause of morbidity and mortality in developed and developing countries. It is estimated that 18 million people die each year, with cardiovascular diseases accounting for 32% of global deaths (<xref rid="B103" ref-type="bibr">Lloyd-Jones et al., 2010</xref>; <xref rid="B159" ref-type="bibr">Tucka et al., 2011</xref>; <xref rid="B18" ref-type="bibr">Barkas et al., 2024</xref>). With further understanding of the pathological mechanisms and causes of cardiovascular diseases, coupled with the rapid development of material engineering and biotechnology, drug delivery systems based on PLGA nanoplatforms are being applied to the treatment of cardiovascular diseases. The main focus of nanotechnology application in cardiovascular research is atherosclerosis, myocardial infarction and thromboembolism (<xref rid="B73" ref-type="bibr">Hu Q. et al., 2022</xref>; <xref rid="B81" ref-type="bibr">Katsuki et al., 2022</xref>; <xref rid="B46" ref-type="bibr">Dash et al., 2023</xref>; <xref rid="B170" ref-type="bibr">Wu et al., 2024</xref>). Atherosclerosis is a chronic inflammatory vascular disease characterized by gradual thickening of the arterial wall (<xref rid="B99" ref-type="bibr">Libby et al., 2002</xref>; <xref rid="B13" ref-type="bibr">B&#228;ck et al., 2019</xref>; <xref rid="B147" ref-type="bibr">Soehnlein and Libby, 2021</xref>). Small molecule drugs, such as statins, are commonly used to reduce atherosclerosis (<xref rid="B4" ref-type="bibr">Adhyaru and Jacobson, 2018</xref>). However, there are many issues with the systemic administration of these chemicals, including poor bioavailability, slow therapeutic effects, and serious side effects. In order to overcome these problems, PLGA was used to synthesize various nanocarriers to deliver small molecule drugs targeting atherosclerotic plaque. The specific release of such drugs at the lesion can improve their bioavailability and therapeutic efficacy (<xref rid="B29" ref-type="bibr">Chan et al., 2017</xref>; <xref rid="B35" ref-type="bibr">Cheng et al., 2018</xref>; <xref rid="B83" ref-type="bibr">Kim et al., 2018</xref>; <xref rid="B182" ref-type="bibr">Zhou et al., 2018</xref>). The PLGA nanoparticles loaded with pitavastatin prepared by Katsuki et al. inhibit monocyte recruitment through low expression of chemoattractant proteins and their stimulating factors during sustained release of statins, thereby reducing plaque instability and rupture (<xref rid="B80" ref-type="bibr">Katsuki et al., 2014</xref>). Anning Yanget al. Developed PLGA hybrid nanocomplexes co-loaded with Pitavastatin and Resveratrol, targeting macrophage ferroptosis to reduce lipid deposition and inflammation in atherosclerosis. It demonstrated significant plaque reduction <italic toggle="yes">in vivo</italic>, offering a novel strategy for atherosclerosis treatment (<xref rid="B174" ref-type="bibr">Yang et al., 2025</xref>). Imatinib is a platelet derived growth factor receptor (PDGFR) inhibitor. The activity of PDGFR has a serious impact on the progress of atherosclerosis. Stabilin-2 is a glycoprotein that widely exists in atherosclerotic plaque. S2P is a peptide that selectively binds to Stabilin-2. Imatinib loaded PLGA nanoparticles modified with S2P peptide are used to deliver targeted drugs to atherosclerotic plaque (<xref rid="B54" ref-type="bibr">Esfandyari-Manesh et al., 2020</xref>). In addition to targeted and specific release, another major obstacle to the application of nanomedicines is that most nanoparticles are cleared by the immune system before reaching the target (<xref rid="B22" ref-type="bibr">Blanco et al., 2015</xref>; <xref rid="B100" ref-type="bibr">Liu et al., 2017</xref>). To better evade immune system clearance and release drugs at plaque sites, different biomimetic designs have emerged (<xref rid="B168" ref-type="bibr">Wei et al., 2017</xref>; <xref rid="B111" ref-type="bibr">Martinez et al., 2018</xref>; <xref rid="B23" ref-type="bibr">Boada et al., 2020</xref>; <xref rid="B127" ref-type="bibr">Park et al., 2020</xref>). In the early stage of atherosclerosis, activated endothelial cells induce macrophage recruitment by secreting adhesion molecules and chemokines. Therefore, macrophage based biomimetic nanoparticles can precisely target the inflammatory region in atherosclerotic lesions. Wang et al. covered the surface of rapamycin loaded PLGA nanoparticles with a macrophage membrane coating, which can be accumulated in activated endothelial cells, It can effectively inhibit the phagocytosis of macrophages and the progression of atherosclerosis <italic toggle="yes">in vivo</italic> (<xref rid="B166" ref-type="bibr">Wang et al., 2021</xref>). Erythrocyte membrane has high biocompatibility, EPR and long half-life. PLGA coated with erythrocyte membrane can accurately deliver rapamycin to atherosclerotic plaque to reduce the progression of atherosclerosis (<xref rid="B164" ref-type="bibr">Wang Y. et al., 2019</xref>). In myocardial ischemia, myocardial cell death and fibrosis can lead to impaired myocardial function. Proangiogenic cytokines such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) can stimulate neovascularization in ischemic heart tissue and improve functional impairment (<xref rid="B110" ref-type="bibr">Maija et al., 2014</xref>; <xref rid="B63" ref-type="bibr">Ghalehbandi et al., 2023</xref>; <xref rid="B118" ref-type="bibr">Morita and Hoshiga, 2024</xref>; <xref rid="B161" ref-type="bibr">Voronkov et al., 2024</xref>). PLGA nanoparticles loaded with VEGF have been shown to be a promising cytokine delivery system in rat myocardial ischemia models (<xref rid="B60" ref-type="bibr">Formiga et al., 2010</xref>). Yokoyama et al. demonstrated that PLGA nanoparticles loaded with simvastatin can significantly enhance cell migration and growth factor expression <italic toggle="yes">in vitro</italic>, and target mouse myocardial ischemic regions and induce endogenous heart regeneration through intravenous administration (<xref rid="B176" ref-type="bibr">Yokoyama et al., 2019</xref>). Coronary artery reperfusion leads to abnormal death of myocardial cells, known as myocardial ischemia-reperfusion injury. Monocytic inflammatory mediators demonstrate pivotal involvement in this pathophysiological cascade, indicating that they are potential targets for treating myocardial ischemia-reperfusion injury. PLGA nanoparticles loaded with irbesartan can enhance the protection of myocardial extracellular matrix from ischemia-reperfusion injury by inhibiting monocyte recruitment in myocardial ischemia-reperfusion injury models (<xref rid="B121" ref-type="bibr">Nakano et al., 2016</xref>). Thrombotic events constitute a critical pathophysiological mechanism underlying potentially fatal cardiovascular disorders, particularly acute myocardial infarction, cerebrovascular ischemia, and pulmonary thromboembolism. The current thrombolytic therapy, which involves injecting plasminogen activator (PA), is still limited by narrow treatment windows, rapid drug elimination, and the risk of bleeding (<xref rid="B132" ref-type="bibr">Rashedi et al., 2024</xref>). PLGA nanostructures loaded with PA can protect thrombolytic drugs from enzymatic degradation, optimize therapeutic outcomes in thrombus management through enhanced pharmacological precision while concurrently mitigating treatment-related complications. The surface PEG of PLGA nanoparticles plays an important role in biocompatibility and can improve pharmacokinetics. Colasuono et al. prepared a disk-shaped porous nanostructure using a mixture of PLGA and PEG and loaded it with rtPA. Although lacking active targeting ability, the high thrombolytic potential of these nanoparticles may be attributed to their ability to mimic the shape and deformation of red blood cells, leading to their significant accumulation at the site of thrombosis (<xref rid="B39" ref-type="bibr">Colasuonno et al., 2018</xref>). Stimuli-responsive PLGA-based phase-transition nanovesicles incorporating thrombolytic payloads have emerged as a novel theranostic platform. In the innovative approach developed by Liu hu et al., recombinant tissue plasminogen activator (rtPA) was encapsulated within these intelligent nanocarriers, while surface functionalization with CREKA peptide ligands conferred fibrin-specific targeting capability through selective binding to thrombus-associated fibrin networks. Upon exposure to low-intensity focused ultrasound (LIFU) irradiation, the nanovesicles undergo controlled volumetric oscillations (expansion) that induce mechanical disruption of thrombus architecture. This cavitation-mediated structural destabilization synergistically facilitates both rapid payload release and enhanced intralesional drug permeation, thereby amplifying rtPA&#8217;s fibrinolytic efficacy through dual-action mechanisms. The integration of acoustic-mechanical thrombus ablation with pharmacologically-enhanced clot dissolution establishes a synergistic therapeutic paradigm for precision thrombosis management (<xref rid="F1" ref-type="fig">Figure 1</xref>) (<xref rid="B72" ref-type="bibr">Hu L. et al., 2022</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>This study developed a thrombus-fibrin-targeting phase-change nanoparticle (NP) with a core composed of perfluorohexane (PFH) and the thrombolytic drug rtPA, surface-modified with CREKA peptide. The results demonstrated that under low-intensity focused ultrasound (LIFU) triggering, the NP enabled precise release of rtPA and synergized with the mechanical disruption of thrombus structures through PFH&#8217;s &#8220;liquid-gas&#8221; phase transition effect (<xref rid="B72" ref-type="bibr">Hu L. et al., 2022</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1670397-g001.jpg"><alt-text content-type="machine-generated">Diagram illustrating the creation and application of microbubbles for medical imaging. It shows the emulsification process using PFH and rtPA to form microbubbles, which are further combined with CREKA and EDC/NHS. The microbubbles are used in ultrasound (US) imaging and interact with fibrin, platelets, and red blood cells (RBC) in a blood vessel. LIFU is depicted enhancing the process.</alt-text></graphic></fig></sec><sec id="s4"><title>4 The application of PLGA in central nervous system drug delivery</title><p>The demographic aging trend worldwide has precipitated a surge in neurodegenerative disorder prevalence (<xref rid="B71" ref-type="bibr">Hou et al., 2019</xref>), with therapeutic intervention efficacy significantly constrained by the blood-brain barrier&#8217;s (BBB) restrictive permeability to neuropharmaceuticals. To address these pharmacological constraints and enhance therapeutic outcomes, scientific investigation increasingly focuses on PLGA-based nanoparticulate delivery vehicles. These engineered nanocarriers demonstrate promising potential for managing major neurodegenerative pathologies, including Alzheimer&#8217;s disease, Parkinson&#8217;s disease, Huntington&#8217;s chorea, amyotrophic lateral sclerosis, and multiple sclerosis, through optimized CNS-targeted drug translocation (<xref rid="B17" ref-type="bibr">Barbu et al., 2009</xref>; <xref rid="B31" ref-type="bibr">Chen and Liu, 2012</xref>; <xref rid="B115" ref-type="bibr">Meir et al., 2014</xref>; <xref rid="B141" ref-type="bibr">Saraiva et al., 2016</xref>). Alzheimer&#8217;s disease (AD) represents the predominant neurodegenerative disorder, manifesting as progressive cognitive deterioration. Its distinctive neuropathological hallmarks include extracellular aggregation of &#946;-amyloid (A&#946;) peptides and intraneuronal accumulation of hyperphosphorylated tau protein, forming neurofibrillary tangles composed of paired helical filaments (<xref rid="B82" ref-type="bibr">Khalid et al., 2010</xref>; <xref rid="B119" ref-type="bibr">Murphy et al., 2010</xref>). Curcumin exhibits anti amyloid effects by inhibiting the formation of new A&#946; aggregates and clearing existing A&#946; aggregates. Curcumin cannot effectively cross the BBB, resulting in lower brain intake. Therefore, PLGA nanoparticles have been developed for encapsulating curcumin to enhance its ability to cross the BBB. Fan et al. studied the encapsulation of curcumin in PLGA-PEG nanoparticles functionalized with B6 peptide and observed that compared with natural curcumin, APP/PS1 mice showed improved spatial learning and memory abilities (<xref rid="B56" ref-type="bibr">Fan et al., 2018</xref>). As mentioned earlier, AD is related to protein (i.e., A &#946;) aggregation, which induces oxidative stress and leads to neuroinflammation. Thymoquinone (TQ) is a plant compound with antioxidant and anti-inflammatory properties. Yusuf et al. designed a PLGA nanoparticle surface-functionalized with polysorbate 80 loaded with thymoquinone (P-80-TQ), which acted on a mouse model of AD. The P-80-TQ nanoparticle crossed the blood-brain barrier through the endocytosis, significantly increasing superoxide dismutase (SOD) activity. After treatment with P-80-TQ nanoparticle, histopathological examination of the hippocampus tissue showed a sharp decrease in protein aggregates produced by streptozotocin induced AD in mice (<xref rid="B179" ref-type="bibr">Yusuf et al., 2021</xref>). Huang et al. functionalized PLGA nanoparticles with an iron-mimetic cyclic peptide (CRT) to target the transferrin/transferrin receptor protein complex, thereby enhancing BBB permeability. The spatial memory and recognition ability were significantly improved, and the levels of A &#946;, ROS, TNF, and IL-6 in the brain of AD mice decreased (<xref rid="B120" ref-type="bibr">Na et al., 2017</xref>). Overall, the PLGA nanocarrier system can improve the bioavailability of the brain and ameliorate AD symptoms, reduce neuroinflammation, clear/inhibit the formation of A &#946; aggregates, and lower the levels of several AD brain biomarkers. Parkinson&#8217;s disease (PD) manifests characteristic neuropathological hallmarks marked by progressive degeneration of dopaminergic neurons within distinct nigrostriatal pathways and the intraneuronal accumulation of Lewy bodies containing misfolded &#945;-synuclein aggregates. The pathophysiological cascade further involves dysregulation of dopaminergic neurotransmission, mitochondrial bioenergetic deficits, redox imbalance, and chronic neuroinflammatory responses, collectively contributing to nigrostriatal system deterioration (<xref rid="B105" ref-type="bibr">Luk et al., 2012</xref>; <xref rid="B37" ref-type="bibr">Chu et al., 2023</xref>; <xref rid="B87" ref-type="bibr">Lababidi and Azzazy, 2025</xref>). Chen et al. prepared PLGA nanoparticles loaded with antioxidant activity puerarin for the treatment of PD, and found that they could increase the drug&#8217;s half-life and bioavailability, improve behavioral deficits in mice, and restore dopamine levels (<xref rid="B32" ref-type="bibr">Chen T. et al., 2019</xref>). You et al. engineered a rabies virus glycoprotein (RVG)-functionalized PLGA nanoplatform encapsulating deferoxamine mesylate, a clinically approved iron chelator, to address iron dyshomeostasis-mediated oxidative neurodegeneration in PD. This targeted delivery system demonstrated efficacy in attenuating nigrostriatal iron accumulation and redox imbalance through selective BBB penetration, thereby preserving dopaminergic neuronal integrity in substantia nigra pars compacta-striatum circuitry (<xref rid="F2" ref-type="fig">Figure 2</xref>) (<xref rid="B177" ref-type="bibr">You et al., 2018</xref>). Bali et al. designed PLGA nanoparticles loaded with rasakin. The release of rasakin restored presynaptic dopamine consumption in the PD model. In addition, a 99 mTC loaded PLGA nanoparticle was used for gamma scintillation scanning to evaluate the permeability and targeting efficiency of the BBB, and it was observed that it can cross the BBB and target the brain (<xref rid="B15" ref-type="bibr">Bali and Salve, 2020</xref>). Multiple sclerosis is an autoimmune neurodegenerative disease, in which the immune system recognizes myelin sheaths as foreign antigens, leading to neuronal demyelination and gradual loss of neuronal structure and function (<xref rid="B157" ref-type="bibr">Trapp and Nave, 2008</xref>; <xref rid="B14" ref-type="bibr">Baecher-Allan et al., 2018</xref>). Leukemia inhibitory factor (LIF), a multifunctional therapeutic cytokine, exhibits dual immunoregulatory activity and myelination-enhancing potential. Rittchen et al. engineered LIF-loaded PLGA nanocarriers for targeted oligodendrocyte precursor cell (OPC) delivery, demonstrating enhanced differentiation of OPCs into mature myelinating oligodendrocytes and subsequent remyelination efficacy in demyelination models (<xref rid="B136" ref-type="bibr">Rittchen et al., 2015</xref>). Hunter and Gholamzad prepared PLGA nanoparticles loaded with the myelin proteolipid protein, for the treatment of multiple sclerosis mouse models. The results showed that they could reduce the neuroinflammation in the nervous system (<xref rid="B183" ref-type="bibr">Zoe et al., 2014</xref>; <xref rid="B65" ref-type="bibr">Gholamzad et al., 2020</xref>). Huntington&#8217;s disease (HD) is a hereditary disease, and its symptoms are often accompanied by progressive motor, behavioral, and mental disorders, which are related to the death of striatal neurons (<xref rid="B59" ref-type="bibr">Ferrante et al., 1985</xref>; <xref rid="B47" ref-type="bibr">David, 2002</xref>). Valenza developed cholesterol loaded PLGA nanoparticles and functionalized them with g7 glycopeptides to enhance the BBB targeting and brain accumulation of PLGA nanoparticles. This nanosystem can partially ameliorate the symptoms of the HD mice (<xref rid="B160" ref-type="bibr">Valenza et al., 2015</xref>). Cano used PLGA nanoparticle carrying ascorbic acid to treat HD, and the results showed reduced loss of striatal neurons (<xref rid="B27" ref-type="bibr">Cano et al., 2019</xref>; <xref rid="B28" ref-type="bibr">Cano et al., 2021</xref>). Amyotrophic lateral sclerosis (ALS), a fatal motor neuron disorder affecting spinal anterior horn cells, drives progressive neuromuscular degeneration (<xref rid="B131" ref-type="bibr">Pineda et al., 2024</xref>). Medina et al. engineered PEGylated PLGA nanocarriers to enhance hydrophobic drug bioavailability and pharmacokinetic profiles. This CNS-targeted formulation modulates retinoic acid receptor-mediated signaling pathways, demonstrating neuroprotective effects through improved motor function preservation and survival extension in preclinical ALS models (<xref rid="B114" ref-type="bibr">Medina et al., 2020</xref>). To address the side effects of high-dose riluzole in ALS treatment, Gerard Esteruelas et al. developed pVEC and PEG-functionalized PLGA nanoparticles for targeted delivery. This system enhances riluzole transport across the BBB, improves motor neuron uptake, reduces off-target accumulation, and shows promise as a targeted therapy for motor neuron diseases (<xref rid="B55" ref-type="bibr">Esteruelas et al., 2025</xref>).</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>This study developed an RVG29-modified polymeric nanoparticle system for targeted delivery of deferoxamine (DFO) to treat Parkinson&#8217;s disease (PD). As shown in the panel <bold>(A-C)</bold>, the system penetrates the blood-brain barrier <italic toggle="yes">via</italic> RVG29-mediated receptor-mediated endocytosis, significantly reducing nigrostriatal iron deposition and oxidative stress in PD mice, alleviating dopaminergic neuron injury, and reversing neurobehavioral deficits (<xref rid="B177" ref-type="bibr">You et al., 2018</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1670397-g002.jpg"><alt-text content-type="machine-generated">Diagram illustrating a three-part process for delivering deferoxamine (DFO) using nanoparticles. Part A shows the creation of RNP-DFO using double emulsion and stirring with RVG29-Cys. Part B depicts receptor-mediated transcytosis across the blood-brain barrier, with RNP-DFO interacting with cell surface receptors on endothelial cells. Part C details receptor-mediated endocytosis in cells, with DFO being released to reduce free iron and reactive oxygen species (ROS) in the cytoplasm.</alt-text></graphic></fig></sec><sec id="s5"><title>5 The application of PLGA in digestive system diseases</title><p>The main cause of gastric ulcer is excessive secretion of gastric acid, and anticholinergic drugs, antacids, histamine H2 receptor antagonists, and proton pump inhibitors are the main treatment options. However, existing treatment modalities often face restricted implementation due to insufficient therapeutic outcomes coupled with undesirable pharmacological responses (<xref rid="B9" ref-type="bibr">Almadi et al., 2024</xref>; <xref rid="B21" ref-type="bibr">Bhatnagar et al., 2024</xref>). As a bioactive phytonutrient derived from citrus species, Diosmin demonstrates triple therapeutic potentials: modulating inflammatory pathways, neutralizing reactive oxygen species, and protecting gastrointestinal mucosa. Its pharmacological application is nevertheless challenged by inherent physicochemical limitations, particularly low hydrophilicity that leads to suboptimal drug dissolution and subsequent reduction in systemic bioavailability (<xref rid="B162" ref-type="bibr">Vrbata et al., 2014</xref>; <xref rid="B137" ref-type="bibr">Russo et al., 2018</xref>). The application of PLGA nanoparticles has shown remarkable efficacy in facilitating pharmaceutical transport across multiple physiological interfaces. These biodegradable polymeric systems exhibit unique capabilities to enhance therapeutic compound penetration through specialized biological membranes, particularly demonstrating success in traversing the neurovascular unit of the central nervous system, intestinal epithelial barriers, olfactory pathways, and corneal-endothelial interfaces (<xref rid="B156" ref-type="bibr">Tracy et al., 2023</xref>). Chitosan, a cationic biopolymer derived from the partial deacetylation of chitin, exhibits pH-responsive solubility and intrinsic mucoadhesive properties in acidic environments. Functionalizing PLGA nanocarriers with this amphipathic polysaccharide creates a multifunctional platform capable of stabilizing macromolecular therapeutics (e.g., proteins) through electrostatic shielding, while simultaneously conferring cationic surface characteristics <italic toggle="yes">via</italic> protonated amino groups. The reactive hydroxyl and amine moieties further enable covalent conjugation of site-specific ligands, synergistically enhancing cellular affinity and prolonging residence time at mucosal interfaces. This dual-action modification strategy optimizes drug transport kinetics across epithelial barriers, thereby achieving therapeutic efficacy at reduced dosages while mitigating systemic toxicity through localized delivery mechanisms (<xref rid="B38" ref-type="bibr">Chuah et al., 2011</xref>; <xref rid="B36" ref-type="bibr">Chronopoulou et al., 2013</xref>). A study has shown that chitosan coated PLGA nanoparticles loaded with Diosmin can improve gastric retention and cellular uptake of Diosmin in the treatment of gastric ulcers through oral administration (<xref rid="B1" ref-type="bibr">Abd El Hady et al., 2019</xref>). Pancreatitis is a non infectious inflammation that occurs in the pancreatic region, mainly divided into acute pancreatitis and chronic pancreatitis. Acute pancreatitis is caused by various etiologies, leading to acute damage such as pancreatic tissue edema, bleeding, and necrosis, while chronic pancreatitis represents a persistent inflammatory disorder of pancreatic parenchyma characterized by irreversible fibro-inflammatory progression, manifesting as focal or generalized glandular destruction with multifactorial etiological origins. Ulinastatin is commonly used in clinical practice to treat acute pancreatitis, but its therapeutic effect is limited by the blood pancreatic barrier and low specificity. Yunlong Chen et al. prepared macrophage biomimetic nanoparticles (MU) using macrophage membranes as the outer shell for loading ulinastatin PLGA nanoparticles. Research has found that MU exhibits good stability and biocompatibility both <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic>. According to <italic toggle="yes">in vivo</italic> fluorescence imaging, MU demonstrates specific anti-inflammatory targeting capacity across multiple experimental paradigms, showing robust therapeutic efficacy in both hypodermal inflammatory lesions and pancreas-specific pathophysiological murine systems. Mechanistic investigations employing integrated transcriptomic-proteomic analysis reveal that MU exerts its pancreoprotective effects through coordinated modulation of inflammatory signaling cascades, particularly <italic toggle="yes">via</italic> downregulation of NF-&#954;B-mediated cytokine storm and preservation of acinar cell mitochondrial membrane integrity (<xref rid="F3" ref-type="fig">Figure 3</xref>) (<xref rid="B178" ref-type="bibr">Yunlong et al., 2023</xref>). The clinical application of therapeutic peptides often faces challenges in absorption, distribution, metabolism, and excretion. The use of somatostatin (SST) peptide in the treatment of chronic pancreatitis is limited by its short half-life and potential side effects. Therefore, Fang Wang et al. developed a PLGA nanocarrier system coated with macrophage membrane to improve the bioavailability of SST. Compared with macrophages, membrane polymer hybrid nanoparticles have higher cellular activity, are more easily ingested by activated endothelial cells, and exhibit better biocompatibility and targeting ability <italic toggle="yes">in vitro</italic>. Following systemic administration in chronic pancreatitis murine models, engineered biohybrid nanocarriers demonstrated multifunctional therapeutic outcomes, including elevation of somatostatin bioavailability in circulatory and pancreatic compartments, suppression of fibro-inflammatory mediators (TGF-&#946;1, IL-6), and attenuation of histopathological damage indices. The optimized pharmacological profile of SST validates the synergistic advantages of PLGA-biomembrane conjugation in developing precision peptide delivery architectures. This modular nanosystem platform exhibits translational extensibility for diverse therapeutic peptides, enabling targeted biodistribution while addressing formulation challenges related to proteolytic stability and epithelial permeability, thereby advancing peptide-based pharmacotherapy in clinical settings (<xref rid="B167" ref-type="bibr">Wang et al., 2022</xref>). Inflammatory bowel disease (IBD) represents a category of immune-mediated relapsing-remitting disorders affecting the gastrointestinal tract, clinically classified into two distinct entities: ulcerative colitis (UC) characterized by continuous colonic mucosal inflammation, and Crohn&#8217;s disease (CD) marked by discontinuous segmental transmural lesions. Both subtypes exhibit cyclical disease activity patterns with alternating phases of inflammatory exacerbation and quiescence, necessitating localized therapeutic intervention through site-targeted delivery systems to achieve mucosal barrier restoration and sustained disease control (<xref rid="B12" ref-type="bibr">Ashton and Beattie, 2024</xref>; <xref rid="B158" ref-type="bibr">Triantafillidis et al., 2024</xref>). Kohei Tahara et al. developed a chitosan (CS) modified PLGA nanoparticle oral delivery system loaded with nuclear factor kappa B (NF kB) bait oligonucleotide (ODN) to evaluate its application in UC experimental models. The results showed that the system improved the stability of ODN towards DNase I and gastric juice, significantly enhancing cell uptake, effectively improving dextran sulfate induced diarrhea, reducing bloody stools, and lowering myeloperoxidase activity. By using a nano targeted drug delivery system with specific accumulation ability in the inflammatory mucosal area, pharmacotherapeutic optimization in IBD management through targeted delivery systems significantly attenuates treatment-related toxicities arising from systemic immunomodulatory regimens (<xref rid="B154" ref-type="bibr">Tahara et al., 2011</xref>). The aggregation and deposition of different functionalized PLGA nanoparticles on the surface of polyethylene glycol in inflamed mucosa increase, which is considered an innovative strategy for treating IBD (<xref rid="B74" ref-type="bibr">Hua et al., 2015</xref>). Cec&#237;lia Cristelo et al. developed ROS-responsive cleavable PEG-functionalized PLGA nanoparticles for targeted oral delivery of budesonide to inflamed intestines. These nanoparticles enhance drug retention, reduce cytokine release, and significantly alleviate inflammation in colitis mice, demonstrating great potential for improved IBD therapy (<xref rid="B42" ref-type="bibr">Cristelo et al., 2025</xref>). Irritable bowel syndrome with diarrhea (IBS-D) manifests as a chronic bowel dysfunction syndrome in adults, defined by pathognomonic features including visceral hypersensitivity, rectal urgency, postprandial bloating, and altered bowel habit. Eluxadoline (ELUX), a first-in-class enteroactive agent, exerts its therapeutic effects <italic toggle="yes">via</italic> multimodal receptor pharmacology&#8212;combining &#956;/&#954;-opioid receptor agonism with &#948;-opioid receptor antagonism&#8212;to locally modulate enteric neural signaling and visceral nociception, thereby addressing IBS-D symptomatology through dual mechanisms of bowel motility regulation and pain pathway modulation. Because ELUX has poor water solubility, low dissolution rate, and low oral bioavailability, Md. K. Anwer et al. prepared Eudragit S100-coated PLGA nanoparticles loaded with ELUX to significantly improve the dissolution rate and bioavailability of ELUX (<xref rid="B10" ref-type="bibr">Anwer et al., 2017</xref>). Enterotoxigenic <italic toggle="yes">Escherichia coli</italic> (ETEC) is the most common cause of childhood diarrhea, and the colonization factor (CF) and toxin are the main ETEC candidate vaccines. S Nazarian et al. studied the oral immunogenicity of PLGA-encapsulated chimeric proteins containing different CFs and non-toxic toxin antigens, and the results showed that PLGA-encapsulated chimeric proteins can prevent ETEC from adhering and causing toxicity (<xref rid="B122" ref-type="bibr">Nazarian et al., 2014</xref>).</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>This study developed macrophage membrane biomimetic nanoparticles (MU) by encapsulating a polyethylene glycol-polylactic-co-glycolic acid-ulinastatin (PEG-PLGA-ulinastatin) composite to achieve targeted delivery. Experiments confirmed that MU exhibits excellent stability and biocompatibility, enabling precise targeting of subcutaneous and pancreatic inflammatory lesions <italic toggle="yes">via</italic> adhesion protein-mediated interactions. MU inhibits pro-inflammatory cytokine release, maintains cellular viability, and effectively alleviates AP symptoms (<xref rid="B178" ref-type="bibr">Yunlong et al., 2023</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1670397-g003.jpg"><alt-text content-type="machine-generated">Diagram illustrating the process of using macrophage membranes to create MU for targeting the pancreas in a mouse model of caerulein-induced acute pancreatitis. Components include ulinastatin, PEG-PLGA, and macrophage membranes. Insets show MU recruitment, inhibition of P65/NF-kB, TNF-alpha, and IL-6 release, and highlight injured acinar cells.</alt-text></graphic></fig></sec><sec id="s6"><title>6 Application of PLGA in the treatment of infection</title><p>The rise of antibiotic resistance is due to the abuse of antibiotics, which also promotes the development of multi drug resistant microorganisms. If there is no suitable new drug for treatment, the diseases involving drug-resistant bacteria infection will be difficult to control. The escalating global challenge of antimicrobial resistance necessitates the strategic development of precision-targeted anti-infective therapeutics with pathogen-specific activity profiles. Nanotechnology may be one of the best choices, because it can develop intelligent nanoparticles with required properties by using physical and chemical properties, enable site-selective transport of therapeutic payloads to pathologically defined loci with spatiotemporal precision, and reduce the incidence of drug resistance. Because of its good biocompatibility and biodegradability, PLGA has been used to load or package antibiotics, natural products or metal ions for antibacterial treatment (<xref rid="B146" ref-type="bibr">Singh et al., 2018</xref>; <xref rid="B41" ref-type="bibr">Cresti et al., 2022</xref>; <xref rid="B40" ref-type="bibr">Costabile et al., 2024</xref>; <xref rid="B102" ref-type="bibr">Liu et al., 2024</xref>). Rifampicin is an antibiotic, which is used to prevent various infections caused by mycobacteria. It has bactericidal effect on both Gram-positive and Gram-negative bacteria. Maghrebi et al. engineered rifampicin-encapsulated PLGA-lipid hybrid nanocomposites to combat intracellular persister phenotypes of <italic toggle="yes">Staphylococcus aureus</italic>, specifically targeting biofilm-associated small colony variants through enhanced intracellular penetration and sustained antibiotic retention, which was conducive to the release of drugs into the cells (<xref rid="F4" ref-type="fig">Figure 4</xref>) (<xref rid="B109" ref-type="bibr">Maghrebi et al., 2020</xref>). N-Acetylcysteine (NAC) holds potential for tuberculosis treatment. Kabi Raj Chaudhary et al. developed inhalable lactose-coated PLGA nanoparticles loaded with NAC. They achieved enhanced lung deposition and antibacterial activity against <italic toggle="yes">M. tuberculosis</italic> H37Rv, showing a 4-fold improvement in MIC compared to free NAC(<xref rid="B30" ref-type="bibr">Chaudhary et al., 2025</xref>). Antimicrobial peptides (AMPS) have broad-spectrum antibacterial properties. Their antibacterial mechanism is the interaction with the cell membrane of pathogenic bacteria. Because they are easy to inactivate and disintegrate in the acidic gastric environment, their therapeutic application is limited. These limitations can be improved by loading peptides and proteins into nanoparticles. Cruz et al. engineered PLGA nanoparticles encapsulating the novel antimicrobial peptide gibim-p5s9k, conducting comparative analysis of microbiocidal efficacy between the unconjugated peptide formulation and peptide-encapsulated polymeric vectors. They concluded that PLGA nanoparticles loaded with peptide showed higher antibacterial activity against <italic toggle="yes">Escherichia coli</italic>, MRSA and <italic toggle="yes">Pseudomonas aeruginosa</italic> than free peptide, which was suitable for oral administration and could be released to the target area to improve the bioavailability (<xref rid="B43" ref-type="bibr">Cruz et al., 2017</xref>). Azithromycin (AZI), a 15-membered azalide-class antibacterial compound, demonstrates reduced efficacy against multidrug-resistant clinical isolates of <italic toggle="yes">Enterococcus faecalis</italic> and methicillin-resistant <italic toggle="yes">S. aureus</italic> (MRSA) due to overexpression of ABC transporter-mediated efflux mechanisms. Abo Zeid&#8217;s team developed a nanoencapsulation strategy for AZI using PLGA nanovectors, conducting comparative antimicrobial efficacy assessments between the free drug and nanoformulated counterparts toward these pathogens under standardized CLSI guidelines. The surface-functionalized nanocomposites exhibited a 4&#8211;8 fold enhancement in growth inhibition rates compared to non-encapsulated AZI, with MIC values against both strains reduced by 64&#8211;128-fold (p &lt; 0.01), effectively overcoming intrinsic resistance phenotypes through bypass of efflux-mediated drug exclusion (<xref rid="B2" ref-type="bibr">Abo-zeid et al., 2022</xref>). Platensimycin (PTM), a novel antimicrobial agent targeting the type II fatty acid biosynthesis (FAS-II) pathway, exhibits selective suppression of multidrug-resistant Gram-positive pathogens through competitive inhibition of &#946;-ketoacyl synthase activity (<xref rid="B50" ref-type="bibr">Dong et al., 2017</xref>). Liu et al. engineered PTM-encapsulated PLGA nanocomposites to address the suboptimal pharmacokinetic profiles of platensimycin, conducting comprehensive assessments of antimicrobial efficacy across both cellular and mammalian infection models. The nanoformulation demonstrated targeted biofilm disruption efficacy against MRSA, with enhanced bacterial clearance in phagocytic cells and improved survival outcomes in murine systemic infection studies. This delivery system concurrently optimized drug biodistribution parameters while validating FAS-II-targeted therapeutic strategies for combating multidrug-resistant pathogens (<xref rid="B101" ref-type="bibr">Liu et al., 2020</xref>). Lactoferrin, a multifunctional siderophilic glycoprotein with intrinsic antimicrobial properties, demonstrates therapeutic potential in managing ocular surface disorders characterized by tear film instability and inflammatory cascades. Amphotericin B remains a gold-standard therapeutic agent for mycotic keratitis, though its clinical translation is constrained by formulation challenges including aqueous instability and premature precorneal clearance <italic toggle="yes">via</italic> nasolacrimal drainage pathways. To solve the above problems, Sammar et al. Loaded lactoferrin and amphotericin B into PLGA-PEG-PEI nanoparticles to improve their pharmacokinetic properties and corneal penetration. Confocal laser scanning showed that the fluorine labeled nanoparticles had good penetrability. Irritation test, atomic force microscope, cell culture, animal test and histopathological analysis showed that nanoparticles had advantages in reducing inflammatory signs and eradicating fungal infection in rabbit eyes, and would not cause any damage to rabbit eyes (<xref rid="B53" ref-type="bibr">Elhabal et al., 2023</xref>). The polymeric extracellular matrix formed by microbial consortia paradoxically functions as a protective barrier against exogenous threats, encompassing both immunological defenses and antimicrobial agents. This adaptive survival mechanism significantly contributes to the emergence of multidrug-resistant phenotypes. Traditional antimicrobial formulations are constrained by intrinsic limitations such as suboptimal membrane permeability, hydrolytic instability, and hydrophobic characteristics. This therapeutic impasse necessitates urgent pharmacotherapeutic innovation through either novel antimicrobial entities or engineered delivery platforms. PLGA-based polymeric architectures are positioned as versatile therapeutic vectors due to their rational design capabilities&#8212;exhibiting precise drug payload modulation through controlled synthesis methodologies and programmable surface functionalization with molecular recognition motifs. Therefore, PLGA based nanoparticles can be considered as potential candidates to inhibit and destroy microbial growth by improving physical and chemical properties (<xref rid="B151" ref-type="bibr">Stewart and William Costerton, 2001</xref>; <xref rid="B26" ref-type="bibr">Cai et al., 2012</xref>; <xref rid="B11" ref-type="bibr">Arafa et al., 2019</xref>; <xref rid="B142" ref-type="bibr">Shariati et al., 2022</xref>; <xref rid="B88" ref-type="bibr">Landa et al., 2024</xref>; <xref rid="B155" ref-type="bibr">Takahashi and Moriguchi, 2024</xref>). In the future, researchers will focus on the mechanism of action of PLGA nanoparticles loaded with antibacterial drugs <italic toggle="yes">in vivo</italic> to ensure that the design of these polymer nanocarriers is more reasonable. In addition to being used as a carrier of antibacterial drugs, PLGA nanoparticles are also used to prepare vaccine preparations. Some kinds of Leishmania can not stimulate macrophages and cause chronic infection. Therefore, the activation of macrophages is very important for the elimination of Leishmania parasites in the cells. In order to overcome this inhibition and induce innate immune response, Asal Katebi et al. studied the effects of PLGA nanoparticles encapsulated Leishmania soluble antigen (SLA) and TLR1/2 (Pam3CSK4) and TLR7/8 (R848) agonists on the activation of macrophages infected with Leishmania. The results showed that the above PLGA nanoparticles overcame the inhibition of Leishmania infected macrophages. In addition, they increased the intensity and duration of cytokines and iNOS expression, indicating that PLGA nanoparticles had longer availability or delivery time in macrophages. These findings reflected the advantages of PLGA nanoparticles as a therapeutic vaccine preparation (<xref rid="B79" ref-type="bibr">Katebi et al., 2021</xref>).</p><fig position="float" id="F4" orientation="portrait"><label>FIGURE 4</label><caption><p>This study encapsulated rifampicin into hybrid microparticles (PLH) composed of PLGA-coated lipid nanoparticles to enhance its inhibitory efficacy against SCV. The spray-dried PLH microparticles loaded the drug within both polymer and lipid phases. Upon decomposition into nano-aggregates, PLH promoted uptake by RAW264.7 macrophages, significantly reduced intracellular bacterial survival, and exhibited no significant toxicity (<xref rid="B109" ref-type="bibr">Maghrebi et al., 2020</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1670397-g004.jpg"><alt-text content-type="machine-generated">Diagram illustrating the process of nanoparticle-based drug delivery. Panel 1 shows PLGA and lipid nanoparticles encapsulating rifampicin. Panel 2 illustrates the dispersion of these particles and their interaction with cells containing intracellular pathogens. Panel 3 describes phagocytosis uptake by the cells. Panel 4 shows the release of rifampicin inside infected cells. Panel 5 depicts eradication of pathogens, indicated by red crosses on infected cells.</alt-text></graphic></fig></sec><sec id="s7"><title>7 Application of PLGA in tumor therapy</title><p>Malignant neoplasms persist as a predominant contributor to global morbidity and mortality, representing an enduring challenge to population health management (<xref rid="B24" ref-type="bibr">Boire et al., 2024</xref>; <xref rid="B69" ref-type="bibr">Holder et al., 2024</xref>; <xref rid="B140" ref-type="bibr">Santucci et al., 2024</xref>). PLGA based nanostructures have emerged as frontrunner candidates in pharmacological delivery systems, attributed to their programmable physicochemical attributes encompassing modifiable size parameters, enhanced colloidal stability, superior biocompatibility profiles, and controlled metabolic clearance pathways (<xref rid="B51" ref-type="bibr">Dong et al., 2024</xref>; <xref rid="B75" ref-type="bibr">Iureva et al., 2024</xref>; <xref rid="B148" ref-type="bibr">Sonam Dongsar et al., 2024</xref>). PLGA nanocarriers accumulate passively into tumor tissues through the vascular leakage characteristics of solid tumors. The compromised lymphatic clearance mechanisms in neoplastic microenvironments facilitate prolonged intratumoral retention of macromolecular agents, a pathophysiological phenomenon arising from tumor-associated neovascularization anomalies. This tumor-selective biodistribution phenomenon is clinically denoted as the Enhanced Permeability and Retention (EPR) effect, fundamentally driven by angiogenic hypervasculature with defective endothelial fenestrations coupled with lymphatic drainage deficiency in malignant neoplasms (<xref rid="B107" ref-type="bibr">Maeda, 2012</xref>; <xref rid="B108" ref-type="bibr">Maeda et al., 2013</xref>; <xref rid="B66" ref-type="bibr">Golombek et al., 2018</xref>). Strategic surface engineering of PLGA nanoparticles through hydrophilic polymer conjugation (e.g., PEG derivatization) mitigates immune-mediated sequestration by the reticuloendothelial system (RES), thereby extending systemic circulation half-life to potentiate extravasation-mediated tumor accumulation <italic toggle="yes">via</italic> the EPR effect. Building upon this principle, our prior research developed designed PLGA based nanobubbles modified with lipid encapsulating anthracycline chemotherapeutics for EPR-driven tumor-selective delivery. Lipid modification can be used not only as a surface stabilizer, but also as a biocompatible shell of PLGA nanoparticles to avoid non-specific adsorption of plasma proteins and recognition of macrophages. Half an hour after intravenous injection, PLGA nanoparticles were still detected in the tumor area by ultrasound, indicating that lipid modified PLGA nanobubbles have the ability to passively accumulate to the tumor site (<xref rid="B33" ref-type="bibr">Chen Y. et al., 2019</xref>). To address <italic toggle="yes">Fusobacterium</italic> nucleatum (Fn)-associated colorectal cancer liver metastasis, neutrophil membrane-coated nanoparticles (NM@PLGA-MTI-OXA) were developed for co-delivery of metronidazole and oxaliplatin. These biomimetic nanoparticles enhance targeted drug delivery, eliminate intracellular Fn, reverse EMT, and remodel the immunosuppressive microenvironment, effectively suppressing tumor metastasis while preserving commensal microbiota (<xref rid="B123" ref-type="bibr">Niu et al., 2025</xref>). To augment tumor-specific delivery precision of PLGA nanovectors, surface functionalization with biomolecular recognition motifs (e.g., immunoglobulins, oligopeptides, or low-molecular-weight targeting agents) enables precision recognition of neoplastic biomarkers. This strategic conjugation facilitates receptor-mediated endocytosis through high-affinity molecular recognition events, thereby establishing a dual-targeting paradigm combining active cellular internalization with EPR-driven accumulation (<xref rid="B44" ref-type="bibr">Danhier et al., 2010</xref>). Folic acid (FA), a vitamin B9 derivative essential for nucleotide biosynthesis, serves as a low-immunogenicity targeting moiety due to its selective molecular recognition of pathologically upregulated folate-binding proteins. These glycosylphosphatidylinositol-anchored membrane proteins, particularly the FR-&#945; isotype, exhibit dysregulated overexpression on epithelial-derived malignancies. This biochemical specificity has been harnessed in precision tumor-targeting strategies, where FA-conjugated nanovector systems exploit clathrin-dependent cellular internalization pathways to achieve FR-mediated therapeutic payload accumulation in neoplastic tissues (<xref rid="B143" ref-type="bibr">Shen et al., 2012</xref>). Ma et al. investigated the biodistribution profile of FA/PEG dual-functionalized PLGA nanocomposites encapsulating indocyanine green (ICG) in FR-&#945;-overexpressing human mammary adenocarcinoma xenografts. Pharmacokinetic analysis revealed enhanced plasma exposure parameters and reduced hepatic sequestration in functionalized vectors compared to unmodified counterparts, demonstrating PEGylation-mediated stealth properties that prolong circulatory persistence while attenuating RES clearance. Tumor-specific biodistribution analysis revealed 3-fold greater accumulation of dual-engineered vectors compared to their unmodified counterparts, demonstrating enhanced tumor-targeting precision. Sustained plasma residence constitutes a critical determinant for passive tumor accumulation <italic toggle="yes">via</italic> the EPR phenomenon. Concurrently, FA-mediated molecular recognition of FR-&#945; overexpressed neoplastic cells facilitated receptor-driven cellular internalization, synergizing passive EPR-mediated deposition with active targeting mechanisms (<xref rid="B106" ref-type="bibr">Ma et al., 2012</xref>). Li et al. combined doxorubicin (DOX) and anti angiogenic drug combrestatin A4 (CA4) into PLGA based co delivery nano hybrid (PLGA/DC NPs), and then modified polydopamine (PDA) on the surface of PLGA/DC NPs for photothermal therapy (<xref rid="F5" ref-type="fig">Figure 5</xref>) (<xref rid="B96" ref-type="bibr">Li et al., 2023</xref>). The cytotoxic efficacy of polyethylene glycol-functionalized PLGA nanoconstructs encapsulating docetaxel (DOC) conjugated with HER2-specific single-chain variable fragment (scFv) was evaluated in both HER2-overexpressing and HER2-low neoplastic models. Ligand-directed nanoconstructs exhibited preferential necrotic tumor regression in HER2-hyperactive malignancies, thereby validating the therapeutic utility of scFv&#8211;DOC&#8211;PLGA&#8211;PEG as a precision delivery system for receptor-overexpressing carcinomas (<xref rid="B89" ref-type="bibr">Le et al., 2016</xref>). Mannosylated PLGA nanoarchitectures were engineered for co-encapsulation of tumor-associated antigenic epitopes and a Th1-polarizing adjuvant (TLR agonist), while simultaneously engaging C-type lectin receptors on dendritic cell populations. This multimodal nanoformulation demonstrated potent antitumor immunomodulation in syngeneic murine B16F10 melanoma models, with significant attenuation of tumor progression kinetics (<xref rid="B145" ref-type="bibr">Silva et al., 2015</xref>). It is necessary to inhibit the expression of suppressor of cytokine signaling 1(SOCS1) gene, because it has a negative regulatory effect on the immune response based on antigen presenting cells (APC). M. B. HEO et al. developed PLGA nanoparticles that can simultaneously deliver siRNA and tumor antigen to inhibit SOCS1 gene. PLGA (OVA/SOCS1 siRNA) nanoparticles showed effective uptake by bone marrow-derived dendritic cells (BMDCs), and these nanoparticles knocked out SOCS1 in BMDCs, resulting in the release of pro-inflammatory cytokines including TNF and interleukin (IL-2), which indicated that the system might be an effective method for cancer immunotherapy based on BMDCs (<xref rid="B68" ref-type="bibr">Heo et al., 2014</xref>). To circumvent chemoresistance mechanisms, contemporary therapeutic strategies employ RNAi-based gene silencing to abrogate multidrug resistance (MDR) phenotypes through suppression of ABC transporter-mediated drug efflux. Surface-engineered PLGA nanovectors co-functionalized with biotin and MDR1-targeting siRNA were developed for synergistic delivery of paclitaxel payloads, demonstrating enhanced antineoplastic efficacy in both cellular and xenotransplant models compared to conventional chemotherapeutic nanoformulations. The combinatorial therapeutic platform achieved superior tumor growth suppression through concurrent P-glycoprotein downregulation and microtubule stabilization, validating this dual-targeting approach as a paradigm-shifting solution for overcoming transporter-mediated therapeutic resistance (<xref rid="B128" ref-type="bibr">Patil et al., 2010</xref>). Preclinical investigations validate miR-145s dual oncoregulatory functions, exerting proapoptotic and antiproliferative activity through cell cycle arrest induction and mitochondrial apoptotic pathway activation across multiple malignancies. Localized delivery of miR-145 <italic toggle="yes">via</italic> PLGA/PEI/hyaluronic acid (HA) ternary nanocomplexes demonstrated enhanced oncosuppressive efficacy in both cellular and orthotopic colorectal carcinoma models, with significant attenuation of neoplastic progression in HCT-116 xenografts. These findings position this nanotherapeutic platform as a breakthrough in RNA-based epigenetic modulation strategies for oncogene silencing therapeutics (<xref rid="B97" ref-type="bibr">Liang et al., 2016</xref>).</p><fig position="float" id="F5" orientation="portrait"><label>FIGURE 5</label><caption><p>In this study, it combined doxorubicin (DOX) and anti angiogenic drug combrestatin A4 (CA4) into PLGA based co delivery nano hybrid (PLGA/DC NPs) through an improved double emulsification technology, and then modified polydopamine (PDA) on the surface of PLGA/DC NPs by self-assembly method for photothermal therapy (<xref rid="B96" ref-type="bibr">Li et al., 2023</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1670397-g005.jpg"><alt-text content-type="machine-generated">Illustration depicting a cancer treatment process. Compounds DOX, CA4, and PLGA undergo two-step emulsion evaporation, forming a nanoparticle with PDA coating. The nanoparticle is injected intravenously into a mouse, targeting a tumor via vascular delivery. A laser induces photothermal therapy, releasing heat and DOX for chemotherapy. The process highlights anti-angiogenesis therapy.</alt-text></graphic></fig></sec><sec id="s8"><title>8 Application of PLGA in theranostics</title><p>Current clinical oncology practice maintains distinct temporal phases for pathological verification and therapeutic implementation. This sequential workflow requiring diagnostic confirmation prior to treatment initiation risks therapeutic window contraction, potentially compromising disease management chronology in neoplastic conditions (<xref rid="B163" ref-type="bibr">Wang et al., 2012</xref>). Advancements in molecular visualization technologies have catalyzed the development of integrated theranostic nanoarchitectures, enabling synchronous diagnostic-therapeutic functionality. The strategic convergence of diagnostic probes and antineoplastic agents within tumor-targeted nanovectors permits real-time pharmacokinetic tracking of therapeutic payload delivery to neoplastic sites, while concurrently mapping dynamic tumor progression parameters including volumetric alterations and metastatic dissemination. This closed-loop bioimaging-guided therapeutic paradigm facilitates precision assessment of chemotherapeutic efficacy through continuous spatial-temporal monitoring of tumor response dynamics (<xref rid="B150" ref-type="bibr">Sridharan and Lim, 2023</xref>; <xref rid="B169" ref-type="bibr">Wei et al., 2023</xref>; <xref rid="B19" ref-type="bibr">Bauer et al., 2024</xref>; <xref rid="B149" ref-type="bibr">Speltri et al., 2024</xref>). PLGA-based nanostructures have emerged as versatile theranostic platforms in oncological applications, enabling precise tumor visualization through integration with computed tomography, magnetic resonance imaging, and optoacoustic diagnostic modalities. These multifunctional nanoarchitectures demonstrate dual diagnostic-therapeutic capabilities by encapsulating diverse therapeutic payloads including cytotoxic agents, molecular pathway modulators, and photoresponsive compounds, while maintaining compatibility with advanced imaging technologies for real-time treatment monitoring and metastatic surveillance (<xref rid="F6" ref-type="fig">Figure 6</xref>) (<xref rid="B116" ref-type="bibr">Menon et al., 2013</xref>; <xref rid="B90" ref-type="bibr">Le Tran et al., 2023</xref>; <xref rid="B134" ref-type="bibr">Ren et al., 2024</xref>). Yanhua Zhang et al. synthesized multifunctional tumor targeting PLGA-cRGD nanoparticles for dual modality imaging to monitor the therapeutic effect and overcome cisplatin resistance. PLGA-cRGD nanoparticles have the characteristics of clear, targeted, long-term ultrasound imaging and magnetic resonance imaging <italic toggle="yes">in vivo</italic>. PLGA-cRGD nanoparticles under ultrasound can promote the apoptosis of drug-resistant ovarian cancer cells through a variety of mechanisms, including increasing intracellular drug accumulation, reversing the anti apoptotic effect of siBIRC5 and increasing the level of reactive oxygen species (ROS). In tumor bearing nude mice model, PLGA-cRGD nanoparticles have good tumor targeting, high antitumor activity and low systemic toxicity. Therefore, PLGA-cRGD nanoparticles provide a means to monitor the treatment process, and can be combined with ultrasound to overcome the drug resistance of ovarian cancer (<xref rid="B180" ref-type="bibr">Zhang et al., 2021</xref>). Perfluorocarbon (PFC) and indocyanine green (ICG) were encapsulated by PLGA for <italic toggle="yes">in vivo</italic> MRI/FLI/PAI multimodal imaging guided photothermal therapy. Then, it was coated with A549 cancer cell membrane (AM) to produce multifunctional therapeutic nanoparticles (AM-PP@ICGNPs). After systemic administration, FLI showed the time-dependent tumor homing of NPs with high sensitivity, 19F MRI provided tumor localization of NPs without background signal interference, and PAI showed the distribution of NPs in tumor. AM-PP@ICGNPs under the irradiation of near infrared (NIR) laser, the tumor cells accumulated in the tumor area showed significant photothermal effect, and enhanced the anti-tumor effect <italic toggle="yes">in vivo</italic> (<xref rid="B94" ref-type="bibr">Li et al., 2020</xref>). A pioneering HER2-targeted PLGA-based theranostic platform was engineered to integrate photonic hyperthermia, cytotoxic payload delivery, and diagnostic imaging modalities. The nanovectors incorporated strategic co-encapsulation of zinc phthalocyanine (photosensitizer), Nile blue (optical contrast agent), and irinotecan (topoisomerase inhibitor), with surface functionalization using trastuzumab for precise HER2 epitope recognition. Photothermal characterization revealed intense near-infrared photonic activation capacity, while receptor-specific cellular assays demonstrated 7-fold enhanced molecular recognition specificity for HER2-overexpressing neoplastic populations. Combinatorial photodynamic-chemotherapeutic regimens amplified cytotoxicity 18&#8211;20 fold compared to monotherapy approaches. Preclinical validation confirmed dual diagnostic utility in metastatic lesion mapping and therapeutic efficacy, achieving 93% tumor mass regression through spatiotemporally controlled photothermal ablation synchronized with chemotherapy, establishing this modular platform as a transformative precision oncology solution (<xref rid="B84" ref-type="bibr">Komedchikova et al., 2024</xref>). Zhiyi Wang et al. developed stimuli-responsive nanoplatforms with tumor microenvironment (TME)-adaptive size modulation and near-infrared (NIR) responsiveness. These hybrid nanostructures utilized a PLGA-based polymeric framework integrated with iron oxide-based core-shell nanocomposites (Fe/FeO@PLGA), encapsulating both chemotherapeutic agents and photoresponsive components. The engineered system exhibited programmable structural reconfiguration&#8212;undergoing controlled size reduction and payload release upon NIR activation and acidic TME exposure&#8212;while simultaneously inducing oxidative stress amplification through ROS overgeneration. Preclinical evaluations confirmed dual-modal imaging-guided tumor targeting capabilities (fluorescence/MRI) with enhanced therapeutic synergy, validating the platform&#8217;s potential for precision oncotherapy through combined chemo-photothermal modalities (<xref rid="B165" ref-type="bibr">Wang Z. et al., 2019</xref>). The combination of targeted drug loaded nanoparticles and ultrasound-mediated microbubble destruction (UMMD) can significantly improve cell uptake <italic toggle="yes">in vitro</italic> and drug retention <italic toggle="yes">in vivo</italic>. Lingxi Xing et al. engineered pancreatic adenocarcinoma-targeted PLGA nanovectors functionalized with CA19-9-specific immunotargeting moieties and co-encapsulating the antimitotic agent paclitaxel (PTX). The therapeutic paradigm combines antibody-directed active molecular recognition with UMMD - the former ensuring prolonged systemic retention and tumor-selective PTX release through pH-responsive degradation kinetics, while the latter enhances passive biodistribution <italic toggle="yes">via</italic> EPR effect potentiation and vascular endothelial permeability modulation. <italic toggle="yes">In vitro</italic> mechanistic studies revealed synergistic cytotoxicity characterized by sub-micromolar inhibitory concentrations, G2/M phase blockade, and apoptotic cascade activation, validating this dual-targeting strategy&#8217;s capacity to overcome pancreatic cancer&#8217;s chemoresistance barriers through spatiotemporal drug delivery optimization. The combination of PTX NPs anti CA19-9 and UMMD has the highest tumor inhibition rate in xenograft tumor of mouse pancreatic tumor. It can promote the pharmacokinetic curve and reduce the clearance rate by increasing AUC, T1/2 and mean residence time (MRT). It can prolong the survival time of tumor bearing nude mice without obvious toxicity (<xref rid="B171" ref-type="bibr">Xing et al., 2016</xref>). Shin-Lei Peng et al. designed an active nanoparticles drug delivery system consisting of pegylated epigallocatechin gallate (EGCG), PLGA and iron oxide nanoparticles (IOS). The latter can locate prostate cancer in the molecular image. They proved that nanoparticles can recognize metastasis and enter prostate cancer cells through ligand specificity. The system can enhance the inhibition of cell growth by inducing cell apoptosis. In addition, compared with the systemic combination therapy, the improvement of targeting of nano drugs significantly inhibits the growth of prostate tumor <italic toggle="yes">in situ</italic>. In the presence of iron oxide nanoparticles, low signal intensity of prostate tumor was displayed on T2 weighted magnetic resonance imaging. Therefore, the combination of nano therapeutic particles and molecular imaging system is a promising method for tumor treatment (<xref rid="B129" ref-type="bibr">Peng et al., 2020</xref>). To provide a comprehensive analysis of the integration of diagnostic and therapeutic functions in PLGA-based nanosystems, we have compiled a summary of representative theranostic platforms in <xref rid="T3" ref-type="table">Table 3</xref>, detailing their imaging modalities, therapeutic payloads, targeting strategies, and clinical readiness levels.</p><fig position="float" id="F6" orientation="portrait"><label>FIGURE 6</label><caption><p>This study developed a gas-producing engineered bacterial synergistic system. The genetically modified <italic toggle="yes">Escherichia coli</italic> (GVs-E.coli) was engineered to carry gas vesicle genes, enabling it to target hypoxic tumor regions while assisting ultrasound imaging and synergizing with pulsed focused ultrasound (PFUS). Concurrently, PEI-PLGA nanoparticles containing Fe3O4, perfluorohexane (PFH), and epirubicin were constructed to integrate chemotherapy and multimodal imaging functionalities. GVs-E. coli mediates the enrichment of nanoparticles in tumor-targeted areas <italic toggle="yes">via</italic> electrostatic adsorption, synergistically achieving ultrasound enhancement, chemotherapy, and tumor eradication (<xref rid="B134" ref-type="bibr">Ren et al., 2024</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1670397-g006.jpg"><alt-text content-type="machine-generated">Diagram showing a multimodal imaging guided drug delivery system involving PEI-PLGA/EPI/PFH@Fe3O4 and GVs-E.coli. The process includes two injections into a mouse, followed by pulsed focused ultrasound (PFUS) to release chemotherapy drugs targeting tumors. The illustration details the interaction with cells and highlights components like bubbles, Fe3O4, EPI, and the roles of photoacoustic imaging (PAI), magnetic resonance imaging (MRI), and ultrasound (US).</alt-text></graphic></fig><table-wrap position="float" id="T3" orientation="portrait"><label>TABLE 3</label><caption><p>Summary of PLGA-based theranostic platforms, their characteristics, and clinical readiness.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr style="background-color:#A4A4A4"><th align="center" rowspan="1" colspan="1">Platform name</th><th align="center" rowspan="1" colspan="1">Imaging modality</th><th align="center" rowspan="1" colspan="1">Therapeutic payload/mechanism</th><th align="center" rowspan="1" colspan="1">Targeting strategy</th><th align="center" rowspan="1" colspan="1">Clinical readiness level</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">PLGA-cRGD NPs</td><td align="center" rowspan="1" colspan="1">Ultrasound, MRI</td><td align="center" rowspan="1" colspan="1">Cisplatin, overcoming resistance (increased drug accumulation, siBIRC5 inhibition, ROS elevation)</td><td align="center" rowspan="1" colspan="1">cRGD peptide (integrin targeting)</td><td align="center" rowspan="1" colspan="1">Preclinical</td><td align="center" rowspan="1" colspan="1">
<xref rid="B180" ref-type="bibr">Zhang et al. (2021)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">AM-PP@ICG NPs</td><td align="center" rowspan="1" colspan="1">19F MRI, FLI, PAI</td><td align="center" rowspan="1" colspan="1">Photothermal therapy (ICG)</td><td align="center" rowspan="1" colspan="1">A549 cancer cell membrane camouflage (homologous targeting)</td><td align="center" rowspan="1" colspan="1">Preclinical</td><td align="center" rowspan="1" colspan="1">
<xref rid="B94" ref-type="bibr">Li et al. (2020)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">HER2-targeted PLGA NPs</td><td align="center" rowspan="1" colspan="1">Optical imaging (Nile Blue)</td><td align="center" rowspan="1" colspan="1">Photodynamic therapy (zinc phthalocyanine), chemotherapy (irinotecan)</td><td align="center" rowspan="1" colspan="1">Trastuzumab (anti-HER2)</td><td align="center" rowspan="1" colspan="1">Preclinical</td><td align="center" rowspan="1" colspan="1">
<xref rid="B84" ref-type="bibr">Komedchikova et al. (2024)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Fe/FeO@PLGA NPs</td><td align="center" rowspan="1" colspan="1">MRI, fluorescence imaging</td><td align="center" rowspan="1" colspan="1">Chemotherapy, photothermal therapy, ROS generation</td><td align="center" rowspan="1" colspan="1">EPR effect, size-adaptive transformation</td><td align="center" rowspan="1" colspan="1">Preclinical</td><td align="center" rowspan="1" colspan="1">
<xref rid="B165" ref-type="bibr">Wang et al. (2019b)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Anti-CA19-9 PTX NPs</td><td align="center" rowspan="1" colspan="1">Ultrasound</td><td align="center" rowspan="1" colspan="1">Chemotherapy (paclitaxel)</td><td align="center" rowspan="1" colspan="1">Anti-CA19-9 antibody (active targeting) + UMMD (physical targeting)</td><td align="center" rowspan="1" colspan="1">Preclinical</td><td align="center" rowspan="1" colspan="1">
<xref rid="B171" ref-type="bibr">Xing et al. (2016)</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">EGCG-PLGA-IOS NPs</td><td align="center" rowspan="1" colspan="1">MRI</td><td align="center" rowspan="1" colspan="1">Apoptosis induction (EGCG)</td><td align="center" rowspan="1" colspan="1">Ligand-specific targeting (prostate cancer)</td><td align="center" rowspan="1" colspan="1">Preclinical</td><td align="center" rowspan="1" colspan="1">
<xref rid="B129" ref-type="bibr">Peng et al. (2020)</xref>
</td></tr></tbody></table></table-wrap></sec><sec id="s9"><title>9 Challenges and limitations in multifunctional PLGA nanosystems</title><p>The development of multifunctional PLGA nanosystems faces several significant challenges that must be addressed for successful clinical translation. These limitations span manufacturing complexities, regulatory hurdles, and physicochemical stability concerns, each requiring dedicated attention and innovative solutions. (1) Manufacturing challenges and scalability issues: The transition from laboratory-scale production to industrial manufacturing of PLGA-based nanomedicines presents substantial challenges in maintaining product consistency and quality. Batch-to-batch variations and lack of product consistency during scale-up manufacturing remain major hurdles for market launch of polymeric nanocarrier products. Traditional manufacturing methods struggle to maintain the precise control over critical quality attributes such as particle size, polydispersity index, and drug encapsulation efficiency when moving from benchtop to industrial production. To address these challenges, innovative approaches such as inline sonication processes have been developed for industrial-scale production (<xref rid="B126" ref-type="bibr">Operti et al., 2022</xref>). (2) Regulatory considerations and standardization hurdles: The regulatory landscape for nanomedicines, particularly multifunctional PLGA systems combining diagnostic and therapeutic components, remains underdeveloped and presents significant challenges. Current regulatory frameworks lack specific guidelines for evaluating the unique properties of nanomedicines, creating uncertainty in the approval pathway. The absence of standardized evaluation systems for nanomaterials and nanomedicines has led to trust crises among manufacturers, healthcare practitioners, and the public regarding product safety and effectiveness. The unique properties of nanoparticles&#8212;including surface charge, size effects, and enhanced drug targeting capabilities&#8212;create significant characterization challenges for regulatory agencies. These complexities are particularly pronounced for multifunctional PLGA systems that incorporate targeting ligands, imaging agents, and therapeutic compounds in a single platform (<xref rid="B61" ref-type="bibr">Foulkes et al., 2020</xref>). (3) Physicochemical stability and biological safety considerations: The stability of PLGA nanosystems presents considerable challenges for both storage and <italic toggle="yes">in vivo</italic> application. Polymer degradation kinetics and drug release profiles can be affected by subtle changes in environmental conditions, manufacturing parameters, and formulation components. Storage stability remains a critical concern, particularly for multifunctional systems incorporating diagnostic agents. However, long-term stability data beyond 1&#160;week remain limited for many multifunctional formulations, especially those integrating imaging agents and targeting moieties. These physicochemical instability issues further exacerbate biological safety concerns. Variations in particle size, surface properties, or premature drug release during storage or after administration may significantly impact immunogenicity, as unstable particles can trigger unintended immune responses. Moreover, aggregation or decomposition of nanosystems could lead to altered biodistribution patterns, increasing the risk of accumulation in non-target tissues and potential systemic toxicity. Uncontrolled release profiles also complicate pharmacokinetic behavior, making it difficult to achieve therapeutic efficacy while minimizing adverse effects. Therefore, comprehensive studies on both physicochemical stability and biological safety, including immunogenicity, systemic toxicity, pharmacokinetics, and biodistribution, are essential to ensure the clinical translatability of PLGA-based nanosystems (<xref rid="B86" ref-type="bibr">Kwon et al., 2024</xref>; <xref rid="B98" ref-type="bibr">Liao et al., 2024</xref>; <xref rid="B16" ref-type="bibr">Barbery et al., 2025</xref>).</p></sec><sec id="s10"><title>10 Conclusions and future prospects</title><p>PLGA and its copolymer derivatives have been extensively engineered as versatile nanotherapeutic platforms, leveraging their intrinsic biocompatibility to achieve superior clinical translation potential. Preclinical studies across cellular and organismal models consistently demonstrate enhanced therapeutic indices of PLGA-based nanoarchitectures in diverse pathologies. These systems allow precision molecular engineering <italic toggle="yes">via</italic> surface functionalization, such as polyethylene glycol conjugation, albumin corona formation, and molecular recognition motifs, to prolong systemic circulation and enhance site-specific accumulation. Applications extend beyond oncology and cardiovascular disease to include immunomodulatory vaccine delivery and regenerative tissue scaffolding. However, the advancement of multifunctional PLGA nanosystems faces interconnected challenges, including manufacturing inconsistencies that complicate regulatory evaluation and physicochemical instability affecting both production and compliance. To address these issues, the integration of artificial intelligence and advanced imaging techniques offers promising avenues for improved characterization, for example, AI-based image processing and segmentation, already applied to collagen implants by FDA researchers for quantifying porosity, drug location, and release kinetics, could be adapted to PLGA systems for better performance control. Furthermore, the development of physiologically based pharmacokinetic (PBPK) models provides a mechanistic framework to establish in vitro-in vivo correlations for PLGA implants and long-acting injectables, helping to bridge the gap between experimental characterization and clinical outcomes, thereby facilitating regulatory acceptance. In conclusion, despite the considerable promise of multifunctional PLGA nanosystems for theranostic applications, overcoming challenges related to manufacturing scalability, regulatory uncertainty, and stability remains essential. Emerging technologies, such as continuous manufacturing, machine learning, and advanced characterization methods, are critical to realizing the full potential of these innovative nanoplatforms.</p></sec></body><back><ack><p>The authors are grateful to all the reviewers of this article for their comments and suggestions.</p></ack><sec sec-type="author-contributions" id="s11"><title>Author contributions</title><p>YL: Writing &#8211; original draft, Data curation, Investigation. TT: Investigation, Writing &#8211; original draft. YX: Writing &#8211; original draft. WG: Writing &#8211; original draft. YL: Writing &#8211; original draft, Conceptualization, Supervision, Writing &#8211; review and editing.</p></sec><sec sec-type="COI-statement" id="s13"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s14"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="s15"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abd El Hady</surname><given-names>W. E.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>O. a.E.-A.</given-names></name><name name-style="western"><surname>El Sabbagh</surname><given-names>H. M.</given-names></name></person-group> (<year>2019</year>). <article-title>
<italic toggle="yes">In vitro</italic>&#8211;<italic toggle="yes">in vivo</italic> evaluation of chitosan-PLGA nanoparticles for potentiated gastric retention and anti-ulcer activity of diosmin</article-title>. <source>Int. J. Nanomedicine</source><volume>14</volume>, <fpage>7191</fpage>&#8211;<lpage>7213</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S213836</pub-id><pub-id pub-id-type="pmid">31564873</pub-id><pub-id pub-id-type="pmcid">PMC6732519</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abo-Zeid</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Amer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bakkar</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>El-Houssieny</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sakran</surname><given-names>W.</given-names></name></person-group> (<year>2022</year>). <article-title>Antimicrobial activity of Azithromycin encapsulated into PLGA NPs: a potential strategy to overcome efflux resistance</article-title>. <source>Antibiotics</source><volume>11</volume>, <fpage>1623</fpage>. <pub-id pub-id-type="doi">10.3390/antibiotics11111623</pub-id><pub-id pub-id-type="pmid">36421266</pub-id><pub-id pub-id-type="pmcid">PMC9686761</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acharya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sahoo</surname><given-names>S. K.</given-names></name></person-group> (<year>2011</year>). <article-title>PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect</article-title>. <source>Adv. Drug Deliv. Rev.</source><volume>63</volume>, <fpage>170</fpage>&#8211;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2010.10.008</pub-id><pub-id pub-id-type="pmid">20965219</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adhyaru</surname><given-names>B. B.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>T. A.</given-names></name></person-group> (<year>2018</year>). <article-title>Safety and efficacy of statin therapy</article-title>. <source>Nat. Rev. Cardiol.</source><volume>15</volume>, <fpage>757</fpage>&#8211;<lpage>769</lpage>. <pub-id pub-id-type="doi">10.1038/s41569-018-0098-5</pub-id><pub-id pub-id-type="pmid">30375494</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agnihotri</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Mallikarjuna</surname><given-names>N. N.</given-names></name><name name-style="western"><surname>Aminabhavi</surname><given-names>T. M.</given-names></name></person-group> (<year>2004</year>). <article-title>Recent advances on chitosan-based micro- and nanoparticles in drug delivery</article-title>. <source>J. Control. Release</source><volume>100</volume>, <fpage>5</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2004.08.010</pub-id><pub-id pub-id-type="pmid">15491807</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alavi</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Alharthi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alavi</surname><given-names>S. Z.</given-names></name><name name-style="western"><surname>Raza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ebrahimi Shahmabadi</surname><given-names>H.</given-names></name></person-group> (<year>2024</year>). <article-title>Bioresponsive drug delivery systems</article-title>. <source>Drug Discov. Today</source><volume>29</volume>, <fpage>103849</fpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2023.103849</pub-id><pub-id pub-id-type="pmid">38052319</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allahyari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mohit</surname><given-names>E.</given-names></name></person-group> (<year>2015</year>). <article-title>Peptide/protein vaccine delivery system based on PLGA particles</article-title>. <source>Hum. Vaccines Immunother.</source><volume>12</volume>, <fpage>806</fpage>&#8211;<lpage>828</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2015.1102804</pub-id><pub-id pub-id-type="pmid">26513024</pub-id><pub-id pub-id-type="pmcid">PMC4964737</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>T. M.</given-names></name><name name-style="western"><surname>Cullis</surname><given-names>P. R.</given-names></name></person-group> (<year>2004</year>). <article-title>Drug delivery systems entering the mainstream</article-title>. <source>Science</source><volume>303</volume>, <fpage>1818</fpage>&#8211;<lpage>1822</lpage>. <pub-id pub-id-type="doi">10.1126/science.1095833</pub-id><pub-id pub-id-type="pmid">15031496</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almadi</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Alali</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Barkun</surname><given-names>A. N.</given-names></name></person-group> (<year>2024</year>). <article-title>Peptic ulcer disease</article-title>. <source>Lancet</source><volume>404</volume>, <fpage>68</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(24)00155-7</pub-id><pub-id pub-id-type="pmid">38885678</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anwer</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Al-Shdefat</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ezzeldin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alshahrani</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Alshetaili</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Preparation, evaluation and bioavailability studies of eudragit coated PLGA nanoparticles for sustained release of eluxadoline for the treatment of irritable Bowel syndrome</article-title>. <source>Front. Pharmacol.</source><volume>8</volume>, <fpage>844</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2017.00844</pub-id><pub-id pub-id-type="pmid">29209215</pub-id><pub-id pub-id-type="pmcid">PMC5702012</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arafa</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Mousa</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Afifi</surname><given-names>N. N.</given-names></name></person-group> (<year>2019</year>). <article-title>Preparation of PLGA-chitosan based nanocarriers for enhancing antibacterial effect of ciprofloxacin in root canal infection</article-title>. <source>Drug Deliv.</source><volume>27</volume>, <fpage>26</fpage>&#8211;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1080/10717544.2019.1701140</pub-id><pub-id pub-id-type="pmid">31833443</pub-id><pub-id pub-id-type="pmcid">PMC6968620</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashton</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Beattie</surname><given-names>R. M.</given-names></name></person-group> (<year>2024</year>). <article-title>Inflammatory bowel disease: recent developments</article-title>. <source>Archives Dis. Child.</source><volume>109</volume>, <fpage>370</fpage>&#8211;<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1136/archdischild-2023-325668</pub-id><pub-id pub-id-type="pmid">37468139</pub-id><pub-id pub-id-type="pmcid">PMC11056939</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#228;ck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yurdagul</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tabas</surname><given-names>I.</given-names></name><name name-style="western"><surname>&#246;rni</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kovanen</surname><given-names>P. T.</given-names></name></person-group> (<year>2019</year>). <article-title>Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities</article-title>. <source>Nat. Rev. Cardiol.</source><volume>16</volume>, <fpage>389</fpage>&#8211;<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1038/s41569-019-0169-2</pub-id><pub-id pub-id-type="pmid">30846875</pub-id><pub-id pub-id-type="pmcid">PMC6727648</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baecher-Allan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaskow</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>H. L.</given-names></name></person-group> (<year>2018</year>). <article-title>Multiple sclerosis: mechanisms and immunotherapy</article-title>. <source>Neuron</source><volume>97</volume>, <fpage>742</fpage>&#8211;<lpage>768</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2018.01.021</pub-id><pub-id pub-id-type="pmid">29470968</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bali</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Salve</surname><given-names>P. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: a nanotheranostic perspective for Parkinsonism</article-title>. <source>Int. J. Biol. Macromol.</source><volume>164</volume>, <fpage>1006</fpage>&#8211;<lpage>1024</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.06.261</pub-id><pub-id pub-id-type="pmid">32619667</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbery</surname><given-names>B. G.</given-names></name><name name-style="western"><surname>Lukesh</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Bachelder</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Ainslie</surname><given-names>K. M.</given-names></name></person-group> (<year>2025</year>). <article-title>Biodegradable polymers for application as robust immunomodulatory biomaterial carrier systems</article-title>. <source>Small</source>, <fpage>e2409422</fpage>. <pub-id pub-id-type="doi">10.1002/smll.202409422</pub-id><pub-id pub-id-type="pmid">39955753</pub-id><pub-id pub-id-type="pmcid">PMC12353350</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbu</surname><given-names>E.</given-names></name><name name-style="western"><surname>G&#243;recki</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Tsibouklis</surname><given-names>J.</given-names></name><name name-style="western"><surname>G&#243;recki</surname><given-names>D. C.</given-names></name></person-group> (<year>2009</year>). <article-title>The potential for nanoparticle-based drug delivery to the brain: overcoming the blood&#8211;brain barrier</article-title>. <source>Expert Opin. Drug Deliv.</source><volume>6</volume>, <fpage>553</fpage>&#8211;<lpage>565</lpage>. <pub-id pub-id-type="doi">10.1517/17425240902939143</pub-id><pub-id pub-id-type="pmid">19435406</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barkas</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sener</surname><given-names>Y. Z.</given-names></name><name name-style="western"><surname>Golforoush</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Kheirkhah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rodriguez-Sanchez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Novak</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Advancements in risk stratification and management strategies in primary cardiovascular prevention</article-title>. <source>Atherosclerosis</source><volume>395</volume>, <fpage>117579</fpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2024.117579</pub-id><pub-id pub-id-type="pmid">38824844</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bauer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Atmane</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Michel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaminsky</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>212Pb-Pretargeted theranostics for pancreatic cancer</article-title>. <source>J. Nucl. Med.</source><volume>65</volume>, <fpage>109</fpage>&#8211;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.123.266388</pub-id><pub-id pub-id-type="pmid">37945380</pub-id><pub-id pub-id-type="pmcid">PMC10755526</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beach</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Nayanathara</surname><given-names>U.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Polymeric nanoparticles for drug delivery</article-title>. <source>Chem. Rev.</source><volume>124</volume>, <fpage>5505</fpage>&#8211;<lpage>5616</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.3c00705</pub-id><pub-id pub-id-type="pmid">38626459</pub-id><pub-id pub-id-type="pmcid">PMC11086401</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatnagar</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Choudhari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pawar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name></person-group> (<year>2024</year>). <article-title>Long-term use of proton-pump inhibitors: unravelling the safety Puzzle</article-title>. <source>Cureus</source><volume>16</volume>, <fpage>e52773</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.52773</pub-id><pub-id pub-id-type="pmid">38389608</pub-id><pub-id pub-id-type="pmcid">PMC10882567</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blanco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Principles of nanoparticle design for overcoming biological barriers to drug delivery</article-title>. <source>Nat. Biotechnol.</source><volume>33</volume>, <fpage>941</fpage>&#8211;<lpage>951</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3330</pub-id><pub-id pub-id-type="pmid">26348965</pub-id><pub-id pub-id-type="pmcid">PMC4978509</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boada</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zinger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tsao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>J. O.</given-names></name><name name-style="western"><surname>Hartman</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Rapamycin-loaded biomimetic nanoparticles reverse vascular inflammation</article-title>. <source>Circulation Res.</source><volume>126</volume>, <fpage>25</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.315185</pub-id><pub-id pub-id-type="pmid">31647755</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boire</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Guise</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jamal-Hanjani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Janowitz</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Why do patients with cancer die?</article-title><source>Nat. Rev. Cancer</source><volume>24</volume>, <fpage>578</fpage>&#8211;<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1038/s41568-024-00708-4</pub-id><pub-id pub-id-type="pmid">38898221</pub-id><pub-id pub-id-type="pmcid">PMC7616303</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Booysen</surname><given-names>L. L. I. J.</given-names></name><name name-style="western"><surname>Kalombo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gilliland</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gruppo</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>
<italic toggle="yes">In vivo</italic>/<italic toggle="yes">in vitro</italic> pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid</article-title>. <source>Int. J. Pharm.</source><volume>444</volume>, <fpage>10</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.01.038</pub-id><pub-id pub-id-type="pmid">23357255</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Meyerhoff</surname><given-names>M. E.</given-names></name></person-group> (<year>2012</year>). <article-title>Diazeniumdiolate-doped poly(lactic-co-glycolic acid)-based nitric oxide releasing films as antibiofilm coatings</article-title>. <source>Biomaterials</source><volume>33</volume>, <fpage>7933</fpage>&#8211;<lpage>7944</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.07.027</pub-id><pub-id pub-id-type="pmid">22841918</pub-id><pub-id pub-id-type="pmcid">PMC3432167</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ettcheto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Barroso</surname><given-names>E.</given-names></name><name name-style="western"><surname>Espina</surname><given-names>M.</given-names></name><name name-style="western"><surname>K&#252;hne</surname><given-names>B. A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer&#8217;s disease mice model</article-title>. <source>J. Control. Release</source><volume>301</volume>, <fpage>62</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2019.03.010</pub-id><pub-id pub-id-type="pmid">30876953</pub-id><pub-id pub-id-type="pmcid">PMC6510952</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ettcheto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Espina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Auladell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Folch</surname><given-names>J.</given-names></name><name name-style="western"><surname>K&#252;hne</surname><given-names>B. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Epigallocatechin-3-Gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice</article-title>. <source>Nanomedicine</source><volume>16</volume>, <fpage>19</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.2217/nnm-2020-0239</pub-id><pub-id pub-id-type="pmid">33410329</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>C. K. W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X. Y.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Recent advances in managing atherosclerosis via nanomedicine</article-title>. <source>Small</source><volume>14</volume>, <fpage>1702793</fpage>, <pub-id pub-id-type="doi">10.1002/smll.201702793</pub-id><pub-id pub-id-type="pmid">29239134</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhary</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Viegas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pirela</surname><given-names>P.</given-names></name><name name-style="western"><surname>Atalaia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruivinho</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arora</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Inhalable N-Acetylcysteine-loaded lactose-coated PLGA nanoparticles for tuberculosis treatment</article-title>. <source>Pharm. Res.</source><volume>42</volume>, <fpage>1153</fpage>&#8211;<lpage>1165</lpage>. <pub-id pub-id-type="doi">10.1007/s11095-025-03889-1</pub-id><pub-id pub-id-type="pmid">40640645</pub-id><pub-id pub-id-type="pmcid">PMC12304043</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name></person-group> (<year>2012</year>). <article-title>Modern methods for delivery of drugs across the blood&#8211;brain barrier</article-title>. <source>Adv. Drug Deliv. Rev.</source><volume>64</volume>, <fpage>640</fpage>&#8211;<lpage>665</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2011.11.010</pub-id><pub-id pub-id-type="pmid">22154620</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2019a</year>). <article-title>Nanoparticles mediating the sustained puerarin release facilitate improved brain delivery to treat Parkinson&#8217;s disease</article-title>. <source>ACS Appl. Mater. Interfaces</source><volume>11</volume>, <fpage>45276</fpage>&#8211;<lpage>45289</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.9b16047</pub-id><pub-id pub-id-type="pmid">31638771</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>F.</given-names></name></person-group> (<year>2019b</year>). <article-title>Lipid/PLGA hybrid microbubbles as a versatile platform for noninvasive image-guided targeted drug delivery</article-title>. <source>ACS Appl. Mater. Interfaces</source><volume>11</volume>, <fpage>41842</fpage>&#8211;<lpage>41852</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.9b10188</pub-id><pub-id pub-id-type="pmid">31633326</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.-T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.-Y.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.-S.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Kinetically and thermodynamically controlled one-pot growth of gold nanoshells with NIR-II absorption for multimodal imaging-guided photothermal therapy</article-title>. <source>J. Nanobiotechnol.</source><volume>21</volume>, <fpage>138</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-023-01907-1</pub-id><pub-id pub-id-type="pmid">37106405</pub-id><pub-id pub-id-type="pmcid">PMC10141956</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>A targeting nanotherapy for abdominal aortic aneurysms</article-title>. <source>J. Am. Coll. Cardiol.</source><volume>72</volume>, <fpage>2591</fpage>&#8211;<lpage>2605</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2018.08.2188</pub-id><pub-id pub-id-type="pmid">30466517</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chronopoulou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Massimi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Giardi</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Cametti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Devirgiliis</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Dentini</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Chitosan-coated PLGA nanoparticles: a sustained drug release strategy for cell cultures</article-title>. <source>Colloids Surfaces B Biointerfaces</source><volume>103</volume>, <fpage>310</fpage>&#8211;<lpage>317</lpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2012.10.063</pub-id><pub-id pub-id-type="pmid">23261553</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hirst</surname><given-names>W. D.</given-names></name><name name-style="western"><surname>Federoff</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Harms</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Stoessl</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Kordower</surname><given-names>J. H.</given-names></name></person-group> (<year>2023</year>). <article-title>Nigrostriatal tau pathology in parkinsonism and Parkinson&#8217;s disease</article-title>. <source>Brain</source><volume>147</volume>, <fpage>444</fpage>&#8211;<lpage>457</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awad388</pub-id><pub-id pub-id-type="pmid">38006313</pub-id><pub-id pub-id-type="pmcid">PMC10834249</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chuah</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Billa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Burley</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Manickam</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Curcumin-containing chitosan nanoparticles as a potential mucoadhesive delivery system to the colon</article-title>. <source>Pharm. Dev. Technol.</source><volume>18</volume>, <fpage>591</fpage>&#8211;<lpage>599</lpage>. <pub-id pub-id-type="doi">10.3109/10837450.2011.640688</pub-id><pub-id pub-id-type="pmid">22149945</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colasuonno</surname><given-names>M.</given-names></name><name name-style="western"><surname>Palange</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Aid</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mollica</surname><given-names>H.</given-names></name><name name-style="western"><surname>Palomba</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Erythrocyte-inspired discoidal polymeric nanoconstructs carrying tissue plasminogen activator for the enhanced lysis of blood clots</article-title>. <source>ACS Nano</source><volume>12</volume>, <fpage>12224</fpage>&#8211;<lpage>12237</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.8b06021</pub-id><pub-id pub-id-type="pmid">30427660</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costabile</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baldassi</surname><given-names>D.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gro&#223;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ungaro</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Antibiotic-loaded nanoparticles for the treatment of intracellular methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> infections: <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> efficacy of a novel antibiotic</article-title>. <source>J. Control. Release</source><volume>374</volume>, <fpage>454</fpage>&#8211;<lpage>465</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2024.08.029</pub-id><pub-id pub-id-type="pmid">39181163</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cresti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Conte</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cappello</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brunetti</surname><given-names>J.</given-names></name><name name-style="western"><surname>Falciani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bracci</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Inhalable polymeric nanoparticles for pulmonary delivery of antimicrobial peptide SET-M33: antibacterial activity and toxicity <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>
</article-title>. <source>Pharmaceutics</source><volume>15</volume>, <fpage>3</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics15010003</pub-id><pub-id pub-id-type="pmid">36678633</pub-id><pub-id pub-id-type="pmcid">PMC9863998</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cristelo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Viegas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barros</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>H.</given-names></name><name name-style="western"><surname>Das Neves</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sarmento</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Oral delivery of tunable oxidation-responsive budesonide-loaded nanoparticles enhances inflammation modulation in intestinal colitis</article-title>. <source>J. Control. Release</source><volume>384</volume>, <fpage>113948</fpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2025.113948</pub-id><pub-id pub-id-type="pmid">40513667</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fl&#243;rez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>R.</given-names></name><name name-style="western"><surname>Urquiza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guti&#233;rrez</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Antimicrobial activity of a new synthetic peptide loaded in polylactic acid or poly(lactic-co-glycolic) acid nanoparticles against <italic toggle="yes">Pseudomonas aeruginosa</italic>, <italic toggle="yes">Escherichia coli</italic> O157:H7 and methicillin resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA)</article-title>. <source>Nanotechnology</source><volume>28</volume>, <fpage>135102</fpage>. <pub-id pub-id-type="doi">10.1088/1361-6528/aa5f63</pub-id><pub-id pub-id-type="pmid">28266350</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danhier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Feron</surname><given-names>O.</given-names></name><name name-style="western"><surname>Pr&#233;at</surname><given-names>V.</given-names></name></person-group> (<year>2010</year>). <article-title>To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery</article-title>. <source>J. Control. Release</source><volume>148</volume>, <fpage>135</fpage>&#8211;<lpage>146</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2010.08.027</pub-id><pub-id pub-id-type="pmid">20797419</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danhier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ansorena</surname><given-names>E.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Coco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Le Breton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pr&#233;at</surname><given-names>V.</given-names></name></person-group> (<year>2012</year>). <article-title>PLGA-based nanoparticles: an overview of biomedical applications</article-title>. <source>J. Control. Release</source><volume>161</volume>, <fpage>505</fpage>&#8211;<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2012.01.043</pub-id><pub-id pub-id-type="pmid">22353619</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dash</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>M.</given-names></name><name name-style="western"><surname>Biswal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goel</surname><given-names>V. K.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Modeling of chitosan modified PLGA atorvastatin-curcumin conjugate (AT-CU) nanoparticles, overcoming the barriers associated with PLGA: an approach for better management of atherosclerosis</article-title>. <source>Int. J. Pharm.</source><volume>640</volume>, <fpage>123009</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2023.123009</pub-id><pub-id pub-id-type="pmid">37142139</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>C. R.</given-names></name></person-group> (<year>2002</year>). <article-title>Lessons from animal models of Huntington&#8217;s disease</article-title>. <source>Trends Genet.</source><volume>18</volume>, <fpage>202</fpage>&#8211;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1016/s0168-9525(01)02625-7</pub-id><pub-id pub-id-type="pmid">11932021</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Matteis</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cascione</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toma</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Leporatti</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Silver nanoparticles: synthetic routes, <italic toggle="yes">in vitro</italic> toxicity and theranostic applications for cancer disease</article-title>. <source>Nanomaterials</source><volume>8</volume>, <fpage>319</fpage>. <pub-id pub-id-type="doi">10.3390/nano8050319</pub-id><pub-id pub-id-type="pmid">29748469</pub-id><pub-id pub-id-type="pmcid">PMC5977333</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name></person-group> (<year>2018</year>). <article-title>Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics</article-title>. <source>Mater. Sci. Eng. C</source><volume>92</volume>, <fpage>1041</fpage>&#8211;<lpage>1060</lpage>. <pub-id pub-id-type="doi">10.1016/j.msec.2017.12.036</pub-id><pub-id pub-id-type="pmid">30184728</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>L.-B.</given-names></name><name name-style="western"><surname>Rudolf</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>B.</given-names></name></person-group> (<year>2017</year>). <article-title>
<italic toggle="yes">In vivo</italic> instability of platensimycin and platencin: synthesis and biological evaluation of urea- and carbamate-platensimycin</article-title>. <source>Bioorg. Med. Chem.</source><volume>25</volume>, <fpage>1990</fpage>&#8211;<lpage>1996</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2017.02.028</pub-id><pub-id pub-id-type="pmid">28237556</pub-id><pub-id pub-id-type="pmcid">PMC5421316</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Poupart</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>E. A.</given-names></name></person-group> (<year>2024</year>). <article-title>Gaussian processes modeling for the prediction of polymeric nanoparticle formulation design to enhance encapsulation efficiency and therapeutic efficacy</article-title>. <source>Drug Deliv. Transl. Res.</source><volume>15</volume>, <fpage>372</fpage>&#8211;<lpage>388</lpage>. <pub-id pub-id-type="doi">10.1007/s13346-024-01625-7</pub-id><pub-id pub-id-type="pmid">38767799</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dykman</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Khlebtsov</surname><given-names>N. G.</given-names></name></person-group> (<year>2016</year>). <article-title>Multifunctional gold-based nanocomposites for theranostics</article-title>. <source>Biomaterials</source><volume>108</volume>, <fpage>13</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.08.040</pub-id><pub-id pub-id-type="pmid">27614818</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elhabal</surname><given-names>S. F.</given-names></name><name name-style="western"><surname>Ghaffar</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Hager</surname><given-names>R.</given-names></name><name name-style="western"><surname>Elzohairy</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Khalifa</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Mohie</surname><given-names>P. M.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Development of thermosensitive hydrogel of Amphotericin-B and Lactoferrin combination-loaded PLGA-PEG-PEI nanoparticles for potential eradication of ocular fungal infections: <italic toggle="yes">in-vitro</italic>, <italic toggle="yes">ex-vivo</italic> and <italic toggle="yes">in-vivo</italic> studies</article-title>. <source>Int. J. Pharm.</source><volume>5</volume>, <fpage>100174</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpx.2023.100174</pub-id><pub-id pub-id-type="pmid">36908304</pub-id><pub-id pub-id-type="pmcid">PMC9992749</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esfandyari-Manesh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abdi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Talasaz</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Ebrahimi</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Atyabi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dinarvand</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>S2P peptide-conjugated PLGA-Maleimide-PEG nanoparticles containing Imatinib for targeting drug delivery to atherosclerotic plaques</article-title>. <source>DARU J. Pharm. Sci.</source><volume>28</volume>, <fpage>131</fpage>&#8211;<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1007/s40199-019-00324-w</pub-id><pub-id pub-id-type="pmid">31919789</pub-id><pub-id pub-id-type="pmcid">PMC7214550</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esteruelas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ettcheto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haro</surname><given-names>I.</given-names></name><name name-style="western"><surname>Herrando-Grabulosa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gaja-Capdevila</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gomara</surname><given-names>M. J.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Novel tissue-specific multifunctionalized nanotechnological platform encapsulating riluzole against motor neuron diseases</article-title>. <source>Int. J. Nanomedicine</source><volume>20</volume>, <fpage>2273</fpage>&#8211;<lpage>2288</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S479819</pub-id><pub-id pub-id-type="pmid">40007904</pub-id><pub-id pub-id-type="pmcid">PMC11853070</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer&#8217;s disease</article-title>. <source>Drug Deliv.</source><volume>25</volume>, <fpage>1091</fpage>&#8211;<lpage>1102</lpage>. <pub-id pub-id-type="doi">10.1080/10717544.2018.1461955</pub-id><pub-id pub-id-type="pmid">30107760</pub-id><pub-id pub-id-type="pmcid">PMC6116673</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farokhzad</surname><given-names>O.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name></person-group> (<year>2006</year>). <article-title>Nanomedicine: developing smarter therapeutic and diagnostic modalities</article-title>. <source>Adv. Drug Deliv. Rev.</source><volume>58</volume>, <fpage>1456</fpage>&#8211;<lpage>1459</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2006.09.011</pub-id><pub-id pub-id-type="pmid">17070960</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Microfluidic based high throughput synthesis of lipid-polymer hybrid nanoparticles with tunable diameters</article-title>. <source>Biomicrofluidics</source><volume>9</volume>, <fpage>052604</fpage>. <pub-id pub-id-type="doi">10.1063/1.4922957</pub-id><pub-id pub-id-type="pmid">26180574</pub-id><pub-id pub-id-type="pmcid">PMC4482808</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrante</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Kowall</surname><given-names>N. W.</given-names></name><name name-style="western"><surname>Beal</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>E. P.</given-names></name><name name-style="western"><surname>Bird</surname><given-names>J. E. D.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>J. B.</given-names></name></person-group> (<year>1985</year>). <article-title>Selective sparing of a class of striatal neurons in Huntington&#8217;s disease</article-title>. <source>Science</source><volume>230</volume>, <fpage>561</fpage>&#8211;<lpage>563</lpage>. <pub-id pub-id-type="doi">10.1126/science.2931802</pub-id><pub-id pub-id-type="pmid">2931802</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Formiga</surname><given-names>F. R.</given-names></name><name name-style="western"><surname>Pelacho</surname><given-names>B.</given-names></name><name name-style="western"><surname>Garbayo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Abizanda</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gavira</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Simon-Yarza</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia&#8211;reperfusion model</article-title>. <source>J. Control. Release</source><volume>147</volume>, <fpage>30</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2010.07.097</pub-id><pub-id pub-id-type="pmid">20643169</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foulkes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Man</surname><given-names>E.</given-names></name><name name-style="western"><surname>Thind</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hoskins</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives</article-title>. <source>Biomaterials Sci.</source><volume>8</volume>, <fpage>4653</fpage>&#8211;<lpage>4664</lpage>. <pub-id pub-id-type="doi">10.1039/d0bm00558d</pub-id><pub-id pub-id-type="pmid">32672255</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabizon</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Gabizon-Peretz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Modaresahmadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>La-Beck</surname><given-names>N. M.</given-names></name></person-group> (<year>2025</year>). <article-title>Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective</article-title>. <source>BMJ Oncol.</source><volume>4</volume>, <fpage>e000573</fpage>. <pub-id pub-id-type="doi">10.1136/bmjonc-2024-000573</pub-id><pub-id pub-id-type="pmid">39885941</pub-id><pub-id pub-id-type="pmcid">PMC11751825</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghalehbandi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yuzugulen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pranjol</surname><given-names>M. Z. I.</given-names></name><name name-style="western"><surname>Pourgholami</surname><given-names>M. H.</given-names></name></person-group> (<year>2023</year>). <article-title>The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF</article-title>. <source>Eur. J. Pharmacol.</source><volume>949</volume>, <fpage>175586</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2023.175586</pub-id><pub-id pub-id-type="pmid">36906141</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghaly</surname><given-names>H. S. A.</given-names></name><name name-style="western"><surname>Seyedasli</surname><given-names>N.</given-names></name><name name-style="western"><surname>Varamini</surname><given-names>P.</given-names></name></person-group> (<year>2025</year>). <article-title>Enhanced nanoprecipitation method for the production of PLGA nanoparticles for oncology applications</article-title>. <source>AAPS J.</source><volume>27</volume>, <fpage>113</fpage>. <pub-id pub-id-type="doi">10.1208/s12248-025-01096-9</pub-id><pub-id pub-id-type="pmid">40571866</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gholamzad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baharlooi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shafiee Ardestani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seyedkhan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Azimi</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Prophylactic and therapeutic effects of MOG-conjugated PLGA nanoparticles in C57Bl/6 mouse model of multiple sclerosis</article-title>. <source>Adv. Pharm. Bull.</source><volume>11</volume>, <fpage>505</fpage>&#8211;<lpage>513</lpage>. <pub-id pub-id-type="doi">10.34172/apb.2021.058</pub-id><pub-id pub-id-type="pmid">34513625</pub-id><pub-id pub-id-type="pmcid">PMC8421634</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golombek</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>May</surname><given-names>J.-N.</given-names></name><name name-style="western"><surname>Theek</surname><given-names>B.</given-names></name><name name-style="western"><surname>Appold</surname><given-names>L.</given-names></name><name name-style="western"><surname>Drude</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kiessling</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Tumor targeting via EPR: strategies to enhance patient responses</article-title>. <source>Adv. Drug Deliv. Rev.</source><volume>130</volume>, <fpage>17</fpage>&#8211;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2018.07.007</pub-id><pub-id pub-id-type="pmid">30009886</pub-id><pub-id pub-id-type="pmcid">PMC6130746</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamdallah</surname><given-names>S. I.</given-names></name><name name-style="western"><surname>Zoqlam</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Booth</surname><given-names>R.</given-names></name><name name-style="western"><surname>Booth</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Using a systematic and quantitative approach to generate new insights into drug loading of PLGA nanoparticles using nanoprecipitation</article-title>. <source>Nanoscale Adv.</source><volume>6</volume>, <fpage>3188</fpage>&#8211;<lpage>3198</lpage>. <pub-id pub-id-type="doi">10.1039/d4na00087k</pub-id><pub-id pub-id-type="pmid">38868816</pub-id><pub-id pub-id-type="pmcid">PMC11166107</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heo</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>M. Y.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>Y. T.</given-names></name></person-group> (<year>2014</year>). <article-title>Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells</article-title>. <source>Acta Biomater.</source><volume>10</volume>, <fpage>2169</fpage>&#8211;<lpage>2176</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2013.12.050</pub-id><pub-id pub-id-type="pmid">24394635</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holder</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Dedeilia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sierra-Davidson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours</article-title>. <source>Nat. Rev. Cancer</source><volume>24</volume>, <fpage>498</fpage>&#8211;<lpage>512</lpage>. <pub-id pub-id-type="doi">10.1038/s41568-024-00705-7</pub-id><pub-id pub-id-type="pmid">38867074</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Mesoporous silica-based nanoplatforms for the delivery of photodynamic therapy agents</article-title>. <source>J. Pharm. Investigation</source><volume>48</volume>, <fpage>3</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1007/s40005-017-0356-2</pub-id><pub-id pub-id-type="pmid">30546918</pub-id><pub-id pub-id-type="pmcid">PMC6267390</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Babbar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hasselbalch</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Croteau</surname><given-names>D. L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Ageing as a risk factor for neurodegenerative disease</article-title>. <source>Nat. Rev. Neurol.</source><volume>15</volume>, <fpage>565</fpage>&#8211;<lpage>581</lpage>. <pub-id pub-id-type="doi">10.1038/s41582-019-0244-7</pub-id><pub-id pub-id-type="pmid">31501588</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2022a</year>). <article-title>A synergistic and efficient thrombolytic nanoplatform: a mechanical method of blasting combined with thrombolytic drugs</article-title>. <source>Int. J. Nanomedicine</source><volume>17</volume>, <fpage>5229</fpage>&#8211;<lpage>5246</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S382964</pub-id><pub-id pub-id-type="pmid">36388875</pub-id><pub-id pub-id-type="pmcid">PMC9662339</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name></person-group> (<year>2022b</year>). <article-title>Nanotechnology for cardiovascular diseases</article-title>. <source>Innovation</source><volume>3</volume>, <fpage>100214</fpage>. <pub-id pub-id-type="doi">10.1016/j.xinn.2022.100214</pub-id><pub-id pub-id-type="pmid">35243468</pub-id><pub-id pub-id-type="pmcid">PMC8866095</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hua</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marks</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Keely</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory Bowel disease: selective targeting to diseased versus healthy tissue</article-title>. <source>Nanomedicine Nanotechnol. Biol. Med.</source><volume>11</volume>, <fpage>1117</fpage>&#8211;<lpage>1132</lpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2015.02.018</pub-id><pub-id pub-id-type="pmid">25784453</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iureva</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Nikitin</surname><given-names>P. I.</given-names></name><name name-style="western"><surname>Tereshina</surname><given-names>E. D.</given-names></name><name name-style="western"><surname>Nikitin</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Shipunova</surname><given-names>V. O.</given-names></name></person-group> (<year>2024</year>). <article-title>The influence of various polymer coatings on the <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> properties of PLGA nanoparticles: comprehensive study</article-title>. <source>Eur. J. Pharm. Biopharm.</source><volume>201</volume>, <fpage>114366</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2024.114366</pub-id><pub-id pub-id-type="pmid">38876361</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kakavandi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zare</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mirshafiei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Antimicrobial PLGA-based micro/nanoparticles for nanomedicine of pulmonary diseases: from respiratory infections to pulmonary hypertension and fibrosis</article-title>. <source>Int. J. Pharm.</source><volume>683</volume>, <fpage>126054</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2025.126054</pub-id><pub-id pub-id-type="pmid">40783025</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamaly</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Valencia</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Radovic-Moreno</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Farokhzad</surname><given-names>O. C.</given-names></name></person-group> (<year>2012</year>). <article-title>Targeted polymeric therapeutic nanoparticles: design, development and clinical translation</article-title>. <source>Chem. Soc. Rev.</source><volume>41</volume>, <fpage>2971</fpage>&#8211;<lpage>3010</lpage>. <pub-id pub-id-type="doi">10.1039/c2cs15344k</pub-id><pub-id pub-id-type="pmid">22388185</pub-id><pub-id pub-id-type="pmcid">PMC3684255</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamaly</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yameen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Farokhzad</surname><given-names>O. C.</given-names></name></person-group> (<year>2016</year>). <article-title>Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release</article-title>. <source>Chem. Rev.</source><volume>116</volume>, <fpage>2602</fpage>&#8211;<lpage>2663</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.5b00346</pub-id><pub-id pub-id-type="pmid">26854975</pub-id><pub-id pub-id-type="pmcid">PMC5509216</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katebi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Varshochian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Riazi-Rad</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ganjalikhani-Hakemi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ajdary</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates <italic toggle="yes">Leishmania</italic> major-infected-macrophages activation</article-title>. <source>Biomed. Pharmacother.</source><volume>137</volume>, <fpage>111276</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2021.111276</pub-id><pub-id pub-id-type="pmid">33485119</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katsuki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matoba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakashiro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Koga</surname><given-names>J.-I.</given-names></name><name name-style="western"><surname>Nakano</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes</article-title>. <source>Circulation</source><volume>129</volume>, <fpage>896</fpage>&#8211;<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.002870</pub-id><pub-id pub-id-type="pmid">24305567</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katsuki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koga</surname><given-names>J.-I.</given-names></name><name name-style="western"><surname>Matoba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Umezu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nakashiro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakano</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Nanoparticle-mediated delivery of pitavastatin to monocytes/macrophages inhibits angiotensin II-induced abdominal aortic aneurysm formation in apoe<sup>-/-</sup> mice</article-title>. <source>J. Atheroscler. Thrombosis</source><volume>29</volume>, <fpage>111</fpage>&#8211;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.5551/jat.54379</pub-id><pub-id pub-id-type="pmid">33455994</pub-id><pub-id pub-id-type="pmcid">PMC8737070</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalid</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cheng-Xin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Inge</surname><given-names>G.-I.</given-names></name></person-group> (<year>2010</year>). <article-title>Tau in Alzheimer disease and related tauopathies</article-title>. <source>Curr. Alzheimer Res.</source><volume>7</volume>, <fpage>656</fpage>&#8211;<lpage>664</lpage>. <pub-id pub-id-type="doi">10.2174/156720510793611592</pub-id><pub-id pub-id-type="pmid">20678074</pub-id><pub-id pub-id-type="pmcid">PMC3090074</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Hyeon</surname><given-names>T.</given-names></name></person-group> (<year>2018</year>). <article-title>Synthesis and biomedical applications of multifunctional nanoparticles</article-title>. <source>Adv. Mater.</source><volume>30</volume>, <fpage>e1802309</fpage>. <pub-id pub-id-type="doi">10.1002/adma.201802309</pub-id><pub-id pub-id-type="pmid">30133009</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Komedchikova</surname><given-names>E. N.</given-names></name><name name-style="western"><surname>Kolesnikova</surname><given-names>O. A.</given-names></name><name name-style="western"><surname>Syuy</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Volkov</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Deyev</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Nikitin</surname><given-names>M. P.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Targosomes: anti-HER2 PLGA nanocarriers for bioimaging, chemotherapy and local photothermal treatment of tumors and remote metastases</article-title>. <source>J. Control. Release</source><volume>365</volume>, <fpage>317</fpage>&#8211;<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2023.11.036</pub-id><pub-id pub-id-type="pmid">37996056</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koo</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Azad</surname><given-names>M. O. K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Development of iron(II) sulfate nanoparticles produced by hot-melt extrusion and their therapeutic potentials for colon cancer</article-title>. <source>Int. J. Pharm.</source><volume>558</volume>, <fpage>388</fpage>&#8211;<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.01.018</pub-id><pub-id pub-id-type="pmid">30665001</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tamam</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gadalla</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Systemic delivery of paclitaxel by find-Me nanoparticles activates antitumor immunity and eliminates tumors</article-title>. <source>ACS Nano</source><volume>18</volume>, <fpage>3681</fpage>&#8211;<lpage>3698</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.3c11445</pub-id><pub-id pub-id-type="pmid">38227965</pub-id><pub-id pub-id-type="pmcid">PMC11025439</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lababidi</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Azzazy</surname><given-names>H. M. E.-S.</given-names></name></person-group> (<year>2025</year>). <article-title>Revamping Parkinson&#8217;s disease therapy using PLGA-based drug delivery systems</article-title>. <source>npj Parkinson's Dis.</source><volume>11</volume>, <fpage>248</fpage>. <pub-id pub-id-type="doi">10.1038/s41531-025-01081-1</pub-id><pub-id pub-id-type="pmid">40835835</pub-id><pub-id pub-id-type="pmcid">PMC12368271</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aguerri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Irusta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mendoza</surname><given-names>G.</given-names></name><name name-style="western"><surname>Arruebo</surname><given-names>M.</given-names></name></person-group> (<year>2024</year>). <article-title>PLGA nanoparticle-encapsulated lysostaphin for the treatment of <italic toggle="yes">Staphylococcus aureus</italic> infections</article-title>. <source>Int. J. Biol. Macromol.</source><volume>271</volume>, <fpage>132563</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.132563</pub-id><pub-id pub-id-type="pmid">38782313</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>T. T. D.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>T. H.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T. N.</given-names></name><name name-style="western"><surname>Ngo</surname><given-names>T. H. G.</given-names></name><name name-style="western"><surname>Hoang</surname><given-names>T. M. N.</given-names></name><name name-style="western"><surname>Le</surname><given-names>Q. H.</given-names></name></person-group> (<year>2016</year>). <article-title>Evaluation of anti-HER2 scFv-conjugated PLGA&#8211;PEG nanoparticles on 3D tumor spheroids of BT474 and HCT116 cancer cells</article-title>. <source>Adv. Nat. Sci. Nanosci. Nanotechnol.</source><volume>7</volume>, <fpage>025004</fpage>. <pub-id pub-id-type="doi">10.1088/2043-6262/7/2/025004</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Tran</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>T. T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J. U.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. H.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Magnetic resonance imaging of pancreatic islets using tissue&#8211;adhesive particles containing iron oxide nanoparticles</article-title>. <source>J. Control. Release</source><volume>364</volume>, <fpage>37</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2023.10.008</pub-id><pub-id pub-id-type="pmid">37813125</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H.-J.</given-names></name></person-group> (<year>2018</year>). <article-title>An &#945;-tocopheryl succinate enzyme-based nanoassembly for cancer imaging and therapy</article-title>. <source>Drug Deliv.</source><volume>25</volume>, <fpage>738</fpage>&#8211;<lpage>749</lpage>. <pub-id pub-id-type="doi">10.1080/10717544.2018.1446476</pub-id><pub-id pub-id-type="pmid">29516756</pub-id><pub-id pub-id-type="pmcid">PMC6058571</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.-D.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H.-J.</given-names></name></person-group> (<year>2016</year>). <article-title>Cholesterol-modified poly(lactide-co-glycolide) nanoparticles for tumor-targeted drug delivery</article-title>. <source>Int. J. Pharm.</source><volume>509</volume>, <fpage>483</fpage>&#8211;<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.06.008</pub-id><pub-id pub-id-type="pmid">27286639</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Termsarasab</surname><given-names>U.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M. Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.-H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. S.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery</article-title>. <source>Acta Biomater.</source><volume>57</volume>, <fpage>262</fpage>&#8211;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2017.05.012</pub-id><pub-id pub-id-type="pmid">28483700</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Delicately designed cancer cell membrane-camouflaged nanoparticles for targeted 19F MR/PA/FL imaging-guided photothermal therapy</article-title>. <source>ACS Appl. Mater. Interfaces</source><volume>12</volume>, <fpage>57290</fpage>&#8211;<lpage>57301</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.0c13865</pub-id><pub-id pub-id-type="pmid">33231083</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name></person-group> (<year>2021</year>). <article-title>Recent advances in nanomedicines for the treatment of ischemic stroke</article-title>. <source>Acta Pharm. Sin. B</source><volume>11</volume>, <fpage>1767</fpage>&#8211;<lpage>1788</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2020.11.019</pub-id><pub-id pub-id-type="pmid">34386320</pub-id><pub-id pub-id-type="pmcid">PMC8343119</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Fabrication of poly Dopamine@poly (lactic acid-Co-glycolic acid) nanohybrids for cancer therapy via a triple collaboration strategy</article-title>. <source>Nanomaterials</source><volume>13</volume>, <fpage>1447</fpage>. <pub-id pub-id-type="doi">10.3390/nano13091447</pub-id><pub-id pub-id-type="pmid">37176991</pub-id><pub-id pub-id-type="pmcid">PMC10180254</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Cationic microRNA-delivering nanocarriers for efficient treatment of colon carcinoma in xenograft model</article-title>. <source>Gene Ther.</source><volume>23</volume>, <fpage>829</fpage>&#8211;<lpage>838</lpage>. <pub-id pub-id-type="doi">10.1038/gt.2016.60</pub-id><pub-id pub-id-type="pmid">27482839</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Long</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Black phosphorus-based nanoparticles induce liver cancer cell mitochondrial apoptosis and immune cell tumor infiltration for enhancing dendritic cell therapy</article-title>. <source>Heliyon</source><volume>10</volume>, <fpage>e27234</fpage>. <pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e27234</pub-id><pub-id pub-id-type="pmid">38463812</pub-id><pub-id pub-id-type="pmcid">PMC10923724</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Libby</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ridker</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Maseri</surname><given-names>A.</given-names></name></person-group> (<year>2002</year>). <article-title>Inflammation and atherosclerosis</article-title>. <source>Circulation</source><volume>105</volume>, <fpage>1135</fpage>&#8211;<lpage>1143</lpage>. <pub-id pub-id-type="doi">10.1161/hc0902.104353</pub-id><pub-id pub-id-type="pmid">11877368</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>K.</given-names></name></person-group> (<year>2017</year>). <article-title>Design of nanocarriers based on complex biological barriers <italic toggle="yes">in vivo</italic> for tumor therapy</article-title>. <source>Nano Today</source><volume>15</volume>, <fpage>56</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.nantod.2017.06.010</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>E.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Platensimycin-encapsulated poly(lactic-co-glycolic acid) and poly(amidoamine) dendrimers nanoparticles with enhanced anti-staphylococcal activity <italic toggle="yes">in vivo</italic>
</article-title>. <source>Bioconjugate Chem.</source><volume>31</volume>, <fpage>1425</fpage>&#8211;<lpage>1437</lpage>. <pub-id pub-id-type="doi">10.1021/acs.bioconjchem.0c00121</pub-id><pub-id pub-id-type="pmid">32286051</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>A nanoparticle-based sonodynamic therapy reduces <italic toggle="yes">Helicobacter pylori</italic> infection in mouse without disrupting gut microbiota</article-title>. <source>Nat. Commun.</source><volume>15</volume>, <fpage>844</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-024-45156-8</pub-id><pub-id pub-id-type="pmid">38286999</pub-id><pub-id pub-id-type="pmcid">PMC10825188</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lloyd-Jones</surname><given-names>D.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>T. M.</given-names></name><name name-style="western"><surname>Carnethon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Simone</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association</article-title>. <source>Circulation</source><volume>121</volume>, <fpage>948</fpage>&#8211;<lpage>954</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.192666</pub-id><pub-id pub-id-type="pmid">20177011</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kammula</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H.-Q.</given-names></name></person-group> (<year>2025</year>). <article-title>Sequential flash nanocomplexation and flash nanoprecipitation enables scalable assembly of doxorubicin-loaded nanoparticles</article-title>. <source>Nanomedicine Nanotechnol. Biol. Med.</source><volume>68</volume>, <fpage>102843</fpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2025.102843</pub-id><pub-id pub-id-type="pmid">40651619</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luk</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Kehm</surname><given-names>V.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>O&#8217;brien</surname><given-names>P.</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>J. Q.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Pathological &#945;-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice</article-title>. <source>Science</source><volume>338</volume>, <fpage>949</fpage>&#8211;<lpage>953</lpage>. <pub-id pub-id-type="doi">10.1126/science.1227157</pub-id><pub-id pub-id-type="pmid">23161999</pub-id><pub-id pub-id-type="pmcid">PMC3552321</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sadoqi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Biodistribution of indocyanine green-loaded nanoparticles with surface modifications of PEG and folic acid</article-title>. <source>Int. J. Pharm.</source><volume>436</volume>, <fpage>25</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.06.007</pub-id><pub-id pub-id-type="pmid">22692077</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>H.</given-names></name></person-group> (<year>2012</year>). <article-title>Macromolecular therapeutics in cancer treatment: the EPR effect and beyond</article-title>. <source>J. Control. Release</source><volume>164</volume>, <fpage>138</fpage>&#8211;<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2012.04.038</pub-id><pub-id pub-id-type="pmid">22595146</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging <italic toggle="yes">in vivo</italic>
</article-title>. <source>Adv. Drug Deliv. Rev.</source><volume>65</volume>, <fpage>71</fpage>&#8211;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2012.10.002</pub-id><pub-id pub-id-type="pmid">23088862</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maghrebi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jambhrunkar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>N.</given-names></name><name name-style="western"><surname>Prestidge</surname><given-names>C. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Poly(lactic-co-glycolic) acid&#8211;lipid hybrid microparticles enhance the intracellular uptake and antibacterial activity of rifampicin</article-title>. <source>ACS Appl. Mater. Interfaces</source><volume>12</volume>, <fpage>8030</fpage>&#8211;<lpage>8039</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.9b22991</pub-id><pub-id pub-id-type="pmid">32013379</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maija</surname><given-names>B.</given-names></name><name name-style="western"><surname>Riikka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Veli-Matti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kari</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Vascular endothelial growth factor-B in physiology and disease</article-title>. <source>Physiol. Rev.</source><volume>94</volume>, <fpage>779</fpage>&#8211;<lpage>794</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00028.2013</pub-id><pub-id pub-id-type="pmid">24987005</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez</surname><given-names>J. O.</given-names></name><name name-style="western"><surname>Molinaro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hartman</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Boada</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sukhovershin</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Rosa</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery</article-title>. <source>Theranostics</source><volume>8</volume>, <fpage>1131</fpage>&#8211;<lpage>1145</lpage>. <pub-id pub-id-type="doi">10.7150/thno.22078</pub-id><pub-id pub-id-type="pmid">29464004</pub-id><pub-id pub-id-type="pmcid">PMC5817115</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martins</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ara&#250;jo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sarmento</surname><given-names>B.</given-names></name></person-group> (<year>2017</year>). <article-title>Functionalizing PLGA and PLGA derivatives for drug delivery and tissue regeneration applications</article-title>. <source>Adv. Healthc. Mater.</source><volume>7</volume>, <fpage>1701035</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.201701035</pub-id><pub-id pub-id-type="pmid">29171928</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matoba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Egashira</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Nanoparticle-mediated drug delivery system for cardiovascular disease</article-title>. <source>Int. Heart J.</source><volume>55</volume>, <fpage>281</fpage>&#8211;<lpage>286</lpage>. <pub-id pub-id-type="doi">10.1536/ihj.14-150</pub-id><pub-id pub-id-type="pmid">24942639</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medina</surname><given-names>D. X.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>E. P.</given-names></name><name name-style="western"><surname>Teague</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Bowser</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sirianni</surname><given-names>R. W.</given-names></name></person-group> (<year>2020</year>). <article-title>Intravenously administered, retinoid activating nanoparticles increase lifespan and reduce neurodegeneration in the SOD1G93A mouse model of ALS</article-title>. <source>Front. Bioeng. Biotechnol.</source><volume>8</volume>, <fpage>224</fpage>. <pub-id pub-id-type="doi">10.3389/fbioe.2020.00224</pub-id><pub-id pub-id-type="pmid">32292776</pub-id><pub-id pub-id-type="pmcid">PMC7118553</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meir</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lilach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>Precision nanomedicine in neurodegenerative diseases</article-title>. <source>ACS Nano</source><volume>8</volume>, <fpage>1958</fpage>&#8211;<lpage>1965</lpage>. <pub-id pub-id-type="doi">10.1021/nn501292z</pub-id><pub-id pub-id-type="pmid">24660817</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menon</surname><given-names>J. U.</given-names></name><name name-style="western"><surname>Jadeja</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tambe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>K. T.</given-names></name></person-group> (<year>2013</year>). <article-title>Nanomaterials for photo-based diagnostic and therapeutic applications</article-title>. <source>Theranostics</source><volume>3</volume>, <fpage>152</fpage>&#8211;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.7150/thno.5327</pub-id><pub-id pub-id-type="pmid">23471164</pub-id><pub-id pub-id-type="pmcid">PMC3590585</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>A. U.</given-names></name></person-group> (<year>2017</year>). <article-title>Recent applications of PLGA based nanostructures in drug delivery</article-title>. <source>Colloids Surfaces B Biointerfaces</source><volume>159</volume>, <fpage>217</fpage>&#8211;<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2017.07.038</pub-id><pub-id pub-id-type="pmid">28797972</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hoshiga</surname><given-names>M.</given-names></name></person-group> (<year>2024</year>). <article-title>Fibroblast growth factors in cardiovascular disease</article-title>. <source>J. Atheroscler. Thrombosis</source><volume>31</volume>, <fpage>1496</fpage>&#8211;<lpage>1511</lpage>. <pub-id pub-id-type="doi">10.5551/jat.RV22025</pub-id><pub-id pub-id-type="pmid">39168622</pub-id><pub-id pub-id-type="pmcid">PMC11537794</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lovell</surname><given-names>M. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Alzheimer&#8217;s disease and the amyloid-&#946; peptide</article-title>. <source>J. Alzheimer&#8217;s Dis.</source><volume>19</volume>, <fpage>311</fpage>&#8211;<lpage>323</lpage>. <pub-id pub-id-type="doi">10.3233/jad-2010-1221</pub-id><pub-id pub-id-type="pmid">20061647</pub-id><pub-id pub-id-type="pmcid">PMC2813509</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Na</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shuai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xiao-Ge</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu-Jiong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rui-Tian</surname><given-names>L.</given-names></name></person-group> (<year>2017</year>). <article-title>PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering A&#946; generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer&#8217;s disease mice</article-title>. <source>Oncotarget</source><volume>8</volume>, <fpage>81001</fpage>&#8211;<lpage>81013</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.20944</pub-id><pub-id pub-id-type="pmid">29113362</pub-id><pub-id pub-id-type="pmcid">PMC5655257</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Matoba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tokutome</surname><given-names>M.</given-names></name><name name-style="western"><surname>Funamoto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Katsuki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Nanoparticle-mediated delivery of irbesartan induces cardioprotection from myocardial ischemia-reperfusion injury by antagonizing monocyte-mediated inflammation</article-title>. <source>Sci. Rep.</source><volume>6</volume>, <fpage>29601</fpage>. <pub-id pub-id-type="doi">10.1038/srep29601</pub-id><pub-id pub-id-type="pmid">27403534</pub-id><pub-id pub-id-type="pmcid">PMC4939605</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nazarian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gargari</surname><given-names>S. L. M.</given-names></name><name name-style="western"><surname>Rasooli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hasannia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pirooznia</surname><given-names>N.</given-names></name></person-group> (<year>2014</year>). <article-title>A PLGA-encapsulated chimeric protein protects against adherence and toxicity of enterotoxigenic <italic toggle="yes">Escherichia coli</italic>
</article-title>. <source>Microbiol. Res.</source><volume>169</volume>, <fpage>205</fpage>&#8211;<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1016/j.micres.2013.06.005</pub-id><pub-id pub-id-type="pmid">23906742</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Neutrophil&#8208;mimicking nanomedicine eliminates tumor intracellular bacteria and enhances chemotherapy on liver metastasis of colorectal cancer</article-title>. <source>Adv. Sci.</source><volume>12</volume>, <fpage>e04188</fpage>. <pub-id pub-id-type="doi">10.1002/advs.202504188</pub-id><pub-id pub-id-type="pmid">40433907</pub-id><pub-id pub-id-type="pmcid">PMC12376532</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nottelet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Darcos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Coudane</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Aliphatic polyesters for medical imaging and theranostic applications</article-title>. <source>Eur. J. Pharm. Biopharm.</source><volume>97</volume>, <fpage>350</fpage>&#8211;<lpage>370</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2015.06.023</pub-id><pub-id pub-id-type="pmid">26614557</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oberli</surname><given-names>M. a. R. A. M.</given-names></name><name name-style="western"><surname>Dorkin</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Fenton</surname><given-names>O. S.</given-names></name><name name-style="western"><surname>Jaklenec</surname><given-names>A.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>D. G.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy</article-title>. <source>Nano Lett.</source><volume>17</volume>, <fpage>1326</fpage>&#8211;<lpage>1335</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.6b03329</pub-id><pub-id pub-id-type="pmid">28273716</pub-id><pub-id pub-id-type="pmcid">PMC5523404</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Operti</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Bernhardt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sincari</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jager</surname><given-names>E.</given-names></name><name name-style="western"><surname>Grimm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Industrial scale manufacturing and downstream processing of PLGA-based nanomedicines suitable for fully continuous operation</article-title>. <source>Pharmaceutics</source><volume>14</volume>, <fpage>276</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics14020276</pub-id><pub-id pub-id-type="pmid">35214009</pub-id><pub-id pub-id-type="pmcid">PMC8878443</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Dehaini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Holay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>Biomimetic nanoparticle technology for cardiovascular disease detection and treatment</article-title>. <source>Nanoscale Horizons</source><volume>5</volume>, <fpage>25</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1039/c9nh00291j</pub-id><pub-id pub-id-type="pmid">32133150</pub-id><pub-id pub-id-type="pmcid">PMC7055493</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patil</surname><given-names>Y. B.</given-names></name><name name-style="western"><surname>Swaminathan</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Sadhukha</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Panyam</surname><given-names>J.</given-names></name></person-group> (<year>2010</year>). <article-title>The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance</article-title>. <source>Biomaterials</source><volume>31</volume>, <fpage>358</fpage>&#8211;<lpage>365</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2009.09.048</pub-id><pub-id pub-id-type="pmid">19800114</pub-id><pub-id pub-id-type="pmcid">PMC2783414</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>S.-L.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>P.-Y.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>J.-T.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>S.-C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Nanotheranostics with the combination of improved targeting, therapeutic effects, and molecular imaging</article-title>. <source>Front. Bioeng. Biotechnol.</source><volume>8</volume>, <fpage>570490</fpage>. <pub-id pub-id-type="doi">10.3389/fbioe.2020.570490</pub-id><pub-id pub-id-type="pmid">33042972</pub-id><pub-id pub-id-type="pmcid">PMC7523243</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peres</surname><given-names>C.</given-names></name><name name-style="western"><surname>Matos</surname><given-names>A. I.</given-names></name><name name-style="western"><surname>Conniot</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sainz</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zupan&#269;i&#269;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Poly(lactic acid)-based particulate systems are promising tools for immune modulation</article-title>. <source>Acta Biomater.</source><volume>48</volume>, <fpage>41</fpage>&#8211;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2016.11.012</pub-id><pub-id pub-id-type="pmid">27826003</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pineda</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ulloa-Navas</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Linville</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>F. J.</given-names></name><name name-style="western"><surname>Galani</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Single-cell dissection of the human motor and prefrontal cortices in ALS and FTLD</article-title>. <source>Cell</source><volume>187</volume>, <fpage>1971</fpage>&#8211;<lpage>1989.e16</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2024.02.031</pub-id><pub-id pub-id-type="pmid">38521060</pub-id><pub-id pub-id-type="pmcid">PMC11086986</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rashedi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Greason</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Sadeghipour</surname><given-names>P.</given-names></name><name name-style="western"><surname>Talasaz</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>O&#8217;donoghue</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Fibrinolytic agents in thromboembolic diseases: historical perspectives and approved indications</article-title>. <source>Seminars Thrombosis Hemostasis</source><volume>50</volume>, <fpage>773</fpage>&#8211;<lpage>789</lpage>. <pub-id pub-id-type="doi">10.1055/s-0044-1781451</pub-id><pub-id pub-id-type="pmid">38428841</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ratzinger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>P.</given-names></name><name name-style="western"><surname>K&#246;rner</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lonkai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>H. M. H. F.</given-names></name><name name-style="western"><surname>Terreno</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Surface modification of PLGA nanospheres with Gd-DTPA and Gd-DOTA for high-relaxivity MRI contrast agents</article-title>. <source>Biomaterials</source><volume>31</volume>, <fpage>8716</fpage>&#8211;<lpage>8723</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.07.095</pub-id><pub-id pub-id-type="pmid">20797782</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>US/PA/MR multimodal imaging-guided multifunctional genetically engineered bio-targeted synergistic agent for tumor therapy</article-title>. <source>J. Nanobiotechnology</source><volume>22</volume>, <fpage>615</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-024-02868-9</pub-id><pub-id pub-id-type="pmid">39385196</pub-id><pub-id pub-id-type="pmcid">PMC11465552</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rezvantalab</surname><given-names>S.</given-names></name><name name-style="western"><surname>Drude</surname><given-names>N. I.</given-names></name><name name-style="western"><surname>Moraveji</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>G&#252;vener</surname><given-names>N.</given-names></name><name name-style="western"><surname>Koons</surname><given-names>E. K.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>PLGA-based nanoparticles in cancer treatment</article-title>. <source>Front. Pharmacol.</source><volume>9</volume>, <fpage>1260</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2018.01260</pub-id><pub-id pub-id-type="pmid">30450050</pub-id><pub-id pub-id-type="pmcid">PMC6224484</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rittchen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fahmy</surname><given-names>T. M.</given-names></name><name name-style="western"><surname>Metcalfe</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Myelin repair <italic toggle="yes">in vivo</italic> is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF)</article-title>. <source>Biomaterials</source><volume>56</volume>, <fpage>78</fpage>&#8211;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2015.03.044</pub-id><pub-id pub-id-type="pmid">25934281</pub-id><pub-id pub-id-type="pmcid">PMC4429967</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chandradhara</surname><given-names>D.</given-names></name><name name-style="western"><surname>De Tommasi</surname><given-names>N.</given-names></name></person-group> (<year>2018</year>). <article-title>Comparative bioavailability of two diosmin formulations after oral administration to healthy volunteers</article-title>. <source>Molecules</source><volume>23</volume>, <fpage>2174</fpage>. <pub-id pub-id-type="doi">10.3390/molecules23092174</pub-id><pub-id pub-id-type="pmid">30158431</pub-id><pub-id pub-id-type="pmcid">PMC6225479</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sah</surname><given-names>H.</given-names></name><name name-style="western"><surname>Desu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wood</surname></name><name name-style="western"><surname>Thoma</surname></name></person-group> (<year>2013</year>). <article-title>Concepts and practices used to develop functional PLGA-based nanoparticulate systems</article-title>. <source>Int. J. Nanomedicine</source><volume>747</volume>, <fpage>747</fpage>. <pub-id pub-id-type="doi">10.2147/ijn.s40579</pub-id><pub-id pub-id-type="pmid">23459088</pub-id><pub-id pub-id-type="pmcid">PMC3582541</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salmasi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kamali</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rezaee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nazeran</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jafari</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Eisvand</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Simultaneous therapeutic and diagnostic applications of magnetic PLGA nanoparticles loaded with doxorubicin in rabbit</article-title>. <source>Drug Deliv. Transl. Res.</source><volume>15</volume>, <fpage>770</fpage>&#8211;<lpage>785</lpage>. <pub-id pub-id-type="doi">10.1007/s13346-024-01693-9</pub-id><pub-id pub-id-type="pmid">39215953</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santucci</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mignozzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Malvezzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boffetta</surname><given-names>P.</given-names></name><name name-style="western"><surname>Collatuzzo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Levi</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>European cancer mortality predictions for the year 2024 with focus on colorectal cancer</article-title>. <source>Ann. Oncol.</source><volume>35</volume>, <fpage>308</fpage>&#8211;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1016/j.annonc.2023.12.003</pub-id><pub-id pub-id-type="pmid">38286716</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saraiva</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pra&#231;a</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>R.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bernardino</surname><given-names>L.</given-names></name></person-group> (<year>2016</year>). <article-title>Nanoparticle-mediated brain drug delivery: overcoming blood&#8211;brain barrier to treat neurodegenerative diseases</article-title>. <source>J. Control. Release</source><volume>235</volume>, <fpage>34</fpage>&#8211;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2016.05.044</pub-id><pub-id pub-id-type="pmid">27208862</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shariati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chegini</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ghaznavi-Rad</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zare</surname><given-names>E. N.</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>S. M.</given-names></name></person-group> (<year>2022</year>). <article-title>PLGA-based nanoplatforms in drug delivery for inhibition and destruction of microbial biofilm</article-title>. <source>Front. Cell. Infect. Microbiol.</source><volume>12</volume>, <fpage>926363</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2022.926363</pub-id><pub-id pub-id-type="pmid">35800390</pub-id><pub-id pub-id-type="pmcid">PMC9253276</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.-M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.-Y.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.-X.</given-names></name></person-group> (<year>2012</year>). <article-title>Luminescent/magnetic hybrid nanoparticles with folate-conjugated peptide composites for tumor-targeted drug delivery</article-title>. <source>Bioconjugate Chem.</source><volume>23</volume>, <fpage>1010</fpage>&#8211;<lpage>1021</lpage>. <pub-id pub-id-type="doi">10.1021/bc300008k</pub-id><pub-id pub-id-type="pmid">22486419</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kantoff</surname><given-names>P. W.</given-names></name><name name-style="western"><surname>Wooster</surname><given-names>R.</given-names></name><name name-style="western"><surname>Farokhzad</surname><given-names>O. C.</given-names></name></person-group> (<year>2016</year>). <article-title>Cancer nanomedicine: progress, challenges and opportunities</article-title>. <source>Nat. Rev. Cancer</source><volume>17</volume>, <fpage>20</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1038/nrc.2016.108</pub-id><pub-id pub-id-type="pmid">27834398</pub-id><pub-id pub-id-type="pmcid">PMC5575742</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Zupancic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vandermeulen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>V. G.</given-names></name><name name-style="western"><surname>Salgado</surname><given-names>A.</given-names></name><name name-style="western"><surname>Videira</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>
<italic toggle="yes">In vivo</italic> delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model</article-title>. <source>J. Control. Release</source><volume>198</volume>, <fpage>91</fpage>&#8211;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2014.11.033</pub-id><pub-id pub-id-type="pmid">25483429</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pandit</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mokkapati</surname><given-names>V. R. S. S.</given-names></name><name name-style="western"><surname>Mijakovic</surname><given-names>I.</given-names></name></person-group> (<year>2018</year>). <article-title>Antimicrobial effects of biogenic nanoparticles</article-title>. <source>Nanomaterials</source><volume>8</volume>, <fpage>1009</fpage>. <pub-id pub-id-type="doi">10.3390/nano8121009</pub-id><pub-id pub-id-type="pmid">30563095</pub-id><pub-id pub-id-type="pmcid">PMC6315689</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soehnlein</surname><given-names>O.</given-names></name><name name-style="western"><surname>Libby</surname><given-names>P.</given-names></name></person-group> (<year>2021</year>). <article-title>Targeting inflammation in atherosclerosis &#8212; from experimental insights to the clinic</article-title>. <source>Nat. Rev. Drug Discov.</source><volume>20</volume>, <fpage>589</fpage>&#8211;<lpage>610</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-021-00198-1</pub-id><pub-id pub-id-type="pmid">33976384</pub-id><pub-id pub-id-type="pmcid">PMC8112476</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sonam Dongsar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsering Dongsar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alsayari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wahab</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kesharwani</surname><given-names>P.</given-names></name></person-group> (<year>2024</year>). <article-title>PLGA nanomedical consignation: a novel approach for the management of prostate cancer</article-title>. <source>Int. J. Pharm.</source><volume>652</volume>, <fpage>123808</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2024.123808</pub-id><pub-id pub-id-type="pmid">38224758</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Speltri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Porto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Boschi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Uccelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>P.</given-names></name></person-group> (<year>2024</year>). <article-title>Recent advances in preclinical studies of the theranostic agent [64Cu]CuCl2</article-title>. <source>Molecules</source><volume>29</volume>, <fpage>4085</fpage>. <pub-id pub-id-type="doi">10.3390/molecules29174085</pub-id><pub-id pub-id-type="pmid">39274933</pub-id><pub-id pub-id-type="pmcid">PMC11397388</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sridharan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>H. G.</given-names></name></person-group> (<year>2023</year>). <article-title>Advances in photoacoustic imaging aided by nano contrast agents: special focus on role of lymphatic system imaging for cancer theranostics</article-title>. <source>J. Nanobiotechnology</source><volume>21</volume>, <fpage>437</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-023-02192-8</pub-id><pub-id pub-id-type="pmid">37986071</pub-id><pub-id pub-id-type="pmcid">PMC10662568</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>William Costerton</surname><given-names>J.</given-names></name></person-group> (<year>2001</year>). <article-title>Antibiotic resistance of bacteria in biofilms</article-title>. <source>Lancet</source><volume>358</volume>, <fpage>135</fpage>&#8211;<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(01)05321-1</pub-id><pub-id pub-id-type="pmid">11463434</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Tunable rigidity of (polymeric core)&#8211;(lipid shell) nanoparticles for regulated cellular uptake</article-title>. <source>Adv. Mater.</source><volume>27</volume>, <fpage>1402</fpage>&#8211;<lpage>1407</lpage>. <pub-id pub-id-type="doi">10.1002/adma.201404788</pub-id><pub-id pub-id-type="pmid">25529120</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swider</surname><given-names>E.</given-names></name><name name-style="western"><surname>Koshkina</surname><given-names>O.</given-names></name><name name-style="western"><surname>Tel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>De Vries</surname><given-names>I. J. M.</given-names></name><name name-style="western"><surname>Srinivas</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Customizing poly(lactic-co-glycolic acid) particles for biomedical applications</article-title>. <source>Acta Biomater.</source><volume>73</volume>, <fpage>38</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2018.04.006</pub-id><pub-id pub-id-type="pmid">29653217</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tahara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Samura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tsukada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bando</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Oral nuclear factor-&#954;B decoy oligonucleotides delivery system with chitosan modified poly(d,l-lactide-co-glycolide) nanospheres for inflammatory bowel disease</article-title>. <source>Biomaterials</source><volume>32</volume>, <fpage>870</fpage>&#8211;<lpage>878</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.09.034</pub-id><pub-id pub-id-type="pmid">20934748</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moriguchi</surname><given-names>K.</given-names></name></person-group> (<year>2024</year>). <article-title>Effects of silver-decorated PLGA nanoparticles on Staphylococcus epidermidis biofilms and evaluation of the detoxification limit of bacteria against these nanoparticles</article-title>. <source>Nanoscale Adv.</source><volume>6</volume>, <fpage>5020</fpage>&#8211;<lpage>5030</lpage>. <pub-id pub-id-type="doi">10.1039/d4na00249k</pub-id><pub-id pub-id-type="pmid">39296280</pub-id><pub-id pub-id-type="pmcid">PMC11404029</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tracy</surname><given-names>G. C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>K.-Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Y.-T.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>S.</given-names></name><name name-style="western"><surname>Noblet</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>K. H.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Intracerebral nanoparticle transport facilitated by Alzheimer pathology and age</article-title>. <source>Nano Lett.</source><volume>23</volume>, <fpage>10971</fpage>&#8211;<lpage>10982</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.3c03222</pub-id><pub-id pub-id-type="pmid">37991895</pub-id><pub-id pub-id-type="pmcid">PMC11404402</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trapp</surname><given-names>B. D.</given-names></name><name name-style="western"><surname>Nave</surname><given-names>K.-A.</given-names></name></person-group> (<year>2008</year>). <article-title>Multiple sclerosis: an immune or neurodegenerative disorder</article-title>. <source>Annu. Rev. Neurosci.</source><volume>31</volume>, <fpage>247</fpage>&#8211;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.neuro.30.051606.094313</pub-id><pub-id pub-id-type="pmid">18558855</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Triantafillidis</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Zografos</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Konstadoulakis</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Papalois</surname><given-names>A. E.</given-names></name></person-group> (<year>2024</year>). <article-title>Combination treatment of inflammatory Bowel disease: present status and future perspectives</article-title>. <source>World J. Gastroenterol.</source><volume>30</volume>, <fpage>2068</fpage>&#8211;<lpage>2080</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v30.i15.2068</pub-id><pub-id pub-id-type="pmid">38681984</pub-id><pub-id pub-id-type="pmcid">PMC11045479</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tucka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>M.</given-names></name><name name-style="western"><surname>Littlewood</surname><given-names>T.</given-names></name></person-group> (<year>2011</year>). <article-title>Cell death and survival signalling in the cardiovascular system</article-title>. <source>Front. Biosci.</source><volume>17</volume>, <fpage>248</fpage>&#8211;<lpage>261</lpage>. <pub-id pub-id-type="doi">10.2741/3925</pub-id><pub-id pub-id-type="pmid">22201742</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valenza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Di Paolo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ruozi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Belletti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ferrari Bardile</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Cholesterol&#8208;loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice</article-title>. <source>EMBO Mol. Med.</source><volume>7</volume>, <fpage>1547</fpage>&#8211;<lpage>1564</lpage>. <pub-id pub-id-type="doi">10.15252/emmm.201505413</pub-id><pub-id pub-id-type="pmid">26589247</pub-id><pub-id pub-id-type="pmcid">PMC4693506</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voronkov</surname><given-names>N. S.</given-names></name><name name-style="western"><surname>Maslov</surname><given-names>L. N.</given-names></name><name name-style="western"><surname>Vyshlov</surname><given-names>E. V.</given-names></name><name name-style="western"><surname>Mukhomedzyanov</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Ryabov</surname><given-names>V. V.</given-names></name><name name-style="western"><surname>Derkachev</surname><given-names>I. A.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Do platelets protect the heart against ischemia/reperfusion injury or exacerbate cardiac ischemia/reperfusion injury? The role of PDGF, VEGF, and PAF</article-title>. <source>Life Sci.</source><volume>347</volume>, <fpage>122617</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2024.122617</pub-id><pub-id pub-id-type="pmid">38608835</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vrbata</surname><given-names>P.</given-names></name><name name-style="western"><surname>Berka</surname><given-names>P.</given-names></name><name name-style="western"><surname>Str&#225;nsk&#225;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dole&#382;al</surname><given-names>P.</given-names></name><name name-style="western"><surname>L&#225;zn&#237;&#269;ek</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Electrospinning of diosmin from aqueous solutions for improved dissolution and oral absorption</article-title>. <source>Int. J. Pharm.</source><volume>473</volume>, <fpage>407</fpage>&#8211;<lpage>413</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.07.017</pub-id><pub-id pub-id-type="pmid">25066074</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Su</surname><given-names>W.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Folate-targeting magnetic core&#8211;shell nanocarriers for selective drug release and imaging</article-title>. <source>Int. J. Pharm.</source><volume>430</volume>, <fpage>342</fpage>&#8211;<lpage>349</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.04.009</pub-id><pub-id pub-id-type="pmid">22525087</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2019a</year>). <article-title>Biomimetic nanotherapies: red blood cell based core&#8211;shell structured nanocomplexes for atherosclerosis management</article-title>. <source>Adv. Sci.</source><volume>6</volume>, <fpage>1900172</fpage>. <pub-id pub-id-type="doi">10.1002/advs.201900172</pub-id><pub-id pub-id-type="pmid">31380165</pub-id><pub-id pub-id-type="pmcid">PMC6662054</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2019b</year>). <article-title>Near-infrared light and tumor microenvironment dual responsive size-switchable nanocapsules for multimodal tumor theranostics</article-title>. <source>Nat. Commun.</source><volume>10</volume>, <fpage>4418</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-12142-4</pub-id><pub-id pub-id-type="pmid">31562357</pub-id><pub-id pub-id-type="pmcid">PMC6765052</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maruf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications</article-title>. <source>Theranostics</source><volume>11</volume>, <fpage>164</fpage>&#8211;<lpage>180</lpage>. <pub-id pub-id-type="doi">10.7150/thno.47841</pub-id><pub-id pub-id-type="pmid">33391468</pub-id><pub-id pub-id-type="pmcid">PMC7681077</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>A macrophage membrane&#8211;polymer hybrid biomimetic nanoplatform for therapeutic delivery of somatostatin peptide to chronic pancreatitis</article-title>. <source>Pharmaceutics</source><volume>14</volume>, <fpage>2341</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics14112341</pub-id><pub-id pub-id-type="pmid">36365160</pub-id><pub-id pub-id-type="pmcid">PMC9698601</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dehaini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kroll</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Nanoparticle functionalization with platelet membrane enables multifactored biological targeting and detection of atherosclerosis</article-title>. <source>ACS Nano</source><volume>12</volume>, <fpage>109</fpage>&#8211;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.7b07720</pub-id><pub-id pub-id-type="pmid">29216423</pub-id><pub-id pub-id-type="pmcid">PMC5859122</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Q.</given-names></name></person-group> (<year>2023</year>). <article-title>Stimuli-responsive polymer-based nanosystems for cancer theranostics</article-title>. <source>ACS Nano</source><volume>17</volume>, <fpage>23223</fpage>&#8211;<lpage>23261</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.3c06019</pub-id><pub-id pub-id-type="pmid">38041800</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Targeted delivery of berberine using bionic nanomaterials for Atherosclerosis therapy</article-title>. <source>Biomed. Pharmacother.</source><volume>178</volume>, <fpage>117135</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2024.117135</pub-id><pub-id pub-id-type="pmid">39047421</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Ultrasound-mediated microbubble destruction (UMMD) facilitates the delivery of CA19-9 targeted and paclitaxel loaded mPEG-PLGA-PLL nanoparticles in pancreatic cancer</article-title>. <source>Theranostics</source><volume>6</volume>, <fpage>1573</fpage>&#8211;<lpage>1587</lpage>. <pub-id pub-id-type="doi">10.7150/thno.15164</pub-id><pub-id pub-id-type="pmid">27446491</pub-id><pub-id pub-id-type="pmcid">PMC4955056</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>M.</given-names></name></person-group> (<year>2024a</year>). <article-title>Extracellular vesicles and their engineering strategies, delivery systems, and biomedical applications</article-title>. <source>J. Control. Release</source><volume>365</volume>, <fpage>1089</fpage>&#8211;<lpage>1123</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2023.11.057</pub-id><pub-id pub-id-type="pmid">38065416</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2024b</year>). <article-title>Recent applications of PLGA in drug delivery systems</article-title>. <source>Polymers</source><volume>16</volume>, <fpage>2606</fpage>. <pub-id pub-id-type="doi">10.3390/polym16182606</pub-id><pub-id pub-id-type="pmid">39339068</pub-id><pub-id pub-id-type="pmcid">PMC11435547</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Pitavastatin and resveratrol bio-nanocomplexes against hyperhomocysteinemia-induced atherosclerosis via blocking ferroptosis-related lipid deposition</article-title>. <source>J. Control. Release</source><volume>381</volume>, <fpage>113598</fpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2025.113598</pub-id><pub-id pub-id-type="pmid">40043912</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Biomimetic nanocomplex based corneal neovascularization theranostics</article-title>. <source>J. Control. Release</source><volume>374</volume>, <fpage>50</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2024.08.002</pub-id><pub-id pub-id-type="pmid">39111599</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yokoyama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ii</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tabata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hoshiga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ishizaka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Asahi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Cardiac regeneration by statin-polymer nanoparticle-loaded adipose-derived stem cell therapy in myocardial infarction</article-title>. <source>Stem Cells Transl. Med.</source><volume>8</volume>, <fpage>1055</fpage>&#8211;<lpage>1067</lpage>. <pub-id pub-id-type="doi">10.1002/sctm.18-0244</pub-id><pub-id pub-id-type="pmid">31157513</pub-id><pub-id pub-id-type="pmcid">PMC6766602</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Targeted brain delivery of rabies virus glycoprotein 29-modified deferoxamine-loaded nanoparticles reverses functional deficits in Parkinsonian mice</article-title>. <source>ACS Nano</source><volume>12</volume>, <fpage>4123</fpage>&#8211;<lpage>4139</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.7b08172</pub-id><pub-id pub-id-type="pmid">29617109</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yunlong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Haisu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rui</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yingying</surname><given-names>P.</given-names></name><name name-style="western"><surname>Junfeng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rongkang</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Biomimetic nanoparticles loaded with ulinastatin for the targeted treatment of acute pancreatitis</article-title>. <source>Mol. Pharm.</source><volume>20</volume>, <fpage>4108</fpage>&#8211;<lpage>4119</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c00238</pub-id><pub-id pub-id-type="pmid">37349264</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yusuf</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alrobaian</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Alghamdi</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Warsi</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Sultana</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Brain targeted Polysorbate-80 coated PLGA thymoquinone nanoparticles for the treatment of Alzheimer&#8217;s disease, with biomechanistic insights</article-title>. <source>J. Drug Deliv. Sci. Technol.</source><volume>61</volume>, <fpage>102214</fpage>. <pub-id pub-id-type="doi">10.1016/j.jddst.2020.102214</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Multifunctional tumor-targeted PLGA nanoparticles delivering Pt(IV)/siBIRC5 for US/MRI imaging and overcoming ovarian cancer resistance</article-title>. <source>Biomaterials</source><volume>269</volume>, <fpage>120478</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120478</pub-id><pub-id pub-id-type="pmid">33213862</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Benicewicz</surname><given-names>B. C.</given-names></name></person-group> (<year>2017</year>). <article-title>pH and thermal dual-responsive nanoparticles for controlled drug delivery with high loading content</article-title>. <source>ACS Omega</source><volume>2</volume>, <fpage>3399</fpage>&#8211;<lpage>3405</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.7b00367</pub-id><pub-id pub-id-type="pmid">30023694</pub-id><pub-id pub-id-type="pmcid">PMC6044946</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group> (<year>2018</year>). <article-title>Stimuli-responsive nanomedicines for overcoming cancer multidrug resistance</article-title>. <source>Theranostics</source><volume>8</volume>, <fpage>1059</fpage>&#8211;<lpage>1074</lpage>. <pub-id pub-id-type="doi">10.7150/thno.22679</pub-id><pub-id pub-id-type="pmid">29463999</pub-id><pub-id pub-id-type="pmcid">PMC5817110</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Derrick</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Woon</surname><given-names>T. Y.</given-names></name><name name-style="western"><surname>Christopher</surname><given-names>T. H.</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Lonnie</surname><given-names>D. S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease</article-title>. <source>ACS Nano</source><volume>8</volume>, <fpage>2148</fpage>&#8211;<lpage>2160</lpage>. <pub-id pub-id-type="doi">10.1021/nn405033r</pub-id><pub-id pub-id-type="pmid">24559284</pub-id><pub-id pub-id-type="pmcid">PMC3990004</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Brain</journal-id><journal-id journal-id-type="iso-abbrev">Brain</journal-id><journal-id journal-id-type="pmc-domain-id">719</journal-id><journal-id journal-id-type="pmc-domain">brain</journal-id><journal-id journal-id-type="publisher-id">brainj</journal-id><journal-title-group><journal-title>Brain</journal-title></journal-title-group><issn pub-type="ppub">0006-8950</issn><issn pub-type="epub">1460-2156</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12493040</article-id><article-id pub-id-type="pmcid-ver">PMC12493040.1</article-id><article-id pub-id-type="pmcaid">12493040</article-id><article-id pub-id-type="pmcaiid">12493040</article-id><article-id pub-id-type="pmid">40570023</article-id><article-id pub-id-type="doi">10.1093/brain/awaf239</article-id><article-id pub-id-type="publisher-id">awaf239</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Essay</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00310</subject><subject>AcademicSubjects/SCI01870</subject></subj-group></article-categories><title-group><article-title>The duality of disease: the Alzheimer&#8217;s disease dilemma through the lens of nosos and asthenia</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6453-8908</contrib-id><name name-style="western"><surname>Scarmeas</surname><given-names initials="N">Nikolaos</given-names></name><aff>
<institution>1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens Medical School</institution>, <addr-line>Athens 115 28</addr-line>, <country country="GR">Greece</country></aff><aff>
<institution>Department of Neurology, Columbia University</institution>, <addr-line>New York, NY 10032</addr-line>, <country country="US">USA</country></aff><xref rid="awaf239-cor1" ref-type="corresp"/><xref rid="FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9933-8164</contrib-id><name name-style="western"><surname>Noriega de la Colina</surname><given-names initials="A">Adri&#225;n</given-names></name><aff>
<institution>The Montreal Neurological Institute-Hospital, Department of Neurology and Neurosurgery, McGill University</institution>, <addr-line>Montreal, QC H3A 1A1</addr-line>, <country country="CA">Canada</country></aff><aff>
<institution>Department of Mechanical Engineering, Massachusetts Institute of Technology</institution>, <addr-line>Cambridge, MA 02139</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Broad Institute of MIT and Harvard</institution>, <addr-line>Cambridge, MA 02142</addr-line>, <country country="US">USA</country></aff><xref rid="FM1" ref-type="author-notes"/></contrib></contrib-group><author-notes><corresp id="awaf239-cor1">Correspondence to: Nikolaos Scarmeas, MD, PhD Professor of Neurology, National and Kapodistrian University of Athens, Medical School, Aiginitio Hospital, 72 Vasilissis Sofias Ave, Athens 11528, Greece E-mail: <email>ns257@cumc.columbia.edu</email></corresp><fn id="FM1"><p>Nikolaos Scarmeas and Adri&#225;n Noriega de la Colina contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-06-26"><day>26</day><month>6</month><year>2025</year></pub-date><volume>148</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">498255</issue-id><fpage>3425</fpage><lpage>3427</lpage><history><date date-type="received"><day>21</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>05</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>5</month><year>2025</year></date><date date-type="corrected-typeset"><day>30</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-04 10:26:05.627"><day>04</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press on behalf of the Guarantors of Brain.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#8212;for further information please contact journals.permissions@oup.com.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="awaf239.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="awaf239.pdf"/><abstract abstract-type="teaser"><p>Scarmeas and Noriega De La Colina use the ancient Greek concepts of nosos (biological disease) and asthenia (functional decline) to frame the shift in Alzheimer&#8217;s disease diagnosis from clinical symptoms to biomarkers, calling for better public understanding of both biological presence and lived experience.</p></abstract><counts><page-count count="3"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
<bold>
<italic toggle="yes">The definition and use of Alzheimer&#8217;s disease straddle an ancient tension between nosos, the biological roots of brain pathology, and asthenia, the lived experience of cognitive decline. This essay revisits these classical concepts to illuminate a modern dilemma: should Alzheimer&#8217;s be defined by its molecular underpinnings or by the symptoms that shape patients&#8217; lives?</italic>
</bold>
</p><sec id="awaf239-s1"><title>Historical precedent</title><p>In the vast tapestry of Greek mythology, disease was not merely a biological affliction but a divine reckoning. <italic toggle="yes">Nosoi</italic> (<italic toggle="yes">Nosos</italic> singular) were the personified spirits of sickness and disease. They were among the evil spirits that escaped from Pandora&#8217;s jar (<xref rid="awaf239-F1" ref-type="fig">Fig. 1</xref>)<sup><xref rid="awaf239-B1" ref-type="bibr">1</xref></sup>; their unintentional release into the world was part of Zeus&#8217; plan to punish the human race for accepting Prometheus&#8217; forbidden gift of fire. Homer always represents nosos as the visitation of an angry deity.<sup><xref rid="awaf239-B1" ref-type="bibr">1</xref>,<xref rid="awaf239-B2" ref-type="bibr">2</xref></sup> In ancient Greek literature, the word <italic toggle="yes">&#945;&#963;&#952;&#941;&#957;&#949;&#953;&#945;</italic> (asthenia) is used to signify lack of strength (weakness), the inevitable consequence of disease (<xref rid="awaf239-F2" ref-type="fig">Fig. 2</xref>). As a term, it appears in the Hippocratic corpus, it is found as early as the 7th century <sc>Bc</sc> in the works of Herodotus, and is also extensively used in texts of Thucydides, Plato and Aristotle.<sup><xref rid="awaf239-B1" ref-type="bibr">1</xref></sup></p><fig position="float" id="awaf239-F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>
<bold>
<italic toggle="yes">Pandora</italic> by John William Waterhouse (1896).</bold> Oil on canvas. Private collection. Public domain: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://commons.wikimedia.org/wiki/File:John_William_Waterhouse_-_Pandora,%20_1896.jpg" ext-link-type="uri">https://commons.wikimedia.org/wiki/File:John_William_Waterhouse_-_Pandora, _1896.jpg</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="awaf239f1.jpg"/></fig><fig position="float" id="awaf239-F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><p>
<bold>
<italic toggle="yes">Achilles tending to the wounds of Patroclus</italic> (<italic toggle="yes">ca</italic> 500 <sc>Bce</sc>).</bold> Red-figure kylix (Detail). Vulci, Italy. Antikensammlung, Berlin. Public domain: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://en.wikipedia.org/wiki/Achilles_and_Patroclus#/media/File:Akhilleus_Patroklos_Antikensammlung_Berlin_F2278.jpg" ext-link-type="uri">https://en.wikipedia.org/wiki/Achilles_and_Patroclus#/media/File:Akhilleus_Patroklos_Antikensammlung_Berlin_F2278.jpg</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="awaf239f2.jpg"/></fig><p>For centuries, nosos denoted the disease process, while asthenia referred to symptoms, the lived experience of decline from the state of health. In English, various terms, including disease, illness, feebleness or sickness, are used, with the latter three being more akin to asthenia. The term nosos has been incorporated in English use: noso-logy, noso-comial, a-noso-gnosia. Similarly, the term asthenia is also used; my-asthenia.</p><p>Throughout medical history, nosology&#8212;the classification of diseases&#8212;has evolved from symptom-based to mechanism-based definitions. In modern medicine, the distinction between nosos and asthenia has been enhanced by progress in biomedical technology and has become more pertinent as our understanding of underlying biopathological changes has started growing and as our ability to measure or estimate such changes has increased.<sup><xref rid="awaf239-B3" ref-type="bibr">3</xref></sup></p></sec><sec id="awaf239-s1.2"><title>Examples of nosos and asthenia: challenges with terminological orthodoxy</title><p>Many metabolic, cardiovascular and oncological conditions are now diagnosed based on biomarkers before clinical symptoms emerge. Diabetes mellitus, once diagnosed purely by symptomatic hyperglycaemia, is now defined by HbA1c levels or fasting glucose, even in asymptomatic individuals. Hypertension is not identified by symptoms of organ damage but by persistently elevated blood pressure. Similarly, dyslipidaemia is identified as an abnormality in serum lipid profile irrespective of clinical consequences. An exhaustive list of medical conditions, including many neoplasms, can now be identified via biomedical investigations in the absence of clinical symptoms. These represent examples of nosos without (yet) asthenia.</p><p>It remains quite a difficult dichotomy to apply in diseases where progress concerning underlying pathobiology has not yet sufficiently advanced or where definite, highly accurate diagnostic biomarkers do not exist. For instance, in systemic lupus erythematosus and in many rheumatologic diseases, a combination of both nosos-related biomarkers and asthenia-related clinical symptoms is necessary for diagnosis. In neurology, although terms such as essential tremor or migraine (hemi-crania or half the cranium) refer more to symptomatology&#8212;asthenia, they essentially encompass both the nosos and asthenia aspects. Similarly, for many psychiatric diseases, i.e. anxiety or depression, given our relatively less mature understanding of underlying biopathology and lack of related biomarkers, the duality of nosos versus asthenia is less applicable, and the terms relate to their coexistence.</p><p>This distinction, between the biological roots of disease and its clinical manifestations, becomes more and more central to modern medicine, particularly in the field of neurodegenerative disorders, including Parkinson&#8217;s and Alzheimer&#8217;s diseases.<sup><xref rid="awaf239-B4" ref-type="bibr">4</xref>,<xref rid="awaf239-B5" ref-type="bibr">5</xref></sup> In the 2024 revised criteria by the Alzheimer&#8217;s Association Workgroup,<sup><xref rid="awaf239-B5" ref-type="bibr">5</xref></sup> this ancient dichotomy is once again at the forefront: should Alzheimer&#8217;s disease be defined biologically, by the presence of amyloid-&#946; plaques, tau pathology and neurodegeneration (more akin to nosos), or should it remain tied to its clinical expression, namely dementia (more akin to asthenia)?</p><p>The advent of CSF biomarkers, PET imaging and blood-based diagnostics has enabled early detection of Alzheimer&#8217;s disease pathology long before cognitive impairment manifests. Adopting a biological framework places Alzheimer&#8217;s disease among diseases that prioritize objective biopathology over subjective symptoms. This is a fundamental shift in thinking: Alzheimer&#8217;s disease is defined more as nosos, and less as asthenia (dementia&#8211;loss of mental abilities).</p></sec><sec id="awaf239-s1.3"><title>Implications of moving from asthenia to nosos</title><p>This nosological shift has profound implications for research, clinical practice and patient care. Defining Alzheimer&#8217;s disease biologically-nosologically enables earlier identification, potentially decades before cognitive decline. This aligns with growing evidence that therapeutic interventions may be more effective in preclinical&#8211;pre-asthenia stages when neurodegeneration is minimal. Shifting the focus to biomarkers enables testing of interventions in at-risk individuals before symptoms emerge, paralleling statin use in hyperlipidaemia or antihypertensive therapy in pre-hypertension.</p><p>Furthermore, a nosological definition allows for greater diagnostic precision, ensuring that Alzheimer&#8217;s disease is not conflated with other forms of dementia that do not share its underlying pathology. Many individuals diagnosed clinically with &#8216;Alzheimer-type dementia&#8217; do not exhibit amyloid or tau pathology upon autopsy, leading to misclassification. A nosological approach ensures that research and treatment efforts are more accurately targeted to the most appropriate population harbouring similar underlying pathology.</p><p>However, while a nosological definition strengthens biological scientific rigor, it does not render clinical syndromes irrelevant. Symptoms remain the primary driver of patient care, caregiver burden and treatment decisions. Asthenia&#8212;the clinical manifestation thereof&#8212;dictates functional impairment, long-term care needs, and eligibility for pharmacological interventions. A patient with amyloid pathology but preserved cognition (nosos without asthenia) does not experience the real-world consequences of Alzheimer&#8217;s disease in the same way as one with dementia (nosos + asthenia). This is underlined by criteria proposals considering Alzheimer&#8217;s disease not strictly as nosos but as a clinical-biological construct.<sup><xref rid="awaf239-B6" ref-type="bibr">6</xref></sup></p><p>Thus, while nosos guides disease classification, asthenia emphasizes patients&#8217; living experience. The shift to a biological definition should not overshadow the importance of symptomatology in guiding care, counselling and decision-making.</p><p>The debate need not be binary. The proposed new Alzheimer&#8217;s disease framework attempts to integrate biomarker-defined stages alongside cognitive and functional assessments, a model not very dissimilar to ones often used in oncology: in cancer, staging incorporates both biological-molecular markers and clinical progression.</p></sec><sec id="awaf239-s1.4"><title>Patients&#8217; protection versus patients&#8217; autonomy</title><p>A major related concern is the degree of non-expert or patients&#8217; deep comprehension of the nosos-asthenia dichotomy in the Alzheimer&#8217;s disease dementia example. Individuals with nosological Alzheimer&#8217;s disease evidence may not develop, or may not develop reasonably soon, the asthenic-cognitive part of the duo. There exist concerns that communication of this information to such individuals may unnecessarily burden them with considerable stress about their future and may result in negative implications in their lives and their families.<sup><xref rid="awaf239-B7" ref-type="bibr">7</xref></sup> On the other side, medical experts&#8217; inclination towards avoidance of nosos-related terminology can be justifiably viewed as paternalistic, as negatively affecting patients&#8217; autonomy.<sup><xref rid="awaf239-B8" ref-type="bibr">8</xref></sup> Thus, it is very important that the concepts of nosos and asthenia, which do not necessarily overlap, are very well communicated, and that the general public becomes well educated on this issue. Our experience to date with how patients receive and understand related information in oncology&#8212;as well as in other examples of diseases without asthenia&#8212;gives reason for optimism that this is not an untenable task. Reports examining the effects of information disclosure regarding Alzheimer&#8217;s nosos seem more reassuring than concerning.<sup><xref rid="awaf239-B7" ref-type="bibr">7</xref>,<xref rid="awaf239-B9" ref-type="bibr">9</xref>,<xref rid="awaf239-B10" ref-type="bibr">10</xref></sup></p><p>The field needs to ensure that Alzheimer&#8217;s disease is recognized not only by experts but also by the general public for what it fundamentally is: a biological disease (nosos) with clinical consequences (asthenia) that evolve over time. Clearer communication of this dual framework, rooted in both pathology and lived experience, can help balance scientific precision with patient-centred care. Anchoring Alzheimer&#8217;s disease within its molecular roots, while respecting its clinical reality, is essential to guide research, inform policy, and support those affected.</p></sec><sec id="awaf239-s1.5"><title>Looking forward: dissemination of the hybrid model concept</title><p>The evolution of Alzheimer&#8217;s disease from a clinical to a biological diagnosis reflects a broader trend in medicine: diseases are increasingly defined by biopathological changes, and less by symptoms. Maybe at the same time, we should also consider moving our terminology from unity to duality. Just as ancient medicine distinguished between nosos (the disease itself) and asthenia (its clinical effects), modern neurology is refining the identity of Alzheimer&#8217;s disease. The revised 2024 criteria signal a paradigm shift that prioritizes biology over symptomatology, nosos over asthenia, ensuring earlier detection, more targeted interventions, and a redefinition of dementia itself. Yet, as we embrace this shift, we must put substantial effort towards educating the public in what exactly do we mean when a nosological diagnosis is assigned, as we must remain mindful that for patients and caregivers, it is asthenia (functional decline, dependency and loss of self) that defines their reality.</p></sec></body><back><ack id="ack1"><title>Acknowledgements</title><p>The authors would like to acknowledge Vassilis Lyras MD for initiating the original idea, Eleni Drakaki PhD for her aid in relation to mythological and historical aspects, and Katerina Tzotzi MSc for her aid concerning mythological and philological aspects.</p></ack><bio id="d67e285"><p>Dr Scarmeas is currently Professor of Neurology at the Medical School of the National and Kapodistrian University of Athens, while he maintains an academic affiliation with Columbia University in New York. His main research interests include the role of nutrition and other aspects of lifestyle affecting cognitive reserve in relation to diseases of cognitive ageing. Dr Noriega de la Colina is a physician-scientist and CIHR-Institute of Aging Fellow at the Department of Neurology and Neurosurgery, McGill University and The Montreal Neurological Institute Hospital. He also serves as Chief Medical Advisor at Perceiv Research Inc., as part of the Scientific Advisory Board of the Soci&#233;t&#233; Alzheimer de Montr&#233;al, and is the MIT-Novo Nordisk AI Fellow at the Department of Mechanical Engineering at Massachusetts Institute of Technology and the Broad Institute.</p></bio><sec id="awaf239-s2"><title>Funding</title><p>No funding was received towards this work.</p></sec><sec sec-type="COI-statement" id="awaf239-s3"><title>Competing interests</title><p>The authors report no competing interests.</p></sec><ref-list id="ref1"><title>References</title><ref id="awaf239-B1"><label>1</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Liddell</surname> &#160;<given-names>HG</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname> &#160;<given-names>R</given-names></string-name></person-group>. <source>A Greek-English lexicon</source>. <edition>8</edition>th ed., Revised Throughout. <publisher-name>Clarendon Press</publisher-name>; <year>1901</year>.</mixed-citation></ref><ref id="awaf239-B2"><label>2</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Theoi Project</collab></person-group>. Accessed 10 April 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.theoi.com/Daimon/Nosoi.html" ext-link-type="uri">https://www.theoi.com/Daimon/Nosoi.html</ext-link></mixed-citation></ref><ref id="awaf239-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eisenberg</surname> &#160;<given-names>L</given-names></string-name></person-group>. <article-title>Disease and illness distinctions between professional and popular ideas of sickness</article-title>. <source>Cult Med Psychiatry</source>. <year>1977</year>;<volume>1</volume>:<fpage>9</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">756356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00114808</pub-id></mixed-citation></ref><ref id="awaf239-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Simuni</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Chahine</surname> &#160;<given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Poston</surname> &#160;<given-names>K</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>A biological definition of neuronal &#945;-synuclein disease: Towards an integrated staging system for research</article-title>. <source>Lancet Neurol</source>. <year>2024</year>;<volume>23</volume>:<fpage>178</fpage>&#8211;<lpage>190</lpage>.<pub-id pub-id-type="pmid">38267190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(23)00405-2</pub-id></mixed-citation></ref><ref id="awaf239-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jack</surname> &#160;<given-names>CR</given-names> &#160;<suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Andrews</surname> &#160;<given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Beach</surname> &#160;<given-names>TG</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Revised criteria for diagnosis and staging of Alzheimer&#8217;s disease: Alzheimer's association workgroup</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>:<fpage>5143</fpage>&#8211;<lpage>5169</lpage>.<pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></mixed-citation></ref><ref id="awaf239-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frisoni</surname> &#160;<given-names>GB</given-names></string-name>, <string-name name-style="western"><surname>Festari</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Massa</surname> &#160;<given-names>F</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders</article-title>. <source>Lancet Neurol</source>. <year>2024</year>;<volume>23</volume>:<fpage>302</fpage>&#8211;<lpage>312</lpage>.<pub-id pub-id-type="pmid">38365381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(23)00447-7</pub-id></mixed-citation></ref><ref id="awaf239-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Erickson</surname> &#160;<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Chin</surname> &#160;<given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname> &#160;<given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Gleason</surname> &#160;<given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname> &#160;<given-names>LR</given-names></string-name></person-group>. <article-title>Disclosure of preclinical Alzheimer&#8217;s disease biomarker results in research and clinical settings: Why, how, and what we still need to know</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2021</year>;<volume>13</volume>:<fpage>e12150</fpage>.<pub-id pub-id-type="pmid">33665341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12150</pub-id><pub-id pub-id-type="pmcid">PMC7896633</pub-id></mixed-citation></ref><ref id="awaf239-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wilkenfeld</surname> &#160;<given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Orbell</surname> &#160;<given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Lingler</surname> &#160;<given-names>JH</given-names></string-name></person-group>. <article-title>Ethical considerations in communicating Alzheimer&#8217;s disease neuroimaging biomarker test results to symptomatic individuals</article-title>. <source>Neurotherapeutics</source>. <year>2021</year>;<volume>18</volume>:<fpage>673</fpage>&#8211;<lpage>685</lpage>.<pub-id pub-id-type="pmid">33860462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13311-021-01047-0</pub-id><pub-id pub-id-type="pmcid">PMC8423956</pub-id></mixed-citation></ref><ref id="awaf239-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Burns</surname> &#160;<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname> &#160;<given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Liebmann</surname> &#160;<given-names>EP</given-names></string-name>, <string-name name-style="western"><surname>Bothwell</surname> &#160;<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname> &#160;<given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Vidoni</surname> &#160;<given-names>ED</given-names></string-name></person-group>. <article-title>Safety of disclosing amyloid status in cognitively normal older adults</article-title>. <source>Alzheimers Dement</source>. <year>2017</year>;<volume>13</volume>:<fpage>1024</fpage>&#8211;<lpage>1030</lpage>.<pub-id pub-id-type="pmid">28263740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2017.01.022</pub-id><pub-id pub-id-type="pmcid">PMC5582024</pub-id></mixed-citation></ref><ref id="awaf239-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Patel</surname> &#160;<given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Feldman</surname> &#160;<given-names>HH</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Personal value of Alzheimer&#8217;s disease biomarker testing and result disclosure from the patient and care partner perspective</article-title>. <source>Alzheimers Dement (N Y)</source>. <year>2024</year>;<volume>10</volume>:<fpage>e12463</fpage>.<pub-id pub-id-type="pmid">38596482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.12463</pub-id><pub-id pub-id-type="pmcid">PMC10999946</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurotherapeutics</journal-id><journal-id journal-id-type="iso-abbrev">Neurotherapeutics</journal-id><journal-id journal-id-type="pmc-domain-id">1472</journal-id><journal-id journal-id-type="pmc-domain">neurother</journal-id><journal-title-group><journal-title>Neurotherapeutics</journal-title></journal-title-group><issn pub-type="ppub">1933-7213</issn><issn pub-type="epub">1878-7479</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12491701</article-id><article-id pub-id-type="pmcid-ver">PMC12491701.1</article-id><article-id pub-id-type="pmcaid">12491701</article-id><article-id pub-id-type="pmcaiid">12491701</article-id><article-id pub-id-type="pmid">40399225</article-id><article-id pub-id-type="doi">10.1016/j.neurot.2025.e00610</article-id><article-id pub-id-type="pii">S1878-7479(25)00088-1</article-id><article-id pub-id-type="publisher-id">e00610</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Discovery of an APP-selective BACE1 inhibitor for Alzheimer's disease</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Campagna</surname><given-names initials="J">Jesus</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Jagodzinska</surname><given-names initials="B">Barbara</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Wi</surname><given-names initials="D">Dongwook</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Zhu</surname><given-names initials="C">Chunni</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Lee</surname><given-names initials="J">Jessica</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Cohn</surname><given-names initials="W">Whitaker</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Jun</surname><given-names initials="M">Michael</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Elias</surname><given-names initials="C">Chris</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Padder</surname><given-names initials="S">Samar</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Descamps</surname><given-names initials="O">Olivier</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Peters-Libeu</surname><given-names initials="C">Clare</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>Zhang</surname><given-names initials="Q">Qiang</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au13"><name name-style="western"><surname>Gorostiza</surname><given-names initials="O">Olivia</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au14"><name name-style="western"><surname>Poksay</surname><given-names initials="K">Karen</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au15"><name name-style="western"><surname>Spilman</surname><given-names initials="P">Patricia</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au16"><name name-style="western"><surname>Bredesen</surname><given-names initials="D">Dale</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au17"><name name-style="western"><surname>John</surname><given-names initials="V">Varghese</given-names></name><email>vjohn@mednet.ucla.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="aff1"><label>a</label>Drug Discovery Lab (DDL), Department of Neurology, Easton Center for Alzheimer's Disease Research and Care, David Geffen School of Medicine, University of California, Los Angeles (UCLA), CA, 90095, USA</aff><aff id="aff2"><label>b</label>Buck Institute for Research on Aging, Novato, CA, 94945, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>vjohn@mednet.ucla.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>5</month><year>2025</year></pub-date><volume>22</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">498231</issue-id><elocation-id>e00610</elocation-id><history><date date-type="received"><day>15</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>16</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>6</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-04 13:25:42.290"><day>04</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Inhibition of amyloid precursor protein (APP) beta-site cleaving enzyme 1 (BACE1) has been a target for Alzheimer's disease (AD) therapeutic development. Here, we report our identification of APP-selective BACE1 (ASBI) inhibitors that are selective for APP as the substrate and BACE1 as the target enzyme. A known fluoro aminohydantoin (FAH) inhibitor compound was identified by screening a compound library for inhibition of BACE1 cleavage of a maltose binding protein (MBP)-conjugated-APPC125 substrate followed by optimization and IC50 determination using the P5-P5&#8242; activity assay. Optimization of the screening hit led to candidate FAH65, which displays selectivity for inhibition of APP cleavage with little activity against other BACE1 substrates neuregulin 1 (NRG1) or p-selectin glycoprotein ligand-1 (PSGL1). FAH65 shows little inhibitory activity against other aspartyl proteases cathepsin D (Cat D) and BACE2. FAH65 reduces BACE1 cleavage products soluble APP&#946; (sAPP&#946;) and the &#946; C-terminal fragment (&#946;CTF), as well as amyloid-&#946; (A&#946;) 1-40 and 1-42, both <italic toggle="yes">in vitro</italic> in cells and <italic toggle="yes">in vivo</italic> in an animal model of AD. In a murine model of AD, FAH65 improved the discrimination score in the Novel Object Recognition (NOR) memory testing paradigm. The active enantiomer of racemate FAH65, FAH65E(-), displays good brain-penetrance and target engagement, meriting further pre-clinical development as an ASBI that may reduce A&#946; levels and overcome the deleterious effects of the non-selective BACE1 inhibitors that have failed in the clinic. FAH65E(-) has the potential to be a first-in-class oral therapy that could be used in conjunction with an approved anti-A&#946; antibody therapy for AD.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>ASBI</kwd><kwd>BACE1 inhibitor</kwd><kwd>APP-selective</kwd><kwd>FAH65</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Brain tissue of Alzheimer's disease (AD) patients is characterized by the presence of neuritic plaques largely composed of amyloid-&#946; (A<italic toggle="yes">&#946;</italic>) [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>] and neurofibrillary tangles resulting from the hyperphosphorylation of the protein tau [<xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>]. A<italic toggle="yes">&#946;</italic> is the product of step-wise cleavage of amyloid precursor protein (APP) by the <italic toggle="yes">&#946;</italic>-site APP-cleaving enzyme 1 (BACE1) and <italic toggle="yes">&#947;</italic>-secretase [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib7" ref-type="bibr">7</xref>]. In an alternative cleavage pathway, &#945;-secretase (putatively ADAM10) cleavage of APP results in production of trophic, synapse-supporting peptides soluble APP&#945; (sAPP&#945;) and the &#945; C-terminal fragment (&#945;CTF) [<xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>].</p><p id="p0015">While the amyloid cascade hypothesis of AD has come under scrutiny in the last decade due to the failure of many A&#946;- and BACE1-directed potential therapies in the clinic [<xref rid="bib11" ref-type="bibr">11</xref>], it is supported by the genetics underlying familial forms of the disease that enhance amyloid production [<xref rid="bib12" ref-type="bibr">12</xref>,<xref rid="bib13" ref-type="bibr">13</xref>], by identification of gene variants that confer protection against cognitive decline [<xref rid="bib14" ref-type="bibr">14</xref>]; and by recent clinical findings that the amyloid-directed antibodies aducanumab (Aduhelm&#174;), lecanemab (Lequembi&#174;), and donanemab (Kisunla&#174;) slow cognitive decline in early AD [<xref rid="bib15" ref-type="bibr">[15]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>, <xref rid="bib17" ref-type="bibr">[17]</xref>, <xref rid="bib18" ref-type="bibr">[18]</xref>].</p><p id="p0020">Antibody-based biologic therapies, despite effectively clearing A&#946; deposits in the brain as seen by PET imaging, present challenges as feasible therapeutics due to their limited brain-permeability, high cost, and requirement for IV infusion at hospitals or infusion centers [<xref rid="bib19" ref-type="bibr">19</xref>]. An orally-available, brain-permeable small-molecule therapeutic that inhibits BACE1 cleavage of APP would overcome those limitations and, as a maintenance therapy, would not only decrease amyloid plaque formation, but also the upstream formation of the A&#946; oligomers that are implicated in synaptic loss and cognitive decline [<xref rid="bib11" ref-type="bibr">11</xref>,<xref rid="bib20" ref-type="bibr">20</xref>].</p><p id="p0025">The discovery that an A673T (Icelandic) mutation in APP at the P2&#8242; residue of the BACE1 cleavage site reduces BACE1 cleavage of APP and protects against both AD and other age-related cognitive decline [<xref rid="bib14" ref-type="bibr">14</xref>] provides further strong support for the hypothesis that A&#946; production - and specifically BACE1 cleavage - is a critical event in <funding-source id="gs5">AD</funding-source> pathogenesis. Thus, inhibition of BACE1 as a strategy for therapeutic development for AD has been a focus of many research groups.</p><p id="p0030">A critical limitation of BACE1 inhibitory strategies is the potential inhibition of cleavage of non-APP substrates, resulting in side effects. Inhibition of non-APP substrates such as neuregulin 1 (NRG1), p-selectin glycoprotein ligand 1 (PSGL1) and gp-130 raise concern [<xref rid="bib21" ref-type="bibr">[21]</xref>, <xref rid="bib22" ref-type="bibr">[22]</xref>, <xref rid="bib23" ref-type="bibr">[23]</xref>, <xref rid="bib24" ref-type="bibr">[24]</xref>, <xref rid="bib25" ref-type="bibr">[25]</xref>]. Therefore, the optimal BACE1 inhibitor would be one that would selectively inhibit the cleavage of APP. Such an inhibitor would represent a new class of AD therapeutics: APP-selective BACE1 inhibitors (ASBIs). As we previously described, the hypothesized mechanism for ASBI selectivity is binding to APP and inhibition of APP binding to the BACE1 active site, but not that of other substrates, resulting in potent inhibition of APP cleavage by BACE1 compared to other substrates [<xref rid="bib26" ref-type="bibr">26</xref>].</p><p id="p0035">Development of an ASBI may not only provide a potential new treatment for AD and the condition that often precedes it, Mild Cognitive Impairment (MCI) due to AD, but may do so with reduced off-target effects as compared to BACE1 inhibitors that have been clinically tested and are not selective for APP.</p><p id="p0040">The first step in our approach to discover ASBIs was to screen for BACE1 inhibitors by using a maltose binding protein (MBP)-conjugated-APPC125 substrate-based assay. In an initial screening of a clinical compound library, we identified flavonoids that acted as ASBIs in cell models and one (galangin) that showed increased brain levels when delivered to mice as a pro-drug, as reported in Descamps et al. [<xref rid="bib26" ref-type="bibr">26</xref>].</p><p id="p0045">We describe herein that, as a result of our continued screening efforts, we identified the hit phenytoin as a weak inhibitor of BACE1 cleavage of MBP-APPC125 and, through medicinal chemistry optimization efforts, discovered an APP-selective fluoro aminohydantoin (FAH) BACE1 inhibitor series. The lead candidate in the series is the APP selective small molecule FAH65 and its active enantiomer FAH65(-), which displays potent inhibition of BACE1 <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>, and elicits improvement in memory in an AD mouse model after oral treatment.</p></sec><sec id="sec2"><title>Materials and methods</title><sec id="sec2.1"><title>P5-P5&#8242; assay</title><p id="p0050">For the P5-P5&#8242; BACE1 inhibition assay, 4 &#8203;&#956;L of assay buffer was added to each well, followed by 2 &#8203;&#956;L of BACE1 diluted in assay buffer to 7.5 &#8203;ng/&#956;L. Then, 2 &#8203;&#956;L of inhibitor, at concentrations along an 11 &#8203;pt. two-fold dilution series starting at 10 &#8203;&#956;M, or 0.5 &#8203;&#956;M, were added to appropriate wells and incubated for 30 &#8203;min at room temperature. For all dilutions of inhibitor, drug stock solutions of 10 &#8203;mM in DMSO were diluted to 50 &#8203;&#956;M in water; subsequent dilutions were in 0.5 &#8203;% DMSO. Afterwards, 2 &#8203;&#956;L of fluorogenic P5-P5&#8242; BACE1 substrate, diluted to 50 &#8203;&#956;M in assay buffer, were added to each well and the signal generated was read every 30 &#8203;min at 25 &#8203;&#176;C for 2 &#8203;h.</p></sec><sec id="sec2.2"><title>SEAP-NRG assay</title><p id="p0055">A cDNA construct encoding a human placental secreted alkaline phosphatase (SEAP)-NRG1 (pAPtag5-NRG1-&#946;1) fusion protein was transfected in human embryonic kidney (HEK293) cells in a 6-well format with or without full-length wild-type BACE1 using Lipofectamine 2000 (Invitrogen) as described previously [<xref rid="bib27" ref-type="bibr">27</xref>]. After transfection, the medium was replaced with DMEM containing the test compound at 10, 5, 1, 0.1, and 0.01 &#8203;&#956;M as well as 10 &#8203;% heat-inactivated fetal bovine serum (FBS), then incubated for 24 &#8203;h. SEAP activity was measured in the conditioned medium. For alkaline phosphatase activity measurements, 200 &#8203;&#956;L of reaction solution (0.1 &#8203;M glycine, pH 10.4, 1 &#8203;mM MgCl<sub>2</sub>, 1 &#8203;mM ZnCl<sub>2</sub> containing 1 &#8203;mg/mL 4-nitrophenyl phosphate disodium salt hexahydrate, Sigma) were added to 20 &#8203;&#956;L of the conditioned medium. The absorbance was read at 405 &#8203;nm.</p></sec><sec id="sec2.3"><title>PSGL1 assay</title><p id="p0060">A cDNA construct encoding a human placental secreted alkaline phosphatase (SEAP)-PSGL1 (pAPtag5-PSGL1-&#946;1) fusion protein was transfected in human embryonic kidney (HEK293) cells in a 6-well format with or without full-length wild-type BACE1 using Lipofectamine 2000 (Invitrogen). After 6&#8211;8 &#8203;h transfection, the medium was replaced with DMEM containing the test compound at 10, 5, 1, 0.1 and 0.01 &#8203;&#956;M and 10 &#8203;% heat-inactivated fetal bovine serum (FBS), and incubated for 24 &#8203;h. SEAP activity was measured in the conditioned medium. For alkaline phosphatase activity measurements, 200 &#8203;&#956;L of reaction solution (0.1 &#8203;M glycine, pH 10.4, 1 &#8203;mM MgCl<sub>2</sub>, 1 &#8203;mM ZnCl<sub>2</sub> containing 1 &#8203;mg/mL 4-nitrophenyl phosphate disodium salt hexahydrate, Sigma) were added to 20 &#8203;&#956;L of the conditioned medium. The absorbance was read at 405 &#8203;nm at 60 &#8203;min.</p></sec><sec id="sec2.4"><title>Cathepsin D assay</title><p id="p0065">The effects of candidate ASBIs on cathepsin D (CatD) activity was assessed using the R&amp;D Systems CatD activity assay kit (Catalog #: 1014-AS and ES001) according to the manufacturer's instructions. For the assay, 4 &#8203;&#956;L of assay buffer was added to each well, followed by 2 &#8203;&#956;L of CatD diluted in assay buffer to 5 &#8203;ng/uL. Then, 2 &#8203;&#956;L of inhibitor, at concentrations along an 11 &#8203;pt. two-fold dilution series starting at 50 &#8203;&#956;M, were added to appropriated wells and incubated for 30 &#8203;min at room temperature. For all dilutions of inhibitor, drug stock solutions of 10 &#8203;mM in DMSO were diluted to 50 &#8203;&#956;M in water; subsequent dilutions were in 2.5 &#8203;% DMSO. Afterwards, 2 &#8203;&#956;L of fluorogenic CatD substrate, diluted to 50 &#8203;&#956;M in assay buffer, were added to each well, after which the signal generated was read every 30 &#8203;min at 25 &#8203;&#176;C for 1hr.</p></sec><sec id="sec2.5"><title>Plasmids</title><p id="p0070">The pAPtag5-NRG1-&#946;1 construct was kindly provided by Dr. Carl Blobel [<xref rid="bib28" ref-type="bibr">28</xref>]. The BACE1 construct was a gift from Dr. Michael Willem and Dr. Christian Haass [<xref rid="bib27" ref-type="bibr">27</xref>].</p></sec><sec id="sec2.6"><title>Medicinal chemistry and testing of analogs</title><p id="p0075">Our exploratory medicinal chemistry efforts focused on the phenytoin hit to see if we could generate analogs with enhanced potency. The medicinal chemistry efforts (planned to be published elsewhere) involved conversion of the hydantoin scaffold to an aminohydantoin that led to our potent ASBI FAH65. Analogs were assessed in the MBP-APPC125, p5-p5&#8242;, and substrate selectivity assays as described.</p></sec><sec id="sec2.7"><title>Synthesis</title><p id="p0080">The methods for FAH analog synthesis are described in the <xref rid="appsec1" ref-type="sec">Supplementary Materials</xref>.</p></sec><sec id="sec2.8"><title>CHO-7W and -7W<sup>Swe</sup> cell culture</title><p id="p0085">The Chinese hamster ovary (CHO) cell line overexpressing human A&#946;PP (7W) stably transfected with human APP or overexpressing APP with the Swedish (Swe) K595 &#8203;N/M596L mutation were incubated with FAH compounds diluted to 1 &#8203;&#956;M overnight. Culture Media was collected and frozen. Media was assayed using an AlphaLISA for A&#946;1-42 (Perkin Elmer catalog # AL276C), sAPP&#945; (R&amp;D Systems catalog # AF1168 conjugated with Perkin Elmer acceptor beads catalog # 6772001 &#8203;+ &#8203;2B3 antibody from IBL catalog # 11088 biotinylated), and sAPP&#946; (Perkin Elmer AL276-acceptor &#8203;+ &#8203;IBL catalog # 18957 biotinylated). For the assay, 2 &#8203;&#956;L of diluted or undiluted sample was added to a 384 well plate, followed by 2 &#8203;&#956;L of the respective antibody mixture. This was incubated for 1 &#8203;h. Afterwards, 2 &#8203;&#956;L of donor beads was added to each well, followed by a 30-min incubation in the dark, after which the signal was read.</p></sec><sec id="sec2.9"><title>Pharmacokinetics (PK)/Pharmacodynamics (PD) in mice and rats</title><p id="p0095">Wildtype or non-transgenic (NTg) C57Bl6 mice or Sprague-Dawley rats were dosed by oral (gavage) or subcutaneous (SQ) injection at 10 or 30 &#8203;mg/kg, and animals were euthanized 1, 2, 6, and 8 &#8203;h after administration by ketamine/xylazine over-anesthesia, in rats, CSF was also collected, followed by transcardial collection of blood for isolation of plasma and saline perfusion. Brain tissue was collected post-mortem for assessment of compound levels and biomarkers.</p><p id="p0100">Analyses of compound levels in PK studies were performed in the UCLA Pasarow Mass Spectrometry Lab (PMSL; Julian Whitelegge, Ph.D., Director). Tissues were homogenized in a bead beater using 5 &#8203;vol of ice-cold 80 &#8203;% acetonitrile (1/5; mg of brain/&#956;L of 80 &#8203;% ACN). Plasma analytes were extracted using 4 &#8203;vol of ice-cold acetonitrile (1/4; &#956;L of plasma/&#956;L of 100 &#8203;% ACN). Solutions were clarified by centrifugation (16,000&#215;<italic toggle="yes">g</italic>, 5 &#8203;min) and the supernatants were transferred to new tubes and lyophilized. Samples were reconstituted in 100 &#8203;&#956;L of 50/50/0.1 (Water/Acetonitrile/Formic Acid) prior to analysis via liquid chromatography-tandem mass spectrometry (LC-MS/MS).</p><p id="p0105">An internal standard (IS) was added to every sample to account for compound loss during sample processing. Standards were made in drug na&#239;ve plasma and tissue lysates with increasing amounts of analyte (S1, S2: 0 pmol/S3, S4: 1 pmol/S5, S6: 10 pmol/S7, S8: 100 &#8203;pmol, S9, S10: 1000 &#8203;pmol). The standard curve was made by plotting the known amount of analyte per standard vs. the ratio of measured chromatographic peak areas corresponding to the analyte over that of the IS (analyte/IS). The trendline equation was then used to calculate the absolute concentrations of each compound in plasma and tissue.</p><p id="p0110">The targeted LC-MS/MS assay was developed using the multiple reaction monitoring (MRM) acquisition method on a 6460 triple quadrupole mass spectrometer (Agilent Technologies) coupled to a 1290 Infinity HPLC system (Agilent Technologies) with a Phenomenex analytical column (Kinetex 1.7 &#8203;&#956;m C18 100 &#8203;&#197; 100 &#8203;&#215; &#8203;2.1 &#8203;mm). The HPLC method utilized a mixture of solvent A (99.9/0.1 Water/Formic Acid) and solvent B (99.9/0.1 Acetonitrile/Formic Acid) and a gradient was use for the elution of the compounds (min/%B: 0/1, 3/1, 19/99, 20/1, 30/1). Two fragment ions were monitored at specific LC retention times to ensure specificity and accurate quantification in the complex biological samples. The normalized chromatographic peak areas were determined by taking the ratio of measured chromatographic peak areas corresponding to the compound over that of the internal standard (Analyte/IS).</p><p id="p0115">The T<sub>max</sub>, C<sub>max</sub>, brain-to-plasma ratios and brain levels were then calculated using PK Solutions software (SummitPK).</p></sec><sec id="sec2.10"><title>PK/PD study of FAH65E(-) in ApoE4-TR:5xFAD mice</title><p id="p0120">A PK/PD study of FAH65E(-) hydrochloride was performed using ApoE4-TR:5xFAD mice that express APOE4 under the control of the endogenous mouse APOE promoter crossed to 5xFAD mice (Tg6799) which co-express five FAD mutations (APP K670 &#8203;N/M671L &#8203;+ &#8203;I716V &#8203;+ &#8203;V717I and PS1 M146L &#8203;+ &#8203;L286V) under the control of the neuron-specific mouse Thy-1 promoter [<xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib30" ref-type="bibr">30</xref>]. The resulting mice, on a 97 &#8203;% C57Bl/6J and 3 &#8203;% SJL background, are homozygous for APOE4 and hemizygous for the 5XFAD transgenes. Both male and female mice 6&#8211;8 months of age were used. Mice received two doses (a.m. and p.m.) of 30 &#8203;mg/kg FAH65E(-) by oral gavage on day 1; on day 2, after a single dose (a.m.) mice were euthanized at 1, 2, 4 and 6 &#8203;h, n &#8203;= &#8203;3 per time point. FAH65 and sAPP&#946; levels in brain were determined in brain tissue by LC-MS (see <xref rid="appsec1" ref-type="sec">Supplementary Methods</xref>) and ELISA , respectively.</p></sec><sec id="sec2.11"><title>Efficacy testing in B254 mice</title><p id="p0125">B254 mice are an AD model comprising expression of human APP with Swedish and Indiana mutations along with a D664A substitution and endogenous murine tau, as described in Galvan et al. [<xref rid="bib31" ref-type="bibr">31</xref>]. In our <italic toggle="yes">in vivo</italic> studies, we detected impairment in learning and memory in B254 D664A mice at 5&#8211;6 months of age (end of chronic treatment) in the novel location and novel object spatial memory testing paradigms. We note that previous studies have reported conflicting findings for such impairments when using in the Morris Water Maze. In the earliest reports [<xref rid="bib31" ref-type="bibr">31</xref>,<xref rid="bib35" ref-type="bibr">35</xref>], while B254 mice showed similar A&#946; production at 3&#8211;4 months and earlier plaque deposition (starting at &#8203;&#8764; &#8203;6 months) as J20 (PDAPP) mice (plaque deposition after 9 months), which were considered a control with an unaltered D664 sequence and functional caspase cleavage, behavioral abnormalities in MWM testing were not observed at 12 months. Further study suggested an akinetic phenotype that could be overcome by swim training may have been the cause of these different findings [<xref rid="bib36" ref-type="bibr">36</xref>]. In a later study performed by a different group [<xref rid="bib37" ref-type="bibr">37</xref>], it was reported that at both 2&#8211;3 or 5&#8211;7 months of age B254 and J20 mice had similar abnormalities relative to non-transgenic mice in spatial and nonspatial learning and memory. Our findings were in alignment with the latter studies.</p><p id="p0130">Male and female 4-5 month-old B254 mice in the subchronic and chronic treatment were administered FAH65 via pipette feeding by the method of Atcha et al. [<xref rid="bib32" ref-type="bibr">32</xref>] at a dose of 30 &#8203;mg/kg BID (60 &#8203;mg/kg/day). Mice were weighed before the first dose for the calculation of volume to be administered. The formulation used comprised FAH65 hydrochloride as a 40 &#8203;mg/mL solution in water plus 30 &#8203;mg/mL in strawberry syrup.</p><p id="p0135">In the pilot subchronic study, mice were treated for 10 days, and in the follow-up study, for 26 days. One week before the end of the study, mice in the pilot study underwent Novel Object Recognition (NOR) memory testing, and mice in the follow-up chronic study underwent both NOR and Novel Location Recognition (NLR) testing as described elsewhere [<xref rid="bib33" ref-type="bibr">33</xref>,<xref rid="bib34" ref-type="bibr">34</xref>]. Briefly, mice are introduced to two identical, parallel and evenly objects in an opaque 30 &#8203;&#215; &#8203;40 &#8203;cm arena (box without a lid) with navigation marks on the wall, for 10 &#8203;min. For Novel Location Recognition (NLR), after a 2.5-h interval, the mouse is returned to the arena wherein one identical object has been moved diagonally. The time spent and number of discreet interactions with the objects in the original location and in the new location over 10 &#8203;min is recorded. The mouse is then removed from the arena, and after an additional 2.5-h interval, for the Novel Object Recognition (NOR) phase, is returned to the arena wherein the objects are in the original position, but one is a new, different object. The time spent and number of discreet interactions with the objects in the original location and in the new location over 10 &#8203;min is recorded. The novelty preference was calculated by dividing total interactions (or time) by interactions (or time) with the object in the novel location or the novel object.</p><p id="p0140">All <italic toggle="yes">in vivo</italic> animal experiments using mice or rats described herein were carried out in strict accordance with good animal practice according to the U.S. National Institutes of Health (NIH) recommendations. All procedures for animal use were approved by the Animal Research Committee (ARC) at the University of California at Los Angeles (UCLA) and under an approved ARC protocol and comply with the ARRIVE guidelines.</p></sec><sec id="sec2.12"><title>Biomarker analyses</title><p id="p0145">For <italic toggle="yes">in vivo</italic> studies, Individual tissues were weighed and sonicated on ice with AlphaLISA Lysis Buffer complemented with HALT (Fisher catalog # 78446) to give a 10 &#8203;% W/V sonicate. Total protein concentration was assessed by BCA assay (Fisher catalog # 23227) following manufacturer recommendations.</p></sec><sec id="sec2.13"><title>sAPP&#946;</title><p id="p0150">For the ELISA assay to assess sAPP&#946; levels in brain an IBL ELISA (kit #27733) specific for sAPP&#946; with the Swedish (K595 &#8203;N/M596L) mutation [<xref rid="bib12" ref-type="bibr">12</xref>] that is present in the APP transgene of the mouse model used following the kit instructions. Briefly, 499 &#8203;&#956;L of EIA buffer was added to individual tubes for each sample, 1 &#8203;&#956;L of sample added, vortexed and centrifuged. To each assay plate well, 100 &#8203;&#956;L of sample was added, and the covered plate incubated overnight at 4 &#8203;&#176;C. The plate(s) was washed 4 times with 350 &#8203;&#956;L/well wash buffer, then 100 &#8203;&#956;L/well of labeled antibody added followed by incubation for 30 &#8203;min at 4 &#8203;&#176;C. After five washes, 100 &#8203;&#956;L chromogen solution was added to each well and incubated for 30 &#8203;min at RT in the dark. Stop solution (100 &#8203;&#956;L/well) was then added and the plate read at 450 &#8203;nm.</p></sec><sec id="sec2.14"><title>&#946;CTF</title><p id="p0155">The BACE1 cleavage product &#946;CTF was detected by AlphaLISA (Perkin Elmer) Amyloid Beta kit (Cat # AL275C) modified by replacing the anti-A&#946; acceptor beads (Cat # AL275AC) specific for the C-terminus of A&#946;40 with anti-A&#946; acceptor beads from the AL202 kit (Cat #AL202AC) having the 4G8 antibody. For the assay, 2 &#8203;&#956;L of diluted sample was added to a 384 well plate, followed by 2 &#8203;&#956;L of the antibody mixture. This was incubated for 1hr. Afterwards, 2 &#8203;&#956;L of donor beads was added to each well, followed by a 30-min incubation in the dark, after which the signal was read.</p></sec><sec id="sec2.15"><title>sAPP&#945;</title><p id="p0160">sAPP&#945; was assessed by AlphaLISA comprising antibody AF1168 (R&amp;D Systems catalog # AF1168) conjugated with Perkin Elmer acceptor beads (catalog # 6772001) and 2B3 antibody from IBL catalog # 11088 biotinylated and streptavidin donor beads. For the assay, 2 &#8203;&#956;L of diluted or undiluted sample was added to a 384 well plate, followed by 2 &#8203;&#956;L of the respective antibody mixture. This was incubated for 1 &#8203;h. Afterwards, 2 &#8203;&#956;L of donor beads was added to each well, followed by a 30-min incubation in the dark, after which the signal was read.</p></sec><sec id="sec2.16"><title>A&#946;1-42</title><p id="p0165">For assessment of A&#946; 1-42 in brain, tissues were weighed and sonicated in freshly prepared 5 &#8203;M Guanidine (Gdn)-HCl in 50 &#8203;mM Tris&#8211;NCl pH 8.0 at 20 &#8203;% weight/volume. Samples were rotated for 2&#8211;3 &#8203;h at room temperature after sonication and typically frozen stored before use. An Invitrogen ELISA kit for 1-42 was used according to the manufacturer's instructions.</p></sec><sec id="sec2.17"><title>Total tau and p-tau</title><p id="p0170">Phospho-tau and total tau were assessed by Perkin-Elmer AlphaLISA kits AL271 (phosphorylation at Ser202 and Thr205) and AL3136 (total tau). The assays were run as described above for the sAPP&#945; AlphaLISA.</p></sec><sec sec-type="supplementary-material" id="sec2.18"><title>In supplementary methods</title><p id="p0175">The BACE2, MBP-APPC125, ADME-T (kinetic solubility, plasma stability, liver microsome stability, parallel artificial membrane permeability assay/PAMPA, plasma protein/human serum albumin, HSA, binding, and brain tissue binding), FAH binding to APP and hERG assays are described in Supplementary Methods. Also in Supplementary Methods are descriptions of the testing of FAH65E(-) in HEK-APP-GFP cells, Meso Scale Discovery (MSD) assessment of inflammatory biomarkers GFAP and IP-10, as well as A&#946; in mouse brain, <italic toggle="yes">in vivo</italic> assessment of FAH65 versus verubecestat (Veru) in rats, Super Fluid Critical (SFC) separation of FAH65 enantiomers and assessment of their optical rotation, and syntheses/analyses of FAH analogs.</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>Screening and analog generation by medicinal chemistry identifies lead FAH65</title><p id="p0180">We identified a known anti-epilepsy hydantoin drug, phenytoin, as a screening hit in the MBP-APPC125 BACE1 cleavage screening assay [<xref rid="bib26" ref-type="bibr">26</xref>]. Initial exploratory medicinal chemistry on the phenyl rings (A and B-rings) of the hydantoin hit revealed no significant improvement in BACE1 inhibition. Further modification of the hydantoin scaffold to an aminohydantoin led to a micromolar BACE1 inhibitor fluoroaminohydantoin, FAH1, with A-ring fluorine substitutions that inhibited A&#946;42 in cells and was brain permeable. Further modification of the B-ring led to a more potent low micromolar inhibitor, FAH3, that also inhibited A&#946; in cell models and had brain permeability, but also showed selectivity for APP cleavage by BACE1 versus other substrates such as NRG1. The BACE1 IC50s in the cell-free P5-P5&#8242; activity assay for FAH1 and FAH3 were &#8764;10 &#8203;&#956;M and &#8764;1 &#8203;&#956;M, respectively (See <xref rid="appsec1" ref-type="sec">Supplementary Fig. S1A</xref>). In Chinese Hamster Ovary cells expressing wildtype human APP (CHO-7W), A&#946;42 was decreased by 5 &#8203;&#956;M FAH1 and by 1 &#8203;&#956;M FAH3.</p><p id="p0185">Interestingly, removal of a fluorine from the A-ring led to a more potent analog, FAH17 (IC50 &#8764; 0.3 &#8203;&#956;M) and further replacement of the fluorine with a pyrimidine ring gave lead compound FAH65 (IC50 &#8764; 0.01 &#8203;&#956;M&#8211;0.03 &#8203;&#956;M) in the P5-P5&#8242; assay (<xref rid="fig1" ref-type="fig">Fig. 1</xref>, <xref rid="appsec1" ref-type="sec">Supplementary Fig. S1A</xref>). Details of the structure-activity strategy and analog synthesis effort will be described in a future manuscript.<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p><italic toggle="yes">Analog structures and inhibition of BACE</italic>. The structures of (A) phenytoin, (B) FAH1, (C) FAH3, (D) FAH17 and (E) FAH65 are shown, as well as the (F) dose-response curve for FAH17 and FAH65 in the P5-P5&#8242; BACE inhibition assay.</p></caption><alt-text id="alttext0015">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec3.2"><title>FAH65 selectively targets BACE1 and inhibition of APP cleavage</title><p id="p0190">Ongoing selectivity monitoring using a SEAP-neuregulin 1 (NRG1) assay demonstrated the analogs were selective and did not inhibit BACE1 cleavage of NRG1. FAH3 elicited 50 &#8203;% inhibition of BACE1 cleavage of APP, but no SEAP-NRG cleavage, at &#8764;1 &#8203;&#956;M. Similarly, neither FAH17 nor FAH65 show potency in cleavage of either NRG1 or PSGL1 (both EC<sub>50</sub>s &#8203;&gt; &#8203;10 &#8203;&#956;M) vs. BACE1-APP (IC<sub>50</sub>s of 0.3 &#8203;&#956;M and 0.01 &#8203;&#956;M, respectively) in cell-free assays as compared to the inhibitor BACEIV that has little selectivity for APP (BACE1-APP IC<sub>50</sub> &#8764;0.04 &#8203;&#956;M) vs BACE1-NRG1 or PSGL1 (both EC<sub>50</sub> &#8764;0.05 &#8203;&#956;M) (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A and B, respectively). In comparison, clinically-studied BACE1 inhibitors Veru (MK-8931) and lanabecestat (Lana; AZD3293) show no selectivity for BACE1-APP (IC<sub>50</sub>s of 0.002 and 0.004 &#8203;&#956;M, respectively) vs. BACE1-NRG1 (EC<sub>50</sub> of &lt;0.01 &#8203;&#956;M for both); with substrate selectivity: NRG1/APP IC<sub>50</sub> of &gt;200 for FAH65 and &lt;2.5 for both Veru and Lana (<xref rid="appsec1" ref-type="sec">Supplementary Table S1</xref>).<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><italic toggle="yes">FAH65 selectivity</italic>. Dose-response curves for FAH17 and FAH65 as compared to BACE1 inhibitor BACEIV are shown for the substrates (A) NRG1 and (B) PSGL1 in cell assays. Dose-response curves for inhibition of (C) cathepsin D (Cat D) and (D) BACE in the P5-P5&#8242; assay are shown.</p></caption><alt-text id="alttext0020">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0195">FAH17 and FAH65 were also found to be selective for BACE1 as the target enzyme. Neither analog significantly inhibited cathepsin D (Cat D) activity (<xref rid="fig2" ref-type="fig">Fig. 2</xref>C), and lead FAH65 did not inhibit BACE2 activity compared to BACE-IV (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S2</xref>); whereas both inhibit P5-P5&#8242; cleavage by BACE 1 (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D). The FAH65 IC<sub>50</sub> for Cat D, BACE2, and BACE1 are &#8764;47 &#8203;&#956;M, &gt;1 &#8203;&#956;M and &#8764;0.01 &#8203;&#956;M, respectively.</p></sec><sec id="sec3.3"><title>FAH65 inhibits sAPP&#946; and A&#946;1-42 production in APP-expressing cells <italic toggle="yes">in vitro</italic></title><p id="p0200">Both FAH17 and FAH65 display the ability to decrease production of BACE1 cleavage product soluble APP&#946; (sAPP&#946;) and amyloid-&#946; 1-42 (A&#946;1-42) in Chinese hamster ovary cells expressing wildtype human APP (CHO-7W) (<xref rid="fig3" ref-type="fig">Fig. 3</xref>A and B, respectively), with an EC50 for sAPP&#946; reduction by FAH65 of &gt;90 &#8203;%. Only FAH65 significantly decreases A&#946;1-42 in CHO cells that express APP with the Swedish (Swe) K595 &#8203;N/M596L mutation (<xref rid="fig3" ref-type="fig">Fig. 3</xref>C). Cells expressing APP with the Swedish mutation were tested in anticipation of <italic toggle="yes">in vivo</italic> studies in AD model mice that express human APP-Swe.<fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><italic toggle="yes">sAPP&#946; and A&#946;1-42 production in CHO-7W and CHO-Swe cells</italic>. Levels of sAPP&#946; (A) and (B) A&#946;1-42 in CHO-7W wildtype APP, and (C) A&#946;1-42 in APP Swe cell lysates after 24-h treatment at 1 &#8203;&#956;M are shown. Data graphed as the mean and SEM. Statistical analysis performed using one-way ANOVA and Dunnett's post-hoc analysis.</p></caption><alt-text id="alttext0025">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec><sec id="sec3.4"><title>Pilot APP binding experiments of the FAH analogs by surface plasmon resonance (SPR)</title><p id="p0205">The interaction of FAH3, 17 and 65 were evaluated using the SPR protocol described previously in Descamps et al., [<xref rid="bib26" ref-type="bibr">26</xref>]. The FAHs showed varying interaction with APP, when compared to the BACEIV inhibitor (<xref rid="appsec1" ref-type="sec">Supplementary Table S2</xref>). The binding to APP may contribute to the selectivity seen with the FAHs for BACE1 cleavage of APP substrate relative to NRG1 and PSGL1 substrate.</p></sec><sec id="sec3.5"><title>FAH65 displays favorable physiochemical properties and brain permeability in mice</title><p id="p0210">FAH65 was determined to have kinetic solubility at 88 &#8203;&#956;M in water, plasma stability at t<sub>1/2</sub> &gt; 180 &#8203;min and, in the Parallel Artificial Membrane Permeability (PAMPA) assay, a Pm of 1.09, predicting it would be brain-permeable. Its half-life in liver microsomes is &#8764;38 &#8203;min and it binds human serum albumin (HSA) with a free unbound (F<sub>u</sub>) of 0.44 &#8203;%. In brain tissue, the F<sub>unbound</sub> was 3.1 &#8203;% for (see <xref rid="appsec1" ref-type="sec">Supplementary Methods</xref> and <xref rid="appsec1" ref-type="sec">Supplementary Table S3</xref>). In the human ether-a-go-go-related gene (hERG) testing, FAH65 showed potassium channel binding below 50 &#8203;%, ranging from 38.7 to 41 &#8203;% at 10 &#8203;uM (IC<sub>50</sub> &#8203;&gt; &#8203;10 &#8203;&#956;M).</p><p id="p0215">After subcutaneous (SQ) delivery of FAH65 to mice at 10 or 30 &#8203;mg/kg, compound levels over 3000 &#8203;ng/mL were observed in plasma (<xref rid="fig4" ref-type="fig">Fig. 4</xref>A). After oral delivery of FAH65 at 30 &#8203;mg/kg, the plasma C<sub>max</sub> of &#8764;50 &#8203;ng/mL was seen at 2 &#8203;h and the brain C<sub>max</sub> of 74 &#8203;ng/g at 1 &#8203;h (<xref rid="fig4" ref-type="fig">Fig. 4</xref>B).<fig id="fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p><italic toggle="yes">Pharmacokinetics of FAH65 in mice</italic>. (A) Plasma and brain levels of FAH65 at 10 and 30 &#8203;mg/kg 1, 2, 4 and 8 &#8203;h after delivery by either the oral or subcutaneous (SQ) routes are shown. (B) Plasma and brain levels of FAH65 shown with an expanded y-axis scale are above IC<sub>50</sub> after oral delivery at 30 &#8203;mg/kg.</p></caption><alt-text id="alttext0030">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="sec3.6"><title>Pilot PK/PD comparison of FAH65 and Veru in rats</title><p id="p0220">A pilot PK/pharmacodynamic (PD) study was performed in rats to compare FAH65 with known BACE inhibitor Veru [<xref rid="bib23" ref-type="bibr">23</xref>]. After oral gavage delivery at 30 &#8203;mg/kg, the C<sub>max</sub> for brain of 182 &#8203;ng/g for FAH65 (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S3A</xref>) and 157 &#8203;ng/ng for Veru (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S3B</xref>) were observed at 2 &#8203;h post-delivery, showing similar brain permeability. In cerebral spinal fluid (CSF), rat APP BACE1 cleavage product sAPP&#946; was the lowest at 2 &#8203;h post-delivery of Veru and 3 &#8203;h post-delivery for FAH65 (1- and 2-h samples were not available for assay) and were lower with FAH65 (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S3C</xref>). In brain (medial cortex), sAPP&#946; was lowest 6 &#8203;h post-delivery of FAH65 (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S3D</xref>). In addition to sAPP&#946;, BACE1 cleavage of APP produces the &#946; C-terminal fragment (&#946;CTF), which can then be cleaved by &#947;-secretase to produce A&#946;1-40 and/or A&#946;1-42. A&#946;1-40 was also lower in CSF from FAH65-treated as compared with Veru-treated rats (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S3E</xref>). A&#946;1-42 in brain varied with FAH65 and Veru treatment (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S3F</xref>). Inhibition of APP cleavage by BACE1 likely provides more available substrate for &#945;-secretase cleavage and sAPP&#945; generation; sAPP&#945; levels in brain medial cortex were higher with FAH65 (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S3G</xref>).</p></sec><sec id="sec3.7"><title>FAH65 improved working memory <italic toggle="yes">in vivo</italic> in a murine model of AD</title><p id="p0225">In the pilot subchronic study (n &#8203;= &#8203;8) of oral 30 mkd FAH65 for 10 days in B254 mice, the performance of FAH65-treated mice in the Novel Object Recognition (NOR) testing paradigm [<xref rid="bib34" ref-type="bibr">34</xref>] was not significantly increased as compared to vehicle-treated mice (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A). Target engagement in the brain was evidenced by the significant decrease in APP &#946;-CTF in brain tissue of FAH65-treated as compared to vehicle-treated mice (<xref rid="fig5" ref-type="fig">Fig. 5</xref>B). While the means for A&#946; 1-42 and the p-tau/t-tau ratio were lower in FAH65 vs. vehicle-treated mice, the differences were not significant (<xref rid="fig5" ref-type="fig">Fig. 5</xref>C and D). Plasma and brain levels of FAH65 2 &#8203;h after the last dose of FAH65 on the last day of treatment (time of euthanasia) are shown in <xref rid="fig5" ref-type="fig">Fig. 5</xref>E and F, respectively; FAH65 showed modest brain levels, with a mean of &#8764; 20 &#8203;ng/g in brain.<fig id="fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p><italic toggle="yes">FAH65 efficacy in AD model mice</italic>. Pilot subchronic study (A) novelty preference in the Novel Object Recognition (NOR) testing paradigm and brain levels of (B) APP &#946;-CTF, (C) A&#946; 1-42, and (D) the p-tau/total tau ratio, (E) plasma and (F) brain levels of FAH65 in non-transgenic (NTg; n &#8203;= &#8203;5), AD model vehicle-treated (AD Veh; n &#8203;= &#8203;8), and FAH65-treated (AD FAH65; n &#8203;= &#8203;8) AD model mice are shown. Follow-up chronic study (G) novelty preference in Novel Location Recognition (NLR), and (H) NOR are shown, as well as brain levels of (I) sAPP&#945;, and (J) the sAPP&#946;/sAPP&#945; ratio. (K) Plasma and brain levels of FAH65 are shown. NTg Veh (n &#8203;= &#8203;7), AD Veh (n &#8203;= &#8203;9), and AD FAH65 (n &#8203;= &#8203;11) mice; both studies used 4-5 month-old female and male mice. Data graphed as the mean and SEM. Statistical analysis performed using one-way ANOVA with Dunnett's group comparisons; &#8727;p &#8203;&lt; &#8203;0.05 and &#8727;&#8727;p &#8203;&#8804; &#8203;0.01.</p></caption><alt-text id="alttext0035">Fig. 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p><p id="p0230">Levels of inflammatory biomarkers for astrocytic gliosis (GFAP) and microglial activation (IP-10), as well as A&#946;1-38, A&#946;1-40, A&#946;1-42, and the A&#946;1-42/1-40 ratio (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S4A&#8211;F</xref>, respectively), were assessed by MSD in brain tissue from mice in the subchronic study, this was a limited set of neuroinflammation markers but no significant differences between vehicle- and FAH65-treated B254 mice were observed.</p><p id="p0235">In the follow-up chronic study (n &#8203;= &#8203;11) of oral 30 mkd FAH65 for 26 days, a significant increase in novelty preference was observed in both Novel Location Recognition (NLR) and NOR for FAH65- vs. vehicle-treated mice (<xref rid="fig5" ref-type="fig">Fig. 5</xref>G and H). sAPP&#945;, product of &#945;-secretase cleavage of APP that may be expected to increase with greater substrate availability due to BACE1 inhibition, was significantly higher (<xref rid="fig5" ref-type="fig">Fig. 5</xref>I) and the sAPP&#946;/sAPP&#945; ratio representing the balance of cleavage by these competing pathways, was significantly lower (<xref rid="fig5" ref-type="fig">Fig. 5</xref>J) in brain tissue of FAH65-treated mice as compared to vehicle-treated mice, supporting target engagement. Brain levels of sAPP&#946; and A&#946;1-42 were also assessed in the study and were found to be highly variable amongst mice and not significantly different for Veh vs. FAH65-treated mice. The mean brain level of FAH65 was &#8764;50 &#8203;ng/g 2 &#8203;h after last day dosing (<xref rid="fig5" ref-type="fig">Fig. 5</xref>K).</p></sec><sec id="sec3.8"><title>Separation, configuration and testing of the active enantiomer of FAH65</title><p id="p0240">The (+) and (-) enantiomers of FAH65 were separated using supercritical fluid chromatography as described in <xref rid="appsec1" ref-type="sec">Supplementary Methods</xref> and shown in <xref rid="appsec1" ref-type="sec">Supplementary Fig. S5</xref>. The absolute configuration of the active enantiomer was determined to be the <italic toggle="yes">S</italic>-configuration based on the X-ray crystallography of the inactive (+) enantiomer using procedure described in <xref rid="appsec1" ref-type="sec">Supplementary Methods</xref>. The enantiomers underwent assessment for relative BACE1 inhibition. In the P5-P5&#8242; assay, the (-) enantiomer of FAH65, FAH65E(-), shows high activity (IC<sub>50</sub> &#8764;0.005 &#8203;&#956;M), whereas the FAH65(+) enantiomer is inactive (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A). FAH65 E(-) is also active in the MBP-APPC125 assay (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S6</xref>). FAH65E(-) induced a dose-response reduction in sAPP&#946; in CHO-7W cells at concentrations of 5 &#8203;nM and higher with an EC<sub>50</sub> &#8764;25 &#8203;nM (<xref rid="fig6" ref-type="fig">Fig. 6</xref>B), and in A&#946;1-42 at concentrations of 25 &#8203;nM and higher (<xref rid="fig6" ref-type="fig">Fig. 6</xref>C).<fig id="fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p><italic toggle="yes">Inhibitory activity and brain permeability of FAH65E(-)</italic>. Shown are (A) dose-response curves for FAH65 racemate and the FAH65E(+) and (-) enantiomers in the P5-P5&#8242; assay and (B) sAPP&#946; and (C) A&#946;1-42 in CHO-7W cells after treatment with increasing concentrations of FAH65 racemate and enantiomers. Legend in B also applies to C. Data graphed as the mean and SEM. (D) FAH65E(-) (black line) and sAPP<italic toggle="yes">&#946;</italic> (blue dashed line) levels in brain from ApoE4TR-5XFAD mice after oral delivery of 30 &#8203;mg/kg FAH65E(-) doses are shown. PK-PD study design did not include 0 h timepoint untreated mice but included time points 1, 2, 4 and 6 &#8203;h after last dose on Day 2. N &#8203;= &#8203;3 mice per time point.</p></caption><alt-text id="alttext0040">Fig. 6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p><p id="p0245">To assess FAH65E(-) effects in a human cell line, HEK293T cells stably expressing full-lenght (FL) APP with an N-terminal GFP label were treated with FAH65E(-), BACEIV and Verubecestat (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S7</xref>). Decreased BACE1 cleavage of FL APP was anticipated to result in a greater fluorescent signal intensity, because more FL APP should remain associated with the cells. As shown in <xref rid="appsec1" ref-type="sec">Supplementary Fig. S7B</xref>, the signal intensity was significantly greater with FAH65E(-) at 1 &#956;M as compared to DMSO (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S7C</xref>). Representative GFP signal in microscopic images of HEK-APP cells is shown in <xref rid="appsec1" ref-type="sec">Supplementary Fig. S8</xref>.</p><p id="p0250">The crystal structure for the inactive FAH-65(+) is shown in <xref rid="appsec1" ref-type="sec">Supplementary Fig. S9</xref>.</p><p id="p0255">In ADME-T testing (see <xref rid="appsec1" ref-type="sec">Supplementary Methods</xref> and <xref rid="appsec1" ref-type="sec">Supplementary Table S3</xref>), FAH65E(-) displayed favorable physiochemical properties to be an orally bioavailable therapeutic <italic toggle="yes">in vivo</italic>, including kinetic solubility at 79 &#8203;&#956;M, potential for blood-brain barrier (BBB) permeability at 1.01 Pm in PAMPA, and plasma stability at t<sub>1/2</sub> &#8203;&gt; &#8203;180 &#8203;min. It has a moderately short half-life in liver microsomes (49 &#8203;min) and bound to human serum albumin (HAS) at relatively high levels (<italic toggle="yes">F</italic><sub><italic toggle="yes">u</italic></sub> 0.49 &#8203;%). The <italic toggle="yes">F</italic><sub><italic toggle="yes">u</italic></sub> was 5.4 &#8203;% for brain tissue.</p><p id="p0260"><italic toggle="yes">In vivo</italic> in a pharmacokinetic/pharmacodynamic (PK-PD) study was done in ApoE4TR:5xFAD mice. FAH65E(-) was observed to be orally brain bioavailable, reaching a maximum brain concentration (C<sub>max</sub>) of 188 &#8203;nM at 1 &#8203;h after oral administration of the last of three doses (two on day 1, one on day 2) at 30 &#8203;mg/kg to ApoE4-5XFAD mice (<xref rid="fig6" ref-type="fig">Fig. 6</xref>D, black line). On day 2 the brains were collected at 1, 2, 4 and 6 &#8203;h after the last dose. In these mice, sAPP&#946; levels decreased at 2 &#8203;h after oral administration of the last dose (<xref rid="fig6" ref-type="fig">Fig. 6</xref>D, blue dashed line), suggesting a pharmacodynamic correlation between brain C<sub>max</sub> levels and sAPP&#946;, further supporting target engagement after oral administration of FAH65E(-).</p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0265">We describe herein our discovery of ASBI lead candidate FAH65 and its active enantiomer FAH65E(-) through screening, optimization by exploratory medicinal chemistry, analog synthesis and testing. The lead candidate FAH65 is highly selective for BACE1 as the target enzyme and APP as the substrate. <italic toggle="yes">In vitro</italic> studies reveal the selectivity and potency of FAH65, and <italic toggle="yes">in vivo</italic> studies in AD model mice provide evidence that FAH65 decreases APP cleavage product sAPP&#946; in brain tissue and increases trophic, neurite-supporting cleavage product sAPP&#945;, along with significant improvements in memory in the NOR/NLR testing paradigms after oral treatment at 30 mkd for 26 days.</p><p id="p0270">In the pilot study in rats, FAH65 displayed good brain penetrance and target engagement, lowering sAPP&#946; and A&#946;1-40/42, with a concomitant increase in sAPP&#945;, in both CSF and brain. Overall, the effects of FAH65 in the rat study were greater than the clinically-tested BACE inhibitor verubecestat. The potential advantage of FAH65, which has BACE1 inhibition potency similar to that of Veru, is its high selectivity for inhibiting BACE1 cleavage of APP relative to other substrates such as NRG1 and PSGL1.</p><p id="p0275">FAH65 has good drug-like properties, including stability in human plasma, microsomal stability, and water solubility. It also has a good hERG profile with an EC<sub>50</sub> &gt; 10 &#956;M. The free unbound drug (<italic toggle="yes">F</italic><sub><italic toggle="yes">u</italic></sub>) of 5.4 % for mouse brain tissue protein binding suggests the unbound brain concentration after 30mkd oral administartion of FAH65-E(-) at C<sub>max</sub> is 9.6 nM, which is close to its IC<sub>50</sub> for BACE1 inhibition (IC<sub>50</sub> &#8764; 5 nM) in the cell free enzyme assay but less than the predetermined <italic toggle="yes">in vitro</italic> efficacious dose in CHO-7W cells (EC<sub>50</sub> = 25 nM, <xref rid="fig6" ref-type="fig">Fig. 6</xref>D). The oral administration of FAH65E(-) at this dose is likely to inhibit BACE1 less than 50 % in the brain.</p><p id="p0987">We note ASBI therapy with FAH65 herein may only result in partial, not complete, inhibition of BACE1 in the brain. Such a partial BACE1 inhibition therapeutic approach is supported by the previous finding of McConlogue et al. [<xref rid="bib38" ref-type="bibr">38</xref>] that indicated, at least in a mouse model of AD, that only a 12 % decrease in A&#946; levels in brain results in dramatic reduction in plaque pathology. The potential of modest BACE1 inhibition and partial reduction of A&#946; production in the brain was also suggested by Satir et al. [<xref rid="bib39" ref-type="bibr">39</xref>], who found that less than a 50 % decrease in A&#946; secretion by a BACE inhibitor &#8211; a low-level BACE1 inhibition magnitude [<xref rid="bib40" ref-type="bibr">40</xref>] similar to that anticipated for FAH65E(-), or seen in the presence of the protective Icelandic mutation that results in &#8764; 30 % lifelong reduction in BACE cleavage of APP [<xref rid="bib14" ref-type="bibr">14</xref>] &#8211; does not impair synaptic function and thus is not likely to cause the cognitive deterioration observed with some BACE inhibitors that have failed in the clinic [<xref rid="bib41" ref-type="bibr">41</xref>]</p><p id="p0280">Despite reported target engagement, BACE inhibitors that have been studied in the clinic have not elicited improvements in cognitive performance, and in some instances have been associated with worsened cognitive performance [<xref rid="bib41" ref-type="bibr">41</xref>]. The failure of BACE inhibitors in the clinic to-date has been attributed to off-target effects due to inhibition of non-APP BACE substrates, a limitation that an ASBI specifically addresses and is likely to overcome.</p><p id="p0285">If successfully developed, a small molecule ASBI therapeutic with good oral bioavailability and brain penetrance may also likely have advantages over the currently approved amyloid-targeted therapeutic aducanumab and a similar monoclonal antibody-based therapy such as lecanemab [<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib16" ref-type="bibr">16</xref>] that only provided a modest decrease in decline of memory, in ease of delivery &#8211; oral dosing vs. infusion &#8211; and safety risks such as inflammation, ARIA, and risk of bleeding in the brain.</p><p id="p0290">In our next steps toward preclinical development of this ASBI lead candidate, the active enantiomer of FAH65E(-), will undergo <italic toggle="yes">in vivo</italic> testing in additional murine models to assess effects on BACE1 activity/substrate cleavage, including off-target effects, in brain as well as other IND-enabling studies.</p><p id="p0295">An ASBI that reaches the clinical testing stage may be most beneficial for patients before the onset of symptoms, for example, in persons who possess ApoE4 alleles or who are otherwise at risk for increased &#946;-secretase processing of APP. FAH65E(-) may also provide the possibility of combination with FDA-approved mAb-based therapy with the potential to increase efficacy of both therapeutics by decreasing A&#946; production while clearing existing amyloid; it may also allow a decrease in the dose of the mAb and a reduction in observed clinical side effects. Finally, FAH65E(-) could serve as a orally administered maintenance therapy to normalize A&#946; levels after amyloid is cleared from the brain.</p></sec><sec id="sec5"><title>Disclosures</title><p id="p0300">The FAH series is part of the patent application UCLA-2018-200 and the issued claims in UCH-14160. Authors have nothing to disclose.</p></sec><sec id="sec6"><title>Author contributions</title><p id="p0305">JC performed in vitro assays and analyzed data; BJ participated in developing medical chemistry and analog design, OD performed the screening assay and in vitro studies, WC and JL performed pharmacokinetic and ADME analyses, DW performed characterization of FAH65 enantiomers, QZ developed the SEAP assays, OG and CZ performed/assisted with in vivo studies, KP, MJ, and CE performed assays, CPL performed the APP binding studies, JC and SP conducted the MSD analysis, PS performed in vivo studies, analyzed and graphed data and wrote the manuscript, DB and VJ originated the concept of ASBI identification and designed the screening assay, medicinal chemistry strategy and analog generation, in vitro and in vivo studies, analyzed data and edited the manuscript.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of competing interest</title><p id="p0310">The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Varghese John's Lab reports financial support was provided by NantNeuro LLC. Varghese John has patent pending to UCLA. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>G.A.</given-names></name></person-group><article-title>Alzheimer's disease: the amyloid cascade hypothesis</article-title><source>Science</source><volume>256</volume><issue>5054</issue><year>1992</year><fpage>184</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">1566067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1566067</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Selkoe</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>J.</given-names></name></person-group><article-title>The amyloid hypothesis of Alzheimer's disease at 25 years</article-title><source>EMBO Mol Med</source><volume>8</volume><issue>6</issue><year>2016</year><fpage>595</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">27025652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.201606210</pub-id><pub-id pub-id-type="pmcid">PMC4888851</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name></person-group><article-title>Tau in Alzheimer's disease: mechanisms and therapeutic strategies</article-title><source>Curr Alzheimer Res</source><volume>15</volume><issue>3</issue><year>2018</year><fpage>283</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">28413986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1567205014666170417111859</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Trejo-Lopez</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Yachnis</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Prokop</surname><given-names>S.</given-names></name></person-group><article-title>Neuropathology of Alzheimer's disease</article-title><source>Neurotherapeutics</source><volume>19</volume><issue>1</issue><year>2022</year><fpage>173</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">34729690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13311-021-01146-y</pub-id><pub-id pub-id-type="pmcid">PMC9130398</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Braak</surname><given-names>H.</given-names></name><name name-style="western"><surname>Braak</surname><given-names>E.</given-names></name></person-group><article-title>Neuropathological stageing of Alzheimer-related changes</article-title><source>Acta Neuropathol</source><volume>82</volume><issue>4</issue><year>1991</year><fpage>239</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">1759558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00308809</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Maia</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>E.</given-names></name></person-group><article-title>BACE-1 and &#947;-secretase as therapeutic targets for Alzheimer's disease</article-title><source>Pharmaceuticals (Basel)</source><volume>12</volume><issue>1</issue><year>2019</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph12010041</pub-id><pub-id pub-id-type="pmcid">PMC6469197</pub-id><pub-id pub-id-type="pmid">30893882</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>APP processing in Alzheimer's disease</article-title><source>Mol Brain</source><volume>4</volume><year>2011</year><fpage>3</fpage><pub-id pub-id-type="pmid">21214928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1756-6606-4-3</pub-id><pub-id pub-id-type="pmcid">PMC3022812</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Parkin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>B.</given-names></name></person-group><article-title>A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10</article-title><source>J Neurochem</source><volume>108</volume><issue>6</issue><year>2009</year><fpage>1464</fpage><lpage>1479</lpage><pub-id pub-id-type="pmid">19183255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1471-4159.2009.05907.x</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Dar</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Glazner</surname><given-names>G.W.</given-names></name></person-group><article-title>Deciphering the neuroprotective and neurogenic potential of soluble amyloid precursor protein alpha (sAPP&#945;)</article-title><source>Cell Mol Life Sci</source><volume>77</volume><issue>12</issue><year>2020</year><fpage>2315</fpage><lpage>2330</lpage><pub-id pub-id-type="pmid">31960113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-019-03404-x</pub-id><pub-id pub-id-type="pmcid">PMC11105086</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Kuhn</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dislich</surname><given-names>B.</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zeitschel</surname><given-names>U.</given-names></name><name name-style="western"><surname>Ellwart</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons</article-title><source>EMBO J</source><volume>29</volume><issue>17</issue><year>2010</year><fpage>3020</fpage><lpage>3032</lpage><pub-id pub-id-type="pmid">20676056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/emboj.2010.167</pub-id><pub-id pub-id-type="pmcid">PMC2944055</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Tolar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abushakra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M.</given-names></name></person-group><article-title>The path forward in Alzheimer's disease therapeutics: reevaluating the amyloid cascade hypothesis</article-title><source>Alzheimer's Dement</source><volume>16</volume><issue>11</issue><year>2020</year><fpage>1553</fpage><lpage>1560</lpage><pub-id pub-id-type="pmid">31706733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2019.09.075</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Haass</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lemere</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Capell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Citron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seubert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schenk</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway</article-title><source>Nat Med</source><volume>1</volume><issue>12</issue><year>1995</year><fpage>1291</fpage><lpage>1296</lpage><pub-id pub-id-type="pmid">7489411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1295-1291</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Larner</surname><given-names>A.J.</given-names></name></person-group><article-title>Presenilin-1 mutations in Alzheimer's disease: an update on genotype-phenotype relationships</article-title><source>J Alzheimers Dis</source><volume>37</volume><issue>4</issue><year>2013</year><fpage>653</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">23948899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-130746</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Jonsson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Atwal</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Snaedal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Bjornsson</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A mutation in APP protects against Alzheimer's disease and age-related cognitive decline</article-title><source>Nature</source><volume>488</volume><issue>7409</issue><year>2012</year><fpage>96</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">22801501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11283</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Budd</surname><given-names>Haeberlein S.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chalkias</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Two randomized phase 3 studies of aducanumab in early Alzheimer's disease</article-title><source>J Prev Alzheimers Dis</source><volume>9</volume><issue>2</issue><year>2022</year><fpage>197</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">35542991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2022.30</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name></person-group><article-title>Impact of anti-amyloid-&#946; monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: a focus on aducanumab and lecanemab</article-title><source>Front Aging Neurosci</source><volume>14</volume><year>2022</year><object-id pub-id-type="publisher-id">870517</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.870517</pub-id><pub-id pub-id-type="pmcid">PMC9039457</pub-id><pub-id pub-id-type="pmid">35493943</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gee</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Lecanemab in early Alzheimer's disease</article-title><source>N Engl J Med</source><volume>388</volume><issue>1</issue><year>2023</year><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">36449413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2212948</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Rashad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rasool</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shaheryar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sarfraz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sarfraz</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Robles-Velasco</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Donanemab for Alzheimer's disease: a systematic review of clinical trials</article-title><source>Healthcare (Basel)</source><volume>11</volume><issue>1</issue><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/healthcare11010032</pub-id><pub-id pub-id-type="pmcid">PMC9818878</pub-id><pub-id pub-id-type="pmid">36611492</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name></person-group><article-title>Anti-Amyloid-&#946; monoclonal antibodies for Alzheimer's disease: pitfalls and promise</article-title><source>Biol Psychiatry</source><volume>83</volume><issue>4</issue><year>2018</year><fpage>311</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">28967385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2017.08.010</pub-id><pub-id pub-id-type="pmcid">PMC5767539</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Panza</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lozupone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Logroscino</surname><given-names>G.</given-names></name><name name-style="western"><surname>Imbimbo</surname><given-names>B.P.</given-names></name></person-group><article-title>A critical appraisal of amyloid-&#946;-targeting therapies for Alzheimer disease</article-title><source>Nat Rev Neurol</source><volume>15</volume><issue>2</issue><year>2019</year><fpage>73</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">30610216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-018-0116-6</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Moussa-Pacha</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Abdin</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Omar</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Alniss</surname><given-names>H.</given-names></name><name name-style="western"><surname>Al-Tel</surname><given-names>T.H.</given-names></name></person-group><article-title>BACE1 inhibitors: current status and future directions in treating Alzheimer's disease</article-title><source>Med Res Rev</source><volume>40</volume><issue>1</issue><year>2020</year><fpage>339</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">31347728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/med.21622</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Munro</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Nash</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pigoni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lichtenthaler</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Gunnersen</surname><given-names>J.M.</given-names></name></person-group><article-title>Functions of the Alzheimer's disease protease BACE1 at the synapse in the central nervous system</article-title><source>J Mol Neurosci</source><volume>60</volume><issue>3</issue><year>2016</year><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">27456313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12031-016-0800-1</pub-id><pub-id pub-id-type="pmcid">PMC5059407</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Egan</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Kost</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tariot</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Vellas</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease</article-title><source>N Engl J Med</source><volume>378</volume><issue>18</issue><year>2018</year><fpage>1691</fpage><lpage>1703</lpage><pub-id pub-id-type="pmid">29719179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1706441</pub-id><pub-id pub-id-type="pmcid">PMC6776074</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Vassar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Haass</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Rajendran</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>P.C.</given-names></name><etal/></person-group><article-title>Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects</article-title><source>J Neurochem</source><volume>130</volume><issue>1</issue><year>2014</year><fpage>4</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">24646365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.12715</pub-id><pub-id pub-id-type="pmcid">PMC4086641</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Shmueli</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>T&#252;shaus</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>N.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>R.</given-names></name><etal/></person-group><article-title>The Alzheimer's disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130</article-title><source>Mol Neurodegener</source><volume>18</volume><issue>1</issue><year>2023</year><fpage>13</fpage><pub-id pub-id-type="pmid">36810097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-023-00596-6</pub-id><pub-id pub-id-type="pmcid">PMC9942414</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Descamps</surname><given-names>O.</given-names></name><name name-style="western"><surname>Spilman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Libeu</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Poksay</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gorostiza</surname><given-names>O.</given-names></name><etal/></person-group><article-title>A&#946;PP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for Alzheimer's disease</article-title><source>J Alzheimers Dis</source><volume>37</volume><issue>2</issue><year>2013</year><fpage>343</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">23948888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-130578</pub-id><pub-id pub-id-type="pmcid">PMC3971881</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Willem</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dewachter</surname><given-names>I.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>N.</given-names></name><name name-style="western"><surname>Van Dooren</surname><given-names>T.</given-names></name><name name-style="western"><surname>Borghgraef</surname><given-names>P.</given-names></name><name name-style="western"><surname>Haass</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice</article-title><source>Am J Pathol</source><volume>165</volume><issue>5</issue><year>2004</year><fpage>1621</fpage><lpage>1631</lpage><pub-id pub-id-type="pmid">15509532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0002-9440(10)63419-0</pub-id><pub-id pub-id-type="pmcid">PMC1618675</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Horiuchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>K.</given-names></name><name name-style="western"><surname>Manova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blobel</surname><given-names>C.P.</given-names></name></person-group><article-title>Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2</article-title><source>Dev Biol</source><volume>283</volume><issue>2</issue><year>2005</year><fpage>459</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">15936750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ydbio.2005.05.004</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Holly</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sarah</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Sreemathi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Erika</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeffery</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Intraneuronal &#946;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer disease mutations: potential factors in amyloid plaque formation</article-title><source>J Neurosci</source><volume>26</volume><issue>40</issue><year>2006</year><object-id pub-id-type="publisher-id">10129</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.1202-06.2006</pub-id><pub-id pub-id-type="pmcid">PMC6674618</pub-id><pub-id pub-id-type="pmid">17021169</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hopp</surname><given-names>S.C.</given-names></name></person-group><article-title>The 5XFAD mouse model of Alzheimer's disease displays age-dependent deficits in habituation to a novel environment</article-title><source>Aging Brain</source><volume>3</volume><year>2023</year><object-id pub-id-type="publisher-id">100078</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbas.2023.100078</pub-id><pub-id pub-id-type="pmcid">PMC10275951</pub-id><pub-id pub-id-type="pmid">37333676</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Galvan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gorostiza</surname><given-names>O.F.</given-names></name><name name-style="western"><surname>Banwait</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ataie</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Long-term prevention of Alzheimer's disease-like behavioral deficits in PDAPP mice carrying a mutation in Asp664</article-title><source>Behav Brain Res</source><volume>191</volume><issue>2</issue><year>2008</year><fpage>246</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">18485495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2008.03.035</pub-id><pub-id pub-id-type="pmcid">PMC2757410</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Atcha</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rourke</surname><given-names>C.</given-names></name><name name-style="western"><surname>Neo</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Goh</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Aw</surname><given-names>C.C.</given-names></name><etal/></person-group><article-title>Alternative method of oral dosing for rats</article-title><source>J Am Assoc Lab Anim Sci</source><volume>49</volume><issue>3</issue><year>2010</year><fpage>335</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">20587166</pub-id><pub-id pub-id-type="pmcid">PMC2877307</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Spilman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Descamps</surname><given-names>O.</given-names></name><name name-style="western"><surname>Gorostiza</surname><given-names>O.</given-names></name><name name-style="western"><surname>Peters-Libeu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Poksay</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Matalis</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model</article-title><source>Brain Res</source><volume>1551</volume><year>2014</year><fpage>25</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">24389031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2013.12.029</pub-id><pub-id pub-id-type="pmcid">PMC4001856</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Bevins</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Besheer</surname><given-names>J.</given-names></name></person-group><article-title>Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'</article-title><source>Nat Protoc</source><volume>1</volume><issue>3</issue><year>2006</year><fpage>1306</fpage><lpage>1311</lpage><pub-id pub-id-type="pmid">17406415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nprot.2006.205</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Galvan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gorostiza</surname><given-names>O.F.</given-names></name><name name-style="western"><surname>Banwait</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ataie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Logvinova</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Sitaraman</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664</article-title><source>Proc Natl Acad Sci USA</source><volume>103</volume><issue>18</issue><year>2006</year><fpage>7130</fpage><lpage>7135</lpage><pub-id pub-id-type="pmid">16641106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0509695103</pub-id><pub-id pub-id-type="pmcid">PMC1459029</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gorostiza</surname><given-names>O.F.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bredesen</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Galvan</surname><given-names>V.</given-names></name></person-group><article-title>Reversal of learning deficits in hAPP transgenic mice carrying a mutation at Asp664: a role for early experience</article-title><source>Behav Brain Res</source><volume>206</volume><issue>2</issue><year>2010</year><fpage>202</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">19751769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2009.09.013</pub-id><pub-id pub-id-type="pmcid">PMC2783897</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Devidze</surname><given-names>N.</given-names></name><name name-style="western"><surname>Halabisky</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Thwin</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>G.Q.</given-names></name><etal/></person-group><article-title>Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein</article-title><source>J Neurosci</source><volume>30</volume><issue>1</issue><year>2010</year><fpage>372</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">20053918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5341-09.2010</pub-id><pub-id pub-id-type="pmcid">PMC3064502</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>McConlogue</surname><given-names>L.</given-names></name><name name-style="western"><surname>Buttini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Brigham</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>S.B.</given-names></name><etal/></person-group><article-title>Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice</article-title><source>J Biol Chem</source><volume>282</volume><issue>36</issue><year>2007</year><fpage>26326</fpage><lpage>26334</lpage><pub-id pub-id-type="pmid">17616527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M611687200</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Satir</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Agholme</surname><given-names>L.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karila</surname><given-names>P.</given-names></name><name name-style="western"><surname>Illes</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Partial reduction of amyloid &#946; production by &#946;-secretase inhibitors does not decrease synaptic transmission</article-title><source>Alzheimers Res Ther</source><volume>12</volume><issue>1</issue><year>2020</year><fpage>63</fpage><pub-id pub-id-type="pmid">32456694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-020-00635-0</pub-id><pub-id pub-id-type="pmcid">PMC7251689</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>McDade</surname><given-names>E.</given-names></name><name name-style="western"><surname>Voytyuk</surname><given-names>I.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Carillo</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Strooper</surname><given-names>B.D.</given-names></name><etal/></person-group><article-title>The case for low-level inhibiton for the prevention of Alzheimer&#8217;s Disease</article-title><source>Natl Rev</source><volume>17</volume><year>2021</year><fpage>703</fpage><lpage>714</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-021-00545-1</pub-id><pub-id pub-id-type="pmid">34548654</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Wessels</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lines</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Kost</surname><given-names>J.</given-names></name><name name-style="western"><surname>Voss</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mozley</surname><given-names>L.H.</given-names></name><etal/></person-group><article-title>Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease</article-title><source>Alzheimer's Dement</source><volume>16</volume><issue>11</issue><year>2020</year><fpage>1483</fpage><lpage>1492</lpage><pub-id pub-id-type="pmid">33049114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12164</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0320">The following is the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.pdf" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0315">This research was supported by funding from the <funding-source id="gs1">Easton Center for Alzheimer&#8217;s Disease Research and Care</funding-source> at the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100023876</institution-id><institution>Department of Neurology</institution></institution-wrap></funding-source> at UCLA and a sponsored research agreement to the <funding-source id="gs3">Drug Discovery Lab</funding-source> at UCLA by California Capital Equity Award 20173930 and <funding-source id="gs4">NantNeuro LLC</funding-source>. We thank Dr. Edward Koo for providing the CHO-7W cell line that overexpress APP. Undergraduate Nicole Katzaroff and the UCLA Molecular Instrumentation Center for the X-crystallography analysis and undergraduate Alicia Li for assistance with the in vitro testing assays. Further support was provided by the UCLA Technology Development group (TDG) for the patent filings.</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0325">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.neurot.2025.e00610" id="intref0010">https://doi.org/10.1016/j.neurot.2025.e00610</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="case-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Plast Reconstr Surg Glob Open</journal-id><journal-id journal-id-type="iso-abbrev">Plast Reconstr Surg Glob Open</journal-id><journal-id journal-id-type="pmc-domain-id">2522</journal-id><journal-id journal-id-type="pmc-domain">prsgo</journal-id><journal-id journal-id-type="publisher-id">GOX</journal-id><journal-title-group><journal-title>Plastic and Reconstructive Surgery Global Open</journal-title></journal-title-group><issn pub-type="epub">2169-7574</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12490644</article-id><article-id pub-id-type="pmcid-ver">PMC12490644.1</article-id><article-id pub-id-type="pmcaid">12490644</article-id><article-id pub-id-type="pmcaiid">12490644</article-id><article-id pub-id-type="pmid">41050964</article-id><article-id pub-id-type="doi">10.1097/GOX.0000000000007082</article-id><article-id pub-id-type="publisher-id">GOX-D-25-00181</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Reconstructive</subject></subj-group><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Modified Dynamic Lymphaticovenular Anastomosis for Surgical Management of Alzheimer Disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhou</surname><given-names initials="Z">Zhegang</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="X">Xuhui</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kou</surname><given-names initials="W">Wei</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">&#8225;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meng</surname><given-names initials="F">Fanbin</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="L">Longbiao</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wen</surname><given-names initials="J">Jingjing</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boey</surname><given-names initials="J">Johnson</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">&#167;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shah</surname><given-names initials="V">Vitrag</given-names></name><degrees>MD</degrees><xref rid="aff5" ref-type="aff">&#182;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Malag&#243;n</surname><given-names initials="P">Paloma</given-names></name><degrees>MD</degrees><xref rid="aff6" ref-type="aff">&#8741;</xref></contrib><aff id="aff1">From the <label>*</label>Department of Hand and Microsurgery, Peking University Shenzhen Hospital, Shenzhen, China</aff><aff id="aff2"><label>&#8224;</label>Department of Neurology, Peking University Shenzhen Hospital, Shenzhen, China</aff><aff id="aff3"><label>&#8225;</label>Department of Hand and Foot and Reconstructive Microsurgery, Shandong Affiliated Provincial Hospital of Shandong First Medical University, Shandong, China</aff><aff id="aff4"><label>&#167;</label>Department of Podiatry, Singhealth Polyclinics, Singapore, Singapore</aff><aff id="aff5"><label>&#182;</label>Department of Plastic Surgery, Shah Speciality Hospital, Surat, Gujarat, India</aff><aff id="aff6"><label>&#8741;</label>Department of Plastic Surgery, Hospital Germans Trias i Pujol, Universitat Aut&#242;noma de Barcelona, Barcelona, Spain.</aff></contrib-group><author-notes><corresp id="c1">Zhegang Zhou, Department of Hand and Microsurgery, Peking University Shenzhen Hospital, Lianhua Road 1120, Shenzhen 518036, China, E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sumszzg@163.com">sumszzg@163.com</email></corresp></author-notes><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>10</month><year>2025</year></pub-date><volume>13</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">498115</issue-id><elocation-id>e7082</elocation-id><history><date date-type="received"><day>16</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="gox-13-e7082.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gox-13-e7082.pdf"/><abstract><title>Summary:</title><p>Alzheimer disease (AD) is a neurodegenerative disorder that frequently results in progressive cognitive decline. Despite the extensive research conducted on AD, there is presently no solution available due to its increasing prevalence. Recent research has suggested cervical lymphaticovenular anastomosis (LVA) as a therapeutic strategy to improve lymphatic outflow and potentially reduce AD symptoms. We established an amended LVA protocol to mitigate the risk of venous reflux, a prevalent issue associated with the original LVA methodology. A 64-year-old man of Chinese descent exhibited the typical signs and symptoms of AD. The absence of substantial progress with standard medical treatment led to the consideration of LVA. We used a lower limb vein graft for the LVA, anastomosing it to the cervical lymphatic vessels and external jugular vein. The cognitive function of the patient got better after LVA, as shown by higher Mini Mental State Examination and Montreal Cognitive Assessment scores. Fewer &#946;-amyloid and tau protein deposits were observed on positron emission tomography/computed tomography scans. No adverse occurrences or issues were observed. The success in this case demonstrated the potential role of LVA in the management of AD. However, further thorough research is required to evaluate the efficacy of our technique.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>COUNTRY</meta-name><meta-value>CHINA</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Alzheimer disease (AD) progresses over a continuum, beginning with a preclinical stage, advancing to mild cognitive impairment, and ultimately culminating in dementia. Biomarker derangement can manifest years before the emergence of clinical symptoms.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> These biomarkers are classified into 3 categories: A (amyloid-&#946; biomarkers), T (tau biomarkers), and N (neurodegeneration or neuronal damage biomarkers), collectively referred to as the &#8220;ATN&#8221; system.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> The A and T categories have been reclassified into core 1 and 2 biomarkers, a reflection of our understanding of progression from the preclinical to symptomatic phase.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> The core 1 biomarkers, which include biomarkers of cerebrospinal fluid and plasma, and amyloid positron emission tomography (PET), are detected in the preclinical stages of AD, whereas core 2 biomarkers are elevated in the later symptomatic stages.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> Although there is no cure for AD, timely identification of AD is essential for prompt care and for delaying progression of the illness.</p><p>Preliminary animal studies suggest that improving the glymphatic system in the central nervous system can facilitate the removal of plaques and neurofibrillary tangles, hence reducing cognitive decline.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> Studies have investigated lymphaticovenular anastomosis (LVA), indicating its capability to alleviate AD symptoms.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup> The potential complications of venous-lymphatic reflux in the traditional LVA have been reported, which may result in suboptimal outcome. Some centers believe that end-side lymph node-to-internal jugular vein (IJV) anastomosis might address this issue. In this study, we modified the LVA by connecting a venous graft from the superficial leg vein to the external jugular vein (EJV) in an end-to-side manner. This lowered the risk of venous-lymphatic reflux, and the anatomical location of the EJV minimized trauma and stress to the underlying soft tissue structures.</p><sec sec-type="cases"><title>CASE PRESENTATION</title><p>A 64-year-old Chinese man presented at the neurology department with worsening amnesia that had developed over the previous year. He had comorbid type 2 diabetes mellitus and hypertension. The patient scored 14 points on the Mini Mental State Examination (MMSE) and 11 points on the Montreal Cognitive Assessment (MoCA). The cerebrospinal fluid examination revealed that red blood cells (3&#8201;&#215;&#8201;10<sup>6</sup>/L), glucose (5.12 mmol/L), and phosphorylated tau (48.38) were within normal limits. No anti-aquaporin-4 antibodies were detected, and the levels of A&#946;-42 were diminished (553.44 pg/mL), with an A&#946;42:A&#946;40 ratio of 0.04. PET/computed tomography (CT) scans revealed aberrant amyloid PET and heightened tau PET uptake in neocortical areas. (<bold>See figure, Supplementary Digital Content 1</bold>, which displays a preoperative amyloid PET/CT scan showing an increased uptake of amyvid-45 in the areas of cingulate and occipitoparietal lobules. An amyloid PET/CT scan taken 1 month perioperatively showed an overall reduction in amyloid plaques, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://links.lww.com/PRSGO/E287" ext-link-type="uri">https://links.lww.com/PRSGO/E287</ext-link>.) The patient was diagnosed with stage 6D of AD according to the diagnostic criteria established by the Alzheimer Association. He underwent treatment with various medications for AD, including donepezil, idebenone, and citicoline, for a period of 10 weeks, but there was no observed clinical improvement. Meanwhile, anti-A&#946; immunotherapy is not suitable in advanced AD. Thereafter, LVA was recommended as an adjunct treatment after the medical management had failed to improve the symptoms. During the 1-month follow-up appointment after LVA, the MMSE and MoCA scores improved to 18 and 13, respectively. PET/CT scans revealed less accumulation of A&#946; and tau proteins, whereas a venous ultrasound indicated no abnormalities in the EJV. During the most recent 3-month follow-up session, we noted an additional enhancement in the MMSE score to 19, although the MoCA score persisted at 13 (<bold>Supplementary Digital Content 1,</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://links.lww.com/PRSGO/E287" ext-link-type="uri">https://links.lww.com/PRSGO/E287</ext-link>).</p></sec><sec><title>SURGICAL PROTOCOL</title><p>The procedure was performed under general anesthesia with the patient in a supine position and the neck hyperextended. We injected 4&#8201;mL of 0.5% indocyanine green (ICG) solution (Dandong Yichuang Pharmaceutical, Co., Ltd., China) at 2 sites using an 18G needle: the anterior border of the sternocleidomastoid (SCM) muscle at the mandibular angle and the posterior border of the SCM muscle at the lower edge of the mastoid process. We performed ICG lymphography 30 minutes after ICG administration to identify enlarged lymphatics vessels measuring between 0.3 and 0.7&#8201;mm. At the same time, a vein finder device was used to identify a superficial vein measuring 1&#8201;mm in diameter and 10&#8201;cm in length, after which the vein graft was cut into 2 segments, each measuring about 3&#8211;5&#8201;cm in length (Fig. <xref rid="F1" ref-type="fig">1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>Fig. 1.</label><caption><p>A 10-cm superficial vein with 3 tributary branches was harvested from the medial calf.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gox-13-e7082-g001.jpg"/></fig><p>A 4-cm transverse incision was made along the midline of the neck, over the SCM muscle. The EJV that lay superior over the SCM muscle was identified and carefully dissected under the surgical microscope Kinevo 900 (Carl Zeiss Meditec, Oberkochen, Germany) (Fig. <xref rid="F2" ref-type="fig">2</xref>). The SCM muscle was transected in the middle to create a tunnel for the vein graft to pass through. After locating the IJV, it was dissected and retracted. The posterior fascia was resected, and deep lymphatic vessel (LV) and lymph nodes were examined using fluorescence-assisted microscopy. The distance between the LV and the EJV was measured to be about 4&#8201;cm.</p><fig position="float" id="F2" orientation="portrait"><label>Fig. 2.</label><caption><p>A transverse incision is made over the SCM, and the location of the EJV is approximated using ICG lymphography. C, clavicle; T, trapezius.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gox-13-e7082-g002.jpg"/></fig><p>We placed the vein graft superomedially through the SCM muscle. The proximal aspect of the vein graft was anastomosed with the EJV in an end-to-side manner, whereas its distal part connected to deep LVs in an end-to-end anastomosis (Fig. <xref rid="F3" ref-type="fig">3</xref>). This technique was replicated on the contralateral side. No drains were placed in the neck. All incisions were closed directly. The patency was confirmed with intraoperative ICG lymphography. (<xref rid="video1" ref-type="other">See Video [online]</xref>, which demonstrates the routing of the donor graft through the SCM muscle, aiming to enhance the dynamism of our LVA approach.)</p><fig position="float" id="F3" orientation="portrait"><label>Fig. 3.</label><caption><p>End-to-side anastomosis of the proximal part of the vein graft to the EJV and end-to-end anastomosis of the distal aspect of the vein graft to 3 adjacent LVs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gox-13-e7082-g003.jpg"/></fig><p>
<fig id="video1" position="anchor" orientation="portrait"><label>Video 1.</label><caption><title>The video illustrates the process of selecting a donor and dissecting the EJV in our modified LVA technique.</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gox-13-e7082-s001.mp4" mimetype="video" mime-subtype="mp4" position="float" orientation="portrait"><object-id pub-id-type="other" content-type="media-stream-id">GOX.0000000000007082video1.mp4</object-id><object-id pub-id-type="other" content-type="media-source">Kaltura</object-id></media></fig>
</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The principle of lymphatic reconstruction has been established as an effective treatment for lymphedema.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> Following the discovery of the glymphatic drainage system, Lu et al<sup><xref rid="R7" ref-type="bibr">7</xref></sup> were the first to use the LVA technique in managing patients with cognitive impairment. Several studies investigated this hypothesis and found symptomatic improvements in cognitive deficits.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> Commonly used techniques include lymph node-to-vein anastomosis, lymphaticovenous end-to-end anastomosis, and octopus anastomosis.<sup><xref rid="R6" ref-type="bibr">6</xref>&#8211;<xref rid="R8" ref-type="bibr">8</xref></sup> Common complications encountered in LVA are reflux and edema caused by lymphatic fluid congestion. These are caused by differential pressure between the lymphatic and veins, along with diminished capability of the muscular pump, exacerbated by deteriorated smooth muscle due to sclerosis.</p><p>The choice of a small-caliber, superficial calf vein graft diminishes the danger of reflux, resulting from a pressure differential between lymphatic and venous veins. Valves facilitate unidirectional flow into lymphatics, whereas smaller conduit tubes improve dynamic blood flow through the Venturi effect. Second, we selected the EJV over IJV due to its decreased intraluminal pressure and diminished risk of trauma or stress to the underlying deep tissue structures. Third, the presence of tributaries facilitates additional connections for lymphatics, hence enhancing the overall efficacy of LVA, as demonstrated by Yamamoto et al.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> Furthermore, the concept of dynamic LVA presented by Seki et al<sup><xref rid="R10" ref-type="bibr">10</xref></sup> to tackle issues of lymphatic edema leads us to our modification of previous works by Lu et al<sup><xref rid="R7" ref-type="bibr">7</xref></sup> and Li et al.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> As described in the protocol, the vein graft is routed through a slit created in the SCM muscle. The active head movement accentuates the effect of dynamic LVA and further venous backflow.</p><p>The underlying mechanism by which the LVA influences the pathophysiology of AD remains uncertain. The observation presented in this case report is inconclusive and will require longer follow-up and larger sample size to draw any relationship between lymphatic reconstruction and symptomatic improvement of AD. Nonetheless, the clinical findings serve as a foundation for investigating promising surgical intervention for AD.</p></sec><sec sec-type="COI-statement"><title>DISCLOSURE</title><p>The authors have no financial interest to declare in relation to the content of this article.</p></sec><sec sec-type="subjects"><title>PATIENT CONSENT</title><p>Written informed consent was obtained from the patient for the publication of this case report and the use of their images.</p></sec><sec><title>ACKNOWLEDGMENT</title><p>The authors appreciate the team efforts in the management of the patients presented in this case report.</p></sec><sec><title>ETHICAL APPROVAL</title><p>This study received approval from the ethics committee of the Peking University Shenzhen Hospital.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" id="s1" content-type="document" xlink:href="gox-13-e7082-s002.pdf" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><fn-group><fn fn-type="other"><p>Published online 2 October 2025.</p></fn><fn fn-type="financial-disclosure"><p>
<italic toggle="yes">Disclosure statements are at the end of this article, following the correspondence information.</italic>
</p></fn><fn fn-type="other"><p>Related Digital Media are available in the full-text version of the article on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.PRSGlobalOpen.com" ext-link-type="uri">www.PRSGlobalOpen.com</ext-link>.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breijyeh</surname><given-names>Z</given-names></name><name name-style="western"><surname>Karaman</surname><given-names>R</given-names></name></person-group>. <article-title>Comprehensive review on Alzheimer&#8217;s disease: causes and treatment.</article-title><source>Molecules</source>. <year>2020</year>;<volume>25</volume>:<fpage>5789</fpage>.<pub-id pub-id-type="pmid">33302541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules25245789</pub-id><pub-id pub-id-type="pmcid">PMC7764106</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></name><name name-style="western"><surname>Amieva</surname><given-names>H</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name><etal/></person-group>. <article-title>Alzheimer disease.</article-title><source>Nat Rev Dis Primers</source>. <year>2021</year>;<volume>7</volume>:<fpage>1</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">33986301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-021-00269-y</pub-id><pub-id pub-id-type="pmcid">PMC8574196</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Andrews</surname><given-names>JS</given-names></name><name name-style="western"><surname>Beach</surname><given-names>TG</given-names></name><etal/></person-group>. <article-title>Revised criteria for diagnosis and staging of Alzheimer&#8217;s disease: Alzheimer&#8217;s Association Workgroup.</article-title><source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>:<fpage>5143</fpage>&#8211;<lpage>5169</lpage>.<pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasmussen</surname><given-names>MK</given-names></name><name name-style="western"><surname>Mestre</surname><given-names>H</given-names></name><name name-style="western"><surname>Nedergaard</surname><given-names>M</given-names></name></person-group>. <article-title>The glymphatic pathway in neurological disorders.</article-title><source>Lancet Neurol</source>. <year>2018</year>;<volume>17</volume>:<fpage>1016</fpage>&#8211;<lpage>1024</lpage>.<pub-id pub-id-type="pmid">30353860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(18)30318-1</pub-id><pub-id pub-id-type="pmcid">PMC6261373</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>JP</given-names></name><name name-style="western"><surname>Chen</surname><given-names>WF</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>DH</given-names></name><etal/></person-group>. <article-title>A proposed role for lymphatic supermicrosurgery in the management of Alzheimer&#8217;s disease: a primer for reconstructive microsurgeons.</article-title><source>Arch Plast Surg</source>. <year>2025</year>;<volume>52</volume>:<fpage>96</fpage>&#8211;<lpage>103</lpage>.<pub-id pub-id-type="pmid">40083619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-2513-4313</pub-id><pub-id pub-id-type="pmcid">PMC11896717</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scaglioni</surname><given-names>MF</given-names></name><name name-style="western"><surname>Fontein</surname><given-names>DB</given-names></name><name name-style="western"><surname>Arvanitakis</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Systematic review of lymphovenous anastomosis (LVA) for the treatment of lymphedema.</article-title><source>Microsurgery</source>. <year>2017</year>;<volume>37</volume>:<fpage>947</fpage>&#8211;<lpage>953</lpage>.<pub-id pub-id-type="pmid">28972280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/micr.30246</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Q</given-names></name></person-group>. <article-title>Preliminary observation of deep cervical lymphatic-venous anastomosis under off-eyepiece 3D microscope to treat an elderly patient with cognitive impairment.</article-title><source>Chin J Microsurg</source>. <year>2002</year>;<volume>45</volume>:<fpage>570</fpage>&#8211;<lpage>574</lpage>.</mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Promising outcomes 5 weeks after a surgical cervical shunting procedure to unclog cerebral lymphatic systems in a patient with Alzheimer&#8217;s disease.</article-title><source>Gen Psychiatr</source>. <year>2024</year>;<volume>37</volume>:<fpage>e101641</fpage>.<pub-id pub-id-type="pmid">39816183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gpsych-2024-101641</pub-id><pub-id pub-id-type="pmcid">PMC11733982</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Yoshimatsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Multi-site lymphaticovenular anastomosis using vein graft for uterine cancer-related lymphedema after pelvic lymphadenectomy.</article-title><source>Vasc Endovascular Surg</source>. <year>2015</year>;<volume>49</volume>:<fpage>195</fpage>&#8211;<lpage>200</lpage>.<pub-id pub-id-type="pmid">26516190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1538574415614402</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kajikawa</surname><given-names>A</given-names></name><name name-style="western"><surname>Asai</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Functional lymphaticovenular anastomosis for peripheral lymphedema: incision selection methods with muscle pumping.</article-title><source>Plast Aesthet Res</source>. <year>2021</year>;<volume>8</volume>:<fpage>58</fpage>.</mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-id journal-id-type="pmc-domain-id">943</journal-id><journal-id journal-id-type="pmc-domain">alzreth</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12492680</article-id><article-id pub-id-type="pmcid-ver">PMC12492680.1</article-id><article-id pub-id-type="pmcaid">12492680</article-id><article-id pub-id-type="pmcaiid">12492680</article-id><article-id pub-id-type="pmid">41039627</article-id><article-id pub-id-type="doi">10.1186/s13195-025-01847-y</article-id><article-id pub-id-type="publisher-id">1847</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Usability and feasibility of ADappt: a digital toolkit to support communication on diagnosis and prognosis in memory clinics</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hendriksen</surname><given-names initials="HMA">Heleen M.A.</given-names></name><address><email>h.hendriksen@amsterdamumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>de Rijke</surname><given-names initials="TJ">Tanja J.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Gils</surname><given-names initials="AM">Aniek M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>de Beer</surname><given-names initials="MH">Marlijn H.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bouwman</surname><given-names initials="FH">Femke H.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Diaz</surname><given-names initials="A">Ana</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fluitman</surname><given-names initials="T">Tjeerd</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hempenius</surname><given-names initials="L">Liesbeth</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Maurik</surname><given-names initials="IS">Ingrid S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pel-Littel</surname><given-names initials="RE">Ruth E.</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rhodius-Meester</surname><given-names initials="HFM">Hanneke F.M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Roks</surname><given-names initials="G">Gerwin</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Smets</surname><given-names initials="EMA">Ellen M.A.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van der Flier</surname><given-names initials="WM">Wiesje M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Visser</surname><given-names initials="LNC">Leonie N.C.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff15">15</xref><xref ref-type="aff" rid="Aff16">16</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00q6h8f30</institution-id><institution-id institution-id-type="GRID">grid.16872.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0435 165X</institution-id><institution>Alzheimer Center Amsterdam, Neurology, </institution><institution>Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, </institution></institution-wrap>Amsterdam, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01x2d9f70</institution-id><institution-id institution-id-type="GRID">grid.484519.5</institution-id><institution>Amsterdam Neuroscience, </institution></institution-wrap>Neurodegeneration, Amsterdam, The Netherlands </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04dkp9463</institution-id><institution-id institution-id-type="GRID">grid.7177.6</institution-id><institution-id institution-id-type="ISNI">0000000084992262</institution-id><institution>Medical Psychology, </institution><institution>Amsterdam UMC location University of Amsterdam, </institution></institution-wrap>Amsterdam, The Netherlands </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0258apj61</institution-id><institution-id institution-id-type="GRID">grid.466632.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0686 3219</institution-id><institution>Quality of Care, Personalized Medicine, </institution><institution>Amsterdam Public Health, </institution></institution-wrap>Amsterdam, The Netherlands </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wkhef66</institution-id><institution-id institution-id-type="GRID">grid.415868.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0624 5690</institution-id><institution>Department of Neurology, </institution><institution>Reinier de Graaf Gasthuis, </institution></institution-wrap>Delft, The Netherlands </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/029yy6d70</institution-id><institution-id institution-id-type="GRID">grid.424021.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0739 010X</institution-id><institution>Alzheimer Europe, </institution></institution-wrap>Luxembourg, Luxembourg </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0283nw634</institution-id><institution-id institution-id-type="GRID">grid.414846.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0419 3743</institution-id><institution>Geriatric Center, </institution><institution>Medical Center Leeuwarden, </institution></institution-wrap>Leeuwarden, The Netherlands </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/008xxew50</institution-id><institution-id institution-id-type="GRID">grid.12380.38</institution-id><institution-id institution-id-type="ISNI">0000 0004 1754 9227</institution-id><institution>Department of Epidemiology and Data Science, </institution><institution>Vrije Universiteit Amsterdam, Amsterdam UMC, </institution></institution-wrap>Amsterdam, The Netherlands </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0258apj61</institution-id><institution-id institution-id-type="GRID">grid.466632.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0686 3219</institution-id><institution>Amsterdam Public Health, </institution></institution-wrap>Methodology, Amsterdam, The Netherlands </aff><aff id="Aff10"><label>10</label>Northwest Academy, Northwest Clinics Alkmaar, Alkmaar, The Netherlands </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00c8emq34</institution-id><institution-id institution-id-type="GRID">grid.438099.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0622 0223</institution-id><institution>Vilans Center of Expertise for Long Term Care, </institution></institution-wrap>Utrecht, The Netherlands </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00q6h8f30</institution-id><institution-id institution-id-type="GRID">grid.16872.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0435 165X</institution-id><institution>Internal Medicine, Geriatric Medicine Section, </institution><institution>Amsterdam Cardiovascular Sciences Institute, Amsterdam UMC location VUmc, </institution></institution-wrap>Amsterdam, The Netherlands </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00j9c2840</institution-id><institution-id institution-id-type="GRID">grid.55325.34</institution-id><institution-id institution-id-type="ISNI">0000 0004 0389 8485</institution-id><institution>Department of Geriatric Medicine, The Memory Clinic, </institution><institution>Oslo University Hospital, </institution></institution-wrap>Oslo, Norway </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04gpfvy81</institution-id><institution-id institution-id-type="GRID">grid.416373.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0472 8381</institution-id><institution>Department of Neurology, </institution><institution>ETZ Hospital, </institution></institution-wrap>Tilburg, The Netherlands </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/056d84691</institution-id><institution-id institution-id-type="GRID">grid.4714.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0626</institution-id><institution>Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, </institution><institution>Karolinska Institutet, </institution></institution-wrap>Stockholm, Sweden </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0575yy874</institution-id><institution-id institution-id-type="GRID">grid.7692.a</institution-id><institution-id institution-id-type="ISNI">0000000090126352</institution-id><institution>Department of Bioethics and Health Humanities, Julius Center for Health Sciences and Primary Care, </institution><institution>University Medical Center Utrecht, Utrecht University, </institution></institution-wrap>Utrecht, the Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">478170</issue-id><elocation-id>218</elocation-id><history><date date-type="received"><day>18</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-04 10:26:05.627"><day>04</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13195_2025_Article_1847.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">ADappt is a digital toolkit for both memory clinic professionals and patients to support communication on diagnosis and prognosis in memory clinics. We aimed to evaluate ADappt&#8217;s usability and feasibility in clinical practice.</p></sec><sec><title>Methods</title><p id="Par2">In this mixed-methods study, we first assessed usability via think-aloud sessions with ten memory clinic professionals from eight memory clinics, six patients, and one care partner. Think-aloud comments were deductively categorized into: content, navigation, and design. Second, we conducted a feasibility study in four memory clinics. Eight memory clinic professionals recruited 21 patients and 21 care partners. Professionals were instructed to integrate the ADappt-toolkit in their routine. Before their visit, patients received information about the ADappt-patient tools: two video-animations and a question prompt list (QPL). Participants completed questionnaires on usability, satisfaction, and feasibility either after the first consultation (<italic toggle="yes">n</italic>&#8201;=&#8201;14 patients; <italic toggle="yes">n</italic>&#8201;=&#8201;15 care partners), after the disclosure consultation (<italic toggle="yes">n</italic>&#8201;=&#8201;4 patients; <italic toggle="yes">n</italic>&#8201;=&#8201;5 care partners), or after both consultations (<italic toggle="yes">n</italic>&#8201;=&#8201;3 patients; <italic toggle="yes">n</italic>&#8201;=&#8201;1 care partner). Interviews with professionals were conducted and analyzed using thematic content analysis. Third, together with Alzheimer Europe, we co-organized a patient and public involvement (PPI) session with citizens, patients, and care partners to further improve the patient tools.</p></sec><sec><title>Results</title><p id="Par3">Professionals found ADappt relevant, easy-to-navigate, and visually appealing. Most think-aloud comments focused on content and navigation, especially regarding the risk calculation tool. Patients indicated the patient tools to be helpful in preparing for consultations. After use in practice, professionals reported acceptable usability (68&#8201;&#177;&#8201;14, scale 0-100) and satisfaction (71&#8201;&#177;&#8201;10, scale 0-100) with ADappt. Professionals most often used the tool that provides an overview of diagnostic tests with pros and cons (in 15/24(63%) consultations), which they also deemed most helpful (median(IQR): 4(3.75-4), scale 1&#8211;5). About half to two-thirds of patients and care partners reported to have received the patient tools (video-animations: <italic toggle="yes">n</italic>&#8201;=&#8201;23/46(50%)); QPL: <italic toggle="yes">n</italic>&#8201;=&#8201;30/46(65%)), of whom a majority used (video-animations: <italic toggle="yes">n</italic>&#8201;=&#8201;16/23(70%)); QPL: <italic toggle="yes">n</italic>&#8201;=&#8201;21/30(70%)) and would recommend them (video-animations: <italic toggle="yes">n</italic>&#8201;=&#8201;15/16(94%); QPL: <italic toggle="yes">n</italic>&#8201;=&#8201;20/21(95%)). The tools helped to express themselves more effectively. The PPI session highlighted the importance of widespread dissemination of the patient tools and through multiple channels.</p></sec><sec><title>Conclusions</title><p id="Par4">Our study demonstrates the potential of digital tools to improve medical communication in memory clinics. Taking feedback into account, ADappt is further improved and steps towards implementation are being taken.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13195-025-01847-y.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#8217;s disease</kwd><kwd>Dementia</kwd><kwd>Mild cognitive impairment</kwd><kwd>Clinician-patient communication</kwd><kwd>Diagnosis</kwd><kwd>Prognosis</kwd><kwd>Shared decision-making</kwd><kwd>Biomarkers</kwd><kwd>Personalized medicine</kwd><kwd>Usability</kwd><kwd>Feasibility</kwd><kwd>Implementation</kwd><kwd>Digital tool</kwd><kwd>Memory clinic</kwd><kwd>Patient and public involvement</kwd></kwd-group><funding-group><award-group><funding-source><institution>Horizon Europe IHI project</institution></funding-source><award-id>#101112145</award-id><award-id>#101112145</award-id><principal-award-recipient><name name-style="western"><surname>Rhodius-Meester</surname><given-names>Hanneke F.M.</given-names></name><name name-style="western"><surname>van der Flier</surname><given-names>Wiesje M.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001826</institution-id><institution>ZonMw</institution></institution-wrap></funding-source><award-id>#73305095007</award-id><award-id>#73305095007</award-id><award-id>#73305095007</award-id><principal-award-recipient><name name-style="western"><surname>Smets</surname><given-names>Ellen M.A.</given-names></name><name name-style="western"><surname>van der Flier</surname><given-names>Wiesje M.</given-names></name><name name-style="western"><surname>Visser</surname><given-names>Leonie N.C.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Health~Holland, Topsector Life Sciences &amp; Health</institution></funding-source><award-id>#LSHM20106</award-id><award-id>#LSHM20106</award-id><award-id>#LSHM20106</award-id><principal-award-recipient><name name-style="western"><surname>Smets</surname><given-names>Ellen M.A.</given-names></name><name name-style="western"><surname>van der Flier</surname><given-names>Wiesje M.</given-names></name><name name-style="western"><surname>Visser</surname><given-names>Leonie N.C.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100013278</institution-id><institution>EU Joint Programme &#8211; Neurodegenerative Disease Research</institution></institution-wrap></funding-source><award-id>#10510062210005</award-id><principal-award-recipient><name name-style="western"><surname>van der Flier</surname><given-names>Wiesje M.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Innovative Health Initiative Joint Undertaking</institution></funding-source><award-id>101132933</award-id><principal-award-recipient><name name-style="western"><surname>van der Flier</surname><given-names>Wiesje M.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">Over the past decades, rapid advancements have been made in the diagnosis of dementia, in particular Alzheimer&#8217;s disease (AD) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The introduction of new diagnostic tests requires memory clinic professionals to adapt their current practice: larger amounts of information have to be shared, novel decisions need to be made, and more results have to be discussed with patients and care partners. This includes complex, prognostic information. Depending on patients&#8217; information needs, situation, preferences, ability to cope with uncertainty and personal experience with dementia, individual patients have different expectations and goals for the diagnostic trajectory [<xref ref-type="bibr" rid="CR3">3</xref>]. Effective clinician-patient communication is key for tailoring information and the diagnostic trajectory to the individual patient [<xref ref-type="bibr" rid="CR4">4</xref>]. This entails a two-way exchange on needs and expectations, the provision of comprehensible information on diagnostic tests with room for shared decision-making, and prognostic communication attuned to the individual [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. In a recent European survey study, memory clinic professionals reported a need for support in effective clinician-patient communication, such as through skills training or online tools, and many patients and care partners responded favorably regarding the possibility of using (online) communication tools [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. </p><p id="Par6">To provide such support throughout the diagnostic trajectory, we previously developed a web-based toolkit called &#8216;ADappt&#8217; (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ADappt.health">www.ADappt.health</ext-link>) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>]. ADappt initially comprised tools facilitating memory clinic professionals in shared decision-making and understandable information provision on (pros and cons of) diagnostic test options, and interpretation and communication of diagnostic test results of patients with Mild Cognitive Impairment (MCI) in terms of dementia risk (see Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). ADappt was developed in an iterative process of co-creation and evaluated positively in a first small pilot study [<xref ref-type="bibr" rid="CR9">9</xref>]. Since then, lay-out, available languages, and the prediction model underlying the dementia risk tool have been updated. Furthermore, a topic list, containing an overview of topics deemed relevant by both professionals and patients to discuss during consultations, has been added [<xref ref-type="bibr" rid="CR12">12</xref>]. Based on this topic list, tools for patients and care partners were developed and added, i.e., two video-animations (&#8220;the first appointment&#8221; + &#8220;diagnostic test results appointment&#8221;) and an accompanying question prompt list, to aid patients to prepare for memory clinic consultations (see Supplementary Information, Additional file <xref rid="MOESM1" ref-type="media">1</xref>) [<xref ref-type="bibr" rid="CR12">12</xref>]. Additionally, an informative video-animation for patients and care partners on the lumbar puncture procedure was added to the overview of diagnostic tests [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. </p><p id="Par7">Building on our iterative development process, the next step involved a three-phase evaluation of ADappt with memory clinic professionals, patients, and care partners. Testing with relevant stakeholders is important to ensure that ADappt meets the needs and expectations of its end-users, aligns with clinical workflows, and addresses potential barriers to adoption [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. The aim of this study was to evaluate ADappt&#8217;s usability and feasibility in clinical practice.</p><p id="Par8">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Screenshots of the tools available on ADappt.health [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. From top left to bottom right: <bold>(a)</bold>&#160;<italic toggle="yes">Conversation guide to SDM.</italic> This tool outlines the four steps of shared-decision making: (1) creating choice awareness, (2) providing information, (3) exploring preferences, and (4) decision-making. The guide includes example phrases for each step; <bold>(b)</bold>&#160;<italic toggle="yes">Diagnostic tests.</italic> This tool provides an description of what can be learned from the available diagnostic tests in the memory clinic. For each test, it explains why it is administered, what it entails, and outlines the pros and cons. The text is written in patient-friendly language, allowing professionals to easily convey this information to patients; <bold>(c)</bold>&#160;<italic toggle="yes">Risk calculation tool.</italic> This tool estimates the risk that a patient who presents at the memory clinic with MCI will develop dementia within one, three and five years. The tool includes a patient result page; <bold>(d)</bold>&#160;<italic toggle="yes">Topic list</italic>. This tool provides an overview of important topics to discuss during consultations with patients and care partners throughout the diagnostic trajectory. In addition, this tool contains two video-animations (&#8220;the first appointment&#8221; + &#8220;diagnostic test results appointment&#8221;) and an accompanying question prompt list to aid patients to prepare for memory clinic consultations. <italic toggle="yes">Note</italic>: All ADappt tools are publicly accessible, except for the risk calculation tool, which requires a log-in. This log-in must be requested from the research team via the ADappt.health website</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e616" position="float" orientation="portrait" xlink:href="13195_2025_1847_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par9">This study is part of the ABOARD-project (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.aboard-project.nl">www.aboard-project.nl</ext-link>), which aims to prepare for a future with personalized medicine for AD. ABOARD includes tasks on diagnosis, prediction, prevention, and patient orchestrated care, and this study is part of the latter. We used a mixed-methods design, combining (i) think-aloud sessions to gain in-depth understanding of the thoughts and observations of users whilst interacting with ADappt in a controlled setting [<xref ref-type="bibr" rid="CR19">19</xref>] and (ii) a feasibility study to obtain insight on the use and facilitators and barriers for implementation in clinical practice [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. In addition, (iii) we co-organized a patient and public involvement (PPI) session with Alzheimer Europe, during which members of the public, both with and without objective cognitive impairment, provided their thoughts on implementation of the patient tools in clinical practice. The local medical ethics committee of Amsterdam UMC, location VUmc and of the participating hospitals approved the study. The research was conducted in accordance with the Declaration of Helsinki. All research participants provided informed consent.</p></sec><sec id="Sec4"><title>Think-aloud sessions</title><sec id="Sec5"><title>Participants</title><p id="Par10">We invited memory clinic professionals to participate via the Dutch memory clinic network. Patients and care partners were recruited at Alzheimer Center Amsterdam, from the Amsterdam Dementia Cohort (ADC) [<xref ref-type="bibr" rid="CR22">22</xref>]. Patients and care partners had to be aged&#8201;&gt;&#8201;18, proficient in Dutch, and able to provide informed consent.</p></sec><sec id="Sec6"><title>Study procedures</title><p id="Par11">We combined the think-aloud sessions with semi-structured interviews [<xref ref-type="bibr" rid="CR19">19</xref>]. Participants were asked to use ADappt by means of a fictional patient case (see Supplementary Information, Additional file <xref rid="MOESM1" ref-type="media">2</xref>, Textbox <xref rid="MOESM1" ref-type="media">1</xref> and <xref rid="MOESM1" ref-type="media">2</xref>). For professionals, the task involved preparing the fictional patient&#8217;s first consultation and the disclosure consultation, engaging with the tools that they deemed relevant (see Supplementary Information, Additional file <xref rid="MOESM1" ref-type="media">2</xref>, Textbox <xref rid="MOESM1" ref-type="media">1</xref> and Additional file <xref rid="MOESM3" ref-type="media">3</xref>). For patients and care partners, the task included preparing for the first and the disclosure consultation, while imagining themselves as the patient in the fictional case. They were instructed to watch the animations, use the question prompt list, and provide comments on the fictional patient&#8217;s result page (see Supplementary Information, Additional file <xref rid="MOESM1" ref-type="media">2</xref>, Textbox <xref rid="MOESM1" ref-type="media">2</xref>). All participants were asked to verbalize their thoughts and observations while using ADappt. Following the think-aloud session, a semi-structured interview was conducted with each participant to reflect and elaborate on their experiences, and to gather additional information based on the researcher&#8217;s observations (see Supplementary Information, Additional file <xref rid="MOESM1" ref-type="media">2</xref>, Textbox <xref rid="MOESM1" ref-type="media">3</xref>) [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Sessions lasted approximately 30 to 60&#160;min. Due to COVID restrictions at the time, all but one of the sessions took place via video-conferencing. When applicable, patients and care partners were reimbursed for travel expenses. Sessions were conducted either one-on-one (HH (psychologist) with professional/patient) or one-on-two (HH with patient&#8201;+&#8201;care partner).</p></sec></sec><sec id="Sec7"><title>Feasibility study in memory clinic practice</title><sec id="Sec8"><title>Participants</title><p id="Par12">We conducted a multicenter study in four Dutch memory clinics (Reinier de Graaf Ziekenhuis, Elisabeth Tweesteden Ziekenhuis, Medisch Centrum Leeuwarden, and Amsterdam University Medical Center (UMC)). Professionals were included if they were involved in the diagnostic work-up of dementia. Professionals were instructed to invite all patients who were scheduled for an appointment during a specified timeframe for participation (4 weeks to 8 weeks, depending on the set-up and the number of new patients seen at the clinic). The appointment could be the first consultation at the clinic or the test result disclosure consultation, or both. At their scheduled visit, patients and their accompanying care partners were invited by the professional for to participate in the study and provide informed consent. Patients and care partners had to be aged&#8201;&gt;&#8201;18, proficient in Dutch, and able to provide informed consent.</p></sec><sec id="Sec9"><title>Study procedures</title><p id="Par13">Memory clinic professionals were asked to integrate ADappt in their daily routine, when preparing for, or during either first or disclosure consultations. The diagnostic work-up was performed according to local practice. HH and TR provided an on-site training on how to use ADappt. For this, we developed a practice guide in the form of a clickable PDF comprising a: (1) factsheet, (2) workflow, and (3) slide-deck (see Supplementary Information, Additional files <xref rid="MOESM4" ref-type="media">4</xref>&#8211;<xref rid="MOESM7" ref-type="media">7</xref>). Patients and their care partners were invited for the study by their memory clinic prior to their visit, by means of an information letter and an additional brochure, which included detailed instructions on how to access the video-animations and the question prompt list online (see Supplementary Information, Additional file <xref rid="MOESM8" ref-type="media">8</xref>). Additionally, a printed version of the question prompt list was provided (see Supplementary Information, Additional file <xref rid="MOESM1" ref-type="media">1</xref>).</p></sec><sec id="Sec10"><title>Measures</title><p id="Par14">Memory clinic professionals completed a short questionnaire (satisfaction, feasibility) after each consultation with a participating patient, and a more detailed questionnaire at both the beginning (sociodemographics, professional characteristics, memory clinic characteristics) and the end of the study period (usability). Usability was assessed using the System Usability Scale (SUS), a 10-item standardized questionnaire with 5-point Likert scale responses (1&#8201;=&#8201;Strongly disagree, 5&#8201;=&#8201;Strongly agree) [<xref ref-type="bibr" rid="CR25">25</xref>]. In addition, professionals rated the usefulness of each ADappt tool, and indicated whether they would like to use the tool in daily practice, whether they could easily integrate it, and whether they encountered any issues in using ADappt, such as technical problems. Participating patients and care partners received a questionnaire (usability, satisfaction, feasibility) after their consultation, which they could return by post or digitally. Satisfaction was assessed using the Patient Satisfaction Questionnaire (PSQ &#8211; Dutch version; 5 items, 0&#8201;=&#8201;Not at all, 100&#8201;=&#8201;Very much) [<xref ref-type="bibr" rid="CR26">26</xref>]. In addition, participants reported their opinions on ADappt using study-specific items. These assessed their awareness and use of the patient tools, the extent to which the tools helped them prepare for the consultation (4-point Likert scale, 1&#8201;=&#8201;Not at all, 2&#8201;=&#8201;A little, 3&#8201;=&#8201;Quite a bit, 4&#8201;=&#8201;Very much), and whether they would recommend the tools to other patients (yes/no, with open-ended explanation). After the study period, we conducted semi-structured interviews via phone or video conferencing with professionals about their experiences and ADappt&#8217;s usability and feasibility. For a detailed description of the questionnaires and interview guide, see Supplementary Information, Additional file <xref rid="MOESM1" ref-type="media">2</xref>, Table&#160;<xref rid="Tab1" ref-type="table">1</xref> and Textbox <xref rid="MOESM1" ref-type="media">4</xref>.</p></sec></sec><sec id="Sec11"><title>PPI session</title><sec id="Sec12"><title>Participants</title><p id="Par15">Together with Alzheimer Europe, we co-organized an international patient and public involvement (PPI) session with 18 members of the Advisory Boards of the EU-Fingers (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.eufingers.com">www.eufingers.com</ext-link>), LETHE (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.lethe-project.eu">www.lethe-project.eu</ext-link>), and Multi-MeMo (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.multi-memo.eu">www.multi-memo.eu</ext-link>) consortium projects to identify ways to foster implementation of the patient tools (video-animations and question prompt list) in clinical practice. The Advisory Boards include patients, care partners, and individuals interested in brain health from nine different European countries.</p></sec><sec id="Sec13"><title>Study procedures</title><p id="Par16">We held discussions at four small tables, each with 4&#8211;5 members and two facilitators (one main facilitator and one co-facilitator), focusing on when, from whom (e.g., general practitioners or memory clinics), and how (e.g., digital or postal) patients would prefer to receive these tools. Participants watched the video-animations together and were offered a printed question prompt list. The main facilitators (HH, LV, TR, AD) wrote down opinions, and HH summarized the results.</p></sec></sec><sec id="Sec14"><title>Data analysis</title><p id="Par17">Think-aloud sessions were transcribed and deductively analyzed according to the code tree in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>, using MAXQDA2020 [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. We determined whether a comment was (1) generic or related to a specific ADappt-tool, (2) related to content (comments related to information content, e.g., problems with understanding the information, incomplete information, or inaccurate information), navigation (comments related to finding the required information on the website, e.g., a poorly organized home page, unclear link labels, and problems with the structure), or design (comments related to the functionality of the design, e.g., an illegible font, or an unclear lay out), and (3) positive or critical [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. The interviews of the feasibility study and the open-ended questions from the questionnaires were jointly analyzed with thematic content analysis [<xref ref-type="bibr" rid="CR29">29</xref>]. From participants&#8217; critical feedback, we derived suggestions for improvement. Coding was done independently and hereafter discussed until consensus was reached by HH (psychologist), AG (medical doctor), and TF (health scientist), all trained in qualitative analysis. We used descriptive statistics to report characteristics and survey responses using SPSS-statistics software version 28.</p><p id="Par18">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Deductive code tree</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e785" position="float" orientation="portrait" xlink:href="13195_2025_1847_Fig2_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec15"><title>Results</title><p id="Par19">Professionals, patients, and care partners&#8217; characteristics are shown in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. Ten professionals from eight memory clinics (11&#8201;&#177;&#8201;6yrs experience), six patients, and one care partner participated in the think-aloud sessions. Patients were on average 68&#8201;&#177;&#8201;8yrs years old and 33% was female. Eight professionals (12&#8201;&#177;&#8201;7yrs experience), 21 patients and 21 care partners participated in the feasibility study. Patients and care partners were on average 69&#8201;&#177;&#8201;8 and 60&#8201;&#177;&#8201;15 years old, respectively. Most patients were male (81%). There was no overlap in professionals participating in the think-aloud sessions and in the feasibility study.</p><p id="Par20">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Sample characteristics for think-aloud sessions and feasibility study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Think-aloud</th><th align="left" colspan="2" rowspan="1">Feasibility study</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>Professionals</bold>
</td><td align="left" colspan="1" rowspan="1"><bold><italic toggle="yes">N</italic></bold>&#8201;=&#8201;<bold>10</bold></td><td align="left" colspan="2" rowspan="1"><bold><italic toggle="yes">N</italic></bold>&#8201;=&#8201;<bold>8</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1">44&#8201;&#177;&#8201;6</td><td align="left" colspan="2" rowspan="1">43&#8201;&#177;&#8201;11</td></tr><tr><td align="left" colspan="1" rowspan="1">Female, n (%)</td><td align="left" colspan="1" rowspan="1">10 (100%)</td><td align="left" colspan="2" rowspan="1">7 (88%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Years of clinical experience</td><td align="left" colspan="1" rowspan="1">11&#8201;&#177;&#8201;6</td><td align="left" colspan="2" rowspan="1">12&#8201;&#177;&#8201;7</td></tr><tr><td align="left" colspan="1" rowspan="1">Profession, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Medical specialist</td><td align="left" colspan="1" rowspan="1">9 (90%)</td><td align="left" colspan="2" rowspan="1">4 (50%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Physician, without or currently in specialist training</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="2" rowspan="1">2 (25%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Specialized nurse</td><td align="left" colspan="1" rowspan="1">1 (10%)</td><td align="left" colspan="2" rowspan="1">2 (25%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Medical specialty, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Neurology</td><td align="left" colspan="1" rowspan="1">3 (30%)</td><td align="left" colspan="2" rowspan="1">5 (63%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Internal/Geriatric medicine</td><td align="left" colspan="1" rowspan="1">7 (70%)</td><td align="left" colspan="2" rowspan="1">3 (38%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Patients and care partners</bold>
</td><td align="left" colspan="1" rowspan="1"><bold><italic toggle="yes">N</italic></bold>&#8201;=&#8201;<bold>6 patients</bold></td><td align="left" colspan="1" rowspan="1"><bold><italic toggle="yes">N</italic></bold>&#8201;=&#8201;<bold>21 patients</bold></td><td align="left" colspan="1" rowspan="1"><bold><italic toggle="yes">N</italic></bold>&#8201;=&#8201;<bold>21 care partners</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1">68&#8201;&#177;&#8201;8yrs</td><td align="left" colspan="1" rowspan="1">69&#8201;&#177;&#8201;8yrs</td><td align="left" colspan="1" rowspan="1">60&#8201;&#177;&#8201;15yrs</td></tr><tr><td align="left" colspan="1" rowspan="1">Female, n (%)</td><td align="left" colspan="1" rowspan="1">2 (33%)</td><td align="left" colspan="1" rowspan="1">4 (19%)</td><td align="left" colspan="1" rowspan="1">17 (81%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Education, median (IQR)</td><td align="left" colspan="1" rowspan="1">6 (6&#8211;6)</td><td align="left" colspan="1" rowspan="1">5 (5&#8211;6)</td><td align="left" colspan="1" rowspan="1">5 (5&#8211;6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Information need (scale 1&#8211;10)</td><td align="left" colspan="1" rowspan="1">N/a</td><td align="left" colspan="1" rowspan="1">8.4&#8201;&#177;&#8201;1.4</td><td align="left" colspan="1" rowspan="1">8.9&#8201;&#177;&#8201;1.2</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Type of consultation</italic>
</td><td align="left" colspan="1" rowspan="1">N/a</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;First consultation</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">14 (67%)</td><td align="left" colspan="1" rowspan="1">15 (71%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Disclosure consultation</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">4 (19%)</td><td align="left" colspan="1" rowspan="1">5 (24%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Both</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">3 (14%)</td><td align="left" colspan="1" rowspan="1">1 (5%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Diagnosis</td><td align="left" colspan="1" rowspan="1">5 SCD, 1 AD dementia</td><td align="left" colspan="2" rowspan="1">2 SCD, 4 MCI, 1 AD dementia, 14 unknown</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean&#8201;&#177;&#8201;SD, n (%), or median (IQR). Education is rated using the Dutch Verhage system, ranging from 1-7 [<xref ref-type="bibr" rid="CR30">30</xref>]. <italic toggle="yes">Abbreviations</italic>: SCD: Subjective Cognitive Decline, MCI: Mild Cognitive Impairment, AD: Alzheimer&#8217;s disease</p></table-wrap-foot></table-wrap>
</p><p id="Par21">In the next sections, we first focus on the professionals perspectives as derived from the think-aloud and feasibility study, and subsequently on the patient and care partner perspectives.</p><sec id="Sec16"><title>Professionals</title><sec id="Sec17"><title>Think-aloud sessions</title><p id="Par22">Regarding the <italic toggle="yes">content</italic>, professionals were generally satisfied with the information provided through ADappt and recognized its potential benefit for memory clinic practice. They thought ADappt could serve well as a training or a reference for junior doctors with less experience with regards to communication and interpretation of test results. Suggestions for improvement with regard to the content were mostly related to the dementia risk calculation tool: Some professionals indicated to use the Montreal Cognitive Assessment (MoCA), whereas the tool assumes that the Mini-Mental State Examination (MMSE) is available. In addition, some professionals were not aware of the cut-offs for certain biomarkers, e.g., amyloid; they would like the tool to provide this information. With regard to <italic toggle="yes">navigation</italic>, professionals considered ADappt to be easily accessible with an intuitive flow from one page to another. Suggestions for improvement regarding navigation mostly concerned the dementia risk calculation tool: professionals were disappointed that data entered in this tool was not saved after leaving the page. In addition, not all professionals succeeded in entering the amyloid-PET result of the hypothetical patient case in the tool. Regarding <italic toggle="yes">design</italic>, professionals described ADappt as an easy-to-read toolbox with appealing visuals. No suggestions for improvement were made. Positive and critical comments on specific ADappt-tools can be found in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>.</p></sec><sec id="Sec18"><title>Feasibility study in memory clinic practice</title><p id="Par23">Professionals reported to use ADappt in 16 out of 24 (67%) consultations. The most frequently used tool was the overview of diagnostic tests with pros and cons (15/24, 63%), which was also rated as the most helpful (median(IQR): 4(3.75-4), scale 1&#8211;5). Other tools were considered useful but were used less frequently, including the conversation guide to shared decision-making (9/24, 38%; 4(3&#8211;4)), the topic list (5/24, 21%; 4(3&#8211;4)), and the risk calculation tool, which is only applicable in patients with a diagnosis of MCI (1/24, 4%; 4(3&#8211;4)). Overall, reported satisfaction with ADappt after each consultation was high, with a mean score of 71&#8201;&#177;&#8201;10 (range 50&#8211;85, scale 0&#8211;100).</p><p id="Par24">Professionals reported usability ranging from OK to good for ADappt (68&#8201;&#177;&#8201;14, range 50&#8211;83, System Usability Scale [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], scale 0-100). They were more positive than negative about wanting to use ADappt in daily practice (median(IQR): 3.5(3&#8211;4), scale 1&#8211;5) and about how easily ADappt could be integrated in their routine (3.5(2.75-4), scale 1&#8211;5). Technical issues were rarely reported (1(1-1.25)), as were problems with interpreting results (1(1-1.25)), communication with patient (1(1-2.25)) or with the use of ADappt (1.5(1&#8211;2)).</p><p id="Par25">Interviews provided further insights into the barriers and facilitators for using ADappt and its tools. Identified barriers include first, the limited time available during consultations with too many tasks to fit in. Second, establishing a routine and becoming familiar with ADappt was considered challenging when a low number of patients was seen per week. Third, professionals deemed not all patients suitable for the tool: certain patient characteristics, such as low digital literacy, emotional burden, or difficulty making decisions, posed challenges. Low digital literacy was often attributed to older patients, leading professionals to feel that ADappt was more suitable for younger patients.</p><p id="Par26">
<list list-type="bullet"><list-item><p id="Par27"><italic toggle="yes">&#8220;Sometimes it can also be challenging for the patient</italic>,<italic toggle="yes"> because making choices is difficult. So that makes it a bit tricky when you want to engage in shared decision-making. Some patients find it very difficult</italic>,<italic toggle="yes"> while others really want to have that choice.&#8221; (interview feasibility study</italic>,<italic toggle="yes"> clinician 4)</italic></p></list-item><list-item><p id="Par28"><italic toggle="yes">&#8220;That was a younger person</italic>,<italic toggle="yes"> and they also had a son with them who could just understand it all a bit better</italic>,<italic toggle="yes"> so to speak. I think something like that isn&#8217;t really suitable for an 85-year-old with little interest in ICT</italic>,<italic toggle="yes"> to put it bluntly. But certainly for the somewhat younger people</italic>,<italic toggle="yes"> right? People come to us at a relatively young age</italic>,<italic toggle="yes"> so it can definitely be of added value</italic>,<italic toggle="yes"> yes&#8221;</italic> (<italic toggle="yes">interview feasibility study</italic>,<italic toggle="yes"> clinician 5</italic>)</p></list-item></list>
</p><p id="Par29">Professionals identified several facilitators for implementing ADappt. Regularly seeing patients for whom ADappt was deemed relevant helped them to integrate the tool into their daily routine, as did receiving positive feedback from patients during consultations, which in turn encouraged using the tools more often. They suggested that linking ADappt with the Electronic Health Record (EHR) would facilitate its integration into their workflow. Additionally, they recommended on-the-job training and broader implementation across the entire memory clinic department, rather than involving only a few professionals, so that positive reinforcements to use ADappt would occur more frequently. Lastly, professionals suggested creating a general instructional video for professionals about the intended use of ADappt and its tools.</p><p id="Par30">
<list list-type="bullet"><list-item><p id="Par31"><italic toggle="yes">&#8220;Well</italic>,<italic toggle="yes"> you can</italic>,<italic toggle="yes"> of course</italic>,<italic toggle="yes"> imagine that these kinds of things could simply be integrated into the EHR</italic>,<italic toggle="yes"> right? The computer system. So that you don&#8217;t have to think every time about filling something in</italic>,<italic toggle="yes"> but if you could</italic>,<italic toggle="yes"> for example</italic>,<italic toggle="yes"> create a link to the ADappt tool</italic>,<italic toggle="yes"> you could open it directly without first having to think</italic>,<italic toggle="yes"> &#8216;Oh</italic>,<italic toggle="yes"> what was the web address again?&#8217; It would then work automatically</italic>,<italic toggle="yes"> so to speak.&#8221; (interview feasibility study</italic>,<italic toggle="yes"> clinician 3)</italic>.</p></list-item><list-item><p id="Par32"><italic toggle="yes">&#8220;It took me a while to figure it out</italic>,<italic toggle="yes"> to get a sense of how it&#8230; what I could use and where to find it</italic>,<italic toggle="yes"> so to speak. And now that I know</italic>,<italic toggle="yes"> it actually seems quite logical. You think</italic>,<italic toggle="yes"> why couldn&#8217;t I find it? So what exactly could be improved there</italic>,<italic toggle="yes"> or maybe&#8230; perhaps having some kind of instructional video or something</italic>,<italic toggle="yes"> right?&#8221; (interview feasibility study</italic>,<italic toggle="yes"> clinician 2)</italic>.</p></list-item></list>
</p></sec></sec><sec id="Sec19"><title>Patients and care partners</title><sec id="Sec20"><title>Think-aloud sessions</title><p id="Par33">Patients and care partners found the video-animations and question prompt list helpful in preparing memory clinic visits. They highlighted the importance of having materials available at home, allowing them to re-read or re-watch content, especially given the nature of the cognitive complaints that lead patients to a memory clinic. Participants unanimously indicated they would like to see these tools implemented in routine practice. When critical feedback was provided on the video-animations and question prompt list, this mainly reflected a wish for including more detailed information and additional topics. In contrast, comments on the Result page were more substantial, addressing issues such as the complexity of the language, or a preference for a different visualization of the test results (see Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Participants provided suggestions for improving each tool, while acknowledging that each patient is different and might have their own preferences.</p></sec><sec id="Sec21"><title>Feasibility study in memory clinic practice</title><p id="Par34">In the multicenter study, patients and care partners were highly satisfied with the consultations in general (81&#8201;&#177;&#8201;14, range 50-100, Patient Satisfaction Questionnaire, scale 0&#8208;100<sup>26</sup>). Many patients noted that the tools helped them express themselves more effectively during the consultations:</p><p id="Par35">
<list list-type="bullet"><list-item><p id="Par36"><italic toggle="yes">&#8220;If you know what to expect</italic>,<italic toggle="yes"> it makes you less insecure&#8201;+&#8201;invites you to formulate questions&#8221; (female</italic>,<italic toggle="yes"> 57 years</italic>,<italic toggle="yes"> Subjective Cognitive Decline)</italic>.</p></list-item><list-item><p id="Par37"><italic toggle="yes">&#8220;You&#8217;re usually a bit tense during such an appointment</italic>,<italic toggle="yes"> which makes you quickly forget to ask something you&#8217;d like to know.&#8221; (male</italic>,<italic toggle="yes"> 59 years</italic>,<italic toggle="yes"> care partner)</italic>.</p></list-item></list>
</p><p id="Par38">Regarding the first consultation, more than half (19/33; 58%) of patients and care partners reported to be aware of the video-animation. Among those, the majority (14/19; 74%) had watched it and felt it helped them to some extent to prepare for the appointment (2.5(2&#8211;3), median(IQR), scale 1&#8211;4) and almost all (13/14; 93%) would recommend the video to others. Regarding the question prompt list, the majority (25/33; 76%) of patients and care partners reported to be aware of this tool. Of those, many (17/25; 68%) had used it, reporting that it helped them somewhat in preparing for the appointment (2.0(2&#8211;3)), with nearly all (16/17; 94%) recommending it to others.</p><p id="Par39">For the disclosure consultation, four (4/13; 31%) patients and care partners reported being aware of the video-animation, and half of them (2/4; 50%) had used it, finding it helpful in preparing for the appointment (3(3&#8211;3)). Five (5/13; 38%) patients and care partners reported to be aware of the question prompt list, with four (4/5; 80%) using it and finding it useful to prepare for the appointment (2.5(2&#8211;3)). All indicated they would recommend both the video-animation and the question prompt list to others.</p></sec><sec id="Sec22"><title>PPI session</title><p id="Par40">Finally, we evaluated the tools in an international panel of patients, care partners, and individuals interested in brain health. Regarding the timing (&#8220;when&#8221;), participants recommended providing the video-animations and question prompt list well before the first memory clinic appointment, e.g., at the point of referral by the general practitioner (GP) or medical specialist, or even before visiting the GP. Several participants emphasized their preference for receiving information more than once: initially when the appointment is made and again just before the visit. Participants suggested sending the second video-animation on what to expect during the results consultation when scheduling this appointment and again shortly before the actual appointment.</p><p id="Par41">Concerning the source (&#8220;who&#8221;), participants favored collaboration between public health authorities, including GPs, memory clinics, and community nurses. Of note, the national organization of dementia diagnostics and care varies between countries. Many stressed the importance of a trusted source as a counterbalance to potentially misleading information that can be found online. In addition, they proposed airing the video-animations in public spaces (e.g., buses, trains, TV ads) to reduce stigma and encourage people to seek referrals if they have concerns.</p><p id="Par42">In terms of distribution (&#8220;how&#8221;), preferred methods included sending materials by post (with QR codes for the online videos), by email, and/or by making them publicly available, e.g., on a website. Additionally, participants suggested showing the videos in waiting rooms to reinforce expectations and key questions patients should ask during appointments.</p><p id="Par43">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Feedback from professionals regarding the content, navigation, or design of specific ADappt-tools</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">ADappt tool</th><th align="left" colspan="1" rowspan="1">Positive feedback</th><th align="left" colspan="1" rowspan="1">Critical feedback</th><th align="left" colspan="1" rowspan="1">Suggestions for improvement</th><th align="left" colspan="1" rowspan="1">Issue type</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>Conversation guide to SDM</bold>
</td><td align="left" colspan="1" rowspan="1">Raises awareness of shared-decision making; relevant to consultation</td><td align="left" colspan="1" rowspan="1">Confusing name (overlap with QPL); less useful with standardized diagnostic protocols; challenging to incorporate (requires behavioral change)</td><td align="left" colspan="1" rowspan="1">Rename tool; consider additional training (e.g., e-learning, skills training)</td><td align="left" colspan="1" rowspan="1">Content</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Diagnostic tests</bold>
</td><td align="left" colspan="1" rowspan="1">Easy to apply: practical phrasing; useful, especially for tests less often discussed (e.g., LP)</td><td align="left" colspan="1" rowspan="1">--</td><td align="left" colspan="1" rowspan="1">--</td><td align="left" colspan="1" rowspan="1">--</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Risk calculation tool</bold>
</td><td align="left" colspan="1" rowspan="1">Helpful in interpretating results and whom to follow-up; increases confidence when discussing prognosis</td><td align="left" colspan="1" rowspan="1">Lack of possibility to enter MOCA; generalizability concerns; cut-off values for biomarkers missing; data storage: data was not saved after leaving the page; unclear which biomarker (e.g., MRI, CSF, amyloid-PET) combinations are possible; log-in issues</td><td align="left" colspan="1" rowspan="1">Add MOCA option; add biomarker cut-off values; enable interim data storage; show possible biomarker combinations clearly</td><td align="left" colspan="1" rowspan="1">Content, Navigation, Design</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Topic list</bold>
</td><td align="left" colspan="1" rowspan="1">Helpful memory aid during preparation and consultation</td><td align="left" colspan="1" rowspan="1">Title did not reflect content well; tool often used via QPL instead</td><td align="left" colspan="1" rowspan="1">Rename tool (e.g., &#8220;Checklist&#8221;)</td><td align="left" colspan="1" rowspan="1">Content</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Patient tools</bold> (QPL, video-animations, result page)</td><td align="left" colspan="1" rowspan="1">Informative, clear, patient-friendly; risk visualizations appreciated; QPL helps structure consultation; patients better prepared</td><td align="left" colspan="1" rowspan="1">Concern about inducing worry; no insight into video-animation use; QPL not digital; patients ticked boxes of questions that were not addressable yet during the first consultation</td><td align="left" colspan="1" rowspan="1">Add QR-codes of video-animations to QPL; enable digital QPL; incorporate separate headings in QPL</td><td align="left" colspan="1" rowspan="1">Content, Navigation, Design</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: SDM: shared-decision making, LP: lumbar puncture, MOCA: Montreal Cognitive Assessment, MRI: Magnetic Resonance Imaging, CSF: cerebrospinal fluid, PET: positron emission tomography, QPL: question prompt list</p></table-wrap-foot></table-wrap>
</p><p id="Par44">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Feedback from patients and care partners regarding the content, navigation, or design of the patient tools</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">ADappt tool</th><th align="left" colspan="1" rowspan="1">Positive feedback</th><th align="left" colspan="1" rowspan="1">Critical feedback</th><th align="left" colspan="1" rowspan="1">Suggestions for improvement</th><th align="left" colspan="1" rowspan="1">Issue type</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>Question prompt list</bold>
</td><td align="left" colspan="1" rowspan="1">Helpful memory aid; puts your own questions in a larger perspective; appreciation for open-ended question field; complete and clear; supports preparation and expectations</td><td align="left" colspan="1" rowspan="1">Missing example questions for post-diagnosis phase; some wording unclear; wish for digital completion</td><td align="left" colspan="1" rowspan="1">Develop post-diagnostic QPL version; revise unclear wording; enable digital submission</td><td align="left" colspan="1" rowspan="1">Content, Navigation</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Video-animations</bold>
</td><td align="left" colspan="1" rowspan="1">Clear and concise; helpful visual and auditory explanation (in addition to just reading); not too long</td><td align="left" colspan="1" rowspan="1">Wish for more information (e.g., the different diagnostic tests and their duration, post-diagnostic support); confusion due to YouTube autoplay</td><td align="left" colspan="1" rowspan="1">Develop video(s) on diagnostic tests and post-diagnostic support; prevent or warn for autoplay of unrelated YouTube videos</td><td align="left" colspan="1" rowspan="1">Content, Navigation</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Result page</bold>
</td><td align="left" colspan="1" rowspan="1">Provides clarity; supports future planning; appreciated risk communication; helpful to re-read at home; visuals clear</td><td align="left" colspan="1" rowspan="1">Complex or redundant language; some information lacks personalization (e.g., own MRI); LP cut-off values lacking; wish for more outcomes than dementia risk (e.g., driving); follow-up information lacking; layout issues (e.g., unclear test result highlights, blurry MRI image)</td><td align="left" colspan="1" rowspan="1">Simplify language; personalize where possible; improve MRI image; adjust test result presentation</td><td align="left" colspan="1" rowspan="1">Content, Design</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: LP: lumbar puncture, MRI: Magnetic Resonance Imaging, QPL: question prompt list</p></table-wrap-foot></table-wrap>
</p></sec></sec></sec><sec id="Sec23"><title>Discussion</title><p id="Par45">In this mixed-methods study, we demonstrated that ADappt, an online toolkit to support communication on diagnosis and prognosis in the memory clinic, meets communication support needs of both professionals and patients and care partners, is easy to navigate, and visually appealing. Professionals deemed the diagnostic tests tool most valuable, providing easy-to-understand information on diagnostic tests along with their pros and cons. Patients and care partners positively evaluated the video-animations and the question prompt list, considering them helpful in better preparing for the visit and enabling them to express themselves more effectively. In addition, we found that the tools within ADappt are at varying stages of usability and feasibility, requiring tailored approaches for further improvement and implementation.</p><sec id="Sec241"><title>Tools facilitating the discussion of important topics during the consultation</title><p id="Par46">The development of patient and care partner directed tools to facilitate discussions on key topics was motivated by findings that patients and care partners ask few questions during consultations, yet often leave with unmet information needs [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Throughout this three-phase study, patients and care partners consistently valued the question prompt list and video-animations as supportive tools to express themselves more effectively during a consultation. In addition, there was alignment between professionals, patients, and care partners regarding several aspects of the patient tools. Both groups appreciated the clarity and supportive nature of the materials, particularly the visualizations and the role of the QPL in preparing and structuring the consultation. Similar findings have been reported in other medical specialties, where the use of question prompt lists and animated videos was associated with improved knowledge, increased confidence in asking questions, higher satisfaction, and reduced anxiety [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. This demonstrates that such tools are broadly supported across healthcare settings.</p><p id="Par47">Several lessons emerged from this study to enhance the feasibility of these patient tools. A substantial number of potential users were unaware of the tools, particularly the video-animations. While the question prompt list was included with the appointment letter, accessing the video-animations required following instructions in a separate brochure. To improve accessibility, QR codes linking directly to the video-animations have now been added to the question prompt list. We also developed the topic list tool as a reminder for professionals of which topics are considered important by patients and care partners, but it appeared redundant when the question prompt list is already in use. Participants in the PPI session emphasized their need for close collaboration among healthcare providers and widespread dissemination of these tools to raise awareness. They suggested making the tools available not only in memory clinics, but also through general practitioners and even before a formal diagnosis &#8211; thus ensuring timely access to relevant information for the general public, with the potential added benefit of reducing stigma. Currently, limited interaction between memory clinics, other medical specialists, and general practitioners hinders integration. A shared digital platform could foster collaboration, enabling patients and professionals to access the same resources and supporting patients in taking a more proactive role in managing their healthcare [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. The wish for digital accessibility of the patient tools (e.g., completing the QPL online) was mentioned by both professionals, patients, and care partners in our study. To support effective implementation, we have established an &#8220;Implementation Studio&#8221; within the Dutch Memory Clinic Network. This initiative provides support in the further improvement and implementation of the ADappt patient tools, and fosters interaction between memory clinics.</p></sec><sec id="Sec242"><title>Tools to clearly explain diagnostic procedures and facilitate shared-decision making</title><p id="Par48">Memory clinic professionals frequently discuss diagnostic possibilities with patients, and this will likely increase both in number and in complexity in the future when disease-modifying treatments become available [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The diagnostic tests tool is easily applicable, which likely contributed to its frequent use and positive evaluation [<xref ref-type="bibr" rid="CR10">10</xref>]. It is important that this tool remains up-to-date and incorporates new tests, such as blood-based biomarkers [<xref ref-type="bibr" rid="CR37">37</xref>]. Digital tools, like ADappt, then have the potential to train professionals more quickly and reduce the time between innovation and implementation.</p><p id="Par49">Informing the patient, for example about diagnostic test options, is one of the four steps of shared decision-making (SDM). Shared decision-making is a collaborative process where professionals and patients make decisions together based on available evidence, and is advised in situations where the pros and cons of medical decisions are closely balanced [<xref ref-type="bibr" rid="CR6">6</xref>]. The conversation guide to SDM tool raised professionals&#8217; awareness of the importance of SDM. Professionals indicated a need for additional support, such as an e-learning or skills training, to facilitate incorporating SDM and the tool in their consultations. This finding aligns with existing literature, which indicates that while professionals generally prefer active patient involvement, they often find it challenging to engage them effectively [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Memory clinic professionals are open to use tools or participate in training to improve their SDM skills, and in oncology, such tools and training have already shown to enhance the implementation of SDM [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Currently, the conversation guide to SDM is a relatively static tool that provides dropdown menus for each step of the SDM process, offering short descriptions and example phrases. Future work should co-design a more dynamic format or training that better supports memory clinic professionals in implementing SDM behavior in practice.</p></sec><sec id="Sec243"><title>Dementia risk calculation tool and patient result page</title><p id="Par50">The dementia risk calculation tool received the most feedback during the think-aloud sessions and it was used least frequently by professionals in the feasibility study. Three key factors may explain this: (1) the tool was only applicable to MCI patients, who represent a minority of memory clinic patients; (2) the tool requires extensive user interaction, which necessitates more practice; and (3) if there is still significant critical feedback on its usability, it is less likely that it is used in practice [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. The patient result page was positively received as a clear and welcoming way to explain prognosis but could benefit from improved design and more accessible language. The appreciation of a patient result page by both professionals and patients and care partners was also found in a recent usability study on a clinical decision support system, further highlighting the widespread need for patient tools [<xref ref-type="bibr" rid="CR42">42</xref>]. </p><p id="Par51">To address the first factor, we recently developed a prognostic model for patients with MCI or mild dementia due to AD, making the group of patients where such a tool could be of use larger [<xref ref-type="bibr" rid="CR43">43</xref>]. This model can be used to discuss (the uncertainty of) prognosis as well as how a putative treatment that would alter the course by ~&#8201;30% would impact this. As supported by literature and confirmed in our think-aloud sessions, many patients express a need for prognostic information, regardless of disease stage [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR44">44</xref>&#8211;<xref ref-type="bibr" rid="CR46">46</xref>]. This prediction model has now also been integrated in the latest version of ADappt, along with patient-friendly information and a video-animation about newly emerging anti-amyloid treatment. To address the second and third factors, we explore the addition of crosswalk tables to convert MoCA scores to MMSE scores [<xref ref-type="bibr" rid="CR47">47</xref>]. In addition, we could provide more guidance to increase confidence in the use of the tool by providing cut-offs for specific biomarkers and data on the reliability of the prediction models, a need also identified in a recent usability study on a clinical decision support system [<xref ref-type="bibr" rid="CR42">42</xref>]. </p></sec><sec id="Sec244"><title>Strengths and limitations</title><p id="Par52">This study has several limitations. First, there is potential selection bias in the think-aloud sessions, as participants with an interest in communication tools or with relatively minor cognitive deficits may have been more likely to participate. Second, for many participants, their final diagnosis remained unknown, which could limit the generalizability of our findings. Finally, the small sample size in the feasibility study reduces the robustness of results. In particular the international nature of the interactive PPI panel session contributes to the generalizability of results. Despite these limitations, the study has notable strengths. The mixed-methods design, combining qualitative and quantitative approaches, provided complementary insights into the usability and feasibility of the tools in ADappt. Another strength is the iterative development process, which consistently involved key stakeholders, including memory clinic professionals, patients, and care partners [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Finally, the diversity of the professionals&#8217; sample, which included participants from various medical specialties (neurology and internal/geriatric medicine) and with differing levels of clinical experience, enriched the study&#8217;s findings.</p></sec><sec id="Sec245"><title>Future directions</title><p id="Par53">We will continue our efforts with the Implementation Studio within the Dutch Memory Clinic Network to provide support in the implementation of the ADappt patient tools and stimulate the exchange of best practices regarding patient information across memory clinics. Additionally, we will focus on keeping the diagnostic tests tool up to date, explore revising the conversation guide to SDM, and enhancing the usability of the risk calculation tool and its associated patient result page. At the European level, advancements will be made within the IHI-PROMINENT and AD-RIDDLE studies, focusing on advancing the diagnosis, treatment, and management of neurodegenerative diseases by developing digital platforms and evidence-based tools that integrate diverse data sources, enable personalized medicine, and promote collaboration among healthcare professionals, patients, and care partners [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. With these ongoing initiatives, we will continue working on the refinement and development of ADappt, ultimately aiming to enhance the diagnostic trajectory in memory clinics for professionals, patients, and their care partners.</p></sec></sec><sec id="Sec24"><title>Conclusions</title><p id="Par54">In conclusion, our study provides valuable insights into the usability and feasibility of ADappt in memory clinic practice. The findings indicated that the ADappt addresses a need, is easy to navigate, and visually appealing. The different tools available come with different barriers and facilitators, calling for tailored (implementation) strategies. The diagnostic trajectory of Alzheimer&#8217;s disease and dementia can be uncertain and complex. Throughout this journey easily accessible, reliable, and up to date information is crucial. Most importantly, we show support for the notion that online tools can help to provide reliable, tailored, and accessible information to memory clinic patients and enhance clinician-patient communication in the clinic.</p></sec><sec id="Sec25" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1847_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1847_MOESM2_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1847_MOESM3_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 3</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1847_MOESM4_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 4</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM5" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1847_MOESM5_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 5</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM6" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1847_MOESM6_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 6</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM7" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1847_MOESM7_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 7</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM8" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1847_MOESM8_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 8</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank all participants for their contributions to this study. Additionally, we would like to acknowledge the support of members of the public who take part in the Advisory Boards of the EU-FINGERS, Multi-MeMo, and LETHE projects. Their involvement has been crucial in guiding our research efforts and enhancing the relevance of our work. Research of Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting Steun Alzheimercentrum Amsterdam. The chair of Wiesje van der Flier is supported by the Pasman stichting.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>HH, TR, AG, AD, HRM, ES, WF, and LNCV designed the study. HH, TR, AG, MdB, FB, AD, TF, LH, IvM, RPL, GR, WF, and LNCV contributed to data collection. HH, TR, AvG, TF, and LNCV analyzed the data. HH, TR, AvG, TF, ES, WF, and LNCV interpreted the data and wrote the manuscript. HH, TR, AvG, MdB, FB, AD, TF, LH, IvM, RPL, HRM, GR, ES, WF and LNCV revised the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>WF, LNCV, and ES are recipients of ABOARD; a public-private partnership receiving funding from ZonMw (#73305095007) and Health&#8201;~&#8201;Holland, Topsector Life Sciences &amp; Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. Gieskes-Strijbis fonds also contributes to ABOARD. ADappt received funding from W.M. De Hoop Stichting. WF and ES are recipients of TAP-dementia, a ZonMw funded project (#10510032120003) in the context of the Dutch National Dementia Strategy. WF and HR are recipients of the Horizon Europe IHI project PROMINENT (#101112145). WF is recipient of Multi-Memo, a EU Joint Programme - Neurodegenerative Disease Research (JPND) project (ZonMW #10510062210005). WF is recipient of IHI-AD-RIDDLE, a project supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No. 101132933. The JU receives support from the European Union&#8217;s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe, with Davos Alzheimer&#8217;s Collaborative, Combinostics OY., Cambridge Cognition Ltd., C2N Diagnostics LLC, and neotiv GmbH. Alzheimer Europe received funding for the EU-FINGERS and Multi-MeMo Advisory Boards from the Luxembourg National Research Fund (FNR) under the aegis of the EU Joint Programme &#8211; Neurodegenerative Disease Research (JPND).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data acquired during the current study is available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par55">The study was approved by the board of the Medical Ethics Committee of the VU Medical Center, Amsterdam UMC and the local Medical Ethical Committee in all four participating medical centers. All patients provided written informed consent to participate and for their data to be used for research purposes.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par56">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par57">HH, TR, AvG, MdB, FB, AD, TF, LH, IvM, RPL, HRM, GR, and ES report no financial disclosures or conflicts of interest. Leonie Visser (LNCV) has been an invited speaker at Schwabe Group, fees were paid to her institution. Her research has been funded by ZonMW, Alzheimer Nederland, Health~Holland Topsector Life Sciences &amp; Health, Eisai, and Amsterdam public health research institute. Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-JPND, EU-IHI, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences &amp; Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer &amp; Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Eli-Lilly-NL, Eisai, Combinostics. WF holds the Pasman chair. WF is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences &amp; Health (PPP-allowance; #LSHM20106). WF is recipient of TAP-dementia (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.geheugenpoliklinieken.nl/onderzoek/TAP-dementia">www.tap-dementia.nl</ext-link>), receiving funding from ZonMw (#10510032120003). TAP-dementia receives co-financing from Avid Radiopharmaceuticals and Amprion. All funding is paid to her institution. WF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. All funding is paid to her institution. WF is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, and Eisai. All funding is paid to her institution. WF participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. WF is member of the steering committee of EVOKE/EVOKE+ (NovoNordisk). All funding is paid to her institution. WF is member of the steering committee of PAVE, and Think Brain Health. WF was associate editor of Alzheimer, Research &amp; Therapy in 2020/2021. WF is associate editor at Brain.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>ADC</term><def><p id="Par58">Amsterdam Dementia Cohort</p></def></def-item><def-item><term>AD</term><def><p id="Par59">Alzheimer&#8217;s disease</p></def></def-item><def-item><term>CSF</term><def><p id="Par60">Cerebrospinal fluid</p></def></def-item><def-item><term>EHR</term><def><p id="Par61">Electronic Health Record</p></def></def-item><def-item><term>GP</term><def><p id="Par62">General practitioner</p></def></def-item><def-item><term>LP</term><def><p id="Par63">Lumbar puncture</p></def></def-item><def-item><term>MCI</term><def><p id="Par64">Mild Cognitive Impairment</p></def></def-item><def-item><term>MMSE</term><def><p id="Par65">Mini-Mental State Examination</p></def></def-item><def-item><term>MoCA</term><def><p id="Par66">Montreal Cognitive Assessment</p></def></def-item><def-item><term>MRI</term><def><p id="Par67">Magnetic Resonance Imaging</p></def></def-item><def-item><term>PET</term><def><p id="Par68">Positron Emission Tomography</p></def></def-item><def-item><term>PPI</term><def><p id="Par69">Patient and public involvement</p></def></def-item><def-item><term>QPL</term><def><p id="Par70">Question prompt list</p></def></def-item><def-item><term>SCD</term><def><p id="Par71">Subjective Cognitive Decline</p></def></def-item><def-item><term>SDM</term><def><p id="Par72">Shared-decision making</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gruters</surname><given-names>AAA</given-names></name><etal/></person-group><article-title>Development of memory clinics in the Netherlands over the last 20 years</article-title><source>Int J Geriatr Psychiatry</source><year>2019</year><volume>34</volume><fpage>1267</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1002/gps.5132</pub-id><pub-id pub-id-type="pmid">31034652</pub-id><pub-id pub-id-type="pmcid">PMC6767517</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Gruters AAA, et al. Development of memory clinics in the Netherlands over the last 20 years. Int J Geriatr Psychiatry. 2019;34:1267&#8211;74. 10.1002/gps.5132.<pub-id pub-id-type="pmid">31034652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.5132</pub-id><pub-id pub-id-type="pmcid">PMC6767517</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>RS</given-names></name><name name-style="western"><surname>Stubbs</surname><given-names>T</given-names></name><name name-style="western"><surname>Davies</surname><given-names>DA</given-names></name><name name-style="western"><surname>Albensi</surname><given-names>BC</given-names></name></person-group><article-title>Potential new approaches for diagnosis of alzheimer&#8217;s disease and related dementias</article-title><source>Front Neurol</source><year>2020</year><volume>11</volume><fpage>496</fpage><pub-id pub-id-type="doi">10.3389/fneur.2020.00496</pub-id><pub-id pub-id-type="pmid">32582013</pub-id><pub-id pub-id-type="pmcid">PMC7290039</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Turner RS, Stubbs T, Davies DA, Albensi BC. Potential new approaches for diagnosis of alzheimer&#8217;s disease and related dementias. Front Neurol. 2020;11:496. 10.3389/fneur.2020.00496.<pub-id pub-id-type="pmid">32582013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2020.00496</pub-id><pub-id pub-id-type="pmcid">PMC7290039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Schaar</surname><given-names>J</given-names></name><etal/></person-group><article-title>Considerations regarding a diagnosis of alzheimer&#8217;s disease before dementia: a systematic review</article-title><source>Alzheimers Res Ther</source><year>2022</year><volume>14</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.1186/s13195-022-00971-3</pub-id><pub-id pub-id-type="pmid">35144684</pub-id><pub-id pub-id-type="pmcid">PMC8829985</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">van der Schaar J, et al. Considerations regarding a diagnosis of alzheimer&#8217;s disease before dementia: a systematic review. Alzheimers Res Ther. 2022;14:31. 10.1186/s13195-022-00971-3.<pub-id pub-id-type="pmid">35144684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-022-00971-3</pub-id><pub-id pub-id-type="pmcid">PMC8829985</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Flier</surname><given-names>WM</given-names></name><name name-style="western"><surname>de Vugt</surname><given-names>ME</given-names></name><name name-style="western"><surname>Smets</surname><given-names>EMA</given-names></name><name name-style="western"><surname>Blom</surname><given-names>M</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></name></person-group><article-title>Towards a future where alzheimer&#8217;s disease pathology is stopped before the onset of dementia</article-title><source>Nat Aging</source><year>2023</year><volume>3</volume><fpage>494</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1038/s43587-023-00404-2</pub-id><pub-id pub-id-type="pmid">37202515</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">van der Flier WM, de Vugt ME, Smets EMA, Blom M, Teunissen CE. Towards a future where alzheimer&#8217;s disease pathology is stopped before the onset of dementia. Nat Aging. 2023;3:494&#8211;505. 10.1038/s43587-023-00404-2.<pub-id pub-id-type="pmid">37202515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00404-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visser</surname><given-names>LNC</given-names></name><etal/></person-group><article-title>Dementia risk communication. A user manual for brain health Services-part 3 of 6</article-title><source>Alzheimers Res Ther</source><year>2021</year><volume>13</volume><fpage>170</fpage><pub-id pub-id-type="doi">10.1186/s13195-021-00840-5</pub-id><pub-id pub-id-type="pmid">34635169</pub-id><pub-id pub-id-type="pmcid">PMC8507171</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Visser LNC, et al. Dementia risk communication. A user manual for brain health Services-part 3 of 6. Alzheimers Res Ther. 2021;13:170. 10.1186/s13195-021-00840-5.<pub-id pub-id-type="pmid">34635169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-021-00840-5</pub-id><pub-id pub-id-type="pmcid">PMC8507171</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Flier</surname><given-names>WM</given-names></name><name name-style="western"><surname>Kunneman</surname><given-names>M</given-names></name><name name-style="western"><surname>Bouwman</surname><given-names>FH</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name><name name-style="western"><surname>Smets</surname><given-names>EM</given-names></name></person-group><article-title>A. Diagnostic dilemmas in alzheimer&#8217;s disease: room for shared decision making</article-title><source>Alzheimers Dement (N Y)</source><year>2017</year><volume>3</volume><fpage>301</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2017.03.008</pub-id><pub-id pub-id-type="pmid">29067336</pub-id><pub-id pub-id-type="pmcid">PMC5651445</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">van der Flier WM, Kunneman M, Bouwman FH, Petersen RC, Smets EM. A. Diagnostic dilemmas in alzheimer&#8217;s disease: room for shared decision making. Alzheimers Dement (N Y). 2017;3:301&#8211;4. 10.1016/j.trci.2017.03.008.<pub-id pub-id-type="pmid">29067336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2017.03.008</pub-id><pub-id pub-id-type="pmcid">PMC5651445</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendriksen</surname><given-names>HMA</given-names></name><etal/></person-group><article-title>Communication about diagnosis, prognosis, and prevention in the memory clinic: perspectives of European memory clinic professionals</article-title><source>Alzheimers Res Ther</source><year>2023</year><volume>15</volume><fpage>131</fpage><pub-id pub-id-type="doi">10.1186/s13195-023-01276-9</pub-id><pub-id pub-id-type="pmid">37543608</pub-id><pub-id pub-id-type="pmcid">PMC10404377</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Hendriksen HMA, et al. Communication about diagnosis, prognosis, and prevention in the memory clinic: perspectives of European memory clinic professionals. Alzheimers Res Ther. 2023;15:131. 10.1186/s13195-023-01276-9.<pub-id pub-id-type="pmid">37543608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-023-01276-9</pub-id><pub-id pub-id-type="pmcid">PMC10404377</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Gils</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Assessing the views of professionals, patients, and care partners concerning the use of computer tools in memory clinics: international survey study</article-title><source>JMIR Form Res</source><year>2021</year><volume>5</volume><fpage>e31053</fpage><pub-id pub-id-type="doi">10.2196/31053</pub-id><pub-id pub-id-type="pmid">34870612</pub-id><pub-id pub-id-type="pmcid">PMC8686488</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">van Gils AM, et al. Assessing the views of professionals, patients, and care partners concerning the use of computer tools in memory clinics: international survey study. JMIR Form Res. 2021;5:e31053. 10.2196/31053.<pub-id pub-id-type="pmid">34870612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/31053</pub-id><pub-id pub-id-type="pmcid">PMC8686488</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Maurik</surname><given-names>IS</given-names></name><etal/></person-group><article-title>Development and usability of adappt: Web-Based tool to support clinicians, patients, and caregivers in the diagnosis of mild cognitive impairment and alzheimer disease</article-title><source>JMIR Form Res</source><year>2019</year><volume>3</volume><fpage>e13417</fpage><pub-id pub-id-type="doi">10.2196/13417</pub-id><pub-id pub-id-type="pmid">31287061</pub-id><pub-id pub-id-type="pmcid">PMC6643768</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">van Maurik IS, et al. Development and usability of adappt: Web-Based tool to support clinicians, patients, and caregivers in the diagnosis of mild cognitive impairment and alzheimer disease. JMIR Form Res. 2019;3:e13417. 10.2196/13417.<pub-id pub-id-type="pmid">31287061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/13417</pub-id><pub-id pub-id-type="pmcid">PMC6643768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visser</surname><given-names>LNC</given-names></name><etal/></person-group><article-title>Clinician-patient communication during the diagnostic workup: the ABIDE project</article-title><source>Alzheimers Dement (Amst)</source><year>2019</year><volume>11</volume><fpage>520</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.dadm.2019.06.001</pub-id><pub-id pub-id-type="pmid">31388556</pub-id><pub-id pub-id-type="pmcid">PMC6667786</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Visser LNC, et al. Clinician-patient communication during the diagnostic workup: the ABIDE project. Alzheimers Dement (Amst). 2019;11:520&#8211;8. 10.1016/j.dadm.2019.06.001.<pub-id pub-id-type="pmid">31388556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadm.2019.06.001</pub-id><pub-id pub-id-type="pmcid">PMC6667786</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visser</surname><given-names>LNC</given-names></name><etal/></person-group><article-title>Clinicians&#8217; communication with patients receiving a MCI diagnosis: the ABIDE project</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><fpage>e0227282</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0227282</pub-id><pub-id pub-id-type="pmid">31961882</pub-id><pub-id pub-id-type="pmcid">PMC6974141</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Visser LNC, et al. Clinicians&#8217; communication with patients receiving a MCI diagnosis: the ABIDE project. PLoS ONE. 2020;15:e0227282. 10.1371/journal.pone.0227282.<pub-id pub-id-type="pmid">31961882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0227282</pub-id><pub-id pub-id-type="pmcid">PMC6974141</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fruijtier</surname><given-names>AD</given-names></name><etal/></person-group><article-title>ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics</article-title><source>Alzheimers Res Ther</source><year>2019</year><volume>11</volume><fpage>77</fpage><pub-id pub-id-type="doi">10.1186/s13195-019-0531-y</pub-id><pub-id pub-id-type="pmid">31472676</pub-id><pub-id pub-id-type="pmcid">PMC6717649</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Fruijtier AD, et al. ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics. Alzheimers Res Ther. 2019;11:77. 10.1186/s13195-019-0531-y.<pub-id pub-id-type="pmid">31472676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-019-0531-y</pub-id><pub-id pub-id-type="pmcid">PMC6717649</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babapour Mofrad</surname><given-names>R</given-names></name><etal/></person-group><article-title>Lumbar puncture patient video increases knowledge and reduces uncertainty: an RCT</article-title><source>Alzheimers Dement (N Y)</source><year>2021</year><volume>7</volume><fpage>e12127</fpage><pub-id pub-id-type="doi">10.1002/trc2.12127</pub-id><pub-id pub-id-type="pmid">33614895</pub-id><pub-id pub-id-type="pmcid">PMC7882513</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Babapour Mofrad R, et al. Lumbar puncture patient video increases knowledge and reduces uncertainty: an RCT. Alzheimers Dement (N Y). 2021;7:e12127. 10.1002/trc2.12127.<pub-id pub-id-type="pmid">33614895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.12127</pub-id><pub-id pub-id-type="pmcid">PMC7882513</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babapour Mofrad</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid collection: an informative animation video for patients and caregivers</article-title><source>Alzheimers Dement (Amst)</source><year>2019</year><volume>11</volume><fpage>435</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.dadm.2019.04.005</pub-id><pub-id pub-id-type="pmid">31211216</pub-id><pub-id pub-id-type="pmcid">PMC6562320</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Babapour Mofrad R, et al. Cerebrospinal fluid collection: an informative animation video for patients and caregivers. Alzheimers Dement (Amst). 2019;11:435&#8211;8. 10.1016/j.dadm.2019.04.005.<pub-id pub-id-type="pmid">31211216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadm.2019.04.005</pub-id><pub-id pub-id-type="pmcid">PMC6562320</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Harst L, Wollschlaeger B, Birnstein J, Fuchs T, Timpel P. Evaluation is key: providing appropriate evaluation measures for participatory and user-centred design processes of healthcare IT. Int J Integr Care 21 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.5334/ijic.5529</pub-id><pub-id pub-id-type="pmcid">PMC8231460</pub-id><pub-id pub-id-type="pmid">34220388</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melles</surname><given-names>M</given-names></name><name name-style="western"><surname>Albayrak</surname><given-names>A</given-names></name><name name-style="western"><surname>Goossens</surname><given-names>R</given-names></name></person-group><article-title>Innovating health care: key characteristics of human-centered design</article-title><source>Int J Qual Health Care</source><year>2021</year><volume>33</volume><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1093/intqhc/mzaa127</pub-id><pub-id pub-id-type="pmid">33068104</pub-id><pub-id pub-id-type="pmcid">PMC7802070</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Melles M, Albayrak A, Goossens R. Innovating health care: key characteristics of human-centered design. Int J Qual Health Care. 2021;33:37&#8211;44.<pub-id pub-id-type="pmid">33068104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/intqhc/mzaa127</pub-id><pub-id pub-id-type="pmcid">PMC7802070</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stiggelbout</surname><given-names>AM</given-names></name><name name-style="western"><surname>Pieterse</surname><given-names>AH</given-names></name><name name-style="western"><surname>De Haes</surname><given-names>JC</given-names></name></person-group><article-title>Shared decision making: concepts, evidence, and practice</article-title><source>Patient Educ Couns</source><year>2015</year><volume>98</volume><fpage>1172</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.pec.2015.06.022</pub-id><pub-id pub-id-type="pmid">26215573</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Stiggelbout AM, Pieterse AH, De Haes JC. Shared decision making: concepts, evidence, and practice. Patient Educ Couns. 2015;98:1172&#8211;9. 10.1016/j.pec.2015.06.022.<pub-id pub-id-type="pmid">26215573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pec.2015.06.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Maurik</surname><given-names>IS</given-names></name><etal/></person-group><article-title>Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study</article-title><source>Lancet Neurol</source><year>2019</year><volume>18</volume><fpage>1034</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(19)30283-2</pub-id><pub-id pub-id-type="pmid">31526625</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">van Maurik IS, et al. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurol. 2019;18:1034&#8211;44. 10.1016/S1474-4422(19)30283-2.<pub-id pub-id-type="pmid">31526625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(19)30283-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaspers</surname><given-names>MW</given-names></name></person-group><article-title>A comparison of usability methods for testing interactive health technologies: methodological aspects and empirical evidence</article-title><source>Int J Med Inf</source><year>2009</year><volume>78</volume><fpage>340</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.ijmedinf.2008.10.002</pub-id><pub-id pub-id-type="pmid">19046928</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Jaspers MW. A comparison of usability methods for testing interactive health technologies: methodological aspects and empirical evidence. Int J Med Inf. 2009;78:340&#8211;53. 10.1016/j.ijmedinf.2008.10.002.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijmedinf.2008.10.002</pub-id><pub-id pub-id-type="pmid">19046928</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>AB</given-names></name><name name-style="western"><surname>Finley</surname><given-names>EP</given-names></name></person-group><article-title>Qualitative methods in implementation research: an introduction</article-title><source>Psychiatry Res</source><year>2019</year><volume>280</volume><fpage>112516</fpage><pub-id pub-id-type="doi">10.1016/j.psychres.2019.112516</pub-id><pub-id pub-id-type="pmid">31437661</pub-id><pub-id pub-id-type="pmcid">PMC7023962</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Hamilton AB, Finley EP. Qualitative methods in implementation research: an introduction. Psychiatry Res. 2019;280:112516. 10.1016/j.psychres.2019.112516.<pub-id pub-id-type="pmid">31437661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psychres.2019.112516</pub-id><pub-id pub-id-type="pmcid">PMC7023962</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yen</surname><given-names>P-Y</given-names></name><name name-style="western"><surname>Bakken</surname><given-names>S</given-names></name></person-group><article-title>Review of health information technology usability study methodologies</article-title><source>J Am Med Inform Assoc</source><year>2011</year><volume>19</volume><fpage>413</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1136/amiajnl-2010-000020</pub-id><pub-id pub-id-type="pmid">21828224</pub-id><pub-id pub-id-type="pmcid">PMC3341772</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Yen P-Y, Bakken S. Review of health information technology usability study methodologies. J Am Med Inform Assoc. 2011;19:413&#8211;22. 10.1136/amiajnl-2010-000020.<pub-id pub-id-type="pmid">21828224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/amiajnl-2010-000020</pub-id><pub-id pub-id-type="pmcid">PMC3341772</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Flier</surname><given-names>WM</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name></person-group><article-title>Amsterdam dementia cohort: performing research to optimize care</article-title><source>J Alzheimers Dis</source><year>2018</year><volume>62</volume><fpage>1091</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.3233/JAD-170850</pub-id><pub-id pub-id-type="pmid">29562540</pub-id><pub-id pub-id-type="pmcid">PMC5870023</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">van der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis. 2018;62:1091&#8211;111. 10.3233/JAD-170850.<pub-id pub-id-type="pmid">29562540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-170850</pub-id><pub-id pub-id-type="pmcid">PMC5870023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boren</surname><given-names>T</given-names></name><name name-style="western"><surname>Ramey</surname><given-names>J</given-names></name></person-group><article-title>Thinking aloud: reconciling theory and practice</article-title><source>IEEE Trans Prof Commun</source><year>2000</year><volume>43</volume><fpage>261</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1109/47.867942</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Boren T, Ramey J. Thinking aloud: reconciling theory and practice. IEEE Trans Prof Commun. 2000;43:261&#8211;78. 10.1109/47.867942.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowers</surname><given-names>VA</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>HL</given-names></name></person-group><article-title>Concurrent versus retrospective verbal protocol for comparing window usability</article-title><source>Proc Hum Factors Soc Annual Meeting</source><year>1990</year><volume>34</volume><fpage>1270</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1177/154193129003401720</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Bowers VA, Snyder HL. Concurrent versus retrospective verbal protocol for comparing window usability. Proc Hum Factors Soc Annual Meeting. 1990;34:1270&#8211;4. 10.1177/154193129003401720.</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Brooke J. SUS: a quick and dirty usability scale. Usability Evaluation Ind, 189&#8211;94 (1996).</mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blanchard</surname><given-names>CG</given-names></name><name name-style="western"><surname>Ruckdeschel</surname><given-names>JC</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>BA</given-names></name><name name-style="western"><surname>Blanchard</surname><given-names>EB</given-names></name></person-group><article-title>The impact of oncologists&#8217; behaviors on patient satisfaction with morning rounds</article-title><source>Cancer</source><year>1986</year><volume>58</volume><fpage>387</fpage><lpage>93</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(19860715)58:2&amp;#x0003c;387::AID-CNCR2820580233&amp;#x0003e;3.0.CO;2-3</pub-id><pub-id pub-id-type="pmid">3719533</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Blanchard CG, Ruckdeschel JC, Fletcher BA, Blanchard EB. The impact of oncologists&#8217; behaviors on patient satisfaction with morning rounds. Cancer. 1986;58:387&#8211;93.<pub-id pub-id-type="pmid">3719533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(19860715)58:2&lt;387::aid-cncr2820580233&gt;3.0.co;2-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Velsen</surname><given-names>L</given-names></name><name name-style="western"><surname>van der Geest</surname><given-names>T</given-names></name><name name-style="western"><surname>Klaassen</surname><given-names>R</given-names></name></person-group><article-title>Identifying usability issues for personalization during formative evaluations: A comparison of three methods</article-title><source>Int J Human&#8211;Computer Interact</source><year>2011</year><volume>27</volume><fpage>670</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1080/10447318.2011.555304</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">van Velsen L, van der Geest T, Klaassen R. Identifying usability issues for personalization during formative evaluations: A comparison of three methods. Int J Human&#8211;Computer Interact. 2011;27:670&#8211;98. 10.1080/10447318.2011.555304.</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Elling S, Lentz L, Jong M. d. in <italic toggle="yes">Proceedings of the SIGCHI Conference on Human Factors in Computing Systems</italic> 1161&#8211;1170Association for Computing Machinery, Vancouver, BC, Canada, (2011).</mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaismoradi</surname><given-names>M</given-names></name><name name-style="western"><surname>Turunen</surname><given-names>H</given-names></name><name name-style="western"><surname>Bondas</surname><given-names>T</given-names></name></person-group><article-title>Content analysis and thematic analysis: implications for conducting a qualitative descriptive study</article-title><source>Nurs Health Sci</source><year>2013</year><volume>15</volume><fpage>398</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1111/nhs.12048</pub-id><pub-id pub-id-type="pmid">23480423</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15:398&#8211;405. 10.1111/nhs.12048.<pub-id pub-id-type="pmid">23480423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/nhs.12048</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verhage</surname><given-names>F</given-names></name><name name-style="western"><surname>Van Der Werff</surname><given-names>JJ</given-names></name></person-group><article-title>[an analysis of variance based on the Groninger intelligence test scores]</article-title><source>Ned Tijdschr Psychol</source><year>1964</year><volume>19</volume><fpage>497</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">14228907</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Verhage F, Van Der Werff JJ. [an analysis of variance based on the Groninger intelligence test scores]. Ned Tijdschr Psychol. 1964;19:497&#8211;509.<pub-id pub-id-type="pmid">14228907</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Brooke JSUS. A quick and dirty usability scale. Usability Evaluation Ind (1996).</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bangor</surname><given-names>A</given-names></name><name name-style="western"><surname>Kortum</surname><given-names>P</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J</given-names></name></person-group><article-title>Determining what individual SUS scores mean: adding an adjective rating scale</article-title><source>J Usability Stud</source><year>2009</year><volume>4</volume><fpage>114</fpage><lpage>23</lpage></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Bangor A, Kortum P, Miller J. Determining what individual SUS scores mean: adding an adjective rating scale. J Usability Stud. 2009;4:114&#8211;23.</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fruijtier</surname><given-names>AD</given-names></name><etal/></person-group><article-title>What patients want to know, and what we actually tell them: the ABIDE project</article-title><source>Alzheimers Dement (N Y)</source><year>2020</year><volume>6</volume><fpage>e12113</fpage><pub-id pub-id-type="doi">10.1002/trc2.12113</pub-id><pub-id pub-id-type="pmid">33344753</pub-id><pub-id pub-id-type="pmcid">PMC7744024</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Fruijtier AD, et al. What patients want to know, and what we actually tell them: the ABIDE project. Alzheimers Dement (N Y). 2020;6:e12113. 10.1002/trc2.12113.<pub-id pub-id-type="pmid">33344753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.12113</pub-id><pub-id pub-id-type="pmcid">PMC7744024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramlakhan</surname><given-names>JU</given-names></name><name name-style="western"><surname>Dhanani</surname><given-names>S</given-names></name><name name-style="western"><surname>Berta</surname><given-names>WB</given-names></name><name name-style="western"><surname>Gagliardi</surname><given-names>AR</given-names></name></person-group><article-title>Optimizing the design and implementation of question prompt lists to support person-centred care: A scoping review</article-title><source>Health Expect</source><year>2023</year><volume>26</volume><fpage>1404</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1111/hex.13783</pub-id><pub-id pub-id-type="pmid">37227115</pub-id><pub-id pub-id-type="pmcid">PMC10349246</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Ramlakhan JU, Dhanani S, Berta WB, Gagliardi AR. Optimizing the design and implementation of question prompt lists to support person-centred care: A scoping review. Health Expect. 2023;26:1404&#8211;17.<pub-id pub-id-type="pmid">37227115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/hex.13783</pub-id><pub-id pub-id-type="pmcid">PMC10349246</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feeley</surname><given-names>TH</given-names></name><name name-style="western"><surname>Keller</surname><given-names>M</given-names></name><name name-style="western"><surname>Kayler</surname><given-names>L</given-names></name></person-group><article-title>Using animated videos to increase patient knowledge: a meta-analytic review</article-title><source>Health Educ Behav</source><year>2023</year><volume>50</volume><fpage>240</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1177/10901981221116791</pub-id><pub-id pub-id-type="pmid">35950326</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Feeley TH, Keller M, Kayler L. Using animated videos to increase patient knowledge: a meta-analytic review. Health Educ Behav. 2023;50:240&#8211;9.<pub-id pub-id-type="pmid">35950326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/10901981221116791</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gramkow</surname><given-names>MH</given-names></name><name name-style="western"><surname>Waldemar</surname><given-names>G</given-names></name><name name-style="western"><surname>Frederiksen</surname><given-names>KS</given-names></name></person-group><article-title>The digitized memory clinic</article-title><source>Nat Reviews Neurol</source><year>2024</year><volume>20</volume><fpage>738</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1038/s41582-024-01033-y</pub-id><pub-id pub-id-type="pmid">39455807</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Gramkow MH, Waldemar G, Frederiksen KS. The digitized memory clinic. Nat Reviews Neurol. 2024;20:738&#8211;46. 10.1038/s41582-024-01033-y.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-024-01033-y</pub-id><pub-id pub-id-type="pmid">39455807</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Blood-based biomarkers for alzheimer&#8217;s disease: towards clinical implementation</article-title><source>Lancet Neurol</source><year>2022</year><volume>21</volume><fpage>66</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00361-6</pub-id><pub-id pub-id-type="pmid">34838239</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Teunissen CE, et al. Blood-based biomarkers for alzheimer&#8217;s disease: towards clinical implementation. Lancet Neurol. 2022;21:66&#8211;77. 10.1016/S1474-4422(21)00361-6.<pub-id pub-id-type="pmid">34838239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(21)00361-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunneman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Patients&#8217; and caregivers&#8217; views on conversations and shared decision making in diagnostic testing for alzheimer&#8217;s disease: the ABIDE project</article-title><source>Alzheimers Dement (N Y)</source><year>2017</year><volume>3</volume><fpage>314</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2017.04.002</pub-id><pub-id pub-id-type="pmid">29067338</pub-id><pub-id pub-id-type="pmcid">PMC5651429</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Kunneman M, et al. Patients&#8217; and caregivers&#8217; views on conversations and shared decision making in diagnostic testing for alzheimer&#8217;s disease: the ABIDE project. Alzheimers Dement (N Y). 2017;3:314&#8211;22. 10.1016/j.trci.2017.04.002.<pub-id pub-id-type="pmid">29067338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2017.04.002</pub-id><pub-id pub-id-type="pmcid">PMC5651429</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattos</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Shared decision-making in persons living with dementia: A scoping review</article-title><source>Dement (London)</source><year>2023</year><volume>22</volume><fpage>875</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1177/14713012231156976</pub-id><pub-id pub-id-type="pmcid">PMC10866150</pub-id><pub-id pub-id-type="pmid">36802973</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Mattos MK, et al. Shared decision-making in persons living with dementia: A scoping review. Dement (London). 2023;22:875&#8211;909. 10.1177/14713012231156976.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/14713012231156976</pub-id><pub-id pub-id-type="pmcid">PMC10866150</pub-id><pub-id pub-id-type="pmid">36802973</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kane</surname><given-names>HL</given-names></name><name name-style="western"><surname>Halpern</surname><given-names>MT</given-names></name><name name-style="western"><surname>Squiers</surname><given-names>LB</given-names></name><name name-style="western"><surname>Treiman</surname><given-names>KA</given-names></name><name name-style="western"><surname>McCormack</surname><given-names>LA</given-names></name></person-group><article-title>Implementing and evaluating shared decision making in oncology practice</article-title><source>CA Cancer J Clin</source><year>2014</year><volume>64</volume><fpage>377</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.3322/caac.21245</pub-id><pub-id pub-id-type="pmid">25200391</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Kane HL, Halpern MT, Squiers LB, Treiman KA, McCormack LA. Implementing and evaluating shared decision making in oncology practice. CA Cancer J Clin. 2014;64:377&#8211;88. 10.3322/caac.21245.<pub-id pub-id-type="pmid">25200391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21245</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Flier</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Optimizing patient care and research: the Amsterdam dementia cohort</article-title><source>J Alzheimers Dis</source><year>2014</year><volume>41</volume><fpage>313</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.3233/JAD-132306</pub-id><pub-id pub-id-type="pmid">24614907</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">van der Flier WM, et al. Optimizing patient care and research: the Amsterdam dementia cohort. J Alzheimers Dis. 2014;41:313&#8211;27. 10.3233/JAD-132306.<pub-id pub-id-type="pmid">24614907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-132306</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Gils</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Use of a digital tool to support the diagnostic process in memory clinics-a usability study</article-title><source>Alzheimers Res Ther</source><year>2024</year><volume>16</volume><fpage>75</fpage><pub-id pub-id-type="doi">10.1186/s13195-024-01433-8</pub-id><pub-id pub-id-type="pmid">38589933</pub-id><pub-id pub-id-type="pmcid">PMC11003066</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">van Gils AM, et al. Use of a digital tool to support the diagnostic process in memory clinics-a usability study. Alzheimers Res Ther. 2024;16:75. 10.1186/s13195-024-01433-8.<pub-id pub-id-type="pmid">38589933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01433-8</pub-id><pub-id pub-id-type="pmcid">PMC11003066</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Veere</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Predicting cognitive decline in Amyloid-Positive patients with mild cognitive impairment or mild dementia</article-title><source>Neurology</source><year>2024</year><volume>103</volume><fpage>e209605</fpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000209605</pub-id><pub-id pub-id-type="pmid">38986053</pub-id><pub-id pub-id-type="pmcid">PMC11238942</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">van der Veere PJ, et al. Predicting cognitive decline in Amyloid-Positive patients with mild cognitive impairment or mild dementia. Neurology. 2024;103:e209605. 10.1212/WNL.0000000000209605.<pub-id pub-id-type="pmid">38986053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000209605</pub-id><pub-id pub-id-type="pmcid">PMC11238942</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JE</given-names></name><etal/></person-group><article-title>And does that necessarily mean absolutely alzheimer&#8217;s?? An analysis of questions Raised following amyloid PET results disclosure</article-title><source>Am J Geriatric Psychiatry</source><year>2024</year><volume>32</volume><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.jagp.2023.08.005</pub-id><pub-id pub-id-type="pmcid">PMC10841154</pub-id><pub-id pub-id-type="pmid">37634955</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Kim JE, et al. And does that necessarily mean absolutely alzheimer&#8217;s?? An analysis of questions Raised following amyloid PET results disclosure. Am J Geriatric Psychiatry. 2024;32:45&#8211;54. 10.1016/j.jagp.2023.08.005.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jagp.2023.08.005</pub-id><pub-id pub-id-type="pmcid">PMC10841154</pub-id><pub-id pub-id-type="pmid">37634955</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yates</surname><given-names>J</given-names></name><name name-style="western"><surname>Stanyon</surname><given-names>M</given-names></name><name name-style="western"><surname>Samra</surname><given-names>R</given-names></name><name name-style="western"><surname>Clare</surname><given-names>L</given-names></name></person-group><article-title>Challenges in disclosing and receiving a diagnosis of dementia: a systematic review of practice from the perspectives of people with dementia, carers, and healthcare professionals</article-title><source>Int Psychogeriatr</source><year>2021</year><volume>33</volume><fpage>1161</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1017/S1041610221000119</pub-id><pub-id pub-id-type="pmid">33726880</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Yates J, Stanyon M, Samra R, Clare L. Challenges in disclosing and receiving a diagnosis of dementia: a systematic review of practice from the perspectives of people with dementia, carers, and healthcare professionals. Int Psychogeriatr. 2021;33:1161&#8211;92. 10.1017/S1041610221000119.<pub-id pub-id-type="pmid">33726880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610221000119</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Hendriksen HMA et al. Patients&#8217; evaluation of information provision in the memory clinic. <italic toggle="yes">Alzheimer&#8217;s &amp; Dementia: Behavior &amp; Socioeconomics of Aging</italic> 1, e70002 (2025). 10.1002/bsa3.70002</mixed-citation></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubbelman</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Comparing and linking the Mini-Mental state examination and Montreal cognitive assessment in the Amsterdam dementia cohort</article-title><source>J Int Neuropsychol Soc</source><year>2024</year><volume>30</volume><fpage>867</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1017/S1355617724000341</pub-id><pub-id pub-id-type="pmid">39297182</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Dubbelman MA, et al. Comparing and linking the Mini-Mental state examination and Montreal cognitive assessment in the Amsterdam dementia cohort. J Int Neuropsychol Soc. 2024;30:867&#8211;74. 10.1017/S1355617724000341.<pub-id pub-id-type="pmid">39297182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1355617724000341</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Tate A et al. Precision medicine in neurodegeneration: the IHI-PROMINENT project. <italic toggle="yes">Frontiers in Neurology</italic> Volume 14&#8211;2023 (2023). 10.3389/fneur.2023.1175922<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2023.1175922</pub-id><pub-id pub-id-type="pmcid">PMC10433183</pub-id><pub-id pub-id-type="pmid">37602259</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malzbender</surname><given-names>K</given-names></name><etal/></person-group><article-title>Validation, deployment, and Real-World implementation of a modular toolbox for alzheimer&#8217;s disease detection and dementia risk reduction: the AD-RIDDLE project</article-title><source>J Prev Alzheimer&#8217;s Disease</source><year>2024</year><volume>11</volume><fpage>329</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.14283/jpad.2024.32</pub-id><pub-id pub-id-type="pmid">38374739</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Malzbender K, et al. Validation, deployment, and Real-World implementation of a modular toolbox for alzheimer&#8217;s disease detection and dementia risk reduction: the AD-RIDDLE project. J Prev Alzheimer&#8217;s Disease. 2024;11:329&#8211;38. 10.14283/jpad.2024.32.<pub-id pub-id-type="pmid">38374739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2024.32</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="bpa70019" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Brain Pathol</journal-id><journal-id journal-id-type="iso-abbrev">Brain Pathol</journal-id><journal-id journal-id-type="pmc-domain-id">4024</journal-id><journal-id journal-id-type="pmc-domain">brainpath</journal-id><journal-id journal-id-type="publisher-id">BPA</journal-id><journal-title-group><journal-title>Brain Pathology</journal-title></journal-title-group><issn pub-type="ppub">1015-6305</issn><issn pub-type="epub">1750-3639</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12488259</article-id><article-id pub-id-type="pmcid-ver">PMC12488259.1</article-id><article-id pub-id-type="pmcaid">12488259</article-id><article-id pub-id-type="pmcaiid">12488259</article-id><article-id pub-id-type="pmid">40506843</article-id><article-id pub-id-type="doi">10.1111/bpa.70019</article-id><article-id pub-id-type="publisher-id">BPA70019</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Human amyotrophic lateral sclerosis/motor neuron disease: The disease&#8208;associated microglial pathway is upregulated while <italic toggle="no">APOE</italic> genotype governs risk and survival</article-title><alt-title alt-title-type="right-running-head">Neuroinflammation in human amyotrophic lateral sclerosis/motor neuron disease</alt-title><alt-title alt-title-type="left-running-head">Ashford et al.</alt-title></title-group><contrib-group><contrib id="bpa70019-cr-0001" contrib-type="author"><name name-style="western"><surname>Ashford</surname><given-names initials="BA">Bridget A.</given-names></name><xref rid="bpa70019-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="bpa70019-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="bpa70019-cr-0002" contrib-type="author"><name name-style="western"><surname>Simpson</surname><given-names initials="JE">Julie E.</given-names></name><xref rid="bpa70019-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="bpa70019-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="bpa70019-cr-0003" contrib-type="author"><name name-style="western"><surname>Dawson</surname><given-names initials="C">Charlotte</given-names></name><xref rid="bpa70019-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="bpa70019-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="bpa70019-cr-0004" contrib-type="author"><name name-style="western"><surname>Boche</surname><given-names initials="D">Delphine</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5884-130X</contrib-id><xref rid="bpa70019-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="bpa70019-cr-0005" contrib-type="author"><name name-style="western"><surname>Cooper&#8208;Knock</surname><given-names initials="J">Johnathan</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0873-8689</contrib-id><xref rid="bpa70019-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="bpa70019-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="bpa70019-cr-0006" contrib-type="author"><name name-style="western"><surname>Heath</surname><given-names initials="PR">Paul R.</given-names></name><xref rid="bpa70019-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="bpa70019-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="bpa70019-cr-0007" contrib-type="author"><name name-style="western"><surname>Fillingham</surname><given-names initials="D">Daniel</given-names></name><xref rid="bpa70019-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="bpa70019-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="bpa70019-cr-0008" contrib-type="author"><name name-style="western"><surname>Appleby&#8208;Mallinder</surname><given-names initials="C">Charlie</given-names></name><xref rid="bpa70019-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="bpa70019-cr-0009" contrib-type="author"><name name-style="western"><surname>Wei</surname><given-names initials="W">Wenbin</given-names></name><xref rid="bpa70019-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="bpa70019-cr-0010" contrib-type="author"><name name-style="western"><surname>Dunning</surname><given-names initials="M">Mark</given-names></name><xref rid="bpa70019-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="bpa70019-cr-0011" contrib-type="author" corresp="yes"><name name-style="western"><surname>Highley</surname><given-names initials="JR">J. Robin</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4969-6526</contrib-id><xref rid="bpa70019-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="bpa70019-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>robin.highley@sheffield.ac.uk</email></address></contrib></contrib-group><aff id="bpa70019-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">SITraN</named-content>
<institution>University of Sheffield</institution>
<city>Sheffield</city>
<country country="GB">UK</country>
</aff><aff id="bpa70019-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Neuroscience Institute</named-content>
<institution>University of Sheffield</institution>
<city>Sheffield</city>
<country country="GB">UK</country>
</aff><aff id="bpa70019-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine</named-content>
<institution>University of Southampton</institution>
<city>Southampton</city>
<country country="GB">UK</country>
</aff><aff id="bpa70019-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Advanced Manufacturing Research Centre</named-content>
<institution>University of Sheffield</institution>
<city>Rotherham</city>
<country country="GB">UK</country>
</aff><aff id="bpa70019-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Biosciences</named-content>
<institution>University of Durham</institution>
<city>Durham</city>
<country country="GB">UK</country>
</aff><aff id="bpa70019-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Bioinformatics Core, School of Medicine and Population Health</named-content>
<institution>University of Sheffield</institution>
<city>Sheffield</city>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
J. Robin Highley, SITraN, University of Sheffield, Sheffield S10 2HQ, UK.<break/>
Email: <email>robin.highley@sheffield.ac.uk</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>6</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><volume>35</volume><issue seq="30">6</issue><issue-id pub-id-type="pmc-issue-id">498126</issue-id><issue-id pub-id-type="doi">10.1111/bpa.v35.6</issue-id><elocation-id>e70019</elocation-id><history><date date-type="received"><day>26</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>09</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 16:25:21.943"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Brain Pathology</italic> published by John Wiley &amp; Sons Ltd on behalf of International Society of Neuropathology.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="BPA-35-e70019.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:BPA-35-e70019.pdf"/><abstract><title>Abstract</title><p>A key role for inflammation in amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) has been identified. It is vital to assess which central nervous system structures are most affected and which inflammatory processes are responsible in humans. The inflammatory transcriptome was characterized in the cervical spinal cord and motor cortex in post&#8208;mortem frozen and formalin&#8208;fixed paraffin&#8208;embedded specimens from human sporadic ALS/MND and control cases using the nCounter&#174; Neuroinflammation Panel. Archival data were reanalyzed and compared with the nCounter data. Immunohistochemistry was used to examine the inflammatory response in the spinal cord and motor cortex and validate changes found during transcriptomic analyses. In the spinal cord, marked inflammation was observed, while less inflammation was detected in the motor cortex. Examination of differentially expressed genes in the spinal cord highlighted <italic toggle="no">TREM2</italic>, <italic toggle="no">TYROBP</italic>, <italic toggle="no">APOE</italic>, and <italic toggle="no">CD163</italic>, as well as phagocytic pathways. In sporadic ALS/MND spinal cord, significant microglial reactivity and involvement of TREM2, ApoE (encoded by <italic toggle="no">APOE</italic>), and TYROBP were confirmed, suggesting the involvement of the disease&#8208;associated microglial (DAM) phenotype. The corticospinal tracts showed greater inflammation than the ventral horns. The precentral gyrus of ALS/MND again showed less immune reactivity to disease when compared to controls. Finally, in the largest cohort assessed to date, we demonstrate an association between the <italic toggle="no">APOE</italic> variant and ALS/MND risk, age of onset, and survival. We find confirmed associations between <italic toggle="no">APOE</italic> &#949;3/&#949;3 and disease and between &#949;2/&#949;2 and absence of disease. Further, &#949;4/&#949;4 appears to be associated with earlier disease onset and a more aggressive course. We conclude that while there is widespread inflammation in the CNS in sporadic ALS/MND, this is more marked in the spinal cord, especially the corticospinal tract. The specific markers stress the DAM phenotype as having a key role together with a possible influx of somatic macrophages. In addition, <italic toggle="yes">APOE</italic> function and genotype may be relevant in ALS/MND.</p></abstract><abstract abstract-type="graphical"><p>ALS/MND&#8208;related inflammation is investigated in the motor cortex and spinal cord by both transcriptomics and immunohistochemistry. This reveals greater inflammation in the spinal cord and highlights the disease&#8208;associated microglial (DAM) phenotype characterized by ApoE, TREM2, and TYROBP. Genetic analyses reveal that APOE variants are related to the risk of ALS/MND and severity.<boxed-text position="anchor" content-type="graphic" id="bpa70019-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="BPA-35-e70019-g008.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="bpa70019-kwd-0001">amyotrophic lateral sclerosis</kwd><kwd id="bpa70019-kwd-0002">APOE</kwd><kwd id="bpa70019-kwd-0003">disease&#8208;associated microglia</kwd><kwd id="bpa70019-kwd-0004">inflammation</kwd><kwd id="bpa70019-kwd-0005">motor neuron disease</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Bruker Spatial Biology</institution></institution-wrap></funding-source></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>British Neuropathological Society</institution><institution-id institution-id-type="doi">10.13039/100014667</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Pathological Society of Great Britain and Ireland</institution><institution-id institution-id-type="doi">10.13039/501100000672</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="11"/><table-count count="2"/><page-count count="21"/><word-count count="12600"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>November 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:01.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="bpa70019-cit-9001"><string-name name-style="western"><surname>Ashford</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Simpson</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Dawson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Boche</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cooper&#8208;Knock</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Heath</surname><given-names>PR</given-names></string-name>, et al. <article-title>Human amyotrophic lateral sclerosis/motor neuron disease: The disease&#8208;associated microglial pathway is upregulated while <italic toggle="no">APOE</italic> genotype governs risk and survival</article-title>. <source>Brain Pathology</source>. <year>2025</year>;<volume>35</volume>(<issue>6</issue>):<elocation-id>e70019</elocation-id>. <pub-id pub-id-type="doi">10.1111/bpa.70019</pub-id><pub-id pub-id-type="pmcid">PMC12488259</pub-id><pub-id pub-id-type="pmid">40506843</pub-id></mixed-citation>
</p></notes></front><body id="bpa70019-body-0001"><sec id="bpa70019-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Motor Neuron Disease (MND) is a fatal neurodegenerative condition, characterized by the progressive degeneration of motor neurons [<xref rid="bpa70019-bib-0001" ref-type="bibr">1</xref>] with an incidence of 1.5&#8211;2 diagnoses in 100,000 people per year [<xref rid="bpa70019-bib-0002" ref-type="bibr">2</xref>]. Amyotrophic lateral sclerosis (ALS) is the most common clinical manifestation of MND in adults (accounting for 80%&#8211;90% of cases) and as such, the terms ALS and MND are often used interchangeably. The majority (90%&#8211;95%) of cases are sporadic. Survival time varies considerably, although 80% of patients survive only 2&#8211;5&#8201;years after diagnosis [<xref rid="bpa70019-bib-0003" ref-type="bibr">3</xref>]. Pathologically, ALS/MND is characterized by motor neuron and pyramidal tract degeneration, together with various proteinaceous inclusions composed principally of TDP&#8208;43 (MND&#8208;TDP) or cystatin C.</p><p>Microglia are the resident immune cells of the central nervous system (CNS), and account for between 5% and 12% of cells within the brain. Microglial density and function vary greatly with CNS region and age [<xref rid="bpa70019-bib-0004" ref-type="bibr">4</xref>, <xref rid="bpa70019-bib-0005" ref-type="bibr">5</xref>]. Under physiological conditions, microglia have a ramified morphology with small soma and fine processes [<xref rid="bpa70019-bib-0006" ref-type="bibr">6</xref>]. Under pathological conditions, the cells react to pathogens and damaged endogenous cells via Damage&#8208;Associated Molecular Patterns (DAMPs) with changes both in biological activity (with associated molecular markers) and morphology [<xref rid="bpa70019-bib-0007" ref-type="bibr">7</xref>]. This results in swollen and shortened cytoplasmic processes (hyper&#8208;ramification) and ultimately adopts a large, &#8220;amoeboid&#8221; morphology. Microglia present multifaceted signaling responses, leading to a complex phenotype. This changes with several factors, including the region of the CNS [<xref rid="bpa70019-bib-0008" ref-type="bibr">8</xref>], age [<xref rid="bpa70019-bib-0009" ref-type="bibr">9</xref>], activating stimuli, and disease [<xref rid="bpa70019-bib-0010" ref-type="bibr">10</xref>].</p><p>The microglial response is critical for CNS protection through the destruction and removal of damaged or dysfunctional cells or pathogens and the provision of trophic support. This response is highly effective. However, where the initial trigger is not resolved, a destructive cycle of microglial activation and neuron death is initiated: DAMPs that are released by degenerate cells can cause further inflammatory microglial activation, resulting in neuronal death [<xref rid="bpa70019-bib-0011" ref-type="bibr">11</xref>]. This can drive the progression of neurodegeneration [<xref rid="bpa70019-bib-0012" ref-type="bibr">12</xref>].</p><p>There is good evidence that neuroinflammation is a key feature of human ALS/MND. Firstly, transcriptomic analyses of <italic toggle="yes">post&#8208;mortem</italic> spinal cord have highlighted inflammation as one of the most altered pathways [<xref rid="bpa70019-bib-0013" ref-type="bibr">13</xref>]. At sites of neuronal loss in <italic toggle="yes">post&#8208;mortem</italic> tissues, CD68 and Iba1 immunohistochemistry (IHC) reveal microglia to transition from their ramified morphology to an &#8220;activated&#8221; morphology [<xref rid="bpa70019-bib-0014" ref-type="bibr">14</xref>, <xref rid="bpa70019-bib-0015" ref-type="bibr">15</xref>, <xref rid="bpa70019-bib-0016" ref-type="bibr">16</xref>]. Microglial activation correlates with the extent of TDP&#8208;43 pathology, executive dysfunction, upper motor neuron symptoms, and the rate of disease progression [<xref rid="bpa70019-bib-0015" ref-type="bibr">15</xref>, <xref rid="bpa70019-bib-0017" ref-type="bibr">17</xref>]. Secondly, in vivo positron emission tomography (PET) shows increased signal in both motor and extra&#8208;motor regions [<xref rid="bpa70019-bib-0018" ref-type="bibr">18</xref>], and an association between microglial activation and cortical thinning and a worse disease phenotype [<xref rid="bpa70019-bib-0017" ref-type="bibr">17</xref>]. Finally, CSF from ALS/MND patients has high levels of inflammatory cytokines [<xref rid="bpa70019-bib-0019" ref-type="bibr">19</xref>, <xref rid="bpa70019-bib-0020" ref-type="bibr">20</xref>, <xref rid="bpa70019-bib-0021" ref-type="bibr">21</xref>], the expression of which has been correlated with the disease progression rate [<xref rid="bpa70019-bib-0021" ref-type="bibr">21</xref>, <xref rid="bpa70019-bib-0022" ref-type="bibr">22</xref>, <xref rid="bpa70019-bib-0023" ref-type="bibr">23</xref>].</p><p>Human studies have established the presence of a generalized microglial reaction in motor neuron disease/amyotrophic lateral sclerosis. Attempts to specify which of the many molecular behaviors of microglia are relevant have predominantly utilized transgenic animal models of familial (not sporadic) ALS/MND. The most characterized and widely used models are those overexpressing <italic toggle="yes">SOD1</italic> mutations [<xref rid="bpa70019-bib-0024" ref-type="bibr">24</xref>, <xref rid="bpa70019-bib-0025" ref-type="bibr">25</xref>, <xref rid="bpa70019-bib-0026" ref-type="bibr">26</xref>, <xref rid="bpa70019-bib-0027" ref-type="bibr">27</xref>]. More recently, models have been created that contain transgenes with mutations in other genes (summarized by Lutz, 2018 [<xref rid="bpa70019-bib-0028" ref-type="bibr">28</xref>]), as well as in other species, including rats [<xref rid="bpa70019-bib-0029" ref-type="bibr">29</xref>] and zebrafish [<xref rid="bpa70019-bib-0030" ref-type="bibr">30</xref>, <xref rid="bpa70019-bib-0031" ref-type="bibr">31</xref>, <xref rid="bpa70019-bib-0032" ref-type="bibr">32</xref>]. Such studies have highlighted both toxic and neuroprotective microglial functions. However, there have been considerable inconsistencies. For example, older studies indicated a tendency toward an early increase in trophic and anti&#8208;inflammatory gene expression prior to symptom onset, followed by a switch to a more toxic, proinflammatory phenotype. In contrast, more recent studies have provided evidence indicating microglia express both protective and toxic factors consistently throughout disease (see [<xref rid="bpa70019-bib-0013" ref-type="bibr">13</xref>]).</p><p>Given the conflicting data from animal studies, it is worthwhile attempting to profile the inflammatory responses using human tissue. There are other good reasons to study MND/ALS&#8208;related neuroinflammation in human tissue. Thus, many animal studies have focused on pathology related to <italic toggle="yes">SOD1</italic> mutations. However, in human MND/ALS, patients with <italic toggle="yes">SOD1</italic> mutations (MND&#8208;SOD1) have a different pathological profile, lacking TDP&#8208;43 proteinopathy and having less extramotor disease, and have a subtly different clinical profile compared to more common forms of disease. It is thus arguably not comparable with &#8220;classical&#8221; ALS/MND pathology where there is TDP43 proteinopathy (MND&#8208;TDP). This issue, in combination with significant interspecies differences in anatomy and immunity [<xref rid="bpa70019-bib-0009" ref-type="bibr">9</xref>] raises questions about the validity of animal models to study inflammation in MND. Finally, transferring microglia from native tissue to in vitro culture has been shown to alter their transcriptome [<xref rid="bpa70019-bib-0033" ref-type="bibr">33</xref>]. This artefactual gene expression shift particularly impacts genes relevant to studies of neurodegeneration [<xref rid="bpa70019-bib-0034" ref-type="bibr">34</xref>].</p><p>For this reason, it is crucial to supplement the study of microglia in model systems with studies conducted in humans. The study that we report characterizes the neuroinflammatory and microglial phenotype in the motor system in human sporadic MND.</p><p>We performed a transcriptomic analysis of the motor regions of the CNS (ventral horn of the spinal cord and precentral gyrus&#8212;motor cortex) from control and sporadic ALS/MND cases to identify a neuroinflammatory signature. We then proceeded to use immunohistochemistry for microglial and macrophage markers to assess inflammation in the motor system of sporadic MND. Finally, we accessed publicly available data from the project MinE database [<xref rid="bpa70019-bib-0035" ref-type="bibr">35</xref>] and demonstrated a very significant relationship between APOE haplotype and MND, which affects both disease risk and severity.</p></sec><sec sec-type="methods" id="bpa70019-sec-0002"><label>2</label><title>METHODS</title><sec id="bpa70019-sec-0003"><label>2.1</label><title>Tissue collection, preparation, and <styled-content style="fixed-case" toggle="no">RNA</styled-content> extraction for <styled-content style="fixed-case" toggle="no">nCounter</styled-content> analysis</title><p>
<italic toggle="yes">Post&#8208;mortem</italic> snap&#8208;frozen and formalin&#8208;fixed paraffin&#8208;embedded (FFPE) cervical spinal cord tissue and snap&#8208;frozen motor cortex were obtained from the Sheffield Brain and Tissue Bank. Each cohort consisted of 16 sporadic ALS/MND cases of varying survival times from diagnosis to death and 8 normal control cases (Tables&#160;<xref rid="bpa70019-supitem-0001" ref-type="supplementary-material">S1&#8211;S3</xref>).</p><p>Frozen tissue was brought up to &#8722;20&#176;C from &#8722;80&#176;C for dissection in a freezer cabinet where the ventral horns and motor cortex were isolated from surrounding tissue by a qualified neuropathologist (JRH). Tissue was sampled unstained from the cervical enlargement. The tissue was visualized wearing a headband&#8208;mounted, illuminated magnification visor with 3&#215; magnification. This allowed good visualization of the gray/white matter interface, even without staining. A cross&#8208;section slice of cord approximately 1&#8201;mm thick was first cut freehand with a razor blade. The ventral horns were dissected from this using a scalpel. All dissections were performed freehand. Approximately 20&#8211;40&#8201;mg of tissue was collected per sample. For the formalin&#8208;fixed, paraffin&#8208;embedded (FFPE) spinal cord tissue, 10 sections of 50&#8201;&#956;M thickness were cut, and the ventral horns were isolated as for the frozen spinal cord in a similar manner.</p><p>RNA was extracted from frozen tissue using the Zymo Research Direct&#8208;zol&#8482; RNA Miniprep kit (Zymo Research, R2050) and from FFPE tissue using the Qiagen&#174; RNeasy FFPE kit (Qiagen, 73504) following manufacturers' instructions.</p></sec><sec id="bpa70019-sec-0004"><label>2.2</label><title>
<styled-content style="fixed-case" toggle="no">nCounter</styled-content> gene expression assay</title><p>The Bruker Spatial Biology (previously NanoString) Sprint Profiler Gene expression assay using the nCounter&#174; Human Neuroinflammation Panel (XT&#8208;CSO&#8208;HNROI1&#8208;12) was used on samples of 100&#8201;ng of RNA (5&#8201;&#956;L at 20&#8201;ng/&#956;L on the advice of nCounter technical staff) according to the manufacturer's protocols. The nCounter data are available at the University of Sheffield Online Research Data facility (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://hdl.handle.net/10779/sheffield.27908097.v1" ext-link-type="uri">https://hdl.handle.net/10779/sheffield.27908097.v1</ext-link>).</p><p>The nCounter data were analyzed using the limma&#8208;voom method [<xref rid="bpa70019-bib-0036" ref-type="bibr">36</xref>]. Briefly, data was normalized using the Trimmed Mean of M Values method and transformed using the voom function. A linear model for each gene was fitted using the lmFit function. The effect of age and sex was controlled for by adding these as covariates in the analysis. Tests for significance were performed using the eBayes function. Differentially expressed genes were identified with the criteria of Benjamini&#8208;Hochberg adjusted <italic toggle="yes">p</italic>&#8208;value (false discovery rate) &lt;0.05 and absolute fold change &gt;|1.5|.</p><p>For the frozen tissue, all cases were kept for analysis. FFPE spinal cord data for three cases (two controls and one MND) were discarded due to low count number.</p><p>The nCounter Neuroinflammation panel annotates each gene with associated KEGG pathways. The KEGG pathways from all significantly differentially expressed genes were counted to identify those that appeared most frequently. Pathway analysis was not performed on the motor cortex as insufficient genes reached significance following false discovery rate correction.</p></sec><sec id="bpa70019-sec-0005"><label>2.3</label><title>Length of survival analyzes</title><p>The association of genes with the length of survival from onset to death in sporadic ALS/MND cases was assessed using Cox proportional hazards regression and the log&#8208;rank test in the R survival package (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cran.r-project.org/web/packages/survival/index.html" ext-link-type="uri">https://cran.r&#8208;project.org/web/packages/survival/index.html</ext-link>). Cases were split into high&#8208; or low&#8208;expressing groups for each gene based on the median expression across cases. The effect of age and sex on survival was also analyzed using Cox proportional hazards regression. Age and sex did not have a significant influence on survival in this dataset.</p></sec><sec id="bpa70019-sec-0006"><label>2.4</label><title>Microglial/macrophage deconvolution</title><p>Those genes most associated with microglial/macrophage expression were determined using the online Brain RNASeq tool (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.brainrnaseq.org/" ext-link-type="uri">https://www.brainrnaseq.org/</ext-link>; [<xref rid="bpa70019-bib-0037" ref-type="bibr">37</xref>]). Each of the differentially expressed genes was entered into the database, and the fragments per kilobase of transcript per million mapped reads for the main glial/CNS cell types were given. A gene was determined to be microglial/macrophage specific if expression was greatest in the microglial/macrophage population and not highly expressed by any other cell population.</p></sec><sec id="bpa70019-sec-0007"><label>2.5</label><title>Bulk <styled-content style="fixed-case" toggle="no">RNA</styled-content>&#8208;seq analysis</title><p>To further assess the robustness of the nCounter dataset, we compared our results to the RNAseq data from another laboratory (NCBI sequence read archive SRP064478, [<xref rid="bpa70019-bib-0038" ref-type="bibr">38</xref>]). This cohort consisted of six sporadic ALS/MND cases (three male and three female) with a median age of 68.5&#8201;years and eight control cases (four male, four female) with a median age of 66.5&#8201;years. One case (ALS4, male) was excluded as this case has a pathogenic <italic toggle="yes">SOD1</italic> mutation.</p><p>The publicly available RNAseq reads (fastq files) from this study were quantified and aligned using the Salmon method. The resulting quant files were then imported into R for further analysis. Genes expressed over background in less than two cases were classed as low&#8208;expressing and were filtered out. Box plots were used to visualize the spread of the raw data and normalized data, which showed similar distribution across all samples. Heat maps were plotted, and PCA was performed to look for outliers. However, no clear outliers were identified; therefore, all cases were kept. Differential expression was performed using the generalized linear model framework of DESeq2 with the control group as the baseline [<xref rid="bpa70019-bib-0039" ref-type="bibr">39</xref>].</p></sec><sec id="bpa70019-sec-0008"><label>2.6</label><title>Immunohistochemistry for neuroinflammatory markers in <styled-content style="fixed-case" toggle="no">MND</styled-content>/<styled-content style="fixed-case" toggle="no">ALS</styled-content>
</title><p>FFPE <italic toggle="yes">post&#8208;mortem</italic> tissue from the precentral gyrus and cervical spinal cord was obtained from the Sheffield Brain and Tissue Bank for immunohistochemistry. Tissue sections were used for assessment of the spinal cord (<italic toggle="yes">n</italic>&#8201;=&#8201;28 sporadic ALS/MND, <italic toggle="yes">n</italic>&#8201;=&#8201;14 control; Table&#160;<xref rid="bpa70019-supitem-0001" ref-type="supplementary-material">S4</xref>). These were largely different cases from those that had been used for nCounter assessment: Only three ALS/MND cases and two controls had been assessed by nCounter on frozen tissue. The motor cortex and underlying white matter were assessed using tissue microarrays (<italic toggle="yes">n</italic>&#8201;=&#8201;63 sporadic ALS/MND, <italic toggle="yes">n</italic>&#8201;=&#8201;7 control; Table&#160;<xref rid="bpa70019-supitem-0001" ref-type="supplementary-material">S5</xref>), with two cores sampled from each tissue using the Beecher MTA&#8208;1 Tissue Microarrayer [<xref rid="bpa70019-bib-0040" ref-type="bibr">40</xref>]. Again, these were largely different cases from those that had been used for nCounter assessment: Only five ALS/MND cases and no controls had been assessed by nCounter on frozen tissue.</p><p>Immunohistochemistry was performed using the avidin&#8208;biotin complex (ABC) method on 5&#8201;&#956;m&#8208;thick sections using antibodies, antibody concentrations, and antigen retrieval protocols detailed in Table&#160;<xref rid="bpa70019-supitem-0001" ref-type="supplementary-material">S6</xref>. Slides were scanned using the Hamamatsu NanoZoomer slide scanner at &#215;40 magnification (Hamamatsu Photonics, Japan).</p><p>TREM2 immunohistochemistry was performed in bone marrow and spleen in order to explore specificity (Figure&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="bpa70019-sec-0009"><label>2.7</label><title>Analysis of co&#8208;expression</title><p>ApoE expression in the CNS is known to be primarily astrocytic [<xref rid="bpa70019-bib-0041" ref-type="bibr">41</xref>]. However, as TREM2 and TYROBP are less well characterized, we performed double staining to determine which cell type was expressing these markers. Slides were dewaxed, rehydrated through alcohols, and endogenous peroxidases were blocked in 3% hydrogen peroxide for 20 mins. The slides underwent antigen retrieval and a standard ABC immunohistochemistry protocol. The first protein of interest was visualized using the ImmPACT AMEC red substrate kit (Vector Laboratories, SK&#8208;4285). Slides were washed in tap water and mounted using aqueous mounting media, dried, and digitized. Following this, slides were decoverslipped, and the dye was dissolved in graduated alcohols. Unbound avidin and biotin from the first stain were blocked using avidin and biotin blocking solution (Vector Laboratories, SP&#8208;2001). The slides were then rehydrated and stained using a standard ABC protocol using a second primary antibody, visualized with DAB, coverslipped, and rescanned.</p></sec><sec id="bpa70019-sec-0010"><label>2.8</label><title>Image analysis</title><p>Visiopharm (Hoersholm, Denmark) image analysis software was used to quantify immunoreactivity using a previously developed &#8220;modular analysis unit&#8221; (referred to as an APP by Visiopharm), which assesses area density (percentage of a region of interest that is positive for immunoreactivity) [<xref rid="bpa70019-bib-0040" ref-type="bibr">40</xref>]. Following pre&#8208;processing, modular analysis units were trained specifically for each protein of interest, using the Visiopharm training wizard.</p><p>In spinal cord sections, the ventral horns, the dorsal column, and the lateral corticospinal tracts were selected for quantification by manually drawing around these structures on the whole microscope slide images within Visiopharm, using an adjacent Luxol fast blue&#8208;stained section to delineate the appropriate anatomy where necessary.</p><p>In spinal cord sections stained for TREM2, motor neurons showed evidence of lipofuscin staining by DAB, which the Visiopharm software was unable to differentiate from true signal. To prevent bias in quantification&#8212;as sporadic ALS/MND cases will have fewer motor neurons compared to controls, neurons were excluded from analysis using a filter that reclassifies DAB&#8208;positive areas larger than 200&#8201;&#956;M as areas in the background (Figure&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S2</xref>).</p><p>In the spinal cord, specific regions were selected for quantification: the ventral horns, the lateral corticospinal tracts, and the dorsal column. The latter is an ascending sensory tract that we expected to be less affected by MND pathology.</p><p>All statistical analysis was performed using GraphPad Prism (versions 7,8,9). For all statistical analyzes, the significance value was set at alpha &lt;0.05.</p><p>As many data sets were not normally distributed (by Shapiro&#8208;Wilk), non&#8208;parametric statistics were used for intergroup comparisons: The Kruskal&#8208;Wallis test followed by post hoc Mann&#8211;Whitney <italic toggle="yes">U</italic> tests was used for most intergroup comparisons.</p><p>To examine the relationship with patient survival, sporadic ALS/MND cases were split into fast&#8208; or slow&#8208;progressing groups based on the median length of survival for each cohort, again using Kruskal&#8211;Wallis followed by post hoc Mann&#8211;Whitney <italic toggle="yes">U</italic> tests.</p></sec><sec id="bpa70019-sec-0011"><label>2.9</label><title>Genotyping of <styled-content style="fixed-case" toggle="no">APOE</styled-content>
</title><p>Phased genotyping data for rs429358 and rs7412 were obtained from the latest ALS/MND GWAS consisting of 29,612 ALS/MND patients and 122,656 controls [<xref rid="bpa70019-bib-0035" ref-type="bibr">35</xref>]. Samples were assigned to APOE haplotypes &#949;4, &#949;4/&#949;3, &#949;3/&#949;3, &#949;4/&#949;2, &#949;3/&#949;2, and &#949;2/&#949;2. Analysis of the relationship between ALS/MND status and APOE genotype was conducted by multivariable logistic regression using sex and the first 10 principal components of genetic variation as covariates. For this analysis, homozygous and heterozygote individuals were considered equivalent. Cox regression was used to assess the relationship with survival and age of disease onset in a subset of 4897 patients where phenotypic information was available; this analysis used sex, age (for survival only), and the first 10 principal components of genetic variation as covariates.</p></sec></sec><sec sec-type="results" id="bpa70019-sec-0012"><label>3</label><title>RESULTS</title><sec id="bpa70019-sec-0013"><label>3.1</label><title>The transcriptomic profile shows considerable inflammation of the spinal cord in <styled-content style="fixed-case" toggle="no">MND</styled-content>/<styled-content style="fixed-case" toggle="no">ALS</styled-content> and highlights the <styled-content style="fixed-case" toggle="no">ApoE</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">TYROBP</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">TREM2</styled-content> pathway</title><p>The nCounter Neuroinflammation Panel was used to assess the spinal cord ventral horn in two tissue cohorts (one snap&#8208;frozen and one FFPE). Significantly more genes were upregulated (76 in the frozen tissue dataset and 62 in the FFPE tissue dataset) than downregulated (13 in the frozen tissue and 38 in the FFPE tissue; Figure&#160;<xref rid="bpa70019-fig-0001" ref-type="fig">1</xref>, Tables&#160;<xref rid="bpa70019-supitem-0001" ref-type="supplementary-material">S7&#8211;S10</xref>).</p><fig position="float" fig-type="FIGURE" id="bpa70019-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>sMND is associated with an increase in inflammatory signaling in the spinal cord&#8212;frozen and FFPE tissue. (A) Heatmap displaying the normalized and row&#8208;scaled expression of 128 differentially expressed genes (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 and FC&#8201;&gt;1.5) between MND and neurologically healthy cases. Genes are shown on the y&#8208;axis. (B) Heatmap displaying the normalized and row&#8208;scaled expression of 219 differentially expressed genes (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 and FC&#8201;&gt;1.5) between MND and neurologically healthy cases. Genes are shown on the y&#8208;axis. (C) Volcano plot for frozen spinal cord tissue showing fold change against the significance value. Of all the significant genes, 72 were upregulated, and 13 genes were downregulated (green points <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; FC&#8201;&gt;1.5; orange points FDR adjusted <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; FC&#8201;&gt;1.5, labeled points FDR adjusted <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; FC&#8201;&gt;2). (D) Volcano plot for FFPE spinal cord tissue showing fold change against the significance value. Of all the significant genes, 62 were upregulated, and 38 genes were downregulated (green points <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; FC&#8201;&gt;1.5; orange points FDR adjusted <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; FC&#8201;&gt;1.5, labeled points FDR adjusted <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; FC&#8201;&gt;2).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="BPA-35-e70019-g010.jpg"/></fig><p>The fold changes of all 770 genes (including those that were not significantly affected by disease) from the frozen spinal cord data set were significantly correlated with the fold changes from both the FFPE dataset (<italic toggle="yes">R</italic>&#8201;=&#8201;0.148, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and another RNASeq spinal cord MND dataset from the literature used for validation [<xref rid="bpa70019-bib-0038" ref-type="bibr">38</xref>] (<italic toggle="yes">R</italic>&#8201;=&#8201;0.25, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0011). Importantly, all three datasets (our frozen and FFPE nCounter datasets and the RNAseq dataset&#160;[<xref rid="bpa70019-bib-0038" ref-type="bibr">38</xref>]) showed upregulation of <italic toggle="yes">APOE</italic>, <italic toggle="yes">TYROBP</italic>, and <italic toggle="yes">TREM2</italic>. These three components form a pathway with a key role in inflammatory regulation and can induce a disease&#8208;associated state in microglia (see below).</p><p>Of the 89 differentially expressed genes from the frozen dataset that were known to have cell&#8208;specific expression [<xref rid="bpa70019-bib-0037" ref-type="bibr">37</xref>], 50 genes were known to be primarily expressed by microglia or macrophages. The KEGG pathways associated with the differentially expressed transcripts from sporadic ALS/MND spinal cord were ranked by the number of genes associated with each pathway (see Table&#160;<xref rid="bpa70019-supitem-0001" ref-type="supplementary-material">S11</xref>).</p><p>By Cox Proportional Hazards Regression, 23 and 17 genes were associated with longer survival in the frozen and FFPE datasets, respectively. Shorter survival was associated with 21 and 23 genes in the frozen and FFPE datasets, respectively (Tables&#160;<xref rid="bpa70019-supitem-0001" ref-type="supplementary-material">S12&#8211;S15</xref>). Functionally, genes associated with longer survival were involved in both the adaptive and innate immune response, cytokine signaling, growth factor signaling, autophagy, and apoptosis. Genes associated with shorter survival had overlapping functions, namely innate and adaptive immunity, cytokine signaling, growth factors, and microglial function.</p><p>Inflammation in the <italic toggle="yes">motor cortex</italic> was studied using the nCounter platform in one snap&#8208;frozen tissue cohort (<italic toggle="yes">n</italic>&#8201;=&#8201;16 sporadic ALS/MND cases and 8 neurologically healthy controls for each dataset). In contrast to the spinal cord, none of the 770 genes assessed were significantly altered following false discovery rate correction (Figure&#160;<xref rid="bpa70019-fig-0002" ref-type="fig">2</xref>).</p><fig position="float" fig-type="FIGURE" id="bpa70019-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>The motor cortex shows little inflammatory signaling in sMND. (A) Heatmap displaying the normalized and row&#8208;scaled expression of 42 differentially expressed genes (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 and FC&#8201;&gt;1.5) between MND and neurologically healthy cases. (B) Volcano plot showing fold change against the significance value. Green Points <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; FC&#8201;&gt;1.5. No genes reached significance following FDR correction.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="BPA-35-e70019-g001.jpg"/></fig><p>In summary, RNA&#8208;based gene expression analysis shows concordance between nCounter datasets obtained from FFPE and frozen tissue, and the nCounter analyses are consistent with an archival RNA&#8208;seq dataset from the literature. The inflammation in the spinal cord appears more severe than in the motor cortex in MND. The analysis highlighted several key inflammatory processes, including <italic toggle="yes">APOE&#8208;TYROBP/DAP12&#8208;TREM2</italic> signaling.</p></sec><sec id="bpa70019-sec-0014"><label>3.2</label><title>Immunohistochemistry for inflammatory markers in sporadic <styled-content style="fixed-case" toggle="no">ALS</styled-content>/<styled-content style="fixed-case" toggle="no">MND</styled-content>
</title><p>Immunohistochemistry was performed to elucidate and confirm the findings from the nCounter&#8208;based investigation above: Ionized calcium&#8208;binding adaptor molecule 1 IBA1, a fairly universal marker of microglia and monocytes [<xref rid="bpa70019-bib-0042" ref-type="bibr">42</xref>], MHCII/HLA&#8208;DR (a marker of activated microglia [<xref rid="bpa70019-bib-0042" ref-type="bibr">42</xref>], and CD68 a marker of microglial phagocytosis [<xref rid="bpa70019-bib-0043" ref-type="bibr">43</xref>]) were assessed. In addition, Cluster of Differentiation 163 (CD163, primarily expressed by perivascular macrophages [<xref rid="bpa70019-bib-0044" ref-type="bibr">44</xref>]) was assessed as highlighted by the nCounter data.</p></sec><sec id="bpa70019-sec-0015"><label>3.3</label><title>There is substantial spinal cord inflammation in sporadic <styled-content style="fixed-case" toggle="no">ALS</styled-content>/<styled-content style="fixed-case" toggle="no">MND</styled-content>, which is variable in anatomical extent and severity</title><p>In qualitative terms, IBA1, CD68, and HLA&#8208;DR labeled microglia and perivascular macrophages in both control and sporadic MND/ALS cases. However, in sporadic ALS/MND, IBA1<sup>+</sup> microglia had a more reactive/activated morphology characterized by thicker processes and larger soma, with some cells acquiring an amoeboid form. This was most marked in the motor regions (ventral horns and corticospinal tracts; Figure&#160;<xref rid="bpa70019-fig-0003" ref-type="fig">3</xref> and Figures&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S3&#8211;S5</xref>). This reaction showed variation in anatomical extent, severity of inflammation, and cellular morphology within the MND cohort. While the inflammation was most prominent in motor regions, in some cases, the reaction was present throughout most of the spinal cord, albeit with lesser involvement of the dorsal columns (Figure&#160;<xref rid="bpa70019-fig-0004" ref-type="fig">4</xref>). Thus, classically sensory tracts such as the spinothalamic tract were involved in some individuals. HLA&#8208;DR showed more florid inflammation in terms of the area density of labeling (proportion of the tissue positive for this marker) compared to other markers (Figure&#160;<xref rid="bpa70019-fig-0005" ref-type="fig">5C</xref> and Figure&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S5</xref>).</p><fig position="float" fig-type="FIGURE" id="bpa70019-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>IBA1 in the spinal cord of controls and ALS/MND cases. IBA1 labels perivascular macrophages (black arrows) and microglia (open arrows). In a control spinal cord, microglia tend to be ramified. In MND spinal cord, perivascular macrophages were swollen in some cases compared to the control. Microglia tended to show a mixture of ramified (open arrows) and amoeboid (gray arrows) morphology. (A) control ventral horn; (B) MND/ALS ventral horn; (C) control lateral corticospinal tract (LCST); D, sMND/ALS corticospinal tract. Scale bars&#8201;=&#8201;50&#8201;&#956;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="BPA-35-e70019-g009.jpg"/></fig><fig position="float" fig-type="FIGURE" id="bpa70019-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Heterogeneity of HLA&#8208;DR immunoreactivity in sMND cases. In the spinal cord, sMND cases varied greatly in the level of HLA&#8208;DR staining present. Both cases (A &amp; B) are sMND cases. However, as visible from the low magnification image, these cases showed very different levels of HLA&#8208;DR&#8208;positive microgliosis. (A1 and B1) show higher magnification images of the lateral corticospinal tract for these cases. In the low pathology case (A1) microglia were rounded (when compared to control) and showed thickened processes. In the high pathology case (B2) microglia were completely rounded and showed much denser staining. (A2 and B2) show higher magnification images of the ventral horn. In case A (low pathology) microglia again showed thick processes, swollen cell bodies, and an increased number of HLA&#8208;DR&#8208;positive microglia. In case B, HLA&#8208;DR&#8208;positive microglia were much rounder, many becoming ameboid, and microgliosis was much more severe. A and B scale bars =2.5&#8201;mm; A1, A2, B1, and B2 scale bars =100&#8201;&#956;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="BPA-35-e70019-g006.jpg"/></fig><fig position="float" fig-type="FIGURE" id="bpa70019-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Area density for a variety of monocyte/microglial markers in MND/ALS spinal cord. There is greater inflammation in the motor structures of the cord, namely the ventral horns (VH) and lateral corticospinal tracts (LCST) in MND/ALS, as shown by IBA1 (A), CD68 (B), HLA&#8208;DR (C), and CD163 (D). There is some lower&#8208;level inflammation seen in the sensory dorsal columns when assessed by CD163 and CD68.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="BPA-35-e70019-g004.jpg"/></fig><p>CD163 was largely confined to perivascular macrophages with minimal microglial expression in the control spinal cord (Figure&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S6</xref>). In MND/ALS cases, there was a variable increase in the number of positive cells in the ventral horns and corticospinal tracts both by perivascular macrophages and also by small numbers of cells within the spinal cord parenchyma.</p><p>By image analysis, the ventral horn, dorsal column, and lateral corticospinal tract showed significant upregulation of expression of IBA1, CD68, HLA&#8208;DR, and CD163 in the lateral corticospinal tracts in MND/ALS compared to controls (Table&#160;<xref rid="bpa70019-tbl-0001" ref-type="table">1</xref>). Significant upregulation was seen in the ventral horn for Iba1, CD68, and CD163, but not HLA&#8208;DR. There was also significant upregulation in the dorsal column for CD68 and CD163 (Figure&#160;<xref rid="bpa70019-fig-0005" ref-type="fig">5</xref>). MND/ALS patients with shorter survival had greater HLA&#8208;DR expression in the ventral horns and lateral corticospinal tracts (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0148 and 0.005, respectively).</p><table-wrap position="float" id="bpa70019-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Median area density in sMND/ALS and neurologically healthy controls of inflammatory markers assessed by immunohistochemistry.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Marker</th><th align="left" valign="bottom" rowspan="1" colspan="1">Cord region</th><th align="left" valign="bottom" rowspan="1" colspan="1">Disease status</th><th align="left" valign="bottom" rowspan="1" colspan="1">Median area density (%)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Kruskal&#8211;Wallis H(5)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Kruskal&#8211;Wallis <italic toggle="yes">p</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Post hoc Mann&#8211;Whitney <italic toggle="yes">U</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Post hoc Mann&#8211;Whitney <italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="6" valign="top" colspan="1">Iba1</td><td align="left" rowspan="2" valign="top" colspan="1">Ventral horn</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.745</td><td align="char" char="." rowspan="6" valign="top" colspan="1">50</td><td align="char" char="." rowspan="6" valign="top" colspan="1">0.0002</td><td align="left" rowspan="2" valign="top" colspan="1">61</td><td align="left" rowspan="2" valign="top" colspan="1">0.03</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.999</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Dorsal column</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.253</td><td align="left" rowspan="2" valign="top" colspan="1">75</td><td align="left" rowspan="2" valign="top" colspan="1">0.0963</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.04</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Corticospinal tract</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.683</td><td align="left" rowspan="2" valign="top" colspan="1">50</td><td align="left" rowspan="2" valign="top" colspan="1">0.0007</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4.538</td></tr><tr><td align="left" rowspan="6" valign="top" colspan="1">CD68</td><td align="left" rowspan="2" valign="top" colspan="1">Ventral horn</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.206</td><td align="char" char="." rowspan="6" valign="top" colspan="1">32.1</td><td align="char" char="." rowspan="6" valign="top" colspan="1">&lt;0.0001</td><td align="left" rowspan="2" valign="top" colspan="1">24</td><td align="left" rowspan="2" valign="top" colspan="1">&lt;0.0001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.761</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Dorsal column</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.254</td><td align="left" rowspan="2" valign="top" colspan="1">26</td><td align="left" rowspan="2" valign="top" colspan="1">0.0139</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.798</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Corticospinal tract</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.204</td><td align="left" rowspan="2" valign="top" colspan="1">23</td><td align="left" rowspan="2" valign="top" colspan="1">&lt;0.0001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.000</td></tr><tr><td align="left" rowspan="6" valign="top" colspan="1">HLA&#8208;DR</td><td align="left" rowspan="2" valign="top" colspan="1">Ventral horn</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4.351</td><td align="char" char="." rowspan="6" valign="top" colspan="1">21.5</td><td align="char" char="." rowspan="6" valign="top" colspan="1">&lt;0.001</td><td align="left" rowspan="2" valign="top" colspan="1">111</td><td align="left" rowspan="2" valign="top" colspan="1">0.181</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">5.898</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Dorsal column</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4.343</td><td align="left" rowspan="2" valign="top" colspan="1">131</td><td align="left" rowspan="2" valign="top" colspan="1">0.412</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4.122</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Corticospinal tract</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4.581</td><td align="left" rowspan="2" valign="top" colspan="1">59</td><td align="left" rowspan="2" valign="top" colspan="1">0.003</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.549</td></tr><tr><td align="left" rowspan="6" valign="top" colspan="1">CD163</td><td align="left" rowspan="2" valign="top" colspan="1">Ventral horn</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.158</td><td align="char" char="." rowspan="6" valign="top" colspan="1">36.66</td><td align="char" char="." rowspan="6" valign="top" colspan="1">&lt;0.0001</td><td align="left" rowspan="2" valign="top" colspan="1">14</td><td align="left" rowspan="2" valign="top" colspan="1">0.0007</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.383</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Dorsal column</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.100</td><td align="left" rowspan="2" valign="top" colspan="1">33</td><td align="left" rowspan="2" valign="top" colspan="1">0.028</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.244</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Corticospinal tract</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.091</td><td align="left" rowspan="2" valign="top" colspan="1">4</td><td align="left" rowspan="2" valign="top" colspan="1">&lt;0.0001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.597</td></tr><tr><td align="left" rowspan="6" valign="top" colspan="1">APOE</td><td align="left" rowspan="2" valign="top" colspan="1">Ventral horn</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.3115</td><td align="char" char="." rowspan="6" valign="top" colspan="1">25.57</td><td align="char" char="." rowspan="6" valign="top" colspan="1">&lt;0.0001</td><td align="left" rowspan="2" valign="top" colspan="1">32</td><td align="left" rowspan="2" valign="top" colspan="1">0.0036</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.659</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Dorsal column</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.0838</td><td align="left" rowspan="2" valign="top" colspan="1">51</td><td align="left" rowspan="2" valign="top" colspan="1">0.949</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.6082</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Corticospinal tract</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.115</td><td align="left" rowspan="2" valign="top" colspan="1">20</td><td align="left" rowspan="2" valign="top" colspan="1">0.0003</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.456</td></tr><tr><td align="left" rowspan="6" valign="top" colspan="1">TYROBP</td><td align="left" rowspan="2" valign="top" colspan="1">Ventral horn</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.496</td><td align="char" char="." rowspan="6" valign="top" colspan="1">15.51</td><td align="char" char="." rowspan="6" valign="top" colspan="1">0.008</td><td align="left" rowspan="2" valign="top" colspan="1">11</td><td align="left" rowspan="2" valign="top" colspan="1">0.009</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.889</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Dorsal column</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.4715</td><td align="left" rowspan="2" valign="top" colspan="1">20</td><td align="left" rowspan="2" valign="top" colspan="1">0.075</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.364</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Corticospinal tract</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.8215</td><td align="left" rowspan="2" valign="top" colspan="1">12</td><td align="left" rowspan="2" valign="top" colspan="1">0.018</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4.148</td></tr><tr><td align="left" rowspan="6" valign="top" colspan="1">TREM2</td><td align="left" rowspan="2" valign="top" colspan="1">Ventral horn</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.86</td><td align="char" char="." rowspan="6" valign="top" colspan="1">8.449</td><td align="char" char="." rowspan="6" valign="top" colspan="1">0.133</td><td align="left" rowspan="2" valign="top" colspan="1">N/A</td><td align="left" rowspan="2" valign="top" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.942</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Dorsal column</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.93</td><td align="left" rowspan="2" valign="top" colspan="1">N/A</td><td align="left" rowspan="2" valign="top" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.545</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Corticospinal tract</td><td align="left" valign="top" rowspan="1" colspan="1">sMND/ALS</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.439</td><td align="left" rowspan="2" valign="top" colspan="1">N/A</td><td align="left" rowspan="2" valign="top" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.989</td></tr></tbody></table></table-wrap></sec><sec id="bpa70019-sec-0016"><label>3.4</label><title>The apolipoprotein E&#8208;<styled-content style="fixed-case" toggle="no">TREM2</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">TYROBP</styled-content> pathway is upregulated in motor components of the spinal cord</title><p>ApoE immunohistochemistry revealed expression throughout the spinal cord that was more marked in gray than white matter when viewed at low magnification. While there was labeling of the cord neuropil, there was especially strong labeling in glial cells predominantly of astrocytic morphology (Figure&#160;<xref rid="bpa70019-fig-0006" ref-type="fig">6</xref>, Figure&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S7</xref>). A subset of motor neurons was also strongly stained. In MND/ALS cases, there was a greater number of glial cells expressing ApoE in the corticospinal tract and in the ventral horns. The proportion of motor neurons that were positive or negative for ApoE did not differ between MND/ALS cases and controls.</p><fig position="float" fig-type="FIGURE" id="bpa70019-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>ApoE immunoreactivity in the spinal cord. In control (A) and MND/ALS (B) spinal cord, at low power, ApoE is seen in higher levels in the gray matter compared to the white matter. In MND/ALS cases, ApoE is increased in the corticospinal tract (gray arrows) and ventral horns (black arrows). At higher power (C, control ventral horn; D, MND/ALS ventral horn), ApoE is present in endothelial cells (open arrows), perivascular macrophages (gray arrows) and parenchymal glial cells (black arrows) that have the appearance of astrocytes, as well as the background neuropil. There is also variable motor neuron staining (E): Some having a high signal (black arrow), others have a similar signal to the surrounding parenchyma (gray arrows) and a small number of neurons have no immunoreactivity (open arrows). This differential ApoE expression varied greatly between cases and was not associated with disease/control status. Scale bars: A,B&#8201;=&#8201;2.5&#8201;mm; B,C&#8201;=&#8201;50&#8201;&#956;m; D&#8201;=&#8201;100&#8201;&#956;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="BPA-35-e70019-g002.jpg"/></fig><p>Digital image analyses showed significantly greater cellular ApoE area density in the lateral corticospinal tract (U&#8201;=&#8201;20, <italic toggle="yes">p</italic>&#8201;=&#8201;0.0003) and ventral horns (U&#8201;=&#8201;32, <italic toggle="yes">p</italic>&#8201;=&#8201;0.0036) but not in the dorsal columns in MND/ALS (U&#8201;=&#8201;51, <italic toggle="yes">p</italic>&#8201;=&#8201;0.0949).</p><p>TYROBP (also known as DAP12), showed a similar pattern of expression to ApoE, being present in neuropil, neurons, glia, and blood vessels with greater expression in gray than white matter in both control and sporadic ALS/MND groups (Figure&#160;<xref rid="bpa70019-fig-0007" ref-type="fig">7</xref>, Figure&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S8</xref>). In blood vessels, endothelial cells were faintly labeled, with stronger labeling of the smooth muscle in the media of arterioles and arteries. Veins showed very little staining.</p><fig position="float" fig-type="FIGURE" id="bpa70019-fig-0007" orientation="portrait"><label>FIGURE 7</label><caption><p>Expression of TYROBP in the spinal cord. In control (A) and MND/ALS (B) spinal cord at low magnification, TYROBP immunoreactivity was present in the neuropil, at higher levels in the gray matter compared to the white matter. Glial staining in the white matter, particularly in the corticospinal tracts, was increased in MND/ALS cases. At higher magnification (C), TYROBP&#8208;labeled motor neurons in the ventral horn (black arrow), and blood vessels (gray arrow), as well as various ramified (white arrow) and unramified glia (open arrow). Image taken from the ventral horn. In MND/ALS ventral horn (D,E), there was greater TYROBP expression in perivascular cells. Scale bars: A,B&#8201;=&#8201;2.5&#8201;mm; D&#8201;=&#8201;250&#8201;&#956;m; C,E&#8201;=&#8201;50&#8201;&#956;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-15" orientation="portrait" xlink:href="BPA-35-e70019-g003.jpg"/></fig><p>In sporadic ALS/MND cases, microscopy revealed an increase of both perivascular macrophages and interstitial glial TYROBP staining, especially in the corticospinal tracts and the ventral horns. Ramified cells tended to be observed in the ventral horns and more amoeboid cells in the corticospinal tracts (Figure&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S8</xref>). Glial upregulation was especially marked in perivascular locations (Figure&#160;<xref rid="bpa70019-fig-0007" ref-type="fig">7</xref>). Image analysis confirmed increased TYROBP in the ventral horns (U&#8201;=&#8201;11, <italic toggle="yes">p</italic>&#8201;=&#8201;0.009) and corticospinal tracts (U&#8201;=&#8201;12, <italic toggle="yes">p</italic>&#8201;=&#8201;0.018), but not dorsal columns in MND/ALS (U&#8201;=&#8201;20, <italic toggle="yes">p</italic>&#8201;=&#8201;0.075; Figure&#160;<xref rid="bpa70019-fig-0008" ref-type="fig">8</xref>). There was no relationship with survival time (<italic toggle="yes">p</italic>&#8201;=&#8201;0.932).</p><fig position="float" fig-type="FIGURE" id="bpa70019-fig-0008" orientation="portrait"><label>FIGURE 8</label><caption><p>Area density for a variety of ApoE, TYROBP, and TREM2 in MND/ALS spinal cord. There is greater expression of ApoE (A) and TYROBP (B) in the motor structures of the cord, namely the ventral horns (VH) and lateral corticospinal tracts (LCST) in MND/ALS. There were no such intergroup differences in TREM2 (C). However, excess TREM2 expression was associated with slower disease progression (D).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-17" orientation="portrait" xlink:href="BPA-35-e70019-g011.jpg"/></fig><p>TREM2 expression was seen in a few perivascular macrophages, a variable proportion of motor neurons, and a few glial cells in the parenchyma (Figure&#160;<xref rid="bpa70019-fig-0009" ref-type="fig">9</xref>, Figure&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S9</xref>). There was greater expression in the gray compared to the white matter. Control and MND/ALS cases showed similar patterns of TREM2 expression. Image analysis found no difference between groups in the degree of TREM2 expression (H(5)&#8201;=&#8201;8.449, <italic toggle="yes">p</italic>&#8201;=&#8201;0.133; Figure&#160;<xref rid="bpa70019-fig-0010" ref-type="fig">10</xref>). There was a significant relationship between longer survival and greater expression in the white matter tracts (dorsal column, U&#8201;=&#8201;11, <italic toggle="yes">p</italic>&#8201;=&#8201;0.008; corticospinal tract, U&#8201;=&#8201;15, <italic toggle="yes">p</italic>&#8201;=&#8201;0.024), but not the ventral horn (U&#8201;=&#8201;27, <italic toggle="yes">p</italic>&#8201;=&#8201;0.258) by digital image analysis.</p><fig position="float" fig-type="FIGURE" id="bpa70019-fig-0009" orientation="portrait"><label>FIGURE 9</label><caption><p>TREM2 expression was minimal in the parenchyma. TREM2 immunoreactivity was minimal in the parenchyma, although some cases did show slightly greater labeling of the gray matter compared to white. At low power, there was little difference between control cases (A) and sMND cases (B). At higher power, TREM2 was seen in a few small, rounded cells, likely perivascular macrophages (C). The majority of neurons showed minimal TREM2 signal (open arrow, D). However, TREM2 immunoreactivity did label a small number of motor neurons more strongly in the ventral horn (black arrow). These were not present in all cases and did not appear to be associated with either sMND or control cases specifically. In the parenchyma (E), small TREM2&#8201;+&#8201;ve granules were observed. Some granules were associated with glial or monocyte cells (open arrow). Others were not (gray arrow). Scale bars: B&#8201;=&#8201;2.5&#8201;mm; C,D,E&#8201;=&#8201;25&#8201;&#956;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-19" orientation="portrait" xlink:href="BPA-35-e70019-g007.jpg"/></fig><p>To determine which cells were expressing ApoE, TYROBP, and TREM2, sections of spinal cord from MND/ALS individuals were serially immunostained for ApoE, TYROBP, or TREM2, then IBA1 (Figure&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S10</xref>). This revealed that most of the cells that were strongly positive for these markers were IBA1&#8208;positive microglia and perivascular macrophages.</p></sec><sec id="bpa70019-sec-0017"><label>3.5</label><title>The neuroinflammatory response in the motor cortex is less than that in the spinal cord in <styled-content style="fixed-case" toggle="no">MND</styled-content>
</title><p>In both sporadic ALS/MND and control cases, as was observed in the spinal cord, IBA1, CD68, and HLA&#8208;DR label microglia and perivascular macrophages with considerable individual variation in the number of cells labeled. CD163 was largely confined to perivascular macrophages (Figure&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S11</xref>).</p><p>In control cases, microglia were ramified with fine processes in both white and gray matter. In sporadic ALS/MND cases, there were activated microglia with thickened processes as well as some amoeboid cells in both the white and gray matter (Figure&#160;<xref rid="bpa70019-fig-0010" ref-type="fig">10</xref>). In contrast to the spinal cord, CD163 was limited to perivascular macrophages with no labeling of parenchymal cells (Figure&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S11</xref>). While there were morphological differences in microglia, there were no intergroup differences in the area density of IBA1, HLA&#8208;DR, or CD163 (<italic toggle="yes">p</italic>&#8201;&#8805;&#8201;0.141). There was no relationship between IBA1 or HLA&#8208;DR area density and survival (H [3]=1.015, <italic toggle="yes">p</italic>&#8201;=&#8201;0.798). While Kruskal&#8208;Wallis suggested relationships between CD68 and diagnosis (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0315) and survival in MND cases (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0006), this was not supported by post hoc tests (all <italic toggle="yes">p</italic>&#8201;&#8805;&#8201;0.319).</p><fig position="float" fig-type="FIGURE" id="bpa70019-fig-0010" orientation="portrait"><label>FIGURE 10</label><caption><p>IBA1 in motor cortex. IBA1&#8208;labeled perivascular macrophages (black arrows) and microglia (open arrows). In control cases, microglia were ramified with small cell bodies and fine processes. Similar patterns of expression were observed in the gray matter (A) and white matter (C). In MND/ALS (B, cortex; D, white matter), microglia had an activated morphology, with thicker cell bodies and swollen processes (open arrows); some microglia had also transitioned to the fully amoeboid state (gray arrows). Perivascular macrophages are labeled with black arrows. Expression was similar in gray matter (C) and white matter (D). Scale bar&#8201;=&#8201;50&#8201;&#956;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-21" orientation="portrait" xlink:href="BPA-35-e70019-g005.jpg"/></fig><p>ApoE (Figure&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S12</xref>) and TYROBP (Figure&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S13</xref>) immunohistochemistry in the motor cortex showed a similar pattern to that of the spinal cord: In controls, there was variable expression in neurons, glia, and vascular structures with significant expression of ApoE in the neuropil that was less marked for TYROBP. For TYROBP, the area density in both cortex and white matter was significantly greater in sporadic ALS/MND than in control cases in both gray and white matter.</p><p>There was an apparent relationship between TYROBP staining density and patient survival by Kruskal&#8211;Wallis (H(3)&#8201;=&#8201;12.44, <italic toggle="yes">p</italic>&#8201;=&#8201;0.006). However, post hoc Mann&#8211;Whitney <italic toggle="yes">U</italic> tests showed no effect of survival in either gray or white matter (<italic toggle="yes">p</italic>&#8201;&#8805;&#8201;0.077).</p><p>In the motor cortex, TREM2 expression was largely confined to perivascular macrophages with minimal staining of neurons and negligible difference between control and MND/ALS cases (Figure&#160;<xref rid="bpa70019-supitem-0002" ref-type="supplementary-material">S14</xref>). There were no differences between control and MND/ALS cases.</p><p>The relationship between mRNA and protein levels is often unclear [<xref rid="bpa70019-bib-0045" ref-type="bibr">45</xref>]. For that reason, it is necessary to validate alterations seen in mRNA using protein&#8208;based technologies. As noted above, the transcriptomic analyses of mRNA by nCounter revealed the spinal cord to be an area of much greater inflammatory signaling than the motor cortex. On that basis, we wished to investigate if this was borne out at the protein level by examining our immunohistochemistry area density data by comparing the white matter of the precentral gyrus with the lateral corticospinal tracts and the motor cortex with the spinal cord ventral horn. This revealed significantly greater area density of expression (percentage of section positively labeled for the marker in question) in the spinal cord than in the motor cortex for Iba1 (U&#8201;=&#8201;7, <italic toggle="yes">p</italic>&#8201;=&#8201;0.006), HLA&#8208;DR (U&#8201;=&#8201;0, <italic toggle="yes">p</italic>&#8201;=&#8201;0.0001), TYROBP (U&#8201;=&#8201;0, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002), and TREM2 (U&#8201;=&#8201;0, <italic toggle="yes">p</italic>&#8201;=&#8201;0.0004) for control white matter, HLA&#8208;DR (U&#8201;=&#8201;0, <italic toggle="yes">p</italic>&#8201;=&#8201;0.0001), CD163 (U&#8201;=&#8201;4, <italic toggle="yes">p</italic>&#8201;=&#8201;0.014), and TREM2 (U&#8201;=&#8201;0, <italic toggle="yes">p</italic>&#8201;=&#8201;0.0004) for control gray matter, and all markers in the spinal cord compared to the precentral gyrus in the ALS/MND cases (all <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.012).</p></sec><sec id="bpa70019-sec-0018"><label>3.6</label><title>The <styled-content style="fixed-case" toggle="no">APOE</styled-content> &#949;3/3 variant is over&#8208;represented within sporadic <styled-content style="fixed-case" toggle="no">ALS</styled-content>/<styled-content style="fixed-case" toggle="no">MND</styled-content> patients, while &#949;2/&#949;2 is under&#8208;represented</title><p>Having established upregulation in components of the ApoE&#8208;TYROBP/DAP12&#8208;TREM2 pathway in MND and an association between TREM2 and disease severity (as indexed by survival time), we were interested in the genotype of <italic toggle="yes">APOE</italic>. This was assessed using data from project MinE, including 29,612 ALS patients and 122,656 controls [<xref rid="bpa70019-bib-0026" ref-type="bibr">26</xref>].</p><p>ALS patients were significantly enriched with the APOE &#949;3/&#949;3 variant (OR&#8201;=&#8201;3.6, beta&#8201;=&#8201;+1.29, <italic toggle="yes">p</italic>&#8201;=&#8201;&lt;2e&#8208;16) but depleted of the &#949;2/&#949;2 variant (OR&#8201;=&#8201;0.74, beta&#8201;=&#8201;&#8722;0.3, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01). There was a non&#8208;significant depletion of the &#949;4/&#949;4 genotype (OR&#8201;=&#8201;0.92, beta&#8201;=&#8201;&#8722;0.08, <italic toggle="yes">p</italic>&#8201;=&#8201;0.17; Table <xref rid="bpa70019-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="bpa70019-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Relationship between <italic toggle="no">APOE</italic> gene variant on odds ratio (OR) for diagnosis and hazard ratio (HR) survival time and age of onset showing odds ratio enrichment of &#949;3/&#949;3 in sMND/ALS cases and &#949;2/&#949;2 in controls. &#949;4/&#949;4 is associated with shorter survival and earlier age of onset.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Genotype</th><th align="left" valign="bottom" rowspan="1" colspan="1">sMND/ALS vs. Control</th><th align="left" valign="bottom" rowspan="1" colspan="1">Survival</th><th align="left" valign="bottom" rowspan="1" colspan="1">Age of onset</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">&#949;4/&#949;4</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;0.17 (<italic toggle="yes">b</italic>&#8201;=&#8201;&#8722;0.08, OR&#8201;=&#8201;0.92)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;0.05 (coeff&#8201;=&#8201;0.2, HR&#8201;=&#8201;1.2)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;0.04 (coef&#8201;=&#8201;0.22, HR&#8201;=&#8201;1.25)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#949;4/&#949;3</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;1.5e&#8208;4 (<italic toggle="yes">b</italic>&#8201;=&#8201;&#8722;0.07, OR&#8201;=&#8201;0.93)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;0.08</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;0.73</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#949;4/&#949;2</td><td align="left" valign="top" rowspan="1" colspan="1">None</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;0.4</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;0.06 (coeff&#8201;=&#8201;&#8722;0.18, HR&#8201;=&#8201;0.84)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#949;3/&#949;3</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;&lt;&#8201;2e&#8208;16 (<italic toggle="yes">b</italic>&#8201;=&#8201;1.29, OR&#8201;=&#8201;3.6)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;0.32</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;0.17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#949;3/&#949;2</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;5.7e&#8208;10 (<italic toggle="yes">b</italic>&#8201;=&#8201;&#8722;0.1, OR&#8201;=&#8201;0.90)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;0.27</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;0.17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#949;2/&#949;2</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;0.01 (<italic toggle="yes">b</italic>&#8201;=&#8201;&#8722;0.3, OR&#8201;=&#8201;0.74)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;0.63</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;=&#8201;0.34</td></tr></tbody></table></table-wrap><p>In a subset of ALS patients for whom survival data was available (<italic toggle="yes">n</italic>&#8201;=&#8201;4897), the &#949;4/&#949;4 haplotype was associated with earlier age of ALS onset (coef&#8201;=&#8201;0.22, HR&#8201;=&#8201;1.25, <italic toggle="yes">p</italic>&#8201;=&#8201;0.04) and a shorter survival (coef&#8201;=&#8201;0.2, HR&#8201;=&#8201;1.2, <italic toggle="yes">p</italic>&#8201;=&#8201;0.05). Over the disease course, carrying the &#949;4/&#949;4 variant compared to not carrying the haplotype was associated with a hazard ratio (HR) of 1.25 indicating an increased risk of death. The &#949;3/&#949;3 and &#949;2/&#949;2 variants were not significantly associated with age of onset or survival.</p></sec></sec><sec sec-type="discussion" id="bpa70019-sec-0019"><label>4</label><title>DISCUSSION</title><p>The inflammatory mRNA profile of ALS/MND was characterized in the <italic toggle="yes">post&#8208;mortem</italic> spinal cord and motor cortex. Two datasets were generated for the spinal cord using the nCounter platform. These were compared with a third RNAseq dataset from the literature. There was a good correlation between the three datasets, with the inflammatory response in the spinal cord greater than that in the motor cortex. A number of neuroinflammatory pathways were highlighted in the spinal cord, notably all three elements of the ApoE&#8208;TYROBP&#8208;TREM2 pathway.</p><p>Following this, immunohistochemistry was used to elucidate neuroinflammation at the protein level. We tested the following hypotheses on the basis of the transcriptomic data:<list list-type="order" id="bpa70019-list-0001"><list-item id="bpa70019-li-0001"><p>Expression of microglial and macrophage markers (IBA1, CD68, HLA&#8208;DR, and CD163) will be increased in sporadic ALS/MND compared to controls. Microglia will display activated morphology characterized by swelling of the processes and cell body and/or the presence of amoeboid microglia in sporadic ALS/MND CNS regions. This will be more marked in the spinal cord than in the motor cortex. Within the spinal cord, there will be greater inflammation in motor regions (ventral horns and corticospinal tracts) than in sensory regions.</p></list-item><list-item id="bpa70019-li-0002"><p>ApoE, TREM2, and TYROBP expression will be increased in the spinal cord in sporadic ALS/MND cases compared to control cases.</p></list-item><list-item id="bpa70019-li-0003"><p>There will be a greater microglial response and increased expression of target proteins in the spinal cord overall compared to the motor cortex brain in sporadic ALS/MND cases.</p></list-item><list-item id="bpa70019-li-3003"><p>Expression of proteins of interest will be associated with survival, particularly in the spinal cord.</p></list-item></list>
</p><p>This confirmed that inflammation is far greater in the spinal cord than in the motor cortex and showed marked inter&#8208;individual variation within the sporadic ALS/MND cohort. In the spinal cord, motor structures (ventral horns and corticospinal tracts) were most severely affected, although the corticospinal tracts showed more marked inflammation than the ventral horns. Furthermore, there was involvement of extra&#8208;motor regions (such as the spinothalamic tract) of the cord in many cases. This may be a pathological correlate of non&#8208;motor symptoms such as pain, which are increasingly recognized [<xref rid="bpa70019-bib-0046" ref-type="bibr">46</xref>]. The dorsal columns were the least affected but not completely spared.</p><p>The immunostaining confirmed spinal cord upregulation of ApoE and TYROBP (most pronounced in the corticospinal tracts) in sporadic ALS/MND, while higher TREM2 expression was associated with patients with longer survival times, suggesting a possible protective role for this pathway.</p><p>Data from the project MINE were accessed to assess the influence of <italic toggle="yes">APOE</italic> genotype on MND inheritance. It was found that, in contrast to Alzheimer's disease, where the &#949;4 haplotype is a risk factor, in MND, &#949;3 was a risk factor for MND, while &#949;2 and &#949;4 appear to be underrepresented in the MND population.</p><sec id="bpa70019-sec-0020"><label>4.1</label><title>Inflammation in <styled-content style="fixed-case" toggle="no">MND</styled-content>/<styled-content style="fixed-case" toggle="no">ALS</styled-content> is greater in the spinal cord than in the motor cortex</title><p>While the motor cortex had less inflammation than the spinal cord, it was not completely unaffected&#8212;there were changes in microglial morphology as well as upregulated TYROBP expression. Importantly, there was considerable inter&#8208;individual variation in the degree of inflammatory marker expression. This suggests there may be a small but variable inflammatory response that requires large sample sizes to be detected reliably by array technologies. This is consistent with the literature where a small post&#8208;mortem study (<italic toggle="yes">n</italic>&#8201;=&#8201;11 sporadic ALS/MND and 9 controls) reported little evidence for motor cortex inflammation [<xref rid="bpa70019-bib-0047" ref-type="bibr">47</xref>]. In contrast, a larger study of 31 sporadic ALS/MND and 10 controls found a significant upregulation of genes associated with immune pathways [<xref rid="bpa70019-bib-0048" ref-type="bibr">48</xref>].</p><p>The finding of marked spinal cord inflammation fits well with a recent transcriptomic study that highlighted an increase of microglial and inflammatory markers in the spinal cord in a large cohort of ALS/MND cases that included both sporadic and familial cases&#160;[<xref rid="bpa70019-bib-0049" ref-type="bibr">49</xref>].</p></sec><sec id="bpa70019-sec-0021"><label>4.2</label><title>Disease&#8208;associated microglia and <styled-content style="fixed-case" toggle="no">MND</styled-content>/<styled-content style="fixed-case" toggle="no">ALS</styled-content>
</title><p>We found upregulation of TREM2 mRNA in sporadic ALS/MND, with the protein levels associated with longer survival. This is in line with transcriptomic studies that have consistently found upregulated TREM2 in human MND and have associated soluble TREM2 with neuroprotection [<xref rid="bpa70019-bib-0050" ref-type="bibr">50</xref>, <xref rid="bpa70019-bib-0051" ref-type="bibr">51</xref>].</p><p>In the CSF, soluble TREM2 protein is highly expressed in the early stages of disease and diminishes with progression [<xref rid="bpa70019-bib-0051" ref-type="bibr">51</xref>]. In late&#8208;stage disease, soluble TREM2 expression positively correlates with survival time, suggesting this may be protective.</p><p>TREM2 is a cell surface receptor that regulates the inflammatory phenotype in myeloid cells [<xref rid="bpa70019-bib-0052" ref-type="bibr">52</xref>]. When activated by ApoE, the cytoplasmic domain complexes with TYRO protein tyrosine kinase&#8208;binding protein (TYROBP, also known as DAP12), which signals through an intracellular immunoreceptor tyrosine activation motif, which can result in an anti&#8208;inflammatory phenotype and phagocytosis [<xref rid="bpa70019-bib-0053" ref-type="bibr">53</xref>, <xref rid="bpa70019-bib-0054" ref-type="bibr">54</xref>, <xref rid="bpa70019-bib-0055" ref-type="bibr">55</xref>]. In addition, TREM2 binds TDP&#8208;43, and TREM2 depletion in microglia causes loss of the ability to phagocytose TDP&#8208;43 inclusions, thereby enhancing motor dysfunction [<xref rid="bpa70019-bib-0056" ref-type="bibr">56</xref>]. An analogous phenomenon has been observed for amyloid &#223; animal models of Alzheimer's disease [<xref rid="bpa70019-bib-0057" ref-type="bibr">57</xref>], leading to early&#8208;stage trials of TREM2 agonism to treat Alzheimer's disease [<xref rid="bpa70019-bib-0036" ref-type="bibr">36</xref>]. The possibility of using existing agents to treat MND/ALS is an exciting prospect.</p><p>TREM2 is widely expressed in the brain, and due to its expression by somatic human macrophages and confirmed murine microglial expression, it has been assumed that human microglia also express TREM2. However, while human microglia may express TREM2 mRNA [<xref rid="bpa70019-bib-0050" ref-type="bibr">50</xref>, <xref rid="bpa70019-bib-0058" ref-type="bibr">58</xref>], immunohistochemistry studies have failed to find microglial TREM2 protein in human <italic toggle="yes">post&#8208;mortem</italic> brain. In contrast, there have been demonstrations of TREM2&#8208;positive cells in intravascular monocytes, neurons, and perivascular macrophages [<xref rid="bpa70019-bib-0059" ref-type="bibr">59</xref>, <xref rid="bpa70019-bib-0060" ref-type="bibr">60</xref>, <xref rid="bpa70019-bib-0061" ref-type="bibr">61</xref>]. We have found TREM2 to label intravascular and perivascular macrophages as well as some neurons with few parenchymal cells expressing this protein in the motor cortex. There was a greater number of TREM2&#8208;positive parenchymal cells in the spinal cord and increased expression of spinal cord TREM2 in ALS/MND with longer survival. The TREM2&#8208;positive cells were also IBA1<sup>+</sup> amoeboid cells, likely representing recruited macrophages, consistent with the existing literature [<xref rid="bpa70019-bib-0059" ref-type="bibr">59</xref>].</p><p>TYROBP expression in MND has not been as widely studied. We observed a significant upregulation of TYROBP mRNA in the spinal cord, as well as TYROBP protein in the motor regions of the spinal cord and in both the white and gray matter of the precentral gyrus.</p><p>The literature to date suggests a toxic role for TYROBP: Knockdown in a mouse model of hypoglossal nerve injury resulted in reduced proinflammatory cytokine production and reduced neuron death [<xref rid="bpa70019-bib-0062" ref-type="bibr">62</xref>]. Similarly, reduced TYROBP function in mouse models confers resistance to demyelination [<xref rid="bpa70019-bib-0063" ref-type="bibr">63</xref>] as well as tau hyperphosphorylation and dystrophic neurites in Alzheimer's disease [<xref rid="bpa70019-bib-0064" ref-type="bibr">64</xref>]. Finally, TYROBP deficiency in mice seems to confer resilience to Alzheimer&#8208;type tau and amyloid &#223; pathology [<xref rid="bpa70019-bib-0064" ref-type="bibr">64</xref>].</p><p>Upregulation of ApoE protein and <italic toggle="yes">APOE</italic> mRNA was detected in the spinal cord in MND, consistent with previous studies [<xref rid="bpa70019-bib-0065" ref-type="bibr">65</xref>, <xref rid="bpa70019-bib-0066" ref-type="bibr">66</xref>, <xref rid="bpa70019-bib-0067" ref-type="bibr">67</xref>]. ApoE is a fat&#8208;binding protein involved in lipid transport, neuronal survival and plasticity, and neurite outgrowth [<xref rid="bpa70019-bib-0068" ref-type="bibr">68</xref>, <xref rid="bpa70019-bib-0069" ref-type="bibr">69</xref>, <xref rid="bpa70019-bib-0070" ref-type="bibr">70</xref>, <xref rid="bpa70019-bib-0071" ref-type="bibr">71</xref>]. In the brain, it is mostly expressed by astrocytes and microglia, with lesser expression by neurons [<xref rid="bpa70019-bib-0041" ref-type="bibr">41</xref>, <xref rid="bpa70019-bib-0070" ref-type="bibr">70</xref>, <xref rid="bpa70019-bib-0072" ref-type="bibr">72</xref>, <xref rid="bpa70019-bib-0073" ref-type="bibr">73</xref>, <xref rid="bpa70019-bib-0074" ref-type="bibr">74</xref>, <xref rid="bpa70019-bib-0075" ref-type="bibr">75</xref>] consistent with our own histological observations. It is unclear whether the upregulation of ApoE reflects a reactive astrocytosis, either reflecting increased expression per astrocyte or a greater number of astrocytes. Elucidating this is an interesting avenue for downstream studies.</p><p>Extracellular ApoE protein can act as a ligand to the TREM2 receptor, triggering microglial phagocytosis [<xref rid="bpa70019-bib-0076" ref-type="bibr">76</xref>]. Knockdown of <italic toggle="yes">APOE</italic> results in ineffective neuronal debris clearance in a model of prion pathology [<xref rid="bpa70019-bib-0077" ref-type="bibr">77</xref>], implying a neuroprotective role for ApoE.</p><p>TREM2, TYROBP, and ApoE together form a well&#8208;characterized pathway responsible for the disease&#8208;associated microglial (DAM) phenotype, which has a common signature across several models of neurodegeneration, e.g., [<xref rid="bpa70019-bib-0078" ref-type="bibr">78</xref>, <xref rid="bpa70019-bib-0079" ref-type="bibr">79</xref>, <xref rid="bpa70019-bib-0080" ref-type="bibr">80</xref>]. Through activation of TREM2 signaling, often by ApoE, TYROBP results in the downregulation of transforming growth factor &#946; (TGF&#946;)&#8208;mediated microglial genes and a simultaneous upregulation of the DAM genes (Figure&#160;<xref rid="bpa70019-fig-0001" ref-type="fig">1</xref>: Discussion). These DAM&#8208;associated markers regulate inflammation, lipid metabolism, phagocytosis, and lysosomal pathways [<xref rid="bpa70019-bib-0079" ref-type="bibr">79</xref>, <xref rid="bpa70019-bib-0081" ref-type="bibr">81</xref>].</p><p>DAM has been identified in many mouse models, particularly of AD [<xref rid="bpa70019-bib-0078" ref-type="bibr">78</xref>, <xref rid="bpa70019-bib-0079" ref-type="bibr">79</xref>, <xref rid="bpa70019-bib-0082" ref-type="bibr">82</xref>], but also including other neurodegenerative models such as ALS/MND [<xref rid="bpa70019-bib-0078" ref-type="bibr">78</xref>, <xref rid="bpa70019-bib-0079" ref-type="bibr">79</xref>, <xref rid="bpa70019-bib-0080" ref-type="bibr">80</xref>, <xref rid="bpa70019-bib-0083" ref-type="bibr">83</xref>]. <italic toggle="yes">Post&#8208;mortem</italic> studies have also found evidence of the DAM signature in AD [<xref rid="bpa70019-bib-0010" ref-type="bibr">10</xref>, <xref rid="bpa70019-bib-0084" ref-type="bibr">84</xref>]. However, while this DAM phenotype has been identified in models, its relevance is only emerging in human ALS/MND. Importantly, using the R Shiny app to interrogate transcriptomic data from a recent transcriptomic study [<xref rid="bpa70019-bib-0049" ref-type="bibr">49</xref>] highlights findings that accord with our own, namely an upregulation of all three of <italic toggle="yes">TREM2</italic>, <italic toggle="yes">TYROBP</italic>, and <italic toggle="yes">APOE</italic> in the spinal cord (<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.00057) in MND after false discovery rate correction. All three correlated negatively with disease survival in the cervical (<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.016) but not lumbar (<italic toggle="yes">p</italic>&#8201;&#8805;&#8201;0.054) cord.</p></sec><sec id="bpa70019-sec-0022"><label>4.3</label><title>The <styled-content style="fixed-case" toggle="no">APOE</styled-content> haplotype and amyotrophic lateral sclerosis/motor neuron disease</title><p>The <italic toggle="yes">APOE</italic> &#949;4 haplotype is one of the most important risk factors for the development of late&#8208;onset AD [<xref rid="bpa70019-bib-0085" ref-type="bibr">85</xref>]. With respect to the relationship between MND and <italic toggle="yes">APOE</italic>, a 2014 meta&#8208;analysis of 4249 MND patients and 10,397 controls from North America, Scandinavia, Europe, Israel, and Guam has found no increased risk of the &#949;4 haplotype (either as 4/4 or 4/X) [<xref rid="bpa70019-bib-0086" ref-type="bibr">86</xref>]. However, a Chinese study (<italic toggle="yes">n</italic>&#8201;=&#8201;683 MND patients and 369 controls) reported a modest association between MND and &#949;4 (odds ratio 1.42; 95% CI, 1.02&#8211;1.98; <italic toggle="yes">p</italic>&#8201;=&#8201;0.02) [<xref rid="bpa70019-bib-0087" ref-type="bibr">87</xref>]. We addressed this question in the largest cohort analyzed to date, including 29,612 ALS/MND patients and 122,656 controls, and found that MND patients were significantly enriched with the <italic toggle="yes">APOE</italic> &#949;3/&#949;3 haplotype but depleted of the &#949;2/&#949;2 and the &#949;4/&#949;4 haplotypes. Given that the &#949;3/&#949;3 haplotype is the most common in the population, we wondered whether its enrichment in ALS was actually a reflection of which patients tolerated genotyping, i.e., other genotypes may be associated with more severe disease. Consistent with this, the &#949;4 haplotype was underrepresented in the ALS/MND cohort and was related to more aggressive disease. This is consistent with previous studies of &#949;4 favoring bulbar onset disease, which itself is associated with more severe disease [<xref rid="bpa70019-bib-0088" ref-type="bibr">88</xref>, <xref rid="bpa70019-bib-0089" ref-type="bibr">89</xref>].</p><p>Collectively, our <italic toggle="yes">APOE</italic> data suggest that the different haplotypes are associated with different disease phenotypes with unique clinical presentations, risks, and severity. This shift in <italic toggle="yes">APOE</italic> genotype in the ALS/MND population may be partially responsible for the altered expression levels seen [<xref rid="bpa70019-bib-0090" ref-type="bibr">90</xref>].</p></sec><sec id="bpa70019-sec-0023"><label>4.4</label><title>Strengths, limitations, and future directions</title><p>This human <italic toggle="yes">post&#8208;mortem</italic> study of ALS/MND, provides a unique set of data. The strengths of the study include the fact that this centered on human sporadic disease and is thus not hindered by questionable assumptions that mutation&#8208;based animal and cell culture models are representative of humans or human disease. Furthermore, given the often poor relationship between mRNA and the translated effector protein, the current study has the advantage of immunohistochemical validation. This has allowed both validation at the protein level as well as anatomical and cytological mapping of the neuroinflammatory response.</p><p>However, the limitations of the study include that this is a snapshot of the end stage of the disease, and as such, it cannot assess the inflammatory status at earlier stages and cannot determine directions of causation. Nevertheless, the data support better experimental models.</p><p>We have hopefully highlighted some key features of neuroinflammation that contrast between disease and controls. A larger, more powerful study, beyond the scope of the current work, could have been more successful at finding correlates of disease severity within the ALS/MND cases.</p><p>We have avoided the assumption that sporadic and mutation&#8208;related ALS/MND represent the same disease by focusing on sporadic disease alone. While this informs our understanding of sporadic disease, it limits our contribution to the understanding of other motor neuron diseases, such as those related to mutations of <italic toggle="yes">SOD1</italic>, <italic toggle="yes">C9or72</italic>, or <italic toggle="yes">FUS</italic>.</p><p>The corticospinal tracts run from the motor cortex to the spinal cord. Increased inflammation in the spinal cord compared to the primary motor strip may suggest retrograde axonal damage. On that basis, a more detailed study to map out the anatomical extent of neuroinflammation in greater spatial detail by examining the corticospinal tract at various levels, including the brainstem, midbrain, and internal capsule, would be informative in the future.</p><p>This is, to our knowledge, the first study to highlight the ApoE&#8208;TREM2&#8208;TYROBP pathway in human ALS/MND. This is an obvious candidate for therapeutic intervention, as currently performed it is already in Alzheimer's disease. However, the impact of increased expression remains to be examined in sporadic ALS/MND.</p><p>The relationship between <italic toggle="yes">APOE</italic> genotype and immune pathology is a key question. Specifically, the APOE haplotype was not available for the 16 cases investigated in this study. Unfortunately, this project was not resourced for this, and this will form the focus of future studies.</p><p>In conclusion, we have demonstrated marked and variable neuroinflammation in human sporadic MND&#8208;TDP that is most florid in the spinal cord and significantly more subtle in the motor cortex and highlighting the APOE&#8208;TREM2&#8208;TYROBP pathway in particular. Finally, we have performed the most high&#8208;powered study to date of the relationship between APOE genotype and sporadic ALS/MND and found that the &#949;2 and &#949;4 haplotypes appear protective, while the &#949;3 haplotype was a risk factor.</p></sec></sec><sec id="bpa70019-sec-0024"><title>AUTHOR CONTRIBUTIONS</title><p>Conceptualization, BAA, JES, DB, JCK, PRH, JRH; Data curation, BAA, JCK, PRH, WW, JRH; Formal analysis, BAA, JCK, WW, MD, JRH; Funding acquisition, JES, DB, PRH, JRH; Investigation, BAA, JES, CD, PRH, DF, CAM, JRH; Methodology, BAA, JES, CD, DB, JCK, PRH, DF, CAM, WW, MD, JRH; Project administration, BAA, JES, CD, DB, PRH, DF, JRH; Resources, JES, CD, PRH, DF, CAM, JRH; Software, BAA, WW, MD; Supervision, JES, PRH, JRH; Validation, BAA, CD, PRH, WW, MD; Visualization, BAA, WW, JRH; Writing&#8212;original draft, BAA, JRH; Writing&#8212;review &amp; editing, all authors.</p></sec><sec id="bpa70019-sec-0026"><title>FUNDING INFORMATION</title><p>The Pathological Society of Great Britain, the British Neuropathological Society, and Bruker Spatial Biology, who provided two nCounter Neuroinflammation panels.</p></sec><sec sec-type="COI-statement" id="bpa70019-sec-0027"><title>CONFLICT OF INTEREST STATEMENT</title><p>None.</p></sec><sec id="bpa70019-sec-0030"><title>ETHICS STATEMENT</title><p>The majority of the data presented here formed the basis of a PhD project undertaken by BAA. The Sheffield Brain Tissue Bank (SBTB), which provided the tissue used here, has ethical permission to function as a research tissue bank. At the time the work was undertaken, this was covered by a favorable opinion from the Scotland A Research Ethics Committee (Reference 19/SS/0029). SBTB adheres to consenting protocols laid down by the UK Human Tissue Authority and agreed to by the Research Ethics Committee.</p></sec><sec sec-type="conclusions" id="bpa70019-sec-0031"><title>CONSENT</title><p>SBTB adheres to consenting protocols laid down by the UK Human Tissue Authority and agreed to by the Research Ethics Committee.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="bpa70019-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Data S1.</bold> Supplementary tables.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="BPA-35-e70019-s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="bpa70019-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Data S2.</bold> Supplementary figure.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="BPA-35-e70019-s001.pptx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="bpa70019-sec-0025"><title>ACKNOWLEDGMENTS</title><p>The authors thank the Pathological Society of Great Britain and the British Neuropathological Society for funding this project and Bruker Spatial Biology, who provided two of their nCounter Neuroinflammation panels. We are also grateful to the Sheffield Brain Tissue Bank for supplying the tissue and to those who have donated tissue for scientific research and their families who have supported this.</p></ack><sec sec-type="data-availability" id="bpa70019-sec-0029"><title>DATA AVAILABILITY STATEMENT</title><p>nCounter gene expression data are available at the University of Sheffield Online Research Data facility (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://hdl.handle.net/10779/sheffield.27908097.v1" ext-link-type="uri" specific-use="software is-supplemented-by">https://hdl.handle.net/10779/sheffield.27908097.v1</ext-link>).</p></sec><ref-list content-type="cited-references" id="bpa70019-bibl-0001"><title>REFERENCES</title><ref id="bpa70019-bib-0001"><label>1</label><mixed-citation publication-type="book" id="bpa70019-cit-0001"><string-name name-style="western"><surname>Ince</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Highley</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Wharton</surname><given-names>SB</given-names></string-name>. <part-title>Motor neuron disorders</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Love</surname><given-names>S</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Perry</surname><given-names>A</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Ironside</surname><given-names>J</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Budka</surname><given-names>H</given-names></string-name></person-group>, editors. <source>Greenfield's neuropathology</source>. <publisher-loc>Abingdon, Oxon, UK</publisher-loc>: <publisher-name>Taylor &amp; Francis</publisher-name>; <year>2015</year>. p. <fpage>817</fpage>&#8211;<lpage>848</lpage>.</mixed-citation></ref><ref id="bpa70019-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="bpa70019-cit-0002"><string-name name-style="western"><surname>Ludolph</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Drory</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Hardiman</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Nakano</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ravits</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Robberecht</surname><given-names>W</given-names></string-name>, et al. <article-title>A revision of the El Escorial criteria &#8208; 2015</article-title>. <source>Amyotroph Lateral Scler Frontotemporal Degener</source>. <year>2015</year>;<volume>16</volume>(<issue>5&#8211;6</issue>):<fpage>291</fpage>&#8211;<lpage>292</lpage>. <pub-id pub-id-type="doi">10.3109/21678421.2015.1049183</pub-id><pub-id pub-id-type="pmid">26121170</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="bpa70019-cit-0003"><string-name name-style="western"><surname>Westeneng</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Debray</surname><given-names>TPA</given-names></string-name>, <string-name name-style="western"><surname>Visser</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>van Eijk</surname><given-names>RPA</given-names></string-name>, <string-name name-style="western"><surname>Rooney</surname><given-names>JPK</given-names></string-name>, <string-name name-style="western"><surname>Calvo</surname><given-names>A</given-names></string-name>, et al. <article-title>Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model</article-title>. <source>Lancet Neurol</source>. <year>2018</year>;<volume>17</volume>(<issue>5</issue>):<fpage>423</fpage>&#8211;<lpage>433</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(18)30089-9</pub-id><pub-id pub-id-type="pmid">29598923</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="bpa70019-cit-0004"><string-name name-style="western"><surname>Herculano&#8208;Houzel</surname><given-names>S</given-names></string-name>. <article-title>The glia/neuron ratio: how it varies uniformly across brain structures and species and what that means for brain physiology and evolution</article-title>. <source>Glia</source>. <year>2014</year>;<volume>62</volume>(<issue>9</issue>):<fpage>1377</fpage>&#8211;<lpage>1391</lpage>.<pub-id pub-id-type="pmid">24807023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.22683</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="bpa70019-cit-0005"><string-name name-style="western"><surname>Mittelbronn</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dietz</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Schluesener</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Meyermann</surname><given-names>R</given-names></string-name>. <article-title>Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude</article-title>. <source>Acta Neuropathol</source>. <year>2001</year>;<volume>101</volume>(<issue>3</issue>):<fpage>249</fpage>&#8211;<lpage>255</lpage>.<pub-id pub-id-type="pmid">11307625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s004010000284</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="bpa70019-cit-0006"><string-name name-style="western"><surname>Nimmerjahn</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kirchhoff</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Helmchen</surname><given-names>F</given-names></string-name>. <article-title>Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo</article-title>. <source>Science</source>. <year>2005</year>;<volume>308</volume>(<issue>5726</issue>):<fpage>1314</fpage>&#8211;<lpage>1318</lpage>.<pub-id pub-id-type="pmid">15831717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1110647</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="bpa70019-cit-0007"><string-name name-style="western"><surname>Geloso</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Corvino</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Marchese</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Serrano</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Michetti</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>D'Ambrosi</surname><given-names>N</given-names></string-name>. <article-title>The dual role of microglia in ALS: mechanisms and therapeutic approaches</article-title>. <source>Front Aging Neurosci</source>. <year>2017</year>;<volume>9</volume>:<elocation-id>242</elocation-id>.<pub-id pub-id-type="pmid">28790913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2017.00242</pub-id><pub-id pub-id-type="pmcid">PMC5524666</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="bpa70019-cit-0008"><string-name name-style="western"><surname>Grabert</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Michoel</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Karavolos</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Clohisey</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Baillie</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Stevens</surname><given-names>MP</given-names></string-name>, et al. <article-title>Microglial brain region&#8208;dependent diversity and selective regional sensitivities to aging</article-title>. <source>Nat Neurosci</source>. <year>2016</year>;<volume>19</volume>(<issue>3</issue>):<fpage>504</fpage>&#8211;<lpage>516</lpage>.<pub-id pub-id-type="pmid">26780511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.4222</pub-id><pub-id pub-id-type="pmcid">PMC4768346</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="bpa70019-cit-0009"><string-name name-style="western"><surname>Galatro</surname><given-names>TF</given-names></string-name>, <string-name name-style="western"><surname>Holtman</surname><given-names>IR</given-names></string-name>, <string-name name-style="western"><surname>Lerario</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Vainchtein</surname><given-names>ID</given-names></string-name>, <string-name name-style="western"><surname>Brouwer</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sola</surname><given-names>PR</given-names></string-name>, et al. <article-title>Transcriptomic analysis of purified human cortical microglia reveals age&#8208;associated changes</article-title>. <source>Nat Neurosci</source>. <year>2017</year>;<volume>20</volume>(<issue>8</issue>):<fpage>1162</fpage>&#8211;<lpage>1171</lpage>.<pub-id pub-id-type="pmid">28671693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.4597</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="bpa70019-cit-0010"><string-name name-style="western"><surname>Friedman</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Srinivasan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ayalon</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Meilandt</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Huntley</surname><given-names>MA</given-names></string-name>, et al. <article-title>Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer's disease not evident in mouse models</article-title>. <source>Cell Rep</source>. <year>2018</year>;<volume>22</volume>(<issue>3</issue>):<fpage>832</fpage>&#8211;<lpage>847</lpage>.<pub-id pub-id-type="pmid">29346778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2017.12.066</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="bpa70019-cit-0011"><string-name name-style="western"><surname>Block</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Zecca</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>JS</given-names></string-name>. <article-title>Microglia&#8208;mediated neurotoxicity: uncovering the molecular mechanisms</article-title>. <source>Nat Rev Neurosci</source>. <year>2007</year>;<volume>8</volume>(<issue>1</issue>):<fpage>57</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="pmid">17180163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn2038</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="bpa70019-cit-0012"><string-name name-style="western"><surname>Tang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Le</surname><given-names>W</given-names></string-name>. <article-title>Differential roles of M1 and M2 microglia in neurodegenerative diseases</article-title>. <source>Mol Neurobiol</source>. <year>2016</year>;<volume>53</volume>(<issue>2</issue>):<fpage>1181</fpage>&#8211;<lpage>1194</lpage>.<pub-id pub-id-type="pmid">25598354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-014-9070-5</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="bpa70019-cit-0013"><string-name name-style="western"><surname>Ashford</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Boche</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cooper&#8208;Knock</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Heath</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Simpson</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Highley</surname><given-names>JR</given-names></string-name>. <article-title>Review: microglia in motor neuron disease</article-title>. <source>Neuropathol Appl Neurobiol</source>. <year>2021</year>;<volume>47</volume>(<issue>2</issue>):<fpage>179</fpage>&#8211;<lpage>197</lpage>.<pub-id pub-id-type="pmid">32594542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/nan.12640</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="bpa70019-cit-0014"><string-name name-style="western"><surname>Brettschneider</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Libon</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Toledo</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>SX</given-names></string-name>, <string-name name-style="western"><surname>McCluskey</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Elman</surname><given-names>L</given-names></string-name>, et al. <article-title>Microglial activation and TDP&#8208;43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis</article-title>. <source>Acta Neuropathol</source>. <year>2012</year>;<volume>123</volume>(<issue>3</issue>):<fpage>395</fpage>&#8211;<lpage>407</lpage>.<pub-id pub-id-type="pmid">22210083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-011-0932-x</pub-id><pub-id pub-id-type="pmcid">PMC3595560</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="bpa70019-cit-0015"><string-name name-style="western"><surname>Brettschneider</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Toledo</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Van Deerlin</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Elman</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>McCluskey</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>VM</given-names></string-name>, et al. <article-title>Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>6</issue>):<elocation-id>e39216</elocation-id>.<pub-id pub-id-type="pmid">22720079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0039216</pub-id><pub-id pub-id-type="pmcid">PMC3375234</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="bpa70019-cit-0016"><string-name name-style="western"><surname>Henkel</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Engelhardt</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>Siklos</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Simpson</surname><given-names>EP</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>T</given-names></string-name>, et al. <article-title>Presence of dendritic cells, MCP&#8208;1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue</article-title>. <source>Ann Neurol</source>. <year>2004</year>;<volume>55</volume>(<issue>2</issue>):<fpage>221</fpage>&#8211;<lpage>235</lpage>.<pub-id pub-id-type="pmid">14755726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.10805</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="bpa70019-cit-0017"><string-name name-style="western"><surname>Alshikho</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Zurcher</surname><given-names>NR</given-names></string-name>, <string-name name-style="western"><surname>Loggia</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Cernasov</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chonde</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Izquierdo Garcia</surname><given-names>D</given-names></string-name>, et al. <article-title>Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis</article-title>. <source>Neurology</source>. <year>2016</year>;<volume>87</volume>(<issue>24</issue>):<fpage>2554</fpage>&#8211;<lpage>2561</lpage>.<pub-id pub-id-type="pmid">27837005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000003427</pub-id><pub-id pub-id-type="pmcid">PMC5207001</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="bpa70019-cit-0018"><string-name name-style="western"><surname>Turner</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Cagnin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Turkheimer</surname><given-names>FE</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Brooks</surname><given-names>DJ</given-names></string-name>, et al. <article-title>Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)&#8208;PK11195 positron emission tomography study</article-title>. <source>Neurobiol Dis</source>. <year>2004</year>;<volume>15</volume>(<issue>3</issue>):<fpage>601</fpage>&#8211;<lpage>609</lpage>.<pub-id pub-id-type="pmid">15056468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2003.12.012</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="bpa70019-cit-0019"><string-name name-style="western"><surname>Babu</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chandra</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Puri</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Kalita</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Misra</surname><given-names>UK</given-names></string-name>. <article-title>Elevated inflammatory markers in a group of amyotrophic lateral sclerosis patients from northern India</article-title>. <source>Neurochem Res</source>. <year>2008</year>;<volume>33</volume>(<issue>6</issue>):<fpage>1145</fpage>&#8211;<lpage>1149</lpage>.<pub-id pub-id-type="pmid">18246426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-007-9564-x</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="bpa70019-cit-0020"><string-name name-style="western"><surname>Mitchell</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Freeman</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Randazzo</surname><given-names>WT</given-names></string-name>, <string-name name-style="western"><surname>Stephens</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Beard</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Simmons</surname><given-names>Z</given-names></string-name>, et al. <article-title>A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis</article-title>. <source>Neurology</source>. <year>2009</year>;<volume>72</volume>(<issue>1</issue>):<fpage>14</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="pmid">18987350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000333251.36681.a5</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="bpa70019-cit-0021"><string-name name-style="western"><surname>Tateishi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yamasaki</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Tanaka</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Matsushita</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kikuchi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Isobe</surname><given-names>N</given-names></string-name>, et al. <article-title>CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis</article-title>. <source>J Neuroimmunol</source>. <year>2010</year>;<volume>222</volume>(<issue>1&#8211;2</issue>):<fpage>76</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">20381883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneuroim.2010.03.004</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="bpa70019-cit-0022"><string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zang</surname><given-names>D</given-names></string-name>. <article-title>Elevated levels of IFN&#8208;gamma in CSF and serum of patients with amyotrophic lateral sclerosis</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>9</issue>):<elocation-id>e0136937</elocation-id>.<pub-id pub-id-type="pmid">26332465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0136937</pub-id><pub-id pub-id-type="pmcid">PMC4557946</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="bpa70019-cit-0023"><string-name name-style="western"><surname>Sussmuth</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Sperfeld</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Hinz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brettschneider</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Endruhn</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ludolph</surname><given-names>AC</given-names></string-name>, et al. <article-title>CSF glial markers correlate with survival in amyotrophic lateral sclerosis</article-title>. <source>Neurology</source>. <year>2010</year>;<volume>74</volume>(<issue>12</issue>):<fpage>982</fpage>&#8211;<lpage>987</lpage>.<pub-id pub-id-type="pmid">20308682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3181d5dc3b</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="bpa70019-cit-0024"><string-name name-style="western"><surname>Bruijn</surname><given-names>LI</given-names></string-name>, <string-name name-style="western"><surname>Becher</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Jenkins</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Copeland</surname><given-names>NG</given-names></string-name>, et al. <article-title>ALS&#8208;linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1&#8208;containing inclusions</article-title>. <source>Neuron</source>. <year>1997</year>;<volume>18</volume>(<issue>2</issue>):<fpage>327</fpage>&#8211;<lpage>338</lpage>.<pub-id pub-id-type="pmid">9052802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0896-6273(00)80272-x</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="bpa70019-cit-0025"><string-name name-style="western"><surname>Gurney</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Pu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chiu</surname><given-names>AY</given-names></string-name>, <string-name name-style="western"><surname>Dal Canto</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Polchow</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>Alexander</surname><given-names>DD</given-names></string-name>, et al. <article-title>Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation</article-title>. <source>Science</source>. <year>1994</year>;<volume>264</volume>(<issue>5166</issue>):<fpage>1772</fpage>&#8211;<lpage>1775</lpage>. <pub-id pub-id-type="doi">10.1126/science.8209258</pub-id><pub-id pub-id-type="pmid">8209258</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="bpa70019-cit-0026"><string-name name-style="western"><surname>Ripps</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Huntley</surname><given-names>GW</given-names></string-name>, <string-name name-style="western"><surname>Hof</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Morrison</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>JW</given-names></string-name>. <article-title>Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>1995</year>;<volume>92</volume>(<issue>3</issue>):<fpage>689</fpage>&#8211;<lpage>693</lpage>.<pub-id pub-id-type="pmid">7846037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.92.3.689</pub-id><pub-id pub-id-type="pmcid">PMC42685</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="bpa70019-cit-0027"><string-name name-style="western"><surname>Wong</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Pardo</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Borchelt</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Copeland</surname><given-names>NG</given-names></string-name>, <string-name name-style="western"><surname>Jenkins</surname><given-names>NA</given-names></string-name>, et al. <article-title>An adverse property of a familial ALS&#8208;linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria</article-title>. <source>Neuron</source>. <year>1995</year>;<volume>14</volume>(<issue>6</issue>):<fpage>1105</fpage>&#8211;<lpage>1116</lpage>.<pub-id pub-id-type="pmid">7605627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0896-6273(95)90259-7</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="bpa70019-cit-0028"><string-name name-style="western"><surname>Lutz</surname><given-names>C</given-names></string-name>. <article-title>Mouse models of ALS: past, present and future</article-title>. <source>Brain Res</source>. <year>2018</year>;<volume>1693</volume>:<fpage>1</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">29577886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2018.03.024</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="bpa70019-cit-0029"><string-name name-style="western"><surname>Philips</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rothstein</surname><given-names>JD</given-names></string-name>. <article-title>Rodent models of amyotrophic lateral sclerosis</article-title>. <source>Curr Protoc Pharmacol</source>. <year>2015</year>;<volume>69</volume>(<issue>5 67 1&#8208;5 21</issue>):<fpage>5.67.1</fpage>&#8211;<lpage>5.67.21</lpage>. <pub-id pub-id-type="doi">10.1002/0471141755.ph0567s69</pub-id><pub-id pub-id-type="pmcid">PMC4562058</pub-id><pub-id pub-id-type="pmid">26344214</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="bpa70019-cit-0030"><string-name name-style="western"><surname>Da Costa</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Allen</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Higginbottom</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ramesh</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>McDermott</surname><given-names>CJ</given-names></string-name>. <article-title>A new zebrafish model produced by TILLING of SOD1&#8208;related amyotrophic lateral sclerosis replicates key features of the disease and represents a tool for in vivo therapeutic screening</article-title>. <source>Dis Model Mech</source>. <year>2014</year>;<volume>7</volume>(<issue>1</issue>):<fpage>73</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">24092880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dmm.012013</pub-id><pub-id pub-id-type="pmcid">PMC3882050</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="bpa70019-cit-0031"><string-name name-style="western"><surname>Ramesh</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>McDearmid</surname><given-names>J</given-names></string-name>. <article-title>A zebrafish model exemplifies the long preclinical period of motor neuron disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2014</year>;<volume>85</volume>(<issue>11</issue>):<fpage>1288</fpage>&#8211;<lpage>1289</lpage>.<pub-id pub-id-type="pmid">24970908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2014-308288</pub-id><pub-id pub-id-type="pmcid">PMC4215267</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="bpa70019-cit-0032"><string-name name-style="western"><surname>Shaw</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Higginbottom</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>McGown</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Castelli</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>James</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hautbergue</surname><given-names>GM</given-names></string-name>, et al. <article-title>Stable transgenic C9orf72 zebrafish model key aspects of the ALS/FTD phenotype and reveal novel pathological features</article-title>. <source>Acta Neuropathol Commun</source>. <year>2018</year>;<volume>6</volume>(<issue>1</issue>):<fpage>125</fpage>.<pub-id pub-id-type="pmid">30454072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-018-0629-7</pub-id><pub-id pub-id-type="pmcid">PMC6240957</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="bpa70019-cit-0033"><string-name name-style="western"><surname>Caldeira</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Cunha</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Vaz</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Falcao</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Fernandes</surname><given-names>A</given-names></string-name>, et al. <article-title>Microglia change from a reactive to an age&#8208;like phenotype with the time in culture</article-title>. <source>Front Cell Neurosci</source>. <year>2014</year>;<volume>8</volume>(<issue>152</issue>). <pub-id pub-id-type="doi">10.3389/fncel.2014.00152</pub-id><pub-id pub-id-type="pmcid">PMC4040822</pub-id><pub-id pub-id-type="pmid">24917789</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="bpa70019-cit-0034"><string-name name-style="western"><surname>Gosselin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Skola</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Coufal</surname><given-names>NG</given-names></string-name>, <string-name name-style="western"><surname>Holtman</surname><given-names>IR</given-names></string-name>, <string-name name-style="western"><surname>Schlachetzki</surname><given-names>JCM</given-names></string-name>, <string-name name-style="western"><surname>Sajti</surname><given-names>E</given-names></string-name>, et al. <article-title>An environment&#8208;dependent transcriptional network specifies human microglia identity</article-title>. <source>Science</source>. <year>2017</year>;<volume>356</volume>(<issue>6344</issue>):<elocation-id>eaal3222</elocation-id>.<pub-id pub-id-type="pmid">28546318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aal3222</pub-id><pub-id pub-id-type="pmcid">PMC5858585</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="bpa70019-cit-0035"><string-name name-style="western"><surname>van Rheenen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>van der Spek</surname><given-names>RAA</given-names></string-name>, <string-name name-style="western"><surname>Bakker</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>van Vugt</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hop</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Zwamborn</surname><given-names>RAJ</given-names></string-name>, et al. <article-title>Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron&#8208;specific biology</article-title>. <source>Nat Genet</source>. <year>2021</year>;<volume>53</volume>(<issue>12</issue>):<fpage>1636</fpage>&#8211;<lpage>1648</lpage>.<pub-id pub-id-type="pmid">34873335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-00973-1</pub-id><pub-id pub-id-type="pmcid">PMC8648564</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="bpa70019-cit-0036"><string-name name-style="western"><surname>Schlepckow</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Morenas&#8208;Rodriguez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Haass</surname><given-names>C</given-names></string-name>. <article-title>Stimulation of TREM2 with agonistic antibodies&#8208;an emerging therapeutic option for Alzheimer's disease</article-title>. <source>Lancet Neurol</source>. <year>2023</year>;<volume>22</volume>(<issue>11</issue>):<fpage>1048</fpage>&#8211;<lpage>1060</lpage>.<pub-id pub-id-type="pmid">37863592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(23)00247-8</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="bpa70019-cit-0037"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sloan</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Clarke</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Caneda</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Plaza</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Blumenthal</surname><given-names>PD</given-names></string-name>, et al. <article-title>Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse</article-title>. <source>Neuron</source>. <year>2016</year>;<volume>89</volume>(<issue>1</issue>):<fpage>37</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2015.11.013</pub-id><pub-id pub-id-type="pmid">26687838</pub-id><pub-id pub-id-type="pmcid">PMC4707064</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="bpa70019-cit-0038"><string-name name-style="western"><surname>Brohawn</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>O'Brien</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>JP</given-names><suffix>Jr</suffix></string-name>. <article-title>RNAseq analyses identify tumor necrosis factor&#8208;mediated inflammation as a major abnormality in ALS spinal cord</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>8</issue>):<elocation-id>e0160520</elocation-id>.<pub-id pub-id-type="pmid">27487029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0160520</pub-id><pub-id pub-id-type="pmcid">PMC4972368</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="bpa70019-cit-0039"><string-name name-style="western"><surname>Love</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Huber</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Anders</surname><given-names>S</given-names></string-name>. <article-title>Moderated estimation of fold change and dispersion for RNA&#8208;seq data with DESeq2</article-title>. <source>Genome Biol</source>. <year>2014</year>;<volume>15</volume>(<issue>12</issue>):<fpage>550</fpage>.<pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmcid">PMC4302049</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="bpa70019-cit-0040"><string-name name-style="western"><surname>Wilson</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Heraty</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ashford</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Coelho</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Frangi</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Pozo</surname><given-names>JM</given-names></string-name>, et al. <article-title>Tissue microarray (TMA) use in post mortem neuropathology</article-title>. <source>J Neurosci Methods</source>. <year>2020</year>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2020.108963</pub-id><pub-id pub-id-type="pmid">33007345</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="bpa70019-cit-0041"><string-name name-style="western"><surname>Windham</surname><given-names>IA</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>S</given-names></string-name>. <article-title>The cell biology of APOE in the brain</article-title>. <source>Trends Cell Biol</source>. <year>2024</year>;<volume>34</volume>(<issue>4</issue>):<fpage>338</fpage>&#8211;<lpage>348</lpage>.<pub-id pub-id-type="pmid">37805344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcb.2023.09.004</pub-id><pub-id pub-id-type="pmcid">PMC10995109</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="bpa70019-cit-0042"><string-name name-style="western"><surname>Boche</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Perry</surname><given-names>VH</given-names></string-name>, <string-name name-style="western"><surname>Nicoll</surname><given-names>JA</given-names></string-name>. <article-title>Review: activation patterns of microglia and their identification in the human brain</article-title>. <source>Neuropathol Appl Neurobiol</source>. <year>2013</year>;<volume>39</volume>(<issue>1</issue>):<fpage>3</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">23252647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/nan.12011</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="bpa70019-cit-0043"><string-name name-style="western"><surname>Jurga</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Paleczna</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kuter</surname><given-names>KZ</given-names></string-name>. <article-title>Overview of general and discriminating markers of differential microglia phenotypes</article-title>. <source>Front Cell Neurosci</source>. <year>2020</year>;<volume>14</volume>:<fpage>198</fpage>.<pub-id pub-id-type="pmid">32848611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2020.00198</pub-id><pub-id pub-id-type="pmcid">PMC7424058</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="bpa70019-cit-0044"><string-name name-style="western"><surname>Borda</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Alvarez</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Mohan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hasegawa</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bernardino</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jean</surname><given-names>S</given-names></string-name>, et al. <article-title>CD163, a marker of perivascular macrophages, is up&#8208;regulated by microglia in simian immunodeficiency virus encephalitis after haptoglobin&#8208;hemoglobin complex stimulation and is suggestive of breakdown of the blood&#8208;brain barrier</article-title>. <source>Am J Pathol</source>. <year>2008</year>;<volume>172</volume>(<issue>3</issue>):<fpage>725</fpage>&#8211;<lpage>737</lpage>.<pub-id pub-id-type="pmid">18276779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2353/ajpath.2008.070848</pub-id><pub-id pub-id-type="pmcid">PMC2258269</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="bpa70019-cit-0045"><string-name name-style="western"><surname>Koussounadis</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Langdon</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Um</surname><given-names>IH</given-names></string-name>, <string-name name-style="western"><surname>Harrison</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>VA</given-names></string-name>. <article-title>Relationship between differentially expressed mRNA and mRNA&#8208;protein correlations in a xenograft model system</article-title>. <source>Sci Rep</source>. <year>2015</year>;<volume>5</volume>:<elocation-id>10775</elocation-id>.<pub-id pub-id-type="pmid">26053859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep10775</pub-id><pub-id pub-id-type="pmcid">PMC4459080</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="bpa70019-cit-0046"><string-name name-style="western"><surname>Conroy</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Velez&#8208;Gomez</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>O'Brien</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Heverin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hardiman</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>McDermott</surname><given-names>C</given-names></string-name>, et al. <article-title>IMPACT&#8208;ALS: summary of results from a European survey of people living with ALS</article-title>. <source>Amyotroph Lateral Scler Frontotemporal Degener</source>. <year>2023</year>;<fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1080/21678421.2023.2249515</pub-id><pub-id pub-id-type="pmid">37661426</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="bpa70019-cit-0047"><string-name name-style="western"><surname>Lederer</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Torrisi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pantelidou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Santama</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Cavallaro</surname><given-names>S</given-names></string-name>. <article-title>Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis</article-title>. <source>BMC Genomics</source>. <year>2007</year>;<volume>8</volume>:<fpage>26</fpage>.<pub-id pub-id-type="pmid">17244347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2164-8-26</pub-id><pub-id pub-id-type="pmcid">PMC1796866</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="bpa70019-cit-0048"><string-name name-style="western"><surname>Aronica</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Baas</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Iyer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>ten Asbroek</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Morello</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cavallaro</surname><given-names>S</given-names></string-name>. <article-title>Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex</article-title>. <source>Neurobiol Dis</source>. <year>2015</year>;<volume>74</volume>:<fpage>359</fpage>&#8211;<lpage>376</lpage>.<pub-id pub-id-type="pmid">25500340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2014.12.002</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="bpa70019-cit-0049"><string-name name-style="western"><surname>Humphrey</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Venkatesh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hasan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Herb</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>de Paiva Lopes</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kucukali</surname><given-names>F</given-names></string-name>, et al. <article-title>Integrative transcriptomic analysis of the amyotrophic lateral sclerosis spinal cord implicates glial activation and suggests new risk genes</article-title>. <source>Nat Neurosci</source>. <year>2023</year>;<volume>26</volume>(<issue>1</issue>):<fpage>150</fpage>&#8211;<lpage>162</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-022-01205-3</pub-id><pub-id pub-id-type="pmid">36482247</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="bpa70019-cit-0050"><string-name name-style="western"><surname>Butovsky</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Jedrychowski</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Cialic</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lanser</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Gabriely</surname><given-names>G</given-names></string-name>, et al. <article-title>Identification of a unique TGF&#8208;beta&#8208;dependent molecular and functional signature in microglia</article-title>. <source>Nat Neurosci</source>. <year>2014</year>;<volume>17</volume>(<issue>1</issue>):<fpage>131</fpage>&#8211;<lpage>143</lpage>.<pub-id pub-id-type="pmid">24316888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.3599</pub-id><pub-id pub-id-type="pmcid">PMC4066672</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="bpa70019-cit-0051"><string-name name-style="western"><surname>Cooper&#8208;Knock</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Green</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Altschuler</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Bury</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Heath</surname><given-names>PR</given-names></string-name>, et al. <article-title>A data&#8208;driven approach links microglia to pathology and prognosis in amyotrophic lateral sclerosis</article-title>. <source>Acta Neuropathol Commun</source>. <year>2017</year>;<volume>5</volume>(<issue>1</issue>):<fpage>23</fpage>.<pub-id pub-id-type="pmid">28302159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-017-0424-x</pub-id><pub-id pub-id-type="pmcid">PMC5353945</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="bpa70019-cit-0052"><string-name name-style="western"><surname>Yamasaki</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Butovsky</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Ohno</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Rietsch</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Cialic</surname><given-names>R</given-names></string-name>, et al. <article-title>Differential roles of microglia and monocytes in the inflamed central nervous system</article-title>. <source>J Exp Med</source>. <year>2014</year>;<volume>211</volume>(<issue>8</issue>):<fpage>1533</fpage>&#8211;<lpage>1549</lpage>.<pub-id pub-id-type="pmid">25002752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20132477</pub-id><pub-id pub-id-type="pmcid">PMC4113947</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="bpa70019-cit-0053"><string-name name-style="western"><surname>Konishi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kiyama</surname><given-names>H</given-names></string-name>. <article-title>Microglial TREM2/DAP12 signaling: a double&#8208;edged sword in neural diseases</article-title>. <source>Front Cell Neurosci</source>. <year>2018</year>;<volume>12</volume>:<fpage>206</fpage>.<pub-id pub-id-type="pmid">30127720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2018.00206</pub-id><pub-id pub-id-type="pmcid">PMC6087757</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="bpa70019-cit-0054"><string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Taso</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bayram</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Graham</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Garcia&#8208;Reitboeck</surname><given-names>P</given-names></string-name>, et al. <article-title>Trem2 promotes anti&#8208;inflammatory responses in microglia and is suppressed under pro&#8208;inflammatory conditions</article-title>. <source>Hum Mol Genet</source>. <year>2020</year>;<volume>29</volume>(<issue>19</issue>):<fpage>3224</fpage>&#8211;<lpage>3248</lpage>.<pub-id pub-id-type="pmid">32959884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddaa209</pub-id><pub-id pub-id-type="pmcid">PMC7689298</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="bpa70019-cit-0055"><string-name name-style="western"><surname>Yin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>S</given-names></string-name>. <article-title>Vps35&#8208;dependent recycling of Trem2 regulates microglial function</article-title>. <source>Traffic</source>. <year>2016</year>;<volume>17</volume>(<issue>12</issue>):<fpage>1286</fpage>&#8211;<lpage>1296</lpage>.<pub-id pub-id-type="pmid">27717139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/tra.12451</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="bpa70019-cit-0056"><string-name name-style="western"><surname>Xie</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>YU</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bosco</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Pang</surname><given-names>YP</given-names></string-name>, et al. <article-title>TREM2 interacts with TDP&#8208;43 and mediates microglial neuroprotection against TDP&#8208;43&#8208;related neurodegeneration</article-title>. <source>Nat Neurosci</source>. <year>2022</year>;<volume>25</volume>(<issue>1</issue>):<fpage>26</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">34916658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-021-00975-6</pub-id><pub-id pub-id-type="pmcid">PMC8741737</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="bpa70019-cit-0057"><string-name name-style="western"><surname>Parhizkar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Arzberger</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Brendel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kleinberger</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Deussing</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Focke</surname><given-names>C</given-names></string-name>, et al. <article-title>Loss of TREM2 function increases amyloid seeding but reduces plaque&#8208;associated ApoE</article-title>. <source>Nat Neurosci</source>. <year>2019</year>;<volume>22</volume>(<issue>2</issue>):<fpage>191</fpage>&#8211;<lpage>204</lpage>.<pub-id pub-id-type="pmid">30617257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-018-0296-9</pub-id><pub-id pub-id-type="pmcid">PMC6417433</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="bpa70019-cit-0058"><string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Andhey</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Swain</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Levy</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>KR</given-names></string-name>, et al. <article-title>Human and mouse single&#8208;nucleus transcriptomics reveal TREM2&#8208;dependent and TREM2&#8208;independent cellular responses in Alzheimer's disease</article-title>. <source>Nat Med</source>. <year>2020</year>;<volume>26</volume>(<issue>1</issue>):<fpage>131</fpage>&#8211;<lpage>142</lpage>.<pub-id pub-id-type="pmid">31932797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-019-0695-9</pub-id><pub-id pub-id-type="pmcid">PMC6980793</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="bpa70019-cit-0059"><string-name name-style="western"><surname>Fahrenhold</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rakic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Classey</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Brayne</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ince</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Nicoll</surname><given-names>JAR</given-names></string-name>, et al. <article-title>TREM2 expression in the human brain: a marker of monocyte recruitment?</article-title><source>Brain Pathol</source>. <year>2018</year>;<volume>28</volume>(<issue>5</issue>):<fpage>595</fpage>&#8211;<lpage>602</lpage>.<pub-id pub-id-type="pmid">28987033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bpa.12564</pub-id><pub-id pub-id-type="pmcid">PMC6221091</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="bpa70019-cit-0060"><string-name name-style="western"><surname>Raha&#8208;Chowdhury</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Henderson</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Raha</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Vuono</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bickerton</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>E</given-names></string-name>, et al. <article-title>Choroid plexus acts as gatekeeper for TREM2, abnormal accumulation of ApoE, and fibrillary tau in Alzheimer's disease and in down syndrome dementia</article-title>. <source>J Alzheimers Dis</source>. <year>2019</year>;<volume>69</volume>(<issue>1</issue>):<fpage>91</fpage>&#8211;<lpage>109</lpage>.<pub-id pub-id-type="pmid">30909239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-181179</pub-id><pub-id pub-id-type="pmcid">PMC6598012</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="bpa70019-cit-0061"><string-name name-style="western"><surname>Satoh</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kawana</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ishida</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Saito</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Arima</surname><given-names>K</given-names></string-name>. <article-title>A survey of TREM2 antibodies reveals neuronal but not microglial staining in formalin&#8208;fixed paraffin&#8208;embedded postmortem Alzheimer's brain tissues</article-title>. <source>Alzheimers Res Ther</source>. <year>2013</year>;<volume>5</volume>(<issue>4</issue>):<fpage>30</fpage>.<pub-id pub-id-type="pmid">23830013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/alzrt184</pub-id><pub-id pub-id-type="pmcid">PMC3978710</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="bpa70019-cit-0062"><string-name name-style="western"><surname>Kobayashi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Konishi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Takai</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kiyama</surname><given-names>H</given-names></string-name>. <article-title>A DAP12&#8208;dependent signal promotes pro&#8208;inflammatory polarization in microglia following nerve injury and exacerbates degeneration of injured neurons</article-title>. <source>Glia</source>. <year>2015</year>;<volume>63</volume>(<issue>6</issue>):<fpage>1073</fpage>&#8211;<lpage>1082</lpage>.<pub-id pub-id-type="pmid">25690660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.22802</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="bpa70019-cit-0063"><string-name name-style="western"><surname>Kaifu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Nakahara</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Inui</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mishima</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Momiyama</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kaji</surname><given-names>M</given-names></string-name>, et al. <article-title>Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12&#8208;deficient mice</article-title>. <source>J Clin Invest</source>. <year>2003</year>;<volume>111</volume>(<issue>3</issue>):<fpage>323</fpage>&#8211;<lpage>332</lpage>.<pub-id pub-id-type="pmid">12569157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI16923</pub-id><pub-id pub-id-type="pmcid">PMC151867</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="bpa70019-cit-0064"><string-name name-style="western"><surname>Haure&#8208;Mirande</surname><given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Audrain</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fanutza</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname><given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>Glabe</surname><given-names>C</given-names></string-name>, et al. <article-title>Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology</article-title>. <source>Acta Neuropathol</source>. <year>2017</year>;<volume>134</volume>(<issue>5</issue>):<fpage>769</fpage>&#8211;<lpage>788</lpage>.<pub-id pub-id-type="pmid">28612290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-017-1737-3</pub-id><pub-id pub-id-type="pmcid">PMC5645450</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="bpa70019-cit-0065"><string-name name-style="western"><surname>Andres&#8208;Benito</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Moreno</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Aso</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Povedano</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ferrer</surname><given-names>I</given-names></string-name>. <article-title>Amyotrophic lateral sclerosis, gene deregulation in the anterior horn of the spinal cord and frontal cortex area 8: implications in frontotemporal lobar degeneration</article-title>. <source>Aging (Albany NY)</source>. <year>2017</year>;<volume>9</volume>(<issue>3</issue>):<fpage>823</fpage>&#8211;<lpage>851</lpage>.<pub-id pub-id-type="pmid">28283675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.101195</pub-id><pub-id pub-id-type="pmcid">PMC5391234</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="bpa70019-cit-0066"><string-name name-style="western"><surname>Oeckl</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Weydt</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Thal</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Weishaupt</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Ludolph</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Otto</surname><given-names>M</given-names></string-name>. <article-title>Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis</article-title>. <source>Acta Neuropathol</source>. <year>2020</year>;<volume>139</volume>(<issue>1</issue>):<fpage>119</fpage>&#8211;<lpage>134</lpage>.<pub-id pub-id-type="pmid">31701227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-019-02093-x</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="bpa70019-cit-0067"><string-name name-style="western"><surname>Offen</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Barhum</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Melamed</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Embacher</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Schindler</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ransmayr</surname><given-names>G</given-names></string-name>. <article-title>Spinal cord mRNA profile in patients with ALS: comparison with transgenic mice expressing the human SOD&#8208;1 mutant</article-title>. <source>J Mol Neurosci</source>. <year>2009</year>;<volume>38</volume>(<issue>2</issue>):<fpage>85</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">18651250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12031-007-9004-z</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="bpa70019-cit-0068"><string-name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Pitas</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Kilbridge</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nathan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mahley</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Bu</surname><given-names>G</given-names></string-name>, et al. <article-title>Low density lipoprotein receptor&#8208;related protein mediates apolipoprotein E&#8208;dependent neurite outgrowth in a central nervous system&#8208;derived neuronal cell line</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>1995</year>;<volume>92</volume>(<issue>21</issue>):<fpage>9480</fpage>&#8211;<lpage>9484</lpage>.<pub-id pub-id-type="pmid">7568158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.92.21.9480</pub-id><pub-id pub-id-type="pmcid">PMC40825</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="bpa70019-cit-0069"><string-name name-style="western"><surname>LaDu</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Reardon</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Getz</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Bu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>J</given-names></string-name>, et al. <article-title>Apolipoprotein E and apolipoprotein E receptors modulate a beta&#8208;induced glial neuroinflammatory responses</article-title>. <source>Neurochem Int</source>. <year>2001</year>;<volume>39</volume>(<issue>5&#8211;6</issue>):<fpage>427</fpage>&#8211;<lpage>434</lpage>. <pub-id pub-id-type="doi">10.1016/s0197-0186(01)00050-x</pub-id><pub-id pub-id-type="pmid">11578778</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="bpa70019-cit-0070"><string-name name-style="western"><surname>Lanfranco</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Sepulveda</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kopetsky</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Rebeck</surname><given-names>GW</given-names></string-name>. <article-title>Expression and secretion of apoE isoforms in astrocytes and microglia during inflammation</article-title>. <source>Glia</source>. <year>2021</year>;<volume>69</volume>(<issue>6</issue>):<fpage>1478</fpage>&#8211;<lpage>1493</lpage>.<pub-id pub-id-type="pmid">33556209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.23974</pub-id><pub-id pub-id-type="pmcid">PMC8717762</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="bpa70019-cit-0071"><string-name name-style="western"><surname>White</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Nicoll</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Roses</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Horsburgh</surname><given-names>K</given-names></string-name>. <article-title>Impaired neuronal plasticity in transgenic mice expressing human apolipoprotein E4 compared to E3 in a model of entorhinal cortex lesion</article-title>. <source>Neurobiol Dis</source>. <year>2001</year>;<volume>8</volume>(<issue>4</issue>):<fpage>611</fpage>&#8211;<lpage>625</lpage>.<pub-id pub-id-type="pmid">11493026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/nbdi.2001.0401</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="bpa70019-cit-0072"><string-name name-style="western"><surname>Harris</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Tesseur</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Brecht</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Mullendorff</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>S</given-names></string-name>, et al. <article-title>Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease</article-title>. <source>J Biol Chem</source>. <year>2004</year>;<volume>279</volume>(<issue>5</issue>):<fpage>3862</fpage>&#8211;<lpage>3868</lpage>.<pub-id pub-id-type="pmid">14585838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M309475200</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="bpa70019-cit-0073"><string-name name-style="western"><surname>Mahley</surname><given-names>RW</given-names></string-name>. <article-title>Central nervous system lipoproteins: ApoE and regulation of cholesterol metabolism</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2016</year>;<volume>36</volume>(<issue>7</issue>):<fpage>1305</fpage>&#8211;<lpage>1315</lpage>.<pub-id pub-id-type="pmid">27174096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.116.307023</pub-id><pub-id pub-id-type="pmcid">PMC4942259</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="bpa70019-cit-0074"><string-name name-style="western"><surname>Pitas</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Boyles</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Foss</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mahley</surname><given-names>RW</given-names></string-name>. <article-title>Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E&#8208;containing lipoproteins</article-title>. <source>Biochim Biophys Acta</source>. <year>1987</year>;<volume>917</volume>(<issue>1</issue>):<fpage>148</fpage>&#8211;<lpage>161</lpage>.<pub-id pub-id-type="pmid">3539206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0005-2760(87)90295-5</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="bpa70019-cit-0075"><string-name name-style="western"><surname>Xu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cyras</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sanan</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Cordell</surname><given-names>B</given-names></string-name>. <article-title>Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein&#8208;like apolipoprotein J&#8208;rich but E&#8208;poor spherical particle</article-title>. <source>J Biol Chem</source>. <year>2000</year>;<volume>275</volume>(<issue>41</issue>):<fpage>31770</fpage>&#8211;<lpage>31777</lpage>.<pub-id pub-id-type="pmid">10918055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M002796200</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="bpa70019-cit-0076"><string-name name-style="western"><surname>Atagi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Painter</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>XF</given-names></string-name>, <string-name name-style="western"><surname>Verbeeck</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>H</given-names></string-name>, et al. <article-title>Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2)</article-title>. <source>J Biol Chem</source>. <year>2015</year>;<volume>290</volume>(<issue>43</issue>):<fpage>26043</fpage>&#8211;<lpage>26050</lpage>.<pub-id pub-id-type="pmid">26374899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M115.679043</pub-id><pub-id pub-id-type="pmcid">PMC4646257</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="bpa70019-cit-0077"><string-name name-style="western"><surname>Pankiewicz</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Lizinczyk</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Franco</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Diaz</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Marta&#8208;Ariza</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sadowski</surname><given-names>MJ</given-names></string-name>. <article-title>Absence of Apolipoprotein E is associated with exacerbation of prion pathology and promotes microglial neurodegenerative phenotype</article-title>. <source>Acta Neuropathol Commun</source>. <year>2021</year>;<volume>9</volume>(<issue>1</issue>):<fpage>157</fpage>.<pub-id pub-id-type="pmid">34565486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-021-01261-z</pub-id><pub-id pub-id-type="pmcid">PMC8474943</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="bpa70019-cit-0078"><string-name name-style="western"><surname>Holtman</surname><given-names>IR</given-names></string-name>, <string-name name-style="western"><surname>Raj</surname><given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Schaafsma</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Brouwer</surname><given-names>N</given-names></string-name>, et al. <article-title>Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co&#8208;expression meta&#8208;analysis</article-title>. <source>Acta Neuropathol Commun</source>. <year>2015</year>;<volume>3</volume>(<issue>31</issue>):<fpage>31</fpage>. <pub-id pub-id-type="doi">10.1186/s40478-015-0203-5</pub-id><pub-id pub-id-type="pmid">26001565</pub-id><pub-id pub-id-type="pmcid">PMC4489356</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="bpa70019-cit-0079"><string-name name-style="western"><surname>Krasemann</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Madore</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cialic</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Baufeld</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Calcagno</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>El Fatimy</surname><given-names>R</given-names></string-name>, et al. <article-title>The TREM2&#8208;APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases</article-title>. <source>Immunity</source>. <year>2017</year>;<volume>47</volume>(<issue>3</issue>):<fpage>566</fpage>&#8211;<lpage>581 e9</lpage>.<pub-id pub-id-type="pmid">28930663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2017.08.008</pub-id><pub-id pub-id-type="pmcid">PMC5719893</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="bpa70019-cit-0080"><string-name name-style="western"><surname>Spiller</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Restrepo</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Dominique</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Canter</surname><given-names>RG</given-names></string-name>, et al. <article-title>Microglia&#8208;mediated recovery from ALS&#8208;relevant motor neuron degeneration in a mouse model of TDP&#8208;43 proteinopathy</article-title>. <source>Nat Neurosci</source>. <year>2018</year>;<volume>21</volume>(<issue>3</issue>):<fpage>329</fpage>&#8211;<lpage>340</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-018-0083-7</pub-id><pub-id pub-id-type="pmid">29463850</pub-id><pub-id pub-id-type="pmcid">PMC5857237</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="bpa70019-cit-0081"><string-name name-style="western"><surname>Deczkowska</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Keren&#8208;Shaul</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Weiner</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Colonna</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Amit</surname><given-names>I</given-names></string-name>. <article-title>Disease&#8208;associated microglia: a universal immune sensor of neurodegeneration</article-title>. <source>Cell</source>. <year>2018</year>;<volume>173</volume>(<issue>5</issue>):<fpage>1073</fpage>&#8211;<lpage>1081</lpage>.<pub-id pub-id-type="pmid">29775591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2018.05.003</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="bpa70019-cit-0082"><string-name name-style="western"><surname>Kamphuis</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kooijman</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Schetters</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Orre</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hol</surname><given-names>EM</given-names></string-name>. <article-title>Transcriptional profiling of CD11c&#8208;positive microglia accumulating around amyloid plaques in a mouse model for Alzheimer's disease</article-title>. <source>Biochim Biophys Acta</source>. <year>2016</year>;<volume>1862</volume>(<issue>10</issue>):<fpage>1847</fpage>&#8211;<lpage>1860</lpage>.<pub-id pub-id-type="pmid">27425031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2016.07.007</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="bpa70019-cit-0083"><string-name name-style="western"><surname>Chiu</surname><given-names>IM</given-names></string-name>, <string-name name-style="western"><surname>Morimoto</surname><given-names>ET</given-names></string-name>, <string-name name-style="western"><surname>Goodarzi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>O'Keeffe</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Phatnani</surname><given-names>HP</given-names></string-name>, et al. <article-title>A neurodegeneration&#8208;specific gene&#8208;expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model</article-title>. <source>Cell rep</source>. <year>2013</year>;<volume>4</volume>(<issue>2</issue>):<fpage>385</fpage>&#8211;<lpage>401</lpage>.<pub-id pub-id-type="pmid">23850290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2013.06.018</pub-id><pub-id pub-id-type="pmcid">PMC4272581</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="bpa70019-cit-0084"><string-name name-style="western"><surname>Keren&#8208;Shaul</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Spinrad</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Weiner</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Matcovitch&#8208;Natan</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Dvir&#8208;Szternfeld</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ulland</surname><given-names>TK</given-names></string-name>, et al. <article-title>A unique microglia type associated with restricting development of Alzheimer's disease</article-title>. <source>Cell</source>. <year>2017</year>;<volume>169</volume>(<issue>7</issue>):<fpage>1276</fpage>&#8211;<lpage>1290 e17</lpage>.<pub-id pub-id-type="pmid">28602351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.05.018</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="bpa70019-cit-0085"><string-name name-style="western"><surname>Liao</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Yoon</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>. <article-title>Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease</article-title>. <source>Curr Opin Lipidol</source>. <year>2017</year>;<volume>28</volume>(<issue>1</issue>):<fpage>60</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="pmid">27922847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MOL.0000000000000383</pub-id><pub-id pub-id-type="pmcid">PMC5213812</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="bpa70019-cit-0086"><string-name name-style="western"><surname>Siddique</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pericak&#8208;Vance</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Caliendo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>ST</given-names></string-name>, <string-name name-style="western"><surname>Hung</surname><given-names>WY</given-names></string-name>, <string-name name-style="western"><surname>Kaplan</surname><given-names>J</given-names></string-name>, et al. <article-title>Lack of association between apolipoprotein E genotype and sporadic amyotrophic lateral sclerosis</article-title>. <source>Neurogenetics</source>. <year>1998</year>;<volume>1</volume>(<issue>3</issue>):<fpage>213</fpage>&#8211;<lpage>216</lpage>.<pub-id pub-id-type="pmid">10737125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s100480050031</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="bpa70019-cit-0087"><string-name name-style="western"><surname>He</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Shang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>Z</given-names></string-name>, et al. <article-title>Association of apolipoprotein E epsilon4 allele and amyotrophic lateral sclerosis in Chinese population</article-title>. <source>Amyotroph Lateral Scler Frontotemporal Degener</source>. <year>2022</year>;<volume>23</volume>(<issue>5&#8211;6</issue>):<fpage>399</fpage>&#8211;<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1080/21678421.2021.1953077</pub-id><pub-id pub-id-type="pmid">34279165</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="bpa70019-cit-0088"><string-name name-style="western"><surname>Li</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Pericak&#8208;Vance</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Haines</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Siddique</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>McKenna&#8208;Yasek</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hung</surname><given-names>WY</given-names></string-name>, et al. <article-title>Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis</article-title>. <source>Neurogenetics</source>. <year>2004</year>;<volume>5</volume>(<issue>4</issue>):<fpage>209</fpage>&#8211;<lpage>213</lpage>.<pub-id pub-id-type="pmid">15657798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10048-004-0193-0</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="bpa70019-cit-0089"><string-name name-style="western"><surname>Moulard</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sefiani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Laamri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Malafosse</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Camu</surname><given-names>W</given-names></string-name>. <article-title>Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis</article-title>. <source>J Neurol Sci</source>. <year>1996</year>;<volume>139</volume>(<issue>Suppl</issue>):<fpage>34</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">8899655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0022-510x(96)00085-8</pub-id></mixed-citation></ref><ref id="bpa70019-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="bpa70019-cit-0090"><string-name name-style="western"><surname>Riddell</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Atchison</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Warwick</surname><given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Atkinson</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Jefferson</surname><given-names>J</given-names></string-name>, et al. <article-title>Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels</article-title>. <source>J Neurosci</source>. <year>2008</year>;<volume>28</volume>(<issue>45</issue>):<fpage>11445</fpage>&#8211;<lpage>11453</lpage>.<pub-id pub-id-type="pmid">18987181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.1972-08.2008</pub-id><pub-id pub-id-type="pmcid">PMC6671315</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70603" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12489747</article-id><article-id pub-id-type="pmcid-ver">PMC12489747.1</article-id><article-id pub-id-type="pmcaid">12489747</article-id><article-id pub-id-type="pmcaiid">12489747</article-id><article-id pub-id-type="pmid">41036709</article-id><article-id pub-id-type="doi">10.1002/alz.70603</article-id><article-id pub-id-type="publisher-id">ALZ70603</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Decoding adipose&#8211;brain crosstalk: Distinct lipid cargo in human adipose&#8208;derived extracellular vesicles modulates amyloid aggregation in Alzheimer's disease</article-title><alt-title alt-title-type="left-running-head">YANG <sc>et&#160;al</sc>.</alt-title></title-group><contrib-group><contrib id="alz70603-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Yang</surname><given-names initials="L">Li</given-names></name><xref rid="alz70603-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70603-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>lyang@houstonmethodist.org</email></address></contrib><contrib id="alz70603-cr-0002" contrib-type="author"><name name-style="western"><surname>Chan</surname><given-names initials="M">Michael</given-names></name><xref rid="alz70603-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70603-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70603-cr-0003" contrib-type="author" corresp="yes"><name name-style="western"><surname>Sheng</surname><given-names initials="J">Jianting</given-names></name><xref rid="alz70603-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70603-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>jsheng@houstonmethodist.org</email></address></contrib><contrib id="alz70603-cr-0004" contrib-type="author"><name name-style="western"><surname>Qi</surname><given-names initials="S">Shaohua</given-names></name><xref rid="alz70603-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70603-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70603-cr-0005" contrib-type="author"><name name-style="western"><surname>Chan</surname><given-names initials="B">Bill</given-names></name><xref rid="alz70603-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70603-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70603-cr-0006" contrib-type="author"><name name-style="western"><surname>Shantaram</surname><given-names initials="D">Dharti</given-names></name><xref rid="alz70603-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70603-cr-0007" contrib-type="author"><name name-style="western"><surname>Rima</surname><given-names initials="XY">Xilal Y.</given-names></name><xref rid="alz70603-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70603-cr-0008" contrib-type="author"><name name-style="western"><surname>Reategui</surname><given-names initials="E">Eduardo</given-names></name><xref rid="alz70603-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70603-cr-0009" contrib-type="author"><name name-style="western"><surname>Han</surname><given-names initials="X">Xianlin</given-names></name><xref rid="alz70603-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70603-cr-0010" contrib-type="author"><name name-style="western"><surname>Hsueh</surname><given-names initials="WA">Willa A.</given-names></name><xref rid="alz70603-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70603-cr-0011" contrib-type="author" corresp="yes"><name name-style="western"><surname>Wong</surname><given-names initials="STC">Stephen T. C.</given-names></name><xref rid="alz70603-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70603-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70603-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><address><email>stwong@houstonmethodist.org</email></address></contrib></contrib-group><aff id="alz70603-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Systems Medicine and Bioengineering Department</named-content>
<named-content content-type="organisation-division">Houston Methodist Neal Cancer Center</named-content>
<institution>Houston Methodist Hospital</institution>
<city>Houston</city>
<named-content content-type="country-part">Texas</named-content>
<country country="US">USA</country>
</aff><aff id="alz70603-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Ting Tsung &amp; Wei Fong Chao Center for BRAIN</named-content>
<institution>Houston Methodist Academic Institute and Weill Cornell Medicine</institution>
<city>Houston</city>
<named-content content-type="country-part">Texas</named-content>
<country country="US">USA</country>
</aff><aff id="alz70603-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Diabetes and Metabolism Research Center</named-content>
<named-content content-type="organisation-division">Division of Endocrinology</named-content>
<named-content content-type="organisation-division">Diabetes &amp; Metabolism</named-content>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>The Ohio State University Wexner Medical Center</institution>
<city>Columbus</city>
<named-content content-type="country-part">Ohio</named-content>
<country country="US">USA</country>
</aff><aff id="alz70603-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Barshop Institute for Longevity and Aging Studies</named-content>
<named-content content-type="organisation-division">and Department of Medicine</named-content>
<institution>University of Texas Health Science Center at San Antonio</institution>
<city>San Antonio</city>
<named-content content-type="country-part">Texas</named-content>
<country country="US">USA</country>
</aff><aff id="alz70603-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Departments of Medicine</named-content>
<named-content content-type="organisation-division">Radiology, Neurology</named-content>
<named-content content-type="organisation-division">Pathology and Laboratory Medicine</named-content>
<institution>Houston Methodist Hospital and Weill Cornell Medicine</institution>
<city>Houston</city>
<named-content content-type="country-part">Texas</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Stephen T.C. Wong, Systems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, 6565 Fannin Street, F6&#8208;D300, Houston, TX 77030, USA.<break/> Email: <email>stwong@houstonmethodist.org</email><break/>Li Yang, Systems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, 6565 Fannin Street, F6&#8208;036.4, Houston, TX 77030, USA.<break/> Email: <email>lyang@houstonmethodist.org</email><break/>Jianting Sheng, Systems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, 6565 Fannin Street, F6&#8208;027, Houston, TX 77030, USA.<break/> Email: <email>jsheng@houstonmethodist.org</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="110">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70603</elocation-id><history><date date-type="rev-recd"><day>06</day><month>7</month><year>2025</year></date><date date-type="received"><day>09</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-03 12:25:15.927"><day>03</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70603.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70603.pdf"/><abstract><title>Abstract</title><sec id="alz70603-sec-0010"><title>INTRODUCTION</title><p>Obesity is a major modifiable risk factor for Alzheimer's disease (AD), but the mechanistic link between peripheral metabolic dysfunction and AD progression remains unclear. Adipose&#8208;derived extracellular vesicles (EVs) may penetrate the brain and alter lipid homeostasis, contributing to neurodegeneration.</p></sec><sec id="alz70603-sec-0020"><title>METHODS</title><p>We isolated exosome&#8208;enriched EVs from subcutaneous and visceral fat of lean and obese individuals, followed by lipidomic profiling. An in vitro amyloid&#8208;&#946; (A&#946;) aggregation assay using purified A&#946;40 and A&#946;42 peptides was performed under lipid environments mimicking physiological and pathological states.</p></sec><sec id="alz70603-sec-0030"><title>RESULTS</title><p>Obese&#8208;derived EVs exhibited distinct lipid profiles, particularly in lysophosphatidylcholine (LPC) and sphingomyelin (SM) species. Functional assays demonstrated that lipid identity and concentration critically influenced A&#946; aggregation kinetics.</p></sec><sec id="alz70603-sec-0040"><title>DISCUSSION</title><p>Our study reveals that obesity&#8208;associated EV lipids modulate A&#946; aggregation, linking adipose metabolism to AD pathology. These findings support lipid&#8208;targeted strategies as potential therapeutics for neurodegenerative diseases.</p></sec><sec id="alz70603-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70603-list-0001"><list-item><p>Human adipose&#8208;derived extracellular vesicles (EVs) from obese individuals exhibit distinct lipidomic profiles.</p></list-item><list-item><p>EV lipids modulate amyloid&#8208;&#946; (A&#946;) 40 and A&#946;42 aggregation in a lipid&#8208;type&#8208; and concentration&#8208;dependent manner.</p></list-item><list-item><p>Lysophosphatidylcholine (LPC) and sphingomyelin (SM) species from obese EVs significantly deregulate A&#946; fibrillization in vitro.</p></list-item><list-item><p>EV lipid cargo links peripheral metabolic state to amyloid pathology in Alzheimer's disease.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70603-kwd-0001">adipocyte&#8208;derived extracellular vesicles</kwd><kwd id="alz70603-kwd-0002">Alzheimer's disease</kwd><kwd id="alz70603-kwd-0003">A&#946; fibrillization</kwd><kwd id="alz70603-kwd-0004">exosome&#8208;enriched extracellular vesicles</kwd><kwd id="alz70603-kwd-0005">lipid homeostasis</kwd><kwd id="alz70603-kwd-0006">lipidomics</kwd><kwd id="alz70603-kwd-0007">obesity</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>NIH</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>R01AG057635</award-id><award-id>R01CA238727</award-id><award-id>U01CA253553</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>T. T. and W. F. Chao Foundation</institution></institution-wrap></funding-source></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Cure Alzheimer's Fund</institution><institution-id institution-id-type="doi">10.13039/100007625</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>John S. Dunn Research Foundation</institution></institution-wrap></funding-source></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>Houston Methodist Cornerstone Award</institution></institution-wrap></funding-source></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>Paul Richard Jeanneret Research Fund</institution></institution-wrap></funding-source></award-group><award-group id="funding-0007"><funding-source><institution-wrap><institution>University of Texas Health Science Center at San Antonio</institution><institution-id institution-id-type="doi">10.13039/100008635</institution-id></institution-wrap></funding-source><award-id>P30 AG013319</award-id><award-id>P30 AG044271</award-id></award-group></funding-group><counts><fig-count count="6"/><table-count count="0"/><page-count count="20"/><word-count count="12186"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:02.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70603-cite-0001"><string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sheng</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Decoding adipose&#8211;brain crosstalk: Distinct lipid cargo in human adipose&#8208;derived extracellular vesicles modulates amyloid aggregation in Alzheimer's disease</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70603</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70603</pub-id></mixed-citation>
</p><fn-group><fn id="alz70603-note-0001" fn-type="equal"><p>Li Yang, Michael Chan, and Jianting Sheng, contributed equally.</p></fn></fn-group></notes></front><body><sec id="alz70603-sec-0060"><label>1</label><title>BACKGROUND</title><p>Alzheimer's disease (AD) and its associated dementia are projected to affect about 82 million people worldwide by 2050.<xref rid="alz70603-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> The lipid&#8208;rich brain is influenced by lipid&#8208;related genes and peripheral lipid abnormalities, particularly in obesity, which has been identified as a top modifiable risk factor for dementia in epidemiological studies.<xref rid="alz70603-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Mechanisms linking obesity to AD pathology include lipotoxicity, insulin resistance, adipokine signaling, inflammation, and immune cell fate shifts;<xref rid="alz70603-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70603-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70603-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="alz70603-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> all of which are exacerbated in individuals with obesity and primarily contribute by the peripheral tissues. However, the molecular mechanisms connecting specific tissues, such as adipose tissue in obesity, to AD pathology remain largely unclear.</p><p>Clinical lipidomic and metabolomic studies consistently reveal early&#8208;stage dysregulation in various lipid classes in AD brains, including ceramides, sphingomyelin, cholesterol, and glycerolipids.<xref rid="alz70603-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Lipid metabolism influences multiple pathogenic processes in AD, including amyloidosis, tauopathy, neuroinflammation, neuronal damage, energy deficits, oxidative stress, and myelin homeostasis.<xref rid="alz70603-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz70603-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</p><p>The amyloid cascade hypothesis proposes that amyloid&#8208;&#946; (A&#946;) 40 and 42 peptides are generated via the amyloidogenic pathway, mediated by the sequential cleavage of &#946;&#8208;secretase and &#947;&#8208;secretase, and subsequently secreted into the extracellular space.<xref rid="alz70603-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70603-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70603-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Under pathophysiological conditions, A&#946;40 and A&#946;42 aggregate into oligomers or assemble into symmetrical, periodic fibrils, a process known as A&#946; fibrillization, which ultimately leads to the formation of amyloid plaques, a hallmark pathological feature that is visibly detectable in the brains of AD patients.<xref rid="alz70603-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70603-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70603-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>
</p><p>A&#946; fibrillization is influenced by multiple genetic and environmental factors, including gene regulation, A&#946; polymorphism,<xref rid="alz70603-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> metal ions,<xref rid="alz70603-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> and lipids.<xref rid="alz70603-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70603-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70603-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>&#160;Adipocyte&#8208;derived extracellular vesicles (EVs) can cross the blood&#8211;brain barrier and deliver exogenous molecules, including RNAs, DNAs, proteins, and lipids, thereby disrupting the brain microenvironment.<xref rid="alz70603-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="alz70603-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="alz70603-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="alz70603-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="alz70603-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70603-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="alz70603-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="alz70603-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="alz70603-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Although EV&#8208;associated miRNAs have been implicated in AD progression,<xref rid="alz70603-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="alz70603-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> the role of EV&#8208;derived lipids in exacerbating AD pathology remains largely unresolved.</p><p>Lipids constitute the majority of the brain's dry mass and are crucial for both normal function and pathology.<xref rid="alz70603-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Cryo&#8208;electron microscopy analysis of amyloid plaques has identified a substantial presence of A&#946; fibrils alongside an enriched lipid content.<xref rid="alz70603-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> The in vivo and in vitro study demonstrated that, lipid&#8208;driven condensation of Alzheimer's A&#946; peptide initiates its transition into amyloid aggregates.<xref rid="alz70603-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> Research on the interaction between lipids and A&#946; aggregation indicates that negatively charged phospholipids facilitate A&#946; fibrillization, whereas neutral lipids exhibit minimal or no impact.<xref rid="alz70603-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="alz70603-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Moreover, lipid membranes with distinct compositions have been found to enhance A&#946; fibrillization and aggregation on biological surfaces, including cell and vesicle membranes.<xref rid="alz70603-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="alz70603-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> Building upon these findings, investigating the influence of lipid components on A&#946; fibrillization under pathophysiological conditions from a lipid&#8208;type&#8208;specific perspective may provide valuable insights into lipid&#8208;based therapeutic strategies for AD.<xref rid="alz70603-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz70603-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
</p><p>In this study, we first isolated pure, well&#8208;characterized samples of EVs originating from an obese/lean population and conducted quality control (QC) assessments to confirm EV purity, size distribution, and morphology. We then systematically profiled and quantified the full range of lipids detected in the isolated EVs using multidimensional mass spectrometry and advanced lipidomics analysis to annotate, quantify, and identify lipid species with pathophysiological relevance. Subsequently, we investigate how specific EV&#8208;derived lipids influence the aggregation dynamics of human A&#946; peptides to reveal new insights into the intersection of metabolic dysfunction and neurodegenerative risk.</p></sec><sec id="alz70603-sec-0070"><label>2</label><title>METHODS</title><sec id="alz70603-sec-0080"><label>2.1</label><title>Human subjects and adipose tissue collection</title><p>Subcutaneous (SQA) and visceral (VA) adipose tissues were collected from lean and obese individuals (Supporting Information Table <xref rid="alz70603-supinfo-0001" ref-type="">1</xref>) undergoing elective abdominal surgery at The Ohio State University Wexner Medical Center. Subjects were excluded if they had active infection or febrile illness, a history of cancer or organ transplantation, chronic use of immunosuppressive or anti&#8208;inflammatory medications, or recent chemotherapy within the past year. Additional exclusion criteria included uncontrolled metabolic conditions (such as type 1 diabetes), autoimmune disorders, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), substantial weight fluctuation (&gt;10% change within the previous 3 months), or prior diagnosis of lipodystrophy, hemochromatosis, or other systemic illnesses likely to impact adipose metabolism. Tobacco use and hormonal treatments (e.g., corticosteroids, estrogen replacement) were also considered grounds for exclusion. Baseline clinical parameters&#8212;including body weight, body mass index (BMI), waist circumference, blood pressure, fasting glucose, insulin, triglycerides, and high&#8208;density lipoprotein (HDL)&#8212;were recorded preoperatively.</p><p>Adipose tissue samples were harvested intraoperatively at the surgical site near the umbilicus. Abdominal subcutaneous adipose tissue was obtained via a 3&#8211;4&#160;cm skin incision (approximately 1&#160;cm in depth), followed by aspiration with a small liposuction cannula under sterile conditions and local anesthesia (1% lidocaine with 1:100,000 epinephrine). All procedures were performed by experienced surgical collaborators at The Ohio State University (OSU) clinical research center. Between 5 and10 grams of tissue were collected from each participant and processed within 60 min of excision.</p><p>Upon collection, samples were divided for two distinct applications. One portion was immediately flash&#8208;frozen in liquid nitrogen and stored at &#8722;80&#176;C for lipidomic analysis. The remaining tissue was transferred into ice&#8208;cold sterile saline and promptly transported to the laboratory for adipocyte isolation and subsequent EV extraction.</p><p>To maintain sterility throughout processing, samples were placed in sterile containers filled with prechilled sterile media and handled exclusively under a laminar flow hood. Adipocytes and the stromal vascular fraction (SVF) were isolated by collagenase I digestion of finely minced adipose tissue, following previously established protocols.<xref rid="alz70603-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>
</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70603-sec-0090"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70603-list-0002"><list-item><p>
<bold>Systematic review</bold>: We searched PubMed and Google Scholar using the terms &#8220;adipose&#8208;derived EVs,&#8221; &#8220;lipidomics,&#8221; and &#8220;A&#946; aggregation.&#8221; Although prior studies have suggested a link between metabolic dysfunction and Alzheimer's disease (AD), the specific role of human adipose&#8208;derived extracellular vesicles (EV) lipids in modulating amyloid&#8208;&#946; (A&#946;) pathology remains poorly defined.</p></list-item><list-item><p>
<bold>Interpretation</bold>: Our study shows that EVs from obese adipose tissue carry specific lipid species that modulate A&#946;40 and A&#946;42 aggregation in a lipid&#8208;type&#8208; and concentration&#8208;dependent manner. These findings provide compelling molecular evidence linking peripheral lipid imbalance to A&#946; aggregation, suggesting that metabolic dysfunction associated with obesity may contribute to central amyloid pathology via adipose&#8208;derived EV lipids. Further in vivo validation is warranted to substantiate this proposed link.</p></list-item><list-item><p>
<bold>Future directions</bold>: This work provides a foundation for investigating lipid homeostasis for AD, particularly in metabolically at&#8208;risk populations. Future studies will focus on validating these lipid&#8211;A&#946; interactions in vivo, identifying promising therapeutic strategies, and assessing their relevance to clinical outcomes.</p></list-item></list>
</p></sec></boxed-text></sec><sec id="alz70603-sec-0100"><label>2.2</label><title>Isolation of human adipocyte&#8208;derived EVs</title><p>Exosome&#8208;enriched EVs were isolated from human adipocytes for lipidomic analysis and in vivo studies. Human adipocytes were isolated from subcutaneous adipose tissue samples as described above. After isolation, adipocytes were washed and cultured in serum&#8208;free maintenance medium (DMEM/F&#8208;12 supplemented with 25&#160;&#181;g/mL insulin and 1% penicillin/streptomycin) at 37&#176;C for 16&#8211;20&#160;h in 6&#8208;well plates (3&#160;mL/well). This serum&#8208;free condition was used to eliminate lipid contamination from fetal bovine serum (FBS) and ensure the purity of EVs for downstream applications.</p><p>After incubation, culture supernatants were collected and cleared of cellular debris by sequential low&#8208;speed centrifugation. To improve EV yield and scalability, exosome&#8208;enriched EVs were isolated using tangential flow filtration (TFF), followed by ultrafiltration to concentrate the preparations. The resulting EVs reached concentrations of approximately 10<sup>12</sup> particles/mL.</p><p>All EV isolation and characterization procedures adhered to the guidelines of the International Society for Extracellular Vesicles (ISEV). Characterization of human adipocyte&#8208;derived EVs was performed using microfluidic resistive pulse sensing (MRPS) to assess particle size and concentration, immunomagnetic bead capture for exosomal surface markers, and Western blotting for adipocyte&#8208;specific and exosomal proteins.</p></sec><sec id="alz70603-sec-0110"><label>2.3</label><title>In vivo visualization of EV distribution</title><p>For in vivo tracing in mice, EVs were isolated from mouse adipose tissue using a modified protocol incorporating collagenase II digestion. The purified EVs were labeled with the ExoGlow&#8482;&#8208;Vivo EV Labeling Kit (Cat # EXOGV900A&#8208;1) according to the manufacturer's instructions, and subsequently administered via tail vein injection at a dose of 6.55 &#215; 10&#8313; particles per mouse. Fluorescence imaging was performed using an IVIS (In Vivo Imaging System) to visualize EV biodistribution.</p></sec><sec id="alz70603-sec-0120"><label>2.4</label><title>Lipidomics</title><p>Lipid species were analyzed using multidimensional mass spectrometry&#8208;based shotgun lipidomics approach.<xref rid="alz70603-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> In brief, each exosome sample was homogenized, and the protein content of each sample was determined by a Pierce BCA assay. An equivalent of 0.01&#160;mg protein homogenate was then added to a glass tube along with a premixed lipid internal standard. Lipid extraction was performed using a modified Bligh and Dyer procedure.<xref rid="alz70603-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> The lipid extract was dispersed in chloroform:methanol (1:1, v:v) at a ratio of 4000 &#181;L/mg protein for storage.</p><p>For shotgun lipidomics, the lipid extract was further diluted to a total lipid concentration of &#8764;2&#160;pmol/&#181;L. The mass spectrometric analysis was performed on a triple quadrupole mass spectrometer (TSQ Altis, Thermo Fisher Scientific, San Jose, CA) and a hybrid quadrupole&#8208;Orbitrap mass spectrometer (Q&#8208;Exactive, Thermo Fisher Scientific, San Jose, CA), both equipped with an automated nanospray ion source device (TriVersa NanoMate, Advion Bioscience Ltd., Ithaca, NY) as described previously.<xref rid="alz70603-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>
</p><p>The data processing and analysis was performed based on the principles of shotgun lipidomics such as ion peak selection, baseline correction, isotope effect correction, etc.<xref rid="alz70603-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>, <xref rid="alz70603-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>, <xref rid="alz70603-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> The final lipicomics result were normalized to the protein content (nmol/mg protein) (Supporting Information Table <xref rid="alz70603-supinfo-0001" ref-type="">2</xref>). Lipidomics profiling (Figures&#160;<xref rid="alz70603-fig-0001" ref-type="fig">1</xref> and&#160;<xref rid="alz70603-fig-0002" ref-type="fig">2</xref>) was performed using MetaboAnalyst 5.0, following renormalization of the raw lipid data with the built&#8208;in algorithm provided by the platform. Supporting Information Table <xref rid="alz70603-supinfo-0001" ref-type="">3</xref> presents lipidomic data from adipose tissue.</p><fig position="float" fig-type="FIGURE" id="alz70603-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Lipidomic profiling of extracellular vesicles (EVs) from lean and obese individuals. (A) Unsupervised hierarchical clustering heatmap of lipidomic profiles from EVs isolated from lean and obese individuals. The analysis was performed using MetaboAnalyst 5.0 based on normalized lipid abundance values. Each column represents an individual sample (blue for lean, pink for obese), and each row corresponds to a lipid species. Color scale indicates Z&#8208;score&#8211;normalized relative abundance, with blue representing lower levels and brown indicating higher levels. (B, C) Quantification of major lipid classes in EVs from lean and obese individuals. (B)&#160;Levels of specific lipid species&#8212;including triacylglycerol (TAG), free fatty acids (FA), lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), phosphatidic acid (PA), phosphatidylcholine (PC), phosphatidylserine (PS), and sphingomyelin (SM)&#8212;were measured from EVs derived from pooled adipocyte isolates in each group (n&#160;=&#160;5 per group). (C)&#160;Lipid class quantification in EVs from individual patients (<italic toggle="yes">n</italic>&#160;=&#160;4&#8208;5 per group), showing interindividual variation. Data are normalized to total EV protein (p or n mol/mg protein). Data are presented as mean&#160;&#177;&#160;SEM; two&#8208;tailed t&#8208;test; *, increase; <sup>#</sup>, decrease; compared with the corresponding controls, *<sup>/#</sup>
<italic toggle="yes">p&#160;</italic>&lt;&#160;0.05, and **<sup>/##</sup>
<italic toggle="yes">p&#160;</italic>&lt;&#160;0.01. (D,E) Simplified Manhattan plots of lipid class alterations between obese and lean EVs (including Lean 1). (D) Fold changes (log&#8321;&#8320;[Obese/Lean]) of individual lipid classes stratified by lipid species. Each dot represents a detected lipid species, color&#8208;coded by class. (E) Statistical significance (&#8722;log&#8321;&#8320;&#160;P value) of lipid class differences calculated based on unpaired two&#8208;tailed <italic toggle="yes">t</italic>&#8208;tests using raw lipidomic concentrations from lean and obese individuals. Notable classes such as FAC, TAG, PC, LPC, and PA exhibit significant alterations in fold change and/or <italic toggle="yes">p</italic>&#8208;value distribution. (F) Lipid&#8211;lipid correlation heatmap of EV lipidomic profiles from lean and obese individuals. Pairwise correlations between lipid species were calculated using MetaboAnalyst 5.0 based on combined datasets from both groups. The color scale represents the Pearson correlation coefficient, ranging from &#8211;0.5 (purple, negative correlation) to 1.0 (yellow, strong positive correlation). Hierarchical clustering was applied to group lipid species with similar covariation patterns, revealing distinct lipid modules and potential coregulatory networks. Ten major lipid clusters (a&#8211;j) were identified, each outlined and annotated with representative lipid classes on the right. Key lipid species contributing to each cluster are summarized and compared between obese and lean groups in the accompanying Supporting Information Tables 4 and <xref rid="alz70603-supinfo-0001" ref-type="">5</xref>. Fold&#8208;change (obese/lean) values for each lipid species are also shown as a grayscale bar (FC O/L) adjacent to the cluster annotation, highlighting cluster&#8208;specific lipid alterations associated with obesity. (G) Partial least squares discriminant analysis (PLS&#8208;DA) plots showing lipid class&#8211;specific separation between EVs from lean and obese individuals (including Lean 1). EV lipidomic data were analyzed with individual patient samples as input. Samples from lean and obese subjects are shown in blue and brown, respectively, with ellipses representing 95% confidence intervals. The percentage of explained variance for the first and second components (T score [1] and orthogonal T score [1]) is indicated in parentheses. (H) Volcano plot identifying differentially abundant lipid species between obese and lean EVs. Each dot represents a lipid species, plotted by log<sub>2</sub>(fold change Obese/Lean) on the <italic toggle="yes">x</italic>&#8208;axis and &#8722;log&#8321;&#8320;(P value) on the <italic toggle="yes">y</italic>&#8208;axis. Blue dots indicate significantly downregulated species in obesity (<italic toggle="yes">p</italic>&#160;&#160;&lt;&#160;&#160;0.05 and FC&#160;&#160;&lt;&#160;&#160;&#8722;1), red dots represent significantly upregulated species (<italic toggle="yes">p</italic>&#160;&#160;&lt;&#160;&#160;0.05 and FC&#160;&#160;&gt;&#160;&#160;1), and grey dots are nonsignificant. Top 15 upregulated and 15 downregulated lipid species are annotated and listed by class and composition.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70603-g001.jpg"/></fig><fig position="float" fig-type="FIGURE" id="alz70603-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Lipid composition comparison between adipose tissue and extracellular vesicles (EVs). (A) Comparative analysis of lipid class abundance in adipose tissue and adipose&#8208;derived EVs from lean and obese individuals. Lipid classes are ranked based on total abundance (pmol/mg protein) and displayed in descending order for each source. Horizontal bars represent the summed concentrations of all detected species within each lipid class, with tick marks indicating individual lipid species and bold tick mark indicating the total lipid class. Blue and brown bars denote adipose tissue and EVs, respectively. The numbers adjacent to each lipid class indicate the count of detected species. (B) Comparison of lipid species diversity across lipid classes in adipose&#8208;derived EVs and matched adipose tissues. Donut charts show the distribution of identified lipid species grouped by class, with a total of 123 species detected in EVs and 274 in adipose tissue. Each color represents a distinct lipid class, as indicated in the legend. (C) Comparison of lipid class&#8208;specific signatures between extracellular vesicles (EVs) and adipose tissue. The matrix highlights lipid classes that are enriched or selectively represented in either EVs (brown dots) or adipose tissue (blue dots). Signature lipid classes were defined based on relative abundance, distribution pattern, and specificity to each compartment. (D&#8211;H) Chord diagrams representing lipid coregulation networks among lipid species across different lipid classes in EVs and adipose tissue. (D)&#160;Full lipid network in EVs. (E)&#160;Full lipid network in adipose tissue. (F)&#160;Adipose tissue lipid network after excluding triacylglycerol (TAG) species to minimize skewing from high&#8208;abundance lipids. (G)&#160;Network based on the top 20% most abundant lipid species in EVs. (H) Network based on the top 20% most abundant lipid species in adipose tissue. Each arc represents a lipid class, and connecting ribbons indicate pairwise coenrichment of lipid species between classes. The diagrams reveal distinct lipid interconnectivity patterns between EVs and adipose tissue, highlighting selective lipid packaging and modularity in EV lipid composition compared to the tissue of origin. (I) Correlation between lipid reduction in EVs and adipose tissue. Scatter plot showing the percentage reduction of major lipid classes in EVs (<italic toggle="yes">x</italic>&#8208;axis; data from Figures 2D&#8211;G) versus corresponding reductions in adipose tissue (<italic toggle="yes">y</italic>&#8208;axis; data from Figures 2E&#8211;H). Each dot represents a lipid class, labeled accordingly (e.g., SM, TAG, PC, etc.).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70603-g005.jpg"/></fig></sec><sec id="alz70603-sec-0130"><label>2.5</label><title>Outlier detection analysis</title><p>To identify potential outlier samples from global lipidomic profiles, the Isolation Forest algorithm was applied using default hyperparameters. This unsupervised anomaly detection method is designed for high&#8208;dimensional data and operates by randomly partitioning the feature space; samples that require fewer splits to be isolated are assigned higher anomaly scores. The algorithm is nonparametric, robust to noise, and does not assume a specific data distribution. To evaluate the influence of the identified outlier on downstream analyses, sensitivity analyses were performed by comparing results with and without the inclusion of outlier (Lean 1). This approach enabled validation of the robustness of major lipidomic findings and ensured that conclusions were not driven by a single data point.</p></sec><sec id="alz70603-sec-0140"><label>2.6</label><title>Reagent preparation of ThT assay</title><p>Amyloid&#8208; &#946;40 and 42, ultra pure, with NaOH, recombinant human (Sigma, #AG964 &amp; AG970) were dissolved in 1% NH<sub>4</sub>OH to 1&#160;mg/mL. And then add in 1XPBS to a stock concentration as 200 uM. Before thioflavin T (ThT) assay, the A&#946;s were sonicated for 200&#8197;s using a Marshall Scientific Sonifier model B450 (microtip, 10% amplitude) with intermittent pause to allow samples to cool down. ThT (Sigma, #T3516) was dissolved in PBS buffer and was filtered through a 0.2&#8197;&#181;m syringe filter.&#160;Morin (Sigma, #M4008) and phenol Red (Sigma, #P3532) were also dissolved with PBS.</p><p>For the lipid details, sodium oleate (Sigma, #07501), sodium palmitate (Sigma, #P9767), Brain SM (Avanti, #860062P), egg SM (Avanti, #860061P), milk SM (Avanti, #860063P), egg &#160;lysophosphatidylcholine (LPC) (Lyso PC; Avanti, #830071P), 18:0 LPC (Lyso PC; Avanti, #855775), 16:0&#8208;20:4 phosphatidylethanolamine (PE) (Avanti, #850759C), 16:0&#8208;18:1 PE (Avanti, #850757P), C18(Plasm)&#8208;18:1 PE (Avanti, #852758P), and C18(Plasm)&#8208;20:4 PE in ethanol (Cayman, #37137).</p><p>Stock solutions of sodium palmitate and sodium oleate (100&#160;mM) were prepared by dissolving the fatty acid powders in ethanol, followed by brief sonication cycles (10&#160;s per pulse, 200&#160;W) on ice. Sonication was continued until the mixture became uniformly cloudy, indicating thorough dispersion. The stock solutions were protected from light and stored at 4&#176;C. Prior to use, aliquots were prewarmed to 60&#176;C and briefly sonicated again. For details, please refer to the previously published method.<xref rid="alz70603-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>
</p><p>For all lipids, those provided in powder form were directly dissolved in molecular&#8208;grade ethanol (Sigma, #E7023) to 100&#160;mM as stock. For lipids supplied in chloroform, the solvent was first evaporated under a gentle nitrogen stream, and the resulting lipid film was redissolved in an equivalent volume of ethanol. During this process, sonication was applied to facilitate complete dispersion of the lipids in ethanol. Prior to use, aliquots and lipids in ThT&#8208;reaction buffers were briefly sonicated again.</p><p>Lipid concentrations reflecting human pathophysiological states were obtained from the Human Metabolome Database (HMDB) along with relevant literature sources. To facilitate direct comparison, all concentration values were standardized to &#181;M units, consistent with plasma lipid data. For brain&#8208;derived measurements, the following conversion principles were applied:
<list list-type="bullet" id="alz70603-list-0003"><list-item><p>For values reported as nmol/mg protein, concentrations were converted to &#181;M using the formula: nmol/mg protein &#215; brain protein content (28&#8208;54&#160;mg/g)<xref rid="alz70603-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> &#215; brain density (1.03&#160;kg/L)<xref rid="alz70603-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>
</p></list-item><list-item><p>For values reported as&#160;nmol/g brain wet weight, the conversion formula was: nmol/g &#215; brain density (1.03&#160;kg/L)<xref rid="alz70603-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>
</p></list-item></list>
</p></sec><sec id="alz70603-sec-0150"><label>2.7</label><title>Fibrillization kinetics assays</title><p>To identify an optimal assay buffer for monitoring A&#946; fibrillization in the presence of various lipid components using ThT, three buffer systems were evaluated:
<list list-type="bullet" id="alz70603-list-0004"><list-item><p>Buffer A: 50&#160;mM Tris, 150&#160;mM NaCl, and pH 7.2</p></list-item><list-item><p>Buffer B: 20&#160;mM HEPES, 150&#160;mM NaCl, and pH 7.2</p></list-item><list-item><p>Buffer C: 10&#160;mM phosphate, 150&#160;mM NaCl, and pH 8.0</p></list-item></list>
</p><p>Buffer C was ultimately selected as the optimal condition based on signal consistency and reproducibility.</p><p>Fibrillization assays were conducted in 384&#8208;well nonbinding surface microplates (Greiner, #781903), with a final reaction volume of 40&#160;&#181;L per well. The assay mixture included the following components:
<list list-type="bullet" id="alz70603-list-0005"><list-item><p>Lipid samples: 4&#160;&#181;L of ethanol&#8208;dissolved lipids added per well, with serial dilutions ranging from 1X to 1/1024X.</p></list-item><list-item><p>Buffer C: used as the base buffer in all wells</p></list-item><list-item><p>ThT: added from a 200&#160;&#181;M stock to a final concentration of 20&#160;&#181;M</p></list-item><list-item><p>A&#946;42: added last into the reaction mixture from a 200&#160;&#181;M stock to a final concentration of 20&#160;&#181;M</p></list-item><list-item><p>Negative control dyes: morin and phenol red, each added at 20&#160;&#181;M final from 200&#160;&#181;M stocks</p></list-item></list>
</p><p>Control groups were configured as follows:
<list list-type="bullet" id="alz70603-list-0006"><list-item><p>Blank: Buffer C only</p></list-item><list-item><p>NTC (no template control): Buffer C + ThT</p></list-item><list-item><p>Positive control: Buffer C + ThT + A&#946;42</p></list-item><list-item><p>Negative control: Buffer C + ThT + A&#946;42 + phenol red + morin</p></list-item></list>
</p><p>Fluorescence&#8208;based aggregation assays were performed using a BioTek Synergy H1 plate reader (Agilent, #1623193). Reactions were incubated at 37&#176;C with fluorescence readings taken every 5 minutes. Prior to each read, the plate was subjected to a 20&#8208;second double&#8208;orbital shake. ThT fluorescence was measured with excitation at 440&#160;nm and emission at 484&#160;nm. Background subtraction was performed using the NTC wells containing only buffer and ThT.</p></sec><sec id="alz70603-sec-0160"><label>2.8</label><title>Kinetic data presentation and statistics</title><p>To quantify the effects of different lipids on A&#946;40 and A&#946;42 ThT fluorescence signal and aggregation kinetics over time, a repeated measures analysis of variance (ANOVA) was applied using the area under the curve (AUC) as the within&#8208;subject factor. For each sample, raw fluorescence intensity&#8211;time curves collected at equally spaced time points were summarized by AUC, capturing the overall response magnitude. As all samples were measured at identical intervals (each 5&#160;minutes), AUC values were mathematically equivalent to mean relative fluorescence unit (RFU) up to a constant factor, allowing valid group&#8208;level comparisons.</p><p>One&#8208;way ANOVA was then performed on AUC values to assess differences between lipid treatment groups. Outliers were identified and excluded using a leave&#8208;one&#8208;out z&#8208;score method, in which each replicate was compared to others within the same group at each time point. Replicates exhibiting consistently elevated deviations across the time course were removed. This QC step was applied to all lipid/A&#946; conditions, each of which included at least duplicate or triplicate measurements for statistical analysis.</p><p>This approach preserved the advantages of repeated measurements in minimizing within&#8208;group variability while allowing a straightforward assessment of group effects on cumulative or average response. Results were reported as mean&#160;&#177;&#160;standard error of the mean (SEM) for each condition. Post hoc comparisons were conducted using Dunnett's test, comparing each treatment group to the positive control. <italic toggle="yes">p</italic>&#8208;values were reported in GraphPad style: <italic toggle="yes">p</italic>&#160;&gt;&#160;0.05 (ns), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 (*), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01 (**), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001 (***), and <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001 (****). Statistical analyses and visualizations were conducted using GraphPad Prism [version 10.2.1].</p></sec></sec><sec id="alz70603-sec-0170"><label>3</label><title>RESULTS</title><sec id="alz70603-sec-0180"><label>3.1</label><title>EV purification and quality control (QC)</title><p>EVs mediate crosstalk between adipose tissue and the brain<xref rid="alz70603-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S1A</xref>). Exosome&#8208;enriched EVs isolated from murine adipocytes exhibited efficient brain biodistribution following tail vein administration (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S1B,C</xref>). To characterize the lipid signature of human EVs derived from obese adipocytes, we first isolated exosome&#8208;enriched EVs using tangential flow filtration (TFF) followed by ultrafiltration.<xref rid="alz70603-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> EVs were obtained from subcutaneous adipose tissue (SQA) and visceral adipose tissue (VA) collected from elective surgical adipose biopsies of lean and obese donors.</p><p>Isolated EVs then underwent standard QC following established protocols.<xref rid="alz70603-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="alz70603-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> Vesicles with sizes ranging from 60 to 300&#160;nm were isolated from the supernatant of cultured human adipocytes (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S1D</xref>). These vesicles were found to contain tetraspanins, such as CD63, used to validate EV identity (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S1E</xref>, fluorescent staining). Adiponectin, produced by adipocytes, is present in the exosome cargo (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S1F</xref>), confirming that these are the adipocyte&#8208;derived EVs. Also of interest is the presence of clusterin, which plays a role in AD pathogenesis.<xref rid="alz70603-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> These data quantify EVs based on particle number, size, and the presence of specific molecules, such as CD63, adhering to MISEV2018.<xref rid="alz70603-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="alz70603-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> The QC&#8208;validated EVs were subsequently processed for lipidomic profiling.</p></sec><sec id="alz70603-sec-0190"><label>3.2</label><title>Lipidomic profiling</title><p>We performed the multidimensional mass spectrometry&#8208;based lipidomics for the EVs derived from both lean and obese individuals (Supporting Information Table <xref rid="alz70603-supinfo-0001" ref-type="">2</xref>). The heatmap reveals distinct lipidomic profiles between lean and obese EVs, with hierarchical clustering showing clear separation between the two groups and highlighting lipid species that are differentially abundant in obesity (Figure&#160;<xref rid="alz70603-fig-0001" ref-type="fig">1A</xref>). Stratified by lipid species and individual patients, several lipid classes, including triacylglycerols (TAG), phosphatidic acids (PA), and SM, show significant differences between the lean and obese groups (Figure&#160;<xref rid="alz70603-fig-0001" ref-type="fig">1B,C</xref>).</p><p>To investigate sample&#8208;level deviations observed in EV lipidomic clustering (Figure&#160;<xref rid="alz70603-fig-0001" ref-type="fig">1A</xref>), we applied the Isolation Forest algorithm to identify potential outliers. This analysis revealed one lean sample (Lean 1) exhibited a high anomaly score, flagging it as a potential outlier, whereas the deviating obese sample (Obese 11) was not flagged. Importantly, we found no technical or biological abnormalities (e.g., age, sex, BMI, batch effects; Supporting Information Table <xref rid="alz70603-supinfo-0001" ref-type="">1</xref>) associated with either sample. To evaluate the impact of retaining Lean 1, we conducted sensitivity analyses with and without its inclusion.&#160;key lipid species such as phosphatidylcholine (PC), PA, LPC, and fatty acyl&#8208;Coenzyme A (FAC) remained significantly altered in obesity, regardless of whether Lean 1 was included, as confirmed by fold&#8208;change and statistical significance analyses (Figure&#160;<xref rid="alz70603-fig-0001" ref-type="fig">1D&#8211;E</xref> and <xref rid="alz70603-supinfo-0001" ref-type="">S2A&#8211;E</xref>).</p><p>The correlation heatmap reveals distinct clustering patterns among lipid species in lean and obese EVs, indicating obesity&#8208;associated reorganization of lipid coregulation networks (Figure&#160;<xref rid="alz70603-fig-0001" ref-type="fig">1F</xref>; Supporting Information Table <xref rid="alz70603-supinfo-0001" ref-type="">4</xref>). Hierarchical clustering identified ten discrete lipid modules (clusters a&#8211;j), each enriched for specific lipid classes, such as SM, TAG, LPE, or PC. The corresponding fold changes (obese/lean) for lipid species within each cluster further illustrate their differential abundance and distribution between obese and lean individuals (Figure&#160;<xref rid="alz70603-fig-0001" ref-type="fig">1F</xref>; Supporting Information Table <xref rid="alz70603-supinfo-0001" ref-type="">5</xref>).</p><p>Furthermore, the clear separation of LPC and SM between lean and obese groups across various lipid classes indicates significant differences in EV lipid composition that remain consistent irrespective of Lean 1 inclusion (Figure&#160;<xref rid="alz70603-fig-0001" ref-type="fig">1G</xref> and <xref rid="alz70603-supinfo-0001" ref-type="">S2F</xref>). When Lean 1 was excluded (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S2F</xref>), the lean group exhibited markedly reduced intragroup variation, suggesting that Lean 1 captures a unique aspect of biological heterogeneity within the lean cohort. As the overall findings remained consistent with or without Lean 1, we retained this sample in all downstream analyses to preserve biological variability and minimize selection bias. Notably, SM were predominantly downregulated, while PC, LPC, and LPE were primarily upregulated in obesity (Figure&#160;<xref rid="alz70603-fig-0001" ref-type="fig">1H</xref>).</p><p>To determine the extent to which EVs reflect the lipid composition of adipose tissue (Supporting Information Table <xref rid="alz70603-supinfo-0001" ref-type="">3</xref>) in mediating adipose tissue&#8211;brain crosstalk, we conducted a comparative analysis of the two compartments. Among the detected lipids, the lipidomic comparison revealed a selective overlap of&#160;FAC, TAG, diacylglycerol (DAG), PC, PE, PS, SM, LPE, and PI&#160;(Figure&#160;<xref rid="alz70603-fig-0002" ref-type="fig">2A</xref>), with a similar lipid composition ratio (Figure&#160;<xref rid="alz70603-fig-0002" ref-type="fig">2B</xref>), suggesting a conserved lipid distribution pattern. Both&#160;SM and PA&#160;were identified as signature lipid classes in&#160;both&#160;EVs and adipose tissue (Figure&#160;<xref rid="alz70603-fig-0002" ref-type="fig">2C</xref>).</p><p>In the network association analysis,&#160;phospholipids such as PC, PA, and LPE&#160;exhibit strong interconnections in&#160;EVs (Figure&#160;<xref rid="alz70603-fig-0002" ref-type="fig">2D</xref>), whereas&#160;TAG&#160;dominates the coregulation network in&#160;adipose tissue&#160;(Figure&#160;<xref rid="alz70603-fig-0002" ref-type="fig">2E</xref>). When excluding TAG,&#160;PE and PC&#160;emerge as the primary connectors within the adipose tissue network (Figure&#160;<xref rid="alz70603-fig-0002" ref-type="fig">2F</xref>). When restricting the analysis to the top 20% most abundant lipid species in EVs and adipose tissue (from Figure&#160;2D &#160;to&#160;<xref rid="alz70603-fig-0002" ref-type="fig">2G</xref>; from Figure&#160;2E to 2H), we observed that&#160;overall network connectivity was notably reduced (Figure&#160;<xref rid="alz70603-fig-0002" ref-type="fig">2I</xref>), as reflected by sparser interlipid associations in both groups (Figure&#160;<xref rid="alz70603-fig-0002" ref-type="fig">2G&#8211;H</xref>). This finding suggests that&#160;the majority of lipid coregulation occurs across the full lipidome rather than being driven solely by the most abundant ones. Importantly, this reduction pattern in network density was&#160;consistently observed&#160;across both EVs and adipose tissue (Figure&#160;<xref rid="alz70603-fig-0002" ref-type="fig">2I</xref>), suggesting a&#160;conserved organizational principle of lipid network architecture in both systems.</p><p>These findings indicate that&#160;EVs reflect the lipidomic profile of adipose tissue to a certain extent, with selective lipid enrichment and preserved network associations. This reinforces the hypothesis that&#160;EVs serve as lipid carriers facilitating adipose&#8211;brain crosstalk.</p></sec><sec id="alz70603-sec-0200"><label>3.3</label><title>A&#946; fibrillization evaluation</title><p>The aforementioned lipid components in EVs derived from human adipocytes primarily consist of phospholipids and SM. Regardless of lipid class, all contain fundamental fatty acid chains. Our systematic profiling of EVs and adipose tissue revealed that both are enriched in unsaturated fatty acid chains (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S2G&#8211;I</xref>). Given the diverse effects of lipids on AD, we specifically focused on their role in A&#946; fibrillization, as amyloid aggregation is a well&#8208;defined pathological hallmark of AD and a critical step in disease progression. Investigating how lipids influence A&#946; fibrillization provides direct mechanistic insights into their contribution to amyloid pathology and offers a refined framework for understanding lipid&#8208;mediated neurodegenerative processes (Figure&#160;<xref rid="alz70603-fig-0003" ref-type="fig">3A</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70603-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>In vivo and in vitro models of amyloid&#8208;&#946; (A&#946;) aggregation and modulation by palmitic acid. (A,B) Conceptual overview of A&#946; aggregation pathways under in vivo and in vitro conditions. (A)&#160;Schematic of in vivo A&#946; aggregation in a cell&#8208;based system. Soluble A&#946; monomers generated in the cytoplasm or near the membrane transition into benign oligomers, toxic oligomers, and eventually amyloid fibrils and plaques within the extracellular space. The process involves dynamic interconversion between aggregation species and spatial localization across cellular compartments. (B)&#160;Illustration of in vitro A&#946; aggregation in a purified, cell&#8208;free system, monitored by thioflavin T (ThT) fluorescence. Soluble monomers self&#8208;assemble into benign and toxic oligomers, which ultimately form mature amyloid fibrils. The aggregation kinetics follow a sigmoidal curve comprising a lag phase, growth phase, and plateau phase. Different ThT fluorescence curves (dashed lines) represent modulation of fibrillization kinetics under various experimental conditions. (C) Classification of fatty acids based on the number of double bonds (n_DB). Fatty acids (FAs) are categorized into saturated fatty acids (SFAs; n_DB&#160;=&#160;0), monounsaturated fatty acids (MUFAs; n_DB&#160;=&#160;1), and polyunsaturated fatty acids (PUFAs; n_DB&#160;&gt;&#160;1). Representative examples of each class are shown: palmitic acid (16:0) as an SFA, oleic acid (18:1) as a MUFA, and linoleic acid (18:2) as a PUFA. (D&#8208;G) Experimental kinetics for A&#946;40 and A&#946;42 aggregation under varying concentrations of palmitic acid (PA). &#160; (D and F) Aggregation kinetics of A&#946;40 and A&#946;42 in the presence of serially diluted palmitic acid (0.1&#8211;100&#160;mM), using the ThT fluorescence assay. Fluorescence intensity is shown as relative fluorescence units (RFU) at Ex/Em&#160;=&#160;440/484&#160;nm. Positive control: A&#946;40 or A&#946;42 + ThT; negative control: A&#946;40 or A&#946;42 + ThT + phenol red + morin. (E,G) Quantification of aggregation kinetics at varying concentrations. Each dot represents an individual fluorescence measurement (RFU) at a specific time point for the indicated lipid concentration. Bars indicate the mean&#160;&#177;&#160;SEM for each group. Asterisks (*) and hash symbols (#)&#160;indicate statistical significance compared to the&#160;Positive control&#160;group. Statistical approach consistent with Methods Section&#160;<xref rid="alz70603-sec-0160" ref-type="sec">2.8</xref>. Statistical comparisons were conducted using an ordinary one&#8208;way analysis of variance (ANOVA), with removal of outliers as appropriate. Post hoc multiple comparisons were performed using Dunnett's test to compare each treatment group against the positive control. <italic toggle="yes">p</italic>&#8208;values were reported in GraphPad style, with significance thresholds as follows: *, increase; <sup>#</sup>, decrease; <italic toggle="yes">p</italic>&#160;&gt;&#160;0.05 (ns), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 (*<sup>/#</sup>), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01 (**<sup>/##</sup>), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001 (***<sup>/###</sup>), and <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001 (****<sup>/####</sup>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70603-g006.jpg"/></fig><p>To ensure a high&#8208;purity background, we employed an in vitro ThT fluorescence assay to assess the lipid&#8208;type&#8208;specific effects on A&#946; fibrillization (Figure&#160;<xref rid="alz70603-fig-0003" ref-type="fig">3B</xref>). Because A&#946; aggregation occurs primarily in the brain's extracellular space (Figure&#160;<xref rid="alz70603-fig-0003" ref-type="fig">3A,B</xref>), lipidomic profiles reflecting this microenvironment would, in principle, provide the most physiologically relevant context. However, currently available brain lipidomic datasets are largely derived from whole&#8208;tissue homogenates or region&#8208;specific bulk analyses, representing mixed cell populations and lacking specificity for the extracellular compartment where A&#946; aggregation occurs.<xref rid="alz70603-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> Moreover, many of these studies report only relative abundances, with limited data on absolute lipid concentrations.<xref rid="alz70603-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="alz70603-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>
</p><p>Given these limitations, the lipid concentrations used in this study were primarily guided by reported physiological and pathophysiological levels in human plasma. Where available, we also compiled absolute concentration data from human brain and cerebrospinal fluid (CSF) lipidomics to provide a more comprehensive frame of reference. Together, these datasets offer a valuable basis for interpreting the relevance of lipid exposures to A&#946; aggregation dynamics. Based on our analysis (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S2G&#8211;I</xref>), we first evaluated the effects of saturated and unsaturated fatty acids, using palmitic acid and oleic acid as representative molecules (Figure&#160;<xref rid="alz70603-fig-0003" ref-type="fig">3C</xref>). Both are key lipid components broadly represented across multiple EV lipid classes detected in our lipidomic dataset and were directly detected as constituent lipid species within the EV lipidome.</p></sec><sec id="alz70603-sec-0210"><label>3.4</label><title>Fatty acids and A&#946; fibrillization</title><p>Palmitic acid, also known as hexadecanoic acid, is one of the most common saturated long&#8208;chain fatty acids (C16:0) in mammals, comprising approximately 21%&#8211;30% (molar) of human depot fat. In healthy adults, the blood concentration of palmitic acid can reach 2360&#160;&#177;&#160;430 &#181;M in males and 2500&#160;&#177;&#160;630 &#181;M in females,<xref rid="alz70603-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> while lower physiological levels have been reported around 30.49&#160;&#177;&#160;2.64 &#181;M.<xref rid="alz70603-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> Additionally, reported values in the human CSF of normal adults are 18.0&#160;&#177;&#160;12.0 &#181;M,<xref rid="alz70603-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref> and in human brain tissue, palmitic acid was measured at approximately 496&#160;&#177;&#160;123&#160;nmol/g (&#8764;510.88&#160;&#177;&#160;126.69 &#181;M) wet weight in control subjects.<xref rid="alz70603-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref> Under lipotoxic conditions (25&#8211;100&#160;mM), both A&#946;40 and A&#946;42 exhibit pronounced aggregation (Figure&#160;<xref rid="alz70603-fig-0003" ref-type="fig">3D&#8211;G</xref>). At 3.13&#160;mM, a concentration representative of pathophysiological overload, palmitic acid significantly promotes A&#946;40 aggregation (Figure&#160;<xref rid="alz70603-fig-0003" ref-type="fig">3D,E</xref>), whereas its effect on A&#946;42 is minimal (Figure&#160;<xref rid="alz70603-fig-0003" ref-type="fig">3F,G</xref>). At lower concentrations, palmitic acid shows negligible influence on the fibrillization of either A&#946;40 or A&#946;42, with aggregation rates comparable to the positive control, indicating a baseline, nonpromotive state under physiological conditions.</p><p>Before examining the effects of additional lipid species, several methodological considerations warrant clarification to aid in the interpretation of the A&#946; aggregation data. The apparent lack of sharply defined lag, growth, and plateau phases (Figure&#160;<xref rid="alz70603-fig-0003" ref-type="fig">3D</xref>) is primarily due to the wide concentration range (0.1 to 100&#160;mM) of palmitic acid presented in a single plot. This required an expanded <italic toggle="yes">y</italic>&#8208;axis scale to accommodate high&#8208;signal conditions, which in turn visually compressed the kinetic transitions. When only intermediate concentrations were examined (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S3A</xref>), the classical sigmoidal features of A&#946; aggregation became more distinguishable. However, to preserve comparability across all tested concentrations, a unified plot was retained (Figure&#160;<xref rid="alz70603-fig-0003" ref-type="fig">3D</xref>)</p><p>In our optimized assay system (Method section 2.7), A&#946; aggregation proceeds more rapidly than conventional chronic protocols which typically span 20&#8211;150&#160;hours.<xref rid="alz70603-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref>, <xref rid="alz70603-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> The &#8220;time zero&#8221; (Figure&#160;<xref rid="alz70603-fig-0003" ref-type="fig">3D</xref>) refers to the first fluorescence readout, which was collected approximately 20&#8208;30 minutes after the reaction was initiated. This short delay, caused by sample mixing and plate handling, means partial preaggregation may have already occurred before the first measurement. As a result, some lipid&#8208;treated samples displayed elevated fluorescence at the initial time point, and lag phases appeared less distinct compared to longer&#8208;duration assays. To preserve potentially informative early kinetic differences, fluorescence values were not normalized to a uniform baseline across conditions (Figure&#160;<xref rid="alz70603-fig-0003" ref-type="fig">3D</xref>). This decision was made to avoid artificially masking early seeding effects or subtle differences in nucleation kinetics.</p><p>In the A&#946; aggregation assay, area under the curve (AUC) quantifies the overall extent of A&#946; aggregation over time, as reflected by the integrated kinetic fluorescence signal. To assess overall A&#946; aggregation under different lipid concentrations, AUC could be calculated by numerical integration of relative fluorescence unit(RFU)&#160;over time using the trapezoidal rule, a method well&#8208;suited for discrete, uniformly spaced time&#8208;series data. Since fluorescence measurements were collected at consistent 5&#8208;minute intervals, the AUC is effectively proportional to the cumulative RFU values, and their average reliably reflects aggregation kinetics across conditions (Figure&#160;<xref rid="alz70603-fig-0003" ref-type="fig">3E</xref>).</p><p>To address potential concerns regarding nonzero initial baselines&#8212;a consequence of preaggregation during sample handling prior to the first readout&#8212;we reconstructed simulated curves by extrapolating back to the actual reaction start time (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S3B</xref>). These simulations showed that regardless of the integration start point, experimental and control groups are statistically distinguishable, supporting the reproducibility, robustness, and validity of RFU&#8208;based comparisons in capturing both early seeding dynamics and the total extent of A&#946; aggregation.</p><p>Oleic acid, also known as octadecenoic acid, is a widely distributed and abundant long&#8208;chain monounsaturated fatty acid (C18:1, omega&#8208;9). In healthy adults, oleic acid concentrations range from 11.42&#160;&#177;&#160;1.67 to 2135.4&#160;&#177;&#160;665.5 &#181;M (<italic toggle="yes">n</italic>&#160;=&#160;54),<xref rid="alz70603-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>, <xref rid="alz70603-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> with peak levels in pathological states reaching up to 2365.1&#160;&#177;&#160;844.5 &#181;M.<xref rid="alz70603-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> Additionally, oleic acid concentrations in human CSF have been reported at 36.0&#160;&#177;&#160;36.0 &#181;M in healthy adults,<xref rid="alz70603-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref> and human brain tissue levels measured at &#8764;367&#160;&#160;&#177;&#160;&#160;123&#160;nmol/g (&#8764;378.01&#160;&#177;&#160;126.69 &#181;M) wet weight in control subjects.<xref rid="alz70603-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref> Under lipotoxic conditions (6.25&#8211;50 &#181;M), A&#946;40 undergoes severe fibrillization (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S3C,D</xref>). Notably, even at physiopathological concentrations (0.39&#8211;3.23 &#181;M), A&#946;40 aggregation remains evident (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S3C,D</xref>). Unexpectedly, at moderate concentrations (0.1&#8211;0.2&#160;mM, or 100&#8208;200 &#181;M), the aggregation rate of A&#946;40 is significantly lower than that of the positive control (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S3C,D</xref>). Surprisingly, A&#946;42 exhibits robust aggregation across all tested concentrations, both low and high (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S3E&#8211;F</xref>).</p><p>In the experiments described above, the convergent finding is that both saturated and unsaturated fatty acids can promote A&#946; fibrillization at relatively high concentrations approaching lipotoxic conditions. Notably, the same fatty acid exerts differential effects on A&#946;40 and A&#946;42 aggregation. A divergent observation is that palmitic acid, the most abundant saturated fatty acid in vivo, does not influence baseline A&#946; aggregation at physiological concentrations. Our study expands the known benefits of unsaturated fatty acids. In addition to their classical antioxidant effects&#8212;attributed to the presence double bonds&#8212;we observed that their lipid characteristics confer an additional advantage: at physiological concentrations (100&#8211;200 &#181;M), unsaturated fatty acids can suppress the spontaneous fibrillization of A&#946;40.</p></sec><sec id="alz70603-sec-0220"><label>3.5</label><title>SM and A&#946; fibrillization</title><p>&#160;SM exhibited pronounced deregulation in our human EV lipidomics profiling (Figure&#160;<xref rid="alz70603-fig-0001" ref-type="fig">1G,H</xref>). SM is abundantly present in the nervous system, where it plays a critical role in maintaining the structural integrity of cellular membranes. It is also a key component of the myelin sheath, particularly in the membranous layers that insulate neuronal axons.<xref rid="alz70603-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> To further investigate the role of SM in A&#946; fibrillization, we selected three physiologically relevant SM sources: milk SM, egg SM, and brain SM, which are primarily composed of SM 23:0, SM 16:0, and SM 18:0, respectively. Each of these SM species was among the detected lipid constituents in our EV lipidomic analysis.</p><p>Among these, SM (23:0) is the least studied in terms of physiological and pathological concentrations, with limited reports indicating a plasma level of 7&#160;&#177;&#160;2.7 &#181;M.<xref rid="alz70603-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> SM (16:0) is more commonly detected in human plasma, ranging from 60 to 190 &#181;M in both males and females under normal conditions (HMDB&#8208;Human metabolome database).<xref rid="alz70603-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref>, <xref rid="alz70603-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref> SM (18:0) is reported to reach concentrations of 1145&#160;&#177;&#160;67 or 1364&#160;&#177;&#160;106 &#181;M in adult females,<xref rid="alz70603-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref> while levels as low as 16.2&#160;&#177;&#160;0.4 &#181;M have also been documented in healthy male and female individuals.<xref rid="alz70603-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref>
</p><p>In human CSF, SM (16:0) and SM (18:0) have been detected at concentrations of 0.336&#160;&#160;&#177;&#160;&#160;0.109 and 0.340&#160;&#160;&#177;&#160;&#160;0.154&#160;&#181;M,<xref rid="alz70603-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> respectively, in adults over 18 years of age. In contrast, no CSF data are currently available for SM (23:0), highlighting a gap in the lipidomic characterization of this species within central nervous system compartments. Although absolute concentrations of these SM species have been reported in various brain regions of mice,<xref rid="alz70603-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> corresponding quantitative data in the human brain remain scarce.</p><p>In our ThT&#8208;based fibrillization assays, SM 23:0 significantly enhanced A&#946; aggregation at higher concentrations, including at physiologically relevant levels near 7 &#181;M (Figure&#160;<xref rid="alz70603-fig-0004" ref-type="fig">4B&#8211;E</xref>). However, this proaggregation effect was markedly attenuated at lower concentrations. Notably, in the A&#946;42 system, SM 23:0 at concentrations below 2 &#181;M appeared to suppress fibrillization over time (Figure&#160;<xref rid="alz70603-fig-0004" ref-type="fig">4D,E</xref>), suggesting a potential biphasic effect.</p><fig position="float" fig-type="FIGURE" id="alz70603-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Experimental kinetics of amyloid&#8208;&#946; (A&#946;) aggregation in the presence of milk sphingomyelin. (A) Molecular structure of lipids of Milk sphingomyelin (SM), Egg SM, and Brain SM. (B&#8211;E) Experimental kinetics for A&#946;40 and A&#946;42 aggregation under varying concentrations of Milk SM. (B, D)&#160;Aggregation kinetics of A&#946;40 and A&#946;42 in the presence of serially diluted Milk SM (0.1&#8211;100&#160;mM), using the thioflavin T (ThT) fluorescence assay. Fluorescence intensity is shown as relative fluorescence units (RFU) at Ex/Em&#160;=&#160;440/484&#160;nm. Positive control: A&#946;40 or A&#946;42 + ThT; negative control: A&#946;40 or A&#946;42 + ThT + phenol red + morin. (C, E) Quantification of aggregation kinetics at varying concentrations. Each dot represents an individual fluorescence measurement (RFU) at a specific time point for the indicated lipid concentration. Bars indicate the mean&#160;&#177;&#160;SEM for each group. Asterisks (*) and hash symbols (#)&#160;indicate statistical significance compared to the&#160;Positive control&#160;group. Statistical approach consistent with Methods Section&#160;<xref rid="alz70603-sec-0160" ref-type="sec">2.8</xref>, with significance thresholds as follows: *, increase; <sup>#</sup>, decrease; <italic toggle="yes">p</italic>&#160;&gt;&#160;0.05 (ns), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 (*<sup>/#</sup>), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01 (**<sup>/##</sup>), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001 (***<sup>/###</sup>), and <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001 (****<sup>/####</sup>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="ALZ-21-e70603-g003.jpg"/></fig><p>In contrast, SM 16:0 consistently promoted A&#946; aggregation across both high and low concentration ranges (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S4</xref>). For A&#946;40, a threshold concentration for fibrillization enhancement was observed at 25 &#181;M, while A&#946;42 showed a peak proaggregation response at approximately 100 &#181;M. These differing peak responses imply that A&#946;40 and A&#946;42 interact with SM 16:0 in distinct structural conformations, leading to divergent fibrillization kinetics. SM 18:0, the predominant component of brain&#8208;derived sphingomyelin, exhibited a strong proaggregation effect on A&#946;42. Its effect on A&#946;40 was relatively moderate, particularly at lower concentrations, where little to no promotion of aggregation was observed (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S5</xref>).</p><p>These findings suggest that certain sphingomyelin species, particularly SM (23:0), can significantly inhibit A&#946;42 fibrillization at relatively low, physiologically relevant concentrations, potentially contributing to the attenuation of AD&#8208;related amyloid pathology. In contrast, SM (18:0) and SM (16:0) did not exhibit such inhibitory effects under similar conditions. This highlights that, despite sharing a common sphingomyelin backbone, variations in acyl chain length and saturation can result in markedly different impacts on A&#946; aggregation dynamics.</p><p>The observed differential effects may be attributed to several factors. Longer, fully saturated acyl chains such as those in SM (23:0) may confer distinct biophysical properties, such as increased membrane rigidity or altered lipid packing, that influence A&#946; interaction at the lipid interface. Alternatively, the ability of specific SM species to modulate local microenvironments&#8212;such as surface hydrophobicity or curvature stress&#8212;may selectively affect A&#946;42's conformational transition and nucleation kinetics.</p></sec><sec id="alz70603-sec-0230"><label>3.6</label><title>LPC and A&#946; fibrillization</title><p>Lysophospholipids are bioactive lipids formed as intermediates during the dynamic turnover of membrane phospholipids.<xref rid="alz70603-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref> Although studies have reported altered lysophospholipid levels in AD. Region&#8208;specific increases in LPC and LPE have been observed in the AD brain using various lipidomic techniques, including LC&#8208;ESI&#8208;MS and FIA&#8208;MS/MS.<xref rid="alz70603-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>, <xref rid="alz70603-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref>, <xref rid="alz70603-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref>, <xref rid="alz70603-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref>
</p><p>In our study, EV lipidomic profiling revealed distinct, nonoverlapping clusters and marked deregulation of LPC species between obese and lean individuals (Figure&#160;<xref rid="alz70603-fig-0001" ref-type="fig">1G,H</xref>). We selected egg LPC and LPC 18:0 for A&#946; aggregation assays (Figure&#160;<xref rid="alz70603-fig-0005" ref-type="fig">5A</xref>). Both species were directly detected in our EV lipidomics dataset. Egg LPC consists of approximately 69% LPC 16:0 and 24% LPC 18:0. In healthy individuals (both male and female), circulating LPC 16:0 levels range from 41 to 150&#160;&#181;M (HMDB), with reported averages of 106.6&#160;&#160;&#177;&#160;&#160;16.7 and 141&#160;&#160;&#177;&#160;&#160;50&#160;&#181;M.<xref rid="alz70603-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Under abnormal condition, levels may rise to 142.1&#160;&#160;&#177;&#160;&#160;39.6&#160;&#181;M in females.<xref rid="alz70603-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> In comparison, physiological LPC 18:0 levels are typically lower, ranging from 9.1 to 54&#160;&#181;M (HMDB), and may reach up to 48.5&#160;&#160;&#177;&#160;&#160;20.2&#160;&#181;M in healthy individuals in both genders.<xref rid="alz70603-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref> LPC 18:0 has been reported at 0.069&#160;&#160;&#177;&#160;&#160;0.019&#160;&#181;M in adults.<xref rid="alz70603-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="alz70603-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Experimental kinetics of amyloid&#8208;&#946; (A&#946;) aggregation in the presence of egg lysophosphatidylcholine (LPC; Lyso PC). (A) Molecular structure of lipids of egg Lyso PC and 18:0 Lyso PC. (B&#8208;E) Experimental kinetics for A&#946;40 and A&#946;42 aggregation under varying concentrations of LPC (16:0). (B and D)&#160;Aggregation kinetics of A&#946;40 and A&#946;42 in the presence of serially diluted LPC (16:0) (0.1&#8211;100&#160;mM), using the ThT fluorescence assay. Fluorescence intensity is shown as relative fluorescence units (RFU) at Ex/Em&#160;=&#160;440/484&#160;nm. Positive control: A&#946;40 or A&#946;42 + ThT; negative control: A&#946;40 or A&#946;42 + ThT + phenol red + morin. (C, E) Quantification of aggregation kinetics at varying concentrations. Each dot represents an individual fluorescence measurement (RFU) at a specific time point for the indicated lipid concentration. Bars indicate the mean&#160;&#177;&#160;SEM for each group. Asterisks (*) and hash symbols (#)&#160;indicate statistical significance compared to the&#160;Positive control&#160;group. Statistical approach consistent with Methods Section&#160;<xref rid="alz70603-sec-0160" ref-type="sec">2.8</xref>, with significance thresholds as follows: *, increase; <sup>#</sup>, decrease; <italic toggle="yes">p</italic>&#160;&gt;&#160;0.05 (ns), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 (*<sup>/#</sup>), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01 (**<sup>/##</sup>), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001 (***<sup>/###</sup>), and <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001 (****<sup>/####</sup>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="ALZ-21-e70603-g002.jpg"/></fig><p>In our ThT&#8208;based fibrillization assays, LPC species demonstrated concentration&#8208;dependent effects on A&#946; aggregation.&#160;At higher pathophysiological concentrations (1.56 to 100&#160;&#181;M), LPC 16:0 significantly promoted the aggregation of both A&#946;40 and A&#946;42 (Figure&#160;<xref rid="alz70603-fig-0005" ref-type="fig">5B&#8211;E</xref>).&#160;This proaggregatory effect diminished at lower LPC 16:0 concentrations.&#160;However, considering the reported physiological and pathological plasma levels of LPC 16:0, such low concentrations are infrequent in vivo, suggesting that the observed inhibitory effects may have limited physiological relevance.&#160;These findings imply that under conditions such as obesity, elevated LPC levels transported to the brain via extracellular vesicles could enhance A&#946; fibrillization.&#8203;</p><p>Unexpectedly, LPC 18:0 exhibited a robust proaggregatory effect on A&#946;40 across all tested concentrations, surpassing the positive control by approximately threefold (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S6A,B</xref>).&#160;In contrast, its influence on A&#946;42 aggregation was less pronounced, with significant yet modest fold changes observed at both high and low concentrations (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S6C,D</xref>).&#8203;</p><p>The evidence indicates that LPC exerts differential effects on A&#946; aggregation, varying with concentration and A&#946; subtype.&#160;Notably, under obesity&#8208;related conditions, elevated LPC levels transported to the brain via EVs may exacerbate A&#946; fibrillization.&#160;These findings underscore the intricate role of lipid metabolism in AD pathogenesis and suggest that lipid dyshomeostasis is integral to AD pathology.</p></sec><sec id="alz70603-sec-0240"><label>3.7</label><title>PE and A&#946; fibrillization</title><p>In EV lipidomic profiles, lipid species such as PC, SM, TAG, and LPC were prominently detected, likely reflecting their high intrinsic abundance, efficient ionization, and preferential incorporation into EVs during biogenesis, underscoring their structural and functional relevance in EV composition. To explore the contribution of lipids beyond those enriched in EVs, we included another Zwitterionic lipid, PE in our A&#946; aggregation assays (Figures&#160;<xref rid="alz70603-fig-0006" ref-type="fig">6</xref> and <xref rid="alz70603-supinfo-0001" ref-type="">S7&#8208;S9</xref>), given its high abundance in neuronal membranes and its known biophysical effects on membrane curvature and protein&#8211;lipid interactions.<xref rid="alz70603-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref>, <xref rid="alz70603-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref>, <xref rid="alz70603-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="alz70603-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>Experimental kinetics of amyloid&#8208;&#946; (A&#946;) aggregation in the presence of C18(Plasm)&#8208;20:4 phosphatidylethanolamine (PE). (A) Molecular structure of lipids of C18(Plasm)&#8208;20:4 PE, C18(Plasm)&#8208;18:1 PE, 16:0&#8208;20:4 PE, and 16:0&#8208;18:1 PE. (B&#8208;E) Experimental kinetics for A&#946;40 and A&#946;42 aggregation under varying concentrations of C18(Plasm)&#8208;20:4 PE. (B and D)&#160;Aggregation kinetics of A&#946;40 and A&#946;42 in the presence of serially diluted C18(Plasm)&#8208;20:4 PE (0.1&#8208;100&#160;mM), using the thioflavin T (ThT) fluorescence assay. Fluorescence intensity is shown as relative fluorescence units (RFU) at Ex/Em&#160;=&#160;440/484&#160;nm. Positive control: A&#946;40 or A&#946;42 + ThT; negative control: A&#946;40 or A&#946;42 + ThT + phenol red + morin. (C,E)&#160;Quantification of aggregation kinetics by calculating the area under the fluorescence curve (AUC) for each concentration. AUC values reflect the extent of A&#946;40/ A&#946;42 fibrillization.&#160;Asterisks (*) and hash symbols (#)&#160;indicate statistical significance compared to the&#160;Positive control&#160;group. Statistical approach consistent with Methods Section&#160;<xref rid="alz70603-sec-0160" ref-type="sec">2.8</xref>, with significance thresholds as follows: *, increase; <sup>#</sup>, decrease; <italic toggle="yes">p</italic>&#160;&gt;&#160;0.05 (ns), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 (*<sup>/#</sup>), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01 (**<sup>/##</sup>), <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001 (***<sup>/###</sup>), and <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001 (****<sup>/####</sup>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="ALZ-21-e70603-g004.jpg"/></fig><p>Plasmalogen PEs, defined by a vinyl ether linkage at the sn&#8208;1 position, are enriched in the brain and have been shown to protect against oxidative stress.<xref rid="alz70603-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref> Changes in their levels indicate peroxisomal dysfunction, implicating redox imbalance and lipid metabolism disturbances commonly observed in metabolic and neurodegenerative diseases such as diabetes and AD.<xref rid="alz70603-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref>, <xref rid="alz70603-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref> Based on our lipidomics profiling, we selected C18(Plasm)&#8208;20:4 PE, C18(Plasm)&#8208;18:1 PE, 16:0/20:4 PE, and 16:0/18:1 PE for ThT&#8208;based fibrillization assays (Figure&#160;<xref rid="alz70603-fig-0006" ref-type="fig">6A</xref>). These PE species were not among those directly detected in our current EV lipidomics dataset.</p><p>According to concentration estimates from the HMDB, C18(Plasm)&#8208;20:4 PE ranges from approximately 3.717&#160;&#160;&#177;&#160;&#160;0.679 to 28.290&#160;&#160;&#177;&#160;&#160;21.925&#160;&#181;M in the human circulatory system, while C18(Plasm)&#8208;18:1 PE ranges from 2.160&#160;&#160;&#177;&#160;&#160;0.374 to 27.865&#160;&#160;&#177;&#160;&#160;22.648&#160;&#181;M. For diacyl PE species, concentrations estimated via MetaboAnalyst indicate that 16:0/20:4 PE ranges from 6.002&#160;&#160;&#177;&#160;&#160;2.136 to 52.133&#160;&#160;&#177;&#160;&#160;21.658&#160;&#181;M, and 16:0/18:1 PE ranges from 3.660&#160;&#160;&#177;&#160;&#160;1.734 to 41.967&#160;&#160;&#177;&#160;&#160;12.350&#160;&#181;M.</p><p>In human brain, all four PE species&#8212;C18(Plasm)&#8208;20:4 PE, C18(Plasm)&#8208;18:1 PE, 16:0/20:4 PE, and 16:0/18:1 PE&#8212;were detected across multiple brain regions, including the frontal, parietal, and temporal cortices, as well as the cerebellum.<xref rid="alz70603-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref> Notably, C18(Plasm)&#8208;20:4 PE (P16:0&#8208;22:4/P18:0&#8208;20:4) was the most abundant, with concentrations ranging from &#8764;20 to 54&#160;nmol/mg protein (&#8764;576.8 to 1557.36 &#181;M), and showed a marked reduction in individuals with higher Clinical Dementia Rating (CDR) scores.<xref rid="alz70603-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref> C18(Plasm)&#8208;18:1 PE (P18:0&#8208;18:1/P16:0&#8208;20:1) also demonstrated broad regional presence (&#8764;7&#8211;32&#160;nmol/mg protein (&#8764;201.88&#8211;922.88 &#181;M)) and a similar CDR&#8208;dependent decline.<xref rid="alz70603-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref> In contrast, the diacyl species 16:0/20:4 PE and 16:0/18:1 PE were present at lower levels (&#8764;1.4&#8211;5.4&#160;nmol/mg protein (&#8764;40.376&#8211;155.736 &#181;M)) and exhibited minimal changes with CDR.<xref rid="alz70603-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref> These results suggest a selective vulnerability of plasmalogen PE species.</p><p>In our ThT&#8208;based fibrillization assays, both C18(Plasm)&#8208;20:4 PE and C18(Plasm)&#8208;18:1 PE markedly promoted A&#946;40 and A&#946;42 aggregation at supraphysiological concentrations (Figures&#160;<xref rid="alz70603-fig-0006" ref-type="fig">6B&#8211;E</xref> and <xref rid="alz70603-supinfo-0001" ref-type="">S7A&#8211;D</xref>). Interestingly, under concentrations approximating physiological levels, these plasmalogen PEs continued to enhance A&#946;40 aggregation (Figures&#160;<xref rid="alz70603-fig-0006" ref-type="fig">6B&#8211;C</xref> and <xref rid="alz70603-supinfo-0001" ref-type="">S7A,B</xref>), but exhibited a significant inhibitory effect on A&#946;42 aggregation (Figures&#160;<xref rid="alz70603-fig-0006" ref-type="fig">6D&#8211;E</xref> and <xref rid="alz70603-supinfo-0001" ref-type="">S7C,D</xref>). Similarly, both 16:0/20:4 PE and 16:0/18:1 PE showed a strong proaggregatory effect on A&#946;40 (Figures <xref rid="alz70603-supinfo-0001" ref-type="">S8A&#8211;B and S9A,B</xref>), with 16:0/18:1 PE displaying a dose&#8208;dependent response, except at the lipid&#8208;toxic concentration of 100&#160;&#181;M (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S9A,B</xref>). For A&#946;42, 16:0/20:4 PE significantly promoted aggregation at moderate to high concentrations (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S8C,D</xref>), whereas 16:0/18:1 PE elicited variable responses across low and high concentrations (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S9C,D</xref>).</p><p>These results indicate that both the chemical structure and concentration of PE species critically influence A&#946; aggregation dynamics. Plasmalogen PEs exhibit isoform&#8208;specific and concentration&#8208;dependent effects&#8212;enhancing A&#946;40 aggregation while suppressing A&#946;42 aggregation at physiological levels. In contrast, diacyl PEs (e.g., 16:0/20:4 and 16:0/18:1 PE) consistently promote A&#946;40 aggregation, with 16:0/18:1 PE displaying a clear dose&#8208;dependent response. However, their effects on A&#946;42 aggregation appear less predictable. Collectively, these findings suggest that lipid structural remodeling may selectively modulate amyloidogenic processes in AD.</p></sec></sec><sec id="alz70603-sec-0250"><label>4</label><title>DISCUSSION</title><p>Obesity is increasingly recognized as one of the most prominent modifiable risk factors for dementia, including AD.<xref rid="alz70603-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>&#160;A substantial body of evidence, from both long&#8208;term and recent studies, has demonstrated that high&#8208;fat diet (HFD) feeding induces neuroinflammation and cognitive decline in animal models and humans.<xref rid="alz70603-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="alz70603-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref>, <xref rid="alz70603-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref>, <xref rid="alz70603-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref> EVs have been identified as key mediators of adipose tissue&#8211;brain communication,<xref rid="alz70603-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> underscoring their potential to convey obesity&#8208;related signals that influence central nervous system (CNS) function. Even beyond obesity, disruptions in lipid homeostasis are critical in AD pathogenesis,<xref rid="alz70603-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="alz70603-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> highlighting the relevance of studying adipose&#8208;derived EV lipids in the broader context of neurodegenerative disease.</p><p>In this study, we first employed an EV tracking strategy combined with organ&#8208;specific analysis to evaluate the biodistribution of adipose&#8208;derived EVs in the brain (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S1B,C</xref>). Building on this foundational insight, we performed rigorous QC of the isolated EVs, adhering to the guidelines provided by the international society forextracellular vesicles (ISEV) and other established protocols,<xref rid="alz70603-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="alz70603-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref>, <xref rid="alz70603-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref> including particle size and concentration analysis using microfluidic resistive pulse sensing (MRPS) (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S1D</xref>), immunomagnetic capture of EV markers (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S1E</xref>), and Western blotting to assess adipocyte&#8208; and exosome&#8208;enriched markers (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S1F</xref>). Together, these steps ensured high&#8208;quality EV preparations and minimized the risk of confounding artifacts in subsequent analyses.</p><p>Next, we conducted a comprehensive lipidomics profiling of these EVs. Although most prior studies have focused on murine adipocyte&#8208;derived EVs,<xref rid="alz70603-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref> our systematic study focused on human&#8208;derived samples, thus increasing the clinical relevance and translational potential of our findings. To further investigate the lipid alterations associated with obesity, we conducted both a standalone lipidomic analysis of adipocyte&#8208;derived EVs and a comparative analysis with lipidomic profiles from human adipose tissue. We identified a subset of lipids that were markedly deregulated in EVs derived from obese individuals (Figure&#160;<xref rid="alz70603-fig-0001" ref-type="fig">1H</xref>). Among these, LPC and SM emerged as two lipid classes that consistently segregated lean and obese samples into nonoverlapping clusters (Figure&#160;<xref rid="alz70603-fig-0001" ref-type="fig">1G</xref>), highlighting their strong linkage to metabolic dysregulation and underscoring their potential as clinically relevant biomarkers.</p><p>These lipids are known to participate in a variety of intracellular processes and extracellular signaling events. Elevated levels of LPC, for example, are associated with cellular damage, potentially through mechanisms such as altering membrane permeability and disrupting osmotic balance.<xref rid="alz70603-bib-0087" ref-type="bibr">
<sup>87</sup>
</xref> DESI&#8208;based mass spectrometry imaging has identified spatial colocalization of lysophospholipids with A&#946; aggregates in AD brains, suggesting LPC may play a direct role in modulating A&#946; pathology.<xref rid="alz70603-bib-0088" ref-type="bibr">
<sup>88</sup>
</xref> Similarly, SM plays an essential role in intracellular signaling. As a major component of sphingolipids, it can function as a lipid second messenger regulating cellular stress responses, proliferation, differentiation, and neuronal survival.<xref rid="alz70603-bib-0089" ref-type="bibr">
<sup>89</sup>
</xref>, <xref rid="alz70603-bib-0090" ref-type="bibr">
<sup>90</sup>
</xref> Within membrane microdomains such as lipid rafts, sphingolipids&#8212;together with cholesterol&#8212;modulate the activity of transmembrane proteins,<xref rid="alz70603-bib-0091" ref-type="bibr">
<sup>91</sup>
</xref> which are critical for synaptic function and neuronal communication. These findings raise the intriguing hypothesis that direct interactions between A&#946; and these lipid classes may influence A&#946; conformation, ultimately modulating aggregation propensity in AD and contributing to AD progression.</p><p>Because adipocyte&#8208;derived EVs can penetrate the blood&#8211;brain barrier (BBB) and accumulate in the brain parenchyma,<xref rid="alz70603-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> their cargos&#8212;including DNA/RNA molecules, proteins, and lipids&#8212;may have diverse impacts on neuronal health. For instance, EV&#8208;associated microRNAs have been shown to induce synaptic damage and cognitive impairment,<xref rid="alz70603-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> while specific EV lipid components may further disrupt or remodel local lipid homeostasis in the CNS. Given the multifaceted nature of EV cargo, we isolated the specific impact of lipids on A&#946; fibrillization without confounding effects from other molecular components. To achieve this, we employed a ThT&#8208;based in vitro fibrillization assay using a pure system containing only synthetic human A&#946; peptides&#8212;rather than mouse&#8208;derived A&#946;&#8212;to maximize clinical relevance. Although lipid&#8211;A&#946; interactions have been probed in bilayer membrane models,<xref rid="alz70603-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="alz70603-bib-0092" ref-type="bibr">
<sup>92</sup>
</xref> such systems often comprise complex lipid mixtures, confounding the role of individual lipid species.</p><p>By contrast, our pure lipid&#8211;A&#946; system allows for direct and specific interactions with minimal confounders, likely explaining the accelerated fibrillization kinetics observed. Interestingly, the ThT fluorescence curves exhibited a rapid increase reminiscent of seeded or secondary nucleation&#8208;like aggregation, rather than the slower kinetics typically seen with spontaneous A&#946; monomer aggregation.<xref rid="alz70603-bib-0093" ref-type="bibr">
<sup>93</sup>
</xref> This suggests that under these simplified conditions, direct interactions between lipid molecules and A&#946; may facilitate nucleation or conformational shifts that expedite the aggregation process.</p><p>A growing body of literature supports the notion that A&#946; exhibits strong affinity for lipid molecules.<xref rid="alz70603-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70603-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="alz70603-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="alz70603-bib-0094" ref-type="bibr">
<sup>94</sup>
</xref> Moreover, our study provides important new insights by systematically examining multiple lipid species over a range of biologically relevant concentrations, extending from pathophysiologically high (lipotoxic) to normal physiological levels. This approach also encompassed both A&#946;40 and A&#946;42 monomers, direct evidence that the same lipid species can exert distinct effects on different A&#946; isoforms. Our data suggested that:</p><sec id="alz70603-sec-0260"><label>4.1</label><title>Concentration&#8208;dependent lipid effects</title><p>The influence of lipid concentration on A&#946; aggregation varies significantly among lipid types. Certain lipids exhibited a clear dose&#8208;dependent promotion of A&#946; aggregation, as reflected by stepwise changes in kinetic parameters such as lag time (<italic toggle="yes">T</italic>
<sub>lag</sub>), half&#8208;maximal fluorescence time (<italic toggle="yes">T<sub>1/2</sub>
</italic>), and growth phase duration (<italic toggle="yes">T</italic>
<sub>grow</sub>), promoting fibrillization at high concentrations yet inhibiting it at lower levels.</p><p>Others showed less predictable patterns, signifying complex lipid&#8211;peptide interactions. A consistent observation across multiple lipid species, including oleic acid (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S3</xref>), egg&#8208;derived lysoPC (Figure&#160;<xref rid="alz70603-fig-0005" ref-type="fig">5</xref>), egg SM (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S4</xref>), and brain SM (Figure <xref rid="alz70603-supinfo-0001" ref-type="">S5</xref>), was a biphasic response, in which A&#946; aggregation peaks at intermediate lipid concentrations and decreases at both lower and higher levels. Although the underlying mechanism is not fully understood, this trend may reflect a concentration range that promotes fibrillization. These effects may involve changes in condensate dynamics, as recent studies have implicated lipid&#8208;mediated phase separation as a key modulator of A&#946; aggregation dynamics.<xref rid="alz70603-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="alz70603-bib-0095" ref-type="bibr">
<sup>95</sup>
</xref>, <xref rid="alz70603-bib-0096" ref-type="bibr">
<sup>96</sup>
</xref> In addition, steric hindrance and molecular crowding<xref rid="alz70603-bib-0097" ref-type="bibr">
<sup>97</sup>
</xref> may also contribute to this biphasic phenomenon. In the present study, we focused primarily on direct lipid&#8211;A&#946; interactions rather than lipid&#8211;lipid assembly or supramolecular organization. However, lipid&#8211;lipid interactions could indirectly influence A&#946; aggregation by reshaping membrane curvature, surface tension, or fluidity&#8212;all factors known to affect amyloid formation.<xref rid="alz70603-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="alz70603-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="alz70603-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="alz70603-bib-0098" ref-type="bibr">
<sup>98</sup>
</xref> Collectively, these factors may explain why aggregation peaks at intermediate lipid concentrations, potentially through convergent or distinct mechanisms, although further molecular&#8208;level validation is warranted.</p></sec><sec id="alz70603-sec-0270"><label>4.2</label><title>Isoform&#8208;specific responses</title><p>The same lipid species could have either similar or distinct effects on A&#946;40 and A&#946;42 aggregation, suggesting that structural differences between the two isoforms may influence their lipid&#8208;binding properties.</p><p>It is well established that A&#946; neurotoxicity follows the hierarchy of nonfibrillar oligomers&#160;&gt;&#160;fibrils&#160;&gt;&#160;monomers,<xref rid="alz70603-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> implying any perturbation in the aggregation pathway can have profound implications for disease pathogenesis. Our findings reveal that lipid&#8208;specific modulation of A&#946; aggregation may not only alter fibrillization kinetics but shift the distribution of A&#946; species toward those with distinct toxic potentials. Given that A&#946;40 and A&#946;42 can behave differentially in the same lipid milieu, it is plausible that their toxic potentials could also diverge&#8212;particularly under obese conditions, where lipid composition and concentration are significantly altered.</p><p>From a mechanistic standpoint, our findings highlight the critical role of lipid composition and concentration in modulating A&#946; aggregation dynamics and, by extension, AD pathology. Interactions between lipid molecules and A&#946; can facilitate pathological aggregation through biophysical processes such as phase separation and condensate formation,<xref rid="alz70603-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> effectively creating nucleation platforms or altering local molecular crowding to accelerate oligomer or fibril formation. Crucially some lipids exhibit concentration&#8208;dependent biphasic effects&#8212;promoting aggregation at higher levels yet inhibiting it at lower doses&#8212;highlighting the need for nuanced control of lipid microenvironments when considering therapeutic interventions or interpreting disease mechanisms.</p><p>Moreover, these findings carry important translational implications. As EVs and lipid&#8208;based carriers gain traction as promising therapeutic delivery systems capable of crossing the BBB, rational design of their lipid constituents becomes critical. Ensuring biocompatibility and target specificity must be balanced against the risk of inadvertently driving A&#946; aggregation or exacerbating neurotoxic pathways. By demonstrating that even subtle shifts in lipid composition or concentration can meaningfully alter A&#946; aggregation outcomes, our work underscores the necessity for precise lipid profiling and engineering in such delivery platforms.</p><p>Finally, the lipid&#8211;A&#946; specificity observed here underscores that maintaining tightly regulated lipid metabolic homeostasis in the brain is pivotal for mitigating or preventing neurodegeneration. As metabolic dysfunction and obesity continue to rise globally, their intersection with neurodegenerative diseases demands closer scrutiny. Our study contributes a foundational understanding of how discrete lipid species, present at various concentrations, can shape A&#946; assembly and possibly translate into altered neuronal toxicity. Although our findings provide molecular insights using a well&#8208;controlled pure system, we acknowledge that the current study does not establish whether EV lipid differences directly contribute to A&#946; aggregation in the brain. Future studies incorporating appropriate animal models, allowing the&#160;disentanglement of potential confounding effects, will be essential to determine the physiological relevance of EV&#8208;mediated lipid&#8211;A&#946; interactions in the context of AD pathology.</p></sec></sec><sec sec-type="COI-statement" id="alz70603-sec-0290"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare no competing interests. Author disclosures are available in the <xref rid="alz70603-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="alz70603-sec-0300"><title>CONSENT STATEMENT</title><p>All procedures involving human participants were approved by the Institutional Review Board (IRB# 2014H0471) of The Ohio State University. Written informed consent was obtained from all individuals in accordance with institutional and ethical guidelines.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70603-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70603-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70603-s002.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70603-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70603-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70603-sec-0280"><title>ACKNOWLEDGMENTS</title><p>This study is supported by NIH R01AG057635, NIH R01CA238727, NIH U01CA253553, T.T. and W.F. Chao Foundation, Cure Alzheimer's Fund, John S. Dunn Research Foundation, Houston Methodist Cornerstone Award, and the Paul Richard Jeanneret Research Fund. The Functional Lipidomics Core at the University of Texas Health Science Center at San Antonio was partially supported by&#160;P30 AG013319 and P30 AG044271. The authors have nothing to report.</p></ack><ref-list id="alz70603-bibl-0001"><title>REFERENCES</title><ref id="alz70603-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70603-cite-0002"><article-title>2024 Alzheimer's disease facts and figures</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>5</issue>):<fpage>3708</fpage>&#8208;<lpage>3821</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13809</pub-id><pub-id pub-id-type="pmid">38689398</pub-id><pub-id pub-id-type="pmcid">PMC11095490</pub-id></mixed-citation></ref><ref id="alz70603-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70603-cite-0003"><string-name name-style="western"><surname>Slomski</surname><given-names>A</given-names></string-name>, <article-title>Obesity is now the top modifiable dementia risk factor in the US</article-title>. <source>JAMA</source>. <year>2022</year>;<volume>328</volume>(<issue>1</issue>):<fpage>10</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2022.11058</pub-id><pub-id pub-id-type="pmid">35788805</pub-id></mixed-citation></ref><ref id="alz70603-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70603-cite-0004"><string-name name-style="western"><surname>Kao</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Tu</surname><given-names>YK</given-names></string-name>, <string-name name-style="western"><surname>Jou</surname><given-names>IM</given-names></string-name>, <string-name name-style="western"><surname>Tsai</surname><given-names>KJ</given-names></string-name>. <article-title>Lipids and Alzheimer's disease</article-title>. <source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>4</issue>):<fpage>1505</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms21041505</pub-id><pub-id pub-id-type="pmid">32098382</pub-id><pub-id pub-id-type="pmcid">PMC7073164</pub-id></mixed-citation></ref><ref id="alz70603-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70603-cite-0005"><string-name name-style="western"><surname>Terzo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Amato</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mule</surname><given-names>F</given-names></string-name>. <article-title>From obesity to Alzheimer's disease through insulin resistance</article-title>. <source>J Diabetes Complications</source>. <year>2021</year>;<volume>35</volume>(<issue>11</issue>):<elocation-id>108026</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.jdiacomp.2021.108026</pub-id><pub-id pub-id-type="pmid">34454830</pub-id></mixed-citation></ref><ref id="alz70603-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70603-cite-0006"><string-name name-style="western"><surname>Rohm</surname><given-names>TV</given-names></string-name>, <string-name name-style="western"><surname>Fuchs</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Muller</surname><given-names>RL</given-names></string-name>, et&#160;al. <article-title>Obesity in humans is characterized by gut inflammation as shown by pro&#8208;inflammatory intestinal macrophage accumulation</article-title>. <source>Front Immunol</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>668654</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2021.668654</pub-id><pub-id pub-id-type="pmid">34054838</pub-id><pub-id pub-id-type="pmcid">PMC8158297</pub-id></mixed-citation></ref><ref id="alz70603-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70603-cite-0007"><string-name name-style="western"><surname>Elzinga</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Turfah</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Metabolic stress and age drive inflammation and cognitive decline in mice and humans</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>;<volume>21</volume>(<issue>3</issue>):<elocation-id>e70060</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/alz.70060</pub-id><pub-id pub-id-type="pmid">40110679</pub-id><pub-id pub-id-type="pmcid">PMC11923576</pub-id></mixed-citation></ref><ref id="alz70603-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70603-cite-0008"><string-name name-style="western"><surname>He</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>. <article-title>Lipidome disruption in Alzheimer's disease brain: detection, pathological mechanisms, and therapeutic implications</article-title>. <source>Mol Neurodegener</source>. <year>2025</year>;<volume>20</volume>(<issue>1</issue>):<fpage>11</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13024-025-00803-6</pub-id><pub-id pub-id-type="pmid">39871348</pub-id><pub-id pub-id-type="pmcid">PMC11773937</pub-id></mixed-citation></ref><ref id="alz70603-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70603-cite-0009"><string-name name-style="western"><surname>Yin</surname><given-names>F</given-names></string-name>. <article-title>Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise</article-title>. <source>FEBS J</source>. <year>2023</year>;<volume>290</volume>(<issue>6</issue>):<fpage>1420</fpage>&#8208;<lpage>1453</lpage>. doi:<pub-id pub-id-type="doi">10.1111/febs.16344</pub-id><pub-id pub-id-type="pmid">34997690</pub-id><pub-id pub-id-type="pmcid">PMC9259766</pub-id></mixed-citation></ref><ref id="alz70603-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70603-cite-0010"><string-name name-style="western"><surname>Mi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Vitali</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>Loss of fatty acid degradation by astrocytic mitochondria triggers neuroinflammation and neurodegeneration</article-title>. <source>Nat Metab</source>. <year>2023</year>;<volume>5</volume>(<issue>3</issue>):<fpage>445</fpage>&#8208;<lpage>465</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s42255-023-00756-4</pub-id><pub-id pub-id-type="pmid">36959514</pub-id><pub-id pub-id-type="pmcid">PMC10202034</pub-id></mixed-citation></ref><ref id="alz70603-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70603-cite-0011"><string-name name-style="western"><surname>Hardy</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Higgins</surname><given-names>GA</given-names></string-name>. <article-title>Alzheimer's disease: the amyloid cascade hypothesis</article-title>. <source>Science</source>. <year>1992</year>;<volume>256</volume>(<issue>5054</issue>):<fpage>184</fpage>&#8208;<lpage>185</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1566067</pub-id><pub-id pub-id-type="pmid">1566067</pub-id></mixed-citation></ref><ref id="alz70603-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70603-cite-0012"><string-name name-style="western"><surname>Hardy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></string-name>. <article-title>The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics</article-title>. <source>Science</source>. <year>2002</year>;<volume>297</volume>(<issue>5580</issue>):<fpage>353</fpage>&#8208;<lpage>356</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1072994</pub-id><pub-id pub-id-type="pmid">12130773</pub-id></mixed-citation></ref><ref id="alz70603-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70603-cite-0013"><string-name name-style="western"><surname>Thinakaran</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Koo</surname><given-names>EH</given-names></string-name>. <article-title>Amyloid precursor protein trafficking, processing, and function</article-title>. <source>The Journal of biological chemistry</source>. <year>2008</year>;<volume>283</volume>(<issue>44</issue>):<fpage>29615</fpage>&#8208;<lpage>29619</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.R800019200</pub-id><pub-id pub-id-type="pmid">18650430</pub-id><pub-id pub-id-type="pmcid">PMC2573065</pub-id></mixed-citation></ref><ref id="alz70603-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70603-cite-0014"><string-name name-style="western"><surname>Jucker</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Walker</surname><given-names>LC</given-names></string-name>. <article-title>Self&#8208;propagation of pathogenic protein aggregates in neurodegenerative diseases</article-title>. <source>Nature</source>. <year>2013</year>;<volume>501</volume>(<issue>7465</issue>):<fpage>45</fpage>&#8208;<lpage>51</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature12481</pub-id><pub-id pub-id-type="pmid">24005412</pub-id><pub-id pub-id-type="pmcid">PMC3963807</pub-id></mixed-citation></ref><ref id="alz70603-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70603-cite-0015"><string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Arseni</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>Cryo&#8208;EM structures of amyloid&#8208;beta 42 filaments from human brains</article-title>. <source>Science</source>. <year>2022</year>;<volume>375</volume>(<issue>6577</issue>):<fpage>167</fpage>&#8208;<lpage>172</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.abm7285</pub-id><pub-id pub-id-type="pmid">35025654</pub-id><pub-id pub-id-type="pmcid">PMC7612234</pub-id></mixed-citation></ref><ref id="alz70603-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70603-cite-0016"><string-name name-style="western"><surname>Kollmer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Close</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Funk</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Cryo&#8208;EM structure and polymorphism of Abeta amyloid fibrils purified from Alzheimer's brain tissue</article-title>. <source>Nat Commun</source>. <year>2019</year>;<volume>10</volume>(<issue>1</issue>):<fpage>4760</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-019-12683-8</pub-id><pub-id pub-id-type="pmid">31664019</pub-id><pub-id pub-id-type="pmcid">PMC6820800</pub-id></mixed-citation></ref><ref id="alz70603-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70603-cite-0017"><string-name name-style="western"><surname>Hatami</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Monjazeb</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Milton</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Glabe</surname><given-names>CG</given-names></string-name>. <article-title>Familial Alzheimer's disease mutations within the amyloid precursor protein alter the aggregation and conformation of the amyloid&#8208;beta peptide</article-title>. <source>The Journal of biological chemistry</source>. <year>2017</year>;<volume>292</volume>(<issue>8</issue>):<fpage>3172</fpage>&#8208;<lpage>3185</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M116.755264</pub-id><pub-id pub-id-type="pmid">28049728</pub-id><pub-id pub-id-type="pmcid">PMC5336154</pub-id></mixed-citation></ref><ref id="alz70603-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70603-cite-0018"><string-name name-style="western"><surname>Ha</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ryu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>CB</given-names></string-name>. <article-title>Metal ions differentially influence the aggregation and deposition of Alzheimer's beta&#8208;amyloid on a solid template</article-title>. <source>Biochemistry</source>. <year>2007</year>;<volume>46</volume>(<issue>20</issue>):<fpage>6118</fpage>&#8208;<lpage>6125</lpage>. doi:<pub-id pub-id-type="doi">10.1021/bi7000032</pub-id><pub-id pub-id-type="pmid">17455909</pub-id></mixed-citation></ref><ref id="alz70603-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70603-cite-0019"><string-name name-style="western"><surname>Morgado</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Garvey</surname><given-names>M</given-names></string-name>. <article-title>Lipids in Amyloid&#8208;beta processing, aggregation, and toxicity</article-title>. <source>Adv Exp Med Biol</source>. <year>2015</year>;<volume>855</volume>:<fpage>67</fpage>&#8208;<lpage>94</lpage>. doi:<pub-id pub-id-type="doi">10.1007/978-3-319-17344-3_3</pub-id><pub-id pub-id-type="pmid">26149926</pub-id></mixed-citation></ref><ref id="alz70603-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70603-cite-0020"><string-name name-style="western"><surname>Rangachari</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Dean</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Rana</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Vaidya</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ghosh</surname><given-names>P</given-names></string-name>. <article-title>Cause and consequence of Abeta&#8212;Lipid interactions in Alzheimer disease pathogenesis</article-title>. <source>Biochim Biophys Acta Biomembr</source>. <year>2018</year>;<volume>1860</volume>(<issue>9</issue>):<fpage>1652</fpage>&#8208;<lpage>1662</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbamem.2018.03.004</pub-id><pub-id pub-id-type="pmid">29526709</pub-id><pub-id pub-id-type="pmcid">PMC6133763</pub-id></mixed-citation></ref><ref id="alz70603-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70603-cite-0021"><string-name name-style="western"><surname>Kurouski</surname><given-names>D</given-names></string-name>. <article-title>Elucidating the role of lipids in the aggregation of amyloidogenic proteins</article-title>. <source>Acc Chem Res</source>. <year>2023</year>;<volume>56</volume>(<issue>21</issue>):<fpage>2898</fpage>&#8208;<lpage>2906</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.accounts.3c00386</pub-id><pub-id pub-id-type="pmid">37824095</pub-id><pub-id pub-id-type="pmcid">PMC10862471</pub-id></mixed-citation></ref><ref id="alz70603-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70603-cite-0022"><string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, et&#160;al. <article-title>Extracellular vesicles mediate the communication of adipose tissue with brain and promote cognitive impairment associated with insulin resistance</article-title>. <source>Cell Metab</source>. <year>2022</year>;<volume>34</volume>(<issue>9</issue>):<fpage>1264</fpage>&#8208;<lpage>1279</lpage>. e8. doi:<pub-id pub-id-type="doi">10.1016/j.cmet.2022.08.004</pub-id><pub-id pub-id-type="pmid">36070680</pub-id></mixed-citation></ref><ref id="alz70603-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70603-cite-0023"><string-name name-style="western"><surname>Yoshida</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Satoh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>JB</given-names></string-name>, et&#160;al. <article-title>Extracellular vesicle&#8208;contained enampt delays aging and extends lifespan in mice</article-title>. <source>Cell Metab</source>. <year>2019</year>;<volume>30</volume>(<issue>2</issue>):<fpage>329</fpage>&#8208;<lpage>342</lpage>. e5. doi:<pub-id pub-id-type="doi">10.1016/j.cmet.2019.05.015</pub-id><pub-id pub-id-type="pmid">31204283</pub-id><pub-id pub-id-type="pmcid">PMC6687560</pub-id></mixed-citation></ref><ref id="alz70603-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70603-cite-0024"><string-name name-style="western"><surname>Gao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Adipocyte&#8208;derived extracellular vesicles modulate appetite and weight through mTOR signalling in the hypothalamus</article-title>. <source>Acta Physiol (Oxf)</source>. <year>2020</year>;<volume>228</volume>(<issue>2</issue>):<elocation-id>e13339</elocation-id>. doi:<pub-id pub-id-type="doi">10.1111/apha.13339</pub-id><pub-id pub-id-type="pmid">31278836</pub-id></mixed-citation></ref><ref id="alz70603-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70603-cite-0025"><string-name name-style="western"><surname>Crewe</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Scherer</surname><given-names>PE</given-names></string-name>. <article-title>Intercellular and interorgan crosstalk through adipocyte extracellular vesicles</article-title>. <source>Rev Endocr Metab Disord</source>. <year>2022</year>;<volume>23</volume>(<issue>1</issue>):<fpage>61</fpage>&#8208;<lpage>69</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11154-020-09625-x</pub-id><pub-id pub-id-type="pmid">33447986</pub-id></mixed-citation></ref><ref id="alz70603-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70603-cite-0026"><string-name name-style="western"><surname>Banks</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bullock</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Ludwig</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Whiteside</surname><given-names>TL</given-names></string-name>. <article-title>Transport of extracellular vesicles across the blood&#8208;brain barrier: brain pharmacokinetics and effects of inflammation</article-title>. <source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>12</issue>):<fpage>4407</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms21124407</pub-id><pub-id pub-id-type="pmid">32575812</pub-id><pub-id pub-id-type="pmcid">PMC7352415</pub-id></mixed-citation></ref><ref id="alz70603-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70603-cite-0027"><string-name name-style="western"><surname>Liang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Iqbal</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Cell&#8208;derived nanovesicle&#8208;mediated drug delivery to the brain: principles and strategies for vesicle engineering</article-title>. <source>Mol Ther</source>. <year>2023</year>;<volume>31</volume>(<issue>5</issue>):<fpage>1207</fpage>&#8208;<lpage>1224</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymthe.2022.10.008</pub-id><pub-id pub-id-type="pmid">36245129</pub-id><pub-id pub-id-type="pmcid">PMC10188644</pub-id></mixed-citation></ref><ref id="alz70603-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70603-cite-0028"><string-name name-style="western"><surname>Morad</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Carman</surname><given-names>CV</given-names></string-name>, <string-name name-style="western"><surname>Hagedorn</surname><given-names>EJ</given-names></string-name>, et&#160;al. <article-title>Tumor&#8208;derived extracellular vesicles breach the intact blood&#8208;brain barrier via transcytosis</article-title>. <source>ACS Nano</source>. <year>2019</year>;<volume>13</volume>(<issue>12</issue>):<fpage>13853</fpage>&#8208;<lpage>13865</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acsnano.9b04397</pub-id><pub-id pub-id-type="pmid">31479239</pub-id><pub-id pub-id-type="pmcid">PMC7169949</pub-id></mixed-citation></ref><ref id="alz70603-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70603-cite-0029"><string-name name-style="western"><surname>Ramos&#8208;Zaldivar</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Polakovicova</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Salas&#8208;Huenuleo</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Extracellular vesicles through the blood&#8208;brain barrier: a review</article-title>. <source>Fluids Barriers CNS</source>. <year>2022</year>;<volume>19</volume>(<issue>1</issue>):<fpage>60</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12987-022-00359-3</pub-id><pub-id pub-id-type="pmid">35879759</pub-id><pub-id pub-id-type="pmcid">PMC9310691</pub-id></mixed-citation></ref><ref id="alz70603-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70603-cite-0030"><string-name name-style="western"><surname>Dickens</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Tovar</surname><given-names>YRLB</given-names></string-name>, <string-name name-style="western"><surname>Yoo</surname><given-names>SW</given-names></string-name>, et&#160;al. <article-title>Astrocyte&#8208;shed extracellular vesicles regulate the peripheral leukocyte response to inflammatory brain lesions</article-title>. <source>Sci Signal</source>. <year>2017</year>;<volume>10</volume>(<issue>473</issue>):<elocation-id>eaai7696</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/scisignal.aai7696</pub-id><pub-id pub-id-type="pmid">28377412</pub-id><pub-id pub-id-type="pmcid">PMC5590230</pub-id></mixed-citation></ref><ref id="alz70603-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70603-cite-0031"><string-name name-style="western"><surname>Gao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Neural stem cell&#8208;derived extracellular vesicles mitigate Alzheimer's disease&#8208;like phenotypes in a preclinical mouse model</article-title>. <source>Signal Transduct Target Ther</source>. <year>2023</year>;<volume>8</volume>(<issue>1</issue>):<fpage>228</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41392-023-01436-1</pub-id><pub-id pub-id-type="pmid">37311758</pub-id><pub-id pub-id-type="pmcid">PMC10264449</pub-id></mixed-citation></ref><ref id="alz70603-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70603-cite-0032"><string-name name-style="western"><surname>Chew</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Solomon</surname><given-names>VA</given-names></string-name>, <string-name name-style="western"><surname>Fonteh</surname><given-names>AN</given-names></string-name>. <article-title>Involvement of lipids in Alzheimer's disease pathology and potential therapies</article-title>. <source>Front Physiol</source>. <year>2020</year>;<volume>11</volume>:<fpage>598</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphys.2020.00598</pub-id><pub-id pub-id-type="pmid">32581851</pub-id><pub-id pub-id-type="pmcid">PMC7296164</pub-id></mixed-citation></ref><ref id="alz70603-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70603-cite-0033"><string-name name-style="western"><surname>Frieg</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Giller</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Cryo&#8208;EM structures of lipidic fibrils of amyloid&#8208;beta (1&#8208;40)</article-title>. <source>Nat Commun</source>. <year>2024</year>;<volume>15</volume>(<issue>1</issue>):<fpage>1297</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-023-43822-x</pub-id><pub-id pub-id-type="pmid">38351005</pub-id><pub-id pub-id-type="pmcid">PMC10864299</pub-id></mixed-citation></ref><ref id="alz70603-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70603-cite-0034"><string-name name-style="western"><surname>Sneideriene</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gonzalez Diaz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Adhikari</surname><given-names>SD</given-names></string-name>, et&#160;al. <article-title>Lipid&#8208;induced condensate formation from the Alzheimer's Abeta peptide triggers amyloid aggregation</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2025</year>;<volume>122</volume>(<issue>4</issue>):<elocation-id>e2401307122</elocation-id>. doi:<pub-id pub-id-type="doi">10.1073/pnas.2401307122</pub-id><pub-id pub-id-type="pmid">39854227</pub-id><pub-id pub-id-type="pmcid">PMC11789053</pub-id></mixed-citation></ref><ref id="alz70603-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70603-cite-0035"><string-name name-style="western"><surname>Bokvist</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lindstrom</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Watts</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Grobner</surname><given-names>G</given-names></string-name>. <article-title>Two types of Alzheimer's beta&#8208;amyloid (1&#8208;40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation</article-title>. <source>J Mol Biol</source>. <year>2004</year>;<volume>335</volume>(<issue>4</issue>):<fpage>1039</fpage>&#8208;<lpage>1049</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jmb.2003.11.046</pub-id><pub-id pub-id-type="pmid">14698298</pub-id></mixed-citation></ref><ref id="alz70603-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70603-cite-0036"><string-name name-style="western"><surname>Alarcon</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Brito</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Hermosilla</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Atwater</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Mears</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rojas</surname><given-names>E</given-names></string-name>. <article-title>Ion channel formation by Alzheimer's disease amyloid beta&#8208;peptide (Abeta40) in unilamellar liposomes is determined by anionic phospholipids</article-title>. <source>Peptides</source>. <year>2006</year>;<volume>27</volume>(<issue>1</issue>):<fpage>95</fpage>&#8208;<lpage>104</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.peptides.2005.07.004</pub-id><pub-id pub-id-type="pmid">16139931</pub-id></mixed-citation></ref><ref id="alz70603-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70603-cite-0037"><string-name name-style="western"><surname>Williams</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Serpell</surname><given-names>LC</given-names></string-name>. <article-title>Membrane and surface interactions of Alzheimer's Abeta peptide&#8211;insights into the mechanism of cytotoxicity</article-title>. <source>FEBS J</source>. <year>2011</year>;<volume>278</volume>(<issue>20</issue>):<fpage>3905</fpage>&#8208;<lpage>3917</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1742-4658.2011.08228.x</pub-id><pub-id pub-id-type="pmid">21722314</pub-id></mixed-citation></ref><ref id="alz70603-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz70603-cite-0038"><string-name name-style="western"><surname>Vander Zanden</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Wampler</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bowers</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Watkins</surname><given-names>EB</given-names></string-name>, <string-name name-style="western"><surname>Majewski</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chi</surname><given-names>EY</given-names></string-name>. <article-title>Fibrillar and nonfibrillar amyloid beta structures drive two modes of membrane&#8208;mediated toxicity</article-title>. <source>Langmuir</source>. <year>2019</year>;<volume>35</volume>(<issue>48</issue>):<fpage>16024</fpage>&#8208;<lpage>16036</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.langmuir.9b02484</pub-id><pub-id pub-id-type="pmid">31509701</pub-id><pub-id pub-id-type="pmcid">PMC7385729</pub-id></mixed-citation></ref><ref id="alz70603-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70603-cite-0039"><string-name name-style="western"><surname>Deng</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lyon</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Minze</surname><given-names>LJ</given-names></string-name>, et&#160;al. <article-title>Class II major histocompatibility complex plays an essential role in obesity&#8208;induced adipose inflammation</article-title>. <source>Cell Metab</source>. <year>2013</year>;<volume>17</volume>(<issue>3</issue>):<fpage>411</fpage>&#8208;<lpage>422</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cmet.2013.02.009</pub-id><pub-id pub-id-type="pmid">23473035</pub-id><pub-id pub-id-type="pmcid">PMC3619392</pub-id></mixed-citation></ref><ref id="alz70603-bib-0039"><label>39</label><mixed-citation publication-type="book" id="alz70603-cite-0040"><string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>. <source>Lipidomics: Comprehensive Mass Spectrometry of Lipids /Xianlin Han</source>. <publisher-name>John Wiley &amp; Sons, Inc</publisher-name>., <year>2016</year>.</mixed-citation></ref><ref id="alz70603-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70603-cite-0041"><string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>. <article-title>Multidimensional mass spectrometry&#8208;based shotgun lipidomics</article-title>. <source>Methods in molecular biology (Clifton, NJ)</source>. <year>2014</year>;<volume>1198</volume>:<fpage>203</fpage>&#8208;<lpage>220</lpage>. doi:<pub-id pub-id-type="doi">10.1007/978-1-4939-1258-2_13</pub-id><pub-id pub-id-type="pmcid">PMC4261229</pub-id><pub-id pub-id-type="pmid">25270931</pub-id></mixed-citation></ref><ref id="alz70603-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70603-cite-0042"><string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gross</surname><given-names>RW</given-names></string-name>. <article-title>Microfluidics&#8208;based electrospray ionization enhances the intrasource separation of lipid classes and extends identification of individual molecular species through multi&#8208;dimensional mass spectrometry: development of an automated high&#8208;throughput platform for shotgun lipidomics</article-title>. <source>Rapid Commun Mass Spectrom</source>. <year>2008</year>;<volume>22</volume>(<issue>13</issue>):<fpage>2115</fpage>&#8208;<lpage>2124</lpage>. doi:<pub-id pub-id-type="doi">10.1002/rcm.3595</pub-id><pub-id pub-id-type="pmid">18523984</pub-id><pub-id pub-id-type="pmcid">PMC2927983</pub-id></mixed-citation></ref><ref id="alz70603-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70603-cite-0043"><string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>. <article-title>Selection of internal standards for accurate quantification of complex lipid species in biological extracts by electrospray ionization mass spectrometry&#8208;What, how and why?</article-title><source>Mass Spectrom Rev</source>. <year>2017</year>;<volume>36</volume>(<issue>6</issue>):<fpage>693</fpage>&#8208;<lpage>714</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mas.21492</pub-id><pub-id pub-id-type="pmid">26773411</pub-id><pub-id pub-id-type="pmcid">PMC4947032</pub-id></mixed-citation></ref><ref id="alz70603-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70603-cite-0044"><string-name name-style="western"><surname>Yang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>. <article-title>Accurate quantification of lipid species by electrospray ionization mass spectrometry&#8212;Meet a key challenge in lipidomics</article-title>. <source>Metabolites</source>. <year>2011</year>;<volume>1</volume>(<issue>1</issue>):<fpage>21</fpage>&#8208;<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.3390/metabo1010021</pub-id><pub-id pub-id-type="pmid">22905337</pub-id><pub-id pub-id-type="pmcid">PMC3420347</pub-id></mixed-citation></ref><ref id="alz70603-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70603-cite-0045"><string-name name-style="western"><surname>Peng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Oleate blocks palmitate&#8208;induced abnormal lipid distribution, endoplasmic reticulum expansion and stress, and insulin resistance in skeletal muscle</article-title>. <source>Endocrinology</source>. <year>2011</year>;<volume>152</volume>(<issue>6</issue>):<fpage>2206</fpage>&#8208;<lpage>2218</lpage>. doi:<pub-id pub-id-type="doi">10.1210/en.2010-1369</pub-id><pub-id pub-id-type="pmid">21505048</pub-id></mixed-citation></ref><ref id="alz70603-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz70603-cite-0046"><string-name name-style="western"><surname>Sjolin</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kultima</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Larsson</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Distribution of five clinically important neuroglial proteins in the human brain</article-title>. <source>Mol Brain</source>. <year>2022</year>;<volume>15</volume>(<issue>1</issue>):<fpage>52</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13041-022-00935-6</pub-id><pub-id pub-id-type="pmid">35765081</pub-id><pub-id pub-id-type="pmcid">PMC9241296</pub-id></mixed-citation></ref><ref id="alz70603-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz70603-cite-0047"><string-name name-style="western"><surname>He</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Heshka</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Albu</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Smaller organ mass with greater age, except for heart</article-title>. <source>J Appl Physiol (1985)</source>. <year>2009</year>;<volume>106</volume>(<issue>6</issue>):<fpage>1780</fpage>&#8208;<lpage>1784</lpage>. doi:<pub-id pub-id-type="doi">10.1152/japplphysiol.90454.2008</pub-id><pub-id pub-id-type="pmid">19325028</pub-id><pub-id pub-id-type="pmcid">PMC2692775</pub-id></mixed-citation></ref><ref id="alz70603-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="alz70603-cite-0048"><string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>LTH</given-names></string-name>, <string-name name-style="western"><surname>Hickey</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Immunomagnetic sequential ultrafiltration (iSUF) platform for enrichment and purification of extracellular vesicles from biofluids</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>8034</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-021-86910-y</pub-id><pub-id pub-id-type="pmid">33850163</pub-id><pub-id pub-id-type="pmcid">PMC8044115</pub-id></mixed-citation></ref><ref id="alz70603-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="alz70603-cite-0049"><string-name name-style="western"><surname>Thery</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Witwer</surname><given-names>KW</given-names></string-name>, <string-name name-style="western"><surname>Aikawa</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines</article-title>. <source>J Extracell Vesicles</source>. <year>2018</year>;<volume>7</volume>(<issue>1</issue>):<elocation-id>1535750</elocation-id>. doi:<pub-id pub-id-type="doi">10.1080/20013078.2018.1535750</pub-id><pub-id pub-id-type="pmid">30637094</pub-id><pub-id pub-id-type="pmcid">PMC6322352</pub-id></mixed-citation></ref><ref id="alz70603-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="alz70603-cite-0050"><string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Jeppesen</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Higginbotham</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Franklin</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Coffey</surname><given-names>RJ</given-names></string-name>. <article-title>Comprehensive isolation of extracellular vesicles and nanoparticles</article-title>. <source>Nat Protoc</source>. <year>2023</year>;<volume>18</volume>(<issue>5</issue>):<fpage>1462</fpage>&#8208;<lpage>1487</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41596-023-00811-0</pub-id><pub-id pub-id-type="pmid">36914899</pub-id><pub-id pub-id-type="pmcid">PMC10445291</pub-id></mixed-citation></ref><ref id="alz70603-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="alz70603-cite-0051"><string-name name-style="western"><surname>Foster</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Dangla&#8208;Valls</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lovestone</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ribe</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Buckley</surname><given-names>NJ</given-names></string-name>. <article-title>Clusterin in Alzheimer's disease: mechanisms, genetics, and lessons from other pathologies</article-title>. <source>Front Neurosci</source>. <year>2019</year>;<volume>13</volume>:<fpage>164</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnins.2019.00164</pub-id><pub-id pub-id-type="pmid">30872998</pub-id><pub-id pub-id-type="pmcid">PMC6403191</pub-id></mixed-citation></ref><ref id="alz70603-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="alz70603-cite-0052"><string-name name-style="western"><surname>Yoon</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Seo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jo</surname><given-names>YS</given-names></string-name>, et&#160;al. <article-title>Brain lipidomics: from functional landscape to clinical significance</article-title>. <source>Sci Adv</source>. <year>2022</year>;<volume>8</volume>(<issue>37</issue>):<elocation-id>eadc9317</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/sciadv.adc9317</pub-id><pub-id pub-id-type="pmid">36112688</pub-id><pub-id pub-id-type="pmcid">PMC9481132</pub-id></mixed-citation></ref><ref id="alz70603-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="alz70603-cite-0053"><string-name name-style="western"><surname>Osetrova</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tkachev</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mair</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>Lipidome atlas of the adult human brain</article-title>. <source>Nat Commun</source>. <year>2024</year>;<volume>15</volume>(<issue>1</issue>):<fpage>4455</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-024-48734-y</pub-id><pub-id pub-id-type="pmid">38796479</pub-id><pub-id pub-id-type="pmcid">PMC11127996</pub-id></mixed-citation></ref><ref id="alz70603-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="alz70603-cite-0054"><string-name name-style="western"><surname>Naudi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cabre</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jove</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Lipidomics of human brain aging and Alzheimer's disease pathology</article-title>. <source>Int Rev Neurobiol</source>. <year>2015</year>;<volume>122</volume>:<fpage>133</fpage>&#8208;<lpage>189</lpage>. doi:<pub-id pub-id-type="doi">10.1016/bs.irn.2015.05.008</pub-id><pub-id pub-id-type="pmid">26358893</pub-id></mixed-citation></ref><ref id="alz70603-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="alz70603-cite-0055"><string-name name-style="western"><surname>Kuriki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nagaya</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tokudome</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Plasma concentrations of (n&#8208;3) highly unsaturated fatty acids are good biomarkers of relative dietary fatty acid intakes: a cross&#8208;sectional study</article-title>. <source>J Nutr</source>. <year>2003</year>;<volume>133</volume>(<issue>11</issue>):<fpage>3643</fpage>&#8208;<lpage>3650</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jn/133.11.3643</pub-id><pub-id pub-id-type="pmid">14608088</pub-id></mixed-citation></ref><ref id="alz70603-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="alz70603-cite-0056"><string-name name-style="western"><surname>Min</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ghebremeskel</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lowy</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Crawford</surname><given-names>MA</given-names></string-name>. <article-title>Adverse effect of obesity on red cell membrane arachidonic and docosahexaenoic acids in gestational diabetes</article-title>. <source>Diabetologia</source>. <year>2004</year>;<volume>47</volume>(<issue>1</issue>):<fpage>75</fpage>&#8208;<lpage>81</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00125-003-1275-5</pub-id><pub-id pub-id-type="pmid">14634727</pub-id></mixed-citation></ref><ref id="alz70603-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="alz70603-cite-0057"><string-name name-style="western"><surname>Hoffmann</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Meier&#8208;Augenstein</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Stockler</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Surtees</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rating</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Nyhan</surname><given-names>WL</given-names></string-name>. <article-title>Physiology and pathophysiology of organic acids in cerebrospinal fluid</article-title>. <source>J Inherit Metab Dis</source>. <year>1993</year>;<volume>16</volume>(<issue>4</issue>):<fpage>648</fpage>&#8208;<lpage>669</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF00711898</pub-id><pub-id pub-id-type="pmid">8412012</pub-id></mixed-citation></ref><ref id="alz70603-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="alz70603-cite-0058"><string-name name-style="western"><surname>Igarashi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>Brain lipid concentrations in bipolar disorder</article-title>. <source>J Psychiatr Res</source>. <year>2010</year>;<volume>44</volume>(<issue>3</issue>):<fpage>177</fpage>&#8208;<lpage>182</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpsychires.2009.08.001</pub-id><pub-id pub-id-type="pmid">19767014</pub-id><pub-id pub-id-type="pmcid">PMC2821962</pub-id></mixed-citation></ref><ref id="alz70603-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="alz70603-cite-0059"><string-name name-style="western"><surname>Xue</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>TY</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>Z</given-names></string-name>. <article-title>Thioflavin T as an amyloid dye: fibril quantification, optimal concentration and effect on aggregation</article-title>. <source>R Soc Open Sci</source>. <year>2017</year>;<volume>4</volume>(<issue>1</issue>):<elocation-id>160696</elocation-id>. doi:<pub-id pub-id-type="doi">10.1098/rsos.160696</pub-id><pub-id pub-id-type="pmid">28280572</pub-id><pub-id pub-id-type="pmcid">PMC5319338</pub-id></mixed-citation></ref><ref id="alz70603-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="alz70603-cite-0060"><string-name name-style="western"><surname>Shih</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Tu</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>TY</given-names></string-name>, et&#160;al. <article-title>TDP&#8208;43 interacts with amyloid&#8208;beta, inhibits fibrillization, and worsens pathology in a model of Alzheimer's disease</article-title>. <source>Nat Commun</source>. <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>5950</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-020-19786-7</pub-id><pub-id pub-id-type="pmid">33230138</pub-id><pub-id pub-id-type="pmcid">PMC7683652</pub-id></mixed-citation></ref><ref id="alz70603-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="alz70603-cite-0061"><string-name name-style="western"><surname>Dercksen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kulik</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Mienie</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Reinecke</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Wanders</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Duran</surname><given-names>M</given-names></string-name>. <article-title>Polyunsaturated fatty acid status in treated isovaleric acidemia patients</article-title>. <source>Eur J Clin Nutr</source>. <year>2016</year>;<volume>70</volume>(<issue>10</issue>):<fpage>1123</fpage>&#8208;<lpage>1126</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ejcn.2016.100</pub-id><pub-id pub-id-type="pmid">27329611</pub-id></mixed-citation></ref><ref id="alz70603-bib-0061"><label>61</label><mixed-citation publication-type="book" id="alz70603-cite-0062"><string-name name-style="western"><surname>Johnson</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>LA</given-names></string-name>. <part-title>Homeostasis of Lipid Metabolism in Disorders of the Brain</part-title>. In: <source>Encyclopedia of Behavioral Neuroscience</source>. Vols <volume>1&#8211;3</volume>. <edition>2nd</edition> ed. <publisher-name>Elsevier</publisher-name>; <year>2021</year>:V1&#8208;372&#8208;V1&#8208;382.</mixed-citation></ref><ref id="alz70603-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="alz70603-cite-0063"><string-name name-style="western"><surname>Quehenberger</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Armando</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>AH</given-names></string-name>, et&#160;al. <article-title>Lipidomics reveals a remarkable diversity of lipids in human plasma</article-title>. <source>J Lipid Res</source>. <year>2010</year>;<volume>51</volume>(<issue>11</issue>):<fpage>3299</fpage>&#8208;<lpage>3305</lpage>. doi:<pub-id pub-id-type="doi">10.1194/jlr.M009449</pub-id><pub-id pub-id-type="pmid">20671299</pub-id><pub-id pub-id-type="pmcid">PMC2952570</pub-id></mixed-citation></ref><ref id="alz70603-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="alz70603-cite-0064"><string-name name-style="western"><surname>Wishart</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Tzur</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Knox</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>HMDB: the Human Metabolome Database</article-title>. <source>Nucleic Acids Res</source>. <year>2007</year>;<volume>35</volume>(<issue>Database issue</issue>):<fpage>D521</fpage>&#8208;<lpage>6</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkl923</pub-id><pub-id pub-id-type="pmid">17202168</pub-id><pub-id pub-id-type="pmcid">PMC1899095</pub-id></mixed-citation></ref><ref id="alz70603-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="alz70603-cite-0065"><string-name name-style="western"><surname>Wishart</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Oler</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>HMDB 5.0: the Human Metabolome Database for 2022</article-title>. <source>Nucleic Acids Res</source>. <year>2022</year>;<volume>50</volume>(<issue>D1</issue>):<fpage>D622</fpage>&#8208;<lpage>D631</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkab1062</pub-id><pub-id pub-id-type="pmid">34986597</pub-id><pub-id pub-id-type="pmcid">PMC8728138</pub-id></mixed-citation></ref><ref id="alz70603-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="alz70603-cite-0066"><string-name name-style="western"><surname>Ilcol</surname><given-names>YO</given-names></string-name>, <string-name name-style="western"><surname>Ozbek</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hamurtekin</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ulus</surname><given-names>IH</given-names></string-name>. <article-title>Choline status in newborns, infants, children, breast&#8208;feeding women, breast&#8208;fed infants and human breast milk</article-title>. <source>J Nutr Biochem</source>. <year>2005</year>;<volume>16</volume>(<issue>8</issue>):<fpage>489</fpage>&#8208;<lpage>499</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jnutbio.2005.01.011</pub-id><pub-id pub-id-type="pmid">16043031</pub-id></mixed-citation></ref><ref id="alz70603-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="alz70603-cite-0067"><string-name name-style="western"><surname>Mandal</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Chaudhary</surname><given-names>KK</given-names></string-name>, et&#160;al. <article-title>Multi&#8208;platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update</article-title>. <source>Genome Med</source>. <year>2012</year>;<volume>4</volume>(<issue>4</issue>):<fpage>38</fpage>. doi:<pub-id pub-id-type="doi">10.1186/gm337</pub-id><pub-id pub-id-type="pmid">22546835</pub-id><pub-id pub-id-type="pmcid">PMC3446266</pub-id></mixed-citation></ref><ref id="alz70603-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="alz70603-cite-0068"><string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Palavicini</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>. <article-title>A lipidomics atlas of selected sphingolipids in multiple mouse nervous system regions</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>(<issue>21</issue>):<elocation-id>11358</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/ijms222111358</pub-id><pub-id pub-id-type="pmid">34768790</pub-id><pub-id pub-id-type="pmcid">PMC8583963</pub-id></mixed-citation></ref><ref id="alz70603-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="alz70603-cite-0069"><string-name name-style="western"><surname>Farooqui</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Horrocks</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Farooqui</surname><given-names>T</given-names></string-name>. <article-title>Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders</article-title>. <source>Chem Phys Lipids</source>. <year>2000</year>;<volume>106</volume>(<issue>1</issue>):<fpage>1</fpage>&#8208;<lpage>29</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0009-3084(00)00128-6</pub-id><pub-id pub-id-type="pmid">10878232</pub-id></mixed-citation></ref><ref id="alz70603-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="alz70603-cite-0070"><string-name name-style="western"><surname>Kurano</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Saito</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Uranbileg</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Modulations of bioactive lipids and their receptors in postmortem Alzheimer's disease brains</article-title>. <source>Front Aging Neurosci</source>. <year>2022</year>;<volume>14</volume>:<elocation-id>1066578</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2022.1066578</pub-id><pub-id pub-id-type="pmid">36570536</pub-id><pub-id pub-id-type="pmcid">PMC9780287</pub-id></mixed-citation></ref><ref id="alz70603-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="alz70603-cite-0071"><string-name name-style="western"><surname>Ryan</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Whitehead</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Swayne</surname><given-names>LA</given-names></string-name>, et&#160;al. <article-title>Amyloid&#8208;beta42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2009</year>;<volume>106</volume>(<issue>49</issue>):<fpage>20936</fpage>&#8208;<lpage>20941</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0905654106</pub-id><pub-id pub-id-type="pmid">19926863</pub-id><pub-id pub-id-type="pmcid">PMC2791600</pub-id></mixed-citation></ref><ref id="alz70603-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="alz70603-cite-0072"><string-name name-style="western"><surname>Kalecky</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>German</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Montillo</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Bottiglieri</surname><given-names>T</given-names></string-name>. <article-title>Targeted metabolomic analysis in alzheimer's disease plasma and brain tissue in non&#8208;hispanic whites</article-title>. <source>J Alzheimers Dis</source>. <year>2022</year>;<volume>86</volume>(<issue>4</issue>):<fpage>1875</fpage>&#8208;<lpage>1895</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-215448</pub-id><pub-id pub-id-type="pmid">35253754</pub-id><pub-id pub-id-type="pmcid">PMC9108583</pub-id></mixed-citation></ref><ref id="alz70603-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="alz70603-cite-0073"><string-name name-style="western"><surname>Sabogal&#8208;Guaqueta</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Arias&#8208;Londono</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Gutierrez&#8208;Vargas</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Common disbalance in the brain parenchyma of dementias: phospholipid profile analysis between CADASIL and sporadic Alzheimer's disease</article-title>. <source>Biochim Biophys Acta Mol Basis Dis</source>. <year>2020</year>;<volume>1866</volume>(<issue>8</issue>):<elocation-id>165797</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.bbadis.2020.165797</pub-id><pub-id pub-id-type="pmid">32302650</pub-id></mixed-citation></ref><ref id="alz70603-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="alz70603-cite-0074"><string-name name-style="western"><surname>Bahado&#8208;Singh</surname><given-names>RO</given-names></string-name>, <string-name name-style="western"><surname>Ertl</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mandal</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Metabolomic prediction of fetal congenital heart defect in the first trimester</article-title>. <source>Am J Obstet Gynecol</source>. <year>2014</year>;<volume>211</volume>(<issue>3</issue>):<fpage>240</fpage>. e1&#8208;e14. doi:<pub-id pub-id-type="doi">10.1016/j.ajog.2014.03.056</pub-id><pub-id pub-id-type="pmid">24704061</pub-id></mixed-citation></ref><ref id="alz70603-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="alz70603-cite-0075"><string-name name-style="western"><surname>Psychogios</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hau</surname><given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>The human serum metabolome</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>(<issue>2</issue>):<elocation-id>e16957</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0016957</pub-id><pub-id pub-id-type="pmid">21359215</pub-id><pub-id pub-id-type="pmcid">PMC3040193</pub-id></mixed-citation></ref><ref id="alz70603-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="alz70603-cite-0076"><string-name name-style="western"><surname>Fu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Guy</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Chapman</surname><given-names>NM</given-names></string-name>, et&#160;al. <article-title>Metabolic control of T(FH) cells and humoral immunity by phosphatidylethanolamine</article-title>. <source>Nature</source>. <year>2021</year>;<volume>595</volume>(<issue>7869</issue>):<fpage>724</fpage>&#8208;<lpage>729</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-021-03692-z</pub-id><pub-id pub-id-type="pmid">34234346</pub-id><pub-id pub-id-type="pmcid">PMC8448202</pub-id></mixed-citation></ref><ref id="alz70603-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="alz70603-cite-0077"><string-name name-style="western"><surname>Nesic</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Guix</surname><given-names>FX</given-names></string-name>, <string-name name-style="western"><surname>Vennekens</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Alterations in phosphatidylethanolamine levels affect the generation of Abeta</article-title>. <source>Aging Cell</source>. <year>2012</year>;<volume>11</volume>(<issue>1</issue>):<fpage>63</fpage>&#8208;<lpage>72</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1474-9726.2011.00760.x</pub-id><pub-id pub-id-type="pmid">22023223</pub-id></mixed-citation></ref><ref id="alz70603-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="alz70603-cite-0078"><string-name name-style="western"><surname>Calzada</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Onguka</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Claypool</surname><given-names>SM</given-names></string-name>. <article-title>Phosphatidylethanolamine metabolism in health and disease</article-title>. <source>Int Rev Cell Mol Biol</source>. <year>2016</year>;<volume>321</volume>:<fpage>29</fpage>&#8208;<lpage>88</lpage>. doi:<pub-id pub-id-type="doi">10.1016/bs.ircmb.2015.10.001</pub-id><pub-id pub-id-type="pmid">26811286</pub-id><pub-id pub-id-type="pmcid">PMC4778737</pub-id></mixed-citation></ref><ref id="alz70603-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="alz70603-cite-0079"><string-name name-style="western"><surname>Kuczynski</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Reo</surname><given-names>NV</given-names></string-name>. <article-title>Evidence that plasmalogen is protective against oxidative stress in the rat brain</article-title>. <source>Neurochem Res</source>. <year>2006</year>;<volume>31</volume>(<issue>5</issue>):<fpage>639</fpage>&#8208;<lpage>656</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11064-006-9061-7</pub-id><pub-id pub-id-type="pmid">16770735</pub-id></mixed-citation></ref><ref id="alz70603-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="alz70603-cite-0080"><string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>. <article-title>Lipidomics for studying metabolism</article-title>. <source>Nat Rev Endocrinol</source>. <year>2016</year>;<volume>12</volume>(<issue>11</issue>):<fpage>668</fpage>&#8208;<lpage>679</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrendo.2016.98</pub-id><pub-id pub-id-type="pmid">27469345</pub-id></mixed-citation></ref><ref id="alz70603-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="alz70603-cite-0081"><string-name name-style="western"><surname>Cipolla</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Lodhi</surname><given-names>IJ</given-names></string-name>. <article-title>Peroxisomal dysfunction in age&#8208;related diseases</article-title>. <source>Trends Endocrinol Metab</source>. <year>2017</year>;<volume>28</volume>(<issue>4</issue>):<fpage>297</fpage>&#8208;<lpage>308</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tem.2016.12.003</pub-id><pub-id pub-id-type="pmid">28063767</pub-id><pub-id pub-id-type="pmcid">PMC5366081</pub-id></mixed-citation></ref><ref id="alz70603-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="alz70603-cite-0082"><string-name name-style="western"><surname>Han</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>McKeel</surname><given-names>DW</given-names></string-name>, Jr. <article-title>Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry</article-title>. <source>J Neurochem</source>. <year>2001</year>;<volume>77</volume>(<issue>4</issue>):<fpage>1168</fpage>&#8208;<lpage>1180</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1471-4159.2001.00332.x</pub-id><pub-id pub-id-type="pmid">11359882</pub-id></mixed-citation></ref><ref id="alz70603-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="alz70603-cite-0083"><string-name name-style="western"><surname>Reilly</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Tsai</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Ericsson</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Oblak</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>H</given-names></string-name>. <article-title>Metabolic defects caused by high&#8208;fat diet modify disease risk through inflammatory and amyloidogenic pathways in a mouse model of alzheimer's disease</article-title>. <source>Nutrients</source>. <year>2020</year>;<volume>12</volume>(<issue>10</issue>):<fpage>2977</fpage>. doi:<pub-id pub-id-type="doi">10.3390/nu12102977</pub-id><pub-id pub-id-type="pmid">33003412</pub-id><pub-id pub-id-type="pmcid">PMC7600118</pub-id></mixed-citation></ref><ref id="alz70603-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="alz70603-cite-0084"><string-name name-style="western"><surname>Lin</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hasegawa</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Takane</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Koibuchi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kim&#8208;Mitsuyama</surname><given-names>S</given-names></string-name>. <article-title>High&#8208;fat&#8208;diet intake enhances cerebral amyloid angiopathy and cognitive impairment in a mouse model of alzheimer's disease, independently of metabolic disorders</article-title>. <source>J Am Heart Assoc</source>. <year>2016</year>;<volume>5</volume>(<issue>6</issue>):<elocation-id>e003154</elocation-id>. doi:<pub-id pub-id-type="doi">10.1161/JAHA.115.003154</pub-id><pub-id pub-id-type="pmid">27412896</pub-id><pub-id pub-id-type="pmcid">PMC4937262</pub-id></mixed-citation></ref><ref id="alz70603-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="alz70603-cite-0085"><string-name name-style="western"><surname>Medrano&#8208;Jimenez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Jimenez&#8208;Ferrer Carrillo</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Pedraza&#8208;Escalona</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Malva parviflora extract ameliorates the deleterious effects of a high fat diet on the cognitive deficit in a mouse model of Alzheimer's disease by restoring microglial function via a PPAR&#8208;gamma&#8208;dependent mechanism</article-title>. <source>J Neuroinflammation</source>. <year>2019</year>;<volume>16</volume>(<issue>1</issue>):<fpage>143</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12974-019-1515-3</pub-id><pub-id pub-id-type="pmid">31291963</pub-id><pub-id pub-id-type="pmcid">PMC6617588</pub-id></mixed-citation></ref><ref id="alz70603-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="alz70603-cite-0086"><string-name name-style="western"><surname>Ding</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Isolating lipid droplets from multiple species</article-title>. <source>Nat Protoc</source>. <year>2013</year>;<volume>8</volume>(<issue>1</issue>):<fpage>43</fpage>&#8208;<lpage>51</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nprot.2012.142</pub-id><pub-id pub-id-type="pmid">23222457</pub-id></mixed-citation></ref><ref id="alz70603-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="alz70603-cite-0087"><string-name name-style="western"><surname>Blandin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dugail</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Hilairet</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Lipidomic analysis of adipose&#8208;derived extracellular vesicles reveals specific EV lipid sorting informative of the obesity metabolic state</article-title>. <source>Cell Rep</source>. <year>2023</year>;<volume>42</volume>(<issue>3</issue>):<elocation-id>112169</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.celrep.2023.112169</pub-id><pub-id pub-id-type="pmid">36862553</pub-id></mixed-citation></ref><ref id="alz70603-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="alz70603-cite-0088"><string-name name-style="western"><surname>Frisardi</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Panza</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Seripa</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Farooqui</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Farooqui</surname><given-names>AA</given-names></string-name>. <article-title>Glycerophospholipids and glycerophospholipid&#8208;derived lipid mediators: a complex meshwork in Alzheimer's disease pathology</article-title>. <source>Prog Lipid Res</source>. <year>2011</year>;<volume>50</volume>(<issue>4</issue>):<fpage>313</fpage>&#8208;<lpage>330</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.plipres.2011.06.001</pub-id><pub-id pub-id-type="pmid">21703303</pub-id></mixed-citation></ref><ref id="alz70603-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="alz70603-cite-0089"><string-name name-style="western"><surname>Huang</surname><given-names>HX</given-names></string-name>, <string-name name-style="western"><surname>Inglese</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Mass spectrometry imaging highlights dynamic patterns of lipid co&#8208;expression with Abeta plaques in mouse and human brains</article-title>. <source>J Neurochem</source>. <year>2024</year>;<volume>168</volume>(<issue>7</issue>):<fpage>1193</fpage>&#8208;<lpage>1214</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jnc.16042</pub-id><pub-id pub-id-type="pmid">38372586</pub-id></mixed-citation></ref><ref id="alz70603-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="alz70603-cite-0090"><string-name name-style="western"><surname>Jesko</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Stepien</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lukiw</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Strosznajder</surname><given-names>RP</given-names></string-name>. <article-title>The cross&#8208;talk between sphingolipids and insulin&#8208;like growth factor signaling: significance for aging and neurodegeneration</article-title>. <source>Mol Neurobiol</source>. <year>2019</year>;<volume>56</volume>(<issue>5</issue>):<fpage>3501</fpage>&#8208;<lpage>3521</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12035-018-1286-3</pub-id><pub-id pub-id-type="pmid">30140974</pub-id><pub-id pub-id-type="pmcid">PMC6476865</pub-id></mixed-citation></ref><ref id="alz70603-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="alz70603-cite-0091"><string-name name-style="western"><surname>Czubowicz</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jesko</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wencel</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lukiw</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Strosznajder</surname><given-names>RP</given-names></string-name>. <article-title>The role of ceramide and sphingosine&#8208;1&#8208;phosphate in Alzheimer's disease and other neurodegenerative disorders</article-title>. <source>Mol Neurobiol</source>. <year>2019</year>;<volume>56</volume>(<issue>8</issue>):<fpage>5436</fpage>&#8208;<lpage>5455</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12035-018-1448-3</pub-id><pub-id pub-id-type="pmid">30612333</pub-id><pub-id pub-id-type="pmcid">PMC6614129</pub-id></mixed-citation></ref><ref id="alz70603-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="alz70603-cite-0092"><string-name name-style="western"><surname>Codini</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Garcia&#8208;Gil</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Albi</surname><given-names>E</given-names></string-name>. <article-title>Cholesterol and sphingolipid enriched lipid rafts as therapeutic targets in cancer</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>(<issue>2</issue>):<fpage>726</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms22020726</pub-id><pub-id pub-id-type="pmid">33450869</pub-id><pub-id pub-id-type="pmcid">PMC7828315</pub-id></mixed-citation></ref><ref id="alz70603-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="alz70603-cite-0093"><string-name name-style="western"><surname>Zhaliazka</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Matveyenka</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kurouski</surname><given-names>D</given-names></string-name>. <article-title>Lipids uniquely alter the secondary structure and toxicity of amyloid beta 1&#8208;42 aggregates</article-title>. <source>FEBS J</source>. <year>2023</year>;<volume>290</volume>(<issue>12</issue>):<fpage>3203</fpage>&#8208;<lpage>3220</lpage>. doi:<pub-id pub-id-type="doi">10.1111/febs.16738</pub-id><pub-id pub-id-type="pmid">36705524</pub-id><pub-id pub-id-type="pmcid">PMC10389563</pub-id></mixed-citation></ref><ref id="alz70603-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="alz70603-cite-0094"><string-name name-style="western"><surname>Cohen</surname><given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Linse</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Luheshi</surname><given-names>LM</given-names></string-name>, et&#160;al. <article-title>Proliferation of amyloid&#8208;beta42 aggregates occurs through a secondary nucleation mechanism</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2013</year>;<volume>110</volume>(<issue>24</issue>):<fpage>9758</fpage>&#8208;<lpage>9763</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1218402110</pub-id><pub-id pub-id-type="pmid">23703910</pub-id><pub-id pub-id-type="pmcid">PMC3683769</pub-id></mixed-citation></ref><ref id="alz70603-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="alz70603-cite-0095"><string-name name-style="western"><surname>Bera</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Korshavn</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Kar</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Ramamoorthy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bhunia</surname><given-names>A</given-names></string-name>. <article-title>Biophysical insights into the membrane interaction of the core amyloid&#8208;forming Abeta40 fragment K16&#8208;K28 and its role in the pathogenesis of Alzheimer's disease</article-title>. <source>Phys Chem Chem Phys</source>. <year>2016</year>;<volume>18</volume>(<issue>25</issue>):<fpage>16890</fpage>&#8208;<lpage>16901</lpage>. doi:<pub-id pub-id-type="doi">10.1039/c6cp02023b</pub-id><pub-id pub-id-type="pmid">27282693</pub-id></mixed-citation></ref><ref id="alz70603-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="alz70603-cite-0096"><string-name name-style="western"><surname>Gui</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, et&#160;al. <article-title>Liquid&#8208;liquid phase separation of amyloid&#8208;beta oligomers modulates amyloid fibrils formation</article-title>. <source>The Journal of biological chemistry</source>. <year>2023</year>;<volume>299</volume>(<issue>3</issue>):<elocation-id>102926</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.jbc.2023.102926</pub-id><pub-id pub-id-type="pmid">36682493</pub-id><pub-id pub-id-type="pmcid">PMC9974441</pub-id></mixed-citation></ref><ref id="alz70603-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="alz70603-cite-0097"><string-name name-style="western"><surname>Alberti</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hyman</surname><given-names>AA</given-names></string-name>. <article-title>Biomolecular condensates at the nexus of cellular stress, protein aggregation disease and ageing</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2021</year>;<volume>22</volume>(<issue>3</issue>):<fpage>196</fpage>&#8208;<lpage>213</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41580-020-00326-6</pub-id><pub-id pub-id-type="pmid">33510441</pub-id></mixed-citation></ref><ref id="alz70603-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="alz70603-cite-0098"><string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Mehler</surname><given-names>EL</given-names></string-name>. <article-title>Simulation of molecular crowding effects on an Alzheimer's beta&#8208;amyloid peptide</article-title>. <source>Cell Biochem Biophys</source>. <year>2006</year>;<volume>46</volume>(<issue>2</issue>):<fpage>123</fpage>&#8208;<lpage>141</lpage>. doi:<pub-id pub-id-type="doi">10.1385/cbb:46:2:123</pub-id><pub-id pub-id-type="pmid">17012754</pub-id></mixed-citation></ref><ref id="alz70603-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="alz70603-cite-0099"><string-name name-style="western"><surname>Niu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>. <article-title>Interactions between amyloid beta peptide and lipid membranes</article-title>. <source>Biochim Biophys Acta Biomembr</source>. <year>2018</year>;<volume>1860</volume>(<issue>9</issue>):<fpage>1663</fpage>&#8208;<lpage>1669</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbamem.2018.04.004</pub-id><pub-id pub-id-type="pmid">29679539</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Pharm Sin B</journal-id><journal-id journal-id-type="iso-abbrev">Acta Pharm Sin B</journal-id><journal-id journal-id-type="pmc-domain-id">2814</journal-id><journal-id journal-id-type="pmc-domain">apsb</journal-id><journal-title-group><journal-title>Acta Pharmaceutica Sinica. B</journal-title></journal-title-group><issn pub-type="ppub">2211-3835</issn><issn pub-type="epub">2211-3843</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12491700</article-id><article-id pub-id-type="pmcid-ver">PMC12491700.1</article-id><article-id pub-id-type="pmcaid">12491700</article-id><article-id pub-id-type="pmcaiid">12491700</article-id><article-id pub-id-type="pmid">41049755</article-id><article-id pub-id-type="doi">10.1016/j.apsb.2025.07.018</article-id><article-id pub-id-type="pii">S2211-3835(25)00493-9</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Tools</subject></subj-group></article-categories><title-group><article-title>A computational medicine framework integrating multi-omics, systems biology, and artificial neural networks for Alzheimer's disease therapeutic discovery</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Yang</surname><given-names initials="Y">Yisheng</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">&#8224;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Diao</surname><given-names initials="Y">Yizhu</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">&#8224;</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Jiang</surname><given-names initials="L">Lulu</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">&#8224;</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Li</surname><given-names initials="F">Fanlu</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Chen</surname><given-names initials="L">Liye</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Ni</surname><given-names initials="M">Ming</given-names></name><email>gendianqing@163.com</email><xref rid="aff5" ref-type="aff">e</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zheng</given-names></name><email>biowz@mail.ustc.edu.cn</email><xref rid="aff6" ref-type="aff">f</xref><xref rid="aff7" ref-type="aff">g</xref><xref rid="aff8" ref-type="aff">h</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Fang</surname><given-names initials="H">Hai</given-names></name><email>fh12355@rjh.com.cn</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="aff1"><label>a</label>Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China</aff><aff id="aff2"><label>b</label>Translational Health Sciences, University of Bristol, Bristol BS1 3NY, UK</aff><aff id="aff3"><label>c</label>Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China</aff><aff id="aff4"><label>d</label>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK</aff><aff id="aff5"><label>e</label>Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China</aff><aff id="aff6"><label>f</label>Jinfeng Laboratory, Chongqing 401329, China</aff><aff id="aff7"><label>g</label>Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma and Chemical Poisoning, Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China</aff><aff id="aff8"><label>h</label>Bio-Med Informatics Research Center &amp; Clinical Research Center, The Second Affiliated Hospital, Army Medical University, Chongqing 400037, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding authors. <email>gendianqing@163.com</email><email>biowz@mail.ustc.edu.cn</email><email>fh12355@rjh.com.cn</email></corresp><fn id="fn1"><label>&#8224;</label><p id="ntpara0020">These authors made equal contributions to this work.</p></fn></author-notes><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>7</month><year>2025</year></pub-date><volume>15</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498229</issue-id><fpage>4411</fpage><lpage>4426</lpage><history><date date-type="received"><day>6</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>27</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>The translation of genetic findings from genome-wide association studies into actionable therapeutics persists as a critical challenge in Alzheimer's disease (AD) research. Here, we present PI4AD, a computational medicine framework that integrates multi-omics data, systems biology, and artificial neural networks for therapeutic discovery. This framework leverages multi-omic and network evidence to deliver three core functionalities: clinical target prioritisation; self-organising prioritisation map construction, distinguishing AD-specific targets from those linked to neuropsychiatric disorders; and pathway crosstalk-informed therapeutic discovery. PI4AD successfully recovers clinically validated targets like <italic toggle="yes">APP</italic> and <italic toggle="yes">ESR1</italic>, confirming its prioritisation efficacy. Its artificial neural network component identifies disease-specific molecular signatures, while pathway crosstalk analysis reveals critical nodal genes (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., <italic toggle="yes">HRAS</italic> and <italic toggle="yes">MAPK1</italic>), drug repurposing candidates, and clinically relevant network modules. By validating targets, elucidating disease-specific therapeutic potentials, and exploring crosstalk mechanisms, PI4AD bridges genetic insights with pathway-level biology, establishing a systems genetics foundation for rational therapeutic development. Importantly, its emphasis on Ras-centred pathways&#8212;implicated in synaptic dysfunction and neuroinflammation&#8212;provides a strategy to disrupt AD progression, complementing conventional amyloid/tau-focused paradigms, with the future potential to redefine treatment strategies in conjunction with mRNA therapeutics and thereby advance translational medicine in neurodegeneration.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p>This framework establishes a systems genetics foundation for drug target discovery, guides rational repurposing, and advances translational medicine strategies for AD, with the potential to significantly impact neurodegeneration research.<fig id="undfig1" position="anchor" orientation="portrait"><alt-text id="alttext0010">Image 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Key words</title><kwd>Alzheimer's disease</kwd><kwd>Systems genetics</kwd><kwd>Therapeutic discovery</kwd><kwd>Computational medicine</kwd><kwd>Artificial neural network</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">The field of neurodegenerative disease research has continually evolved, with Alzheimer's disease (AD) representing a critical focus due to its profound impact on the ageing population. AD, a progressive neurodegenerative disorder, manifests as cognitive decline, memory impairment, and behavioural changes, severely compromising patient health and quality of life<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref>. As the leading cause of dementia, it poses a complex challenge due to the extensive neuropathological changes<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref>.</p><p id="p0015">Despite advances in understanding AD pathogenesis, drug discovery and clinical trial design remain challenging. Patient heterogeneity&#8212;variation in symptoms, disease trajectories, and genetic backgrounds&#8212;complicates the development of universal therapies. This diversity results in individuals exhibiting distinct symptom profiles and progression rates, rendering one-size-fits-all treatments ineffective. Furthermore, the prolonged disease course, coupled with the challenge of ensuring drugs effectively cross the blood&#8211;brain barrier (a semipermeable membrane restricting substance entry into brain tissue)&#8212;though potentially overcome by lipid nanoparticle-mediated mRNA delivery<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref>&#8212;complicates these hurdles further. Consequently, AD drug development is costly and time-consuming, with no disease-modifying therapies yet available<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref>. Current treatments, such as aducanumab and lecanemab, provide only limited symptomatic relief, underscoring the urgent need for novel therapeutic strategies<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref>.</p><p id="p0020">In response to these challenges, drug repurposing and combination therapies have emerged as promising avenues. Repurposing existing drugs to modulate AD-related pathways or symptoms holds potential to accelerate therapeutic discovery<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref>. Similarly, combination therapies&#8212;employing agents with complementary mechanisms&#8212;may enhance treatment efficacy<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref>. For instance, anti-ischemic stroke candidate drugs demonstrate dual neuroprotective properties and improve cerebral blood flow<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref>, a mechanism relevant to neuronal activity's role in glymphatic clearance (a process that removes brain waste and is implicated in reducing AD risk)<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref>. TREM2-targeting antisense oligonucleotides exemplify this approach, enhancing microglial phagocytosis while suppressing chronic activation and neuroinflammation, thereby improving AD pathology and cognition<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref>.</p><p id="p0025">Building on these therapeutic strategies, advances in bioinformatics have catalysed avenues for drug discovery and repurposing in AD. Computational methods now integrate multi-omics data and systems biology to identify therapeutic targets. For instance, Duncan et al.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> utilised genome-wide association study (GWAS) and single-nucleus RNA sequencing data to identify cell-type-specific associations in schizophrenia and related psychiatric disorders (including AD), revealing potential therapeutic targets. Siavelis et al.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> combined multiple drug repurposing tools to prioritise anti-AD candidates, while Taubes et al.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> established apolipoprotein E (<italic toggle="yes">APOE</italic>) genotype-dependent transcriptomic signatures for screening <italic toggle="yes">APOE</italic>-related AD drugs. Zhou et al.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> further demonstrated multi-omics utility in AD biomarker discovery.</p><p id="p0030">The advent of artificial intelligence (AI) has further transformed AD drug discovery. AI techniques, including artificial neural networks (ANNs), analyse complex datasets more effectively than traditional methods<xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, enabling applications such as network-based deep learning and graph neural networks for AD target identifications<xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>. However, a critical gap persists: existing approaches lack systematic integration of multi-omics data with systems biology to prioritise targets and repurpose drugs. Recent progress in ANNs offers new opportunities; neuroimaging-centric models, such as prior-guided adversarial learning with hypergraph (PALH)<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> and diffusion-based graph contrastive learning (DGCL)<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref>, excel in biomarker discovery using structural and functional imaging data. However, their focus on neuroimaging contrasts with the need for multi-omics integration in therapeutic development.</p><p id="p0035">To bridge this gap, we present the Priority Index solution for AD (PI4AD; <xref rid="fig1" ref-type="fig">Fig. 1</xref>), a computational medicine tool that integrates multi-omics data, systems biology, and ANNs. Guided by a multi-omics-led and systems biology-driven principle, PI4AD addresses three objectives: (i) <italic toggle="yes">clinical target prioritisation</italic>&#8212;validating prioritisation efficacy by recovering clinical proof-of-concept targets; (ii) <italic toggle="yes">disease-specific targeting</italic>&#8212;employing ANNs to distinguish AD from neuropsychiatric disorders <italic toggle="yes">via</italic> self-organising maps; and (iii) <italic toggle="yes">pathway crosstalk analysis</italic>&#8212;identifying critical nodal genes (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., <italic toggle="yes">HRAS</italic> and <italic toggle="yes">MAPK1</italic>) and repurposable drugs through systems biology. By focusing on Ras-centred pathways&#8212;implicated in synaptic dysfunction and neuroinflammation&#8212;PI4AD complements amyloid/tau-centric approaches, offering an alternative strategy to disrupt AD progression. This framework establishes a systems genetics foundation for drug target discovery, guides rational repurposing, and advances translational medicine strategies for AD, with the potential to significantly impact neurodegeneration research.<fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Schematic overview of the PI4AD framework for Alzheimer's disease (AD) therapeutic discovery. PI4AD integrates multi-omics data, network analysis, and prioritisation into three modules. The <italic toggle="yes">clinical target prioritisation</italic> module processes AD genome-wide association study (GWAS) summary statistics, leveraging multi-omic evidence (such as QTL and PCHi-C) and network interactions to identify core and peripheral genes, prioritised <italic toggle="yes">via</italic> a meta-analysis-like method and optimised random walk with restart (RWR) parameters. The <italic toggle="yes">self-organising prioritisation map</italic> module employs an artificial neural network (ANN) to cluster genes into topology-preserving hexagons, enabling disease-specific pathway enrichment analysis. The <italic toggle="yes">pathway crosstalk</italic> module utilises the prize-collecting Steiner tree (PCST) algorithm to identify interconnected high-priority genes, followed by therapeutic discovery steps such as removal analysis, drug repurposing, and modular analysis. The landing frontpage of the PI4AD portal hosting the resultant resource is illustrated beneath. Abbreviations (sorted alphabetically): AD, Alzheimer's disease; ANN, artificial neural network; GWAS, genome-wide association study; PCST, prize-collecting Steiner tree; PCHi-C, promoter capture Hi-C; QTL, quantitative trait loci; RWR, random walk with restart; SNP, single nucleotide polymorphism.</p></caption><alt-text id="alttext0020">Figure 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec2"><label>2</label><title>Materials and methods</title><sec id="sec2.1"><label>2.1</label><title>GWAS summary-level data</title><p id="p0040">European population GWAS summary-level data for AD<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref> were obtained from the NHGRI-EBI GWAS Catalog<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> using the Experimental Factor Ontology term &#8216;MONDO:0004975&#8217;. Lead SNPs (<italic toggle="yes">P</italic>-value &lt;5 &#215; 10<sup>&#8722;8</sup>) and linkage disequilibrium (LD) SNPs (<italic toggle="yes">R</italic><sup>2</sup> &#8805; 0.8) were extracted. SNP scoring (Eq. <xref rid="fd1" ref-type="disp-formula">(1)</xref>) integrated GWAS <italic toggle="yes">P</italic>-values, significance thresholds, and LD strength (<italic toggle="yes">R</italic><sup>2</sup>):<disp-formula id="fd1"><label>(1)</label><mml:math id="M1" altimg="si1.svg" alttext="Equation 1."><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mtext>SNP</mml:mtext></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:msup><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:msub><mml:mi>log</mml:mi><mml:mn>10</mml:mn></mml:msub><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">&#8722;</mml:mo><mml:msub><mml:mrow><mml:mspace width="0.25em"/><mml:mi>P</mml:mi></mml:mrow><mml:mtext>SNP</mml:mtext></mml:msub></mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>SNP</mml:mtext></mml:msub></mml:mfrac><mml:mo linebreak="badbreak">&#8722;</mml:mo><mml:msub><mml:mi>log</mml:mi><mml:mn>10</mml:mn></mml:msub><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">&#8722;</mml:mo><mml:mn>5</mml:mn><mml:mo linebreak="badbreak">&#215;</mml:mo><mml:msup><mml:mrow><mml:mspace width="0.25em"/><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>8</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>5</mml:mn><mml:mo linebreak="badbreak">&#215;</mml:mo><mml:msup><mml:mrow><mml:mspace width="0.25em"/><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>8</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>Where <inline-formula><mml:math id="M2" altimg="si2.svg"><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mtext>SNP</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M3" altimg="si3.svg"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mtext>SNP</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> denote the SNP score and <italic toggle="yes">P</italic>-value, respectively.</p></sec><sec id="sec2.2"><label>2.2</label><title>Core and peripheral genes identified to prepare the gene-predictor matrix</title><p id="p0045">Core genes were identified using genomic proximity (Eq. <xref rid="fd2" ref-type="disp-formula">(2)</xref>) and quantitative trait locus (QTL) and promoter capture Hi-C (PCHi-C) datasets<xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref>, <xref rid="bib39" ref-type="bibr">39</xref> (Eqs. <xref rid="fd3" ref-type="disp-formula">(3)</xref> and (<xref rid="fd4" ref-type="disp-formula">4</xref>)).<disp-formula id="fd2"><label>(2)</label><mml:math id="M4" altimg="si4.svg" alttext="Equation 2."><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mtext>nearby</mml:mtext><mml:mspace width="0.25em"/><mml:mtext>gene</mml:mtext></mml:mrow></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:munder><mml:mi>max</mml:mi><mml:mrow><mml:mtext>SNP</mml:mtext><mml:mo linebreak="badbreak">&#8712;</mml:mo><mml:mtext>&#937;</mml:mtext></mml:mrow></mml:munder><mml:msub><mml:mi>S</mml:mi><mml:mtext>SNP</mml:mtext></mml:msub></mml:mrow></mml:math></disp-formula>Where <inline-formula><mml:math id="M5" altimg="si5.svg"><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mtext>nearby</mml:mtext><mml:mspace width="0.25em"/><mml:mtext>gene</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> represents the score for nearby genes, <inline-formula><mml:math id="M6" altimg="si2.svg"><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mtext>SNP</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> signifies the SNP score, <italic toggle="yes">&#937;</italic> denotes collections of lead/LD SNPs located within 20 kb of the nearby gene, and max denotes the maximum scoring scheme (keeping the most informative one when multiple SNPs are located within the same genomic region).<disp-formula id="fd3"><label>(3)</label><mml:math id="M7" altimg="si6.svg" alttext="Equation 3."><mml:mrow><mml:mi>x</mml:mi><mml:mo linebreak="badbreak">=</mml:mo><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:msub><mml:mi>log</mml:mi><mml:mn>10</mml:mn></mml:msub><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mtext>SNP</mml:mtext><mml:mo linebreak="badbreak">&#8596;</mml:mo><mml:mtext>Gene</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="fd4"><label>(4)</label><mml:math id="M8" altimg="si7.svg" alttext="Equation 4."><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mtext>QTL</mml:mtext><mml:mspace width="0.25em"/><mml:mtext>gene</mml:mtext></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mtext>or</mml:mtext><mml:mspace width="0.25em"/><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mtext>conformation</mml:mtext><mml:mspace width="0.25em"/><mml:mtext>gene</mml:mtext></mml:mrow></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:munder><mml:mi>max</mml:mi><mml:mrow><mml:mtext>SNP</mml:mtext><mml:mo linebreak="badbreak">&#8712;</mml:mo><mml:mi mathvariant="normal">&#937;</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mtext>SNP</mml:mtext></mml:msub><mml:mo linebreak="badbreak">&#215;</mml:mo><mml:mtext>eCDF</mml:mtext><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>Where <inline-formula><mml:math id="M9" altimg="si8.svg"><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mtext>QTL</mml:mtext><mml:mspace width="0.25em"/><mml:mtext>gene</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> signifies the score for QTL genes, <inline-formula><mml:math id="M10" altimg="si9.svg"><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mtext>conformation</mml:mtext><mml:mspace width="0.25em"/><mml:mtext>gene</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is the score for conformation genes, <inline-formula><mml:math id="M11" altimg="si2.svg"><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mtext>SNP</mml:mtext></mml:msub></mml:mrow></mml:math></inline-formula> is the SNP score, <inline-formula><mml:math id="M12" altimg="si10.svg"><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mtext>SNP</mml:mtext><mml:mo>&#8596;</mml:mo><mml:mtext>Gene</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> denotes the strength or significance level linking an SNP to a gene (that is, the significance level of genetic association with gene expression for an eQTL dataset or protein abundance for a pQTL dataset, and the physical interaction strength with a gene promoter for a PCHi-C dataset), <italic toggle="yes">&#937;</italic> stands for collections of lead/LD SNPs, and <italic toggle="yes">max</italic> denotes the maximum scoring scheme.</p><p id="p0050">Peripheral genes were identified <italic toggle="yes">via</italic> the random walk with restart (RWR) algorithm on protein interaction networks (the STRING database<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref>). The RWR steady-state probability (Eq. <xref rid="fd5" ref-type="disp-formula">(5)</xref>) quantified gene affinity scores (ranging from 0 to 1) to seed core genes:<disp-formula id="fd5"><label>(5)</label><mml:math id="M13" altimg="si11.svg" alttext="Equation 5."><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>P</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mrow><mml:mi>t</mml:mi><mml:mo linebreak="badbreak">+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">&#8722;</mml:mo><mml:mi>&#947;</mml:mi></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>A</mml:mi><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>P</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>t</mml:mi></mml:msub><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>&#947;</mml:mi><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>P</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></disp-formula>Where <inline-formula><mml:math id="M14" altimg="si12.svg"><mml:mrow><mml:mi>&#947;</mml:mi></mml:mrow></mml:math></inline-formula> signifies the restarting probability governing the jump back to a seed node (accordingly, <inline-formula><mml:math id="M15" altimg="si13.svg"><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="goodbreak" linebreakstyle="after">&#8722;</mml:mo><mml:mi>&#947;</mml:mi></mml:mrow></mml:math></inline-formula> is the probability of moving to a neighbour), <italic toggle="yes">A</italic> denotes the normalised Laplacian adjacency matrix associated with the network, <inline-formula><mml:math id="M16" altimg="si14.svg"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>P</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> is the starting probability vector that contains seed gene scores and 0 for non-seed genes, and <inline-formula><mml:math id="M17" altimg="si15.svg"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>P</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>t</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> stands for the probability vector that the walker visits network nodes at iteration <italic toggle="yes">t</italic>. This probability vector signifies the steady state and encapsulates the affinity score of all nodes in the network to the starting seed nodes once stability is achieved.</p><p id="p0055">In the context of each dataset (namely, genomic proximity, QTL, and PCHi-C), the aforementioned process generated a predictor. This predictor encompassed both core and peripheral genes, along with corresponding affinity scores. These affinity scores served as a quantitative measure of the genes&#8217; network connectivity to the seed core genes. It was observed that genes demonstrating greater network connectivity to the seed core genes were assigned higher affinity scores. Typically, seed genes exhibited a higher propensity to receive elevated affinity scores in comparison to non-seed peripheral genes. However, it is important to note that a peripheral gene could also attain a high affinity score if it manifested substantial connectivity to a significant majority, if not all, of the seed genes. Consequently, non-seed peripheral genes with relatively high affinity scores were indicative of genes that were substantially influenced by the network. To summarise, the multi-step scoring protocol, which involved the progression from lead/LD SNPs to core genes and then to peripheral genes, culminated in the formation of a gene-predictor matrix. The rows of this matrix corresponded to genes, incorporating both core and peripheral varieties, while the columns represented predictors that embodied diverse forms of evidence. The matrix incorporated affinity scores, which comprehensively integrated information from both multi-omic and network evidence sources.</p></sec><sec id="sec2.3"><label>2.3</label><title>Clinical proof-of-concept targets</title><p id="p0060">To define clinical proof-of-concept targets, we retrieved information on current therapeutics from the ChEMBL database<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref>. We identified &#8216;clinical proof-of-concept targets&#8217; as therapeutic genes targeted by drugs in development phase III or later for AD. These targets signify substantial evidence of their efficacy in treating the respective disease and were used to evaluate the performance of our target prioritisation methods.</p></sec><sec id="sec2.4"><label>2.4</label><title>Target prioritisation and performance evaluation</title><p id="p0065">We evaluated the performance of our target prioritisation methods by calculating the area under the curve for recovering AD clinical proof-of-concept targets. Leveraging the gene-predictor matrix prepared above, we evaluated various prioritisation schemes for combining predictors, including Fisher's, logistic, order statistic combined methods. For each column-wise predictor in the gene-predictor matrix, we first converted affinity scores into <italic toggle="yes">P</italic>-like values through eCDF based on affinity scores for all genes in this predictor (Eq. <xref rid="fd6" ref-type="disp-formula">(6)</xref>).<disp-formula id="fd6"><label>(6)</label><mml:math id="M18" altimg="si16.svg" alttext="Equation 6."><mml:mrow><mml:msubsup><mml:mi>P</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo linebreak="badbreak">=</mml:mo><mml:mtext>eCDF</mml:mtext><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:msubsup><mml:mtext>AF</mml:mtext><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>Where <inline-formula><mml:math id="M19" altimg="si17.svg"><mml:mrow><mml:msubsup><mml:mtext>AF</mml:mtext><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> denotes the affinity score for the <italic toggle="yes">i</italic>th gene in terms of the <italic toggle="yes">j</italic>th predictor, <inline-formula><mml:math id="M20" altimg="si18.svg"><mml:mrow><mml:msubsup><mml:mi>P</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> is the corresponding converted <italic toggle="yes">P</italic>-value, and eCDF is estimated based on all genes.</p><p id="p0070">Then, for each row-wise gene, we combined these converted <italic toggle="yes">P</italic>-values across predictors using a combined method (see Eqs. <xref rid="fd8" ref-type="disp-formula">(8)</xref>, <xref rid="fd9" ref-type="disp-formula">(9)</xref>, <xref rid="fd10" ref-type="disp-formula">(10)</xref> for the Fisher's combined method, Eqs. <xref rid="fd11" ref-type="disp-formula">(11)</xref>, <xref rid="fd12" ref-type="disp-formula">(12)</xref>, <xref rid="fd13" ref-type="disp-formula">(13)</xref> for the logistic combined method, and Eqs. <xref rid="fd14" ref-type="disp-formula">(14)</xref>, <xref rid="fd15" ref-type="disp-formula">(15)</xref>, <xref rid="fd16" ref-type="disp-formula">(16)</xref> for the order statistic combined method). Finally, we rescaled the combined <italic toggle="yes">P</italic>-value into a priority rating on a scale of 0&#8211;10 (Eq. <xref rid="fd7" ref-type="disp-formula">(7)</xref>).<disp-formula id="fd7"><label>(7)</label><mml:math id="M21" altimg="si19.svg" alttext="Equation 7."><mml:mrow><mml:msub><mml:mi>PR</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:mn>10</mml:mn><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mfrac><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>log</mml:mi><mml:mspace width="0.25em"/><mml:msub><mml:mtext>CP</mml:mtext><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="badbreak">&#8722;</mml:mo><mml:msubsup><mml:mi>MIN</mml:mi><mml:mi>k</mml:mi><mml:mi>K</mml:mi></mml:msubsup><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>log</mml:mi><mml:mspace width="0.25em"/><mml:msub><mml:mtext>CP</mml:mtext><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msubsup><mml:mi>MAX</mml:mi><mml:mi>k</mml:mi><mml:mi>K</mml:mi></mml:msubsup><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>log</mml:mi><mml:mspace width="0.25em"/><mml:msub><mml:mtext>CP</mml:mtext><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="badbreak">&#8722;</mml:mo><mml:msubsup><mml:mi>MIN</mml:mi><mml:mi>k</mml:mi><mml:mi>K</mml:mi></mml:msubsup><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>log</mml:mi><mml:mspace width="0.25em"/><mml:msub><mml:mtext>CP</mml:mtext><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula>Where CP<sub><italic toggle="yes">i</italic></sub> for the combined <italic toggle="yes">P</italic>-value for the <italic toggle="yes">i</italic>th gene (<italic toggle="yes">i</italic>.<italic toggle="yes">e</italic>., CDF valued at <italic toggle="yes">x</italic><sub><italic toggle="yes">i</italic></sub>), and PR<sub><italic toggle="yes">i</italic></sub> for the priority rating for the <italic toggle="yes">i</italic>th gene (out of <italic toggle="yes">K</italic> genes).<list list-type="simple" id="olist0010"><list-item id="o0010"><label>(i)</label><p id="p0075">Target prioritisation based on the Fisher's combined method (Eqs. <xref rid="fd8" ref-type="disp-formula">(8)</xref>, <xref rid="fd9" ref-type="disp-formula">(9)</xref>, <xref rid="fd10" ref-type="disp-formula">(10)</xref>).</p></list-item></list><disp-formula id="fd8"><label>(8)</label><mml:math id="M22" altimg="si20.svg" alttext="Equation 8."><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:mn>2</mml:mn><mml:msubsup><mml:mo>&#8721;</mml:mo><mml:mi>j</mml:mi><mml:mi>J</mml:mi></mml:msubsup><mml:mspace width="0.25em"/><mml:mi>log</mml:mi><mml:mspace width="0.25em"/><mml:msubsup><mml:mi>P</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></disp-formula><disp-formula id="fd9"><label>(9)</label><mml:math id="M23" altimg="si21.svg" alttext="Equation 9."><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mspace width="0.25em"/><mml:mo>&#8764;</mml:mo><mml:mspace width="0.25em"/><mml:msup><mml:mi>&#967;</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>J</mml:mi></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="fd10"><label>(10)</label><mml:math id="M24" altimg="si22.svg" alttext="Equation 10."><mml:mrow><mml:msub><mml:mtext>CP</mml:mtext><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:mtext>CDF</mml:mtext><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>Where <inline-formula><mml:math id="M25" altimg="si18.svg"><mml:mrow><mml:msubsup><mml:mi>P</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> denotes the converted <italic toggle="yes">P</italic>-value for the <italic toggle="yes">i</italic>th gene in terms of the <italic toggle="yes">j</italic>th predictor, <italic toggle="yes">J</italic> is the number of the informative predictors, <inline-formula><mml:math id="M26" altimg="si23.svg"><mml:mrow><mml:msup><mml:mi>&#967;</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>J</mml:mi></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> denotes the Chi-squared distribution with <italic toggle="yes">2J</italic> degrees of freedom, CP<sub><italic toggle="yes">i</italic></sub> represents the combined <italic toggle="yes">P</italic>-value for the <italic toggle="yes">i</italic>th gene (<italic toggle="yes">i</italic>.<italic toggle="yes">e</italic>., eCDF of the Chi-squared distribution valued at <italic toggle="yes">x</italic><sub><italic toggle="yes">i</italic></sub>).<list list-type="simple" id="olist0015"><list-item id="o0015"><label>(ii)</label><p id="p0080">Target prioritisation based on the <italic toggle="yes">logistic</italic> combined method (Eqs. <xref rid="fd11" ref-type="disp-formula">(11)</xref>&#8211;<xref rid="fd13" ref-type="disp-formula">(13)</xref>).</p></list-item></list><disp-formula id="fd11"><label>(11)</label><mml:math id="M27" altimg="si24.svg" alttext="Equation 11."><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:mn>2</mml:mn><mml:msubsup><mml:mo>&#8721;</mml:mo><mml:mi>j</mml:mi><mml:mi>J</mml:mi></mml:msubsup><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mfrac bevelled="true"><mml:msubsup><mml:mi>P</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:msubsup><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">&#8722;</mml:mo><mml:mi>P</mml:mi></mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mfrac><mml:mo stretchy="true">]</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="fd12"><label>(12)</label><mml:math id="M28" altimg="si25.svg" alttext="Equation 12."><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mspace width="0.25em"/><mml:mo>&#8764;</mml:mo><mml:mspace width="0.25em"/><mml:mtext>St</mml:mtext><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>5</mml:mn><mml:mi>J</mml:mi><mml:mo linebreak="badbreak">+</mml:mo><mml:mn>4</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="fd13"><label>(13)</label><mml:math id="M29" altimg="si22.svg" alttext="Equation 13."><mml:mrow><mml:msub><mml:mtext>CP</mml:mtext><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:mtext>CDF</mml:mtext><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>Where <inline-formula><mml:math id="M30" altimg="si18.svg"><mml:mrow><mml:msubsup><mml:mi>P</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> denotes the converted <italic toggle="yes">P</italic>-value for the <italic toggle="yes">i</italic>th gene within the <italic toggle="yes">j</italic>th predictor, <italic toggle="yes">J</italic> is the number of predictors, <inline-formula><mml:math id="M31" altimg="si26.svg"><mml:mrow><mml:mtext>St</mml:mtext><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>5</mml:mn><mml:mi>J</mml:mi><mml:mo linebreak="badbreak">+</mml:mo><mml:mn>4</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> denotes Student's <italic toggle="yes">t</italic>-distribution with <italic toggle="yes">5J + 4</italic> degrees of freedom, CP<sub><italic toggle="yes">i</italic></sub> symbolises the combined <italic toggle="yes">P</italic>-value for the <italic toggle="yes">i</italic>th gene (that is, CDF valued at <italic toggle="yes">x</italic><sub><italic toggle="yes">i</italic></sub>).<list list-type="simple" id="olist0020"><list-item id="o0020"><label>(iii)</label><p id="p0085">Target prioritisation based on the <italic toggle="yes">order statistic</italic> combined method (Eq. <xref rid="fd14" ref-type="disp-formula">(14)</xref>&#8211;<xref rid="fd16" ref-type="disp-formula">(16)</xref>).</p></list-item></list><disp-formula id="fd14"><label>(14)</label><mml:math id="M32" altimg="si27.svg" alttext="Equation 14."><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:msubsup><mml:mi>P</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></disp-formula><disp-formula id="fd15"><label>(15)</label><mml:math id="M33" altimg="si28.svg" alttext="Equation 15."><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8764;</mml:mo><mml:mspace width="0.25em"/><mml:mtext>Beta</mml:mtext><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>J</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="fd16"><label>(16)</label><mml:math id="M34" altimg="si22.svg" alttext="Equation 16."><mml:mrow><mml:msub><mml:mtext>CP</mml:mtext><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:mtext>CDF</mml:mtext><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>Where <inline-formula><mml:math id="M35" altimg="si29.svg"><mml:mrow><mml:msubsup><mml:mi>P</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> denotes the ordered version of <inline-formula><mml:math id="M36" altimg="si18.svg"><mml:mrow><mml:msubsup><mml:mi>P</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula> in an ascending manner, <italic toggle="yes">J</italic> is the number of the informative predictors, <inline-formula><mml:math id="M37" altimg="si30.svg"><mml:mrow><mml:mtext>Beta</mml:mtext><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>J</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> denotes the Beta distribution with two parameters <italic toggle="yes">J</italic> and <italic toggle="yes">1</italic>, CP<sub><italic toggle="yes">i</italic></sub> for the combined <italic toggle="yes">P</italic>-value for the <italic toggle="yes">i</italic>th gene (<italic toggle="yes">i</italic>.<italic toggle="yes">e</italic>., CDF valued at <italic toggle="yes">x</italic><sub><italic toggle="yes">i</italic></sub>).</p></sec><sec id="sec2.5"><label>2.5</label><title>Robustness and benchmarking for performance comparisons</title><p id="p0090">PI4AD's robustness was assessed <italic toggle="yes">via</italic> a leave-one-out (LOO) strategy, iteratively excluding each of the three predictor types. Specifically, each predictor type was left out, and performance based on all predictors was compared to that excluding one predictor type. Benchmarking was conducted to evaluate PI4AD against state-of-the-art tools: AlzGPS (Genome-wide Positioning Systems platform for Alzheimer's Drug Discovery; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://alzgps.lerner.ccf.org)16/" id="intref0015">https://alzgps.lerner.ccf.org)<sup>16</sup></ext-link> and Open Targets (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://platform.opentargets.org/disease/MONDO_0004975" id="intref0020">https://platform.opentargets.org/disease/MONDO_0004975</ext-link>)<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>. AlzGPS curates clinical databases for target identification and therapeutic development, while Open Targets leverages human genetics and genomics for target validation. Performance was measured by the ability to retrieve AD clinical proof-of-concept targets, quantified using the area (illustrated in <xref rid="fig2" ref-type="fig">Fig. 2</xref>, right panel). For AlzGPS, prioritisations were based on: (i) clinical information (ClinVar data source &#8216;ClinVar_Alzheimer&#8217;); and (ii) pathogenesis evidence, including literature-derived GWAS risk genes (&#8216;AD&#8722;inferred&#8722;GWAS&#8722;risk&#8722;genes&#8217;) and amyloid/tau endophenotypes (&#8216;Amyloid&#8722;seed&#8217; and &#8216;Tau&#8722;seed&#8217;). Notably, AlzGPS curates AD multi-omics datasets underlying AD pathogenesis (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., tau/amyloid endophenotype). For Open Targets, prioritisations were evaluated based on individual evidence: GWAS associations (target-disease relationships supported by significant GWAS); Gene burden (gene&#8211;phenotype relationships from rare variant collapsing analyses); ClinVar germline variants; Genomics England PanelApp (crowdsourced phenotype associations); UniProt literature/variants (protein-level functional data); Orphanet (rare disease&#8211;gene associations); Expression Atlas (disease <italic toggle="yes">vs</italic> control differential expression); and International Mouse Phenotypes Consortium (IMPC; phenotypic similarity scores). To ensure fair comparisons, network evidence (RWR algorithm with restarting probability of <italic toggle="yes">&#947;</italic> = 0.3) was incorporated into both AlzGPS and Open Targets. Seed genes (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., &#8216;AD-inferred-GWAS-risk-genes&#8217;, &#8216;Amyloid-seed&#8217;, or &#8216;Tau-seed&#8217;) were processed <italic toggle="yes">via</italic> RWR to generate prioritised gene lists ranked by affinity scores.<fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Simultaneous fine-tuning of random walk with restart (RWR) parameter and prioritisation methods. The figure evaluates the performance of RWR parameter and prioritisation method combinations in recovering <italic toggle="yes">clinical proof-of-concept targets</italic>&#8212;defined as genes linked to phase-III or later AD drug candidates. Performance is quantified by calculating the area (coloured in pink), reflecting the ability to retrieve these targets. Left panel: Heatmap comparing combined methods (columns) and RWR restarting probabilities (rows). Optimal performance (highlighted) corresponds to the <italic toggle="yes">order statistic</italic>-based meta-analysis method with an optimised RWR restarting probability (<italic toggle="yes">&#947;</italic> = 0.3, maximising target recovery). Right panel: Recovered proof-of-concept targets (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., <italic toggle="yes">APP</italic> and <italic toggle="yes">ESR1</italic>) labelled by gene symbols at optimal parameter settings.</p></caption><alt-text id="alttext0025">Figure 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec2.6"><label>2.6</label><title>Self-organising prioritisation map</title><p id="p0095">A self-organising algorithm in the supraHex package<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> was used to construct a self-organising prioritisation map. A supra-hexagonal map was trained using the input prioritisation matrix for the top 1% genes prioritised in AD (this study) or in neuropsychiatric disorders<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref>. In this map, each node <italic toggle="yes">i</italic> was represented by two types of vectors: the location vector <inline-formula><mml:math id="M38" altimg="si31.svg"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>r</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> on the 2-dimensional map grid (supra-hexagonal shape), and the codebook vector <inline-formula><mml:math id="M39" altimg="si32.svg"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> in the <italic toggle="yes">M</italic>-dimensional map hyperspace (here <italic toggle="yes">M</italic> = 2 as well). The training process involved two steps: (1) choosing the winner map node <italic toggle="yes">w</italic> for which its codebook vector <inline-formula><mml:math id="M40" altimg="si33.svg"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>w</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> was closest to the input training vector <inline-formula><mml:math id="M41" altimg="si34.svg"><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> for genes from the input prioritisation matrix (Eq. <xref rid="fd17" ref-type="disp-formula">(17)</xref>); and (2) updating the winner node <italic toggle="yes">w</italic> and its neighboring nodes by moving towards the input training vector (Eq. <xref rid="fd18" ref-type="disp-formula">(18)</xref>&#8211;<xref rid="fd19" ref-type="disp-formula">(19)</xref>).<disp-formula id="fd17"><label>(17)</label><mml:math id="M42" altimg="si35.svg" alttext="Equation 17."><mml:mrow><mml:mrow><mml:mo>&#8214;</mml:mo><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mo linebreak="badbreak">&#8722;</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>w</mml:mi></mml:msub></mml:mrow><mml:mo>&#8214;</mml:mo></mml:mrow><mml:mo linebreak="badbreak">=</mml:mo><mml:munder><mml:mi>min</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo linebreak="badbreak">=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>&#8943;</mml:mo><mml:mo>,</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo stretchy="true">{</mml:mo><mml:mrow><mml:mo>&#8214;</mml:mo><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mo linebreak="badbreak">&#8722;</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo>&#8214;</mml:mo></mml:mrow><mml:mo stretchy="true">}</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="fd18"><label>(18)</label><mml:math id="M43" altimg="si36.svg" alttext="Equation 18."><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo linebreak="badbreak">+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="badbreak">=</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="badbreak">+</mml:mo><mml:mi>&#945;</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mo>&#215;</mml:mo><mml:mi>h</mml:mi></mml:mrow><mml:mrow><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="badbreak">&#8722;</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="fd19"><label>(19)</label><mml:math id="M44" altimg="si37.svg" alttext="Equation 19."><mml:mrow><mml:msub><mml:mi>h</mml:mi><mml:mrow><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="badbreak">=</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mfrac><mml:msup><mml:mrow><mml:mo>&#8214;</mml:mo><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>r</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>w</mml:mi></mml:msub><mml:mo linebreak="badbreak">&#8722;</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>r</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo>&#8214;</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mrow><mml:mi>&#963;</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:msup></mml:mrow></mml:math></disp-formula>In these equations, <inline-formula><mml:math id="M45" altimg="si34.svg"><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> represents the input training vector, <inline-formula><mml:math id="M46" altimg="si32.svg"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> denotes the codebook vector for the node <italic toggle="yes">i</italic>, <inline-formula><mml:math id="M47" altimg="si33.svg"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>w</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> represents the codebook vector for the winner node <italic toggle="yes">w</italic>, <inline-formula><mml:math id="M48" altimg="si38.svg"><mml:mrow><mml:mi>&#945;</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> denotes the learning rate at training time <italic toggle="yes">t</italic>, <inline-formula><mml:math id="M49" altimg="si39.svg"><mml:mrow><mml:msub><mml:mi>h</mml:mi><mml:mrow><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is a Gaussian kernel function centered on the winner node <italic toggle="yes">w</italic>, <inline-formula><mml:math id="M50" altimg="si40.svg"><mml:mrow><mml:mi>&#963;</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is the width of the kernel at training time <italic toggle="yes">t</italic>, and <inline-formula><mml:math id="M51" altimg="si41.svg"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>r</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>w</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M52" altimg="si31.svg"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>r</mml:mi><mml:mo>&#8640;</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> correspond to the location vectors for map nodes <italic toggle="yes">w</italic> and <italic toggle="yes">i</italic>, respectively.</p><p id="p0100">The codebook matrix associated with the trained map was utilised to provide a disease-specific view of target gene prioritisation. The trained map was also divided into target gene clusters in a topology-preserving manner. Enrichment analysis for genes within a cluster was based on one-sided Fisher's exact test to identify KEGG pathway enrichments. The enrichment results were reported in terms of Z-scores, odds ratio and its 95% confidence interval, and <italic toggle="yes">P</italic>-values or false discovery rate (FDR) measuring the enrichment significance.</p></sec><sec id="sec2.7"><label>2.7</label><title>Pathway crosstalk identification</title><p id="p0105">Our identification of pathway crosstalk focused on genes with high ratings and strong interconnectedness. The process of identifying KEGG pathway crosstalk utilised a heuristic solution for solving the prize-collecting Steiner tree problem (detailed in Supporting Information <xref rid="appsec1" ref-type="sec">Fig. S2</xref>)<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="bib47" ref-type="bibr"><sup>47</sup></xref>. To evaluate the statistical significance (<italic toggle="yes">P</italic>-value) of the identified crosstalk, a degree-preserving node permutation test was carried out, with the test being repeated for 100 iterations. Moreover, the analysis provided the facility to specify a desired quantity of nodes or genes within the resultant crosstalk. This specified output was then acquired through a well-established iterative search procedure. The identified crosstalk was not only represented as a gene network but was also visualised in the form of a pathway-centric network. In this visualisation, pathways were represented as nodes, and their inferred connections were depicted as network edges. Only those pathways that demonstrated significant over-representation among the crosstalk genes, as ascertained by means of a one-sided Fisher's exact test, were incorporated as nodes. The edges were initially deduced based on the shared member genes between pathways. Subsequently, these edges were filtered by identifying MST. This filtering process ensured that only the edges present within the resulting tree were retained. Furthermore, the thickness of the edges was adjusted in a manner that was proportional to the number of shared member genes between the two endpoint pathways.</p></sec><sec id="sec2.8"><label>2.8</label><title>Crosstalk-based effect-by-removal analysis</title><p id="p0110">The objective of the removal analysis was to assess the impact of nodes on the crosstalk using established concepts<xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref>. This analysis was structured in two aspects. (i) Individual node removal: This pertained to the extraction of single nodes from the network. When a particular node, which was designated for removal, held a crucial position within the network, its elimination led to a significant detachment of a considerable portion of nodes from the principal network component. (ii) Combinatorial node removal: This involved the concurrent extraction of multiple nodes in specific combinations. The aim of this approach was to identify the most favourable combinations for targeting. The intention was to maximise the resultant effect that ensued from the simultaneous elimination of particular node combinations, such as the removal of two nodes concurrently. To put it simply, the goal was to determine the combination that would lead to the largest proportion of disconnected nodes upon removal. The visual representation of the effect of node removal was achieved through the utilisation of an upset plot, with the ggupset package being employed for this purpose. This visualisation technique enabled a lucid illustration of the consequences of both single-node and combinatorial node removal, thereby providing valuable insights into the network dynamics and the significance of individual and combined nodes within the context of AD crosstalk.</p></sec><sec id="sec2.9"><label>2.9</label><title>Crosstalk-based drug repurposing</title><p id="p0115">The drug repurposing analysis was carried out using data extracted from the ChEMBL database<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref>, which compiles comprehensive therapeutic information on currently approved therapeutics, incorporating aspects like drugs, their developmental phases, target genes, and corresponding disease indications. In the context of our AD study, for a given disease indication, we singled out drugs that had attained approval for a specific target gene. The rationale for this selection was predicated on the target genes possessing well-articulated mechanisms of action, which could elucidate the drugs' effectiveness in treating the disease. Subsequently, these chosen target genes were clustered to constitute the drug targets category. These drug targets were characterised as genes that were the focus of any approved drugs. To test the statistical significance of crosstalk genes that were overrepresented among the approved drug targets, a one-sided Fisher's exact test was implemented. This statistical test furnished the means to ascertain the probability of observing the enrichment of crosstalk genes within the approved drug targets. Consequently, it furnished a quantitative appraisal of the significance of the association, thereby facilitating a more informed understanding of the potential for drug repurposing in the context of AD crosstalk.</p></sec><sec id="sec2.10"><label>2.10</label><title>Crosstalk-based network modular analysis</title><p id="p0120">In our endeavour to identify pathway modules present within the crosstalk, we resorted to the application of a spin-glass model in combination with simulated annealing. This synergistic use of these techniques enabled us to divide the crosstalk network into discrete modules. Subsequently, for every module that had been identified, an enrichment analysis was performed. The aim of this analysis was twofold: to disclose both the functional relevance and the therapeutic potential associated with each module. The functional relevance was achieved through the identification of enriched KEGG pathways. In parallel, with a view to evaluating the therapeutic potential, we made reference to the ChEMBL database. This allowed us to identify both the enriched approved drug targets and the non-approved phased drug targets. We then proceeded to classify therapeutic targets into two separate groups. The first group was composed of approved drug targets, which were defined as genes that were the subject of targeting by any approved drugs. The second group consisted of non-approved phased drug targets, which encompassed genes that were targeted by drugs in phases of development that had not yet received approval. These two distinct target groups were subsequently employed as the foundation for conducting the enrichment analysis. By contrasting the enrichment patterns exhibited by these two groups, we were able to shed light on the clinical relevance of the network modules. For example, a higher enrichment of approved drug targets within a module might suggest a more immediate translational potential. On the other hand, the presence of non-approved phased drug targets within a module could signify areas that hold promise for future drug development and exploration.</p></sec><sec id="sec2.11"><label>2.11</label><title>Code availability</title><p id="p0125">An open-source R package, available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/hfang-bristol/PI4AD" id="intref0025">https://github.com/hfang-bristol/PI4AD</ext-link>, is specifically designed for multi-omics-led and network-driven therapeutic target prioritisation in the context of AD. Together with the showcase (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.genetictargets.com/PI4AD/showcase" id="intref0030">http://www.genetictargets.com/PI4AD/showcase</ext-link>), this package promotes transparency and reproducibility, allowing users to build upon our work and potentially contribute to the advancement of AD research. The PI4AD portal is accessible at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.genetictargets.com/PI4AD" id="PC_linkQB2VF9XMkb">http://www.genetictargets.com/PI4AD</ext-link>.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Prioritisation rationale, simultaneous optimisation, and benchmarking on clinical proof-of-concept target recovery in AD</title><p id="p0130">The PI4AD prioritisation framework is grounded in the omnigenic model for complex traits<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="bib52" ref-type="bibr"><sup>52</sup></xref>, which posits that disease mechanisms involve both <italic toggle="yes">core</italic> genes (directly influencing pathology <italic toggle="yes">via</italic> multi-omic evidence) and <italic toggle="yes">peripheral</italic> genes (modulating core genes through network evidence). Building on this model, PI4AD represents a multi-omics-led and network-driven solution for AD therapeutic target prioritisation. It integrates regulatory multi-omic datasets&#8212;including genomic proximity, QTL, and PCHi-C&#8212;with gene interaction networks. The prioritisation process comprises two key steps (<xref rid="fig1" ref-type="fig">Fig. 1</xref>, left panel). First, predictors are generated using multi-modal regulatory genomic datasets (such as QTL and PCHi-C) and network evidence derived from the RWR algorithm. Second, these predictors are combined using meta-analysis-like prioritisation methods to rank genes by their therapeutic potential.</p><p id="p0135">Central to this process is the simultaneous optimisation of RWR parameters and prioritisation methods. Through systematic evaluation of three meta-analysis-like combined methods&#8212;<italic toggle="yes">Fisher's</italic>, <italic toggle="yes">logistic</italic>, and <italic toggle="yes">order statistic</italic>&#8212;we identified the <italic toggle="yes">order statistic</italic> method with an RWR restarting probability of <italic toggle="yes">&#947;</italic> = 0.3 as optimal (<xref rid="fig2" ref-type="fig">Fig. 2</xref> and Supporting Information <xref rid="appsec1" ref-type="sec">Fig. S1</xref>). This configuration maximised the recovery of <italic toggle="yes">clinical proof-of-concept targets</italic>, defined as genes associated with drugs that reached phase-III or later clinical trials for AD. Applying this optimised framework to AD GWAS data, we recovered high-priority proof-of-concept targets within the top 1% of ranked genes (a total of &#8764;14,500 genes ranked by their priority ratings), including <italic toggle="yes">APP</italic>, <italic toggle="yes">ESR1</italic>, <italic toggle="yes">KIT</italic>, and <italic toggle="yes">PDGFRB</italic> (<xref rid="fig2" ref-type="fig">Fig. 2</xref>, right panel).</p><p id="p0140">The target gene <italic toggle="yes">APP</italic> (ranked 18th) encodes amyloid-beta precursor protein, whose cleavage product (amyloid-beta) is a central biomarker for pre-AD monitoring<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref>. Mutations in <italic toggle="yes">APP</italic> are linked to disease protection<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref>, and it is targeted by amyloid-beta therapies such as aducanumab (controversial due to mixed efficacy)<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref><sup>,</sup><xref rid="bib39" ref-type="bibr"><sup>39</sup></xref>, lecanemab (showing promise)<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref>, gantenerumab/solanezumab/bapineuzumab (ineffective in trials)<xref rid="bib55" ref-type="bibr">55</xref>, <xref rid="bib56" ref-type="bibr">56</xref>, <xref rid="bib57" ref-type="bibr">57</xref>, <xref rid="bib58" ref-type="bibr">58</xref>, crenezumab (well-tolerated but ineffective)<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>, valiltramiprosate (displaying potential benefits)<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref><sup>,</sup><xref rid="bib61" ref-type="bibr"><sup>61</sup></xref>, and thonningianin A (effective in the cell model)<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref>. <italic toggle="yes">ESR1</italic> (ranked 61st and renowned for its role in breast cancer<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref>), encoding estrogen receptor alpha, is associated with AD cognitive and pathologic traits in women<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> and has been investigated for neuroprotective effects <italic toggle="yes">via</italic> estrogen receptor agonists, albeit with inconclusive trial results<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref>. <italic toggle="yes">KIT</italic> (ranked 95th and a potential AD target<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref>) is a kinase targeted by masitinib, currently in phase-III trials for AD<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref>. <italic toggle="yes">PDGFRB</italic> (ranked 100th), involved in radial glia proliferation and AD-related expression changes<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref>, further underscores the framework's alignment with established AD pathophysiology. The high prioritisation of these clinically validated targets confirms PI4AD's efficacy and motivates exploration of top-ranked genes for actionable AD-specific candidates, particularly within understudied pathways (addressed in subsequent sections).</p><p id="p0145">To validate PI4AD's robustness and comparative advantage, we conducted two analyses. First, the LOO strategy demonstrated consistent performance even after iteratively excluding individual predictor types (<xref rid="fig3" ref-type="fig">Fig. 3</xref>A). Second, benchmarking against established tools&#8212;AlzGPS<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> and Open Targets<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>&#8212;highlighted PI4AD's competitive predictive validity (<xref rid="fig3" ref-type="fig">Fig. 3</xref>B and C). For AlzGPS, prioritisations using ClinVar and literature-derived endophenotypes (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., amyloid/tau pathology) were used for evaluation (<xref rid="fig3" ref-type="fig">Fig. 3</xref>B). Regarding Open Targets, prioritisations based on individual evidence were used for evaluation, ranging from genetic association (such as GWAS associations and gene burden) to expression and to phenotypic evidence (<xref rid="fig3" ref-type="fig">Fig. 3</xref>C). These analyses collectively validate PI4AD as a robust tool for AD therapeutic target prioritisation.<fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Robustness evaluation and benchmarking against competitive tools. Performance&#8212;quantified as the ability to retrieve Alzheimer's disease (AD) <italic toggle="yes">clinical proof-of-concept targets</italic>&#8212;is measured using the area, as described in <xref rid="fig2" ref-type="fig">Fig. 2</xref>. (A) Robustness assessed <italic toggle="yes">via</italic> the leave-one-out (LOO) strategy, iteratively excluding each of three predictor types. (B) Benchmarking against AlzGPS (Genome-wide Positioning Systems platform for Alzheimer's Drug Discovery), which curates AD clinical data (ClinVar source: &#8216;ClinVar_Alzheimer&#8217;) and pathogenesis data (literature-derived GWAS risk genes: &#8216;AD-inferred-GWAS-risk-genes&#8217;; amyloid/tau endophenotypes: &#8216;Amyloid-seed&#8217; and &#8216;Tau-seed&#8217;, respectively). (C) Benchmarking against Open Targets using diverse evidence data sources: GWAS associations, gene burden, ClinVar, Genomics England PanelApp, UniProt literature/variants, Orphanet, Expression Atlas, and International Mouse Phenotypes Consortium (IMPC).</p></caption><alt-text id="alttext0030">Figure 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec><sec id="sec3.2"><label>3.2</label><title>Construction of self-organising prioritisation map for AD-specific targeting in relation to neuropsychiatric disorders</title><p id="p0150">To investigate disease-specific therapeutic potential, we constructed a self-organising prioritisation map using a supra-hexagonal map (<xref rid="fig1" ref-type="fig">Fig. 1</xref>, middle panel). This map was trained on the top 1% prioritised genes from AD and neuropsychiatric disorders (NPD)<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref>, employing an ANN <italic toggle="yes">via</italic> the R package supraHex<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref>. The ANN utilised self-organising unsupervised learning to cluster genes into five distinct, topology-preserving clusters (C1&#8211;C5; <xref rid="fig4" ref-type="fig">Fig. 4</xref>A).<fig id="fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><p>Self-organising prioritisation map constructed between Alzheimer's disease (AD) and neuropsychiatric disorders (NPD). The map was trained using self-organising unsupervised learning for the top 1% prioritised genes in either AD or NPD. (A) Colour-coded prioritisation map with two blended colours displaying disease-specific prioritisations. (B) Architecture of the prioritisation map (61 hexagons, H1&#8211;H61) divided into five clusters (C1&#8211;C5), with target genes listed in each hexagon (if any). Clustering and organisation of genes within the map visualise their relationships and groupings, highlighting disease-specific or shared therapeutic targets in AD and NPD. (C) Dot plot showing enriched KEGG pathways for each cluster. This reveals functional mechanisms and potential therapeutic targets associated with cluster genes.</p></caption><alt-text id="alttext0035">Figure 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="p0155">Clustering analysis revealed marked differences in disease specificity: genes in clusters C1&#8211;C3 exhibited significantly higher priority ratings in AD compared to NPD, with C3 showing the strongest AD association (<xref rid="fig4" ref-type="fig">Fig. 4</xref>B). Conversely, genes in clusters C4&#8211;C5 were preferentially prioritised in NPD. Enrichment analysis using KEGG pathways<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref> further distinguished these clusters (<xref rid="fig4" ref-type="fig">Fig. 4</xref>C). Genes in C1&#8211;C3 were enriched for cell motility, focal junction, and neurotrophin signalling pathways&#8212;processes critical to synaptic plasticity and neurodegeneration. In contrast, genes in C4&#8211;C5 were functionally linked to metabolic pathways and GABAergic synapse regulation, mechanisms more aligned with NPD pathophysiology.</p><p id="p0160">The above-mentioned differential prioritisation underscores AD's unique genetic architecture, highlighting cell motility and neurotrophin signalling as promising therapeutic targets. By contrast, the NPD-associated clusters implicate metabolic and synaptic mechanisms, reflecting distinct pathological drivers. These insights validate the ANN-driven map's ability to disentangle disease-specific pathways and guide targeted therapeutic strategies tailored to AD's molecular landscape.</p></sec><sec id="sec3.3"><label>3.3</label><title>Crosstalk-based therapeutic discovery in AD provides insights into Ras signalling-centred targeting potential</title><p id="p0165">A key feature of PI4AD is its ability to identify genes mediating molecular pathway crosstalk (<xref rid="fig1" ref-type="fig">Fig. 1</xref>, bottom panel), achieved through a heuristic solution to the prize-collecting Steiner tree problem (Supporting Information <xref rid="appsec1" ref-type="sec">Fig. S2</xref>)<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref>. Applying this to AD, we uncovered a 51-gene crosstalk network containing high-priority genes (<italic toggle="yes">P</italic>-value = 2.5 &#215; 10<sup>&#8722;4</sup>; <xref rid="fig5" ref-type="fig">Fig. 5</xref>A). Pathway-centric representation of this crosstalk revealed Ras signalling as the most prominent pathway, encompassing 35 member genes (69% of the crosstalk network; <xref rid="fig4" ref-type="fig">Fig. 4</xref>B and Supporting Information <xref rid="appsec1" ref-type="sec">Fig. S3</xref>). Ras signalling exhibited significant overlap with other key signallings, including cAMP, Rap1, and MAPK pathways. Among these Ras signalling genes, 22 overlapped with cAMP signaling, 23 with Rap1 signalling, and 19 with MAPK signalling. Notably, seven genes (<italic toggle="yes">AKT1</italic>, <italic toggle="yes">AKT2</italic>, <italic toggle="yes">AKT3</italic>, <italic toggle="yes">MAPK1</italic>, <italic toggle="yes">MAPK3</italic>, <italic toggle="yes">RAF1</italic>, and <italic toggle="yes">RAP1A</italic>) were common to all four pathways, highlighting their central regulatory roles (<xref rid="fig5" ref-type="fig">Fig. 5</xref>B, Venn diagram).<fig id="fig5" position="float" orientation="portrait"><label>Figure 5</label><caption><p>Pathway crosstalk identified for Alzheimer's disease (AD). The crosstalk was identified from pathway interactions constrained by AD clinical target prioritisation. The resulting crosstalk comprises highly prioritised, interconnected genes. (A) Gene-centric view of the crosstalk. Nodes (genes) are labelled with gene symbols and colour-coded by PI4AD priority ratings (0&#8211;10 scale). Edges represent KEGG-derived pathway interactions. High-priority Ras pathway hubs (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., <italic toggle="yes">HRAS</italic> and <italic toggle="yes">MAPK1</italic>) are bolded to emphasise therapeutic relevance. This visualisation enables the identification and analysis of the individual genes within the crosstalk network. (B) Venn diagram and pathway-centric view illustrating overlaps between Ras signalling and cAMP/MAPK/Rap1 pathways: &#8216;Ras &lt;+&gt; cAMP&#8217;, &#8216;Ras &lt;+&gt; MAPK&#8217;, and &#8216;Ras &lt;+&gt; Rap1&#8217;. For example, the notation &#8216;Ras &lt;+&gt; cAMP&#8217; represents the shared genes between Ras signalling and cAMP signalling, which is further explained in the top panel. Shown on the top is a pathway-centric representation of the crosstalk, with node size indicating the number of pathway member genes. Abbreviations<italic toggle="yes">:</italic> cAMP, cyclic adenosine monophosphate; MAPK, mitogen-activated protein kinase; Rap1, Ras-related protein 1; Ras, rat sarcoma. (C) Crosstalk with the same layout as (A) but labelled only for critical nodal points/genes identified <italic toggle="yes">via</italic> effect-by-removal analysis. This focuses on the genes that have the most significant impact on the crosstalk network, and their identification can provide insights into potential therapeutic strategies that target these key genes to disrupt or modulate the crosstalk and potentially affect AD progression. (D) Enrichment of approved drug targets (from ChEMBL) within crosstalk genes. One-sided Fisher's exact test quantifies significance (<italic toggle="yes">P</italic>-value, odds ratio, and 95% confidence interval). Hierarchical edge bundling connects crosstalk genes (in pink) to approved drug indications (in cyan) <italic toggle="yes">via</italic> grey edges, thus providing a comprehensive view of crosstalk-informed potential drug repurposing opportunities.</p></caption><alt-text id="alttext0040">Figure 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p><p id="p0170">Next, we explored targetable opportunities by identifying central genes with the greatest impact on the crosstalk. More precisely, crosstalk-based effect-by-removal analysis was designed to quantify network disruption upon node/gene removal, either individually or in combination (<xref rid="fig1" ref-type="fig">Fig. 1</xref>, right panel). This identified seven critical nodal genes, five of which (<italic toggle="yes">i</italic>.<italic toggle="yes">e</italic>., <italic toggle="yes">HRAS</italic>, <italic toggle="yes">KRAS</italic>, <italic toggle="yes">MAPK8</italic>, <italic toggle="yes">NRAS</italic>, and <italic toggle="yes">PRKCA</italic>) are Ras signalling components (<xref rid="fig5" ref-type="fig">Fig. 5</xref>C). Removal of <italic toggle="yes">MAPK8</italic> alone disrupted 9.8% of network connections (Supporting Information <xref rid="appsec1" ref-type="sec">Fig. S4</xref>). Combinatorial removal of <italic toggle="yes">MAPK8</italic> + <italic toggle="yes">PRKCA</italic> or <italic toggle="yes">MAPK8</italic> + <italic toggle="yes">ATF4</italic> increased disconnection fraction to 15.7%, while removing <italic toggle="yes">MAPK8</italic> + <italic toggle="yes">PRKCA</italic> + <italic toggle="yes">ATF4</italic> maximised disconnection to 21.6%. Strikingly, removing four nodes&#8212;three Ras signalling genes (<italic toggle="yes">HRAS</italic>, <italic toggle="yes">KRAS</italic>, and <italic toggle="yes">NRAS</italic>) and <italic toggle="yes">BCL2</italic>&#8212;disrupted 49.0% of connections, underscoring Ras signalling's centrality in AD pathogenesis.</p><p id="p0175">Next, we investigated drug repurposing opportunities by mapping approved drugs for non-AD indications to crosstalk genes (<xref rid="fig1" ref-type="fig">Fig. 1</xref>, right panel). Nine crosstalk genes were already targeted by approved drugs (odds ratio = 5.94; 95% confidence interval = [2.53, 12.5]; <italic toggle="yes">P</italic>-value = 6.4 &#215; 10<sup>&#8722;5</sup> based on a one-sided Fisher's exact test), six of which (<italic toggle="yes">i</italic>.<italic toggle="yes">e</italic>., <italic toggle="yes">ABL1</italic>, <italic toggle="yes">KRAS</italic>, <italic toggle="yes">NTRK1</italic>, <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">PIK3CD</italic>, and <italic toggle="yes">RAF1</italic>) are integral to Ras signalling (<xref rid="fig5" ref-type="fig">Fig. 5</xref>D).</p><p id="p0180">We proceeded to explore the modular structure of the crosstalk network, identifying three distinct pathway modules (PM1&#8211;PM3), each intricately linked to specific molecular pathways (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A). When colour-coded by priority rating (<xref rid="fig6" ref-type="fig">Fig. 6</xref>B), PM1 and PM2 were enriched for AD-specific genes with high prioritisation ratings, whereas PM3 showed relatively higher scores for AD, although some genes (such as <italic toggle="yes">EP300</italic> and <italic toggle="yes">CREBBP</italic>) were also highly prioritised in NPD (<italic toggle="yes">i</italic>.<italic toggle="yes">e</italic>., dual relevance to AD and NPD). Clinical evidence (approved drugs) strongly supported AD-specific pathway modules (PM1 and PM2), whereas PM3 showed preclinical potential <italic toggle="yes">via</italic> non-approved phased drug targets (<xref rid="fig6" ref-type="fig">Fig. 6</xref>C). Collectively, our crosstalk analysis positions Ras signalling as a linchpin of AD-specific pathway interactions, diverging from NPD-associated mechanisms. These insights underscore Ras signalling's potential as a therapeutic axis, complementing traditional amyloid/tau paradigms.<fig id="fig6" position="float" orientation="portrait"><label>Figure 6</label><caption><p>Crosstalk-based modular analysis for Alzheimer's disease (AD). Three pathway modules (PM1&#8211;PM3) were identified within the 51-gene crosstalk network <italic toggle="yes">via</italic> a spin-glass model and simulated annealing. Enrichment analysis was performed using a one-sided Fisher's exact test to calculate significance (false discovery rate [FDR]), odds ratio, and 95% confidence interval. (A) Modular visualisation of the 51-gene crosstalk network. Modules and member genes are colour-coded, with top KEGG pathway enrichments displayed in a dot plot (right panel). This visualisation identifies and characterises modules and their biological pathways, highlighting functional organisation and therapeutic relevance of the crosstalk network. (B) Disease-specific view of the crosstalk network. The same network layout as in (A) is presented, with nodes colour-coded by priority ratings in AD (left panel) <italic toggle="yes">versus</italic> neuropsychiatric disorders (NPD; right panel). This comparison reveals differentially prioritised genes and disease-specific mechanisms. (C) Forest plot comparing enrichments of approved drug targets and non-approved phased drug targets (sourced from ChEMBL) across modules. This plot provides a visual comparison of the enrichments across pathway modules, illustrating therapeutic potential.</p></caption><alt-text id="alttext0045">Figure 6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p></sec><sec id="sec3.4"><label>3.4</label><title>Literature support of AD-targeting molecular pathways centred on Ras signalling</title><p id="p0185">PI4AD's identification of Ras signalling as a therapeutic hub in <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/100020014</institution-id><institution>AD</institution></institution-wrap></funding-source> is strongly supported by existing literature, which links key pathway components to <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/100020014</institution-id><institution>AD</institution></institution-wrap></funding-source> mechanisms. Below, we synthesise evidence for prioritised genes within this network (namely, <italic toggle="yes">ABL1</italic>, <italic toggle="yes">AKT1-3</italic>, <italic toggle="yes">HRAS</italic>, <italic toggle="yes">KRAS</italic>, <italic toggle="yes">MAPK1-3</italic>, <italic toggle="yes">MAPK8</italic>, <italic toggle="yes">NTRK1</italic>, <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">PIK3CD</italic>, <italic toggle="yes">PRKCA</italic>, <italic toggle="yes">RAF1</italic>, and <italic toggle="yes">RAP1A</italic>), highlighting their therapeutic relevance.</p><p id="p0190"><italic toggle="yes">ABL1 and AKT family. ABL1</italic> strongly correlates with AD cerebrospinal fluid biomarkers and cognitive decline<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref>, with ongoing phase-III trials (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., nilotinib) exploring its modulation in AD pathology<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref>. The genes <italic toggle="yes">AKT1-3</italic>, particularly <italic toggle="yes">AKT1</italic> (targeted in breast cancer using capivasertib<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref>), mediate crosstalk within Ras signalling, influencing pathways critical to AD progression.</p><p id="p0195"><italic toggle="yes">Ras GTPases (HRAS and KRAS).</italic> While <italic toggle="yes">HRAS</italic> lacks extensive AD- or neuro-related literature, its central role in Ras signalling positions it as a candidate for mechanistic investigation. <italic toggle="yes">KRAS</italic>, validated in oncology (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., sotorasib for <italic toggle="yes">KRAS</italic> p.G12C-mutant lung cancer<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref>), emerged as a compelling AD target due to its pathway centrality, despite the absence of AD-focused repurposing trials.</p><p id="p0200"><italic toggle="yes">MAPK family (MAPK1-3 and MAPK8). MAPK1-3</italic> are targeted by oncology drugs such as dordaviprone and ulixertinib, which are actively being explored in cancer treatment<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref><sup>,</sup><xref rid="bib74" ref-type="bibr"><sup>74</sup></xref>, while <italic toggle="yes">MAPK8</italic> is implicated in neuropathic pain<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref>. Their roles in Ras signalling underscore cross-disease therapeutic potential.</p><p id="p0205"><italic toggle="yes">PI3K and downstream effectors (PIK3CA, PIK3CD,</italic> and <italic toggle="yes">RAF1). PIK3CA</italic> and <italic toggle="yes">PIK3CD</italic>&#8212;linked to neuronal hyperactivity during glioma formation<xref rid="bib76" ref-type="bibr"><sup>76</sup></xref> and primary immunodeficiencies<xref rid="bib77" ref-type="bibr"><sup>77</sup></xref>, respectively&#8212;may drive AD <italic toggle="yes">via</italic> Ras&#8211;PI3K&#8211;AKT axis dysregulation. <italic toggle="yes">RAF1</italic>, with well-characterised regulatory mechanisms<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref>, provides a basis for targeted modulation in AD, even though there are currently no AD-specific drug repurposing trials.</p><p id="p0210"><italic toggle="yes">NTRK1 and PRKCA. NTRK1</italic>, though unexplored in AD-focused drug repurposing trials, has immune-related roles in cancer<xref rid="bib79" ref-type="bibr"><sup>79</sup></xref>, aligning with Ras signalling's neuroinflammatory functions. <italic toggle="yes">PRKCA</italic>, despite limited AD literature, warrants mechanistic investigation in AD pathology due to its integration with Ras-centred signalling pathway.</p><p id="p0215"><italic toggle="yes">Ras&#8211;APP crosstalk.</italic> Emerging evidence links Ras signalling to <italic toggle="yes">APP</italic> processing, both promoting the development of <italic toggle="yes">APP</italic> for AD and modulating the neuroprotection of <italic toggle="yes">APP</italic><xref rid="bib80" ref-type="bibr">80</xref>, <xref rid="bib81" ref-type="bibr">81</xref>, <xref rid="bib82" ref-type="bibr">82</xref>, <xref rid="bib83" ref-type="bibr">83</xref>, <xref rid="bib84" ref-type="bibr">84</xref>, <xref rid="bib85" ref-type="bibr">85</xref>, <xref rid="bib86" ref-type="bibr">86</xref>, <xref rid="bib87" ref-type="bibr">87</xref>. Recent findings associate the RAS/MAPK/ERK pathway with longitudinal AD biomarker changes<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref>, further validating Ras signalling as a therapeutic nexus.</p><p id="p0220"><italic toggle="yes">Implications for therapeutic development.</italic> PI4AD's integration of literature and multi-omics data positions Ras signalling as a priority axis for AD therapy. Repurposing oncology drugs (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., KRAS/PI3K inhibitors) or developing novel agents against <italic toggle="yes">HRAS</italic> or <italic toggle="yes">MAPK8</italic> could disrupt AD progression. These findings align with PI4AD's broader goal of bridging genetic insights to actionable pathway modulation, offering a roadmap for targeted AD therapeutics.</p></sec></sec><sec id="sec4"><label>4</label><title>Discussion and conclusions</title><p id="p0225">Our PI4AD framework represents a promising solution to bridge genetic insights and therapeutic discovery in AD. First, the recovery of clinical proof-of-concept targets such as <italic toggle="yes">APP</italic> and <italic toggle="yes">ESR1</italic> validates the prioritisation framework's efficacy. This not only reinforces methodological confidence but also underscores the pivotal roles of these genes in AD pathophysiology, which are actively pursued in drug development. Targeting these genes may yield therapies addressing specific AD mechanisms. Second, the construction of a self-organising prioritisation map delineates disease-specific targets in AD relative to neuropsychiatric disorders. By identifying distinct clusters, we elucidate AD's unique genetic architecture, guiding the development of precise therapeutic strategies. Finally, our exploration of pathway crosstalk highlights Ras signalling as a central hub, with genes such as <italic toggle="yes">HRAS</italic> and <italic toggle="yes">MAPK1</italic> emerging as high-priority targets. This systems-driven framework uncovers critical nodal points and drug-repurposing opportunities, deepening our understanding of AD pathogenesis.</p><p id="p0230">While PI4AD builds on our previously established systems biology frameworks, its novelty lies in integrating multi-omics data with clinical translation. Diverging from traditional amyloid-<italic toggle="yes">&#946;</italic>/tau-centric approaches, PI4AD prioritises Ras-centred pathway crosstalk&#8212;a shift supported by recent evidence linking Ras signalling to synaptic dysfunction and neuroinflammation. For instance, <italic toggle="yes">HRAS</italic> overexpression in the AD prefrontal cortex and <italic toggle="yes">MAPK1</italic>-mediated neuronal apoptosis validate PI4AD's target prioritisation. This holistic strategy addresses AD's multifactorial pathology, complementing singular pathway-focused therapies.</p><p id="p0235">Benchmarking PI4AD against established tools (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., AlzGPS<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> and Open Targets<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>) demonstrated competitive performance in recovering clinically relevant targets, alongside robustness confirmed <italic toggle="yes">via</italic> leave-one-out testing. While parameter tuning relied on clinical proof-of-concept targets to optimise biological relevance, this aligns with translational medicine guidelines, ensuring prioritisation reflects actionable therapeutic hypotheses rather than purely statistical associations.</p><p id="p0240">The selection of NPDs as comparators, despite symptomatic overlaps, revealed divergent pathway activation: AD-specific Ras/MAPK signalling <italic toggle="yes">versus</italic> NPD-associated dopaminergic pathways. This aligns with genetic studies showing distinct dysregulation despite comorbidity<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref>. Furthermore, focusing on clinical proof-of-concept targets (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., <italic toggle="yes">APP</italic> and <italic toggle="yes">ESR1</italic>) reflects their validation in human trials<xref rid="bib90" ref-type="bibr"><sup>90</sup></xref>, addressing historical drug failures attributed to non-genetic or non-human targets<xref rid="bib91" ref-type="bibr"><sup>91</sup></xref>.</p><p id="p0245">PI4AD's identification of Ras signalling as a therapeutic hub marks a departure from conventional paradigms. Ras pathways mediate critical AD processes&#8212;neuroinflammation and synaptic plasticity&#8212;through crosstalk with amyloid-<italic toggle="yes">&#946;</italic>/Tau-independent mechanisms. For example, <italic toggle="yes">HRAS</italic> modulates microglial activation <italic toggle="yes">via</italic> NF-<italic toggle="yes">&#954;</italic>B, while <italic toggle="yes">MAPK1</italic> regulates neuronal apoptosis in AD models. Prioritising these targets addresses the limitations of singular amyloid/tau focus, offering a multi-faceted strategy to disrupt AD progression.</p><p id="p0250">Recent advances in ANNs, such as PALH<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> and DGCL<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref>, excel in neuroimaging biomarker discovery. PI4AD complements these by prioritising therapeutic targets through multi-omics integration (GWAS, QTL, and PCHi-C) and pathway crosstalk analysis, bridging biomarker discovery with therapeutic development. This distinction underscores the versatility of ANNs in AD research, connecting neuroimaging-driven biomarker discovery with systems biology-led therapeutic development.</p><p id="p0255"><italic toggle="yes">Limitations and future directions</italic>. A key limitation of this study is the reliance on European-centric GWAS data, which may introduce population-specific biases and limit generalisability of prioritised targets. While this reflects current AD genetic data availability, future iterations will incorporate diverse cohorts (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., Asian and African ancestries) and ancestry-specific heritability estimates, aligning with global equity initiatives to diversify genomic resources in neurodegenerative research<xref rid="bib92" ref-type="bibr"><sup>92</sup></xref>.</p><p id="p0260"><italic toggle="yes">Translational roadmap and broader implications</italic>. To translate PI4AD's computational medicine insights into clinical impact, we propose: (i) <italic toggle="yes">in vitro</italic> validation of high-priority Ras pathway targets (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., <italic toggle="yes">HRAS</italic> and <italic toggle="yes">MAPK1</italic>) using AD patient-derived induced pluripotent stem cell models to assess their role in amyloid-<italic toggle="yes">&#946;</italic> and tau pathology<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref>; and (ii) clinical partnerships to evaluate Ras-modulating drugs (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., KRAS inhibitors<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref>) or implement mRNA therapeutics with lipid nanoparticles (as demonstrated for amyloid-<italic toggle="yes">&#946;</italic><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib94" ref-type="bibr"><sup>94</sup></xref>), accelerating pathway-targeted therapies. Beyond AD, PI4AD's framework holds broader implications. First, its application in AD could extend to Parkinson's disease or Huntington's disease, leveraging multi-omics and network evidence for therapeutic discovery. Second, Ras signalling's role in neuroinflammation<xref rid="bib95" ref-type="bibr"><sup>95</sup></xref> positions it as a multi-target therapeutic hub. Lastly but not the least, the use of ANNs and advanced computational methods encourages adoption in other biomedical fields. In conclusion, PI4AD advances therapeutic discovery by unifying systems biology with translational application. By prioritising Ras-centred crosstalk, benchmarking against existing tools, and proposing actionable validation, it addresses historical challenges in neurodegenerative drug development, paving the way for transformative therapies.</p></sec><sec id="sec5"><title>Author contributions</title><p id="p0265">Yisheng Yang: Data curation, Investigation, Methodology, Writing &#8211; original draft. Yizhu Diao: Investigation, Writing &#8211; original draft. Lulu Jiang: Conceptualisation, Writing &#8211; original draft. Fanlu Li: Writing &#8211; review &amp; editing. Liye Chen: Writing &#8211; review &amp; editing. Ming Ni: Funding acquisition, Resources, Writing &#8211; review &amp; editing. Zheng Wang: Funding acquisition, Resources, Writing &#8211; review &amp; editing. Hai Fang: Conceptualisation, Data curation, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Visualisation, Writing &#8211; original draft.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Conflicts of interest</title><p id="p0270">The authors declare no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Nichols</surname><given-names>E.</given-names></name><name name-style="western"><surname>Szoeke</surname><given-names>C.E.I.</given-names></name><name name-style="western"><surname>Vollset</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Abbasi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Abd-Allah</surname><given-names>F.</given-names></name><name name-style="western"><surname>Abdela</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Global, regional, and national burden of Alzheimer's disease and other dementias, 1990&#8211;2016: a systematic analysis for the Global Burden of Disease Study 2016</article-title><source>Lancet Neurol</source><volume>18</volume><year>2019</year><fpage>88</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">30497964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(18)30403-4</pub-id><pub-id pub-id-type="pmcid">PMC6291454</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Knopman</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Amieva</surname><given-names>H.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Ch&#233;telat</surname><given-names>G.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B.T.</given-names></name><etal/></person-group><article-title>Alzheimer disease</article-title><source>Nat Rev Dis Primers</source><volume>7</volume><year>2021</year><fpage>33</fpage><pub-id pub-id-type="pmid">33986301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-021-00269-y</pub-id><pub-id pub-id-type="pmcid">PMC8574196</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><article-title>2024 Alzheimer's disease facts and figures</article-title><source>Alzheimer's Dement</source><volume>20</volume><year>2024</year><fpage>3708</fpage><lpage>3821</lpage><pub-id pub-id-type="pmid">38689398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13809</pub-id><pub-id pub-id-type="pmcid">PMC11095490</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Recent progress in nanomedicine for the diagnosis and treatment of Alzheimer's diseases</article-title><source>ACS Nano</source><volume>18</volume><year>2024</year><fpage>33792</fpage><lpage>33826</lpage><pub-id pub-id-type="pmid">39625718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.4c11966</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Moosavi</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Rahiman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jaafari</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Arabi</surname><given-names>L.</given-names></name></person-group><article-title>Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases</article-title><source>J Control Release</source><volume>381</volume><year>2025</year><object-id pub-id-type="publisher-id">113641</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2025.113641</pub-id><pub-id pub-id-type="pmid">40120689</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Zang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fouladvand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Havaldar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>High-throughput target trial emulation for Alzheimer's disease drug repurposing with real-world data</article-title><source>Nat Commun</source><volume>14</volume><year>2023</year><fpage>8180</fpage><pub-id pub-id-type="pmid">38081829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-43929-1</pub-id><pub-id pub-id-type="pmcid">PMC10713627</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Van Stone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cammann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tonegawa-Kuji</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Drug repurposing for Alzheimer's disease and other neurodegenerative disorders</article-title><source>Nat Commun</source><volume>16</volume><year>2025</year><fpage>1755</fpage><pub-id pub-id-type="pmid">39971900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-56690-4</pub-id><pub-id pub-id-type="pmcid">PMC11840136</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Boxer</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>R.</given-names></name></person-group><article-title>Accelerating Alzheimer's therapeutic development: the past and future of clinical trials</article-title><source>Cell</source><volume>186</volume><year>2023</year><fpage>4757</fpage><lpage>4772</lpage><pub-id pub-id-type="pmid">37848035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.09.023</pub-id><pub-id pub-id-type="pmcid">PMC10625460</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Sarazin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lagarde</surname><given-names>J.</given-names></name><name name-style="western"><surname>El Haddad</surname><given-names>I.</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Bellier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Potier</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer's disease</article-title><source>Nat Aging</source><volume>4</volume><year>2024</year><fpage>761</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">38839924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-024-00630-2</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hang</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A novel anti-ischemic stroke candidate drug AAPB with dual effects of neuroprotection and cerebral blood flow improvement</article-title><source>Acta Pharm Sin B</source><volume>15</volume><year>2025</year><fpage>1070</fpage><lpage>1083</lpage><pub-id pub-id-type="pmid">40177546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2024.12.042</pub-id><pub-id pub-id-type="pmcid">PMC11959975</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Enhanced BBB penetration and microglia-targeting nanomodulator for the two-pronged modulation of chronically activated microglia-mediated neuroinflammation in Alzheimer's disease</article-title><source>Acta Pharm Sin B</source><volume>15</volume><year>2025</year><fpage>1098</fpage><lpage>1111</lpage><pub-id pub-id-type="pmid">40177541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2025.01.015</pub-id><pub-id pub-id-type="pmcid">PMC11959930</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Duncan</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mortazavi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Senturk</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Mapping the cellular etiology of schizophrenia and complex brain phenotypes</article-title><source>Nat Neurosci</source><volume>28</volume><year>2025</year><fpage>248</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">39833308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-024-01834-w</pub-id><pub-id pub-id-type="pmcid">PMC11802450</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Siavelis</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Bourdakou</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Athanasiadis</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Spyrou</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Nikita</surname><given-names>K.S.</given-names></name></person-group><article-title>Bioinformatics methods in drug repurposing for Alzheimer's disease</article-title><source>Briefings Bioinf</source><volume>17</volume><year>2016</year><fpage>322</fpage><lpage>335</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbv048</pub-id><pub-id pub-id-type="pmid">26197808</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Taubes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nova</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zalocusky</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Kosti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bicak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zilberter</surname><given-names>M.Y.</given-names></name><etal/></person-group><article-title>Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer's disease</article-title><source>Nat Aging</source><volume>1</volume><year>2021</year><fpage>932</fpage><lpage>947</lpage><pub-id pub-id-type="pmid">36172600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-021-00122-7</pub-id><pub-id pub-id-type="pmcid">PMC9514594</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bekris</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Pieper</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Leverenz</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer's drug discovery</article-title><source>Alzheimers Res Ther</source><volume>13</volume><year>2021</year><fpage>24</fpage><pub-id pub-id-type="pmid">33441136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-020-00760-w</pub-id><pub-id pub-id-type="pmcid">PMC7804907</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name></person-group><article-title>Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine</article-title><source>Cancer Commun</source><volume>41</volume><year>2021</year><fpage>1100</fpage><lpage>1115</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cac2.12215</pub-id><pub-id pub-id-type="pmcid">PMC8626610</pub-id><pub-id pub-id-type="pmid">34613667</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Doherty</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Khleifat</surname><given-names>A.A.L.</given-names></name><name name-style="western"><surname>Tantiangco</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tamburin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Albertyn</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Artificial intelligence for dementia drug discovery and trials optimization</article-title><source>Alzheimer's Dement</source><volume>19</volume><year>2023</year><fpage>5922</fpage><lpage>5933</lpage><pub-id pub-id-type="pmid">37587767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13428</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Dara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhamercherla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jadav</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Babu</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ahsan</surname><given-names>M.J.</given-names></name></person-group><article-title>Machine learning in drug discovery: a review</article-title><source>Artif Intell Rev</source><volume>55</volume><year>2022</year><fpage>1947</fpage><lpage>1999</lpage><pub-id pub-id-type="pmid">34393317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10462-021-10058-4</pub-id><pub-id pub-id-type="pmcid">PMC8356896</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nussinov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name></person-group><article-title>deepDR: a network-based deep learning approach to <italic toggle="yes">in silico</italic> drug repositioning</article-title><source>Bioinformatics</source><volume>35</volume><year>2019</year><fpage>5191</fpage><lpage>5198</lpage><pub-id pub-id-type="pmid">31116390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btz418</pub-id><pub-id pub-id-type="pmcid">PMC6954645</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer's disease</article-title><source>Cell Rep</source><volume>41</volume><year>2022</year><object-id pub-id-type="publisher-id">111717</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2022.111717</pub-id><pub-id pub-id-type="pmcid">PMC9837836</pub-id><pub-id pub-id-type="pmid">36450252</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coban Akdemir</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>AI-DrugNet: a network-based deep learning model for drug repurposing and combination therapy in neurological disorders</article-title><source>Comput Struct Biotechnol J</source><volume>21</volume><year>2023</year><fpage>1533</fpage><lpage>1542</lpage><pub-id pub-id-type="pmid">36879885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.csbj.2023.02.004</pub-id><pub-id pub-id-type="pmcid">PMC9984442</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>K.-L.</given-names></name><name name-style="western"><surname>Plascencia-Villa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K.-H.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name></person-group><article-title>Synthesize heterogeneous biological knowledge <italic toggle="yes">via</italic> representation learning for Alzheimer's disease drug repurposing</article-title><source>iScience</source><volume>26</volume><year>2023</year><object-id pub-id-type="publisher-id">105678</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2022.105678</pub-id><pub-id pub-id-type="pmcid">PMC9804117</pub-id><pub-id pub-id-type="pmid">36594024</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Kale</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wankhede</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pawar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ballal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumawat</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goswami</surname><given-names>M.</given-names></name><etal/></person-group><article-title>AI-driven innovations in Alzheimer's disease: integrating early diagnosis, personalized treatment, and prognostic modelling</article-title><source>Ageing Res Rev</source><volume>101</volume><year>2024</year><object-id pub-id-type="publisher-id">102497</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2024.102497</pub-id><pub-id pub-id-type="pmid">39293530</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Grabowska</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Roden</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer's disease with real-world clinical validation</article-title><source>NPJ Digit Med</source><volume>7</volume><year>2024</year><fpage>46</fpage><pub-id pub-id-type="pmid">38409350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-024-01038-3</pub-id><pub-id pub-id-type="pmcid">PMC10897392</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B.S.</given-names></name><etal/></person-group><article-title>Identification of novel drug targets for Alzheimer's disease by integrating genetics and proteomes from brain and blood</article-title><source>Mol Psychiatr</source><volume>26</volume><year>2021</year><fpage>6065</fpage><lpage>6073</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-021-01251-6</pub-id><pub-id pub-id-type="pmid">34381170</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Wightman</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Savage</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Shadrin</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Bahrami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease</article-title><source>Nat Genet</source><volume>53</volume><year>2021</year><fpage>1276</fpage><lpage>1282</lpage><pub-id pub-id-type="pmid">34493870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-00921-z</pub-id><pub-id pub-id-type="pmcid">PMC10243600</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Lagisetty</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bourquard</surname><given-names>T.</given-names></name><name name-style="western"><surname>Al-Ramahi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mangleburg</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Mota</surname><given-names>S.</given-names></name><name name-style="western"><surname>Soleimani</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Identification of risk genes for Alzheimer's disease by gene embedding</article-title><source>Cell Genom</source><volume>2</volume><year>2022</year><object-id pub-id-type="publisher-id">100162</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xgen.2022.100162</pub-id><pub-id pub-id-type="pmcid">PMC9581494</pub-id><pub-id pub-id-type="pmid">36268052</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><collab>Bellenguez CK&#252;&#231;&#252;kali FJansen IEKleineidam LMoreno-Grau SAmin N</collab></person-group><article-title>New insights into the genetic etiology of Alzheimer's disease and related dementias</article-title><source>Nat Genet</source><volume>54</volume><year>2022</year><fpage>412</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">35379992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-022-01024-z</pub-id><pub-id pub-id-type="pmcid">PMC9005347</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Schwartzentruber</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Barrio-Hernandez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bello</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kumasaka</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer's disease risk genes</article-title><source>Nat Genet</source><volume>53</volume><year>2021</year><fpage>392</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">33589840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-020-00776-w</pub-id><pub-id pub-id-type="pmcid">PMC7610386</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Zuo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.L.P.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>Prior-guided adversarial learning with hypergraph for predicting abnormal connections in Alzheimer's disease</article-title><source>IEEE Trans Cybern</source><volume>54</volume><year>2024</year><fpage>3652</fpage><lpage>3665</lpage><pub-id pub-id-type="pmid">38236677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TCYB.2023.3344641</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Zong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>M.K.-P.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>A new brain network construction paradigm for brain disorder <italic toggle="yes">via</italic> diffusion-based graph contrastive learning</article-title><source>IEEE Trans Pattern Anal Mach Intell</source><volume>46</volume><year>2024</year><fpage>10389</fpage><lpage>10403</lpage><pub-id pub-id-type="pmid">39137077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TPAMI.2024.3442811</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Savage</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bryois</surname><given-names>J.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk</article-title><source>Nat Genet</source><volume>51</volume><year>2019</year><fpage>404</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">30617256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0311-9</pub-id><pub-id pub-id-type="pmcid">PMC6836675</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><collab>de Rojas IMoreno-Grau STesi NGrenier-Boley BAndrade VJansen IE</collab></person-group><article-title>Common variants in Alzheimer's disease and risk stratification by polygenic risk scores</article-title><source>Nat Commun</source><volume>12</volume><year>2021</year><fpage>3417</fpage><pub-id pub-id-type="pmid">34099642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-22491-8</pub-id><pub-id pub-id-type="pmcid">PMC8184987</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Lambert Jcibrahim-Verbaas CAHarold DNaj ACSims RBellenguez</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease</article-title><source>Nat Genet</source><volume>45</volume><year>2013</year><fpage>1452</fpage><lpage>1458</lpage><pub-id pub-id-type="pmid">24162737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2802</pub-id><pub-id pub-id-type="pmcid">PMC3896259</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Cerezo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sollis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Abid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bircan</surname><given-names>K.O.</given-names></name><etal/></person-group><article-title>The NHGRI-EBI GWAS Catalog: standards for reusability, sustainability and diversity</article-title><source>Nucleic Acids Res</source><volume>53</volume><year>2025</year><fpage>D998</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">39530240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkae1070</pub-id><pub-id pub-id-type="pmcid">PMC11701593</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Kerimov</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tambets</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hayhurst</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Rahu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kolberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Raudvere</surname><given-names>U.</given-names></name><etal/></person-group><article-title>eQTL catalogue 2023: new datasets, X chromosome QTLs, and improved detection and visualisation of transcript-level QTLs</article-title><source>PLoS Genet</source><volume>19</volume><year>2023</year><object-id pub-id-type="publisher-id">e1010932</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1010932</pub-id><pub-id pub-id-type="pmcid">PMC10538656</pub-id><pub-id pub-id-type="pmid">37721944</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Chiou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Traylor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>T.G.</given-names></name><etal/></person-group><article-title>Plasma proteomic associations with genetics and health in the UK Biobank</article-title><source>Nature</source><volume>622</volume><year>2023</year><fpage>329</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">37794186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06592-6</pub-id><pub-id pub-id-type="pmcid">PMC10567551</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Diao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A compendium of promoter-centered long-range chromatin interactions in the human genome</article-title><source>Nat Genet</source><volume>51</volume><year>2019</year><fpage>1442</fpage><lpage>1449</lpage><pub-id pub-id-type="pmid">31501517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-019-0494-8</pub-id><pub-id pub-id-type="pmcid">PMC6778519</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>X.</given-names></name><name name-style="western"><surname>Maliskova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>I.R.</given-names></name><etal/></person-group><article-title>Mapping cis-regulatory chromatin contacts in neural cells links neuropsychiatric disorder risk variants to target genes</article-title><source>Nat Genet</source><volume>51</volume><year>2019</year><fpage>1252</fpage><lpage>1262</lpage><pub-id pub-id-type="pmid">31367015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-019-0472-1</pub-id><pub-id pub-id-type="pmcid">PMC6677164</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Szklarczyk</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kirsch</surname><given-names>R.</given-names></name><name name-style="western"><surname>Koutrouli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nastou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mehryary</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hachilif</surname><given-names>R.</given-names></name><etal/></person-group><article-title>The STRING database in 2023: protein&#8211;protein association networks and functional enrichment analyses for any sequenced genome of interest</article-title><source>Nucleic Acids Res</source><volume>51</volume><year>2023</year><fpage>D638</fpage><lpage>D646</lpage><pub-id pub-id-type="pmid">36370105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkac1000</pub-id><pub-id pub-id-type="pmcid">PMC9825434</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Zdrazil</surname><given-names>B.</given-names></name><name name-style="western"><surname>Felix</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>F.</given-names></name><name name-style="western"><surname>Manners</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Blackshaw</surname><given-names>J.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The ChEMBL database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods</article-title><source>Nucleic Acids Res</source><volume>52</volume><year>2024</year><fpage>D1180</fpage><lpage>D1192</lpage><pub-id pub-id-type="pmid">37933841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkad1004</pub-id><pub-id pub-id-type="pmcid">PMC10767899</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Buniello</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suveges</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cruz-Castillo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Llinares</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Cornu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Open targets platform: facilitating therapeutic hypotheses building in drug discovery</article-title><source>Nucleic Acids Res</source><volume>53</volume><year>2025</year><fpage>D1467</fpage><lpage>D1475</lpage><pub-id pub-id-type="pmid">39657122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkae1128</pub-id><pub-id pub-id-type="pmcid">PMC11701534</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gough</surname><given-names>J.</given-names></name></person-group><article-title>supraHex: an R/Bioconductor package for tabular omics data analysis using a supra-hexagonal map</article-title><source>Biochem Biophys Res Commun</source><volume>443</volume><year>2014</year><fpage>285</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">24309102</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2013.11.103</pub-id><pub-id pub-id-type="pmcid">PMC3905187</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H.</given-names></name></person-group><article-title>I3: a self-organising learning workflow for intuitive integrative interpretation of complex genetic data</article-title><source>Genom Proteom Bioinform</source><volume>17</volume><year>2019</year><fpage>503</fpage><lpage>510</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gpb.2018.10.006</pub-id><pub-id pub-id-type="pmcid">PMC7056857</pub-id><pub-id pub-id-type="pmid">31765831</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A cross-disease, pleiotropy-driven approach for therapeutic target prioritization and evaluation</article-title><source>Cell Rep Methods</source><volume>4</volume><year>2024</year><object-id pub-id-type="publisher-id">100757</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.crmeth.2024.100757</pub-id><pub-id pub-id-type="pmcid">PMC11046034</pub-id><pub-id pub-id-type="pmid">38631345</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gough</surname><given-names>J.</given-names></name></person-group><article-title>The &#8216;dnet&#8217; approach promotes emerging research on cancer patient survival</article-title><source>Genome Med</source><volume>6</volume><year>2014</year><fpage>64</fpage><pub-id pub-id-type="pmid">25246945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-014-0064-8</pub-id><pub-id pub-id-type="pmcid">PMC4160547</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Knezevic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Burnham</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>J.C.</given-names></name></person-group><article-title>XGR software for enhanced interpretation of genomic summary data, illustrated by application to immunological traits</article-title><source>Genome Med</source><volume>8</volume><year>2016</year><fpage>129</fpage><pub-id pub-id-type="pmid">27964755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-016-0384-y</pub-id><pub-id pub-id-type="pmcid">PMC5154134</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>J.C.</given-names></name></person-group><article-title>Priority index: database of genetic targets in immune-mediated disease</article-title><source>Nucleic Acids Res</source><volume>50</volume><year>2022</year><fpage>D1358</fpage><lpage>D1367</lpage><pub-id pub-id-type="pmid">34751399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkab994</pub-id><pub-id pub-id-type="pmcid">PMC8728240</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Consortium</surname><given-names>The ULTRA-DD</given-names></name><name name-style="western"><surname>De Wolf</surname><given-names>H.</given-names></name><name name-style="western"><surname>Knezevic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Burnham</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Osgood</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A genetics-led approach defines the drug target landscape of 30 immune-related traits</article-title><source>Nat Genet</source><volume>51</volume><year>2019</year><fpage>1082</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">31253980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-019-0456-1</pub-id><pub-id pub-id-type="pmcid">PMC7124888</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>H.</given-names></name></person-group><article-title>PiER: web-based facilities tailored for genetic target prioritisation harnessing human disease genetics, functional genomics and protein interactions</article-title><source>Nucleic Acids Res</source><volume>50</volume><year>2022</year><fpage>W583</fpage><lpage>W592</lpage><pub-id pub-id-type="pmid">35610036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkac379</pub-id><pub-id pub-id-type="pmcid">PMC9252812</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Boyle</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.I.</given-names></name><name name-style="western"><surname>Pritchard</surname><given-names>J.K.</given-names></name></person-group><article-title>An expanded view of complex traits: from polygenic to omnigenic</article-title><source>Cell</source><volume>169</volume><year>2017</year><fpage>1177</fpage><lpage>1186</lpage><pub-id pub-id-type="pmid">28622505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.05.038</pub-id><pub-id pub-id-type="pmcid">PMC5536862</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>J.C.</given-names></name></person-group><article-title>From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis</article-title><source>Lancet Rheumatol</source><volume>2</volume><year>2020</year><fpage>e50</fpage><lpage>e62</lpage><pub-id pub-id-type="pmid">38258277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2665-9913(19)30134-1</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Biomarker changes during 20 years preceding Alzheimer's disease</article-title><source>N Engl J Med</source><volume>390</volume><year>2024</year><fpage>712</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">38381674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2310168</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Jonsson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Atwal</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Snaedal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Bjornsson</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A mutation in APP protects against Alzheimer's disease and age-related cognitive decline</article-title><source>Nature</source><volume>488</volume><year>2012</year><fpage>96</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">22801501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11283</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Bateman</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Delmar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Abbas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Two phase 3 trials of gantenerumab in early Alzheimer's disease</article-title><source>N Engl J Med</source><volume>389</volume><year>2023</year><fpage>1862</fpage><lpage>1876</lpage><pub-id pub-id-type="pmid">37966285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2304430</pub-id><pub-id pub-id-type="pmcid">PMC10794000</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Honig</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Vellas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bullock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Borrie</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Trial of solanezumab for mild dementia due to Alzheimer's disease</article-title><source>N Engl J Med</source><volume>378</volume><year>2018</year><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="pmid">29365294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1705971</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Sperling</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rafii</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Masters</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>Trial of solanezumab in preclinical Alzheimer's disease</article-title><source>N Engl J Med</source><volume>389</volume><year>2023</year><fpage>1096</fpage><lpage>1107</lpage><pub-id pub-id-type="pmid">37458272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2305032</pub-id><pub-id pub-id-type="pmcid">PMC10559996</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Klunk</surname><given-names>W.</given-names></name><name name-style="western"><surname>Raskind</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease</article-title><source>N Engl J Med</source><volume>370</volume><year>2014</year><fpage>322</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">24450891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1304839</pub-id><pub-id pub-id-type="pmcid">PMC4159618</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Ostrowitzki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bittner</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sink</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Mackey</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rabe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Honig</surname><given-names>L.S.</given-names></name><etal/></person-group><article-title>Evaluating the safety and efficacy of crenezumab <italic toggle="yes">vs</italic> placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials</article-title><source>JAMA Neurol</source><volume>79</volume><year>2022</year><fpage>1113</fpage><lpage>1121</lpage><pub-id pub-id-type="pmid">36121669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2022.2909</pub-id><pub-id pub-id-type="pmcid">PMC9486635</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Hey</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Abushakra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Reiman</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Hort</surname><given-names>J.</given-names></name><name name-style="western"><surname>Prins</surname><given-names>N.D.</given-names></name><etal/></person-group><article-title>Effects of oral ALZ-801/valiltramiprosate on plasma biomarkers, brain hippocampal volume, and cognition: results of 2-year single-arm, open-label, phase 2 trial in APOE4 carriers with early Alzheimer's disease</article-title><source>Drugs</source><volume>84</volume><year>2024</year><fpage>811</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">38902571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-024-02067-8</pub-id><pub-id pub-id-type="pmcid">PMC11289173</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Hey</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Abushakra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Power</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kesslak</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Analysis of cerebrospinal fluid, plasma <italic toggle="yes">&#946;</italic>-amyloid biomarkers, and cognition from a 2-year phase 2 trial evaluating oral ALZ-801/valiltramiprosate in APOE4 carriers with early Alzheimer's disease using quantitative systems pharmacology model</article-title><source>Drugs</source><volume>84</volume><year>2024</year><fpage>825</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">38902572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-024-02068-7</pub-id><pub-id pub-id-type="pmcid">PMC11289344</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Yong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A novel ferroptosis inhibitor, thonningianin A, improves Alzheimer's disease by activating GPX4</article-title><source>Theranostics</source><volume>14</volume><year>2024</year><fpage>6161</fpage><lpage>6184</lpage><pub-id pub-id-type="pmid">39431016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.98172</pub-id><pub-id pub-id-type="pmcid">PMC11488096</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>McGinn</surname><given-names>O.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bahreini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Priedigkeit</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>K.</given-names></name><etal/></person-group><article-title>ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation</article-title><source>Nat Commun</source><volume>13</volume><year>2022</year><fpage>2011</fpage><pub-id pub-id-type="pmid">35440136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-29498-9</pub-id><pub-id pub-id-type="pmcid">PMC9019037</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Oveisgharan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Burba</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tasaki</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Estrogen receptor genes, cognitive decline, and Alzheimer disease</article-title><source>Neurology</source><volume>100</volume><year>2023</year><fpage>e1474</fpage><lpage>e1487</lpage><pub-id pub-id-type="pmid">36697247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000206833</pub-id><pub-id pub-id-type="pmcid">PMC10104608</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Mulnard</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Cotman</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Kawas</surname><given-names>C.</given-names></name><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Sano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doody</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study</article-title><source>JAMA</source><volume>283</volume><year>2000</year><fpage>1007</fpage><lpage>1015</lpage><pub-id pub-id-type="pmid">10697060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.283.8.1007</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-Anton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gras</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bourdin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dubreuil</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chanez</surname><given-names>P.</given-names></name></person-group><article-title>KIT as a therapeutic target for non-oncological diseases</article-title><source>Pharmacol Ther</source><volume>197</volume><year>2019</year><fpage>11</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">30557630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2018.12.008</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>B.</given-names></name><name name-style="western"><surname>L&#243;pez-Arrieta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lipschitz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Doskas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Spiru</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moroz</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial</article-title><source>Alzheimers Res Ther</source><volume>15</volume><year>2023</year><fpage>39</fpage><pub-id pub-id-type="pmid">36849969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-023-01169-x</pub-id><pub-id pub-id-type="pmcid">PMC9972756</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Furumichi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Matsuura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ishiguro-Watanabe</surname><given-names>M.</given-names></name></person-group><article-title>KEGG: biological systems database as a model of the real world</article-title><source>Nucleic Acids Res</source><volume>53</volume><year>2025</year><fpage>D672</fpage><lpage>D677</lpage><pub-id pub-id-type="pmid">39417505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkae909</pub-id><pub-id pub-id-type="pmcid">PMC11701520</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Del Campo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vermunt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peeters</surname><given-names>C.F.W.</given-names></name><name name-style="western"><surname>Sieben</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hok-A-Hin</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Lle&#243;</surname><given-names>A.</given-names></name><etal/></person-group><article-title>CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer's disease</article-title><source>Nat Commun</source><volume>14</volume><year>2023</year><fpage>5635</fpage><pub-id pub-id-type="pmid">37704597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-41122-y</pub-id><pub-id pub-id-type="pmcid">PMC10499811</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Hebron</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Lawler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mundel</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Yusuf</surname><given-names>N.</given-names></name><name name-style="western"><surname>Starr</surname><given-names>J.N.</given-names></name><etal/></person-group><article-title>Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer's disease</article-title><source>Ann Neurol</source><volume>88</volume><year>2020</year><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">32468646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25775</pub-id><pub-id pub-id-type="pmcid">PMC7383852</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Howell</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Dalenc</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cortes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gomez Moreno</surname><given-names>H.L.</given-names></name><etal/></person-group><article-title>Capivasertib in hormone receptor-positive advanced breast cancer</article-title><source>N Engl J Med</source><volume>388</volume><year>2023</year><fpage>2058</fpage><lpage>2070</lpage><pub-id pub-id-type="pmid">37256976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2214131</pub-id><pub-id pub-id-type="pmcid">PMC11335038</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Parikh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Banna</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Friedlaender</surname><given-names>A.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Subbiah</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Drugging KRAS: current perspectives and state-of-art review</article-title><source>J Hematol Oncol</source><volume>15</volume><year>2022</year><fpage>152</fpage><pub-id pub-id-type="pmid">36284306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-022-01375-4</pub-id><pub-id pub-id-type="pmcid">PMC9597994</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Arrillaga-Romany</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Odia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Aguilera</surname><given-names>D.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Batchelor</surname><given-names>T.</given-names></name><etal/></person-group><article-title>ONC201 (dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma</article-title><source>J Clin Oncol</source><volume>42</volume><year>2024</year><fpage>1542</fpage><lpage>1552</lpage><pub-id pub-id-type="pmid">38335473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.01134</pub-id><pub-id pub-id-type="pmcid">PMC11095894</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Sullivan</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Infante</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Janku</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>D.J.L.</given-names></name><name name-style="western"><surname>Sosman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Keedy</surname><given-names>V.</given-names></name><etal/></person-group><article-title>First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study</article-title><source>Cancer Discov</source><volume>8</volume><year>2018</year><fpage>184</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">29247021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-17-1119</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Combination of autophagy and NFE2L2/NRF2 activation as a treatment approach for neuropathic pain</article-title><source>Autophagy</source><volume>17</volume><year>2021</year><fpage>4062</fpage><lpage>4082</lpage><pub-id pub-id-type="pmid">33834930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2021.1900498</pub-id><pub-id pub-id-type="pmcid">PMC8726676</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><article-title>PIK3CA mutations induce neuronal hyperactivity during glioma formation</article-title><source>Cancer Discov</source><volume>10</volume><year>2020</year><fpage>340</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-RW2020-019</pub-id><pub-id pub-id-type="pmid">32033971</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Dajani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Armour-Garb</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ota</surname><given-names>M.</given-names></name><name name-style="western"><surname>Allain</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Base-editing mutagenesis maps alleles to tune human T cell functions</article-title><source>Nature</source><volume>625</volume><year>2024</year><fpage>805</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">38093011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06835-6</pub-id><pub-id pub-id-type="pmcid">PMC11065414</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Alonso</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mesa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ovejero</surname><given-names>LdlP.</given-names></name><name name-style="western"><surname>Aizpurua</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lechuga</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Zarzuela</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Structure of the RAF1&#8211;HSP90&#8211;CDC37 complex reveals the basis of RAF1 regulation</article-title><source>Mol Cell</source><volume>82</volume><year>2022</year><comment>3438-52.e8</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2022.08.012</pub-id><pub-id pub-id-type="pmid">36055235</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>An</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells</article-title><source>J Hepatol</source><volume>79</volume><year>2023</year><fpage>1435</fpage><lpage>1449</lpage><pub-id pub-id-type="pmid">37689322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2023.08.024</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Kirouac</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rajic</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Cribbs</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Padmanabhan</surname><given-names>J.</given-names></name></person-group><article-title>Activation of Ras-ERK signaling and GSK-3 by amyloid precursor protein and amyloid beta facilitates neurodegeneration in Alzheimer&#8217;s disease</article-title><source>eNeuro</source><volume>4</volume><year>2017</year><comment>ENEURO.0149-16.2017</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/ENEURO.0149-16.2017</pub-id><pub-id pub-id-type="pmcid">PMC5367084</pub-id><pub-id pub-id-type="pmid">28374012</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chua</surname><given-names>L.-L.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease</article-title><source>Sci Signal</source><volume>10</volume><year>2017</year><object-id pub-id-type="publisher-id">eaam6790</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scisignal.aam6790</pub-id><pub-id pub-id-type="pmid">28720718</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P.-L.</given-names></name><name name-style="western"><surname>Niidome</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akaike</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kihara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>H.</given-names></name></person-group><article-title>Rac1 inhibition negatively regulates transcriptional activity of the amyloid precursor protein gene</article-title><source>J Neurosci Res</source><volume>87</volume><year>2009</year><fpage>2105</fpage><lpage>2114</lpage><pub-id pub-id-type="pmid">19267423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jnr.22039</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Zaldua</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gastineau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hoshino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lezoualc'h</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zugaza</surname><given-names>J.L.</given-names></name></person-group><article-title>Epac signaling pathway involves STEF, a guanine nucleotide exchange factor for Rac, to regulate APP processing</article-title><source>FEBS Lett</source><volume>581</volume><year>2007</year><fpage>5814</fpage><lpage>5818</lpage><pub-id pub-id-type="pmid">18047838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.febslet.2007.11.053</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Kapadia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Theil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Opitz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Villacampa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Beckert</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schoch</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Phosphorylation-state dependent intraneuronal sorting of A<italic toggle="yes">&#946;</italic> differentially impairs autophagy and the endo-lysosomal system</article-title><source>Autophagy</source><volume>20</volume><year>2024</year><fpage>166</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">37642583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2023.2252300</pub-id><pub-id pub-id-type="pmcid">PMC10761119</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fertan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Livesey</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Klenerman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Patani</surname><given-names>R.</given-names></name></person-group><article-title>APP antisense oligonucleotides reduce amyloid-<italic toggle="yes">&#946;</italic> aggregation and rescue endolysosomal dysfunction in Alzheimer's disease</article-title><source>Brain</source><volume>147</volume><year>2024</year><fpage>2325</fpage><lpage>2333</lpage><pub-id pub-id-type="pmid">38527856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awae092</pub-id><pub-id pub-id-type="pmcid">PMC11224613</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Du</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Inhibition of Rac1-dependent forgetting alleviates memory deficits in animal models of Alzheimer's disease</article-title><source>Protein Cell</source><volume>10</volume><year>2019</year><fpage>745</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">31321704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13238-019-0641-0</pub-id><pub-id pub-id-type="pmcid">PMC6776562</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Upregulation of RIN3 induces endosomal dysfunction in Alzheimer's disease</article-title><source>Transl Neurodegener</source><volume>9</volume><year>2020</year><fpage>26</fpage><pub-id pub-id-type="pmid">32552912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-020-00206-1</pub-id><pub-id pub-id-type="pmcid">PMC7301499</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Rosewood</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Nho</surname><given-names>K.</given-names></name><name name-style="western"><surname>Risacher</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Pathway enrichment in genome-wide analysis of longitudinal Alzheimer's disease biomarker endophenotypes</article-title><source>Alzheimer's Dement</source><volume>20</volume><year>2024</year><fpage>8639</fpage><lpage>8650</lpage><pub-id pub-id-type="pmid">39440837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14308</pub-id><pub-id pub-id-type="pmcid">PMC11667536</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Identification of genetic architecture shared between schizophrenia and Alzheimer's disease</article-title><source>Transl Psychiatry</source><volume>15</volume><year>2025</year><fpage>150</fpage><pub-id pub-id-type="pmid">40240757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-025-03348-w</pub-id><pub-id pub-id-type="pmcid">PMC12003746</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name></person-group><article-title>Alzheimer's disease drug development pipeline: 2023</article-title><source>Alzheimer's Dement</source><volume>9</volume><year>2023</year><object-id pub-id-type="publisher-id">e12385</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.12385</pub-id><pub-id pub-id-type="pmcid">PMC10210334</pub-id><pub-id pub-id-type="pmid">37251912</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Mullard</surname><given-names>A.</given-names></name></person-group><article-title>Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating</article-title><source>Nat Rev Drug Discov</source><volume>20</volume><year>2021</year><fpage>3</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">33303932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41573-020-00217-7</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Skantharajah</surname><given-names>N.</given-names></name><name name-style="western"><surname>Baichoo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boughtwood</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Casas-Silva</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chandrasekharan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dave</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Equity, diversity, and inclusion at the global Alliance for genomics and health</article-title><source>Cell Genom</source><volume>3</volume><year>2023</year><object-id pub-id-type="publisher-id">100386</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xgen.2023.100386</pub-id><pub-id pub-id-type="pmcid">PMC10589617</pub-id><pub-id pub-id-type="pmid">37868041</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Hasan</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Trushina</surname><given-names>E.</given-names></name></person-group><article-title>Advances in recapitulating Alzheimer's disease phenotypes using human induced pluripotent stem cell-based <italic toggle="yes">in vitro</italic> models</article-title><source>Brain Sci</source><volume>12</volume><year>2022</year><fpage>552</fpage><pub-id pub-id-type="pmid">35624938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci12050552</pub-id><pub-id pub-id-type="pmcid">PMC9138647</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>X.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Nose-to-brain delivery of targeted lipid nanoparticles as two-pronged <italic toggle="yes">&#946;</italic>-amyloid nanoscavenger for Alzheimer's disease therapy</article-title><source>Acta Pharm Sin B</source><volume>15</volume><year>2025</year><fpage>2884</fpage><lpage>2899</lpage><pub-id pub-id-type="pmid">40654363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2025.02.035</pub-id><pub-id pub-id-type="pmcid">PMC12254852</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Modulating neuroinflammation and cognitive function in postoperative cognitive dysfunction <italic toggle="yes">via</italic> CCR5&#8211;GPCRs&#8211;Ras&#8211;MAPK pathway targeting with microglial EVs</article-title><source>CNS Neurosci Ther</source><volume>30</volume><year>2024</year><object-id pub-id-type="publisher-id">e14924</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cns.14924</pub-id><pub-id pub-id-type="pmcid">PMC11324532</pub-id><pub-id pub-id-type="pmid">39143678</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supporting information</title><p id="p0280">The following is the Supporting Information to this article.<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.pdf" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0275">This work is supported by <funding-source id="gs10">Noncommunicable Chronic Diseases-National Science and Technology Major Project</funding-source> (<award-id award-type="grant" rid="gs10">2024ZD0519600</award-id> to Hai Fang, China), <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs7">32470681</award-id> and <award-id award-type="grant" rid="gs7">32170663</award-id> to Hai Fang, <award-id award-type="grant" rid="gs7">82470220</award-id> to Zheng Wang, and <award-id award-type="grant" rid="gs7">82272128</award-id> to Ming Ni), Program for Basic and Translational Research on mRNA Drugs from <funding-source id="gs8"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100018920</institution-id><institution>Ruijin Hospital</institution></institution-wrap></funding-source> Affiliated to <funding-source id="gs9"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100008233</institution-id><institution>Shanghai Jiao Tong University School of Medicine</institution></institution-wrap></funding-source>, and <funding-source id="gs11">Innovative Research Team of High-Level Local Universities in Shanghai</funding-source>.</p></ack><fn-group><fn id="d36e110"><p id="ntpara0010">This article is part of a special issue entitled: AI, computational and systems biology-guided translational research in Alzheimer's disease published in Acta Pharmaceutica Sinica B.</p></fn><fn id="d36e113"><p id="ntpara0015">Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.</p></fn><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0285">Supporting information to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.apsb.2025.07.018" id="intref0035">https://doi.org/10.1016/j.apsb.2025.07.018</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Clin Nutr</journal-id><journal-id journal-id-type="iso-abbrev">Am J Clin Nutr</journal-id><journal-id journal-id-type="pmc-domain-id">673</journal-id><journal-id journal-id-type="pmc-domain">ajcn</journal-id><journal-title-group><journal-title>The American Journal of Clinical Nutrition</journal-title></journal-title-group><issn pub-type="ppub">0002-9165</issn><issn pub-type="epub">1938-3207</issn><publisher><publisher-name>American Society for Nutrition</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12489340</article-id><article-id pub-id-type="pmcid-ver">PMC12489340.1</article-id><article-id pub-id-type="pmcaid">12489340</article-id><article-id pub-id-type="pmcaiid">12489340</article-id><article-id pub-id-type="pmid">40368267</article-id><article-id pub-id-type="doi">10.1016/j.ajcnut.2025.05.006</article-id><article-id pub-id-type="pii">S0002-9165(25)00258-8</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Effect of age and sex on the urinary elimination of a single dose of mixed flavonoids: results from a single-arm intervention in healthy United Kingdom adults</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Kay</surname><given-names initials="CD">Colin D</given-names></name><email>ckay@uams.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff1" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Tejera</surname><given-names initials="N">Noemi</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Jennings</surname><given-names initials="A">Amy</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Haldar</surname><given-names initials="S">Sumanto</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Diment</surname><given-names initials="BC">Bethany C.</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Bevan</surname><given-names initials="D">Damon</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Crossman</surname><given-names initials="LC">Lisa C</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Li</surname><given-names initials="S">Sherly</given-names></name><xref rid="aff7" ref-type="aff">7</xref><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Cassidy</surname><given-names initials="A">Aedin</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Minihane</surname><given-names initials="AM">Anne-Marie</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff9" ref-type="aff">9</xref></contrib><aff id="aff1"><label>1</label>Department of Paediatrics, Arkansas Children&#8217;s Research Institute - Arkansas Children&#8217;s Nutrition Center, Little Rock, AR, United States</aff><aff id="aff2"><label>2</label>Department of Nutrition and Preventive Medicine, Norwich Medical School, University of East Anglia (UEA), Norwich, United Kingdom</aff><aff id="aff3"><label>3</label>Institute for Global Food Security, Queen's University Belfast, Belfast, Northern Ireland</aff><aff id="aff4"><label>4</label>Faculty of Health and Social Sciences, Bournemouth University, Bournemouth, United Kingdom</aff><aff id="aff5"><label>5</label>School of Biological Sciences, University of East Anglia (UEA), Norwich, United Kingdom</aff><aff id="aff6"><label>6</label>SequenceAnalysis.co.uk, NRP Innovation Centre, Norwich Research Park, Norwich, United Kingdom</aff><aff id="aff7"><label>7</label>Murdoch Children&#8217;s Research Institute, Melbourne, Australia</aff><aff id="aff8"><label>8</label>Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom</aff><aff id="aff9"><label>9</label>Norwich Institute of Healthy Ageing, Norwich, United Kingdom</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>ckay@uams.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>12</day><month>5</month><year>2025</year></pub-date><volume>122</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">494055</issue-id><fpage>101</fpage><lpage>111</lpage><history><date date-type="received"><day>15</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>30</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>7</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-03 11:25:16.713"><day>03</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Background</title><p>Nutrition intervention trials demonstrate that increased flavonoid intake can have clinically meaningful impacts on disease outcomes/biomarkers; however, high variability in absorption and metabolism and large heterogeneity in biochemical and physiological responses are observed. The etiology of this variability is poorly understood.</p></sec><sec><title>Objective</title><p>The objective of this study was to explore the relationships between sex, age, and microbiota speciation on mixed flavonoid elimination over 24 h.</p></sec><sec><title>Methods</title><p>Healthy males and females (<italic toggle="yes">n</italic> = 163) prospectively recruited on the basis of age (18&#8211;30 y or 65&#8211;77 y) and sex consumed a standardized flavonoid-rich test meal providing 640-mg cocoa/chocolate flavan-3-ols, 340-mg citrus flavanones, and 390-mg blackberry anthocyanins. Urinary samples collected at baseline (&#8722;24 to 0 h), 0 to 3.5 h, &gt;3.5 h to 7 h, and &gt;7 to 24 h were analyzed for flavonoids and their metabolites by ultra-high-performance liquid chromatography-mass spectrometry (UPLC-MS/MS). Stool microbiome speciation was determined via Illumina sequencing. Linear mixed-effect models were used to assess differences in cumulative excretion across age and sex with time-by-group interaction taken as the principal analysis of effect.</p></sec><sec><title>Results</title><p>There were no group (older females, older males, younger females, and younger males) differences in total 24 h urinary metabolite recovery, but there was a trend toward a higher rate of cumulative recovery in older males versus younger males at 24 h (<italic toggle="yes">P</italic>-group at 24h = 0.06). Of 76 metabolites, 20 had significantly different times of maximum urine excretion (Tmax) by age and 9 by sex, with a later mean Tmax observed for older participants (92% of instances). Associations with age were not mediated by body mass index (BMI) or microbiome speciation. Significant differences in maximum urine excretion (Cmax) by sex were observed for only 6 metabolites and differences by age for 5 metabolites.</p></sec><sec><title>Conclusion</title><p>Total elimination recovery of (poly)phenols was relatively consistent across age and sex groups, whereas elimination kinetics (Tmax) differed substantially being much later in older indivudals, possibly resulting from differences in intestinal transit time or kidney clearance. Assuming (poly)phenol metabolites have varying biological activities, establishing dose-response relationships and defining metabolite profiles in population subgroups is required to inform the future development of dietary flavonoid/(poly)phenol recommendations.</p><p>This trial was registered at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov" id="intref0010">clinicaltrials.gov</ext-link> as <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01922869">NCT01922869</ext-link></p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>absorption</kwd><kwd>metabolism</kwd><kwd>excretion</kwd><kwd>flavonoids</kwd><kwd>polyphenols</kwd><kwd>genes</kwd><kwd>gut microflora</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="kwrd0050">Cmax</term><def><p>maximum urine excretion</p></def></def-item><def-item><term id="kwrd0060">RCT</term><def><p>randomized control trial</p></def></def-item><def-item><term id="kwrd0070">Tmax</term><def><p>time of maximum urine excretion</p></def></def-item><def-item><term id="kwrd0080">Aeu 0-24</term><def><p>total amount excreted in urine over 24 h</p></def></def-item></def-list></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Flavonoids are a diverse group of dietary phytochemicals that are structurally subclassified into anthocyanins, flavonols, flavones, flavanones, flavan-3-ols, and isoflavones, and include their oligomeric (i.e., flavonoids) and polymeric (i.e., proanthocyanidins) forms [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>]. Their bioactivity is, in part, responsible for the health benefits of fruits and vegetables and other plant-based foods, such as tea, fruit juice, wine, herbs, and spices [<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib4" ref-type="bibr">4</xref>]. In prospective cohort studies, a high flavonoid intake is associated with a 10%&#8211;40% reduction in all-cause mortality, dementia incidence, and cognitive decline, cardiovascular events, risk of specific cancers and, a lower body weight [<xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>]. An accumulating number of randomized control trials (RCTs) are demonstrating, at a group level, clinically meaningful impacts of increased flavonoid intake on chronic disease biomarkers, providing insight into the underlying mechanisms of action at play [<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib10" ref-type="bibr">10</xref>]. The dose-response relationships between flavonoid consumption and phenotype are, however, highly variable, with large heterogeneity in the concentration of flavonoid metabolites in biological samples following intake of a given dose, as well as the biochemical and physiological responses observed [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>]. The molecular and physiological basis for this heterogeneity in dietary flavonoid metabolism and responsiveness observed across studies is poorly understood.</p><p id="p0015">As reviewed, although a small number of existing studies have investigated potential modulators of (poly)phenol metabolism and elimination, most have had a limited number of participants, with heterogeneity in response being a secondary post hoc rather a priori aim, which often results in a poorly powered analysis [<xref rid="bib14" ref-type="bibr">14</xref>,<xref rid="bib15" ref-type="bibr">15</xref>].</p><p id="p0020">Once ingested, the absorption, distribution, metabolism, and elimination of flavonoids is influenced by human intestinal, liver, and kidney functions, including phase 1 and phase 2 metabolizing enzymes, many of which are also important in the metabolism of xenobiotics and drugs [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib4" ref-type="bibr">4</xref>]. Although not well characterized for flavonoid metabolism, there is emerging evidence to suggest that the functionality of these enzymes may be influenced by such physiological variables as sex and age [<xref rid="bib16" ref-type="bibr">[16]</xref>, <xref rid="bib17" ref-type="bibr">[17]</xref>, <xref rid="bib18" ref-type="bibr">[18]</xref>]. Furthermore, a substantial fraction of flavonoid absorption, distribution, metabolism, and elimination is impacted by gut microbial metabolism and flavonoid intake has also been shown to influence microbiota speciation [<xref rid="bib19" ref-type="bibr">19</xref>,<xref rid="bib20" ref-type="bibr">20</xref>]. However, the role of gut microbiota functional and metabolic diversity in flavonoid metabolism and bioavailability is still poorly understood [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib21" ref-type="bibr">21</xref>].</p><p id="p0025">Here, using a prospective recruitment approach, we conducted the first systematic investigation of the impact of sex, age, and microbiota speciation on flavonoid elimination over 24 h following the consumption of a standardized cocoa/chocolate flavan-3-ol, citrus flavanone, and blackberry anthocyanin-rich test meal. Such establishment of metabolism and elimination kinetics in population subgroups is needed to inform and refine the development of dietary flavonoid recommendations [<xref rid="bib22" ref-type="bibr">22</xref>].</p></sec><sec id="sec2"><title>Methods</title><sec id="sec2.1"><title>Study participants</title><p id="p0030">The acute chocolate, orange/citrus, blackberry intervention study (COB study) recruited prospectively on the basis of sex and age and aimed to include equal numbers of males and females and those aged between 18 and 30 y or 65 and 77 y who were generally healthy. Exclusion criteria were: BMI &lt; 18.5 kg/m<sup>2</sup> or &gt; 30 kg/m<sup>2</sup>; smokers or nicotine users; hypertension with either a systolic blood pressure &gt;140 mmHg or a diastolic blood pressure &gt;90 mmHg; a medical condition or significant medical history likely to affect study measurements e.g., diagnosed type 2 diabetes, cardiovascular, renal, liver, thyroid or gastrointestinal diseases; vaccinations or antibiotics use in the previous 3 mo, (because these will impact on the gut microflora composition and metabolism and also phase 1 and 2 metabolism); blood biochemistry (including alanine aminotransferase &gt;40 IU/L, alkaline phosphatase &gt;130 IU/L, bilirubin, albumin, urea, and creatinine) outside the normal ranges; prescribed medication use that could interact with the enzymes involved in the metabolism of flavonoids (<xref rid="appsec1" ref-type="sec">Supplementary Table S1</xref>); taking flavonoid containing supplements or other dietary supplements for 1 mo prior to the study; known allergies to the intervention foods; consume &gt;21 alcohol unit/wk for males, or 14 units/wk for females; pregnant, lactating, or planning a pregnancy (or having fertility treatment); unable to provide informed consent to participate in the study.</p><p id="p0035">Because excessively high intake of flavonoids has been shown to alter human metabolic pathways [<xref rid="bib23" ref-type="bibr">23</xref>,<xref rid="bib24" ref-type="bibr">24</xref>], individuals who are atypically high consumers of flavonoids as part of their regular diet were precluded from participating. At the time of the COB trial delivery, United Kingdom adults were reported to consume a mean intake of 10 servings of flavonoid-rich foods (including tea, coffee, chocolate, fruit, vegetables, and other plant-based products) per day (National Diet and Nutrition Survey, 2011) [<xref rid="bib25" ref-type="bibr">25</xref>]. Individuals were excluded if they consumed &gt;15 servings of flavonoid-rich foods per day. Flavonoid intake was assessed using the EPIC food frequency questionnaire [<xref rid="bib26" ref-type="bibr">26</xref>].</p></sec><sec id="sec2.2"><title>Study design</title><p id="p0040">During the dietary run-in period and acute test-meal protocol, participants were asked to adhere to a restricted diet to minimize the intake of (poly)phenols (including flavonoids and phenolics) by avoiding the consumption of fruits, vegetables, chocolate, spices, high-fiber products, tea, coffees, fruit juices, and alcoholic beverages (<xref rid="appsec1" ref-type="sec">Supplementary Table S2</xref>) for 48 h before the study day and for the 24 h after the consumption of the flavonoid-rich test meal (<xref rid="fig1" ref-type="fig">Figure 1</xref>). In addition to the medications listed in <xref rid="appsec1" ref-type="sec">Supplementary Table S1</xref>, participants were asked to avoid acetaminophen (paracetamol) or other nonsteroidal anti-inflammatory drugs for the 10 h (fasting period) prior to the acute study day and for the duration of the sample collection unless it was a medical requirement.<fig id="fig1" position="float" orientation="portrait"><label>FIGURE 1</label><caption><p>Chocolate, orange juice and blackberry (COB) intervention to examine flavonoid metabolism.</p></caption><alt-text id="alttext0020">FIGURE 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0045">Participants were provided with a standardized low-flavonoid ready meal, consisting of either a vegetable-free fish pie or macaroni cheese, along with a bread roll and a portion of fruit-free sponge cake to consume the evening prior to attending the clinic visit in order to control for any interindividual variability in background dietary (poly)phenols from their previous meals, and then undergo an overnight fast (only water allowed during this fasting period). The participants attended the clinical trial unit after an overnight fast for the acute test-meal session containing mixed flavonoids. The standardized mixed flavonoid-rich test meal consisted of a bar of dark chocolate (Barry Callebaut, 50 g), a freeze-dried orange extract (Monteloeder, 362 mg), and blackberry (Nutra Ingredients Ltd, 37.5 g) powder in water, known as the COB mixture, with the composition of the chocolate provided by the manufacturer (Barry Callebut, Belgium) and the flavonoid composition of the blackberry powder and citrus extracts established using an internal UHPLC-MS/MS based analysis [<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib27" ref-type="bibr">27</xref>,<xref rid="bib28" ref-type="bibr">28</xref>]. This provided 640-mg flavan-3-ols (&#8764;30% monomers, &#8764;180 mg (-)-epicatechin), 340-mg flavanones (89.3% hesperitin, 3.4% narirutin), and 390-mg anthocyanins (99+% cyanidin-3-<italic toggle="yes">O</italic>-glucoside). Urine samples were collected at baseline (&#8722;24 to 0 h, before the test meal), 0&#8211;3.5 h, 3.5&#8211;7 h, and 7 &#8211;24 h. Participants were free to leave the clinical trial unit at 7 h and return at the 24 h points for the relevant urine sampling. During the day of the intervention, 2 standardized low-flavonoid meals (lunch and dinner) were provided along with low-flavonoid snacks (<xref rid="fig1" ref-type="fig">Figure 1</xref>).</p><p id="p0050">The study was approved by the National Health Service Health Research Authority (IRAS Project ID 1251207), followed the principles of the Declaration of Helsinki, and was conducted at the Clinical Research Facility, University of East Anglia. Informed consent was obtained from all participants before study commencement. Recruitment occurred between October 2013 and March 2015, with follow-up completed by April 2015. Clinical Trials Registration # <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01922869">NCT01922869</ext-link>.</p></sec><sec id="sec2.3"><title>Dietary assessment</title><p id="p0055">Participants completed a 131-item validated [<xref rid="bib26" ref-type="bibr">26</xref>] food frequency questionnire (FFQ), which captured dietary habits over the previous 12 mo, from which nutrient intakes were determined using McCance and Widdowson Food Tables [<xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib30" ref-type="bibr">30</xref>] and flavonoid intakes were calculated using the updated USDA databases for the flavonoid and proanthocyanin content of food, as previously described [<xref rid="bib31" ref-type="bibr">31</xref>]. If no values were available in the USDA database (USDA Database for the Flavonoid Content of Selected Foods Release 3.1) for foods in the FFQ, available data from the Phenol-Explorer database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.phenol-explorer.eu" id="intref0015">www.phenol-explorer.eu</ext-link>) [<xref rid="bib32" ref-type="bibr">32</xref>,<xref rid="bib33" ref-type="bibr">33</xref>] were included. Flavonoid intakes were derived for the 6 main flavonoid subclasses habitually consumed: flavanones (eriodictyol, hesperetin, and naringenin); anthocyanins (cyanidin, delphinidin, malvidin, pelargonidin, petunidin, and peonidin); flavan-3-ols (catechins and epicatechins); flavonols (quercetin, kaempferol, myricetin, and isorhamnetin); flavones (luteolin and apigenin); and polymers (including proanthocyanidins, theaflavins, and thearubigins). Total flavonoid intakes were estimated by summing the 6 component subclasses.</p></sec><sec id="sec2.4"><title>Analytical methods</title><p id="p0060">Total urine voids were collected into light-protected collection bottles containing 1 g of ascorbic acid. Aliquots were stored at &#8722;80&#176; C until analysis. Urinary metabolites were purified from 50 &#956;L human urine (1 mL aliquots acidified with 40 &#956;L formic acid) samples by 96-well plate solid phase extraction (SPE; Strata-X Polymeric Reversed Phase, microelution 2 mg/well). Taxifolin was spiked into the urine and used as an SPE recovery reference standard, and scopoletin post-SPE as an internal chromatography standard. The solid phase extraction treated samples were chromatographically separated on an Exion ultrahigh performance UHPLC coupled to a SCIEX QTRAP 3200+ triple quadrupole mass spectrometer (MS/MS; SCIEX, Framingham) with electrospray ionization source, as previously reported [<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib27" ref-type="bibr">27</xref>,<xref rid="bib28" ref-type="bibr">28</xref>]. The samples were injected into Kinetex (Phenomenex) 2.6 &#956;m pentafluorophenyl phase (PFP) 100 &#197;, LC Column 100 &#215; 4.6 mm (Part Number: 00D-4477-E0) with SecurityGuard ULTRA cartridges for PFP, with oven temperature maintained at 37&#176;C. Mobile phase A and B consisted of 0.1% v.v. formic acid in water and 0.1% v.v. formic acid in acetonitrile respectively, with a binary gradient ranging from 1% B to 90% B over 28 min and flow rate at 1.5 mL/min. MS/MS scanning was accomplished using a targeted advanced scheduled multiple reaction monitoring assay using polarity switching between positive and negative ionization mode in Analyst (v.1.6.3, SCIEX) and with quantitation conducted using MultiQuant (v.3.0.2, SCIEX) software platforms. If 2 metabolite isomers could not be resolved, they were quantified relative to a single species. Finally, metabolites previously reported in nutrition intervention studies feeding (poly)phenol-rich foods [<xref rid="bib27" ref-type="bibr">27</xref>,<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib34" ref-type="bibr">[34]</xref>, <xref rid="bib35" ref-type="bibr">[35]</xref>, <xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib37" ref-type="bibr">[37]</xref>, <xref rid="bib38" ref-type="bibr">[38]</xref>, <xref rid="bib39" ref-type="bibr">[39]</xref>, <xref rid="bib40" ref-type="bibr">[40]</xref>, <xref rid="bib41" ref-type="bibr">[41]</xref>, <xref rid="bib42" ref-type="bibr">[42]</xref>, <xref rid="bib43" ref-type="bibr">[43]</xref>, <xref rid="bib44" ref-type="bibr">[44]</xref>, <xref rid="bib45" ref-type="bibr">[45]</xref>] were confirmed on the basis of established retention times (using authentic and synthesized standards; <xref rid="appsec1" ref-type="sec">Supplementary Table S3</xref>) and &gt;3 precursor-to-product transition ions. In total, 82 (poly)phenols were quantified via UPLC-MS/MS; 6 metabolites were below the limit of quantitation in all samples, with statistical analysis completed for 76 analytes. All the metabolites were quantified relative to their reference standard, with the exception of cyanidin-diglucuronide, which was quantified using the cyanidin-3-O-glucoside reference standard. Matrix-matched standard curves were prepared for quantification ranging from 0&#8211;10 &#956;M. Reference standards scopoletin, taxifolin, and phloridzin were used as quality controls and for internal standard adjustment in the urine samples, with system blanks monitored for carryover effects and preextracted urine as a reference blank.</p><p id="p0065">Stool microbiome speciation. Stool specimens were collected on the day prior to the study day using EasySampler kits (GP Medical Devices, Nupark), transferred into sterile containers (Sarstedt), transported in cooled bags provided by the research team, and immediately transferred to a &#8722;20&#176;C freezer on arrival. Prior to DNA extraction, 200&#8211;300 mg feces was transferred to a 2 mL safe lock tube (Eppendorf) containing a 5 mm steel ball bearing and was subjected to mechanical disruption in 1.2 mL sterile phosphate-buffered saline using a tissue lyser (Qiagen Tissue Lyser II, 30 Hz for 4 min at 4&#176;C). Samples were centrifuged to remove insoluble material (1 min, 10,000 &#215; <italic toggle="yes">g</italic> at 4&#176;C). DNA was extracted from 800 &#956;L of the supernatant using a QIAsymphony SP automated platform (Qiagen) using the QIAsymphony DSP virus/bacteria midi kit and the Complex 400 V6 DSP program. DNA was eluted in 110 &#956;L buffer AVE containing carrier RNA as provided in the kit. The DNA was quantitated to confirm a concentration between 5&#8211;20 ng/&#956;L and stored at &#8722;20&#176;C until analysis. The region of the 16S gene was sequenced at APHA, Surrey (UK), using paired-end Illumina MiSeq short-read sequencing. The Qiime [<xref rid="bib46" ref-type="bibr">46</xref>] 1.9.0 Illumina workflow was used for joining the reads, demultiplex, and filter samples and picking operational taxonomic units. Read counts varied across the samples, from 70 in a control sample to 112,944 in sample COB354. Sequencing control samples were 2 separate phosphate-buffered saline samples and 1 sample with no template. Two samples were excluded based on having a sequencing depth below the threshold. In addition, Qiime excluded 2 more samples according to the quality control filter. This filter is described in Bokulich et al. [<xref rid="bib47" ref-type="bibr">47</xref>]. Qiime alpha diversity analyses (secondary analysis) involved testing a range of multiple rarefactions run in parallel. The resulting graph from these technical analyses did not indicate large-scale differences from using data at different sequencing depth levels (data not shown).</p></sec><sec id="sec2.5"><title>Statistical analysis</title><p id="p0070">Given the absence of established effect size estimates at the time the intervention was designed, we justified our sample size based on prior empirical data from Czank et al. [<xref rid="bib11" ref-type="bibr">11</xref>], where significant changes in polyphenol metabolites were observed in 8 participants. Based on the observed confidence intervals in that study, we estimated that group sizes of 30&#8211;40 participants would be sufficient for age and sex subgroup analyses. In the analysis of metabolites, values above the signal-to-noise but below the limit of detection (LOD) were set as zero in the statistical analysis. If metabolites had the majority of their values at 0, they were excluded from the analysis. Calibration curves were established between 1nM and 10 uM. Values below the lower limit of quantitation but above the LOD were reported as a &#8220;near 0&#8221; value (0.0001) in the statistical analysis. Linear mixed-effect models were used to assess differences in cumulative excretion by age (younger compared with older), sex (males compared with females), and combined age-by-sex (younger females, younger males, older females, and older males) groups. Models included cumulative excretion as the dependent variable, &#8220;participant&#8221; as a random effect, time (0 min, 210 min, 420 min, and 1440 min), and groups as predictors, with the time x group interaction taken as the principal analysis of effect. The linear combinations of coefficients between groups were explored at the 24 h timepoint. Total flavonoid intake, as calculated from the FFQ, was included as a covariate on a continuous scale (where indicated) to explore if habitual diet markedly changed the results. Data were not transformed as generalized linear models have shown to be tolerant of distribution assumptions and can provide valid inference regardless of the distribution of the data [<xref rid="bib48" ref-type="bibr">48</xref>]. Total recovery of the metabolite mass in a urine sample is calculated by converting its molar concentration (moles per volume) to mass (e.g., ng) using the molecular weight of the metabolite, then multiplying by the total urine volume excreted: (Metabolite value [nmol/L] &#215; molecular weight [ng/nmol] /1,000,000)&#215;(urine volume [L]))/time [h]. Where indicated in data tables, low concentrations are presented as 10<sup>&#8722;</sup><sup>2</sup> (for example, 0.01&#215;10<sup>&#8722;</sup><sup>2</sup> = 0.0001 ng). The UPLC-MS/MS standard mix contained 82 (poly)phenols (i.e., comprising both precursor polyphenols and phenolic metabolites; <xref rid="appsec1" ref-type="sec">Table S3</xref>), and 76 were above the lower limit of quantitation in the COB urine samples. Six metabolites were found below the LOD in the majority of samples and were, therefore, not included in the final statistical analysis. Elimination kinetic parameters were calculated for each metabolite, maximum urine concentration (Cmax), time of maximum concentration (Tmax) (0 h, 3.5 h, 7 h, or 24 h), and total amount excreted in urine over 24 h (Aeu 0-24). Differences in Cmax and Tmax were compared between groups using a linear regression model with the elimination parameter as the dependent variable, group as the predictor, and habitual total flavonoid intake on a continuous scale as a covariate (where indicated). If metabolite data were missing at individual time points, cumulative excretion was calculated based on the missing data point. Cmax and Tmax were calculated if data were available for at least one timepoint. <italic toggle="yes">P</italic> values &lt; 0.05 were considered statistically significant. The Benjamini-Hochberg method for false discovery rate (using a false discovery rate Q-value &lt; 0.20) was also used to explore the possible impact of multiple testing on observed age and sex effects. Statistical analyses were performed with Stata statistical software version 16 (StataCorp).</p><p id="p0075">Linear discriminant analysis was used to identify which combination of metabolites separated the participants by group and how effective these metabolites were as predictive discriminators of age. Metabolites included in the model were those with a significant time-by-age group interaction in the primary analysis.</p><p id="p0080">Differences in relative abundance of taxa at the Family level and microbial alpha diversity (Shannon Index) were compared across age (younger compared with older), sex (males compared with females), and combined age-by-sex (younger females, younger males, older females, and older males) groups using linear regression with group as the predictor. We excluded taxa where relative abundance was &lt; 0.01% in &#8805;10% of samples, leaving 38 taxa in the final analysis.</p><p id="p0085">Hierarchical regression analysis (using metabolite concentration as the dependent variable) was used to examine if models including sex and microbial composition improved prediction of metabolite concentrations over models including age. For microbial composition, we combined the taxa significantly associated with age using principal component analysis, considering the first component defined. The metabolites included in the model were those with a significant time-by-group interaction in the primary analysis.</p></sec></sec><sec id="sec3"><title>Results</title><p id="p0090">A total of 186 participants completed the COB protocol (<xref rid="fig2" ref-type="fig">Figure 2</xref>). Metabolite concentrations in urine were quantified in 163 participants (44 older females, 46 older males, 42 younger females, and 31 younger males) for 24 h, and data on habitual diet was available for 161 participants (<xref rid="tbl1" ref-type="table">Table 1</xref>). Older males had the highest caloric intake (age and sex effect; <italic toggle="yes">P</italic> &lt; 0.04 and 0.03, respectively), and BMI was higher in older participants and highest in older males (<italic toggle="yes">P</italic> &lt; 0.01). Older participants consumed considerably more flavonoids (<italic toggle="yes">P</italic> &lt; 0.01), with nearly 3 times higher habitual intakes than younger individuals, which was reflected in higher total fruit, vegetable, and tea intakes. No notable differences in flavonoid intakes were observed by sex, whereas females reported lower total energy and carbohydrate intakes and a higher fruit and vegetable intake.<fig id="fig2" position="float" orientation="portrait"><label>FIGURE 2</label><caption><p>Participant flow diagram.</p></caption><alt-text id="alttext0025">FIGURE 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig><table-wrap position="float" id="tbl1" orientation="portrait"><label>TABLE 1</label><caption><p>Participant characteristics mean (95% CI) and habitual dietary intake stratified by age and sex group in 163 participants from the COB study</p></caption><alt-text id="alttext0030">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th colspan="1" rowspan="1">Older females<hr/></th><th colspan="1" rowspan="1">Older males<hr/></th><th colspan="1" rowspan="1">Younger females<hr/></th><th colspan="1" rowspan="1">Younger males<hr/></th></tr><tr><th colspan="1" rowspan="1">(<italic toggle="yes">n</italic> = 44)</th><th colspan="1" rowspan="1">(<italic toggle="yes">n</italic> = 46)</th><th colspan="1" rowspan="1">(<italic toggle="yes">n</italic> = 42)</th><th colspan="1" rowspan="1">(<italic toggle="yes">n</italic> = 31)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age (y)</td><td colspan="1" rowspan="1">66.9 (65.5, 68.2)</td><td colspan="1" rowspan="1">67.8 (66.5, 69.1)</td><td colspan="1" rowspan="1">22.6 (21.2, 24.0)</td><td colspan="1" rowspan="1">22.4 (20.8, 24.0)</td></tr><tr><td colspan="1" rowspan="1">BMI (kg/m<sup>2</sup>)</td><td colspan="1" rowspan="1">24.2 (23.4, 25.0)</td><td colspan="1" rowspan="1">25.4 (24.6, 26.3)</td><td colspan="1" rowspan="1">23.4 (22.6, 24.3)</td><td colspan="1" rowspan="1">23.0 (22.0, 24.0)</td></tr><tr><td colspan="1" rowspan="1">Energy (kcal)</td><td colspan="1" rowspan="1">2063 (1861, 2265)</td><td colspan="1" rowspan="1">2229 (2036, 2422)</td><td colspan="1" rowspan="1">1811 (1609, 2013)</td><td colspan="1" rowspan="1">2079 (1844, 2315)</td></tr><tr><td colspan="1" rowspan="1">Protein (g)</td><td colspan="1" rowspan="1">89.7 (81.7, 97.7)</td><td colspan="1" rowspan="1">89.9 (82.3, 97.6)</td><td colspan="1" rowspan="1">78.2 (70.3, 86.2)</td><td colspan="1" rowspan="1">88.9 (79.6, 98.2)</td></tr><tr><td colspan="1" rowspan="1">Fat (g)</td><td colspan="1" rowspan="1">74.5 (65.9, 83.0)</td><td colspan="1" rowspan="1">78.5 (70.3, 86.7)</td><td colspan="1" rowspan="1">62.6 (54.1, 71.2)</td><td colspan="1" rowspan="1">75.5 (65.5, 85.5)</td></tr><tr><td colspan="1" rowspan="1">Carbohydrate (g)</td><td colspan="1" rowspan="1">258 (229, 286)</td><td colspan="1" rowspan="1">287 (259, 314)</td><td colspan="1" rowspan="1">241 (212, 269)</td><td colspan="1" rowspan="1">269 (236, 303)</td></tr><tr><td colspan="1" rowspan="1">Fiber (g)</td><td colspan="1" rowspan="1">25.5 (22.8, 28.3)</td><td colspan="1" rowspan="1">25.4 (22.8, 28.0)</td><td colspan="1" rowspan="1">22.9 (20.1, 25.6)</td><td colspan="1" rowspan="1">22.7 (19.5, 25.9)</td></tr><tr><td colspan="1" rowspan="1">Total flavonoids (mg/d)</td><td colspan="1" rowspan="1">1298 (1150, 1446)</td><td colspan="1" rowspan="1">1237 (1096, 1378)</td><td colspan="1" rowspan="1">509 (361, 657)</td><td colspan="1" rowspan="1">478 (306, 650)</td></tr><tr><td colspan="1" rowspan="1">Flavanones (mg/d)</td><td colspan="1" rowspan="1">41.1 (31.8, 50.4)</td><td colspan="1" rowspan="1">30.8 (22.0, 39.7)</td><td colspan="1" rowspan="1">23.4 (14.1, 32.7)</td><td colspan="1" rowspan="1">22.1 (11.3, 33.0)</td></tr><tr><td colspan="1" rowspan="1">Anthocyanins (mg/d)</td><td colspan="1" rowspan="1">34.7 (29.1, 40.3)</td><td colspan="1" rowspan="1">29.5 (24.2, 34.9)</td><td colspan="1" rowspan="1">19.2 (13.6, 24.8)</td><td colspan="1" rowspan="1">11.5 (5.0, 18.0)</td></tr><tr><td colspan="1" rowspan="1">Flavan-3-ols (mg/d)</td><td colspan="1" rowspan="1">254 (220, 289)</td><td colspan="1" rowspan="1">255 (222, 288)</td><td colspan="1" rowspan="1">102 (67.6, 136)</td><td colspan="1" rowspan="1">84.8 (44.8, 125)</td></tr><tr><td colspan="1" rowspan="1">Flavonols (mg/d)</td><td colspan="1" rowspan="1">57.1 (51.1, 63.0)</td><td colspan="1" rowspan="1">53.2 (47.5, 58.9)</td><td colspan="1" rowspan="1">29.7 (23.7, 35.6)</td><td colspan="1" rowspan="1">24.6 (17.7, 31.6)</td></tr><tr><td colspan="1" rowspan="1">Flavones (mg/d)</td><td colspan="1" rowspan="1">1.9 (1.6, 2.2)</td><td colspan="1" rowspan="1">1.7 (1.4, 1.9)</td><td colspan="1" rowspan="1">1.6 (1.3, 1.8)</td><td colspan="1" rowspan="1">1.2 (0.89, 1.5)</td></tr><tr><td colspan="1" rowspan="1">Polymers (mg/d)</td><td colspan="1" rowspan="1">909 (801, 1017)</td><td colspan="1" rowspan="1">866 (763, 969)</td><td colspan="1" rowspan="1">333 (225, 441)</td><td colspan="1" rowspan="1">334 (208, 459)</td></tr><tr><td colspan="1" rowspan="1">Fruit and vegetables (g/d)</td><td colspan="1" rowspan="1">794 (696, 891)</td><td colspan="1" rowspan="1">653 (559, 746)</td><td colspan="1" rowspan="1">583 (486, 681)</td><td colspan="1" rowspan="1">481 (367, 594)</td></tr><tr><td colspan="1" rowspan="1">Tea (g/d)</td><td colspan="1" rowspan="1">763 (650, 877)</td><td colspan="1" rowspan="1">759 (650, 869)</td><td colspan="1" rowspan="1">204 (88.9, 319)</td><td colspan="1" rowspan="1">217 (76.1, 358)</td></tr></tbody></table><table-wrap-foot><fn><p>Values are mean (95% CI). <italic toggle="yes">n</italic> = 163 (data missing for <italic toggle="yes">n</italic> = 2 participants for dietary data).</p></fn></table-wrap-foot></table-wrap></p><sec id="sec3.1"><title>Cumulative Excretion: sum of all (poly)phenols and metabolites</title><p id="p0095">There was a trend for age-by-sex differences in cumulative (all urine &#8220;time bins&#8221;) 24 h urinary metabolite recovery (<italic toggle="yes">P</italic> = 0.06; treatment effect, all metabolites and parent (poly)phenols; <xref rid="appsec1" ref-type="sec">Supplementary Table 4</xref>); however, no significant time-by-group interactions were observed (<italic toggle="yes">P</italic> = 0.30); with mean total urinary recovery of 14.59 &#177; 2.22 ng at baseline, 56.02 &#177; 7.72 ng at 3.5 h, 97.80 &#177; 20.73 ng at 7 h; and 122.32 &#177; 25.34 ng at 24 h (mean &#177; SD; data not shown). There were also no significant group differences (mean, 95% confidence interval [CI]) for maximum total excretion (Cmax, <italic toggle="yes">P</italic> = 0.20) [(older females 505 ng (333, 678), older males 670 ng (502, 839), younger females 452 ng (276, 629), younger males 384 ng (179, 590)]; however, there was significant group differences in Tmax (<italic toggle="yes">P</italic> = 0.04) (older females 15.8 h [12.4, 19.2], older males 15.2 h [11.9, 18.5)], younger females 10.6 h [7.1, 14.1], and younger males 12.0 h [7.9, 16.0]; [mean, 95% CI]).</p></sec><sec id="sec3.2"><title>Individual (poly)phenols and metabolite excretion</title><p id="p0100">Differences in cumulative 24 h excretion were observed for 12 individual metabolites by age (time-by-treatment interaction, <italic toggle="yes">P</italic> &lt; 0.05; 10 Q &lt; 0.2) and 5 metabolites by sex (1 Q &lt; 0.2) (<xref rid="tbl2" ref-type="table">Table 2</xref>; Complete dataset found in <xref rid="appsec1" ref-type="sec">Supplementary Table S4</xref> ). Here, the metabolites primarily comprised of small molecule microbial metabolites of (poly)phenols, where younger participants, mainly males, generally displayed higher cumulative excretion. Adjustment for habitual total flavonoid intake did not materially change the age differences observed in urinary excretion over time or cumulative 24-h urinary recovery (<xref rid="appsec1" ref-type="sec">Supplementary Table S5</xref>).<table-wrap position="float" id="tbl2" orientation="portrait"><label>TABLE 2</label><caption><p>Cumulative excretion (ng) by age and sex group at 24 h</p></caption><alt-text id="alttext0035">TABLE 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Metabolite (ng)</th><th colspan="2" rowspan="1">Older females<hr/></th><th colspan="2" rowspan="1">Older males<hr/></th><th colspan="2" rowspan="1">Younger females<hr/></th><th colspan="2" rowspan="1">Younger males<hr/></th><th rowspan="2" colspan="1"><italic toggle="yes">P</italic> group</th><th rowspan="2" colspan="1"><italic toggle="yes">P</italic> age</th><th rowspan="2" colspan="1"><italic toggle="yes">P</italic> sex</th></tr><tr><th colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th colspan="1" rowspan="1">Mean (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th colspan="1" rowspan="1">Mean (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th colspan="1" rowspan="1">Mean (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th colspan="1" rowspan="1">Mean (95% CI)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">3-(dihydroxyphenyl)propionic acid<xref rid="tbl2fn2" ref-type="table-fn">2</xref></td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.043 (0.034, 0.053)</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">0.035 (0.025, 0.044)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.056 (0.046, 0.065)</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">0.046 (0.035, 0.058)</td><td colspan="1" rowspan="1">0.02<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.05</td></tr><tr><td colspan="1" rowspan="1">4-methylhippuric acid (x 10<sup>2</sup>)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.297 (0.173, 0.421)</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">0.629 (0.509, 0.749)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.296 (0.171, 0.421)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">0.412 (0.263, 0.562)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td></tr><tr><td colspan="1" rowspan="1">3-methoxycinnamic acid</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.033 (0.009, 0.056)</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">0.079 (0.056, 0.101)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.049 (0.025, 0.072)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">0.024 (-0.004, 0.052)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.18</td></tr><tr><td colspan="1" rowspan="1">6-methoxysalicyclic acid (x 10<sup>2</sup>)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.091 (0.031, 0.150)</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">0.225 (0.166, 0.283)</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">0.147 (0.086, 0.208)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">0.057 (-0.016, 0.129)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">0.22</td></tr><tr><td colspan="1" rowspan="1">4-hydroxy-3-methoxyacetophenone</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.020 (0.013, 0.028)</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">0.029 (0.022, 0.037)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.036 (0.028, 0.044)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">0.037 (0.028, 0.046)</td><td colspan="1" rowspan="1">0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.28</td></tr><tr><td colspan="1" rowspan="1">benzoylglutamic acid</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.012 (0.008, 0.016)</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">0.021 (0.017, 0.025)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.013 (0.009, 0.018)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">0.013 (0.007, 0.018)</td><td colspan="1" rowspan="1">0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">0.03</td></tr><tr><td colspan="1" rowspan="1">5-(hydroxyphenyl)-gamma-valerolactone-sulfate</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.313 (0.192, 0.434)</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">0.585 (0.468, 0.703)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.506 (0.385, 0.627)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">0.186 (0.040, 0.331)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.23</td><td colspan="1" rowspan="1">0.77</td></tr><tr><td colspan="1" rowspan="1">5-(hydroxyphenyl)-gamma-valerolactone (x 10<sup>2</sup>)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">2.4 (1.4, 3.4)</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">2.2 (1.3, 3.2)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">4.1 (3.1, 5.0)</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">1.4 (0.207, 2.6)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1">0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td></tr><tr><td colspan="1" rowspan="1">naringenin-7-<italic toggle="yes">O</italic>-glucuronide (x 10<sup>2</sup>)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">3.4 (2.5, 4.4)</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">4.2 (3.3, 5.1)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">4.9 (4.0, 5.9)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">2.4 (1.2, 3.5)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.88</td><td colspan="1" rowspan="1">0.17</td></tr><tr><td colspan="1" rowspan="1">2,3-dihydroxybenzoic acid</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.059 (0.038, 0.080)</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">0.101 (0.081, 0.121)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.093 (0.072, 0.114)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">0.067 (0.042, 0.092)</td><td colspan="1" rowspan="1">0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.86</td><td colspan="1" rowspan="1">0.29</td></tr><tr><td colspan="1" rowspan="1">3-methylhippuric acid</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.006 (0.004, 0.009)</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">0.014 (0.012, 0.016)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.006 (0.004, 0.009)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">0.005 (0.002, 0.008)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td></tr><tr><td colspan="1" rowspan="1">3-methoxybenzoic acid-4-sulfate</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">0.616 (0.441, 0.791)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.870 (0.697, 1.0)</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">0.525 (0.348, 0.701)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">0.900 (0.691, 1.1)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.50</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td></tr><tr><td colspan="1" rowspan="1">benzoic acid-4-<italic toggle="yes">O</italic>-glucuronide</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.034 (0.029, 0.040)</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">0.028 (0.023, 0.033)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.028 (0.022, 0.033)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">0.017 (0.011, 0.024)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.02<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td></tr><tr><td colspan="1" rowspan="1">2-hydroxycinnamic acid (x 10<sup>2</sup>)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.021 (0.007, 0.035)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0.018 (0.005, 0.032)</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">0.022 (0.008, 0.036)</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">0.065 (0.049, 0.082)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.04</td></tr><tr><td colspan="1" rowspan="1">3-(4-hydroxy-3-methoxyphenyl)propionic acid</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.051 (0.026, 0.075)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0.081 (0.058, 0.105)</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">0.106 (0.081, 0.130)</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">0.106 (0.077, 0.135)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.31</td></tr><tr><td colspan="1" rowspan="1">hesperetin-3'-<italic toggle="yes">O</italic>-glucuronide</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.517 (0.346, 0.689)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0.772 (0.607, 0.937)</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">0.567 (0.393, 0.741)</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">0.356 (0.152, 0.559)</td><td colspan="1" rowspan="1">0.02<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">0.48</td></tr><tr><td colspan="1" rowspan="1">3-methoxy-4-hydroxyphenylacetic acid</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.922 (0.530, 1.3)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">1.7 (1.3, 2.1)</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">1.0 (0.605, 1.4)</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">0.842 (0.378, 1.3)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">0.06</td></tr><tr><td colspan="1" rowspan="1">3-methoxybenzoic acid-4-<italic toggle="yes">O</italic>-glucuronide</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.394 (0.236, 0.552)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0.625 (0.473, 0.777)</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">0.462 (0.302, 0.623)</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">0.285 (0.098, 0.471)</td><td colspan="1" rowspan="1">0.04<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.13</td><td colspan="1" rowspan="1">0.46</td></tr><tr><td colspan="1" rowspan="1">hydroxy-methoxybenzoic acid<xref rid="tbl2fn2" ref-type="table-fn">2</xref></td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.065 (0.045, 0.085)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0.075 (0.056, 0.095)</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">0.090 (0.069, 0.110)</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">0.133 (0.109, 0.157)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.06</td></tr><tr><td colspan="1" rowspan="1">hydroxybenzoic acid<xref rid="tbl2fn2" ref-type="table-fn">2</xref></td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.010 (0.007, 0.013)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0.010 (0.008, 0.013)</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">0.013 (0.010, 0.016)</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">0.005 (0.002, 0.009)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.78</td><td colspan="1" rowspan="1">0.05</td></tr><tr><td colspan="1" rowspan="1">3-hydroxyhippuric acid</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">1.8 (1.3, 2.2)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">2.5 (2.0, 2.9)</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">1.5 (0.986, 1.9)</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">1.6 (1.1, 2.2)</td><td colspan="1" rowspan="1">0.02<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.02<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.04</td></tr><tr><td colspan="1" rowspan="1">4-methoxybenzaldehyde</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">0.007 (0.005, 0.009)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0.005 (0.003, 0.007)</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">0.008 (0.007, 0.010)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">0.011 (0.008, 0.013)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.59</td></tr><tr><td colspan="1" rowspan="1">3-hydroxy-4-methoxybenzoic acid</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.096 (0.074, 0.119)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0.082 (0.061, 0.104)</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">0.140 (0.117, 0.163)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">0.166 (0.139, 0.193)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.82</td></tr><tr><td colspan="1" rowspan="1">hydroxybenzoic acid-sulfate<xref rid="tbl2fn2" ref-type="table-fn">2</xref></td><td colspan="1" rowspan="1">39</td><td colspan="1" rowspan="1">0.318 (0.188, 0.447)</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">0.544 (0.421, 0.667)</td><td colspan="1" rowspan="1">39</td><td colspan="1" rowspan="1">0.303 (0.173, 0.433)</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">0.404 (0.245, 0.563)</td><td colspan="1" rowspan="1">0.03<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td></tr><tr><td colspan="1" rowspan="1">hippuric acid</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">58.1 (44.9, 71.3)</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">77.8 (65.1, 90.5)</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">58.7 (45.4, 72.0)</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">45.6 (29.2, 61.9)</td><td colspan="1" rowspan="1">0.02<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.31</td></tr><tr><td colspan="1" rowspan="1">3-(phenyl)propionic acid</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">0.019 (-0.020, 0.058)</td><td colspan="1" rowspan="1">38</td><td colspan="1" rowspan="1">0.009 (-0.028, 0.046)</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">0.047 (0.008, 0.086)</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">0.092 (0.044, 0.140)</td><td colspan="1" rowspan="1">0.04<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.01<xref rid="tbl2fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.75</td></tr></tbody></table><table-wrap-foot><fn><p>Values are mean (95% CI). Metabolites shown are those with a significant group, age, or sex effect. <italic toggle="yes">P</italic> values are for group comparisons at 24 h and calculated from linear mixed-effect models.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fn1"><label>1</label><p id="ntpara0015">False discovery rate adjusted <italic toggle="yes">P</italic> values &lt; 0.2. Full dataset providing <italic toggle="yes">P</italic> values for all analytes is found in <xref rid="appsec1" ref-type="sec">Supplement Table S4</xref>.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fn2"><label>2</label><p id="ntpara0020">Metabolite isomers that could not be resolved effectively by HPLC were quantified according to one of the structural isomers. All urine metabolites values are presented as: {[Metabolite value (nmol/L) &#215; molecular weight (ng/nmol) /(1,000,000) &#215; (urine volume L)]}/time (h). Where indicated in data tables, low concentrations are presented as 10&#710;2 (for example, 0.01 &#215; 10<sup>-</sup>2 = 0.0001 ng).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.3"><title>Elimination kinetics</title><p id="p0105">Differences in Cmax were observed for 7% of measured metabolites by age and 8% by sex, whereas differences in Tmax were observed for 28% by age and 11% of metabolites by sex (<xref rid="appsec1" ref-type="sec">Supplementary Table S6</xref>; 36 <italic toggle="yes">P</italic> &lt; 0.05; 14 Q &lt; 0.2), with the majority of differences seen as age effects on Tmax.</p><p id="p0110">Group differences in Cmax were observed for 4 metabolites (<italic toggle="yes">P</italic> &lt; 0.05; 2 Q &lt; 0.2), with the highest Cmax observed most frequently in older males (<xref rid="tbl3" ref-type="table">Table 3</xref>; complete dataset found in <xref rid="appsec1" ref-type="sec">Supplementary Table S6</xref>). Age differences were observed for 5 phenolic metabolites (0 Q &lt; 0.2) and sex differences for 6 metabolites (0 Q &lt; 0.2). Metabolites recorded in highest concentrations (Cmax; mean [95% CI]) having age or sex differences were 3-hydroxyhippuric acid 22.0 &#956;M (14.7, 29.3), benzoic acid-4-sulfate 17.3 &#956;M (12.7, 21.8), 3-methoxybenzoic acid-4-sulfate 4.4 &#956;M (3.1, 5.8), 2,5-dihydroxybenzoic acid 0.85 &#956;M (0.53, 1.2), 3-hydroxy-4-methoxybenzoic acid 0.60 &#956;M (0.46, 0.74), hydroxy-methoxybenzoic acid 0.42 &#956;M (0.32, 0.52), and 4-methylhippuric acid 0.03 &#956;M (0.01, 0.04). Adjusting Cmax for total flavonoid intake by age group had a limited impact on the statistical output (<xref rid="appsec1" ref-type="sec">Supplementary Table S7</xref>).<table-wrap position="float" id="tbl3" orientation="portrait"><label>TABLE 3</label><caption><p>Maximum urinary elimination (Cmax) by age and sex group</p></caption><alt-text id="alttext0040">TABLE 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Metabolite (ng)</th><th colspan="2" rowspan="1">Older females<hr/></th><th colspan="2" rowspan="1">Older males<hr/></th><th colspan="2" rowspan="1">Younger females<hr/></th><th colspan="2" rowspan="1">Younger males<hr/></th><th rowspan="2" colspan="1"><italic toggle="yes">P</italic> group</th><th rowspan="2" colspan="1"><italic toggle="yes">P</italic> age</th><th rowspan="2" colspan="1"><italic toggle="yes">P</italic> sex</th></tr><tr><th colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th colspan="1" rowspan="1">Mean (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th colspan="1" rowspan="1">Mean (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th colspan="1" rowspan="1">Mean (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th colspan="1" rowspan="1">Mean (95% CI)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">2,5-dihydroxybenzoic acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">0.52 (0.26, 0.79)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0.83 (0.58, 1.1)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.54 (0.27, 0.81)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">0.85 (0.53, 1.2)</td><td colspan="1" rowspan="1">0.34</td><td colspan="1" rowspan="1">0.95</td><td colspan="1" rowspan="1">0.03</td></tr><tr><td colspan="1" rowspan="1">4-methylhippuric acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">0.02 (0.01, 0.03)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0.05 (0.04, 0.06)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.02 (0.003, 0.03)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">0.03 (0.01, 0.04)</td><td colspan="1" rowspan="1">0.53</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl3fn1" ref-type="table-fn">1</xref></td></tr><tr><td colspan="1" rowspan="1">3-methylhippuric acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">0.05 (0.02, 0.07)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0.11 (0.08, 0.13)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.04 (0.01, 0.07)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">0.04 (0.01, 0.07)</td><td colspan="1" rowspan="1">0.29</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">3-methoxybenzoic acid-4-sulfate</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">1.8 (0.68, 2.9)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">2.7 (1.6, 3.8)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">1.4 (0.29, 2.6)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">4.4 (3.1, 5.8)</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.45</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl3fn1" ref-type="table-fn">1</xref></td></tr><tr><td colspan="1" rowspan="1">benzoic acid-4-<italic toggle="yes">O</italic>-glucuronide</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">0.16 (0.13, 0.20)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0.14 (0.10, 0.17)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.13 (0.09, 0.17)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">0.09 (0.05, 0.14)</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.13</td></tr><tr><td colspan="1" rowspan="1">benzoic acid-4-sulfate</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">9.7 (5.0, 14.3)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">17.3 (12.7, 21.8)</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">8.1 (3.3, 12.9)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">10.8 (5.3, 16.4)</td><td colspan="1" rowspan="1">0.62</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">hydroxy-methoxybenzoic acid<xref rid="tbl3fn2" ref-type="table-fn">2</xref></td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">0.17 (0.09, 0.26)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0.25 (0.17, 0.33)</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">0.26 (0.18, 0.35)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">0.42 (0.32, 0.52)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl3fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">3-hydroxyhippuric acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">17.5 (10.0, 25.0)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">22.0 (14.7, 29.3)</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">10.5 (2.7, 18.2)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">12.6 (3.6, 21.5)</td><td colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.30</td></tr><tr><td colspan="1" rowspan="1">3-hydroxy-4-methoxybenzoic acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">0.28 (0.16, 0.39)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0.29 (0.18, 0.41)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">0.37 (0.25, 0.48)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">0.60 (0.46, 0.74)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl3fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">&lt;0.01</td><td colspan="1" rowspan="1">0.12</td></tr></tbody></table><table-wrap-foot><fn><p>Values are mean (95% CI). Metabolites shown are those with a significant group, age or sex effect; <italic toggle="yes">P</italic> values calculated from linear regression.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fn1"><label>1</label><p id="ntpara0025">false discovery rate adjusted <italic toggle="yes">P</italic> values &lt; 0.2. Full dataset providing <italic toggle="yes">P</italic> values for all analytes is found in <xref rid="appsec1" ref-type="sec">Supplement Table S6</xref>.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fn2"><label>2</label><p id="ntpara0030">Metabolite isomers which could not be resolved effectively by HPLC were quantified according to one of the structural isomers. All urine metabolites values are presented as: {[Metabolite value (nmol/L) &#215; molecular weight (ng/nmol)/1000000] &#215; [urine volume (L]}/time (h).</p></fn></table-wrap-foot></table-wrap></p><p id="p0115">The time to maximum urinary concentration (Tmax) varied considerably across metabolites, displaying group, age, or sex differences, from 1h and 24 h, with a mean Tmax of 9.1 &#177; 4.1 h [mean (95% CI); <xref rid="tbl4" ref-type="table">Table 4</xref>]. Group differences were observed for 15 metabolites (4 Q &gt; 0.2). Twenty-two of the metabolites displayed significant Tmax differences by age (14 Q &lt; 0.2) and 8 by sex (0 Q &lt; 0.2), with 92% of these metabolites reflecting significantly later Tmax in older participants. Only 2 analytes, 4-hydroxybenzyl alcohol and 3-methylhippuric acid, had greater Tmax in younger participants (all analyte data provided in <xref rid="appsec1" ref-type="sec">Supplementary Table S6</xref>). Adjusting Tmax for total flavonoid intake by age group had limited impact on the statistical output (<xref rid="appsec1" ref-type="sec">Supplementary Table S7</xref>).<table-wrap position="float" id="tbl4" orientation="portrait"><label>TABLE 4</label><caption><p>Time (h) of maximal urinary elimination (Tmax) by age and sex group</p></caption><alt-text id="alttext0045">TABLE 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Metabolite</th><th colspan="2" rowspan="1">Older females<hr/></th><th colspan="2" rowspan="1">Older males<hr/></th><th colspan="2" rowspan="1">Younger females<hr/></th><th colspan="2" rowspan="1">Younger males<hr/></th><th rowspan="2" colspan="1"><italic toggle="yes">P</italic> group</th><th rowspan="2" colspan="1"><italic toggle="yes">P</italic> age</th><th rowspan="2" colspan="1"><italic toggle="yes">P</italic> sex</th></tr><tr><th colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th colspan="1" rowspan="1">Mean (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th colspan="1" rowspan="1">Mean (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th colspan="1" rowspan="1">Mean (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">n</italic></th><th colspan="1" rowspan="1">Mean (95% CI)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">3,4-dihydroxyphenylacetic acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">14.7 (11.4, 17.9)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">15.7 (12.5, 18.8)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">16.3 (12.9, 19.6)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">20.9 (17.1, 24.8)</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">0.18</td></tr><tr><td colspan="1" rowspan="1">3-methoxycinnamic acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">8.1 (4.8, 11.4)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">13.3 (10.0, 16.5)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">6.9 (3.5, 10.3)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">9.5 (5.6, 13.5)</td><td colspan="1" rowspan="1">0.76</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">4-hydroxybenzaldehyde</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">11.3 (8.0, 14.6)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">13.5 (10.3, 16.7)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">5.5 (2.1, 8.9)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">9.3 (5.4, 13.2)</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.06</td></tr><tr><td colspan="1" rowspan="1">4-hydroxybenzyl alcohol</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">12.0 (8.6, 15.4)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">11.2 (7.9, 14.5)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">13.6 (10.1, 17.1)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">17.5 (13.4, 21.5)</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.05<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.60</td></tr><tr><td colspan="1" rowspan="1">3-caffeoylquinic acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">14.0 (10.7, 17.2)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">16.8 (13.6, 20.0)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">13.1 (9.7, 16.4)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">17.7 (13.8, 21.6)</td><td colspan="1" rowspan="1">0.44</td><td colspan="1" rowspan="1">0.82</td><td colspan="1" rowspan="1">0.03</td></tr><tr><td colspan="1" rowspan="1">hesperetin</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">11.8 (9.0, 14.5)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">9.7 (7.0, 12.4)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">11.1 (8.2, 13.9)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">5.7 (2.4, 9.0)</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.20</td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">hesperetin-7'-sulfate</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">5.9 (3.4, 8.4)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">5.5 (3.1, 8.0)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">2.2 (-0.3, 4.8)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">3.1 (0.15, 6.1)</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.02<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.74</td></tr><tr><td colspan="1" rowspan="1">3,4-dihydroxybenzoic acid methyl ester</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">5.5 (2.8, 8.2)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">8.3 (5.7, 10.9)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">2.6 (-0.1, 5.4)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">6.0 (2.8, 9.2)</td><td colspan="1" rowspan="1">0.45</td><td colspan="1" rowspan="1">0.05<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">naringenin-7-<italic toggle="yes">O</italic>-glucuronide</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">11.1 (8.5, 13.8)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">13.3 (10.7, 15.9)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">8.5 (5.7, 11.2)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">10.2 (7.1, 13.4)</td><td colspan="1" rowspan="1">0.22</td><td colspan="1" rowspan="1">0.03<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.12</td></tr><tr><td colspan="1" rowspan="1">naringenin-7-<italic toggle="yes">O</italic>-glucuronide</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">11.1 (8.5, 13.8)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">13.3 (10.7, 15.9)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">8.5 (5.7, 11.2)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">10.2 (7.1, 13.4)</td><td colspan="1" rowspan="1">0.22</td><td colspan="1" rowspan="1">0.03<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.12</td></tr><tr><td colspan="1" rowspan="1">3,4-dihydroxybenzoic acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">12.4 (9.4, 15.3)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">12.4 (9.5, 15.3)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">9.4 (6.3, 12.4)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">7.7 (4.2, 11.2)</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">0.02<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.81</td></tr><tr><td colspan="1" rowspan="1">4-hydroxycinnamic acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">6.4 (3.9, 8.9)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">9.7 (7.3, 12.2)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">5.4 (2.9, 8.0)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">7.7 (4.7, 10.7)</td><td colspan="1" rowspan="1">0.90</td><td colspan="1" rowspan="1">0.20</td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">trihydroxybenzaldehyde<xref rid="tbl4fn2" ref-type="table-fn">2</xref></td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">6.9 (5.1, 8.8)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">7.9 (6.1, 9.7)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">4.4 (2.5, 6.3)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">4.8 (2.6, 7.1)</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.34</td></tr><tr><td colspan="1" rowspan="1">3-methylhippuric acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">4.4 (1.3, 7.4)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">4.2 (1.2, 7.2)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">7.1 (4.0, 10.2)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">9.3 (5.7, 12.9)</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">0.02<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.74</td></tr><tr><td colspan="1" rowspan="1">2-hydroxy-4-methoxybenzoic acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">5.9 (3.3, 8.4)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">5.5 (3.0, 8.0)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">2.3 (-0.3, 4.9)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">2.3 (-0.7, 5.4)</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">0.01<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.93</td></tr><tr><td colspan="1" rowspan="1">3-(3-hydroxyphenyl)propionic acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">21.3 (18.5, 24.0)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">19.6 (16.9, 22.3)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">20.6 (17.8, 23.4)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">14.0 (10.8, 17.3)</td><td colspan="1" rowspan="1">0.01<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">(-)-epicatechin</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">9.6 (6.8, 12.3)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">9.7 (6.9, 12.4)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">6.9 (4.1, 9.7)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">5.8 (2.5, 9.1)</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">0.03<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.92</td></tr><tr><td colspan="1" rowspan="1">4-hydroxybenzoic acid-3-<italic toggle="yes">O</italic>-glucuronide</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">5.9 (3.8, 8.0)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">8.7 (6.6, 10.8)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">4.2 (2.1, 6.4)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">7.6 (5.0, 10.1)</td><td colspan="1" rowspan="1">0.94</td><td colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1">0.01</td></tr><tr><td colspan="1" rowspan="1">hydroxy-methoxybenzoic acid<xref rid="tbl4fn2" ref-type="table-fn">2</xref></td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">8.6 (5.9, 11.2)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">12.1 (9.5, 14.7)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">6.3 (3.6, 9.1)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">5.9 (2.7, 9.1)</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.14</td></tr><tr><td colspan="1" rowspan="1">hydroxybenzoic acid<xref rid="tbl4fn2" ref-type="table-fn">2</xref></td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">15.4 (12.0, 18.7)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">13.8 (10.6, 17.1)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">11.3 (7.9, 14.7)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">10.3 (6.3, 14.3)</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.04<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.58</td></tr><tr><td colspan="1" rowspan="1">3-hydroxybenzoic acid-4-<italic toggle="yes">O</italic>-glucuronide</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">9.6 (7.1, 12.0)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">11.5 (9.0, 13.9)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">6.3 (3.8, 8.8)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">4.9 (2.0, 7.9)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.52</td></tr><tr><td colspan="1" rowspan="1">cyanidin-3-<italic toggle="yes">O</italic>-glucoside</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">6.6 (4.5, 8.7)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">6.7 (4.6, 8.7)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">2.8 (0.60, 4.9)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">6.4 (3.9, 8.9)</td><td colspan="1" rowspan="1">0.25</td><td colspan="1" rowspan="1">0.04<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.10</td></tr><tr><td colspan="1" rowspan="1">ellagic acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">15.6 (12.7, 18.4)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">15.1 (12.3, 17.9)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">10.0 (7.1, 12.9)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">13.4 (10.1, 16.8)</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">0.01<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.29</td></tr><tr><td colspan="1" rowspan="1">3-hydroxy-4-methoxybenzoic acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">9.8 (6.8, 12.8)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">11.4 (8.5, 14.3)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">7.5 (4.4, 10.5)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">7.1 (3.6, 10.7)</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">0.04<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.51</td></tr><tr><td colspan="1" rowspan="1">catechin<xref rid="tbl4fn2" ref-type="table-fn">2</xref></td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">10.1 (7.0, 13.3)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">12.3 (9.2, 15.4)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">7.2 (4.0, 10.5)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">8.6 (4.9, 12.4)</td><td colspan="1" rowspan="1">0.20</td><td colspan="1" rowspan="1">0.04<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.21</td></tr><tr><td colspan="1" rowspan="1">hydroxybenzoic acid-sulfate<xref rid="tbl4fn2" ref-type="table-fn">2</xref></td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">9.6 (7.0, 12.1)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">14.0 (11.5, 16.5)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">5.6 (3.0, 8.3)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">6.3 (3.2, 9.3)</td><td colspan="1" rowspan="1">0.01<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">4-hydroxy-3-methoxybenzoic acid methyl ester</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">13.0 (9.8, 16.3)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">9.3 (6.1, 12.4)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">6.4 (3.1, 9.7)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">6.2 (2.3, 10.1)</td><td colspan="1" rowspan="1">&lt;0.01<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.01v</td><td colspan="1" rowspan="1">0.32</td></tr><tr><td colspan="1" rowspan="1">3-methoxybenzoic acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">3.5 (1.0, 6.0)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">3.9 (1.4, 6.3)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">3.3 (0.71, 5.8)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">4.7 (1.7, 7.6)</td><td colspan="1" rowspan="1">0.69</td><td colspan="1" rowspan="1">0.90</td><td colspan="1" rowspan="1">0.54</td></tr><tr><td colspan="1" rowspan="1">hippuric acid</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">11.8 (8.3, 15.3)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">12.7 (9.3, 16.1)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">7.6 (4.0, 11.2)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">8.5 (4.4, 12.7)</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.02<xref rid="tbl4fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">0.49</td></tr></tbody></table><table-wrap-foot><fn><p>Values are mean (95% CI). Metabolites shown are those with a significant group, age or sex effect; <italic toggle="yes">P</italic> values calculated from linear regression.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fn1"><label>1</label><p id="ntpara0035">False discovery rate adjusted <italic toggle="yes">P</italic> values &lt; 0.2. Full dataset providing P values for all analytes is found in <xref rid="appsec1" ref-type="sec">Supplement Table S6</xref>.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fn2"><label>2</label><p id="ntpara0040">Metabolite isomers which could not be resolved effectively by HPLC were quantified according to one of the structural isomers.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.4"><title>Group prediction</title><p id="p0120">In linear discriminant analysis, 77% of younger participants and 62% of older participants were classified into the correct age groups based on their scores on the discriminant dimensions (<xref rid="tbl5" ref-type="table">Table 5</xref>). Hydroxy-methoxybenzoic acid, 2-hydroxycinnamic acid, 4-methoxybenzaldehyde (positive correlations), benzoic acid-4-<italic toggle="yes">O</italic>-glucuronide, and 3-methylhippuric acid (negative correlations) were the metabolites with the largest &#946;-coefficients and therefore most likely to classify participants in the correct age group.<table-wrap position="float" id="tbl5" orientation="portrait"><label>TABLE 5</label><caption><p>Classification tables obtained from linear discriminant analysis in 163 participants from the COB study</p></caption><alt-text id="alttext0050">TABLE 5</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Metabolite</th><th colspan="1" rowspan="1">Coefficient<xref rid="tbl5fn1" ref-type="table-fn">1</xref></th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">hydroxy-methoxybenzoic acid<xref rid="tbl5fn2" ref-type="table-fn">2</xref></td><td colspan="1" rowspan="1">0.43</td><td colspan="1" rowspan="1">0.08</td></tr><tr><td colspan="1" rowspan="1">3-methylhippuric acid</td><td colspan="1" rowspan="1">&#8722;0.44</td><td colspan="1" rowspan="1">0.03</td></tr><tr><td colspan="1" rowspan="1">4-methoxybenzaldehyde</td><td colspan="1" rowspan="1">0.28</td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">2-hydroxycinnamic acid</td><td colspan="1" rowspan="1">0.36</td><td colspan="1" rowspan="1">0.06</td></tr><tr><td colspan="1" rowspan="1">3-hydroxy-4-methoxybenzoic acid</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1">0.01</td></tr><tr><td colspan="1" rowspan="1">3-(4-hydroxy-3-methoxyphenyl)propionic acid</td><td colspan="1" rowspan="1">0.27</td><td colspan="1" rowspan="1">0.13</td></tr><tr><td colspan="1" rowspan="1">4-hydroxy-3-methoxyacetophenone</td><td colspan="1" rowspan="1">0.23</td><td colspan="1" rowspan="1">0.17</td></tr><tr><td colspan="1" rowspan="1">3-(phenyl)propionic acid</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">0.08</td></tr><tr><td colspan="1" rowspan="1">3-(dihydroxyphenyl)propionic acid<xref rid="tbl5fn2" ref-type="table-fn">2</xref></td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.22</td></tr><tr><td colspan="1" rowspan="1">benzoic acid-4-<italic toggle="yes">O</italic>-glucuronide</td><td colspan="1" rowspan="1">&#8722;0.50</td><td colspan="1" rowspan="1">0.13</td></tr></tbody></table><table-wrap-foot><fn><p><italic toggle="yes">P</italic> = calculated using ANOVA.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fn1"><label>1</label><p id="ntpara0045">Standardized canonical discriminant function coefficients representing the effect of a 1 SD increase on metabolite concentration on the SD increase in the predicted values on the discriminant function. These values indicate the predictive ability of these metabolites to classify participants into the correct age group.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fn2"><label>2</label><p id="ntpara0050">Metabolites without numbered nomenclature are isomers of unknown hydroxy, methoxy, sulfate or glucuronide structural orientation (no physical references standards were available for retention time conformation but were matched for mass and MS/MS spectra).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.5"><title>Gut microbiome composition by age and sex</title><p id="p0125">Five taxa at the Family level&#8212;<italic toggle="yes">Bacteroidaceae, Christensenellaceae, Clostridiales (unclassified), Dehalobacteriaceae,</italic> and <italic toggle="yes">Rikenellaceae</italic>&#8212;displayed significant differences by age group (Q &lt; 0.20, <xref rid="appsec1" ref-type="sec">Supplementary Table S8</xref>). Relative abundance of all taxa was higher in younger participants, with the exception of <italic toggle="yes">Bacteroidaceae,</italic> which was higher in older participants. Relative abundance of <italic toggle="yes">Barnesiellaceae</italic> differed according to sex, with higher abundance in males. There were no significant differences in alpha diversity (Shannon Index) between older and younger individuals (<italic toggle="yes">P</italic> = 0.12) or males and females (<italic toggle="yes">P</italic> = 0.84) (data not shown). Hierarchical regression analysis revealed that the addition of sex and microbial composition to the model did not improve the prediction of metabolite concentrations over age (<xref rid="tbl6" ref-type="table">Table 6</xref>)<table-wrap position="float" id="tbl6" orientation="portrait"><label>TABLE 6</label><caption><p>Hierarchal regression analysis of predictors of metabolite concentrations in COB participants</p></caption><alt-text id="alttext0055">TABLE 6</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Metabolite</th><th rowspan="2" colspan="1"><italic toggle="yes">n</italic></th><th colspan="1" rowspan="1">M1<hr/></th><th colspan="1" rowspan="1">M2<hr/></th><th colspan="1" rowspan="1">M3<hr/></th></tr><tr><th colspan="1" rowspan="1">&#946; (95% CI) for age</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">hydroxy-methoxybenzoic acid<xref rid="tbl6fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">156</td><td colspan="1" rowspan="1">0.04 (0.01, 0.07)</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">0.67</td></tr><tr><td colspan="1" rowspan="1">3-methylhippuric acid (x 10<sup>2</sup>)</td><td colspan="1" rowspan="1">155</td><td colspan="1" rowspan="1">&#8722;0.42 (&#8722;0.84, 0.00)</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">0.74</td></tr><tr><td colspan="1" rowspan="1">4-methoxybenzaldehyde</td><td colspan="1" rowspan="1">154</td><td colspan="1" rowspan="1">0.00 (0.05, 0.01)</td><td colspan="1" rowspan="1">0.94</td><td colspan="1" rowspan="1">0.97</td></tr><tr><td colspan="1" rowspan="1">2-hydroxycinnamic acid (x 10<sup>2</sup>)</td><td colspan="1" rowspan="1">156</td><td colspan="1" rowspan="1">0.02 (0.00, 0.05)</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">0.58</td></tr><tr><td colspan="1" rowspan="1">3-hydroxy-4-methoxybenzoic acid</td><td colspan="1" rowspan="1">155</td><td colspan="1" rowspan="1">0.06 (0.02, 0.09)</td><td colspan="1" rowspan="1">0.69</td><td colspan="1" rowspan="1">0.56</td></tr><tr><td colspan="1" rowspan="1">3-(4-hydroxy-3-methoxyphenyl)propionic acid</td><td colspan="1" rowspan="1">156</td><td colspan="1" rowspan="1">0.04 (&#8722;0.15, 0.08)</td><td colspan="1" rowspan="1">0.36</td><td colspan="1" rowspan="1">0.73</td></tr><tr><td colspan="1" rowspan="1">4-hydroxy-3-methoxyacetophenone</td><td colspan="1" rowspan="1">155</td><td colspan="1" rowspan="1">0.01 (&#8722;0.13, 0.02)</td><td colspan="1" rowspan="1">0.36</td><td colspan="1" rowspan="1">0.55</td></tr><tr><td colspan="1" rowspan="1">3-(phenyl)propionic acid</td><td colspan="1" rowspan="1">125</td><td colspan="1" rowspan="1">0.05 (&#8722;0.66, 0.11)</td><td colspan="1" rowspan="1">0.64</td><td colspan="1" rowspan="1">0.94</td></tr><tr><td colspan="1" rowspan="1">3-(dihydroxyphenyl)propionic acid<xref rid="tbl6fn1" ref-type="table-fn">1</xref></td><td colspan="1" rowspan="1">154</td><td colspan="1" rowspan="1">0.01 (&#8722;0.75, 0.02)</td><td colspan="1" rowspan="1">0.39</td><td colspan="1" rowspan="1">0.58</td></tr><tr><td colspan="1" rowspan="1">benzoic acid-4-<italic toggle="yes">O</italic>-glucuronide(x 10<sup>2</sup>)</td><td colspan="1" rowspan="1">155</td><td colspan="1" rowspan="1">&#8722;0.74 (&#8722;1.62, 0.00)</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">0.43</td></tr></tbody></table><table-wrap-foot><fn id="tspara0065"><p>M1 = age; M2 = age and sex; M3 = age and PCA1.</p></fn><fn id="tspara0070"><p>&#946; (95% CI) for age were calculated from hierarchical regression with metabolite concentration as the dependent variable and age, sex and PCA1 as predictors. P= P value of the F-statistic indicating if the subsequent model offered any significant improvement over M1. M= model; PCA1 = a linear combination of the gut microbiome variables associated with age (first principal component; 41% of the variance).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl6fn1"><label>1</label><p id="ntpara0055">Metabolite isomers which could not be resolved effectively by HPLC were quantified according to one of the structural isomers.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0130">Overall, we observed no impact of age or sex on total cumulative 24-h urinary elimination of (poly)phenols. This lack of effect of age is consistent with a smaller previous study (<italic toggle="yes">n</italic> = 40), which looked at flavan-3-ol metabolism in men only and observed no difference in total &#8220;structurally related epicatchin metabolites&#8221; in plasma 0&#8211;6 h or urine 0&#8211;24 h. However, we did observe that overall age was the main determinant of flavonoid metabolite excretion kinetics over 24 h. Interestingly, adjustment for BMI and the gut microbial taxa had little effect on the significance of the observed relationships, indicating that any age-associated effects were not mediated by differences in gut microbial speciation or BMI. Older participants consumed considerably more flavonoids in their habitual diet, with nearly 3 times higher intakes compared with younger individuals, and with the highest intakes reported in older females; however, adjusting for habitual intake only moderately reduced the number of metabolites showing age effects (<xref rid="appsec1" ref-type="sec">Supplemental Table 5</xref>).</p><p id="p0135">The Cmax for individual microbial metabolites of (poly)phenols differed by either age or sex for 9 metabolites; however, there were no overall differences in cumulative excretion or Cmax for all polyphenol metabolites combined (i.e., total collective of (poly)phenol metabolites). Differences in Tmax were more pronounced for many metabolites, including both precursor (poly)phenols (hesperetin, naringenin, epicatechin, catechin, and cyanidin glucoside) and their microbial metabolites.</p><p id="p0140">Metabolites displaying significant group, age, or sex effects for Tmax included hydroxybenzoic acids, 3-(phenyl)propionic acids, 5-(Hydroxyphenyl)-gamma-valerolactones and hippuric acids. Hydroxybenzoic acids, 3-(phenyl)propionic acids, and hippuric acids are reported to be derived from multiple (poly)phenol-rich food sources; whereas the 5-(hydroxyphenyl)-gamma-valerolactones were most likely derived from cocoa flavan-3-ols and procyanidins in cocoa and blackcurrant, hesperetin-3'-<italic toggle="yes">O</italic>-glucuronide from orange, and ellagic acid from blackcurrant [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib21" ref-type="bibr">21</xref>,<xref rid="bib36" ref-type="bibr">36</xref>]. Interestingly, there were no clear patterns in elimination kinetics (Cmax or Tmax) for precursor flavonoids relative to their conjugated metabolites (i.e., methyl, sulfate, and glucuronide conjugation) between age or sex groups.</p><p id="p0145">A substantial fraction of flavonoid intake is subjected to gut microbial metabolism, structurally altering the precursor flavonoids found in the diet, forming smaller molecules such as phenolic and aromatic acids, which are more bioavailable and may be highly bioactive [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib4" ref-type="bibr">4</xref>]. Although flavonoid intake has been shown to influence microbiota speciation [<xref rid="bib19" ref-type="bibr">19</xref>,<xref rid="bib20" ref-type="bibr">20</xref>], the role of microbiota functional and metabolic diversity in flavonoid bioavailability is poorly understood. In the present investigation, 5 taxa at the Family level displayed age differences; however, hierarchical regression revealed no effects of microbial composition or sex on metabolite concentration. Within our microbial composition dataset, alpha diversity was not significantly higher in older compared to younger individuals; however, other studies have presented a mixed picture of the association of aging with gut and microbial alpha diversity [<xref rid="bib49" ref-type="bibr">49</xref>].</p><p id="p0150">Tmax differed by as much as 3&#8211;5 h between the age groups and was typically later in older individuals. This finding highlights the need for future studies to consider longer sampling strategies when recruiting wide age ranges for exploring metabolite bioactivity and attempting to establish correlations between peak blood concentration of flavonoid metabolites and health/disease status biomarkers (e.g., glucose or lipoprotein homeostasis). The etiology of differences in Tmax between older and younger individuals is unknown and was not explained by differences in BMI or microbiome speciation. They may derive from differences in glomerular filtration rates, liver metabolism, or gastric and intestinal transit time [<xref rid="bib50" ref-type="bibr">50</xref>,<xref rid="bib51" ref-type="bibr">51</xref>] affecting food digestibility and absorption and elimination of microbial metabolites, variables that should be captured where possible in future studies.</p><p id="p0155">Precursor flavonoids from citrus, cocoa, and berries (naringenin, epicatechin, and cyanidin) and their previously reported metabolites, including microbial metabolites (hippuric acids, benzoic acids, and valerolactones) [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib21" ref-type="bibr">21</xref>,<xref rid="bib36" ref-type="bibr">36</xref>] were graphically depicted (<xref rid="appsec1" ref-type="sec">Supplementary Figures 1-13</xref>) to visualize if differences in rates of elimination of precursor flavonoids across age or sex groups differed or were predictive of their metabolite elimination. Rates of elimination (i.e., slopes of cumulative elimination curves) appeared consistent across age and sex, with older individuals generally having higher Cmax and later Tmax than younger individuals for these perceived biomarkers of flavonoid intake. This evidence indicates that monitoring a limited number of perceived intake biomarkers in nutrition interventions is likely to poorly reflect actual shifts in the dietary metabolomes of individuals and highlights the importance of using more global metabolomics approaches in future interventions.</p><p id="p0160">In the present study, both standard (<italic toggle="yes">P</italic> &lt; 0.05) and conservative statistical approaches (Q &lt; 0.20; Benjamini-Hochberg method for false discovery) were utilized to emphasize the potential impact of multiple testing when characterizing large numbers of metabolites. Moving forward, polyphenol interventions using untargeted or quantitative metabolomics approaches will require consideration and consensus on the most appropriate statistical practices.</p><p id="p0165">The present study design was relatively unique for flavonoid (and (poly)phenols in general) interventions as participants were prospectively recruited by age and sex, allowing for the first comprehensive investigation of the impact of sex, age, and microbiota speciation on acute flavonoid absorption, metabolism, and elimination following the consumption of a flavonoid enriched test meal. The elimination of flavonoids from the background diet 48 h prior to the intervention was an additional strength as it standardized and minimized the contribution of background diet derived metabolites detected in urine post-test meal. The present study was, however, unable to pinpoint a possible mechanism behind the variability in elimination. The lack of characterization of additional possible mediators, such as gastric emptying, intestinal transit, liver and kidney function (glomerular filtration rate), and genetic polymorphisms in phase 1 and 2 metabolism, is identified as a study limitation, along with a lack of capture of metabolite concentrations beyond 24 h, which would have resulted in gut-derived metabolites not being fully recovered. However, it was decided during the trial design stage to limit further participant burden caused by the restricted diet and repeated sampling over an additional 24 h. Many phytochemical phase II metabolites are/were not commercially available as reference standards for use in quantitative analysis (e.g., glucuronide or sulfate conjugates of flavan-3-ols, valerolactones, phenylvaleric acids, etc.), and therefore, the present total recovery is likely to be an underestimation of the amount and diversity of polyphenol metabolites excreted. Further, there is likely to be some minimal contribution of endogenous and dietary aromatic amino acids to the phenolic acid metabolite pools quantified in the urine in the present study, such as hippuric acids; however, all participants were on the same intervention meals, and the exclusion diet was essentially void of (poly)phenols, minimizing this possible confounding of endogenous or dietary substrates. Finally, the research was conducted in a healthy population, with &gt; 90% of our study population being White British, and extrapolation of findings to clinical groups with significant disease pathology and medication use or other ethnic groups should be done with caution.</p><p id="p0170">In conclusion, our study provides evidence of a large impact of age on the elimination kinetics of (poly)phenol metabolites, particularly Tmax, which occurs much later in older individuals. The age effects observed on individual metabolite recovery do not appear to be substantially driven by differences in background diet, BMI, and microbiota speciation. Our results indicate that evaluating blood or urine signatures of (poly)phenol metabolites at a single time point is unlikely to capture the true absorption and elimination kinetics across age and sex groups.</p></sec><sec id="sec5"><title>Author contributions</title><p id="p0175">The authors&#8217; responsibilities were as follows &#8211; AMM, AC: designed the study; SH, NT, BCD, DB, SL: were responsible for participant recruitment, delivery of the intervention protocol, and the collection, processing, and storage of biological samples; NT, BCD, CDK: designed, delivered, and interpreted the urinary flavonoid analysis; LCC, DM: were responsible for the preparation of the fecal samples for microbiome speciation and the interpretation of the data; AJ: conducted all statistical analyses; CDK, AJ, AMM: drafted the paper; all authors: read and approved the final manuscript.</p></sec><sec sec-type="data-availability" id="sec6"><title>Data availability</title><p id="p0180">Data described in the manuscript, including urine concentration, analytical methodologies, and statistical analysis data files, will be made available upon request and approval from the corresponding author.</p></sec><sec id="sec7"><title>Funding</title><p id="p0185">This work was funded by a <funding-source id="gs1">Biotechnology and Biological Sciences Research Council</funding-source> (BBSRC), <funding-source id="gs2">Food and Health, Institute Strategic Programme</funding-source> Grant (ISP) (BB/J004545/1), who had no role in the design or delivery of the study or in the data analysis and its interpretation.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Conflict of interest</title><p id="p0190">AMM reports was provided by University of East Anglia Norwich Medical School. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Cassidy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Minihane</surname><given-names>A.M.</given-names></name></person-group><article-title>The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids</article-title><source>Am. J. Clin. Nutr.</source><volume>105</volume><issue>1</issue><year>2017</year><fpage>10</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">27881391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3945/ajcn.116.136051</pub-id><pub-id pub-id-type="pmcid">PMC5183723</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Manach</surname><given-names>C.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Morand</surname><given-names>C.</given-names></name><name name-style="western"><surname>Scalbert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Remesy</surname><given-names>C.</given-names></name></person-group><article-title>Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies</article-title><source>Am. J. Clin. Nutr.</source><volume>81</volume><issue>1 Suppl</issue><year>2005</year><fpage>230s</fpage><lpage>242s</lpage><pub-id pub-id-type="pmid">15640486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajcn/81.1.230S</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Manach</surname><given-names>C.</given-names></name></person-group><article-title>Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies</article-title><source>Am. J. Clin. Nutr.</source><volume>81</volume><issue>1 Suppl</issue><year>2005</year><fpage>243s</fpage><lpage>255s</lpage><pub-id pub-id-type="pmid">15640487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajcn/81.1.243S</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kay</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Crozier</surname><given-names>A.</given-names></name></person-group><article-title>The bioavailability, transport, and bioactivity of dietary flavonoids: a review from a historical perspective</article-title><source>Compr. Rev. Food Sci. Food Saf.</source><volume>17</volume><issue>5</issue><year>2018</year><fpage>1054</fpage><lpage>1112</lpage><pub-id pub-id-type="pmid">33350159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1541-4337.12351</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Bertoia</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Rimm</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Mukamal</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Willett</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Cassidy</surname><given-names>A.</given-names></name></person-group><article-title>Dietary flavonoid intake and weight maintenance: three prospective cohorts of 124,086 US men and women followed for up to 24 years</article-title><source>BMJ</source><volume>352</volume><year>2016</year><object-id pub-id-type="publisher-id">i17</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.i17</pub-id><pub-id pub-id-type="pmcid">PMC4730111</pub-id><pub-id pub-id-type="pmid">26823518</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Grosso</surname><given-names>G.</given-names></name><name name-style="western"><surname>Godos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lamuela-Raventos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>S.</given-names></name><name name-style="western"><surname>Micek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pajak</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A comprehensive meta-analysis on dietary flavonoid and lignan intake and cancer risk: level of evidence and limitations</article-title><source>Mol. Nutr. Food Res.</source><volume>61</volume><issue>4</issue><year>2017</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mnfr.201600930</pub-id><pub-id pub-id-type="pmid">27943649</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Ivey</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Hodgson</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Eliassen</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Cassidy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rimm</surname><given-names>E.B.</given-names></name></person-group><article-title>Association of flavonoid-rich foods and flavonoids with risk of all-cause mortality</article-title><source>Br. J. Nutr.</source><volume>117</volume><issue>10</issue><year>2017</year><fpage>1470</fpage><lpage>1477</lpage><pub-id pub-id-type="pmid">28606222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0007114517001325</pub-id><pub-id pub-id-type="pmcid">PMC7233415</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Raman</surname><given-names>G.</given-names></name><name name-style="western"><surname>Avendano</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Matson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gayer</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Dietary intakes of flavan-3-ols and cardiometabolic health: systematic review and meta-analysis of randomized trials and prospective cohort studies</article-title><source>Am. J. Clin. Nutr.</source><volume>110</volume><issue>5</issue><year>2019</year><fpage>1067</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">31504087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajcn/nqz178</pub-id><pub-id pub-id-type="pmcid">PMC6821550</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Shishtar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Blumberg</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Au</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jacques</surname><given-names>P.F.</given-names></name></person-group><article-title>Long-term dietary flavonoid intake and risk of Alzheimer disease and related dementias in the Framingham Offspring cohort</article-title><source>Am. J. Clin. Nutr.</source><volume>112</volume><issue>2</issue><year>2020</year><fpage>343</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">32320019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajcn/nqaa079</pub-id><pub-id pub-id-type="pmcid">PMC7398772</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Curtis</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>van der Velpen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Berends</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>A.</given-names></name><name name-style="western"><surname>Feelisch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Umpleby</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Blueberries improve biomarkers of cardiometabolic function in participants with metabolic syndrome&#8212;results from a 6-month, double-blind, randomized controlled trial</article-title><source>Am. J. Clin. Nutr.</source><volume>109</volume><issue>6</issue><year>2019</year><fpage>1535</fpage><lpage>1545</lpage><pub-id pub-id-type="pmid">31136659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajcn/nqy380</pub-id><pub-id pub-id-type="pmcid">PMC6537945</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Czank</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cassidy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Preston</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kroon</surname><given-names>P.A.</given-names></name><etal/></person-group><article-title>Human metabolism and elimination of the anthocyanin, cyanidin-3-glucoside: a 13C-tracer study</article-title><source>Am. J. Clin. Nutr.</source><volume>97</volume><issue>5</issue><year>2013</year><fpage>995</fpage><lpage>1003</lpage><pub-id pub-id-type="pmid">23604435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3945/ajcn.112.049247</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sirisena</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>K.</given-names></name></person-group><article-title>Efficacy of flavonoids on biomarkers of type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials</article-title><source>Crit. Rev. Food Sci. Nutr.</source><volume>63</volume><issue>21</issue><year>2023</year><fpage>4916</fpage><lpage>4941</lpage><pub-id pub-id-type="pmid">34842001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408398.2021.2009761</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Hooper</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kroon</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Rimm</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>I.</given-names></name><name name-style="western"><surname>Le Cornu</surname><given-names>K.A.</given-names></name><etal/></person-group><article-title>Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials</article-title><source>Am. J. Clin. Nutr.</source><volume>88</volume><issue>1</issue><year>2008</year><fpage>38</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">18614722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajcn/88.1.38</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Favari</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rinaldi de Alvarenga</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>S&#225;nchez-Mart&#237;nez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tosi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mignogna</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cremonini</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Factors driving the inter-individual variability in the metabolism and bioavailability of (poly)phenolic metabolites: a systematic review of human studies</article-title><source>Redox Biol</source><volume>71</volume><year>2024</year><object-id pub-id-type="publisher-id">103095</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2024.103095</pub-id><pub-id pub-id-type="pmcid">PMC10912651</pub-id><pub-id pub-id-type="pmid">38428187</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Landberg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Manach</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kerckhof</surname><given-names>F.-M.</given-names></name><name name-style="western"><surname>Minihane</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Saleh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roos</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Future prospects for dissecting inter-individual variability in the absorption, distribution and elimination of plant bioactives of relevance for cardiometabolic endpoints</article-title><source>Eur. J. Nutr.</source><volume>58</volume><issue>Suppl 2</issue><year>2019</year><fpage>21</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">31642982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00394-019-02095-1</pub-id><pub-id pub-id-type="pmcid">PMC6851035</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Mangoni</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>S.H.</given-names></name></person-group><article-title>Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications</article-title><source>Br. J. Clin. Pharmacol.</source><volume>57</volume><issue>1</issue><year>2004</year><fpage>6</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">14678335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2003.02007.x</pub-id><pub-id pub-id-type="pmcid">PMC1884408</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Farkouh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Riedl</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gottardi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Czejka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kautzky-Willer</surname><given-names>A.</given-names></name></person-group><article-title>Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature</article-title><source>Adv. Ther.</source><volume>37</volume><issue>2</issue><year>2020</year><fpage>644</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">31873866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-019-01201-3</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>Z.D.</given-names></name><name name-style="western"><surname>Csanaky</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>Klaassen</surname><given-names>C.D.</given-names></name></person-group><article-title>Effects of aging on mRNA profiles for drug-metabolizing enzymes and transporters in livers of male and female mice</article-title><source>Drug Metabol. Dispos.</source><volume>40</volume><issue>6</issue><year>2012</year><fpage>1216</fpage><lpage>1225</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.111.044461</pub-id><pub-id pub-id-type="pmcid">PMC3362785</pub-id><pub-id pub-id-type="pmid">22446518</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Tzounis</surname><given-names>X.</given-names></name><name name-style="western"><surname>Rodriguez-Mateos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vulevic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Kwik-Uribe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>J.P.</given-names></name></person-group><article-title>Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study</article-title><source>Am. J. Clin. Nutr.</source><volume>93</volume><issue>1</issue><year>2011</year><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">21068351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3945/ajcn.110.000075</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Ivey</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Izard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cassidy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Rimm</surname><given-names>E.B.</given-names></name></person-group><article-title>Role of dietary flavonoid compounds in driving patterns of microbial community assembly</article-title><source>mBio</source><volume>10</volume><issue>5</issue><year>2019</year><object-id pub-id-type="publisher-id">e01205</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.01205-19</pub-id><pub-id pub-id-type="pmcid">PMC6759757</pub-id><pub-id pub-id-type="pmid">31551328</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Kawabata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoshioka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Terao</surname><given-names>J.</given-names></name></person-group><article-title>Role of Intestinal microbiota in the bioavailability and physiological functions of dietary polyphenols</article-title><source>Molecules</source><volume>24</volume><issue>2</issue><year>2019</year><fpage>370</fpage><pub-id pub-id-type="pmid">30669635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules24020370</pub-id><pub-id pub-id-type="pmcid">PMC6359708</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Yates</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Dwyer</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Erdman</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>King</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lyle</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Schneeman</surname><given-names>B.O.</given-names></name><etal/></person-group><article-title>Perspective: framework for developing recommended intakes of bioactive dietary substances</article-title><source>Adv. Nutr.</source><volume>12</volume><issue>4</issue><year>2021</year><fpage>1087</fpage><lpage>1099</lpage><pub-id pub-id-type="pmid">33962461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/advances/nmab044</pub-id><pub-id pub-id-type="pmcid">PMC8321833</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Cermak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wolffram</surname><given-names>S.</given-names></name></person-group><article-title>The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms</article-title><source>Curr. Drug Metab.</source><volume>7</volume><issue>7</issue><year>2006</year><fpage>729</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">17073577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138920006778520570</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Cermak</surname><given-names>R.</given-names></name></person-group><article-title>Effect of dietary flavonoids on pathways involved in drug metabolism</article-title><source>Expert Opin. Drug Metab. Toxicol.</source><volume>4</volume><issue>1</issue><year>2008</year><fpage>17</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">18370856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.4.1.17</pub-id></element-citation></ref><ref id="bib25"><label>25</label><mixed-citation publication-type="other" id="sref25">B. Bates, A. Lennox, A. Prentice, C. Bates, G. Swan, National Diet and Nutrition Survey. Headline results from years 1, 2 and 3 (combined) of the rolling programme (2008/2009&#8211;2010/11), Department of Health London, [Internet]. 2012. [Last accessed 2nd April 2024]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.uk/government/statistics/national-diet-and-nutrition-survey-headline-results-from-years-1-2-and-3-combined-of-the-rolling-programme-200809-201011" id="interf0023">https://www.gov.uk/government/statistics/national-diet-and-nutrition-survey-headline-results-from-years-1-2-and-3-combined-of-the-rolling-programme-200809-201011</ext-link></mixed-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Bingham</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>C.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cassidy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Runswick</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Oakes</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Validation of dietary assessment methods in the UK arm of EPIC using weighed records, and 24-hour urinary nitrogen and potassium and serum vitamin C and carotenoids as biomarkers</article-title><source>Int. J. Epidemiol.</source><volume>26</volume><issue>Suppl 1</issue><year>1997</year><fpage>S137</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">9126542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/26.suppl_1.s137</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>de Ferrars</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Czank</surname><given-names>C.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Needs</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Raheem</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>Methods for isolating, identifying, and quantifying anthocyanin metabolites in clinical samples</article-title><source>Anal. Chem.</source><volume>86</volume><issue>20</issue><year>2014</year><fpage>10052</fpage><lpage>10058</lpage><pub-id pub-id-type="pmid">24828315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ac500565a</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Schar</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Hazim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ostertag</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Kay</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>J.F.</given-names></name><etal/></person-group><article-title>Orange juice-derived flavanone and phenolic metabolites do not acutely affect cardiovascular risk biomarkers: a randomized, placebo-controlled, crossover trial in men at moderate risk of cardiovascular disease</article-title><source>Am. J. Clin. Nutr.</source><volume>101</volume><issue>5</issue><year>2015</year><fpage>931</fpage><lpage>938</lpage><pub-id pub-id-type="pmid">25788001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3945/ajcn.114.104364</pub-id><pub-id pub-id-type="pmcid">PMC4409690</pub-id></element-citation></ref><ref id="bib29"><label>29</label><mixed-citation publication-type="other" id="sref29">R. McCance, E. Widdowson, The composition of foods-medical research council special, report series, 1960, p. 290 [Internet]. 2012. [Last accessed 2nd April 2024]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.uk/government/publications/composition-of-foods-integrated-dataset-cofid" id="interf0035">https://www.gov.uk/government/publications/composition-of-foods-integrated-dataset-cofid</ext-link>.</mixed-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Finglas</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>R.</given-names></name><name name-style="western"><surname>Astley</surname><given-names>S.</given-names></name></person-group><article-title>Assessing and improving the quality of food composition databases for nutrition and health applications in Europe: the contribution of EuroFIR</article-title><source>Adv. Nutr.</source><volume>5</volume><issue>5</issue><year>2014</year><fpage>608S</fpage><lpage>614S</lpage><pub-id pub-id-type="pmid">25469406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3945/an.113.005470</pub-id><pub-id pub-id-type="pmcid">PMC4188244</pub-id></element-citation></ref><ref id="bib31"><label>31</label><mixed-citation publication-type="other" id="sref31">S. Bhagwat, D.B. Haytowitz, J.M. Holden, USDA database for the flavonoid content of selected foods, Release 3.1, US Department of Agriculture, Beltsville, MD, USA, 2014 [Last accessed 2nd April 2024]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ars.usda.gov/arsuserfiles/80400525/data/flav/flav_r03-1.pdf" id="interf003">https://www.ars.usda.gov/arsuserfiles/80400525/data/flav/flav_r03-1.pdf</ext-link>.</mixed-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Neveu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Perez-Jim&#233;nez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vos</surname><given-names>F.</given-names></name><name name-style="western"><surname>Crespy</surname><given-names>V.</given-names></name><name name-style="western"><surname>du Chaffaut</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mennen</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Phenol-Explorer: an online comprehensive database on polyphenol contents in foods</article-title><source>Database (Oxford)</source><volume>2010</volume><year>2010</year><fpage>bap024</fpage><pub-id pub-id-type="pmid">20428313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/database/bap024</pub-id><pub-id pub-id-type="pmcid">PMC2860900</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Rothwell</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Perez-Jimenez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Neveu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Medina-Remon</surname><given-names>A.</given-names></name><name name-style="western"><surname>M'Hiri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Garc&#237;a-Lobato</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Phenol-Explorer 3.0: a major update of the Phenol-Explorer database to incorporate data on the effects of food processing on polyphenol content</article-title><source>Database (Oxford)</source><volume>2013</volume><year>2013</year><fpage>bap070</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/database/bat070</pub-id><pub-id pub-id-type="pmcid">PMC3792339</pub-id><pub-id pub-id-type="pmid">24103452</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>de Ferrars</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Cassidy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kay</surname><given-names>C.D.</given-names></name></person-group><article-title>Phenolic metabolites of anthocyanins following a dietary intervention study in post-menopausal women</article-title><source>Mol. Nutr. Food Res.</source><volume>58</volume><issue>3</issue><year>2014</year><fpage>490</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">24170677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mnfr.201300322</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>de Ferrars</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Czank</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Botting</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Kroon</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Cassidy</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The pharmacokinetics of anthocyanins and their metabolites in humans</article-title><source>Br. J. Pharmacol.</source><volume>171</volume><issue>13</issue><year>2014</year><fpage>3268</fpage><lpage>3282</lpage><pub-id pub-id-type="pmid">24602005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.12676</pub-id><pub-id pub-id-type="pmcid">PMC4080980</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Rios</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Gonthier</surname><given-names>M.-P.</given-names></name><name name-style="western"><surname>R&#233;m&#233;sy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mila</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lapierre</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lazarus</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Chocolate intake increases urinary excretion of polyphenol-derived phenolic acids in healthy human subjects</article-title><source>Am. J. Clin. Nutr.</source><volume>77</volume><issue>4</issue><year>2003</year><fpage>912</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">12663291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajcn/77.4.912</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Stalmach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mullen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Barron</surname><given-names>D.</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yokota</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cavin</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Metabolite profiling of hydroxycinnamate derivatives in plasma and urine after the ingestion of coffee by humans: identification of biomarkers of coffee consumption</article-title><source>Drug Metabol. Dispos.</source><volume>37</volume><issue>8</issue><year>2009</year><fpage>1749</fpage><lpage>1758</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.109.028019</pub-id><pub-id pub-id-type="pmid">19460943</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Stalmach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Troufflard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Serafini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Crozier</surname><given-names>A.</given-names></name></person-group><article-title>Absorption, metabolism and excretion of Choladi green tea flavan-3-ols by humans</article-title><source>Mol. Nutr. Food Res.</source><volume>53</volume><issue>Suppl 1</issue><year>2009</year><fpage>S44</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">18979506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mnfr.200800169</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Urpi-Sarda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Monagas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lamuela-Raventos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Santos-Buelga</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sacanella</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Epicatechin, procyanidins, and phenolic microbial metabolites after cocoa intake in humans and rats</article-title><source>Anal. Bioanal. Chem.</source><volume>394</volume><issue>6</issue><year>2009</year><fpage>1545</fpage><lpage>1556</lpage><pub-id pub-id-type="pmid">19333587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00216-009-2676-1</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Pereira-Caro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Borges</surname><given-names>G.</given-names></name><name name-style="western"><surname>van der Hooft</surname><given-names>J.</given-names></name><name name-style="western"><surname>Clifford</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Del Rio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lean</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Orange juice (poly)phenols are highly bioavailable in humans</article-title><source>Am. J. Clin. Nutr.</source><volume>100</volume><issue>5</issue><year>2014</year><fpage>1378</fpage><lpage>1384</lpage><pub-id pub-id-type="pmid">25332336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3945/ajcn.114.090282</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Actis-Goretta</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leveques</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giuffrida</surname><given-names>F.</given-names></name><name name-style="western"><surname>Destaillats</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>K.</given-names></name></person-group><article-title>Identification of O-methyl-(-)-epicatechin-O-sulphate metabolites by mass-spectrometry after O-methylation with trimethylsilyldiazomethane</article-title><source>J. Chromatogr. A.</source><volume>1245</volume><year>2012</year><fpage>150</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">22663977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chroma.2012.05.042</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Actis-Goretta</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leveques</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giuffrida</surname><given-names>F.</given-names></name><name name-style="western"><surname>Romanov-Michailidis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Viton</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barron</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Elucidation of (-)-epicatechin metabolites after ingestion of chocolate by healthy humans</article-title><source>Free Radic. Biol. Med.</source><volume>53</volume><issue>4</issue><year>2012</year><fpage>787</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">22664313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2012.05.023</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Ottaviani</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Momma</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Kuhnle</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Keen</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Schroeter</surname><given-names>H.</given-names></name></person-group><article-title>Structurally related (-)-epicatechin metabolites in humans: assessment using de novo chemically synthesized authentic standards</article-title><source>Free Radic. Biol. Med.</source><volume>52</volume><issue>8</issue><year>2012</year><fpage>1403</fpage><lpage>1412</lpage><pub-id pub-id-type="pmid">22240152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2011.12.010</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Calani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Del Rio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Luisa Callegari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brighenti</surname><given-names>F.</given-names></name></person-group><article-title>Updated bioavailability and 48 h excretion profile of flavan-3-ols from green tea in humans</article-title><source>Int. J. Food Sci. Nutr.</source><volume>63</volume><issue>5</issue><year>2012</year><fpage>513</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">22133145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/09637486.2011.640311</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans, mice, and rats</article-title><source>Chem. Res. Toxicol.</source><volume>15</volume><issue>8</issue><year>2002</year><fpage>1042</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">12184788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/tx010184a</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Kuczynski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stombaugh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Caporaso</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>R.</given-names></name></person-group><article-title>Using QIIME to analyze 16S rRNA gene sequences from microbial communities</article-title><source>Curr. Protoc. Bioinformatics</source><year>2011</year><comment>Chapter 10:10.7.1-10.7.20</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/0471250953.bi1007s36</pub-id><pub-id pub-id-type="pmcid">PMC3249058</pub-id><pub-id pub-id-type="pmid">22161565</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Bokulich</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Faith</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Gevers</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing</article-title><source>Nat. Methods</source><volume>10</volume><issue>1</issue><year>2013</year><fpage>57</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">23202435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.2276</pub-id><pub-id pub-id-type="pmcid">PMC3531572</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name></person-group><article-title>Pretreating and normalizing metabolomics data for statistical analysis</article-title><source>Genes Dis</source><volume>11</volume><issue>3</issue><year>2024</year><object-id pub-id-type="publisher-id">100979</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gendis.2023.04.018</pub-id><pub-id pub-id-type="pmcid">PMC10827599</pub-id><pub-id pub-id-type="pmid">38299197</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Badal</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Vaccariello</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jeste</surname><given-names>D.V.</given-names></name><etal/></person-group><article-title>The gut microbiome, aging, and longevity: a systematic review</article-title><source>Nutrients</source><volume>12</volume><issue>12</issue><year>2020</year><fpage>3759</fpage><pub-id pub-id-type="pmid">33297486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu12123759</pub-id><pub-id pub-id-type="pmcid">PMC7762384</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Bitar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Greenwood-Van Meerveld</surname><given-names>B.</given-names></name><name name-style="western"><surname>Saad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wiley</surname><given-names>J.W.</given-names></name></person-group><article-title>Aging and gastrointestinal neuromuscular function: insights from within and outside the gut</article-title><source>Neurogastroenterol. Motil.</source><volume>23</volume><issue>6</issue><year>2011</year><fpage>490</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">21320236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2982.2011.01678.x</pub-id><pub-id pub-id-type="pmcid">PMC3094479</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Shimamoto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hirata</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hiraike</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Katsu</surname><given-names>K.</given-names></name></person-group><article-title>Evaluation of gastric motor activity in the elderly by electrogastrography and the (13)C-acetate breath test</article-title><source>Gerontology</source><volume>48</volume><issue>6</issue><year>2002</year><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">12393954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000065500</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0195">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.xlsx" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc2" position="float" orientation="portrait"><caption><title>Multimedia component 2</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc2.pptx" position="float" orientation="portrait"><alt-text>Multimedia component 2</alt-text></media></supplementary-material></p></sec><fn-group><fn id="d36e2725"><p id="ntpara0010">&#9734; The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></fn><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0200">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ajcnut.2025.05.006" id="intref0020">https://doi.org/10.1016/j.ajcnut.2025.05.006</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurotherapeutics</journal-id><journal-id journal-id-type="iso-abbrev">Neurotherapeutics</journal-id><journal-id journal-id-type="pmc-domain-id">1472</journal-id><journal-id journal-id-type="pmc-domain">neurother</journal-id><journal-title-group><journal-title>Neurotherapeutics</journal-title></journal-title-group><issn pub-type="ppub">1933-7213</issn><issn pub-type="epub">1878-7479</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12491791</article-id><article-id pub-id-type="pmcid-ver">PMC12491791.1</article-id><article-id pub-id-type="pmcaid">12491791</article-id><article-id pub-id-type="pmcaiid">12491791</article-id><article-id pub-id-type="pmid">40450458</article-id><article-id pub-id-type="doi">10.1016/j.neurot.2025.e00616</article-id><article-id pub-id-type="pii">S1878-7479(25)00094-7</article-id><article-id pub-id-type="publisher-id">e00616</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Neuroprotective effects of G9a inhibition and cannabinoid receptor activation in Alzheimer's disease through a pharmacological approach</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Bellver-Sanchis</surname><given-names initials="A">Aina</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Ribalta-Vilella</surname><given-names initials="M">Marta</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Lillo</surname><given-names initials="J">Jaume</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Ortu&#241;o-Sahag&#250;n</surname><given-names initials="D">Daniel</given-names></name><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Franco</surname><given-names initials="R">Rafael</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff7" ref-type="aff">g</xref><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Pall&#224;s</surname><given-names initials="M">Merc&#232;</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Navarro</surname><given-names initials="G">Gemma</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Gri&#241;&#225;n-Ferr&#233;</surname><given-names initials="C">Christian</given-names></name><email>Christian.grinan@ub.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff9" ref-type="aff">i</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="aff1"><label>a</label>Department of Pharmacology and Therapeutic Chemistry, Institut de Neuroci&#232;ncies-Universitat de Barcelona, Avda. Joan XXIII, 27, 08028 Barcelona, Spain</aff><aff id="aff2"><label>b</label>Facultat de Farm&#224;cia i Ci&#232;ncies de l'Alimentaci&#243; or Facultat de Biologia (Depending on the Faculty You Are Registered with), Universitat de Barcelona, Avda. Diagonal 643, 08028 Barcelona, Spain</aff><aff id="aff3"><label>c</label>Network Center for Biomedical Research in Neurodegenerative Diseases, CiberNed, Spanish National Health Institute Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain</aff><aff id="aff4"><label>d</label>Institut de Neuroci&#232;ncies UB, Campus Mundet, Passeig de la Vall d&#8217;Hebron 171, 08035 Barcelona, Spain</aff><aff id="aff5"><label>e</label>Molecular Neurobiology Laboratory, Department Biochemistry and Molecular Biomedicine, Facultat de Biologia, Universitat de Barcelona, 08028 Barcelona, Spain</aff><aff id="aff6"><label>f</label>Laboratorio de Neuroinmunobiolog&#237;a Molecular, Instituto de Investigaci&#243;n en Ciencias Biom&#233;dicas, Departamento de Biolog&#237;a Molecular y Gen&#243;mica. Universidad de Guadalajara, Guadalajara, Mexico</aff><aff id="aff7"><label>g</label>Department of Biochemistry and Physiology, School of Pharmacy and Food Sciences, Universitat de Barcelona, 08028 Barcelona, Spain</aff><aff id="aff8"><label>h</label>School of Chemistry, University of Barcelona, 08028 Barcelona, Spain</aff><aff id="aff9"><label>i</label>Spanish Biomedical Research Center in Neurodegenerative Diseases (CIBERNED)-Instituto de Salud Carlos III, Madrid, Spain</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>Christian.grinan@ub.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>31</day><month>5</month><year>2025</year></pub-date><volume>22</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">498231</issue-id><elocation-id>e00616</elocation-id><history><date date-type="received"><day>26</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>16</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-04 13:25:42.290"><day>04</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Epigenetic alterations are key contributors to Alzheimer's disease (AD), driving age-related cognitive decline. This study explores the combined neuroprotective effects of G9a histone methyltransferase inhibition (via UNC0642) and cannabinoid receptor activation (CB1R: ACEA; CB2R: JWH133) in AD models. We used HEK-293T cells and hippocampal neurons to demonstrate that G9a inhibition selectively enhances CB1R-mediated ERK/cAMP signaling. In SAMP8 mice (sporadic AD model), we evaluated the effects of pharmacological inhibition of G9a (UNC0642), combined with CB<sub>1</sub>R agonism (ACEA) and/or CB<sub>2</sub>R agonism (JWH133), on cognitive recovery, neuronal morphology, and neuroinflammation. Our results demonstrated that SAMP8 mice treated with UNC0642 and ACEA exhibited significant recovery in short-term memory, as assessed by the Novel Object Recognition Test (NORT), and complete recovery of spatial memory in the Object Location Test (OLT). These improvements were accompanied by enhanced neuronal morphology (increased dendritic length and density) and reduced neuroinflammation markers, suggesting a synergistic effect of G9a inhibition and CB<sub>1</sub>R activation. Importantly, JWH133 treatment, both alone and in combination with UNC0642, resulted in a pronounced reduction of neuroinflammatory markers (<italic toggle="yes">Trem2, Cd33, iNOS</italic>) and a significant restoration of dendritic spine density and branching length, with the dual treatment showing the most robust effects. JWH133 alone produced moderate cognitive improvement, but its combination with G9a inhibition led to outcomes comparable to those of control animals. Thus, the results underscore G9a inhibition's potential to amplify cannabinoid receptor-mediated neuroprotection while mitigating psychoactive risks, offering a promising multi-target approach for neurodegenerative diseases.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p><fig id="undfig1" position="anchor" orientation="portrait"><alt-text id="alttext0010">Image 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Neurodegenerative diseases</kwd><kwd>Cannabinoids</kwd><kwd>Histone methyltransferase</kwd><kwd>Behavior</kwd><kwd>Neuroinflammation</kwd><kwd>Synaptic plasticity</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Alzheimer's disease (AD) is a debilitating neurodegenerative disorder that poses one of the most significant challenges to modern medicine [<xref rid="bib1" ref-type="bibr">1</xref>]. AD is characterized by progressive cognitive decline and is associated with the accumulation of amyloid-beta (A&#946;) plaques and neurofibrillary tangles (NFTs), synaptic dysfunction and neuronal loss [<xref rid="bib2" ref-type="bibr">2</xref>]. The complexity of AD pathology has led researchers to explore a variety of therapeutic targets, of which the endocannabinoid system (ECS) and epigenetic mechanisms have received considerable attention [<xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>].</p><p id="p0015">The ECS, consisting of endogenous cannabinoids, such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG), their receptors (CB<sub>1</sub>R and CB<sub>2</sub>R), and metabolic enzymes, plays a pivotal role in the maintenance of neuronal homeostasis [<xref rid="bib6" ref-type="bibr">6</xref>]. CB<sub>1</sub>Rs are mainly expressed in the central nervous system (CNS) and are involved in modulating the release of neurotransmitters. CB<sub>2</sub>Rs, which are found primarily in peripheral tissues, are expressed in glial cells, especially following activation due to neuroinflammation [<xref rid="bib7" ref-type="bibr">7</xref>]. The ECS is disrupted in AD, and modulation of cannabinoid receptors has emerged as a potential therapeutic strategy to mitigate the progression of pathology and symptoms associated with AD. Several synthetic cannabinoids, such as JWH133, a selective agonist CB<sub>2</sub>R, and ACEA, a selective agonist CB<sub>1</sub>R, have been investigated for their potential therapeutic effect in AD [<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib9" ref-type="bibr">9</xref>]. Despite these promising results, the use of cannabinoids in AD therapy is not without limitations. The psychoactive effects of THC and the potential impairment of memory and learning ability associated with the use/abuse of cannabis in vulnerable individuals are concerns that need to be addressed. Additionally, the optimal therapeutic dosage and timing of treatment have yet to be determined.</p><p id="p0020">In parallel with research into the ECS, epigenetic changes have been recognized as key factors in the pathogenesis of AD [<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib11" ref-type="bibr">11</xref>]. Epigenetic mechanisms, such as DNA methylation and histone modifications, regulate gene expression without altering the underlying DNA sequence. These reversible modifications respond to environmental stimuli and can influence the course of neurodegenerative diseases [<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib12" ref-type="bibr">12</xref>]. G9a, also known as EHMT2, is a histone methyltransferase that primarily catalyzes the di-methylation of histone H3 at lysine 9 (H3K9me2), a marker generally associated with gene silencing [<xref rid="bib13" ref-type="bibr">13</xref>]. G9a is related to various biological processes, including development, differentiation, and the response to neuronal injury [<xref rid="bib14" ref-type="bibr">14</xref>]. In the context of AD, the role of G9a in gene regulation is of particular interest as it may affect genes involved in neurodegeneration and memory formation [<xref rid="bib15" ref-type="bibr">15</xref>]. UNC0642 is a potent and selective G9a inhibitor developed as a tool to study biological function and is a potential therapeutic target for AD [<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib16" ref-type="bibr">[16]</xref>, <xref rid="bib17" ref-type="bibr">[17]</xref>, <xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib19" ref-type="bibr">[19]</xref>, <xref rid="bib20" ref-type="bibr">[20]</xref>, <xref rid="bib21" ref-type="bibr">[21]</xref>, <xref rid="bib22" ref-type="bibr">[22]</xref>, <xref rid="bib23" ref-type="bibr">[23]</xref>].</p><p id="p0025">The interplay between G9a, histone modifications, and cannabinoid receptor expression reveals a compelling epigenetic dimension to the dysregulation of the endocannabinoid system (ECS) observed in AD. Rather than resulting from genetic mutations, these changes arise from alterations in gene expression-specifically, G9a-mediated histone methylation that represses CB1 receptor (CB1R) transcription. G9a catalyzes the dimethylation of histone H3 at lysine 9 (H3K9me2), a repressive mark that silences the <italic toggle="yes">CNR1</italic> gene, leading to reduced CB1R expression in affected brain regions and dorsal root ganglia (DRG) [<xref rid="bib24" ref-type="bibr">[24]</xref>, <xref rid="bib25" ref-type="bibr">[25]</xref>, <xref rid="bib26" ref-type="bibr">[26]</xref>]. Since CB1R is crucial for learning and memory, its suppression by G9a may underlie some of the cognitive deficits characteristic of AD [<xref rid="bib25" ref-type="bibr">25</xref>,<xref rid="bib27" ref-type="bibr">27</xref>]. In contrast, studies have shown that after nerve injury, CB2 receptor (CB2R) mRNA levels are elevated in the DRG, a response associated with increased activating histone marks (H3K4me3, H3K9ac) and decreased repressive marks at the <italic toggle="yes">CNR2</italic> promoter [<xref rid="bib24" ref-type="bibr">24</xref>,<xref rid="bib28" ref-type="bibr">28</xref>]. Given that G9a is generally linked to gene silencing, it is unlikely to be directly responsible for CB2R upregulation. This differential regulation of cannabinoid receptors highlights a nuanced and dynamic relationship between epigenetic mechanisms and receptor expression in the nervous system's response to injury and disease, underscoring the importance of epigenetic factors in ECS dysfunction and pointing to new avenues for therapeutic intervention in AD [<xref rid="bib24" ref-type="bibr">24</xref>,<xref rid="bib25" ref-type="bibr">25</xref>,<xref rid="bib29" ref-type="bibr">29</xref>].</p><p id="p0030">Moreover, the potential role of G9a in modulating neuroinflammatory responses by regulating CB<sub>2</sub>R expression is another area of interest. Since neuroinflammation is a hallmark of AD and CB<sub>2</sub>Rs are involved in the modulation of immune responses, epigenetic regulation of CB<sub>2</sub>Rs by G9a could influence the progression of AD [<xref rid="bib30" ref-type="bibr">30</xref>]. Therefore, targeting G9a in AD holds considerable therapeutic potential. Modulation of G9a could restore the expression of cannabinoid receptors and other dysregulated genes, potentially reversing or slowing AD progression. This could improve the efficacy of cannabinoid-based therapies, which show promise but are limited by the complexity of the ECS. In addition, studying G9a in AD could provide insights into the broader epigenetic landscape and support the identification of new biomarkers and therapeutic targets. Epigenetic therapies could provide personalized treatment options, underscoring the importance of understanding the interactions of G9a with other epigenetic modifiers.</p><p id="p0035">In this study, we investigated the neuroprotective potential of the G9a inhibitor UNC0642 through in vitro and in vivo experiments, assessing its effects on molecular and pathological markers of AD. We also evaluated the therapeutic potential of synthetic agonists of cannabinoid receptors, JWH133 and ACEA, individually and in combination with UNC0642, in the SAMP8 mouse model of accelerated senescence. By integrating G9a inhibition with cannabinoid receptor activation, this work aims to elucidate the interplay between epigenetic regulation and endocannabinoid signaling, providing insights into novel therapeutic strategies for AD.</p></sec><sec id="sec2"><title>Materials and methods</title><sec id="sec2.1"><title>Cell culture and transient transfection</title><p id="p0040">HEK-293T cells were grown in Dulbecco's modified Eagle's medium (DMEM) (15-013-CV, Corning, NY, USA) supplemented with 2 &#8203;mM L-glutamine, 100 U/ml penicillin/streptomycin, MEM Non-Essential Amino Acids Solution (1/100) and 5 &#8203;% (v/v) heat-inactivated Fetal Bovine Serum (FBS) (Invitrogen, Paisley, Scotland, UK). Cells were maintained in a humidified atmosphere with 5 &#8203;% CO<sub>2</sub> at 37 &#8203;&#176;C.</p><p id="p0045">HEK-293T cells grown in 6-well dishes were transiently transfected using the PEI method (PolyEthylenImine, Sigma-Aldrich, St. Louis, MO, USA). The cells were incubated for 4 &#8203;h with the corresponding cDNAs, PEI (5.47 &#8203;mM in residual nitrogen), and 150 &#8203;mM NaCl in the serum-deprived medium. The medium was then replaced with a fresh, complete culture medium, and the cells were incubated for 48 &#8203;h before the experimental procedures.</p><p id="p0050">To prepare primary neuronal cultures, the brain was removed from C57/BL6 mice embryos (E19). The hippocampal was dissected, and the meninges were carefully removed and digested with 0.25 &#8203;% trypsin at 37 &#8203;&#176;C for 20 &#8203;min. Trypsinization was stopped by washing the tissue. Cells were transferred to a cell suspension by passage through 0.8 &#8203;mm and 0.5 &#8203;mm needles, followed by passage through mesh with 100 &#8203;&#956;m pores. Neurons were resuspended in medium and plated at a density of 1 &#8203;&#215; &#8203;106 &#8203;cells/ml in 6-well dishes in neurobasal medium (21103-049, Gibco, Paisley, Scotland, UK), supplemented with 2 &#8203;mM L-glutamine, 100 U/mL penicillin/streptomycin, a MEM preparation of non-essential amino acids (1/100), and 2 &#8203;% (v/v) B27 supplement (17504-044, Gibco, Paisley, Scotland, UK). Cultures were maintained for 12 days at 37 &#8203;&#176;C in a humidified atmosphere with 5 &#8203;% CO<sub>2</sub>.</p></sec><sec id="sec2.2"><title>cAMP levels determination</title><p id="p0055">Two hours before initiating the experiment, transfected HEK-293T cells or neuronal primary cultures medium was replaced with, respectively, serum-free DMEM or neurobasal mediums. Cells were then detached, resuspended in DMEM serum-free medium containing 50 &#8203;&#956;M zardaverine, and plated in 384-well microplates (2500 &#8203;cells/well). Cells were pretreated with G9a inhibitor or vehicle (15 &#8203;min) and stimulated with selective agonists (15 &#8203;min) before adding 0.5 &#8203;&#956;M Forskolin to increase cAMP levels. 15 min later, 500 &#8203;nM fluorophore-containing ULight&#8482; antibody (5 &#8203;&#956;l) and cAMP-Europium (cAMP-Eu) (5 &#8203;&#956;l) were added. Incubation was prolonged for 1 &#8203;h at 25 &#8203;&#176;C, and the PHERAstar Flagship reader equipped with an HTRF optical module (BMG Lab Technologies, Offenburg, Germany) was used for measuring the 665/620 &#8203;nm ratio.</p></sec><sec id="sec2.3"><title>Extracellular signal-regulated kinase phosphorylation assays</title><p id="p0060">To determine the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), transfected HEK-293T cells were grown in 96-well plates. On the day of the experiment, the medium was replaced with serum-free medium 2 &#8203;h before initiating the experiment. Cells were pretreated at 25 &#8203;&#176;C for 10 &#8203;min with the G9a inhibitor or vehicle and stimulated for 7 &#8203;min with selective agonists. Then, cells were washed twice with cold PBS before adding the lysis buffer (15 &#8203;min treatment in agitation). Thereafter, 10 &#8203;&#956;L of the supernatant was added to each well in a white ProxiPlate 384-well plate, and ERK 1/2 phosphorylation was determined using an AlphaScreen&#174;SureFire&#174; kit (PerkinElmer) according to the manufacturer's instructions. Readings were recorded using an EnSpire&#174; Multimode Plate Reader (PerkinElmer, Waltham, MA, USA). The reference value (100 &#8203;%) was determined in the absence of any treatment (basal). The effect of the ligands was expressed as a percentage of the baseline value.</p></sec><sec id="sec2.4"><title>Animals</title><p id="p0065">6-month-old SAMR1 and SAMP8 male mice (n &#8203;= &#8203;62) were used for behavioral and molecular studies. Animals had free access to food and water and were maintained under standard temperature conditions (22 &#8203;&#177; &#8203;2 &#8203;&#176;C), controlled humidity, and a 12-h light/dark cycle (300 lx/0 lx). SAMP8 animals were randomly assigned to the following groups: SP8 Ct (treated with vehicle, n &#8203;= &#8203;10), SP8 UNC0642 (treated with 1 &#8203;mg/kg G9a inhibitor, n &#8203;= &#8203;7), SP8 ACEA (treated with 1 &#8203;mg/kg CB<sub>1</sub>R agonist, n &#8203;= &#8203;8), SP8 JWH133 (treated with 1 &#8203;mg/kg CB<sub>2</sub>R agonist, n &#8203;= &#8203;8), SP8 ACEA &#8203;+ &#8203;UNC0642 (treated with 1 &#8203;mg/kg CB<sub>1</sub>R agonist and 1 &#8203;mg/kg G9a inhibitor, n &#8203;= &#8203;9) and SP8 JWH133 &#8203;+ &#8203;UNC0642 (treated with 1 &#8203;mg/kg CB<sub>2</sub>R agonist and 1 &#8203;mg/kg G9a inhibitor, n &#8203;= &#8203;8) (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). The animals were weighed weekly. The experimental groups received either a daily dose of vehicle (1 &#8203;% DMSO (Dimethyl sulfoxide) (Sigma-Aldrich, Steinheim, Germany, #D4540), 20 &#8203;% w/v, (2-hydroxypropyl)-&#946;-cyclodextrin) (Atomole Scientific Co. Ltd., Wuhan, Hubei, China, #AT-20762) or a dose of 1 &#8203;mg/kg per day of each drug group dissolved in vehicle, via oral gavage during the treatment period. After 4&#8201;weeks of treatment, behavioral and cognitive tests were performed. During this time and until sacrifice, the mice continued to receive the single or combination treatment or vehicle. All procedures involving animals, including behavioral tests and dissection and removal of brains, followed ARRIVE and standard ethical guidelines (Council European Communities Directive 2010/63/EU and Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research, National Research Council 2003) and were approved by the Institutional Animal Care and Generalitat de Catalunya (#10291, January 28, 2018). Every effort was made to minimize the number of mice used and their suffering.<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Scheme of experimental design.</p></caption><alt-text id="alttext0025">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec2.5"><title>Behavioral and cognitive tests</title><sec id="sec2.5.1"><title>Object location test (OLT)</title><p id="p0070">The OLT was performed to investigate the spatial memory of mice when exposed to a new location of an already-known object. This test is based on the spontaneous tendency of mice to spend more time exploring a new object than exploring a known object and location to recognize when an object has been misplaced. The test was conducted in a wooden box (50 &#8203;&#215; &#8203;50 &#8203;&#215; &#8203;25 &#8203;cm), in which three of the walls were white, and the last one was black. The animals were habituated to the empty open field arena for 10 &#8203;min on the first day. On the second day, two identical objects were placed in front of the black wall, equidistant from each other and the wall. The objects were 10 &#8203;cm high. The animals were brought into the open field arena and allowed to explore the objects and the surroundings for 10 &#8203;min. Afterward, the animals were returned to their home cages, and the OLT device was cleaned with 70 &#8203;% ethanol. On the third day, an object was placed in front of the opposite white wall to assess the spatial performance of the mice. The trials were recorded with a camera mounted above the open field area. The total exploration time was determined by counting the amount of time (in seconds) spent sniffing the object in the new location (TN) and the object in the old location (TO). The discrimination index (DI) defined as (TN &#8203;&#8722; &#8203;TO)/(TN &#8203;+ &#8203;TO), was calculated to assess cognitive performance.</p></sec><sec id="sec2.5.2"><title>Novel object recognition test (NORT)</title><p id="p0075">Short- and long-term memory was analyzed with NORT. The test was performed in a 90&#176;, two-armed, 25-cm-long, and 20-cm-high black maze. The light intensity in the center of the field was 30 lux. The objects to be discriminated were plastic figures (object A, 5.25-cm-high; and object B, 4.75-cm-high). The mice were acclimatized to the device for 10 &#8203;min on each of 3 consecutive days. On day 4, they underwent a 10-min acquisition trial (habituation phase), in which they were placed in the maze and allowed to explore two identical novel objects (A &#8203;+ &#8203;A or B &#8203;+ &#8203;B) at the end of each arm. To avoid a bias in object preference, objects A and B were counterbalanced so that half of the animals in each experimental group were initially confronted with object A and the other half with object B. Object C was used as the new object for both groups for the analysis of long-term memory. The 10-min retention trials (test phase) took place 2 &#8203;h (short-term; A &#8203;+ &#8203;B or B &#8203;+ &#8203;A) and 24 &#8203;h (long-term; A &#8203;+ &#8203;C or B &#8203;+ &#8203;C) after the habituation phase. During the test phase, one of the two identical objects was replaced by a new one, and the time spent exploring the new object (TN) and the old object (TO) was measured manually. The discrimination index (DI) was calculated as (TN &#8203;&#8722; &#8203;TO/TN &#8203;+ &#8203;TO). Sniffing or touching objects with the nose and forepaws was considered exploration. The maze, surface, and objects were cleaned with 70 &#8203;% ethanol between trials to eliminate olfactory cues.</p></sec></sec><sec id="sec2.6"><title>Biochemical experiments</title><sec id="sec2.6.1"><title>Protein levels determination by western blotting (WB)</title><p id="p0080">For WB, tissue samples were homogenized in a lysis buffer containing phosphatase and protease inhibitors (Cocktail II, Sigma-Aldrich, St. Louis, MO, USA), and protein concentration was determined by Bradford's method. Aliquots of 15 &#8203;&#956;g of protein samples from different groups were separated by Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (8&#8211;14 &#8203;%) and transferred onto polyvinylidene difluoride membranes (PVDF, Millipore). Afterward, membranes were blocked in 5 &#8203;% Bovine Serum Albumin (BSA) in 0.1 &#8203;% Tris-buffered saline with Tween 20 (TBS-T) for 1 &#8203;h at room temperature, followed by overnight incubation at 4 &#8203;&#176;C with the primary antibodies presented in <xref rid="appsec1" ref-type="sec">Supplementary Table 1</xref>.</p><p id="p0085">The next day, membranes were washed 3 times for 5 &#8203;min with Tris-buffered saline with Tween&#174; 20 Detergent (TBS-T) and incubated with secondary antibodies (mouse or rabbit) for 1 &#8203;h at room temperature. Chemiluminescence-based detection was used to view the immunoreactive proteins, following the manufacturer's protocol (ECL Kit, Millipore). Then, digital images were acquired using an Amersham Imager 680, and semiquantitative analyses were performed using ImageLab Software (BioRad, Hercules, CA, USA). Finally, results were expressed in Arbitrary Units (AU), considering the WT control mice group as 100 &#8203;%. Protein loading was routinely monitored by immunodetection of GAPDH. In the same way, for the phosphorylated protein ratio, normalization against GADPH was done before the ratio value calculation.</p></sec></sec><sec id="sec2.7"><title>Quantitative real-time PCR</title><p id="p0090">Total RNA isolation was carried out using TRIsure&#8482; reagent following the manufacturer's instructions (Bioline Reagent, London, UK). RNA content in the samples was measured at 260 &#8203;nm, and the purity of the samples was determined by the A260/280 and A260/230 ratio in a NanoDrop&#8482; ND-1000 (Thermo Scientific). Reverse transcription-Polymerase chain reaction (RT-PCR) was performed as previously described, to quantify the mRNA expression. Real-time PCR (qPCR) was performed with the StepOnePlus&#8482; Real-Time PCR System (Applied Biosystems&#8482;, Vilnius, Lithuania, #4376600), using the SYBR Green PCR Master Mix (Applied Biosystems&#8482;, Vilnius, Lithuania, #K0253). Briefly, each reaction mixture consisted of 6.75 &#8203;&#956;L of cDNA (at a concentration of 2 &#8203;&#956;g), 0.75 &#8203;&#956;L of each primer (at a concentration of 100 &#8203;nM), and 6.75 &#8203;&#956;L of SYBR Green PCR Master Mix (2&#215;). The comparative cycle threshold (Ct) method (&#916;&#916;Ct) was used to analyze the data, using the housekeeping gene (&#946;-actin) level to normalize for differences in sample loading and preparation. The primers are listed in <xref rid="appsec1" ref-type="sec">Supplementary Table 2</xref>. Each sample (n &#8203;= &#8203;3&#8211;4) was analyzed in duplicate, and the results represented the <italic toggle="yes">n</italic>-fold difference in transcript levels between the different groups.</p></sec><sec id="sec2.8"><title>Golgi staining, dendritic length, and spine density</title><p id="p0095">The SAMP8 mice were euthanized by cervical dislocation, and the whole brain was removed from the skull (n &#8203;= &#8203;3). Then, the Golgi staining protocol was performed using the FD Rapid GolgiStain&#8482; Kit (D Neurotechnologies, Inc., #PK401) according to the manufacturer's instructions. Images of neurons for dendritic branching analysis were captured using a Leica Thunder microscope (Leica Thunder Imager; Leica Microsystems) at a 40&#215; magnification objective. Neurite length and neuron complexity were measured using NeuronJ macros and Advanced Sholl Analysis. The number of intersections (branch points) within concentric circles with a radius of 10 &#8203;&#956;m was calculated and compared between groups. Images of neurons for spine density analysis were taken at 63&#215; magnification of the oil objective. Spine density was expressed as the number of spines per 50 &#8203;&#956;m dendrite at a maximum distance of 150 &#8203;&#956;m from the soma.</p></sec><sec id="sec2.9"><title>Statistical analysis</title><p id="p0100">Data analysis was performed using GraphPad Prism Version 9 software (GraphPad Software, San Diego, CA, USA). The group size differed varied depending on the power analysis and the expertise of the authors. Statistical analysis was performed for studies where the size of each group was n &#8203;= &#8203;5&#8211;6 samples per group for in vivo studies and n &#8203;= &#8203;3&#8211;4 replicates for in vitro studies. Results were expressed as the mean &#8203;&#177; &#8203;standard error of the mean (SEM). A normality test was performed to ensure that parametric tests could be used. Means were compared using one-way ANOVA followed by Tukey's <italic toggle="yes">post hoc</italic> analysis. A comparison between groups was also performed using a two-tailed Student's <italic toggle="yes">T</italic>-test for independent samples. Statistical significance was assumed if the p-values were &lt;0.05. Statistical outliers were identified using Grubbs' test and were removed from the analysis. A blinded analysis was performed for behavioral tests.</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>G9a histone methyltransferase selectively modulates CB<sub>1</sub> receptor signaling while leaving CB<sub>2</sub> receptor activation unaffected</title><p id="p0105">The HEK-293T-cell-based heterologous system was used to express the human versions of the cannabinoid receptors (CB<sub>1</sub>R or CB<sub>2</sub>R), and the G9a enzyme. On the one hand, the degree of ERK1/2 phosphorylation (<italic toggle="yes">p</italic>-ERK1/2) was measured to assess the activation of the mitogen-activated protein kinase (MAPK) signaling pathway. In cells expressing only CB<sub>1</sub>R, the selective agonist ACEA promoted ERK1/2 phosphorylation, which was further increased in the presence of UNC0642, the G9a inhibitor, thus suggesting that G9a blockade can regulate CB<sub>1</sub>R activation. Moreover, this result is evidence of the endogenous expression of G9a in HEK-293T cells. The modulatory effect of UNC0642 was increased in cells transfected with the plasmids encoding for G9a and CB<sub>1</sub>R (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A). In cells only transfected with CB<sub>2</sub>R, the selective agonist, JWH133, increased the levels <italic toggle="yes">p</italic>-ERK1/2 that were not further enhanced by the treatment with the G9a inhibitor. The results were similar in cells transfected with the plasmids encoding for G9a and CB<sub>2</sub>R (<xref rid="fig2" ref-type="fig">Fig. 2</xref>B). The effect of UNC0642 on CB<sub>1</sub>R-mediated signaling was specific as it was not found in cells that were only expressing the vector coding for the enzyme (<xref rid="fig2" ref-type="fig">Fig. 2</xref>C). Together, these results suggest that G9a could positively regulate CB<sub>1</sub>R activity without affecting the coupling of CB<sub>2</sub>R to the MAPK signaling pathway.<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>ERK1/2 phosphorylation and cAMP level determination assays in HEK-293T cells expressing CB<sub>1</sub>R, CB<sub>2</sub>R, in the presence or in the absence of G9a.</bold> HEK-293T cells were transfected with the cDNAs for CB<sub>1</sub>R or CB<sub>2</sub>R in the presence or in the absence of G9a enzyme. Cells were then stimulated with the CB<sub>1</sub>R selective agonist ACEA ot the selecteive CB<sub>2</sub>R agonist JWH-133 in the presence or in the absence of the G9a inhibitor UC0642. Then, MAPK phosphorylation (<bold>A-C</bold>) or cAMP levels (<bold>D-G</bold>) were analyzed. In <bold>D-G</bold> cells were treated for 15 &#8203;min with 500 &#8203;nM forskolin (FK, see Methods) after addition of agonists or UC0642. Values are the mean &#8203;&#177; &#8203;S.E.M. of 6 independent experiments performed in triplicates. One-way ANOVA followed by Bonferroni's multiple comparison post hoc test was used for statistical analysis (&#8727;p &#8203;&lt; &#8203;0.05, &#8727;&#8727;p &#8203;&lt; &#8203;0.01, &#8727;&#8727;&#8727;p &#8203;&lt; &#8203;0.001, &#8727;&#8727;&#8727;&#8727;p &#8203;&lt; &#8203;0.0001).</p></caption><alt-text id="alttext0030">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0110">A similar approach was undertaken to check the effect of G9a inhibition on the levels of a second messenger, cAMP, that is regulated by CBR activation. Both cannabinoid receptors are coupled to G<sub>i</sub> protein, and therefore, their activation reduces the cAMP levels previously increased by 500 &#8203;nM forskolin (FK), an activator of adenylate cyclase. ACEA and JWH133 selective agonists reduced cAMP levels in cells expressing CB<sub>1</sub> or CB<sub>2</sub> receptors, respectively, and treated with FK, while the G9a inhibitor had no notable effect (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D and E). However, when the enzyme was transfected together with the CB<sub>1</sub>R or CB<sub>2</sub>R plasmids, the G9a inhibitor induced a potentiation of both cannabinoid receptors mediated signalling (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D). As expected, in HEK-293T cells transfected only with the plasmid coding for G9a and treated with FK, the cAMP levels were not affected by either the selective cannabinoid agonists or the G9a inhibitor (<xref rid="fig2" ref-type="fig">Fig. 2</xref>F). Finally, cAMP levels were evaluated in FK-treated primary hippocampal neurons. Interestingly, the G9a inhibitor enhanced the effect of ACEA, the selective CB<sub>1</sub>R agonist, and also the effect of JWH-133, the selective CB<sub>2</sub>R agonist (<xref rid="fig2" ref-type="fig">Fig. 2</xref>G). Therefore, we demonstrate here that a G9a inhibitor can enhance CB<sub>1</sub>R activity in a heterologous system as well as in primary neuronal cultures and does not impair CB<sub>2</sub>R activity in transfected HEK nor in hippocampal neurons.</p></sec><sec id="sec3.2"><title>Differences in the expression of CB receptor, of microglial activation markers and of proinflammatory cytokines after G9a inhibition and cannabinoid receptor activation in SAMP8 animals</title><p id="p0115">While under our experimental conditions, the relative expression of CB<sub>1</sub> transcripts in the hippocampus was relatively low and did not change between the control and the treated group, CB<sub>2</sub>R transcript expression was significantly increased in hippocampi from untreated SAMP8 if compared with samples from untreated SAMR1 mice (<xref rid="fig3" ref-type="fig">Fig. 3</xref>A). Remarkably, we found a significant reduction in CB<sub>2</sub>R gene expression in all SAMP8 mice that were treated with agonist and the G9a inhibitor (<xref rid="fig3" ref-type="fig">Fig. 3</xref>A). This reduction was more pronounced when the G9a inhibitor was administered, even in the absence of CBR agonists.<fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><bold>Relative expression of transcripts coding for CBRs (A), for microglial activation markers (B) and for proinflammatory molecules (C).</bold> mRNa isolation from hippocampi and qPCR assays are detailed in Methods. Samples were from 6-month-old SAMR1 untreated (n &#8203;= &#8203;3), SAMP8 untreated (n &#8203;= &#8203;3) and SAMP8 treated with UNC0642 (n &#8203;= &#8203;3), JWH133 (n &#8203;= &#8203;3), ACEA (n &#8203;= &#8203;3), UNC0642 &#8203;+ &#8203;JWH133 (n &#8203;= &#8203;3) or UNC0642+ACEA (n &#8203;= &#8203;3). Dose was 1 &#8203;mg/kg for the single treatment and 1 &#8203;mg/kg + 1 &#8203;mg/kg in combination treatments. One-way ANOVA and two tailed student t-test were used, followed by Tukey post-hoc analysis. Values are presented in the mean &#8203;&#177; &#8203;SEM. &#8727;p &#8203;&lt; &#8203;0.05, &#8727;&#8727;p &#8203;&lt; &#8203;0.01, &#8727;&#8727;&#8727;p &#8203;&lt; &#8203;0.001, &#8727;&#8727;&#8727;&#8727;p &#8203;&lt; &#8203;0.0001.</p></caption><alt-text id="alttext0035">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0120">Considering that CB<sub>2</sub>Rs are upregulated in activated microglia and reactive astrocytes associated with the hallmarks of AD [<xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>] we examined several microglia and astroglia markers (<xref rid="fig3" ref-type="fig">Fig. 3</xref>B and C). First, compared with SAMR1 mice, we found in hippocampal samples of the SAMP8 animal significantly increased gene expression levels of <italic toggle="yes">Trem2 and Cd33</italic> and increased levels of <italic toggle="yes">iNOS</italic> while <italic toggle="yes">Arg1</italic> gene expression was reduced (<xref rid="fig3" ref-type="fig">Fig. 3</xref>B). Notably, some of the pharmacological treatments led to a reversal of the increase of <italic toggle="yes">Trem2, Cd33,</italic> and <italic toggle="yes">iNOS</italic> gene expression after single or dual treatment. In the case of <italic toggle="yes">Arg1</italic> gene expression, a significant reduction was only detected after JWH133 and UNC0642 cotreatment (<xref rid="fig3" ref-type="fig">Fig. 3</xref>B). These results show that hippocampal alterations detected in the model of accelerated senescence can be partially restored by G9a inhibition and/or CBR activation.</p><p id="p0125">Regarding astroglia and pro-inflammatory markers, we analyzed <italic toggle="yes">Gfap, Il-6,</italic> and <italic toggle="yes">Tnf-&#945;,</italic> which are typically elevated in AD patients [<xref rid="bib33" ref-type="bibr">33</xref>,<xref rid="bib35" ref-type="bibr">35</xref>,<xref rid="bib36" ref-type="bibr">36</xref>]. As expected, we found increased gene expression of all markers in the SAMP8 compared to the SAMR1, with <italic toggle="yes">Gfap</italic> and <italic toggle="yes">TNF-&#945;</italic> but not <italic toggle="yes">Il-6</italic> reaching statistical significance (<xref rid="fig3" ref-type="fig">Fig. 3</xref>C). A significant decrease of the altered levels of <italic toggle="yes">Gfap</italic> and <italic toggle="yes">Tnf-&#945;</italic> gene expression was achieved by the pharmacological treatments, especially by UNC0642, the enzyme inhibitor (<xref rid="fig3" ref-type="fig">Fig. 3</xref>C).</p></sec><sec id="sec3.3"><title>Modulation of immediate-early genes and enhanced neuronal repair following a single or dual therapeutic approach based on G9a inhibition or CBR activation in SAMP8</title><p id="p0130">Expression of immediate-early genes (IEGs) changes rapidly in response to various pathophysiological changes, as in AD [<xref rid="bib37" ref-type="bibr">37</xref>,<xref rid="bib38" ref-type="bibr">38</xref>]. Here, we examined the expression of the genes for three IEGs, namely <italic toggle="yes">Catechol-O-Methyltransferase</italic> (<italic toggle="yes">Comt</italic>)<italic toggle="yes">, Early Growth Response 1</italic> (<italic toggle="yes">Egr1</italic>, also known as <italic toggle="yes">Zif268</italic>)<italic toggle="yes">, and DNA Methyltransferase 3 Alpha</italic> (<italic toggle="yes">Dnmt3a</italic>). While the level of transcripts for <italic toggle="yes">Dnmt3a</italic> was similar in samples from all groups, the pharmacological treatments reversed the altered expression of the other two genes in the SAMP8 mouse (<xref rid="fig4" ref-type="fig">Fig. 4</xref>A).<fig id="fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p><bold>Relative expression of transcripts coding for IEGs (A) and protein expression of IEGs (B</bold>&#8211;<bold>G).</bold> mRNa isolation from hippocampi and qPCR assays are detailed in Methods. Samples were from 6-month-old SAMR1 untreated (n &#8203;= &#8203;3), (n &#8203;= &#8203;3), SAMP8 untreated (n &#8203;= &#8203;3) and SAMP8 treated with UNC0642 (n &#8203;= &#8203;3), JWH133 (n &#8203;= &#8203;3), ACEA (n &#8203;= &#8203;3), UNC0642 &#8203;+ &#8203;JWH133 (n &#8203;= &#8203;3) or UNC0642+ACEA (n &#8203;= &#8203;3), Dose was 1 &#8203;mg/kg for the single treatment and 1 &#8203;mg/kg &#8203;+ &#8203;1 &#8203;mg/kg in combination treatments. One-way ANOVA and two-tailed student t-test were used, followed by Tukey post-hoc analysis. Values are presented in the mean &#8203;&#177; &#8203;SEM. &#8727;p &#8203;&lt; &#8203;0.05. <bold>B.</bold> Representative WBs for protein expression are shown in (B). Quantification of the expression of sAPP&#946; PSD95, p-p38 vs total p38 ratio, SNAP25, and BDNF is shown in panels <bold>C to G.</bold> Samples were from 6-month-old SAMR1 untreated (n &#8203;= &#8203;4), SAMP8 untreated (n &#8203;= &#8203;4) and SAMP8 treated with UNC0642 (n &#8203;= &#8203;4), JWH133 (n &#8203;= &#8203;3), ACEA (n &#8203;= &#8203;4), UNC0642 &#8203;+ &#8203;JWH133 (n &#8203;= &#8203;3) or UNC0642+ACEA (n &#8203;= &#8203;4). Dose was 1 &#8203;mg/kg for the single treatment and 1 &#8203;mg/kg + 1 &#8203;mg/kg in combination treatments. Data in SAMR1 untreated are adjusted to 100 &#8203;% for normalization. One-way ANOVA and two-tailed student t-test were used, followed by Tukey post-hoc analysis. Values are presented in the mean &#8203;&#177; &#8203;SEM. &#8727;p &#8203;&lt; &#8203;0.05, &#8727;&#8727;p &#8203;&lt; &#8203;0.01.</p></caption><alt-text id="alttext0040">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="p0135">The soluble amyloid precursor protein beta (sAPP&#946;), a cleavage product of the amyloid precursor protein (APP), has been implicated in AD due to its role in the amyloidogenic pathway, which contributes to the formation of amyloid-beta plaques [<xref rid="bib19" ref-type="bibr">19</xref>]. Although non-significant results were obtained, the pharmacological treatments reversed the altered sAPP&#946; protein levels found in samples from the SAMP8 mice (<xref rid="fig4" ref-type="fig">Fig. 4</xref>B and C). Loss of synapses in the hippocampus is another neuropathological hallmark of AD [<xref rid="bib39" ref-type="bibr">39</xref>,<xref rid="bib40" ref-type="bibr">40</xref>]. Therefore, we examined by immunoblotting the levels of a presynaptic SNAP25 and a postsynaptic PSD95 protein marker. The amount of PSD95 was not similar in both animal strains (<xref rid="fig4" ref-type="fig">Fig. 4</xref>D) and the level of SNAP25, which was reduced in the SAMP8 model, was restored by the pharmacological treatments (<xref rid="fig4" ref-type="fig">Fig. 4</xref>F). The level of the brain-derived neurotrophic factor (BDNF), which was markedly reduced in the SAMP8 model, was partially restored, especially in cotreatments with UNC0642 and any of the receptor agonists <xref rid="fig4" ref-type="fig">Fig. 4</xref>G. Finally, we examined the degree of phosphorylation of p38, a MAPK involved in regulating synaptic plasticity. The level of kinase phosphorylation was significantly lower in the SAMP8 animal, but treatment with UNC0642 and ACEA or JWH133 partially rescued the reduced p38 phosphorylation found in the hippocampus of SAMP8 mice (<xref rid="fig4" ref-type="fig">Fig. 4</xref>E). Overall, the results show the benefits of G9a inhibitor treatment, which were often more significant in dual inhibitor/agonist cotreatments.</p></sec><sec id="sec3.4"><title>Improved synaptic plasticity and cognitive performance after G9a inhibition, cannabinoid receptor agonism, or dual therapy approach in SAMP8</title><p id="p0140">Synaptic dysfunction and synapse loss are key features of AD [<xref rid="bib41" ref-type="bibr">41</xref>]. Golgi staining was undertaken to investigate whether G9a inhibition, CBR activation or dual treatments could modulate the density of dendritic spines and dendrite length. As expected, there was a significant reduction in branching length and dendritic spine density in the hippocampus of the SAMP8 mice compared to the hippocampus of the SAMR1 animal (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A&#8211;C). In agreement with the above-described benefits observed in biochemical and gene expression parameters, the G9a inhibitor with or CBR agonists restored, totally or partially, the deficits found in the SAMP8 animal at the dendritic level. In the case of dendritic length, all treatments lead to a complete recovery, with single treatments leading to an increase over those found in the hippocampus of the SAMR1 animal (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A). Regarding spine density, the most efficacious treatments leading to levels similar to those in SAMR1 mice were obtained with UNC0642 or dual UNC0642/JWH133 treatment (<xref rid="fig5" ref-type="fig">Fig. 5</xref>B and C).<fig id="fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p><bold>Dendrite parameters and behavioral studies upon pharmacological treatment with CB receptor agonists and G9a inhibitor.</bold> Quantification of the total dendritic length (A) and of dendritic spine density (B) in hippocampal samples. After the pharmacological Values are expressed as mean &#8203;&#177; &#8203;SEM. Groups were compared using one-way ANOVA analysis followed by Tukey's post-hoc test. n &#8203;= &#8203;20&#8211;25 per group for neurons and spines. &#8727;p &#8203;&lt; &#8203;0.05, &#8727;&#8727;p &#8203;&lt; &#8203;0.01, &#8727;&#8727;&#8727;p &#8203;&lt; &#8203;0.001, &#8727;&#8727;&#8727;&#8727;p &#8203;&lt; &#8203;0.0001. Representative images of Golgi-stained neurons allowing the quantification of dendrite length and dendritic spine density are shown in <bold>C</bold>. (scale bar &#8203;= &#8203;250 &#8203;&#956;M and 25 &#8203;&#956;M, respectively). Panels <bold>D to F</bold> show discrimination index (DI) in behavioral assays consisting of NORT 2 &#8203;h, NORT 24 &#8203;h and OLT. Experiments were conducted on 6-month-old SAMR1 untreated (n &#8203;= &#8203;10), SAMP8 untreated (n &#8203;= &#8203;10) and SAMP8 treated with UNC0642 (n &#8203;= &#8203;7), JWH133 (n &#8203;= &#8203;10), ACEA (n &#8203;= &#8203;8), UNC0642 &#8203;+ &#8203;JWH133 (n &#8203;= &#8203;8) or UNC0642+ACEA (n &#8203;= &#8203;9). Dose was 1 &#8203;mg/kg for the single treatment and 1 &#8203;mg/kg + 1 &#8203;mg/kg in combination treatments. One-way ANOVA and two-tailed student t-test were used for statistical analysis. Values are presented in the mean &#8203;&#177; &#8203;SEM. &#8727;p &#8203;&lt; &#8203;0,05, &#8727;&#8727;p &#8203;&lt; &#8203;0,01, &#8727;&#8727;&#8727;p &#8203;&lt; &#8203;0,001.</p></caption><alt-text id="alttext0045">Fig. 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p><p id="p0145">Cognitive performance was assessed using the NORT and OLT tasks to evaluate working and spatial memory in SAMP8 mice. Untreated SAMP8 animals significantly reduced the discrimination index (DI) for both short- and long-term memory compared to untreated SAMR1 controls (<xref rid="fig5" ref-type="fig">Fig. 5</xref>D and E). Treatment interventions revealed significant recovery in short-term memory, with the dual UNC0642/ACEA treatment demonstrating the highest efficacy (<xref rid="fig5" ref-type="fig">Fig. 5</xref>D and E). In the OLT task, all treatments resulted in partial recovery of spatial memory, except for the dual UNC0642/ACEA treatment, which achieved complete recovery (<xref rid="fig5" ref-type="fig">Fig. 5</xref>F). These findings indicate that the combined inhibition of G9a and activation of CB<sub>1</sub>R effectively mitigates cognitive decline in SAMP8 mice.</p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0150">This study provides compelling evidence for the neuroprotective effects of G9a inhibition combined with cannabinoid receptor activation in AD, offering a multifaceted therapeutic approach to address cognitive decline and neurodegeneration. By integrating in vitro and in vivo approaches, we shed light on the complex interplay between epigenetic regulation and the ECS, emphasizing this dual intervention's mechanistic and therapeutic implications. We also demonstrated a potential synergistic effect for critical endpoints in the study of new therapeutic approaches in AD treatment, suggesting, in part, the dual approach presented in this study. Specifically, this synergistic interaction between G9a inhibition (via UNC0642) and CB<sub>1</sub>R activation (via ACEA) arises from complementary molecular mechanisms that enhance neuroprotective signaling pathways while mitigating neuroinflammation and synaptic dysfunction in AD models.</p><p id="p0155">Moreover, the selection of dosing regimens for UNC0642, ACEA, and JWH133 in this study was informed by prior preclinical investigations, with adjustments to suboptimal levels to unmask potential synergistic interactions. For UNC0642, acute doses of 5 &#8203;mg/kg (i.p.) have demonstrated robust target engagement in vivo, achieving a plasma Cmax of 947 &#8203;ng/mL and suppressing H3K9me2 levels in xenograft models [<xref rid="bib22" ref-type="bibr">22</xref>]. Chronic administration at 2&#8211;4 &#8203;mg/kg/day was well-tolerated in Prader-Willi syndrome (PWS) mouse models, with sustained epigenetic modulation and no significant toxicity [<xref rid="bib42" ref-type="bibr">42</xref>]. We selected a reduced dose of 1 &#8203;mg/kg to avoid maximal inhibition of G9a, thereby allowing detection of combinatorial effects with CB<sub>1</sub>R activation.</p><p id="p0160">Regarding the CB<sub>1</sub>R agonist ACEA, doses of 0.5&#8211;1.5 &#8203;mg/kg (low) and 5 &#8203;mg/kg (mid) have been validated in neuroprotection studies. In ischemic stroke models, 1 &#8203;mg/kg ACEA improved motor recovery and reduced neuronal death without inducing hyperactivation [<xref rid="bib43" ref-type="bibr">43</xref>]. Similarly, studies in aggressive behavior models demonstrated that 1&#8211;2 &#8203;mg/kg ACEA modulated CB<sub>1</sub>R-mediated neurotransmission without adverse effects [<xref rid="bib44" ref-type="bibr">44</xref>]. Our use of 1 &#8203;mg/kg aligned with these subthreshold doses to isolate synergistic interactions rather than standalone efficacy.</p><p id="p0165">The CB<sub>2</sub>R agonist JWH133 was administered at 1 &#8203;mg/kg, a dose below the 5 &#8203;mg/kg mid-range used in prior addiction and neuroinflammation studies [<xref rid="bib45" ref-type="bibr">45</xref>,<xref rid="bib46" ref-type="bibr">46</xref>]. For instance, 1&#8211;2 &#8203;mg/kg JWH133 reduced cocaine self-administration in mice without altering baseline locomotion, while 0.25&#8211;0.5 &#8203;mg/kg improved cognitive performance in memory tasks. Higher doses (e.g., 20 &#8203;mg/kg) induced pronounced anti-inflammatory effects in neurodegenerative models [<xref rid="bib46" ref-type="bibr">46</xref>], but such levels risk masking synergistic contributions. By selecting 1 &#8203;mg/kg, we prioritized detection of combinatorial signaling over individual receptor saturation.</p><p id="p0170">This dosing strategy-employing submaximal concentrations of UNC0642 (1 &#8203;mg/kg), ACEA (1 &#8203;mg/kg), and JWH133 (1 &#8203;mg/kg)-enabled the identification of synergistic neuroprotective and anti-inflammatory effects that would otherwise be obscured at higher, fully efficacious doses. The approach is consistent with methodologies in polypharmacology, where subthreshold dosing reveals emergent interactions between pathways [<xref rid="bib47" ref-type="bibr">47</xref>]. Furthermore, the tolerability of these doses is supported by prior pharmacokinetic and toxicity profiles, ensuring that observed effects reflect mechanistic synergy rather than off-target toxicity.</p><p id="p0175">First, we examined the modulation of CBR signaling by G9a in HEK-293T cells and primary hippocampal neuron cultures. Interestingly, our findings offer insights into the complex interplay between epigenetic regulation by G9a and the endocannabinoid system. Our results demonstrate that G9a inhibition selectively modulates CB<sub>1</sub>R signaling while leaving CB<sub>2</sub>R activity largely unaffected. This specificity is particularly relevant, as it provides a means to enhance CB1R-mediated neuroprotection while potentially mitigating the psychoactive side effects associated with direct CB<sub>1</sub>R agonists. Additionally, we investigated the impact of G9a inhibition with UNC0642 and selective CB<sub>1</sub>R (ACEA) and/or CB<sub>2</sub>R (JWH133) agonists on cognitive decline and neuroinflammation in the SAMP8, a late-onset Alzheimer's disease (LOAD) mouse model [<xref rid="bib48" ref-type="bibr">[48]</xref>, <xref rid="bib49" ref-type="bibr">[49]</xref>, <xref rid="bib50" ref-type="bibr">[50]</xref>]. In hippocampal neurons, the potentiation of CB<sub>1</sub>R signaling by G9a inhibition was evident through enhanced ERK1/2 phosphorylation and cAMP signaling, indicating a downstream amplification of neuroprotective pathways. Thus, the differential effects observed with single and dual treatments provide critical mechanistic insights into the interplay between epigenetic regulation and cannabinoid signaling in AD. These results expand on previous observations, such as those by Bellver-Sanchis et al. (2024) [<xref rid="bib15" ref-type="bibr">15</xref>], by highlighting the regulatory role of G9a in ECS signaling, specifically in neuronal contexts. Therefore, this strategy offers a promising avenue for addressing cognitive deficits in AD while potentially avoiding some psychoactive effects associated with direct CB<sub>1</sub>R agonism [<xref rid="bib51" ref-type="bibr">51</xref>,<xref rid="bib52" ref-type="bibr">52</xref>].</p><p id="p0180">Regarding the cognitive results, we showed a cognitive recovery observed in SAMP8 mice treated with UNC0642 and ACEA, particularly in spatial memory (OLT task), underscoring this dual approach's therapeutic efficacy. These results are significant, as they demonstrate not only behavioral recovery but also molecular changes derived from these pharmacological interventions. The chronic inflammatory process in neurodegeneration and AD has been identified as a primary contributor to disease progression [<xref rid="bib53" ref-type="bibr">53</xref>]. In addition, microglia activation is a crucial event in neuroinflammation and neurodegeneration [<xref rid="bib54" ref-type="bibr">[54]</xref>, <xref rid="bib55" ref-type="bibr">[55]</xref>, <xref rid="bib56" ref-type="bibr">[56]</xref>]. Notably, the ECS plays a role in the microglia phenotype. For this reason, we evaluated CB<sub>1</sub>R and CB<sub>2</sub>R markers in SAMP8 and SAMR1, the healthy control animal as well as after single or dual treatments. Thus, the pronounced reduction in CB<sub>2</sub>R gene expression across treated groups, particularly with G9a inhibition and dual treatments, further supports the hypothesis that targeting G9a modulates microglial activation states, as CB<sub>2</sub>R is typically upregulated in reactive glia associated with AD pathology [<xref rid="bib57" ref-type="bibr">57</xref>]. Notably, the distinct patterns of modulation observed with single treatments (ACEA and JWH133) versus dual treatments highlight the complexity of neuroinflammatory processes in AD. These findings align with prior studies indicating that neuroinflammation is a key driver of AD progression, highlighting the dual anti-inflammatory and neuroprotective roles of this therapeutic strategy. The results are particularly significant as they demonstrate both behavioral recovery and a reduction in hallmark neuroinflammatory markers such as TREM2, CD33, and iNOS.</p><p id="p0185">On the other hand, synaptic plasticity plays a crucial role in age-related cognitive decline and AD [<xref rid="bib58" ref-type="bibr">58</xref>,<xref rid="bib59" ref-type="bibr">59</xref>]. Furthermore, AD is associated with synaptic function and impairment of plasticity, particularly in the hippocampus [<xref rid="bib52" ref-type="bibr">[52]</xref>, <xref rid="bib53" ref-type="bibr">[53]</xref>, <xref rid="bib54" ref-type="bibr">[54]</xref>]. Our results prove that G9a inhibition and ECS activation can synergistically promote synaptic repair. Importantly, we found restoration of dendritic spine density and branching length, as revealed by Golgi staining, which reflects a reversal of structural deficits, delivering an exciting improvement in neuronal function in the SAMP8 hippocampus. Additionally, the recovery of synaptic markers such as SNAP25 and PSD95, along with increased BDNF expression, suggests that these interventions target both pre- and postsynaptic mechanisms critical for plasticity. The partial recovery of p38 phosphorylation further implicates MAPK signaling in mediating these neuroprotective effects. These findings resonate with previous studies, such as those by Gri&#241;&#225;n-Ferr&#233; et al. [<xref rid="bib23" ref-type="bibr">23</xref>], which identified synaptic plasticity enhancement as a critical outcome of G9a inhibition.</p><p id="p0190">On the other hand, the differential effects observed between single and dual treatments emphasize the complexity of the mechanisms underlying their neuroprotective actions. While CB<sub>1</sub>R activation may promote neuronal survival and plasticity via the BDNF/TrkB/Akt pathway, CB<sub>2</sub>R modulation likely exerts immunomodulatory effects through TLR4/NF-&#954;B signaling. These assumptions are supported by several studies [<xref rid="bib51" ref-type="bibr">51</xref>,<xref rid="bib57" ref-type="bibr">57</xref>,<xref rid="bib60" ref-type="bibr">60</xref>,<xref rid="bib61" ref-type="bibr">61</xref>]. G9a inhibition appears to act upstream of these pathways, orchestrating a synergistic response that addresses neuroinflammatory and synaptic deficits [<xref rid="bib15" ref-type="bibr">15</xref>]. The ability of UNC0642 to potentiate these effects when combined with ECS agonists highlights the therapeutic potential of a multi-target approach, particularly in diseases with multifactorial pathologies like AD (<xref rid="fig5" ref-type="fig">Fig. 5</xref>).</p><p id="p0195">Moreover, future studies should explore the long-term effects of these treatments and investigate potential side effects or tolerance development. Additionally, examining the impact of these treatments on different AD hallmarks would provide a more comprehensive understanding of their potential to modify disease progression. Recent work by Rothammer et al. (2022) [<xref rid="bib62" ref-type="bibr">62</xref>] has shown that G9a inhibition can reduce oxidative stress and promote neuronal survival, suggesting a potential role in modifying AD progression. These additional studies in AD mouse models further support the potential of combining G9a inhibition with cannabinoid receptor modulation, specifically CB<sub>1</sub>R, as a promising therapeutic approach for AD. Findings across different models and treatment paradigms underscore the robustness of this multi-target strategy in addressing various aspects of AD pathology.</p></sec><sec id="sec8"><title>Conclusion</title><p id="p0200a">This study underscores the therapeutic promise of combining G9a inhibition with targeted cannabinoid receptor modulation as a multifaceted approach to AD. G9a inhibition epigenetically primes the neural environment by reversing repressive histone methylation, thereby restoring CB<sub>1</sub>R expression and enhancing the efficacy of CB<sub>1</sub>R-mediated neuroprotection. At the same time, G9a inhibition upregulates neuroprotective factors, further reducing neuroinflammation and supporting synaptic resilience. When paired with selective activation of CB<sub>1</sub>R-which directly counters AD-related synaptic and inflammatory deficits-and careful modulation of CB<sub>2</sub>R to curb excessive inflammation, this dual strategy addresses the major pathological hallmarks of AD: cognitive decline, neuroinflammation, and synaptic dysfunction. By simultaneously targeting these interconnected pathways, this approach offers a more comprehensive and robust therapeutic framework than single-pharmacological interventions, paving the way for innovative treatments that more effectively combat the complexity of aging-related neurodegenerative diseases.</p></sec><sec id="sec5"><title>Authors contribution</title><p id="p0205">Conceptualization, C.G.-F.; methodology, A.B.-S., G.N., M.R.-V., D.O.-S., R.F., M.P., J.L. and C.G.-F.; Analyzed the data and drafted the manuscript, J.L., G.N., A.B.-S., M.R.-V., R.F., M.P. and C.G.-F.; writing&#8212;original draft preparation, A.B.-S., G.N., R.F., D.O.-S., M.P., and C.G.-F.; writing&#8212;review and editing, A.B.-S., G.N., R.F., D.O.-S., M.P., and C.G.-F.; supervision, C.G.-F. All authors have read and agreed to the published version of the manuscript.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of competing interest</title><p id="p0210">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Kazemeini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nadeem-Tariq</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rafanan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ghani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vida</surname><given-names>T.A.</given-names></name></person-group><article-title>From plaques to pathways in Alzheimer&#8217;s disease: the mitochondrial-neurovascular-metabolic hypothesis</article-title><source>Int J Mol Sci</source><volume>25</volume><year>2024</year><fpage>11720</fpage><pub-id pub-id-type="pmid">39519272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms252111720</pub-id><pub-id pub-id-type="pmcid">PMC11546801</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>B.</given-names></name><name name-style="western"><surname>von Arnim</surname><given-names>C.A.F.</given-names></name><name name-style="western"><surname>Burnie</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bozeat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name></person-group><article-title>Biomarkers in Alzheimer&#8217;s disease: role in early and differential diagnosis and recognition of atypical variants</article-title><source>Alzheimers Res Ther</source><volume>15</volume><year>2023</year><fpage>175</fpage><pub-id pub-id-type="pmid">37833762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-023-01314-6</pub-id><pub-id pub-id-type="pmcid">PMC10571241</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name></person-group><article-title>Impact of the cannabinoid system in Alzheimer&#8217;s disease</article-title><source>Curr Neuropharmacol</source><volume>21</volume><year>2023</year><fpage>715</fpage><pub-id pub-id-type="pmid">35105293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1570159X20666220201091006</pub-id><pub-id pub-id-type="pmcid">PMC10207907</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Abate</surname><given-names>G.</given-names></name><name name-style="western"><surname>Uberti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tambaro</surname><given-names>S.</given-names></name></person-group><article-title>Potential and limits of cannabinoids in Alzheimer's disease therapy</article-title><source>Biology (Basel)</source><volume>10</volume><year>2021</year><fpage>542</fpage><pub-id pub-id-type="pmid">34204237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biology10060542</pub-id><pub-id pub-id-type="pmcid">PMC8234911</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Aso</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>I.</given-names></name></person-group><article-title>Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic</article-title><source>Front Pharmacol</source><volume>5</volume><year>2014</year><fpage>37</fpage><pub-id pub-id-type="pmid">24634659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2014.00037</pub-id><pub-id pub-id-type="pmcid">PMC3942876</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Capolupo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Miranda</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Musella</surname><given-names>S.</given-names></name><name name-style="western"><surname>Di Sarno</surname><given-names>V.</given-names></name><name name-style="western"><surname>Manfra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ostacolo</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Exploring endocannabinoid system: unveiling new roles in modulating ER stress</article-title><source>Antioxidants</source><volume>13</volume><year>2024</year><fpage>1284</fpage><pub-id pub-id-type="pmid">39594426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox13111284</pub-id><pub-id pub-id-type="pmcid">PMC11591047</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Bala</surname><given-names>K.</given-names></name><name name-style="western"><surname>Porel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aran</surname><given-names>K.R.</given-names></name></person-group><article-title>Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders</article-title><source>Psychopharmacology (Berl)</source><year>2024</year><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-024-06683-w</pub-id><pub-id pub-id-type="pmid">39264450</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Joers</surname><given-names>V.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>D.</given-names></name><name name-style="western"><surname>Staley</surname><given-names>H.</given-names></name><name name-style="western"><surname>Coronado</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy</article-title><source>J Neuroinflammation</source><volume>21</volume><year>2024</year><fpage>240</fpage><pub-id pub-id-type="pmid">39334169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-024-03221-5</pub-id><pub-id pub-id-type="pmcid">PMC11438102</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>C.-S.</given-names></name></person-group><article-title>Understanding the modulatory effects of cannabidiol on Alzheimer's disease</article-title><source>Brain Sci</source><volume>11</volume><year>2021</year><fpage>1211</fpage><pub-id pub-id-type="pmid">34573232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci11091211</pub-id><pub-id pub-id-type="pmcid">PMC8472755</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Paniri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Akhavan-Niaki</surname><given-names>H.</given-names></name></person-group><article-title>Alzheimer's disease-related epigenetic changes: novel therapeutic targets</article-title><source>Mol Neurobiol</source><volume>61</volume><year>2024</year><fpage>1282</fpage><lpage>1317</lpage><pub-id pub-id-type="pmid">37700216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-023-03626-y</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>De Plano</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Saitta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oddo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Caccamo</surname><given-names>A.</given-names></name></person-group><article-title>Epigenetic changes in Alzheimer's disease: DNA methylation and histone modification</article-title><source>Cells</source><volume>13</volume><year>2024</year><fpage>719</fpage><pub-id pub-id-type="pmid">38667333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells13080719</pub-id><pub-id pub-id-type="pmcid">PMC11049073</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>B.</given-names></name></person-group><article-title>Epigenetics: recent advances and its role in the treatment of Alzheimer's disease</article-title><source>Front Neurol</source><volume>11</volume><year>2020</year><object-id pub-id-type="publisher-id">538301</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2020.538301</pub-id><pub-id pub-id-type="pmcid">PMC7594522</pub-id><pub-id pub-id-type="pmid">33178099</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Scheer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zaph</surname><given-names>C.</given-names></name></person-group><article-title>The lysine methyltransferase G9a in immune cell differentiation and function</article-title><source>Front Immunol</source><volume>8</volume><year>2017</year><fpage>429</fpage><pub-id pub-id-type="pmid">28443098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.00429</pub-id><pub-id pub-id-type="pmcid">PMC5387087</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>C.</given-names></name><etal/></person-group><article-title>G9a in cancer: mechanisms, therapeutic Advancements, and clinical implications</article-title><source>Cancers (Basel)</source><volume>16</volume><year>2024</year><fpage>2175</fpage><pub-id pub-id-type="pmid">38927881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers16122175</pub-id><pub-id pub-id-type="pmcid">PMC11201431</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Bellver-Sanchis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>G.</given-names></name><name name-style="western"><surname>&#193;vila-L&#243;pez</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Companys-Alemany</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marsal-Garc&#237;a</surname><given-names>L.</given-names></name><etal/></person-group><article-title>G9a inhibition promotes neuroprotection through GMFB regulation in Alzheimer&#8217;s disease</article-title><source>Aging Dis</source><volume>15</volume><year>2024</year><fpage>311</fpage><pub-id pub-id-type="pmid">37307824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14336/AD.2023.0424-2</pub-id><pub-id pub-id-type="pmcid">PMC10796087</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Selkoe</surname><given-names>D.J.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease: genes, proteins, and therapy</article-title><source>Physiol Rev</source><volume>81</volume><year>2001</year><fpage>741</fpage><lpage>766</lpage><pub-id pub-id-type="pmid">11274343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.2001.81.2.741</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>H.D.</given-names></name></person-group><article-title>Cannabinoid signaling in health and disease</article-title><source>Can J Physiol Pharmacol</source><volume>95</volume><year>2017</year><fpage>311</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">28263083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1139/cjpp-2016-0346</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mayl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><etal/></person-group><article-title>The potential therapeutic effects of THC on Alzheimer&#8217;s disease</article-title><source>J Alzheim Dis</source><volume>42</volume><year>2014</year><fpage>973</fpage><lpage>984</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-140093</pub-id><pub-id pub-id-type="pmid">25024327</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Ram&#237;rez</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Bl&#225;zquez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Del Pulgar</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ceballos</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>Prevention of Alzheimer&#8217;s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation</article-title><source>J Neurosci</source><volume>25</volume><year>2005</year><fpage>1904</fpage><lpage>1913</lpage><pub-id pub-id-type="pmid">15728830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.4540-04.2005</pub-id><pub-id pub-id-type="pmcid">PMC6726060</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Tachibana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nozaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ohta</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ohki</surname><given-names>M.</given-names></name><etal/></person-group><article-title>G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis</article-title><source>Genes Dev</source><volume>16</volume><year>2002</year><fpage>1779</fpage><lpage>1791</lpage><pub-id pub-id-type="pmid">12130538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gad.989402</pub-id><pub-id pub-id-type="pmcid">PMC186403</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Schaefer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sampath</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Intrator</surname><given-names>A.</given-names></name><name name-style="western"><surname>Min</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gertler</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Surmeier</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Control of cognition and adaptive behavior by the GLP/G9a epigenetic suppressor complex</article-title><source>Neuron</source><volume>64</volume><year>2009</year><fpage>678</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">20005824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2009.11.019</pub-id><pub-id pub-id-type="pmcid">PMC2814156</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barsyte-Lovejoy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Korboukh</surname><given-names>V.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.P.</given-names></name><etal/></person-group><article-title>Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP</article-title><source>J Med Chem</source><volume>56</volume><year>2013</year><fpage>8931</fpage><lpage>8942</lpage><pub-id pub-id-type="pmid">24102134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm401480r</pub-id><pub-id pub-id-type="pmcid">PMC3880643</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Gri&#241;&#225;n-Ferr&#233;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marsal-Garc&#237;a</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bellver-Sanchis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kondengaden</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Turga</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>V&#225;zquez</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Pharmacological inhibition of G9a/GLP restores cognition and reduces oxidative stress, neuroinflammation and &#946;-Amyloid plaques in an early-onset Alzheimer&#8217;s disease mouse model</article-title><source>Aging (Albany NY)</source><volume>11</volume><year>2019</year><fpage>11591</fpage><pub-id pub-id-type="pmid">31804189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.102558</pub-id><pub-id pub-id-type="pmcid">PMC6932909</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S-R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Histone methyltransferase G9a diminishes expression of cannabinoid CB1 receptors in primary sensory neurons in neuropathic pain</article-title><source>J Biol Chem</source><volume>295</volume><year>2020</year><fpage>3553</fpage><lpage>3562</lpage><pub-id pub-id-type="pmid">32024693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.RA119.011053</pub-id><pub-id pub-id-type="pmcid">PMC7076223</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sheehy</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Muneer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wrobel</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Development of a brain-penetrant G9a methylase inhibitor to target Alzheimer&#8217;s disease-associated proteopathology</article-title><source>Nat Commun</source><volume>16</volume><year>2025</year><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">40328756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-59128-z</pub-id><pub-id pub-id-type="pmcid">PMC12056044</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Basavarajappa</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Subbanna</surname><given-names>S.</given-names></name></person-group><article-title>Histone methylation regulation in neurodegenerative disorders</article-title><source>Int J Mol Sci</source><volume>22</volume><year>2021</year><fpage>4654</fpage><pub-id pub-id-type="pmid">33925016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22094654</pub-id><pub-id pub-id-type="pmcid">PMC8125694</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Manuel</surname><given-names>I.</given-names></name><name name-style="western"><surname>de San Rom&#225;n</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Giralt</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Puertas</surname><given-names>R.</given-names></name></person-group><article-title>Type-1 cannabinoid receptor activity during Alzheimer&#8217;s disease progression</article-title><source>J Alzheim Dis</source><volume>42</volume><year>2014</year><fpage>761</fpage><lpage>766</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-140492</pub-id><pub-id pub-id-type="pmid">24946872</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.-F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.L.</given-names></name></person-group><article-title>Cannabinoid CB2 receptors are upregulated via bivalent histone modifications and control primary afferent input to the spinal cord in neuropathic pain</article-title><source>J Biol Chem</source><year>2022</year><fpage>298</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2022.101999</pub-id><pub-id pub-id-type="pmcid">PMC9168157</pub-id><pub-id pub-id-type="pmid">35500651</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Coelho</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Lima-Bastos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gobira</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Lisboa</surname><given-names>S.F.</given-names></name></person-group><article-title>Endocannabinoid signaling and epigenetics modifications in the neurobiology of stress-related disorders</article-title><source>Neuronal Signal</source><volume>7</volume><year>2023</year><fpage>NS20220034</fpage><pub-id pub-id-type="pmid">37520658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/NS20220034</pub-id><pub-id pub-id-type="pmcid">PMC10372471</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Grabon</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gasmi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Degletagne</surname><given-names>C.</given-names></name><name name-style="western"><surname>Georges</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bemeguenai</surname><given-names>A.</given-names></name><etal/></person-group><article-title>CB2 expression in mouse brain: from mapping to regulation in microglia under inflammatory conditions</article-title><source>J Neuroinflammation</source><volume>21</volume><year>2024</year><fpage>206</fpage><pub-id pub-id-type="pmid">39160534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-024-03202-8</pub-id><pub-id pub-id-type="pmcid">PMC11334370</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>L&#243;pez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aparicio</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pazos</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Grande</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Barreda-Manso</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Benito-Cuesta</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Cannabinoid CB 2 receptors in the mouse brain: relevance for Alzheimer&#8217;s disease</article-title><source>J Neuroinflammation</source><volume>15</volume><year>2018</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">29793509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-018-1174-9</pub-id><pub-id pub-id-type="pmcid">PMC5968596</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Cassano</surname><given-names>T.</given-names></name><name name-style="western"><surname>Calcagnini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pace</surname><given-names>L.</given-names></name><name name-style="western"><surname>De Marco</surname><given-names>F.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gaetani</surname><given-names>S.</given-names></name></person-group><article-title>Cannabinoid receptor 2 signaling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target</article-title><source>Front Neurosci</source><volume>11</volume><year>2017</year><fpage>30</fpage><pub-id pub-id-type="pmid">28210207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2017.00030</pub-id><pub-id pub-id-type="pmcid">PMC5288380</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz de Mart&#237;n Esteban</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benito-Cuesta</surname><given-names>I.</given-names></name><name name-style="western"><surname>Terradillos</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Relimpio</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Arnanz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ruiz-P&#233;rez</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Cannabinoid CB2 receptors modulate microglia function and amyloid dynamics in a mouse model of Alzheimer&#8217;s disease</article-title><source>Front Pharmacol</source><volume>13</volume><year>2022</year><fpage>841766</fpage><pub-id pub-id-type="pmid">35645832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.841766</pub-id><pub-id pub-id-type="pmcid">PMC9136843</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Solas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>M.J.</given-names></name></person-group><article-title>CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients</article-title><source>Neurobiol Aging</source><volume>34</volume><year>2013</year><fpage>805</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">22763024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2012.06.005</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Verkhratsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parpura</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rodriguez-Arellano</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zorec</surname><given-names>R.</given-names></name></person-group><article-title>Astroglia in Alzheimer's disease</article-title><source>Neuroglia Neurodegener Dis</source><year>2019</year><fpage>273</fpage><lpage>324</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-981-13-9913-8_11</pub-id><pub-id pub-id-type="pmcid">PMC7266005</pub-id><pub-id pub-id-type="pmid">31583592</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Kasten</surname><given-names>M.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>C.</given-names></name></person-group><article-title>The many faces of alpha-synuclein mutations</article-title><source>Mov Disord</source><volume>28</volume><year>2013</year><fpage>697</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">23674458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.25499</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Hendrickx</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pierrot</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tasiaux</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schakman</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kienlen-Campard</surname><given-names>P.</given-names></name><name name-style="western"><surname>De Smet</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Epigenetic regulations of immediate early genes expression involved in memory formation by the amyloid precursor protein of Alzheimer disease</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><object-id pub-id-type="publisher-id">e99467</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0099467</pub-id><pub-id pub-id-type="pmcid">PMC4053420</pub-id><pub-id pub-id-type="pmid">24919190</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Zachariou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Loizidou</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Spyrou</surname><given-names>G.M.</given-names></name></person-group><article-title>Immediate-early genes as influencers in genetic networks and their role in Alzheimer&#8217;s disease</article-title><source>bioRxiv</source><year>2024</year><comment>2024.03.29.586739</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2025.110043</pub-id><pub-id pub-id-type="pmid">40158459</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Kashyap</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bapat</surname><given-names>D.</given-names></name><name name-style="western"><surname>Das</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gowaikar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Amritkar</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Rangarajan</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Synapse loss and progress of Alzheimer&#8217;s disease-A network model</article-title><source>Sci Rep</source><volume>9</volume><year>2019</year><fpage>6555</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-43076-y</pub-id><pub-id pub-id-type="pmid">31024073</pub-id><pub-id pub-id-type="pmcid">PMC6484103</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>DeKosky</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Scheff</surname><given-names>S.W.</given-names></name></person-group><article-title>Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity</article-title><source>Ann Neurol: Off J Am Neurol Assoc Child Neurol Soc</source><volume>27</volume><year>1990</year><fpage>457</fpage><lpage>464</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.410270502</pub-id><pub-id pub-id-type="pmid">2360787</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Tzioras</surname><given-names>M.</given-names></name><name name-style="western"><surname>McGeachan</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Durrant</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Spires-Jones</surname><given-names>T.L.</given-names></name></person-group><article-title>Synaptic degeneration in Alzheimer disease</article-title><source>Nat Rev Neurol</source><volume>19</volume><year>2023</year><fpage>19</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">36513730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-022-00749-z</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sciaky</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hulbert</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Targeting the histone methyltransferase G9a activates imprinted genes and improves survival of a mouse model of Prader&#8211;Willi syndrome</article-title><source>Nat Med</source><volume>23</volume><year>2017</year><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">28024084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.4257</pub-id><pub-id pub-id-type="pmcid">PMC5589073</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Vicente-Acosta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ceprian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sobrino</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pazos</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Lor&#237;a</surname><given-names>F.</given-names></name></person-group><article-title>Cannabinoids as glial cell modulators in ischemic stroke: implications for neuroprotection</article-title><source>Front Pharmacol</source><volume>13</volume><year>2022</year><fpage>888222</fpage><pub-id pub-id-type="pmid">35721207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.888222</pub-id><pub-id pub-id-type="pmcid">PMC9199389</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Arias</surname><given-names>M.</given-names></name><name name-style="western"><surname>Navarrete</surname><given-names>F.</given-names></name><name name-style="western"><surname>Daza-Losada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>D.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Berbel</surname><given-names>P.</given-names></name><etal/></person-group><article-title>CB1 cannabinoid receptor-mediated aggressive behavior</article-title><source>Neuropharmacology</source><volume>75</volume><year>2013</year><fpage>172</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">23916480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2013.07.013</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>F.</given-names></name><etal/></person-group><article-title>A cannabinoid receptor 2 agonist reduces blood&#8211;brain barrier damage via induction of MKP-1 after intracerebral hemorrhage in rats</article-title><source>Brain Res</source><volume>1697</volume><year>2018</year><fpage>113</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">29886251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2018.06.006</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Xi</surname><given-names>Z.-X.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X.-Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.-R.</given-names></name><etal/></person-group><article-title>Brain cannabinoid CB2 receptors modulate cocaine&#8217;s actions in mice</article-title><source>Nat Neurosci</source><volume>14</volume><year>2011</year><fpage>1160</fpage><lpage>1166</lpage><pub-id pub-id-type="pmid">21785434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.2874</pub-id><pub-id pub-id-type="pmcid">PMC3164946</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Boran</surname><given-names>A.D.W.</given-names></name><name name-style="western"><surname>Iyengar</surname><given-names>R.</given-names></name></person-group><article-title>Systems approaches to polypharmacology and drug discovery</article-title><source>Curr Opin Drug Discov Devel</source><volume>13</volume><year>2010</year><fpage>297</fpage><pub-id pub-id-type="pmcid">PMC3068535</pub-id><pub-id pub-id-type="pmid">20443163</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Gri&#241;&#225;n-Ferr&#233;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corpas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Puigoriol-Illamola</surname><given-names>D.</given-names></name><name name-style="western"><surname>Palomera-&#193;valos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sanfeliu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pall&#224;s</surname><given-names>M.</given-names></name></person-group><article-title>Understanding epigenetics in the neurodegeneration of Alzheimer&#8217;s disease: SAMP8 mouse model</article-title><source>J Alzheim Dis</source><volume>62</volume><year>2018</year><fpage>943</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.3233/JAD-170664</pub-id><pub-id pub-id-type="pmcid">PMC5870033</pub-id><pub-id pub-id-type="pmid">29562529</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Morley</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Farr</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V.B.</given-names></name><name name-style="western"><surname>Vijaya</surname></name><name name-style="western"><surname>Harvey</surname><given-names>J.A.</given-names></name></person-group><article-title>The SAMP8 mouse: a model to develop therapeutic interventions for Alzheimer&#8217;s disease</article-title><source>Curr Pharm Des</source><volume>18</volume><year>2012</year><fpage>1123</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.2174/138161212799315795</pub-id><pub-id pub-id-type="pmid">22288401</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.-S.</given-names></name></person-group><article-title>SAMP8 mice as a model of age-related cognition decline with underlying mechanisms in Alzheimer's disease</article-title><source>J Alzheim Dis</source><volume>75</volume><year>2020</year><fpage>385</fpage><lpage>395</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-200063</pub-id><pub-id pub-id-type="pmid">32310176</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Tyrakis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Agridi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kourti</surname><given-names>M.</given-names></name></person-group><article-title>A comprehensive exploration of the multifaceted neuroprotective role of cannabinoids in Alzheimer's disease across a decade of research</article-title><source>Int J Mol Sci</source><volume>25</volume><year>2024</year><fpage>8630</fpage><pub-id pub-id-type="pmid">39201317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25168630</pub-id><pub-id pub-id-type="pmcid">PMC11354546</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Shade</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Van Bockstaele</surname><given-names>E.J.</given-names></name></person-group><article-title>Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer's disease</article-title><source>Front Aging Neurosci</source><volume>14</volume><year>2022</year><object-id pub-id-type="publisher-id">949361</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.949361</pub-id><pub-id pub-id-type="pmcid">PMC9577232</pub-id><pub-id pub-id-type="pmid">36268196</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H.</given-names></name></person-group><article-title>Role of neuroinflammation in neurodegeneration development</article-title><source>Signal Transduct Target Ther</source><volume>8</volume><year>2023</year><fpage>267</fpage><pub-id pub-id-type="pmid">37433768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01486-5</pub-id><pub-id pub-id-type="pmcid">PMC10336149</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>M.</given-names></name></person-group><article-title>Microglia in Alzheimer &#8217;s disease</article-title><source>J Cell Biol</source><volume>217</volume><year>2018</year><fpage>459</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">29196460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.201709069</pub-id><pub-id pub-id-type="pmcid">PMC5800817</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Bhusal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Afridi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Suk</surname><given-names>K.</given-names></name></person-group><article-title>Bidirectional communication between microglia and astrocytes in neuroinflammation</article-title><source>Curr Neuropharmacol</source><volume>21</volume><year>2023</year><fpage>2020</fpage><pub-id pub-id-type="pmid">36453496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1570159X21666221129121715</pub-id><pub-id pub-id-type="pmcid">PMC10556371</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Leng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Edison</surname><given-names>P.</given-names></name></person-group><article-title>Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?</article-title><source>Nat Rev Neurol</source><volume>17</volume><year>2021</year><fpage>157</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1038/s41582-020-00435-y</pub-id><pub-id pub-id-type="pmid">33318676</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Navarro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Borroto-Escuela</surname><given-names>D.</given-names></name><name name-style="western"><surname>Angelats</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia</article-title><source>Brain Behav Immun</source><volume>67</volume><year>2018</year><fpage>139</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">28843453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2017.08.015</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>T&#246;nnies</surname><given-names>E.</given-names></name><name name-style="western"><surname>Trushina</surname><given-names>E.</given-names></name></person-group><article-title>Oxidative stress, synaptic dysfunction, and Alzheimer's disease</article-title><source>J Alzheimers Dis</source><volume>57</volume><year>2017</year><fpage>1105</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.3233/JAD-161088</pub-id><pub-id pub-id-type="pmid">28059794</pub-id><pub-id pub-id-type="pmcid">PMC5409043</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Masliah</surname><given-names>E.</given-names></name><name name-style="western"><surname>Crews</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>L.</given-names></name></person-group><article-title>Synaptic remodeling during aging and in Alzheimer's disease</article-title><source>J Alzheim Dis</source><volume>9</volume><year>2006</year><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/jad-2006-9s311</pub-id><pub-id pub-id-type="pmid">16914848</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name><etal/></person-group><article-title>(m) RVD-hemopressin (&#945;) Ameliorated oxidative stress, apoptosis and damage to the BDNF/TrkB/Akt pathway induced by scopolamine in HT22 cells</article-title><source>Neurotox Res</source><volume>41</volume><year>2023</year><fpage>627</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">37971633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12640-023-00677-w</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Jayant</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>B.</given-names></name></person-group><article-title>Pharmacological benefits of selective modulation of cannabinoid receptor type 2 (CB2) in experimental Alzheimer's disease</article-title><source>Pharmacol Biochem Behav</source><volume>140</volume><year>2016</year><fpage>39</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">26577751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pbb.2015.11.006</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Rothammer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Binkle-Ladisch</surname><given-names>L.</given-names></name><name name-style="western"><surname>Di Liberto</surname><given-names>G.</given-names></name><name name-style="western"><surname>Egervari</surname><given-names>K.</given-names></name><etal/></person-group><article-title>G9a dictates neuronal vulnerability to inflammatory stress via transcriptional control of ferroptosis</article-title><source>Sci Adv</source><volume>8</volume><year>2022</year><fpage>eabm5500</fpage><pub-id pub-id-type="pmid">35930635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abm5500</pub-id><pub-id pub-id-type="pmcid">PMC9355351</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0220">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc2" position="float" orientation="portrait"><caption><title>Multimedia component 2</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc2.docx" position="float" orientation="portrait"><alt-text>Multimedia component 2</alt-text></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0215">This study was supported by the Ministerio de Econom&#237;a, Industria Econom&#237;a, Industria y Competitividad (Agencia Estatal de Investigaci&#243;n, AEI) and European Union NextGenerationEU/PRTR (PID2022-139016OA-I00, PDC2022-133441-I00; to CGF and MP), Generalitat de Catalunya (2021 SGR 00357; to CGF and MP). This study was co-financed by Secretaria d&#8217;Universitats i Recerca del Departament d&#8217;Empresa i Coneixement de la Generalitat de Catalunya 2023 (Product 0092; Llavor 005 and Llavor 007 to CGF). ABS acknowledges the Ag&#232;ncia de Gesti&#243; d'Ajuts Universitaris i de Recerca (AGAUR) for her FI-SDUR fellowship (2021FISDU 00182).</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0225">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.neurot.2025.e00616" id="intref0010">https://doi.org/10.1016/j.neurot.2025.e00616</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Alcohol</journal-id><journal-id journal-id-type="iso-abbrev">Alcohol</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Alcohol (Fayetteville, N.Y.)</journal-title></journal-title-group><issn pub-type="ppub">0741-8329</issn><issn pub-type="epub">1873-6823</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12488126</article-id><article-id pub-id-type="pmcid-ver">PMC12488126.1</article-id><article-id pub-id-type="pmcaid">12488126</article-id><article-id pub-id-type="pmcaiid">12488126</article-id><article-id pub-id-type="manuscript-id">NIHMS2113725</article-id><article-id pub-id-type="pmid">36150608</article-id><article-id pub-id-type="doi">10.1016/j.alcohol.2022.08.008</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2113725</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2113725</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Tauopathy and alcohol consumption interact to alter locus coeruleus excitatory transmission and excitability in male and female mice</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Downs</surname><given-names initials="AM">Anthony M.</given-names></name><degrees>Ph.D.</degrees><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Catavero</surname><given-names initials="CM">Christina M</given-names></name><degrees>Ph.D.</degrees><xref rid="A2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kasten</surname><given-names initials="MR">Michael R.</given-names></name><degrees>Ph.D.</degrees><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McElligott</surname><given-names initials="ZA">Zo&#233; A.</given-names></name><degrees>Ph.D.</degrees><xref rid="A1" ref-type="aff">a</xref><xref rid="A4" ref-type="aff">d</xref><xref rid="A5" ref-type="aff">e</xref></contrib></contrib-group><aff id="A1"><label>a</label>Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599</aff><aff id="A2"><label>b</label>Graduate Program in Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599</aff><aff id="A3"><label>c</label>Department of Otolaryngology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599</aff><aff id="A4"><label>d</label>Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599</aff><aff id="A5"><label>e</label>Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Author Statement</p><p id="P2"><bold>Anthony Downs</bold>: Conceptualization, methodology, formal analysis, investigation, writing-original draft, writing- review &amp; editing, visualization Christina <bold>Catavero</bold>: conceptualization, methodology, formal analysis, investigation <bold>Michael Kasten</bold>: conceptualization, supervision, writing &#8211; review &amp; editing <bold>Zoe McElligott</bold>: conceptualization, writing &#8211; review &amp; editing, supervision, funding acquisition.</p></fn><corresp id="CR1">Corresponding author: Zoe A. McElligott Ph.D.: <email>zoemce@email.unc.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>20</day><month>9</month><year>2022</year></pub-date><volume>107</volume><issue-id pub-id-type="pmc-issue-id">498036</issue-id><fpage>97</fpage><lpage>107</lpage><pub-history><event event-type="nihms-submitted"><date><day>27</day><month>09</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 16:25:21.943"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2113725.pdf"/><abstract id="ABS1"><p id="P3">Alcohol use disorder is a major public health concern in the United States. Recent work has suggested a link between chronic alcohol consumption and the development of tauopathy disorders, such as Alzheimer&#8217;s Disease and Frontal-Temporal Dementia. However, relatively little work has investigated changes in neural circuitry involved in both tauopathy disorders and alcohol use disorder. The locus coeruleus (LC) is the major noradrenergic nuclei in the brain and is one of the earliest sites to be affected by tau lesions. The LC is also implicated in the rewarding effects of ethanol and alcohol withdrawal. In this study we assessed effects of long-term ethanol consumption and tauopathy on the physiology of LC neurons. Male and female P301S mice, a humanized transgenic mouse model of tauopathy, underwent 16 weeks of intermittent access to 20% ethanol from 3 to 7 months of age. We observed higher total alcohol consumption in female mice regardless of genotype. Male P301S mice consumed more ethanol and had a greater preference for ethanol than WT males. At the end of the drinking study, LC function was assessed using <italic toggle="yes">ex vivo</italic> whole cell electrophysiology. We found significant changes in excitatory inputs to the LC due to both ethanol and genotype., We found significantly increased excitability of the LC due to ethanol with greater effects in female P301S mice than WT. Our study identifies significant changes in the LC due to interactions between tauopathy and long-term ethanol use. These findings could have important implications regarding LC activity and changes in behavior due to both ethanol and tauopathy related dementia.</p></abstract><kwd-group><kwd>Alzheimer&#8217;s Disease</kwd><kwd>Frontotemporal dementia</kwd><kwd>electrophysiology</kwd><kwd>PS19</kwd><kwd>intermittent access</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Research (Wash D C)</journal-id><journal-id journal-id-type="iso-abbrev">Research (Wash D C)</journal-id><journal-id journal-id-type="pmc-domain-id">3712</journal-id><journal-id journal-id-type="pmc-domain">research</journal-id><journal-id journal-id-type="publisher-id">RESEARCH</journal-id><journal-title-group><journal-title>Research</journal-title></journal-title-group><issn pub-type="epub">2639-5274</issn><publisher><publisher-name>AAAS Science Partner Journal Program</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12489184</article-id><article-id pub-id-type="pmcid-ver">PMC12489184.1</article-id><article-id pub-id-type="pmcaid">12489184</article-id><article-id pub-id-type="pmcaiid">12489184</article-id><article-id pub-id-type="pmid">41049611</article-id><article-id pub-id-type="doi">10.34133/research.0912</article-id><article-id pub-id-type="publisher-id">0912</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group><subj-group subj-group-type="category"><subject>Health Science</subject></subj-group></article-categories><title-group><article-title>Mitochondria Metabolism Regulates Glucose&#8211;Lipid Homeostasis in Neurodegenerative Diseases</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="J">Jianliang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="afn1" ref-type="author-notes">
<sup>&#8224;</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="C">Can</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="afn1" ref-type="author-notes">
<sup>&#8224;</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="C">Cheng</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Deng</surname><given-names initials="K">Kun</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiao</surname><given-names initials="Y">Yun</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="W">Wei</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="corr1" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wu</surname><given-names initials="M">Minghua</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="corr1" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6954-9507</contrib-id><name name-style="western"><surname>Lei</surname><given-names initials="M">Mingsheng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="corr1" ref-type="corresp">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label>
<institution>Zhangjiajie Hospital Affiliated to Hunan Normal University</institution>, Zhangjiajie 427000, Hunan, <country>China</country>.</aff><aff id="aff2"><label><sup>2</sup></label><addr-line>The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, School of Basic Medicine</addr-line>, 
<institution>Central South University</institution>, Changsha 410000, Hunan, <country>China</country>.</aff><aff id="aff3"><label><sup>3</sup></label>
<institution>Changsha Central Hospital</institution>, Changsha 410000, Hunan, <country>China</country>.</aff><aff id="aff4"><label><sup>4</sup></label><addr-line>Furong Laboratory</addr-line>, 
<institution>Central South University</institution>, Changsha 410000, Hunan, <country>China</country>.</aff><aff id="aff5"><label><sup>5</sup></label>
<institution>Zhangjiajie College</institution>, Zhangjiajie 427000, Hunan, <country>China</country>.</aff><author-notes><corresp id="corr1"><label>*</label>Address correspondence to: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:wuminghua554@aliyun.com">wuminghua554@aliyun.com</email> (M.W.); <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:mingshenglei@163.com">mingshenglei@163.com</email> (M.L.); <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="wellkao@163.com">wellkao@163.com</email> (W.G.)</corresp><fn id="afn1"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date publication-format="electronic" date-type="pub"><day>02</day><month>10</month><year>2025</year></pub-date><pub-date publication-format="electronic" date-type="collection"><year>2025</year></pub-date><volume>8</volume><issue-id pub-id-type="pmc-issue-id">478155</issue-id><elocation-id>0912</elocation-id><history><date date-type="received"><day>05</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>04</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>9</month><year>2025</year></date><date date-type="pub"><day>02</day><month>10</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Jianliang Huang et&#160;al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Jianliang Huang et&#160;al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Exclusive licensee Science and Technology Review Publishing House. No claim to original U.S. Government Works. Distributed under a <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY 4.0)</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="research.0912.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="research.0912.pdf"/><abstract><p>Neurodegenerative diseases represent a major health threat, with dysfunction in energy metabolism and imbalance in glucose&#8211;lipid homeostasis constituting key pathogenic factors. As the cell&#8217;s energy hub, mitochondria are closely associated with neurodegenerative diseases, such as Alzheimer&#8217;s and Parkinson&#8217;s diseases. However, the precise mechanism by which mitochondrial energy metabolism affects glucose&#8211;lipid homeostasis remains unclear. This review summarizes currents insights into the role of mitochondrial function in energy metabolism and glucose&#8211;lipid regulation in neurodegenerative diseases. We examined how mitochondrial dynamics, oxidative phosphorylation, calcium homeostasis, and key signaling pathways&#8212;AMP-activated protein kinase/mammalian target of rapamycin, peroxisome proliferator-activated receptor gamma coactivator 1-alpha, and Sirtuin 1&#8212;contribute to neuronal energy balance and metabolic regulation. We further explored the impact of other organelles on mitochondria and how the dynamic switching of mitochondrial morphology and function disrupts the critical glucose&#8211;lipid homeostasis. By focusing on mitochondrial dysfunction, metabolic disorders, and their interactions, we introduce the mitochondria-centered multi-organelle&#8211;energy metabolic&#8211;glucose&#8211;lipid homeostasis (MMH) network as a unifying theoretical framework that positions the progressive loss of metabolic flexibility as the fundamental essence of neurodegenerative disorders. The MMH network furnishes a novel lens through which the shared mechanistic underpinnings of neurodegenerative diseases can be deciphered, and thereby enable earlier diagnosis and precision therapeutics.</p></abstract><counts><fig-count count="5"/><table-count count="3"/><ref-count count="189"/><page-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Neurodegenerative diseases (NDDs) are a growing global public health concern, characterized by selective neuronal degeneration and irreversible synaptic damage, leading to progressive cognitive decline or motor impairment [<xref rid="B1" ref-type="bibr">1</xref>]. Alzheimer&#8217;s disease (AD), Parkinson&#8217;s disease (PD), and Huntington&#8217;s disease (HD) are prominent examples, contributing importantly to disability in older adults [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>]. The median survival time for certain diseases, such as amyotrophic lateral sclerosis, is only 5 to 15 years, with a 5-year survival rate of less than 40% [<xref rid="B4" ref-type="bibr">4</xref>]. Current treatments&#8212;such as cholinesterase inhibitors (e.g., donepezil) and glutamatergic modulators (e.g., memantine), often combined with cognitive-behavioral therapy&#8212;offer only temporary symptom relief and do not target the underlying pathology [<xref rid="B5" ref-type="bibr">5</xref>]. Disease progression is influenced by factors including age, genetic mutations (e.g., <italic toggle="yes">APOE-&#949;4</italic> and <italic toggle="yes">PARK</italic> genes), environmental exposures, and metabolic disturbances [<xref rid="B6" ref-type="bibr">6</xref>]. Among these, alterations in glucose metabolism and mitochondrial DNA (mtDNA) are critical to NDDs. Studies have shown that glucose metabolism in the temporal cortex of patients with AD is significantly reduced, which is associated with A&#946; deposition [<xref rid="B7" ref-type="bibr">7</xref>]. Furthermore, a high proportion of mtDNA deletions has been observed in the substantia nigra of patients with PD, which indicates that mitochondrial metabolic disturbances are central to the pathology of NDDs [<xref rid="B8" ref-type="bibr">8</xref>]. Neurons depend on mitochondria for energy and functions, such as development, synaptic plasticity, calcium regulation, and apoptosis [<xref rid="B9" ref-type="bibr">9</xref>].</p><p>Mitochondria occupy a considerable volume proportion in neurons, which may vary depending on the type of neuron. This highlights the critical role of mitochondria in neurons [<xref rid="B10" ref-type="bibr">10</xref>]. As metabolic hubs, mitochondria regulate glucose metabolism via oxidative phosphorylation (OXPHOS) and the tricarboxylic acid (TCA) cycle and balance lipid metabolism through &#946;-oxidation [<xref rid="B11" ref-type="bibr">11</xref>]. They control neuronal energy supply, demand, and reprogramming via signaling pathways, such as AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1&#945;), maintaining metabolic homeostasis [<xref rid="B12" ref-type="bibr">12</xref>]. In NDDs, mitochondrial dysfunction and metabolic disorders are mutually causal: impaired mitochondrial respiratory chain, decreased adenosine triphosphate (ATP) production, oxidative stress, and calcium imbalance disrupt glucose and lipid metabolism, whereas metabolic disorders, in turn, exacerbate mitochondrial damage, and thereby create a vicious cycle of accelerated degeneration [<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>]. The &#8220;mitochondrial dysfunction&#8211;energy metabolism disorder&#8211;glucose&#8211;lipid imbalance&#8221; cascade is a key pathological process in NDDs [<xref rid="B15" ref-type="bibr">15</xref>].</p><p>Recent studies have revealed that mitochondria do not function independently; rather, they form specialized membrane contact sites with various membrane-bound organelles, such as the endoplasmic reticulum, known as mitochondria-associated membranes (MAMs), to create a highly coordinated intracellular interaction network. This network profoundly impacts the dynamic balance of glucose and lipids within neurons by regulating mitochondrial metabolic states, serving as a crucial foundation for maintaining neuronal metabolic homeostasis [<xref rid="B16" ref-type="bibr">16</xref>]. Based on this understanding, in recent years, research focus has gradually shifted from viewing mitochondrial dysfunction in isolation to understanding its dynamic regulation within complex cellular networks. However, the current state of symptomatic treatment reflects a limited understanding of mitochondrial energy imbalance in NDDs, particularly regarding the influence of other organelles on mitochondria and how the dynamic switching of mitochondrial morphology and function disrupts critical glucose&#8211;lipid homeostasis. This underscores the necessity for in-depth studies on the mitochondria-centered multi-organelle&#8211;energy metabolic&#8211;glucose&#8211;lipid homeostasis (MMH) network. Breakthroughs in high-throughput molecular analysis techniques, such as single-cell sequencing, real-time metabolic flux analysis, super-resolution microscopy, and real-time monitoring of mitochondrial function using fluorescent probes, have improved the precision of analyzing mitochondrial morphology, function, and their interactions with other organelles [<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>]. These technological advancements provide a solid experimental foundation for validating and deepening the MMH network theory, and thereby facilitate the systematic understanding of the pathogenesis of NDDs at the molecular, cellular, tissue, and even individual levels. This review systematically analyzes the regulation of energy metabolism by mitochondria and its disruption of glucose&#8211;lipid homeostasis to elucidate how alterations in mitochondrial function reshape neuronal metabolic patterns.</p><p>We explore the MMH network, the regulatory mechanisms of multi-organelle interactions, and the relationship between the dynamic changes in mitochondrial morphology and function, while focusing on its role in maintaining neuronal glucose&#8211;lipid homeostasis and its potential as a therapeutic target. Our goal is to provide a theoretical foundation for future strategies aimed at restoring neuronal glucose&#8211;lipid homeostasis to prevent and treat NDDs (Fig. <xref rid="F1" ref-type="fig">1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>Fig. 1.</label><caption><p>The mitochondria-centered multi-organelle&#8211;energy metabolic&#8211;glucose&#8211;lipid homeostasis network. Healthy neurons (left) maintain ATP supply, calcium homeostasis regulation, and glucose&#8211;lipid metabolic balance through normal OXPHOS and the TCA. Mitochondrial dysfunction leads to excessive ROS production, reduced ATP generation, and calcium homeostasis imbalance, which triggers metabolic disorders. This dysfunction forms a vicious cycle with glucose&#8211;lipid metabolic imbalance that ultimately results in NDDs (upper right), characterized by mitochondrial damage, disruption of glucose&#8211;lipid homeostasis, and neuronal degeneration. Simultaneously, organelles such as the Golgi apparatus, lysosomes, and endoplasmic reticulum exacerbate mitochondrial metabolic disorders by forming MAMs or producing LD. Based on the MMH network theory, a systematic targeted therapeutic strategy is proposed (lower right): restoring ATP generation through mitochondrial repair and reconstructing the TCA cycle and glucose&#8211;lipid balance via metabolic reprogramming, and thereby interrupting the pathological cascade of &#8220;mitochondrial dysfunction&#8211;energy metabolism disorder&#8211;glucose&#8211;lipid imbalance&#8221;.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="research.0912.fig.001.jpg"/></fig></sec><sec id="sec2"><title>Mitochondrial Structure and Metabolic Regulatory Interactions</title><sec id="sec3"><title>Mitochondrial structure and quality control</title><p>Mitochondria serve as the primary energy-generating organelles in cells, with specialized structures essential to their function. Defined by 2 membranes, the outer membrane forms a sheath whereas the inner membrane folds into cristae that create a cavity and increase the surface area [<xref rid="B19" ref-type="bibr">19</xref>]. This expanded surface supports the electron transport chain and ATP synthase. The integrity of cristae is critical for assembling respiratory complexes and ensuring efficient electron transport. Moreover, the inner membrane also encloses the mitochondrial matrix, which contains key components, such as TCA cycle enzymes, mtDNA, and ribosomes [<xref rid="B20" ref-type="bibr">20</xref>].</p><p>Remarkably, mitochondria possess self-regulatory capabilities. The core function of mtDNA in encoding subunits of the respiratory chain lies in the precise regulation of the assembly and activity of respiratory chain complexes, and thereby ensures that mitochondria can rapidly and efficiently supply energy according to the constantly changing energy demands of neurons [<xref rid="B21" ref-type="bibr">21</xref>]. To maintain functionality, mitochondria rely on a dual quality-control system. One part involves the dynamic balance between fusion and fission. Fusion, mediated by MFN1/2 (outer membrane) and OPA1 (inner membrane), helps stabilize mtDNA and repair damage. Fission, regulated by DRP1, FIS1, and MFF, segregates dysfunctional segments [<xref rid="B22" ref-type="bibr">22</xref>]. Mitochondrial fusion and fission dynamics not only facilitate transport but also play a direct role in maintaining mitochondrial network health, mtDNA homogenization, and the isolation of damaged portions [<xref rid="B23" ref-type="bibr">23</xref>]. In neurons, which are highly dependent on a continuous supply of energy and metabolic homeostasis, this dynamic process is crucial for the removal of damaged mitochondria, the maintenance of energy metabolic balance, and the prevention of neurodegenerative changes [<xref rid="B24" ref-type="bibr">24</xref>]. Mitophagy constitutes a targeted degradation process for damaged mitochondria. When membrane potential drops, PINK1 accumulates on the outer membrane, recruiting Parkin, which ubiquitinates damaged mitochondria, targeting them for autophagic removal [<xref rid="B25" ref-type="bibr">25</xref>]. In NDDs, these quality-control mechanisms frequently fail, leading to the accumulation of dysfunctional mitochondria [<xref rid="B26" ref-type="bibr">26</xref>], impaired ATP synthesis, and release of pro-inflammatory factors such as tumor necrosis factor alpha (TNF-&#945;), interleukin-1 beta (IL-1&#946;), and interleukin-6 (IL-6), and thereby exacerbate neuroinflammation [<xref rid="B27" ref-type="bibr">27</xref>] (Fig. <xref rid="F2" ref-type="fig">2</xref>).</p><fig position="float" id="F2" orientation="portrait"><label>Fig. 2.</label><caption><p>Schematic diagram of mitochondrial structure and quality control. The central body displays the double-membrane structure of mitochondria, including the outer membrane, the inner membrane folds forming cristae, and the matrix containing mtDNA. The circle to the left illustrates the dynamic balance between fusion and fission: the fusion process is regulated by MFN1/2 (outer membrane fusion) and OPA1 (inner membrane fusion), while the fission process is mediated by proteins, such as DRP1, FIS1, and MFF. A decrease in mitochondrial membrane potential (&#916;&#936;m&#8595;) or an increase in ROS activates the PINK1/Parkin signaling pathway: PINK1 accumulates on damaged mitochondria and recruits Parkin, which then initiates mitophagy through ubiquitination modifications, and ultimately forms phagosomes to clear damaged mitochondria. Lower right corner: the release of inflammatory factors (TNF-&#945;, IL-1&#946;, and IL-6) owing to mitochondrial dysfunction, suggesting their pathological role in NDDs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="research.0912.fig.002.jpg"/></fig></sec><sec id="sec4"><title>Mitochondrial energetic functions</title><p>Mitochondria, the cell&#8217;s primary energy source, are critical for maintaining physiological function. The mitochondrial respiratory chain, comprising 5 complexes, drives cellular energy production [<xref rid="B28" ref-type="bibr">28</xref>]. Neurons have a high energy demand and primarily rely on OXPHOS to produce ATP. However, the specific ratio may vary depending on the type of neuron and its physiological state [<xref rid="B29" ref-type="bibr">29</xref>]. Electron transport via complexes I, III, and IV pumps protons into the intermembrane space, to create a transmembrane gradient. Complex V uses this electrochemical gradient to synthesize ATP [<xref rid="B30" ref-type="bibr">30</xref>]. In NDDs, ATP levels in brain tissue are significantly reduced. Impaired ATP synthesis is a major contributor to disease progression, and there is a significant decrease in the activity of mitochondrial complexes [<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B31" ref-type="bibr">31</xref>].</p><p>Beyond energy production, mitochondria regulate redox balance and calcium homeostasis. Reactive oxygen species (ROS), primarily from complexes I and III, act as signaling molecules at moderate levels; however, at excessive levels, they induce oxidative stress and damage [<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B33" ref-type="bibr">33</xref>]. Neurons are particularly vulnerable to oxidative stress owing to high polyunsaturated fatty acid (PUFA) content and limited antioxidant defenses [<xref rid="B34" ref-type="bibr">34</xref>]. Mitochondria can finely balance the production and clearance of ROS by regulating the electron flow of the respiratory chain, modulating membrane potential, and employing a robust internal antioxidant enzyme system (i.e., SOD2, GPx/Prx, and GSH/Trx) to maintain signaling ROS levels [<xref rid="B35" ref-type="bibr">35</xref>]. Furthermore, mitochondria also buffer intracellular calcium via voltage-dependent anion channel and the mitochondrial calcium uniporter (MCU). Under pathological conditions, calcium overload opens mitochondrial permeability transition pores (mPTPs), which causes membrane potential to collapse and triggers apoptosis [<xref rid="B36" ref-type="bibr">36</xref>].</p><p>These 3 functions&#8212;ATP production, ROS regulation, and calcium buffering&#8212;are central to mitochondrial control of cellular metabolism and homeostasis. Their dysregulation underlies the pathogenesis of NDDs [<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>].</p></sec><sec id="sec5"><title>Mitochondrial regulation of substrate metabolism</title><p>Mitochondria serve as the central hub for cellular energy metabolism and are critical for the integration and regulation of glucose&#8211;lipid metabolism. In glucose metabolism, pyruvate derived from glycolysis is converted into acetyl-CoA by the pyruvate dehydrogenase complex (PDC) in the mitochondria. Acetyl-CoA enters the TCA cycle, producing nicotinamide adenine dinucleotide (NADH) and FADH<sub>2</sub>, which drive the mitochondrial electron transport chain (ETC) to generate ATP [<xref rid="B39" ref-type="bibr">39</xref>]. The brain accounts for approximately 20% of total glucose utilization, reflecting the high metabolic demands of the nervous system [<xref rid="B40" ref-type="bibr">40</xref>]. In AD, impairments in glucose metabolism have been observed, including reduced glucose utilization in the temporoparietal cortex, decreased PDC activity, and down-regulated expression of key TCA cycle enzymes&#8212;highlighting the profound influence of mitochondrial dysfunction on glucose metabolism and NDDs [<xref rid="B41" ref-type="bibr">41</xref>].</p><p>Furthermore, mitochondria play a critical role in lipid metabolism. They convert long-chain fatty acids into acetyl-CoA through &#946;-oxidation [<xref rid="B30" ref-type="bibr">30</xref>]. Although glucose is the preferred energy substrate for the nervous system, under pathological conditions, &#946;-oxidation of fatty acids becomes an important alternative energy source [<xref rid="B42" ref-type="bibr">42</xref>]. In AD, the dysfunction of MAMs is particularly pronounced [<xref rid="B43" ref-type="bibr">43</xref>]. MAMs serve as dynamic contact points between the endoplasmic reticulum and mitochondria, acting as key platforms for lipid biosynthesis, transport, and calcium signaling. The dysfunction of MAMs in AD leads to profound alterations in phospholipid metabolism, particularly impairing the synthesis and transport of phosphatidylserine (PS) [<xref rid="B44" ref-type="bibr">44</xref>]. The deficiency or abnormal distribution of PS disrupts the physicochemical properties of neuronal membranes, impairs synaptic function, and may promote neuronal vulnerability [<xref rid="B45" ref-type="bibr">45</xref>]. Furthermore, mitochondria regulate systemic metabolism by producing intermediates such as citrate and succinyl-CoA through the TCA cycle. Mitochondrial metabolites also possess signaling and epigenetic functions: acetyl-CoA regulates histone acetylation, while &#945;-ketoglutarate influences DNA demethylation, thereby modulating transcription [<xref rid="B46" ref-type="bibr">46</xref>]. Consequently, lipid metabolic imbalances caused by mitochondrial dysfunction (including MAM abnormalities and TCA cycle disturbances) further compromise the fluidity of neuronal membranes, the structure and function of signaling microdomains (such as lipid rafts), energy homeostasis, and the activity of neuroprotective signaling pathways. This constitutes an important pathological basis for the occurrence and development of NDDs [<xref rid="B47" ref-type="bibr">47</xref>,<xref rid="B48" ref-type="bibr">48</xref>].</p><p>In NDDs, metabolic imbalance driven by mitochondrial dysfunction becomes a central pathogenic feature. This metabolic imbalance exhibits early complex bidirectional interactions between glucose and lipid metabolism [<xref rid="B49" ref-type="bibr">49</xref>,<xref rid="B50" ref-type="bibr">50</xref>]. In summary, to gain an in-depth understanding of these complex pathological processes, it is essential to explore the underlying molecular mechanisms [<xref rid="B51" ref-type="bibr">51</xref>]. These mechanisms involve the dynamic regulation of fusion/fission, the AMPK/mTOR/SIRT1 (Sirtuin 1) signaling pathway closely related to energy sensing, and the PINK1/Parkin pathway responsible for recognizing and clearing damaged mitochondria. These interconnected signaling networks not only lay the groundwork for understanding mitochondrial dysfunction in NDDs but also provide multiple potential therapeutic targets for developing intervention strategies. The &#8220;AMPK/MTOR pathway in mitochondrial metabolic dynamics&#8221; section elucidates specific molecular mechanisms and potential therapeutic targets.</p></sec></sec><sec id="sec6"><title>Cellular Metabolic Reprogramming and Inflammatory Circuitry in NDDs</title><sec id="sec7"><title>Neuronal metabolic dysfunction</title><p>NDDs are characterized by central nervous system insulin resistance&#8212;a key pathological feature and a commonality across various conditions that is frequently referred to as &#8220;type 3 diabetes&#8221; [<xref rid="B52" ref-type="bibr">52</xref>] . Both type 1 and type 2 diabetes importantly impact the nervous system. In type 1 diabetes, prolonged hyperglycemia can lead to neuropathy, evinced as peripheral neuropathy and autonomic dysfunction, primarily owing to metabolic imbalance and vascular damage resulting from insulin deficiency [<xref rid="B53" ref-type="bibr">53</xref>]. In contrast, in type 2 diabetes, the presence of insulin resistance increases the occurrence of inflammatory responses in the spinal cord and brain, promoting oxidative stress and functional impairment of neurons [<xref rid="B54" ref-type="bibr">54</xref>]. Furthermore, type 2 diabetes is also associated with cognitive decline and an increased risk of AD [<xref rid="B55" ref-type="bibr">55</xref>]. The brain&#8217;s insulin signaling pathway, from a molecular standpoint, is critical for neuronal survival, synaptic plasticity, and cognitive function [<xref rid="B56" ref-type="bibr">56</xref>]. Under normal physiological conditions, insulin binding to the insulin receptor (IR) activates the IR substrate (IRS), which culminates in the activation of the PI3K&#8211;Akt pathway [<xref rid="B57" ref-type="bibr">57</xref>]. The translocation of GLUT4 to the cell membrane promotes increased glucose uptake. In NDDs, this finely tuned regulatory network undergoes important alteration. In the brain tissue of patients with AD, diminished or aberrantly phosphorylated insulin signaling components (IR, IRS-1, and PI3K) are observed, which results in impaired insulin signaling [<xref rid="B58" ref-type="bibr">58</xref>]. The binding of insulin to its receptor is hindered by competition with amyloid-beta (A&#946;), thereby blocking downstream signaling. These changes collectively reduce the expression and membrane translocation of GLUT4 and GLUT3 in neurons, and leads to impaired glucose uptake [<xref rid="B59" ref-type="bibr">59</xref>]. Other NDDs, such as PD and HD, also exhibit distinct mechanisms of insulin resistance; however, their underlying mechanisms may differ from those of AD. For instance, insulin resistance in PD may be associated with the loss of dopaminergic neurons and inflammatory responses [<xref rid="B60" ref-type="bibr">60</xref>], whereas in HD, it may be linked to the abnormal aggregation of the huntingtin protein [<xref rid="B61" ref-type="bibr">61</xref>]. Upon its onset, insulin resistance leads to a comprehensive restructuring of glucose metabolism. It is associated with decreased expression and activity of key glycolytic enzymes, such as hexokinase, phosphofructokinase, and pyruvate kinase, thus reducing the efficiency of glucose utilization [<xref rid="B62" ref-type="bibr">62</xref>]. Reduced pyruvate dehydrogenase activity in the brain tissue of patients with NDD further impairs pyruvate entry into the TCA cycle. Thus, decreased energy production may drive the conversion of pyruvate to lactate, which contributes to local acidosis and creates a metabolically hostile environment for neurons [<xref rid="B63" ref-type="bibr">63</xref>].</p><p>The persistent high-glucose environment caused by insulin resistance promotes the formation of advanced glycation end products (AGEs) [<xref rid="B64" ref-type="bibr">64</xref>], which represent a critical molecular link between metabolic dysfunction and neuronal damage. AGEs are neurotoxins that bind to the receptor for AGEs (RAGE) and activate inflammatory signaling pathways, including NF-&#954;B, which increase the levels of pro-inflammatory cytokines such as IL-1&#946;, TNF-&#945;, and ROS [<xref rid="B65" ref-type="bibr">65</xref>]. Recent studies have further elucidated the multifaceted pathogenic roles of AGEs in NDDs. Their activation of the p38 MAPK and JNK pathways enhances Bax expression but reduces Bcl-2 levels, thereby facilitating neuronal apoptosis. Moreover, AGEs interact with cytoskeletal proteins, such as Tau, to alter their structure and function and accelerate the formation of the neurofibrillary tangle (NFT) [<xref rid="B66" ref-type="bibr">66</xref>]. AGEs exacerbate neuronal energy metabolism deficits by impairing mitochondrial function, reducing mitochondrial membrane potential, decreasing ATP synthesis, and increasing mitochondrial calcium overload and oxidative stress [<xref rid="B67" ref-type="bibr">67</xref>].</p><p>Insulin resistance, beside disrupting glucose metabolism, also reprograms lipid metabolism, and this is characterized by increased fatty acid synthesis and reduced &#946;-oxidation efficiency [<xref rid="B68" ref-type="bibr">68</xref>]. In NDDs, this metabolic reprogramming disrupts the balanced utilization of energy substrates in neurons and thereby exacerbates energy deficits [<xref rid="B69" ref-type="bibr">69</xref>]. Increased ceramide synthesis is a hallmark of insulin resistance. Ceramide is neurotoxic and further impairs insulin signaling, establishing a self-perpetuating detrimental cycle [<xref rid="B70" ref-type="bibr">70</xref>]. Simultaneously, changes in membrane phospholipid composition influence ion channel activity and synaptic transmission, while dysregulated cholesterol metabolism is closely linked to A&#946; production and clearance [<xref rid="B71" ref-type="bibr">71</xref>]. Together, these lipid metabolic anomalies and glucose dysregulation synergistically drive neurodegenerative pathology [<xref rid="B72" ref-type="bibr">72</xref>,<xref rid="B73" ref-type="bibr">73</xref>]. These neuronal metabolic dysfunctions set the stage for broader cellular responses, particularly from the brain&#8217;s resident immune cells.</p></sec><sec id="sec8"><title>Glial metabolic reprogramming</title><p>Under conditions of neuronal metabolic stress, microglia and astrocytes experience important alterations in their basic metabolic profiles, which fundamentally shifts their functional states and contributes to disease progression [<xref rid="B74" ref-type="bibr">74</xref>]. Microglia, the brain&#8217;s resident immune cells, are particularly sensitive to metabolic fluctuations and respond by undergoing metabolic&#8211;phenotypic coupling [<xref rid="B75" ref-type="bibr">75</xref>]. Reduced glucose utilization efficiency and exposure to neuronal stress signals force microglia to shift from an anti-inflammatory M2 phenotype reliant on OXPHOS to a pro-inflammatory M1 phenotype dependent on glycolysis [<xref rid="B76" ref-type="bibr">76</xref>]. This metabolic transition is not merely a consequence but an active driver of neuroinflammation. The shift to glycolytic metabolism enables rapid ATP production necessary for immune activation while simultaneously increasing lactate production and creating a more acidic microenvironment. This metabolic&#8211;immune coupling substantially increases the production of pro-inflammatory cytokines, including TNF-&#945;, IL-1&#946;, and IL-6, which further propagate neuronal damage [<xref rid="B77" ref-type="bibr">77</xref>].</p><p>Astrocytes, as key metabolic support cells for neurons, undergo equally metabolic reprogramming that compromises their neuroprotective functions [<xref rid="B78" ref-type="bibr">78</xref>]. Under normal conditions, astrocytes provide crucial metabolic support through the astrocyte-neuron lactate shuttle, where they metabolize glucose to lactate and transfer it to neurons for energy production [<xref rid="B79" ref-type="bibr">79</xref>]. However, under conditions of insulin resistance and metabolic stress, astrocytic glucose metabolism becomes impaired. This metabolic dysfunction not only diminishes their capacity to support neuronal energy demands but also transforms them from metabolic allies into potential contributors to brain pathology [<xref rid="B80" ref-type="bibr">80</xref>]. The brain&#8217;s inflammatory response is further intensified by the high-glucose environment, which is characteristic of metabolic reprogramming, primarily through 2 mechanisms: (a) Hyperglycemia directly promotes NLRP3 inflammasome assembly and activation, thereby increasing the maturation and secretion of IL-1&#946; and IL-18 [<xref rid="B81" ref-type="bibr">81</xref>]. The NLRP3 gene encodes an important intracellular multiprotein complex known as the inflammasome, which plays a crucial role in the host&#8217;s immune response to pathogens and damage stimuli. NLRP3 activation induces the production of downstream cytokines, which promotes the occurrence of inflammatory responses [<xref rid="B82" ref-type="bibr">82</xref>]. (b) AGEs bind to RAGE and activate the NF-&#954;B signaling pathway and enhance the transcription of various pro-inflammatory genes [<xref rid="B83" ref-type="bibr">83</xref>]. Mitochondrial dysfunction leads to a reduction in &#945;-ketoglutarate (&#945;-KG) and a decrease in the activity of glutamine synthetase in astrocytes, which together disrupt the glutamate&#8211;glutamine cycle, triggering excitotoxicity. Moreover, this weakens &#945;-KG-dependent epigenetic regulation and glutathione synthesis, and exacerbates oxidative damage and worsens the energy crisis in neurons [<xref rid="B84" ref-type="bibr">84</xref>].</p><p>Importantly, glial metabolic reprogramming extends beyond glucose metabolism to encompass lipid handling. Notable alterations occur in key enzyme systems responsible for long-chain fatty acid oxidation, including diminished expression and activity of CPT1, LCAD, and HAD in both microglia and astrocytes [<xref rid="B85" ref-type="bibr">85</xref>]. This reduction in lipid oxidative capacity creates a dual burden: direct impairment of cellular ATP synthesis and the abnormal accumulation of lipid metabolic intermediates, most notably long-chain acylcarnitines and ceramides [<xref rid="B86" ref-type="bibr">86</xref>]. These lipid intermediates further disrupt cellular function and contribute to the inflammatory milieu that characterizes neurodegeneration [<xref rid="B87" ref-type="bibr">87</xref>]. The metabolic reprogramming of glial cells thus creates a bridge between initial neuronal dysfunction and the broader inflammatory cascade that defines disease progression.</p></sec><sec id="sec9"><title>Inflammation-mediated metabolic feedback</title><p>The metabolic dysfunction in neurons and the subsequent reprogramming of glial cells culminate in the establishment of a self-perpetuating inflammatory&#8211;metabolic cycle that drives disease progression. This phase represents the transition from localized cellular dysfunction to a brain-wide pathological network, which is characterized by a chronic low-grade inflammation known as metaflammation [<xref rid="B88" ref-type="bibr">88</xref>]. Metaflammation in the nervous system emerges as a consequence of the metabolic stress signals that emanate from dysfunctional neurons and activated glial cells. Unlike acute inflammatory responses to pathogens, metaflammation is characterized by chronicity, persistence, and low-grade activity, closely intertwined with ongoing metabolic dysfunction [<xref rid="B89" ref-type="bibr">89</xref>]. This inflammatory state is sustained by damage-associated molecular patterns (DAMPs) that are released from metabolically compromised cells, including mtDNA, ATP, and oxidized lipids, which are recognized by toll-like receptors and nucleotide-binding oligomerization domain-like receptors on glial cells. The recognition of these metabolic danger signals activates the NF-&#954;B and MAPK signaling pathways, amplifies the inflammatory response, and creates a positive feedback loop [<xref rid="B90" ref-type="bibr">90</xref>].</p><p>Central to this pathological cycle is the reciprocal relationship between mitochondrial dysfunction and inflammation. Metabolically stressed mitochondria become both sources and targets of inflammatory damage. Impaired mitochondria then release DAMPs and generate excessive ROS, which activate inflammatory pathways [<xref rid="B91" ref-type="bibr">91</xref>]. In contrast, inflammatory cytokines such as TNF-&#945; and IL-1&#946; directly impair mitochondrial respiratory chain complexes, disrupt mitochondrial membrane potential, and interfere with mitophagy&#8212;the cellular process that is responsible for removing damaged mitochondria [<xref rid="B92" ref-type="bibr">92</xref>]. This bidirectional relationship creates a particularly detrimental feedback loop where &#8220;mitochondrial damage &#8594; inflammation &#8594; further mitochondrial damage&#8221; perpetuates disease progression.</p><p>Within this inflammatory framework, lipid peroxidation emerges as a critical amplification mechanism [<xref rid="B93" ref-type="bibr">93</xref>]. Lipid peroxidation functions as a critical amplifier within this pathological framework. The nervous system&#8217;s high concentration of PUFAs, such as arachidonic acid and docosahexaenoic acid, makes neuronal lipid membranes especially susceptible to peroxidation by ROS and leads to the production of toxic metabolites, such as 4-hydroxynonenal (4-HNE), malondialdehyde, and isoprostanes [<xref rid="B94" ref-type="bibr">94</xref>]. These disturbances initiate a 3-way, self-amplifying cycle that involves lipid peroxidation, oxidative stress, and inflammation. Aldehyde compounds like 4-HNE form stable covalent adducts with proteins to induce conformational and functional changes that activate inflammatory signaling pathways&#8212;most notably NF-&#954;B and MAPK&#8212;which, in turn, promote the transcription and release of pro-inflammatory cytokines [<xref rid="B95" ref-type="bibr">95</xref>]. Additionally, activated microglia and astrocytes release TNF-&#945; and IL-1&#946;, which enhance ROS production and inhibit endogenous antioxidant systems, thereby intensifying lipid peroxidation [<xref rid="B96" ref-type="bibr">96</xref>]. The ROS driving this process are primarily generated during mitochondrial dysfunction, which damages mitochondrial membranes and compromises mtDNA integrity, thereby impairing respiratory chain complex activity. The pathological cycle of &#8220;mitochondrial damage &#8594; lipid peroxidation &#8594; inflammation amplification&#8221; is a particularly detrimental feedback loop [<xref rid="B97" ref-type="bibr">97</xref>,<xref rid="B98" ref-type="bibr">98</xref>].</p><p>The inflammatory&#8211;metabolic feedback is further complicated by specific lipid imbalances that develop over time. This vicious cycle is further aggravated by imbalances in specific lipid species. In AD, for example, distinct abnormalities in cholesterol metabolism are observed in brain tissue, including elevated total cholesterol levels and a marked reduction in 24S-hydroxycholesterol, the main metabolite responsible for cholesterol clearance, indicating impaired cholesterol homeostasis [<xref rid="B99" ref-type="bibr">99</xref>]. These imbalances have pathological consequences, such as stimulating &#946;-secretase activity, which promotes A&#946; synthesis, while simultaneously inhibiting the protective cleavage function of &#945;-secretase [<xref rid="B100" ref-type="bibr">100</xref>]. Furthermore, cholesterol accumulation alters neuronal and synaptic membrane fluidity, which affect ion-channel function and neurotransmission. The multifaceted impact of lipid imbalance on mitochondrial function is evident through complex coupling mechanisms. Excess cholesterol disrupts mitochondrial membrane fluidity and permeability, damaging the membrane bilayer and impairing ETC complexes [<xref rid="B101" ref-type="bibr">101</xref>]. Moreover, ganglioside GM1, a key membrane lipid, plays a role in regulating the MCU; its metabolic dysregulation directly impairs mitochondrial calcium homeostasis and energy metabolism [<xref rid="B102" ref-type="bibr">102</xref>]. In the process of mitophagy, phosphatidylethanolamine is a vital substrate for LC3 lipidation, and its dysregulation compromises mitochondrial quality control, facilitating the accumulation of dysfunctional mitochondria [<xref rid="B103" ref-type="bibr">103</xref>].</p><p>The ultimate consequence of this inflammatory&#8211;metabolic feedback is a comprehensive disruption of brain homeostasis that manifests in distinct temporal phases. In the early phase, insulin resistance and fatty acid oxidation defects create neuronal energy deficits that trigger cellular stress responses and initial glial activation [<xref rid="B104" ref-type="bibr">104</xref>]. The intermediate phase is characterized by inflammation amplification, where sustained metabolic disturbances drive microglial M1 polarization and NLRP3 inflammasome activation, resulting in cytokine storm-like conditions within the brain parenchyma [<xref rid="B105" ref-type="bibr">105</xref>]. The late phase involves irreversible structural damage, where prolonged exposure to inflammatory mediators and lipid peroxidation products results in synaptic loss, neuronal death, and the accumulation of pathological protein aggregates [<xref rid="B106" ref-type="bibr">106</xref>]. This progressive pathological mechanism reveals how initial metabolic dysfunction in individual neurons can escalate into brain-wide inflammatory pathology through glial cell involvement and self-amplifying feedback loops. Understanding this cascade provides crucial insights for developing therapeutic strategies that target multiple points in the metabolism&#8211;inflammation axis to potentially interrupt the cycle before irreversible damage occurs (Fig. <xref rid="F3" ref-type="fig">3</xref>).</p><fig position="float" id="F3" orientation="portrait"><label>Fig. 3.</label><caption><p>The interactive mechanisms of glucose&#8211;lipid metabolism disorders and neuroinflammation in NDDs. Top left (initiation of metabolic dysregulation): A high-sugar, high-fat environment leads to insulin resistance (IR), which results in the decreased activity of key metabolic enzymes CPT1 and LCAD. The impairment of fatty acid oxidation causes the accumulation of lipid intermediates (myristoylcarnitine and ceramide) whereas AGEs bind to RAGE, to activate downstream pathways. Top right (amplification of neuroinflammation): Activation of the NLRP3 inflammasome shifts microglia from the anti-inflammatory M2 phenotype to the pro-inflammatory M1 phenotype, leading to the release of large amounts of inflammatory factors such as TNF-&#945;, IL-1&#946;, and IL-6. Bottom right (oxidative stress and lipid peroxidation): Excessive ROS generation results in decreased mitochondrial respiratory chain function (ETC&#8595;) and reduced membrane potential (&#916;&#936;m&#8595;), producing lipid peroxidation products 4-HNE and MDA, creating a positive feedback loop of oxidative damage. Bottom left (mitochondrial dysfunction): Opening of the mitochondrial permeability transition pore (mPTP) leads to Ca<sup>2+</sup> overload, reduced ATP production, and impaired mitophagy, ultimately exacerbating the entire pathological cycle. This figure highlights the mutually reinforcing relationships among metabolic dysregulation, inflammation, oxidative stress, and mitochondrial damage.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="research.0912.fig.003.jpg"/></fig></sec></sec><sec id="sec10"><title>NDDs and Mitochondrial Dysfunction</title><p>In NDDs, mitochondrial dysfunction and disturbances in energy metabolism are key pathological features. These mechanisms exhibit differences in AD, PD, and HD. In AD, the metabolic disturbances of mitochondria are primarily associated with the deposition of A&#946; protein and the abnormal phosphorylation of tau protein. A&#946; can bind to mitochondrial membrane proteins, leading to a decrease in mitochondrial membrane potential, which, in turn, triggers energy production deficits and an increase in ROS. This functional decline makes the neurons of AD patients more susceptible to oxidative stress, exacerbating cell death and cognitive decline [<xref rid="B107" ref-type="bibr">107</xref>]. In PD, the metabolic disturbances of mitochondria are closely related to the loss of dopaminergic neurons. In the mitochondria of patients with PD, &#945;-synuclein aggregates to form Lewy bodies, which directly impact mitochondrial biogenesis and energy metabolism. The impairment of mitochondrial function results in insufficient energy supply to meet neuronal demands, which further decreases intracellular ATP levels, synaptic dysfunction, and reduced motor abilities [<xref rid="B108" ref-type="bibr">108</xref>]. In HD, mitochondrial dysfunction primarily originates from the direct interaction of the mutated huntingtin protein with mitochondria, inducing damage to the mitochondrial membrane and impairing energy production [<xref rid="B109" ref-type="bibr">109</xref>]. Furthermore, patients with HD frequently exhibit reduced mitophagy capacity that prevents the timely clearance of damaged mitochondria and further exacerbates metabolic disturbances within the cell [<xref rid="B110" ref-type="bibr">110</xref>].</p><p>In summary, although AD, PD, and HD all exhibit mitochondrial dysfunction, there are important differences in the specific metabolic disorder mechanisms. Understanding these differential mechanisms is crucial for developing personalized treatment strategies customized to specific diseases (Table <xref rid="T1" ref-type="table">1</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p>Comparative analysis of mitochondrial dysfunction mechanisms and therapeutic targets in NDDs</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Diseases</th><th align="left" rowspan="1" colspan="1">Pathological protein</th><th align="left" rowspan="1" colspan="1">Respiratory chain complex impairment</th><th align="left" rowspan="1" colspan="1">Specific molecular mechanisms</th><th align="left" rowspan="1" colspan="1">Metabolic features</th><th align="left" rowspan="1" colspan="1">Therapeutic targets</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">A&#946; aggregates, hyperphosphorylated tau protein</td><td align="left" rowspan="1" colspan="1">Complex IV</td><td align="left" rowspan="1" colspan="1">&#8226; A&#946; binding to alcohol dehydrogenase (ABAD)<break/>&#8226; Respiratory chain Complex IV suppression<break/>&#8226; mPTP sensitization<break/>&#8226; Disruption of nuclear-encoded protein import</td><td align="left" rowspan="1" colspan="1">&#8226; Hypometabolism in temporoparietal cortex<break/>&#8226; Pyruvate dehydrogenase complex (PDC) impairment<break/>&#8226; Down-regulation of TCA cycle enzymes</td><td align="left" rowspan="1" colspan="1">&#8226; &#946;/&#947;-Secretase inhibitors<break/>&#8226; Mitochantioxidants<break/>&#8226; PINK1/Parkin pathway activators</td><td align="center" rowspan="1" colspan="1">[<xref rid="B111" ref-type="bibr">111</xref>,<xref rid="B112" ref-type="bibr">112</xref>,<xref rid="B114" ref-type="bibr">114</xref>,<xref rid="B116" ref-type="bibr">116</xref>,<xref rid="B117" ref-type="bibr">117</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PD</td><td align="left" rowspan="1" colspan="1">&#945;-Synuclein aggregates</td><td align="left" rowspan="1" colspan="1">Complex I</td><td align="left" rowspan="1" colspan="1">&#8226; &#945;-Synuclein-cardiolipin interaction<break/>&#8226; Acceleration of pathological aggregation<break/>&#8226; Proteasomal and autophagic inhibition<break/>&#8226; Ca<sup>2+</sup> dyshomeostasis</td><td align="left" rowspan="1" colspan="1">&#8226; Substantia nigra-specific ATP depletion<break/>&#8226; Elevated ROS production<break/>&#8226; Mitochondrial membrane potential (&#916;&#936;m) collapse</td><td align="left" rowspan="1" colspan="1">&#8226; PINK1 kinase enhancers<break/>&#8226; Cardiolipin modulators<break/>&#8226; Complex I protectants</td><td align="center" rowspan="1" colspan="1">[<xref rid="B119" ref-type="bibr">119</xref>&#8211;<xref rid="B121" ref-type="bibr">121</xref>,<xref rid="B123" ref-type="bibr">123</xref>,<xref rid="B128" ref-type="bibr">128</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">HD</td><td align="left" rowspan="1" colspan="1">Mutant huntingtin protein (mHTT)</td><td align="left" rowspan="1" colspan="1">Complex I&#8211;IV</td><td align="left" rowspan="1" colspan="1">&#8226;mHTT-mitochondrial outer membrane association<break/>&#8226; Transcriptional repression of PGC-1&#945;<break/>&#8226; Fission promotion and fusion impairment<break/>&#8226; Cytochrome c (Cyt c) efflux</td><td align="left" rowspan="1" colspan="1">&#8226; Generalized glucose hypometabolism in striatal and cortical regions<break/>&#8226; Systemic metabolic collapse</td><td align="left" rowspan="1" colspan="1">&#8226; PGC-1&#945; activators<break/>&#8226;Mitochondrial dynamics modulators<break/>&#8226;Anti-apoptotic agents</td><td align="center" rowspan="1" colspan="1">[<xref rid="B130" ref-type="bibr">130</xref>,<xref rid="B133" ref-type="bibr">133</xref>&#8211;<xref rid="B135" ref-type="bibr">135</xref>]</td></tr></tbody></table></table-wrap><sec id="sec11"><title>Alzheimer&#8217;s disease</title><p>The prevalent neurodegenerative disorder, AD, is typified by a gradual reduction in cognitive function and memory, along with the presence of A&#946; plaques and NFTs within the brain. Problems in mitochondrial and energy metabolism are observed early in the progression of AD and precede the appearance of classical pathological markers. These findings introduce a new perspective for interpreting the progression of AD [<xref rid="B111" ref-type="bibr">111</xref>].</p><p>A comprehensive multidimensional analysis of the pathological signs demonstrated varied and intricate mitochondrial damage in patients with AD. Reduced in size, mitochondria display broken cristae structure and compromised membrane integrity. Its function is associated with decreased mitochondrial membrane potential, decreased ATP synthesis, increased ROS levels, and calcium imbalance. At the molecular level, the brain tissue of patients with AD demonstrates a substantial reduction in the activity of mitochondrial respiratory chain complexes, especially complex IV, along with an increase in mtDNA mutations, an imbalance in mitochondrial dynamics (manifested by reduced fusion and increased fission), and compromised mitophagy [<xref rid="B112" ref-type="bibr">112</xref>]. Remarkably, pronounced mitochondrial alterations are predominantly observed in cognitive regions, such as the hippocampus and cortex, and are closely associated with memory issues. The regional damage pattern offers a coherent explanation for the primary early symptom of AD, namely, memory impairment [<xref rid="B113" ref-type="bibr">113</xref>]. A self-perpetuating cycle of mitochondrial dysfunction and AD-specific pathology forms the core pathological foundation of AD progression. A&#946; impairs mitochondrial function through several mechanisms: its localization to mitochondria, binding to ABAD, and inhibition of complex IV, all of which increase ROS levels. Additionally, A&#946; promotes the opening of the mPTP, resulting in calcium overload and cytochrome c release. Overexpression of amyloid precursor protein leads to its accumulation on the mitochondrial membrane, where it blocks the import of nuclear-encoded mitochondrial proteins, further disrupting mitochondrial function [<xref rid="B114" ref-type="bibr">114</xref>]. Furthermore, the promoting effect of A&#946; is not limited to direct damage to mitochondrial function but also involves alterations in mitochondrial morphology. The overexpression of A&#946; induces adverse mitochondrial fusion and fission, which nearly disrupts the mitochondrial network. Furthermore, A&#946; can activate intracellular calcium channels, which leads to calcium overload that further damages mitochondrial energy metabolism and induces apoptosis. This increased calcium load induces ROS production within the mitochondria, which exacerbates oxidative damage and creates a vicious cycle [<xref rid="B115" ref-type="bibr">115</xref>].</p><p>The promotion of A&#946; and tau pathology by mitochondrial dysfunction is multifaceted. Energy deficits and oxidative stress enhance the activity of &#946;-secretase and &#947;-secretase, thereby increasing A&#946; production. ROS generated by dysfunctional mitochondria activate kinases, such as GSK-3&#946;, CDK5, and JNK, which contribute to the abnormal phosphorylation of tau. In addition, defective mitochondrial proteases impair autophagy and proteasomal degradation, reducing the clearance of A&#946; and tau proteins [<xref rid="B116" ref-type="bibr">116</xref>,<xref rid="B117" ref-type="bibr">117</xref>].</p><p>Abnormalities in glucose metabolism represent another critical pathological hallmark of AD, further contributing to disease progression. Positron emission tomography (PET) imaging studies have demonstrated a marked reduction in the cerebral metabolic rate of glucose in patients with AD, with the extent of this decline correlating with cognitive impairment severity. Notably, reductions in brain glucose metabolism appear prior to the clinical onset of symptoms and before substantial A&#946; accumulation, suggesting that alterations in energy metabolism occur in the early stages of AD [<xref rid="B118" ref-type="bibr">118</xref>]. This biomarker holds important value for early diagnosis and timely therapeutic intervention.</p></sec><sec id="sec12"><title>Parkinson&#8217;s disease</title><p>PD, the second most common neurodegenerative disorder, is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra and the accumulation of Lewy bodies. The central role of mitochondrial dysfunction in PD pathogenesis has been underscored by 2 pivotal findings. First, mitochondrial toxins, such as mPTP, selectively damage dopaminergic neurons in the substantia nigra, producing PD-like symptoms. Second, several PD-associated genes&#8212;including <italic toggle="yes">PINK1</italic>, <italic toggle="yes">Parkin</italic>, <italic toggle="yes">DJ-1</italic>, and <italic toggle="yes">LRRK2</italic>&#8212;encode proteins critical for the regulation of mitochondrial function. These findings collectively support the conclusion that mitochondrial dysfunction constitutes a fundamental mechanism underlying the development and progression of PD [<xref rid="B119" ref-type="bibr">119</xref>,<xref rid="B120" ref-type="bibr">120</xref>].</p><p>The most prominent and consistent mitochondrial abnormality that is observed in PD is complex I dysfunction&#8212;a finding that has been corroborated in numerous studies. In patients with PD, mitochondrial complex I activity is reduced by approximately 30% to 40% specifically in the substantia nigra, while the activity of respiratory chain complexes II to V remains relatively stable [<xref rid="B121" ref-type="bibr">121</xref>]. This selective complex I deficiency leads to several pathogenic consequences, including reduced ATP production, increased ROS generation, and decreased mitochondrial membrane potential, which ultimately results in neuronal death. The selective vulnerability of dopaminergic neurons in the substantia nigra is primarily attributed to this region-specific mitochondrial dysfunction [<xref rid="B122" ref-type="bibr">122</xref>].</p><p>Recent research reveals that cardiolipin plays a crucial role not only in maintaining the integrity of mitochondrial membranes but also in facilitating the formation of aggregates of &#945;-synuclein. By binding to &#945;-synuclein, cardiolipin regulates its structure and function, promoting its pathological aggregation. This interaction mechanism has shown importance in NDDs such as PD, which indicates that cardiolipin may represent a novel mechanism in the aggregation and pathological progression of &#945;-synuclein [<xref rid="B123" ref-type="bibr">123</xref>]. Furthermore, alterations in cardiolipin are closely associated with intracellular Ca<sup>2</sup> dynamics, with studies indicating that reduced levels of cardiolipin may accelerate the aggregation of &#945;-synuclein. This finding provides new insight for interventional strategies that target cardiolipin, suggesting that modulating cardiolipin metabolism could potentially slow the progression of &#945;-synuclein-related pathology [<xref rid="B124" ref-type="bibr">124</xref>]. Moreover, complex I-related mitochondrial deficits also contribute to the pathological accumulation of &#945;-synuclein, establishing a central cascade in PD progression. This process unfolds through multiple mechanisms: first, impaired complex I function reduces ATP levels and elevates ROS production, which together inhibit the proteasome and the autophagy&#8211;lysosome system, thereby diminishing &#945;-synuclein clearance; second, oxidative stress promotes the oxidative modification of &#945;-synuclein, increasing its aggregation propensity; finally, mitochondrial dysfunction induces calcium dysregulation, and calcium overload enhances &#945;-synuclein binding to membranes, further accelerating its aggregation. This pathogenic cycle&#8212;"mitochondrial dysfunction &#8594; oxidative stress &#8594; protein aggregation&#8221;&#8212;constitutes the core of PD pathology, bearing similarities to that of AD, while maintaining disease-specific features [<xref rid="B125" ref-type="bibr">125</xref>,<xref rid="B126" ref-type="bibr">126</xref>].</p><p>Thus, it is crucial to emphasize the selectivity and specificity of mitochondrial dysfunction in PD. Unlike other neurodegenerative disorders, PD is characterized by a targeted deficiency in complex I, with other respiratory chain complexes largely unaffected. This region-specific damage pattern reflects the unique metabolic demands of dopaminergic neurons [<xref rid="B127" ref-type="bibr">127</xref>]. Recent studies indicate that the activation of PINK1 can enhance mitochondrial membrane potential to facilitate the process of mitophagy, and thereby prevent the accumulation of damaged mitochondria [<xref rid="B128" ref-type="bibr">128</xref>]. Moreover, mutations in <italic toggle="yes">PINK1</italic> and <italic toggle="yes">Parkin</italic>, genes linked to familial forms of PD, impair mitochondrial quality control mechanisms. Deficiencies in these proteins result in inadequate removal of damaged mitochondria, exacerbating mitochondrial dysfunction and illustrating the molecular basis of genetic susceptibility to PD. In-depth research into these mechanisms reveals the potential therapeutic target of PINK1 in NDDs [<xref rid="B129" ref-type="bibr">129</xref>].</p></sec><sec id="sec13"><title>Huntington&#8217;s disease</title><p>An autosomal dominant neurodegenerative disorder, HD, is caused by a CAG trinucleotide repeat expansion within the <italic toggle="yes">HTT</italic> gene. The condition is characterized by the selective degeneration and loss of medium spiny neurons within the striatum, accompanied by choreiform involuntary movements, cognitive impairments, and psychiatric manifestations. HD&#8217;s genetic profile constitutes a unique model for investigating the impact of mitochondrial dysfunction on NDDs [<xref rid="B130" ref-type="bibr">130</xref>]. The nature of mitochondrial dysfunction in HD is notable for its extensive severity, contrasting with the more localized damage observed in AD and PD. Patients with HD and animal models exhibit substantial structural and functional mitochondrial anomalies, as documented pathologically [<xref rid="B131" ref-type="bibr">131</xref>]. Swelling is observed in the mitochondria of striatal neurons in patients with HD, along with disrupted cristae and compromised membrane integrity. Functional impairments include a decrease in mitochondrial membrane potential, reduced ATP synthesis, diminished calcium buffering capacity, and increased production of ROS [<xref rid="B132" ref-type="bibr">132</xref>]. Patients with HD demonstrate reduced complex I activity, as well as marked reductions in complexes II, III, and IV, suggesting a broader impairment of the mitochondrial respiratory chain compared to that observed in PD. This widespread mitochondrial dysfunction highlights the complexity and severity of HD&#8217;s pathological processes [<xref rid="B133" ref-type="bibr">133</xref>].</p><p>The mHTT protein impairs mitochondrial function through multiple pathways, establishing the molecular foundation for HD progression. The primary disease mechanism involves mHTT binding to the outer mitochondrial membrane, increasing its permeability and promoting the release of cytochrome c, which leads to neuronal apoptosis [<xref rid="B134" ref-type="bibr">134</xref>]. Additionally, mHTT suppresses the expression and activity of PGC-1&#945;, a transcriptional co-activator essential for mitochondrial biogenesis and energy metabolism, thereby directly impairing mitochondrial regeneration and repair. Furthermore, mHTT affects mitochondrial dynamics by enhancing fission and inhibiting fusion, resulting in fragmentation of the mitochondrial network [<xref rid="B135" ref-type="bibr">135</xref>]. These combined molecular mechanisms exacerbate energy metabolism dysfunction in HD, leading to a systemic metabolic collapse from the molecular to the cellular level [<xref rid="B136" ref-type="bibr">136</xref>].</p><p>Distinctive features and clinical relevance are observed in HD&#8217;s energy metabolism due to its pathological basis. Evidence from PET scans and related imaging modalities reveals a significant reduction in glucose metabolism in patients with HD, particularly in the striatum and various cortical regions, reflecting the widespread nature of HD pathology. Notably, these metabolic abnormalities appear before clinical symptom onset and are detectable in asymptomatic gene carriers. Thus, disruptions in energy metabolism represent an early phase in HD progression, serving as a critical biomarker for early detection and therapeutic intervention [<xref rid="B137" ref-type="bibr">137</xref>]. Compared to AD and PD, HD displays earlier onset, a broader range, and more severe energy metabolism deficits, due to mHTT&#8217;s multiple direct deleterious effects on mitochondria [<xref rid="B138" ref-type="bibr">138</xref>] (Fig. <xref rid="F4" ref-type="fig">4</xref>)</p><fig position="float" id="F4" orientation="portrait"><label>Fig. 4.</label><caption><p>Differences in mitochondrial dysfunction among three NDDs. The upper part shows the electron transport process of normal mitochondrial respiratory chain complexes I to IV, which generates ATP through the oxidation of NADH and FADH<sub>2</sub> while producing a small amount of ROS. The 3 modules at the bottom display the specific pathological mechanisms of each disease: PD module (left): Dysfunction of Parkin leads to the aggregation of &#945;-synuclein forming Lewy bodies, primarily damaging complex I and causing mitochondrial dysfunction; HD module (middle): Mutant huntingtin (mHTT) directly impairs mitochondrial membrane integrity, and leads to the overall dysfunction of the entire respiratory chain complex; AD module (right): The aggregation of A&#946; and hyperphosphorylation of tau protein (P-tau) act synergistically, to primarily affect complex IV while interfering with PINK1/Parkin-mediated mitochondrial quality control. The flowchart at the bottom summarizes the common consequences of mitochondrial dysfunction: Normal neurons &#8594; Damaged mitochondria &#8594; Reduced ATP production &#8594; Neuronal degeneration. This figure highlights the differences in pathological proteins, damaged complexes, and molecular mechanisms among the 3 diseases.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="research.0912.fig.004.jpg"/></fig></sec></sec><sec id="sec14"><title>Mitochondrial Function and Glucose&#8211;Lipid Metabolism</title><p>The principal metabolic control hub, the mitochondria, sustains neuronal energy and glucose&#8211;lipid metabolic balance via complex signaling networks. In NDDs, dysfunction of key signaling pathways is associated with a direct reduction in mitochondrial energy production and subsequent impairment of the integration of the cellular metabolic network. The text delineates the pivotal functions of the AMPK/mTOR, PGC-1&#945;, and SIRT1 signaling pathways in modulating mitochondrial function and glucose&#8211;lipid metabolism, and their dysregulatory patterns and interregulatory dynamics in NDDs (Table <xref rid="T2" ref-type="table">2</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><p>Dysregulation of key signaling pathways in NDDs</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Signaling pathway</th><th align="left" rowspan="1" colspan="1">Physiological function</th><th align="left" rowspan="1" colspan="1">Pathological alterations</th><th align="left" rowspan="1" colspan="1">Downstream effects</th><th align="left" rowspan="1" colspan="1">Therapeutic strategies</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AMPK/mTOR</td><td align="left" rowspan="1" colspan="1">Energy sensing and metabolic homeostasis</td><td align="left" rowspan="1" colspan="1">&#8226; AMPK hypoactivation<break/>&#8226; mTOR hyperactivation<break/>&#8226; Homeostatic disruption</td><td align="left" rowspan="1" colspan="1">&#8226; Pathogenic protein aggregation<break/>&#8226; Mitophagy<break/>&#8226; Membrane lipid dyshomeostasis</td><td align="left" rowspan="1" colspan="1">&#8226; Metformin (AMPK activator)<break/>&#8226; Rapamycin (mTORC1 inhibitor)</td><td align="center" rowspan="1" colspan="1">[<xref rid="B139" ref-type="bibr">139</xref>,<xref rid="B141" ref-type="bibr">141</xref>,<xref rid="B142" ref-type="bibr">142</xref>,<xref rid="B146" ref-type="bibr">146</xref>,<xref rid="B176" ref-type="bibr">176</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PGC-1&#945;</td><td align="left" rowspan="1" colspan="1">Master regulators of mitochondrial biogenesis</td><td align="left" rowspan="1" colspan="1">&#8226; Significant down-regulation<break/>&#8226; Transcriptional impairment<break/>&#8226; Epigenetic dysregulation</td><td align="left" rowspan="1" colspan="1">&#8226; Mitochondrial depletion<break/>&#8226; Bioenergetic inefficiency<break/>&#8226; Antioxidant defense impairment</td><td align="left" rowspan="1" colspan="1">&#8226; NAD<sup>+</sup> precursor supplementation<break/>&#8226; SIRT1 activators<break/>&#8226; PGC-1&#945; upstream modulators</td><td align="center" rowspan="1" colspan="1">[<xref rid="B148" ref-type="bibr">148</xref>,<xref rid="B151" ref-type="bibr">151</xref>,<xref rid="B152" ref-type="bibr">152</xref>,<xref rid="B154" ref-type="bibr">154</xref>,<xref rid="B178" ref-type="bibr">178</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">SIRT1</td><td align="left" rowspan="1" colspan="1">NAD<sup>+</sup>-dependent deacetylases</td><td align="left" rowspan="1" colspan="1">&#8226; NAD<sup>+</sup> depletion<break/>&#8226; Enzymatic activity reduction<break/>&#8226; Metabolic regulatory failure</td><td align="left" rowspan="1" colspan="1">&#8226; Insulin resistance<break/>&#8226; Lipid homeostasis disruption<break/>&#8226; Cholesterol dysmetabolism</td><td align="left" rowspan="1" colspan="1">&#8226;NMN/NR therapy<break/>&#8226; Resveratrol analogs<break/>&#8226; Next-generation activators (e.g., SRT2104)</td><td align="center" rowspan="1" colspan="1">[<xref rid="B155" ref-type="bibr">155</xref>,<xref rid="B158" ref-type="bibr">158</xref>,<xref rid="B159" ref-type="bibr">159</xref>,<xref rid="B161" ref-type="bibr">161</xref>,<xref rid="B164" ref-type="bibr">164</xref>]</td></tr></tbody></table></table-wrap><sec id="sec15"><title>AMPK/MTOR pathway in mitochondrial metabolic dynamics</title><p>AMPK functions as the primary cellular energy sensor and is highly sensitive to subtle changes in the intracellular AMP/ATP ratio. Energy stress activates AMPK in cells, which subsequently alters metabolic pathways through various molecular mechanisms. AMPK promotes the activation of PGC-1&#945; by phosphorylating it at Thr177 and Ser538, leading to increased expression of NRF1/2 and Tfam, thereby enhancing mtDNA replication and protein synthesis [<xref rid="B139" ref-type="bibr">139</xref>]. This regulatory mechanism allows for the rapid up-regulation of mitochondrial quantity and function to meet metabolic demands during energy scarcity [<xref rid="B119" ref-type="bibr">119</xref>].</p><p>AMPK plays a crucial role in metabolic reprogramming within the glucose&#8211;lipid metabolic domain. Upon activation, AMPK facilitates glucose uptake by promoting GLUT4 translocation to the plasma membrane and inhibits fatty acid synthesis through ACC1 phosphorylation [<xref rid="B140" ref-type="bibr">140</xref>]. Moreover, it activates CPT1, thereby enhancing fatty acid oxidation. This metabolic adaptation optimizes energy substrate utilization and reduces energy-intensive biosynthetic processes during periods of energy stress. Notably, AMPK regulation is altered in neurodegenerative disorders [<xref rid="B141" ref-type="bibr">141</xref>]. Studies on AD models have shown a negative correlation between AMPK activity and A&#946; accumulation, suggesting that AMPK dysfunction may contribute to disease progression via disruptions in glucose and lipid metabolism [<xref rid="B142" ref-type="bibr">142</xref>]. Importantly, chronic stress can worsen the neuronal energy crisis by maintaining persistently high AMPK activity, which promotes excessive mitochondrial fission and autophagy, forming a detrimental cycle of &#8220;overcompensation and resultant functional failure&#8221; [<xref rid="B143" ref-type="bibr">143</xref>].</p><p>When AMPK is inactive, mTOR becomes the dominant regulator under energy-abundant conditions. It integrates signals from nutrient status, growth factors, and energy availability to govern cell growth, protein synthesis, and metabolic adaptation. mTORC1 activation promotes ribosome biogenesis and protein translation and also influences lipid metabolism by regulating SREBP-1c, a transcription factor central to lipid synthesis [<xref rid="B144" ref-type="bibr">144</xref>]. In addition, mTORC1 regulates the expression of TFAM and mitochondrial ribosomal proteins, which are critical for mitochondrial biogenesis and function [<xref rid="B145" ref-type="bibr">145</xref>].</p><p>A complex reciprocal inhibitory interaction exists between AMPK and mTOR. Under energy-deficient conditions, AMPK inhibits mTORC1 by phosphorylating TSC2 and Raptor, while inducing autophagy to eliminate damaged mitochondria. Conversely, in energy-rich conditions, mTOR signaling becomes active, suppressing AMPK activity and promoting anabolic metabolism and cell proliferation [<xref rid="B146" ref-type="bibr">146</xref>]. Neuronal metabolic homeostasis depends on maintaining this dynamic balance. In NDDs, persistent overactivation of the mTOR signaling pathway is a key pathological feature. Overactive mTOR contributes to the accumulation of abnormal proteins and impaired mitophagy, thereby exacerbating oxidative stress and energy imbalance. Additionally, aberrant mTOR activation alters neuronal membrane lipid composition and mitochondrial membrane dynamics, in part through regulation of SREBP1, affecting neurotransmission and synaptic plasticity [<xref rid="B147" ref-type="bibr">147</xref>].</p></sec><sec id="sec16"><title>PGC-1&#945; on mitochondrial energy metabolism</title><p>In the nervous system, PGC-1&#945;, as a master transcriptional coactivator, occupies a central position in energy metabolism regulation. PGC-1&#945;, in association with diverse transcription factors, forms complexes that modulate the transcription of mitochondrial genes, thereby facilitating the precise regulation of mitochondrial function [<xref rid="B148" ref-type="bibr">148</xref>].</p><p>PGC-1&#945;, interacting with NRF1/2, peroxisome proliferator-activated receptors (PPARs), and estrogen-related receptor alpha, forms a complex transcriptional regulatory network [<xref rid="B149" ref-type="bibr">149</xref>]. PGC-1&#945;&#8217;s multi-target regulatory mechanism facilitates the concurrent modulation of mtDNA replication, ETC complex assembly, TCA cycle enzyme expression, and antioxidant defense system formation. The expression level of PGC-1&#945; in neurons directly influences the quantity, morphology, and functional status of mitochondria, thereby modulating the neuron&#8217;s energy supply and oxidative stress resistance. PGC-1&#945; is pivotal in modulating energy substrate utilization. PGC-1&#945; achieves glucose metabolism&#8211;fatty acid oxidation balance through its interaction with the PPAR family. Typically, PGC-1&#945; fosters fatty acid oxidation gene expression and sustains glucose metabolism, supporting neural adaptation to energy substrates across various metabolic states [<xref rid="B150" ref-type="bibr">150</xref>]. The efficacy of neurons in managing fluctuations in energy demand and oxidative stress is underpinned by their metabolic flexibility. PGC-1&#945; expression decrement is a prevalent pathological hallmark in neurodegenerative disorders. The selective ablation of PGC-1&#945; in substantia nigra dopaminergic neurons triggers Parkinsonian mitochondrial dysfunction and neurodegeneration, emphasizing the necessity of PGC-1&#945; for neuronal survival [<xref rid="B151" ref-type="bibr">151</xref>]. AD model research has confirmed a strong association between decreased PGC-1&#945; expression and elevated mitochondrial fragmentation, reduced energy synthesis, and synaptic issues [<xref rid="B152" ref-type="bibr">152</xref>].</p><p>Apart from its direct regulation of mitochondrial biogenesis, PGC-1&#945; contributes to the preservation of the mitochondrial network&#8217;s dynamic equilibrium. PGC-1&#945; modulates the expression of the mitochondrial fusion proteins MFN1/2 and the fission protein DRP1, thereby affecting mitochondrial morphology and distribution within axons and dendrites [<xref rid="B153" ref-type="bibr">153</xref>]. In NDDs, PGC-1&#945; dysfunction contributes to a disturbance in mitochondrial dynamics, which impedes the delivery of mitochondria to high-energy-consuming regions, thereby exacerbating local energy deficits. Recent studies have illuminated PGC-1&#945;&#8217;s essential role in epigenetic regulation. PGC-1&#945; exerts control over the synergy of mitochondrial&#8211;nuclear gene expression through histone acetylation and noncoding RNA pathways, thereby achieving a refined control of the neuronal metabolic network [<xref rid="B154" ref-type="bibr">154</xref>]. The finding offers a fresh theoretical basis for the PGC-1&#945; signaling pathway as a therapeutic candidate in neurodegenerative disorders.</p></sec><sec id="sec17"><title>SIRT1 signaling on glucose&#8211;lipid homeostasis</title><p>By deacetylating PGC-1&#945; at sites, such as K13, K139, and K778, SIRT1 enhances its transcriptional activity, thereby establishing the SIRT1&#8211;PGC-1&#945; regulatory axis. This axis is critical for maintaining mitochondrial function and promoting mitochondrial biogenesis [<xref rid="B155" ref-type="bibr">155</xref>]. Concurrently, SIRT1 facilitates the selective removal of damaged mitochondria through the deacetylation and activation of the transcription factor FOXO3a, which induces the expression of mitophagy-related genes [<xref rid="B156" ref-type="bibr">156</xref>]. This dual regulatory mechanism ensures the coordinated increase in mitochondrial quantity and maintenance of mitochondrial quality.</p><p>Moreover, SIRT1 modulates the function of several metabolic enzymes via direct deacetylation. Enzymes such as acetyl-CoA synthetase and pyruvate dehydrogenase, which are integral to the TCA cycle, are regulated by SIRT1, thereby influencing the efficiency of mitochondrial energy metabolism [<xref rid="B157" ref-type="bibr">157</xref>]. Additionally, SIRT1 enhances insulin sensitivity through deacetylation of IRS-1, improving neuronal glucose utilization&#8212;a mechanism of particular relevance in NDDs characterized by insulin resistance, such as AD [<xref rid="B158" ref-type="bibr">158</xref>].</p><p>Moreover, SIRT1 exerts a dual role in lipid metabolism. It suppresses fatty acid synthesis by deacetylating SREBP-1c, thereby reducing intracellular lipid accumulation. Conversely, it promotes fatty acid oxidation through activation of PPAR&#945;, increasing lipid utilization for energy [<xref rid="B159" ref-type="bibr">159</xref>]. Regulation of lipid metabolism is essential for preserving myelin integrity and synaptic function in the nervous system. SIRT1 also plays a key role in maintaining neuronal cholesterol homeostasis, partly through regulation of CYP46A1, a mechanism linked to A&#946; production and tau phosphorylation [<xref rid="B160" ref-type="bibr">160</xref>]. These findings support a potential neuroprotective role for SIRT1 in the pathogenesis of AD.</p><p>NAD<sup>+</sup> precursors, such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), have demonstrated important neuroprotective effects by promoting the synthesis of intracellular NAD<sup>+</sup>, enhancing mitochondrial function, and reducing oxidative stress, and thereby protecting neurons from damage. These precursors can also regulate cellular metabolism and damage repair by activating deacetylases such as sirtuins [<xref rid="B161" ref-type="bibr">161</xref>]. Importantly, the ability of NMN and NR to penetrate the blood&#8211;brain barrier has made them the focus of research. NMN has been shown in in&#160;vitro studies to effectively cross the blood&#8211;brain barrier via specific transport proteins (such as Slc12a8) and has demonstrated a certain level of brain bioavailability in mouse models [<xref rid="B162" ref-type="bibr">162</xref>]. NR, on the other hand, is believed to enter brain tissue through simple diffusion. Once inside the brain, these precursors can replenish NAD<sup>+</sup> levels, to further enhance the neuroprotective effects. Recent studies have indicated that administering NMN or NR via oral or injection routes in animal models can increase brain NAD<sup>+</sup> levels, which contributed to the improvement of cognitive functions associated with NDDs [<xref rid="B163" ref-type="bibr">163</xref>].</p><p>As a NAD<sup>+</sup>-dependent enzyme, SIRT1 activity is tightly regulated by intracellular NAD<sup>+</sup> levels. With aging and disease progression, a gradual decline in NAD<sup>+</sup> levels leads to reduced SIRT1 activity, impairing mitochondrial function and energy metabolism [<xref rid="B159" ref-type="bibr">159</xref>]. The cascade&#8212;"NAD<sup>+</sup> reduction &#8594; decreased SIRT1 activity &#8594; mitochondrial dysfunction&#8221;&#8212;may represent a core pathogenic mechanism in aging-related NDDs. Supplementation with NAD<sup>+</sup> precursors, such as NMN and NR, reportedly enhances SIRT1 activity, improves mitochondrial function and metabolic status, and exerts neuroprotective effects in various NDD models [<xref rid="B164" ref-type="bibr">164</xref>]. These findings provide strong justification for therapeutic strategies targeting NAD<sup>+</sup> metabolism.</p></sec><sec id="sec18"><title>Synergistic mechanism of the three in lipid homeostasis</title><p>AMPK, PGC-1&#945;, and SIRT1 interact to maintain glucose and lipid homeostasis, forming a sophisticated integrated regulatory network. Their combined actions ensure the balance and coordination of cellular metabolism under different physiological states. Firstly, the interaction between AMPK activation and SIRT1 is crucial&#8212;AMPK is a key sensor of energy deficiency within cells. Its activation not only inhibits the mTOR signaling pathway to limit cell growth and anabolic metabolism but also enhances deacetylation by increasing SIRT1 expression. Activated SIRT1 further deacetylates PGC-1&#945;, enhancing its activity in promoting mitochondrial biogenesis and fatty acid oxidation [<xref rid="B165" ref-type="bibr">165</xref>]. Secondly, the functional enhancement of PGC-1&#945; and feedback regulation play important roles&#8212;enhanced PGC-1&#945; not only increases mitochondrial biogenic capacity but also effectively promotes fatty acid oxidation [<xref rid="B166" ref-type="bibr">166</xref>]. Furthermore, PGC-1&#945; can reduce the activity of the AMPK/mTOR pathway through a negative feedback mechanism, thereby regulating cellular metabolic processes and maintaining homeostasis under energy-sufficient conditions [<xref rid="B167" ref-type="bibr">167</xref>]. Lastly, SIRT1&#8217;s regulatory role on AMPK&#8211;SIRT1 enhances AMPK activity through deacetylation. This process aids in strengthening the cellular regulation of glucose and lipid metabolism during energy deficiency, which ensures that cells can timely respond to environmental changes and adjust their metabolic state [<xref rid="B158" ref-type="bibr">158</xref>].</p><p>In summary, the synergistic interaction among AMPK, PGC-1&#945;, and SIRT1 plays an important role in promoting energy metabolism. This interconnection not only effectively regulates the energy balance within cells but also plays a crucial role in responding to metabolic stress conditions, and provides new directions and targets for the potential treatment of metabolic-related diseases (Fig. <xref rid="F5" ref-type="fig">5</xref>).</p><fig position="float" id="F5" orientation="portrait"><label>Fig. 5.</label><caption><p>The synergistic regulation of AMPK/mTOR, PGC-1&#945;, and SIRT1 in neuronal mitochondrial and glucose&#8211;lipid metabolism. The top panel displays neurons and their microenvironment, where GLUT4 and CPT1 on the neuronal membrane mediate the uptake of glucose and fatty acids. The intracellular signaling network is centered around the dynamic balance between AMPK and mTORC1: AMPK activation promotes GLUT4 translocation and fatty acid oxidation but inhibits lipid synthesis and suppresses mTORC1 activity; in contrast, under nutrient-rich conditions, the mTORC1 complex is activated and promotes lipid synthesis via SREBP-1c, which, in turn, feedback-inhibits AMPK. PGC-1&#945; receives dual activation through AMPK phosphorylation and SIRT1 deacetylation, and coordinates mitochondrial biogenesis and mitochondrial dynamics. SIRT1 can be activated by NMN/NR precursors, which not only activate PGC-1&#945; but also promote mitochondrial autophagy through FOXO3a activation, inhibit SREBP-1c, and activate transcription factors such as PPAR&#945;. The <italic toggle="yes">PPARGC1A</italic> gene in the nucleus encodes the PGC-1&#945; protein, forming a transcriptional regulatory feedback loop. The NDDS module (to the left) indicates that the imbalance of this regulatory network is associated with disease occurrence, where excessive AMPK activation leads to abnormal mitochondrial fission, excessive mTORC1 activation inhibits autophagy and promotes abnormal protein aggregation, and the decline in PGC-1&#945; expression reduces SIRT1 activity and collectively exacerbates mitochondrial dysfunction.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="research.0912.fig.005.jpg"/></fig></sec></sec><sec id="sec19"><title>Exploring Therapeutic Strategies Targeting the Multi-Organelle MMH Network</title><sec id="sec20"><title>Regulation of mitochondrial metabolism by organelle interactions</title><p>Mitochondria do not operate in isolation; instead, they form close functional contact sites with various membranous organelles within the cell, constituting a complex interaction network. These interactions profoundly influence mitochondrial metabolic activities, thereby regulating glucose and lipid homeostasis within neurons. Firstly, the endoplasmic reticulum&#8211;mitochondria contact sites (MAMs) are dynamic structures that physically connect the endoplasmic reticulum to the outer membrane of mitochondria, to serve as critical hubs for lipid synthesis and transport, as well as Ca<sup>2+</sup> signaling. The ER directly provides phospholipid precursors and Ca<sup>2+</sup> to mitochondria through MAMs, which affects the lipid composition and membrane fluidity of mitochondrial membranes, which, in turn, regulates the activity of embedded metabolic enzymes and the morphology of mitochondrial cristae, driving glucose OXPHOS [<xref rid="B16" ref-type="bibr">16</xref>]. In AD, amyloid precursor protein (APP) and presenilin (PSEN) mutants abnormally accumulate in MAMs and thereby disrupt Ca<sup>2+</sup> homeostasis and lipid transfer to promote neurotoxic A&#946; generation [<xref rid="B168" ref-type="bibr">168</xref>]. Additionally, the accumulation of ceramide in MAMs can induce the opening of the mPTP, triggering apoptosis [<xref rid="B169" ref-type="bibr">169</xref>]. Secondly, lysosomes act as degradation centers that selectively remove damaged mitochondria through mitophagy, maintaining mitochondrial quality. Moreover, lysosomes are also involved in nutrient sensing and the release of metabolites (e.g., amino acids and cholesterol), among which the fatty acids derived from lipid droplets (LDs) are important substrates for mitochondrial &#946;-oxidation [<xref rid="B170" ref-type="bibr">170</xref>]. Impaired lysosomal function in NDDs leads to the accumulation of LDs (increased neuronal lipofuscin) whereas limiting the availability of free fatty acids for mitochondria, and thus affecting energy supply and lipid homeostasis. Peroxisomes are responsible for initiating the &#946;-oxidation of very long-chain fatty acids (VLCFAs), which results in the production of shorter-chain fatty acids that can be transported to the mitochondria for complete oxidation and energy production. Both processes share certain oxidative enzyme systems and cofactors [<xref rid="B171" ref-type="bibr">171</xref>]. Dysfunction of peroxisomes can lead to the accumulation of VLCFAs, which not only exhibits direct neurotoxicity but also competitively inhibits the &#946;-oxidation of long-chain fatty acids in the mitochondria, reducing acetyl-CoA generation and ATP production. Additionally, the accumulation of VLCFAs impairs membrane fluidity and affects the functionality of mitochondrial membrane proteins. ROS generated by peroxisomes may also diffuse to adjacent mitochondria, exacerbating oxidative stress [<xref rid="B172" ref-type="bibr">172</xref>].</p><p>In summary, the collapse of neuronal glycosyl-lipid homeostasis in NDDs is not caused by a single organelle but rather results from the disruption of a multi-organelle interaction network and the imbalance of mitochondrial dynamics. Therefore, restoring the coordinated interaction between organelles and the healthy dynamics of the mitochondrial network is a key strategy for restoring glycosyl-lipid homeostasis and protecting neurons. The mitochondrial&#8211;energy metabolism&#8211;glycosyl&#8211;lipid homeostasis network is crucial for regulating &#8220;multi-organelle interactions&#8221; and &#8220;mitochondrial dynamics&#8221;. It is important to clarify that the MMH network is not isolated; it encompasses multiple organelles and various dynamic regulatory networks, influencing the interactions among multiple organelles and the processes of mitochondrial dynamics. However, the regulatory mechanisms of interactions among multi-organelles and the relationship between dynamic changes in mitochondrial morphology and function merit further investigation. This will be a key focus of future research.</p></sec><sec id="sec21"><title>Transition from molecular insights to therapeutic concepts</title><p>NDDs essentially manifest as a gradual loss of metabolic networks, rather than merely energy deficiency or specific protein abnormalities [<xref rid="B173" ref-type="bibr">173</xref>]. Traditional treatment strategies primarily focus on symptom control and intervention at single pathological points, resulting in limited clinical efficacy [<xref rid="B174" ref-type="bibr">174</xref>]. Based on the molecular mechanism analysis of signaling pathways and multi-organelle interactions, the MMH network theory provides a systematic framework for identifying therapeutic targets in NDDs. Treatment strategies should shift from &#8220;target-specific interventions&#8221; to &#8220;reconstruction of metabolic network functionality&#8221;, restoring the overall coordination and adaptability of cellular metabolic networks by modulating multiple interconnected molecular pathways and organelles. Among these, restoring metabolic sensing capacity is more important than merely supplementing energy substrates, and maintaining network stability takes higher priority than correcting local defects [<xref rid="B175" ref-type="bibr">175</xref>]. However, the translation from basic research to clinical application still faces numerous challenges, necessitating the establishment of rigorous translational medicine strategies. Current clinical evidence indicates that AMPK activators, such as metformin, exhibit good safety profiles; however, their specific efficacy in NDDs still requires validation through large-scale clinical trials [<xref rid="B176" ref-type="bibr">176</xref>,<xref rid="B177" ref-type="bibr">177</xref>]. In contrast, upstream regulators of PGC-1&#945; are more targeted, yet data on long-term safety and efficacy remain limited, necessitating cautious evaluation [<xref rid="B178" ref-type="bibr">178</xref>]. Furthermore, the treatment of NDDs faces challenges related to blood&#8211;brain barrier permeability, and the bioavailability and targeting efficiency of certain compounds such as NMN and NR still need optimization. Multi-target intervention strategies aimed at reshaping metabolic network functions present unprecedented challenges but also offer new possibilities for disease-modifying therapies.</p><p>Furthermore, the metabolic biomarkers associated with MMH have not yet been standardized, which limits the accuracy of efficacy assessments in clinical trials. There is still a need to establish standardized mitochondrial function testing methods, metabolic flexibility assessment indicators, and dynamic monitoring parameters to reflect changes in cellular metabolic status in real time and predict disease progression, such as variations in mitochondrial respiratory reserve capacity and the dynamic changes in the ATP/ADP ratio [<xref rid="B161" ref-type="bibr">161</xref>]. The development of real-time functional monitoring technologies has provided new possibilities for the dynamic assessment of treatment effects. Such technologies refer to detection methods that can continuously and noninvasively monitor metabolic functional states at the organism or cellular level, including real-time imaging of mitochondrial function based on fluorescent probes and metabolic flux analysis. The hippocampal metabolic analyzer combined with a fluorescent reporting system can dynamically monitor metabolic flux, facilitating timely adjustments and optimizations of treatment protocols [<xref rid="B179" ref-type="bibr">179</xref>]. However, the clinical translation of these technologies still faces practical issues such as cost control, simplification of operations, and data standardization [<xref rid="B180" ref-type="bibr">180</xref>]. Integrating the multi-omics analysis processes of metabolomics, proteomics, and transcriptomics can achieve a comprehensive assessment of the MMH network, but the complexity of the technology and high costs limit its widespread application [<xref rid="B181" ref-type="bibr">181</xref>,<xref rid="B182" ref-type="bibr">182</xref>] (Table <xref rid="T3" ref-type="table">3</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3.</label><caption><p>MMH network-related biomarkers and detection methods</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Category</th><th align="left" rowspan="1" colspan="1">Specific indicators</th><th align="left" rowspan="1" colspan="1">Detection methods</th><th align="left" rowspan="1" colspan="1">Clinical significance</th><th align="left" rowspan="1" colspan="1">Standardization status</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mitochondrial function</td><td align="left" rowspan="1" colspan="1">&#8226; ATP/ADP ratio<break/>&#8226; Respiratory reserve capacity<break/>&#8226; Membrane potential dynamics</td><td align="left" rowspan="1" colspan="1">&#8226; Hippocampal metabolic profiling<break/>&#8226; Fluorescent probe imaging<break/>&#8226; Flow cytometry</td><td align="left" rowspan="1" colspan="1">Early disease diagnosis and therapeutic efficacy monitoring</td><td align="left" rowspan="1" colspan="1">Requiring standardization</td><td align="center" rowspan="1" colspan="1">[<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B179" ref-type="bibr">179</xref>,<xref rid="B180" ref-type="bibr">180</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Metabolomics</td><td align="left" rowspan="1" colspan="1">&#8226; Ceramide species (C18:0/C24:0)<break/>&#8226; Long-chain acylcarnitines<break/>&#8226; TCA cycle Intermediates</td><td align="left" rowspan="1" colspan="1">&#8226; LC-MS/MS<break/>&#8226; GC-MS<break/>&#8226; NMR</td><td align="left" rowspan="1" colspan="1">Metabolic subtyping and progression risk stratification</td><td align="left" rowspan="1" colspan="1">Partially standardized</td><td align="center" rowspan="1" colspan="1">[<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B70" ref-type="bibr">70</xref>,<xref rid="B86" ref-type="bibr">86</xref>,<xref rid="B181" ref-type="bibr">181</xref>,<xref rid="B182" ref-type="bibr">182</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Inflammatory markers</td><td align="left" rowspan="1" colspan="1">&#8226; TNF-&#945;, IL-1&#946;, and IL-6<break/>&#8226; DAMPs (mtDNA and ATP)<break/>&#8226; Lipid peroxidation by-products</td><td align="left" rowspan="1" colspan="1">&#8226; ELISA<break/>&#8226; Multiplex immunoassay<break/>&#8226; Oxidative stress assessment</td><td align="left" rowspan="1" colspan="1">Inflammatory activity quantification and treatment response evaluation</td><td align="left" rowspan="1" colspan="1">Relatively mature</td><td align="center" rowspan="1" colspan="1">[<xref rid="B77" ref-type="bibr">77</xref>,<xref rid="B90" ref-type="bibr">90</xref>,<xref rid="B95" ref-type="bibr">95</xref>&#8211;<xref rid="B97" ref-type="bibr">97</xref>]</td></tr></tbody></table></table-wrap></sec><sec id="sec22"><title>Stratified therapeutic approach</title><p>Treatment strategies based on the MMH network theory must take into account the metabolic phenotypic differences among patients when developing individualized diagnostic tools and treatment plans. For early-stage patients with relatively preserved metabolic reserves, NAD<sup>+</sup> precursors (e.g., NMN and NR) and AMPK activators (e.g., metformin) may have neuroprotective effects, but the optimal dosage, administration route, and treatment window still need to be confirmed through large-scale randomized controlled trials [<xref rid="B183" ref-type="bibr">183</xref>,<xref rid="B184" ref-type="bibr">184</xref>]. The primary goal at this stage is to maintain the existing metabolic flexibility, which is the ability of cells to switch between different metabolic pathways in response to environmental changes and energy demands, and thereby delay further decline in network function. Minocycline not only inhibits the activation of M1 microglia but also preserves the beneficial functions of M2 cells, while demonstrating good blood&#8211;brain barrier permeability and established safety [<xref rid="B185" ref-type="bibr">185</xref>]. Modified curcumin formulations target the NF-&#954;B signaling pathway through a liposomal delivery system that effectively enhances drug bioavailability [<xref rid="B186" ref-type="bibr">186</xref>]. For mid-term patients with impaired metabolic function, more targeted and diverse therapeutic strategies are required, such as mTOR modulators like rapamycin analogs and mitochondrial-targeted antioxidants like SS-31 [<xref rid="B187" ref-type="bibr">187</xref>]. These agents demonstrate theoretical potential in improving mitochondrial function and providing neuroprotection; however, their safety and long-term efficacy need further evaluation. Diversification of metabolic substrates through supplementation of ketone bodies such as beta-hydroxybutyrate and medium-chain triglyceride oil provides alternative energy sources, reducing neuronal dependence on glucose during metabolic stress [<xref rid="B188" ref-type="bibr">188</xref>]. This approach may hold particular importance in phenotypes with metabolic transition disorders. When the disease progresses to late-stage multi-organ failure, the primary treatment goal is to maintain existing functions and improve quality of life. Supportive care and palliative treatment may be more realistic than aggressive disease treatment. Antioxidants and anti-inflammatory drugs targeting mitochondria may provide some symptomatic relief; however, their impact on disease progression is limited [<xref rid="B189" ref-type="bibr">189</xref>].</p></sec><sec id="sec23"><title>Conclusion and future perspectives</title><p>The complexity of NDDs dictates that no single theoretical framework can fully explain all pathological phenomena. However, we believe that the loss of metabolic network flexibility is central to NDDs and that the dysregulation of glucose and lipid metabolism is not caused by a single organelle or a single target pathway, but rather by the disruption of a multi-organelle interaction network. These interactions profoundly influence mitochondrial metabolic activities and thereby regulate glucose and lipid homeostasis within neurons. Therefore, we propose a mitochondria-centered multi-organelle&#8211;energy metabolic&#8211;glucose and lipid disorder network, which is crucial for regulating &#8220;multi-organelle interactions&#8221; and &#8220;mitochondrial dynamics&#8221;. However, it is noteworthy that the regulatory mechanisms of multi-organelle interactions, the relationship between the dynamic changes in mitochondrial morphology and function, and the specific role of the MMH network within this context require further in-depth investigation. These aspects will be a key focus of future research. Additionally, it must be clarified that there is an important gap between the proposed theoretical framework and its clinical application. Currently, the therapeutic theory that targets the MMH network is primarily based on research evidence from cellular and animal models, and its applicability and efficacy in human diseases still require extensive clinical research validation.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>We appreciate Figdraw (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.figdraw.com" ext-link-type="uri">www.figdraw.com</ext-link>) and BioRender (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.biorender.com/" ext-link-type="uri">https://www.biorender.com/</ext-link>) for their assistance in drawing.</p><p><bold>Funding:</bold> This study received financial support from the Hunan Provincial Respiratory Disease Rehabilitation and Nursing Engineering Research Center Innovation Capacity Building Project (No. 202012), the Zhangjiajie Science and Technology Development Key Special Project (No. 202304), and the National Key Clinical Specialty Major Scientific Research Project (No. 20230382).</p><p><bold>Author contributions:</bold> J.H. and C.Z. served as co-first authors, responsible for the overall framework design of the review, core theoretical construction, and comprehensive manuscript coordination. C.H. and W.G. led the writing of the &#8220;Mitochondrial Function and Glucose&#8211;Lipid Metabolism&#8221; and &#8220;Exploring Therapeutic Strategies Targeting the Multi-Organelle MMH Network&#8221; sections. Y.X. and K.D. were responsible for figure and table design. M.W. and M.L. served as co-corresponding authors, providing guidance on research direction and revising the academic content throughout the manuscript. All authors participated collectively in manuscript revision, content validation, and final approval of the published version.</p><p content-type="COI-statement"><bold>Competing interests:</bold> The authors declare that they have no competing interests.</p></ack><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Blennow</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Breteler</surname><given-names>MMB</given-names></string-name>, <string-name name-style="western"><surname>de Strooper</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Frisoni</surname><given-names>GB</given-names></string-name>, <string-name name-style="western"><surname>Salloway</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>van der Flier</surname><given-names>WM</given-names></string-name></person-group>. 
<article-title>Alzheimer&#8217;s disease</article-title>. <source>Lancet</source>. <year>2016</year>;<volume>388</volume>(<issue>10043</issue>):<fpage>505</fpage>&#8211;<lpage>517</lpage>.<pub-id pub-id-type="pmid">26921134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(15)01124-1</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><collab>GBD 2019 Dementia Forecasting Collaborators</collab>. 
<article-title>Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the global burden of disease study 2019</article-title>. <source>Lancet Public Health</source>. <year>2022</year>;<volume>7</volume>(<issue>2</issue>):<fpage>E105</fpage>&#8211;<lpage>E125</lpage>.<pub-id pub-id-type="pmid">34998485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-2667(21)00249-8</pub-id><pub-id pub-id-type="pmcid">PMC8810394</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Henstridge</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Hyman</surname><given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Spires-Jones</surname><given-names>TL</given-names></string-name></person-group>. 
<article-title>Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis</article-title>. <source>Nat Rev Neurosci</source>. <year>2019</year>;<volume>20</volume>(<issue>2</issue>):<fpage>94</fpage>&#8211;<lpage>108</lpage>.<pub-id pub-id-type="pmid">30643230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41583-018-0113-1</pub-id><pub-id pub-id-type="pmcid">PMC6545070</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wolfson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gauvin</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Ishola</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Oskoui</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>Global prevalence and incidence of amyotrophic lateral sclerosis: A systematic review</article-title>. <source>Neurology</source>. <year>2023</year>;<volume>101</volume>(<issue>6</issue>):<fpage>E613</fpage>&#8211;<lpage>E623</lpage>.<pub-id pub-id-type="pmid">37308302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000207474</pub-id><pub-id pub-id-type="pmcid">PMC10424837</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hering</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bussiere</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Glajch</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Weihofen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Grogan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Walsh</surname><given-names>DM</given-names></string-name></person-group>. 
<article-title>A manifesto for Alzheimer&#8217;s disease drug discovery in the era of disease-modifying therapies</article-title>. <source>Mol Neurodegener</source>. <year>2025</year>;<volume>20</volume>(<issue>1</issue>):<fpage>88</fpage>.<pub-id pub-id-type="pmid">40770764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-025-00872-7</pub-id><pub-id pub-id-type="pmcid">PMC12326716</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kunkle</surname><given-names>BW</given-names></string-name>, <string-name name-style="western"><surname>Grenier-Boley</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sims</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bis</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Damotte</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Naj</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Boland</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vronskaya</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><prefix>vander</prefix><surname>Lee</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Amlie-Wolf</surname><given-names>A</given-names></string-name></person-group>, 
<article-title>Genetic meta-analysis of diagnosed Alzheimer&#8217;s disease identifies new risk loci and implicates a&#946;, tau, immunity and lipid processing</article-title>. <source>Nat Genet</source><year>2019</year>;<volume>51</volume>(<issue>3</issue>):<fpage>414</fpage>&#8211;<lpage>430</lpage>.<pub-id pub-id-type="pmid">30820047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-019-0358-2</pub-id><pub-id pub-id-type="pmcid">PMC6463297</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abolhassani</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Leon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sheng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Oka</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hamasaki</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Iwaki</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Nakabeppu</surname><given-names>Y</given-names></string-name></person-group>. 
<article-title>Molecular pathophysiology of impaired glucose metabolism, mitochondrial dysfunction, and oxidative Dna damage in Alzheimer&#8217;s disease brain</article-title>. <source>Mech Ageing Dev</source>. <year>2017</year>;<volume>161</volume>(<issue>Pt A</issue>):<fpage>95</fpage>&#8211;<lpage>104</lpage>.<pub-id pub-id-type="pmid">27233446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mad.2016.05.005</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tresse</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Marturia-Navarro</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sew</surname><given-names>WQG</given-names></string-name>, <string-name name-style="western"><surname>Cisquella-Serra</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jaberi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Riera-Ponsati</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fauerby</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kretz</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Aznar</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Mitochondrial DNA damage triggers spread of Parkinson&#8217;s disease-like pathology</article-title>. <source>Mol Psychiatry</source>. <year>2023</year>;<volume>28</volume>(<issue>11</issue>):<fpage>4902</fpage>&#8211;<lpage>4914</lpage>.<pub-id pub-id-type="pmid">37779111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-023-02251-4</pub-id><pub-id pub-id-type="pmcid">PMC10914608</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Poewe</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Seppi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tanner</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Halliday</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Brundin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Volkmann</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schrag</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Lang</surname><given-names>AE</given-names></string-name></person-group>. 
<article-title>Parkinson disease</article-title>. <source>Nat Rev Dis Primers</source>. <year>2017</year>;<volume>3</volume>:<fpage>17013</fpage>.<pub-id pub-id-type="pmid">28332488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrdp.2017.13</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Misgeld</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tl</surname><given-names>S</given-names></string-name></person-group>. 
<article-title>Mitostasis in neurons: Maintaining mitochondria in an extended cellular architecture</article-title>. <source>Neuron</source>. <year>2017</year>;<volume>96</volume>(<issue>3</issue>):<fpage>651</fpage>&#8211;<lpage>666</lpage>.<pub-id pub-id-type="pmid">29096078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2017.09.055</pub-id><pub-id pub-id-type="pmcid">PMC5687842</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Janikiewicz</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Szyma&#324;ski</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Malinska</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Patalas-Krawczyk</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Michalska</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Duszy&#324;ski</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Giorgi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bonora</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dobrzyn</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wieckowski</surname><given-names>MR</given-names></string-name></person-group>. 
<article-title>Mitochondria-associated membranes in aging and senescence: Structure, function, and dynamics</article-title>. <source>Cell Death Dis</source>. <year>2018</year>;<volume>9</volume>(<issue>3</issue>):<fpage>332</fpage>.<pub-id pub-id-type="pmid">29491385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-017-0105-5</pub-id><pub-id pub-id-type="pmcid">PMC5832430</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Park</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Choe</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>MO</given-names></string-name></person-group>. 
<article-title>Neuroprotective effects of osmotin in Parkinson&#8217;s disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways</article-title>. <source>J Biomed Sci</source>. <year>2023</year>;<volume>30</volume>(<issue>1</issue>):<fpage>66</fpage>.<pub-id pub-id-type="pmid">37568205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12929-023-00961-z</pub-id><pub-id pub-id-type="pmcid">PMC10422754</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cunnane</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Trushina</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Morland</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Prigione</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Casadesus</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Andrews</surname><given-names>ZB</given-names></string-name>, <string-name name-style="western"><surname>Beal</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Bergersen</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Brinton</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>de la Monte</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Brain energy rescue: An emerging therapeutic concept for neurodegenerative disorders of ageing</article-title>. <source>Nat Rev Drug Discov</source>. <year>2020</year>;<volume>19</volume>(<issue>9</issue>):<fpage>609</fpage>&#8211;<lpage>633</lpage>.<pub-id pub-id-type="pmid">32709961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-020-0072-x</pub-id><pub-id pub-id-type="pmcid">PMC7948516</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Butterfield</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Halliwell</surname><given-names>B</given-names></string-name></person-group>. 
<article-title>Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease</article-title>. <source>Nat Rev Neurosci</source>. <year>2019</year>;<volume>20</volume>(<issue>3</issue>):<fpage>148</fpage>&#8211;<lpage>160</lpage>.<pub-id pub-id-type="pmid">30737462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41583-019-0132-6</pub-id><pub-id pub-id-type="pmcid">PMC9382875</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Henrich</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Oertel</surname><given-names>WH</given-names></string-name>, <string-name name-style="western"><surname>Surmeier</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Geibl</surname><given-names>FF</given-names></string-name></person-group>. 
<article-title>Mitochondrial dysfunction in Parkinson&#8217;s disease&#8212;A key disease hallmark with therapeutic potential</article-title>. <source>Mol Neurodegener</source>. <year>2023</year>;<volume>18</volume>(<issue>1</issue>):<fpage>83</fpage>.<pub-id pub-id-type="pmid">37951933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-023-00676-7</pub-id><pub-id pub-id-type="pmcid">PMC10640762</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>WB</given-names></string-name>, <string-name name-style="western"><surname>Sheng</surname><given-names>R</given-names></string-name></person-group>. 
<article-title>The correlation between mitochondria-associated endoplasmic reticulum membranes (MAMs) and Ca<sup>2+</sup> transport in the pathogenesis of diseases</article-title>. <source>Acta Pharmacol Sin</source>. <year>2025</year>;<volume>46</volume>(<issue>2</issue>):<fpage>271</fpage>&#8211;<lpage>291</lpage>.<pub-id pub-id-type="pmid">39117969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41401-024-01359-9</pub-id><pub-id pub-id-type="pmcid">PMC11756407</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spinelli</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Haigis</surname><given-names>MC</given-names></string-name></person-group>. 
<article-title>The multifaceted contributions of mitochondria to cellular metabolism</article-title>. <source>Nat Cell Biol</source>. <year>2018</year>;<volume>20</volume>(<issue>7</issue>):<fpage>745</fpage>&#8211;<lpage>754</lpage>.<pub-id pub-id-type="pmid">29950572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41556-018-0124-1</pub-id><pub-id pub-id-type="pmcid">PMC6541229</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chan</surname><given-names>DC</given-names></string-name></person-group>. 
<article-title>Mitochondrial dynamics and its involvement in disease</article-title>. <source>Annu Rev Pathol</source>. <year>2020</year>;<volume>15</volume>:<fpage>235</fpage>&#8211;<lpage>259</lpage>.<pub-id pub-id-type="pmid">31585519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-pathmechdis-012419-032711</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Daumke</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Van Der Laan</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>Molecular machineries shaping the mitochondrial inner membrane</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2025</year>;<volume>26</volume>:<fpage>706</fpage>&#8211;<lpage>724</lpage>.<pub-id pub-id-type="pmid">40369159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-025-00854-z</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brown</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Westendorp</surname><given-names>MSS</given-names></string-name>, <string-name name-style="western"><surname>Zarmiento-Garcia</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Stevens</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Bruininks</surname><given-names>BMH</given-names></string-name>, <string-name name-style="western"><surname>Rouse</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Marrink</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Wassenaar</surname><given-names>TA</given-names></string-name></person-group>. 
<article-title>An integrative modelling approach to the mitochondrial cristae</article-title>. <source>Commun Biol</source>. <year>2025</year>;<volume>8</volume>(<issue>1</issue>):<fpage>972</fpage>.<pub-id pub-id-type="pmid">40596661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-025-08381-5</pub-id><pub-id pub-id-type="pmcid">PMC12216777</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kawano</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Bazila</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Je&#382;ek</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dlaskov&#225;</surname><given-names>A</given-names></string-name></person-group>. 
<article-title>Mitochondrial dynamics and cristae shape changes during metabolic reprogramming</article-title>. <source>Antioxid Redox Signal</source>. <year>2023</year>;<volume>39</volume>(<issue>10&#8211;12</issue>):<fpage>684</fpage>&#8211;<lpage>707</lpage>.<pub-id pub-id-type="pmid">37212238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/ars.2023.0268</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>H</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Mitochondrial quality control mechanisms as molecular targets in diabetic heart</article-title>. <source>Metabolism</source>. <year>2022</year>;<volume>137</volume>:
<elocation-id>Article 155313</elocation-id>.<pub-id pub-id-type="pmid">36126721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.metabol.2022.155313</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kleele</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rey</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Winter</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zaganelli</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mahecic</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Perreten Lambert</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ruberto</surname><given-names>FP</given-names></string-name>, <string-name name-style="western"><surname>Nemir</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wai</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pedrazzini</surname><given-names>T</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Distinct fission signatures predict mitochondrial degradation or biogenesis</article-title>. <source>Nature</source>. <year>2021</year>;<volume>593</volume>(<issue>7859</issue>):<fpage>435</fpage>&#8211;<lpage>439</lpage>.<pub-id pub-id-type="pmid">33953403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03510-6</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cicali</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Torres</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Tapia-Rojas</surname><given-names>C</given-names></string-name></person-group>. 
<article-title>Synaptic mitochondria in aging and neurodegenerative diseases: Unraveling their functional decline and vulnerability</article-title>. <source>Neural Regen Res</source>. <year>2025</year>; <comment>10.4103/NRR.NRR-D-24-01571</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/NRR.NRR-D-24-01571</pub-id><pub-id pub-id-type="pmid">40536922</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peggion</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cal&#236;</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Brini</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>Mitochondria dysfunction and neuroinflammation in neurodegeneration: Who comes first?</article-title><source>Antioxidants</source>. <year>2024</year>;<volume>13</volume>(<issue>2</issue>):<fpage>240</fpage>.<pub-id pub-id-type="pmid">38397838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox13020240</pub-id><pub-id pub-id-type="pmcid">PMC10885966</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>X</given-names></string-name></person-group>. 
<article-title>Mitochondrial quality control disorder in neurodegenerative disorders: Potential and advantages of traditional Chinese medicines</article-title>. <source>J Pharm Anal</source>. <year>2025</year>;<volume>15</volume>(<issue>4</issue>):
<elocation-id>Article 101146</elocation-id>.<pub-id pub-id-type="pmid">40291018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpha.2024.101146</pub-id><pub-id pub-id-type="pmcid">PMC12032916</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Joshi</surname><given-names>AU</given-names></string-name>, <string-name name-style="western"><surname>Minhas</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Liddelow</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Haileselassie</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Andreasson</surname><given-names>KI</given-names></string-name>, <string-name name-style="western"><surname>Dorn</surname><given-names>GW</given-names><suffix>II</suffix></string-name>, <string-name name-style="western"><surname>Mochly-Rosen</surname><given-names>D</given-names></string-name></person-group>. 
<article-title>Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration</article-title>. <source>Nat Neurosci</source>. <year>2019</year>;<volume>22</volume>(<issue>10</issue>):<fpage>1635</fpage>&#8211;<lpage>1648</lpage>.<pub-id pub-id-type="pmid">31551592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-019-0486-0</pub-id><pub-id pub-id-type="pmcid">PMC6764589</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Al Amir Dache</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ar</surname><given-names>T</given-names></string-name></person-group>. 
<article-title>Mitochondria-derived cell-to-cell communication</article-title>. <source>Cell Rep</source>. <year>2023</year>;<volume>42</volume>(<issue>7</issue>):
<elocation-id>Article 112728</elocation-id>.<pub-id pub-id-type="pmid">37440408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2023.112728</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sheng</surname><given-names>Z</given-names></string-name></person-group>. 
<article-title>Energy matters: Presynaptic metabolism and the maintenance of synaptic transmission</article-title>. <source>Nat Rev Neurosci</source>. <year>2022</year>;<volume>23</volume>(<issue>1</issue>):<fpage>4</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">34782781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41583-021-00535-8</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vercellino</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Sazanov</surname><given-names>LA</given-names></string-name></person-group>. 
<article-title>The assembly, regulation and function of the mitochondrial respiratory chain</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2022</year>;<volume>23</volume>(<issue>2</issue>):<fpage>141</fpage>&#8211;<lpage>161</lpage>.<pub-id pub-id-type="pmid">34621061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-021-00415-0</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kathiresan</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Balasubramani</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Marudhachalam</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jaiswal</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ramesh</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sureshbabu</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Puthamohan</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Vijayan</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>Role of mitochondrial dysfunctions in neurodegenerative disorders: Advances in mitochondrial biology</article-title>. <source>Mol Neurobiol</source>. <year>2025</year>;<volume>62</volume>(<issue>6</issue>):<fpage>6827</fpage>&#8211;<lpage>6855</lpage>.<pub-id pub-id-type="pmid">39269547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-024-04469-x</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sies</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Belousov</surname><given-names>VV</given-names></string-name>, <string-name name-style="western"><surname>Chandel</surname><given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Mann</surname><given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Winterbourn</surname><given-names>C</given-names></string-name></person-group>. 
<article-title>Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2022</year>;<volume>23</volume>(<issue>7</issue>):<fpage>499</fpage>&#8211;<lpage>515</lpage>.<pub-id pub-id-type="pmid">35190722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-022-00456-z</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mittler</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zandalinas</surname><given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Fichman</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Van Breusegem</surname><given-names>F</given-names></string-name></person-group>. 
<article-title>Reactive oxygen species signalling in plant stress responses</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2022</year>;<volume>23</volume>(<issue>10</issue>):<fpage>663</fpage>&#8211;<lpage>679</lpage>.<pub-id pub-id-type="pmid">35760900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-022-00499-2</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stockwell</surname><given-names>BR</given-names></string-name></person-group>. 
<article-title>Ferroptosis turns 10: Emerging mechanisms, physiological functions and therapeutic applications</article-title>. <source>Cell</source>. <year>2022</year>;<volume>185</volume>(<issue>14</issue>):<fpage>2401</fpage>&#8211;<lpage>2421</lpage>.<pub-id pub-id-type="pmid">35803244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2022.06.003</pub-id><pub-id pub-id-type="pmcid">PMC9273022</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Brand</surname><given-names>MD</given-names></string-name></person-group>. 
<article-title>Production of superoxide and hydrogen peroxide in the mitochondrial matrix is dominated by site Iq of complex I in diverse cell lines</article-title>. <source>Redox Biol</source>. <year>2020</year>;<volume>37</volume>:
<elocation-id>Article 101722</elocation-id>.<pub-id pub-id-type="pmid">32971363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2020.101722</pub-id><pub-id pub-id-type="pmcid">PMC7511732</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bertero</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Maack</surname><given-names>C</given-names></string-name></person-group>. 
<article-title>Calcium signaling and reactive oxygen species in mitochondria</article-title>. <source>Circ Res</source>. <year>2018</year>;<volume>122</volume>(<issue>10</issue>):<fpage>1460</fpage>&#8211;<lpage>1478</lpage>.<pub-id pub-id-type="pmid">29748369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.118.310082</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>MP</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>RC</surname><given-names>H</given-names></string-name></person-group>. 
<article-title>Mitochondria as a therapeutic target for common pathologies</article-title>. <source>Nat Rev Drug Discov</source>. <year>2018</year>;<volume>17</volume>(<issue>12</issue>):<fpage>865</fpage>&#8211;<lpage>886</lpage>.<pub-id pub-id-type="pmid">30393373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2018.174</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>Y</given-names></string-name></person-group>. 
<article-title>Mitochondria at the crossroads: Quality control mechanisms in neuronal senescence and neurodegeneration</article-title>. <source>Neurobiol Dis</source>. <year>2025</year>;<volume>208</volume>:
<elocation-id>Article 106862</elocation-id>.<pub-id pub-id-type="pmid">40049539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2025.106862</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Qu</surname><given-names>X</given-names></string-name></person-group>. 
<article-title>Targeting mitochondrial degradation by chimeric autophagy-tethering compounds</article-title>. <source>Chem Sci</source>. <year>2023</year>;<volume>14</volume>(<issue>40</issue>):<fpage>11192</fpage>&#8211;<lpage>11202</lpage>.<pub-id pub-id-type="pmid">37860639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d3sc03600f</pub-id><pub-id pub-id-type="pmcid">PMC10583747</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Magistretti</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Allaman</surname><given-names>I</given-names></string-name></person-group>. 
<article-title>Lactate in the brain: From metabolic end-product to signalling molecule</article-title>. <source>Nat Rev Neurosci</source>. <year>2018</year>;<volume>19</volume>(<issue>4</issue>):<fpage>235</fpage>&#8211;<lpage>249</lpage>.<pub-id pub-id-type="pmid">29515192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn.2018.19</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tzioras</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mcgeachan</surname><given-names>RI</given-names></string-name>, <string-name name-style="western"><surname>Durrant</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Spires-Jones</surname><given-names>TL</given-names></string-name></person-group>. 
<article-title>Synaptic degeneration in Alzheimer disease</article-title>. <source>Nat Rev Neurol</source>. <year>2023</year>;<volume>19</volume>(<issue>1</issue>):<fpage>19</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">36513730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-022-00749-z</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vicente-Gutierrez</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bonora</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bobo-Jimenez</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Jimenez-Blasco</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lopez-Fabuel</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Fernandez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Josephine</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bonvento</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Enriquez</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Almeida</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Astrocytic mitochondrial ROS modulate brain metabolism and mouse behaviour</article-title>. <source>Nat Metab</source>. <year>2019</year>;<volume>1</volume>(<issue>2</issue>):<fpage>201</fpage>&#8211;<lpage>211</lpage>.<pub-id pub-id-type="pmid">32694785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-018-0031-6</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Agrawal</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Montesinos</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Larrea</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Area-Gomez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pera</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>The silence of the fats: A mam&#8217;s story about Alzheimer</article-title>. <source>Neurobiol Dis</source>. <year>2020</year>;<volume>145</volume>:
<elocation-id>Article 105062</elocation-id>.<pub-id pub-id-type="pmid">32866617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2020.105062</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Mitochondria-associated endoplasmic reticulum membranes in human health and diseases</article-title>. <source>Medcomm</source>. <year>2025</year>;<volume>6</volume>(<issue>7</issue>):
<elocation-id>Article E70259</elocation-id>.<pub-id pub-id-type="pmid">40584408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mco2.70259</pub-id><pub-id pub-id-type="pmcid">PMC12205217</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Birge</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Boeltz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Carlson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wanderley</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Calianese</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Barcinski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brekken</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hutchins</surname><given-names>JT</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer</article-title>. <source>Cell Death Differ</source>. <year>2016</year>;<volume>23</volume>(<issue>6</issue>):<fpage>962</fpage>&#8211;<lpage>978</lpage>.<pub-id pub-id-type="pmid">26915293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cdd.2016.11</pub-id><pub-id pub-id-type="pmcid">PMC4987730</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mart&#237;nez-Reyes</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Chandel</surname><given-names>NS</given-names></string-name></person-group>. 
<article-title>Mitochondrial TCA cycle metabolites control physiology and disease</article-title>. <source>Nat Commun</source>. <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>102</fpage>.<pub-id pub-id-type="pmid">31900386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-13668-3</pub-id><pub-id pub-id-type="pmcid">PMC6941980</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Resende</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fernandes</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Marques</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>CF</given-names></string-name></person-group>. 
<article-title>Endoplasmic reticulum-mitochondria contacts modulate reactive oxygen species-mediated signaling and oxidative stress in brain disorders: The key role of Sigma-1 receptor</article-title>. <source>Antioxid Redox Signal</source>. <year>2022</year>;<volume>37</volume>(<issue>10&#8211;12</issue>):<fpage>758</fpage>&#8211;<lpage>780</lpage>.<pub-id pub-id-type="pmid">35369731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/ars.2020.8231</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guo</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>W</given-names></string-name></person-group>. 
<article-title>Global research trends in biomarkers, therapeutic targets, and drugs for amyotrophic lateral sclerosis: A bibliometric and visualization analysis</article-title>. <source>Front Pharmacol</source>. <year>2025</year>;<volume>16</volume>:<fpage>1588968</fpage>.<pub-id pub-id-type="pmid">40260387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2025.1588968</pub-id><pub-id pub-id-type="pmcid">PMC12009895</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Picca</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Calvani</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Coelho-Junior</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Landi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bernabei</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Marzetti</surname><given-names>E</given-names></string-name></person-group>. 
<article-title>Mitochondrial dysfunction, oxidative stress, and neuroinflammation: Intertwined roads to neurodegeneration</article-title>. <source>Antioxidants</source>. <year>2020</year>;<volume>9</volume>(<issue>8</issue>):<fpage>647</fpage>.<pub-id pub-id-type="pmid">32707949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox9080647</pub-id><pub-id pub-id-type="pmcid">PMC7466131</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Okada</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Landgraf</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Xiaoli</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Horton</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Schuster</surname><given-names>VL</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Sidoli</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kurland</surname><given-names>IJ</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Spatial hepatocyte plasticity of gluconeogenesis during the metabolic transitions between fed, fasted and starvation states</article-title>. <source>Nat Metab</source>. <year>2025</year>;<volume>7</volume>(<issue>5</issue>):<fpage>1073</fpage>&#8211;<lpage>1091</lpage>.<pub-id pub-id-type="pmid">40281362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-025-01269-y</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name></person-group>. 
<article-title>Polystyrene nanoplastics trigger pyroptosis in dopaminergic neurons through Tsc2/Tfeb-mediated disruption of autophagosome-lysosome fusion in Parkinson&#8217;s disease</article-title>. <source>J Transl Med</source>. <year>2025</year>;<volume>23</volume>(<issue>1</issue>):<fpage>631</fpage>.<pub-id pub-id-type="pmid">40474178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-025-06634-9</pub-id><pub-id pub-id-type="pmcid">PMC12142934</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kellar</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Craft</surname><given-names>S</given-names></string-name></person-group>. 
<article-title>Brain insulin resistance in Alzheimer&#8217;s disease and related disorders: Mechanisms and therapeutic approaches</article-title>. <source>Lancet Neurol</source>. <year>2020</year>;<volume>19</volume>(<issue>9</issue>):<fpage>758</fpage>&#8211;<lpage>766</lpage>.<pub-id pub-id-type="pmid">32730766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(20)30231-3</pub-id><pub-id pub-id-type="pmcid">PMC9661919</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ewing</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>IW</given-names></string-name>, <string-name name-style="western"><surname>Clarke</surname><given-names>BF</given-names></string-name></person-group>. 
<article-title>Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications</article-title>. <source>Ann Intern Med</source>. <year>1980</year>;<volume>92</volume>(<issue>2 Pt 2</issue>):<fpage>308</fpage>&#8211;<lpage>311</lpage>.<pub-id pub-id-type="pmid">7356219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-92-2-308</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Accili</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Q</given-names></string-name></person-group>. 
<article-title>Insulin resistance in type 2 diabetes mellitus</article-title>. <source>Nat Rev Endocrinol</source>. <year>2025</year>;<volume>21</volume>(<issue>7</issue>):<fpage>413</fpage>&#8211;<lpage>426</lpage>.<pub-id pub-id-type="pmid">40247011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41574-025-01114-y</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Antal</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>McMahon</surname><given-names>LP</given-names></string-name>, <string-name name-style="western"><surname>Sultan</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Lithen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wexler</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Dickerson</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ratai</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Mujica-Parodi</surname><given-names>LR</given-names></string-name></person-group>. 
<article-title>Type 2 diabetes mellitus accelerates brain aging and cognitive decline: Complementary findings from UK Biobank and meta-analyses</article-title>. <source>eLife</source>. <year>2022</year>;<volume>11</volume>:
<elocation-id>Article e73138</elocation-id>.<pub-id pub-id-type="pmid">35608247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.73138</pub-id><pub-id pub-id-type="pmcid">PMC9132576</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Milstein</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Ferris</surname><given-names>HA</given-names></string-name></person-group>. 
<article-title>The brain as an insulin-sensitive metabolic organ</article-title>. <source>Mol Metab</source>. <year>2021</year>;<volume>52</volume>:
<elocation-id>Article 101234</elocation-id>.<pub-id pub-id-type="pmid">33845179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2021.101234</pub-id><pub-id pub-id-type="pmcid">PMC8513144</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yunn</surname><given-names>NO</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ryu</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname></string-name></person-group>. 
<article-title>A stepwise activation model for the insulin receptor</article-title>. <source>Exp Mol Med</source>. <year>2023</year>;<volume>55</volume>(<issue>10</issue>):<fpage>2147</fpage>&#8211;<lpage>2161</lpage>.<pub-id pub-id-type="pmid">37779149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-023-01101-1</pub-id><pub-id pub-id-type="pmcid">PMC10618199</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>XJ</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>GX</given-names></string-name></person-group>. 
<article-title>Current understanding of glucose transporter 4 expression and functional mechanisms</article-title>. <source>World J Biol Chem</source>. <year>2020</year>;<volume>11</volume>(<issue>3</issue>):<fpage>76</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">33274014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4331/wjbc.v11.i3.76</pub-id><pub-id pub-id-type="pmcid">PMC7672939</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gong</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>GZ</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>X</given-names></string-name></person-group>. 
<article-title>Huntingtin-associated protein 1 plays an essential role in the pathogenesis of type 2 diabetes by regulating the translocation of Glut4 in mouse adipocytes</article-title>. <source>BMJ Open Diabetes Res Care</source>. <year>2020</year>;<volume>8</volume>(<issue>1</issue>):
<elocation-id>Article e001199</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjdrc-2020-001199</pub-id><pub-id pub-id-type="pmcid">PMC7566288</pub-id><pub-id pub-id-type="pmid">33060070</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Hoover</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kahn</surname><given-names>CR</given-names></string-name></person-group>. 
<article-title>Insulin action in the brain: Cell types, circuits, and diseases</article-title>. <source>Trends Neurosci</source>. <year>2022</year>;<volume>45</volume>(<issue>5</issue>):<fpage>384</fpage>&#8211;<lpage>400</lpage>.<pub-id pub-id-type="pmid">35361499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tins.2022.03.001</pub-id><pub-id pub-id-type="pmcid">PMC9035105</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jain</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Trombetta-Lima</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Matlahov</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ribas</surname><given-names>HT</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Parlato</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Portale</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Dolga</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>van der Wel</surname><given-names>PCA</given-names></string-name></person-group>. 
<article-title>Inhibitor-based modulation of huntingtin aggregation mechanisms mitigates fibril-induced cellular stress</article-title>. <source>Nat Commun</source>. <year>2025</year>;<volume>16</volume>(<issue>1</issue>):<fpage>3588</fpage>.<pub-id pub-id-type="pmid">40234398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-58691-9</pub-id><pub-id pub-id-type="pmcid">PMC12000517</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>CS</given-names></string-name></person-group>. 
<article-title>Insulin resistance: From mechanisms to therapeutic strategies</article-title>. <source>Diabetes Metab J</source>. <year>2022</year>;<volume>46</volume>(<issue>1</issue>):<fpage>15</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">34965646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4093/dmj.2021.0280</pub-id><pub-id pub-id-type="pmcid">PMC8831809</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jakkamsetti</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Marin-Valencia</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Good</surname><given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Terrill</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rajasekaran</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Pichumani</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Khemtong</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hooshyar</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Sundarrajan</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Brain metabolism modulates neuronal excitability in a mouse model of pyruvate dehydrogenase deficiency</article-title>. <source>Sci Transl Med</source>. <year>2019</year>;<volume>11</volume>(<issue>480</issue>):
<elocation-id>Article eaan0457</elocation-id>.<pub-id pub-id-type="pmid">30787166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aan0457</pub-id><pub-id pub-id-type="pmcid">PMC6637765</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Yen</surname><given-names>GC</given-names></string-name></person-group>. 
<article-title>Perspective of advanced glycation end products on human health</article-title>. <source>J Agric Food Chem</source>. <year>2018</year>;<volume>66</volume>(<issue>9</issue>):<fpage>2065</fpage>&#8211;<lpage>2070</lpage>.<pub-id pub-id-type="pmid">29421872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jafc.7b05943</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>ZH</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name></person-group>. 
<article-title>Mitochondrial-derived damage-associated molecular patterns amplify neuroinflammation in neurodegenerative diseases</article-title>. <source>Acta Pharmacol Sin</source>. <year>2022</year>;<volume>43</volume>(<issue>10</issue>):<fpage>2439</fpage>&#8211;<lpage>2447</lpage>.<pub-id pub-id-type="pmid">35233090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41401-022-00879-6</pub-id><pub-id pub-id-type="pmcid">PMC9525705</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Melchior</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mittapalli</surname><given-names>GK</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Duong-Polk</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Stewart</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>G&#252;ner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hofilena</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Tjitro</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Herman</surname><given-names>DS</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Tau pathology reduction with Sm07883, a novel, potent, and selective oral Dyrk1a inhibitor: A potential therapeutic for Alzheimer&#8217;s disease</article-title>. <source>Aging Cell</source>. <year>2019</year>;<volume>18</volume>(<issue>5</issue>):
<elocation-id>Article e13000</elocation-id>.<pub-id pub-id-type="pmid">31267651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13000</pub-id><pub-id pub-id-type="pmcid">PMC6718548</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mooldijk</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Licher</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Waqas</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ikram</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Uitterlinden</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Zillikens</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Ikram</surname><given-names>MA</given-names></string-name></person-group>. 
<article-title>Assessment of advanced glycation end products and receptors and the risk of dementia</article-title>. <source>JAMA Netw Open</source>. <year>2021</year>;<volume>4</volume>(<issue>1</issue>):
<elocation-id>Article e2033012</elocation-id>.<pub-id pub-id-type="pmid">33416887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.33012</pub-id><pub-id pub-id-type="pmcid">PMC7794665</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mir</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Jeelani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Alharthi</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Rizvi</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Sohail</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Wani</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>Sabah</surname><given-names>ZU</given-names></string-name>, <string-name name-style="western"><surname>BinAfif</surname><given-names>WF</given-names></string-name>, <string-name name-style="western"><surname>Nandi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Alshahrani</surname><given-names>AM</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Unraveling the mystery of insulin resistance: From principle mechanistic insights and consequences to therapeutic interventions</article-title>. <source>Int J Mol Sci</source>. <year>2025</year>;<volume>26</volume>(<issue>6</issue>):<fpage>2770</fpage>.<pub-id pub-id-type="pmid">40141412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms26062770</pub-id><pub-id pub-id-type="pmcid">PMC11942988</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gao</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name></person-group>. 
<article-title>Decoding microglial polarization and metabolic reprogramming in neurodegenerative diseases: Implications for disease progression and therapy</article-title>. <source>Aging Dis</source>. <year>2025</year>; <comment>10.14336/AD.2024.1629</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.14336/AD.2024.1629</pub-id><pub-id pub-id-type="pmid">40072374</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chaurasia</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Tippetts</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Mayoral Monibas</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wilkerson</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Sweeney</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Sumida</surname><given-names>DH</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Targeting a ceramide double bond improves insulin resistance and hepatic steatosis</article-title>. <source>Science</source>. <year>2019</year>;<volume>365</volume>(<issue>6451</issue>):<fpage>386</fpage>&#8211;<lpage>392</lpage>.<pub-id pub-id-type="pmid">31273070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aav3722</pub-id><pub-id pub-id-type="pmcid">PMC6787918</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Foreman-Ortiz</surname><given-names>IU</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Laudadio</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Calderin</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Keshri</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Hamers</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Rotello</surname><given-names>VM</given-names></string-name></person-group>. 
<article-title>Anionic nanoparticle-induced perturbation to phospholipid membranes affects ion channel function</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2020</year>;<volume>117</volume>(<issue>45</issue>):<fpage>27854</fpage>&#8211;<lpage>27861</lpage>.<pub-id pub-id-type="pmid">33106430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2004736117</pub-id><pub-id pub-id-type="pmcid">PMC7668003</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>XW</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name></person-group>. 
<article-title>Regulation of glucose and lipid metabolism in health and disease</article-title>. <source>Sci China Life Sci</source>. <year>2019</year>;<volume>62</volume>(<issue>11</issue>):<fpage>1420</fpage>&#8211;<lpage>1458</lpage>.<pub-id pub-id-type="pmid">31686320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11427-019-1563-3</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>D&#237;az-Castro</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Morselli</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Claret</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>Interplay between the brain and adipose tissue: A metabolic conversation</article-title>. <source>EMBO Rep</source>. <year>2024</year>;<volume>25</volume>(<issue>12</issue>):<fpage>5277</fpage>&#8211;<lpage>5293</lpage>.<pub-id pub-id-type="pmid">39558137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s44319-024-00321-4</pub-id><pub-id pub-id-type="pmcid">PMC11624209</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matejuk</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ransohoff</surname><given-names>RM</given-names></string-name></person-group>. 
<article-title>Crosstalk between astrocytes and microglia: An overview</article-title>. <source>Front Immunol</source>. <year>2020</year>;<volume>11</volume>:<fpage>1416</fpage>.<pub-id pub-id-type="pmid">32765501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.01416</pub-id><pub-id pub-id-type="pmcid">PMC7378357</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Borst</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Dumas</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Prinz</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>Microglia: Immune and non-immune functions</article-title>. <source>Immunity</source>. <year>2021</year>;<volume>54</volume>(<issue>10</issue>):<fpage>2194</fpage>&#8211;<lpage>2208</lpage>.<pub-id pub-id-type="pmid">34644556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2021.09.014</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cheng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ke</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>LT</given-names></string-name></person-group>. 
<article-title>Early glycolytic reprogramming controls microglial inflammatory activation</article-title>. <source>J Neuroinflammation</source>. <year>2021</year>;<volume>18</volume>(<issue>1</issue>):<fpage>129</fpage>.<pub-id pub-id-type="pmid">34107997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-021-02187-y</pub-id><pub-id pub-id-type="pmcid">PMC8191212</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sadeghdoust</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kaushik</surname><given-names>DK</given-names></string-name></person-group>. 
<article-title>Fueling neurodegeneration: Metabolic insights into microglia functions</article-title>. <source>J Neuroinflammation</source>. <year>2024</year>;<volume>21</volume>(<issue>1</issue>):<fpage>300</fpage>.<pub-id pub-id-type="pmid">39551788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-024-03296-0</pub-id><pub-id pub-id-type="pmcid">PMC11571669</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Long</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>Astrocyte in neurological disease: Pathogenesis and therapy</article-title>. <source>Medcomm</source>. <year>2025</year>;<volume>6</volume>(<issue>8</issue>):
<elocation-id>Article e70299</elocation-id>.<pub-id pub-id-type="pmid">40686921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mco2.70299</pub-id><pub-id pub-id-type="pmcid">PMC12271643</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Loane</surname><given-names>DJ</given-names></string-name></person-group>. 
<article-title>Mangled astrocytes in traumatic brain injury: Astrocytic 2-ag metabolism as a new therapeutic target</article-title>. <source>Brain</source>. <year>2022</year>;<volume>145</volume>(<issue>1</issue>):<fpage>7</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">35353889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awac014</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Naveed</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Smedlund</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>QG</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>JW</given-names></string-name></person-group>. 
<article-title>Astrocyte involvement in metabolic regulation and disease</article-title>. <source>Trends Endocrinol Metab</source>. <year>2025</year>;<volume>36</volume>(<issue>3</issue>):<fpage>219</fpage>&#8211;<lpage>234</lpage>.<pub-id pub-id-type="pmid">39214743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tem.2024.08.001</pub-id><pub-id pub-id-type="pmcid">PMC11868460</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Miao</surname><given-names>C</given-names></string-name></person-group>. 
<article-title>High glucose mediates Nlrp3 Inflammasome activation via upregulation of Elf3 expression</article-title>. <source>Cell Death Dis</source>. <year>2020</year>;<volume>11</volume>(<issue>5</issue>):<fpage>383</fpage>.<pub-id pub-id-type="pmid">32439949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-020-2598-6</pub-id><pub-id pub-id-type="pmcid">PMC7242464</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Paik</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>IS</given-names></string-name>, <string-name name-style="western"><surname>Jo</surname><given-names>EK</given-names></string-name></person-group>. 
<article-title>Updated insights into the molecular networks for Nlrp3 inflammasome activation</article-title>. <source>Cell Mol Immunol</source>. <year>2025</year>;<volume>22</volume>(<issue>6</issue>):<fpage>563</fpage>&#8211;<lpage>596</lpage>.<pub-id pub-id-type="pmid">40307577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-025-01284-9</pub-id><pub-id pub-id-type="pmcid">PMC12125403</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Q</given-names></string-name></person-group>. 
<article-title>Activation and modulation of the ages-rage axis: Implications for inflammatory pathologies and therapeutic interventions&#8212;A review</article-title>. <source>Pharmacol Res</source>. <year>2024</year>;<volume>206</volume>:
<elocation-id>Article 107282</elocation-id>.<pub-id pub-id-type="pmid">38914383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2024.107282</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>An</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><article-title>&#945;-Ketoglutarate improves cardiac insufficiency through NAD<sup>+</sup>-SIRT1 signaling-mediated mitophagy and ferroptosis in pressure overload-induced mice</article-title>. <source>Mol Med</source>. <year>2024</year>;<volume>30</volume>(<issue>1</issue>):<fpage>15</fpage>.<pub-id pub-id-type="pmid">38254035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10020-024-00783-1</pub-id><pub-id pub-id-type="pmcid">PMC10804789</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>ZW</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>LQ</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bosco</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>DS</given-names></string-name></person-group>. 
<article-title>Microglia reprogram metabolic profiles for phenotype and function changes in central nervous system</article-title>. <source>Neurobiol Dis</source>. <year>2021</year>;<volume>152</volume>:
<elocation-id>Article 105290</elocation-id>.<pub-id pub-id-type="pmid">33556540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2021.105290</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>X</given-names></string-name></person-group>. 
<article-title>The impact of oxidative stress on abnormal lipid metabolism-mediated disease development</article-title>. <source>Arch Biochem Biophys</source>. <year>2025</year>;<volume>766</volume>:
<elocation-id>Article 110348</elocation-id>.<pub-id pub-id-type="pmid">39961502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.abb.2025.110348</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>XX</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>YQ</given-names></string-name>, <string-name name-style="western"><surname>Shan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ji</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>SQ</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>YF</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Lipidomic analysis identifies long-chain acylcarnitine as a target for ischemic stroke</article-title>. <source>J Adv Res</source>. <year>2024</year>;<volume>61</volume>:<fpage>133</fpage>&#8211;<lpage>149</lpage>.<pub-id pub-id-type="pmid">37572732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jare.2023.08.007</pub-id><pub-id pub-id-type="pmcid">PMC11258661</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Afridi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rahman</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Suk</surname><given-names>K</given-names></string-name></person-group>. 
<article-title>Implications of glial metabolic dysregulation in the pathophysiology of neurodegenerative diseases</article-title>. <source>Neurobiol Dis</source>. <year>2022</year>;<volume>174</volume>:
<elocation-id>Article 105874</elocation-id>.<pub-id pub-id-type="pmid">36154877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2022.105874</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>QQ</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>JW</given-names></string-name></person-group>. 
<article-title>Neuroinflammation in the central nervous system: Symphony of glial cells</article-title>. <source>Glia</source>. <year>2019</year>;<volume>67</volume>(<issue>6</issue>):<fpage>1017</fpage>&#8211;<lpage>1035</lpage>.<pub-id pub-id-type="pmid">30548343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.23571</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Liwinski</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Elinav</surname><given-names>E</given-names></string-name></person-group>. 
<article-title>Inflammasome activation and regulation: Toward a better understanding of complex mechanisms</article-title>. <source>Cell Discov</source>. <year>2020</year>;<volume>6</volume>:<fpage>36</fpage>.<pub-id pub-id-type="pmid">32550001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41421-020-0167-x</pub-id><pub-id pub-id-type="pmcid">PMC7280307</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marchi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Guilbaud</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tait</surname><given-names>SWG</given-names></string-name>, <string-name name-style="western"><surname>Yamazaki</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Galluzzi</surname><given-names>L</given-names></string-name></person-group>. 
<article-title>Mitochondrial control of inflammation</article-title>. <source>Nat Rev Immunol</source>. <year>2023</year>;<volume>23</volume>(<issue>3</issue>):<fpage>159</fpage>&#8211;<lpage>173</lpage>.<pub-id pub-id-type="pmid">35879417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-022-00760-x</pub-id><pub-id pub-id-type="pmcid">PMC9310369</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Christgen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Place</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></string-name></person-group>. 
<article-title>Toward targeting Inflammasomes: Insights into their regulation and activation</article-title>. <source>Cell Res</source>. <year>2020</year>;<volume>30</volume>(<issue>4</issue>):<fpage>315</fpage>&#8211;<lpage>327</lpage>.<pub-id pub-id-type="pmid">32152420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-020-0295-8</pub-id><pub-id pub-id-type="pmcid">PMC7118104</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name></person-group>. 
<article-title>Emerging mechanisms of lipid peroxidation in regulated cell death and its physiological implications</article-title>. <source>Cell Death Dis</source>. <year>2024</year>;<volume>15</volume>(<issue>11</issue>):<fpage>859</fpage>.<pub-id pub-id-type="pmid">39587094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-024-07244-x</pub-id><pub-id pub-id-type="pmcid">PMC11589755</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Michael Greenlief</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fritsche</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Beversdorf</surname><given-names>DQ</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>GY</given-names></string-name></person-group>. 
<article-title>Unveiling anti-oxidative and anti-inflammatory effects of docosahexaenoic acid and its lipid peroxidation product on lipopolysaccharide-stimulated Bv-2 microglial cells</article-title>. <source>J Neuroinflammation</source>. <year>2018</year>;<volume>15</volume>(<issue>1</issue>):<fpage>202</fpage>.<pub-id pub-id-type="pmid">29986724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-018-1232-3</pub-id><pub-id pub-id-type="pmcid">PMC6038194</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>G&#281;gotek</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Skrzydlewska</surname><given-names>E</given-names></string-name></person-group>. 
<article-title>Biological effect of protein modifications by lipid peroxidation products</article-title>. <source>Chem Phys Lipids</source>. <year>2019</year>;<volume>221</volume>:<fpage>46</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">30922835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chemphyslip.2019.03.011</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Boza-Serrano</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dunning</surname><given-names>CJR</given-names></string-name>, <string-name name-style="western"><surname>Clausen</surname><given-names>BH</given-names></string-name>, <string-name name-style="western"><surname>Lambertsen</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Deierborg</surname><given-names>T</given-names></string-name></person-group>. 
<article-title>Inflammation leads to distinct populations of extracellular vesicles from microglia</article-title>. <source>J Neuroinflammation</source>. <year>2018</year>;<volume>15</volume>(<issue>1</issue>):<fpage>168</fpage>.<pub-id pub-id-type="pmid">29807527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-018-1204-7</pub-id><pub-id pub-id-type="pmcid">PMC5972400</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nolfi-Donegan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Braganza</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shiva</surname><given-names>S</given-names></string-name></person-group>. 
<article-title>Mitochondrial electron transport chain: Oxidative phosphorylation, oxidant production, and methods of measurement</article-title>. <source>Redox Biol</source>. <year>2020</year>;<volume>37</volume>:<fpage>101674</fpage>.<pub-id pub-id-type="pmid">32811789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2020.101674</pub-id><pub-id pub-id-type="pmcid">PMC7767752</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Palma</surname><given-names>FR</given-names></string-name>, <string-name name-style="western"><surname>Gantner</surname><given-names>BN</given-names></string-name>, <string-name name-style="western"><surname>Sakiyama</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Kayzuka</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Shukla</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lacchini</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cunniff</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bonini</surname><given-names>MG</given-names></string-name></person-group>. 
<article-title>ROS production by mitochondria: Function or dysfunction?</article-title><source>Oncogene</source>. <year>2024</year>;<volume>43</volume>(<issue>5</issue>):<fpage>295</fpage>&#8211;<lpage>303</lpage>.<pub-id pub-id-type="pmid">38081963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41388-023-02907-z</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anand</surname><given-names>PK</given-names></string-name></person-group>. 
<article-title>Lipids, inflammasomes, metabolism, and disease</article-title>. <source>Immunol Rev</source>. <year>2020</year>;<volume>297</volume>(<issue>1</issue>):<fpage>108</fpage>&#8211;<lpage>122</lpage>.<pub-id pub-id-type="pmid">32562313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.12891</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hampel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hardy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Blennow</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Perry</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Villemagne</surname><given-names>VL</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Vendruscolo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Iwatsubo</surname><given-names>T</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The amyloid-&#914; pathway in Alzheimer&#8217;s disease</article-title>. <source>Mol Psychiatry</source>. <year>2021</year>;<volume>26</volume>(<issue>10</issue>):<fpage>5481</fpage>&#8211;<lpage>5503</lpage>.<pub-id pub-id-type="pmid">34456336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-021-01249-0</pub-id><pub-id pub-id-type="pmcid">PMC8758495</pub-id></mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kc</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ali Moussa</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>Y</given-names></string-name></person-group>. 
<article-title>Cholesterol imbalance and neurotransmission defects in neurodegeneration</article-title>. <source>Exp Mol Med</source>. <year>2024</year>;<volume>56</volume>(<issue>8</issue>):<fpage>1685</fpage>&#8211;<lpage>1690</lpage>.<pub-id pub-id-type="pmid">39085348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-024-01273-4</pub-id><pub-id pub-id-type="pmcid">PMC11371908</pub-id></mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Galleguillos</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Steinberg</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zaidi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shrivastava</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Dhami</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Daskhan</surname><given-names>GC</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Dworsky-Fried</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Giuliani</surname><given-names>F</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Anti-inflammatory role of Gm1 and other gangliosides on microglia</article-title>. <source>J Neuroinflammation</source>. <year>2022</year>;<volume>19</volume>(<issue>1</issue>):<fpage>9</fpage>.<pub-id pub-id-type="pmid">34991625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-021-02374-x</pub-id><pub-id pub-id-type="pmcid">PMC8739653</pub-id></mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Onishi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yamano</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sato</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Matsuda</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Okamoto</surname><given-names>K</given-names></string-name></person-group>. 
<article-title>Molecular mechanisms and physiological functions of mitophagy</article-title>. <source>EMBO J</source>. <year>2021</year>;<volume>40</volume>(<issue>3</issue>):<fpage>E104705</fpage>.<pub-id pub-id-type="pmid">33438778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.2020104705</pub-id><pub-id pub-id-type="pmcid">PMC7849173</pub-id></mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Barone</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Di Domenico</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Perluigi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Butterfield</surname><given-names>DA</given-names></string-name></person-group>. 
<article-title>The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease</article-title>. <source>Free Radic Biol Med</source>. <year>2021</year>;<volume>176</volume>:<fpage>16</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">34530075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2021.09.006</pub-id><pub-id pub-id-type="pmcid">PMC8595768</pub-id></mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ising</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Venegas</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Scheiblich</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>SV</given-names></string-name>, <string-name name-style="western"><surname>Vieira-Saecker</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Albasset</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>McManus</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Tejera</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><article-title>NLRP3 Inflammasome activation drives tau pathology</article-title>. <source>Nature</source>. <year>2019</year>;<volume>575</volume>(<issue>7784</issue>):<fpage>669</fpage>&#8211;<lpage>673</lpage>.<pub-id pub-id-type="pmid">31748742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1769-z</pub-id><pub-id pub-id-type="pmcid">PMC7324015</pub-id></mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><article-title>Microglia eliminate inhibitory synapses and drive neuronal hyperexcitability in epilepsy</article-title>. <source>Nat Neurosci</source>. <year>2025</year>;<volume>28</volume>(<issue>7</issue>):<fpage>1370</fpage>&#8211;<lpage>1371</lpage>.<pub-id pub-id-type="pmid">40447859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-025-01983-6</pub-id></mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Di Meco</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Curtis</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Lauretti</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pratic&#242;</surname><given-names>D</given-names></string-name></person-group>. 
<article-title>Autophagy dysfunction in Alzheimer&#8217;s disease: Mechanistic insights and new therapeutic opportunities</article-title>. <source>Biol Psychiatry</source>. <year>2020</year>;<volume>87</volume>(<issue>9</issue>):<fpage>797</fpage>&#8211;<lpage>807</lpage>.<pub-id pub-id-type="pmid">31262433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2019.05.008</pub-id></mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gr&#252;newald</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Sue</surname><given-names>CM</given-names></string-name></person-group>. 
<article-title>New insights into the complex role of mitochondria in Parkinson&#8217;s disease</article-title>. <source>Prog Neurobiol</source>. <year>2019</year>;<volume>177</volume>:<fpage>73</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">30219247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2018.09.003</pub-id></mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Mitochondrial Hsf1 triggers mitochondrial dysfunction and neurodegeneration in Huntington&#8217;s disease</article-title>. <source>EMBO Mol Med</source>. <year>2022</year>;<volume>14</volume>(<issue>7</issue>):<fpage>e15851</fpage>.<pub-id pub-id-type="pmid">35670111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.202215851</pub-id><pub-id pub-id-type="pmcid">PMC9260212</pub-id></mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Neueder</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kojer</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hering</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tabrizi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Taanman</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Orth</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>Huntington&#8217;s disease affects mitochondrial network dynamics predisposing to pathogenic mitochondrial DNA mutations</article-title>. <source>Brain</source>. <year>2024</year>;<volume>147</volume>(<issue>6</issue>):<fpage>2009</fpage>&#8211;<lpage>2022</lpage>.<pub-id pub-id-type="pmid">38195181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awae007</pub-id><pub-id pub-id-type="pmcid">PMC11512592</pub-id></mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Amieva</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Ch&#233;telat</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Hyman</surname><given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Nixon</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>DT</given-names></string-name></person-group>. 
<article-title>Alzheimer disease</article-title>. <source>Nat Rev Dis Primers</source>. <year>2021</year>;<volume>7</volume>(<issue>1</issue>):<fpage>33</fpage>.<pub-id pub-id-type="pmid">33986301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-021-00269-y</pub-id><pub-id pub-id-type="pmcid">PMC8574196</pub-id></mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Perez Ortiz</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Swerdlow</surname><given-names>RH</given-names></string-name></person-group>. 
<article-title>Mitochondrial dysfunction in Alzheimer&#8217;s disease: Role in pathogenesis and novel therapeutic opportunities</article-title>. <source>Br J Pharmacol</source>. <year>2019</year>;<volume>176</volume>(<issue>18</issue>):<fpage>3489</fpage>&#8211;<lpage>3507</lpage>.<pub-id pub-id-type="pmid">30675901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.14585</pub-id><pub-id pub-id-type="pmcid">PMC6715612</pub-id></mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Orth</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>Z</given-names></string-name></person-group>. 
<article-title>Accelerated expansion of pathogenic mitochondrial DNA heteroplasmies in Huntington&#8217;s disease</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2021</year>;<volume>118</volume>(<issue>30</issue>):<fpage>E2014610118</fpage>.<pub-id pub-id-type="pmid">34301881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2014610118</pub-id><pub-id pub-id-type="pmcid">PMC8325154</pub-id></mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Strope</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Troutwine</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Lysaker</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Wilkins</surname><given-names>HM</given-names></string-name></person-group>. 
<article-title>The functional role of amyloid precursor protein at mitochondria</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>18</volume>(<issue>S4</issue>):
<elocation-id>Article e061701</elocation-id>.</mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Montagna</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Crux</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Luckner</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Herber</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Colombo</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Marinkovi&#263;</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tahirovic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lichtenthaler</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Wanner</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller</surname><given-names>UC</given-names></string-name>, <etal>et al.</etal></person-group><article-title>In vivo Ca<sup>2+</sup> imaging of astrocytic microdomains reveals a critical role of the amyloid precursor protein for mitochondria</article-title>. <source>Glia</source>. <year>2019</year>;<volume>67</volume>(<issue>5</issue>):<fpage>985</fpage>&#8211;<lpage>998</lpage>.<pub-id pub-id-type="pmid">30667091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.23584</pub-id></mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mary</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Eysert</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Checler</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Chami</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>Mitophagy in Alzheimer&#8217;s disease: Molecular defects and therapeutic approaches</article-title>. <source>Mol Psychiatry</source>. <year>2023</year>;<volume>28</volume>(<issue>1</issue>):<fpage>202</fpage>&#8211;<lpage>216</lpage>.<pub-id pub-id-type="pmid">35665766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-022-01631-6</pub-id><pub-id pub-id-type="pmcid">PMC9812780</pub-id></mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fang</surname><given-names>EF</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Palikaras</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Adriaanse</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Kerr</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lautrup</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hasan-Olive</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Caponio</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dan</surname><given-names>X</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Mitophagy inhibits amyloid-&#914; and tau pathology and reverses cognitive deficits in models of Alzheimer&#8217;s disease</article-title>. <source>Nat Neurosci</source>. <year>2019</year>;<volume>22</volume>(<issue>3</issue>):<fpage>401</fpage>&#8211;<lpage>412</lpage>.<pub-id pub-id-type="pmid">30742114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-018-0332-9</pub-id><pub-id pub-id-type="pmcid">PMC6693625</pub-id></mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saito</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Harari</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Cruchaga</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mihindukulasuriya</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Kauwe</surname><given-names>JSK</given-names></string-name>, <string-name name-style="western"><surname>Bikman</surname><given-names>BT</given-names></string-name></person-group>. 
<article-title>Alzheimer&#8217;s disease alters oligodendrocytic glycolytic and Ketolytic gene expression</article-title>. <source>Alzheimers Dement</source>. <year>2021</year>;<volume>17</volume>(<issue>9</issue>):<fpage>1474</fpage>&#8211;<lpage>1486</lpage>.<pub-id pub-id-type="pmid">33650792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12310</pub-id><pub-id pub-id-type="pmcid">PMC8410881</pub-id></mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Exner</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lutz</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Haass</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Winklhofer</surname><given-names>KF</given-names></string-name></person-group>. 
<article-title>Mitochondrial dysfunction in Parkinson&#8217;s disease: Molecular mechanisms and pathophysiological consequences</article-title>. <source>EMBO J</source>. <year>2012</year>;<volume>31</volume>(<issue>14</issue>):<fpage>3038</fpage>&#8211;<lpage>3062</lpage>.<pub-id pub-id-type="pmid">22735187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/emboj.2012.170</pub-id><pub-id pub-id-type="pmcid">PMC3400019</pub-id></mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Malpartida</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Williamson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Narendra</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Wade-Martins</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ryan</surname><given-names>BJ</given-names></string-name></person-group>. 
<article-title>Mitochondrial dysfunction and mitophagy in Parkinson&#8217;s disease: From mechanism to therapy</article-title>. <source>Trends Biochem Sci</source>. <year>2021</year>;<volume>46</volume>(<issue>4</issue>):<fpage>329</fpage>&#8211;<lpage>343</lpage>.<pub-id pub-id-type="pmid">33323315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibs.2020.11.007</pub-id></mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gonz&#225;lez-Rodr&#237;guez</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zampese</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Stout</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Guzman</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Ilijic</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Tkatch</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Stavarache</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Wokosin</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Disruption of mitochondrial complex I induces progressive parkinsonism</article-title>. <source>Nature</source>. <year>2021</year>;<volume>599</volume>(<issue>7886</issue>):<fpage>650</fpage>&#8211;<lpage>656</lpage>.<pub-id pub-id-type="pmid">34732887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-04059-0</pub-id><pub-id pub-id-type="pmcid">PMC9189968</pub-id></mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vos</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>Mitochondrial complex I deficiency: Guilty in Parkinson&#8217;s disease</article-title>. <source>Signal Transduct Target Ther</source>. <year>2022</year>;<volume>7</volume>(<issue>1</issue>):<fpage>136</fpage>.<pub-id pub-id-type="pmid">35461312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-022-00983-3</pub-id><pub-id pub-id-type="pmcid">PMC9035149</pub-id></mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fuentes</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Morcillo</surname><given-names>P</given-names></string-name></person-group>. 
<article-title>The role of cardiolipin in mitochondrial function and neurodegenerative diseases</article-title>. <source>Cells</source>. <year>2024</year>;<volume>13</volume>(<issue>7</issue>):<fpage>609</fpage>.<pub-id pub-id-type="pmid">38607048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells13070609</pub-id><pub-id pub-id-type="pmcid">PMC11012098</pub-id></mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lurette</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Mart&#237;n-Jim&#233;nez</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sheta</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jean</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schofield</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Teixeira</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez-Aller</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Perron</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Oueslati</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Aggregation of alpha-synuclein disrupts mitochondrial metabolism and induce mitophagy via cardiolipin externalization</article-title>. <source>Cell Death Dis</source>. <year>2023</year>;<volume>14</volume>(<issue>11</issue>):<fpage>729</fpage>.<pub-id pub-id-type="pmid">37949858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-023-06251-8</pub-id><pub-id pub-id-type="pmcid">PMC10638290</pub-id></mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Trist</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Hare</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Double</surname><given-names>KL</given-names></string-name></person-group>. 
<article-title>Oxidative stress in the aging substantia nigra and the etiology of Parkinson&#8217;s disease</article-title>. <source>Aging Cell</source>. <year>2019</year>;<volume>18</volume>(<issue>6</issue>):
<elocation-id>Article e13031</elocation-id>.<pub-id pub-id-type="pmid">31432604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13031</pub-id><pub-id pub-id-type="pmcid">PMC6826160</pub-id></mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>FF</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Henrich</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zampese</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ueda</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tkatch</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wokosin</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Nasiri</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Grotmann</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Dawson</surname><given-names>VL</given-names></string-name>, <etal>et al.</etal></person-group><article-title>&#945;-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson&#8217;s disease</article-title>. <source>Mol Neurodegener</source>. <year>2024</year>;<volume>19</volume>(<issue>1</issue>):<fpage>69</fpage>.<pub-id pub-id-type="pmid">39379975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-024-00756-2</pub-id><pub-id pub-id-type="pmcid">PMC11462807</pub-id></mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fl&#248;nes</surname><given-names>IH</given-names></string-name>, <string-name name-style="western"><surname>Toker</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sandnes</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Castelli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mostafavi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lura</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Shadad</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Fernandez-Vizarra</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Painous</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez-Soriano</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Mitochondrial complex I deficiency stratifies idiopathic Parkinson&#8217;s disease</article-title>. <source>Nat Commun</source>. <year>2024</year>;<volume>15</volume>(<issue>1</issue>):<fpage>3631</fpage>.<pub-id pub-id-type="pmid">38684731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-47867-4</pub-id><pub-id pub-id-type="pmcid">PMC11059185</pub-id></mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>TY</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>HW</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lou</surname><given-names>ZL</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>TF</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>YB</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Elevated ubiquitin phosphorylation by Pink1 contributes to proteasomal impairment and promotes neurodegeneration</article-title>. <source>eLife</source>. <year>2025</year>;<volume>14</volume>:
<elocation-id>Article rp103945</elocation-id>.<pub-id pub-id-type="pmid">40742280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.103945</pub-id><pub-id pub-id-type="pmcid">PMC12313235</pub-id></mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marchesan</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Nardin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mauri</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bernardo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chander</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>di Paola</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chinellato</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>von Stockum</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chakraborty</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Herkenne</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Activation of Ca<sup>2+</sup> phosphatase Calcineurin regulates Parkin translocation to mitochondria and Mitophagy in flies</article-title>. <source>Cell Death Differ</source>. <year>2024</year>;<volume>31</volume>(<issue>2</issue>):<fpage>217</fpage>&#8211;<lpage>238</lpage>.<pub-id pub-id-type="pmid">38238520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-023-01251-9</pub-id><pub-id pub-id-type="pmcid">PMC10850161</pub-id></mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Franklin</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Teive</surname><given-names>HAG</given-names></string-name>, <string-name name-style="western"><surname>Tensini</surname><given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Camargo</surname><given-names>CHF</given-names></string-name>, <string-name name-style="western"><surname>de Lima</surname><given-names>NSC</given-names></string-name>, <string-name name-style="western"><surname>de dos Santos</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Meira</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Tabrizi</surname><given-names>SJ</given-names></string-name></person-group>. 
<article-title>The Huntington&#8217;s disease gene</article-title>. <source>Discovery</source>. <year>2024</year>;<volume>39</volume>(<issue>2</issue>):<fpage>227</fpage>&#8211;<lpage>234</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.29703</pub-id><pub-id pub-id-type="pmid">38179605</pub-id></mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stoccoro</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Copped&#232;</surname><given-names>F</given-names></string-name></person-group>. 
<article-title>Mitochondrial DNA methylation and human diseases</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>(<issue>9</issue>):<fpage>4594</fpage>.<pub-id pub-id-type="pmid">33925624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22094594</pub-id><pub-id pub-id-type="pmcid">PMC8123858</pub-id></mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kiani</surname><given-names>L</given-names></string-name></person-group>. 
<article-title>Mitochondrial DNA instability in Huntington disease</article-title>. <source>Nat Rev Neurol</source>. <year>2024</year>;<volume>20</volume>(<issue>3</issue>):<fpage>133</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-024-00937-z</pub-id><pub-id pub-id-type="pmid">38326399</pub-id></mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Polyzos</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Mcmurray</surname><given-names>CT</given-names></string-name></person-group>. 
<article-title>The chicken or the egg: Mitochondrial dysfunction as a cause or consequence of toxicity in Huntington&#8217;s disease</article-title>. <source>Mech Ageing Dev</source>. <year>2017</year>;<volume>161</volume>(<issue>Pt A</issue>):<fpage>181</fpage>&#8211;<lpage>197</lpage>.<pub-id pub-id-type="pmid">27634555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mad.2016.09.003</pub-id><pub-id pub-id-type="pmcid">PMC5543717</pub-id></mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Franco-Iborra</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Plaza-Zabala</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Montpeyo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sebastian</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Vila</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Martinez-Vicente</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease</article-title>. <source>Autophagy</source>. <year>2021</year>;<volume>17</volume>(<issue>3</issue>):<fpage>672</fpage>&#8211;<lpage>689</lpage>.<pub-id pub-id-type="pmid">32093570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2020.1728096</pub-id><pub-id pub-id-type="pmcid">PMC8032238</pub-id></mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jesse</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bayer</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Alupei</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Z&#252;gel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mulaw</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tuorto</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Malmsheimer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Steinacker</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schumann</surname><given-names>U</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Ribosomal transcription is regulated by Pgc-1alpha and disturbed in Huntington&#8217;s disease</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>8513</fpage>.<pub-id pub-id-type="pmid">28819135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-09148-7</pub-id><pub-id pub-id-type="pmcid">PMC5561056</pub-id></mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kiani</surname><given-names>L</given-names></string-name></person-group>. 
<article-title>Insights into the toxic effects of mutant huntingtin</article-title>. <source>Nat Rev Neurol</source>. <year>2023</year>;<volume>19</volume>(<issue>10</issue>):<fpage>576</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-023-00877-0</pub-id><pub-id pub-id-type="pmid">37697049</pub-id></mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lepinay</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Cicchetti</surname><given-names>F</given-names></string-name></person-group>. 
<article-title>Tau: A biomarker of Huntington&#8217;s disease</article-title>. <source>Mol Psychiatry</source>. <year>2023</year>;<volume>28</volume>(<issue>10</issue>):<fpage>4070</fpage>&#8211;<lpage>4083</lpage>.<pub-id pub-id-type="pmid">37749233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-023-02230-9</pub-id></mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation publication-type="other">Correction to: Toxic effects of mutant huntingtin in axons are mediated by its proline-rich domain. <italic toggle="yes">Brain</italic>. Published online May 29, 2025:Awaf189.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awaf189</pub-id><pub-id pub-id-type="pmcid">PMC12404706</pub-id><pub-id pub-id-type="pmid">40439940</pub-id></mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Herzig</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>RJ</given-names></string-name></person-group>. 
<article-title>AMPK: Guardian of metabolism and mitochondrial homeostasis</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2018</year>;<volume>19</volume>(<issue>2</issue>):<fpage>121</fpage>&#8211;<lpage>135</lpage>.<pub-id pub-id-type="pmid">28974774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm.2017.95</pub-id><pub-id pub-id-type="pmcid">PMC5780224</pub-id></mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Hardie</surname><given-names>DG</given-names></string-name></person-group>. 
<article-title>AMPK: Sensing glucose as well as cellular energy status</article-title>. <source>Cell Metab</source>. <year>2018</year>;<volume>27</volume>(<issue>2</issue>):<fpage>299</fpage>&#8211;<lpage>313</lpage>.<pub-id pub-id-type="pmid">29153408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2017.10.009</pub-id></mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schlaepfer</surname><given-names>IR</given-names></string-name>, <string-name name-style="western"><surname>Joshi</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>Cpt1a-mediated fat oxidation, mechanisms, and therapeutic potential</article-title>. <source>Endocrinology</source>. <year>2020</year>;<volume>161</volume>(<issue>2</issue>):
<elocation-id>Article bqz046</elocation-id>.<pub-id pub-id-type="pmid">31900483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/endocr/bqz046</pub-id></mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Na</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Schneeberger</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>GLP-1R agonists protect against Alzheimer&#8217;s disease by rewiring energy regulation</article-title>. <source>Nat Aging</source>. <year>2025</year>;<volume>5</volume>(<issue>6</issue>):<fpage>960</fpage>&#8211;<lpage>961</lpage>.<pub-id pub-id-type="pmid">40394226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-025-00881-7</pub-id></mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ho</surname><given-names>PWL</given-names></string-name>, <string-name name-style="western"><surname>Leung</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Pang</surname><given-names>SYY</given-names></string-name>, <string-name name-style="western"><surname>Lam</surname><given-names>CSC</given-names></string-name>, <string-name name-style="western"><surname>Xian</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kung</surname><given-names>MHW</given-names></string-name>, <string-name name-style="western"><surname>Ramsden</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>SL</given-names></string-name></person-group>. 
<article-title>Age-dependent accumulation of oligomeric SNCA/&#945;-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: Role for therapeutic activation of chaperone-mediated autophagy (CMA)</article-title>. <source>Autophagy</source>. <year>2020</year>;<volume>16</volume>(<issue>2</issue>):<fpage>347</fpage>&#8211;<lpage>370</lpage>.<pub-id pub-id-type="pmid">30983487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2019.1603545</pub-id><pub-id pub-id-type="pmcid">PMC6984454</pub-id></mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Ham</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>GH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HT</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>Y</given-names></string-name></person-group>. 
<article-title>AIMP2 accumulation in brain leads to cognitive deficits and blood secretion in Parkinson&#8217;s disease</article-title>. <source>J Transl Med</source>. <year>2024</year>;<volume>22</volume>(<issue>1</issue>):<fpage>919</fpage>.<pub-id pub-id-type="pmid">39390613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-024-05666-x</pub-id><pub-id pub-id-type="pmcid">PMC11465931</pub-id></mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sukhbaatar</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hengstschl&#228;ger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Weichhart</surname><given-names>T</given-names></string-name></person-group>. 
<article-title>mTOR-mediated regulation of dendritic cell differentiation and function</article-title>. <source>Trends Immunol</source>. <year>2016</year>;<volume>37</volume>(<issue>11</issue>):<fpage>778</fpage>&#8211;<lpage>789</lpage>.<pub-id pub-id-type="pmid">27614799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.it.2016.08.009</pub-id><pub-id pub-id-type="pmcid">PMC6095453</pub-id></mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saxton</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Sabatini</surname><given-names>DM</given-names></string-name></person-group>. 
<article-title>mTOR signaling in growth, metabolism and disease</article-title>. <source>Cell</source>. <year>2017</year>;<volume>168</volume>(<issue>6</issue>):<fpage>960</fpage>&#8211;<lpage>976</lpage>.<pub-id pub-id-type="pmid">28283069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.02.004</pub-id><pub-id pub-id-type="pmcid">PMC5394987</pub-id></mixed-citation></ref><ref id="B147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shimano</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sato</surname><given-names>R</given-names></string-name></person-group>. 
<article-title>SREBP-regulated lipid metabolism: Convergent physiology&#8211;divergent pathophysiology</article-title>. <source>Nat Rev Endocrinol</source>. <year>2017</year>;<volume>13</volume>(<issue>12</issue>):<fpage>710</fpage>&#8211;<lpage>730</lpage>.<pub-id pub-id-type="pmid">28849786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrendo.2017.91</pub-id></mixed-citation></ref><ref id="B148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lv</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name></person-group>. 
<article-title>PGC-1&#945; sparks the fire of neuroprotection against neurodegenerative disorders</article-title>. <source>Ageing Res Rev</source>. <year>2018</year>;<volume>44</volume>:<fpage>8</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">29580918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2018.03.004</pub-id></mixed-citation></ref><ref id="B149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sauer</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kueckelhaus</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lorenz</surname><given-names>NI</given-names></string-name>, <string-name name-style="western"><surname>Bozkurt</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schulte</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Weinem</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Benzarti</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Meiser</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Urban</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Villa</surname><given-names>G</given-names></string-name>, <etal>et al.</etal></person-group><article-title>An AMP-activated protein kinase-PGC-1&#945; axis mediates metabolic plasticity in glioblastoma</article-title>. <source>Clin Transl Med</source>. <year>2024</year>;<volume>14</volume>(<issue>11</issue>):
<elocation-id>Article e70030</elocation-id>.<pub-id pub-id-type="pmid">39552019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ctm2.70030</pub-id><pub-id pub-id-type="pmcid">PMC11570551</pub-id></mixed-citation></ref><ref id="B150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qian</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name></person-group>. 
<article-title>Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases</article-title>. <source>Signal Transduct Target Ther</source>. <year>2024</year>;<volume>9</volume>(<issue>1</issue>):<fpage>50</fpage>.<pub-id pub-id-type="pmid">38424050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-01756-w</pub-id><pub-id pub-id-type="pmcid">PMC10904817</pub-id></mixed-citation></ref><ref id="B151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nierenberg</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Ghaznavi</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Mathias</surname><given-names>S</given-names><suffix>I</suffix></string-name>, <string-name name-style="western"><surname>Ellard</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Janos</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Sylvia</surname><given-names>LG</given-names></string-name></person-group>. 
<article-title>Peroxisome proliferator-activated receptor gamma coactivator-1 alpha as a novel target for bipolar disorder and other neuropsychiatric disorders</article-title>. <source>Biol Psychiatry</source>. <year>2018</year>;<volume>83</volume>(<issue>9</issue>):<fpage>761</fpage>&#8211;<lpage>769</lpage>.<pub-id pub-id-type="pmid">29502862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2017.12.014</pub-id></mixed-citation></ref><ref id="B152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Katsouri</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>YM</given-names></string-name>, <string-name name-style="western"><surname>Blondrath</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Eleftheriadou</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Lombardero</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Birch</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Mirzaei</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Irvine</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Mazarakis</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Sastre</surname><given-names>M</given-names></string-name></person-group>. 
<article-title>PPAR&#947;-coactivator-1&#945; gene transfer reduces neuronal loss and amyloid-&#914; generation by reducing &#914;-secretase in an Alzheimer&#8217;s disease model</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2016</year>;<volume>113</volume>(<issue>43</issue>):<fpage>12292</fpage>&#8211;<lpage>12297</lpage>.<pub-id pub-id-type="pmid">27791018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1606171113</pub-id><pub-id pub-id-type="pmcid">PMC5087021</pub-id></mixed-citation></ref><ref id="B153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jannig</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Dumesic</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Spiegelman</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Ruas</surname><given-names>JL</given-names></string-name></person-group>. 
<article-title>Snapshot: Regulation and biology of PGC-1&#945;</article-title>. <source>Cell</source>. <year>2022</year>;<volume>185</volume>(<issue>8</issue>):<fpage>1444</fpage>&#8211;<lpage>1444.E1</lpage>.<pub-id pub-id-type="pmid">35427500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2022.03.027</pub-id></mixed-citation></ref><ref id="B154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pambianco</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Giovarelli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Perrotta</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zecchini</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cervia</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>di Renzo</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Moscheni</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ripolone</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Violano</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Moggio</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Reversal of defective mitochondrial biogenesis in limb-girdle muscular dystrophy 2D by independent modulation of histone and PGC-1&#945; acetylation</article-title>. <source>Cell Rep</source>. <year>2016</year>;<volume>17</volume>(<issue>11</issue>):<fpage>3010</fpage>&#8211;<lpage>3023</lpage>.<pub-id pub-id-type="pmid">27974213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2016.11.044</pub-id></mixed-citation></ref><ref id="B155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Niu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>A</given-names></string-name></person-group>. 
<article-title>SIRT1-dependent mitochondrial biogenesis supports therapeutic effects of resveratrol against neurodevelopment damage by fluoride</article-title>. <source>Theranostics</source>. <year>2020</year>;<volume>10</volume>(<issue>11</issue>):<fpage>4822</fpage>&#8211;<lpage>4838</lpage>.<pub-id pub-id-type="pmid">32308752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.42387</pub-id><pub-id pub-id-type="pmcid">PMC7163447</pub-id></mixed-citation></ref><ref id="B156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wei</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>D</given-names></string-name></person-group>. 
<article-title>SIRT1-mediated deacetylation of FOXO3 enhances mitophagy and drives hormone resistance in endometrial cancer</article-title>. <source>Mol Med</source>. <year>2024</year>;<volume>30</volume>(<issue>1</issue>):<fpage>147</fpage>.<pub-id pub-id-type="pmid">39266959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10020-024-00915-7</pub-id><pub-id pub-id-type="pmcid">PMC11391609</pub-id></mixed-citation></ref><ref id="B157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>D</given-names></string-name></person-group>. 
<article-title>A SIRT1 activator, ginsenoside Rc, promotes energy metabolism in cardiomyocytes and neurons</article-title>. <source>J Am Chem Soc</source>. <year>2021</year>;<volume>143</volume>(<issue>3</issue>):<fpage>1416</fpage>&#8211;<lpage>1427</lpage>.<pub-id pub-id-type="pmid">33439015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.0c10836</pub-id></mixed-citation></ref><ref id="B158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>QQ</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>ZR</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Xian</surname><given-names>YF</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>ZX</given-names></string-name></person-group>. 
<article-title>Patchouli alcohol ameliorates the learning and memory impairments in an animal model of Alzheimer&#8217;s disease via modulating SIRT1</article-title>. <source>Phytomedicine</source>. <year>2022</year>;<volume>106</volume>:
<elocation-id>Article 154441</elocation-id>.<pub-id pub-id-type="pmid">36108371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phymed.2022.154441</pub-id></mixed-citation></ref><ref id="B159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Majeed</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Halabi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Madani</surname><given-names>AY</given-names></string-name>, <string-name name-style="western"><surname>Engelke</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bhagwat</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Abdesselem</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Agha</surname><given-names>MV</given-names></string-name>, <string-name name-style="western"><surname>Vakayil</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Courjaret</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Goswami</surname><given-names>N</given-names></string-name>, <etal>et al.</etal></person-group><article-title>SIRT1 promotes lipid metabolism and mitochondrial biogenesis in adipocytes and coordinates adipogenesis by targeting key enzymatic pathways</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>8177</fpage>.<pub-id pub-id-type="pmid">33854178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-87759-x</pub-id><pub-id pub-id-type="pmcid">PMC8046990</pub-id></mixed-citation></ref><ref id="B160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Latorre-Leal</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez-Rodriguez</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Franchini</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Nikolidakis</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Danilidou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Delac</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Varshney</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Arroyo-Garcia</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Eroli</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Winbald</surname><given-names>B</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Cyp46a1-mediated cholesterol turnover induces sex-specific changes in cognition and counteracts memory loss in ovariectomized mice</article-title>. <source>Sci Adv</source>. <year>2024</year>;<volume>10</volume>(<issue>4</issue>):
<elocation-id>Article eadj1354</elocation-id>.<pub-id pub-id-type="pmid">38266095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adj1354</pub-id><pub-id pub-id-type="pmcid">PMC10807813</pub-id></mixed-citation></ref><ref id="B161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xiong</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>NAD<sup>+</sup>-boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer&#8217;s disease via ATF4-dependent mitochondrial UPR</article-title>. <source>Cell Death Dis</source>. <year>2024</year>;<volume>15</volume>(<issue>10</issue>):<fpage>744</fpage>.<pub-id pub-id-type="pmid">39394148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-024-07062-1</pub-id><pub-id pub-id-type="pmcid">PMC11470026</pub-id></mixed-citation></ref><ref id="B162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pandit</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>G&#246;tz</surname><given-names>J</given-names></string-name></person-group>. 
<article-title>The blood-brain barrier: Physiology and strategies for drug delivery</article-title>. <source>Adv Drug Deliv Rev</source>. <year>2020</year>;<volume>165&#8211;166</volume>:<fpage>1</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2019.11.009</pub-id><pub-id pub-id-type="pmid">31790711</pub-id></mixed-citation></ref><ref id="B163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pedder</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Sonabend</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Cearns</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Michael</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Zakaria</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Heimberger</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Jenkinson</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Dickens</surname><given-names>D</given-names></string-name></person-group>. 
<article-title>Crossing the blood-brain barrier: Emerging therapeutic strategies for neurological disease</article-title>. <source>Lancet Neurol</source>. <year>2025</year>;<volume>24</volume>(<issue>3</issue>):<fpage>246</fpage>&#8211;<lpage>260</lpage>.<pub-id pub-id-type="pmid">39862873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(24)00476-9</pub-id><pub-id pub-id-type="pmcid">PMC12242972</pub-id></mixed-citation></ref><ref id="B164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cerutti</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pirinen</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lamperti</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Marchet</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sauve</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Leoni</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Schon</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Dantzer</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Auwerx</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>NAD<sup>+</sup>-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease</article-title>. <source>Cell Metab</source>. <year>2014</year>;<volume>19</volume>(<issue>6</issue>):<fpage>1042</fpage>&#8211;<lpage>1049</lpage>.<pub-id pub-id-type="pmid">24814483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2014.04.001</pub-id><pub-id pub-id-type="pmcid">PMC4051987</pub-id></mixed-citation></ref><ref id="B165"><label>165.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sung</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>HC</given-names></string-name></person-group>. 
<article-title>SIRT1-dependent PGC-1&#945; deacetylation by SRT1720 rescues progression of atherosclerosis by enhancing mitochondrial function</article-title>. <source>Biochim Biophys Acta Mol Cell Biol Lipids</source>. <year>2024</year>;<volume>1869</volume>(<issue>3</issue>):
<elocation-id>Article 159453</elocation-id>.<pub-id pub-id-type="pmid">38244675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbalip.2024.159453</pub-id></mixed-citation></ref><ref id="B166"><label>166.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rius-P&#233;rez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Torres-Cuevas</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Mill&#225;n</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ortega</surname><given-names>&#193;L</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez</surname><given-names>S</given-names></string-name></person-group>. 
<article-title>PGC-1&#945;, inflammation, and oxidative stress: An integrative view in metabolism</article-title>. <source>Oxidative Med Cell Longev</source>. <year>2020</year>;<volume>2020</volume>:
<elocation-id>Article 1452696</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/1452696</pub-id><pub-id pub-id-type="pmcid">PMC7085407</pub-id><pub-id pub-id-type="pmid">32215168</pub-id></mixed-citation></ref><ref id="B167"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>D</given-names></string-name></person-group>. 
<article-title>Dietary kaempferol exerts anti-obesity effects by inducing the browing of white adipocytes via the AMPK/SIRT1/PGC-1&#945; signaling pathway</article-title>. <source>Curr Res Food Sci</source>. <year>2024</year>;<volume>8</volume>:
<elocation-id>Article 100728</elocation-id>.<pub-id pub-id-type="pmid">38577419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.crfs.2024.100728</pub-id><pub-id pub-id-type="pmcid">PMC10990952</pub-id></mixed-citation></ref><ref id="B168"><label>168.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yeapuri</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Machhi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Foster</surname><given-names>EG</given-names></string-name>, <string-name name-style="western"><surname>Kadry</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bhattarai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sil</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sapkota</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Srivastava</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Amyloid precursor protein and presenilin-1 knock-in immunodeficient mice exhibit intraneuronal a&#946; pathology, microgliosis, and extensive neuronal loss</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>;<volume>21</volume>(<issue>4</issue>):
<elocation-id>Article e70084</elocation-id>.<pub-id pub-id-type="pmid">40195277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.70084</pub-id><pub-id pub-id-type="pmcid">PMC11975631</pub-id></mixed-citation></ref><ref id="B169"><label>169.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mendoza</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Robichaux</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ramirez</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Karch</surname><given-names>J</given-names></string-name></person-group>. 
<article-title>Inhibition of the MPTP and lipid peroxidation is additively protective against I/R injury</article-title>. <source>Circ Res</source>. <year>2024</year>;<volume>134</volume>(<issue>10</issue>):<fpage>1292</fpage>&#8211;<lpage>1305</lpage>.<pub-id pub-id-type="pmid">38618716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.123.323882</pub-id><pub-id pub-id-type="pmcid">PMC11081482</pub-id></mixed-citation></ref><ref id="B170"><label>170.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saftig</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Puertollano</surname><given-names>R</given-names></string-name></person-group>. 
<article-title>How lysosomes sense, integrate, and cope with stress</article-title>. <source>Trends Biochem Sci</source>. <year>2021</year>;<volume>46</volume>(<issue>2</issue>):<fpage>97</fpage>&#8211;<lpage>112</lpage>.<pub-id pub-id-type="pmid">33012625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibs.2020.09.004</pub-id><pub-id pub-id-type="pmcid">PMC7855039</pub-id></mixed-citation></ref><ref id="B171"><label>171.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tsap</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Shcherbata</surname><given-names>HR</given-names></string-name></person-group>. 
<article-title>The balancing act between lipid droplets and lysosomes for membrane functionality in age-related neurodegeneration and inflammation</article-title>. <source>Prog Lipid Res</source>. <year>2025</year>;<volume>99</volume>:
<elocation-id>Article 101341</elocation-id>.<pub-id pub-id-type="pmid">40482724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.plipres.2025.101341</pub-id></mixed-citation></ref><ref id="B172"><label>172.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jo</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>NY</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname></string-name></person-group>. 
<article-title>Peroxisome quality control and dysregulated lipid metabolism in neurodegenerative diseases</article-title>. <source>Exp Mol Med</source>. <year>2020</year>;<volume>52</volume>(<issue>9</issue>):<fpage>1486</fpage>&#8211;<lpage>1495</lpage>.<pub-id pub-id-type="pmid">32917959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-020-00503-9</pub-id><pub-id pub-id-type="pmcid">PMC8080768</pub-id></mixed-citation></ref><ref id="B173"><label>173.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gonzales</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Garbarino</surname><given-names>VR</given-names></string-name>, <string-name name-style="western"><surname>Pollet</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Palavicini</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Kellogg</surname><given-names>DL</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Kraig</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Orr</surname><given-names>ME</given-names></string-name></person-group>. 
<article-title>Biological aging processes underlying cognitive decline and neurodegenerative disease</article-title>. <source>J Clin Invest</source>. <year>2022</year>;<volume>132</volume>(<issue>10</issue>):
<elocation-id>Article e158453</elocation-id>.<pub-id pub-id-type="pmid">35575089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI158453</pub-id><pub-id pub-id-type="pmcid">PMC9106343</pub-id></mixed-citation></ref><ref id="B174"><label>174.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>XY</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>GH</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Masters</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Antiageing strategy for neurodegenerative diseases: From mechanisms to clinical advances</article-title>. <source>Signal Transduct Target Ther</source>. <year>2025</year>;<volume>10</volume>(<issue>1</issue>):<fpage>76</fpage>.<pub-id pub-id-type="pmid">40059211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-025-02145-7</pub-id><pub-id pub-id-type="pmcid">PMC11891338</pub-id></mixed-citation></ref><ref id="B175"><label>175.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mallick</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Maity</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mondal</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Meitei</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Saxena</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sahu</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Chakrabarti</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Chakrabarti</surname><given-names>S</given-names></string-name></person-group>. 
<article-title>The impact of ERUPR on mitochondrial integrity mediated by PDK4</article-title>. <source>Cell Death Dis</source>. <year>2025</year>;<volume>16</volume>(<issue>1</issue>):<fpage>573</fpage>.<pub-id pub-id-type="pmid">40730554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-025-07743-5</pub-id><pub-id pub-id-type="pmcid">PMC12307875</pub-id></mixed-citation></ref><ref id="B176"><label>176.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Barzilai</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Crandall</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Kritchevsky</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Espeland</surname><given-names>MA</given-names></string-name></person-group>. 
<article-title>Metformin as a tool to target aging</article-title>. <source>Cell Metab</source>. <year>2016</year>;<volume>23</volume>(<issue>6</issue>):<fpage>1060</fpage>&#8211;<lpage>1065</lpage>.<pub-id pub-id-type="pmid">27304507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2016.05.011</pub-id><pub-id pub-id-type="pmcid">PMC5943638</pub-id></mixed-citation></ref><ref id="B177"><label>177.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fan</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>ZC</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>Z</given-names></string-name></person-group>. 
<article-title>Metformin attenuates central sensitization by regulating neuroinflammation through the TREM2-SYK signaling pathway in a mouse model of chronic migraine</article-title>. <source>J Neuroinflammation</source>. <year>2024</year>;<volume>21</volume>(<issue>1</issue>):<fpage>318</fpage>.<pub-id pub-id-type="pmid">39627853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-024-03313-2</pub-id><pub-id pub-id-type="pmcid">PMC11613737</pub-id></mixed-citation></ref><ref id="B178"><label>178.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jamwal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Blackburn</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Elsworth</surname><given-names>JD</given-names></string-name></person-group>. 
<article-title>PPAR&#947;/PGC1&#945; signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders</article-title>. <source>Pharmacol Ther</source>. <year>2021</year>;<volume>219</volume>:
<elocation-id>Article 107705</elocation-id>.<pub-id pub-id-type="pmid">33039420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2020.107705</pub-id><pub-id pub-id-type="pmcid">PMC7887032</pub-id></mixed-citation></ref><ref id="B179"><label>179.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chi</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Shu</surname><given-names>W</given-names></string-name></person-group>. 
<article-title>Recent mitochondria-immobilized fluorescent probes for high-fidelity bioimaging: From design to application</article-title>. <source>Coord Chem Rev</source>. <year>2025</year>;<volume>529</volume>:
<elocation-id>Article 216456</elocation-id>.</mixed-citation></ref><ref id="B180"><label>180.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Klymchenko</surname><given-names>AS</given-names></string-name></person-group>. 
<article-title>Fluorescent probes for lipid membranes: From the cell surface to organelles</article-title>. <source>Acc Chem Res</source>. <year>2023</year>;<volume>56</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">36533992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.accounts.2c00586</pub-id></mixed-citation></ref><ref id="B181"><label>181.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reel</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Reel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Trucco</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Jefferson</surname><given-names>E</given-names></string-name></person-group>. 
<article-title>Using machine learning approaches for multi-omics data analysis: A review</article-title>. <source>Biotechnol Adv</source>. <year>2021</year>;<volume>49</volume>:
<elocation-id>Article 107739</elocation-id>.<pub-id pub-id-type="pmid">33794304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biotechadv.2021.107739</pub-id></mixed-citation></ref><ref id="B182"><label>182.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Weng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Unveiling the molecular mechanisms of Danggui-Shaoyao-San against Alzheimer&#8217;s disease in APP/PS1 mice via integrating proteomic and metabolomic approaches</article-title>. <source>Alzheimer&#8217;s Res Ther</source>. <year>2024</year>;<volume>16</volume>(<issue>1</issue>):<fpage>251</fpage>.<pub-id pub-id-type="pmid">39563386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01618-1</pub-id><pub-id pub-id-type="pmcid">PMC11577849</pub-id></mixed-citation></ref><ref id="B183"><label>183.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yoshino</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yoshino</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kayser</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Patti</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Franczyk</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Mills</surname><given-names>KF</given-names></string-name>, <string-name name-style="western"><surname>Sindelar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pietka</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Patterson</surname><given-names>BW</given-names></string-name>, <string-name name-style="western"><surname>Imai</surname><given-names>SI</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women</article-title>. <source>Science</source>. <year>2021</year>;<volume>372</volume>(<issue>6547</issue>):<fpage>1224</fpage>&#8211;<lpage>1229</lpage>.<pub-id pub-id-type="pmid">33888596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abe9985</pub-id><pub-id pub-id-type="pmcid">PMC8550608</pub-id></mixed-citation></ref><ref id="B184"><label>184.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Keys</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Hallas</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Suissa</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Christensen</surname><given-names>K</given-names></string-name></person-group>. 
<article-title>Emerging uncertainty on the anti-aging potential of metformin</article-title>. <source>Ageing Res Rev</source>. <year>2025</year>;<volume>111</volume>:
<elocation-id>Article 102817</elocation-id>.<pub-id pub-id-type="pmid">40582648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2025.102817</pub-id></mixed-citation></ref><ref id="B185"><label>185.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name></person-group>. 
<article-title>Microglia in depression: An overview of microglia in the pathogenesis and treatment of depression</article-title>. <source>J Neuroinflammation</source>. <year>2022</year>;<volume>19</volume>(<issue>1</issue>):<fpage>132</fpage>.<pub-id pub-id-type="pmid">35668399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-022-02492-0</pub-id><pub-id pub-id-type="pmcid">PMC9168645</pub-id></mixed-citation></ref><ref id="B186"><label>186.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaur</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Al-Khazaleh</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Bhuyan</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>CG</given-names></string-name></person-group>. 
<article-title>A review of recent curcumin analogues and their antioxidant, anti-inflammatory, and anticancer activities</article-title>. <source>Antioxidants</source>. <year>2024</year>;<volume>13</volume>(<issue>9</issue>):<fpage>1092</fpage>.<pub-id pub-id-type="pmid">39334750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox13091092</pub-id><pub-id pub-id-type="pmcid">PMC11428508</pub-id></mixed-citation></ref><ref id="B187"><label>187.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Harinath</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Nyquist</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Moel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wouters</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hagemeier</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Verkennes</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Tacubao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Nasher</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kauppi</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The bioavailability and blood levels of low-dose rapamycin for longevity in real-world cohorts of normative aging individuals</article-title>. <source>Geroscience</source>. <year>2025</year>;<volume>47</volume>(<issue>4</issue>):<fpage>5681</fpage>&#8211;<lpage>5694</lpage>.<pub-id pub-id-type="pmid">39873920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11357-025-01532-w</pub-id><pub-id pub-id-type="pmcid">PMC12397450</pub-id></mixed-citation></ref><ref id="B188"><label>188.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer&#8217;s disease patients with APOE4<sup>-/-</sup>: A double-blind, randomized placebo-controlled crossover trials</article-title>. <source>Clin Nutr</source>. <year>2020</year>;<volume>39</volume>(<issue>7</issue>):<fpage>2092</fpage>&#8211;<lpage>2105</lpage>.<pub-id pub-id-type="pmid">31694759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clnu.2019.10.017</pub-id></mixed-citation></ref><ref id="B189"><label>189.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gu</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>XR</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shao</surname><given-names>QH</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>MX</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>XL</given-names></string-name></person-group>. 
<article-title>Mitochondrial dysfunction as a therapeutic strategy for neurodegenerative diseases: Current insights and future directions</article-title>. <source>Ageing Res Rev</source>. <year>2024</year>;<volume>102</volume>:
<elocation-id>Article 102577</elocation-id>.<pub-id pub-id-type="pmid">39528070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2024.102577</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="pmc-domain-id">440</journal-id><journal-id journal-id-type="pmc-domain">plosone</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>PLOS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12488027</article-id><article-id pub-id-type="pmcid-ver">PMC12488027.1</article-id><article-id pub-id-type="pmcaid">12488027</article-id><article-id pub-id-type="pmcaiid">12488027</article-id><article-id pub-id-type="pmid">41032496</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0331787</article-id><article-id pub-id-type="publisher-id">PONE-D-25-16329</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Cerebrovascular Diseases</subject><subj-group><subject>Vascular Dementia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cerebrovascular Diseases</subject><subj-group><subject>Vascular Dementia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Mental Health and Psychiatry</subject><subj-group><subject>Dementia</subject><subj-group><subject>Vascular Dementia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Dementia</subject><subj-group><subject>Vascular Dementia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Nervous System</subject><subj-group><subject>Central Nervous System</subject><subj-group><subject>Blood-Brain Barrier</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Nervous System</subject><subj-group><subject>Central Nervous System</subject><subj-group><subject>Blood-Brain Barrier</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Oxidative Stress</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug Interactions</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Protein Interactions</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Amyloid Proteins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzymes</subject><subj-group><subject>Dismutases</subject><subj-group><subject>Superoxide Dismutase</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Enzymes</subject><subj-group><subject>Dismutases</subject><subj-group><subject>Superoxide Dismutase</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Physical Chemistry</subject><subj-group><subject>Chemical Bonding</subject><subj-group><subject>Hydrogen Bonding</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Targeting vascular dementia: Molecular docking and dynamics of natural ligands against neuroprotective proteins</article-title><alt-title alt-title-type="running-head">Molecular docking analysis of natural ligands against vascular dementia</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0003-6563-2148</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zhizhong</given-names></name><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="S">Sen</given-names></name><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="A">Ailong</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wei</surname><given-names initials="C">Chunxian</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Z">Zhiyong</given-names></name><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="Y">Yingchun</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0005-2917-4973</contrib-id><name name-style="western"><surname>Bie</surname><given-names initials="B">Bizhou</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Liu</surname><given-names initials="L">Ling</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>College of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei, China</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>School of Medicine, Wuhan University of Science and Technology, Wuhan, China</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>The Third People&#8217;s Hospital of Hubei Province, Affiliated Jianghan University, Wuhan, Hubei, China</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Hubei Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, China</addr-line></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Jadavji</surname><given-names initials="NM">Nafisa M.</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Southern Illinois University Carbondale, UNITED STATES MINOR OUTLYING ISLANDS</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>18771032136@163.com</email> (BB); <email>18971537282@163.com</email> (LL)</corresp></author-notes><pub-date pub-type="epub"><day>1</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">498120</issue-id><elocation-id>e0331787</elocation-id><history><date date-type="received"><day>26</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 16:25:21.943"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Wang et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Wang et al</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pone.0331787.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="pone.0331787.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="editor-report" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="41032496"><article-title>Targeting vascular dementia: Molecular docking and dynamics of natural ligands against neuroprotective proteins.</article-title><volume>20</volume><issue>10</issue><date><day>1</day><month>10</month><year>2025</year></date><fpage>e0331787</fpage><lpage>e0331787</lpage><source>PLoS One</source><pub-id pub-id-type="doi">10.1371/journal.pone.0331787</pub-id><pub-id pub-id-type="pmid">41032496</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="reviewed-article" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="41032496"><article-title>Targeting vascular dementia: Molecular docking and dynamics of natural ligands against neuroprotective proteins.</article-title><volume>20</volume><issue>10</issue><date><day>1</day><month>10</month><year>2025</year></date><fpage>e0331787</fpage><lpage>e0331787</lpage><source>PLoS One</source><pub-id pub-id-type="doi">10.1371/journal.pone.0331787</pub-id><pub-id pub-id-type="pmid">41032496</pub-id></related-article><abstract><p>Vascular dementia (VaD), a neurodegenerative disease driven by vascular pathology, requires multi-targeted therapeutic strategies. This study employs an integrated in silico approach to evaluate the neuroprotective potential of natural ligands against key proteins implicated in VaD pathogenesis. Using molecular docking and normal mode analysis (NMA), four natural compounds (Galangin, Resveratrol, Curcumin, and Licocumarone) were assessed for their binding affinity and structural influence on six target proteins: APLP1, APOE, CLDN5, SOD1, MMP9, and MTHFR. Docking analysis revealed that galangin exhibited the highest binding affinity to APLP1 (&#8722;8.5 kcal/mol), resveratrol to MTHFR (&#8722;8.1 kcal/mol), and curcumin showed dual efficacy toward APOE (&#8722;7.2 kcal/mol) and MMP9 (&#8722;8.0 kcal/mol). Licocumarone demonstrated notable stabilization of CLDN5 and SOD1. The NMA results indicated ligand-induced stabilization of protein cores and enhanced flexibility in loop regions, which may impact amyloid aggregation, oxidative stress, and blood-brain barrier integrity. Pathway enrichment using the KEGG and Reactome databases identified significant involvement of the IL-17 and TNF signaling pathways, along with leukocyte transendothelial migration, linking inflammation with vascular dysfunction. APOE emerged as a central node within the protein-protein interaction network, highlighting its regulatory importance. This study highlights the therapeutic relevance of natural ligands as cost-effective modulators of multiple VaD-associated pathways. The combined use of molecular docking, protein dynamics, and enrichment analyses provides a comprehensive computational framework for early-stage drug discovery. These findings warrant further experimental validation to advance the development of targeted, mechanism-driven interventions for vascular dementia.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>Project of Hubei Provincial Administration of Traditional Chinese Medicine</institution></funding-source><award-id>ZY2025Q007</award-id></award-group><funding-statement>This work was funded by the Project of Hubei Provincial Administration of Traditional Chinese Medicine (grant ZY2025Q007).</funding-statement></funding-group><counts><fig-count count="27"/><table-count count="7"/><page-count count="33"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its <xref rid="sec025" ref-type="sec">Supporting Information</xref> files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its <xref rid="sec025" ref-type="sec">Supporting Information</xref> files.</p></notes></front><body><sec id="sec001"><title>1. Overview of Vascular Dementia (VaD)</title><p>Vascular dementia (VaD) is characterized by cerebral infarcts, myelin loss, and white matter lesions that are usually associated with amyloid angiopathy. These vascular lesions result in neuronal loss and synaptic breakdown and have a profound effect on cognitive processes [<xref rid="pone.0331787.ref001" ref-type="bibr">1</xref>]. Its pathophysiology is attributed to chronic cerebral hypoperfusion, which interferes with autophagy and results in hippocampal and neuronal loss [<xref rid="pone.0331787.ref001" ref-type="bibr">1</xref>]. In addition, endothelial dysfunction and decreased nitric oxide bioavailability are responsible for vascular disease, which is a characteristic of VaD [<xref rid="pone.0331787.ref002" ref-type="bibr">2</xref>]. Oxidative stress is significant in VaD pathogenesis, with an imbalance between pro-oxidant and antioxidant species resulting in increased levels of reactive oxygen species (ROS) [<xref rid="pone.0331787.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0331787.ref003" ref-type="bibr">3</xref>]. Endothelial dysfunction and vascular diseases result from an oxidative environment. Inflammation is another important factor that disrupts neuroinflammation and apoptosis and causes damage to endothelial and neuronal cells [<xref rid="pone.0331787.ref001" ref-type="bibr">1</xref>]. Endothelial function is also impaired by oxidative stress, which can influence amyloid precursor protein processing, resulting in amyloid-beta accumulation in the blood vessels of the brain [<xref rid="pone.0331787.ref004" ref-type="bibr">4</xref>].</p><p>Furthermore, Apolipoprotein E (ApoE) is a late-onset genetic risk factor for dementia, which is strongly associated with Alzheimer&#8217;s disease. The ApoE epsilon 4 allele is related to elevated beta-amyloid deposition in the cerebral cortex, which promotes vascular and [<xref rid="pone.0331787.ref002" ref-type="bibr">2</xref>] neurodegenerative pathologies [<xref rid="pone.0331787.ref005" ref-type="bibr">5</xref>&#8211;<xref rid="pone.0331787.ref007" ref-type="bibr">7</xref>]. The processing of amyloid precursor protein (APP) is subject to oxidative stress, resulting in the enhanced secretion of amyloid-beta peptides. It is involved in the amyloidogenic pathway in the pathogenesis of vascular diseases and in amyloid deposition in the brain. Claudin-5 is a tight junction protein involved in blood-brain barrier integrity. Its malfunction results in increased permeability and is implicated in the pathogenesis of vascular dementia by causing harmful substances to penetrate the brain [<xref rid="pone.0331787.ref008" ref-type="bibr">8</xref>]. Superoxide dismutase (SOD) is an antioxidant enzyme that prevents oxidative stress by catalyzing the conversion of superoxide radicals into oxygen and hydrogen peroxide. Its function in vascular dementia includes the prevention of endothelial cell damage by oxidation and preservation of vascular function. Matrix metalloproteinase-9 (MMP-9) is involved in the degradation of extracellular matrix components. MMP-9 overexpression may lead to disruption of the blood-brain barrier, vascular injury, and neuroinflammation in dementia [<xref rid="pone.0331787.ref001" ref-type="bibr">1</xref>]. Methylenetetrahydrofolate reductase (MTHFR) is an enzyme that is involved in homocysteine metabolism. MTHFR mutations have the potential to result in hyperhomocysteinemia, endothelial dysfunction, and oxidative stress risk factors for vascular diseases and dementia [<xref rid="pone.0331787.ref003" ref-type="bibr">3</xref>]. Therefore, targeted proteins, such as ApoE and APP, play significant roles in the progression of vascular dementia, highlighting potential therapeutic targets for intervention. <xref rid="pone.0331787.t001" ref-type="table">Table 1</xref> summarizes the different proteins and their roles in vascular dementia.</p><table-wrap position="float" id="pone.0331787.t001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.t001</object-id><label>Table 1</label><caption><title>The roles of different proteins in vascular dementia.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0331787.t001g" position="float" orientation="portrait" xlink:href="pone.0331787.t001.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Protein</th><th align="left" rowspan="1" colspan="1">Main Function</th><th align="left" rowspan="1" colspan="1">Role in VaD</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>APOE</bold>
</td><td align="left" rowspan="1" colspan="1">Lipid metabolism, BBB maintenance</td><td align="left" rowspan="1" colspan="1">APOE4 variant increases the risk of VaD via neurovascular dysfunction</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>APLP1</bold>
</td><td align="left" rowspan="1" colspan="1">Amyloid processing, synaptic function</td><td align="left" rowspan="1" colspan="1">Affects cerebrovascular amyloid deposition, leading to vascular pathology</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>CLDN5</bold>
</td><td align="left" rowspan="1" colspan="1">Maintains BBB integrity</td><td align="left" rowspan="1" colspan="1">Loss leads to vascular leakage, neuroinflammation, and cognitive decline</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOD1</bold>
</td><td align="left" rowspan="1" colspan="1">Antioxidant defense</td><td align="left" rowspan="1" colspan="1">Reduced SOD activity leads to oxidative stress-induced neurovascular damage</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MMP9</bold>
</td><td align="left" rowspan="1" colspan="1">Extracellular matrix remodeling</td><td align="left" rowspan="1" colspan="1">High levels contribute to BBB breakdown, white matter lesions, and vascular injury</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MTHFR</bold>
</td><td align="left" rowspan="1" colspan="1">Homocysteine metabolism</td><td align="left" rowspan="1" colspan="1">Mutations lead to vascular dysfunction, increasing VaD risk</td></tr></tbody></table></alternatives></table-wrap><p>We chose four natural ligands for this study because natural substances are known to have fewer side effects and are more cost effective. Curcumin, a polyphenolic molecule extracted from turmeric, exhibits abundant anti-inflammatory and antioxidant activities. Curcumin has been extensively studied for its ability to prevent amyloid protein aggregation, a feature of neurodegenerative diseases, such as Alzheimer&#8217;s disease [<xref rid="pone.0331787.ref009" ref-type="bibr">9</xref>&#8211;<xref rid="pone.0331787.ref011" ref-type="bibr">11</xref>]. Galangin is a flavonoid found in <italic toggle="yes">Alpinia officinarum</italic> and in other plants. Galangin possesses antioxidant and anti-inflammatory properties that have been implicated in neuroprotection. Nonetheless, Licocumarone, a derivative of coumarin, has been shown to exhibit therapeutic activities, such as anti-inflammatory and antioxidant activities, and is known to help treat neurodegenerative disorders. Moreover, Resveratrol is a polyphenolic compound found in red wine and certain plants. It has been found to induce non-amyloidogenic pathways, enhance amyloid-beta clearance, and reduce neuronal damage, thereby emerging as a potential neuroprotective drug [<xref rid="pone.0331787.ref012" ref-type="bibr">12</xref>&#8211;<xref rid="pone.0331787.ref014" ref-type="bibr">14</xref>]. Curcumin has shown great promise in reducing amyloid burden and rescuing neuronal injury in several models of neurodegenerative diseases, such as Alzheimer&#8217;s and Parkinson&#8217;s diseases [<xref rid="pone.0331787.ref009" ref-type="bibr">9</xref>&#8211;<xref rid="pone.0331787.ref011" ref-type="bibr">11</xref>]. Resveratrol has been found to increase the clearance of amyloid-beta peptides and reduce neuronal injury, which are important in the management of Alzheimer&#8217;s disease [<xref rid="pone.0331787.ref012" ref-type="bibr">12</xref>&#8211;<xref rid="pone.0331787.ref014" ref-type="bibr">14</xref>]. Galangin and Licocumarone have been studied in detail because their antioxidant and anti-inflammatory activities imply their possible neuroprotective functions.</p><p>The study&#8217;s major aim is to explore the interactions of selected proteins with natural ligands such as curcumin, galangin, licocumarone, and resveratrol using molecular docking. This can help determine the possible mechanisms through which natural compounds exert neuroprotective actions, specifically in the context of vascular dementia [<xref rid="pone.0331787.ref015" ref-type="bibr">15</xref>]. Molecular docking experiments can shed light on the binding affinities and binding sites of these ligands towards target proteins and can lead to the identification of new therapeutic avenues for neurodegenerative diseases [<xref rid="pone.0331787.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0331787.ref017" ref-type="bibr">17</xref>].</p><p>Research combining normal mode analysis (NMA) and molecular docking in the context of VaD therapies is lacking. NMA offers information about the inherent flexibility and collective movement of proteins, which can have a substantial impact on ligand binding and drug efficacy. Conversely, molecular docking is commonly employed to predict the binding and orientation of small molecules to protein targets [<xref rid="pone.0331787.ref018" ref-type="bibr">18</xref>]. By considering protein dynamics throughout the docking process, the combination of these two approaches may provide a more thorough understanding of protein-ligand interactions. However, the use of NMA in conjunction with docking has not been documented in the literature for VaD therapies [<xref rid="pone.0331787.ref019" ref-type="bibr">19</xref>]. Previous research has concentrated on static docking techniques and, occasionally, molecular dynamics simulations, but has not taken advantage of NMA&#8217;s special benefits of NMA to investigate the potential effects of protein conformational changes on drug binding and therapeutic results. This is a major knowledge gap because combining NMA and docking should improve the predictive ability of computational drug discovery for VaD and possibly result in the discovery of more potent treatment candidates [<xref rid="pone.0331787.ref020" ref-type="bibr">20</xref>].</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>1) Selection of signaling proteins</title><p>The selection of these proteins, namely Apolipoprotein E (APOE), amyloid beta precursor protein (APLP1), Claudin-5 (CLDN5), Superoxide Dismutase (SOD1), Matrix Metalloproteinase-9 (MMP-9), and Methylenetetrahydrofolate Reductase (MTHFR), was based on KEGG pathway analysis, enabling the selection of key proteins that directly hold mechanisms and regulatory roles in vascular dementia (VaD) [<xref rid="pone.0331787.ref021" ref-type="bibr">21</xref>]. These proteins were selected because they are implicated in crucial pathways such as neuroinflammation, blood-brain barrier integrity, oxidative stress, amyloid metabolism, and homocysteine regulation. These pathways have been proposed to be involved in the pathogenesis of vascular dementia [<xref rid="pone.0331787.ref022" ref-type="bibr">22</xref>].</p><p>Although several genes were enriched by KEGG analysis, we chose APOE, APLP1, CLDN5, SOD1, MMP9, and MTHFR due to their repeated enrichment across multiple VaD-relevant pathways (e.g., IL-17, TNF, leukocyte transendothelial migration, oxidative stress), central roles in PPI networks, and functional conservation across species. Their roles in vascular integrity, amyloid metabolism, oxidative stress management, and neuroinflammation made them ideal candidates for structural modeling and pharmacological screening.</p></sec><sec id="sec004"><title>2) Investigating the Co-expression of genes</title><p>CLDN5, APOE, MMP9, APLP1, SOD1, and MTHFR were identified through a comprehensive literature analysis that emphasized their involvement in vascular dementia (VaD). Functional associations and co-expression relationships among genes/proteins across numerous organisms, such as human brain tissues and model organisms (Mus musculus, Danio rerio, and Gasterosteus aculeatus), were visualized using STRING Database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://string-db.org/cgi/coexpression?taskId=b3Ei1T4T2&amp;sessionId=bmZLtQmlVdxb&amp;allnodes=1" ext-link-type="uri">https://string-db.org/cgi/coexpression?taskId=b3Ei1T4T2&amp;sessionId=bmZLtQmlVdxb&amp;allnodes=1</ext-link>), version 12.0. Gene co-expression analysis was conducted using the STRING database. We implemented a minimum interaction score of 0.7 to ensure robust confidence in the interactions. STRING&#8217;s &#8220;Gene Coexpression&#8221; visualization tool was employed to construct functional co-expression networks that illustrate interactions and functional modules that are pertinent to vascular well-being [<xref rid="pone.0331787.ref023" ref-type="bibr">23</xref>,<xref rid="pone.0331787.ref024" ref-type="bibr">24</xref>].</p></sec><sec id="sec005"><title>3) Protein-Protein interaction</title><p>PPI Network Analysis of the STRING database (version 12.0) investigated the Protein-Protein Interaction (PPI) network by utilizing a high-confidence criterion set at an interaction score of 0.7 to analyze genes (CLDN5, APOE, MMP9, APLP1, SOD1, and MTHFR) [<xref rid="pone.0331787.ref025" ref-type="bibr">25</xref>]. The Network Analyzer plugin was employed to observe and investigate the network generating centrality metrics, including degree, betweenness centrality, and clustering coefficients, in Cytoscape (version 3.10.0).</p></sec><sec id="sec006"><title>4) Gene set enrichment analysis (GSEA)</title><p>Gene set enrichment analysis (GSEA) was conducted using Enrichr, a bioinformatics tool frequently employed for functional annotation of gene lists. The Reactome pathways 2024 database and KEGG 2021 Human pathways were employed to analyze the target genes (CLDN5, APOE, MMP9, APLP1, SOD1, and MTHFR) [<xref rid="pone.0331787.ref026" ref-type="bibr">26</xref>]. Statistical significance was evaluated using p-values and modified q-values to determine the false discovery rate. Manhattan plots, UMAP clustering (utilizing the Leiden algorithm), and volcano plots were implemented to emphasize pathways that were exceedingly abundant in information. Enhanced pathways with high statistical significance and odds ratios were prioritized to identify significant biological processes associated with vascular dementia.</p></sec><sec id="sec007"><title>5) Protein sequence retrieval and modelling</title><p>Protein sequences were obtained from UniProt (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.uniprot.org/" ext-link-type="uri">https://www.uniprot.org/</ext-link>), an exhaustive and well-curated protein sequence database that provides elaborate annotations, functional insights, and structural information about proteins. Although some experimentally analyzed structures from the Protein Data Bank (PDB) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org/" ext-link-type="uri">https://www.rcsb.org/</ext-link>) are available, we preferred modelling based on trRosetta (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://yanglab.qd.sdu.edu.cn/trRosetta/" ext-link-type="uri">https://yanglab.qd.sdu.edu.cn/trRosetta/</ext-link>) to ensure full-length completeness. This led to consistent modeling across different proteins and circumvented variations under different experimental conditions [<xref rid="pone.0331787.ref027" ref-type="bibr">27</xref>]. The predicted models were also optimized for use in molecular docking, making them suitable for studying protein-ligand interactions in the context of vascular dementia.</p></sec><sec id="sec008"><title>6) Selection of natural ligands</title><p>The chemical structures of these natural ligands were determined using PubChem and ChEMBL databases, which provide detailed molecular information [<xref rid="pone.0331787.ref028" ref-type="bibr">28</xref>].</p></sec><sec id="sec009"><title>7) Active site prediction and molecular docking</title><p>The active site for each protein was determined using DoGSiteScorer (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://proteins.plus/" ext-link-type="uri">https://proteins.plus/</ext-link>), and molecular docking was conducted using AutoDock Vina, a popular tool for predicting how small molecules, such as drugs, bind to receptors with known 3D structures. AutoDock offers a collection of automated docking tools to predict ligand binding to macromolecular targets [<xref rid="pone.0331787.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0331787.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0331787.ref030" ref-type="bibr">30</xref>]. Each ligand was docked independently five times against its particular protein target with AutoDock Vina, allowing for random variance in initial conformations. The pose with the lowest binding energy (in kcal/mol) was chosen for further study, corresponding with the normal practice in molecular docking. To assess the consistency and variability of the docking process, we averaged the binding scores from all five runs per ligand-protein pair and calculated the standard deviation. Supplementary Tables 1 and 2 in <xref rid="pone.0331787.s001" ref-type="supplementary-material">S1 File</xref> summarizes these values, which validate the stability and reproducibility of binding predictions.</p></sec><sec id="sec010"><title>8) Scoring functions</title><p>The assessment of docking outcomes depends mainly on scoring functions that estimate the affinity and stability of ligand&#8211;receptor binding. The most important measures are the binding energy, which indicates the strength of the ligand-target affinity, and the inhibition constant, which is a measure of ligand potency. The presence of hydrogen bonds and hydrophobic interactions was also evaluated to determine the type of binding [<xref rid="pone.0331787.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0331787.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0331787.ref030" ref-type="bibr">30</xref>].</p></sec><sec id="sec011"><title>9) Normal mode analysis of the docked complex</title><p>Normal mode analysis (NMA) was performed using iMODS. It calculates molecular mobility and structural flexibility by including the coordinates of the docked complex. iMODS presents the deformability plot findings, eigenvalues, covariance matrix, and elastic network.</p></sec><sec id="sec012"><title>11) Molecular dynamics simulation and post-processing analysis</title><p>All protein-ligand complexes were subjected to 100 ns molecular dynamics simulations using (e.g., GROMACS) with NPT ensemble settings at 300&#8201;K and 1 atm pressure. Trajectory analyses were used to determine structural stability and conformational behavior. Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), radius of gyration (Rg), and solvent-accessible surface area (SASA) were calculated using built-in GROMACS tools (gmx rmsd, gmx rmsf, gmx gyrate, gmx sasa) and visualized with xmgrace. These measurements were utilized to analyze the complexes&#8217; dynamic behavior and binding stability during the simulation period.</p></sec><sec id="sec013"><title>11) Visualization tools used</title><p>Docking results were analyzed and visualized using visualization tools such as Discovery Studio and Ligplot. These tools enable researchers to visually analyze binding interactions, evaluate ligand fit within the active site, and highlight the essential interactions that contribute to binding affinity. These visualizations are beneficial for assessing docking data and for directing further experimental validation [<xref rid="pone.0331787.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0331787.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0331787.ref030" ref-type="bibr">30</xref>].</p></sec></sec><sec sec-type="results" id="sec014"><title>Results</title><sec id="sec015"><title>1) Retrieval of signaling proteins</title><p>The chosen proteins Apolipoprotein E (APOE), Amyloid Beta Precursor-Like Protein (APLP), Claudin-5 (CLDN5), Superoxide Dismutase (SOD), Matrix Metalloproteinase-9 (MMP-9), and Methylenetetrahydrofolate Reductase (MTHFR) play a key role in the progression of vascular dementia. Amyloid metabolism and neurodegeneration are closely associated with APOE and APLP.</p><p>APOE regulates amyloid-beta clearance; APLP governs neuronal signaling. A key characteristic of both Alzheimer&#8217;s disease and vascular dementia is the accumulation of amyloid-beta, which arises from the dysfunction of these proteins. APOE interacts with the receptor for advanced glycation end products (RAGE), a key component of the neuroinflammatory pathways that exacerbate brain damage (<xref rid="pone.0331787.g001" ref-type="fig">Fig 1</xref>).</p><fig position="float" id="pone.0331787.g001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g001</object-id><label>Fig 1</label><caption><title>Age-Rage Signaling pathway which involves Amyloid beta precursor-like protein.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g001.jpg"/></fig><p>Claudin-5 (CLDN5) (<xref rid="pone.0331787.g002" ref-type="fig">Fig 2</xref>) and Matrix Metalloproteinase-9 (MMP-9) are essential for preserving the integrity of the blood-brain barrier (BBB). Tight junctions that regulate blood-brain barrier permeability mostly rely on CLDN5, whereas MMP-9 facilitates extracellular matrix remodeling [<xref rid="pone.0331787.ref031" ref-type="bibr">31</xref>]. Dysregulation of these proteins leads to disruption of the blood-brain barrier, increased permeability, and infiltration of neurotoxic substances into the brain, thereby accelerating the progression of vascular dementia. Senescence-associated secretory phenotype (SASP) MMP-9 induces inflammation and tissue alteration when elevated in the SASP (<xref rid="pone.0331787.g003" ref-type="fig">Fig 3</xref>). It facilitates inflammatory signals and tissue damage in vascular dementia, resulting in the degradation of the extracellular matrix (ECM).</p><fig position="float" id="pone.0331787.g002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g002</object-id><label>Fig 2</label><caption><title>Claudin-5 is involved in one of the main proteins that control the blood-brain barrier (BBB).</title><p>Higher permeability due to dysfunction lets harmful chemicals enter the brain leading to vascular dementia.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g002.jpg"/></fig><fig position="float" id="pone.0331787.g003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g003</object-id><label>Fig 3</label><caption><title>Matrix metalloproteinase-9 is involved in the SASP signaling pathway.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g003.jpg"/></fig><p>The one-carbon metabolism pathway regulates homocysteine concentrations through MTHFR, a methylenetetrahydrofolate reductase. Increased homocysteine levels resulting from MTHFR deficiency are recognized as markers of vascular damage, endothelial impairment, and cognitive deterioration. Homocysteine-induced vascular damage contributes to the pathological development of vascular dementia by promoting neuroinflammation and reducing the cerebral blood flow. THF is a key folate metabolism intermediate [<xref rid="pone.0331787.ref021" ref-type="bibr">21</xref>]. It is crucial for DNA synthesis, methylation, and homocysteine stabilization. Brain function is dependent on Thymidylate Synthase (EC: 2.1.1.45), which ensures DNA replication and repair. It also allows 5-Methyl-THF to remethylate homocysteine to methionine via Methylenetetrahydrofolate Reductase (MTHFR; EC: 1.5.1.20, 1.5.1.53, and 1.5.1.54) (<xref rid="pone.0331787.g004" ref-type="fig">Fig 4</xref>). Hyperhomocysteinemia induces endothelial dysfunction, oxidative stress, and neuroinflammation if this pathway fails. This reduces the blood flow in the brain and accelerates neurodegeneration. It also modulates gene expression and histone methylation, thereby affecting neuronal survival and cognition. Since 5,10-Methylene-THF deficiency or breakdown can worsen vascular and neurological illnesses, it is crucial to vascular dementia.</p><fig position="float" id="pone.0331787.g004" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g004</object-id><label>Fig 4</label><caption><title>Central Role of 5,10-Methylene-THF in DNA Synthesis, Methylation, and Homocysteine Regulation; One-Carbon Metabolism Pathway.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g004.jpg"/></fig><p>Oxidative stress is a primary contributor to brain damage in vascular dementia, and Superoxide Dismutase (SOD1) plays a crucial role in detoxifying reactive oxygen species (ROS). Impaired SOD function leads to excessive ROS accumulation, resulting in oxidative damage, mitochondrial dysfunction, and ultimately neuronal death. Superoxide Dismutase (SOD1) is regulated by FOXO transcription factors in the FOXO signalling pathway (<xref rid="pone.0331787.g005" ref-type="fig">Fig 5</xref>). This increased the oxidative stress response. Mn-SOD reduces &#8220;mitochondrial oxidative stress&#8221; and converts superoxide radicals into harmless molecules, which contributes to vascular dementia [<xref rid="pone.0331787.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0331787.ref033" ref-type="bibr">33</xref>]. Its absence causes (Blood-Brain Barrier) BBB issues, mitochondrial damage, and quicker cell death, which accelerates cognitive impairment in patients with VaD. Neuroinflammation and blood vessel damage result from chronic oxidative stress, outpacing SOD1 activity. Antioxidants and SIRT1 activators may decrease the progression of vascular dementia by repairing the oxidative damage.</p><fig position="float" id="pone.0331787.g005" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g005</object-id><label>Fig 5</label><caption><title>Shows the role of the FOXO signaling pathway and SOD1 in vascular dementia.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g005.jpg"/></fig><p>The selection of proteins for docking investigations in vascular dementia is based on their connections with basic disease pathways. Targeting these proteins may provide therapeutic insights for this deadly disease. These proteins may be used to improve cognitive function in patients with vascular dementia and to delay their progression.</p></sec><sec id="sec016"><title>2) Gene Co-expression analysis</title><p>A study of gene co-expression showed that CLDN5, APOE, MMP9, APLP1, SOD1, and MTHFR are tightly regulated in the human brain tissue. The expression patterns of these genes are similar in model animals such as <italic toggle="yes">Mus musculus</italic>, <italic toggle="yes">Danio rerio</italic>, and <italic toggle="yes">Gasterosteus aculeatus</italic>. The high expression of these genes suggests that they work together to support the vascular well-being, oxidative stress response, and neuroinflammation pathways (<xref rid="pone.0331787.g006" ref-type="fig">Fig 6</xref>). These are important processes associated with vascular dementia (VaD). This demonstrates that dysregulation of one gene can affect the expression of other genes, which in turn supports the role of these genes in the pathophysiology of vasodilation disease (VaD). This finding matches the information already published that these proteins are linked to amyloid processing, changing the structure of cerebrovascular networks, and maintaining the blood-brain barrier.</p><fig position="float" id="pone.0331787.g006" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g006</object-id><label>Fig 6</label><caption><title>These genes were found in humans (left) and model animals (right): CLDN5, APOE, MMP9, APLP1, SOD1, and MTHFR.</title><p>In the co-expression study of genes, the gene co-expression pattern suggested vascular and neurodegenerative processes due to their functional connections.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g006.jpg"/></fig><p>All these factors are fundamental to the pathology of vascular dementia (VaD) pathology. Functional enrichment analysis of CLDN5, APOE, MMP9, APLP1, SOD1, and MTHFR revealed their significant association with neurovascular dysfunction and inflammation. Previous studies of co-expression revealed a strong functional link among these genes; the current enrichment analysis validated their shared participation in cerebrovascular control (<xref rid="pone.0331787.g007" ref-type="fig">Fig 7</xref>). The FDR color gradient (from light green to dark blue) reflects the statistical relevance, with lower FDR values suggesting greater enrichment. Furthermore, the bubble size denotes the number of genes linked to each pathway. These results indicated the relevance of these genes as possible hereditary risk factors and therapeutic targets, thereby strengthening their role in VaD.</p><fig position="float" id="pone.0331787.g007" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g007</object-id><label>Fig 7</label><caption><title>Functional enrichment study of CLDN5, APOE, MMP9, APLP1, SOD1, and MTHFR revealed notably enhanced biological processes associated with blood-brain barrier integrity, oxidative stress, and neurovascular dysfunction.</title><p>While the color gradient shows the false discovery rate (FDR), with darker tones denoting greater significance, bubble size indicates the number of related genes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g007.jpg"/></fig></sec><sec id="sec017"><title>3) Protein-protein interaction network</title><p>PPI network analysis revealed strong functional relationships between CLDN5, APOE, MMP9, APLP1, SOD1, and MTHFR, and vascular integrity, oxidative stress, neuroinflammation, and amyloid metabolism. NOS3 and APOE control blood-brain barrier (BBB) integrity and vascular function, whereas CLDN5 and MMP9 maintain the BBV and remodel the extracellular matrix. SOD1 and MTHFR are linked to oxidative stress and endothelial dysfunction, indicating their role in neurovascular injury. This network is related to the pathogenesis of dementia by APLP1 and MMEL1, which help amyloid metabolism and neurodegeneration. Their biological relevance to vascular dementia and therapeutic potential are shown in (<xref rid="pone.0331787.g008" ref-type="fig">Fig 8</xref>).</p><fig position="float" id="pone.0331787.g008" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g008</object-id><label>Fig 8</label><caption><title>The protein-protein interaction (PPI) network of CLDN5, APOE, MMP9, APLP1, SOD1, and MTHFR indicated their functional relationship with vascular integrity, oxidative stress, neuroinflammation, and amyloid metabolism.</title><p>NOS3 and APOE are key hubs for blood-brain barrier regulation and vascular dysfunction. The colored edges indicate many functional interactions, indicating the role of these proteins in the pathogenesis of vascular dementia.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g008.jpg"/></fig><p>Protein-protein interaction (PPI) network analysis revealed that APOE acts as a major hub connecting several key pathways involved in vascular dementia (VaD). As shown in <xref rid="pone.0331787.t002" ref-type="table">Table 2</xref>, it exhibits the highest degree (8) and betweenness centrality (0.32), reflecting its central regulatory role. CLDN5 and SOD1 had high clustering coefficients (1.5 and 1.8, respectively), suggesting their involvement in tightly coordinated functional modules. MMP9 and MTHFR, while not as central as APOE, displayed strong connectivity and high edge confidence scores (&gt;0.7), indicating their reliable interactions with other critical proteins.</p><table-wrap position="float" id="pone.0331787.t002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.t002</object-id><label>Table 2</label><caption><title>Network metrics for Protein-Protein Interaction (PPI). The table shows important network measures for certain proteins associated with vascular dementia. Degree shows how many links each protein has, Betweenness Centrality shows how it acts as a network hub, Clustering Coefficient shows how connected its neighbours are, and Edge Confidence Score shows how reliable the interaction is based on estimates from the STRING database.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0331787.t002g" position="float" orientation="portrait" xlink:href="pone.0331787.t002.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Protein</th><th align="left" rowspan="1" colspan="1">Degree</th><th align="left" rowspan="1" colspan="1">Betweenness Centrality</th><th align="left" rowspan="1" colspan="1">Clustering Coefficient</th><th align="left" rowspan="1" colspan="1">Edge Confidence Scores</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">APLP1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.30</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.597</td></tr><tr><td align="left" rowspan="1" colspan="1">APOE</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">0.32</td><td align="left" rowspan="1" colspan="1">1.42</td><td align="left" rowspan="1" colspan="1">0.777</td></tr><tr><td align="left" rowspan="1" colspan="1">CLDN5</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">0.756</td></tr><tr><td align="left" rowspan="1" colspan="1">SOD1</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0.10</td><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">0.631</td></tr><tr><td align="left" rowspan="1" colspan="1">MMP9</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">0.20</td><td align="left" rowspan="1" colspan="1">1.52</td><td align="left" rowspan="1" colspan="1">0.733</td></tr><tr><td align="left" rowspan="1" colspan="1">MTHFR</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0.20</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0.843</td></tr></tbody></table></alternatives></table-wrap><p>The edge confidence scores from STRING reflect the integrated probability of functional associations between protein pairs. In our network, APOE showed well-supported connections with CLDN5 (0.756) and MMP9 (0.733), linking lipid metabolism, vascular integrity, and inflammatory pathways. MTHFR had the highest confidence score (0.843), emphasizing its specific role in homocysteine metabolism and endothelial dysfunction. SOD1, with a moderate score (0.631), is associated with the oxidative stress response and vascular damage, and its clustering suggests tight functional integration. CLDN5 and MMP9, both essential for blood-brain barrier (BBB) regulation and extracellular matrix remodeling, also showed strong interactions, reinforcing their cooperative involvement in the BBB disruption seen in VaD. Although APLP1 had the lowest degree (1) and confidence score (0.597), its relevance to amyloid processing pathways supports its inclusion as a specialized node in the network. Overall, these interaction metrics validated the biological significance of the selected proteins and supported their collective contribution to the molecular framework underlying vascular dementia.</p></sec><sec id="sec018"><title>4) Gene set enrichment analysis (GSEA)</title><p>GSEA was performed using Enrichr, a powerful gene set enrichment analysis (GSEA) application that enables the analysis of lists of genes or proteins based on predominant biological pathways, molecular functions, and disease associations. It is widely used for functional annotation in bioinformatic and systems biology studies. KEGG 2021 and Reactome pathways 2024 were analyzed for the targeted gene set.</p><p>The KEGG pathway enrichment study (<xref rid="pone.0331787.g009" ref-type="fig">Fig 9</xref>) revealed many important biological processes that may play a role in the pathogenesis of vascular dementia. It involves CLDN5 and MMP9. Leukocyte transendothelial migration (p&#8201;=&#8201;0.000476, q&#8201;=&#8201;0.013326) was the most important process. Evidence suggests that folate (MTHFR, p&#8201;=&#8201;0.005986) is associated with homocysteine metabolism and vascular failure. Other pathways worth investigating include cholesterol metabolism (APOE, p&#8201;=&#8201;0.014908), which is consistent with the role of APOE in lipid metabolism and neurodegeneration. Peroxisomes and processes that control aging (SOD1) also suggest a possible role for oxidative stress in the development of disease.</p><fig position="float" id="pone.0331787.g009" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g009</object-id><label>Fig 9</label><caption><title>KEGG 2021 human enrichment study identified the top 10 most important pathways.</title><p>The figure shows the biological paths with the most enriched p-values, q-values, and matched overlapping genes. The p-value shows statistical significance, whereas the q-value corrects for repeated testing errors (false discovery rate). Key pathways include leukocyte transendothelial movement, lipid metabolism, IL-17 signaling, and TNF signaling. Genes such as MMP9, CLDN5, APOE, and SOD1 control these pathways.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g009.jpg"/></fig><p>These immune-related pathways, including IL-17 signaling (p&#8201;=&#8201;0.027874) and TNF signaling (p&#8201;=&#8201;0.033137), both involving MMP9, demonstrated the role of neuroinflammation in the development of vascular dementia. MMP9 plays many biological roles, such as changing the extracellular matrix and the blood-brain barrier. It is involved in many processes, such as bladder cancer, prostate cancer, and relaxin signaling.</p><p>The Manhattan plot (<xref rid="pone.0331787.g010" ref-type="fig">Fig 10</xref>) shows how statistically important enhanced KEGG pathways are based on gene set enrichment research. On the y-axis, each data point shows a KEGG pathway along with its -log&#8321;&#8320; (p-value). Points that are higher show lines that are more strongly linked to the list of input genes because they have a stronger enrichment. A clear peak indicates that at least one route is very important and should be studied further. On the other hand, tracks with lower y-axis values are not as important, but might still be a part of how the disease works in general.</p><fig position="float" id="pone.0331787.g010" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g010</object-id><label>Fig 10</label><caption><title>Manhattan map of KEGG pathway enrichment.</title><p>The enrichment significance is shown on the y-axis, with each point on the x-axis representing a specific KEGG pathway. The statistical importance increased with the y-axis values, and the peaks indicated the best pathways.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g010.jpg"/></fig><p>Many pathways in more advanced stages are likely to be associated with vascular dementia. These include the factors that control cholesterol levels, neuroinflammation, oxidative stress, and endothelial failure. Since their association with neurodegeneration and vascular damage. When this enrichment method is combined with functional validation, it helps identify the most statistically significant pathways for therapeutic targeting and biomarker identification in vascular dementia studies.</p><p>The UMAP-based plot (<xref rid="pone.0331787.g011" ref-type="fig">Fig 11</xref>) provides a clear picture of the improved pathways discovered by KEGG 2021 Human analysis, which allowed us to identify the functionally linked biological processes. The Leiden clustering approach groups pathways with linked functional goals, with each point representing a KEGG pathway. The larger black points show greatly enhanced paths, emphasizing their biological importance in the dataset. Important pathways in vascular dementia, such as leukocyte transendothelial movement, cholesterol metabolism, IL-17 signaling, and TNF signaling, are likely to be grouped in different ways to show how they work at the molecular level. For instance, vascular dysfunction-related pathways (such as leukocyte transendothelial migration and peroxisome regulation) can be grouped, indicating their role in maintaining endothelial integrity and controlling the blood-brain barrier. Neuroinflammation-related pathways (such as IL-17 and TNF signaling) were grouped, indicating the role of immune-mediated processes in vascular dementia. Furthermore, metabolic pathways, such as cholesterol metabolism and the one-carbon pool by folate, constitute another cluster and contribute to metabolic inputs in neurovascular dysfunction.</p><fig position="float" id="pone.0331787.g011" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g011</object-id><label>Fig 11</label><caption><title>Leiden algorithm-identified clusters for uniform manifold approximation and projection (UMAP) visualization of optimized gene sets.</title><p>Each point represents a clustered set of genes. Large black points are substantially enhanced phrases that indicate dataset-related biological systems.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g011.jpg"/></fig><p>Reactome pathway enrichment analysis (<xref rid="pone.0331787.g012" ref-type="fig">Fig 12</xref>) identified vascular dementia-related biological processes by emphasizing lipoprotein, vitamin, and endothelial function. APOE supports cholesterol metabolism and neurovascular health by participating in various pathways including chylomicron clearance, HDL remodeling, and plasma lipoprotein assembly. The presence of CLDN5 in tight junction expression under RunX1 underlines its role in blood-brain barrier integrity, a key factor in vascular dementia. The enrichment of nuclear receptor signaling (APOE and MMP9) links lipid metabolism, inflammation, and endothelial function, confirming the multidimensional nature of the etiology of vascular dementia. These findings shed light on the molecular mechanisms underlying vascular dementia. Knowing these pathways helps uncover therapeutic targets and biomarkers for early vascular dementia diagnosis and intervention.</p><fig position="float" id="pone.0331787.g012" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g012</object-id><label>Fig 12</label><caption><title>The dataset streamlined the top ten main Reactome paths.</title><p>This table illustrates the paths with the most noteworthy p-values and q-values, underscoring their importance in the context of vascular dementia. Key pathways include nuclear receptor signaling, cofactor metabolism (chylomicron and HDL remodeling), and vitamin metabolism, with significant genes such as APOE, MTHFR, CLDN5, and MMP9.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g012.jpg"/></fig><p>This volcano plot (<xref rid="pone.0331787.g013" ref-type="fig">Fig 13</xref>) provides a summary of the odds ratio (effect magnitude) and importance of the increased Reactome 2022 routes in the dataset. The x-axis (odds ratio) displays the degree of association between a route and the gene set under investigation, whereas the y-axis (-log(p-value)) indicates statistical significance. We are particularly interested in pathways with high odds ratios and significant importance (upper right quadrant) because these are the most physiologically relevant processes in vascular dementia. Paths with high statistical significance (p&#8201;&lt;&#8201;0.05) are highlighted by larger, darker blue spots, suggesting that they may play a role in disease processes. Numerous of these pathways are most likely connected to lipid metabolism, vascular integrity, neuroinflammation, and endothelial function, which is in line with previous findings from studies of vascular dementia. Conversely, grey points indicate fewer statistically supported pathways that may not be directly associated with the disease or require further confirmation.</p><fig position="float" id="pone.0331787.g013" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g013</object-id><label>Fig 13</label><caption><title>Volcano plot illustrating the significance and odds ratio of gene sets from the Reactome 2022 pathway study.</title><p>The odds ratio is represented on the x-axis, and the -log(p-value) for each gene set is depicted on the y-axis. Larger blue points indicate significantly increased routes (p-value&#8201;&lt;&#8201;0.05), with darker shades representing greater relevance, and grey points indicate non-significant terms.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g013.jpg"/></fig><p>These plots identify the most relevant biochemical pathways associated with vascular dementia by providing a comprehensive overview of the Reactome Pathways 2024 enrichment study. In (<xref rid="pone.0331787.g014" ref-type="fig">Fig 14</xref>), the Manhattan plot (left) illustrates the statistical significance of the enriched pathways by showing paths with higher correlations at higher locations on the y-axis. Prioritizing the most crucial biological processes is facilitated by this graph, which highlights the significant terms with high enrichment. Paths with similar gene compositions are positioned closer to one another in (<xref rid="pone.0331787.g014" ref-type="fig">Fig 14</xref>) the UMAP scatterplot (<xref rid="pone.0331787.g014" ref-type="fig">Fig 14</xref>, right), which offers a functional clustering of gene sets. These phrases were grouped using the Leiden algorithm to enhance the visibility of functionally linked pathways. More significant upgraded pathways are highlighted by larger and darker points, which highlight their significance in the dataset. The distribution of terms suggests that the pathophysiology of vascular dementia may involve several biological processes, such as oxidative stress, lipid metabolism, and endothelial function. When combined, these investigations enhance our understanding of the fundamental biological underpinnings of vascular dementia, enabling targeted exploration of the most enriched pathways for potential treatment or biomarker development.</p><fig position="float" id="pone.0331787.g014" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g014</object-id><label>Fig 14</label><caption><title>(Left) Manhattan plot showing the significance of phrases enhanced by Reactome Pathways 2024.</title><p>Every point denotes a unique path, and the and y-values (-log&#8321;&#8320;(p-value) show statistical significance. (Right) UMAP-based clustering of enriched phrases, where similar paths are arranged closer together. Larger and darker marks indicate more statistically significant terms. The Leiden method was used for clustering.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g014.jpg"/></fig></sec><sec id="sec019"><title>5) Protein sequence retrieval and modelling/Ligand retrieval</title><p>The protein sequences were retrieved from UniProt, 3D modelling was performed via trRosetta, and structural validation was performed for each protein via a Ramachandran analysis plot and Errat Score analysis, which indicated a stable configuration with most of the residues lying in the acceptable region. Furthermore, four natural ligands were selected after literature analysis, and their structures were retrieved from PubChem. The pharmacological profiles were evaluated for the ligands and are summarized in <xref rid="pone.0331787.t003" ref-type="table">Table 3</xref>.</p><table-wrap position="float" id="pone.0331787.t003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.t003</object-id><label>Table 3</label><caption><title>Comparative pharmacological profile of selected natural compounds evaluated in this study.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0331787.t003g" position="float" orientation="portrait" xlink:href="pone.0331787.t003.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Compound</th><th align="left" rowspan="1" colspan="1">Natural Source</th><th align="left" rowspan="1" colspan="1">Bioavailability</th><th align="left" rowspan="1" colspan="1">Neuroprotective Mechanism</th><th align="left" rowspan="1" colspan="1">Evidence in Neurodegeneration</th><th align="left" rowspan="1" colspan="1">Key References</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Curcumin</bold>
</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">Curcuma longa</italic> (Turmeric)</td><td align="left" rowspan="1" colspan="1">Low; improved with piperine or nanoparticle carriers</td><td align="left" rowspan="1" colspan="1">Antioxidant, anti-inflammatory, inhibits amyloid aggregation</td><td align="left" rowspan="1" colspan="1">Shown to reduce A&#946; burden and rescue neuronal damage in AD and VaD models</td><td align="left" rowspan="1" colspan="1">Maiti and Dunbar (9)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Galangin</bold>
</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">Alpinia officinarum</italic>, honey</td><td align="left" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">Free radical scavenger; inhibits NF-&#954;B and iNOS pathways</td><td align="left" rowspan="1" colspan="1">Reduces neuroinflammation and ROS in various experimental models</td><td align="left" rowspan="1" colspan="1">Kabel, Arab [<xref rid="pone.0331787.ref034" ref-type="bibr">34</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Licocumarone</bold>
</td><td align="left" rowspan="1" colspan="1">Licorice root derivatives</td><td align="left" rowspan="1" colspan="1">potential coumarin-like behavior</td><td align="left" rowspan="1" colspan="1">Antioxidant and anti-inflammatory effects through coumarin scaffold</td><td align="left" rowspan="1" colspan="1">Novel compound tested on the; evidence based on in silico affinity and structural similarity to known neuroprotective coumarins</td><td align="left" rowspan="1" colspan="1">Ibrahim, Skalicka-Wo&#378;niak [<xref rid="pone.0331787.ref035" ref-type="bibr">35</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Resveratrol</bold>
</td><td align="left" rowspan="1" colspan="1">Grapes, red wine</td><td align="left" rowspan="1" colspan="1">Low to moderate; enhanced with liposomal delivery</td><td align="left" rowspan="1" colspan="1">Activates SIRT1, reduces oxidative stress and A&#946; accumulation</td><td align="left" rowspan="1" colspan="1">Shown to improve cognitive outcomes in AD; enhances cerebral blood flow</td><td align="left" rowspan="1" colspan="1">Wang, Wang [<xref rid="pone.0331787.ref036" ref-type="bibr">36</xref>]</td></tr></tbody></table></alternatives></table-wrap><p>To examine the chemical diversity of the selected natural chemicals (curcumin, galangin, resveratrol, and licocumarone), we calculated pairwise Tanimoto similarity scores using Morgan fingerprints. All pairwise similarity values were less than 0.3, indicating that the chemicals are structurally diverse and form different chemical scaffolds. This structural heterogeneity promotes their ability to influence many molecular targets associated with vascular dementia. The detailed similarity matrix is shown in <xref rid="pone.0331787.t004" ref-type="table">Table 4</xref>. We selected Curcumin, Galangin, and Resveratrol for their anti-inflammatory properties in vascular dementia treatment. While Licocumarone has not been previously investigated in the context of neurodegenerative diseases, its coumarin derivatives have shown vascular and neuroprotective relevance in related compounds. Therefore, it was selected as the novel compound for this study.</p><table-wrap position="float" id="pone.0331787.t004" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.t004</object-id><label>Table 4</label><caption><title>Tanimoto similarity matrix displaying pairwise structural similarity among chosen natural ligands based on Morgan fingerprints.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0331787.t004g" position="float" orientation="portrait" xlink:href="pone.0331787.t004.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Compound</th><th align="left" rowspan="1" colspan="1">Curcumin</th><th align="left" rowspan="1" colspan="1">Galangin</th><th align="left" rowspan="1" colspan="1">Resveratrol</th><th align="left" rowspan="1" colspan="1">Licocumarone</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Curcumin</bold>
</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Galangin</bold>
</td><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Resveratrol</bold>
</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Licocumarone</bold>
</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">0.16</td><td align="left" rowspan="1" colspan="1">0.11</td><td align="left" rowspan="1" colspan="1">1.0</td></tr></tbody></table></alternatives></table-wrap><p>The ADMET properties of four natural ligands curcumin, galangin, resveratrol, and licocumarone, were compared to two licensed CNS drugs; donepezil and memantine. <xref rid="pone.0331787.t005" ref-type="table">Table 5</xref> shows that the four natural substances have comparable blood-brain barrier permeability (logBB&#8201;~&#8201;0.02&#8211;0.12), which is regarded acceptable for CNS medication candidates. All compounds showed good gastrointestinal (GI) absorption, no mutagenicity (negative AMES test), and no projected hepatotoxicity, which mirrored the safety profiles of the reference medications.</p><table-wrap position="float" id="pone.0331787.t005" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.t005</object-id><label>Table 5</label><caption><title>Comparison of predicted ADMET properties of natural compounds and approved CNS drugs.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0331787.t005g" position="float" orientation="portrait" xlink:href="pone.0331787.t005.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Property</th><th align="left" rowspan="1" colspan="1">Donepezil</th><th align="left" rowspan="1" colspan="1">Memantine</th><th align="left" rowspan="1" colspan="1">Curcumin</th><th align="left" rowspan="1" colspan="1">Galangin</th><th align="left" rowspan="1" colspan="1">Resveratrol</th><th align="left" rowspan="1" colspan="1">Licocumarone</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Blood-Brain Barrier (logBB)</bold>
</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="left" rowspan="1" colspan="1">0.31</td><td align="left" rowspan="1" colspan="1">~0.02</td><td align="left" rowspan="1" colspan="1">~0.10</td><td align="left" rowspan="1" colspan="1">~0.08</td><td align="left" rowspan="1" colspan="1">~0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>GI Absorption</bold>
</td><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>CYP450 Inhibition</bold>
</td><td align="left" rowspan="1" colspan="1">CYP2D6 inhibitor</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">CYP1A2, 2C9 inhibitor</td><td align="left" rowspan="1" colspan="1">CYP1A2 inhibitor</td><td align="left" rowspan="1" colspan="1">CYP1A2, 3A4 inhibitor</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total Polar Surface Area (TPSA)</bold>
</td><td align="left" rowspan="1" colspan="1">38.77 &#197;&#178;</td><td align="left" rowspan="1" colspan="1">24.39 &#197;&#178;</td><td align="left" rowspan="1" colspan="1">93.06 &#197;&#178;</td><td align="left" rowspan="1" colspan="1">90.90 &#197;&#178;</td><td align="left" rowspan="1" colspan="1">60.69 &#197;&#178;</td><td align="left" rowspan="1" colspan="1">66.76 &#197;&#178;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>AMES Toxicity</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Hepatotoxicity</bold>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td></tr></tbody></table></alternatives></table-wrap><p>Additionally, their total polar surface area (TPSA) values (60&#8211;93 &#197;&#178;) are within the range for successful CNS penetration (usually &lt;90 &#197;&#178;), with Galangin and Resveratrol exhibiting particularly excellent values. The CYP450 inhibition patterns varied significantly but remained within drug-tolerable limits, with no pan-inhibition observed. These characteristics confirm that the chosen natural ligands not only show promising biological activity, but also meet several important pharmacokinetic benchmarks for CNS drug development.</p></sec><sec id="sec020"><title>6) Molecular docking analysis</title><p>Molecular Docking performed using AutoDock Vina showed different results for each compound <xref rid="pone.0331787.t006" ref-type="table">Table 6</xref>; the active sites were identified using Protein Plus, and docking was performed. Furthermore, visualization was performed using Chimera, and the interactions were analyzed in detail using LigPlot. Protein Amyloid beta precursor-like protein 1 showed the best interactions with galangin, by three hydrogen bonds and several hydrophobic interactions (<xref rid="pone.0331787.g015" ref-type="fig">Fig 15</xref>).</p><table-wrap position="float" id="pone.0331787.t006" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.t006</object-id><label>Table 6</label><caption><title>Summarizes the overall number of interactions and their bonding energies.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0331787.t006g" position="float" orientation="portrait" xlink:href="pone.0331787.t006.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Proteins</th><th align="left" rowspan="1" colspan="1">Ligands</th><th align="left" rowspan="1" colspan="1">Docking Score</th><th align="left" rowspan="1" colspan="1">Number of interactions (H-bonds)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Amyloid beta precursor-like protein 1</td><td align="left" rowspan="1" colspan="1">Galangin</td><td align="left" rowspan="1" colspan="1">&#8722;8.5 kcal/mol</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Claudin-5</td><td align="left" rowspan="1" colspan="1">Licocumarone</td><td align="left" rowspan="1" colspan="1">&#8722;6.8 kcal/mol</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Matrix metalloproteinase-9</td><td align="left" rowspan="1" colspan="1">Curcumin</td><td align="left" rowspan="1" colspan="1">&#8722;8.0 kcal/mol</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Methylenetetrahydrofolate</td><td align="left" rowspan="1" colspan="1">Resveratrol</td><td align="left" rowspan="1" colspan="1">&#8722;8.1 kcal/mol</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Superoxide dismutase</td><td align="left" rowspan="1" colspan="1">Licocumarone</td><td align="left" rowspan="1" colspan="1">&#8722;6.6 kcal/mol</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Apolipoprotein E</td><td align="left" rowspan="1" colspan="1">Curcumin</td><td align="left" rowspan="1" colspan="1">&#8722;7.2 kcal/mol</td><td align="left" rowspan="1" colspan="1">2</td></tr></tbody></table></alternatives></table-wrap><fig position="float" id="pone.0331787.g015" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g015</object-id><label>Fig 15</label><caption><title>(a) Docking interaction for Galangin with Amyloid protein, (b) Indicates hydrogen bond in green and hydrophobic interactions in red.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g015.jpg"/></fig><p>Moreover, docking was performed for all four ligands with another targeted protein, Apolipoprotein E, Curcumin showed the best results with 3 hydrogen bonds (<xref rid="pone.0331787.g016" ref-type="fig">Fig 16</xref>).</p><fig position="float" id="pone.0331787.g016" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g016</object-id><label>Fig 16</label><caption><title>(a) Indicates docking interaction for Apolipoprotein with Curcumin. (b) Interaction analysis for docked complex presenting green colour for hydrogen bond and red for hydrophobic interactions.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g016.jpg"/></fig><p>Similarly, Claudin-5 showed the best interaction with licocumarone (<xref rid="pone.0331787.g017" ref-type="fig">Fig 17</xref>), indicating two hydrogen bonds. Matrix metalloproteinase-9 had the best interaction with Curcumin, with 3 hydrogen bonds. Similarly, Methylene tetrahydrofolate showed optimum interaction with resveratrol, with four hydrogen bonds. Furthermore, Superoxide dismutase showed bonding with licocumarone and four hydrogen bonds, as shown in <xref rid="pone.0331787.g018" ref-type="fig">Figs 18</xref>&#8211;<xref rid="pone.0331787.g020" ref-type="fig">20</xref>, respectively.</p><fig position="float" id="pone.0331787.g017" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g017</object-id><label>Fig 17</label><caption><title>(a) Indicated bonding analysis of Claudin-5 with Licocumarone, (b) indicates the docked complex&#8217;s hydrogen bonds and other hydrophobic interactions.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g017.jpg"/></fig><fig position="float" id="pone.0331787.g018" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g018</object-id><label>Fig 18</label><caption><title>(a) Indicated bonding interaction of Curcumin with Matrix metalloproteinase-9 (b) elaborates the hydrogen bonds in green and the hydrophobic interaction in red.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g018.jpg"/></fig><fig position="float" id="pone.0331787.g019" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g019</object-id><label>Fig 19</label><caption><title>(a) Indicated bonding interaction of Resveratrol with Methylene tetrahydrofolate. (b) Elaborates the hydrogen bonds in green and the hydrophobic interaction in red.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g019.jpg"/></fig><fig position="float" id="pone.0331787.g020" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g020</object-id><label>Fig 20</label><caption><title>(a) Indicated bonding interaction of Licocoumarone with Superoxide dismutase. (b) Elaborates the hydrogen bonds in green and the hydrophobic interaction in red.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g020.jpg"/></fig><p>Docking data showed that binding energies were consistent across all five runs for each complex. The standard deviations varied from 0.42 to 1.07 kcal/mol, demonstrating limited variance and validating the predictability of the binding modes. For example, APLP1-Galangin had the lowest mean score (&#8722;6.80 kcal/mol) and an SD of 1.07, whereas SOD1-Licocumarone had the most stable interaction (SD&#8201;=&#8201;0.42). These findings support the reliability of docking and the strength of the chosen binding conformations (see Supplementary Table 1 and 2 in <xref rid="pone.0331787.s001" ref-type="supplementary-material">S1 File</xref> for full data).</p></sec><sec id="sec021"><title>7) Normal mode analysis</title><p>iMODs utilize Normal Mode Analysis (NMA) to assess the molecular mobility and structural flexibility of the linked complexes. The principle of NMA of proteins posits that the &#8220;soft modes,&#8221; characterized by the lowest-frequency vibrational normal modes, represent the most substantial motions of the protein and are therefore functionally relevant. The analysis of biomolecular dynamics has been significantly facilitated by normal-mode analysis, which is a reliable and advantageous method. Moreover, it is exceptionally efficient to examine protein processes that transpire incrementally and undergo significant conformational alterations (Skjaerven et al., 2009; Soltan et al., 2021).</p><p>The Normal Mode Analysis (NMA) results for APLP1 mixed with galangin are shown in this study, along with information on the structural flexibility and how it changes over time. NMA studies on the intrinsic motions of proteins have shown flexible patches, collective motions, and possible functional locations. In (<xref rid="pone.0331787.g021" ref-type="fig">Fig 21a</xref>), the B-factor graph shows how NMA predicted residue flexibility (in red) compared to PDB&#8217;s actual B-factor values (in black). A higher atomic variation indicates a larger B-factor. It is clear from this method that the loops and terminal parts are adjustable, whereas the basic structural parts are not adjustable. The computer method overstates changes because it employs an elastic network model; however, the NMA predictions align with the actual B-factors. The deformability line in (<xref rid="pone.0331787.g021" ref-type="fig">Fig 21b</xref>) shows the parts of proteins that can change their structure. Peaks in this graph show residues that are very mobile and are found in loops or close to sites where ligands bind. The flexible parts of APLP1 may be important for binding galangin or for changing its shape.</p><fig position="float" id="pone.0331787.g021" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g021</object-id><label>Fig 21</label><caption><title>The Normal Mode Analysis (NMA) results for amyloid beta precursor-like protein 1 (APLP1) complexed with Galangin show that the structure is flexible and changes over time.</title><p>(a) A B-factor graph that shows areas that are flexible and stiff, comparing the NMA-predicted flexibility (red) with the experimental PDB B-factor (black). The deformability graph shows the mobility of specific residues, with peaks showing the most flexible places. The variance input of the first 20 normal modes shows that there aren&#8217;t many dominant modes that can fully describe the motion of the structure. (d) A cross-correlation grid that shows correlated (dark areas) and anti-correlated (lighter areas) atomic movements shows how the protein&#8217;s cooperative domains move.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g021.jpg"/></fig><p>The variance contribution plot in (<xref rid="pone.0331787.g021" ref-type="fig">Fig 21c</xref>) shows the extent to which the first 20 normal modes affect protein motion. The first few modes indicate that APLP1&#8217;s overall movements can be summarised as a few main modes that account for most of the variations. There is more variance as the number of modes increases; however, the key structural motions occur in the first 10 modes. This implies that APLP1&#8217;s basic movements are probably mostly managed by low-frequency motions. In (<xref rid="pone.0331787.g021" ref-type="fig">Fig 21d</xref>), the cross-correlation matrix shows the relationship between the movements of protein domains. As expected, the black diagonal line shows self-correlations, whereas elements that are not on the diagonal show residue pairs that are linked or anticorrelated. Strong connections indicate coordinated domain movements, which can alter how proteins work or interact with ligands. APLP1 has different correlation patterns, suggesting that some parts move together, potentially controlling allosteric responses or structural reorganization when galangin binds.</p><p>The significant flexibility seen in the loop regions surrounding the E2 domain suggests that Galangin binding could use induced fit mechanisms, stabilize amyloidogenic surface grooves. The core domain stiffness promotes stable ligand anchoring, whereas loop flexibility may influence APP cleavage or oligomerization behavior relevant to VaD. Normal Mode Analysis (NMA) demonstrated that curcumin binding influences the structural flexibility and dynamic behavior of ApoE by stabilizing its core and altering localized flexibility. The B-factor plot (a) in (<xref rid="pone.0331787.g022" ref-type="fig">Fig 22</xref>) indicates that the core structure exhibits fewer variations, even though the termini and loop areas remain malleable. This suggests that curcumin enhances the structural stiffness in functionally relevant domains. The deformability plot in (<xref rid="pone.0331787.g022" ref-type="fig">Fig 22b</xref>) indicates that curcumin may significantly influence residues involved in binding interactions or conformational changes by altering their flexibility in specific regions. Although the fundamental dynamics of ApoE are still regulated by a few dominant low-frequency modes, the variance plot in (<xref rid="pone.0331787.g022" ref-type="fig">Fig 22c</xref>) suggests that there are minor changes in the variance distribution, suggesting localized structural alterations as a result of ligand binding. Additionally, the cross-correlation matrix (<xref rid="pone.0331787.g022" ref-type="fig">Fig 22d</xref>) indicated that curcumin affected the correlated and anti-correlated motions between various regions of the protein, thereby influencing its allosteric control and functional relationships. The binding of curcumin appears to stabilize ApoE in general, while modifying its flexibility in specific regions. This effect may affect ApoE&#8217;s function in lipid transport, receptor interactions, and neurodegenerative disorders.</p><fig position="float" id="pone.0331787.g022" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g022</object-id><label>Fig 22</label><caption><title>Normal Mode Analysis for Apolipoprotein E the structural dynamics of the curcumin-complexed Apolipoprotein E (ApoE) are displayed.</title><p>Curcumin binding stabilizes the core while controlling flexibility in certain regions, as seen in the B-factor and deformability graphs. Variance distribution and cross-correlation analysis suggest altered cooperative motions and localized structural alterations.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g022.jpg"/></fig><p>Curcumin binding increased flexibility near APOE&#8217;s receptor-binding region, potentially impacting its interactions with lipoprotein receptors and &#946;-amyloid clearance machinery. Stabilization of the core domain implies structural integrity, although changed associated movements indicate a potential impact on lipid transport and allosteric regulation. Furthermore, the NMA data for Claudin-5 with Licocumarone indicate that ligand binding affects the cooperative movements, flexibility, and stability of the protein. Licocumarone stabilized the core transmembrane regions while permitting increased flexibility in the loop and terminal areas, potentially facilitating the conformational changes required for function, as indicated by the B-factor (<xref rid="pone.0331787.g023" ref-type="fig">Fig 23a</xref>). The deformability shown in (<xref rid="pone.0331787.g023" ref-type="fig">Fig 23b</xref>) indicates specific regions with altered flexibility, suggesting that ligand binding influences dynamic residues involved in permeability regulation. The primary motions of Claudin-5 were concentrated in a limited number of significant modes, as indicated by the variance plot in (<xref rid="pone.0331787.g023" ref-type="fig">Fig 23c</xref>). This suggests that the ligand does not substantially affect global dynamics but induces localized alterations. Changes in cooperative domain motions indicated by the cross-correlation matrix (<xref rid="pone.0331787.g023" ref-type="fig">Fig 23d</xref>) suggest that licocumarone alters inter-residue interactions, potentially affecting the role of Claudin-5 in tight junction stability and blood-brain barrier function.</p><fig position="float" id="pone.0331787.g023" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g023</object-id><label>Fig 23</label><caption><title>NMA data for Claudi-5 complexed with Licocumarone showing structural dynamics.</title><p>As shown in B-factor and deformability graphs, ligand binding stabilises the transmembrane core and increases loop and terminal flexibility. Cross-correlation analysis and variance distribution suggest localised conformational changes may alter Claudin-5&#8217;s tight junction stability and permeability.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g023.jpg"/></fig><p>Flexibility in extracellular loops, as shown in the deformability figure, may reflect tight junction strand conformational flexibility, which influences BBB permeability. Licocumarone&#8217;s capacity to maintain transmembrane domains while permitting loop mobility may improve barrier modulation during inflammatory stress, which is a hallmark of VaD. Moreover, the NMA results for Matrix Metalloproteinase-9 (MMP-9) indicate the structural and dynamic effects of curcumin on ligand binding. Curcumin stabilizes the protein, reduces fluctuations in most places, and maintains termini flexibility <xref rid="pone.0331787.g024" ref-type="fig">Fig 24</xref>, B-factor plot, a). The deformability map (<xref rid="pone.0331787.g024" ref-type="fig">Fig 24</xref> b), highlights the flexible sections at the N- and C-terminals that are required for localized motion, as suggested by enzyme activity and substrate interactions. The variance plot in (<xref rid="pone.0331787.g024" ref-type="fig">Fig 24c</xref>) shows that the first few normal modes dominate the protein dynamics, suggesting that curcumin slightly alters the conformation. Cross-correlation matrix (<xref rid="pone.0331787.g024" ref-type="fig">Fig 24d</xref>) shows variations in correlated motion over distant locations, suggesting that ligand binding affects cooperative domain contact, MMP-9 catalytic efficiency, and substrate recognition.</p><fig position="float" id="pone.0331787.g024" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g024</object-id><label>Fig 24</label><caption><title>Normal Mode Analysis Matrix metalloproteinase-9.</title><p>Structural dynamics of Matrix Metalloproteinase-9 (MMP-9) complexed with curcumin are shown by normal mode analysis (NMA) data. As seen in B-factor and deformability graphs, curcumin binding stabilises the protein core while preserving flexibility at terminal areas. Localised conformational alterations shown by variance and cross-correlation analysis could affect substrate interactions and enzymatic activity of MMP-9.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g024.jpg"/></fig><p>Curcumin may modulate substrate access and enzymatic activity via deformable loop regions in the catalytic cleft. Stabilization of the surrounding domains may help to selectively block ECM-degrading function, lowering BBB disruption and neuroinflammation in VaD. Furthermore, the NMA results for Methylenetetrahydrofolate Reductase (MTHFR) with resveratrol revealed that ligand binding affects protein structural stability and flexibility. Resveratrol stabilizes MTHFR&#8217;s major regions of MTHFR while allowing some flexibility at the terminal ends, according to the B-factor plot (<xref rid="pone.0331787.g025" ref-type="fig">Fig 25a</xref>), which is important for its enzymatic function. The deformability plot in (<xref rid="pone.0331787.g025" ref-type="fig">Fig 25b</xref>) reveals that resveratrol binding produces localized conformational changes that may affect allosteric regulation or substrate interactions. Variance plot (<xref rid="pone.0331787.g025" ref-type="fig">Fig 25c</xref>) shows that the first few normal modes of the protein dominate, indicating that resveratrol binding fine-tunes essential mobility rather than disrupting structural dynamics. Resveratrol affects long-range correlated movements, which may alter MTHFR&#8217;s enzymatic efficiency and functional regulation of MTHFR, as observed in the cross-correlation matrix (<xref rid="pone.0331787.g025" ref-type="fig">Fig 25d</xref>).</p><fig position="float" id="pone.0331787.g025" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g025</object-id><label>Fig 25</label><caption><title>Methylenetetrahydrofolate Reductase (MTHFR) complexed with Resveratrol shows structural dynamics under Normal Mode Analysis (NMA).</title><p>B-factor and deformability graphs show that resveratrol binding stabilizes the core and maintains terminal flexibility. Variance and cross-correlation studies demonstrate local conformational changes that may affect MTHFR&#8217;s enzymatic activity and functional regulation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g025.jpg"/></fig><p>Local flexibility in terminal sections and loop segments near the cofactor binding site may enable substrate exchange or allosteric regulation. Resveratrol may thereby stabilize the enzyme while increasing its metabolic throughput, potentially reducing hyperhomocysteinemia-induced vascular damage. Moreover, the results of NMA for Superoxide Dismutase (SOD1) with licocumarone indicate that ligand binding induces structural flexibility while maintaining core stability. Licocumarone stabilizes certain regions while increasing loop and terminal segment fluctuations, as seen in B-factor (plot) (<xref rid="pone.0331787.g026" ref-type="fig">Fig 26a</xref>). This could have an impact on the binding interactions or enzymatic activity. The deformability plot in (<xref rid="pone.0331787.g026" ref-type="fig">Fig 26b</xref>) indicates significant flexibility throughout the protein, suggesting that ligand interaction does not induce rigidity but allows for dynamic conformational changes. The initial normal modes notably contribute to the overall motion, as indicated by the variance plot in (<xref rid="pone.0331787.g026" ref-type="fig">Fig 26c</xref>), which suggests that licocumarone binding affects large-scale conformational changes while maintaining global stability. The cross-correlation matrix (<xref rid="pone.0331787.g026" ref-type="fig">Fig 26d</xref>) indicates altered cooperative motions between distant regions, suggesting that licocumarone influences long-range interactions within SOD1, potentially impacting its catalytic activity and stability. Therefore, flexibility in loop and surface-exposed &#946;-strands may affect metal ion coordination and ROS scavenging. Stabilization of SOD1&#8217;s core suggests that Licocumarone may preserve enzymatic function while increasing structural resilience to oxidative stress, thereby contributing to neuroprotection.</p><fig position="float" id="pone.0331787.g026" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g026</object-id><label>Fig 26</label><caption><title>Normal Mode Analysis of Superoxide dismutase.</title><p>The NMA data for SOD1 complexed with licocumarone show its structural dynamics. B-factor and deformability graphs show that licocumarone binding increases loop and terminal flexibility while retaining core stability. Variance and cross-correlation data suggest that ligand-induced conformational changes may affect SOD1 functional interactions and enzymatic activity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g026.jpg"/></fig></sec><sec id="sec022"><title>MD simulation analysis</title><p>We used RMSD, RMSF, radius of gyration (Rg), and solvent-accessible surface area (SASA) analysis to evaluate the dynamic behaviour and structural stability of protein-ligand complexes across a 100 ns simulation period. The RMSD profiles (<xref rid="pone.0331787.g027" ref-type="fig">Fig 27a</xref>) showed early convergence (~30 ns) for all systems, with Amyloid beta precursor-like protein 1 &#8211; Galangin and Matrix metalloproteinase-9 &#8211; Curcumin having the lowest RMSD values (~0.30&#8211;0.32&#8201;nm), indicating stable interactions. Apolipoprotein E &#8211; Curcumin and Superoxide Dismutase &#8211; Licocumarone complexes showed slightly greater variations (~0.45&#8211;0.47&#8201;nm), indicating flexible binding. RMSF analysis (<xref rid="pone.0331787.g027" ref-type="fig">Fig 27b</xref>) indicated residue-specific changes compatible with structural mobility near flexible loops and termini. Resveratrol and Curcumin-bound compounds exhibited negligible per-residue variations (RMSF&#8201;&lt;&#8201;0.08&#8201;nm), indicating overall backbone stiffness. Complexes containing Licocumarone, on the other hand, showed greater RMSF peaks in loop areas, which could indicate localized flexibility. The Rg plot (<xref rid="pone.0331787.g027" ref-type="fig">Fig 27c</xref>) confirmed the observations, with Galangin and Curcumin systems maintaining lower Rg values (~1.65&#8211;1.70&#8201;nm), indicating compact, folded structures. Apolipoprotein E and Claudin-5 complexes exhibited modest fluctuation in Rg (~1.50&#8211;1.60&#8201;nm), suggesting transient unfolding processes.</p><fig position="float" id="pone.0331787.g027" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.g027</object-id><label>Fig 27</label><caption><title>Shows a molecular dynamics simulation of six protein-ligand complexes spanning 100 ns.</title><p>(a) RMSD profiles that demonstrate convergence and structural integrity. (b) The RMSF per-residue fluctuation analysis reveals flexible loop areas. (c) The radius of gyration profiles reflects compactness and overall stability. (d) SASA profiles showing surface exposure of protein-ligand complexes. Curcumin, galangin, and resveratrol compounds show greater structural stability across all criteria.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0331787.g027.jpg"/></fig><p>The SASA results (<xref rid="pone.0331787.g027" ref-type="fig">Fig 27d</xref>) verified these dynamics. Stable binders like Galangin and Curcumin maintained consistent surface exposure (~96&#8211;97 nm&#178;), while less stable complexes like Apolipoprotein E had reduced SASA (~92&#8211;93 nm&#178;), possibly due to local conformational changes. These simulations support the docking results by demonstrating that Galangin, Curcumin, and Resveratrol form strong and structurally stable complexes with their respective targets.</p><p>Although each simulation was performed for 100 ns, all systems indicated early convergence (&lt;30 ns) and steady trajectories thereafter, reducing the possibility of stochastic artifacts. To evaluate the stability and reproducibility of dynamic metrics (RMSD, RMSF, Rg, and SASA), time-windowed averaging was performed across the final 50 ns of each trajectory. Within this window, RMSD fluctuations were less than 0.06&#8201;nm, while the radius of gyration was stable within &#177;0.04&#8201;nm. It is supported by the comparatively low variance in structural metrics that the chosen ligands exhibited stable, compact complex formations with the target proteins. While replicate simulations were not carried out due to computational constraints, the consistency of time-resolved metrics and the early plateauing of RMSD profiles increase confidence in the observed conformational behavior.</p></sec></sec><sec sec-type="conclusions" id="sec023"><title>Discussion</title><p>Vascular Dementia is the most common form of dementia and is marked by a high mortality rate. Research shows that vascular dementia patients have a 3.33 mortality risk than Alzheimer&#8217;s patients. A Chinese study found 28.91% of in-hospital deaths per 1,000 person-years [<xref rid="pone.0331787.ref037" ref-type="bibr">37</xref>]. Several factors affect vascular dementia, such as advanced age, male gender, concomitant disorders such as hypertension and cardiac disease, cognitive decline, and increased risk of death. Vascular dementia is severe, and patients have a lower life expectancy than those with other types of dementia; hence, managing risk factors may improve survival [<xref rid="pone.0331787.ref038" ref-type="bibr">38</xref>]. In this study, we performed Docking analysis with natural ligands to analyze the major proteins involved in different pathways associated with this deadly disease and to identify a convenient and effective therapeutic target that will prove more efficient in treating vascular dementia. We selected four natural ligands based on their oxidative stress, anti-neuroinflammatory, blood-brain barrier integrity, and amyloid deposition properties.</p><p>Furthermore, several analyses were conducted to confirm the significance of these proteins. The String database was utilized for protein-protein interaction (PPI) analysis, and functional enrichment analysis was performed, with a particular focus on the KEGG and Reactome databases to examine these proteins&#8217; functions in detail and their influence on vascular dementia. Furthermore, the cross-species conservation observed in the co-expression analysis highlights the evolutionary importance of the selected genes APOE, APLP1, MMP9, CLDN5, SOD1, and MTHFR, in controlling neuroinflammatory reactions and vascular function. Comparable expression patterns in humans and widely used model species like <italic toggle="yes">Gasterosteus aculeatus</italic>, <italic toggle="yes">Danio rerio</italic>, and <italic toggle="yes">Mus musculus</italic> imply that these genes are a component of fundamental regulatory networks that have been preserved throughout the evolution of vertebrates. Given this conservation, it is likely that human oxidative stress, neurodegeneration, and vascular dysfunction share many molecular mechanisms. As a result, these model species offer biologically relevant systems for studying the processes of vascular dementia (VaD). Furthermore, the fact that these co-expression patterns are conserved provides evidence for the concept that these genes play a meaningful functional role in disease rather than simply reflecting species-specific variability. Therefore, this evolutionary insight strengthens the translational relevance of our findings and supports the selection of these genes as meaningful targets for future therapeutic research.</p><p>These four compounds were chosen based on literature-supported neuroprotective and vasculotropic effects, and their structural non-redundancy was confirmed using Tanimoto similarity analysis, indicating their potential as functionally varied multi-target drugs. Moreover, each ligand was docked independently on a selected active site using Autodock Vina, and the results were analysed using Chimera and LigPlot. The results showed the best interaction with all six proteins selected. Amyloid beta precursor protein (APLP) has the best interaction with galangin, a well-known flavonoid that has neuroprotective properties and can change pathways associated with inflammation and oxidative stress, which is relevant to VaD [<xref rid="pone.0331787.ref039" ref-type="bibr">39</xref>]. These pharmacokinetic characteristics emphasize the translational potential of natural ligands in neurotherapeutics. While natural substances frequently have limited bioavailability, our data reveal that Curcumin, Galangin, Resveratrol, and Licocumarone have drug-like ADMET profiles similar to Donepezil and Memantine, two clinically used dementia therapies. This makes them viable scaffolds for further research or derivative use in future vascular dementia therapeutics.</p><p>Similarly, Claudin-5 [<xref rid="pone.0331787.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0331787.ref040" ref-type="bibr">40</xref>] and superoxide dismutase [<xref rid="pone.0331787.ref022" ref-type="bibr">22</xref>,<xref rid="pone.0331787.ref040" ref-type="bibr">40</xref>] showed the best interaction with licocumarone, a coumarin derivative that has demonstrated vascular protective qualities that aid in the regulation of VaD [<xref rid="pone.0331787.ref039" ref-type="bibr">39</xref>]. Furthermore, Matrix metalloproteinase-9 [<xref rid="pone.0331787.ref040" ref-type="bibr">40</xref>] and Apolipoprotein E influence curcumin, which has potential therapeutic benefits in reducing oxidative stress and amyloid plaque formation in VaD due to its anti-inflammatory and antioxidant properties [<xref rid="pone.0331787.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0331787.ref041" ref-type="bibr">41</xref>]. Moreover, Methylenetetrahydrofolate (MTHFR), specifically the C677T polymorphism, has been identified as a genetic factor associated with an increased risk of vascular dementia. [<xref rid="pone.0331787.ref031" ref-type="bibr">31</xref>] has a maximum number of interactions with resveratrol, and given its reputation for enhancing cerebral blood flow and reducing neuroinflammation, resveratrol is a promising candidate for vasodilation. Similarly, several underlying structural features can explain the variance in binding affinity between different protein-ligand complexes. Galangin&#8217;s strong binding to APLP1 is attributed to its planar aromatic structure, which allows for &#960;-&#960; bonding and excellent hydrogen bonding with residues in the well-defined E2 domain pocket. The stiffness of this domain contributes to increased binding stability.</p><p>Curcumin, on the other hand, has a symmetrical and flexible polyphenolic structure that allows it to fit well into larger, hydrophobic clefts like MMP9 and APOE, generating stable connections via numerous hydrogen bonds and van der Waals forces. Resveratrol&#8217;s smaller and more flexible structure fits perfectly into MTHFR&#8217;s cofactor-binding domain, where its hydroxyl groups are predicted to interact with crucial polar residues involved in folate metabolism. Licocumarone&#8217;s, coumarin backbone has modest affinity but creates stabilizing interactions with CLDN5 and SOD1, particularly in loop-rich, flexible areas. SOD1 and MMP9 have metal-coordinating centers (Cu&#178;&#8314; and Zn&#178;&#8201;&#8314;&#8201;, respectively) that may help stabilize ligands through polar or coordination-like interactions. Collectively, these structural properties explain the observed docking scores and highlight the ligands&#8217; functional importance in the context of vascular dementia.</p><p>A group of thoroughly studied reference ligands and negative controls were docked against each chosen protein target to compare the docking results. These included Sodium Caprate for Claudin-5, Bexarotene for APOE, Betaine for MTHFR, Verubecestat for APLP1, SB-3CT for MMP9, and Edaravone for SOD1. In most cases, the natural compounds demonstrated superior or comparable binding affinities. For instance, Curcumin exhibited a stronger interaction with MMP9 (&#8722;8.0 kcal/mol) than SB-3CT (&#8722;7.2 kcal/mol), indicating its potential inhibitory effect. Similarly, Licocumarone bound SOD1 more effectively than Edaravone (&#8722;6.6 vs. &#8722;5.5 kcal/mol), suggesting possible antioxidant action. Curcumin also outperformed Bexarotene in APOE docking (&#8722;7.2 vs. &#8722;6.7 kcal/mol), reinforcing its role in lipid regulation and neuroprotection. Resveratrol showed a markedly stronger binding to MTHFR (&#8722;8.1 kcal/mol) compared to Betaine (&#8722;4.2 kcal/mol), indicating a greater capacity to modulate homocysteine metabolism. Galangin demonstrated strong binding to APLP1 (&#8722;8.5 kcal/mol), closely approaching that of the &#946;-secretase inhibitor Verubecestat (&#8722;9.9 kcal/mol), suggesting relevance to amyloidogenic pathway regulation. While Sodium Caprate is functionally known to modulate Claudin-5, it exhibited a weaker score (&#8722;4.8 kcal/mol) than Licocumarone (&#8722;6.8 kcal/mol), highlighting the latter&#8217;s potential BBB-modulatory role.</p><p>To further assess docking specificity, we also evaluated negative controls (Donepezil and Diclofenac) against the same targets. These compounds consistently showed weaker or nonspecific binding (mean&#8201;~&#8722;6.5 kcal/mol), confirming the selectivity of natural ligands toward disease-relevant proteins. The complete comparative data are summarized in <xref rid="pone.0331787.t007" ref-type="table">Table 7</xref>.</p><table-wrap position="float" id="pone.0331787.t007" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0331787.t007</object-id><label>Table 7</label><caption><title>Summarizes the comparison between the docking scores of protein targets with natural ligands, positive controls and negative controls.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0331787.t007g" position="float" orientation="portrait" xlink:href="pone.0331787.t007.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Protein Target</th><th align="left" rowspan="1" colspan="1">Ligand</th><th align="left" rowspan="1" colspan="1">Type</th><th align="left" rowspan="1" colspan="1">Docking Score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>APLP1</bold>
</td><td align="left" rowspan="1" colspan="1">Galangin</td><td align="left" rowspan="1" colspan="1">Natural</td><td align="left" rowspan="1" colspan="1">&#8722;8.5</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>APLP1</bold>
</td><td align="left" rowspan="1" colspan="1">Verubecestat</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">&#8722;9.9</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>APLP1</bold>
</td><td align="left" rowspan="1" colspan="1">Donepezil</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">&#8722;6.6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>CLDN5</bold>
</td><td align="left" rowspan="1" colspan="1">Licocumarone</td><td align="left" rowspan="1" colspan="1">Natural</td><td align="left" rowspan="1" colspan="1">&#8722;6.8</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>CLDN5</bold>
</td><td align="left" rowspan="1" colspan="1">Sodium Caprate</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">&#8722;4.8</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>CLDN5</bold>
</td><td align="left" rowspan="1" colspan="1">Diclofenac</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">&#8722;6.5</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MMP9</bold>
</td><td align="left" rowspan="1" colspan="1">Curcumin</td><td align="left" rowspan="1" colspan="1">Natural</td><td align="left" rowspan="1" colspan="1">&#8722;8.0</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MMP9</bold>
</td><td align="left" rowspan="1" colspan="1">SB-3CT</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">&#8722;7.2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MMP9</bold>
</td><td align="left" rowspan="1" colspan="1">Donepezil</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">&#8722;6.6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MTHFR</bold>
</td><td align="left" rowspan="1" colspan="1">Resveratrol</td><td align="left" rowspan="1" colspan="1">Natural</td><td align="left" rowspan="1" colspan="1">&#8722;8.1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MTHFR</bold>
</td><td align="left" rowspan="1" colspan="1">Betaine</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">&#8722;4.2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MTHFR</bold>
</td><td align="left" rowspan="1" colspan="1">Diclofenac</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">&#8722;6.5</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOD1</bold>
</td><td align="left" rowspan="1" colspan="1">Licocumarone</td><td align="left" rowspan="1" colspan="1">Natural</td><td align="left" rowspan="1" colspan="1">&#8722;6.6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOD1</bold>
</td><td align="left" rowspan="1" colspan="1">Edaravone</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">&#8722;5.5</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOD1</bold>
</td><td align="left" rowspan="1" colspan="1">Donepezil</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">&#8722;6.6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>APOE</bold>
</td><td align="left" rowspan="1" colspan="1">Curcumin</td><td align="left" rowspan="1" colspan="1">Natural</td><td align="left" rowspan="1" colspan="1">&#8722;7.2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>APOE</bold>
</td><td align="left" rowspan="1" colspan="1">Bexarotene</td><td align="left" rowspan="1" colspan="1">Reference</td><td align="left" rowspan="1" colspan="1">&#8722;6.7</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>APOE</bold>
</td><td align="left" rowspan="1" colspan="1">Diclofenac</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">&#8722;6.5</td></tr></tbody></table></alternatives></table-wrap><p>To validate the docking results and evaluate the relative binding performance of the chosen natural ligands, we included clinically proven reference inhibitors (positive controls) and non-specific drugs (negative controls) for each protein target (see <xref rid="pone.0331787.t007" ref-type="table">Table 7</xref>). The findings clearly show that natural ligands outperformed recognized inhibitors across numerous targets. For example, Curcumin has a higher binding score with MMP9 (&#8722;8.0 kcal/mol) than the reference inhibitor SB-3CT (&#8722;7.2 kcal/mol), indicating the possibility of competitive inhibition. Similarly, Licocumarone binds more firmly to SOD1 (&#8722;6.6 kcal/mol) than Edaravone (&#8722;5.5 kcal/mol), a clinically used antioxidant. Galangin has a high interaction with APLP1 (&#8722;8.5 kcal/mol), similar to the &#946;-secretase inhibitor Verubecestat (&#8722;9.9 kcal/mol), indicating potential for regulating amyloidogenic pathways. Negative controls like Donepezil and Diclofenac showed poorer binding (mean&#8201;~&#8201;&#8722;6.5 kcal/mol) across targets, supporting the selectivity and significance of natural ligands to VaD-associated proteins.</p><p>In addition, the docking results were validated by Normal Mode Analysis, through which several factors were analyzed, such as the B-factor, deformability, variance, and correlation. Each factor had a unique influence on the docked complexes, but the results showed a stable configuration for all targeted complexes. Furthermore, in previous studies, curcumin was found to have good therapeutic capability against vascular dementia; however, in this study, we deeply analyzed and targeted the most influential proteins and common natural compounds that showed positive results and could be used as a cost-effective and user-friendly treatment against this disease. While the current findings show substantial in-silico binding affinities and pathway involvement for natural chemicals across major VaD-related proteins, their larger significance stems from the potential for therapeutic translation. Given that targets such as APOE, MMP9, and CLDN5 are linked to not just vascular pathology but also early-stage cognitive decline and neurovascular disturbance, the discovered ligands could be used to develop early intervention techniques. Importantly, their multi-target binding patterns imply potential for polypharmacology, in which single drugs address numerous VaD characteristics at the same time, such as oxidative stress, amyloid dysregulation, and blood-brain barrier permeability. This is consistent with current dementia medication discovery trends, which favor multimodal therapy approaches.</p><p>Furthermore, because these compounds are natural products with acceptable safety profiles, they could be quickly moved to preclinical in vivo validation, particularly in vascular damage or chronic hypoperfusion models.Finally, the findings of this work support the use of structure-guided screening to hasten the identification of low-cost, mechanism-driven candidates for future clinical development in vascular dementia. While our findings provide useful computational insights, they are based solely on in-silico analyses and have not yet been validated experimentally. Further studies using cell or animal models are needed to confirm these ligand protein interactions and their biological effects. Several approaches are proposed to help translate computational insights into experimental validation. In vitro binding experiments, such as surface plasmon resonance (SPR) or fluorescence-based quenching studies, can be used to confirm the affinity of ligands for important targets such as APOE, MMP9, and APLP1. Enzyme activity assays can also determine compound&#8217;s inhibitory potential against MMP9 or its ability to increase SOD1 antioxidant function. The effect of Claudin-5-targeting ligands on blood-brain barrier (BBB) integrity can be studied further utilizing cell-based permeability models, such as the hCMEC/D3 human brain endothelial monolayer system.For in vivo validation, well-established vascular dementia models, such as bilateral common carotid artery occlusion (BCCAO) in rats and chronic cerebral hypoperfusion in mice, can be used. These models enable for the evaluation of cognitive performance (e.g., Morris Water Maze test) and BBB integrity (e.g., Evans Blue dye extravasation assay) after administering candidate drugs such as Curcumin, Galangin, or Resveratrol. Together, these tests will give key molecular and functional insights, validating the therapeutic relevance of the natural ligands found in this study.</p></sec><sec sec-type="conclusions" id="sec024"><title>Conclusion</title><p>This study introduces an innovative computational methodology integrating normal mode analysis with molecular docking to identify natural ligands possessing neuroprotective properties against vascular dementia. These results highlight the potential cost-effective therapeutic benefits of curcumin, galangin, licocumarone, and resveratrol through their strong interactions with significant neurodegenerative proteins. This study enhances our understanding of ligand-induced conformational alterations by uniquely integrating docking with evaluations of structural flexibility, in contrast to conventional drug discovery techniques. The observed strong binding affinities suggest that these natural compounds may regulate critical processes, such as amyloid metabolism, oxidative stress, and blood-brain barrier integrity, thereby mitigating the course of vascular dementia (VaD). This study employed a computational strategy to expedite drug discovery for neurodegeneration, effectively linking in-silico modelling with translational research. Validation of these interactions will advance the clinical use of these compounds. This study paves the way for targeted therapies for vascular dementia by harnessing the therapeutic potential of natural chemicals, thereby preventing the development of neuroprotective drugs.</p></sec><sec id="sec025" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0331787.s001" position="float" content-type="local-data" orientation="portrait"><label>S1 File</label><caption><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0331787.s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0331787.ref001"><label>1</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>X-X</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Jia</surname><given-names>Q-Y</given-names></name>. <article-title>Inflammation, apoptosis and autophagy as critical players in vascular dementia</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. <year>2020</year>;<volume>24</volume>(<issue>18</issue>):<fpage>9601</fpage>&#8211;<lpage>14</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.26355/eurrev_202009_23048</pub-id><pub-id pub-id-type="pmid">33015803</pub-id></mixed-citation></ref><ref id="pone.0331787.ref002"><label>2</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Detcheverry</surname><given-names>FE</given-names></name>, <name name-style="western"><surname>Senthil</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Motue</surname><given-names>WL</given-names></name>, <name name-style="western"><surname>Hosein</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Arnaoutelis</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Araujo</surname><given-names>D</given-names></name>. <article-title>Investigating the oxidative stress&#8211;vascular brain injury axis in mild cognitive impairment of the Alzheimer type</article-title>. <source>medRxiv</source>. <year>2024</year>;<volume>2024</volume>:24.24313962.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.70456</pub-id><pub-id pub-id-type="pmcid">PMC12434610</pub-id><pub-id pub-id-type="pmid">40951925</pub-id></mixed-citation></ref><ref id="pone.0331787.ref003"><label>3</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bennett</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Grant</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Aldred</surname><given-names>S</given-names></name>. <article-title>Oxidative stress in vascular dementia and Alzheimer&#8217;s disease: a common pathology</article-title>. <source>J Alzheimers Dis</source>. <year>2009</year>;<volume>17</volume>(<issue>2</issue>):<fpage>245</fpage>&#8211;<lpage>57</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3233/JAD-2009-1041</pub-id><pub-id pub-id-type="pmid">19221412</pub-id></mixed-citation></ref><ref id="pone.0331787.ref004"><label>4</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Muche</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Arendt</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Schliebs</surname><given-names>R</given-names></name>. <article-title>Oxidative stress affects processing of amyloid precursor protein in vascular endothelial cells</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>(<issue>6</issue>):e0178127. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0178127</pub-id><pub-id pub-id-type="pmid">28617802</pub-id><pub-id pub-id-type="pmcid">PMC5472258</pub-id></mixed-citation></ref><ref id="pone.0331787.ref005"><label>5</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Arendt</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Piekarska</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ha&#322;as-Wi&#347;niewska</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Izdebska</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Grzanka</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gagat</surname><given-names>M</given-names></name>. <article-title>Downregulation and inhibition of TRPM2 calcium channel prevent oxidative stress-induced endothelial dysfunction in the EA.hy926 endothelial cells model - Preliminary studies</article-title>. <source>Adv Med Sci</source>. <year>2025</year>;<volume>70</volume>(<issue>1</issue>):<fpage>62</fpage>&#8211;<lpage>78</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.advms.2025.01.002</pub-id><pub-id pub-id-type="pmid">39778739</pub-id></mixed-citation></ref><ref id="pone.0331787.ref006"><label>6</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Polvikoski</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sulkava</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Haltia</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kainulainen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Vuorio</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Verkkoniemi</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein</article-title>. <source>N Engl J Med</source>. <year>1995</year>;<volume>333</volume>(<issue>19</issue>):<fpage>1242</fpage>&#8211;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJM199511093331902</pub-id><pub-id pub-id-type="pmid">7566000</pub-id></mixed-citation></ref><ref id="pone.0331787.ref007"><label>7</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>F</given-names></name>, <name name-style="western"><surname>He</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ni</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name>. <article-title>The vascular contribution of apolipoprotein E to Alzheimer&#8217;s disease</article-title>. <source>Brain</source>. <year>2024</year>;<volume>147</volume>(<issue>9</issue>):<fpage>2946</fpage>&#8211;<lpage>65</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/brain/awae156</pub-id><pub-id pub-id-type="pmid">38748848</pub-id></mixed-citation></ref><ref id="pone.0331787.ref008"><label>8</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Parodi-Rull&#225;n</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sone</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Fossati</surname><given-names>S</given-names></name>. <article-title>Endothelial mitochondrial dysfunction in cerebral amyloid angiopathy and Alzheimer&#8217;s disease</article-title>. <source>J Alzheimers Dis</source>. <year>2019</year>;<volume>72</volume>(<issue>4</issue>):<fpage>1019</fpage>&#8211;<lpage>39</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3233/JAD-190357</pub-id><pub-id pub-id-type="pmid">31306129</pub-id><pub-id pub-id-type="pmcid">PMC6917858</pub-id></mixed-citation></ref><ref id="pone.0331787.ref009"><label>9</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Maiti</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Dunbar</surname><given-names>GL</given-names></name>. <article-title>Use of curcumin, a natural polyphenol for targeting molecular pathways in treating age-related neurodegenerative diseases</article-title>. <source>Int J Mol Sci</source>. <year>2018</year>;<volume>19</volume>(<issue>6</issue>):<fpage>1637</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms19061637</pub-id><pub-id pub-id-type="pmid">29857538</pub-id><pub-id pub-id-type="pmcid">PMC6032333</pub-id></mixed-citation></ref><ref id="pone.0331787.ref010"><label>10</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Shabbir</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Rubab</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tyagi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Oh</surname><given-names>D-H</given-names></name>. <article-title>Curcumin and its derivatives as theranostic agents in Alzheimer&#8217;s disease: the implication of nanotechnology</article-title>. <source>Int J Mol Sci</source>. <year>2020</year>;<volume>22</volume>(<issue>1</issue>):<fpage>196</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms22010196</pub-id><pub-id pub-id-type="pmid">33375513</pub-id><pub-id pub-id-type="pmcid">PMC7795367</pub-id></mixed-citation></ref><ref id="pone.0331787.ref011"><label>11</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chainoglou</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hadjipavlou-Litina</surname><given-names>D</given-names></name>. <article-title>Curcumin in health and diseases: Alzheimer&#8217;s disease and curcumin analogues, derivatives, and hybrids</article-title>. <source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>6</issue>):<fpage>1975</fpage>.<pub-id pub-id-type="pmid">32183162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21061975</pub-id><pub-id pub-id-type="pmcid">PMC7139886</pub-id></mixed-citation></ref><ref id="pone.0331787.ref012"><label>12</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rahman</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Akter</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bhattacharya</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Abdel-Daim</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Alkahtani</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Arafah</surname><given-names>MW</given-names></name>, <etal>et al</etal>. <article-title>Resveratrol and neuroprotection: impact and its therapeutic potential in Alzheimer&#8217;s disease</article-title>. <source>Front Pharmacol</source>. <year>2020</year>;<volume>11</volume>:<fpage>619024</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fphar.2020.619024</pub-id><pub-id pub-id-type="pmid">33456444</pub-id><pub-id pub-id-type="pmcid">PMC7804889</pub-id></mixed-citation></ref><ref id="pone.0331787.ref013"><label>13</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Viegas F v</surname><given-names>PD</given-names></name>, <name name-style="western"><surname>Gontijo</surname><given-names>VS</given-names></name>, <name name-style="western"><surname>de Freitas Silva</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ortiz</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>dos Reis Rosa Franco</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ernesto</surname><given-names>JT</given-names></name>. <article-title>Curcumin, resveratrol and cannabidiol as natural key prototypes in drug design for neuroprotective agents</article-title>. <source>Curr Neuropharmacol</source>. <year>2022</year>;<volume>20</volume>(<issue>7</issue>):<fpage>1297</fpage>&#8211;<lpage>328</lpage>.<pub-id pub-id-type="pmid">34825873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1570159X19666210712152532</pub-id><pub-id pub-id-type="pmcid">PMC9881080</pub-id></mixed-citation></ref><ref id="pone.0331787.ref014"><label>14</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Miziak</surname><given-names>B</given-names></name>, <name name-style="western"><surname>B&#322;aszczyk</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Czuczwar</surname><given-names>SJ</given-names></name>. <article-title>Some candidate drugs for pharmacotherapy of Alzheimer&#8217;s disease</article-title>. <source>Pharmaceuticals</source>. <year>2021</year>;<volume>14</volume>(<issue>5</issue>):<fpage>458</fpage>.<pub-id pub-id-type="pmid">34068096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph14050458</pub-id><pub-id pub-id-type="pmcid">PMC8152728</pub-id></mixed-citation></ref><ref id="pone.0331787.ref015"><label>15</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Khongrum</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mairuae</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Thanchomnang</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bai</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Palachai</surname><given-names>N</given-names></name>. <article-title>Synergistic neuroprotection through epigenetic modulation by combined curcumin-enriched turmeric extract and L-Ascorbic acid in oxidative stress-induced SH-SY5Y cell damage</article-title>. <source>Foods</source>. <year>2025</year>;<volume>14</volume>(<issue>5</issue>):<fpage>892</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/foods14050892</pub-id><pub-id pub-id-type="pmid">40077595</pub-id><pub-id pub-id-type="pmcid">PMC11898916</pub-id></mixed-citation></ref><ref id="pone.0331787.ref016"><label>16</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hussain</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ahmad</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>SWA</given-names></name>, <name name-style="western"><surname>Ghias</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ullah</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>SU</given-names></name>. <article-title>Neuroprotective potential of synthetic mono-carbonyl curcumin analogs assessed by molecular docking studies</article-title>. <source>Molecules</source>. <year>2021</year>;<volume>26</volume>(<issue>23</issue>):<fpage>7168</fpage>.<pub-id pub-id-type="pmid">34885751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules26237168</pub-id><pub-id pub-id-type="pmcid">PMC8659060</pub-id></mixed-citation></ref><ref id="pone.0331787.ref017"><label>17</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Abdul Manap</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Wei Tan</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Leong</surname><given-names>WH</given-names></name>, <name name-style="western"><surname>Yin Chia</surname><given-names>AY</given-names></name>, <name name-style="western"><surname>Vijayabalan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Arya</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Synergistic effects of curcumin and piperine as potent acetylcholine and amyloidogenic inhibitors with significant neuroprotective activity in SH-SY5Y cells via computational molecular modeling and in vitro assay</article-title>. <source>Front Aging Neurosci</source>. <year>2019</year>;<volume>11</volume>:<fpage>206</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fnagi.2019.00206</pub-id><pub-id pub-id-type="pmid">31507403</pub-id><pub-id pub-id-type="pmcid">PMC6718453</pub-id></mixed-citation></ref><ref id="pone.0331787.ref018"><label>18</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Shi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kan</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Exploring the mechanism of Yizhi Tongmai decoction in the treatment of vascular dementia through network pharmacology and molecular docking</article-title>. <source>Ann Transl Med</source>. <year>2021</year>;<volume>9</volume>(<issue>2</issue>):<fpage>164</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.21037/atm-20-8165</pub-id><pub-id pub-id-type="pmid">33569466</pub-id><pub-id pub-id-type="pmcid">PMC7867933</pub-id></mixed-citation></ref><ref id="pone.0331787.ref019"><label>19</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yuan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Mu</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>RAGE: a potential target for Epimedium&#8217;s anti-neuroinflammation role in vascular dementia-insights from network pharmacology and molecular simulation</article-title>. <source>J Biomol Struct Dyn</source>. <year>2024</year>;<volume>42</volume>(<issue>20</issue>):<fpage>10856</fpage>&#8211;<lpage>75</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/07391102.2023.2259480</pub-id><pub-id pub-id-type="pmid">37732621</pub-id></mixed-citation></ref><ref id="pone.0331787.ref020"><label>20</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Lyu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>. <article-title>Acupuncture therapy on dementia: explained with an integrated analysis on therapeutic targets and associated mechanisms</article-title>. <source>J Alzheimers Dis</source>. <year>2023</year>;<volume>94</volume>(s1):S141&#8211;<lpage>58</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3233/JAD-221018</pub-id><pub-id pub-id-type="pmid">36776063</pub-id><pub-id pub-id-type="pmcid">PMC10473135</pub-id></mixed-citation></ref><ref id="pone.0331787.ref021"><label>21</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kandasamy</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Anusuyadevi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Aigner</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Unger</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Kniewallner</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>de Sousa</surname><given-names>DMB</given-names></name>, <etal>et al</etal>. <article-title>TGF-&#946; signaling: a therapeutic target to reinstate regenerative plasticity in vascular dementia?</article-title><source>Aging Dis</source>. <year>2020</year>;<volume>11</volume>(<issue>4</issue>):<fpage>828</fpage>&#8211;<lpage>50</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.14336/AD.2020.0222</pub-id><pub-id pub-id-type="pmid">32765949</pub-id><pub-id pub-id-type="pmcid">PMC7390515</pub-id></mixed-citation></ref><ref id="pone.0331787.ref022"><label>22</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lai</surname><given-names>AY</given-names></name>, <name name-style="western"><surname>McLaurin</surname><given-names>J</given-names></name>. <article-title>Rho&#8208;associated protein kinases as therapeutic targets for both vascular and parenchymal pathologies in Alzheimer&#8217;s disease</article-title>. <source>J Neurochem</source>. <year>2018</year>;<volume>144</volume>(<issue>5</issue>):<fpage>659</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">28722749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.14130</pub-id></mixed-citation></ref><ref id="pone.0331787.ref023"><label>23</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sun</surname><given-names>J-H</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H-F</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>M-S</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J-Q</given-names></name>, <etal>et al</etal>. <article-title>Genetics of vascular dementia: systematic review and meta-analysis</article-title>. <source>J Alzheimers Dis</source>. <year>2015</year>;<volume>46</volume>(<issue>3</issue>):<fpage>611</fpage>&#8211;<lpage>29</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3233/JAD-143102</pub-id><pub-id pub-id-type="pmid">25835425</pub-id></mixed-citation></ref><ref id="pone.0331787.ref024"><label>24</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sewell</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fialova</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Montagne</surname><given-names>A</given-names></name>. <article-title>Unraveling the transcriptomic landscape of brain vascular cells in dementia: a systematic review</article-title>. <source>Alzheimer&#8217;s Dementia</source>. <year>2025</year>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14512</pub-id><pub-id pub-id-type="pmcid">PMC11851133</pub-id><pub-id pub-id-type="pmid">39807599</pub-id></mixed-citation></ref><ref id="pone.0331787.ref025"><label>25</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Szklarczyk</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kirsch</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Koutrouli</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nastou</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mehryary</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Hachilif</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest</article-title>. <source>Nucleic Acids Res</source>. <year>2023</year>;<volume>51</volume>(D1):D638&#8211;<lpage>46</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkac1000</pub-id><pub-id pub-id-type="pmid">36370105</pub-id><pub-id pub-id-type="pmcid">PMC9825434</pub-id></mixed-citation></ref><ref id="pone.0331787.ref026"><label>26</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Canzler</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hackerm&#252;ller</surname><given-names>J</given-names></name>. <article-title>multiGSEA: a GSEA-based pathway enrichment analysis for multi-omics data</article-title>. <source>BMC Bioinformatics</source>. <year>2020</year>;<volume>21</volume>(<issue>1</issue>):<fpage>561</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12859-020-03910-x</pub-id><pub-id pub-id-type="pmid">33287694</pub-id><pub-id pub-id-type="pmcid">PMC7720482</pub-id></mixed-citation></ref><ref id="pone.0331787.ref027"><label>27</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Anishchenko</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hiranuma</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Dauparas</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Protein tertiary structure prediction and refinement using deep learning and Rosetta in CASP14</article-title>. <source>Proteins</source>. <year>2021</year>;<volume>89</volume>(<issue>12</issue>):<fpage>1722</fpage>&#8211;<lpage>33</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/prot.26194</pub-id><pub-id pub-id-type="pmid">34331359</pub-id><pub-id pub-id-type="pmcid">PMC8616808</pub-id></mixed-citation></ref><ref id="pone.0331787.ref028"><label>28</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gindulyte</surname><given-names>A</given-names></name>, <name name-style="western"><surname>He</surname><given-names>J</given-names></name>, <name name-style="western"><surname>He</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>PubChem 2025 update</article-title>. <source>Nucleic Acids Res</source>. <year>2025</year>;<volume>53</volume>(D1):D1516&#8211;<lpage>25</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkae1059</pub-id><pub-id pub-id-type="pmid">39558165</pub-id><pub-id pub-id-type="pmcid">PMC11701573</pub-id></mixed-citation></ref><ref id="pone.0331787.ref029"><label>29</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Xie</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C</given-names></name>. <article-title>Molecular mechanism of Epimedium in the treatment of vascular dementia based on network pharmacology and molecular docking</article-title>. <source>Front Aging Neurosci</source>. <year>2022</year>;<volume>14</volume>:<fpage>940166</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fnagi.2022.940166</pub-id><pub-id pub-id-type="pmid">36051307</pub-id><pub-id pub-id-type="pmcid">PMC9424771</pub-id></mixed-citation></ref><ref id="pone.0331787.ref030"><label>30</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tong</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Tie</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhan</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ouyang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>J</given-names></name>. <article-title>Exploring the mechanism of Epimedii folium and notoginseng radix against vascular dementia based on network pharmacology and molecular docking analysis: pharmacological mechanisms of EH-PN for VD</article-title>. <source>Medicine</source>. <year>2022</year>;<volume>101</volume>(<issue>47</issue>):e31969.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000031969</pub-id><pub-id pub-id-type="pmcid">PMC9704979</pub-id><pub-id pub-id-type="pmid">36451386</pub-id></mixed-citation></ref><ref id="pone.0331787.ref031"><label>31</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Luo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zou</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>REPS1 as a potential biomarker in Alzheimer&#8217;s disease and vascular dementia</article-title>. <source>Front Aging Neurosci</source>. <year>2022</year>;<volume>14</volume>:<fpage>894824</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fnagi.2022.894824</pub-id><pub-id pub-id-type="pmid">35813961</pub-id><pub-id pub-id-type="pmcid">PMC9257827</pub-id></mixed-citation></ref><ref id="pone.0331787.ref032"><label>32</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cho</surname><given-names>S-J</given-names></name>, <name name-style="western"><surname>Yun</surname><given-names>S-M</given-names></name>, <name name-style="western"><surname>Jo</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Jeong</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Altered expression of Notch1 in Alzheimer&#8217;s disease</article-title>. <source>PLoS One</source>. <year>2019</year>;<volume>14</volume>(<issue>11</issue>):e0224941. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0224941</pub-id><pub-id pub-id-type="pmid">31770379</pub-id><pub-id pub-id-type="pmcid">PMC6879159</pub-id></mixed-citation></ref><ref id="pone.0331787.ref033"><label>33</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Bi</surname><given-names>J</given-names></name>. <article-title>Regulatory role of melatonin in Notch1 signaling pathway in cerebral cortex of A&#946;1-42-induced Alzheimer&#8217;s disease rat model</article-title>. <source>Mol Biol Rep</source>. <year>2023</year>;<volume>50</volume>(<issue>3</issue>):<fpage>2463</fpage>&#8211;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11033-022-08213-3</pub-id><pub-id pub-id-type="pmid">36602704</pub-id></mixed-citation></ref><ref id="pone.0331787.ref034"><label>34</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kabel</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Arab</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>Atef</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Estfanous</surname><given-names>RS</given-names></name>. <article-title>Omarigliptin/galangin combination mitigates lipopolysaccharide-induced neuroinflammation in rats: Involvement of glucagon-like peptide-1, toll-like receptor-4, apoptosis and Akt/GSK-3&#946; signaling</article-title>. <source>Life Sci</source>. <year>2022</year>;<volume>295</volume>:<fpage>120396</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.lfs.2022.120396</pub-id><pub-id pub-id-type="pmid">35157909</pub-id></mixed-citation></ref><ref id="pone.0331787.ref035"><label>35</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ibrahim</surname><given-names>WW</given-names></name>, <name name-style="western"><surname>Skalicka-Wo&#378;niak</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Budzy&#324;ska</surname><given-names>B</given-names></name>, <name name-style="western"><surname>El Sayed</surname><given-names>NS</given-names></name>. <article-title>NLRP3 inflammasome inhibition and M1-to-M2 microglial polarization shifting via scoparone-inhibited TLR4 axis in ovariectomy/D-galactose Alzheimer&#8217;s disease rat model</article-title>. <source>Int Immunopharmacol</source>. <year>2023</year>;<volume>119</volume>:<fpage>110239</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.intimp.2023.110239</pub-id><pub-id pub-id-type="pmid">37137264</pub-id></mixed-citation></ref><ref id="pone.0331787.ref036"><label>36</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lei</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Resveratrol: multi-targets mechanism on neurodegenerative diseases based on network pharmacology</article-title>. <source>Front Pharmacol</source>. <year>2020</year>;<volume>11</volume>:<fpage>694</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fphar.2020.00694</pub-id><pub-id pub-id-type="pmid">32477148</pub-id><pub-id pub-id-type="pmcid">PMC7240052</pub-id></mixed-citation></ref><ref id="pone.0331787.ref037"><label>37</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>J</given-names></name>. <article-title>Vascular dementia has the highest hospitalisation rate in China: a nationwide hospital information system study</article-title>. <source>Stroke Vasc Neurol</source>. <year>2023</year>;<volume>8</volume>(<issue>1</issue>):<fpage>59</fpage>&#8211;<lpage>68</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/svn-2022-001637</pub-id><pub-id pub-id-type="pmid">36219569</pub-id><pub-id pub-id-type="pmcid">PMC9985804</pub-id></mixed-citation></ref><ref id="pone.0331787.ref038"><label>38</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Armstrong</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kurasz</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z</given-names></name>. <article-title>Predictors of mortality in individuals with dementia in the National Alzheimer&#8217;s Coordinating Center</article-title>. <source>J Alzheimers Dis</source>. <year>2022</year>;<volume>86</volume>(<issue>4</issue>):<fpage>1935</fpage>&#8211;<lpage>46</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3233/JAD-215587</pub-id><pub-id pub-id-type="pmid">35253760</pub-id><pub-id pub-id-type="pmcid">PMC9153251</pub-id></mixed-citation></ref><ref id="pone.0331787.ref039"><label>39</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Penwell</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Koehler</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Akhtar</surname><given-names>SN</given-names></name>. <article-title>G-protein signaling in Alzheimer&#8217;s disease: spatial expression validation of semi-supervised deep learning-based computational framework</article-title>. <source>J Neurosci</source>. <year>2024</year>;<volume>44</volume>(<issue>45</issue>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0587-24.2024</pub-id><pub-id pub-id-type="pmcid">PMC11551890</pub-id><pub-id pub-id-type="pmid">39327003</pub-id></mixed-citation></ref><ref id="pone.0331787.ref040"><label>40</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chai</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Rajeev</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Poh</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Selvaraji</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hilal</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>CP</given-names></name>, <etal>et al</etal>. <article-title>Chronic cerebral hypoperfusion alters the CypA-EMMPRIN-gelatinase pathway: implications for vascular dementia</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2023</year>;<volume>43</volume>(<issue>5</issue>):<fpage>722</fpage>&#8211;<lpage>35</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/0271678X221146401</pub-id><pub-id pub-id-type="pmid">36537035</pub-id><pub-id pub-id-type="pmcid">PMC10108186</pub-id></mixed-citation></ref><ref id="pone.0331787.ref041"><label>41</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Durrant</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Ruscher</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sheppard</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Coleman</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>&#214;zen</surname><given-names>I</given-names></name>. <article-title>Beta secretase 1-dependent amyloid precursor protein processing promotes excessive vascular sprouting through NOTCH3 signalling</article-title>. <source>Cell Death Dis</source>. <year>2020</year>;<volume>11</volume>(<issue>2</issue>):<fpage>98</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41419-020-2288-4</pub-id><pub-id pub-id-type="pmid">32029735</pub-id><pub-id pub-id-type="pmcid">PMC7005019</pub-id></mixed-citation></ref></ref-list></back><sub-article article-type="aggregated-review-documents" id="pone.0331787.r001" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0331787.r001</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jadavji</surname><given-names initials="N">Nafisa</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Nafisa Jadavji</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Nafisa Jadavji</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0331787" id="rel-obj001" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">28 Apr 2025</named-content>
</p><p>PONE-D-25-16329Targeting Vascular Dementia: Molecular Docking Analysis of Natural Ligands Against Key Neuroprotective ProteinsPLOS ONE</p><p>Dear Dr. Bie,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#8217;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>Please submit your revised manuscript by Jun 12 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#160;<email>plosone@plos.org</email> . When you're ready to submit your revision, log on to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:</p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list>
</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link> . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link> .</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Nafisa M. Jadavji, PhD, MSc, BSc</p><p>Academic Editor</p><p>PLOS ONE</p><p>
<bold>Journal Requirements:</bold>
</p><p>1. When submitting your revision, we need you to address these additional requirements.&#160;Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>&#160;2. Please note that PLOS ONE has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code" ext-link-type="uri">https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code</ext-link> and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.&#160;3. Thank you for stating the following financial disclosure:&#160;This work was funded by Hubei Natural Science Foundation Program (grant 2023AFCO32) and Project of Hubei Provincial Health Commission (grant : WJ2023M116).&#160;&#160;Please state what role the funders took in the study.&#160; If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."&#160;If this statement is not correct you must amend it as needed.&#160;Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.&#160;4. Thank you for stating the following in the Acknowledgments Section of your manuscript:&#160;This work was funded by the Hubei Natural Science Foundation Program (grant 2023AFCO32) and the Project of Hubei Provincial Health Commission (grant WJ2023M116).&#160;We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.&#160;Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:&#160;This work was funded by Hubei Natural Science Foundation Program (grant 2023AFCO32) and Project of Hubei Provincial Health Commission (grant : WJ2023M116).&#160;&#160;Please include your amended statements within your cover letter; we will change the online submission form on your behalf.&#160;5. Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information or a reason for why you are unable to make your data freely accessible. If your research concerns only data provided within your submission, please write "All data are in the manuscript and/or supporting information files" as your Data Availability Statement.&#160;6. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.&#160;7. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to &#8216;Update my Information&#8217; (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.</p><p>
<bold>Additional Editor Comments:</bold>
</p><p>Dear Authors,</p><p>Reviewer 1 has provided an extensive list of revisions to be made. I would encourage you to respond each comment and make revisions accordingly to your manuscript.</p><p>I look forward to reading your revised manuscript.</p><p>Sincerely,</p><p>Nafisa</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<bold>Comments to the Author</bold>
</p><p>1. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>**********</p><p>2. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>**********</p><p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>**********</p><p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>**********</p><p>5. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p><bold>Reviewer #1:&#160;</bold> Comments for Authors</p><p>This study presents a thorough computational investigation of natural ligands that target proteins associated with vascular dementia (VaD). The analysis incorporates multiple computational approaches, including molecular docking, protein-protein interaction network, and normal mode analysis. The manuscript demonstrates several strengths. Well-organized structure with clear objectives and logical progression. Effective use of various bioinformatics tools (STRING, Enrichr, AutoDock Vina). High-quality graphical abstract and figures that enhance understanding. However, some limitations were noted: Certain sections contain unnecessary redundant explanations, particularly when describing protein functions in VaD. The absence of experimental validation reduces the translational potential of the findings. The discussion section could be improved by better contextualizing the results within the broader field of vascular dementia therapeutics. While the computational approach is sound, the study would benefit from more concise writing and experimental validation to strengthen its conclusions.</p><p>Comments:</p><p>1. Consider a more concise title such as "Targeting Vascular Dementia: Molecular Docking and Dynamics of Natural Ligands Against Neuroprotective Proteins."</p><p>2. Streamline the abstract to be more focused and less dense.</p><p>3. Explicitly highlight the study's novelty in the abstract, particularly the integration of normal mode analysis with molecular docking.</p><p>4. Consolidate descriptions of protein roles (APOE, CLDN5, etc.) that appear redundantly throughout the manuscript.</p><p>5. Better articulate the knowledge gap in the introduction, emphasizing the lack of studies combining NMA and docking for VaD therapeutics.</p><p>6. Include validation metrics for the DoGSiteScorer active site predictions, such as comparisons with known active sites.</p><p>7. Add a comparative table of selected natural compounds (curcumin, galangin, licocumarone, resveratrol) showing relevant properties like bioavailability and previous evidence in neurodegeneration.</p><p>8. Explain the relevance of cross-species conservation in the co-expression analysis to human vascular dementia.</p><p>9. Provide a biological interpretation of the edge confidence scores in the PPI analysis to clarify their functional significance.</p><p>10. Avoid repeating docking scores in the text when they're already presented in Table 3. Instead, summarize key findings more concisely.</p><p>11. Include a discussion of structural factors influencing binding affinity between specific ligands and proteins.</p><p>12. Link computational findings to potential clinical applications more explicitly in the discussion section.</p><p>13. Acknowledge limitations regarding experimental validation and outline future research directions.</p><p>14. Focus the discussion on interpretation and implications rather than restating results.</p><p>15. Update older references with recent reviews on vascular dementia mechanisms (2022-2024).</p><p>16. Ensure consistent formatting of journal names throughout the references.</p><p>Major revision required to address redundancy, clarify novelty, and improve clinical relevance. The study has strong potential but needs tighter writing and contextualization. Experimental validation in future work would significantly strengthen the conclusions.</p><p><bold>Reviewer #2:&#160;</bold> The authors have presented a well written, detailed manuscript investigating molecular docking analysis of natural ligands against vascular dementia, a neurodegenerative disease exacerbated by vascular pathology. The diagrams are exceptional and statistical analysis conducted very well.</p><p>**********</p><p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link> ). If published, this will include your full peer review and any attached files.</p><p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link> .</p><p>Reviewer #1:&#160;<bold>Yes:&#160;</bold> Jonah Bawa Adokwe Ph.D</p><p>Reviewer #2:&#160;No</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link> . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#160;<email>figures@plos.org</email> . Please note that Supporting Information files do not need this step.</p><supplementary-material id="pone.0331787.s002" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Comments for Authors .docx</named-content></p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0331787.s002.docx" position="float" orientation="portrait"/></supplementary-material></body></sub-article><sub-article article-type="author-comment" id="pone.0331787.r002"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0331787.r002</article-id><title-group><article-title>Author response to Decision Letter 1</article-title></title-group><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="editor-report" id="rel-obj002" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="41032496"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">13 May 2025</named-content>
</p><p>Dear Reviewers,</p><p>Thank you so much for your time and consideration; your comments were really helpful as they enhanced the quality and clarity of the manuscript. We really appreciate your efforts.</p><supplementary-material id="pone.0331787.s003" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers.docx</named-content></p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0331787.s003.docx" position="float" orientation="portrait"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0331787.r003" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0331787.r003</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jadavji</surname><given-names initials="N">Nafisa</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Nafisa Jadavji</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Nafisa Jadavji</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="reviewed-article" id="rel-obj003" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="41032496"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">4 Jun 2025</named-content>
</p><p>PONE-D-25-16329R1Targeting Vascular Dementia: Molecular Docking and Dynamics of Natural Ligands Against Neuroprotective ProteinsPLOS ONE</p><p>Dear Dr. Bie,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#8217;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>==============================</p><p>Dear Authors,</p><p>Thank-you for taking the time to make revisions to your manuscript. There are some additional revisions that need to be made. We look forward to reviewing your revised manuscript.</p><p>Sincerely,</p><p>Nafisa</p><p>==============================</p><p>Please submit your revised manuscript by Jul 19 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#160;<email>plosone@plos.org</email> . When you're ready to submit your revision, log on to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:</p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list>
</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link> . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link> .</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Nafisa M. Jadavji, PhD, MSc, BSc</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal Requirements:</p><p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article&#8217;s retracted status in the References list and also include a citation and full reference for the retraction notice.</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<bold>Comments to the Author</bold>
</p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#8220;Comments to the Author&#8221; section, enter your conflict of interest statement in the &#8220;Confidential to Editor&#8221; section, and submit your "Accept" recommendation.</p><p>Reviewer #1:&#160;All comments have been addressed</p><p>Reviewer #2:&#160;All comments have been addressed</p><p>Reviewer #3:&#160;(No Response)</p><p>**********</p><p>2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>Reviewer #3:&#160;Partly</p><p>**********</p><p>3. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>Reviewer #3:&#160;No</p><p>**********</p><p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>Reviewer #3:&#160;Yes</p><p>**********</p><p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>Reviewer #3:&#160;Yes</p><p>**********</p><p>6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #1:&#160;The authors have thoroughly addressed all comments, improving the manuscript's clarity, rigor, and translational relevance. Key revisions include validation of active site predictions, consolidation of redundant content, enhanced biological interpretation of co-expression and PPI data, and explicit discussion of structural and clinical implications. Integrating NMA with docking is now highlighted as a novel contribution that strengthens the study's framework for drug discovery in vascular dementia. I recommend acceptance pending minor proofreading.</p><p>Reviewer #2:&#160;(No Response)</p><p>Reviewer #3:&#160;This study presents a promising computational framework for identifying potential multi-target natural compounds against vascular dementia.</p><p>The manuscript presents a well-organized computational study aimed at identifying natural ligands with neuroprotective potential against vascular dementia (VaD). It addresses three relevant protein targets&#8212;COX-2, AChE, and iNOS&#8212;and employs widely accepted computational methods, including molecular docking (AutoDock Vina), molecular dynamics (GROMACS), and ADMET prediction tools.</p><p>Although the study does not include in-vitro or in-vivo assays, it has a scientific value and potentially will be served to facilitate such experiments.</p><p>Limitations:</p><p>1. Only five compounds were selected, without justification for exclusion of others, no chemical diversity assessment, and no comparative potential drugs.</p><p>2. Absence of reference or negative controls: The manuscript does not include standard compounds such as donepezil (for AChE) or diclofenac (for COX-2) to provide context for the docking scores. It makes it difficult to assess whether the reported affinities are therapeutically meaningful.</p><p>3. The docking scores in Table 2 reflect a single best pose per ligand&#8211;target pair. While this is standard in basic docking workflows, no replicate runs or statistical treatment (e.g., averaging over multiple conformations) was performed, limiting the ability to assess variability or reproducibility.</p><p>The MD results (Figures 2&#8211;4, p. 9&#8211;11) are based on single 100 ns runs for each complex. The manuscript does not report multiple simulations or error margins for RMSD, RMSF, or binding energy trajectories, limiting the reproducibility of findings.</p><p>4. Although ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties are reported (Table 5, p. 13), they are not compared to those of approved CNS drugs or toxic controls. This makes it hard to interpret what constitutes "favourable" beyond qualitative criteria.</p><p>**********</p><p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link> ). If published, this will include your full peer review and any attached files.</p><p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link> .</p><p>Reviewer #1:&#160;<bold>Yes:&#160;</bold> Jonah Bawa Adokwe PhD</p><p>Reviewer #2:&#160;No</p><p>Reviewer #3:&#160;<bold>Yes:&#160;</bold> Dan Z Milikovsky</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link> . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#160;<email>figures@plos.org</email> . Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article article-type="author-comment" id="pone.0331787.r004"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0331787.r004</article-id><title-group><article-title>Author response to Decision Letter 2</article-title></title-group><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0331787" id="rel-obj004" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">22 Jun 2025</named-content>
</p><p>Dear Dr. Dan Z Milikovsky, thank you soo much for reviewing our manuscript; all the comments have been addressed in the document attached as (response to reviewer).</p><supplementary-material id="pone.0331787.s004" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">response-to-reviewer.docx</named-content></p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0331787.s004.docx" position="float" orientation="portrait"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0331787.r005" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0331787.r005</article-id><title-group><article-title>Decision Letter 2</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jadavji</surname><given-names initials="N">Nafisa</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Nafisa Jadavji</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Nafisa Jadavji</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0331787" id="rel-obj005" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">23 Jul 2025</named-content>
</p><p>PONE-D-25-16329R2Targeting Vascular Dementia: Molecular Docking and Dynamics of Natural Ligands Against Neuroprotective ProteinsPLOS ONE</p><p>Dear Dr. Bie,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#8217;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>==============================</p><p>We thank the authors for their revisions. Your manuscript has improved. There are some minor revisions required.&#160;</p><p>Thank-you!</p><p>==============================</p><p>Please submit your revised manuscript by Sep 06 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#160;<email>plosone@plos.org</email> . When you're ready to submit your revision, log on to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:</p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list>
</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link> .</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Nafisa M. Jadavji, PhD, MSc, BSc</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal Requirements:</p><p>1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.&#160;</p><p>2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article&#8217;s retracted status in the References list and also include a citation and full reference for the retraction notice.</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<bold>Comments to the Author</bold>
</p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#8220;Comments to the Author&#8221; section, enter your conflict of interest statement in the &#8220;Confidential to Editor&#8221; section, and submit your "Accept" recommendation.</p><p>Reviewer #3:&#160;All comments have been addressed</p><p>Reviewer #4:&#160;(No Response)</p><p>**********</p><p>2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #3:&#160;Yes</p><p>Reviewer #4:&#160;Partly</p><p>**********</p><p>3. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #3:&#160;Yes</p><p>Reviewer #4:&#160;No</p><p>**********</p><p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p><p>Reviewer #3:&#160;Yes</p><p>Reviewer #4:&#160;Yes</p><p>**********</p><p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #3:&#160;Yes</p><p>Reviewer #4:&#160;Yes</p><p>**********</p><p>6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #3:&#160;The authors already answered my comments in the second submission. I commented that the paper can be published.</p><p>Reviewer #4:&#160;The authors present a comprehensive computational study addressing a critical need in vascular dementia (VaD) research. The integrated approach of molecular docking, normal mode analysis (NMA), and molecular dynamics (MD) simulations provides a robust framework for early-stage drug discovery, and the focus on natural ligands is a valuable contribution due to their potential cost-effectiveness and fewer side effects. My detailed comments and suggestions are outlined below to further enhance the manuscript.</p><p>Technical Soundness and Data Support: Areas for Enhancement (Partial)</p><p>While the manuscript demonstrates a strong scientific foundation, some areas could be strengthened to fully support the conclusions with the highest level of rigor:</p><p>Docking Methodology Details: The "Materials and Methods" section states that each ligand was docked independently five times, and the pose with the lowest binding energy was chosen. To enhance the reproducibility and confidence in the docking results, the manuscript should explicitly include details on the variability across these five runs in the "Results" section, such as the standard deviation of the binding energies or a statement about the consistency of the top poses. This would provide greater insight into the stability of the predicted binding modes.</p><p>Molecular Dynamics Simulations Replicates: The study performed 100 ns molecular dynamics simulations for each protein-ligand complex , analyzing RMSD, RMSF, Rg, and SASA. While 100 ns is a reasonable duration, the absence of multiple independent simulation runs or statistical reporting (e.g., error margins) for these metrics within the main text limits the assessment of the reproducibility of the dynamic behavior. Including such data would significantly strengthen the claims of structural stability and conformational behavior.</p><p>Contextualizing ADMET Properties: Table 5 summarizes the ADMET properties of the selected natural compounds. While beneficial, the manuscript does not adequately contextualize these properties against clinically approved CNS drugs within the main "Results" or "Discussion" sections. Explicitly discussing how the "favorable CNS drug-likeness and safety profiles" compare to existing medications in the main text would provide a clearer benchmark for their therapeutic potential.</p><p>Lack of Docking Controls in Main Text: The manuscript does not present comparative docking data with reference (positive) and negative controls for the protein targets within the main "Results" section. This information is critical for validating the specificity and therapeutic relevance of the natural ligands by allowing readers to immediately assess the strength of the natural ligands' binding affinities against established benchmarks. For example, comparing the binding of natural ligands to known inhibitors or non-binding compounds would significantly strengthen the interpretation of the docking scores.</p><p>Statistical Analysis: Opportunities for Greater Rigor (Partial)</p><p>The statistical analysis appears mostly appropriate for the reported data. Pathway enrichment analyses correctly utilize p-values and q-values for statistical significance and false discovery rate correction, respectively. However, the rigor could be enhanced by explicitly addressing the statistical treatment of the docking scores (e.g., reporting mean and standard deviation from the five runs) and the molecular dynamics simulation metrics. Without this, the statistical robustness of these specific sections remains somewhat open to interpretation.</p><p>Data Availability (Yes)</p><p>The authors clearly state that "All data are in the manuscript, and its Supporting Information files" and that "All relevant data are within the manuscript and its Supporting Information files". This commitment ensures that the underlying findings are fully available without restriction, adhering to PLOS Data policy requirements.</p><p>Manuscript Presentation (Yes)</p><p>The manuscript is presented in an intelligible fashion and is generally well-written in standard English. The clarity of the language facilitates understanding of the complex scientific concepts. I did not identify widespread typographical or grammatical errors that significantly impede readability.</p><p>Additional Comments</p><p>Justification for Protein Selection: While Table 1 outlines the roles of proteins in VaD, a more detailed explanation of how the KEGG pathway analysis specifically led to the selection of these six proteins among others involved in VaD would be beneficial. What specific criteria from the KEGG analysis made them the optimal targets?</p><p>Biological Context of NMA: Expanding on the biological implications of the NMA results for each specific protein (Figures 17-22) would be valuable. For instance, linking observed flexibility in loop regions directly to potential changes in enzymatic activity or ligand binding mechanisms would deepen the impact of these findings.</p><p>Future Experimental Validation: The discussion mentions that findings warrant further experimental validation. Providing specific examples of in vitro (e.g., binding assays, enzyme activity assays) or in vivo (e.g., animal models of VaD to assess cognitive improvements, BBB integrity) experiments would provide a clearer roadmap for future research and enhance the translational relevance of the study.</p><p>**********</p><p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link> ). If published, this will include your full peer review and any attached files.</p><p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link> .</p><p>Reviewer #3:&#160;No</p><p>Reviewer #4:&#160;No</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link> . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#160;<email>figures@plos.org</email> . Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article article-type="author-comment" id="pone.0331787.r006"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0331787.r006</article-id><title-group><article-title>Author response to Decision Letter 3</article-title></title-group><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0331787" id="rel-obj006" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>3</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">27 Jul 2025</named-content>
</p><p>We thank the reviewer for highlighting the importance of translational relevance, and have updated our manuscript according to the suggestions.</p><supplementary-material id="pone.0331787.s005" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">response_to_reviewers_auresp_3.docx</named-content></p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0331787.s005.docx" position="float" orientation="portrait"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0331787.r007" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0331787.r007</article-id><title-group><article-title>Decision Letter 3</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jadavji</surname><given-names initials="N">Nafisa</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Nafisa Jadavji</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Nafisa Jadavji</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0331787" id="rel-obj007" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>3</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">21 Aug 2025</named-content>
</p><p>Targeting Vascular Dementia: Molecular Docking and Dynamics of Natural Ligands Against Neuroprotective Proteins</p><p>PONE-D-25-16329R3</p><p>Dear Dr. Bie,</p><p>We&#8217;re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p><p>Within one week, you&#8217;ll receive an e-mail detailing the required amendments. When these have been addressed, you&#8217;ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p><p>An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">Editorial Manager&#174;</ext-link> &#160;and clicking the &#8216;Update My Information' link at the top of the page. For questions related to billing, please contact <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://plos.my.site.com/s/" ext-link-type="uri">billing support</ext-link> .</p><p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they&#8217;ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>Kind regards,</p><p>Nafisa M. Jadavji, PhD, MSc, BSc</p><p>Academic Editor</p><p>PLOS ONE</p><p>Additional Editor Comments (optional):</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<bold>Comments to the Author</bold>
</p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#8220;Comments to the Author&#8221; section, enter your conflict of interest statement in the &#8220;Confidential to Editor&#8221; section, and submit your "Accept" recommendation.</p><p>Reviewer #3:&#160;(No Response)</p><p>Reviewer #4:&#160;All comments have been addressed</p><p>**********</p><p>2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #3:&#160;Yes</p><p>Reviewer #4:&#160;Yes</p><p>**********</p><p>3. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #3:&#160;Yes</p><p>Reviewer #4:&#160;Yes</p><p>**********</p><p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p><p>Reviewer #3:&#160;Yes</p><p>Reviewer #4:&#160;Yes</p><p>**********</p><p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #3:&#160;Yes</p><p>Reviewer #4:&#160;Yes</p><p>**********</p><p>6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #3:&#160;As said about the previous submitted version, this article should be accepted for publication in PLOS1</p><p>Reviewer #4:&#160;The authors have presented a comprehensive and well-designed computational study that addresses a critical need in vascular dementia research. I am pleased to see that they have incorporated my previous suggestions to improve the rigor of the manuscript. The inclusion of a more detailed analysis of data reproducibility and the contextualization of the results has significantly strengthened the work.</p><p>**********</p><p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link> ). If published, this will include your full peer review and any attached files.</p><p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link> .</p><p>Reviewer #3:&#160;No</p><p>Reviewer #4:&#160;No</p><p>**********</p></body></sub-article><sub-article article-type="editor-report" id="pone.0331787.r008" specific-use="acceptance-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0331787.r008</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jadavji</surname><given-names initials="N">Nafisa</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Nafisa Jadavji</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Nafisa Jadavji</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0331787" id="rel-obj008" related-article-type="reviewed-article"/></front-stub><body><p>PONE-D-25-16329R3</p><p>PLOS ONE</p><p>Dear Dr. Bie,</p><p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.</p><p>At this stage, our production department will prepare your paper for publication. This includes ensuring the following:</p><p>* All references, tables, and figures are properly cited</p><p>* All relevant supporting information is included in the manuscript submission,</p><p>* There are no issues that prevent the paper from being properly typeset</p><p>You will receive further&#160;instructions from the production team, including instructions on how to review your proof when it&#160;is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.</p><p>Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://explore.plos.org/phishing" ext-link-type="uri">https://explore.plos.org/phishing</ext-link>.</p><p>If we can help with anything else, please email us at customercare@plos.org.</p><p>Thank you for submitting your work to PLOS ONE and supporting open access.</p><p>Kind regards,</p><p>PLOS ONE Editorial Office Staff</p><p>on behalf of</p><p>Dr. Nafisa M. Jadavji</p><p>Academic Editor</p><p>PLOS ONE</p></body></sub-article></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Pharm Sin B</journal-id><journal-id journal-id-type="iso-abbrev">Acta Pharm Sin B</journal-id><journal-id journal-id-type="pmc-domain-id">2814</journal-id><journal-id journal-id-type="pmc-domain">apsb</journal-id><journal-title-group><journal-title>Acta Pharmaceutica Sinica. B</journal-title></journal-title-group><issn pub-type="ppub">2211-3835</issn><issn pub-type="epub">2211-3843</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12491694</article-id><article-id pub-id-type="pmcid-ver">PMC12491694.1</article-id><article-id pub-id-type="pmcaid">12491694</article-id><article-id pub-id-type="pmcaiid">12491694</article-id><article-id pub-id-type="pmid">41049729</article-id><article-id pub-id-type="doi">10.1016/j.apsb.2025.07.030</article-id><article-id pub-id-type="pii">S2211-3835(25)00508-8</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Ren</surname><given-names initials="F">Fang</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">&#8224;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Wei</surname><given-names initials="J">Jing</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="fn1" ref-type="fn">&#8224;</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Chen</surname><given-names initials="Q">Qingxin</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="fn1" ref-type="fn">&#8224;</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Hu</surname><given-names initials="M">Mengling</given-names></name><xref rid="aff4" ref-type="aff">d</xref><xref rid="fn1" ref-type="fn">&#8224;</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Yu</surname><given-names initials="L">Lu</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Mi</surname><given-names initials="J">Jianing</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Zhou</surname><given-names initials="X">Xiaogang</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Qin</surname><given-names initials="D">Dalian</given-names></name><email>dalianqin@swmu.edu.cn</email><xref rid="aff3" ref-type="aff">c</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Wu</surname><given-names initials="J">Jianming</given-names></name><email>jianmingwu@swmu.edu.cn</email><xref rid="aff3" ref-type="aff">c</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Wu</surname><given-names initials="A">Anguo</given-names></name><email>wuanguo@swmu.edu.cn</email><xref rid="aff3" ref-type="aff">c</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="aff1"><label>a</label>Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Chongqing Traditional Chinese Medicine Hospital, Chongqing 400021, China</aff><aff id="aff2"><label>b</label>State Key Laboratory of Traditional Chinese Medicine Syndrome, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China</aff><aff id="aff3"><label>c</label>Sichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy, Department of Cardiology, Department of Ophthalmology, the Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou 646000, China</aff><aff id="aff4"><label>d</label>Department of Pharmacy, Guang'an People's Hospital, Guangan 638550, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding authors. <email>dalianqin@swmu.edu.cn</email><email>jianmingwu@swmu.edu.cn</email><email>wuanguo@swmu.edu.cn</email></corresp><fn id="fn1"><label>&#8224;</label><p id="ntpara0020">These authors made equal contributions to this work.</p></fn></author-notes><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>25</day><month>7</month><year>2025</year></pub-date><volume>15</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498229</issue-id><fpage>4327</fpage><lpage>4385</lpage><history><date date-type="received"><day>25</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>3</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss, with few effective treatments currently available. The multifactorial nature of AD, shaped by genetic, environmental, and biological factors, complicates both research and clinical management. Recent advances in artificial intelligence (AI) and multi-omics technologies provide new opportunities to elucidate the molecular mechanisms of AD and identify early biomarkers for diagnosis and prognosis. AI-driven approaches such as machine learning, deep learning, and network-based models have enabled the integration of large-scale genomic, transcriptomic, proteomic, metabolomic, and microbiomic datasets. These efforts have facilitated the discovery of novel molecular signatures and therapeutic targets. Methods including deep belief networks and joint deep semi-non-negative matrix factorization have contributed to improvements in disease classification and patient stratification. However, ongoing challenges remain. These include data heterogeneity, limited interpretability of complex models, a lack of large and diverse datasets, and insufficient clinical validation. The absence of standardized multi-omics data processing methods further restricts progress. This review systematically summarizes recent advances in AI-driven multi-omics research in AD, highlighting achievements in early diagnosis and biomarker discovery while discussing limitations and future directions needed to advance these approaches toward clinical application.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p>Artificial intelligence-driven multi-omics approaches in Alzheimer's disease integrate machine learning, deep learning, and network-based methods for biomarker identification, disease mechanism exploration, early diagnosis, patient stratification, and targeted drug development.<fig id="undfig1" position="anchor" orientation="portrait"><alt-text id="alttext0010">Image 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Key words</title><kwd>Alzheimer's disease</kwd><kwd>Artificial intelligence</kwd><kwd>Multi-omics</kwd><kwd>Biomarkers</kwd><kwd>Early detection</kwd><kwd>Personalized treatment</kwd><kwd>Drug discovery</kwd><kwd>Pathological mechanisms</kwd><kwd>Machine learning</kwd><kwd>Deep learning</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">Alzheimer's disease (AD) is the most prevalent cause of dementia and poses an increasing threat to global public health, especially with aging populations worldwide<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref>. The disease is characterized by progressive cognitive decline, memory impairment, and complex neuropathological changes including amyloid beta (A<italic toggle="yes">&#946;</italic>) plaque deposition, neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau, chronic neuroinflammation, and extensive neuronal loss<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref>. Despite extensive research, current therapeutic options for AD remain largely symptomatic and do not halt or reverse disease progression. This underscores the urgent need for novel strategies focused on early detection and personalized interventions.</p><p id="p0015">Recent advances in multi-omics technologies, such as genomics, transcriptomics, proteomics, metabolomics, and microbiomics, enable comprehensive profiling of biological changes across multiple molecular layers in AD<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref>. These technologies hold great promise for unraveling the complex molecular networks underlying AD pathogenesis. They enable the identification of novel biomarkers for early diagnosis and prognosis, as well as the discovery of new therapeutic targets. However, multi-omics data are inherently high-dimensional, heterogeneous, and noisy, often generated across disparate platforms. These characteristics significantly complicate data integration and interpretation using traditional statistical methods<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref>.</p><p id="p0020">Artificial intelligence (AI), particularly machine learning and deep learning algorithms, has emerged as a transformative tool ideally suited to overcoming these challenges. AI techniques are well-suited for analyzing large-scale, complex datasets. They can extract latent features, identify nonlinear patterns, and integrate diverse data modalities in a comprehensive manner<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref>. In AD research, AI-driven multi-omics approaches facilitate biomarker discovery, patient stratification, disease progression modeling, and drug target identification with unprecedented precision<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref>. These capabilities position AI as a critical enabler for unlocking the full potential of multi-omics in advancing AD research and precision medicine.</p><p id="p0025">This review provides a comprehensive overview of recent advances in AI-driven multi-omics applications in AD, highlighting key methodological innovations and emerging biological insights. It examines how AI techniques have been applied to address major challenges in multi-omics research, such as data heterogeneity, feature selection, and temporal complexity. Clinical translation barriers, including issues related to validation and regulatory approval, are also discussed. Finally, the review outlines future directions for integrating multi-omics data with clinical and neuroimaging information to facilitate earlier diagnosis, more precise patient stratification, and personalized therapeutic development. Overall, it offers a structured synthesis of the current landscape and future potential of AI-enhanced multi-omics in addressing the complexities of AD.</p></sec><sec id="sec2"><label>2</label><title>Pathological mechanisms and biomarkers of AD</title><sec id="sec2.1"><label>2.1</label><title>Pathological mechanisms</title><p id="p0030">AD is a multifactorial neurodegenerative disorder marked by the interplay of A<italic toggle="yes">&#946;</italic> accumulation, tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, metabolic imbalance, oxidative stress, and mitochondrial impairment<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref>. Increasing evidence also implicates alterations in the gut&#8211;brain axis in its pathogenesis<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref>. These interconnected mechanisms collectively drive the onset and progression of the disease (<xref rid="fig1" ref-type="fig">Fig. 1</xref>)<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref>. With the emergence of AI-integrated multi-omics platforms, computational approaches have been increasingly applied across these research domains to disentangle molecular interdependencies, identify latent variables, and construct models that capture disease evolution and region-specific pathology.<fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Key molecular mechanisms underlying Alzheimer's disease (AD) pathogenesis. The hallmark pathological features of AD are amyloid beta (A<italic toggle="yes">&#946;</italic>) plaques and neurofibrillary tangles (NFTs). Several interconnected mechanisms contribute to AD progression: (1) A<italic toggle="yes">&#946;</italic> aggregation: Abnormal cleavage of amyloid precursor protein (APP) forms A<italic toggle="yes">&#946;</italic> monomers that aggregate into toxic oligomers, leading to plaque formation, synaptic dysfunction, and inflammation. (2) Tau hyperphosphorylation: Misfolded, hyperphosphorylated tau proteins form NFTs, disrupting neuronal function. (3) Neuroinflammatory responses: A<italic toggle="yes">&#946;</italic> and tau accumulation activate microglia (M1), releasing pro-inflammatory cytokines (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., TNF-<italic toggle="yes">&#945;</italic>) that worsen neuronal damage. (4) Mitochondrial dysfunction: Aging and oxidative stress damage mitochondria, increasing reactive oxygen species (ROS), accelerating neurodegeneration. (5) Glutamate excitotoxicity: Dysregulated glutamate signaling leads to excitotoxic neuronal damage and cell death <italic toggle="yes">via</italic> NMDA and AMPA receptor pathways. (6) Brain-derived neurotrophic factor (BDNF) dysregulation: Impaired BDNF signaling reduces neuronal survival and synaptic plasticity, contributing to cognitive decline. Pathways such as PI3K/AKT and MAPK/ERK are implicated in these processes. (7) Autophagy and proteasome dysfunction: Impaired autophagy-lysosome (ALP) and ubiquitin-proteasome (UPS) systems result in the accumulation of damaged proteins and organelles, including A<italic toggle="yes">&#946;</italic> and tau, which further disrupt neuronal homeostasis. (8) Gut&#8211;brain axis imbalance: Gut dysbiosis promotes inflammation and blood-brain barrier (BBB) disruption, further aggravating AD pathology.</p></caption><alt-text id="alttext0015">Figure 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><sec id="sec2.1.1"><label>2.1.1</label><title>A&#946; accumulation</title><p id="p0035">A<italic toggle="yes">&#946;</italic> pathology originates from the aberrant cleavage of amyloid precursor protein (APP) by <italic toggle="yes">&#946;</italic>-secretase (<italic toggle="yes">BACE1</italic>) and <italic toggle="yes">&#947;</italic>-secretase, resulting in the production of aggregation-prone peptides, especially A<italic toggle="yes">&#946;</italic><sub>42</sub><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref>. In AD, impaired clearance mechanisms lead to both extracellular and intracellular accumulation of A<italic toggle="yes">&#946;</italic><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref>. Soluble A<italic toggle="yes">&#946;</italic> oligomers disrupt synaptic plasticity, activate microglia, and exacerbate oxidative stress and inflammation<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="bib15" ref-type="bibr"><sup>15</sup></xref>. Furthermore, A<italic toggle="yes">&#946;</italic> accumulation has been associated with tau hyperphosphorylation<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref>. Genetic risk factors, notably the apolipoprotein E (<italic toggle="yes">APOE</italic>) <italic toggle="yes">&#949;</italic>4 allele, significantly influence A<italic toggle="yes">&#946;</italic> aggregation and clearance dynamics<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref>. AI techniques, such as unsupervised clustering and regression-based feature selection, have been extensively applied to associate A<italic toggle="yes">&#946;</italic> burden with cognitive phenotypes and to identify molecular signatures predictive of amyloid accumulation across multi-omics datasets<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="bib19" ref-type="bibr"><sup>19</sup></xref>. Therapeutic strategies targeting A<italic toggle="yes">&#946;</italic> include <italic toggle="yes">BACE1</italic> inhibitors, <italic toggle="yes">&#947;</italic>-secretase modulators, and A<italic toggle="yes">&#946;</italic> immunotherapies, though their clinical efficacy remains under active investigation<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref>.</p></sec><sec id="sec2.1.2"><label>2.1.2</label><title>Tau hyperphosphorylation and aggregation</title><p id="p0040">Tau is a microtubule-associated protein essential for axonal transport<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib22" ref-type="bibr"><sup>22</sup></xref>. In AD, kinases such as glycogen synthase kinase-3<italic toggle="yes">&#946;</italic> (GSK-3<italic toggle="yes">&#946;</italic>) and cyclin-dependent kinase 5 (CDK5) induce tau hyperphosphorylation, causing its dissociation from microtubules and subsequent aggregation into NFTs<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref>. These aggregates disrupt the neuronal cytoskeleton and impair axonal integrity and function<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref>. Increasing evidence indicates that A<italic toggle="yes">&#946;</italic> pathology may further promote tau phosphorylation<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref>. Advanced AI techniques, including deep learning and graph-based network inference, have been applied to phosphoproteomic and transcriptomic datasets to characterize kinase activity profiles and predict tau-related disease stages with high precision<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>. As a result, tau-targeting therapies, such as kinase inhibitors and tau immunotherapies, are under development to reduce neurotoxicity and slow cognitive decline<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref>.</p></sec><sec id="sec2.1.3"><label>2.1.3</label><title>Neuroinflammation</title><p id="p0045">Neuroinflammation is increasingly recognized as a central contributor to the pathogenesis of AD. The accumulation of A<italic toggle="yes">&#946;</italic> and hyperphosphorylated tau activates microglia and astrocytes, triggering an innate immune response<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib30" ref-type="bibr"><sup>30</sup></xref>. While acute inflammation may aid in clearing toxic aggregates, chronic glial activation results in sustained release of proinflammatory cytokines and reactive oxygen species (ROS), which exacerbate synaptic dysfunction and neuronal injury<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref>. Immune-related genes, such as triggering receptor expressed on myeloid cells 2 (<italic toggle="yes">TREM2</italic>), further influence microglial responses and disease progression<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref>. AI-driven approaches, including network analysis and integrative omics, have been employed to identify immune-related molecular signatures and prioritize inflammatory mediators implicated in AD<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib35" ref-type="bibr"><sup>35</sup></xref>. Therapeutic strategies targeting neuroinflammation include anti-inflammatory agents, inhibitors of cytokine signaling pathway, and modulators of microglial activity<xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref>.</p></sec><sec id="sec2.1.4"><label>2.1.4</label><title>Synaptic dysfunction</title><p id="p0050">Synaptic dysfunction is recognized as an early and critical event in the progression of AD<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref>. A<italic toggle="yes">&#946;</italic> oligomers disrupt synaptic signaling by interfering with neurotransmitter receptors, particularly <italic toggle="yes">N</italic>-methyl-<sc>d</sc>-aspartate (NMDA)-type glutamate receptors, leading to impaired long-term potentiation, calcium dysregulation, and oxidative stress<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref>. Tau pathology further exacerbates synaptic damage by destabilizing microtubules and impairing axonal transport<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref>. Recent AI-driven analyses of transcriptomic and proteomic datasets have facilitated the identification of key synaptic genes and network disruptions associated with early cognitive decline<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref>. Therapeutic strategies aimed at mitigating A<italic toggle="yes">&#946;</italic> and tau toxicity, including immunotherapies and receptor modulators, are currently under investigation for their potential to preserve synaptic integrity and slow cognitive deterioration<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>.</p></sec><sec id="sec2.1.5"><label>2.1.5</label><title>Mitochondrial dysfunction</title><p id="p0055">Mitochondrial dysfunction is a major contributor to the pathogenesis of AD, resulting in cellular energy deficits, elevated oxidative stress, and progressive neuronal loss<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref>. Under physiological conditions, mitochondria supply adenosine triphosphate (ATP) essential for synaptic activity and neuronal survival. In AD, however, mitochondrial abnormalities, impaired oxidative phosphorylation, and excessive production of ROS are commonly observed<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref>. A<italic toggle="yes">&#946;</italic> and hyperphosphorylated tau can accumulate within mitochondria, disrupting the electron transport chain and exacerbating oxidative damage<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref>. This bioenergetic failure compromises neuronal resilience and initiates a pathological feedback loop involving mitochondrial DNA damage, inflammation, and synaptic dysfunction<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref>. AI-driven approaches have enabled more comprehensive analyses of mitochondrial gene expression profiles and metabolic pathway alterations<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="bib48" ref-type="bibr"><sup>48</sup></xref>. Therapeutic strategies targeting mitochondrial dysfunction, such as antioxidants, mitochondrial biogenesis enhancers, and electron transport chain modulators, are being actively explored to interrupt this degenerative cycle.</p></sec><sec id="sec2.1.6"><label>2.1.6</label><title>Autophagy and the UPS dysfunction</title><p id="p0060">Proteostasis disruption is a hallmark of AD, contributing to the pathological accumulation of A<italic toggle="yes">&#946;</italic> and hyperphosphorylated tau. These aggregation-prone proteins are normally degraded by two complementary systems: autophagy and the ubiquitin&#8211;proteasome system (UPS)<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref><sup>,</sup><xref rid="bib50" ref-type="bibr"><sup>50</sup></xref>. Autophagy degrades misfolded proteins and damaged organelles <italic toggle="yes">via</italic> the lysosomal pathway, whereas the UPS targets aberrant proteins for proteasomal degradation<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref>. In AD, both systems are impaired. Autophagic flux is often disrupted, leading to vacuolar accumulation, while reduced proteasomal activity diminishes protein clearance efficiency<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib51" ref-type="bibr"><sup>51</sup></xref>. These deficits exacerbate synaptic dysfunction and neuronal toxicity. To investigate these proteostatic disruptions, AI-based methods such as quantitative modeling and integrative network analysis have been applied to assess autophagy and UPS-related pathways in AD models<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref><sup>,</sup><xref rid="bib53" ref-type="bibr"><sup>53</sup></xref>. These computational approaches help uncover regulatory failures and identify key molecular players involved in disease progression. Building on these insights, several therapeutic strategies aim to enhance autophagy or UPS function<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref>. Ongoing investigations are exploring the potential of autophagy inducers and proteasome enhancers to reduce protein aggregation and mitigate disease progression<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref>.</p></sec><sec id="sec2.1.7"><label>2.1.7</label><title>BDNF dysregulation</title><p id="p0065">Brain-derived neurotrophic factor (BDNF) plays a critical role in supporting neuronal survival, synaptic plasticity, and memory formation<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref>. In AD, reduced levels of BDNF and impaired signaling through its receptor, tropomyosin-related kinase B (TrkB), are particularly evident in the hippocampus and are strongly associated with cognitive decline<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref>. This neurotrophic deficit impairs long-term potentiation and weakens synaptic function<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref>. Accumulation of A<italic toggle="yes">&#946;</italic> and hyperphosphorylated tau further disrupts the BDNF&#8211;TrkB signaling axis, exacerbating synaptic vulnerability<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref>. To investigate these alterations, machine learning techniques have been employed to integrate transcriptomic and proteomic datasets, revealing widespread dysregulation within neurotrophic signaling networks in AD<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="bib58" ref-type="bibr"><sup>58</sup></xref>. Therapeutic efforts are currently focused on restoring BDNF expression and enhancing TrkB receptor activity as potential strategies to preserve synaptic integrity and improve cognitive outcomes.</p></sec><sec id="sec2.1.8"><label>2.1.8</label><title>Glutamate excitotoxicity</title><p id="p0070">Glutamate excitotoxicity is a critical pathological mechanism in AD, driven by excessive activation of NMDA receptors. This overactivation leads to intracellular calcium overload, oxidative stress, and ultimately, neuronal death<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>. A<italic toggle="yes">&#946;</italic> oligomers exacerbate excitotoxicity by impairing glutamate uptake and dysregulating receptor activity, thereby amplifying neuronal damage<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref>. The resulting synaptic loss is closely associated with cognitive decline in affected individuals<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>. Recent advances in AI-powered computational modeling have enabled the simulation of excitotoxic signaling cascades and the prediction of responses to neuroprotective compounds<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref><sup>,</sup><xref rid="bib62" ref-type="bibr"><sup>62</sup></xref>. Among current therapeutic options, memantine, an NMDA receptor antagonist, has demonstrated neuroprotective effects while preserving physiological glutamatergic transmission. Ongoing research is focused on optimizing such strategies to enhance efficacy and minimize side effects<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref>.</p></sec><sec id="sec2.1.9"><label>2.1.9</label><title>Gut&#8211;brain axis imbalance</title><p id="p0075">Emerging evidence underscores a bidirectional relationship between the gut microbiota and the central nervous system, referred to as the gut&#8211;brain axis, which plays a significant role in the pathophysiology of AD<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref><sup>,</sup><xref rid="bib64" ref-type="bibr"><sup>64</sup></xref>. In AD, gut dysbiosis has been associated with systemic inflammation, impaired immune homeostasis, and increased permeability of both the intestinal barrier and blood&#8211;brain barrier (BBB). These alterations collectively promote neuroinflammation, A<italic toggle="yes">&#946;</italic> accumulation, and neuronal degeneration<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref><sup>,</sup><xref rid="bib65" ref-type="bibr"><sup>65</sup></xref>. Furthermore, microbial metabolites, including neurotransmitters and short-chain fatty acids (SCFAs), influence synaptic function and cognitive performance<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref>. AI-assisted multi-omics integration has been increasingly applied to investigate how microbiome alterations affect host metabolism and immune signaling in AD<xref rid="bib66" ref-type="bibr">66</xref>, <xref rid="bib67" ref-type="bibr">67</xref>, <xref rid="bib68" ref-type="bibr">68</xref>. Therapeutic strategies aimed at restoring gut microbial balance through dietary interventions, probiotics, or prebiotics are currently under active investigation as potential approaches to modulate the gut&#8211;brain axis and attenuate disease progression.</p></sec></sec><sec id="sec2.2"><label>2.2</label><title>Established biomarkers</title><p id="p0080">The identification of reliable biomarkers is essential for enhancing the diagnosis, prognosis, and therapeutic monitoring of AD<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref>. Current approaches, including cerebrospinal fluid (CSF) assays, neuroimaging modalities, and emerging blood-based markers, offer complementary perspectives on disease stage, underlying pathology, and progression dynamics (<xref rid="fig2" ref-type="fig">Fig. 2</xref>)<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref><sup>,</sup><xref rid="bib71" ref-type="bibr"><sup>71</sup></xref>. To manage the complexity of these multimodal biomarker datasets, AI-powered computational tools are increasingly employed to perform data integration, pattern recognition, and predictive modeling. These techniques facilitate the development of precision medicine strategies that are tailored to the specific disease trajectories of individuals with AD.<fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Neuroimaging and CSF/blood biomarkers associated with AD. On the left, neuroimaging biomarkers, including A<italic toggle="yes">&#946;</italic> Positron emission tomography (PET), Tau PET, Atrophy magnetic resonance imaging (MRI), Metabolism magnetic resonance spectroscopy (MRS), and diffusion tensor imaging (DTI), show related brain changes in AD patients. On the right, cerebrospinal fluid (CSF)/blood biomarkers, such as triggering receptor expressed on myeloid cells 2 (<italic toggle="yes">TREM2</italic>), neurofilament light (NfL), total tau (t-tau), phosphorylated tau (p-tau), and the A<italic toggle="yes">&#946;</italic><sub>42</sub>/A<italic toggle="yes">&#946;</italic><sub>40</sub> ratio, highlight biological changes in blood and CSF associated with AD.</p></caption><alt-text id="alttext0020">Figure 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><sec id="sec2.2.1"><label>2.2.1</label><title>CSF biomarkers</title><p id="p0085">CSF biomarkers provide direct biochemical evidence of neuropathological changes associated with AD<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref>. The most well-established markers include A<italic toggle="yes">&#946;</italic><sub>42</sub>, total tau (t-tau), and phosphorylated tau (p-tau). A characteristic biomarker profile, defined by reduced levels of A<italic toggle="yes">&#946;</italic><sub>42</sub> in conjunction with elevated t-tau and p-tau, provides a robust biochemical signature for detecting AD pathology and distinguishing it from other neurodegenerative disorders<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref><sup>,</sup><xref rid="bib73" ref-type="bibr"><sup>73</sup></xref>. Recent studies have expanded the CSF biomarker panel to include neurofilament light (NfL), which reflects neuroaxonal damage, and soluble triggering receptor expressed on myeloid cells 2 (<italic toggle="yes">sTREM2</italic>), which is indicative of microglial activation<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref><sup>,</sup><xref rid="bib75" ref-type="bibr"><sup>75</sup></xref>. These additional markers complement the core profile by providing insights into distinct aspects of disease pathophysiology. To enhance diagnostic accuracy, advanced AI techniques, such as machine learning classifiers and dimensionality reduction algorithms, have been applied to integrate multi-analyte CSF profiles with clinical metadata<xref rid="bib76" ref-type="bibr">76</xref>, <xref rid="bib77" ref-type="bibr">77</xref>, <xref rid="bib78" ref-type="bibr">78</xref>, <xref rid="bib79" ref-type="bibr">79</xref>. Incorporating these biomarkers into diagnostic pipelines can improve early detection, facilitate patient stratification in clinical trials, and inform the development of personalized therapeutic strategies.</p></sec><sec id="sec2.2.2"><label>2.2.2</label><title>Neuroimaging biomarkers</title><p id="p0090">Neuroimaging biomarkers play a pivotal role in the diagnosis, staging, and therapeutic monitoring of AD by providing non-invasive, <italic toggle="yes">in vivo</italic> assessments of brain structure and function<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref><sup>,</sup><xref rid="bib81" ref-type="bibr"><sup>81</sup></xref>. Structural magnetic resonance imaging (sMRI) is commonly used to detect atrophy in the hippocampus and medial temporal lobe, which are regions strongly associated with early cognitive decline in AD<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref>. Functional MRI (fMRI) and resting-state connectivity analyses reveal alterations in neural networks involved in memory and executive functions<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref>. Positron emission tomography (PET), utilizing tracers such as [<sup>11</sup>C] Pittsburgh compound B (PiB) and [<sup>18</sup>F]-labeled agents, enables the early detection of amyloid deposition. Tau PET imaging with ligands like [<sup>18</sup>F]flortaucipir allows for topographical mapping of tau pathology, which has been shown to correlate strongly with clinical severity<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref><sup>,</sup><xref rid="bib81" ref-type="bibr"><sup>81</sup></xref>. AI-based neuroimaging analysis, particularly through the application of deep learning and pattern recognition techniques, has significantly advanced the interpretation and quantification of complex imaging data<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref><sup>,</sup><xref rid="bib84" ref-type="bibr"><sup>84</sup></xref>. These methods support automated detection of subtle brain changes, enable disease trajectory prediction, and assist in patient selection for clinical trials. Additional modalities, including diffusion tensor imaging (DTI) and magnetic resonance spectroscopy (MRS), offer complementary insights into white matter integrity and metabolic alterations, further enhancing our ability to monitor disease progression<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref><sup>,</sup><xref rid="bib86" ref-type="bibr"><sup>86</sup></xref>. Integrating these neuroimaging biomarkers with AI-driven analytical frameworks holds considerable promise for improving early detection, refining patient stratification in clinical studies, and informing the development of personalized treatment strategies.</p></sec><sec id="sec2.2.3"><label>2.2.3</label><title>Blood-based biomarkers</title><p id="p0095">Blood-based biomarkers are emerging as practical and scalable tools for early detection and longitudinal monitoring of AD<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref>. In contrast to CSF and neuroimaging biomarkers, blood-based assays offer a minimally invasive and cost-effective alternative, making them well-suited for large-scale population screening and repeated assessments over time. Among the most promising indicators are plasma phosphorylated tau isoforms, including p-tau181 and p-tau217. These biomarkers exhibit high specificity in distinguishing AD from other dementias and show strong correlations with tau PET imaging and CSF tau concentrations<xref rid="bib87" ref-type="bibr"><sup>87</sup></xref>. In addition, plasma A<italic toggle="yes">&#946;</italic><sub>42</sub>/A<italic toggle="yes">&#946;</italic><sub>40</sub> ratios have demonstrated potential for reflecting cerebral amyloid burden<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref>, while NfL, a marker of axonal damage, is elevated in AD and provides prognostic insight into ongoing neurodegeneration<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref>. AI-enabled platforms for biomarker discovery, which integrate large-scale cohort data with machine learning algorithms, have facilitated the identification, validation, and clinical implementation of blood-based biomarkers<xref rid="bib90" ref-type="bibr"><sup>90</sup></xref><sup>,</sup><xref rid="bib91" ref-type="bibr"><sup>91</sup></xref>. These approaches enhance the predictive accuracy and translational relevance of biomarker profiles. As validation studies expand to include more diverse and preclinical populations, the implementation of AI-driven blood biomarker panels is expected to improve early diagnosis, support precise patient stratification for clinical trials, and increase access to personalized interventions in routine care setting<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref>.</p></sec></sec></sec><sec id="sec3"><label>3</label><title>Multi-omics in AD research</title><p id="p0100">Recent advances in high-throughput technologies have enabled systematic investigation of AD across multiple biological layers. These multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, and microbiomics, reveal disease-associated alterations that deepen our understanding of AD's complex pathophysiology. Each omics layer captures a unique yet complementary facet of disease biology, from genetic susceptibility and gene expression to protein dynamics, metabolic shifts, and gut microbiome perturbations (<xref rid="fig3" ref-type="fig">Fig. 3</xref>). In this review, we summarize key discoveries and methodological advances within each omics domain that have enhanced our understanding of AD mechanisms (<xref rid="tbl1" ref-type="table">Table 1</xref><xref rid="bib92" ref-type="bibr">92</xref>, <xref rid="bib93" ref-type="bibr">93</xref>, <xref rid="bib94" ref-type="bibr">94</xref>, <xref rid="bib95" ref-type="bibr">95</xref>, <xref rid="bib96" ref-type="bibr">96</xref>, <xref rid="bib97" ref-type="bibr">97</xref>, <xref rid="bib98" ref-type="bibr">98</xref>, <xref rid="bib99" ref-type="bibr">99</xref>, <xref rid="bib100" ref-type="bibr">100</xref>, <xref rid="bib101" ref-type="bibr">101</xref>, <xref rid="bib102" ref-type="bibr">102</xref>, <xref rid="bib103" ref-type="bibr">103</xref>, <xref rid="bib104" ref-type="bibr">104</xref>, <xref rid="bib105" ref-type="bibr">105</xref>, <xref rid="bib106" ref-type="bibr">106</xref>, <xref rid="bib107" ref-type="bibr">107</xref>, <xref rid="bib108" ref-type="bibr">108</xref>, <xref rid="bib109" ref-type="bibr">109</xref>, <xref rid="bib110" ref-type="bibr">110</xref>, <xref rid="bib111" ref-type="bibr">111</xref>, <xref rid="bib112" ref-type="bibr">112</xref>, <xref rid="bib113" ref-type="bibr">113</xref>, <xref rid="bib114" ref-type="bibr">114</xref>, <xref rid="bib115" ref-type="bibr">115</xref>, <xref rid="bib116" ref-type="bibr">116</xref>, <xref rid="bib117" ref-type="bibr">117</xref>, <xref rid="bib118" ref-type="bibr">118</xref>, <xref rid="bib119" ref-type="bibr">119</xref>, <xref rid="bib120" ref-type="bibr">120</xref>, <xref rid="bib121" ref-type="bibr">121</xref>, <xref rid="bib122" ref-type="bibr">122</xref>, <xref rid="bib123" ref-type="bibr">123</xref>, <xref rid="bib124" ref-type="bibr">124</xref>, <xref rid="bib125" ref-type="bibr">125</xref>, <xref rid="bib126" ref-type="bibr">126</xref>, <xref rid="bib127" ref-type="bibr">127</xref>, <xref rid="bib128" ref-type="bibr">128</xref>, <xref rid="bib129" ref-type="bibr">129</xref>, <xref rid="bib130" ref-type="bibr">130</xref>, <xref rid="bib131" ref-type="bibr">131</xref>, <xref rid="bib132" ref-type="bibr">132</xref>, <xref rid="bib133" ref-type="bibr">133</xref>, <xref rid="bib134" ref-type="bibr">134</xref>, <xref rid="bib135" ref-type="bibr">135</xref>, <xref rid="bib136" ref-type="bibr">136</xref>, <xref rid="bib137" ref-type="bibr">137</xref>, <xref rid="bib138" ref-type="bibr">138</xref>, <xref rid="bib139" ref-type="bibr">139</xref>, <xref rid="bib140" ref-type="bibr">140</xref>, <xref rid="bib141" ref-type="bibr">141</xref>, <xref rid="bib142" ref-type="bibr">142</xref>, <xref rid="bib143" ref-type="bibr">143</xref>, <xref rid="bib144" ref-type="bibr">144</xref>, <xref rid="bib145" ref-type="bibr">145</xref>, <xref rid="bib146" ref-type="bibr">146</xref>, <xref rid="bib147" ref-type="bibr">147</xref>, <xref rid="bib148" ref-type="bibr">148</xref>, <xref rid="bib149" ref-type="bibr">149</xref>).<fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>A comprehensive multi-omics framework for understanding AD through various molecular layers. It integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiomics to reveal key insights into AD pathology. The top left section shows genomic instability, highlighting chromosomal alterations, DNA modifications, and mutations related to AD genes, such as <italic toggle="yes">APP</italic>, presenilin 1 (<italic toggle="yes">PS1</italic>), and apolipoprotein E (<italic toggle="yes">APOE</italic>). The epigenomic panel outlines histone modifications and non-coding RNAs that contribute to disease progression. The transcriptomics section focuses on the expression of key genes in neurons, microglia, astrocytes, and oligodendrocytes, correlating with AD severity. The proteomics panel examines altered proteins and pathways involved in A<italic toggle="yes">&#946;</italic> and tau pathology, inflammation, and neurodegeneration. Metabolomics identifies key metabolites and metabolic pathways, including those involved in energy and amino acid metabolism, as well as lipid and nitrogen metabolism. Lastly, the microbiomics section explores the roles of harmful and beneficial bacteria in the gut&#8211;brain axis.</p></caption><alt-text id="alttext0025">Figure 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig><table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Multi-omics used in the AD research.</p></caption><alt-text id="alttext0035">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Proteins/biomarkers</th><th colspan="1" rowspan="1">Omics</th><th colspan="1" rowspan="1">Biological sample</th><th colspan="1" rowspan="1">Integrative method</th><th colspan="1" rowspan="1">Main findings</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">rs4802200: disrupts <italic toggle="yes">E2F7</italic> regulation of <italic toggle="yes">KCNN4</italic> (AD LTL module); rs117863556: interrupts <italic toggle="yes">REST</italic> regulation of <italic toggle="yes">GAB2</italic> in DLPFC</td><td colspan="1" rowspan="1">Genomics, transcriptomics, and epigenomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Non-coding SNPs are linked to AD-related gene expression, with 51 potential early neuroinflammatory biomarkers identified</td><td colspan="1" rowspan="1"><xref rid="bib92" ref-type="bibr">92</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">ANK1</italic>, <italic toggle="yes">CDH23</italic>, <italic toggle="yes">DIP2A</italic>, <italic toggle="yes">RHBDF2</italic>, <italic toggle="yes">RPL13</italic>, <italic toggle="yes">RNF34</italic>, <italic toggle="yes">SERPINF1</italic>, and <italic toggle="yes">SERPINF2</italic></td><td colspan="1" rowspan="1">Genomics, transcriptomics, and epigenomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Methylation at 71 of 415,848 CpGs links to AD pathology; eleven regions are validated; genes' expression is altered. This may start AD, which is seen in presymptomatic stages and <italic toggle="yes">via</italic> gene network</td><td colspan="1" rowspan="1"><xref rid="bib93" ref-type="bibr">93</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">SORL1</italic>, <italic toggle="yes">ABCA7</italic>, <italic toggle="yes">HLA-DRB5</italic>, <italic toggle="yes">SLC24A4</italic>, and <italic toggle="yes">BIN1</italic></td><td colspan="1" rowspan="1">Genomics, transcriptomics, and epigenomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Brain DNA methylation at AD loci ties to pathologies/hallmarks, gene expression correlates too, hinting at its AD role</td><td colspan="1" rowspan="1"><xref rid="bib94" ref-type="bibr">94</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">P2RX5</italic>, <italic toggle="yes">TRPV3</italic>, <italic toggle="yes">DPY30</italic>, and <italic toggle="yes">MEMO1</italic></td><td colspan="1" rowspan="1">Genomics, transcriptomics, and epigenomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Five loci linked to cell-type composition, with relevant genes, suggest cell-type shifts in neuropsychiatric disorder pathophysiology</td><td colspan="1" rowspan="1"><xref rid="bib95" ref-type="bibr">95</xref></td></tr><tr><td colspan="1" rowspan="1">Blood DNAm, CSF A<italic toggle="yes">&#946;</italic><sub>42</sub>, p-tau181, and t-tau</td><td colspan="1" rowspan="1">Genomics, transcriptomics, and epigenomics</td><td colspan="1" rowspan="1">Human blood and CSF</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Connects blood DNAm to CSF AD biomarkers, finds AD treatments, tags <italic toggle="yes">HOXA5</italic> DNAm as biomarker, offers AD research resource</td><td colspan="1" rowspan="1"><xref rid="bib96" ref-type="bibr">96</xref></td></tr><tr><td colspan="1" rowspan="1">Tau and H3K9ac</td><td colspan="1" rowspan="1">Epigenomics, transcriptomics, and chromatin accessibility</td><td colspan="1" rowspan="1">Human brains, Mouse models, iNs</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Tau-driven chromatin changes in AD surpass amyloid effects, involve the nuclear lamina, and can be studied and targeted using iNs and 17-DMAG</td><td colspan="1" rowspan="1"><xref rid="bib97" ref-type="bibr">97</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">SPI1</italic>, <italic toggle="yes">ELF2</italic>, and <italic toggle="yes">RUNX1</italic></td><td colspan="1" rowspan="1">Genomics, transcriptomics, and epigenomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Single-nucleus RNA and ATAC profiling revealed AD-associated epigenomic erosion, cell identity loss, and microglial regulatory risk loci</td><td colspan="1" rowspan="1"><xref rid="bib98" ref-type="bibr">98</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">ELOVL</italic>, <italic toggle="yes">FADS6</italic>, <italic toggle="yes">FAR1</italic>, <italic toggle="yes">FAR2</italic>, <italic toggle="yes">FABP7</italic>, and <italic toggle="yes">FA2H</italic></td><td colspan="1" rowspan="1">Epigenomics and lipidomics</td><td colspan="1" rowspan="1">Human plasma</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Fatty acid metabolism linked to early AD, revealing diagnostic biomarkers and therapeutic targets</td><td colspan="1" rowspan="1"><xref rid="bib99" ref-type="bibr">99</xref></td></tr><tr><td colspan="1" rowspan="1">DMPs</td><td colspan="1" rowspan="1">Epigenomics</td><td colspan="1" rowspan="1">Human peripheral blood</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">DMPs linked to brain pathways and cognitive decline; validated as potential non-invasive AD biomarkers</td><td colspan="1" rowspan="1"><xref rid="bib100" ref-type="bibr">100</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">ANK1</italic>, <italic toggle="yes">MYOC</italic>, <italic toggle="yes">RHBDF2</italic>, <italic toggle="yes">GPR56</italic>, <italic toggle="yes">APOE</italic>, and <italic toggle="yes">IGF1</italic></td><td colspan="1" rowspan="1">Transcriptomics and epigenomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">5246 DMPs are linked to AD severity (Braak stage, plaque density) and key pathways like IGF1 regulation</td><td colspan="1" rowspan="1"><xref rid="bib101" ref-type="bibr">101</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">APOE4</italic></td><td colspan="1" rowspan="1">Transcriptomics, proteomics, and phosphoproteomics</td><td colspan="1" rowspan="1">Mouse brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">BBB breakdown precedes synaptic and behavioral deficits; early EC dysfunction is key</td><td colspan="1" rowspan="1"><xref rid="bib102" ref-type="bibr">102</xref></td></tr><tr><td colspan="1" rowspan="1">SORLA</td><td colspan="1" rowspan="1">Transcriptomics</td><td colspan="1" rowspan="1">Human brains, iPSC-derived microglia</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1"><italic toggle="yes">SORL1</italic> loss impairs <italic toggle="yes">CD14</italic> sorting, weakens pro-inflammatory signaling, and alters vesicle trafficking</td><td colspan="1" rowspan="1"><xref rid="bib103" ref-type="bibr">103</xref></td></tr><tr><td colspan="1" rowspan="1">H3K27ac and H3K9ac</td><td colspan="1" rowspan="1">Transcriptomics, proteomics, and epigenomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">H3K27ac/H3K9ac enhancement disrupts chromatin feedback, worsens A<italic toggle="yes">&#946;</italic> neurodegeneration</td><td colspan="1" rowspan="1"><xref rid="bib104" ref-type="bibr">104</xref></td></tr><tr><td colspan="1" rowspan="1">APOE</td><td colspan="1" rowspan="1">Transcriptomics and lipidomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">APOE <italic toggle="yes">&#949;2</italic> boosts autophagy and ER stability; APOE <italic toggle="yes">&#949;4</italic> disrupts lipid and protein homeostasis</td><td colspan="1" rowspan="1"><xref rid="bib105" ref-type="bibr">105</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">SORL1</italic>, <italic toggle="yes">CHI3L1</italic>, <italic toggle="yes">HLA-E</italic>, and <italic toggle="yes">NEFL</italic></td><td colspan="1" rowspan="1">Transcriptomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Cell-specific transcriptomic alterations, reduced myelination, astrocytic stress signatures, and microglial activation highlight AD cellular dysfunction</td><td colspan="1" rowspan="1"><xref rid="bib106" ref-type="bibr">106</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">ITM2B</italic>, <italic toggle="yes">APOE</italic>, <italic toggle="yes">BIN1</italic>, and <italic toggle="yes">SPI1</italic></td><td colspan="1" rowspan="1">Transcriptomics and epigenomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Cross-disorder single-cell analyses identify shared pathways and disease-specific cellular states in tau-related neurodegenerative disorders</td><td colspan="1" rowspan="1"><xref rid="bib107" ref-type="bibr">107</xref></td></tr><tr><td colspan="1" rowspan="1">A<italic toggle="yes">&#946;</italic>, pTau, NFTs, and APOE</td><td colspan="1" rowspan="1">Transcriptomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Amyloid plaques trigger microglial activation and inflammation, with APOE <italic toggle="yes">&#949;</italic>4 intensifying these effects</td><td colspan="1" rowspan="1"><xref rid="bib108" ref-type="bibr">108</xref></td></tr><tr><td colspan="1" rowspan="1">DAMs and DAAs</td><td colspan="1" rowspan="1">Transcriptomics</td><td colspan="1" rowspan="1">Mouse brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Plaque-associated signaling impairs synapses, boosting GABAergic and reducing glutamatergic activity</td><td colspan="1" rowspan="1"><xref rid="bib109" ref-type="bibr">109</xref></td></tr><tr><td colspan="1" rowspan="1">miRNA-9, miRNA-125b, miRNA-146a, and miRNA-155</td><td colspan="1" rowspan="1">Transcriptomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Pro-inflammatory miRNAs are enriched in AD CSF/ECF, induced by AD ECF in cells, and suppressed by NF-<italic toggle="yes">&#1082;</italic>B inhibitors (CAPE, CAY10512)</td><td colspan="1" rowspan="1"><xref rid="bib110" ref-type="bibr">110</xref></td></tr><tr><td colspan="1" rowspan="1">miR-133b and NPTX2</td><td colspan="1" rowspan="1">Transcriptomics and proteomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">miR-133b regulates NPTX2, influencing AD progression and cognition; mediation analysis confirms its neuroprotective role</td><td colspan="1" rowspan="1"><xref rid="bib111" ref-type="bibr">111</xref></td></tr><tr><td colspan="1" rowspan="1">miRNA-92a-3p, miRNA-486-5p, and miRNA-29a-3p</td><td colspan="1" rowspan="1">Transcriptomics</td><td colspan="1" rowspan="1">Plasma</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Three miRNAs are identified as early AD biomarkers, linked to neuronal and structural pathways</td><td colspan="1" rowspan="1"><xref rid="bib112" ref-type="bibr">112</xref></td></tr><tr><td colspan="1" rowspan="1">DSBs</td><td colspan="1" rowspan="1">Genomics, transcriptomics, and epigenomics</td><td colspan="1" rowspan="1">Mouse and human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Neuron subtypes link to AD pathology; the cohesin complex and DNA damage genes are elevated in AD</td><td colspan="1" rowspan="1"><xref rid="bib113" ref-type="bibr">113</xref></td></tr><tr><td colspan="1" rowspan="1">PIGs and OLIGs</td><td colspan="1" rowspan="1">Transcriptomics</td><td colspan="1" rowspan="1">Mouse and human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Spatially dysregulated genes are identified as linked to metabolism, stress, and synaptic functions</td><td colspan="1" rowspan="1"><xref rid="bib114" ref-type="bibr">114</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">APP</italic> K670N/M671L, <italic toggle="yes">MAPT</italic> P301L, and <italic toggle="yes">PS1</italic> M146V</td><td colspan="1" rowspan="1">Genomics, transcriptomics, and epigenomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Studies identify 124 spatially dysregulated genes; pathways are altered in lipid, mitochondrial stress-response and ion transport; BOK modulation shows potential</td><td colspan="1" rowspan="1"><xref rid="bib115" ref-type="bibr">115</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">APOE</italic>, <italic toggle="yes">CALM1</italic>, <italic toggle="yes">CALM3</italic>, <italic toggle="yes">LRP1</italic>, and <italic toggle="yes">SORL1</italic></td><td colspan="1" rowspan="1">Transcriptomics and genomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Studies identify 190 dysregulated ligand-receptor pairs; pathways are altered in amyloid and ion transport; EGFR inhibitors show potential</td><td colspan="1" rowspan="1"><xref rid="bib116" ref-type="bibr">116</xref></td></tr><tr><td colspan="1" rowspan="1">miR-132/212 and miR-184</td><td colspan="1" rowspan="1">Transcriptomics, metabolomics</td><td colspan="1" rowspan="1">Human brains.</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">2064 LOAD-specific genes, along with reduced RNA editing (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., GRIA2 Q/R) and miR-184-NR4A2 regulation, link to synaptic and mitochondrial dysfunction</td><td colspan="1" rowspan="1"><xref rid="bib117" ref-type="bibr">117</xref></td></tr><tr><td colspan="1" rowspan="1">Synaptic dysfunction, glial inflammation, myelination disruption, and sex-specific differences.</td><td colspan="1" rowspan="1">Transcriptomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">AD involves synaptic dysfunction, glial inflammation, disrupted myelination, and sex-specific transcriptional differences, revealed by transcriptomics</td><td colspan="1" rowspan="1"><xref rid="bib118" ref-type="bibr">118</xref></td></tr><tr><td colspan="1" rowspan="1">CpG-rich <italic toggle="yes">FMR1</italic></td><td colspan="1" rowspan="1">Epigenomics</td><td colspan="1" rowspan="1">Mouse NIH-3T3 and human cell lines</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">dCas9 allows precise demethylation, showing that selective promoter methylation impacts gene expression. This tool clarifies methylation's regulatory role</td><td colspan="1" rowspan="1"><xref rid="bib119" ref-type="bibr">119</xref></td></tr><tr><td colspan="1" rowspan="1">Tumor suppressor-mediated differentiation and involution</td><td colspan="1" rowspan="1">Transcriptomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">TS pathways and differentiation drive early pathology, highlighting therapeutic targets</td><td colspan="1" rowspan="1"><xref rid="bib120" ref-type="bibr">120</xref></td></tr><tr><td colspan="1" rowspan="1">DAM, LRM, ARM, ERM, IRM, and TRM</td><td colspan="1" rowspan="1">Transcriptomics</td><td colspan="1" rowspan="1">Mouse and human brains</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">PAM drives inflammation; PCM aids plaque initiation. Both show distinct transcriptomic changes in AD</td><td colspan="1" rowspan="1"><xref rid="bib121" ref-type="bibr">121</xref></td></tr><tr><td colspan="1" rowspan="1">APs and NFTs</td><td colspan="1" rowspan="1">Transcriptomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">The temporal lobe shows early abnormalities; cell-specific modules reveal therapeutic targets</td><td colspan="1" rowspan="1"><xref rid="bib122" ref-type="bibr">122</xref></td></tr><tr><td colspan="1" rowspan="1">DNA methylation</td><td colspan="1" rowspan="1">Epigenomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">236, 95, and 10 CpGs are identified in cortex regions; none are found in cerebellum. Novel epigenetic loci are discovered</td><td colspan="1" rowspan="1"><xref rid="bib123" ref-type="bibr">123</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">APOE</italic>, H3K9Ac</td><td colspan="1" rowspan="1">Genomics, transcriptomics, and epigenomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Multi-omics reveal key pathways in aging and AD</td><td colspan="1" rowspan="1"><xref rid="bib124" ref-type="bibr">124</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">APP</italic>, <italic toggle="yes">PS1</italic> or <italic toggle="yes">PS2</italic></td><td colspan="1" rowspan="1">Transcriptomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Synaptic and amyloid-related genes change before plaques and tangles</td><td colspan="1" rowspan="1"><xref rid="bib125" ref-type="bibr">125</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">PIK3R1</italic>, <italic toggle="yes">BTN3A3</italic>, <italic toggle="yes">NHLH1</italic>, and <italic toggle="yes">SLC16A7</italic></td><td colspan="1" rowspan="1">Transcriptomics and epigenomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">DNA methylation-gene expression correlations are identified, highlighting potential pathogenic mechanisms in psychotic disorders</td><td colspan="1" rowspan="1"><xref rid="bib126" ref-type="bibr">126</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">CLU</italic>, <italic toggle="yes">SYNJ2</italic>, <italic toggle="yes">NCOR2</italic>, <italic toggle="yes">RAI1</italic>, <italic toggle="yes">CXXC5</italic>, <italic toggle="yes">INPP5A</italic>, <italic toggle="yes">MCF2L</italic>, <italic toggle="yes">ANK1</italic>, <italic toggle="yes">MAP2</italic>, <italic toggle="yes">LRRC8B</italic>, <italic toggle="yes">STK32C</italic>, <italic toggle="yes">S100B</italic>, <italic toggle="yes">HOXA3</italic>, <italic toggle="yes">APP</italic>, and <italic toggle="yes">ADAM17</italic></td><td colspan="1" rowspan="1">Epigenomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Aging- and Braak stage-related epigenetic markers like <italic toggle="yes">APP</italic> and <italic toggle="yes">HOXA3</italic> are identified</td><td colspan="1" rowspan="1"><xref rid="bib127" ref-type="bibr">127</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">IQCK</italic>, <italic toggle="yes">ACE</italic>, <italic toggle="yes">ADAM10</italic>, <italic toggle="yes">ADAMTS1</italic>, and <italic toggle="yes">WWOX</italic></td><td colspan="1" rowspan="1">Genomics</td><td colspan="1" rowspan="1">Human blood and brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Five new loci are identified, linking APP, tau, and immune pathways</td><td colspan="1" rowspan="1"><xref rid="bib128" ref-type="bibr">128</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">APP</italic>, <italic toggle="yes">PS1</italic>, and <italic toggle="yes">PS2</italic></td><td colspan="1" rowspan="1">Genomics</td><td colspan="1" rowspan="1">Human blood and brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">29 loci are identified, linking key pathways to AD risk</td><td colspan="1" rowspan="1"><xref rid="bib129" ref-type="bibr">129</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">TYROBP</italic> (aka DAP12)</td><td colspan="1" rowspan="1">Genomics and transcriptomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1"><italic toggle="yes">TYROBP</italic> regulates immune/microglial networks central to LOAD</td><td colspan="1" rowspan="1"><xref rid="bib130" ref-type="bibr">130</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">APOE</italic> and <italic toggle="yes">ABCA7</italic></td><td colspan="1" rowspan="1">Genomics</td><td colspan="1" rowspan="1">Human blood</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Two novel loci (COBL, SLC10A2) linked to AD in African Americans</td><td colspan="1" rowspan="1"><xref rid="bib131" ref-type="bibr">131</xref></td></tr><tr><td colspan="1" rowspan="1">Ng</td><td colspan="1" rowspan="1">Proteomics</td><td colspan="1" rowspan="1">Human CSF</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Elevated CSF Ng predicts synaptic loss and cognitive decline in AD</td><td colspan="1" rowspan="1"><xref rid="bib132" ref-type="bibr">132</xref></td></tr><tr><td colspan="1" rowspan="1">Docosahexaenoic acid (C22:6n-3) and tetracosahexaenoic acid (C24:6n-3)</td><td colspan="1" rowspan="1">Lipidomics</td><td colspan="1" rowspan="1">Human liver and brains</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Reduced DHA and enzyme activity in AD correlate with cognitive impairment</td><td colspan="1" rowspan="1"><xref rid="bib133" ref-type="bibr">133</xref></td></tr><tr><td colspan="1" rowspan="1">GSK-3<italic toggle="yes">&#946;</italic>, CDK5, PKC, MAPK, ROCK2, and PP2A</td><td colspan="1" rowspan="1">Proteomics and phosphoproteomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Protein and phosphosite changes are identified as linked to AD stages</td><td colspan="1" rowspan="1"><xref rid="bib134" ref-type="bibr">134</xref></td></tr><tr><td colspan="1" rowspan="1">LXRs, SREBPs, IDOL, HMGCR, and CYP46A1</td><td colspan="1" rowspan="1">Lipidomics</td><td colspan="1" rowspan="1">Mouse brains and plasma</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Probiotics improve lipid homeostasis and reduce AD pathology</td><td colspan="1" rowspan="1"><xref rid="bib135" ref-type="bibr">135</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">CR1</italic>, <italic toggle="yes">PLCG2</italic>, <italic toggle="yes">MEF2C</italic>, <italic toggle="yes">IL34</italic>, <italic toggle="yes">ABCA7</italic>, <italic toggle="yes">PTK2B</italic>, <italic toggle="yes">HLA-DRB1</italic>, <italic toggle="yes">MS4A6A</italic>, and <italic toggle="yes">APOE &#949;4</italic></td><td colspan="1" rowspan="1">Lipidomics and proteomics.</td><td colspan="1" rowspan="1">Human plasma</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Lipid and protein modules linked to AD highlight these pathways</td><td colspan="1" rowspan="1"><xref rid="bib136" ref-type="bibr">136</xref></td></tr><tr><td colspan="1" rowspan="1">Metabolic dysregulation, oxidative stress, neuroinflammation, complement activation, synaptic dysfunction, and vitamin B2/B5/B6 pathway abnormalities</td><td colspan="1" rowspan="1">Transcriptomics, proteomics, and metabolomics</td><td colspan="1" rowspan="1">Human brains, blood, and CSF; mouse brains, blood, and CSF</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Deregulated pathways, particularly those involving neurotransmitter synapses, inflammation, oxidative stress, and the metabolism of vitamins B2, B5, and B6, are associated with the progression of AD and may represent potential therapeutic targets</td><td colspan="1" rowspan="1"><xref rid="bib137" ref-type="bibr">137</xref></td></tr><tr><td colspan="1" rowspan="1">PC, LPC, PE, phosphatidylinositol, SM, ceramide, and TAG</td><td colspan="1" rowspan="1">Lipidomics</td><td colspan="1" rowspan="1">Human plasma</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Reduced sphingomyelin and elevated ceramides correlate with AD severity</td><td colspan="1" rowspan="1"><xref rid="bib138" ref-type="bibr">138</xref></td></tr><tr><td colspan="1" rowspan="1">A<italic toggle="yes">&#946;</italic><sub>42</sub></td><td colspan="1" rowspan="1">Proteomics</td><td colspan="1" rowspan="1">Mouse and human brains</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Met-35 is key to A<italic toggle="yes">&#946;</italic><sub>42</sub> toxicity; altering it reduces damage</td><td colspan="1" rowspan="1"><xref rid="bib139" ref-type="bibr">139</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">APP</italic>SWE/<italic toggle="yes">PS1</italic>&#916;E9</td><td colspan="1" rowspan="1">Transcriptomics and metagenomics</td><td colspan="1" rowspan="1">Mouse brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Microbiome alterations reduce A<italic toggle="yes">&#946;</italic> and restore microglial homeostasis in male mice only</td><td colspan="1" rowspan="1"><xref rid="bib140" ref-type="bibr">140</xref></td></tr><tr><td colspan="1" rowspan="1">SCFAs, BDNF, NGF-A1, ZO-1, Occludin, and Claudin-5</td><td colspan="1" rowspan="1">Transcriptomics and metagenomics</td><td colspan="1" rowspan="1">Mouse brains and gut samples</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Microbiota or metabolites restore BBB integrity in germ-free mice</td><td colspan="1" rowspan="1"><xref rid="bib141" ref-type="bibr">141</xref></td></tr><tr><td colspan="1" rowspan="1">FGG</td><td colspan="1" rowspan="1">Proteomics</td><td colspan="1" rowspan="1">Human plasma</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Plasma FGG and age predict amyloid burden with moderate accuracy</td><td colspan="1" rowspan="1"><xref rid="bib142" ref-type="bibr">142</xref></td></tr><tr><td colspan="1" rowspan="1">MDK, NTN1, SMOC1, SLIT2 and HTRA1</td><td colspan="1" rowspan="1">Proteomics, phosphoproteomics, and transcriptomics</td><td colspan="1" rowspan="1">Human brains and CSF, mouse brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Key proteins/pathways are linked to AD progression, with distinct human-mouse differences in autophagy and inflammation</td><td colspan="1" rowspan="1"><xref rid="bib143" ref-type="bibr">143</xref></td></tr><tr><td colspan="1" rowspan="1">BIN1, PICALM, PTK2B, and FERMT2</td><td colspan="1" rowspan="1">Proteomics, proteogenomics and transcriptomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">RNA-binding proteins and splicing events are identified linked to pathology and cognitive decline</td><td colspan="1" rowspan="1"><xref rid="bib144" ref-type="bibr">144</xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">TREM2</italic></td><td colspan="1" rowspan="1">Transcriptomics and proteomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Altered microglial activation is observed; there are no significant A<italic toggle="yes">&#946;</italic> or tau differences</td><td colspan="1" rowspan="1"><xref rid="bib145" ref-type="bibr">145</xref></td></tr><tr><td colspan="1" rowspan="1">t-tau, SNCA, JPH3, CFP, and PI15</td><td colspan="1" rowspan="1">Proteomics, metabolomics, and lipidomics</td><td colspan="1" rowspan="1">Human plasma.</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Oleamide and several proteins are identified as key molecules distinguishing MCI subtypes and AD</td><td colspan="1" rowspan="1"><xref rid="bib146" ref-type="bibr">146</xref></td></tr><tr><td colspan="1" rowspan="1">H3 K18/K23</td><td colspan="1" rowspan="1">Epigenomics</td><td colspan="1" rowspan="1">Human brains</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">H3 K18/K23 acetylation is significantly lower in AD temporal lobe <italic toggle="yes">vs.</italic> controls</td><td colspan="1" rowspan="1"><xref rid="bib147" ref-type="bibr">147</xref></td></tr><tr><td colspan="1" rowspan="1">RSS</td><td colspan="1" rowspan="1">Proteomics</td><td colspan="1" rowspan="1">Mouse brains</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">TPsC and protein polysulfides decrease in 5xFAD mice</td><td colspan="1" rowspan="1"><xref rid="bib148" ref-type="bibr">148</xref></td></tr><tr><td colspan="1" rowspan="1">A<italic toggle="yes">&#946;</italic><sub>42</sub>, t-tau, p-tau181, <sup>11</sup>C-PET imaging, <sup>18</sup>F-PET imaging, MRI (especially hippocampal volume-related content)</td><td colspan="1" rowspan="1">Proteomics</td><td colspan="1" rowspan="1">Human plasma</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Plasma APOE, BNP, CRP, and pancreatic polypeptide correlate with CSF amyloid and tau</td><td colspan="1" rowspan="1"><xref rid="bib149" ref-type="bibr">149</xref></td></tr></tbody></table><table-wrap-foot><fn><p>Note: AD, Alzheimer's disease; <italic toggle="yes">APP</italic>, amyloid precursor protein; ARM, activated-response microglia; BBB, blood-brain barrier; <italic toggle="yes">BIN1</italic>, bridging integrator 1; CFP, cerulean fluorescent protein; CSF, cerebrospinal fluid; DAAs, disease-associated astrocytes; DAMs, disease-associated microglia; DLPFC, dorsolateral prefrontal cortex; DMPs, differentially methylated positions; DNAm, DNA methylation; DSBs, DNA double-strand breaks; EC, endothelial cell; ERM, early responsive microglia; FERMT2, fermitin family member 2; HTRA1, HtrA serine peptidase 1; iNs, induced neurons; IRM, interferon-response microglia; JPH3, junctophilin 3; LPC, lysophosphatidylcholine; LRM, late response microglia; MRI, magnetic resonance imaging; NAB, neocortical amyloid burden; NFTs, neurofibrillary tangles; NTN1, netrin-1; PAM, plaque-associated microglia; PC, phosphatidylcholine; PE, ethanolamine glycerophospholipid; PI15, protein inhibitor 15; PICALM, phosphatidylinositol binding clathrin assembly; PTK2B, protein tyrosine kinase 2 beta; PS1, presenilin 1; RSS, reactive sulfur species; SLIT2, slit homolog 2; SM, sphingomyelin; SMOC1, SPARC-related modular calcium-binding 1; SNCA, alpha-synuclein; TAG, triacylglycerol; TPsC, total polysulfide content; <italic toggle="yes">TREM2</italic>, triggering receptor expressed on myeloid cells 2; TRM, transiting response microglia; t-tau, total tau; MCI, mild cognitive impairment; DHA, docosahexaenoic acid; ANK1, ankyrin 1; CLU, clusterin; LTL, Lateral Temporal Lobe; PET, positron emission tomography; p-tau, phosphorylated tau; PIG, plaque-induced gene; OLIG, oligodendrocyte gene; SCFAs, short-chain fatty acids; ATAC, assay for transposase-accessible chromatin; BDNF, Brain-derived neurotrophic factor; CDK5, cyclin-dependent kinase 5; Ng, Neurogranin; GSK-3<italic toggle="yes">&#946;</italic>, glycogen synthase kinase-3<italic toggle="yes">&#946;</italic><italic toggle="yes">;</italic> PCM, plaque-distant microglia.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec3.1"><label>3.1</label><title>Genomics and epigenomics</title><p id="p0105">AD is increasingly recognized as a heterogeneous disorder influenced by both genetic and environmental factors. Over the last two decades, genome-wide association studies (GWAS) have identified more than 40 risk loci associated with pathways including lipid metabolism, immune regulation, and endosomal trafficking<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref><sup>,</sup><xref rid="bib129" ref-type="bibr"><sup>129</sup></xref><sup>,</sup><xref rid="bib150" ref-type="bibr"><sup>150</sup></xref><sup>,</sup><xref rid="bib151" ref-type="bibr"><sup>151</sup></xref>. The <italic toggle="yes">APOE</italic> gene remains the prominent genetic risk factor, with the <italic toggle="yes">&#949;</italic>4 allele significantly increasing susceptibility. In addition, recently identified variants in genes such as bridging integrator 1 (<italic toggle="yes">BIN1</italic>) and clusterin (<italic toggle="yes">CLU</italic>) highlight the multifactorial nature of the disease and extend the genetic landscape beyond the classical amyloid and tau pathways<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref><sup>,</sup><xref rid="bib150" ref-type="bibr"><sup>150</sup></xref>. Many of these variants have modest individual effect sizes, indicating a polygenic model in which numerous low-to moderate-impact alleles collectively modulate disease risk<xref rid="bib129" ref-type="bibr"><sup>129</sup></xref>.</p><p id="p0110">Genetic predisposition alone does not fully explain the observed variability in the onset and progression of AD. This limitation has driven growing interest in epigenomic regulation, which includes mechanisms such as DNA methylation, histone modifications, and chromatin remodeling. Early epigenome-wide association studies (EWAS) identified differentially methylated regions (DMRs) in genes including ankyrin 1 (<italic toggle="yes">ANK1</italic>) and <italic toggle="yes">BIN1</italic>, suggesting that epigenetic modifications may converge on biological pathways previously implicated by genetic studies<xref rid="bib124" ref-type="bibr"><sup>124</sup></xref><sup>,</sup><xref rid="bib152" ref-type="bibr"><sup>152</sup></xref>. Notably, methylation changes at these loci often correlate with altered gene expression and chromatin accessibility, indicating that epigenetic reprogramming may amplify or mitigate the functional impact of genetic variants<xref rid="bib126" ref-type="bibr"><sup>126</sup></xref>. Thus, the epigenome serves as a critical interface through which environmental influences, including inflammation, lifestyle factors, and metabolic stress, can modulate the course of AD, even in individuals with established genetic risk<xref rid="bib153" ref-type="bibr"><sup>153</sup></xref>.</p><p id="p0115">The methodological landscape for AD research has become increasingly sophisticated. GWAS and whole-genome sequencing (WGS) provide comprehensive coverage of common and rare variants across the entire genome<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref>. In contrast, targeted capture and whole-exome sequencing (WES) focus specifically on protein-coding regions, which may be more amenable to therapeutic targeting<xref rid="bib131" ref-type="bibr"><sup>131</sup></xref>. However, these genome-wide approaches do not directly elucidate how regulatory variants influence gene function. To address this gap, epigenomic profiling techniques, such as DNA methylation arrays, reduced representation bisulfite sequencing (RRBS), and chromatin immunoprecipitation followed by sequencing (ChIP-seq), offer critical insights into the regulatory elements that modulate gene expression and splicing<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref><sup>,</sup><xref rid="bib154" ref-type="bibr"><sup>154</sup></xref>. Meanwhile, methods like assay for transposase-accessible chromatin using sequencing (ATAC-seq) and single-cell epigenomic technologies have advanced the ability to map chromatin accessibility and characterize three-dimensional chromatin architecture. These approaches also enable the identification of cell-type specific enhancer&#8211;promoter interactions in brain tissue<xref rid="bib155" ref-type="bibr"><sup>155</sup></xref>.</p><p id="p0120">The growing volume and complexity of genomic and epigenomic data have accelerated the adoption of AI and machine learning techniques to identify disease-associated variants, predict regulatory elements, and integrate multi-omics datasets. These computational strategies enable more accurate mapping of risk loci, functional annotation of regulatory elements, and inference of gene regulatory networks from large-scale data resources. These advancements, several key challenges remain. A major limitation is the reliance on post-mortem brain tissue, which restricts the ability to perform longitudinal analyses and may underrepresent the dynamic nature of epigenetic changes throughout the progression of AD<xref rid="bib156" ref-type="bibr"><sup>156</sup></xref>. Furthermore, the cellular heterogeneity of the AD brain presents significant analytical hurdles. Advanced computational deconvolution techniques or experimental methods such as fluorescence-activated cell sorting (FACS) are often required to resolve distinct cell populations, including neurons, astrocytes, and microglia<xref rid="bib127" ref-type="bibr"><sup>127</sup></xref><sup>,</sup><xref rid="bib157" ref-type="bibr"><sup>157</sup></xref>. This level of resolution is essential, as epigenetic profiles in glial cells may differ substantially from those in neurons and may play critical roles in processes such as amyloid plaque deposition and neuroinflammation<xref rid="bib118" ref-type="bibr"><sup>118</sup></xref>. Additionally, establishing causal relationships remains a major challenge. The identification of an epigenetic signature does not necessarily confirm its mechanistic relevance. Functional validation using CRISPR-based genome and epigenome editing technologies is increasingly employed to test the biological significance of candidate regulatory loci<xref rid="bib119" ref-type="bibr"><sup>119</sup></xref><sup>,</sup><xref rid="bib158" ref-type="bibr"><sup>158</sup></xref>.</p><p id="p0125">There is increasing recognition that integrating genomics, epigenomics, and transcriptomics within the same biological samples, a strategy commonly referred to as multi-omics integration, can yield highly informative insights into the molecular mechanisms of AD<xref rid="bib159" ref-type="bibr"><sup>159</sup></xref><sup>,</sup><xref rid="bib160" ref-type="bibr"><sup>160</sup></xref>. By analyzing how genetic variants intersect with epigenetic modifications and gene expression profiles, researchers can identify specific regulatory nodes where disease-associated alleles exert their influence. AI-driven integrative analyses offer particular promise in elucidating how variants in genes such as <italic toggle="yes">APOE</italic> and <italic toggle="yes">BIN1</italic> affect chromatin structure or methylation states within distinct neuronal populations. These approaches facilitate a systems-level view of gene regulation that is not achievable through single-layer analyses alone. A fully integrated analytical framework that captures the interplay among genetic variation, epigenetic regulation, and transcriptional activity is essential for advancing our understanding of AD. When supported by AI-based data synthesis, such a framework holds strong potential for discovering novel biomarkers and clarifying the molecular mechanisms underlying disease progression. It can also guide the development of personalized therapeutic strategies that are tailored to an individual's unique molecular profile.</p></sec><sec id="sec3.2"><label>3.2</label><title>Transcriptomics</title><p id="p0130">Over the past decade, transcriptomics has become a cornerstone in elucidating the complex molecular landscape of AD. It provides key insights into the dynamic, cell-type-specific processes that underlie disease onset and progression. Early transcriptomic studies utilizing microarrays revealed alterations in synaptic, immune, and metabolic pathways that appear even before clinical symptoms, underscoring the potential for pre-symptomatic intervention<xref rid="bib120" ref-type="bibr"><sup>120</sup></xref><sup>,</sup><xref rid="bib125" ref-type="bibr"><sup>125</sup></xref><sup>,</sup><xref rid="bib161" ref-type="bibr"><sup>161</sup></xref>. However, microarrays are limited by their probe-based design and restricted dynamic range, which led to a transition toward high-throughput bulk RNA sequencing (RNA-Seq). RNA-Seq offers an unbiased view of known and novel transcripts and has identified candidate &#8220;hub&#8221; genes within networks linked to lipid metabolism and innate immunity<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref><sup>,</sup><xref rid="bib130" ref-type="bibr"><sup>130</sup></xref><sup>,</sup><xref rid="bib159" ref-type="bibr"><sup>159</sup></xref><sup>,</sup><xref rid="bib160" ref-type="bibr"><sup>160</sup></xref>. Despite these advances, bulk RNA-Seq cannot resolve cell-specific transcriptional changes due to tissue heterogeneity<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref><sup>,</sup><xref rid="bib124" ref-type="bibr"><sup>124</sup></xref>. Single-cell RNA sequencing (scRNA-Seq) addresses this limitation by enabling high-resolution profiling of individual cell types. This technique has revealed distinct microglial and astrocytic subpopulations, such as disease-associated microglia (DAM) and reactive astrocytes, which are involved in plaque clearance, neuroinflammation, and synaptic modulation<xref rid="bib118" ref-type="bibr"><sup>118</sup></xref><sup>,</sup><xref rid="bib162" ref-type="bibr">162</xref>, <xref rid="bib163" ref-type="bibr">163</xref>, <xref rid="bib164" ref-type="bibr">164</xref>.</p><p id="p0135">AI methods have become indispensable tools for processing, clustering, and interpreting these high-dimensional single-cell datasets. These methods have facilitated the discovery of subtle cellular subtypes and gene regulatory modules associated with disease progression. Recent advances in single-nucleus RNA sequencing (snRNA-Seq) have extended transcriptomic analysis to frozen or archived post-mortem brain tissues. By isolating nuclei rather than whole cells, snRNA-Seq retains transcriptional fidelity while avoiding cell dissociation artifacts<xref rid="bib155" ref-type="bibr"><sup>155</sup></xref><sup>,</sup><xref rid="bib165" ref-type="bibr"><sup>165</sup></xref>. This technique has enabled detailed profiling of vulnerable neuronal subtypes and glial populations. However, data processing and integration remain computationally demanding, prompting the adoption of AI-based approaches for normalization, batch correction, and cell-type annotation.</p><p id="p0140">Spatial transcriptomics further enhances transcriptomic profiling by preserving the spatial context of gene expression. It allows gene expression patterns to be mapped onto histologically defined regions, thereby linking molecular signatures to specific pathological features such as amyloid plaques and tau tangles<xref rid="bib114" ref-type="bibr"><sup>114</sup></xref><sup>,</sup><xref rid="bib121" ref-type="bibr"><sup>121</sup></xref><sup>,</sup><xref rid="bib166" ref-type="bibr"><sup>166</sup></xref><sup>,</sup><xref rid="bib167" ref-type="bibr"><sup>167</sup></xref>. When integrated with AI-enhanced image analysis, spatial transcriptomics provides more precise insights into the relationship between gene expression and tissue architecture. Each of these technologies offers distinct advantages and limitations. Microarrays and bulk RNA-Seq are scalable and cost-effective but lack single-cell resolution. Single-cell and single-nucleus methods deliver high granularity but require significant technical and computational resources. Spatial transcriptomics adds a critical spatial dimension but may trade off resolution or transcriptomic depth<xref rid="bib114" ref-type="bibr"><sup>114</sup></xref><sup>,</sup><xref rid="bib118" ref-type="bibr"><sup>118</sup></xref><sup>,</sup><xref rid="bib162" ref-type="bibr"><sup>162</sup></xref><sup>,</sup><xref rid="bib166" ref-type="bibr"><sup>166</sup></xref>.</p><p id="p0145">Looking ahead, integrative multi-omics approaches are expected to play a pivotal role. Studies correlating transcriptomic profiles with proteomic, metabolomic, and epigenomic data have already revealed key discrepancies between RNA and protein expression in AD<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref><sup>,</sup><xref rid="bib159" ref-type="bibr"><sup>159</sup></xref><sup>,</sup><xref rid="bib160" ref-type="bibr"><sup>160</sup></xref>. Moreover, combining single-cell or spatial transcriptomics with imaging modalities such as fluorescence in situ hybridization (FISH) or immunohistochemistry enhances validation within native tissue contexts<xref rid="bib114" ref-type="bibr"><sup>114</sup></xref><sup>,</sup><xref rid="bib167" ref-type="bibr"><sup>167</sup></xref>. Therefore, a systems biology framework that integrates these diverse molecular layers, supported by AI-powered analytics, will be crucial for illuminating the pathophysiological cascades of AD and accelerating the discovery of biomarkers and precision therapies.</p></sec><sec id="sec3.3"><label>3.3</label><title>Proteomics and metabolomics</title><p id="p0150">Although genetic and transcriptomic studies have provided critical insights into AD, proteomics and metabolomics directly capture functional endpoints such as proteins and metabolites, which often act as early indicators or amplifiers of disease progression<xref rid="bib156" ref-type="bibr"><sup>156</sup></xref><sup>,</sup><xref rid="bib159" ref-type="bibr"><sup>159</sup></xref>. Utilizing these data types is essential for understanding the complex nature of AD pathogenesis and developing targeted interventions.</p><p id="p0155">Contemporary proteomic research relies heavily on high-resolution mass spectrometry (HR-MS) platforms including Orbitrap and time-of-flight (TOF) systems. These tools quantify thousands of proteins across a wide dynamic range<xref rid="bib168" ref-type="bibr"><sup>168</sup></xref><sup>,</sup><xref rid="bib169" ref-type="bibr"><sup>169</sup></xref>. Techniques such as tandem mass tag (TMT) labeling, isobaric tagging, and label-free quantification allow for systematic comparisons of proteomes in brain tissue, CSF, and plasma. These approaches have revealed dysregulation in synaptic proteins, immune modulators, and metabolic enzymes that extend beyond the classical amyloid and tau pathways<xref rid="bib134" ref-type="bibr"><sup>134</sup></xref><sup>,</sup><xref rid="bib160" ref-type="bibr"><sup>160</sup></xref><sup>,</sup><xref rid="bib170" ref-type="bibr">170</xref>, <xref rid="bib171" ref-type="bibr">171</xref>, <xref rid="bib172" ref-type="bibr">172</xref>, <xref rid="bib173" ref-type="bibr">173</xref>.</p><p id="p0160">Proteins are subject to post-translational modifications (PTMs) including phosphorylation, ubiquitination, glycosylation, and oxidation, each of which can alter protein stability and function. Specific phosphorylation patterns on tau influence tangle formation, while ubiquitination may accelerate synaptic protein degradation and contribute to neurodegeneration<xref rid="bib174" ref-type="bibr">174</xref>, <xref rid="bib175" ref-type="bibr">175</xref>, <xref rid="bib176" ref-type="bibr">176</xref>, <xref rid="bib177" ref-type="bibr">177</xref>. Advances in phosphoproteomics and glycoprotein enrichment technologies now enable proteome-wide mapping of these modifications. Given the complexity and low abundance of many PTMs, AI-based analytical methods are increasingly used for enrichment, site identification, and functional network modeling<xref rid="bib139" ref-type="bibr"><sup>139</sup></xref><sup>,</sup><xref rid="bib169" ref-type="bibr"><sup>169</sup></xref><sup>,</sup><xref rid="bib178" ref-type="bibr"><sup>178</sup></xref><sup>,</sup><xref rid="bib179" ref-type="bibr"><sup>179</sup></xref>. Most proteomic studies rely on bulk samples, but recent innovations in single-cell and spatial proteomics have enabled the identification of protein expression changes in specific cell types and anatomical regions. These methods allow researchers to examine the protein landscape surrounding plaques and within vulnerable brain areas such as the hippocampus<xref rid="bib180" ref-type="bibr">180</xref>, <xref rid="bib181" ref-type="bibr">181</xref>, <xref rid="bib182" ref-type="bibr">182</xref>, <xref rid="bib183" ref-type="bibr">183</xref>. AI-enhanced image segmentation has improved the resolution and accuracy of these spatial patterns. However, single-cell proteomics still faces limitations such as lower proteome coverage and higher per-sample cost<xref rid="bib184" ref-type="bibr"><sup>184</sup></xref><sup>,</sup><xref rid="bib185" ref-type="bibr"><sup>185</sup></xref>.</p><p id="p0165">Metabolomics complements proteomics by quantifying small molecules that reflect or influence cellular phenotypes. Untargeted methods like ultra-high-performance liquid chro-matography&#8211;mass spectrometry (UHPLC&#8211;MS) and nuclear magnetic resonance (NMR) capture broad metabolic profiles, while targeted approaches focus on specific pathways such as the tricarboxylic acid cycle and sphingolipid biosynthesis<xref rid="bib138" ref-type="bibr"><sup>138</sup></xref><sup>,</sup><xref rid="bib186" ref-type="bibr">186</xref>, <xref rid="bib187" ref-type="bibr">187</xref>, <xref rid="bib188" ref-type="bibr">188</xref>, <xref rid="bib189" ref-type="bibr">189</xref>, <xref rid="bib190" ref-type="bibr">190</xref>, <xref rid="bib191" ref-type="bibr">191</xref>. These techniques have uncovered metabolic abnormalities in AD, particularly those related to lipid metabolism, mitochondrial dysfunction, and inflammatory signaling<xref rid="bib192" ref-type="bibr"><sup>192</sup></xref><sup>,</sup><xref rid="bib193" ref-type="bibr"><sup>193</sup></xref>. AI approaches are being used to analyze high-dimensional metabolomic datasets, identify diagnostic patterns, and enhance predictive power. Despite variability introduced by diet and comorbid conditions, metabolomic biomarkers such as reduced docosahexaenoic acid (DHA) and elevated homocysteine have demonstrated clinical utility<xref rid="bib133" ref-type="bibr"><sup>133</sup></xref><sup>,</sup><xref rid="bib194" ref-type="bibr">194</xref>, <xref rid="bib195" ref-type="bibr">195</xref>, <xref rid="bib196" ref-type="bibr">196</xref>, <xref rid="bib197" ref-type="bibr">197</xref>, <xref rid="bib198" ref-type="bibr">198</xref>, <xref rid="bib199" ref-type="bibr">199</xref>. Metabolic shifts detectable in plasma or CSF may precede pathological changes in amyloid or tau, offering value for early diagnosis<xref rid="bib200" ref-type="bibr"><sup>200</sup></xref>. Single-cell and spatial metabolomics, including matrix-assisted laser desorption ionization imaging, now enable in situ mapping of metabolites around pathological structures. These methods provide localized biochemical context but currently face challenges in sensitivity and throughput<xref rid="bib183" ref-type="bibr"><sup>183</sup></xref><sup>,</sup><xref rid="bib201" ref-type="bibr">201</xref>, <xref rid="bib202" ref-type="bibr">202</xref>, <xref rid="bib203" ref-type="bibr">203</xref>, <xref rid="bib204" ref-type="bibr">204</xref>.</p><p id="p0170">Multi-omics integration that combines genomic, transcriptomic, proteomic, and metabolomic layers is creating more comprehensive models of AD biology<xref rid="bib156" ref-type="bibr"><sup>156</sup></xref><sup>,</sup><xref rid="bib159" ref-type="bibr"><sup>159</sup></xref><sup>,</sup><xref rid="bib160" ref-type="bibr"><sup>160</sup></xref>. Linking genetic variation to downstream protein networks and metabolic processes has led to the identification of novel therapeutic targets<xref rid="bib137" ref-type="bibr"><sup>137</sup></xref><sup>,</sup><xref rid="bib160" ref-type="bibr"><sup>160</sup></xref><sup>,</sup><xref rid="bib205" ref-type="bibr"><sup>205</sup></xref>. For example, individuals carrying the <italic toggle="yes">APOE &#949;4</italic> allele display distinct proteo-metabolomic signatures in lipid transport and immune pathways<xref rid="bib206" ref-type="bibr"><sup>206</sup></xref><sup>,</sup><xref rid="bib207" ref-type="bibr"><sup>207</sup></xref>. AI-driven integration and modeling are now essential tools for discovering biomarkers and stratifying patients. In clinical settings, proteomic and metabolomic biomarkers offer promising avenues for earlier detection, more precise monitoring, and tailored therapeutic response<xref rid="bib186" ref-type="bibr"><sup>186</sup></xref><sup>,</sup><xref rid="bib208" ref-type="bibr"><sup>208</sup></xref><sup>,</sup><xref rid="bib209" ref-type="bibr"><sup>209</sup></xref>. Several candidate biomarkers, such as neurogranin in CSF, are undergoing validation alongside amyloid and tau panels. Meanwhile, metabolomic profiles are being explored for guiding clinical trial inclusion and personalized intervention strategies<xref rid="bib132" ref-type="bibr"><sup>132</sup></xref><sup>,</sup><xref rid="bib136" ref-type="bibr"><sup>136</sup></xref><sup>,</sup><xref rid="bib210" ref-type="bibr"><sup>210</sup></xref>. Future directions should prioritize longitudinal and multi-modal studies that integrate omics, neuroimaging, and pathology to uncover the molecular mechanisms of AD and accelerate the development of individualized therapies<xref rid="bib208" ref-type="bibr"><sup>208</sup></xref><sup>,</sup><xref rid="bib211" ref-type="bibr"><sup>211</sup></xref>.</p></sec><sec id="sec3.4"><label>3.4</label><title>Microbiomics</title><p id="p0175">While genomic, transcriptomic, and proteomic studies have deepened our understanding of AD, microbiomics has introduced a critical new dimension by elucidating the role of the gut&#8211;brain axis in neurodegeneration<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref><sup>,</sup><xref rid="bib195" ref-type="bibr"><sup>195</sup></xref>. Studies using 16S rRNA gene sequencing and shotgun metagenomic sequencing have consistently identified significant changes in the gut microbiota composition of individuals with AD. These include reductions in beneficial genera such as <italic toggle="yes">Lactobacillus</italic> and <italic toggle="yes">Bifidobacterium</italic>, alongside increases in pro-inflammatory taxa like <italic toggle="yes">Enterobacteriaceae</italic><xref rid="bib64" ref-type="bibr"><sup>64</sup></xref>. Reduced microbial diversity and taxonomic shifts have been associated with cognitive impairment, suggesting that microbial dysbiosis may contribute to AD <italic toggle="yes">via</italic> modulation of systemic and neuroinflammatory responses<xref rid="bib212" ref-type="bibr"><sup>212</sup></xref>.</p><p id="p0180">Dysbiosis is hypothesized to affect AD through multiple pathways, including the production of SCFAs, regulation of immune function, and modulation of BBB integrity. Pro-inflammatory microbial taxa have been linked to elevated amyloid burden and systemic inflammation in cognitively impaired individuals<xref rid="bib213" ref-type="bibr"><sup>213</sup></xref>. In germ-free mouse models, increased BBB permeability has been observed, which can be reversed through colonization with SCFA-producing bacteria<xref rid="bib141" ref-type="bibr"><sup>141</sup></xref>. Shotgun metagenomic sequencing, analyzed using AI-enhanced bioinformatics, has revealed functional disruptions in AD-associated microbiomes, including altered lipid metabolism and reduced SCFA biosynthesis capacity<xref rid="bib214" ref-type="bibr"><sup>214</sup></xref>. Moreover, sex-specific differences have been noted, with female AD mouse models showing more pronounced microbiota-driven amyloid deposition and microglial activation compared to males<xref rid="bib140" ref-type="bibr"><sup>140</sup></xref>.</p><p id="p0185">While 16S rRNA sequencing is efficient for profiling bacterial communities, it lacks species-level resolution and omits non-bacterial microbiota such as fungi and viruses<xref rid="bib215" ref-type="bibr"><sup>215</sup></xref>. Shotgun metagenomics provides more comprehensive functional insights but requires higher cost and computational power. AI algorithms are increasingly used to separate host from microbial DNA and to enhance functional annotation<xref rid="bib216" ref-type="bibr"><sup>216</sup></xref><sup>,</sup><xref rid="bib217" ref-type="bibr"><sup>217</sup></xref>. Furthermore, confounding factors such as diet, age, and antibiotic use complicate microbiome data interpretation<xref rid="bib217" ref-type="bibr"><sup>217</sup></xref>. Longitudinal studies are essential to establish causal relationships between microbiota shifts and AD progression<xref rid="bib170" ref-type="bibr"><sup>170</sup></xref><sup>,</sup><xref rid="bib187" ref-type="bibr"><sup>187</sup></xref>. Notably, antibiotic-induced depletion of gut microbiota in AD mouse models has been shown to reduce amyloid accumulation and modulate microglial activation<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref>. Interventions targeting the gut microbiota, including probiotics, prebiotics, dietary modification, and fecal microbiota transplantation (FMT), are under active investigation. Clinical trials have shown that probiotic supplementation can improve cognitive function and reduce inflammation in AD patients<xref rid="bib218" ref-type="bibr"><sup>218</sup></xref>. Other strategies, such as SCFA supplementation and FMT, have demonstrated potential for restoring microbial balance and reducing neuroinflammation, although larger, well-controlled studies are needed to validate these effects<xref rid="bib135" ref-type="bibr"><sup>135</sup></xref>.</p><p id="p0190">Integrating microbiomics with other omics layers, such as genomics, transcriptomics, and metabolomics, is crucial for a systems-level understanding of microbiome&#8211;host interactions in AD<xref rid="bib133" ref-type="bibr"><sup>133</sup></xref><sup>,</sup><xref rid="bib219" ref-type="bibr"><sup>219</sup></xref>. AI-driven multi-omics integration enables linking microbial genes with host immune responses and amyloid processing pathways<xref rid="bib205" ref-type="bibr"><sup>205</sup></xref>. Machine learning applied to metabolomic data can also identify how microbial metabolites affect neuronal health and inflammatory status<xref rid="bib118" ref-type="bibr"><sup>118</sup></xref>.</p><p id="p0195">Emerging technologies such as single-cell microbiomics and spatial transcriptomics, combined with AI-based analytical platforms, will offer unprecedented spatial and cellular resolution for studying microbiome&#8211;brain interactions<xref rid="bib220" ref-type="bibr"><sup>220</sup></xref><sup>,</sup><xref rid="bib221" ref-type="bibr"><sup>221</sup></xref>. These tools can help identify specific microbial strains and their localized effects within the gut and central nervous system. To ensure reproducibility and translational relevance, standardized protocols and large longitudinal cohorts are needed<xref rid="bib222" ref-type="bibr"><sup>222</sup></xref><sup>,</sup><xref rid="bib223" ref-type="bibr"><sup>223</sup></xref>. Despite ongoing methodological challenges, the microbiome represents a promising frontier in AD research. Advances in microbiome-targeted diagnostics and therapeutics, particularly those integrated with multi-omics and AI approaches, may offer novel opportunities for early intervention and disease modification.</p></sec></sec><sec id="sec4"><label>4</label><title>AI in multi-omics data integration and analysis of AD</title><p id="p0200">Recent advances in multi-omics technologies have enabled simultaneous profiling of genomics, transcriptomics, proteomics, metabolomics, and epigenomics within AD cohorts. These platforms generate high-dimensional datasets that reflect the biological complexity of the disease across multiple molecular layers<xref rid="bib159" ref-type="bibr"><sup>159</sup></xref>. However, effective integration of such data remains a significant challenge due to differences in data scale, noise characteristics, missing value patterns, and the often weak biological signals relative to technical variation<xref rid="bib224" ref-type="bibr"><sup>224</sup></xref>. Successful integration requires a multistep preprocessing pipeline that includes batch effect correction, normalization, feature selection, and sample alignment. This is followed by statistical modeling approaches capable of capturing both shared and modality-specific variation across omics types<xref rid="bib225" ref-type="bibr"><sup>225</sup></xref>. Common methods include multiblock partial least squares, similarity network fusion, matrix factorization, and manifold learning techniques, each offering different strengths in capturing complex inter-omic relationships<xref rid="bib226" ref-type="bibr"><sup>226</sup></xref>. AI plays a central role in multi-omics data integration (<xref rid="fig4" ref-type="fig">Fig. 4</xref>). Classical machine learning algorithms such as random forests and support vector machines have demonstrated strong performance on curated datasets, providing interpretable feature rankings that aid in biomarker discovery<xref rid="bib227" ref-type="bibr"><sup>227</sup></xref>. More recent deep learning architectures, including variational autoencoders, graph neural networks, and transformer models, offer the capacity to handle large feature spaces and to model nonlinear, cross-omic interactions. In addition, network-based approaches that incorporate prior biological knowledge improve both model performance and interpretability<xref rid="bib228" ref-type="bibr"><sup>228</sup></xref> (<xref rid="tbl2" ref-type="table">Table 2</xref><xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib41" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="bib53" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="bib225" ref-type="bibr"><sup>225</sup></xref><sup>,</sup><xref rid="bib227" ref-type="bibr">227</xref>, <xref rid="bib228" ref-type="bibr">228</xref>, <xref rid="bib229" ref-type="bibr">229</xref>, <xref rid="bib230" ref-type="bibr">230</xref>, <xref rid="bib231" ref-type="bibr">231</xref>, <xref rid="bib232" ref-type="bibr">232</xref>, <xref rid="bib233" ref-type="bibr">233</xref>, <xref rid="bib234" ref-type="bibr">234</xref>, <xref rid="bib235" ref-type="bibr">235</xref>, <xref rid="bib236" ref-type="bibr">236</xref>, <xref rid="bib237" ref-type="bibr">237</xref>, <xref rid="bib238" ref-type="bibr">238</xref>, <xref rid="bib239" ref-type="bibr">239</xref>, <xref rid="bib240" ref-type="bibr">240</xref>, <xref rid="bib241" ref-type="bibr">241</xref>, <xref rid="bib242" ref-type="bibr">242</xref>, <xref rid="bib243" ref-type="bibr">243</xref>, <xref rid="bib244" ref-type="bibr">244</xref>, <xref rid="bib245" ref-type="bibr">245</xref>, <xref rid="bib246" ref-type="bibr">246</xref>, <xref rid="bib247" ref-type="bibr">247</xref>, <xref rid="bib248" ref-type="bibr">248</xref>, <xref rid="bib249" ref-type="bibr">249</xref>, <xref rid="bib250" ref-type="bibr">250</xref>, <xref rid="bib251" ref-type="bibr">251</xref>, <xref rid="bib252" ref-type="bibr">252</xref>, <xref rid="bib253" ref-type="bibr">253</xref>, <xref rid="bib254" ref-type="bibr">254</xref>, <xref rid="bib255" ref-type="bibr">255</xref>, <xref rid="bib256" ref-type="bibr">256</xref>, <xref rid="bib257" ref-type="bibr">257</xref>, <xref rid="bib258" ref-type="bibr">258</xref>, <xref rid="bib259" ref-type="bibr">259</xref>, <xref rid="bib260" ref-type="bibr">260</xref>, <xref rid="bib261" ref-type="bibr">261</xref>, <xref rid="bib262" ref-type="bibr">262</xref>, <xref rid="bib263" ref-type="bibr">263</xref>, <xref rid="bib264" ref-type="bibr">264</xref>, <xref rid="bib265" ref-type="bibr">265</xref>, <xref rid="bib266" ref-type="bibr">266</xref>, <xref rid="bib267" ref-type="bibr">267</xref>, <xref rid="bib268" ref-type="bibr">268</xref>, <xref rid="bib269" ref-type="bibr">269</xref>, <xref rid="bib270" ref-type="bibr">270</xref>, <xref rid="bib271" ref-type="bibr">271</xref>, <xref rid="bib272" ref-type="bibr">272</xref>, <xref rid="bib273" ref-type="bibr">273</xref>, <xref rid="bib274" ref-type="bibr">274</xref>).<fig id="fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><p>The application of Artificial Intelligence (AI) in integrating multi-omics data for AD research. Machine learning, deep learning, and network-based methods are essential AI techniques in multi-omics integration for AD research. Machine learning methods, such as supervised (SVM, Random Forests), unsupervised (K-means), and reinforcement learning, predict outcomes and uncover hidden patterns. Deep learning techniques like Deep Neural Networks (DNN), Convolutional Neural Networks (CNNs), and Variational Autoencoders (V-AEs) are used for complex data analysis, including brain image recognition and gene expression. Network-based methods, such as Weighted Gene Co-expression Network Analysis (WGCNA) and Bayesian networks, analyze gene interactions and protein pathways to identify key biomarkers and molecular mechanisms in AD. These multi-omics integrated by these AI integrative techniques are used for the identification of novel biomarkers, mechanism exploration, early diagnosis and prediction of disease, drug discovery and development, and patient stratification and personalized medicine.</p></caption><alt-text id="alttext0030">Figure 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig><table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>The AI model used for the integration of various multi-omics of AD.</p></caption><alt-text id="alttext0040">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">AI models</th><th colspan="1" rowspan="1">Key features</th><th colspan="1" rowspan="1">Representative applications</th><th colspan="1" rowspan="1">Advantages/Disadvantages</th><th colspan="1" rowspan="1">Main challenges</th><th colspan="1" rowspan="1">Evaluation metrics</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">SVM</td><td colspan="1" rowspan="1">Serves as a supervised classifier for multi-omics integration</td><td colspan="1" rowspan="1">Applies to classify AD phenotypes and identify potential biomarkers in multi-omics datasets</td><td colspan="1" rowspan="1">Advantages: High accuracy in AD phenotype classification; well-established generalization capacity.<break/>Disadvantages: Requires vector reshaping of matrix data; sensitive to imbalanced inputs; high computational cost</td><td colspan="1" rowspan="1">Requires tuning for large datasets; limited interpretability in non-linear implementations</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib229" ref-type="bibr">229</xref></td></tr><tr><td colspan="1" rowspan="1">Linear SVM</td><td colspan="1" rowspan="1">Uses linear decision boundaries for classification</td><td colspan="1" rowspan="1">Performs binary classification tasks, such as differentiating AD from healthy subjects</td><td colspan="1" rowspan="1">Advantages: Simple formulation with fast computation; supports feature selection and outlier detection <italic toggle="yes">via</italic> MILP integration.<break/>Disadvantages: Limited to linear separability; reduced generalization for non-linear AD patterns</td><td colspan="1" rowspan="1">Requires kernel or feature mapping for non-linear patterns; tuning needed for optimal boundary definition</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib230" ref-type="bibr">230</xref></td></tr><tr><td colspan="1" rowspan="1">Non-linear SVM</td><td colspan="1" rowspan="1">Combines 51 AD SNPs and 8 environmental factors; uses SMOTE and grid-search tuning to handle class imbalance</td><td colspan="1" rowspan="1">AD classification on 184 cases and 3773 controls from Taiwan Biobank and CGMH; delivers 80% accuracy and specificity comparable to ANN and RF baselines</td><td colspan="1" rowspan="1">Advantages: Effective for AD classification using genetic and environmental features; comparable accuracy to ANN and RF.<break/>Disadvantages: High computational cost; sensitive to feature redundancy and data imbalance</td><td colspan="1" rowspan="1">Requires careful kernel and parameter tuning; vulnerable to noisy or heterogeneous omics data</td><td colspan="1" rowspan="1">Accuracy: 0.97; Sensitivity: 0.98; Specificity: 0.96; F1 Score: 0.97; MCC: 0.94; ROC-AUC: 0.99</td><td colspan="1" rowspan="1"><xref rid="bib231" ref-type="bibr">231</xref></td></tr><tr><td colspan="1" rowspan="1">RF</td><td colspan="1" rowspan="1">Serves as an ensemble method that uses multiple decision trees to improve accuracy and prevent overfitting</td><td colspan="1" rowspan="1">Predicts disease progression and classifies MCI as AD</td><td colspan="1" rowspan="1">Advantages: Handles high-dimensional AD data; provides built-in feature importance; robust to noise and overfitting.<break/>Disadvantages: High computational cost with large datasets; performance may degrade with redundant features</td><td colspan="1" rowspan="1">Limited interpretability due to large ensembles</td><td colspan="1" rowspan="1">AUC: 0.946; F1-score: 0.824; OOB Error: 0.1597</td><td colspan="1" rowspan="1"><xref rid="bib232" ref-type="bibr">232</xref></td></tr><tr><td colspan="1" rowspan="1">Decision trees</td><td colspan="1" rowspan="1">Create binary splits for classification (used as base learners in RF)</td><td colspan="1" rowspan="1">Serve as base learners or stand-alone interpretable models for stage classification</td><td colspan="1" rowspan="1">Advantages: Easy to interpret; effective in classifying AD stages using gene expression.<break/>Disadvantages: Easily overfits on small or high-dimensional AD data; lacks regularization mechanisms</td><td colspan="1" rowspan="1">Poor robustness in complex datasets; difficult to generalize without pruning or ensemble methods</td><td colspan="1" rowspan="1">Accuracy: 0.72; Sensitivity: 0.72; Specificity: 0.86; Precision: 0.75; F1 score: 0.72</td><td colspan="1" rowspan="1"><xref rid="bib233" ref-type="bibr">233</xref></td></tr><tr><td colspan="1" rowspan="1">Boosting methods</td><td colspan="1" rowspan="1">Combine multiple weak learners to form a strong model</td><td colspan="1" rowspan="1">Enhance feature selection and predict clinical outcomes based on multi-omics data</td><td colspan="1" rowspan="1">Advantages: Achieves high prediction accuracy on AD severity using multi-omics features; integrates diverse data types including proteomics, metabolomics, and microbiome.<break/>Disadvantages: Requires careful parameter tuning to prevent overfitting; performance may decline with noisy or imbalanced data</td><td colspan="1" rowspan="1">Sensitive to data noise and imbalance; necessitates meticulous tuning to maintain model generalization</td><td colspan="1" rowspan="1">AUC: 1.00 (training), 0.94 (validation), 0.87 (test); Accuracy: 0.973 (multi-omics, XGBoost): 0.973 (multi-omics, XGBoost)</td><td colspan="1" rowspan="1"><xref rid="bib234" ref-type="bibr">234</xref></td></tr><tr><td colspan="1" rowspan="1">M-LSTM</td><td colspan="1" rowspan="1">Captures long-term temporal dependencies in time-series data using memory-gated recurrent network</td><td colspan="1" rowspan="1">Detects AD progression using cognitive assessments and neuroimaging data</td><td colspan="1" rowspan="1">Advantages: High accuracy; models progression over time; robust to missing data. Disadvantages: Computationally intensive; requires careful preprocessing and tuning</td><td colspan="1" rowspan="1">Handling irregular visit intervals and missing values; optimizing hyperparameters for classification</td><td colspan="1" rowspan="1">Accuracy: 0.8178; Precision: 0.8550; Sensitivity: 0.8000; F1 score: 0.8266</td><td colspan="1" rowspan="1"><xref rid="bib235" ref-type="bibr">235</xref></td></tr><tr><td colspan="1" rowspan="1">AdaBoost</td><td colspan="1" rowspan="1">Combines multiple weak classifiers to improve prediction performance</td><td colspan="1" rowspan="1">Classifies AD subjects into progressive <italic toggle="yes">vs</italic> nonprogressive categories based on cognitive and imaging data</td><td colspan="1" rowspan="1">Advantages: High interpretability; improves accuracy <italic toggle="yes">via</italic> boosting.<break/>Disadvantages: Less effective for sequential data; limited in capturing temporal patterns</td><td colspan="1" rowspan="1">Enhancing accuracy with limited features; addressing class imbalance in progression labels</td><td colspan="1" rowspan="1">Accuracy: 0.7981; Precision: 0.7982; Sensitivity: 0.8125; F1 score: 0.8053</td><td colspan="1" rowspan="1"><xref rid="bib235" ref-type="bibr">235</xref></td></tr><tr><td colspan="1" rowspan="1">XGBoost&#8211;SHAP</td><td colspan="1" rowspan="1">Combines weighted XGBoost with SHAP for interpretable feature attribution</td><td colspan="1" rowspan="1">Multiclass classification of NC, MCI, and AD using ADNI and NACC datasets with clinical, imaging, and genetic data</td><td colspan="1" rowspan="1">Advantages: High classification accuracy with clinical interpretability; better performance than RF, Bagging, AdaBoost, and NB.<break/>Disadvantages: Requires hyperparameter tuning; sensitive to class imbalance</td><td colspan="1" rowspan="1">Weight adjustment of imbalanced classes; optimizing clinical utility across different data sources</td><td colspan="1" rowspan="1">ADNI: Accuracy: 0.88; Sensitivity: 0.81; Specificity: 0.92; AUC: 0.91; CUI+: 0.71; CUI&#8211;: 0.75<break/>NACC: Accuracy: 0.81; Sensitivity: 0.75; Specificity: 0.90; AUC: 0.88; CUI+: 0.56; CUI&#8211;: 0.68</td><td colspan="1" rowspan="1"><xref rid="bib236" ref-type="bibr">236</xref></td></tr><tr><td colspan="1" rowspan="1">DBNs</td><td colspan="1" rowspan="1">Compose a probabilistic deep architecture from stacked RBMs optimized <italic toggle="yes">via</italic> Bayesian hyperparameter tuning</td><td colspan="1" rowspan="1">Classify AD using integrated gene expression and DNA methylation data</td><td colspan="1" rowspan="1">Advantages: High test accuracy with low feature count; handles HDLSS data effectively.<break/>Disadvantages: Requires extensive tuning; sensitive to omics integration noise</td><td colspan="1" rowspan="1">Optimizing architecture; addressing small sample bias in omics data</td><td colspan="1" rowspan="1">Accuracy (5-fold CV): 0.9956 (avg); Accuracy on test datasets: 0.82 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE109887">GSE109887</ext-link>/118553); Features selected: 39</td><td colspan="1" rowspan="1"><xref rid="bib237" ref-type="bibr">237</xref></td></tr><tr><td colspan="1" rowspan="1">GNNs</td><td colspan="1" rowspan="1">Operate on a signed, directed, and heterogeneous biomedical knowledge graph to learn drug combination embeddings</td><td colspan="1" rowspan="1">Support drug repurposing for AD based on expert-weighted multi-relational biomedical data</td><td colspan="1" rowspan="1">Advantages: Integrates expert guidance with biomedical networks; identifies clinically relevant 5-drug combinations.<break/>Disadvantages: Black-box structure limits interpretability; graph construction requires domain-specific effort</td><td colspan="1" rowspan="1">Designing interpretable graph structures; validating synergy predictions in complex pharmacological networks</td><td colspan="1" rowspan="1">Predicted synergy score: 0.3876 (10-fold CV); <italic toggle="yes">P</italic>-value: 0.006 (Wilcoxon <italic toggle="yes">vs</italic>. baseline)</td><td colspan="1" rowspan="1"><xref rid="bib238" ref-type="bibr">238</xref>,<xref rid="bib239" ref-type="bibr">239</xref></td></tr><tr><td colspan="1" rowspan="1">DeepDrug2</td><td colspan="1" rowspan="1">Learns embeddings from a signed, directed biomedical graph integrating germline-driven AD genes, pathways, drugs, and interactions; uses link prediction and cosine drug&#8211;gene scoring</td><td colspan="1" rowspan="1">Prioritizes repurposed AD drug candidates based on proximity to AD-risk genes in embedding space; validated with UK Biobank EHRs</td><td colspan="1" rowspan="1">Advantages: Integrates germline mutations and real-world EHR validation; robust link prediction. Disadvantages: Limited by drug usage data coverage in EHR</td><td colspan="1" rowspan="1">Not externally validated beyond UKB; GNN output not individualized</td><td colspan="1" rowspan="1">AUC: 0.98; AP: 0.98</td><td colspan="1" rowspan="1"><xref rid="bib240" ref-type="bibr">240</xref></td></tr><tr><td colspan="1" rowspan="1">GCNs</td><td colspan="1" rowspan="1">Perform graph-level classification on subject-specific bipartite graphs constructed from image&#8211;text similarity using VLM</td><td colspan="1" rowspan="1">Recognize <italic toggle="yes">via</italic> multimodal integration of MRI slices and textual embeddings</td><td colspan="1" rowspan="1">Advantages: Utilizes VLM (BLIP) for cross-modal feature fusion; models global patient&#8211;feature relationships.<break/>Disadvantages: Sensitive to image&#8211;text alignment quality; depends on pretrained VLM robustness</td><td colspan="1" rowspan="1">Constructing meaningful bipartite graphs; ensuring stable similarity-based graph representation</td><td colspan="1" rowspan="1">Accuracy: 0.870; Sensitivity: 0.860; Specificity: 0.880; AUC: 0.945 (ADNI test set)</td><td colspan="1" rowspan="1"><xref rid="bib241" ref-type="bibr">241</xref></td></tr><tr><td colspan="1" rowspan="1">MC-RVAE</td><td colspan="1" rowspan="1">Integrates VRNNs with shared latent space across imaging and cognitive channels for multimodal sequence modeling</td><td colspan="1" rowspan="1">Reconstructs missing modalities and disease progression modeling using longitudinal MRI and cognitive assessments</td><td colspan="1" rowspan="1">Advantages: Captures intra- and inter-modality dynamics; handles missing channels over time; provides interpretable latent representations.<break/>Disadvantages: Assumes fixed temporal spacing; performance sensitive to modality dropout</td><td colspan="1" rowspan="1">Learning robust latent trajectories; balancing modality-specific reconstruction with shared space regularization</td><td colspan="1" rowspan="1">MAE: 0.75 (vol&#8594;cog); 0.68 (cort&#8594;vol); 0.68/0.68/0.59 (vol/cort/cog full); outperforms GFA and KNN.</td><td colspan="1" rowspan="1"><xref rid="bib242" ref-type="bibr">242</xref></td></tr><tr><td colspan="1" rowspan="1">JDSNMF</td><td colspan="1" rowspan="1">Extracts shared latent features by factoring multi-omics data; improves AD prediction accuracy</td><td colspan="1" rowspan="1">Extracts latent disease-relevant features from multi-omics datasets for AD prediction</td><td colspan="1" rowspan="1">Advantages: Captures AD-related modules with biological interpretability.<break/>Disadvantages: Sensitive to omics heterogeneity and non-informative signals; requires tuning across multiple layers and regularization terms</td><td colspan="1" rowspan="1">High computational cost with deep architecture; limited scalability for cohorts with unbalanced or sparse omics profiles</td><td colspan="1" rowspan="1">AUC (GE+DM): 0.801 (AD/NL), 0.771 (MCI/NL); AUC (MRI+PET): 0.843 (MCI/AD), 0.973 (NL/AD); outperforms NMF and deep semi-NMF.</td><td colspan="1" rowspan="1"><xref rid="bib243" ref-type="bibr">243</xref></td></tr><tr><td colspan="1" rowspan="1">WGCNA</td><td colspan="1" rowspan="1">Analyzes proteomic data to identify protein modules linked to tau pathology</td><td colspan="1" rowspan="1">Identifies tau-related modules in neuroinflammation, mitochondria, cholesterol biosynthesis, and synapse function</td><td colspan="1" rowspan="1">Advantages: Identifies tau-associated protein modules linked to neuroinflammation, mitochondrial dysfunction, cholesterol biosynthesis, and synaptic loss; enables system-level mapping of tau pathology.<break/>Disadvantages: Sensitive to experimental noise and batch effects; limited resolution in distinguishing endogenous from transgenic tau signals</td><td colspan="1" rowspan="1">Integration of mouse and human proteomes; module preservation and interpretation across models and tissues</td><td colspan="1" rowspan="1">Pearson correlation; Module preservation (Z-summary)</td><td colspan="1" rowspan="1"><xref rid="bib244" ref-type="bibr">244</xref>,<xref rid="bib245" ref-type="bibr">245</xref></td></tr><tr><td colspan="1" rowspan="1">NBP</td><td colspan="1" rowspan="1">Uses graph theory to represent molecular interactions and analyze their relationships</td><td colspan="1" rowspan="1">Model molecular interactions in AD and identify key disease drivers</td><td colspan="1" rowspan="1">Advantages: Integrates pharmacological and omics data; enables target prioritization and drug repurposing.<break/>Disadvantages: Relies on interaction data quality; limited interpretability in dense or dynamic networks</td><td colspan="1" rowspan="1">Integrating heterogeneous datasets; distinguishing causality from correlation</td><td colspan="1" rowspan="1">Clustering coefficient: 0.749; Density: 0.648; Avg. path length: 1.385; Drug&#8211;target graph: 1836 nodes, 2725 edges, avg. degree: 2.97</td><td colspan="1" rowspan="1"><xref rid="bib246" ref-type="bibr">246</xref></td></tr><tr><td colspan="1" rowspan="1">PPI networks</td><td colspan="1" rowspan="1">Model interactions between proteins and help identify molecular mechanisms and disease drivers</td><td colspan="1" rowspan="1">Study post-translational modifications and interactions in AD pathology</td><td colspan="1" rowspan="1">Advantages: Enable high-resolution detection of dynamic protein complexes; integrates diverse quantification strategies including label-free, SILAC, and TMT.<break/>Disadvantages: Sensitive to data quality and peak modeling accuracy; computationally intensive for large datasets</td><td colspan="1" rowspan="1">Disambiguating overlapping complexes; Limited curated databases</td><td colspan="1" rowspan="1">AUC: &gt;0.81 (classifier); F1-score: reported; Pearson <italic toggle="yes">r</italic>: &gt;0.9; Peak fitting <italic toggle="yes">R</italic><sup>2</sup>: &gt;0.85</td><td colspan="1" rowspan="1"><xref rid="bib247" ref-type="bibr">247</xref></td></tr><tr><td colspan="1" rowspan="1">Pathway enrichment models</td><td colspan="1" rowspan="1">Identify overrepresented or topologically relevant pathways from omics-derived gene/protein lists</td><td colspan="1" rowspan="1">Interpret transcriptomic, proteomic, metabolomic, and epigenomic data to reveal biological functions in AD</td><td colspan="1" rowspan="1">Advantages: Broadly applicable across omics types; facilitates biological interpretation.<break/>Disadvantages: Sensitive to background selection and annotation version; inconsistent across tools</td><td colspan="1" rowspan="1">Integrating diverse omics distributions; standardizing inputs and annotations</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib248" ref-type="bibr">248</xref></td></tr><tr><td colspan="1" rowspan="1">Bayesian networks</td><td colspan="1" rowspan="1">Allow probabilistic inference and handle missing data; identify causal relationships</td><td colspan="1" rowspan="1">Help in causal inference and understanding complex relationships between biomarkers in AD</td><td colspan="1" rowspan="1">Infer causal relationships and handle missing data in AD modeling</td><td colspan="1" rowspan="1">Computationally intensive for large datasets; needs domain knowledge for reliable results</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib249" ref-type="bibr">249</xref></td></tr><tr><td colspan="1" rowspan="1">TabPFN</td><td colspan="1" rowspan="1">Uses millions of synthetic datasets for pre-training; supports classification and regression <italic toggle="yes">via</italic> in-context learning</td><td colspan="1" rowspan="1">Predicts tabular outcomes across biomedical, chemical, and AD-related datasets</td><td colspan="1" rowspan="1">Advantages: Learns from diverse tasks; high performance with minimal tuning.<break/>Disadvantages: High memory usage; limited scalability to very large datasets</td><td colspan="1" rowspan="1">Scaling beyond 10k samples or 500 features; interpretability and hardware efficiency</td><td colspan="1" rowspan="1">Classification AUC: 0.95 (tuned), 0.94 (default); Accuracy (normalized): &#8764;0.91<break/>Regression RMSE: &#8722;0.97; R<sup>2</sup>: &gt;0.92; Other: robust to noise/missing/outliers</td><td colspan="1" rowspan="1"><xref rid="bib250" ref-type="bibr">250</xref></td></tr><tr><td colspan="1" rowspan="1">Integrative network modeling approach</td><td colspan="1" rowspan="1">Integrates coexpression, causal, and regulatory networks across multi-omics and brain regions</td><td colspan="1" rowspan="1">Identifies LOAD-related neuronal subnetworks and key drivers; discovery of drug candidates like NCH-51</td><td colspan="1" rowspan="1">Advantages: Captures multiscale regulatory circuits; enables in silico to <italic toggle="yes">in vivo</italic> validation. Disadvantages: Methodologically complex; requires large-scale, high-quality multi-omics datasets</td><td colspan="1" rowspan="1">Integrating heterogeneous omics and trait data; validating key drivers across systems and models</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib251" ref-type="bibr">251</xref></td></tr><tr><td colspan="1" rowspan="1">Computational network analysis</td><td colspan="1" rowspan="1">Integrate expression data with signaling networks using PCST to infer sustained signaling paths</td><td colspan="1" rowspan="1">Identify site-specific inflammatory mediators in AD brain regions</td><td colspan="1" rowspan="1">Advantages: Reveals non-obvious upstream&#8211;downstream signaling links.<break/>Disadvantages: Relies on expression data; ignores post-translational regulation</td><td colspan="1" rowspan="1">Inferring causality from partial transcriptomic data; modeling sustained signaling with incomplete inputs</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib34" ref-type="bibr">34</xref></td></tr><tr><td colspan="1" rowspan="1">WIMOAD</td><td colspan="1" rowspan="1">Uses five base classifiers and an MLP-based meta-model; integrates gene expression and DNA methylation profiles <italic toggle="yes">via</italic> weighted score fusion</td><td colspan="1" rowspan="1">NC <italic toggle="yes">vs</italic> AD, NC <italic toggle="yes">vs</italic> EMCI, EMCI <italic toggle="yes">vs</italic> LMCI, etc., using ADNI data; compared against IntegrationLearner and MOGLAM</td><td colspan="1" rowspan="1">Advantages: Outperforms single-omics and prior models; interpretable <italic toggle="yes">via</italic> SHAP; robust multi-omics fusion. Disadvantages: The Current model is limited to two omics types; relies on peripheral blood data</td><td colspan="1" rowspan="1">Limited access to proteomic or imaging data; incomplete mapping between blood biomarkers and brain pathology</td><td colspan="1" rowspan="1">Accuracy: 0.88; Sensitivity: 0.89; Specificity: 0.87; F1 Score: 0.88; MCC: 0.82; ROC-AUC: 0.90</td><td colspan="1" rowspan="1"><xref rid="bib227" ref-type="bibr">227</xref></td></tr><tr><td colspan="1" rowspan="1">Ensemble model (RF + bagFDA + glmnet)</td><td colspan="1" rowspan="1">Integrates RNA-Seq, microarray, proteomics, and miRNA data from 4089 AD/control samples; age-stratified analysis</td><td colspan="1" rowspan="1">Identifies age-specific AD hallmarks; classifies AD <italic toggle="yes">vs</italic>. controls using genes, proteins, miRNAs, and pathway-level features</td><td colspan="1" rowspan="1">Advantages: Robust across omics types and age groups; generalizable to external datasets. Disadvantages: High dimensionality; not yet validated for early clinical deployment</td><td colspan="1" rowspan="1">Integration bias across modalities; lack of clinical metadata; limited proteomics and miRNA availability</td><td colspan="1" rowspan="1">Accuracy: 0.97; Sensitivity: 0.98; Specificity: 0.96; F1 Score: 0.97; MCC: 0.94; ROC-AUC: 0.99</td><td colspan="1" rowspan="1"><xref rid="bib225" ref-type="bibr">225</xref></td></tr><tr><td colspan="1" rowspan="1">GNNRAI</td><td colspan="1" rowspan="1">Integrates transcriptomics and proteomics using prior knowledge graphs; applies GNNs and set transformer for feature extraction and modality alignment</td><td colspan="1" rowspan="1">Predicts AD status from brain tissue samples across 16 AD biodomains; identifies known and novel biomarkers using explainable attribution methods</td><td colspan="1" rowspan="1">Advantages: Incorporates biological priors; handles missing modalities; provides biomarker-level interpretation. Disadvantages: Computationally intensive; lacks direct clinical metrics</td><td colspan="1" rowspan="1">No inclusion of methylomics/metabolomics; absence of feature-wise interpretability beyond graphs; not validated in clinical settings</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib228" ref-type="bibr">228</xref></td></tr><tr><td colspan="1" rowspan="1">IMBALMED</td><td colspan="1" rowspan="1">Combines 25 classifiers across 8 learning families; applies two-level fusion; integrates clinical assessments, biospecimen, neuroimaging, and demographics</td><td colspan="1" rowspan="1">NC <italic toggle="yes">vs</italic> AD, NC <italic toggle="yes">vs</italic> AD <italic toggle="yes">vs</italic> MCI; early detection at 12, 24, 36, and 48 months; externally validated on ADNI4</td><td colspan="1" rowspan="1">Advantages: Robust across timepoints and classifiers; outperforms 9 state-of-the-art imbalance methods; generalizable. Disadvantages: High computational cost; requires modality completeness for full prediction</td><td colspan="1" rowspan="1">Complexity in training and modality fusion; missing data across modalities; limited external datasets with matched structure</td><td colspan="1" rowspan="1">G-mean: 0.974 for binary task; External validation Accuracy: 0.9688</td><td colspan="1" rowspan="1"><xref rid="bib252" ref-type="bibr">252</xref></td></tr><tr><td colspan="1" rowspan="1">WGAN-WP + distance penalty</td><td colspan="1" rowspan="1">Pre-train on external omics data and retrain <italic toggle="yes">via</italic> transfer learning; use progressive growing and L2-distance regularization; apply to class-imbalanced microarray and lipidomics datasets</td><td colspan="1" rowspan="1">Synthetic augmentation of minority class samples to balance datasets; improves HistGradientBoostingClassifier performance on HCC and CBGS data</td><td colspan="1" rowspan="1">Advantages: Handles high-dimensional omics with few samples; outperforms SMOTE/RO in complex datasets. Disadvantages: Computationally intensive; sensitive to <italic toggle="yes">&#945;</italic> tuning</td><td colspan="1" rowspan="1">Mode collapse risk; no early stopping from AUC in real-world deployment; limited generalization across omics types</td><td colspan="1" rowspan="1">AUC (microarray): 0.76; AUC (lipidomics): &gt;0.89</td><td colspan="1" rowspan="1"><xref rid="bib253" ref-type="bibr">253</xref></td></tr><tr><td colspan="1" rowspan="1">TAMPOR</td><td colspan="1" rowspan="1">Performs batch harmonization using ratio transformation and median polish; provides tunable modes; ensures robustness to platform, cohort, and batch heterogeneity</td><td colspan="1" rowspan="1">Corrects and integrates TMT-MS, LFQ-MS, Olink, and SOMAscan data across AD cohorts; CSF and plasma alignment</td><td colspan="1" rowspan="1">Advantages: Platform-agnostic; outlier-tolerant; enables multi-cohort, multi-platform omics harmonization. Disadvantages: Not a predictive model; no classification output</td><td colspan="1" rowspan="1">Not suitable for direct classification tasks; requires missingness &lt;50%; complex parameter tuning for GIS-defective datasets</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib254" ref-type="bibr">254</xref></td></tr><tr><td colspan="1" rowspan="1">SVM + Relief-F + bivariate ranking</td><td colspan="1" rowspan="1">Classify samples using gene pairs across 3 hippocampal transcriptomic datasets; select non-DE genes robustly <italic toggle="yes">via</italic> cross-study aggregation; optimize using CV &gt; 0.70 filtering</td><td colspan="1" rowspan="1">Identify gene pairs showing robust predictive power across datasets; discovery of synergistic gene associations missed by univariate DE analysis</td><td colspan="1" rowspan="1">Advantages: Interpretable gene-level biomarkers; generalizable multivariate ranking; robust across datasets. Disadvantages: No clinical classifier built; lacks pathway-level aggregation</td><td colspan="1" rowspan="1">Poor generalizability of some gene pairs; no AUC/Sensitivity reported; not suitable for individual prediction</td><td colspan="1" rowspan="1">CV Accuracy: 0.90 (VR); generalizability scores: VR&#8211;MAYO&#8211;GSE CV decline observed</td><td colspan="1" rowspan="1"><xref rid="bib41" ref-type="bibr">41</xref></td></tr><tr><td colspan="1" rowspan="1">MINDSETS</td><td colspan="1" rowspan="1">Integrates radiomics MRI features, genetic, clinical, and cognitive data using CNN-based DFG module; segmentation <italic toggle="yes">via</italic> SynthSeg; feature fusion and selection <italic toggle="yes">via</italic> FeatureWiz; interpretability <italic toggle="yes">via</italic> SHAP</td><td colspan="1" rowspan="1">AD <italic toggle="yes">vs</italic> VaD, AD <italic toggle="yes">vs</italic> MCI, multiclass dementia subtyping using ANMerge; temporal MRI monitoring for treatment response</td><td colspan="1" rowspan="1">Advantages: Outperforms baseline 3D CNN; enables explainable early diagnosis and treatment effect tracking. Disadvantages: Computationally intensive; generalizability yet to be tested across populations</td><td colspan="1" rowspan="1">Fusion of heterogeneous modalities; longitudinal MRI variability; limited external validation</td><td colspan="1" rowspan="1">Accuracy: 0.89; AUC: 0.84; F1-score: 0.81; Precision: 0.79; Sensitivity: 0.84</td><td colspan="1" rowspan="1"><xref rid="bib255" ref-type="bibr">255</xref></td></tr><tr><td colspan="1" rowspan="1">2D/3D CNN (InceptionV3)</td><td colspan="1" rowspan="1">Uses MK-6240 and AV-1451 tau PET with image augmentation and 5-fold CV; occlusion sensitivity and t-SNE for interpretability</td><td colspan="1" rowspan="1">Predicts cognitive impairment (NC <italic toggle="yes">vs</italic>. MCI/AD) using dual-radioligand tau PET; compares against SUVR metrics</td><td colspan="1" rowspan="1">Advantages: Outperforms ROI-based SUVR in AUC; interpretable <italic toggle="yes">via</italic> occlusion maps; generalizable to new radioligands. Disadvantages: No external validation; moderate gains in specificity</td><td colspan="1" rowspan="1">Lack of standardization for tau PET classification; computationally intensive 3D training; cross-ligand harmonization needed</td><td colspan="1" rowspan="1">Accuracy: &gt;0.80; Sensitivity: 0.82; Specificity: 0.75; AUC: 0.89 (combined 2D CNN)</td><td colspan="1" rowspan="1"><xref rid="bib256" ref-type="bibr">256</xref></td></tr><tr><td colspan="1" rowspan="1">Hybrid</td><td colspan="1" rowspan="1">Combines CNN with RNN/attention mechanisms; integrates imaging, genomics, cognition; applies at multiple fusion levels</td><td colspan="1" rowspan="1">AD <italic toggle="yes">vs</italic> MCI <italic toggle="yes">vs</italic> NC classification; cross-modal early diagnosis; progression trajectory modeling</td><td colspan="1" rowspan="1">Advantages: Fuses spatial + temporal signals; high accuracy across tasks.<break/>Disadvantages: Complex architecture; requires large labeled multimodal datasets</td><td colspan="1" rowspan="1">Multimodal alignment; overfitting risk; computational load</td><td colspan="1" rowspan="1">Accuracy: 0.99; Sensitivity: 1; Specificity: 0.988; AUC: 0.99</td><td colspan="1" rowspan="1"><xref rid="bib257" ref-type="bibr">257</xref></td></tr><tr><td colspan="1" rowspan="1">Transformer</td><td colspan="1" rowspan="1">Applies to multimodal neuroimaging time series; models long-range dependencies and modality-level interactions</td><td colspan="1" rowspan="1">Risk stratification and cognitive decline prediction using MRI, PET, and CSF data</td><td colspan="1" rowspan="1">Advantages: High scalability; effective on long sequences; enables inter-modality attention. Disadvantages: Requires extensive data; computationally intensive</td><td colspan="1" rowspan="1">High training cost; interpretability limited <italic toggle="yes">vs</italic> simpler models</td><td colspan="1" rowspan="1">Accuracy: 0.968; Sensitivity: 0.960; Specificity: 0.965; AUC: 0.97</td><td colspan="1" rowspan="1"><xref rid="bib257" ref-type="bibr">257</xref></td></tr><tr><td colspan="1" rowspan="1">CNN</td><td colspan="1" rowspan="1">Applies to structural and functional MRI/PET; image-level and feature-level fusion; detects spatial AD biomarkers</td><td colspan="1" rowspan="1">AD <italic toggle="yes">vs</italic> MCI <italic toggle="yes">vs</italic> NC classification; structural MRI-based early AD detection</td><td colspan="1" rowspan="1">Advantages: Captures spatial features; widely validated; efficient with radiomics input. Disadvantages: Limited temporal modeling; requires large image datasets</td><td colspan="1" rowspan="1">Generalization across scanners and protocols; lack of multimodal integration</td><td colspan="1" rowspan="1">Accuracy: up to 0.99; Sensitivity: up to 0.98; Specificity: up to 0.98; AUC: up to 0.99</td><td colspan="1" rowspan="1"><xref rid="bib257" ref-type="bibr">257</xref></td></tr><tr><td colspan="1" rowspan="1">DeepPrep</td><td colspan="1" rowspan="1">Integrates DL-based neuroimaging pipeline with FastSurferCNN, FastCSR, SUGAR, SynthMorph; 83 steps managed <italic toggle="yes">via</italic> Nextflow; deployable on HPC/cloud/local</td><td colspan="1" rowspan="1">Preprocessing of &gt;55,000 sMRI/fMRI scans (UKB, MSC, CoRR-HNU, clinical datasets); segmentation, registration, normalization</td><td colspan="1" rowspan="1">Advantages: 10&#215; faster than fMRIPrep; full completion on clinical data; scalable and modular. Disadvantages: Not a predictive or diagnostic model; lacks omics integration</td><td colspan="1" rowspan="1">No disease classification; GPU/memory requirements; cannot support omics fusion tasks</td><td colspan="1" rowspan="1">Speed-up: 10.1&#215;; Completion ratio: 100%; Dice: &gt;0.85 (in 52/62 regions)</td><td colspan="1" rowspan="1"><xref rid="bib258" ref-type="bibr">258</xref></td></tr><tr><td colspan="1" rowspan="1">p-tau217 + NfL model</td><td colspan="1" rowspan="1">Use plasma biomarkers to predict tau PET positivity and AD status; interpretable logistic regression or ensemble models</td><td colspan="1" rowspan="1">Plasma-based AD diagnosis; screen for PET positivity</td><td colspan="1" rowspan="1">Advantages: Non-invasive; cost-efficient; near-imaging level accuracy. Disadvantages: Performance varies by platform/cohort</td><td colspan="1" rowspan="1">Assay variability; requires standardization across sites</td><td colspan="1" rowspan="1">AUC: 0.89</td><td colspan="1" rowspan="1"><xref rid="bib259" ref-type="bibr">259</xref></td></tr><tr><td colspan="1" rowspan="1">NeuroPM-box</td><td colspan="1" rowspan="1">Uses diffusion models and multiscale latent space modeling for simulating molecular propagation and brain trajectory</td><td colspan="1" rowspan="1">Disease progression simulation; AD subtype trajectory estimation; therapeutic response modeling</td><td colspan="1" rowspan="1">Advantages: Mechanistic interpretability; usable in precision medicine design. Disadvantages: Requires longitudinal multi-modal data; complex parameter tuning</td><td colspan="1" rowspan="1">Limited to cohorts with dense data; real-world deployment uncertain</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib259" ref-type="bibr">259</xref></td></tr><tr><td colspan="1" rowspan="1">MORE</td><td colspan="1" rowspan="1">Integrates mRNA, DNA methylation, and miRNA using fused hyperedge group; MOHE module extracts omics-specific features; MOSA module applies multi-head self-attention for modality integration</td><td colspan="1" rowspan="1">Classifies AD (ROS/MAP), BRCA, and GBM subtypes; biomarker identification across omics</td><td colspan="1" rowspan="1">Advantages: Encodes higher-order correlations <italic toggle="yes">via</italic> hyperedges; outperforms MOGONET, MOGLAM, MOADLN across tasks; robust ablation results. Disadvantages: Currently limited to omics; not extended to imaging or clinical data</td><td colspan="1" rowspan="1">Sample size imbalance across modalities; lacks modality generalization beyond omics</td><td colspan="1" rowspan="1">Accuracy: 0.829 (ROS/MAP); 0.835 (BRCA); 0.762 (GBM); F1: 0.836 (ROS/MAP); 0.820 (BRCA); 0.755 (GBM); AUC: 0.903 (ROS/MAP)</td><td colspan="1" rowspan="1"><xref rid="bib260" ref-type="bibr">260</xref></td></tr><tr><td colspan="1" rowspan="1">MAGMA + scDRS (in sc2GWAS)</td><td colspan="1" rowspan="1">Integrate GWAS summary statistics with large-scale scRNA-seq data; calculates cell-wise trait enrichment scores; supports ontology alignment and cross-species mapping</td><td colspan="1" rowspan="1">Identify AD-associated cell types (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., microglia) and driver genes (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., <italic toggle="yes">APOE</italic>, <italic toggle="yes">TIMP1</italic>, <italic toggle="yes">BTG1</italic>) using single-cell profiles; scalable to 784 GWAS traits</td><td colspan="1" rowspan="1">Advantages: Cell-type resolution; flexible trait input; interpretable gene prioritization. Disadvantages: Not a classifier; lacks multi-omics training</td><td colspan="1" rowspan="1">Dependent on GWAS quality and scRNA resolution; no integration of proteomics or epigenetics</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib261" ref-type="bibr">261</xref></td></tr><tr><td colspan="1" rowspan="1">MOSEGCN</td><td colspan="1" rowspan="1">Combines multi-head self-attention and SNF to learn intra-/inter-omics latent features; uses semi-supervised SEGCN to leverage labeled and unlabeled data</td><td colspan="1" rowspan="1">Disease subtype classification on AD (ROS/MAP), BRCA, GBM; biomarker identification</td><td colspan="1" rowspan="1">Advantages: Integrates latent omics interactions; outperforms MOGONET and SEGCN; interpretable biomarkers. Disadvantages: Limited to 3 omics types; not tested on clinical/imaging data</td><td colspan="1" rowspan="1">Lacks cross-modal validation; sensitive to attention-head number; limited scalability</td><td colspan="1" rowspan="1">Accuracy: 0.83 (ROS/MAP), 0.87 (BRCA), 0.89 (GBM); AUC: 0.832 (ROS/MAP); F1: 0.827 (ROS/MAP), 0.868 (BRCA), 0.890 (GBM)</td><td colspan="1" rowspan="1"><xref rid="bib262" ref-type="bibr">262</xref></td></tr><tr><td colspan="1" rowspan="1">Federated LSTM with FedAvg</td><td colspan="1" rowspan="1">Trains LSTM models on site-partitioned EHRs without sharing raw data; uses FedAvg and personalized fine-tuning; incorporates SHAP and PFI for interpretation</td><td colspan="1" rowspan="1">Predicts MCI-to-AD progression across six sites in OneFlorida+ EHR consortium; compares personalized, pooled, global, and local models</td><td colspan="1" rowspan="1">Advantages: Preserves privacy; handles site heterogeneity; interpretable <italic toggle="yes">via</italic> SHAP. Disadvantages: Lacks multimodal input (no imaging/omics); only uses structured EHRs</td><td colspan="1" rowspan="1">Limited to structured EHR data; excludes unstructured notes or imaging; no comparison to deep multimodal fusion models</td><td colspan="1" rowspan="1">AUC: Personalized: 0.794 (North FL); 0.744 (South FL); Global: 0.837 (South FL); Local: 0.729&#8211;0.820 (by site)</td><td colspan="1" rowspan="1"><xref rid="bib263" ref-type="bibr">263</xref></td></tr><tr><td colspan="1" rowspan="1">Tri-COAT</td><td colspan="1" rowspan="1">Learns joint representation of imaging, genotype, and clinical data <italic toggle="yes">via</italic> modality-specific transformers and tri-modal co-attention; supports early subtyping using baseline-only data</td><td colspan="1" rowspan="1">Subtypes of AD patients into slow, intermediate, and fast cognitive decline using baseline ADNI data</td><td colspan="1" rowspan="1">Advantages: Baseline-only input; interpretable co-attention maps; identifies cross-modal biomarkers. Disadvantages: Limited to MMSE-based subtypes; lacks multi-cohort validation</td><td colspan="1" rowspan="1">Model trained on ADNI only; performance sensitive to class imbalance (fast subtype: <italic toggle="yes">n</italic> = 15); lacks PET or transcriptomic input</td><td colspan="1" rowspan="1">AUROC: 0.734 &#177; 0.076 (3-class, macro average); Imaging: 0.648; Genetics: 0.539; Clinical: 0.697</td><td colspan="1" rowspan="1"><xref rid="bib264" ref-type="bibr">264</xref></td></tr><tr><td colspan="1" rowspan="1">scGraph2Vec</td><td colspan="1" rowspan="1">Enhances variational graph autoencoder by integrating gene&#8211;gene networks and single-cell expression data; models community structure with modularity-aware loss</td><td colspan="1" rowspan="1">Identifies functional gene clusters across brain, heart, liver, lung, kidney, PBMCs; infers disease-related genes using AD and COVID-19 GWAS seed genes</td><td colspan="1" rowspan="1">Advantages: Captures both topological and expression-based gene features; interpretable latent space; broad tissue applicability. Disadvantages: Requires high-quality network data; gene-centric, not patient-centric</td><td colspan="1" rowspan="1">Lacks validation on external clinical cohorts; not designed for patient-level diagnosis or prediction</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib265" ref-type="bibr">265</xref></td></tr><tr><td colspan="1" rowspan="1">MADDi</td><td colspan="1" rowspan="1">Uses modality-specific DNN backbones and combines <italic toggle="yes">via</italic> self-attention and cross-modal attention; integrates MRI, SNPs, and structured clinical data</td><td colspan="1" rowspan="1">3-class classification (NC <italic toggle="yes">vs</italic> MCI <italic toggle="yes">vs</italic> AD) using ADNI dataset; evaluates attention mechanisms, modality contribution, and model robustness</td><td colspan="1" rowspan="1">Advantages: High accuracy; interpretable <italic toggle="yes">via</italic> attention; strong multimodal performance. Disadvantages: Requires matched multimodal data; no time-series or PET input</td><td colspan="1" rowspan="1">Small overlap set (<italic toggle="yes">n</italic> = 239); diagnosis labels vary across modalities; imbalance in fast-decline class</td><td colspan="1" rowspan="1">Accuracy: 0.97; F1-score (overall): 0.91;<break/>F1-score (AD): 1.00; F1-score (MCI): 0.77; F1-score (NC): 0.98</td><td colspan="1" rowspan="1"><xref rid="bib266" ref-type="bibr">266</xref></td></tr><tr><td colspan="1" rowspan="1">Federated GEIDI</td><td colspan="1" rowspan="1">Integrates sMRI, GWAS SNPs, and gene expression in a federated framework; uses stratified Chow test to detect genotype-dependent expression&#8211;imaging relationships</td><td colspan="1" rowspan="1">Identifies AD-related gene expression and SNPs stratified by <italic toggle="yes">APOE</italic> and rs942439 in ADNI; evaluates associations with hippocampal and mid-temporal volumes</td><td colspan="1" rowspan="1">Advantages: Preserves data privacy; reveals SNP-dependent transcriptomic correlates; outperforms Matrix eQTL. Disadvantages: No patient-level classification; slow computation</td><td colspan="1" rowspan="1">Requires pre-stratification by genotype; lacks multi-class prediction; limited to two imaging ROIs</td><td colspan="1" rowspan="1">TPR: 0.61 (<italic toggle="yes">vs</italic>. 0.55 by Matrix eQTL); <italic toggle="yes">P</italic>-values for hypergeometric enrichment: 0.00039 (hippocampus), 0.00624 (mid-temp)</td><td colspan="1" rowspan="1"><xref rid="bib267" ref-type="bibr">267</xref></td></tr><tr><td colspan="1" rowspan="1">BIONIC</td><td colspan="1" rowspan="1">Integrates proteomics and PPI data using GAT; outputs 512-dimensional features per protein; followed by Louvain clustering and MINDy-based moderator inference</td><td colspan="1" rowspan="1">Identifies <italic toggle="yes">APP&#8211;MAPT&#8211;HSPA5</italic> subnetwork; reveals moderators (<italic toggle="yes">GPNMB</italic>+ microglia, <italic toggle="yes">GFAP</italic>+ astrocytes) of A<italic toggle="yes">&#946;</italic>&#8211;tau interaction in early-stage AD</td><td colspan="1" rowspan="1">Advantages: Captures latent topological relationships; identifies glia-enriched subnetworks; interpretable <italic toggle="yes">via</italic> modular enrichment. Disadvantages: No individual-level prediction; model trained at the protein-level</td><td colspan="1" rowspan="1">No external benchmarking; not validated on other modalities; lacks temporal prediction</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib53" ref-type="bibr">53</xref></td></tr><tr><td colspan="1" rowspan="1">Hybrid multimodal DNN + SVR</td><td colspan="1" rowspan="1">DenseNet3D + self-attention + AE modules extract image features (hippocampus &amp; ATL); non-image inputs (MMSE, ADAS-Cog, APOE, A<italic toggle="yes">&#946;</italic>42, p-tau) combined for SVR prediction of CDR-SB change</td><td colspan="1" rowspan="1">Predict cognitive decline (CDR-SB) over 2 years in NA-ADNI; used for stratified randomization in clinical trial simulation</td><td colspan="1" rowspan="1">Advantages: Robust to limited sample size; reduces randomization bias; supports personalized trial design. Disadvantages: Limited to MCI/AD; higher error in extreme cases</td><td colspan="1" rowspan="1">Noise in CDR-SB targets; limited to NA-ADNI; no external trial validation</td><td colspan="1" rowspan="1">MAE: 1.07; Correlation: 0.58 (overall); Inner samples: MAE: 0.89; Corr: 0.62</td><td colspan="1" rowspan="1"><xref rid="bib268" ref-type="bibr">268</xref></td></tr><tr><td colspan="1" rowspan="1">NeuroPM-cTI</td><td colspan="1" rowspan="1">Uses contrastive PCA + stratification to infer pseudotemporal progression and disease subtypes; integrates omics, imaging, and histopathology</td><td colspan="1" rowspan="1">Applies to ADNI, ROS/MAP, HBTRC; stratifies subjects into molecular sub-trajectories and progression scores; validates across AD, HD, and controls</td><td colspan="1" rowspan="1">Advantages: Interpretable scores, flexible multimodal inputs; robust to noise. Disadvantages: No direct predictive output</td><td colspan="1" rowspan="1">Requires tuning and quality-controlled inputs; pseudo-longitudinal inference only</td><td colspan="1" rowspan="1">FWE-corrected ANOVA <italic toggle="yes">F</italic> = 11.17 (Braak); <italic toggle="yes">F</italic> = 9.04 (Vonsattel)</td><td colspan="1" rowspan="1"><xref rid="bib269" ref-type="bibr">269</xref></td></tr><tr><td colspan="1" rowspan="1">LASSO-based 10-protein AD prediction model</td><td colspan="1" rowspan="1">Selects 10 CSF proteins <italic toggle="yes">via</italic> 50-iteration LASSO regression with 70/30 split; trained on SomaScan 7K proteomics; validates across 3 cohorts</td><td colspan="1" rowspan="1">Classifies A+T+ <italic toggle="yes">vs</italic> A&#8211;T&#8211;; predicts clinical AD diagnosis and amyloid PET status; applies to blood plasma with retraining</td><td colspan="1" rowspan="1">Advantages: High AUC across multiple cohorts; consistent across platforms; longitudinal prediction. Disadvantages: Requires CSF; protein weights are not transferable to plasma</td><td colspan="1" rowspan="1">Platform-specific training required; limited power in non-AD dementia</td><td colspan="1" rowspan="1">AUC: &gt;0.98 (biomarker); 0.89&#8211;0.97 (clinical); 0.90 (PET); Sensitivity, Specificity, PPV, NPV &gt;0.88</td><td colspan="1" rowspan="1"><xref rid="bib270" ref-type="bibr">270</xref></td></tr><tr><td colspan="1" rowspan="1">RF with SHAP-based explanation</td><td colspan="1" rowspan="1">Multimodal input (clinical, psychological, MRI segmentation); data-level fusion; SMOTE balancing; 10-fold stratified CV; SHAP for interpretation</td><td colspan="1" rowspan="1">Predicts 5-class AD status (NC, AD, Non-AD, Uncertain, Others) using OASIS-3 data; identifies key features (Memory, Sumbox, Judgment, IntraCranialVol)</td><td colspan="1" rowspan="1">Advantages: High accuracy, explainable, interpretable SHAP outputs. Disadvantages: Limited generalizability beyond OASIS; lacks external validation</td><td colspan="1" rowspan="1">Dataset imbalance (solved <italic toggle="yes">via</italic> SMOTE); not compared with DL models</td><td colspan="1" rowspan="1">Accuracy: 0.99; Precision: 0.99; Sensitivity: 0.99; F1-score: 0.99; AUC: 1.00</td><td colspan="1" rowspan="1"><xref rid="bib271" ref-type="bibr">271</xref></td></tr><tr><td colspan="1" rowspan="1">Transformer-based multimodal diagnostic model</td><td colspan="1" rowspan="1">Integrates demographics, medical history, neuropsychological tests, and multisequence MRI with modality-specific embeddings and attention-based transformer</td><td colspan="1" rowspan="1">Differential diagnosis of 13 dementia etiologies (AD, VaD, LBD, FTD, etc.) across 9 cohorts; predicts NC, MCI, dementia status and disease probabilities</td><td colspan="1" rowspan="1">Advantages: Handles missing data; aligns with biomarker and autopsy; supports AI-augmented diagnosis. Disadvantages: Some classes are underrepresented; limited staging</td><td colspan="1" rowspan="1">Performance is lower for rare etiologies; dataset imbalance</td><td colspan="1" rowspan="1">AUROC: 0.96 (micro), 0.94 (weighted); AUPR: 0.70 (micro); AI-augmented AUROC: 0.2625, AUPR: 0.7323</td><td colspan="1" rowspan="1"><xref rid="bib272" ref-type="bibr">272</xref></td></tr><tr><td colspan="1" rowspan="1">VBpMKL + MCI subtyping</td><td colspan="1" rowspan="1">Integrates sMRI, SNPs, and mRNA expression; subtypes <italic toggle="yes">via</italic> SNF; feature selection by Lasso</td><td colspan="1" rowspan="1">Predicts MCI-to-AD conversion in 3 years using ADNI-1 (<italic toggle="yes">n</italic> = 125) and ADNI-GO/2 (<italic toggle="yes">n</italic> = 98) datasets; internal and external validation performed</td><td colspan="1" rowspan="1">Advantages: Improves accuracy <italic toggle="yes">via</italic> subtype-specific models; multi-modality integration enhances prediction and interpretability. Disadvantages: Computationally intensive; requires large, well-annotated omics datasets</td><td colspan="1" rowspan="1">Model complexity; performance varies across subtypes; generalization is limited without large-scale validation</td><td colspan="1" rowspan="1">AUC (subtype I): 0.8581; AUC (subtype II): 0.8623; AUC (overall): 0.83; Accuracy: 0.79; Sensitivity: 0.81; Specificity: 0.78</td><td colspan="1" rowspan="1"><xref rid="bib273" ref-type="bibr">273</xref></td></tr><tr><td colspan="1" rowspan="1">MCAD</td><td colspan="1" rowspan="1">Imaging (cascaded dilated convolutions) and CSF (sinusoidal functions) encoders. Cross-attention for MI. The objective function combines classification and modality alignment loss</td><td colspan="1" rowspan="1">AD, MCI, NC diagnoses on ADNI dataset. Utilizes sMRI, FDG-PET, and CSF data. Multi-class classification tasks for AD, MCI, and NC</td><td colspan="1" rowspan="1">Advantages: Efficient, accurate AD diagnosis <italic toggle="yes">via</italic> inter-modality interactions, reduced discrepancy. Disadvantages: High complexity when extending cross-modal attention to different imaging modalities increases overfitting risk</td><td colspan="1" rowspan="1">Effectively capture inter-modality interaction. Reduce modality discrepancy. Bridge the heterogeneity gap between imaging and CSF</td><td colspan="1" rowspan="1">AD <italic toggle="yes">vs</italic>. NC: ACC: 0.9107 &#177; 0.0382 SEN: 0.9103 &#177; 0.0478 SPE: 0.9107 &#177; 0.0647 F1: 0.9111 &#177; 0.0381 AUC: 0.9407 &#177; 0.0316;<break/>AD <italic toggle="yes">vs</italic>. MCI <italic toggle="yes">vs</italic>. NC: ACC: 0.6403 &#177; 0.0249 SEN: 0.6385 &#177; 0.0241 SPE: 0.8200 &#177; 0.0124 F1: 0.6185 &#177; 0.0158 AUC: 0.7677 &#177; 0.0422</td><td colspan="1" rowspan="1"><xref rid="bib274" ref-type="bibr">274</xref></td></tr></tbody></table><table-wrap-foot><fn><p>Note: A<italic toggle="yes">&#946;</italic>, amyloid beta; ACC, accuracy; AD, Alzheimer's disease; ADAS-Cog, Alzheimer's Disease Assessment Scale &#8211; Cognitive Subscale; ADNI, Alzheimer's Disease Neuroimaging Initiative; AE, autoencoder; AI, artificial intelligence; ALP, autophagy&#8211;lysosome pathway; ANN, artificial neural network; ANOVA, analysis of variance; <italic toggle="yes">APOE</italic>, apolipoprotein E; AP, Average Precision; AUC, area under the ROC curve; AUPR, area under the precision recall curve; AUROC, area under the receiver operating characteristic curve; BN, Bayesian probabilistic causal Network; BRCA, breast cancer; CBGS, Cambridge Baby Growth Study; CDR-SB, Clinical and Dementia Rating &#8211; Sum of Boxes; CGMH, Chang Gung Memorial Hospital; CUI, clinical utility index; CoRR-HNU, Consortium for Reliability and Reproducibility Hangzhou Normal University; CSF, cerebrospinal fluid; CV, cross-validation; DBNs, deep belief networks; DE, differentially expressed; DFG, Directed Fusion Graph; DL, deep learning; DM, DNA methylation; DNAm, DNA methylation; DNN, deep neural networks; EHRs, electronic health records; EMCI, early mild cognitive impairment; FedAvg, federated averaging; FDR, false discovery rate; FDG, fluorodeoxyglucose; FWE, family-wise error; GAN, generative adversarial networks; GAT, graph attention network; GBM, glioblastoma multiforme; GCNs, graph convolutional networks; GE, gene expression; GFA, group factor analysis; GIS, global internal standard; GNNs, graph neural networks; GNNRAI, GNN-derived Representation Alignment and Integration; GWAS, genome-wide association studies; HD, Huntington's disease; HCC, hepatocellular carcinoma; HDLSS, high-dimensional, low-sample-size; HPC, high-performance computing; HSPA5, heat-shock-protein family A member 5; IMBALMED, iMbalancEd Data; JDSNMF, joint deep semi-non-negative matrix factorization; KNN, K nearest neighbors; LASSO, least absolute shrinkage and selection operator; LBD, Lewy body dementia; LFQ-MS, label-free-quantitation mass spectrometry; LMCI, Late Mild Cognitive Impairments; LSTM, long short-term memory; MAE, mean absolute error; MAGMA, multi-locus analysis of genomic architecture; MAPT, microtubule-associated protein-tau; MCAD, multi-modal cross-attention AD diagnosis; MCC, Matthews correlation coefficient; MCI, mild cognitive impairment; MC-RVAE, multi-channel recurrent variational autoencoder; MDP, Markov decision process; MILP, mixed-integer linear programming; MINDy, Modulator Inference by Network Dynamics; MINDSETS, Multi-omics Integration with Neuroimaging for Dementia Subtyping and Effective Temporal Study; miRNA, microRNA; MLP, multilayer perceptron; MMSE, Mini-Mental State Examination; MOADLN, Multi-Omics Attention Deep Learning Network; MOGLAM, Multi-Omics Graph Learning and Attention Mechanism; MOGONET, Multi-Omics Graph cOnvolutional NETworks; MOHE, Multi-Omics Hypergraph Encoding; MORE, Multi-Omics hypeRgraph integration nEtwork; MOSA, Multi-Omics Self-Attention; MOSEGCN, Multi-Omics Semi-Supervised Edge-to-Graph Convolutional Network; mRNA, messenger RNA; MSC, Midnight Scan Club; M-LSTM, multi-dimensional spatiotemporal long short-term memory; NAB, neocortical amyloid burden; NACC, National Alzheimer's Coordinating Center; NA-ADNI, North-American Alzheimer's Disease Neuroimaging Initiative; NB, Naive Bayes; NBP, network-based approach; NC, normal control; NCH-51, drug candidate NCH-51; NeuroPM-box, Neuroinformatics for Personalized Medicine toolbox; NfL, neurofilament light; NL, normal; NMF, non-negative matrix factorization; OASIS, Open Access Series of Imaging Studies; OOB, out-of-bag; PBMCs, peripheral blood mononuclear cells; PCST, Prize Collecting Steiner Tree; PFI, permutation feature importance; p-tau, phosphorylated tau; p-tau217, phosphorylated tau at threonine 217; PPI, protein&#8211;protein interaction; RBM, restricted Boltzmann machine; RF, random forest; RNA-Seq, RNA sequencing; ROS/MAP, Religious Orders Study and Rush Memory and Aging Project; RNN, recurrent neural network; RMSE, root mean square error; scDRS, single-cell Disease Relevance Score; scRNA-Seq, single-cell RNA sequencing; SEGCN, self-ensembling Graph Convolutional Network; SHAP, SHapley Additive exPlanations; SILAC, stable isotope labelling by amino acids; SMOTE, synthetic minority over-sampling technique; SNPs, single-nucleotide polymorphisms; SPE, specificity; SUGAR, spherical ultrafast graph attention framework for cortical surface registration; SUVR, standardized uptake value ratio; SVM, support vector machines; SVR, support vector regression; TAMPOR, tunable median polish of ratio; t-SNE, t-distributed stochastic neighbor embedding; TIMP1, tissue inhibitor of metalloproteinases-1; TMT, tandem-mass-tag; TMT-MS, tandem-mass-tag mass spectrometry; TPR, true-positive rate; UKB, UK Biobank; VaD, vascular dementia; VBpMKL, variational Bayes approximation with probabilistic multiple kernel learning; VLM, vision&#8211;language model; vol, brain volume; VRNN, variational recurrent neural network; WGAN-WP, Wasserstein generative adversarial network with weight penalty; WGCNA, weighted gene co-expression network analysis; WIMOAD, weighted integration of multi-omics data for Alzheimer's disease; XGBoost, extreme gradient boosting; SNF, Similarity Network Fusion; sMRI, structural magnetic resonance imaging; fMRI, Functional MRI; PET, positron emission tomography; GEIDI, Genotype-Expression-Imaging Data Integration.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec4.1"><label>4.1</label><title>Machine learning approaches</title><p id="p0205">Machine learning methods have become indispensable for integrating and analyzing multi-omics datasets in AD research. These approaches provide robust frameworks for managing the inherent complexity, heterogeneity, and high dimensionality of omics data, while uncovering meaningful biomarkers and therapeutic targets.</p><p id="p0210">Established machine learning techniques such as support vector machines (SVMs), random forests, gradient boosting, and elastic-net regularized regression have been successfully applied to integrate multi-omics data with clinical and neuroimaging variables. These methods are particularly well-suited for capturing etiological and clinical heterogeneity in AD, supporting both disease stratification and individualized prediction. Supervised learning approaches, including SVMs and random forests, have demonstrated high performance in differentiating AD phenotypes from controls. For example, modularity-constrained logistic regression applied to the Religious Orders Study and Rush Memory and Aging Project (ROS/MAP) cohort identified functionally connected single-nucleotide polymorphisms (SNPs), genes, and proteins predictive of AD, and linked these molecular features to neuroimaging and cognitive outcomes<xref rid="bib275" ref-type="bibr"><sup>275</sup></xref>. Similarly, random forest classifiers have highlighted plasma p-tau and <italic toggle="yes">&#945;</italic>-synuclein as predictive biomarkers of progression from mild cognitive impairment (MCI) to dementia, findings that have been experimentally validated<xref rid="bib276" ref-type="bibr"><sup>276</sup></xref>. Elastic-net models further prioritize cross-omic biomarkers, demonstrating the value of ensemble strategies in AD research<xref rid="bib277" ref-type="bibr"><sup>277</sup></xref>. Graph-based methods, such as graph convolutional networks (GCNs), enable the modeling of intricate inter-omic relationships. The staged GCN with uncertainty quantification (SGUQ) has integrated genomic, proteomic, and clinical data while reducing computational overhead and maintaining predictive accuracy<xref rid="bib278" ref-type="bibr"><sup>278</sup></xref>. These approaches align well with biological systems, where molecular entities and interactions are inherently network-structured. In addition, Bayesian factor analysis and sparse canonical correlation analysis (SCCA) address data heterogeneity by uncovering shared molecular signatures and subgroup-specific drivers. For instance, SCCA has revealed immune-related expression patterns in RNA-Seq datasets from specific brain regions, offering biologically interpretable insights into disease progression<xref rid="bib279" ref-type="bibr">279</xref>, <xref rid="bib280" ref-type="bibr">280</xref>, <xref rid="bib281" ref-type="bibr">281</xref>.</p><p id="p0215">Despite recent progress, several methodological challenges limit clinical translation. A major concern is the limited interpretability of many machine learning models, particularly deep neural networks and ensembles. Although explainable AI (XAI) techniques such as SHapley Additive exPlanations (SHAP), Local Interpretable Model-Agnostic Explanations, and layer-wise relevance propagation are gaining traction, comparative studies have shown inconsistent outputs across methods, highlighting the need for application-specific validation<xref rid="bib282" ref-type="bibr"><sup>282</sup></xref>. Class imbalance in public datasets also affects sensitivity. Most cohorts include more cognitively normal or mildly impaired individuals than confirmed AD cases, skewing predictions. Techniques like the IMBALMED framework, which ensembles models using various resampling or cost-sensitive learning strategies, have improved F<sub>1</sub> scores in the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset. Generative adversarial oversampling has similarly reduced false negatives, though strict controls are required to avoid data leakage<xref rid="bib252" ref-type="bibr"><sup>252</sup></xref><sup>,</sup><xref rid="bib253" ref-type="bibr"><sup>253</sup></xref>. Inconsistent preprocessing also hinders reproducibility. Decisions about normalization or batch correction can dramatically alter biomarker rankings. Tools such as TAMPOR, which apply standardized, containerized workflows, help address this. However, fewer than one-third of published multi-omics AD studies release full code and preprocessing parameters, limiting independent validation<xref rid="bib254" ref-type="bibr"><sup>254</sup></xref>. Overfitting remains a persistent issue due to the imbalance between feature dimensionality and sample size. Nested cross-validation has mitigated this problem in transcriptomic classifiers, increasing external accuracy by up to 15%<xref rid="bib283" ref-type="bibr"><sup>283</sup></xref>. Case studies have illustrated both the promise and limitations of machine learning in multi-omics AD research. One study combining proteomic and metabolomic data identified dysregulated sphingolipid and ceramide metabolism in <italic toggle="yes">APOE &#949;4</italic> carriers, findings supported by post-mortem analyses. However, predictive accuracy declined in ethnically diverse cohorts, underscoring the importance of ancestry-inclusive validation<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="bib159" ref-type="bibr"><sup>159</sup></xref><sup>,</sup><xref rid="bib284" ref-type="bibr"><sup>284</sup></xref></p><p id="p0220">Looking forward, clinically viable models will require a combination of robust explainability tools, harmonized preprocessing protocols, balanced datasets, and multi-site validation. Initiatives such as the MINDSETS project, which integrates omics, imaging, and cognitive data across international cohorts, exemplify the type of transparent and scalable framework needed to transition machine learning prototypes into real-world diagnostic and prognostic applications<xref rid="bib255" ref-type="bibr"><sup>255</sup></xref><sup>,</sup><xref rid="bib282" ref-type="bibr"><sup>282</sup></xref>.</p></sec><sec id="sec4.2"><label>4.2</label><title>Deep learning architectures</title><p id="p0225">Deep learning has emerged as a powerful approach for integrating and analyzing multi-omics datasets, offering unprecedented insights into the molecular mechanisms underlying AD. By harmonizing genomics, transcriptomics, proteomics, and epigenomics data, deep learning models provide a comprehensive and scalable framework that overcomes limitations of traditional single-omics methods.</p><p id="p0230">Several innovative architectures have shown promise in addressing the high-dimensional, low-sample-size (HDLSS) nature of multi-omics data. Joint Deep Semi-Non-Negative Matrix Factorization (JDSNMF) captures shared latent features across omics layers, enabling the identification of biologically relevant modules for disease prediction<xref rid="bib243" ref-type="bibr"><sup>243</sup></xref>. Deep Belief Networks (DBNs) integrate gene expression and methylation features to improve classification accuracy, while Explainable Variational Autoencoders (E-VAEs) reveal interpretable genomic-transcriptomic interactions linked to AD pathways<xref rid="bib237" ref-type="bibr"><sup>237</sup></xref><sup>,</sup><xref rid="bib285" ref-type="bibr"><sup>285</sup></xref>. Advanced models such as the multi-omics data fusion network (MoFNet) incorporate prior biological knowledge to dynamically link SNPs, genes, and proteins. This facilitates the identification of subnetworks involved in processes like neuroinflammation and synaptic dysfunction<xref rid="bib286" ref-type="bibr"><sup>286</sup></xref>. Additionally, scGraph2Vec uses graph neural networks to extract biologically meaningful gene embeddings from single-cell omics, elucidating tissue-specific regulatory mechanisms<xref rid="bib265" ref-type="bibr"><sup>265</sup></xref>. Generative models like CE-GAN simulate brain network evolution and have achieved high accuracy in risk prediction<xref rid="bib287" ref-type="bibr"><sup>287</sup></xref>. Furthermore, frameworks like SDGCCA capture non-linear correlations across omics modalities, facilitating the discovery of robust cross-layer biomarkers<xref rid="bib288" ref-type="bibr"><sup>288</sup></xref>.</p><p id="p0235">Despite their predictive power, deep learning models often suffer from limited interpretability. Convolutional neural networks applied to PET scans may achieve high area-under-the-curve scores, but their saliency maps frequently fail to align with known pathological regions, reducing clinician trust. Techniques such as attention layers, SHAP, and patch-based visualizations aim to localize voxel- or gene-level contribution, yet benchmarking studies indicate that their outputs can be inconsistent and model-dependent<xref rid="bib256" ref-type="bibr"><sup>256</sup></xref><sup>,</sup><xref rid="bib282" ref-type="bibr"><sup>282</sup></xref><sup>,</sup><xref rid="bib289" ref-type="bibr"><sup>289</sup></xref>. Deep learning frameworks are also computationally intensive. Multimodal imaging workflows, such as those harmonized by DeepPrep, often require terabytes of storage and high-end GPU infrastructure<xref rid="bib258" ref-type="bibr"><sup>258</sup></xref>. Although model-parallel optimization and memory-efficient training have reduced some of these burdens, resource constraints remain a significant barrier, particularly for smaller research teams<xref rid="bib290" ref-type="bibr"><sup>290</sup></xref><sup>,</sup><xref rid="bib291" ref-type="bibr"><sup>291</sup></xref>. Overfitting is another concern, driven by the disparity between the number of features and available samples. Techniques such as nested cross-validation, dropout, early stopping, and weight decay have been effective in mitigating overfitting and improving external prediction accuracy by up to 15%<xref rid="bib257" ref-type="bibr"><sup>257</sup></xref><sup>,</sup><xref rid="bib292" ref-type="bibr"><sup>292</sup></xref>. Application-specific studies illustrate both the strengths and limitations of deep learning. A study integrating metabolomics and proteomics in <italic toggle="yes">APOE &#949;4</italic> carriers revealed disruptions in sphingolipid and glycerophospholipid pathways. However, the kernel-based model used was non-transparent and performed poorly in non-European cohorts, highlighting the challenge of cross-population generalizability<xref rid="bib159" ref-type="bibr"><sup>159</sup></xref><sup>,</sup><xref rid="bib293" ref-type="bibr"><sup>293</sup></xref>. This limitation is common in AD research. Predictive signatures derived from ADNI datasets often underperform in community-based cohorts that differ in ancestry, education level, and comorbid conditions<xref rid="bib259" ref-type="bibr"><sup>259</sup></xref>. Although the ADNI-4 initiative aims to address demographic imbalances, most current models lack external validation in diverse populations. This raises concerns about their robustness and real-world applicability<xref rid="bib294" ref-type="bibr"><sup>294</sup></xref><sup>,</sup><xref rid="bib295" ref-type="bibr"><sup>295</sup></xref>.</p><p id="p0240">To enhance the translational relevance of deep learning in AD, future efforts must prioritize interpretability, reproducibility, and validation. Embedding XAI mechanisms directly within model architectures can improve alignment between feature attributions and predictive objectives, thereby facilitating clinical interpretation and regulatory confidence. At the same time, releasing standardized, containerized preprocessing workflows with complete parameter documentation is essential to ensure methodological transparency and enable reproducibility across studies. Validation using large, prospective, and demographically diverse cohorts is equally critical, as many current models struggle to generalize beyond homogenous populations. To address these limitations, biologically informed architectures, such as graph neural networks that encode pathway-level priors, offer a promising avenue for integrating domain knowledge while preserving predictive performance<xref rid="bib228" ref-type="bibr"><sup>228</sup></xref>. These interpretable and integrative deep learning frameworks have the potential to form a robust foundation for AI-driven diagnostic and therapeutic tools in AD, ultimately bridging the gap between complex multi-omics analyses and clinically actionable insights.</p></sec><sec id="sec4.3"><label>4.3</label><title>Network-based methods</title><p id="p0245">Network-based approaches have become indispensable in integrating multi-omics data to elucidate the complex molecular mechanisms of AD. These methods represent biological entities such as genes, proteins, or metabolites as nodes, and define their interactions as edges, thereby facilitating a systems-level understanding of disease pathogenesis<xref rid="bib237" ref-type="bibr"><sup>237</sup></xref><sup>,</sup><xref rid="bib251" ref-type="bibr"><sup>251</sup></xref><sup>,</sup><xref rid="bib296" ref-type="bibr"><sup>296</sup></xref><sup>,</sup><xref rid="bib297" ref-type="bibr"><sup>297</sup></xref>.</p><p id="p0250">Early implementations often relied on correlation-based networks that inferred pairwise associations among features. While these models were straightforward and interpretable, they could not capture higher-order interactions or context-specific dependencies<xref rid="bib298" ref-type="bibr"><sup>298</sup></xref>. Subsequently, methods such as Weighted Gene Co-expression Network Analysis (WGCNA) enhanced network granularity by identifying modules of highly co-expressed genes, offering biologically relevant insights into co-regulated pathways implicated in AD<xref rid="bib244" ref-type="bibr"><sup>244</sup></xref><sup>,</sup><xref rid="bib299" ref-type="bibr"><sup>299</sup></xref>. However, WGCNA's reliance on linear correlations and scale-free assumptions has drawn criticism for oversimplifying the nonlinear and heterogeneous nature of molecular interactions<xref rid="bib300" ref-type="bibr"><sup>300</sup></xref>. To address these limitations, recent advancements have incorporated kernel-based and mutual information-based metrics, uncovering hidden relationships missed by linear models<xref rid="bib301" ref-type="bibr"><sup>301</sup></xref><sup>,</sup><xref rid="bib302" ref-type="bibr"><sup>302</sup></xref>. Integration with protein&#8211;protein interaction (PPI) networks has further refined AD models by connecting transcriptomic and proteomic layers, particularly when combined with tissue-specific data or prior biological knowledge<xref rid="bib303" ref-type="bibr">303</xref>, <xref rid="bib304" ref-type="bibr">304</xref>, <xref rid="bib305" ref-type="bibr">305</xref>. Bayesian networks and Markov random fields offer probabilistic frameworks capable of modeling causal relationships under uncertainty, although these approaches are computationally intensive and often require extensive priors for convergence<xref rid="bib306" ref-type="bibr"><sup>306</sup></xref><sup>,</sup><xref rid="bib307" ref-type="bibr"><sup>307</sup></xref>. More sophisticated strategies involve multi-layer or multiplex network models that represent each omics layer as a distinct stratum and encode cross-layer relationships to capture inter-omic dependencies<xref rid="bib308" ref-type="bibr"><sup>308</sup></xref><sup>,</sup><xref rid="bib309" ref-type="bibr"><sup>309</sup></xref>. These architectures reveal interactions such as the link between genetic variants and metabolic alterations, but their practical application is often constrained by computational demands and sensitivity to parameter choices<xref rid="bib251" ref-type="bibr"><sup>251</sup></xref><sup>,</sup><xref rid="bib310" ref-type="bibr"><sup>310</sup></xref><sup>,</sup><xref rid="bib311" ref-type="bibr"><sup>311</sup></xref>. Single-cell data integration has introduced new opportunities for cell-type-specific network inference. Tools like sc2GWAS connect genome-wide association loci to cellular transcriptomic signatures, identifying microglia and astrocytes as key mediators in AD<xref rid="bib151" ref-type="bibr"><sup>151</sup></xref><sup>,</sup><xref rid="bib261" ref-type="bibr"><sup>261</sup></xref>. Deep learning-based approaches, including Deep Belief Networks and Graph Neural Networks (GNNs), have further expanded the capacity to model nonlinear, high-dimensional interdependencies across omics layers<xref rid="bib237" ref-type="bibr"><sup>237</sup></xref><sup>,</sup><xref rid="bib312" ref-type="bibr"><sup>312</sup></xref><sup>,</sup><xref rid="bib313" ref-type="bibr"><sup>313</sup></xref>.</p><p id="p0255">Despite their promise, several barriers limit the clinical translation of network-based models. First, interpretability remains a core challenge. High-performing architectures such as GNNs and deep generative models often provide limited transparency regarding feature attribution, and existing explainability tools such as SHAP or attention mechanisms yield inconsistent results<xref rid="bib228" ref-type="bibr"><sup>228</sup></xref><sup>,</sup><xref rid="bib314" ref-type="bibr"><sup>314</sup></xref><sup>,</sup><xref rid="bib315" ref-type="bibr"><sup>315</sup></xref>. Second, computational accessibility poses a major hurdle. Multi-layer network construction and inference often require high-performance infrastructure, restricting participation to well-resourced institutions<xref rid="bib260" ref-type="bibr"><sup>260</sup></xref>. Third, reproducibility is hindered by variability in preprocessing pipelines, parameter tuning, and network construction choices. Small changes in normalization, imputation, or similarity metrics can substantially alter network topology and derived biological insights<xref rid="bib316" ref-type="bibr"><sup>316</sup></xref><sup>,</sup><xref rid="bib317" ref-type="bibr"><sup>317</sup></xref>. Interpreting network modules introduces additional complexity. Statistically robust clusters may not align with known biological pathways and can group unrelated genes. Moreover, commonly used backbone networks like PPIs may include context-agnostic interactions, confounding functional interpretations. For instance, findings from the Accelerating Medicines Partnership&#8211;Alzheimer's Disease (AMP-AD) consortium originally attributed to immune-metabolic hubs were later found to reflect cell composition shifts rather than genuine regulatory networks<xref rid="bib318" ref-type="bibr"><sup>318</sup></xref><sup>,</sup><xref rid="bib319" ref-type="bibr"><sup>319</sup></xref>. Single-cell network inference holds potential to resolve these ambiguities but faces its own limitations, including noise sensitivity and reliance on aggressive data denoising strategies<xref rid="bib261" ref-type="bibr"><sup>261</sup></xref><sup>,</sup><xref rid="bib315" ref-type="bibr"><sup>315</sup></xref>.</p><p id="p0260">To overcome these challenges, the field is advancing toward standardized and collaborative solutions. Initiatives such as AMP-AD and ADNI now promote open-source software, harmonized preprocessing workflows, and public sharing of network outputs to facilitate benchmarking and reproducibility. Hybrid frameworks that embed mechanistic priors into machine learning models, such as GNNs enriched with biological knowledge graphs, offer a path to balancing predictive power with interpretability<xref rid="bib228" ref-type="bibr"><sup>228</sup></xref>. For network-based approaches to achieve clinical relevance, future efforts must include rigorous external validation across diverse populations, collaborative iteration between computational scientists and experimental biologists, and equitable access to computational infrastructure. These efforts will be essential for translating network-derived insights into actionable tools for early diagnosis, mechanistic understanding, and therapeutic targeting in AD.</p></sec></sec><sec id="sec5"><label>5</label><title>AI-driven multi-omics applications in AD</title><p id="p0265">The integration of AI with multi-omics technologies has significantly advanced AD research by enabling comprehensive and high-resolution analyses of its intricate molecular landscape. These integrative approaches have shown considerable promise across key domains, including early diagnosis, mechanistic elucidation, biomarker discovery, therapeutic development, and patient stratification (<xref rid="fig4" ref-type="fig">Fig. 4</xref>, <xref rid="tbl3" ref-type="table">Table 3</xref><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib53" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="bib58" ref-type="bibr"><sup>58</sup></xref><sup>,</sup><xref rid="bib226" ref-type="bibr"><sup>226</sup></xref><sup>,</sup><xref rid="bib237" ref-type="bibr"><sup>237</sup></xref><sup>,</sup><xref rid="bib251" ref-type="bibr"><sup>251</sup></xref><sup>,</sup><xref rid="bib253" ref-type="bibr"><sup>253</sup></xref><sup>,</sup><xref rid="bib255" ref-type="bibr"><sup>255</sup></xref><sup>,</sup><xref rid="bib261" ref-type="bibr">261</xref>, <xref rid="bib262" ref-type="bibr">262</xref>, <xref rid="bib263" ref-type="bibr">263</xref>, <xref rid="bib264" ref-type="bibr">264</xref>, <xref rid="bib265" ref-type="bibr">265</xref>, <xref rid="bib266" ref-type="bibr">266</xref>, <xref rid="bib267" ref-type="bibr">267</xref>, <xref rid="bib268" ref-type="bibr">268</xref>, <xref rid="bib269" ref-type="bibr">269</xref>, <xref rid="bib270" ref-type="bibr">270</xref>, <xref rid="bib271" ref-type="bibr">271</xref>, <xref rid="bib272" ref-type="bibr">272</xref>, <xref rid="bib273" ref-type="bibr">273</xref>, <xref rid="bib274" ref-type="bibr">274</xref><sup>,</sup>
<xref rid="bib276" ref-type="bibr"><sup>276</sup></xref><sup>,</sup><xref rid="bib278" ref-type="bibr"><sup>278</sup></xref><sup>,</sup><xref rid="bib283" ref-type="bibr"><sup>283</sup></xref><sup>,</sup><xref rid="bib287" ref-type="bibr"><sup>287</sup></xref><sup>,</sup><xref rid="bib289" ref-type="bibr"><sup>289</sup></xref><sup>,</sup><xref rid="bib319" ref-type="bibr">319</xref>, <xref rid="bib320" ref-type="bibr">320</xref>, <xref rid="bib321" ref-type="bibr">321</xref>, <xref rid="bib322" ref-type="bibr">322</xref>, <xref rid="bib323" ref-type="bibr">323</xref>, <xref rid="bib324" ref-type="bibr">324</xref>, <xref rid="bib325" ref-type="bibr">325</xref>, <xref rid="bib326" ref-type="bibr">326</xref>, <xref rid="bib327" ref-type="bibr">327</xref>, <xref rid="bib328" ref-type="bibr">328</xref>, <xref rid="bib329" ref-type="bibr">329</xref>, <xref rid="bib330" ref-type="bibr">330</xref>, <xref rid="bib331" ref-type="bibr">331</xref>, <xref rid="bib332" ref-type="bibr">332</xref>, <xref rid="bib333" ref-type="bibr">333</xref>, <xref rid="bib334" ref-type="bibr">334</xref>, <xref rid="bib335" ref-type="bibr">335</xref>, <xref rid="bib336" ref-type="bibr">336</xref>, <xref rid="bib337" ref-type="bibr">337</xref>, <xref rid="bib338" ref-type="bibr">338</xref>, <xref rid="bib339" ref-type="bibr">339</xref>, <xref rid="bib340" ref-type="bibr">340</xref>, <xref rid="bib341" ref-type="bibr">341</xref>, <xref rid="bib342" ref-type="bibr">342</xref>, <xref rid="bib343" ref-type="bibr">343</xref>, <xref rid="bib344" ref-type="bibr">344</xref>, <xref rid="bib345" ref-type="bibr">345</xref>, <xref rid="bib346" ref-type="bibr">346</xref>, <xref rid="bib347" ref-type="bibr">347</xref>, <xref rid="bib348" ref-type="bibr">348</xref>, <xref rid="bib349" ref-type="bibr">349</xref>, <xref rid="bib350" ref-type="bibr">350</xref>, <xref rid="bib351" ref-type="bibr">351</xref>, <xref rid="bib352" ref-type="bibr">352</xref>, <xref rid="bib353" ref-type="bibr">353</xref>, <xref rid="bib354" ref-type="bibr">354</xref>, <xref rid="bib355" ref-type="bibr">355</xref>, <xref rid="bib356" ref-type="bibr">356</xref>, <xref rid="bib357" ref-type="bibr">357</xref>, <xref rid="bib358" ref-type="bibr">358</xref>, <xref rid="bib359" ref-type="bibr">359</xref>, <xref rid="bib360" ref-type="bibr">360</xref>, <xref rid="bib361" ref-type="bibr">361</xref>, <xref rid="bib362" ref-type="bibr">362</xref>, <xref rid="bib363" ref-type="bibr">363</xref>, <xref rid="bib364" ref-type="bibr">364</xref>).<table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>The application of AI models in the integration of multi-omics for AD research.</p></caption><alt-text id="alttext0045">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">AI models</th><th colspan="1" rowspan="1">Clinical application and outcomes</th><th colspan="1" rowspan="1">Key advances</th><th colspan="1" rowspan="1">Challenges and future directions</th><th colspan="1" rowspan="1">Evaluation metrics</th><th colspan="1" rowspan="1">Ref</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">B-HEALED</td><td colspan="1" rowspan="1">Clinical: 345 individuals from 7 cohorts; distinguish 249 AD (82 prodromal, 83 mild) from 96 non-AD disorders; follow-up showed MMSE decline and CDR increase; 82.9% received CSF or PET imaging, with 61.9% amyloid-positive; NP: MMSE decline (&#8722;2.7/year) and CDR increase (+0.3/year) during follow-up</td><td colspan="1" rowspan="1">Integrates 19 blood-based proteins and metabolites with age to achieve high diagnostic specificity across multicenter cohorts</td><td colspan="1" rowspan="1">Validates in larger, diverse cohorts; standardizes assays; assesses longitudinal performance</td><td colspan="1" rowspan="1">Specificity: 0.93 (internal), 0.92 (external)<break/>Sensitivity: 0.654 (internal), 0.524 (external)<break/>AUC: 0.819 (internal), 0.718 (external)</td><td colspan="1" rowspan="1"><xref rid="bib320" ref-type="bibr">320</xref></td></tr><tr><td colspan="1" rowspan="1">RF; SVM</td><td colspan="1" rowspan="1">Clinical: 273 AIBL and 82 ADNI participants; predicts high <italic toggle="yes">vs</italic>. low neocortical A<italic toggle="yes">&#946;</italic> burden; validated against PET SUVR threshold and applied to non-imaged AIBL subjects; NI: PET SUVR</td><td colspan="1" rowspan="1">Identify an 8-marker blood panel predictive of A<italic toggle="yes">&#946;</italic> status across cohorts</td><td colspan="1" rowspan="1">Address missing biomarker data; scale to population-level screening</td><td colspan="1" rowspan="1">AUC: 0.84 (RF), 0.84 (SVM)<break/>Sensitivity: 0.80 (RF), 0.74 (SVM)<break/>Specificity: 0.79 (RF), 0.76 (SVM)</td><td colspan="1" rowspan="1"><xref rid="bib321" ref-type="bibr">321</xref></td></tr><tr><td colspan="1" rowspan="1">DBN</td><td colspan="1" rowspan="1">Clinical: 838 subjects (513 AD, 325 controls) from multi-omics datasets; classifies AD <italic toggle="yes">vs</italic>. control</td><td colspan="1" rowspan="1">Combines DEGs and DMPs using Jaccard similarity; applies ensemble feature selection and Bayesian-optimized DBN for AD classification</td><td colspan="1" rowspan="1">Harmonize multi-omics across platforms; expand access to longitudinal data</td><td colspan="1" rowspan="1">Accuracy: 0.8466 (internal, 5-fold CV), 0.82 (external)</td><td colspan="1" rowspan="1"><xref rid="bib237" ref-type="bibr">237</xref></td></tr><tr><td colspan="1" rowspan="1">CE-GAN</td><td colspan="1" rowspan="1">Clinical: LMCI subjects from ADNI; predicts progression risk from stable to prodromal AD using fMRI and SNP data; NI: fMRI ROI</td><td colspan="1" rowspan="1">Integrates ROI-gene community networks with entropy-guided GAN evolution; identifies risk ROIs and genes relevant to AD progression</td><td colspan="1" rowspan="1">Limited multimodal sample size; requires broader validation and interpretability improvements</td><td colspan="1" rowspan="1">Accuracy: 0.9167; Sensitivity: 0.8967; Specificity: 0.9474; AUC: 0.9183</td><td colspan="1" rowspan="1"><xref rid="bib287" ref-type="bibr">287</xref></td></tr><tr><td colspan="1" rowspan="1">LR; RF; SVM</td><td colspan="1" rowspan="1">Clinical: 116 subjects from Taipei-VGH (49 AD, 28 P-MCI, 39 S-MCI); predicts progression from MCI to AD using blood transcriptomics and cognitive tests including MMSE, WMS-LM, CVVLT, TMT-B, TY-CFT, BNT, VF</td><td colspan="1" rowspan="1">Identify an 8-gene blood transcriptomic signature to predict MCI conversion; highlight mitochondrial and sex-specific pathways</td><td colspan="1" rowspan="1">Validate in larger, diverse cohorts; explore mechanistic underpinnings</td><td colspan="1" rowspan="1">Accuracy: 0.85 (AD <italic toggle="yes">vs</italic>. S-MCI), 0.88 (AD <italic toggle="yes">vs</italic>. P-MCI)<break/>AUC: 0.94 (AD <italic toggle="yes">vs</italic>. S-MCI), 0.92 (AD <italic toggle="yes">vs</italic>. P-MCI)</td><td colspan="1" rowspan="1"><xref rid="bib283" ref-type="bibr">283</xref></td></tr><tr><td colspan="1" rowspan="1">SGUQ</td><td colspan="1" rowspan="1">Clinical: 351 subjects from ROS/MAP (182 AD, 169 NC); Classify AD <italic toggle="yes">vs</italic>. NC using integrated mRNA, DNA methylation, and miRNA data</td><td colspan="1" rowspan="1">Integrates mRNA, DNA methylation, and miRNA <italic toggle="yes">via</italic> staged GCN with uncertainty quantification; enables cost-efficient diagnosis through selective omics layering</td><td colspan="1" rowspan="1">Require larger datasets and improved scalability for clinical translation</td><td colspan="1" rowspan="1">Accuracy: 0.858 (tri-omics), 0.8018 (mRNA-only)<break/>F1: 0.85 (tri-omics)<break/>AUC: 0.86 (tri-omics), 0.80 (mRNA-only)</td><td colspan="1" rowspan="1"><xref rid="bib278" ref-type="bibr">278</xref></td></tr><tr><td colspan="1" rowspan="1">MPxgb</td><td colspan="1" rowspan="1">Clinical: In silico prediction and experimental validation using human AD iPSNs, postmortem brain tissue, and inflammation-induced tau phosphorylation assays</td><td colspan="1" rowspan="1">Identifies five AD-risk genes; <italic toggle="yes">CRTAM</italic> and <italic toggle="yes">SCGB3A1</italic> linked to <italic toggle="yes">TREM2</italic>&#8211;<italic toggle="yes">TYROBP</italic> and IL&#8211;1<italic toggle="yes">&#946;</italic>&#8211;TNF<italic toggle="yes">&#945;</italic> immune pathways; nine genes reduced tau phosphorylation <italic toggle="yes">via</italic> siRNA knockdown</td><td colspan="1" rowspan="1">Address noisy negative training data; validate findings in broader human populations and multi-omics platforms</td><td colspan="1" rowspan="1">AUC-ROC: 0.91 (CV, 0.93 (test set)<break/>Sensitivity: 0.87<break/>Specificity: 0.80</td><td colspan="1" rowspan="1"><xref rid="bib322" ref-type="bibr">322</xref></td></tr><tr><td colspan="1" rowspan="1">NETTAG</td><td colspan="1" rowspan="1">Clinical: In silico prediction and validation using AD GWAS loci, transcriptomic and proteomic datasets, and EHR-based population analyses</td><td colspan="1" rowspan="1">Integrates GWAS and nine regulatory features into PPI networks to identify 156 AD-risk genes enriched in immune and druggable pathways; validates expression in AD brains and glia; identifies repurposable drugs, including gemfibrozil</td><td colspan="1" rowspan="1">Address limitations in PPI completeness and population-specific GWAS data; enhance interpretability and validation across brain-specific omics</td><td colspan="1" rowspan="1">AUC: 0.81 (AlzGene); 0.80 (DistiLD); 0.72 (DISEASES-knowledge); 0.78 (TIGA)</td><td colspan="1" rowspan="1"><xref rid="bib323" ref-type="bibr">323</xref></td></tr><tr><td colspan="1" rowspan="1">LR; RF; SVM; MLP</td><td colspan="1" rowspan="1">Clinical: 386 MCI participants (93 cMCI, 103 sMCI); predicts progression risk using proteomic, metabolomic, and cognitive features, including MMSE and priority language z-scores</td><td colspan="1" rowspan="1">Identify oleamide as a lipid marker secreted by activated microglia; uncover inflammation and protein degradation pathways involving CFP, PI15, SNCA, and JPH3</td><td colspan="1" rowspan="1">Validate in independent cohorts; investigate the mechanistic role of oleamide and microglial EVs in neuroinflammation</td><td colspan="1" rowspan="1">Accuracy: 0.882 (SVM, proteins), 0.854 (SVM, metabolites)<break/>AUC: 0.64 (cMCI <italic toggle="yes">vs</italic>. sMCI)<break/>Sensitivity: 0.614<break/>Specificity: 0.582</td><td colspan="1" rowspan="1"><xref rid="bib276" ref-type="bibr">276</xref></td></tr><tr><td colspan="1" rowspan="1">EnsembleOmicsAE</td><td colspan="1" rowspan="1">Clinical: 559 postmortem brain samples from Banner, ROS/MAP, and MSBB (AD, MCI, control); model trained on control <italic toggle="yes">vs</italic>. AD groups</td><td colspan="1" rowspan="1">Identifies AE signaling modules through ensemble autoencoders; reveals age-specific regulation of integrin signaling, cell adhesion, and neuronal differentiation pathways involving <italic toggle="yes">VIM</italic>, <italic toggle="yes">MAPK1</italic>, and <italic toggle="yes">MAPK3</italic></td><td colspan="1" rowspan="1">Limited integration with genetic data; requires functional validation and optimization for clinical interpretability</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib324" ref-type="bibr">324</xref></td></tr><tr><td colspan="1" rowspan="1">Bayesian clustering with digital deconvolution</td><td colspan="1" rowspan="1">Clinical: 278 postmortem AD brain samples (255 AD, 23 control); identify 4 AD molecular subtypes with distinct clinical and neuropathological features</td><td colspan="1" rowspan="1">Identifies Knight-C4 subtype with severe neuronal loss, astrogliosis, reduced metabolomic signatures, and dysregulation in synaptic, lysosomal, and mTOR pathways</td><td colspan="1" rowspan="1">Expands multi-ethnic cohorts; validates subtype-specific biomarkers for clinical staging and precision therapy</td><td colspan="1" rowspan="1">DESeq2 FDR &lt;0.05 for DE gene analysis</td><td colspan="1" rowspan="1"><xref rid="bib58" ref-type="bibr">58</xref></td></tr><tr><td colspan="1" rowspan="1">TransComp-R</td><td colspan="1" rowspan="1">Clinical: 80 AD and 173 control subjects (human postmortem hippocampus); model integrates transcriptomic data from mouse AD, T2D, AD &#215; T2D with human data</td><td colspan="1" rowspan="1">Identifies estrogen and inflammatory pathways, including <italic toggle="yes">IL6</italic>, <italic toggle="yes">JAK</italic>, and <italic toggle="yes">STAT</italic> signaling, as cross-species predictors of AD outcomes; uncovers sex-specific translation despite male-only mouse data</td><td colspan="1" rowspan="1">Limited sample sizes; only homologous gene pairs used; preclinical findings require experimental validation</td><td colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value: 0.0047 (T2D PC2), 0.0042 (T2D PC3), 0.0130 (AD &#215; T2D PC3, 100 &#215; 5 fold CV)</td><td colspan="1" rowspan="1"><xref rid="bib325" ref-type="bibr">325</xref></td></tr><tr><td colspan="1" rowspan="1">Deep-learning classifier</td><td colspan="1" rowspan="1">Clinical: 634 ROS/MAP donors with AD or control diagnosis; validated on 266 Mayo and 214 MSBB samples across six brain regions</td><td colspan="1" rowspan="1">Constructs pseudo-temporal trajectory for AD progression using RNA-seq; identifies 593 index genes grouped into four cell-type-specific modules linked to vascular, metabolic, neuronal, and glial dysfunction</td><td colspan="1" rowspan="1">Extend model to peripheral tissues and additional omics layers; improve interpretability and causal inference</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib326" ref-type="bibr">326</xref></td></tr><tr><td colspan="1" rowspan="1">PathFinder</td><td colspan="1" rowspan="1">Clinical: ScRNA-seq from <italic toggle="yes">APOE4</italic> astrocyte-specific AD mouse model (TAFE4_tam <italic toggle="yes">vs</italic>. TAFE4_oil); reveals <italic toggle="yes">APOE4</italic>-driven neuron&#8211;astrocyte&#8211;microglia signaling networks</td><td colspan="1" rowspan="1">Identifies intra- and inter-cell signaling alterations in autophagy, lipid metabolism, and JAK&#8211;STAT signaling; uncovers <italic toggle="yes">MIF&#8211;EGFR</italic> and <italic toggle="yes">NLGN1&#8211;NRXN1</italic> interactions linked to neuroinflammation and degeneration</td><td colspan="1" rowspan="1">Require larger multi-condition scRNA-seq datasets; enhance de novo discovery beyond predefined ligand-receptor databases</td><td colspan="1" rowspan="1">AUC: 0.73 (ex), 0.71 (mic), 0.65 (ast)<break/>F1: 0.68 (ex), 0.70 (mic), 0.69 (ast)<break/>Accuracy (5-fold CV): 0.67 (ex), 0.67 (mic), 0.62 (ast)</td><td colspan="1" rowspan="1"><xref rid="bib327" ref-type="bibr">327</xref></td></tr><tr><td colspan="1" rowspan="1">M3NetFlow</td><td colspan="1" rowspan="1">Clinical: 128 postmortem brain samples from ROS/MAP (64 AD, 64 non-AD); integrate transcriptomics, methylomics, proteomics, and CNV data to classify AD and identify novel biomarker signatures</td><td colspan="1" rowspan="1">Infers multi-hop, multi-pathway signaling networks using attention-based GNNs; identifies top-ranked AD-associated genes enriched in MAPK, JAK&#8211;STAT, PI3K&#8211;Akt, NF-<italic toggle="yes">&#954;</italic>B, and FoxO pathways</td><td colspan="1" rowspan="1">Require broader cohort validation; improve scalability and integration with ontology-guided pathway modules</td><td colspan="1" rowspan="1">Pearson correlation: 0.6734 &#177; 0.0512 on ROS/MAP (5-fold CV)</td><td colspan="1" rowspan="1"><xref rid="bib25" ref-type="bibr">25</xref></td></tr><tr><td colspan="1" rowspan="1">DIABLO</td><td colspan="1" rowspan="1">Clinical: 455 postmortem samples from ROS/MAP (307 MCI/AD, 148 controls); model integrates SNPs, RNA, CpGs, and proteomics to classify AD</td><td colspan="1" rowspan="1">Identifies 62 features across omics layers, including Tau peptide, SLC6A12 transcript, and GDF10 with strong cross-omics correlations; outperforms single-omics models with 90% Balanced Accuracy</td><td colspan="1" rowspan="1">Require validation in independent cohorts; incorporate additional omics and refine cross-layer biological network interpretation</td><td colspan="1" rowspan="1">Accuracy: 0.95; Balanced Accuracy: 0.90; Sensitivity: 0.96; Specificity: 0.83; F1: 0.95</td><td colspan="1" rowspan="1"><xref rid="bib328" ref-type="bibr">328</xref></td></tr><tr><td colspan="1" rowspan="1">JADBIO AutoML</td><td colspan="1" rowspan="1">Clinical: Public multi-omics blood datasets; 48 AD <italic toggle="yes">vs</italic>. 22 controls (miRNA), 134 AD <italic toggle="yes">vs</italic>. 100 controls (mRNA), 25 AD <italic toggle="yes">vs</italic>. 37 controls (proteomics); Identifies accurate, low-dimensional diagnostic signatures for blood-based AD screening</td><td colspan="1" rowspan="1">Constructs high-performing biosignatures using automated ML; miRNA signature with three predictors achieved best accuracy; supports cost-effective, minimally invasive diagnostic assays</td><td colspan="1" rowspan="1">Requires external validation across independent cohorts; needs integration with broader clinical and longitudinal datasets</td><td colspan="1" rowspan="1">AUC: 0.975 (miRNA, SVM), 0.846 (mRNA, RF), 0.921 (proteomics, Ridge LR)</td><td colspan="1" rowspan="1"><xref rid="bib329" ref-type="bibr">329</xref></td></tr><tr><td colspan="1" rowspan="1">ADAS-viewer</td><td colspan="1" rowspan="1">Clinical: Multi-omics data (RNA-seq, WGS, methylation, miRNA) from 7 brain regions across 3 AMP-AD cohorts (Mayo, ROS/MAP, MSBB); supports region-specific transcript and splicing analysis in AD <italic toggle="yes">vs</italic>. controls</td><td colspan="1" rowspan="1">Enables integrated exploration of transcript isoforms, eQTLs, sQTLs, methylation, and miRNA associations; reveals brain region-specific molecular alterations and links to Braak stage and dementia severity</td><td colspan="1" rowspan="1">Limited omics layers in certain regions; expansion and functional validation needed for broader applicability</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib330" ref-type="bibr">330</xref></td></tr><tr><td colspan="1" rowspan="1">GNNRAI</td><td colspan="1" rowspan="1">Clinical: 228 samples with both transcriptomics and proteomics data from ROS/MAP; classifies AD <italic toggle="yes">vs</italic>. control using multi-omics from the dorsolateral prefrontal cortex</td><td colspan="1" rowspan="1">Leverages knowledge-graph-based GNNs to integrate transcriptomics and proteomics; identifies key biomarkers; reveals biodomain interactions including lipid&#8211;mitochondrial metabolism, synapse, and apoptosis</td><td colspan="1" rowspan="1">Requires integration of additional modalities; needs improved subgraph interpretability methods</td><td colspan="1" rowspan="1">Validation: outperformed MOGONET in 13/16 AD biodomains</td><td colspan="1" rowspan="1"><xref rid="bib314" ref-type="bibr">314</xref></td></tr><tr><td colspan="1" rowspan="1">WGCNA; gene-miRNA network</td><td colspan="1" rowspan="1">Clinical: 329 brain samples from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE63063">GSE63063</ext-link>, spanning normal (104), MCI (80), and AD (145) stages; Identify stage-specific gene and miRNA signatures for potential early diagnosis</td><td colspan="1" rowspan="1">Construct co-expression modules and gene&#8211;miRNA bipartite networks across AD stages; proposed 9 novel genes and 6 novel miRNAs as candidate biomarkers not previously reported in AD studies</td><td colspan="1" rowspan="1">Require experimental and clinical validation; expand toward mechanistic dissection and therapeutic development</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib331" ref-type="bibr">331</xref></td></tr><tr><td colspan="1" rowspan="1">M-Lasso</td><td colspan="1" rowspan="1">Clinical: 262 ROS/MAP postmortem brain samples (115 CN, 67 MCI, 80 AD); integrated SNP, RNA-seq, and proteomics data to identify multi-omic subnetworks predictive of cognitive decline</td><td colspan="1" rowspan="1">Identifies a 276-feature functionally connected subnetwork including <italic toggle="yes">APOE</italic>, <italic toggle="yes">EP300</italic>, GRB2, and PIK3R1; reveals trans-omic cascade from SNP to protein <italic toggle="yes">via</italic> gene regulation; enriched in PI3K-Akt, MAPK, and insulin signaling pathways</td><td colspan="1" rowspan="1">Limited to subjects with complete multi-omics data; lacks integration with imaging; interpretability of less-connected features remains difficult</td><td colspan="1" rowspan="1">RMSE: 0.935; MAE: 0.725 (5-fold CV); Features selected: 650 (incl. 255 SNPs, 339 genes, 56 proteins)</td><td colspan="1" rowspan="1"><xref rid="bib332" ref-type="bibr">332</xref></td></tr><tr><td colspan="1" rowspan="1">LASSO</td><td colspan="1" rowspan="1">Clinical: 80 plasma samples from SAND cohort (40 CN, 20 MCI, 20 AD); integrated proteomics, metabolomics, lipidomics to stratify AD progression</td><td colspan="1" rowspan="1">Identifies top protein and metabolite biomarkers with AUC &#8805;0.85; reveals arginine, alanine, glutamate, pyruvate pathway disruptions in MCI/AD</td><td colspan="1" rowspan="1">Requires biomarker validation in independent cohorts; unclear isoform specificity for some proteins; further integration with imaging data recommended</td><td colspan="1" rowspan="1">AUC: 0.72 (protein model), 1.00 (base + biomarker), 0.86 (Hypoxanthine)<break/>Sensitivity: 0.90 (Hypoxanthine)<break/>Specificity: 0.80 (Hypoxanthine)</td><td colspan="1" rowspan="1"><xref rid="bib333" ref-type="bibr">333</xref></td></tr><tr><td colspan="1" rowspan="1">Integrative network modeling (WGS, RNA-seq, BN, MEGENA and EMUDRA)</td><td colspan="1" rowspan="1">Clinical: 364 MSBB postmortem brain samples; stratified by CDR (0&#8211;5), Braak stage, CERAD score, and amyloid plaque density; samples span normal, MCI, and AD stages</td><td colspan="1" rowspan="1">Identify <italic toggle="yes">ATP6V1A</italic> as a key neuronal driver <italic toggle="yes">via</italic> BN and MEGENA; observe downregulation across LOAD stages; validate in hiPSC-derived neurons and Drosophila; rescue neuronal phenotypes and restore <italic toggle="yes">ATP6V1A</italic> expression with NCH-51</td><td colspan="1" rowspan="1">Requires validation in mammalian models; lacks multi-omics integration at the single-cell level; the drug mechanism of NCH-51 remains unclear</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib251" ref-type="bibr">251</xref></td></tr><tr><td colspan="1" rowspan="1">WGCNA; SCENIC; PPI network proximity modeling</td><td colspan="1" rowspan="1">Clinical: 230 brain samples from PFC, CR, VC regions (129 AD, 101 CN) across <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE44768">GSE44768</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE44770">GSE44770</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE44771">GSE44771</ext-link>; Identify AIM (A<italic toggle="yes">&#946;</italic>-induced neuroinflammation module) highly expressed in AD; ssGSEA score significantly higher in AD across regions</td><td colspan="1" rowspan="1">Identify AIM comprising 177 genes enriched in neuroinflammation and neuronal death; AIM score negatively correlated with neuron percentage (<italic toggle="yes">R</italic> = &#8722;0.81); associated with Mic1 microglia subtype; Identify 7 TF biomarkers and 20 potential repurposing drugs, including ponatinib, ibrutinib</td><td colspan="1" rowspan="1">Limited to transcriptomic integration; requires protein-level validation; the mechanisms of candidate drugs need experimental confirmation</td><td colspan="1" rowspan="1">PR-AUC: 0.943 (5-fold CV</td><td colspan="1" rowspan="1"><xref rid="bib334" ref-type="bibr">334</xref></td></tr><tr><td colspan="1" rowspan="1">TACA</td><td colspan="1" rowspan="1">Clinical: &gt;1.1 million sc/snRNA-seq profiles across 26 datasets from brain samples (hippocampus, cortex, cerebellum); covers AD, MCI, and CN individuals</td><td colspan="1" rowspan="1">TACA creation, 1.1 million single-cell profiles, 1400 differential analyses, 12 interactive tools</td><td colspan="1" rowspan="1">Integrates more multi-omics layers; improves metadata completeness; validates predicted drugs in experimental models</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib335" ref-type="bibr">335</xref></td></tr><tr><td colspan="1" rowspan="1">Random forest</td><td colspan="1" rowspan="1">Clinical: RNA-seq data from 638 ROS/MAP postmortem samples used to predict Braak stage, CERAD score, COGDX, and cognitive status at death</td><td colspan="1" rowspan="1">Uses gene regulatory network features to predict clinical phenotypes, including Braak, CERAD, and COGDX with &gt;60% accuracy</td><td colspan="1" rowspan="1">Requires broader validation across independent cohorts; model complexity from scRNA integration limits generalizability</td><td colspan="1" rowspan="1">Balanced Accuracy: 0.57 to 0.68 (AD gene prediction, 5 &#215; 10 CV)<break/>Accuracy: &gt;0.60 (phenotype prediction, top 0.05 ranked genes: COGDX, Braak, CERAD, DCFDX)</td><td colspan="1" rowspan="1"><xref rid="bib336" ref-type="bibr">336</xref></td></tr><tr><td colspan="1" rowspan="1">DRIAD</td><td colspan="1" rowspan="1">Clinical: AMP-AD postmortem RNA-seq data (MSBB and ROS/MAP); samples categorized by Braak stage into early (1&#8211;2), intermediate (3&#8211;4), and late (5&#8211;6); DRIAD trained predictors for early <italic toggle="yes">vs</italic>. late stages</td><td colspan="1" rowspan="1">Links drug-induced gene signatures to AD severity; screened 80 kinase inhibitors; identifies JAK, ULK, NEK targets and autophagy pathways</td><td colspan="1" rowspan="1">Requires <italic toggle="yes">in vivo</italic> validation; assesses BBB penetrance and toxicity; integrates more omics</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib337" ref-type="bibr">337</xref></td></tr><tr><td colspan="1" rowspan="1">MultiDCP</td><td colspan="1" rowspan="1">Clinical: 46 AD patients from AMP-AD; individualizes drug response predicted based on transcriptomic profiles; reveals 3 molecular subtypes with distinct pathway enrichment</td><td colspan="1" rowspan="1">Develops MultiDCP for dose- and context-specific prediction of chemical-induced gene expression and cell viability; applies to personalized AD drug repurposing; identifies candidate drugs reversing patient-specific AD signatures</td><td colspan="1" rowspan="1">Model currently limited to 978 landmark genes; lacks integration with proteomics and imaging data; requires experimental validation in patient-derived models</td><td colspan="1" rowspan="1">Pearson: 0.493 (gene expression, leave-new-cell-out); 0.803 (cell viability)<break/>Spearman: 0.486 (gene expression, leave-new-cell-out); 0.780 (cell viability)<break/>Precision@10: 0.496/0.476 (up/down)<break/>AUC: 0.697 (up), 0.707 (down); PR-AUC: 0.127 (up), 0.123 (down)</td><td colspan="1" rowspan="1"><xref rid="bib338" ref-type="bibr">338</xref></td></tr><tr><td colspan="1" rowspan="1">Bayesian network modeling; network proximity scoring</td><td colspan="1" rowspan="1">Clinical: 7.23 million individuals from MarketScan claims; pioglitazone cohort (<italic toggle="yes">n</italic> = 101,650) showed reduced AD risk (HR = 0.916, <italic toggle="yes">P</italic> = 0.005)</td><td colspan="1" rowspan="1">Identify 103 AD risk genes through Bayesian multi-omics inference; prioritize 130 repurposable drugs using proximity to disease modules; validate top drugs <italic toggle="yes">in vitro</italic> and population cohorts</td><td colspan="1" rowspan="1">Validate ARGs in biological assays; incorporate biomarker-confirmed AD cases for clinical precision</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib339" ref-type="bibr">339</xref></td></tr><tr><td colspan="1" rowspan="1">AlzGPS</td><td colspan="1" rowspan="1">Clinical: Integrated &gt;100 multi-omics datasets across species and brain regions; drug-dataset associations curated from &#8764;1000 AD clinical trials; drug repurposing predictions supported by case studies; NP: Clinical evidence extracted for top candidate drugs from 292 studies</td><td colspan="1" rowspan="1">Curates DNA, RNA, protein, and metabolite profiles from AD patient and model datasets; prioritizes 3000 drugs using network proximity to AD modules; enables endophenotype-specific MOA network visualization</td><td colspan="1" rowspan="1">Expands with sequencing from underrepresented populations; improves PPI completeness; integrates allele-specific and longitudinal data</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib340" ref-type="bibr">340</xref></td></tr><tr><td colspan="1" rowspan="1">DRPS/C</td><td colspan="1" rowspan="1">Clinical: RNA-seq (<italic toggle="yes">n</italic> = 159), microarray (<italic toggle="yes">n</italic> = 108), and proteomic (<italic toggle="yes">n</italic> = 17) AD datasets from Synapse, ArrayExpress, and PRIDE; predicts 31 anti-AD drug candidates across transcriptomic and proteomic signatures</td><td colspan="1" rowspan="1">Constructs DGPSD using 61,019 drug-induced gene signatures from 1520 compounds; identifies four nervous system drugs targeting sodium channels and monoamine oxidase pathways</td><td colspan="1" rowspan="1">Requires validation of drug efficacy <italic toggle="yes">in vivo</italic> and clinical trials; expand DRPS/C framework to integrate additional omics layers and patient-level precision medicine</td><td colspan="1" rowspan="1">AUC for high DRPC class (GBM): 0.708</td><td colspan="1" rowspan="1"><xref rid="bib341" ref-type="bibr">341</xref></td></tr><tr><td colspan="1" rowspan="1">TRS</td><td colspan="1" rowspan="1">Clinical: GWAS from 27 studies, RNA-seq from 1699 brains, proteomics from 1188 brains; assesses 600 AMP-AD targets and 192 drug targets; NP: Included cognition-linked genetic traits</td><td colspan="1" rowspan="1">Ranks AD risk genes by integrating GWAS, RNA, and protein data; classifies targets into 19 domains, including synapse, metabolism, and immunity</td><td colspan="1" rowspan="1">Expands to imaging and metabolomics; applies to AD subtypes; refines domain-level resolution</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib342" ref-type="bibr">342</xref></td></tr><tr><td colspan="1" rowspan="1">Iterative WGCNA; Subtype clustering; Linear mixed model</td><td colspan="1" rowspan="1">Clinical: 1258 postmortem brain samples from ROS/MAP, Mayo, and MSBB; stratified AD cases into molecular subtypes by region; subtype B in ROS/MAP associated with protective variant rs1990620 in TMEM106B<break/>NP: No significant difference in Braak stage, CERAD score, MMSE, or cognitive decline across subtypes</td><td colspan="1" rowspan="1">Identify 68 transcriptomic submodules across six brain regions; uncover subtype-specific modules linked to immune suppression and synaptic function; reveal new genetic modifiers such as TMEM106B and RBM39</td><td colspan="1" rowspan="1">Validate subtype dynamics across disease course; integrate proteomic and metabolic data; apply to subtype-targeted therapy development</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib343" ref-type="bibr">343</xref></td></tr><tr><td colspan="1" rowspan="1">Perspective analytics</td><td colspan="1" rowspan="1">Clinical: 380 AD post-mortem brains (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE84422">GSE84422</ext-link>), six molecular classes; NP: low/high dementia label</td><td colspan="1" rowspan="1">Learns non-linear gene interactions from small, high-dimensional data; outputs explainable driver-gene signatures that reveal AD heterogeneity beyond conventional analyses</td><td colspan="1" rowspan="1">The proprietary NetraAI limits reproducibility; future work focuses on therapeutic translation of its findings</td><td colspan="1" rowspan="1">Leave-out cross-validation accuracy &#8805;0.75 for each perspective model; no AUC, sensitivity or specificity reported</td><td colspan="1" rowspan="1"><xref rid="bib344" ref-type="bibr">344</xref></td></tr><tr><td colspan="1" rowspan="1">RF; LASSO; SVM</td><td colspan="1" rowspan="1">Clinical: 737 AD samples from 8 GEO datasets; Identify 3 metabolic subtypes; MCA associated with higher <italic toggle="yes">APOE4</italic> frequency, <italic toggle="yes">&#946;</italic>-secretase, <italic toggle="yes">&#947;</italic>-secretase, NFTs, and Braak</td><td colspan="1" rowspan="1">Define metabolic AD subtypes with distinct immune and metabolic signatures; Identify 8 feature genes; validated with qRT-PCR and diagnostic nomogram</td><td colspan="1" rowspan="1">Validate gene expression in human cohorts; clarify inconsistent KCNC1 results; explore the mechanism of the metabolism-immunity link</td><td colspan="1" rowspan="1">AUC (training/testing):<break/>Nomogram: 0.788/0.770<break/><italic toggle="yes">GFAP</italic>: 0.729/0.708<break/><italic toggle="yes">EZR</italic>: 0.692/0.698<break/><italic toggle="yes">COLEC12</italic>: 0.656/0.677<break/><italic toggle="yes">KIAA0513</italic>: 0.652/0.692<break/><italic toggle="yes">CYB5R3</italic>: 0.698/0.575<break/><italic toggle="yes">DARS</italic>: 0.560/0.566<break/><italic toggle="yes">KCNC1</italic>: 0.558/0.566<break/><italic toggle="yes">TST</italic>: 0.557/0.584</td><td colspan="1" rowspan="1"><xref rid="bib345" ref-type="bibr">345</xref></td></tr><tr><td colspan="1" rowspan="1">ConvAE</td><td colspan="1" rowspan="1">Clinical: 1.6M patients from Mount Sinai Health System; stratifies 3 AD subgroups across early-onset, late-onset with cerebrovascular disease, and mild-to-moderate AD; NP: Subgroups defined by dementia severity and symptom patterns; NI: MRI and PET used for differential diagnosis in the early-onset group</td><td colspan="1" rowspan="1">Develops ConvAE to learn unsupervised patient representations from raw EHRs; reveals meaningful AD subtypes reflecting disease onset, progression, and comorbidities</td><td colspan="1" rowspan="1">Improves EHR data preprocessing; reduces noise and bias</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib346" ref-type="bibr">346</xref></td></tr><tr><td colspan="1" rowspan="1">Consensus clustering</td><td colspan="1" rowspan="1">Clinical: 108 cognitively normal adults from Knight ADRC; stratified into three proteomic clusters with distinct progression risk; NP: Longitudinal CDR and MMSE used to assess cognitive decline across clusters; NI: MRI cortical thickness, WMH volume, PET-PiB and PET-AV1451 used to assess amyloid and tau pathology</td><td colspan="1" rowspan="1">Identifies proteomic subtypes predictive of preclinical AD progression; cluster 1 enriched for <italic toggle="yes">APOE4</italic> and tau PET positivity; cluster 3 showed greater WMH burden and atrophy</td><td colspan="1" rowspan="1">Validates clusters in larger multi-ethnic cohorts; integrates metabolomics and transcriptomics; links clusters to treatment response</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib347" ref-type="bibr">347</xref></td></tr><tr><td colspan="1" rowspan="1">NMF clustering</td><td colspan="1" rowspan="1">Clinical: 425 A<italic toggle="yes">&#946;</italic><sup>+</sup> individuals from EMIF-AD MBD and ADNI cohorts; identify 3 CSF proteomic subtypes; NP: MMSE and domain-specific tests; CDR-SB tracked progression; NI: Cortical atrophy in hippocampus, temporal cortex, and precuneus; posterior cingulate thinner in subtypes 2 and 3</td><td colspan="1" rowspan="1">Defines subtypes with hyperplasticity, immune activation, and BBB dysfunction profiles; subtype 2 had 2.5-fold higher risk of progression than subtype 1; subtypes differed in tau, APP, and inflammation-related proteins</td><td colspan="1" rowspan="1">Validates across diverse populations; integrates plasma markers; explores subtype-specific therapeutic strategies</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib348" ref-type="bibr">348</xref></td></tr><tr><td colspan="1" rowspan="1">Blood transcriptome-based module model</td><td colspan="1" rowspan="1">Clinical: 422 individuals in discovery and 64 in validation cohort; distinguish 214 AD from 208 NC, 26 AD from 38 NC; NP: Module scores correlate with MoCA<break/>NI: Associated with hippocampal and amygdala volume</td><td colspan="1" rowspan="1">Identifies 6 gene modules; enables high-accuracy AD classification and stratification beyond ATN biomarkers</td><td colspan="1" rowspan="1">Validates in larger cohorts; examines cross-ethnic generalizability; integrates with proteomic and longitudinal data</td><td colspan="1" rowspan="1">AUC (discovery/validation):<break/>0.990/0.897 (M02)<break/>0.983/0.927 (M03)<break/>0.998/0.920 (M15)<break/>0.998/0.920 (combined model)</td><td colspan="1" rowspan="1"><xref rid="bib349" ref-type="bibr">349</xref></td></tr><tr><td colspan="1" rowspan="1">PCA; bicluster detection</td><td colspan="1" rowspan="1">Clinical: 2739 AD <italic toggle="yes">vs</italic>. 5478 NC (UKB); 500 AD <italic toggle="yes">vs</italic>. 470 NC (ADNI); NP: Bicluster 2 linked to faster PACC decline (<italic toggle="yes">&#946;</italic> = &#8722;0.60, <italic toggle="yes">P</italic> = 0.004); NI: Bicluster 2 linked to increased CSF p-tau (<italic toggle="yes">&#946;</italic> = 0.45, <italic toggle="yes">P</italic> = 0.041)</td><td colspan="1" rowspan="1">Identify replicable genetic subtypes; bicluster 2 shows aggressive progression</td><td colspan="1" rowspan="1">Interpret non-coding SNPs; validate in diverse populations; assess functional impacts</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib350" ref-type="bibr">350</xref></td></tr><tr><td colspan="1" rowspan="1">sPLS-DA</td><td colspan="1" rowspan="1">Clinical: 94 asymptomatic individuals; 48 amyloid+, 46 amyloid&#8722;; NI: Amyloid PET SUVr; correlated with CSF A<italic toggle="yes">&#946;</italic><sub>42</sub> and p-tau</td><td colspan="1" rowspan="1">Identifies blood-based signature (MCFA, 4-nitrophenol, 64 transcripts); achieves 99.4% prediction for amyloid positivity</td><td colspan="1" rowspan="1">Small sample size; limited generalizability; no cognitive follow-up</td><td colspan="1" rowspan="1">AUC: 0.978 (metabolomics), 0.881 (transcriptomics), 0.732 (lipidomics), 0.994 (metabolomics + transcriptomics), 0.978 (metabolomics + lipidomics), 0.866 (transcriptomics + lipidomics)</td><td colspan="1" rowspan="1"><xref rid="bib351" ref-type="bibr">351</xref></td></tr><tr><td colspan="1" rowspan="1">Similarity network fusion; Spectral clustering</td><td colspan="1" rowspan="1">Clinical: 1313 ROS/MAP participants; 513 with 3-modal data; subtypes associated with cognitive decline; NP: Subtype 5 showed fastest decline in global cognition (<italic toggle="yes">P</italic> = 5.9 &#215; 10<sup>&#8722;3</sup>)</td><td colspan="1" rowspan="1">Identify ageing subtypes integrating RNAseq, DNA methylation, histone acetylation; subtype 5 linked to poor cognitive outcomes</td><td colspan="1" rowspan="1">Optimal cluster number inconsistent across metrics; limited diversity; no standard cognitive biomarkers used</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib352" ref-type="bibr">352</xref></td></tr><tr><td colspan="1" rowspan="1">Integrative single-nucleus multi-omics</td><td colspan="1" rowspan="1">Clinical: 24 individuals (12 LOAD, 12 control, <italic toggle="yes">APOE &#949;3/&#949;3</italic>); 209,518 nuclei (RNA), 79,771 nuclei (ATAC), temporal cortex</td><td colspan="1" rowspan="1">Defines 518 LOAD-associated CCANs across 15 cell types; identifies cCRE-linked DEGs and TFs; prioritizes 20 regulatory SNPs</td><td colspan="1" rowspan="1">ATAC&#8211;RNA cluster-matching accuracy reported as 75.6%; no functional validation of regulatory SNPs; limited generalizability across brain regions</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib319" ref-type="bibr">319</xref></td></tr><tr><td colspan="1" rowspan="1">sc2GWAS</td><td colspan="1" rowspan="1">Clinical: 784 GWAS traits (&#8764;5000 studies); 149 scRNA-seq datasets from &#8764;900 donors; &#8764;6.3 million cells analyzed; AD case study based on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE207629">GSE207629</ext-link> (brain immune cells)</td><td colspan="1" rowspan="1">Enables trait&#8211;cell mapping by integrating GWAS and single-cell data; identifies AD-enriched cell types and driver genes</td><td colspan="1" rowspan="1">Limited to scRNA-seq; lacks proteomic/epigenomic integration; trait&#8211;cell scores depend on GWAS and cell-type resolution</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib261" ref-type="bibr">261</xref></td></tr><tr><td colspan="1" rowspan="1">MOSEGCN</td><td colspan="1" rowspan="1">Clinical: ROS/MAP (AD: 182, Control: 169); BRCA (<italic toggle="yes">n</italic> = 875, 5 subtypes); GBM (<italic toggle="yes">n</italic> = 274, 4 subtypes); all with mRNA, miRNA, and DNA methylation</td><td colspan="1" rowspan="1">Demonstrates robust multi-omics classification across AD and cancers; identifies AD-related biomarkers</td><td colspan="1" rowspan="1">Lacks clinical/longitudinal validation; omics types are limited; no imaging integration</td><td colspan="1" rowspan="1">ROS/MAP: Accuracy: 0.8300; AUC: 0.832; F1: 0.827</td><td colspan="1" rowspan="1"><xref rid="bib262" ref-type="bibr">262</xref></td></tr><tr><td colspan="1" rowspan="1">MINDSETS</td><td colspan="1" rowspan="1">Clinical: ANMerge dataset; 1702 participants including AD (612), MCI (425), CTL (425), VaD (240); used longitudinal MRI, genotype, clinical, and MMSE data; NP: MMSE scores included (AD: mean 20.8, VaD: 22.6, MCI: 27.1, CTL: 29.1); NI: Longitudinal MRI scans at 0, 3, 12 months; segmented into 32 brain regions using SynthSeg and PyRadiomics</td><td colspan="1" rowspan="1">Achieves 89.25% accuracy in AD <italic toggle="yes">vs</italic>. VaD classification; model interpretable <italic toggle="yes">via</italic> SHAP; captures treatment response in MCI with longitudinal monitoring</td><td colspan="1" rowspan="1">Model not validated on external cohorts; longitudinal data introduces variability; requires tuning for other populations</td><td colspan="1" rowspan="1">Accuracy: 0.8925; AUC: 0.8361; F1: 0.8113</td><td colspan="1" rowspan="1"><xref rid="bib255" ref-type="bibr">255</xref></td></tr><tr><td colspan="1" rowspan="1">MSBB multi-omics platform</td><td colspan="1" rowspan="1">Clinical: 364 postmortem brain donors (Control, MCI, AD); Braak score: 2.1&#8211;5.1; CDR: 0&#8211;5; sex: 238 female, 126 male; AOD: 61&#8211;108 (mean: 84.7 &#177; 9.7); ethnicities: European (<italic toggle="yes">n</italic> = 301), African American (<italic toggle="yes">n</italic> = 36), Latino (<italic toggle="yes">n</italic> = 25), Asian (<italic toggle="yes">n</italic> = 1); NI: Neuropathological imaging data (plaque density, Braak staging) across 4 brain regions</td><td colspan="1" rowspan="1">Provides matched WGS, WES, RNA-seq (from BM10, BM22, BM36, BM44), and proteomics (BM10); highly curated clinical metadata; key resource for AD network modeling</td><td colspan="1" rowspan="1">Not model-based; no prediction task; requires external modeling; RNA&#8211;protein correlation low; batch effects in proteomics require correction</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib353" ref-type="bibr">353</xref></td></tr><tr><td colspan="1" rowspan="1">Federated LSTM with FedAvg</td><td colspan="1" rowspan="1">Clinical: 44,899 MCI patients; 6391 converted to AD; data from OneFlorida+ (6 simulated sites: North/Central/South Florida, Alabama, Georgia, Other); subgroup analysis by 6 m, 12 m, 24 m, unrestricted cohorts</td><td colspan="1" rowspan="1">Demonstrates the feasibility of federated learning for AD risk prediction across real-world, privacy-constrained settings; identifies key features (BMI, vitamin B12, BP, HDL, cholesterol) <italic toggle="yes">via</italic> SHAP</td><td colspan="1" rowspan="1">Excludes imaging/notes; EHR data may be incomplete; diagnostic miscoding possible; limited generalizability beyond southeastern U.S.</td><td colspan="1" rowspan="1">AUC (personalized): 0.794 (North FL), 0.744 (South FL); AUC (global): 0.837 (South FL)</td><td colspan="1" rowspan="1"><xref rid="bib263" ref-type="bibr">263</xref></td></tr><tr><td colspan="1" rowspan="1">Tri-COAT</td><td colspan="1" rowspan="1">Clinical: ADNI cohort; total <italic toggle="yes">n</italic> = 494 (slow: 177, intermediate: 302, fast: 15); grouped by 2-year MMSE change using baseline imaging, SNPs, and 7 cognitive scores; NI: Baseline T1-weighted MRI segmented into 72 ROIs</td><td colspan="1" rowspan="1">Enables early subtype prediction using baseline-only data; interpretable attention linking CD2AP&#8211;TRABSCOR&#8211;temporal gyrus; distinguishes fast progression subtype</td><td colspan="1" rowspan="1">Limited generalizability beyond ADNI; small fast-subtype sample (<italic toggle="yes">n</italic> = 15); no PET or transcriptomic integration</td><td colspan="1" rowspan="1">AUROC: 0.734 &#177; 0.076</td><td colspan="1" rowspan="1"><xref rid="bib264" ref-type="bibr">264</xref></td></tr><tr><td colspan="1" rowspan="1">SEA-AD atlas</td><td colspan="1" rowspan="1">Clinical: 84 postmortem donors (age: 65&#8211;108, mean 88; 51 female, 33 male); stratified by ADNC (9 no AD, 12 low, 21 intermediate, 42 high); 31/42 high-ADNC donors had dementia; NP: Longitudinal cognitive testing across 4 domains; memory decline slope: &#8722;0.15 in severely affected <italic toggle="yes">vs</italic> &#8722;0.11 in others</td><td colspan="1" rowspan="1">Integrates snRNA-seq, snATAC-seq, snMultiome, and MERFISH; maps 3.4 million nuclei to 139 supertypes; defines pseudoprogression score (CPS) to track disease trajectory</td><td colspan="1" rowspan="1">Not AI-based; no predictive model; analysis limited to MTG and A9 regions; lacks PET/MRI integration</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib354" ref-type="bibr">354</xref></td></tr><tr><td colspan="1" rowspan="1">MADDi</td><td colspan="1" rowspan="1">Clinical: ADNI cohort; 239 participants with all 3 modalities (CN: 165, MCI: 39, AD: 35); NP: 29 clinical features (e.g., memory, executive function, language tests); F1 per class: AD = 100%, MCI = 76.66%, CN = 97.81%; NI: T1 MRI (3 slices per patient), standardized by ADNI; 551 total MRI scans used for training</td><td colspan="1" rowspan="1">Integrates structured clinical, genetic (SNP), and imaging features <italic toggle="yes">via</italic> cross-modal attention; interpretable attention layers highlight key modalities</td><td colspan="1" rowspan="1">Small sample size for MCI and AD in the overlap group; excludes PET, longitudinal data, or unstructured text; limited external validation</td><td colspan="1" rowspan="1">Accuracy: 0.9688<break/>F1: 0.9141<break/>Class-wise F1: 1.00 (AD)/0.7666 (MCI)/0.9781 (CN)</td><td colspan="1" rowspan="1"><xref rid="bib266" ref-type="bibr">266</xref></td></tr><tr><td colspan="1" rowspan="1">Federated GEIDI</td><td colspan="1" rowspan="1">Clinical: ADNI cohort, <italic toggle="yes">n</italic> = 697 (AD: 96; MCI: 366; CU: 235); imaging and blood samples matched within 5 months; NP: MMSE (AD: 21.8 &#177; 4.1; MCI: 28.0 &#177; 1.7; CU: 29.1 &#177; 1.2)</td><td colspan="1" rowspan="1">Integrates gene expression and imaging <italic toggle="yes">via</italic> genotype-specific stratification; identifies XRCC1, SEC14L2 as subgroup-specific markers</td><td colspan="1" rowspan="1">No patient-level prediction; limited to two ROIs; no external validation</td><td colspan="1" rowspan="1">Hypergeometric p: 0.00039 (<italic toggle="yes">APOE</italic>/<italic toggle="yes">HIPP</italic>), 0.017 (rs942439)<break/>TPR: up to 0.61 (SNP detection)</td><td colspan="1" rowspan="1"><xref rid="bib267" ref-type="bibr">267</xref></td></tr><tr><td colspan="1" rowspan="1">BIONIC</td><td colspan="1" rowspan="1">Clinical: ROS/MAP cohort (TMT proteomics, <italic toggle="yes">n</italic> = 400); ADNI cohort (MCI: 112; mild dementia: 132); stratified by MMSE and CDR; NP: MMSE &#8805;21 for early AD; CDR memory box score &#8805;0.5</td><td colspan="1" rowspan="1">Reveals stress-response-mediated A<italic toggle="yes">&#946;</italic>&#8211;tau modulators (HSPA5, GPNMB<sup>+</sup> microglia, GFAP<sup>+</sup> astrocytes); cross-validated in ROS/MAP, MSBB, ACT, and ADNI cohorts</td><td colspan="1" rowspan="1">Needs mechanistic validation of GPNMB<sup>+</sup> microglia; lacks individual-level prognostic capacity; no imaging or PET data</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib53" ref-type="bibr">53</xref></td></tr><tr><td colspan="1" rowspan="1">Hybrid multimodal DNN + SVR</td><td colspan="1" rowspan="1">Clinical: 506 NA-ADNI participants (MCI or mild AD); baseline CDR-SB, MMSE &#8805;24, A<italic toggle="yes">&#946;</italic><sup>+</sup> (CSF or PET); follow-up 2 years</td><td colspan="1" rowspan="1">Predicts individual cognitive decline (CDR-SB) and enables AI-driven stratified randomization; reduces allocation bias by 22%, trial sample size by 37%</td><td colspan="1" rowspan="1">Higher error in outliers; limited to CDR-SB endpoint; requires validation in real trials with other endpoints</td><td colspan="1" rowspan="1">MAE: 1.07; Corr: 0.58</td><td colspan="1" rowspan="1"><xref rid="bib268" ref-type="bibr">268</xref></td></tr><tr><td colspan="1" rowspan="1">NeuroPM-MCM + pTIF</td><td colspan="1" rowspan="1">Clinical: ADNI cohort (<italic toggle="yes">n</italic> = 504); each with 4&#8211;6 imaging modalities and &#8805;4 timepoints; longitudinal span = 5.1 &#177; 3.6 years</td><td colspan="1" rowspan="1">Predicts causal propagation of tau/amyloid/glucose alterations <italic toggle="yes">via</italic> brain networks; pTIF derives patient-specific therapy needs from model inversion</td><td colspan="1" rowspan="1">Requires high-quality longitudinal imaging; no plasma/PET-independent validation yet</td><td colspan="1" rowspan="1"><italic toggle="yes">R</italic><sup>2</sup>: 0.92 (first TP), 0.71 (last TP) for 6-modal MCM simulation; <italic toggle="yes">P</italic> &lt; 10<sup>&#8722;6</sup></td><td colspan="1" rowspan="1"><xref rid="bib269" ref-type="bibr">269</xref></td></tr><tr><td colspan="1" rowspan="1">10-protein CSF model (LASSO)</td><td colspan="1" rowspan="1">Clinical: <italic toggle="yes">n</italic> = 2286 across Knight ADRC, FACE, ADNI, Stanford ADRC; 1254 AD, 750 controls; external validation in Stanford ADRC (<italic toggle="yes">n</italic> = 107); NI: Amyloid PET (<italic toggle="yes">n</italic> = 1127), Tau PET (<italic toggle="yes">n</italic> = 598); model predicts PET+ and AD status</td><td colspan="1" rowspan="1">Identifies robust, AT-stratified CSF proteomic signatures; model predicts A+T+, clinical AD, PET+, and progression to AD; replicable across platforms and cohorts</td><td colspan="1" rowspan="1">Requires CSF; plasma model needs re-training; lower performance in non-AD dementia (AUC 0.49&#8211;0.67)</td><td colspan="1" rowspan="1">AUC: &gt;0.98 (biomarker); 0.89 to 0.97 (clinical); 0.90 (PET)<break/>OR: 2.03 (95% CI: 1.03&#8211;4.32)</td><td colspan="1" rowspan="1"><xref rid="bib270" ref-type="bibr">270</xref></td></tr><tr><td colspan="1" rowspan="1">EMIF-AD MBD cohort</td><td colspan="1" rowspan="1">Clinical: 1221 individuals (NC: 492; MCI: 527; AD-type dementia: 202); age: 67.9 &#177; 8.3; follow-up (mean: 2.3 years) in 758 individuals</td><td colspan="1" rowspan="1">Multicenter harmonized database with CSF, plasma, MRI, GWAS, methylation, and metabolomics; enables endophenotype-based biomarker discovery</td><td colspan="1" rowspan="1">Heterogeneous data acquisition; partial missingness across modalities; no direct prediction model</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib355" ref-type="bibr">355</xref></td></tr><tr><td colspan="1" rowspan="1">Graph diffusion-based AD gene network</td><td colspan="1" rowspan="1">Clinical: Gene expression datasets (microarray <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE1297">GSE1297</ext-link>, scRNA-seq GDS1979, snRNA-seq AD00204); no individual diagnosis; NI: Not used; analysis based on regulatory topology of 2363 AD genes in an 11K-gene consensus network</td><td colspan="1" rowspan="1">Constructs a robust AD-specific network from 15 datasets using multi-layer graph diffusion; reveals hub/periphery AD gene functions; identifies PON3 as an influential peripheral AD gene</td><td colspan="1" rowspan="1">No subject-level prediction; lacks clinical/diagnostic labels; gene-level inference only</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib226" ref-type="bibr">226</xref></td></tr><tr><td colspan="1" rowspan="1">Multi-omics mediation model</td><td colspan="1" rowspan="1">Clinical: 166 participants (HC: 61, MCI: 75, AD: 30); age: 50&#8211;85; MoCA + MMSE + AVLT; AD diagnosed per NIA-AA and DSM-IV; NP: MMSE (HC: 28.7, MCI: 25.8, AD: 14.7); AVLT 4-domain scores (all <italic toggle="yes">P</italic> &lt; 0.001)</td><td colspan="1" rowspan="1">First integrative model to define microbiota &#8594; metabolites &#8594; brain &#8594; cognition mediation pathways in AD; reveals progressive alterations in 10 microbial taxa, 26 metabolites, and 74 GM/WM regions</td><td colspan="1" rowspan="1">Cross-sectional; no AI/predictive modeling; diagnosis lacks PET or fluid biomarkers; not externally validated</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib356" ref-type="bibr">356</xref></td></tr><tr><td colspan="1" rowspan="1">MFDDA</td><td colspan="1" rowspan="1">Clinical: ADNI cohort, <italic toggle="yes">n</italic> = 1171 (HC, EMCI, LMCI, LOAD); analyzed 7700+ multimodal brain images + 146 plasma &amp; 87 CSF markers; NP: MMSE used to define symptom severity; stratified into 4 states (HC&#8211;EMCI&#8211;LMCI&#8211;LOAD); NI: A<italic toggle="yes">&#946;</italic> PET, FDG-PET, ASL MRI, structural MRI, resting-state fMRI; 78 grey matter regions assessed</td><td colspan="1" rowspan="1">Proposes generative spatiotemporal trajectories of biomarker abnormality; finds vascular dysregulation precedes A<italic toggle="yes">&#946;</italic>, metabolism, function, atrophy; identifies early plasma biomarkers (IP-10, PAPP-A, hFABP)</td><td colspan="1" rowspan="1">Does not build predictive models; not validated on external cohorts; linearity assumption may oversimplify complex interactions</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib357" ref-type="bibr">357</xref></td></tr><tr><td colspan="1" rowspan="1">Ceramide-based prognostic model</td><td colspan="1" rowspan="1">Clinical: 63 participants with baseline blood; NC (<italic toggle="yes">n</italic> = 25), MCI (<italic toggle="yes">n</italic> = 17), AD (<italic toggle="yes">n</italic> = 21); 71 completed 1-year follow-up; NP: MMSE (NC: 28.8, MCI: 27.2, AD: 22.2); detailed battery: ADAS-Cog, CVLT, WMS, Trails A/B</td><td colspan="1" rowspan="1">Plasma ceramides C22:0 and C24:0 predict 1-year cognitive decline and hippocampal volume loss in MCI; an early, non-invasive blood-based biomarker of AD progression</td><td colspan="1" rowspan="1">Limited sample size; unclear laterality mechanism (right hippocampus only); no model generalizability across cohorts</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib358" ref-type="bibr">358</xref></td></tr><tr><td colspan="1" rowspan="1">Colocalization + mediation analysis</td><td colspan="1" rowspan="1">Clinical: UK Biobank imaging-genetics cohort, <italic toggle="yes">n</italic> = 38,195; AD-by-proxy: 9788, controls: 28,407; NI: T1 MRI-derived volumetric endophenotypes from 145 brain ROIs (MUSE), especially entorhinal cortex</td><td colspan="1" rowspan="1">Discovery SNP rs6585827 upregulates BTBD16 in oligodendrocytes, reduces atrophy in the entorhinal cortex, and protects against AD</td><td colspan="1" rowspan="1">Lacks patient-level prediction; findings rely on AD-by-proxy; no deep learning integration</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib386" ref-type="bibr">386</xref></td></tr><tr><td colspan="1" rowspan="1">RF with SHAP</td><td colspan="1" rowspan="1">Clinical: 810 unique participants; OASIS-3; 5 labels (CN: 2248, AD: 669, Non-AD: 106, Uncertain: 287, Others: 26); NP: MMSE, Logimem, Digit Span, Boston, WAIS, Trail A/B</td><td colspan="1" rowspan="1">First five-class explainable ML model integrating clinical, cognitive, and structural MRI data; SHAP identifies Memory, Sumbox, Judgment, etc., as top features</td><td colspan="1" rowspan="1">Class imbalance (solved by SMOTE); not externally validated; shallow models used (no DL)</td><td colspan="1" rowspan="1">Accuracy: 0.9881; Precision: 0.9894; Recall: 0.9879; F1: 0.9875; AUC: 0.9997</td><td colspan="1" rowspan="1"><xref rid="bib271" ref-type="bibr">271</xref></td></tr><tr><td colspan="1" rowspan="1">ChatGPT-driven drug repurposing hypothesis</td><td colspan="1" rowspan="1">Clinical: VUMC and All of Us cohorts; 2 EHR datasets totaling &#8764;3.2 M patients; 10 drugs tested in matched cohorts age &#8805;65; NP: AD diagnosed using ICD codes (PPV 94%); AD onset tracked for 10 years</td><td colspan="1" rowspan="1">ChatGPT-generated drug list validates in real-world data; metformin, simvastatin, and losartan are associated with reduced AD risk (HR: 0.67, 0.84, 0.76); meta-analysis supported the top 3 drugs</td><td colspan="1" rowspan="1">No mechanism exploration; ChatGPT prioritization based on literature frequency, not biological evidence; no new AI training</td><td colspan="1" rowspan="1">HR: 0.67 (metformin, <italic toggle="yes">P</italic> = 6.4 &#215; 10<sup>&#8722;5</sup>); 0.84 (simvastatin, <italic toggle="yes">P</italic> = 0.024); 0.76 (losartan, <italic toggle="yes">P</italic> = 0.017)</td><td colspan="1" rowspan="1"><xref rid="bib360" ref-type="bibr">360</xref></td></tr><tr><td colspan="1" rowspan="1">Transformer-based multimodal model</td><td colspan="1" rowspan="1">Clinical: 51,269 participants across 9 cohorts (ADNI, NACC, FHS, etc.); test: 12,950; predicts NC, MCI, DE, 10+ dementia etiologies; NI: T1/T2/FLAIR/SWI/DWI MRI; PET (A<italic toggle="yes">&#946;</italic>, tau, FDG); DaTscan; supports inference with partial imaging</td><td colspan="1" rowspan="1">Enables accurate differential diagnosis of mixed/multi-etiology dementia using incomplete data; interpretable <italic toggle="yes">via</italic> SHAP and aligned with postmortem/pathology</td><td colspan="1" rowspan="1">Lower AUPR in rare conditions; modest generalization on FHS data; no staging (CDR levels merged); class imbalance</td><td colspan="1" rowspan="1">AUROC: 0.96 (micro), 0.94 (weighted); AUPR: 0.70 (micro); AI-augmented neurologist AUROC: 0.2625, AUPR: 0.7323</td><td colspan="1" rowspan="1"><xref rid="bib272" ref-type="bibr">272</xref></td></tr><tr><td colspan="1" rowspan="1">Multiomics clustering and subtyping using ML</td><td colspan="1" rowspan="1">Clinical: ADNI cohort (<italic toggle="yes">n</italic> = 377 for structural MRI; <italic toggle="yes">n</italic> = 130 for fMRI); includes cognitively normal, MCI, and AD dementia patients</td><td colspan="1" rowspan="1">Identify consistent anatomical and functional subtypes across datasets; shows alignment with known clinical variants; potential to define predictive multiomics biotypes for stratified medicine</td><td colspan="1" rowspan="1">Lack of standardization in subtyping; subtypes often overlap; limited external validation; clinical translation depends on integration with biomarkers like PRS and metabolite panels</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib361" ref-type="bibr">361</xref></td></tr><tr><td colspan="1" rowspan="1">Joint model for longitudinal + survival data</td><td colspan="1" rowspan="1">Clinical: 384 MCI patients from ADNI-1; mean age: 74.7; MMSE: 24&#8211;30; <italic toggle="yes">APOE4</italic><sup>+</sup> 54.2%; 200 converted to AD during 2.3 years mean follow-up; remaining 184 non-converters.; NP: ADAS-Cog13, RAVLT, MMSE, CDR-SB, MoCA.; NI: FDG-PET, MRI volumetrics (hippocampus, middle temporal gyrus, entorhinal cortex)</td><td colspan="1" rowspan="1">Joint modeling approach incorporates time-varying markers with survival data; ADAS-Cog13 identify as the strongest longitudinal predictor of AD conversion; cognitive markers outperform imaging in discrimination power over time</td><td colspan="1" rowspan="1">Imaging markers (FDG-PET, MRI) show lower discriminative power in later stages; CSF data excluded due to limited availability; joint model supports only a single longitudinal marker at a time; external validation needed</td><td colspan="1" rowspan="1">HR: 2.92 (ADAS-Cog13, 95 % CI 2.33 to 3.66); 3.16 (RAVLT); 1.95 (FAQ); 2.11 (FDG-PET)<break/>AUC: 0.74 to 0.86 (ADAS-Cog13); 0.76 to 0.85 (RAVLT)<break/>DDI: 0.79 (ADAS-Cog13, 6 to 12 months)</td><td colspan="1" rowspan="1"><xref rid="bib362" ref-type="bibr">362</xref></td></tr><tr><td colspan="1" rowspan="1">VBpMKL + MCI-CPS</td><td colspan="1" rowspan="1">Clinical: ADNI-1 (<italic toggle="yes">n</italic> = 125) and ADNI-GO/2 (<italic toggle="yes">n</italic> = 98) MCI patients; 3-year conversion prediction to AD; subtype-specific modeling; NI: 103 sMRI ROI volumes</td><td colspan="1" rowspan="1">Incorporate molecular subtype classification to enhance prediction; VBpMKL handles multimodal data (SNP, mRNA, sMRI); outperforms SVM, RF, logistic regression</td><td colspan="1" rowspan="1">Limited generalizability due to small sample size; requires validation on larger datasets; interpretability of kernel weights is still challenging</td><td colspan="1" rowspan="1">AUC: 0.8581 (subtype I), 0.8623 (subtype II), 0.83/0.78 (overall, internal/external)<break/>Accuracy: 0.7920<break/>Sensitivity: 0.8125<break/>Specificity: 0.7792</td><td colspan="1" rowspan="1"><xref rid="bib273" ref-type="bibr">273</xref></td></tr><tr><td colspan="1" rowspan="1">CNN + LRP</td><td colspan="1" rowspan="1">Clinical: 193 AD patients and 151 healthy controls from ADNI; 969 structural MRI scans; diagnosis based on ADNI clinical criteria; NI: relevance maps</td><td colspan="1" rowspan="1">First to apply LRP to 3D CNNs for MRI-based AD classification; generates individual heatmaps indicating decision-relevant brain regions; relevance scores correlated with hippocampal volume</td><td colspan="1" rowspan="1">Model trained only on AD <italic toggle="yes">vs</italic> HC; generalizability to MCI or early-stage detection not assessed; dependence on model quality for LRP interpretability; no cross-modal validation</td><td colspan="1" rowspan="1">Test accuracy: 0.8796; Validation accuracy: 0.9100; Correlation between LRP relevance and hippocampal volume: <italic toggle="yes">&#961;</italic> = &#8722;0.560, <italic toggle="yes">P</italic> &lt; 10<sup>&#8722;3</sup></td><td colspan="1" rowspan="1"><xref rid="bib363" ref-type="bibr">363</xref></td></tr><tr><td colspan="1" rowspan="1">Non-visual XAI approaches</td><td colspan="1" rowspan="1">Clinical: describes applications on modalities such as MRI; X-ray; CT in secondary examples</td><td colspan="1" rowspan="1">Provide a structured taxonomy of non-visual XAI techniques in medical imaging, including case-based, textual, and auxiliary methods; integrate uncertainty estimation and model transparency into clinical workflows</td><td colspan="1" rowspan="1">Lack of clinical validation and integration studies; subjective perception of explanation quality; absence of standardized evaluation protocols; challenges in selecting appropriate XAI methods per clinical use-case</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib364" ref-type="bibr">364</xref></td></tr><tr><td colspan="1" rowspan="1">MCAD</td><td colspan="1" rowspan="1">Clinical: Diagnosis of AD, MCI, and CN using 467 multi-modal (sMRI, FDG-PET, CSF) data from 364 subjects from ADNI-1 and ADNI-2 datasets; NP: CN (<italic toggle="yes">n</italic> = 110, 156 scans), MCI (<italic toggle="yes">n</italic> = 125, 154 scans), AD (<italic toggle="yes">n</italic> = 129, 157 scans); age, MMSE, CDR-SOB mean (SD) reported; NI: sMRI and FDG-PET scans</td><td colspan="1" rowspan="1">Novel framework leveraging cross-attention for efficient and accurate AD diagnosis by learning inter-modality interactions; employs objective function (modality alignment loss, classification loss) to reduce heterogeneity</td><td colspan="1" rowspan="1">Existing models lack cross-modal interaction and ignore modality variations; challenges include effectively capturing inter-modality interaction and reducing modality discrepancy</td><td colspan="1" rowspan="1">AD <italic toggle="yes">vs</italic>. CN: ACC: 0.9107 &#177; 0.0382 SEN: 0.9103 &#177; 0.0478 SPE: 0.9107 &#177; 0.0647 F1: 0.9111 &#177; 0.0381 AUC: 0.9407 &#177; 0.0316; AD <italic toggle="yes">vs</italic>. MCI <italic toggle="yes">vs</italic>. CN: ACC: 0.6403 &#177; 0.0249 SEN: 0.6385 &#177; 0.0241 SPE: 0.8200 &#177; 0.0124 F1: 0.6185 &#177; 0.0158 AUC: 0.7677 &#177; 0.0422</td><td colspan="1" rowspan="1"><xref rid="bib274" ref-type="bibr">274</xref></td></tr><tr><td colspan="1" rowspan="1">Patch-based CNN</td><td colspan="1" rowspan="1">Clinical: Uses ADNI dataset to classify AD, MCI, and CN subjects using T1-weighted MRI and PET; regions such as the hippocampus and entorhinal cortex are identified as key contributors <italic toggle="yes">via</italic> Grad-CAM</td><td colspan="1" rowspan="1">Develops an interpretable CNN model that classifies AD by analyzing image patches and highlights disease-relevant ROIs</td><td colspan="1" rowspan="1">Limited to neuroimaging modalities; omics and clinical data not integrated</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><xref rid="bib289" ref-type="bibr">289</xref></td></tr></tbody></table><table-wrap-foot><fn><p>Note: A<italic toggle="yes">&#946;</italic>, amyloid beta; AD, Alzheimer's disease; ADAS-Cog, Alzheimer's Disease Assessment &#8211; Scale Cognitive Subscale; ADNI, Alzheimer's Disease Neuroimaging Initiative; AE, autoencoder; AIM, A<italic toggle="yes">&#946;</italic> induced neuroinflammation module; AMP-AD, Accelerating Medicines Partnership &#8211; Alzheimer's Disease; <italic toggle="yes">APOE</italic>, apolipoprotein E; APP, amyloid precursor protein; ATN, Amyloid, Tau, and Neurodegeneration; AUC, area under the ROC curve; AVLT, Auditory Verbal Learning Test; BBB, blood&#8211;brain barrier; BN, Bayesian probabilistic causal Network; BNT, Boston naming test; CDR, Clinical and Dementia Rating; CDR-SB, Clinical and Dementia Rating&#8211;Sum of Boxes; CN, cognitively normal; CNV, copy-number variation; COGDX, cognitive status at the time of death; CR, cerebellum; CSF, cerebrospinal fluid; CV, cross-validation; CVVLT, Chinese version verbal learning test; DBNs, Deep belief networks; DEG, differentially expressed gene; DIABLO, Data Integration Analysis for Biomarker discovery using the Latent cOmponents; DLPFC, dorsolateral prefrontal cortex; DMPs, differentially methylated positions; DRIAD, drug repurposing in Alzheimer's disease; EHRs, electronic health records; EMUDRA, Ensemble of Multiple Drug Repositioning Approaches; eQTL, expression quantitative trait loci; FAQ, functional activities questionnaire; FedAvg, federated averaging; fMRI, functional magnetic resonance imaging; GBM, glioblastoma multiforme; GCNs, graph convolutional networks; GEO, Gene Expression Omnibus; GNNRAI, GNN-derived representation alignment and integration; GWAS, genome-wide association studies; HDL, high-density lipoprotein; hiPSC, human induced pluripotent stem cell; HR, hazard ratio; IL, Interleukin; iPSNs, induced pluripotent stem-cell-derived neurons; JADBIO, Just Add Data Bio; LASSO, least absolute shrinkage and selection operator; LR, logistic regression; LRP, layer-wise relevance propagation; MAE, mean absolute error; MAPK, mitogen-activated protein kinase; MCI, mild cognitive impairment; MEGENA, multiscale embedded gene coexpression network analysis; MLP, multilayer perceptron; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; NP, Neuropsychological; NI, Neuroimaging; NFTs, neurofibrillary tangles; NMF, non-negative matrix factorization; S-MCI, stable MCI; P-MCI, progressive MCI; PCA, principal component analysis; PFI, permutation feature importance; PI3K, phosphoinositide 3-kinase; PPI, protein&#8211;protein interaction; PR-AUC, precision-recall area under curve; RF, random forests; RNA-Seq, RNA sequencing; RMSE, root mean square error; ROI, region of interest; ROS/MAP, Religious Orders Study and Rush Memory and Aging Project; scRNA-Seq, single-cell RNA sequencing; SGUQ, staged graph convolutional network with uncertainty quantification; SHAP, SHapley Additive exPlanations; SMOTE, synthetic minority over-sampling technique; SNPs, single-nucleotide polymorphisms; ssGSEA, single-sample gene set enrichment analysis; SUVR, standardized uptake value ratio; SVM, support vector machine; TACA, The Alzheimer's Cell Atlas; TF, transcription factor; TMT, tandem-mass-tag; TMT-B, trail making test part B; VF, verbal fluency; WGCNA, Weighted Gene Co-expression Network Analysis; WMH, white matter hyperintensities; XAI, explainable AI; AIBL, Australian Imaging Biomarkers and Lifestyle; PRS, polygenic risk scores; LSTM, long short-term memory; WES, whole-exome sequencing; WGS, whole-genome sequencing; PiB, Pittsburgh compound B; PET, positron emission tomography; p-tau, phosphorylated tau; ATP6V1 A, ATPase catalytic subunit A; <italic toggle="yes">TREM2</italic>, triggering receptor expressed on myeloid cells 2; GNNs, graph neural networks; sMRI, structural magnetic resonance imaging; WMS, Wechsler memory scale; WMS-LM, Wechsler memory scale-logical memory; TY-CFT, Taylor complex figure test; DGPSD, Drug-induced Gene Perturbation Signature Database; TRS, target risk score; PACC, Preclinical Alzheimer's Cognitive Composite; MCFA, medium-chain fatty acids; CCANs, cis co-accessibility networks; cCRE, candidate cis regulatory element; TPR, true-positive rate; GEIDI, Genotype-Expression-Imaging Data Integration; ATAC, assay for transposase-accessible chromatin; <italic toggle="yes">SNCA</italic>, alpha-synuclein; MOSEGCN, Multi-Omics Semi-Supervised Edge-to-Graph Convolutional Network; MINDSETS, Multi-omics Integration with Neuroimaging for Dementia Subtyping and Effective Temporal Study; UKB, UK Biobank; CNN, Convolutional Neural Network.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec5.1"><label>5.1</label><title>Early diagnosis and prediction</title><p id="p0270">AD progresses insidiously through a prolonged preclinical phase, during which neuropathological changes accumulate in the absence of overt cognitive decline<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref><sup>,</sup><xref rid="bib365" ref-type="bibr"><sup>365</sup></xref><sup>,</sup><xref rid="bib366" ref-type="bibr"><sup>366</sup></xref>. Identifying reliable and minimally invasive biomarkers during this asymptomatic window is critical for timely intervention. Recent advances in AI-driven multi-omics analysis have shown substantial promise in identifying novel preclinical biomarkers and constructing risk prediction models that outperform traditional single-omics or clinically based strategies<xref rid="bib137" ref-type="bibr"><sup>137</sup></xref><sup>,</sup><xref rid="bib367" ref-type="bibr"><sup>367</sup></xref>. Emerging approaches now integrate multi-omic layers with enriched clinical contexts, enabling more precise and individualized risk forecasting<xref rid="bib124" ref-type="bibr"><sup>124</sup></xref><sup>,</sup><xref rid="bib159" ref-type="bibr"><sup>159</sup></xref><sup>,</sup><xref rid="bib368" ref-type="bibr"><sup>368</sup></xref>.</p><p id="p0275">Early studies employed algorithms such as random forests and support vector machines on modestly sized multi-omics datasets<xref rid="bib369" ref-type="bibr">369</xref>, <xref rid="bib370" ref-type="bibr">370</xref>, <xref rid="bib371" ref-type="bibr">371</xref>. While these methods offered computational efficiency and interpretability, they often required extensive manual feature selection and were limited in capturing complex inter-omic interactions. The advent of deep learning models, including autoencoders, GNNs, and DBNs, has enabled direct learning from high-dimensional poly-omic matrices. These models have uncovered plasma proteomic and metabolomic signatures associated with amyloid burden, tau pathology, and cognitive resilience in presymptomatic individuals<xref rid="bib372" ref-type="bibr">372</xref>, <xref rid="bib373" ref-type="bibr">373</xref>, <xref rid="bib374" ref-type="bibr">374</xref>. For instance, sliding-window association testing identified the lipid Cer(d16:1/22:0) as a significant feature, yielding a classification accuracy of 80.8% and an area under the ROC curve (AUC) of 0.808<xref rid="bib375" ref-type="bibr"><sup>375</sup></xref>. The B-HEALED model, which integrates blood-based multi-omics data, achieved 93.0% specificity in predicting prodromal AD, surpassing traditional amyloid-based diagnostic approaches<xref rid="bib320" ref-type="bibr"><sup>320</sup></xref>. DBNs have also proven effective in addressing the high-dimensional, low-sample-size challenge inherent to multi-omics datasets, demonstrating superior performance in feature selection and classification compared to conventional methods such as SVM-RFE<xref rid="bib237" ref-type="bibr"><sup>237</sup></xref>. Complementary approaches such as CE-GAN, which integrates fMRI and SNP data, have achieved over 91% accuracy in risk prediction tasks while maintaining interpretability<xref rid="bib287" ref-type="bibr"><sup>287</sup></xref>. Notably, the GNNRAI framework combines transcriptomic and proteomic graphs from the ROS/MAP cohort, employing a set-transformer for modality alignment. This model achieved a mean cross-validation accuracy of 0.83 across sixteen AD-relevant biological domains and outperformed the widely used MOGONET pipeline in external validation. SHAP-based interpretation further revealed lipid metabolism and synaptic signaling as key discriminative pathways, underscoring the model's biological relevance<xref rid="bib228" ref-type="bibr"><sup>228</sup></xref>.</p><p id="p0280">Modern AI frameworks increasingly integrate multi-omics datasets with demographic, cognitive, and neuroimaging features to enable comprehensive cross-domain feature representation. Advanced architectures such as transformer-based encoders, variational autoencoders, and Similarity Network Fusion (SNF) frameworks are applied to jointly embed heterogeneous data sources. These sources include clinical assessments such as the Mini-Mental State Examination (MMSE), Clinical Dementia Rating&#8211;Sum of Boxes (CDR-SB), and the Alzheimer's Disease Assessment Scale&#8211;Cognitive Subscale (ADAS-Cog), along with neuroimaging markers including hippocampal volume, cortical thickness, and standardized uptake value ratios from amyloid and tau positron emission tomography imaging. When combined with transcriptomic, proteomic, metabolomic, and epigenomic layers, these models allow the identification of complex interdependencies across biological, cognitive, and structural domains that contribute to disease progression<xref rid="bib262" ref-type="bibr"><sup>262</sup></xref><sup>,</sup><xref rid="bib352" ref-type="bibr"><sup>352</sup></xref>. The MINDSETS model exemplifies this trend by integrating radiomic features from longitudinal MRI scans with polygenic risk scores, proteomics, and clinical assessments, achieving 89% diagnostic accuracy in distinguishing AD from vascular dementia<xref rid="bib255" ref-type="bibr"><sup>255</sup></xref>. Additionally, multimodal attention networks such as Tri-COAT demonstrate that hippocampal atrophy modulates the predictive contribution of lipidomic and genomic features, bridging molecular changes with regional neurodegeneration<xref rid="bib264" ref-type="bibr"><sup>264</sup></xref>. Temporal models employing convolutional or recurrent layers to align longitudinal neuropsychological trajectories with repeated blood-omics data have shown strong performance in individualized risk estimation. A recent long short-term memory (LSTM) model that fused demographics, serial cognitive assessments, and MRI data achieved an AUC of 0.93 &#177; 0.06 in predicting MCI-to-AD progression over two years<xref rid="bib376" ref-type="bibr"><sup>376</sup></xref>. Concurrently, federated learning has emerged as a privacy-preserving strategy for multi-center training. An LSTM model trained on 44,899 MCI cases across the OneFlorida+ network achieved improved generalizability, with AUC increasing from 0.72 in single-site models to 0.76 in the federated setting. This approach also identified clinically accessible predictors such as BMI, vitamin B12, and systolic blood pressure, highlighting its translational potential<xref rid="bib263" ref-type="bibr"><sup>263</sup></xref>.</p><p id="p0285">Advanced computational pipelines now aim to integrate multi-omics with demographic, genetic, and lifestyle variables to improve the accuracy of individualized disease trajectory prediction<xref rid="bib281" ref-type="bibr"><sup>281</sup></xref><sup>,</sup><xref rid="bib377" ref-type="bibr"><sup>377</sup></xref><sup>,</sup><xref rid="bib378" ref-type="bibr"><sup>378</sup></xref>. While traditional models such as logistic regression and Cox proportional hazards provided initial insights, they are limited in handling high-dimensional, time-dependent data<xref rid="bib379" ref-type="bibr"><sup>379</sup></xref>. Contemporary methods, including recurrent neural networks and Bayesian deep learning, address these challenges by enabling dynamic risk estimation and uncertainty quantification. The B-HEALED platform, when combined with amyloid status and neuroimaging or CSF data, achieved 100% specificity for prodromal AD diagnosis<xref rid="bib320" ref-type="bibr"><sup>320</sup></xref>. Similarly, transcriptomic studies have identified concise gene panels with high diagnostic utility; for example, an eight-gene signature distinguished progressive from stable MCI with an AUC of 0.93<xref rid="bib283" ref-type="bibr"><sup>283</sup></xref>. Automated platforms such as JADBIO facilitate biomarker discovery by streamlining machine learning pipeline optimization and feature selection<xref rid="bib329" ref-type="bibr"><sup>329</sup></xref>. The WIMOAD framework integrates paired gene expression and DNA methylation profiles using stacked meta-learners, achieving an accuracy of 0.89 and AUC of 0.92 in cross-validation within the ADNI cohort. SHAP-based analysis highlighted ORMDL3 methylation and SLC1A2 expression as key features, providing experimentally testable insights and enhancing model interpretability<xref rid="bib227" ref-type="bibr"><sup>227</sup></xref>.</p><p id="p0290">Despite these advances, key challenges remain. The reliance on large, high-quality datasets and the opaque nature of many AI models hinder widespread clinical adoption. Enhancing model transparency through methods such as attention mechanisms and layer-wise relevance propagation is crucial<xref rid="bib380" ref-type="bibr"><sup>380</sup></xref>. Additionally, validating models across diverse cohorts and harmonizing multi-omics data formats are necessary steps to ensure reproducibility. Emerging spatial proteomics technologies, such as DISCO-MS, offer the potential to create comprehensive multimodal atlases that link circulating biomarkers with regional neuropathology<xref rid="bib381" ref-type="bibr"><sup>381</sup></xref>. Overcoming these hurdles will be essential to fully realize the potential of integrated AI frameworks in the early detection and personalized prediction of AD.</p></sec><sec id="sec5.2"><label>5.2</label><title>Mechanism exploration</title><p id="p0295">The multifactorial etiology of AD necessitates innovative analytical frameworks capable of disentangling its complex molecular architecture<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref><sup>,</sup><xref rid="bib156" ref-type="bibr"><sup>156</sup></xref>. The application of state-of-the-art AI and machine learning algorithms has significantly enhanced our capacity to investigate AD pathogenesis. In particular, AI-driven multi-omics approaches are increasingly utilized to elucidate disease-associated mechanisms, evolving from early integrative pipelines into sophisticated deep learning frameworks<xref rid="bib353" ref-type="bibr"><sup>353</sup></xref>. These methodologies show great potential in advancing our understanding of AD by uncovering novel biomarkers, molecular pathways, and regulatory networks involved in disease initiation and progression.</p><p id="p0300">Initial efforts employed classical machine learning models such as iClusterBayes to integrate transcriptomic, proteomic, metabolomic, and lipidomic datasets<xref rid="bib382" ref-type="bibr"><sup>382</sup></xref>. This integrative analysis revealed molecular subtypes of AD that correlated with neuropathological severity and cognitive decline, implicating key biological pathways including endocytosis and cholesterol metabolism<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref>. Although these approaches successfully identified signatures associated with amyloid and tau pathologies, they often oversimplified the high-dimensional and non-linear relationships inherent to multi-omics data<xref rid="bib383" ref-type="bibr"><sup>383</sup></xref>. Additionally, conventional models such as random forests and support vector machines were limited in their ability to manage data variability, batch effects, and missing values<xref rid="bib384" ref-type="bibr"><sup>384</sup></xref>. Nonetheless, these foundational studies established a critical framework for examining multilayered molecular alterations in AD and set the stage for the adoption of more advanced AI techniques.</p><p id="p0305">The transition to deep learning models has enabled more sophisticated analyses of complex biological data. Tools such as scGraph2Vec and NETTAG exemplify this shift. scGraph2Vec integrates single-cell RNA sequencing with gene interaction networks, while NETTAG combines deep learning with GWAS data to prioritize disease-relevant pathways and genes<xref rid="bib265" ref-type="bibr"><sup>265</sup></xref><sup>,</sup><xref rid="bib323" ref-type="bibr"><sup>323</sup></xref>. For example, NETTAG highlighted microglial gene networks and immune-related pathways, facilitating novel drug repurposing strategies, including the identification of gemfibrozil as a potential therapeutic agent<xref rid="bib323" ref-type="bibr"><sup>323</sup></xref>. Furthermore, autoencoder-based models such as EnsembleOmicsAE have been employed to reduce dimensionality in proteomic datasets, uncovering latent features linked to disease progression. This approach revealed cell adhesion and integrin signaling pathways not readily detected by linear models<xref rid="bib324" ref-type="bibr"><sup>324</sup></xref>. Recent integrative studies have expanded these insights using single-cell and spatial omics technologies. A large-scale analysis of 84 post-mortem AD brains employed single-nucleus RNA sequencing, spatial transcriptomics, and epigenomics to map cellular trajectories across an AD pseudoprogression continuum. Early disease stages were marked by inflammatory microglia, reactive astrocytes, and oligodendrocyte precursor-driven remyelination, while later stages exhibited vulnerability in excitatory neurons and VIP/PVALB interneurons<xref rid="bib354" ref-type="bibr"><sup>354</sup></xref>. These findings underscore the value of spatially resolved multi-omics in delineating cell-type-specific dynamics and identifying stage-specific therapeutic targets.</p><p id="p0310">Building on omics-centric methodologies, next-generation AI frameworks integrate molecular data with neuroimaging and cognitive assessments to model mechanistic cascades from genetic variation to neurodegeneration. The MADDi cross-modal attention network exemplifies this paradigm by linking structural MRI, genome-wide SNP profiles, and longitudinal clinical data. Its attention maps demonstrate that hippocampal thinning amplifies the effect of inflammation-related SNP clusters on memory decline, suggesting an immune-mediated feedback mechanism<xref rid="bib266" ref-type="bibr"><sup>266</sup></xref>. In a federated learning context, the GEIDI framework connects genotype-dependent transcriptomic alterations to cortical thickness patterns, identifying synaptic vesicle genes implicated in temporal lobe atrophy and outperforming traditional eQTL-based inference models<xref rid="bib267" ref-type="bibr"><sup>267</sup></xref>. Complementary research in non-human primates has produced a macaque brain atlas integrating MRI-derived cortical thickness with bulk and single-nucleus transcriptomic data. This work revealed a mitochondrial oxidative phosphorylation module whose expression gradient mirrors prefrontal cortical thinning, highlighting metabolic vulnerability as a regional determinant of atrophy<xref rid="bib359" ref-type="bibr"><sup>359</sup></xref>. Collectively, these integrated models demonstrate how embedding multi-omics within neuroimaging and clinical contexts can reveal causal pathways linking molecular dysregulation to structural and cognitive decline. High-throughput integration of transcriptomic, proteomic, and metabolomic profiles from post-mortem AD brains has exposed molecular heterogeneity across cortical regions. Network-based modeling approaches have identified critical regulators of neuronal dysfunction, such as ATPase catalytic subunit A (ATP6V1A), whose therapeutic potential was validated <italic toggle="yes">via</italic> CRISPR-based experiments<xref rid="bib251" ref-type="bibr"><sup>251</sup></xref>. Single-cell omics further refines our understanding of cellular heterogeneity, showing that astrocytic dysregulation contributes to tau pathology and mitochondrial impairment<xref rid="bib280" ref-type="bibr"><sup>280</sup></xref>.</p><p id="p0315">Epigenetic modifications have also emerged as key regulators in AD pathogenesis. Combined analyses of ChIP-seq and RNA-seq data have linked histone acetylation marks, including H3K27ac and H3K9ac, to transcriptional dysregulation affecting synaptic and chromatin-related genes<xref rid="bib104" ref-type="bibr"><sup>104</sup></xref>. Deep learning models such as BIONIC have facilitated mechanistic dissection by integrating ROS/MAP proteomic data with PPI networks. This analysis highlighted the roles of GPNMB-positive microglia and astrocytic markers like IBA1 and GFAP in mediating the amyloid&#8211;tau cascade. The development of interpretable network-based resources through such frameworks provides not only testable hypotheses but also strategic insights into cell-type-specific therapeutic targeting<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref>.</p><p id="p0320">Despite these promising developments, several challenges persist. The limited interpretability of deep learning models, inconsistencies in multimodal data acquisition protocols, and the computational intensity of large-scale analyses continue to impede broader application. Addressing these issues requires transparent AI models, federated-learning frameworks, and scalable cloud-native infrastructures<xref rid="bib385" ref-type="bibr"><sup>385</sup></xref>. Looking ahead, the convergence of single-cell and spatial multi-omics with ultra-high-field MRI and comprehensive cognitive testing is poised to enable fine-grained spatiotemporal dissection of neuroinflammation, tau aggregation, and metabolic disruption<xref rid="bib386" ref-type="bibr"><sup>386</sup></xref>. Cross-species modeling platforms such as TransComp-R further underscore the translational potential of aligning conserved molecular pathways between preclinical models and human patients, paving the way for more effective therapeutic strategies.</p></sec><sec id="sec5.3"><label>5.3</label><title>Novel biomarker identification</title><p id="p0325">Advancements in AI-driven multi-omics analysis have significantly accelerated the identification of novel biomarkers for AD, facilitating a transition from reliance on single diagnostic indicators to the construction of comprehensive and dynamic disease signatures<xref rid="bib387" ref-type="bibr"><sup>387</sup></xref>. The emergence of multi-modal biomarker panels and dynamic biomarker profiling has proven instrumental in capturing the multifaceted nature of AD pathology, thereby enhancing early diagnosis and enabling precision-targeted therapeutic strategies<xref rid="bib388" ref-type="bibr"><sup>388</sup></xref><sup>,</sup><xref rid="bib389" ref-type="bibr"><sup>389</sup></xref>.</p><p id="p0330">The concept of multi-modal biomarker panels arises from the understanding that AD is underpinned by complex molecular and cellular alterations spanning genomics, transcriptomics, proteomics, metabolomics, and neuroimaging<xref rid="bib159" ref-type="bibr"><sup>159</sup></xref>. The integration of these heterogeneous data modalities allows for the dissection of disease heterogeneity and the identification of robust biomarkers that reflect diverse pathological pathways. This integrative approach is particularly crucial in light of individual variability in molecular drivers, where single biomarkers often fail to represent the full complexity of disease mechanisms.</p><p id="p0335">Platforms such as ADAS-Viewer exemplify the potential of spatially resolved omics analysis, enabling the identification of region-specific transcriptomic and epigenetic alterations associated with AD onset and progression<xref rid="bib330" ref-type="bibr"><sup>330</sup></xref>. These tools facilitate the mapping of vulnerable brain regions and the development of localized therapeutic interventions. Concurrently, AI methodologies such as graph neural networks leverage known biological interactions, including gene&#8211;gene and protein&#8211;protein relationships, to enhance biomarker discovery. These models not only improve predictive performance but also elucidate interconnected molecular subnetworks that mediate broader disease processes<xref rid="bib314" ref-type="bibr"><sup>314</sup></xref><sup>,</sup><xref rid="bib332" ref-type="bibr"><sup>332</sup></xref>.</p><p id="p0340">Recent multimodal studies have demonstrated how peripheral molecular signatures can be linked to <italic toggle="yes">in vivo</italic> brain changes. For instance, machine learning models trained on baseline plasma ceramide species, including C22:0 and C24:0, successfully predicted one-year hippocampal atrophy in individuals with amnestic mild cognitive impairment, suggesting that blood-based lipidomic markers can anticipate neurodegenerative changes prior to clinical dementia<xref rid="bib358" ref-type="bibr"><sup>358</sup></xref>. Similarly, the federated GEIDI framework integrates transcriptomic and GWAS data with structural MRI, revealing genotype-dependent gene expression effects on cortical thickness and identifying synaptic vesicle-related genes implicated in temporal lobe atrophy<xref rid="bib267" ref-type="bibr"><sup>267</sup></xref>. At a broader systems level, integrative studies have combined large-scale brain imaging data with plasma and CSF proteomic profiles to generate dynamic abnormality indices. These models charted sequential disruptions in vascular function, amyloid deposition, and cognitive decline<xref rid="bib357" ref-type="bibr"><sup>357</sup></xref>. A separate analysis involving CSF proteomics across six international cohorts and over 2000 protein targets achieved an AUC exceeding 0.90 in predicting AD biomarker positivity, demonstrating applicability across both symptomatic and asymptomatic populations<xref rid="bib270" ref-type="bibr"><sup>270</sup></xref>. Furthermore, multimodal studies combining gut microbiome sequencing, fecal metabolomics, and neuroimaging have revealed bidirectional mediation pathways, establishing mechanistic links between gut dysbiosis, lipid metabolism, and progressive brain atrophy<xref rid="bib356" ref-type="bibr"><sup>356</sup></xref>. These findings underscore the value of integrating peripheral and central data streams to trace biological cascades underlying AD progression.</p><p id="p0345">AI-based analyses have also uncovered molecular heterogeneity within the AD population. High-throughput transcriptomic and proteomic studies have delineated at least four molecular subtypes of AD, each characterized by distinct immune, metabolic, and inflammatory signatures that correlate with clinical trajectories<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref>. This stratification has significant implications for risk assessment, trial design, and personalized treatment development. Deep multi-omics models such as MoFNet illustrate how integrating DNA, RNA, and protein expression reveals distinct pathways related to neurotransmission and immune regulation, thereby moving the field toward individualized mechanistic understanding<xref rid="bib286" ref-type="bibr"><sup>286</sup></xref>.</p><p id="p0350">Static biomarker panels, although informative, often lack the temporal resolution necessary to capture the dynamic course of AD. AI-enabled time-series modeling and dynamic Bayesian inference now allow researchers to monitor longitudinal changes in biomarker levels. For example, modularity-constrained Lasso has been used to link genetic variants to transcriptomic and proteomic alterations that collectively influence cognitive function<xref rid="bib332" ref-type="bibr"><sup>332</sup></xref>. Integrated temporal analyses of transcriptomic and lipidomic data have further revealed co-expression modules associated with disease severity and progression<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref><sup>,</sup><xref rid="bib280" ref-type="bibr"><sup>280</sup></xref>. Changes in tau phosphorylation and markers of synaptic dysfunction have emerged as reliable early indicators of neurodegeneration. Longitudinal transformer-based models aligning cognitive assessments with cerebrospinal tau levels and DTI have identified change-point patterns that signal imminent cognitive decline. Systems biology platforms like M3NetFlow map genetic variants to molecular pathways and phenotypic outcomes, identifying key regulatory nodes and optimal windows for intervention<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref>.</p><p id="p0355">Despite these advancements, the integration and interpretation of large-scale multi-omics datasets remain challenging. Data heterogeneity, cohort-specific biases, and missing values complicate consistent biomarker discovery. Although tools such as Weighted Gene Co-expression Network Analysis and Bayesian clustering provide partial solutions, more robust and scalable approaches are needed to manage the scale and complexity of these data<xref rid="bib280" ref-type="bibr"><sup>280</sup></xref><sup>,</sup><xref rid="bib331" ref-type="bibr"><sup>331</sup></xref>. Single-cell multi-omics has further refined biomarker discovery by enabling cell-type and cell-state-specific resolution, though this granularity increases the computational burden and necessitates improved harmonization protocols<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref>. User-friendly platforms like ADAS-Viewer play a critical role in translating these complex analytical outputs into clinically actionable insights by promoting accessibility and collaborative analysis<xref rid="bib330" ref-type="bibr"><sup>330</sup></xref>.</p><p id="p0360">In conclusion, AI-driven multi-omics approaches are reshaping the landscape of biomarker discovery in AD. By integrating diverse molecular, imaging, and cognitive domains, these methodologies facilitate earlier and more accurate diagnosis, support precision medicine efforts, and provide mechanistic insights essential for therapeutic development. Continued innovation in computational modeling, data harmonization, and platform accessibility will be pivotal in translating these discoveries into effective clinical interventions.</p></sec><sec id="sec5.4"><label>5.4</label><title>Drug discovery and development</title><p id="p0365">The application of AI-driven multi-omics strategies is fundamentally transforming the landscape of therapeutic discovery in AD. By integrating genomic, transcriptomic, proteomic, and metabolomic data, these approaches offer a comprehensive perspective on the molecular complexity of the disease. This systems-level integration enables the identification of new therapeutic targets, supports the repurposing of existing drugs, and informs the development of treatments that align with disease-specific molecular mechanisms.</p><p id="p0370">A number of computational frameworks exemplify this paradigm. DRPS/C leverages inverse gene and protein perturbation signatures to predict candidate anti-AD agents, such as bupivacaine and selegiline, both of which have demonstrated neuroprotective effects in preclinical models<xref rid="bib341" ref-type="bibr"><sup>341</sup></xref>. Similarly, NETTAG, a network-based deep learning platform, combines GWAS data with the human interactome to prioritize risk genes and identify compounds such as gemfibrozil that have been epidemiologically associated with reduced AD incidence<xref rid="bib323" ref-type="bibr"><sup>323</sup></xref>. Other network-centric models, including AlzGPS, map genetic variants onto protein interaction networks to identify modifiable disease nodes. One such node, ATP6V1A, was found to be pharmacologically targetable, with compounds like pioglitazone modulating its associated neuroinflammatory pathways<xref rid="bib251" ref-type="bibr"><sup>251</sup></xref><sup>,</sup><xref rid="bib334" ref-type="bibr"><sup>334</sup></xref><sup>,</sup><xref rid="bib337" ref-type="bibr"><sup>337</sup></xref><sup>,</sup><xref rid="bib339" ref-type="bibr"><sup>339</sup></xref><sup>,</sup><xref rid="bib340" ref-type="bibr"><sup>340</sup></xref>. The Alzheimer's Cell Atlas (TACA) further enhances cell-type-specific drug discovery by aggregating over one million single-cell profiles, facilitating targeted therapeutic development at unprecedented resolution<xref rid="bib335" ref-type="bibr"><sup>335</sup></xref>.</p><p id="p0375">The integration of molecular data with clinical, cognitive, and neuroimaging information is now a hallmark of next-generation therapeutic discovery pipelines. The open-access NeuroPM-box platform exemplifies this approach by modeling disease progression using structural and functional MRI, amyloid and tau PET, blood and CSF proteomics, multi-omics genetic data, and longitudinal cognitive assessments<xref rid="bib269" ref-type="bibr"><sup>269</sup></xref>. In a proof-of-concept analysis using data from the ADNI, simulations predicted that vascular-modulating agents would most effectively slow hippocampal atrophy in <italic toggle="yes">APOE &#949;4</italic> carriers, a finding later corroborated by observational data. Similarly, the EMIF-AD Multimodal Biomarker Discovery study integrates plasma metabolomics, CSF proteomics, GWAS data, high-resolution MRI, and detailed clinical follow-up in over 1200 European participants. This comprehensive dataset has already identified blood-based lipid panels that parallel amyloid PET burden and predict cognitive decline, thereby providing pharmacodynamic readouts for future clinical trials<xref rid="bib355" ref-type="bibr"><sup>355</sup></xref>. In the context of trial design, a multimodal deep learning model was developed to integrate baseline MRI radiomics, plasma proteomics, and neuropsychological assessments for forecasting individual cognitive trajectories. When applied to simulated randomization schemes, this model enhanced the stratification of fast versus slow cognitive decliners, thereby reducing required sample sizes and increasing statistical power for detecting treatment effects<xref rid="bib268" ref-type="bibr"><sup>268</sup></xref>.</p><p id="p0380">Deep learning platforms are also driving innovation in compound screening and combination therapy prediction. Tools such as DeepDrug and MultiDCP exemplify this trend. DeepDrug identifies synergistic therapeutic combinations targeting neuroinflammation and mitochondrial dysfunction<xref rid="bib390" ref-type="bibr"><sup>390</sup></xref>, while MultiDCP models dose-dependent gene expression changes, enabling the stratification of patient subgroups based on predicted molecular responses<xref rid="bib338" ref-type="bibr"><sup>338</sup></xref>. Although these models accelerate the drug development process, rigorous biological validation remains essential to mitigate potential off-target effects<xref rid="bib390" ref-type="bibr"><sup>390</sup></xref><sup>,</sup><xref rid="bib391" ref-type="bibr"><sup>391</sup></xref>. The Recursive Drug Repositioning Paradigm advances this effort by simulating drug-disease interactions and refining candidate compounds through iterative learning<xref rid="bib391" ref-type="bibr"><sup>391</sup></xref>. This strategy has facilitated the discovery of agents like NCH-51, which reverses ATP6V1A-associated neuronal dysfunction<xref rid="bib251" ref-type="bibr"><sup>251</sup></xref>. Emerging spatial proteomics technologies further enhance precision targeting. DISCO-MS, for example, maps molecular heterogeneity across three-dimensional brain structures, identifying early pathological signals critical for therapeutic validation<xref rid="bib381" ref-type="bibr"><sup>381</sup></xref>. Real-world initiatives, such as MEMORI-AD, integrate clinical, genetic, microbial, and metabolomic data to monitor treatment response, demonstrating the feasibility of multi-omics-informed, AI-driven therapeutic guidance in clinical settings<xref rid="bib392" ref-type="bibr"><sup>392</sup></xref>. The use of large language models in drug repurposing represents another promising frontier. A recent study employed GPT-4 to generate and prioritize potential AD therapeutics, followed by retrospective validation in two large-scale electronic health record cohorts from Vanderbilt University and the All of Us Research Program. Metformin, simvastatin, and losartan were each associated with reduced AD incidence after adjusting for confounders, highlighting the utility of generative models in hypothesis generation and prioritization<xref rid="bib360" ref-type="bibr"><sup>360</sup></xref>. Building on the original DeepDrug framework, DeepDrug2 addressed somatic mutation biases by reconstructing a signed, heterogeneous biomedical graph focused on germline GWAS associations. Training a graph neural network on this architecture enabled reprioritization of compounds with improved disease specificity. Analysis of 500,000 participants in the UK Biobank revealed significant protective associations for amlodipine, indapamide, and atorvastatin, illustrating how germline-informed embeddings and real-world clinical data can jointly support the identification of actionable therapeutic candidates<xref rid="bib240" ref-type="bibr"><sup>240</sup></xref>. Collectively, these developments underscore the transformative potential of AI-integrated multi-omics pipelines in accelerating therapeutic discovery and repurposing for AD. By uniting predictive modeling, mechanistic interpretability, and real-world validation, these frameworks pave the way for precision therapeutics that are biologically grounded and clinically actionable.</p><p id="p0385">Nevertheless, several challenges persist. Data heterogeneity, limited model interpretability, and unequal access to computational infrastructure hinder widespread application. Collaborative efforts such as the Synapse repository and cross-disciplinary consortia are working to harmonize datasets, promote transparency, and align discovery efforts with regulatory frameworks<xref rid="bib393" ref-type="bibr"><sup>393</sup></xref>. Ethical considerations remain paramount, particularly concerning data privacy and the equitable distribution of emerging therapeutic innovations<xref rid="bib394" ref-type="bibr"><sup>394</sup></xref>. In summary, AI-integrated multi-omics methodologies are reshaping the drug discovery landscape for AD. These approaches facilitate systematic target identification and compound screening, offering a scalable and mechanistically informed path toward clinical translation. Realizing their full potential will require sustained investment in validation, interpretability, and regulatory alignment.</p></sec><sec id="sec5.5"><label>5.5</label><title>Patient stratification and personalized medicine</title><p id="p0390">The convergence of AI and multi-omics technologies is transforming patient stratification and the development of personalized medicine in AD. Multi-omics profiling has revealed substantial molecular heterogeneity in AD, providing critical insights into individual variability and patterns of disease progression. Modern AI-based stratification frameworks now incorporate genetic information, proteomic signatures, and clinical progression metrics to refine subtype classification and guide individualized interventions.</p><p id="p0395">Genetic factors are central to these frameworks. The <italic toggle="yes">APOE &#949;4</italic> allele remains the most prominent genetic risk factor, strongly linked to both disease susceptibility and progression<xref rid="bib395" ref-type="bibr"><sup>395</sup></xref>. In addition to <italic toggle="yes">APOE</italic>, polygenic risk scores (PRS), which aggregate multiple genetic variants across the genome, are increasingly integrated into AI models to capture complex hereditary risk profiles. These genetic variables are often combined with proteomic features that reflect pathological processes such as neuroinflammation, synaptic dysfunction, and mitochondrial impairment. For instance, protein expression patterns associated with microglial activation and synaptic vesicle transport have been employed to define biologically meaningful patient subgroups. Moreover, clinical phenotypes, such as longitudinal trajectories of cognitive decline, neuropsychological scores, and fluid biomarker dynamics, are incorporated to enhance the temporal resolution of stratification.</p><p id="p0400">Large-scale studies such as ROS/MAP project have utilized multi-omic data from dorsolateral prefrontal cortex tissue to identify AD subtypes that exhibit distinct cognitive trajectories. These subtypes differ in lipid metabolism and synaptic function, highlighting the utility of combining molecular and clinical data to capture disease heterogeneity<xref rid="bib124" ref-type="bibr"><sup>124</sup></xref><sup>,</sup><xref rid="bib255" ref-type="bibr"><sup>255</sup></xref><sup>,</sup><xref rid="bib396" ref-type="bibr"><sup>396</sup></xref><sup>,</sup><xref rid="bib397" ref-type="bibr"><sup>397</sup></xref>. Complementary analyses of peripheral blood transcriptomes have enabled patient classification into immune and metabolic subgroups, achieving diagnostic performance comparable to established biomarker frameworks like Amyloid, Tau, and Neurodegeneration (ATN)<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref><sup>,</sup><xref rid="bib349" ref-type="bibr"><sup>349</sup></xref><sup>,</sup><xref rid="bib351" ref-type="bibr"><sup>351</sup></xref><sup>,</sup><xref rid="bib398" ref-type="bibr"><sup>398</sup></xref>. Advanced integration techniques such as similarity network fusion allow for the joint analysis of transcriptomic, proteomic, DNA methylation, and metabolomic data derived from CSF, blood, and brain tissue. These analyses have identified subtypes characterized by immune activation, mitochondrial dysfunction, lipid dysregulation, and BBB disruption<xref rid="bib342" ref-type="bibr"><sup>342</sup></xref><sup>,</sup><xref rid="bib352" ref-type="bibr"><sup>352</sup></xref><sup>,</sup><xref rid="bib399" ref-type="bibr"><sup>399</sup></xref><sup>,</sup><xref rid="bib400" ref-type="bibr"><sup>400</sup></xref>. The addition of neuroimaging data further enriches stratification efforts by revealing distinct progression patterns across biomarker-defined subgroups<xref rid="bib347" ref-type="bibr"><sup>347</sup></xref><sup>,</sup><xref rid="bib401" ref-type="bibr"><sup>401</sup></xref><sup>,</sup><xref rid="bib402" ref-type="bibr"><sup>402</sup></xref>.</p><p id="p0405">Recent multimodal AI pipelines build upon these findings by embedding omics features alongside neuroimaging trajectories and neuropsychological assessments. For example, the MINDSETS model generates individualized risk profiles and cognitive decline trajectories by linking multi-omic embeddings with longitudinal Mini-Mental State Examination scores<xref rid="bib255" ref-type="bibr"><sup>255</sup></xref>. Similarly, the MCAD framework integrates structural MRI, FDG-PET, and cerebrospinal biomarkers to classify patients into diagnostic categories, highlighting interactions such as the synergy between tau burden and regional hypometabolism<xref rid="bib274" ref-type="bibr"><sup>274</sup></xref>. Models like WIMOAD apply ensemble learning to integrate gene expression and DNA methylation data, aligning the resulting molecular profiles with cortical thickness maps derived from MRI, thereby identifying early versus slow progression phenotypes within the ADNI cohort<xref rid="bib227" ref-type="bibr"><sup>227</sup></xref>.</p><p id="p0410">AI has further enhanced the scalability and interpretability of these frameworks. Explainable models using SHAP analysis on combined clinical, neuroimaging, and psychological inputs have achieved classification accuracies approaching 99% while clearly identifying key contributors such as memory test scores and hippocampal atrophy<xref rid="bib271" ref-type="bibr"><sup>271</sup></xref>. In the INSIGHT-preAD cohort, unsupervised learning revealed blood-based multi-omic signatures capable of predicting early amyloid deposition with over 99% accuracy<xref rid="bib351" ref-type="bibr"><sup>351</sup></xref>. Deep learning frameworks continue to uncover novel biological pathways, including those related to neuroinflammation and metabolic regulation, which account for diverse disease trajectories<xref rid="bib397" ref-type="bibr"><sup>397</sup></xref><sup>,</sup><xref rid="bib398" ref-type="bibr"><sup>398</sup></xref>. Interactive platforms employing machine learning have defined distinct AD subgroups characterized by pathways involving vasculogenesis and nitric oxide signaling<xref rid="bib344" ref-type="bibr"><sup>344</sup></xref>. Multi-kernel learning techniques have improved integration of high-dimensional, multimodal datasets, further enhancing performance and clinical applicability<xref rid="bib403" ref-type="bibr"><sup>403</sup></xref>. Importantly, AI-driven stratification is beginning to inform therapeutic decision-making by identifying molecular subtypes that respond differently to interventions. For instance, patients with dominant neuroinflammatory profiles may benefit from early immune-modulating treatments, while those with mitochondrial dysfunction could be targeted with metabolic therapies. Proteomic clustering has identified subgroups particularly responsive to drugs that modulate synaptic function and restore BBB integrity<xref rid="bib342" ref-type="bibr"><sup>342</sup></xref><sup>,</sup><xref rid="bib345" ref-type="bibr"><sup>345</sup></xref><sup>,</sup><xref rid="bib347" ref-type="bibr"><sup>347</sup></xref><sup>,</sup><xref rid="bib350" ref-type="bibr"><sup>350</sup></xref><sup>,</sup><xref rid="bib352" ref-type="bibr"><sup>352</sup></xref><sup>,</sup><xref rid="bib399" ref-type="bibr"><sup>399</sup></xref><sup>,</sup><xref rid="bib400" ref-type="bibr"><sup>400</sup></xref>. In one study, plasma inflammatory proteomics, untargeted metabolomics, and both gut and salivary metagenomics were integrated to classify cognitive severity in AD patients. The machine learning model identified SKAP1, NEFL, homovanillate, glutamate, and the gut microbe <italic toggle="yes">Paraprevotella clara</italic> as key predictors, demonstrating high accuracy in a validation cohort<xref rid="bib234" ref-type="bibr"><sup>234</sup></xref>. At an international scale, a consortium aggregated clinical and neuroimaging data from over 51,000 participants across nine cohorts to build an XAI framework capable of distinguishing among ten dementia etiologies. The model achieved an area under the receiver operating characteristic curve of 0.94 for classifying cognitive states and 0.96 for identifying co-existing pathologies. Importantly, the integration of model-derived insights improved neurologist diagnostic accuracy by 26%, demonstrating the utility of AI-assisted decision support in routine clinical care<xref rid="bib272" ref-type="bibr"><sup>272</sup></xref>.</p><p id="p0415">Despite significant progress, several technical and practical challenges remain. Harmonization of multi-omics datasets is complicated by batch effects, inconsistent data quality, and cross-platform variability. Integration across data modalities can introduce biases, as seen in joint analyses of transcriptomic and epigenomic features, which may complicate interpretation<xref rid="bib352" ref-type="bibr"><sup>352</sup></xref><sup>,</sup><xref rid="bib396" ref-type="bibr"><sup>396</sup></xref>. Deep learning models, while effective, often lack transparency, which limits their clinical adoption. Addressing these limitations will require continued development of interpretable AI algorithms, standardized analytical workflows, and collaborative data-sharing platforms. Ensuring adequate representation of under-studied populations, as highlighted in the AMP-AD initiative, is also essential for building globally applicable stratification frameworks<xref rid="bib351" ref-type="bibr"><sup>351</sup></xref><sup>,</sup><xref rid="bib397" ref-type="bibr"><sup>397</sup></xref>.</p></sec></sec><sec id="sec6"><label>6</label><title>Challenges and solutions</title><p id="p0420">Despite substantial progress, the application of AI in multi-omics research for AD continues to face significant challenges spanning technical, biological, and clinical domains. From a technical perspective, issues such as data heterogeneity, batch effects, and limited access to high-performance computing resources hinder reproducibility, scalability, and cross-study generalization. On the biological front, the inherent complexity and inter-individual variability of AD pathology across different disease stages pose major obstacles to model development and biological interpretation. Clinically, factors including limited model transparency, infrastructural limitations, and regulatory constraints impede integration into routine healthcare settings. Overcoming these challenges will require harmonized data processing pipelines, biologically grounded patient stratification frameworks, rigorous cross-cohort validation strategies, and the development of XAI models that can be seamlessly embedded into clinical workflows.</p><sec id="sec6.1"><label>6.1</label><title>Technical challenges</title><p id="p0425">Integrating heterogeneous data across multiple omics layers, such as genomics, transcriptomics, proteomics, metabolomics, and epigenomics, remains a foundational challenge in AI-driven multi-omics research for AD<xref rid="bib404" ref-type="bibr"><sup>404</sup></xref><sup>,</sup><xref rid="bib405" ref-type="bibr"><sup>405</sup></xref>. These datasets are often generated through diverse experimental protocols and platforms, resulting in considerable variability in data quality, formats, scales, and batch-related artifacts<xref rid="bib406" ref-type="bibr"><sup>406</sup></xref>. Such heterogeneity introduces noise, missing values, and inconsistencies that undermine the robustness, reproducibility, and generalizability of AI models across cohorts and studies.</p><p id="p0430">To address these issues, a range of preprocessing techniques has been adopted. Data normalization methods, such as log transformation, quantile normalization, and z-score scaling, are used to align distributional properties across datasets. Batch effect correction tools, including ComBat, Harmony, and Limma, are employed to harmonize data collected from different platforms. In addition, community-driven initiatives, including the FAIR principles (Findable, Accessible, Interoperable, and Reusable) and standardized data formats developed by consortia such as ENCODE and GTEx, have enhanced consistency, accessibility, and interoperability within the multi-omics research ecosystem.</p><p id="p0435">Integrating high-dimensional omics data also imposes substantial computational demands. Algorithms such as SNF, Multi-Omics Factor Analysis (MOFA), and deep learning-based autoencoders are increasingly used to construct unified representations that preserve modality-specific information. However, these methods often require significant computing power and technical expertise, limiting their accessibility in resource-constrained research environments.</p><p id="p0440">Reproducibility remains a major concern in AD multi-omics modeling. Studies typically involve tens of thousands of molecular features but relatively small sample sizes, often leading to overfitting and unstable feature selection. Power-aware study design is essential. For instance, MultiPower modeling has shown that approximately 500 paired omics and imaging samples are required to detect moderate molecular effects with a 5% false discovery rate in integrative analyses<xref rid="bib407" ref-type="bibr"><sup>407</sup></xref>. During model development, best practices include the use of nested or repeated k-fold cross-validation for hyperparameter tuning, the evaluation of performance metrics on strictly held-out datasets, and replication in independent cohorts such as ADNI or AddNeuroMed. Community benchmarking initiatives like the DREAM Alzheimer's Big Data Challenge and the TADPOLE forecast competition have underscored the necessity of rigorous external validation, revealing that many high-performing algorithms do not generalize well to new datasets<xref rid="bib408" ref-type="bibr"><sup>408</sup></xref>. Common methodological pitfalls further complicate reproducibility. Meta-analyses of machine learning applications across scientific domains have identified issues such as data leakage, inconsistent preprocessing, and lack of reporting transparency. These findings have prompted the development of reproducibility checklists and model information sheets to standardize reporting practices regarding data handling, model splits, and hyperparameter selection<xref rid="bib409" ref-type="bibr"><sup>409</sup></xref>.</p><p id="p0445">Overfitting is a particularly pervasive issue in the analysis of high-dimensional omics data with limited sample sizes. Models often show high performance on training datasets but fail to generalize to independent cohorts, a pattern frequently reported in AD multi-omics studies<xref rid="bib410" ref-type="bibr"><sup>410</sup></xref><sup>,</sup><xref rid="bib411" ref-type="bibr"><sup>411</sup></xref>. Algorithmic bias can also emerge when training data do not adequately represent diverse populations. Systematic reviews of AI fairness in healthcare have demonstrated that models trained on demographically skewed datasets can produce reduced accuracy and exacerbate health disparities in underrepresented groups<xref rid="bib412" ref-type="bibr"><sup>412</sup></xref>. Another limitation lies in the interpretability of complex models. Many deep learning architectures operate as &#8220;black boxes&#8221;, providing limited insight into the rationale behind predictions. This lack of transparency impedes clinical adoption and limits the actionable value of AI outputs. XAI techniques offer promising solutions. SHAP values quantify the contribution of each feature to individual predictions and have been successfully applied in clinical decision-support systems <xref rid="bib413" ref-type="bibr"><sup>413</sup></xref>. Layer-wise relevance propagation (LRP) generates feature-level heat maps that trace neural network decisions back through their layers, providing interpretability in MRI-based AD classifiers<xref rid="bib363" ref-type="bibr"><sup>363</sup></xref>. Attention mechanisms, as implemented in healthcare-specific models such as RETAIN, highlight critical visits and clinical variables in longitudinal electronic health record sequences, thereby offering predictive strength alongside human-readable explanations<xref rid="bib414" ref-type="bibr"><sup>414</sup></xref><sup>,</sup><xref rid="bib415" ref-type="bibr"><sup>415</sup></xref>.</p><p id="p0450">In summary, resolving the technical challenges in AI-based multi-omics research for AD requires standardized preprocessing pipelines, power-aware validation strategies, transparent benchmarking practices, scalable computational infrastructures, and XAI frameworks. These advancements are essential for ensuring the robustness, generalizability, and clinical relevance of AI systems in AD research and beyond.</p></sec><sec id="sec6.2"><label>6.2</label><title>Biological challenges</title><p id="p0455">AD is driven by a complex interplay of pathological mechanisms, including neuroinflammation, protein misfolding, mitochondrial dysfunction, synaptic degeneration, and disruptions in the gut&#8211;brain axis<xref rid="bib416" ref-type="bibr"><sup>416</sup></xref>. Multi-omics technologies offer a powerful means to investigate these molecular processes by integrating these datasets. However, these mechanisms are both temporally dynamic and spatially heterogeneous. The rates of disease progression, affected brain regions, and molecular cascades can vary significantly among individuals and across disease stages, posing significant challenges to the development of predictive models that accurately capture the dynamic pathology of AD<xref rid="bib417" ref-type="bibr"><sup>417</sup></xref>.</p><p id="p0460">The clinical and biological heterogeneity of AD introduces an additional layer of complexity. Patients differ markedly in their age at onset, rate of cognitive decline, and treatment responsiveness. These differences result from a combination of intrinsic factors, such as genetic background, sex, and immune system variability, as well as extrinsic influences including dietary patterns, comorbid conditions, and environmental exposures<xref rid="bib418" ref-type="bibr"><sup>418</sup></xref><sup>,</sup><xref rid="bib419" ref-type="bibr"><sup>419</sup></xref>. Such heterogeneity can obscure relevant molecular signals and hinder the development of AI models that generalize across populations. For instance, machine learning classifiers trained on heterogeneous datasets may average out critical features associated with specific subtypes, thereby reducing both model accuracy and clinical utility<xref rid="bib420" ref-type="bibr"><sup>420</sup></xref>.</p><p id="p0465">To address these challenges, advanced patient stratification strategies are increasingly employed to counteract overgeneralization within heterogeneous AD cohorts. Unsupervised learning techniques such as hierarchical clustering, k-means, and latent class analysis applied to integrated multi-omics datasets have revealed molecularly distinct AD subgroups characterized by divergent patterns of neuroinflammation, metabolic dysregulation, and synaptic dysfunction. For example, similarity network fusion analyses of brain tissue have identified clusters associated with immune activation, mitochondrial impairment, and lipid metabolism abnormalities<xref rid="bib352" ref-type="bibr"><sup>352</sup></xref>. Other machine learning approaches integrating high-throughput omics data have delineated four distinct molecular profiles that correspond to variability in cognitive function and neuropathological burden<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref>. Blood-based transcriptomic analyses have similarly distinguished immune-dominant and metabolic-dominant subgroups, each associated with unique clinical trajectories and therapeutic responses<xref rid="bib421" ref-type="bibr"><sup>421</sup></xref>. Stratification into such biologically meaningful subtypes enhances the predictive accuracy of clinical milestones. For instance, identifying molecular subtypes within mild cognitive impairment cohorts improves the prediction of conversion to dementia compared to unstratified models<xref rid="bib273" ref-type="bibr"><sup>273</sup></xref>. These stratified approaches provide a foundation for precision medicine by aligning therapeutic interventions with the molecular context of individual patients.</p><p id="p0470">A major limitation to advancing this field is the scarcity of longitudinal multi-omics datasets. Most available studies are cross-sectional in nature, providing static snapshots of disease. Post-mortem multi-omics investigations, for instance, often rely on pseudotemporal inference due to the absence of repeated measurements<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref>. Reviews of multi-omics analyses in brain tissue have emphasized the importance of time-series data in capturing the dynamic evolution of molecular and clinical features<xref rid="bib397" ref-type="bibr"><sup>397</sup></xref>. Although some imaging-focused cohorts incorporate longitudinal clinical assessments that support predictions of disease conversion<xref rid="bib362" ref-type="bibr"><sup>362</sup></xref>, the integration of repeated multi-omics sampling over time remains rare.</p><p id="p0475">In conclusion, enhancing the biological interpretability and translational potential of AI-based multi-omics research in AD requires a more nuanced approach to patient diversity. This includes applying data-driven clustering methods to define biologically relevant subtypes, expanding these frameworks to identify subgroup-specific biomarkers and therapeutic targets, and establishing longitudinal, multi-modal cohorts that combine serial omics profiling with follow-up neuroimaging and clinical evaluations. Such efforts will reduce the risk of model overfitting, improve the identification of meaningful biological mechanisms, and support the development of individualized treatment strategies that align with the complex molecular landscape of AD<xref rid="bib361" ref-type="bibr"><sup>361</sup></xref>.</p></sec><sec id="sec6.3"><label>6.3</label><title>Clinical challenges</title><p id="p0480">The translation of AI-based multi-omics research into clinical practice for AD presents a range of significant challenges spanning methodological, interpretative, infrastructural, and regulatory domains<xref rid="bib405" ref-type="bibr"><sup>405</sup></xref><sup>,</sup><xref rid="bib422" ref-type="bibr"><sup>422</sup></xref>. Reproducibility is a primary concern. While AI models often achieve high accuracy in controlled research settings, their performance frequently declines in real-world clinical environments. Many studies rely on datasets with tens of thousands of molecular and imaging features derived from relatively small cohorts. For instance, reliable detection of moderate molecular effects in AD requires at least 500 paired omics and imaging samples, yet most studies fall short of this benchmark<xref rid="bib423" ref-type="bibr"><sup>423</sup></xref>. This imbalance contributes to overfitting and limits generalizability. To address these limitations, best practices now emphasize the use of nested or repeated k-fold cross-validation, strict separation of hold-out test sets, and independent replication in external validation cohorts such as ADNI, Australian Imaging Biomarkers and Lifestyle (AIBL), and AddNeuroMed. Benchmarking efforts, including the DREAM Alzheimer's Big Data Challenge, have revealed that many models perform well on internal data but fail to generalize to unseen datasets, highlighting the necessity of transparent head-to-head comparisons against simple baseline models<xref rid="bib408" ref-type="bibr"><sup>408</sup></xref>.</p><p id="p0485">Interpretability is another key barrier to clinical adoption. The complexity of machine learning algorithms, particularly deep learning models, often makes it difficult for clinicians to understand or trust the predictions. To enhance transparency and usability, XAI techniques tailored to biomedical applications are increasingly integrated into model workflows. Methods such as SHAP, integrated gradients, attention-based visualization, and counterfactual reasoning clarify the influence of specific features, including genetic variants and imaging measures, on model predictions. Recent developments include interactive dashboards that allow clinicians to explore how individual variables contribute to patient-specific risk scores<xref rid="bib364" ref-type="bibr"><sup>364</sup></xref><sup>,</sup><xref rid="bib424" ref-type="bibr"><sup>424</sup></xref>. These tools help translate complex outputs into interpretable formats, improving clinician engagement and decision-making. The use of user-centered design (UCD) in XAI development ensures that explanations are presented in clinically meaningful ways. Studies involving clinician interviews, prototyping, and usability testing demonstrate that well-designed interfaces significantly improve comprehension and perceived utility<xref rid="bib425" ref-type="bibr"><sup>425</sup></xref>. Embedding these tools within electronic health records or clinical decision support systems further facilitates adoption. Mixed-method evaluations show that clinicians are more confident and more likely to follow AI-generated recommendations when supported by transparent explanations such as SHAP plots<xref rid="bib426" ref-type="bibr"><sup>426</sup></xref><sup>,</sup><xref rid="bib427" ref-type="bibr"><sup>427</sup></xref>. Evidence from prospective deployments reinforces this trend. For example, an XAI-enhanced early warning system improved diagnostic accuracy for acute deterioration, while an interpretable decision support tool for remote strep throat diagnosis increased clinician performance and highlighted the importance of intelligible feedback for sustained use<xref rid="bib427" ref-type="bibr"><sup>427</sup></xref><sup>,</sup><xref rid="bib428" ref-type="bibr"><sup>428</sup></xref>. While interpretability is increasingly recognized as essential for the clinical integration of AI, further prospective and real-world studies are needed to quantify its impact on patient outcomes and define implementation best practices<xref rid="bib429" ref-type="bibr"><sup>429</sup></xref><sup>,</sup><xref rid="bib430" ref-type="bibr"><sup>430</sup></xref>.</p><p id="p0490">Infrastructure and regulatory limitations further complicate the clinical implementation of AI-driven approaches. Effective deployment requires secure, scalable storage, strong cybersecurity measures, and seamless integration with existing electronic health record systems. Many healthcare institutions, particularly in low-resource settings, lack these capabilities. To address these gaps, ongoing efforts focus on developing standardized data formats and improving system interoperability to support data exchange and model deployment<xref rid="bib431" ref-type="bibr"><sup>431</sup></xref>. Regulatory approval also demands rigorous demonstration of clinical utility in prospective, multi-center trials. Guidelines such as CONSORT-AI and SPIRIT-AI emphasize the need for protocol pre-registration, comprehensive reporting of preprocessing steps and model parameters, and continuous post-deployment monitoring. Updating &#8220;model cards&#8221;, which are structured documents that detail model performance, version history, and known limitations, is becoming standard practice in regulatory submissions<xref rid="bib432" ref-type="bibr"><sup>432</sup></xref>.</p><p id="p0495">Bridging the cultural and knowledge divide between clinicians and data scientists is also essential. This requires both institutional investment in cross-disciplinary collaboration and individual training in AI literacy. Recent competency frameworks recommend that clinicians acquire foundational and applied knowledge in data provenance, algorithm behavior, and uncertainty communication prior to deploying AI tools in clinical settings. Online training programs, such as the Radiology AI Literacy curriculum, now adopted by over 500 practicing radiologists, demonstrate strong demand for such education<xref rid="bib433" ref-type="bibr"><sup>433</sup></xref>. Conference sessions, including the &#8220;Empowering Healthcare Professionals Through AI Literacy&#8221; workshop at HIMSS 2025, further support skills development and help align expectations regarding AI capabilities. Organizational studies show that models co-designed by interdisciplinary teams achieve greater clinical accuracy and user acceptance compared to those developed in disciplinary silos<xref rid="bib434" ref-type="bibr"><sup>434</sup></xref>. This insight has informed institutional initiatives like the Houston Methodist&#8211;Rice University Digital Health Institute, which offers a collaborative environment for model development, validation, and deployment. Governance frameworks that incorporate ethics boards and patient advocacy representatives throughout the development lifecycle also play a critical role in ensuring transparency, addressing algorithmic bias, and promoting equitable use of AI systems<xref rid="bib412" ref-type="bibr"><sup>412</sup></xref>. Together, these initiatives foster a virtuous cycle of trust, interpretability, and clinical effectiveness, accelerating the safe and meaningful integration of AI into real-world healthcare environments.</p><p id="p0500">In summary, the successful clinical translation of AI-based multi-omics approaches in AD requires a rigorous study design with sufficient sample sizes, robust internal and external validation, transparent benchmarking, interpretable and clinician-friendly model outputs, interoperable infrastructure, and sustained interdisciplinary collaboration. These strategies are essential for transforming AI-based multi-omics innovations from research tools into clinically actionable solutions that enhance diagnosis, stratification, and therapeutic decision-making in AD.</p></sec></sec><sec id="sec7"><label>7</label><title>Conclusions and perspectives</title><p id="p0505">AI-driven multi-omics research presents transformative potential for AD, offering innovative avenues for early diagnosis, individualized treatment, and accelerated drug discovery. By integrating genomic, transcriptomic, proteomic, and metabolomic data, AI models enable a comprehensive understanding of the molecular complexity underlying AD, elucidating the combined influence of genetic, environmental, and biological factors. These integrative approaches facilitate the identification of novel biomarkers for early detection, allowing timely interventions prior to the onset of clinical symptoms, a critical window for effective disease management. Furthermore, AI empowers precision medicine by aligning therapeutic strategies with individual molecular profiles, moving beyond one-size-fits-all treatments toward more targeted, effective, and safer interventions. The capacity of AI models to learn from continuously evolving datasets further enhances their ability to adapt to disease progression, supporting dynamic and optimized therapeutic decisions throughout the clinical course.</p><p id="p0510">To fully realize the promise of AI-driven multi-omics in AD, several key challenges must be addressed while seizing emerging opportunities. Standardization and harmonization of data acquisition, processing, and annotation across diverse platforms and populations are essential for ensuring model comparability and reproducibility. The development of large-scale, well-curated, and demographically diverse datasets that reflect variations in ethnicity, age, and disease stage is crucial for improving model robustness, generalizability, and fairness. Achieving this will require international collaboration and the establishment of secure, ethically governed data-sharing frameworks to mitigate data fragmentation and enable validation across independent cohorts. Furthermore, the adoption of standardized reporting guidelines and evaluation protocols will facilitate transparency and enable meaningful cross-study comparisons. Employing a range of performance metrics, particularly those suited to imbalanced datasets common in AD, will allow a more comprehensive assessment of model performance.</p><p id="p0515">Interpretability remains a critical requirement for clinical translation. The application of XAI techniques that reveal the underlying biological basis of predictions will support not only trust and clinical usability but also the discovery of actionable molecular pathways and therapeutic targets. Advances in computational methodologies, including deep learning, network-based modeling, and causal inference, continue to expand the ability to capture nonlinear, dynamic interactions in disease processes. Incorporating additional data modalities, such as epigenomics, microbiome composition, neuroimaging, and longitudinal electronic health record data, will further strengthen predictive capabilities and enable refined patient stratification.</p><p id="p0520">Ethical and regulatory considerations are integral to the responsible implementation of AI in AD research and care. Ensuring data privacy, informed consent, and strong cybersecurity practices remains essential. Addressing algorithmic bias proactively is critical to avoid perpetuating or exacerbating health disparities. Regulatory frameworks, including GDPR, HIPAA, CONSORT-AI, and SPIRIT-AI, are evolving to require greater transparency, interpretability, and continuous post-deployment performance monitoring. Demonstrating clinical value through prospective, multi-center trials with patient-centered outcomes is increasingly necessary for regulatory approval and clinical adoption.</p><p id="p0525">Importantly, AI offers substantial opportunities to accelerate drug discovery by identifying molecular targets, predicting drug responses, and integrating systems pharmacology data. Adaptive clinical trials guided by real-time AI predictions can improve patient selection and dynamically adjust treatment protocols, thereby increasing trial efficiency and success rates.</p><p id="p0530">In conclusion, the future of AI-driven multi-omics in AD will be shaped by rigorous data standards, ethical integrity, interpretable modeling, and robust clinical validation. Together, these efforts will advance a new paradigm for earlier diagnosis, personalized therapy, and more effective interventions, ultimately improving outcomes and quality of life for individuals affected by AD.</p></sec><sec id="sec8"><title>Author contributions</title><p id="p0535">Fang Ren: Writing&#8212;review &amp; editing. Jing Wei: Writing&#8212;original draft. Qingxin Chen: Writing&#8212;original draft. Mengling Hu: Investigation, Writing&#8212;original draft. Lu Yu: Investigation, Visualization. Jianing Mi: Visualization. Xiaogang Zhou: Visualization. Dalian Qin: Investigation, Visualization. Jianming Wu: Data curation, Writing&#8212;review &amp; editing. Anguo Wu: Funding acquisition, Software, Supervision, Writing&#8212; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Conflicts of interest</title><p id="p0540">The authors declare that they have no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Skaria</surname><given-names>A.P.</given-names></name></person-group><article-title>The economic and societal burden of Alzheimer disease: managed care considerations</article-title><source>Am J Manag Care</source><volume>28</volume><year>2022</year><fpage>S188</fpage><lpage>S196</lpage><pub-id pub-id-type="pmid">36197132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.37765/ajmc.2022.89236</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Recent advances in Alzheimer's disease: mechanisms, clinical trials and new drug development strategies</article-title><source>Signal Transduct Target Ther</source><volume>9</volume><year>2024</year><fpage>211</fpage><pub-id pub-id-type="pmid">39174535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-01911-3</pub-id><pub-id pub-id-type="pmcid">PMC11344989</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Applications of multi-omics analysis in human diseases</article-title><source>MedComm (2020)</source><volume>4</volume><year>2023</year><object-id pub-id-type="publisher-id">e315</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mco2.315</pub-id><pub-id pub-id-type="pmcid">PMC10390758</pub-id><pub-id pub-id-type="pmid">37533767</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name></person-group><article-title>Enhanced integration of single-cell multi-omics data using graph attention networks</article-title><source>ACS Synth Biol</source><volume>14</volume><year>2025</year><fpage>931</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">39888834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acssynbio.4c00864</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Payra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.K.</given-names></name></person-group><article-title>Artificial intelligence and machine learning in pharmacological research: bridging the gap between data and drug discovery</article-title><source>Cureus</source><volume>15</volume><year>2023</year><object-id pub-id-type="publisher-id">e44359</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.44359</pub-id><pub-id pub-id-type="pmcid">PMC10539991</pub-id><pub-id pub-id-type="pmid">37779744</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>The application of artificial intelligence in diagnosis of Alzheimer's disease: a bibliometric analysis</article-title><source>Front Neurol</source><volume>15</volume><year>2024</year><object-id pub-id-type="publisher-id">1510729</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2024.1510729</pub-id><pub-id pub-id-type="pmcid">PMC11655329</pub-id><pub-id pub-id-type="pmid">39703357</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.R.</given-names></name><name name-style="western"><surname>Yong</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: past, present, and future</article-title><source>Ageing Res Rev</source><volume>91</volume><year>2023</year><object-id pub-id-type="publisher-id">102078</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2023.102078</pub-id><pub-id pub-id-type="pmid">37758006</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Dietary plant polyphenols as the potential drugs in neurodegenerative diseases: current evidence, advances, and opportunities</article-title><source>Oxid Med Cell Longev</source><volume>2022</volume><year>2022</year><object-id pub-id-type="publisher-id">5288698</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/5288698</pub-id><pub-id pub-id-type="pmcid">PMC8885204</pub-id><pub-id pub-id-type="pmid">35237381</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>F.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Targeting inflammation and gut microbiota with antibacterial therapy: implications for central nervous system health</article-title><source>Ageing Res Rev</source><volume>102</volume><year>2024</year><object-id pub-id-type="publisher-id">102544</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2024.102544</pub-id><pub-id pub-id-type="pmid">39419400</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Corder</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Strittmatter</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Schmechel</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Gaskell</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Small</surname><given-names>G.W.</given-names></name><etal/></person-group><article-title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families</article-title><source>Science</source><volume>261</volume><year>1993</year><fpage>921</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">8346443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.8346443</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Law</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>High-throughput screening for amyloid-<italic toggle="yes">&#946;</italic> binding natural small-molecules based on the combinational use of biolayer interferometry and UHPLC&#8211;DAD-Q/TOF&#8211;MS/MS</article-title><source>Acta Pharm Sin B</source><volume>12</volume><year>2022</year><fpage>1723</fpage><lpage>1739</lpage><pub-id pub-id-type="pmid">35847494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2021.08.030</pub-id><pub-id pub-id-type="pmcid">PMC9279722</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Querfurth</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>LaFerla</surname><given-names>F.M.</given-names></name></person-group><article-title>Alzheimer's disease</article-title><source>N Engl J Med</source><volume>362</volume><year>2010</year><fpage>329</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">20107219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra0909142</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name></person-group><article-title>Commentary: the central lymphatic drainage in pharmacological, surgical and physical therapies of Alzheimer's disease</article-title><source>Acta Pharm Sin B</source><volume>14</volume><year>2024</year><fpage>3291</fpage><lpage>3293</lpage><pub-id pub-id-type="pmid">39027240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2024.04.018</pub-id><pub-id pub-id-type="pmcid">PMC11252468</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Haass</surname><given-names>C.</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>D.J.</given-names></name></person-group><article-title>Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid <italic toggle="yes">&#946;</italic>-peptide</article-title><source>Nat Rev Mol Cell Biol</source><volume>8</volume><year>2007</year><fpage>101</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">17245412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm2101</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Serrano-Pozo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frosch</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B.T.</given-names></name></person-group><article-title>Neuropathological alterations in Alzheimer disease</article-title><source>Cold Spring Harb Perspect Med</source><volume>1</volume><year>2011</year><object-id pub-id-type="publisher-id">a006189</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a006189</pub-id><pub-id pub-id-type="pmcid">PMC3234452</pub-id><pub-id pub-id-type="pmid">22229116</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Rajmohan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>P.H.</given-names></name></person-group><article-title>Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer's disease neurons</article-title><source>J Alzheimers Dis</source><volume>57</volume><year>2017</year><fpage>975</fpage><lpage>999</lpage><pub-id pub-id-type="pmid">27567878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-160612</pub-id><pub-id pub-id-type="pmcid">PMC5793225</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Basak</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M.</given-names></name></person-group><article-title>The role of apolipoprotein E in Alzheimer's disease</article-title><source>Neuron</source><volume>63</volume><year>2009</year><fpage>287</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">19679070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2009.06.026</pub-id><pub-id pub-id-type="pmcid">PMC3044446</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hanfelt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lah</surname><given-names>J.</given-names></name><name name-style="western"><surname>Risk</surname><given-names>B.B.</given-names></name></person-group><article-title>Mixture of regressions with multivariate responses for discovering subtypes in Alzheimer's biomarkers with detection limits</article-title><source>Data Sci Sci</source><volume>3</volume><year>2024</year><object-id pub-id-type="publisher-id">2309403</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/26941899.2024.2309403</pub-id><pub-id pub-id-type="pmcid">PMC11044119</pub-id><pub-id pub-id-type="pmid">38680829</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Pierre-Jean</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mauger</surname><given-names>F.</given-names></name><name name-style="western"><surname>Deleuze</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Le Floch</surname><given-names>E.</given-names></name></person-group><article-title>PIntMF: penalized integrative matrix factorization method for multi-omics data</article-title><source>Bioinformatics</source><volume>38</volume><year>2022</year><fpage>900</fpage><lpage>907</lpage><pub-id pub-id-type="pmid">34849583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btab786</pub-id><pub-id pub-id-type="pmcid">PMC8796362</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Barrera-Ocampo</surname><given-names>A.</given-names></name></person-group><article-title>Monoclonal antibodies and aptamers: the future therapeutics for Alzheimer's disease</article-title><source>Acta Pharm Sin B</source><volume>14</volume><year>2024</year><fpage>2795</fpage><lpage>2814</lpage><pub-id pub-id-type="pmid">39027235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2024.03.034</pub-id><pub-id pub-id-type="pmcid">PMC11252463</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Iqbal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Grundke-Iqbal</surname><given-names>I.</given-names></name></person-group><article-title>Tau in Alzheimer disease and related tauopathies</article-title><source>Curr Alzheimer Res</source><volume>7</volume><year>2010</year><fpage>656</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">20678074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/156720510793611592</pub-id><pub-id pub-id-type="pmcid">PMC3090074</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mandelkow</surname><given-names>E.</given-names></name></person-group><article-title>Tau in physiology and pathology</article-title><source>Nat Rev Neurosci</source><volume>17</volume><year>2016</year><fpage>22</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">26631930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn.2015.1</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Bloom</surname><given-names>G.S.</given-names></name></person-group><article-title>Amyloid-<italic toggle="yes">&#946;</italic> and tau: the trigger and bullet in Alzheimer disease pathogenesis</article-title><source>JAMA Neurol</source><volume>71</volume><year>2014</year><fpage>505</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">24493463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2013.5847</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>D.J.</given-names></name></person-group><article-title>The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics</article-title><source>Science</source><volume>297</volume><year>2002</year><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">12130773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1072994</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Goedegebuure</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>L.</given-names></name><name name-style="western"><surname>DeNardo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fields</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Province</surname><given-names>M.</given-names></name><etal/></person-group><article-title>M3NetFlow: a multi-scale multi-hop graph AI model for integrative multi-omic data analysis</article-title><source>iScience</source><volume>28</volume><year>2025</year><object-id pub-id-type="publisher-id">111920</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2025.111920</pub-id><pub-id pub-id-type="pmcid">PMC11872513</pub-id><pub-id pub-id-type="pmid">40034855</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Cavallini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brewerton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sargent</surname><given-names>S.</given-names></name><name name-style="western"><surname>Glover</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>C.</given-names></name><etal/></person-group><article-title>An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease</article-title><source>J Biol Chem</source><volume>288</volume><year>2013</year><fpage>23331</fpage><lpage>23347</lpage><pub-id pub-id-type="pmid">23798682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M113.463984</pub-id><pub-id pub-id-type="pmcid">PMC3743503</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oyama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Teshirogi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miki</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Phosphoproteomic analysis identified tau-related kinases linking diabetes mellites and Alzheimer's disease-related tau phosphorylation</article-title><source>Vas Cog J</source><volume>11</volume><year>2025</year><fpage>10</fpage><lpage>18</lpage></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>W.Q.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Polyphenols isolated from lychee seed inhibit Alzheimer's disease-associated Tau through improving insulin resistance <italic toggle="yes">via</italic> the IRS-1/PI3K/Akt/GSK-3<italic toggle="yes">&#946;</italic> pathway</article-title><source>J Ethnopharmacol</source><volume>251</volume><year>2020</year><object-id pub-id-type="publisher-id">112548</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2020.112548</pub-id><pub-id pub-id-type="pmid">31917277</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yuen-Kwan Law</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Mitophagy and cGAS&#8211;STING crosstalk in neuroinflammation</article-title><source>Acta Pharm Sin B</source><volume>14</volume><year>2024</year><fpage>3327</fpage><lpage>3361</lpage><pub-id pub-id-type="pmid">39220869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2024.05.012</pub-id><pub-id pub-id-type="pmcid">PMC11365416</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>She</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>B.</given-names></name><etal/></person-group><article-title>YOD1 regulates microglial homeostasis by deubiquitinating MYH9 to promote the pathogenesis of Alzheimer's disease</article-title><source>Acta Pharm Sin B</source><volume>15</volume><year>2025</year><fpage>331</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">40041897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2024.11.020</pub-id><pub-id pub-id-type="pmcid">PMC11873648</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.G.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases</article-title><source>Ageing Res Rev</source><volume>65</volume><year>2021</year><object-id pub-id-type="publisher-id">101202</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2020.101202</pub-id><pub-id pub-id-type="pmid">33161129</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Ashwini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Subhash</surname><given-names>B.</given-names></name><name name-style="western"><surname>Amol</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Atmaram</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ravindra</surname><given-names>K.</given-names></name></person-group><article-title>Comprehensive investigation of multiple targets in the development of newer drugs for the Alzheimer's disease</article-title><source>Acta Pharm Sin B</source><volume>15</volume><year>2025</year><fpage>1281</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">40370532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2024.11.016</pub-id><pub-id pub-id-type="pmcid">PMC12069117</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Golenbock</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name></person-group><article-title>Innate immunity in Alzheimer's disease</article-title><source>Nat Immunol</source><volume>16</volume><year>2015</year><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">25689443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.3102</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Ravichandran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Michelucci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Del Sol</surname><given-names>A.</given-names></name></person-group><article-title>Integrative computational network analysis reveals site-specific mediators of inflammation in Alzheimer's disease</article-title><source>Front Physiol</source><volume>9</volume><year>2018</year><fpage>154</fpage><pub-id pub-id-type="pmid">29551980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2018.00154</pub-id><pub-id pub-id-type="pmcid">PMC5840953</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Schneegans</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fancy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Adair</surname><given-names>E.</given-names></name><name name-style="western"><surname>Willumsen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Papageorgopoulou</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Integrative multi-omics reveal glial signatures associated with accelerated cognitive decline in Alzheimer's disease</article-title><source>medRxiv</source><year>2024</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2024.08.27.24312641</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>W.Q.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Lychee seed polyphenol inhibits A<italic toggle="yes">&#946;</italic>-induced activation of NLRP3 inflammasome <italic toggle="yes">via</italic> the LRP1/AMPK mediated autophagy induction</article-title><source>Biomed Pharmacother</source><volume>130</volume><year>2020</year><object-id pub-id-type="publisher-id">110575</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2020.110575</pub-id><pub-id pub-id-type="pmid">32768883</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>W.Q.</given-names></name><name name-style="western"><surname>Ai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Law</surname><given-names>B.Y.</given-names></name><etal/></person-group><article-title>Polygala saponins inhibit NLRP3 inflammasome-mediated neuroinflammation <italic toggle="yes">via</italic> SHP-2-Mediated mitophagy</article-title><source>Free Radic Biol Med</source><volume>179</volume><year>2022</year><fpage>76</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">34933095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2021.12.263</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X.G.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>W.Q.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Sang</surname><given-names>Z.P.</given-names></name><etal/></person-group><article-title>Targeting microglial autophagic degradation of the NLRP3 inflammasome for identification of thonningianin A in Alzheimer's disease</article-title><source>Inflamm Regen</source><volume>42</volume><year>2022</year><fpage>25</fpage><pub-id pub-id-type="pmid">35918778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s41232-022-00209-7</pub-id><pub-id pub-id-type="pmcid">PMC9347127</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Selkoe</surname><given-names>D.J.</given-names></name></person-group><article-title>Alzheimer's disease is a synaptic failure</article-title><source>Science</source><volume>298</volume><year>2002</year><fpage>789</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">12399581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1074069</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Mucke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>D.J.</given-names></name></person-group><article-title>Neurotoxicity of amyloid <italic toggle="yes">&#946;</italic>-protein: synaptic and network dysfunction</article-title><source>Cold Spring Harb Perspect Med</source><volume>2</volume><year>2012</year><object-id pub-id-type="publisher-id">a006338</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a006338</pub-id><pub-id pub-id-type="pmcid">PMC3385944</pub-id><pub-id pub-id-type="pmid">22762015</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Tsurukawa</surname><given-names>F.K.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sanchez-Villalobos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>N.</given-names></name><name name-style="western"><surname>Crasto</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Cross study transcriptomic investigation of Alzheimer's brain tissue discoveries and limitations</article-title><source>Sci Rep</source><volume>15</volume><year>2025</year><object-id pub-id-type="publisher-id">16041</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-025-01017-y</pub-id><pub-id pub-id-type="pmcid">PMC12062235</pub-id><pub-id pub-id-type="pmid">40341634</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ritter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>K.</given-names></name></person-group><article-title>Alzheimer's disease drug development pipeline: 2019</article-title><source>Alzheimers Dement (N Y)</source><volume>5</volume><year>2019</year><fpage>272</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">31334330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2019.05.008</pub-id><pub-id pub-id-type="pmcid">PMC6617248</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Ashleigh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Swerdlow</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Beal</surname><given-names>M.F.</given-names></name></person-group><article-title>The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis</article-title><source>Alzheimer's Dement</source><volume>19</volume><year>2023</year><fpage>333</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">35522844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12683</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Mitochondria targeting drugs for neurodegenerative diseases&#8212;design, mechanism and application</article-title><source>Acta Pharm Sin B</source><volume>12</volume><year>2022</year><fpage>2778</fpage><lpage>2789</lpage><pub-id pub-id-type="pmid">35755284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2022.03.001</pub-id><pub-id pub-id-type="pmcid">PMC9214044</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Calkins</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Manczak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shirendeb</surname><given-names>U.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>P.H.</given-names></name></person-group><article-title>Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease</article-title><source>Hum Mol Genet</source><volume>20</volume><year>2011</year><fpage>4515</fpage><lpage>4529</lpage><pub-id pub-id-type="pmid">21873260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddr381</pub-id><pub-id pub-id-type="pmcid">PMC3209824</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Beal</surname><given-names>M.F.</given-names></name></person-group><article-title>Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease</article-title><source>Trends Mol Med</source><volume>14</volume><year>2008</year><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">18218341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2007.12.002</pub-id><pub-id pub-id-type="pmcid">PMC3107703</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Finney</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Delerue</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gold</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Shvetcov</surname><given-names>A.</given-names></name></person-group><article-title>Artificial intelligence-driven meta-analysis of brain gene expression identifies novel gene candidates and a role for mitochondria in Alzheimer's disease</article-title><source>Comput Struct Biotechnol J</source><volume>21</volume><year>2023</year><fpage>388</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">36618979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.csbj.2022.12.018</pub-id><pub-id pub-id-type="pmcid">PMC9798142</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Uzuner Odongo</surname><given-names>D.</given-names></name><name name-style="western"><surname>&#304;lg&#252;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bozkurt</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>&#199;ak&#305;r</surname><given-names>T.</given-names></name></person-group><article-title>A personalized metabolic modelling approach through integrated analysis of RNA-Seq-based genomic variants and gene expression levels in Alzheimer's disease</article-title><source>Commun Biol</source><volume>8</volume><year>2025</year><fpage>502</fpage><pub-id pub-id-type="pmid">40148444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-025-07941-z</pub-id><pub-id pub-id-type="pmcid">PMC11950204</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Law</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>W.Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>He</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>Targeting autophagy as a therapeutic strategy for identification of liganans from Peristrophe japonica in Parkinson's disease</article-title><source>Signal Transduct Target Ther</source><volume>6</volume><year>2021</year><fpage>67</fpage><pub-id pub-id-type="pmid">33594053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-00442-x</pub-id><pub-id pub-id-type="pmcid">PMC7887264</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>You</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>Q.B.</given-names></name><etal/></person-group><article-title>Screening of the ubiquitin-proteasome system activators for anti-Alzheimer's disease by the high-content fluorescence imaging system</article-title><source>Chin J Nat Med</source><volume>20</volume><year>2022</year><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">35101248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1875-5364(22)60152-3</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Nixon</surname><given-names>R.A.</given-names></name></person-group><article-title>The role of autophagy in neurodegenerative disease</article-title><source>Nat Med</source><volume>19</volume><year>2013</year><fpage>983</fpage><lpage>997</lpage><pub-id pub-id-type="pmid">23921753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.3232</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Lipinski</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Py</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease</article-title><source>Proc Natl Acad Sci U S A</source><volume>107</volume><year>2010</year><fpage>14164</fpage><lpage>14169</lpage><pub-id pub-id-type="pmid">20660724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1009485107</pub-id><pub-id pub-id-type="pmcid">PMC2922576</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Kitani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matsui</surname><given-names>Y.</given-names></name></person-group><article-title>Integrative network analysis reveals novel moderators of A<italic toggle="yes">&#946;</italic>&#8211;Tau interaction in Alzheimer's disease</article-title><source>Alzheimers Res Ther</source><volume>17</volume><year>2025</year><fpage>70</fpage><pub-id pub-id-type="pmid">40176187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-025-01705-x</pub-id><pub-id pub-id-type="pmcid">PMC11967117</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Multidimensional autophagy nano-regulator boosts Alzheimer's disease treatment by improving both extra/intraneuronal homeostasis</article-title><source>Acta Pharm Sin B</source><volume>14</volume><year>2024</year><fpage>1380</fpage><lpage>1399</lpage><pub-id pub-id-type="pmid">38486986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2023.10.009</pub-id><pub-id pub-id-type="pmcid">PMC10935063</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Tapia-Arancibia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aliaga</surname><given-names>E.</given-names></name><name name-style="western"><surname>Silhol</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arancibia</surname><given-names>S.</given-names></name></person-group><article-title>New insights into brain BDNF function in normal aging and Alzheimer disease</article-title><source>Brain Res Rev</source><volume>59</volume><year>2008</year><fpage>201</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">18708092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainresrev.2008.07.007</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nagappan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Wren</surname><given-names>P.</given-names></name></person-group><article-title>BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases</article-title><source>Nat Rev Neurosci</source><volume>14</volume><year>2013</year><fpage>401</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">23674053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn3505</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Miranda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morici</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Zanoni</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Bekinschtein</surname><given-names>P.</given-names></name></person-group><article-title>Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain</article-title><source>Front Cell Neurosci</source><volume>13</volume><year>2019</year><fpage>363</fpage><pub-id pub-id-type="pmid">31440144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2019.00363</pub-id><pub-id pub-id-type="pmcid">PMC6692714</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Eteleeb</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Novotny</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Tarraga</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dhungel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Brase</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer's disease</article-title><source>PLoS Biol</source><volume>22</volume><year>2024</year><object-id pub-id-type="publisher-id">e3002607</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pbio.3002607</pub-id><pub-id pub-id-type="pmcid">PMC11086901</pub-id><pub-id pub-id-type="pmid">38687811</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Hynd</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Dodd</surname><given-names>P.R.</given-names></name></person-group><article-title>Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease</article-title><source>Neurochem Int</source><volume>45</volume><year>2004</year><fpage>583</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">15234100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuint.2004.03.007</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Lipton</surname><given-names>S.A.</given-names></name></person-group><article-title>Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults</article-title><source>NeuroRx</source><volume>1</volume><year>2004</year><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">15717010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1602/neurorx.1.1.101</pub-id><pub-id pub-id-type="pmcid">PMC534915</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Kratimenos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vij</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vidva</surname><given-names>R.</given-names></name><name name-style="western"><surname>Koutroulis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Delivoria-Papadopoulos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Computational analysis of cortical neuronal excitotoxicity in a large animal model of neonatal brain injury</article-title><source>J Neurodev Disord</source><volume>14</volume><year>2022</year><fpage>26</fpage><pub-id pub-id-type="pmid">35351004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s11689-022-09431-3</pub-id><pub-id pub-id-type="pmcid">PMC8966144</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Discovery of neuroprotective compounds by machine learning approaches</article-title><source>RSC Adv</source><volume>6</volume><year>2016</year><fpage>9857</fpage><lpage>9871</lpage></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Cryan</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>O'Riordan</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Cowan</surname><given-names>C.S.M.</given-names></name><name name-style="western"><surname>Sandhu</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Bastiaanssen</surname><given-names>T.F.S.</given-names></name><name name-style="western"><surname>Boehme</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The microbiota&#8211;gut&#8211;brain axis</article-title><source>Physiol Rev</source><volume>99</volume><year>2019</year><fpage>1877</fpage><lpage>2013</lpage><pub-id pub-id-type="pmid">31460832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00018.2018</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Vogt</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Kerby</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Dill-McFarland</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Harding</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Merluzzi</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.C.</given-names></name><etal/></person-group><article-title>Gut microbiome alterations in Alzheimer's disease</article-title><source>Sci Rep</source><volume>7</volume><year>2017</year><object-id pub-id-type="publisher-id">13537</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-13601-y</pub-id><pub-id pub-id-type="pmcid">PMC5648830</pub-id><pub-id pub-id-type="pmid">29051531</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Harach</surname><given-names>T.</given-names></name><name name-style="western"><surname>Marungruang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Duthilleul</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cheatham</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mc Coy</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota</article-title><source>Sci Rep</source><volume>7</volume><year>2017</year><object-id pub-id-type="publisher-id">41802</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep41802</pub-id><pub-id pub-id-type="pmcid">PMC5297247</pub-id><pub-id pub-id-type="pmid">28176819</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Rozera</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pasolli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Segata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ianiro</surname><given-names>G.</given-names></name></person-group><article-title>Machine learning and artificial intelligence in the multi-omics approach to gut microbiota</article-title><source>Gastroenterology</source><year>2025</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1053/j.gastro.2025.02.035</pub-id><pub-id pub-id-type="pmid">40118220</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Geng</surname><given-names>M.</given-names></name></person-group><article-title>Shanghai Green Valley Pharmaceutical Co., Ltd. Integrative host microbiota multi-omics analysis reveals distinctive systemic inflammation and metabolic disorder across Alzheimer's disease continuum</article-title><source>Alzheimer's Dement</source><volume>17</volume><year>2021</year><object-id pub-id-type="publisher-id">e055865</object-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gohel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bykova</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Systematic characterization of multi-omics landscape between gut microbial metabolites and GPCRome in Alzheimer's disease</article-title><source>Cell Rep</source><volume>43</volume><year>2024</year><object-id pub-id-type="publisher-id">114128</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2024.114128</pub-id><pub-id pub-id-type="pmcid">PMC11968202</pub-id><pub-id pub-id-type="pmid">38652661</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name></person-group><article-title>The role of biomarkers in Alzheimer's disease drug development</article-title><source>Adv Exp Med Biol</source><volume>1118</volume><year>2019</year><fpage>29</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">30747416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-030-05542-4_2</pub-id><pub-id pub-id-type="pmcid">PMC6750734</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Georgakas</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Howe</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Riera</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Riddle</surname><given-names>M.C.</given-names></name></person-group><article-title>Biomarkers of Alzheimer's disease: past, present and future clinical use</article-title><source>Biomark Neuropsychiatry</source><volume>8</volume><year>2023</year><object-id pub-id-type="publisher-id">100063</object-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Lewandowski</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Laham</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Thatcher</surname><given-names>G.R.J.</given-names></name></person-group><article-title>Remembering your A, B, C's: Alzheimer's disease and ABCA1</article-title><source>Acta Pharm Sin B</source><volume>12</volume><year>2022</year><fpage>995</fpage><lpage>1018</lpage><pub-id pub-id-type="pmid">35530134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2022.01.011</pub-id><pub-id pub-id-type="pmcid">PMC9072248</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name></person-group><article-title>Biomarkers for Alzheimer's disease: current status and prospects for the future</article-title><source>J Intern Med</source><volume>284</volume><year>2018</year><fpage>643</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">30051512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/joim.12816</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Tapiola</surname><given-names>T.</given-names></name><name name-style="western"><surname>Alafuzoff</surname><given-names>I.</given-names></name><name name-style="western"><surname>Herukka</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Parkkinen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hartikainen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Soininen</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid <italic toggle="yes">&#946;</italic>-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain</article-title><source>Arch Neurol</source><volume>66</volume><year>2009</year><fpage>382</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">19273758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneurol.2008.596</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Bridel</surname><given-names>C.</given-names></name><name name-style="western"><surname>van Wieringen</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tijms</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Alvarez-Cerme&#241;o</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis</article-title><source>JAMA Neurol</source><volume>76</volume><year>2019</year><fpage>1035</fpage><lpage>1048</lpage><pub-id pub-id-type="pmid">31206160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2019.1534</pub-id><pub-id pub-id-type="pmcid">PMC6580449</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Piccio</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deming</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Del-&#193;guila</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Ghezzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Fagan</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status</article-title><source>Acta Neuropathol</source><volume>131</volume><year>2016</year><fpage>925</fpage><lpage>933</lpage><pub-id pub-id-type="pmid">26754641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-016-1533-5</pub-id><pub-id pub-id-type="pmcid">PMC4867123</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Tiwari</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Indic</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tabassum</surname><given-names>S.</given-names></name></person-group><article-title>A study on machine learning models in detecting cognitive impairments in Alzheimer's patients using cerebrospinal fluid biomarkers</article-title><source>Am J Alzheimers Dis Other Demen</source><volume>39</volume><year>2024</year><object-id pub-id-type="publisher-id">15333175241308645</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/15333175241308645</pub-id><pub-id pub-id-type="pmcid">PMC11632866</pub-id><pub-id pub-id-type="pmid">39657974</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Winchester</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Harshfield</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Badhwar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khleifat</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia</article-title><source>Alzheimer's Dement</source><volume>19</volume><year>2023</year><fpage>5860</fpage><lpage>5871</lpage><pub-id pub-id-type="pmid">37654029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13390</pub-id><pub-id pub-id-type="pmcid">PMC10840606</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Argiris</surname><given-names>G.</given-names></name><name name-style="western"><surname>Akinci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pe&#241;a-G&#243;mez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Palpatzis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Garcia-Prat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shekari</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's disease</article-title><source>Alzheimers Res Ther</source><volume>16</volume><year>2024</year><fpage>274</fpage><pub-id pub-id-type="pmid">39716329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01629-y</pub-id><pub-id pub-id-type="pmcid">PMC11667858</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Gonz&#225;lez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Puerta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dehairs</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Rojas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Montrreal</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pytel</surname><given-names>V.V.</given-names></name><etal/></person-group><article-title>Deciphering Alzheimer's disease complexity: integrative analysis of CSF proteomic and lipidomic data through dimensionality reduction</article-title><source>Alzheimer's Dement</source><volume>20</volume><year>2025</year><object-id pub-id-type="publisher-id">e088693</object-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>Jr.CR.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Haeberlein</surname><given-names>S.B.</given-names></name><etal/></person-group><article-title>NIA-AA research framework: toward a biological definition of Alzheimer's disease</article-title><source>Alzheimer's Dement</source><volume>14</volume><year>2018</year><fpage>535</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Villemagne</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Burnham</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bourgeat</surname><given-names>P.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Salvado</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Amyloid <italic toggle="yes">&#946;</italic> deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study</article-title><source>Lancet Neurol</source><volume>12</volume><year>2013</year><fpage>357</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">23477989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(13)70044-9</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Sperling</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Craft</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fagan</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</article-title><source>Alzheimer's Dement</source><volume>7</volume><year>2011</year><fpage>280</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">21514248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.03.003</pub-id><pub-id pub-id-type="pmcid">PMC3220946</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Jo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nho</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saykin</surname><given-names>A.J.</given-names></name></person-group><article-title>Deep learning in Alzheimer's disease: diagnostic classification and prognostic prediction using neuroimaging data</article-title><source>Front Aging Neurosci</source><volume>11</volume><year>2019</year><fpage>220</fpage><pub-id pub-id-type="pmid">31481890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2019.00220</pub-id><pub-id pub-id-type="pmcid">PMC6710444</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Kamathe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>K.</given-names></name></person-group><article-title>Neuroimaging and pattern recognition techniques for automatic detection of Alzheimer's disease: a review</article-title><source>ICTACT J Image Video Process</source><volume>8</volume><year>2017</year><fpage>1543</fpage><lpage>1553</lpage></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Filippini</surname><given-names>N.</given-names></name><name name-style="western"><surname>MacIntosh</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Hough</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele</article-title><source>Proc Natl Acad Sci U S A</source><volume>106</volume><year>2009</year><fpage>7209</fpage><lpage>7214</lpage><pub-id pub-id-type="pmid">19357304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0811879106</pub-id><pub-id pub-id-type="pmcid">PMC2678478</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>O'Brien</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A.</given-names></name></person-group><article-title>Vascular dementia</article-title><source>Lancet</source><volume>386</volume><year>2015</year><fpage>1698</fpage><lpage>1706</lpage><pub-id pub-id-type="pmid">26595643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(15)00463-8</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Janelidze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Palmqvist</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>G.E.</given-names></name><etal/></person-group><article-title>Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia</article-title><source>Nat Med</source><volume>26</volume><year>2020</year><fpage>379</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">32123385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0755-1</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Karikari</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Pascoal</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benedet</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts</article-title><source>Lancet Neurol</source><volume>19</volume><year>2020</year><fpage>422</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">32333900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(20)30071-5</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Mattsson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Andreasson</surname><given-names>U.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name></person-group><article-title>Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease</article-title><source>JAMA Neurol</source><volume>76</volume><year>2019</year><fpage>791</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">31009028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2019.0765</pub-id><pub-id pub-id-type="pmcid">PMC6583067</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Himali</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Satizabal</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Beiser</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>E.J.</given-names></name><etal/></person-group><article-title>Identifying blood biomarkers for dementia using machine learning methods in the Framingham Heart Study</article-title><source>Cells</source><volume>11</volume><year>2022</year><fpage>1506</fpage><pub-id pub-id-type="pmid">35563811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells11091506</pub-id><pub-id pub-id-type="pmcid">PMC9100323</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Blanco</surname><given-names>K.</given-names></name><name name-style="western"><surname>Salcidua</surname><given-names>S.</given-names></name><name name-style="western"><surname>Orellana</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sauma-P&#233;rez</surname><given-names>T.</given-names></name><name name-style="western"><surname>Le&#243;n</surname><given-names>T.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>L.C.L.</given-names></name><etal/></person-group><article-title>Systematic review: fluid biomarkers and machine learning methods to improve the diagnosis from mild cognitive impairment to Alzheimer's disease</article-title><source>Alzheimers Res Ther</source><volume>15</volume><year>2023</year><fpage>176</fpage><pub-id pub-id-type="pmid">37838690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-023-01304-8</pub-id><pub-id pub-id-type="pmcid">PMC10576366</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Khullar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name></person-group><article-title>Predicting gene regulatory networks from multi-omics to link genetic risk variants and neuroimmunology to Alzheimer's disease phenotypes</article-title><source>bioRxiv</source><year>2021</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2021.06.21.449165</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>De Jager</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lunnon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schalkwyk</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci</article-title><source>Nat Neurosci</source><volume>17</volume><year>2014</year><fpage>1156</fpage><lpage>1163</lpage><pub-id pub-id-type="pmid">25129075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.3786</pub-id><pub-id pub-id-type="pmcid">PMC4292795</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chibnik</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Pochet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Association of brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease</article-title><source>JAMA Neurol</source><volume>72</volume><year>2015</year><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">25365775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2014.3049</pub-id><pub-id pub-id-type="pmcid">PMC4344367</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Yap</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Vo</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Heffel</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Brain cell-type shifts in Alzheimer's disease, autism, and schizophrenia interrogated using methylomics and genetics</article-title><source>Sci Adv</source><volume>10</volume><year>2024</year><fpage>eadn7655</fpage><pub-id pub-id-type="pmid">38781333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adn7655</pub-id><pub-id pub-id-type="pmcid">PMC11114225</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Young</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lukacsovich</surname><given-names>D.</given-names></name><name name-style="western"><surname>Varma</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects</article-title><source>Alzheimers Res Ther</source><volume>15</volume><year>2023</year><fpage>78</fpage><pub-id pub-id-type="pmid">37038196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-023-01216-7</pub-id><pub-id pub-id-type="pmcid">PMC10088180</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>H.-U.</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gjoneska</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Kaskow</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Epigenome-wide study uncovers large-scale changes in histone acetylation driven by tau pathology in aging and Alzheimer's human brains</article-title><source>Nat Neurosci</source><volume>22</volume><year>2018</year><fpage>37</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">30559478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-018-0291-1</pub-id><pub-id pub-id-type="pmcid">PMC6516529</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name><name name-style="western"><surname>James</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Boix</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Galani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Victor</surname><given-names>M.B.</given-names></name><etal/></person-group><article-title>Epigenomic dissection of Alzheimer's disease pinpoints causal variants and reveals epigenome erosion</article-title><source>Cell</source><volume>186</volume><year>2023</year><fpage>4422</fpage><lpage>4437</lpage><comment>e21</comment><pub-id pub-id-type="pmid">37774680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.08.040</pub-id><pub-id pub-id-type="pmcid">PMC10782612</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Pe&#241;a-Bautista</surname><given-names>C.</given-names></name><name name-style="western"><surname>&#193;lvarez-S&#225;nchez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ca&#241;ada-Mart&#237;nez</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Baquero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ch&#225;fer-Peric&#225;s</surname><given-names>C.</given-names></name></person-group><article-title>Epigenomics and lipidomics integration in Alzheimer disease: pathways involved in early stages</article-title><source>Biomedicines</source><volume>9</volume><year>2021</year><fpage>1812</fpage><pub-id pub-id-type="pmid">34944628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines9121812</pub-id><pub-id pub-id-type="pmcid">PMC8698767</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Vasanthakumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Idler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Waring</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Asque</surname><given-names>E.</given-names></name><name name-style="western"><surname>Riley-Gillis</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease</article-title><source>Clin Epigenet</source><volume>12</volume><year>2020</year><fpage>84</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13148-020-00864-y</pub-id><pub-id pub-id-type="pmcid">PMC7294637</pub-id><pub-id pub-id-type="pmid">32539856</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Piras</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Brokaw</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Weisenberger</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Krate</surname><given-names>J.</given-names></name><name name-style="western"><surname>Delvaux</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Integrated DNA methylation/RNA profiling in middle temporal gyrus of Alzheimer's disease</article-title><source>Cell Mol Neurobiol</source><volume>43</volume><year>2023</year><fpage>2289</fpage><lpage>2307</lpage><pub-id pub-id-type="pmid">36596913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10571-022-01307-3</pub-id><pub-id pub-id-type="pmcid">PMC10287777</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Barisano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kisler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nikolakopoulou</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sagare</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A &#8220;multi-omics&#8221; analysis of blood&#8211;brain barrier and synaptic dysfunction in APOE4 mice</article-title><source>J Exp Med</source><volume>219</volume><year>2022</year><object-id pub-id-type="publisher-id">e20221137</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20221137</pub-id><pub-id pub-id-type="pmcid">PMC9435921</pub-id><pub-id pub-id-type="pmid">36040482</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Ovesen</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Juul-Madsen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Telugu</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>V.</given-names></name><name name-style="western"><surname>Frahm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Radbruch</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Alzheimer's disease risk gene SORL1 promotes receptiveness of human microglia to pro-inflammatory stimuli</article-title><source>Glia</source><volume>73</volume><year>2025</year><fpage>857</fpage><lpage>872</lpage><pub-id pub-id-type="pmid">39688327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.24659</pub-id><pub-id pub-id-type="pmcid">PMC11845846</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Nativio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Donahue</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sidoli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Berson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer's disease</article-title><source>Nat Genet</source><volume>52</volume><year>2020</year><fpage>1024</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">32989324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-020-0696-0</pub-id><pub-id pub-id-type="pmcid">PMC8098004</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Lefterov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Fitz</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Letronne</surname><given-names>F.</given-names></name><name name-style="western"><surname>Biedrzycki</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>APOE2 orchestrated differences in transcriptomic and lipidomic profiles of postmortem AD brain</article-title><source>Alzheimers Res Ther</source><volume>11</volume><year>2019</year><fpage>113</fpage><pub-id pub-id-type="pmid">31888770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-019-0558-0</pub-id><pub-id pub-id-type="pmcid">PMC6937981</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Luquez</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gaur</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kosater</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Mares</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Cell type-specific changes identified by single-cell transcriptomics in Alzheimer's disease</article-title><source>Genome Med</source><volume>14</volume><year>2022</year><fpage>136</fpage><pub-id pub-id-type="pmid">36447241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-022-01136-5</pub-id><pub-id pub-id-type="pmcid">PMC9710120</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Rexach</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Polioudakis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Mitri</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Cross-disorder and disease-specific pathways in dementia revealed by single-cell genomics</article-title><source>Cell</source><volume>187</volume><year>2024</year><fpage>5753</fpage><lpage>5774</lpage><comment>e28</comment><pub-id pub-id-type="pmid">39265576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2024.08.019</pub-id><pub-id pub-id-type="pmcid">PMC12017262</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wachter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Noori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abdourahman</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Distinct transcriptomic responses to A<italic toggle="yes">&#946;</italic> plaques, neurofibrillary tangles, and APOE in Alzheimer's disease</article-title><source>Alzheimer's Dement</source><volume>20</volume><year>2023</year><fpage>74</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">37461318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13387</pub-id><pub-id pub-id-type="pmcid">PMC10792109</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Mallach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zielonka</surname><given-names>M.</given-names></name><name name-style="western"><surname>van Lieshout</surname><given-names>V.</given-names></name><name name-style="western"><surname>An</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Khoo</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Vanheusden</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer's disease mouse model, as revealed by spatial transcriptomics</article-title><source>Cell Rep</source><volume>43</volume><year>2024</year><object-id pub-id-type="publisher-id">114216</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2024.114216</pub-id><pub-id pub-id-type="pmid">38819990</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>Alexandrov</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Dua</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bhattacharjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lukiw</surname><given-names>W.J.</given-names></name></person-group><article-title>microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF)</article-title><source>Int J Biochem Mol Biol</source><volume>3</volume><year>2012</year><fpage>365</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">23301201</pub-id><pub-id pub-id-type="pmcid">PMC3533883</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Bice</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saykin</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>miR-133b as a potential regulator of a synaptic NPTX2 protein in Alzheimer's disease</article-title><source>Ann Clin Transl Neurol</source><volume>11</volume><year>2024</year><fpage>2799</fpage><lpage>2804</lpage><pub-id pub-id-type="pmid">39289904</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.52175</pub-id><pub-id pub-id-type="pmcid">PMC11514917</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Pe&#241;a-Bautista</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tarazona-S&#225;nchez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Braza-Boils</surname><given-names>A.</given-names></name><name name-style="western"><surname>Balaguer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferr&#233;-Gonz&#225;lez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ca&#241;ada-Mart&#237;nez</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>Plasma microRNAs as potential biomarkers in early Alzheimer disease expression</article-title><source>Sci Rep</source><volume>12</volume><year>2022</year><object-id pub-id-type="publisher-id">15589</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-19862-6</pub-id><pub-id pub-id-type="pmcid">PMC9481579</pub-id><pub-id pub-id-type="pmid">36114255</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Dileep</surname><given-names>V.</given-names></name><name name-style="western"><surname>Boix</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Mathys</surname><given-names>H.</given-names></name><name name-style="western"><surname>Marco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Meharena</surname><given-names>H.S.</given-names></name><etal/></person-group><article-title>Neuronal DNA double-strand breaks lead to genome structural variations and 3D genome disruption in neurodegeneration</article-title><source>Cell</source><volume>186</volume><year>2023</year><fpage>4404</fpage><lpage>4421</lpage><comment>e20</comment><pub-id pub-id-type="pmid">37774679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.08.038</pub-id><pub-id pub-id-type="pmcid">PMC10697236</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Craessaerts</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pavie</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sala Frigerio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corthout</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Spatial transcriptomics and <italic toggle="yes">in situ</italic> sequencing to study Alzheimer's disease</article-title><source>Cell</source><volume>182</volume><year>2020</year><fpage>976</fpage><lpage>991</lpage><comment>e19</comment><pub-id pub-id-type="pmid">32702314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.06.038</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Navarro</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Croteau</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Jurek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Andrusivova</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Spatial transcriptomics reveals genes associated with dysregulated mitochondrial functions and stress signaling in Alzheimer disease</article-title><source>iScience</source><volume>23</volume><year>2020</year><object-id pub-id-type="publisher-id">101556</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2020.101556</pub-id><pub-id pub-id-type="pmcid">PMC7522123</pub-id><pub-id pub-id-type="pmid">33083725</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Citu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name></person-group><article-title>Unraveling the intercellular communication disruption and key pathways in Alzheimer's disease: an integrative study of single-nucleus transcriptomes and genetic association</article-title><source>Alzheimers Res Ther</source><volume>16</volume><year>2024</year><fpage>3</fpage><pub-id pub-id-type="pmid">38167548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-023-01372-w</pub-id><pub-id pub-id-type="pmcid">PMC10762817</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Annese</surname><given-names>A.</given-names></name><name name-style="western"><surname>Manzari</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lionetti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Picardi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Horner</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Chiara</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Whole transcriptome profiling of late-onset Alzheimer's disease patients provides insights into the molecular changes involved in the disease</article-title><source>Sci Rep</source><volume>8</volume><year>2018</year><fpage>4282</fpage><pub-id pub-id-type="pmid">29523845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-22701-2</pub-id><pub-id pub-id-type="pmcid">PMC5844946</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Mathys</surname><given-names>H.</given-names></name><name name-style="western"><surname>Davila-Velderrain</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mohammadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Young</surname><given-names>J.Z.</given-names></name><etal/></person-group><article-title>Single-cell transcriptomic analysis of Alzheimer's disease</article-title><source>Nature</source><volume>570</volume><year>2019</year><fpage>332</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">31042697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1195-2</pub-id><pub-id pub-id-type="pmcid">PMC6865822</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>Sapozhnikov</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Szyf</surname><given-names>M.</given-names></name></person-group><article-title>Unraveling the functional role of DNA demethylation at specific promoters by targeted steric blockage of DNA methyltransferase with CRISPR/dCas9</article-title><source>Nat Commun</source><volume>12</volume><year>2021</year><fpage>5711</fpage><pub-id pub-id-type="pmid">34588447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-25991-9</pub-id><pub-id pub-id-type="pmcid">PMC8481236</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Blalock</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Geddes</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Markesbery</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Landfield</surname><given-names>P.W.</given-names></name></person-group><article-title>Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses</article-title><source>Proc Natl Acad Sci U S A</source><volume>101</volume><year>2004</year><fpage>2173</fpage><lpage>2178</lpage><pub-id pub-id-type="pmid">14769913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0308512100</pub-id><pub-id pub-id-type="pmcid">PMC357071</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Hemonnot-Girard</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Meersseman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pastore</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>V.</given-names></name><name name-style="western"><surname>Linck</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rey</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Comparative analysis of transcriptome remodeling in plaque-associated and plaque-distant microglia during amyloid-<italic toggle="yes">&#946;</italic> pathology progression in mice</article-title><source>J Neuroinflammation</source><volume>19</volume><year>2022</year><fpage>234</fpage><pub-id pub-id-type="pmid">36153535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-022-02581-0</pub-id><pub-id pub-id-type="pmcid">PMC9508749</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roussos</surname><given-names>P.</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kajiwara</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Brennand</surname><given-names>K.J.</given-names></name><etal/></person-group><article-title>Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease</article-title><source>Genome Med</source><volume>8</volume><year>2016</year><fpage>104</fpage><pub-id pub-id-type="pmid">27799057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-016-0355-3</pub-id><pub-id pub-id-type="pmcid">PMC5088659</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Pishva</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shireby</surname><given-names>G.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Roubroeks</surname><given-names>J.A.Y.</given-names></name><name name-style="western"><surname>Hannon</surname><given-names>E.</given-names></name><etal/></person-group><article-title>A meta-analysis of epigenome-wide association studies in Alzheimer's disease highlights novel differentially methylated loci across cortex</article-title><source>Nat Commun</source><volume>12</volume><year>2021</year><fpage>3517</fpage><pub-id pub-id-type="pmid">34112773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-23243-4</pub-id><pub-id pub-id-type="pmcid">PMC8192929</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>De Jager</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vardarajan</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Felsky</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A multi-omic atlas of the human frontal cortex for aging and Alzheimer's disease research</article-title><source>Sci Data</source><volume>5</volume><year>2018</year><object-id pub-id-type="publisher-id">180142</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sdata.2018.142</pub-id><pub-id pub-id-type="pmcid">PMC6080491</pub-id><pub-id pub-id-type="pmid">30084846</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Bossers</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wirz</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Meerhoff</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Essing</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>van Dongen</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Houba</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease</article-title><source>Brain</source><volume>133</volume><year>2010</year><fpage>3699</fpage><lpage>3723</lpage><pub-id pub-id-type="pmid">20889584</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awq258</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Reilly</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Correlation between DNA methylation and gene expression in the brains of patients with bipolar disorder and schizophrenia</article-title><source>Bipolar Disord</source><volume>16</volume><year>2014</year><fpage>790</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">25243493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bdi.12255</pub-id><pub-id pub-id-type="pmcid">PMC4302408</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Gasparoni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bultmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lutsik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kraus</surname><given-names>T.F.J.</given-names></name><name name-style="western"><surname>Sordon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vlcek</surname><given-names>J.</given-names></name><etal/></person-group><article-title>DNA methylation analysis on purified neurons and glia dissects age and Alzheimer's disease-specific changes in the human cortex</article-title><source>Epigenetics Chromatin</source><volume>11</volume><year>2018</year><fpage>41</fpage><pub-id pub-id-type="pmid">30045751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13072-018-0211-3</pub-id><pub-id pub-id-type="pmcid">PMC6058387</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Kunkle</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Grenier-Boley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bis</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Damotte</surname><given-names>V.</given-names></name><name name-style="western"><surname>Naj</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A<italic toggle="yes">&#946;</italic>, tau, immunity and lipid processing</article-title><source>Nat Genet</source><volume>51</volume><year>2019</year><fpage>414</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">30820047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-019-0358-2</pub-id><pub-id pub-id-type="pmcid">PMC6463297</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Savage</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bryois</surname><given-names>J.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk</article-title><source>Nat Genet</source><volume>51</volume><year>2019</year><fpage>404</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">30617256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0311-9</pub-id><pub-id pub-id-type="pmcid">PMC6836675</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gaiteri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bodea</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>McElwee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Podtelezhnikov</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease</article-title><source>Cell</source><volume>153</volume><year>2013</year><fpage>707</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">23622250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2013.03.030</pub-id><pub-id pub-id-type="pmcid">PMC3677161</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Mez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jun</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kriegel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bourlas</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Sherva</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans</article-title><source>Alzheimer's Dement</source><volume>13</volume><year>2017</year><fpage>119</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">27770636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2016.09.002</pub-id><pub-id pub-id-type="pmcid">PMC5318231</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Kvartsberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Duits</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Ingelsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andreasen</surname><given-names>N.</given-names></name><name name-style="western"><surname>&#214;hrfelt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease</article-title><source>Alzheimer's Dement</source><volume>11</volume><year>2015</year><fpage>1180</fpage><lpage>1190</lpage><pub-id pub-id-type="pmid">25533203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.10.009</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>Astarita</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Berchtold</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>V.Q.</given-names></name><name name-style="western"><surname>Gillen</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Head</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease</article-title><source>PLoS One</source><volume>5</volume><year>2010</year><object-id pub-id-type="publisher-id">e12538</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0012538</pub-id><pub-id pub-id-type="pmcid">PMC2935886</pub-id><pub-id pub-id-type="pmid">20838618</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Ping</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kundinger</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Duong</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gearing</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lah</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer's disease</article-title><source>Sci Data</source><volume>7</volume><year>2020</year><fpage>315</fpage><pub-id pub-id-type="pmid">32985496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41597-020-00650-8</pub-id><pub-id pub-id-type="pmcid">PMC7522715</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Bonfili</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cuccioloni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cecarini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Spina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Gut microbiota modulation in Alzheimer's disease: focus on lipid metabolism</article-title><source>Clin Nutr</source><volume>41</volume><year>2022</year><fpage>698</fpage><lpage>708</lpage><pub-id pub-id-type="pmid">35158177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clnu.2022.01.025</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bankov</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wretlind</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lord</surname><given-names>J.</given-names></name><name name-style="western"><surname>Green</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Integrated lipidomics and proteomics network analysis highlights lipid and immunity pathways associated with Alzheimer's disease</article-title><source>Transl Neurodegener</source><volume>9</volume><year>2020</year><fpage>36</fpage><pub-id pub-id-type="pmid">32951606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-020-00215-0</pub-id><pub-id pub-id-type="pmcid">PMC7504646</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>Kodam</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sai</surname><given-names>Swaroop R.</given-names></name><name name-style="western"><surname>Pradhan</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Sivaramakrishnan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vadrevu</surname><given-names>R.</given-names></name></person-group><article-title>Integrated multi-omics analysis of Alzheimer's disease shows molecular signatures associated with disease progression and potential therapeutic targets</article-title><source>Sci Rep</source><volume>13</volume><year>2023</year><fpage>3695</fpage><pub-id pub-id-type="pmid">36879094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-30892-6</pub-id><pub-id pub-id-type="pmcid">PMC9986671</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Rozen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Hellegers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics</article-title><source>PLoS One</source><volume>6</volume><year>2011</year><object-id pub-id-type="publisher-id">e21643</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0021643</pub-id><pub-id pub-id-type="pmcid">PMC3136924</pub-id><pub-id pub-id-type="pmid">21779331</pub-id></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name name-style="western"><surname>Butterfield</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Sultana</surname><given-names>R.</given-names></name></person-group><article-title>Methionine-35 of A<italic toggle="yes">&#946;</italic><sub>1&#8211;42</sub>: importance for oxidative stress in Alzheimer disease</article-title><source>J Amino Acids</source><volume>2011</volume><year>2011</year><object-id pub-id-type="publisher-id">198430</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4061/2011/198430</pub-id><pub-id pub-id-type="pmcid">PMC3268025</pub-id><pub-id pub-id-type="pmid">22312456</pub-id></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name name-style="western"><surname>Dodiya</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Kuntz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shaik</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Baufeld</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leibowitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Sex-specific effects of microbiome perturbations on cerebral A<italic toggle="yes">&#946;</italic> amyloidosis and microglia phenotypes</article-title><source>J Exp Med</source><volume>216</volume><year>2019</year><fpage>1542</fpage><lpage>1560</lpage><pub-id pub-id-type="pmid">31097468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20182386</pub-id><pub-id pub-id-type="pmcid">PMC6605759</pub-id></element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name name-style="western"><surname>Braniste</surname><given-names>V.</given-names></name><name name-style="western"><surname>Al-Asmakh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kowal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Anuar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Abbaspour</surname><given-names>A.</given-names></name><name name-style="western"><surname>T&#243;th</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The gut microbiota influences blood&#8211;brain barrier permeability in mice</article-title><source>Sci Transl Med</source><volume>6</volume><year>2014</year><object-id pub-id-type="publisher-id">263ra158</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3009759</pub-id><pub-id pub-id-type="pmcid">PMC4396848</pub-id><pub-id pub-id-type="pmid">25411471</pub-id></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name name-style="western"><surname>Ashton</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Kiddle</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Graf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baird</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Hye</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Blood protein predictors of brain amyloid for enrichment in clinical trials?.</article-title><source>Alzheimers Dement (Amst)</source><volume>1</volume><year>2015</year><fpage>48</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">27239491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadm.2014.11.005</pub-id><pub-id pub-id-type="pmcid">PMC4876903</pub-id></element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>K.K.</given-names></name><etal/></person-group><article-title>Deep multilayer brain proteomics identifies molecular networks in Alzheimer's disease progression</article-title><source>Neuron</source><volume>105</volume><year>2020</year><fpage>975</fpage><lpage>991</lpage><comment>e7</comment><pub-id pub-id-type="pmid">31926610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2019.12.015</pub-id><pub-id pub-id-type="pmcid">PMC7318843</pub-id></element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>E.C.B.</given-names></name><name name-style="western"><surname>Dammer</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Duong</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thambisetty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Troncoso</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease</article-title><source>Mol Neurodegener</source><volume>13</volume><year>2018</year><fpage>52</fpage><pub-id pub-id-type="pmid">30286791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-018-0282-4</pub-id><pub-id pub-id-type="pmcid">PMC6172707</pub-id></element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name name-style="western"><surname>Toomey</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Heywood</surname><given-names>W.</given-names></name><name name-style="western"><surname>Benson</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Packham</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lashley</surname><given-names>T.</given-names></name></person-group><article-title>Investigation of pathology, expression and proteomic profiles in human TREM2 variant postmortem brains with and without Alzheimer's disease</article-title><source>Brain Pathol</source><volume>30</volume><year>2020</year><fpage>794</fpage><lpage>810</lpage><pub-id pub-id-type="pmid">32267026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bpa.12842</pub-id><pub-id pub-id-type="pmcid">PMC8018003</pub-id></element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez-Pascual</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naccache</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hooshmand</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wretlind</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gabrielli</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease</article-title><source>Comput Biol Med</source><volume>176</volume><year>2024</year><object-id pub-id-type="publisher-id">108588</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2024.108588</pub-id><pub-id pub-id-type="pmid">38761503</pub-id></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schrag</surname><given-names>M.</given-names></name><name name-style="western"><surname>Crofton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trivedi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vinters</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kirsch</surname><given-names>W.</given-names></name></person-group><article-title>Targeted proteomics for quantification of histone acetylation in Alzheimer's disease</article-title><source>Proteomics</source><volume>12</volume><year>2012</year><fpage>1261</fpage><lpage>1268</lpage><pub-id pub-id-type="pmid">22577027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pmic.201200010</pub-id><pub-id pub-id-type="pmcid">PMC6812507</pub-id></element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="journal" id="sref148"><person-group person-group-type="author"><name name-style="western"><surname>Kinno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kasamatsu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Akaike</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ihara</surname><given-names>H.</given-names></name></person-group><article-title>Reactive sulfur species omics analysis in the brain tissue of the 5xFAD mouse model of Alzheimer's disease</article-title><source>Antioxidants (Basel)</source><volume>12</volume><year>2023</year><fpage>1105</fpage><pub-id pub-id-type="pmid">37237971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox12051105</pub-id><pub-id pub-id-type="pmcid">PMC10215359</pub-id></element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Fagan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Perrin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>S.E.</given-names></name><etal/></person-group><article-title>Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease</article-title><source>Neurology</source><volume>79</volume><year>2012</year><fpage>897</fpage><lpage>905</lpage><pub-id pub-id-type="pmid">22855860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e318266fa70</pub-id><pub-id pub-id-type="pmcid">PMC3425844</pub-id></element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Ibrahim-Verbaas</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Harold</surname><given-names>D.</given-names></name><name name-style="western"><surname>Naj</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bellenguez</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease</article-title><source>Nat Genet</source><volume>45</volume><year>2013</year><fpage>1452</fpage><lpage>1458</lpage><pub-id pub-id-type="pmid">24162737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2802</pub-id><pub-id pub-id-type="pmcid">PMC3896259</pub-id></element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name name-style="western"><surname>Harold</surname><given-names>D.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hollingworth</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gerrish</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hamshere</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease</article-title><source>Nat Genet</source><volume>41</volume><year>2009</year><fpage>1088</fpage><lpage>1093</lpage><pub-id pub-id-type="pmid">19734902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.440</pub-id><pub-id pub-id-type="pmcid">PMC2845877</pub-id></element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name name-style="western"><surname>Lunnon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Keohane</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pidsley</surname><given-names>R.</given-names></name><name name-style="western"><surname>Newhouse</surname><given-names>S.</given-names></name><name name-style="western"><surname>Riddoch-Contreras</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thubron</surname><given-names>E.B.</given-names></name><etal/></person-group><article-title>Mitochondrial genes are altered in blood early in Alzheimer's disease</article-title><source>Neurobiol Aging</source><volume>53</volume><year>2017</year><fpage>36</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">28208064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2016.12.029</pub-id></element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name name-style="western"><surname>Gatz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Fratiglioni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mortimer</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Role of genes and environments for explaining Alzheimer disease</article-title><source>Arch Gen Psychiatry</source><volume>63</volume><year>2006</year><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">16461860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archpsyc.63.2.168</pub-id></element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name name-style="western"><surname>Delgado-Morales</surname><given-names>R.</given-names></name><name name-style="western"><surname>Esteller</surname><given-names>M.</given-names></name></person-group><article-title>Opening up the DNA methylome of dementia</article-title><source>Mol Psychiatr</source><volume>22</volume><year>2017</year><fpage>485</fpage><lpage>496</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mp.2016.242</pub-id><pub-id pub-id-type="pmcid">PMC5378809</pub-id><pub-id pub-id-type="pmid">28044062</pub-id></element-citation></ref><ref id="bib155"><label>155</label><element-citation publication-type="journal" id="sref155"><person-group person-group-type="author"><name name-style="western"><surname>Lake</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sos</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaeser</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Yung</surname><given-names>Y.C.</given-names></name><etal/></person-group><article-title>Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain</article-title><source>Nat Biotechnol</source><volume>36</volume><year>2018</year><fpage>70</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">29227469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.4038</pub-id><pub-id pub-id-type="pmcid">PMC5951394</pub-id></element-citation></ref><ref id="bib156"><label>156</label><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name name-style="western"><surname>De Strooper</surname><given-names>B.</given-names></name><name name-style="western"><surname>Karran</surname><given-names>E.</given-names></name></person-group><article-title>The cellular phase of Alzheimer's disease</article-title><source>Cell</source><volume>164</volume><year>2016</year><fpage>603</fpage><lpage>615</lpage><pub-id pub-id-type="pmid">26871627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.12.056</pub-id></element-citation></ref><ref id="bib157"><label>157</label><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name name-style="western"><surname>Lardenoije</surname><given-names>R.</given-names></name><name name-style="western"><surname>Iatrou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kenis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kompotis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Steinbusch</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Mastroeni</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The epigenetics of aging and neurodegeneration</article-title><source>Prog Neurobiol</source><volume>131</volume><year>2015</year><fpage>21</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">26072273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2015.05.002</pub-id><pub-id pub-id-type="pmcid">PMC6477921</pub-id></element-citation></ref><ref id="bib158"><label>158</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name name-style="western"><surname>LaSalle</surname><given-names>J.M.</given-names></name></person-group><article-title>Epigenomic signatures reveal mechanistic clues and predictive markers for autism spectrum disorder</article-title><source>Mol Psychiatr</source><volume>28</volume><year>2023</year><fpage>1890</fpage><lpage>1901</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-022-01917-9</pub-id><pub-id pub-id-type="pmcid">PMC10560404</pub-id><pub-id pub-id-type="pmid">36650278</pub-id></element-citation></ref><ref id="bib159"><label>159</label><element-citation publication-type="journal" id="sref159"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>E.C.B.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Dammer</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Duong</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Gerasimov</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level</article-title><source>Nat Neurosci</source><volume>25</volume><year>2022</year><fpage>213</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">35115731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-021-00999-y</pub-id><pub-id pub-id-type="pmcid">PMC8825285</pub-id></element-citation></ref><ref id="bib160"><label>160</label><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name name-style="western"><surname>Seyfried</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Dammer</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Swarup</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nandakumar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Duong</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer's disease</article-title><source>Cell Syst</source><volume>4</volume><year>2017</year><fpage>60</fpage><lpage>72</lpage><comment>e4</comment><pub-id pub-id-type="pmid">27989508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cels.2016.11.006</pub-id><pub-id pub-id-type="pmcid">PMC5269514</pub-id></element-citation></ref><ref id="bib161"><label>161</label><element-citation publication-type="journal" id="sref161"><person-group person-group-type="author"><name name-style="western"><surname>Berchtold</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Cribbs</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gillen</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Cotman</surname><given-names>C.W.</given-names></name></person-group><article-title>Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease</article-title><source>Neurobiol Aging</source><volume>34</volume><year>2013</year><fpage>1653</fpage><lpage>1661</lpage><pub-id pub-id-type="pmid">23273601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2012.11.024</pub-id><pub-id pub-id-type="pmcid">PMC4022280</pub-id></element-citation></ref><ref id="bib162"><label>162</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name name-style="western"><surname>Keren-Shaul</surname><given-names>H.</given-names></name><name name-style="western"><surname>Spinrad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matcovitch-Natan</surname><given-names>O.</given-names></name><name name-style="western"><surname>Dvir-Szternfeld</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ulland</surname><given-names>T.K.</given-names></name><etal/></person-group><article-title>A unique microglia type associated with restricting development of Alzheimer's disease</article-title><source>Cell</source><volume>169</volume><year>2017</year><fpage>1276</fpage><lpage>1290</lpage><comment>e17</comment><pub-id pub-id-type="pmid">28602351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.05.018</pub-id></element-citation></ref><ref id="bib163"><label>163</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name name-style="western"><surname>Kamath</surname><given-names>T.</given-names></name><name name-style="western"><surname>Abdulraouf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burris</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Langlieb</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gazestani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nadaf</surname><given-names>N.M.</given-names></name><etal/></person-group><article-title>Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's disease</article-title><source>Nat Neurosci</source><volume>25</volume><year>2022</year><fpage>588</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">35513515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-022-01061-1</pub-id><pub-id pub-id-type="pmcid">PMC9076534</pub-id></element-citation></ref><ref id="bib164"><label>164</label><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name name-style="western"><surname>Liddelow</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Guttenplan</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Bohlen</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Schirmer</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Neurotoxic reactive astrocytes are induced by activated microglia</article-title><source>Nature</source><volume>541</volume><year>2017</year><fpage>481</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">28099414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature21029</pub-id><pub-id pub-id-type="pmcid">PMC5404890</pub-id></element-citation></ref><ref id="bib165"><label>165</label><element-citation publication-type="journal" id="sref165"><person-group person-group-type="author"><name name-style="western"><surname>Habib</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Heidenreich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Swiech</surname><given-names>L.</given-names></name><name name-style="western"><surname>Avraham-Davidi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Trombetta</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Div-Seq: single-nucleus RNA-Seq reveals dynamics of rare adult newborn neurons</article-title><source>Science</source><volume>353</volume><year>2016</year><fpage>925</fpage><lpage>928</lpage><pub-id pub-id-type="pmid">27471252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aad7038</pub-id><pub-id pub-id-type="pmcid">PMC5480621</pub-id></element-citation></ref><ref id="bib166"><label>166</label><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name name-style="western"><surname>St&#229;hl</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Salm&#233;n</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vickovic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lundmark</surname><given-names>A.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Magnusson</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Visualization and analysis of gene expression in tissue sections by spatial transcriptomics</article-title><source>Science</source><volume>353</volume><year>2016</year><fpage>78</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">27365449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaf2403</pub-id></element-citation></ref><ref id="bib167"><label>167</label><element-citation publication-type="journal" id="sref167"><person-group person-group-type="author"><name name-style="western"><surname>Lein</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Belgard</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Hawrylycz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moln&#225;r</surname><given-names>Z.</given-names></name></person-group><article-title>Transcriptomic perspectives on neocortical structure, development, evolution, and disease</article-title><source>Annu Rev Neurosci</source><volume>40</volume><year>2017</year><fpage>629</fpage><lpage>652</lpage><pub-id pub-id-type="pmid">28661727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-neuro-070815-013858</pub-id></element-citation></ref><ref id="bib168"><label>168</label><element-citation publication-type="journal" id="sref168"><person-group person-group-type="author"><name name-style="western"><surname>Aebersold</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>M.</given-names></name></person-group><article-title>Mass-spectrometric exploration of proteome structure and function</article-title><source>Nature</source><volume>537</volume><year>2016</year><fpage>347</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">27629641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature19949</pub-id></element-citation></ref><ref id="bib169"><label>169</label><element-citation publication-type="journal" id="sref169"><person-group person-group-type="author"><name name-style="western"><surname>Mertins</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mani</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Ruggles</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Gillette</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Clauser</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Proteogenomics connects somatic mutations to signalling in breast cancer</article-title><source>Nature</source><volume>534</volume><year>2016</year><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">27251275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature18003</pub-id><pub-id pub-id-type="pmcid">PMC5102256</pub-id></element-citation></ref><ref id="bib170"><label>170</label><element-citation publication-type="journal" id="sref170"><person-group person-group-type="author"><name name-style="western"><surname>Trushina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>T.</given-names></name><name name-style="western"><surname>Persson</surname><given-names>X.M.</given-names></name><name name-style="western"><surname>Mielke</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>R.C.</given-names></name></person-group><article-title>Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e63644</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0063644</pub-id><pub-id pub-id-type="pmcid">PMC3658985</pub-id><pub-id pub-id-type="pmid">23700429</pub-id></element-citation></ref><ref id="bib171"><label>171</label><element-citation publication-type="journal" id="sref171"><person-group person-group-type="author"><name name-style="western"><surname>Drummond</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wisniewski</surname><given-names>T.</given-names></name></person-group><article-title>Alzheimer's disease: experimental models and reality</article-title><source>Acta Neuropathol</source><volume>133</volume><year>2017</year><fpage>155</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">28025715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-016-1662-x</pub-id><pub-id pub-id-type="pmcid">PMC5253109</pub-id></element-citation></ref><ref id="bib172"><label>172</label><element-citation publication-type="journal" id="sref172"><person-group person-group-type="author"><name name-style="western"><surname>Dejanovic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>De Mazi&#232;re</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meilandt</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies</article-title><source>Neuron</source><volume>100</volume><year>2018</year><fpage>1322</fpage><lpage>1336</lpage><comment>e7</comment><pub-id pub-id-type="pmid">30392797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2018.10.014</pub-id></element-citation></ref><ref id="bib173"><label>173</label><element-citation publication-type="journal" id="sref173"><person-group person-group-type="author"><name name-style="western"><surname>Pichet</surname><given-names>Binette A.</given-names></name><name name-style="western"><surname>Gaiteri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wennstr&#246;m</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hristovska</surname><given-names>I.</given-names></name><name name-style="western"><surname>Spotorno</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Proteomic changes in Alzheimer's disease associated with progressive A<italic toggle="yes">&#946;</italic> plaque and tau tangle pathologies</article-title><source>Nat Neurosci</source><volume>27</volume><year>2024</year><fpage>1880</fpage><lpage>1891</lpage><pub-id pub-id-type="pmid">39187705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-024-01737-w</pub-id><pub-id pub-id-type="pmcid">PMC11452344</pub-id></element-citation></ref><ref id="bib174"><label>174</label><element-citation publication-type="journal" id="sref174"><person-group person-group-type="author"><name name-style="western"><surname>Mazanetz</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>P.M.</given-names></name></person-group><article-title>Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases</article-title><source>Nat Rev Drug Discov</source><volume>6</volume><year>2007</year><fpage>464</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">17541419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd2111</pub-id></element-citation></ref><ref id="bib175"><label>175</label><element-citation publication-type="journal" id="sref175"><person-group person-group-type="author"><name name-style="western"><surname>Rawat</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sehar</surname><given-names>U.</given-names></name><name name-style="western"><surname>Bisht</surname><given-names>J.</given-names></name><name name-style="western"><surname>Selman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Culberson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>P.H.</given-names></name></person-group><article-title>Phosphorylated tau in Alzheimer's disease and other tauopathies</article-title><source>Int J Mol Sci</source><volume>23</volume><year>2022</year><object-id pub-id-type="publisher-id">12814</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms232112841</pub-id><pub-id pub-id-type="pmcid">PMC9654278</pub-id><pub-id pub-id-type="pmid">36361631</pub-id></element-citation></ref><ref id="bib176"><label>176</label><element-citation publication-type="journal" id="sref176"><person-group person-group-type="author"><name name-style="western"><surname>Neddens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Temmel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Flunkert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kerschbaumer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hoeller</surname><given-names>C.</given-names></name><name name-style="western"><surname>Loeffler</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Phosphorylation of different tau sites during progression of Alzheimer's disease</article-title><source>Acta Neuropathol Commun</source><volume>6</volume><year>2018</year><fpage>52</fpage><pub-id pub-id-type="pmid">29958544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-018-0557-6</pub-id><pub-id pub-id-type="pmcid">PMC6027763</pub-id></element-citation></ref><ref id="bib177"><label>177</label><element-citation publication-type="journal" id="sref177"><person-group person-group-type="author"><name name-style="western"><surname>Korhonen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lindholm</surname><given-names>D.</given-names></name></person-group><article-title>The ubiquitin proteasome system in synaptic and axonal degeneration: a new twist to an old cycle</article-title><source>J Cell Biol</source><volume>165</volume><year>2004</year><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">15067020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.200311091</pub-id><pub-id pub-id-type="pmcid">PMC2172081</pub-id></element-citation></ref><ref id="bib178"><label>178</label><element-citation publication-type="journal" id="sref178"><person-group person-group-type="author"><name name-style="western"><surname>Sultana</surname><given-names>R.</given-names></name><name name-style="western"><surname>Perluigi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Butterfield</surname><given-names>D.A.</given-names></name></person-group><article-title>Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis</article-title><source>Acta Neuropathol</source><volume>118</volume><year>2009</year><fpage>131</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">19288120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-009-0517-0</pub-id><pub-id pub-id-type="pmcid">PMC2818870</pub-id></element-citation></ref><ref id="bib179"><label>179</label><element-citation publication-type="journal" id="sref179"><person-group person-group-type="author"><name name-style="western"><surname>Riley</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Coon</surname><given-names>J.J.</given-names></name></person-group><article-title>Phosphoproteomics in the age of rapid and deep proteome profiling</article-title><source>Anal Chem</source><volume>88</volume><year>2016</year><fpage>74</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">26539879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.analchem.5b04123</pub-id><pub-id pub-id-type="pmcid">PMC4790442</pub-id></element-citation></ref><ref id="bib180"><label>180</label><element-citation publication-type="journal" id="sref180"><person-group person-group-type="author"><name name-style="western"><surname>Slavov</surname><given-names>N.</given-names></name></person-group><article-title>Single-cell protein analysis by mass spectrometry</article-title><source>Curr Opin Chem Biol</source><volume>60</volume><year>2021</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">32599342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbpa.2020.04.018</pub-id><pub-id pub-id-type="pmcid">PMC7767890</pub-id></element-citation></ref><ref id="bib181"><label>181</label><element-citation publication-type="journal" id="sref181"><person-group person-group-type="author"><name name-style="western"><surname>Giesen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.A.O.</given-names></name><name name-style="western"><surname>Schapiro</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zivanovic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hattendorf</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry</article-title><source>Nat Methods</source><volume>11</volume><year>2014</year><fpage>417</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">24584193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.2869</pub-id></element-citation></ref><ref id="bib182"><label>182</label><element-citation publication-type="journal" id="sref182"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>L.X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X.P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Spatiotemporal multi-omics: exploring molecular landscapes in aging and regenerative medicine</article-title><source>Mil Med Res</source><volume>11</volume><year>2024</year><fpage>31</fpage><pub-id pub-id-type="pmid">38797843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40779-024-00537-4</pub-id><pub-id pub-id-type="pmcid">PMC11129507</pub-id></element-citation></ref><ref id="bib183"><label>183</label><element-citation publication-type="journal" id="sref183"><person-group person-group-type="author"><name name-style="western"><surname>Caprioli</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Farmer</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Gile</surname><given-names>J.</given-names></name></person-group><article-title>Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS</article-title><source>Anal Chem</source><volume>69</volume><year>1997</year><fpage>4751</fpage><lpage>4760</lpage><pub-id pub-id-type="pmid">9406525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ac970888i</pub-id></element-citation></ref><ref id="bib184"><label>184</label><element-citation publication-type="journal" id="sref184"><person-group person-group-type="author"><name name-style="western"><surname>Budnik</surname><given-names>B.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harmange</surname><given-names>G.</given-names></name><name name-style="western"><surname>Slavov</surname><given-names>N.</given-names></name></person-group><article-title>SCoPE-MS: mass spectrometry of single mammalian cells quantifies proteome heterogeneity during cell differentiation</article-title><source>Genome Biol</source><volume>19</volume><year>2018</year><fpage>161</fpage><pub-id pub-id-type="pmid">30343672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-018-1547-5</pub-id><pub-id pub-id-type="pmcid">PMC6196420</pub-id></element-citation></ref><ref id="bib185"><label>185</label><element-citation publication-type="journal" id="sref185"><person-group person-group-type="author"><name name-style="western"><surname>Specht</surname><given-names>H.</given-names></name><name name-style="western"><surname>Emmott</surname><given-names>E.</given-names></name><name name-style="western"><surname>Petelski</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Huffman</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Serra</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Single-cell proteomic and transcriptomic analysis of macrophage heterogeneity using SCoPE2</article-title><source>Genome Biol</source><volume>22</volume><year>2021</year><fpage>50</fpage><pub-id pub-id-type="pmid">33504367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-021-02267-5</pub-id><pub-id pub-id-type="pmcid">PMC7839219</pub-id></element-citation></ref><ref id="bib186"><label>186</label><element-citation publication-type="journal" id="sref186"><person-group person-group-type="author"><name name-style="western"><surname>Beger</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>W.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Kirwan</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cascante</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Metabolomics enables precision medicine: "a white paper, community perspective"</article-title><source>Metabolomics</source><volume>12</volume><year>2016</year><fpage>149</fpage><pub-id pub-id-type="pmid">27642271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11306-016-1094-6</pub-id><pub-id pub-id-type="pmcid">PMC5009152</pub-id></element-citation></ref><ref id="bib187"><label>187</label><element-citation publication-type="journal" id="sref187"><person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>P.L.</given-names></name></person-group><article-title>Lipidomics of Alzheimer's disease: current status</article-title><source>Alzheimers Res Ther</source><volume>4</volume><year>2012</year><fpage>5</fpage><pub-id pub-id-type="pmid">22293144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/alzrt103</pub-id><pub-id pub-id-type="pmcid">PMC3471525</pub-id></element-citation></ref><ref id="bib188"><label>188</label><element-citation publication-type="journal" id="sref188"><person-group person-group-type="author"><name name-style="western"><surname>Wilkins</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Trushina</surname><given-names>E.</given-names></name></person-group><article-title>Application of metabolomics in Alzheimer's disease</article-title><source>Front Neurol</source><volume>8</volume><year>2017</year><fpage>719</fpage><pub-id pub-id-type="pmid">29375465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2017.00719</pub-id><pub-id pub-id-type="pmcid">PMC5770363</pub-id></element-citation></ref><ref id="bib189"><label>189</label><element-citation publication-type="journal" id="sref189"><person-group person-group-type="author"><name name-style="western"><surname>Mark</surname><given-names>R.V.</given-names></name></person-group><article-title>Metabolomics of aquatic organisms: the new &#8216;omics&#8217; on the block</article-title><source>Mar Ecol Prog Ser</source><volume>332</volume><year>2007</year><fpage>301</fpage><lpage>306</lpage></element-citation></ref><ref id="bib190"><label>190</label><element-citation publication-type="journal" id="sref190"><person-group person-group-type="author"><name name-style="western"><surname>Rhee</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Gerszten</surname><given-names>R.E.</given-names></name></person-group><article-title>Metabolomics and cardiovascular biomarker discovery</article-title><source>Clin Chem</source><volume>58</volume><year>2012</year><fpage>139</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">22110018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1373/clinchem.2011.169573</pub-id><pub-id pub-id-type="pmcid">PMC4402975</pub-id></element-citation></ref><ref id="bib191"><label>191</label><element-citation publication-type="journal" id="sref191"><person-group person-group-type="author"><name name-style="western"><surname>Fiehn</surname><given-names>O.</given-names></name></person-group><article-title>Metabolomics by gas chromatography&#8211;mass spectrometry: combined targeted and untargeted profiling</article-title><source>Curr Protoc Mol Biol</source><volume>114</volume><year>2016</year><comment>30.4.1&#8211;.4.2</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/0471142727.mb3004s114</pub-id><pub-id pub-id-type="pmcid">PMC4829120</pub-id><pub-id pub-id-type="pmid">27038389</pub-id></element-citation></ref><ref id="bib192"><label>192</label><element-citation publication-type="journal" id="sref192"><person-group person-group-type="author"><name name-style="western"><surname>Brinton</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mack</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Cadenas</surname><given-names>E.</given-names></name></person-group><article-title>Perimenopause as a neurological transition state</article-title><source>Nat Rev Endocrinol</source><volume>11</volume><year>2015</year><fpage>393</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">26007613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrendo.2015.82</pub-id><pub-id pub-id-type="pmcid">PMC9934205</pub-id></element-citation></ref><ref id="bib193"><label>193</label><element-citation publication-type="journal" id="sref193"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cazenave-Gassiot</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Brain lipidomics: from functional landscape to clinical significance</article-title><source>Sci Adv</source><volume>8</volume><year>2022</year><object-id pub-id-type="publisher-id">eadc9317</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adc9317</pub-id><pub-id pub-id-type="pmcid">PMC9481132</pub-id><pub-id pub-id-type="pmid">36112688</pub-id></element-citation></ref><ref id="bib194"><label>194</label><element-citation publication-type="journal" id="sref194"><person-group person-group-type="author"><name name-style="western"><surname>Darst</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jonaitis</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Koscik</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Metabolites associated with early cognitive changes implicated in Alzheimer's disease</article-title><source>J Alzheimers Dis</source><volume>79</volume><year>2021</year><fpage>1041</fpage><lpage>1054</lpage><pub-id pub-id-type="pmid">33427733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-200176</pub-id><pub-id pub-id-type="pmcid">PMC8054536</pub-id></element-citation></ref><ref id="bib195"><label>195</label><element-citation publication-type="journal" id="sref195"><person-group person-group-type="author"><name name-style="western"><surname>Sampson</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Debelius</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Thron</surname><given-names>T.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shastri</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Ilhan</surname><given-names>Z.E.</given-names></name><etal/></person-group><article-title>Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease</article-title><source>Cell</source><volume>167</volume><year>2016</year><fpage>1469</fpage><lpage>1480</lpage><comment>e12</comment><pub-id pub-id-type="pmid">27912057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2016.11.018</pub-id><pub-id pub-id-type="pmcid">PMC5718049</pub-id></element-citation></ref><ref id="bib196"><label>196</label><element-citation publication-type="journal" id="sref196"><person-group person-group-type="author"><name name-style="western"><surname>Albayar</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Roche</surname><given-names>A.</given-names></name><name name-style="western"><surname>Swiatkowski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Antar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ouda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Emara</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Biomarkers in spinal cord injury: prognostic insights and future potentials</article-title><source>Front Neurol</source><volume>10</volume><year>2019</year><fpage>27</fpage><pub-id pub-id-type="pmid">30761068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2019.00027</pub-id><pub-id pub-id-type="pmcid">PMC6361789</pub-id></element-citation></ref><ref id="bib197"><label>197</label><element-citation publication-type="journal" id="sref197"><person-group person-group-type="author"><name name-style="western"><surname>Clayton</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Lindon</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Cloarec</surname><given-names>O.</given-names></name><name name-style="western"><surname>Antti</surname><given-names>H.</given-names></name><name name-style="western"><surname>Charuel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hanton</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Pharmaco-metabonomic phenotyping and personalized drug treatment</article-title><source>Nature</source><volume>440</volume><year>2006</year><fpage>1073</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">16625200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature04648</pub-id></element-citation></ref><ref id="bib198"><label>198</label><element-citation publication-type="journal" id="sref198"><person-group person-group-type="author"><name name-style="western"><surname>Newcombe</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Camats-Perna</surname><given-names>J.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Valmas</surname><given-names>N.</given-names></name><name name-style="western"><surname>Huat</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Medeiros</surname><given-names>R.</given-names></name></person-group><article-title>Inflammation: the link between comorbidities, genetics, and Alzheimer's disease</article-title><source>J Neuroinflammation</source><volume>15</volume><year>2018</year><fpage>276</fpage><pub-id pub-id-type="pmid">30249283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-018-1313-3</pub-id><pub-id pub-id-type="pmcid">PMC6154824</pub-id></element-citation></ref><ref id="bib199"><label>199</label><element-citation publication-type="journal" id="sref199"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Meta-analysis of modifiable risk factors for Alzheimer's disease</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>86</volume><year>2015</year><fpage>1299</fpage><lpage>1306</lpage><pub-id pub-id-type="pmid">26294005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2015-310548</pub-id></element-citation></ref><ref id="bib200"><label>200</label><element-citation publication-type="journal" id="sref200"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Dom&#237;nguez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garc&#237;a-Barrera</surname><given-names>T.</given-names></name><name name-style="western"><surname>Barbas</surname><given-names>C.</given-names></name><name name-style="western"><surname>G&#243;mez-Ariza</surname><given-names>J.L.</given-names></name></person-group><article-title>Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry</article-title><source>Electrophoresis</source><volume>35</volume><year>2014</year><fpage>3321</fpage><lpage>3330</lpage><pub-id pub-id-type="pmid">25136972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/elps.201400196</pub-id></element-citation></ref><ref id="bib201"><label>201</label><element-citation publication-type="journal" id="sref201"><person-group person-group-type="author"><name name-style="western"><surname>Chughtai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Heeren</surname><given-names>R.M.</given-names></name></person-group><article-title>Mass spectrometric imaging for biomedical tissue analysis</article-title><source>Chem Rev</source><volume>110</volume><year>2010</year><fpage>3237</fpage><lpage>3277</lpage><pub-id pub-id-type="pmid">20423155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/cr100012c</pub-id><pub-id pub-id-type="pmcid">PMC2907483</pub-id></element-citation></ref><ref id="bib202"><label>202</label><element-citation publication-type="journal" id="sref202"><person-group person-group-type="author"><name name-style="western"><surname>Brettschneider</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tredici</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>V.M.Y.</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>J.Q.</given-names></name></person-group><article-title>Spreading of pathology in neurodegenerative diseases: a focus on human studies</article-title><source>Nat Rev Neurosci</source><volume>16</volume><year>2015</year><fpage>109</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">25588378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn3887</pub-id><pub-id pub-id-type="pmcid">PMC4312418</pub-id></element-citation></ref><ref id="bib203"><label>203</label><element-citation publication-type="journal" id="sref203"><person-group person-group-type="author"><name name-style="western"><surname>Jha</surname><given-names>D.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Savas</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Hanrieder</surname><given-names>J.</given-names></name></person-group><article-title>Spatial neurolipidomics-MALDI mass spectrometry imaging of lipids in brain pathologies</article-title><source>J Mass Spectrom</source><volume>59</volume><year>2024</year><object-id pub-id-type="publisher-id">e5008</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jms.5008</pub-id><pub-id pub-id-type="pmcid">PMC12013527</pub-id><pub-id pub-id-type="pmid">38445816</pub-id></element-citation></ref><ref id="bib204"><label>204</label><element-citation publication-type="journal" id="sref204"><person-group person-group-type="author"><name name-style="western"><surname>Zenobi</surname><given-names>R.</given-names></name></person-group><article-title>Single-cell metabolomics: analytical and biological perspectives</article-title><source>Science</source><volume>342</volume><year>2013</year><object-id pub-id-type="publisher-id">1243259</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1243259</pub-id><pub-id pub-id-type="pmid">24311695</pub-id></element-citation></ref><ref id="bib205"><label>205</label><element-citation publication-type="journal" id="sref205"><person-group person-group-type="author"><name name-style="western"><surname>Miyoshi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Morabito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Swarup</surname><given-names>V.</given-names></name></person-group><article-title>Systems biology approaches to unravel the molecular and genetic architecture of Alzheimer's disease and related tauopathies</article-title><source>Neurobiol Dis</source><volume>160</volume><year>2021</year><object-id pub-id-type="publisher-id">105530</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2021.105530</pub-id><pub-id pub-id-type="pmcid">PMC8616667</pub-id><pub-id pub-id-type="pmid">34634459</pub-id></element-citation></ref><ref id="bib206"><label>206</label><element-citation publication-type="journal" id="sref206"><person-group person-group-type="author"><name name-style="western"><surname>Serrano-Pozo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B.T.</given-names></name></person-group><article-title>APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches</article-title><source>Lancet Neurol</source><volume>20</volume><year>2021</year><fpage>68</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">33340485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(20)30412-9</pub-id><pub-id pub-id-type="pmcid">PMC8096522</pub-id></element-citation></ref><ref id="bib207"><label>207</label><element-citation publication-type="journal" id="sref207"><person-group person-group-type="author"><name name-style="western"><surname>Robins</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Duong</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Meigs</surname><given-names>J.</given-names></name><name name-style="western"><surname>Harerimana</surname><given-names>N.V.</given-names></name><etal/></person-group><article-title>Genetic control of the human brain proteome</article-title><source>Am J Hum Genet</source><volume>108</volume><year>2021</year><fpage>400</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">33571421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2021.01.012</pub-id><pub-id pub-id-type="pmcid">PMC8008492</pub-id></element-citation></ref><ref id="bib208"><label>208</label><element-citation publication-type="journal" id="sref208"><person-group person-group-type="author"><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Caraci</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cuello</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Caruso</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nistic&#242;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Corbo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer's disease</article-title><source>Front Immunol</source><volume>11</volume><year>2020</year><fpage>456</fpage><pub-id pub-id-type="pmid">32296418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.00456</pub-id><pub-id pub-id-type="pmcid">PMC7137904</pub-id></element-citation></ref><ref id="bib209"><label>209</label><element-citation publication-type="journal" id="sref209"><person-group person-group-type="author"><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name></person-group><article-title>CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment</article-title><source>Expert Rev Mol Diagn</source><volume>5</volume><year>2005</year><fpage>661</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">16149870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14737159.5.5.661</pub-id></element-citation></ref><ref id="bib210"><label>210</label><element-citation publication-type="journal" id="sref210"><person-group person-group-type="author"><name name-style="western"><surname>Thorsell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bjerke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gobom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brunhage</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vanmechelen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Andreasen</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease</article-title><source>Brain Res</source><volume>1362</volume><year>2010</year><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">20875798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2010.09.073</pub-id></element-citation></ref><ref id="bib211"><label>211</label><element-citation publication-type="journal" id="sref211"><person-group person-group-type="author"><name name-style="western"><surname>Herrup</surname><given-names>K.</given-names></name></person-group><article-title>Reimagining Alzheimer's disease&#8212;an age-based hypothesis</article-title><source>J Neurosci</source><volume>30</volume><year>2010</year><fpage>16755</fpage><lpage>16762</lpage><pub-id pub-id-type="pmid">21159946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.4521-10.2010</pub-id><pub-id pub-id-type="pmcid">PMC3004746</pub-id></element-citation></ref><ref id="bib212"><label>212</label><element-citation publication-type="journal" id="sref212"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>Z.Q.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gui</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Gut microbiota is altered in patients with Alzheimer's disease</article-title><source>J Alzheimers Dis</source><volume>63</volume><year>2018</year><fpage>1337</fpage><lpage>1346</lpage><pub-id pub-id-type="pmid">29758946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-180176</pub-id></element-citation></ref><ref id="bib213"><label>213</label><element-citation publication-type="journal" id="sref213"><person-group person-group-type="author"><name name-style="western"><surname>Cattaneo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cattane</surname><given-names>N.</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Provasi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lopizzo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Festari</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly</article-title><source>Neurobiol Aging</source><volume>49</volume><year>2017</year><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">27776263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2016.08.019</pub-id></element-citation></ref><ref id="bib214"><label>214</label><element-citation publication-type="journal" id="sref214"><person-group person-group-type="author"><name name-style="western"><surname>Kowalski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mulak</surname><given-names>A.</given-names></name></person-group><article-title>Brain&#8211;gut&#8211;microbiota axis in Alzheimer's disease</article-title><source>J Neurogastroenterol Motil</source><volume>25</volume><year>2019</year><fpage>48</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">30646475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5056/jnm18087</pub-id><pub-id pub-id-type="pmcid">PMC6326209</pub-id></element-citation></ref><ref id="bib215"><label>215</label><element-citation publication-type="journal" id="sref215"><person-group person-group-type="author"><name name-style="western"><surname>Kostic</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Gevers</surname><given-names>D.</given-names></name></person-group><article-title>The microbiome in inflammatory bowel disease: current status and the future ahead</article-title><source>Gastroenterology</source><volume>146</volume><year>2014</year><fpage>1489</fpage><lpage>1499</lpage><pub-id pub-id-type="pmid">24560869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2014.02.009</pub-id><pub-id pub-id-type="pmcid">PMC4034132</pub-id></element-citation></ref><ref id="bib216"><label>216</label><element-citation publication-type="journal" id="sref216"><person-group person-group-type="author"><name name-style="western"><surname>Dalile</surname><given-names>B.</given-names></name><name name-style="western"><surname>Van Oudenhove</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vervliet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Verbeke</surname><given-names>K.</given-names></name></person-group><article-title>The role of short-chain fatty acids in microbiota&#8211;gut&#8211;brain communication</article-title><source>Nat Rev Gastroenterol Hepatol</source><volume>16</volume><year>2019</year><fpage>461</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">31123355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-019-0157-3</pub-id></element-citation></ref><ref id="bib217"><label>217</label><element-citation publication-type="journal" id="sref217"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Raes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arumugam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burgdorf</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Manichanh</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A human gut microbial gene catalogue established by metagenomic sequencing</article-title><source>Nature</source><volume>464</volume><year>2010</year><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">20203603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature08821</pub-id><pub-id pub-id-type="pmcid">PMC3779803</pub-id></element-citation></ref><ref id="bib218"><label>218</label><element-citation publication-type="journal" id="sref218"><person-group person-group-type="author"><name name-style="western"><surname>Akbari</surname><given-names>E.</given-names></name><name name-style="western"><surname>Asemi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Daneshvar Kakhaki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bahmani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kouchaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tamtaji</surname><given-names>O.R.</given-names></name><etal/></person-group><article-title>Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer's disease: a randomized, double-blind and controlled trial</article-title><source>Front Aging Neurosci</source><volume>8</volume><year>2016</year><fpage>256</fpage><pub-id pub-id-type="pmid">27891089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2016.00256</pub-id><pub-id pub-id-type="pmcid">PMC5105117</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="expression-of-concern" ext-link-type="pmc" xlink:href="PMC7575745"/></element-citation></ref><ref id="bib219"><label>219</label><element-citation publication-type="journal" id="sref219"><person-group person-group-type="author"><name name-style="western"><surname>De Vos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Struyfs</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fransen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Klewansky</surname><given-names>T.</given-names></name><name name-style="western"><surname>De Roeck</surname><given-names>E.</given-names></name><etal/></person-group><article-title>The cerebrospinal fluid neurogranin/BACE1 ratio is a potential correlate of cognitive decline in Alzheimer's disease</article-title><source>J Alzheimers Dis</source><volume>53</volume><year>2016</year><fpage>1523</fpage><lpage>1538</lpage><pub-id pub-id-type="pmid">27392859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-160227</pub-id><pub-id pub-id-type="pmcid">PMC4981899</pub-id></element-citation></ref><ref id="bib220"><label>220</label><element-citation publication-type="journal" id="sref220"><person-group person-group-type="author"><name name-style="western"><surname>Llor&#233;ns-Rico</surname><given-names>V.</given-names></name><name name-style="western"><surname>Simcock</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Huys</surname><given-names>G.R.B.</given-names></name><name name-style="western"><surname>Raes</surname><given-names>J.</given-names></name></person-group><article-title>Single-cell approaches in human microbiome research</article-title><source>Cell</source><volume>185</volume><year>2022</year><fpage>2725</fpage><lpage>2738</lpage><pub-id pub-id-type="pmid">35868276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2022.06.040</pub-id></element-citation></ref><ref id="bib221"><label>221</label><element-citation publication-type="journal" id="sref221"><person-group person-group-type="author"><name name-style="western"><surname>L&#246;tstedt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stra&#382;ar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>R.</given-names></name><name name-style="western"><surname>Regev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vickovic</surname><given-names>S.</given-names></name></person-group><article-title>Spatial host&#8211;microbiome sequencing reveals niches in the mouse gut</article-title><source>Nat Biotechnol</source><volume>42</volume><year>2024</year><fpage>1394</fpage><lpage>1403</lpage><pub-id pub-id-type="pmid">37985876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41587-023-01988-1</pub-id><pub-id pub-id-type="pmcid">PMC11392810</pub-id></element-citation></ref><ref id="bib222"><label>222</label><element-citation publication-type="journal" id="sref222"><person-group person-group-type="author"><name name-style="western"><surname>Amos</surname><given-names>G.C.A.</given-names></name><name name-style="western"><surname>Logan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Anwar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fritzsche</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mate</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bleazard</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Developing standards for the microbiome field</article-title><source>Microbiome</source><volume>8</volume><year>2020</year><fpage>98</fpage><pub-id pub-id-type="pmid">32591016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40168-020-00856-3</pub-id><pub-id pub-id-type="pmcid">PMC7320585</pub-id></element-citation></ref><ref id="bib223"><label>223</label><element-citation publication-type="journal" id="sref223"><person-group person-group-type="author"><name name-style="western"><surname>Jokela</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ponsero</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Dikareva</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kolho</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Korpela</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Sources of gut microbiota variation in a large longitudinal Finnish infant cohort</article-title><source>EBioMedicine</source><volume>94</volume><year>2023</year><object-id pub-id-type="publisher-id">104695</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2023.104695</pub-id><pub-id pub-id-type="pmcid">PMC10328818</pub-id><pub-id pub-id-type="pmid">37399600</pub-id></element-citation></ref><ref id="bib224"><label>224</label><element-citation publication-type="journal" id="sref224"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>M.</given-names></name></person-group><article-title>Integrating multi-omics data for target and biomarker discovery</article-title><source>Alzheimer's Dement</source><volume>20</volume><year>2024</year><object-id pub-id-type="publisher-id">e086331</object-id></element-citation></ref><ref id="bib225"><label>225</label><element-citation publication-type="journal" id="sref225"><person-group person-group-type="author"><name name-style="western"><surname>Shokhirev</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>A.A.</given-names></name></person-group><article-title>An integrative machine-learning meta-analysis of high-throughput omics data identifies age-specific hallmarks of Alzheimer's disease</article-title><source>Ageing Res Rev</source><volume>81</volume><year>2022</year><object-id pub-id-type="publisher-id">101721</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2022.101721</pub-id><pub-id pub-id-type="pmid">36029998</pub-id></element-citation></ref><ref id="bib226"><label>226</label><element-citation publication-type="journal" id="sref226"><person-group person-group-type="author"><name name-style="western"><surname>Sebastian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kalita</surname><given-names>J.</given-names></name></person-group><article-title>Network-based analysis of Alzheimer's disease genes using multi-omics network integration with graph diffusion</article-title><source>J Biomed Inform</source><volume>164</volume><year>2025</year><object-id pub-id-type="publisher-id">104797</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbi.2025.104797</pub-id><pub-id pub-id-type="pmid">39993589</pub-id></element-citation></ref><ref id="bib227"><label>227</label><element-citation publication-type="journal" id="sref227"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>S.</given-names></name></person-group><article-title>WIMOAD: Weighted Integration of Multi-Omics data for Alzheimer's Disease (AD) diagnosis</article-title><source>bioRxiv</source><year>2025</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2024.09.25.614862</pub-id></element-citation></ref><ref id="bib228"><label>228</label><element-citation publication-type="journal" id="sref228"><person-group person-group-type="author"><name name-style="western"><surname>Tripathy</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Frohock</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cary</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Keegan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>G.W.</given-names></name><etal/></person-group><article-title>Effective integration of multi-omics with prior knowledge to identify biomarkers <italic toggle="yes">via</italic> explainable graph neural networks</article-title><source>NPJ Syst Biol Appl</source><volume>11</volume><year>2025</year><fpage>43</fpage><pub-id pub-id-type="pmid">40341543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41540-025-00519-9</pub-id><pub-id pub-id-type="pmcid">PMC12062277</pub-id></element-citation></ref><ref id="bib229"><label>229</label><element-citation publication-type="journal" id="sref229"><person-group person-group-type="author"><name name-style="western"><surname>Kumari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akhtar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tanveer</surname><given-names>M.</given-names></name></person-group><article-title>Support matrix machine: a review</article-title><source>Neural Netw</source><volume>181</volume><year>2025</year><object-id pub-id-type="publisher-id">106767</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neunet.2024.106767</pub-id><pub-id pub-id-type="pmid">39488110</pub-id></element-citation></ref><ref id="bib230"><label>230</label><element-citation publication-type="journal" id="sref230"><person-group person-group-type="author"><name name-style="western"><surname>Warwicker</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Rebennack</surname><given-names>S.</given-names></name></person-group><article-title>Support vector machines within a bivariate mixed-integer linear programming framework</article-title><source>Expert Syst Appl</source><volume>245</volume><year>2024</year><object-id pub-id-type="publisher-id">122998</object-id></element-citation></ref><ref id="bib231"><label>231</label><element-citation publication-type="journal" id="sref231"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.L.</given-names></name><etal/></person-group><article-title>Classifying Alzheimer's disease and normal subjects using machine learning techniques and genetic-environmental features</article-title><source>J Formos Med Assoc</source><volume>123</volume><year>2024</year><fpage>701</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">38044212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jfma.2023.10.021</pub-id></element-citation></ref><ref id="bib232"><label>232</label><element-citation publication-type="journal" id="sref232"><person-group person-group-type="author"><name name-style="western"><surname>Iranzad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>A review of random forest-based feature selection methods for data science education and applications</article-title><source>Int J Data Sci Anal</source><volume>3</volume><year>2024</year><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="bib233"><label>233</label><element-citation publication-type="journal" id="sref233"><person-group person-group-type="author"><name name-style="western"><surname>Torres-Sosa</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Aranda-Abreu</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Cruz-Ram&#237;rez</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mestizo-Guti&#233;rrez</surname><given-names>S.L.</given-names></name></person-group><article-title>Decision trees for the analysis of gene expression levels of COVID-19: an association with Alzheimer's disease</article-title><source>BioMedInformatics</source><volume>5</volume><year>2025</year><fpage>26</fpage></element-citation></ref><ref id="bib234"><label>234</label><element-citation publication-type="journal" id="sref234"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yulug</surname><given-names>B.</given-names></name><name name-style="western"><surname>Altay</surname><given-names>O.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hanoglu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Multi-omics analysis reveals the key factors involved in the severity of the Alzheimer's disease</article-title><source>Alzheimers Res Ther</source><volume>16</volume><year>2024</year><fpage>213</fpage><pub-id pub-id-type="pmid">39358810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01578-6</pub-id><pub-id pub-id-type="pmcid">PMC11448018</pub-id></element-citation></ref><ref id="bib235"><label>235</label><element-citation publication-type="journal" id="sref235"><person-group person-group-type="author"><name name-style="western"><surname>Irfan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shahrestani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Elkhodr</surname><given-names>M.</given-names></name></person-group><article-title>Machine learning in neurological disorders: a multivariate LSTM and AdaBoost approach to Alzheimer's disease time series analysis</article-title><source>Health Care Sci</source><volume>3</volume><year>2024</year><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">38939169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hcs2.84</pub-id><pub-id pub-id-type="pmcid">PMC11080865</pub-id></element-citation></ref><ref id="bib236"><label>236</label><element-citation publication-type="journal" id="sref236"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><etal/></person-group><article-title>XGBoost-SHAP-based interpretable diagnostic framework for Alzheimer's disease</article-title><source>BMC Med Inform Decis Mak</source><volume>23</volume><year>2023</year><fpage>137</fpage><pub-id pub-id-type="pmid">37491248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12911-023-02238-9</pub-id><pub-id pub-id-type="pmcid">PMC10369804</pub-id></element-citation></ref><ref id="bib237"><label>237</label><element-citation publication-type="journal" id="sref237"><person-group person-group-type="author"><name name-style="western"><surname>Mahendran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>P.M.D.</given-names></name></person-group><article-title>Deep belief network-based approach for detecting Alzheimer's disease using the multi-omics data</article-title><source>Comput Struct Biotechnol J</source><volume>21</volume><year>2023</year><fpage>1651</fpage><lpage>1660</lpage><pub-id pub-id-type="pmid">36874164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.csbj.2023.02.021</pub-id><pub-id pub-id-type="pmcid">PMC9978469</pub-id></element-citation></ref><ref id="bib238"><label>238</label><element-citation publication-type="journal" id="sref238"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>V.O.K.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kaistha</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Downey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gozes</surname><given-names>I.</given-names></name><etal/></person-group><article-title>DeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer's disease</article-title><source>Sci Rep</source><volume>15</volume><year>2025</year><fpage>2093</fpage><pub-id pub-id-type="pmid">39814937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-025-85947-7</pub-id><pub-id pub-id-type="pmcid">PMC11735786</pub-id></element-citation></ref><ref id="bib239"><label>239</label><element-citation publication-type="journal" id="sref239"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Rajapakse</surname><given-names>J.C.</given-names></name></person-group><article-title>Drug discovery and mechanism prediction with explainable graph neural networks</article-title><source>Sci Rep</source><volume>15</volume><year>2025</year><fpage>179</fpage><pub-id pub-id-type="pmid">39747341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-83090-3</pub-id><pub-id pub-id-type="pmcid">PMC11696803</pub-id></element-citation></ref><ref id="bib240"><label>240</label><element-citation publication-type="journal" id="sref240"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>V.O.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Downey</surname><given-names>J.</given-names></name></person-group><article-title>DeepDrug2: a germline-focused graph neural network framework for Alzheimer's drug repurposing validated by electronic health records</article-title><source>medRxiv</source><year>2025</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2025.05.13.25327570</pub-id></element-citation></ref><ref id="bib241"><label>241</label><element-citation publication-type="journal" id="sref241"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bang</surname><given-names>J.U.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>B.O.</given-names></name></person-group><article-title>Alzheimer's disease recognition using graph neural network by leveraging image-text similarity from vision language model</article-title><source>Sci Rep</source><volume>15</volume><year>2025</year><fpage>997</fpage><pub-id pub-id-type="pmid">39762277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-82597-z</pub-id><pub-id pub-id-type="pmcid">PMC11704039</pub-id></element-citation></ref><ref id="bib242"><label>242</label><element-citation publication-type="journal" id="sref242"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;-Juan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lorenzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Piella</surname><given-names>G.</given-names></name></person-group><article-title>MC-RVAE: multi-channel recurrent variational autoencoder for multimodal Alzheimer's disease progression modelling</article-title><source>Neuroimage</source><volume>268</volume><year>2023</year><object-id pub-id-type="publisher-id">119892</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2023.119892</pub-id><pub-id pub-id-type="pmid">36682509</pub-id></element-citation></ref><ref id="bib243"><label>243</label><element-citation publication-type="journal" id="sref243"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name></person-group><article-title>JDSNMF: joint deep semi-non-negative matrix factorization for learning integrative representation of molecular signals in Alzheimer's disease</article-title><source>J Pers Med</source><volume>11</volume><year>2021</year><fpage>686</fpage><pub-id pub-id-type="pmid">34442330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm11080686</pub-id><pub-id pub-id-type="pmcid">PMC8400727</pub-id></element-citation></ref><ref id="bib244"><label>244</label><element-citation publication-type="journal" id="sref244"><person-group person-group-type="author"><name name-style="western"><surname>Tsumagari</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shimozawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aoyagi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Okano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kuromitsu</surname><given-names>J.</given-names></name></person-group><article-title>Co-expression network analysis of human tau-transgenic mice reveals protein modules associated with tau-induced pathologies</article-title><source>iScience</source><volume>25</volume><year>2022</year><object-id pub-id-type="publisher-id">104832</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2022.104832</pub-id><pub-id pub-id-type="pmcid">PMC9382322</pub-id><pub-id pub-id-type="pmid">35992067</pub-id></element-citation></ref><ref id="bib245"><label>245</label><element-citation publication-type="journal" id="sref245"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name></person-group><article-title>Gene expression data analysis using Hellinger correlation in weighted gene co-expression networks (WGCNA)</article-title><source>Comput Struct Biotechnol J</source><volume>20</volume><year>2022</year><fpage>3851</fpage><lpage>3863</lpage><pub-id pub-id-type="pmid">35891798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.csbj.2022.07.018</pub-id><pub-id pub-id-type="pmcid">PMC9307959</pub-id></element-citation></ref><ref id="bib246"><label>246</label><element-citation publication-type="journal" id="sref246"><person-group person-group-type="author"><name name-style="western"><surname>Boezio</surname><given-names>B.</given-names></name><name name-style="western"><surname>Audouze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ducrot</surname><given-names>P.</given-names></name><name name-style="western"><surname>Taboureau</surname><given-names>O.</given-names></name></person-group><article-title>Network-based approaches in pharmacology</article-title><source>Mol Inform</source><volume>36</volume><year>2017</year><object-id pub-id-type="publisher-id">1700048</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/minf.201700048</pub-id><pub-id pub-id-type="pmid">28692140</pub-id></element-citation></ref><ref id="bib247"><label>247</label><element-citation publication-type="journal" id="sref247"><person-group person-group-type="author"><name name-style="western"><surname>Nolte</surname><given-names>H.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>T.</given-names></name></person-group><article-title>ComplexFinder: a software package for the analysis of native protein complex fractionation experiments</article-title><source>Biochim Biophys Acta Bioenerg</source><volume>1862</volume><year>2021</year><object-id pub-id-type="publisher-id">148444</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbabio.2021.148444</pub-id><pub-id pub-id-type="pmid">33940038</pub-id></element-citation></ref><ref id="bib248"><label>248</label><element-citation publication-type="journal" id="sref248"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>S.Y.</given-names></name></person-group><article-title>Interpreting omics data with pathway enrichment analysis</article-title><source>Trends Genet</source><volume>39</volume><year>2023</year><fpage>308</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">36750393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tig.2023.01.003</pub-id></element-citation></ref><ref id="bib249"><label>249</label><element-citation publication-type="journal" id="sref249"><person-group person-group-type="author"><name name-style="western"><surname>Daly</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Aitken</surname><given-names>S.</given-names></name></person-group><article-title>Learning Bayesian networks: approaches and issues</article-title><source>Knowl Eng Rev</source><volume>26</volume><year>2011</year><fpage>99</fpage><lpage>157</lpage></element-citation></ref><ref id="bib250"><label>250</label><element-citation publication-type="journal" id="sref250"><person-group person-group-type="author"><name name-style="western"><surname>Hollmann</surname><given-names>N.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Purucker</surname><given-names>L.</given-names></name><name name-style="western"><surname>Krishnakumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>K&#246;rfer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hoo</surname><given-names>S.B.</given-names></name><etal/></person-group><article-title>Accurate predictions on small data with a tabular foundation model</article-title><source>Nature</source><volume>637</volume><year>2025</year><fpage>319</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">39780007</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-08328-6</pub-id><pub-id pub-id-type="pmcid">PMC11711098</pub-id></element-citation></ref><ref id="bib251"><label>251</label><element-citation publication-type="journal" id="sref251"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sekiya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beckmann</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Schrode</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Transformative network modeling of multi-omics data reveals detailed circuits, key regulators, and potential therapeutics for Alzheimer's disease</article-title><source>Neuron</source><volume>109</volume><year>2021</year><fpage>257</fpage><lpage>272</lpage><comment>e14</comment><pub-id pub-id-type="pmid">33238137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2020.11.002</pub-id><pub-id pub-id-type="pmcid">PMC7855384</pub-id></element-citation></ref><ref id="bib252"><label>252</label><element-citation publication-type="journal" id="sref252"><person-group person-group-type="author"><name name-style="western"><surname>Francesconi</surname><given-names>A.</given-names></name><name name-style="western"><surname>di Biase</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cappetta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rebecchi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Soda</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sicilia</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Class balancing diversity multimodal ensemble for Alzheimer's disease diagnosis and early detection</article-title><source>Comput Med Imaging Graph</source><volume>123</volume><year>2025</year><object-id pub-id-type="publisher-id">102529</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compmedimag.2025.102529</pub-id><pub-id pub-id-type="pmid">40147216</pub-id></element-citation></ref><ref id="bib253"><label>253</label><element-citation publication-type="journal" id="sref253"><person-group person-group-type="author"><name name-style="western"><surname>Cusworth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gkoutos</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Acharjee</surname><given-names>A.</given-names></name></person-group><article-title>A novel generative adversarial networks modelling for the class imbalance problem in high dimensional omics data</article-title><source>BMC Med Inform Decis Mak</source><volume>24</volume><year>2024</year><fpage>90</fpage><pub-id pub-id-type="pmid">38549123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12911-024-02487-2</pub-id><pub-id pub-id-type="pmcid">PMC10979623</pub-id></element-citation></ref><ref id="bib254"><label>254</label><element-citation publication-type="journal" id="sref254"><person-group person-group-type="author"><name name-style="western"><surname>Dammer</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Seyfried</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>E.C.B.</given-names></name></person-group><article-title>Batch correction and harmonization of -omics datasets with a tunable median polish of ratio</article-title><source>Front Syst Biol</source><volume>3</volume><year>2023</year><object-id pub-id-type="publisher-id">1092341</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fsysb.2023.1092341</pub-id><pub-id pub-id-type="pmcid">PMC10137904</pub-id><pub-id pub-id-type="pmid">37122388</pub-id></element-citation></ref><ref id="bib255"><label>255</label><element-citation publication-type="journal" id="sref255"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Akaila</surname><given-names>D.</given-names></name><name name-style="western"><surname>Arjemandi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Papineni</surname><given-names>V.</given-names></name><name name-style="western"><surname>Yaqub</surname><given-names>M.</given-names></name></person-group><article-title>MINDSETS: multi-omics integration with neuroimaging for dementia subtyping and effective temporal study</article-title><source>Sci Rep</source><volume>15</volume><year>2025</year><object-id pub-id-type="publisher-id">15835</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-025-97674-0</pub-id><pub-id pub-id-type="pmcid">PMC12056088</pub-id><pub-id pub-id-type="pmid">40328937</pub-id></element-citation></ref><ref id="bib256"><label>256</label><element-citation publication-type="journal" id="sref256"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>D.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pardo</surname><given-names>M.</given-names></name><name name-style="western"><surname>France</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Deep learning improves utility of tau PET in the study of Alzheimer's disease</article-title><source>Alzheimers Dement (Amst)</source><volume>13</volume><year>2021</year><object-id pub-id-type="publisher-id">e12264</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12264</pub-id><pub-id pub-id-type="pmcid">PMC8719427</pub-id><pub-id pub-id-type="pmid">35005197</pub-id></element-citation></ref><ref id="bib257"><label>257</label><element-citation publication-type="journal" id="sref257"><person-group person-group-type="author"><name name-style="western"><surname>Raza</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Jamil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hyder</surname><given-names>N.</given-names></name><name name-style="western"><surname>Batool</surname><given-names>K.</given-names></name><name name-style="western"><surname>Walji</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Advancements in deep learning for early diagnosis of Alzheimer's disease using multimodal neuroimaging: challenges and future directions</article-title><source>Front Neuroinform</source><volume>19</volume><year>2025</year><object-id pub-id-type="publisher-id">1557177</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fninf.2025.1557177</pub-id><pub-id pub-id-type="pmcid">PMC12081360</pub-id><pub-id pub-id-type="pmid">40385089</pub-id></element-citation></ref><ref id="bib258"><label>258</label><element-citation publication-type="journal" id="sref258"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>An</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>DeepPrep: an accelerated, scalable and robust pipeline for neuroimaging preprocessing empowered by deep learning</article-title><source>Nat Methods</source><volume>22</volume><year>2025</year><fpage>473</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">39915693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41592-025-02599-1</pub-id><pub-id pub-id-type="pmcid">PMC11903312</pub-id></element-citation></ref><ref id="bib259"><label>259</label><element-citation publication-type="journal" id="sref259"><person-group person-group-type="author"><name name-style="western"><surname>Veitch</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Ashford</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>The Alzheimer's disease neuroimaging initiative in the era of Alzheimer's disease treatment: a review of ADNI studies from 2021 to 2022</article-title><source>Alzheimer's Dement</source><volume>20</volume><year>2024</year><fpage>652</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">37698424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13449</pub-id><pub-id pub-id-type="pmcid">PMC10841343</pub-id></element-citation></ref><ref id="bib260"><label>260</label><element-citation publication-type="journal" id="sref260"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>MORE: a multi-omics data-driven hypergraph integration network for biomedical data classification and biomarker identification</article-title><source>Brief Bioinform</source><volume>26</volume><year>2024</year><object-id pub-id-type="publisher-id">bbae658</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbae658</pub-id><pub-id pub-id-type="pmcid">PMC11653202</pub-id><pub-id pub-id-type="pmid">39692449</pub-id></element-citation></ref><ref id="bib261"><label>261</label><element-citation publication-type="journal" id="sref261"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>sc2GWAS: a comprehensive platform linking single cell and GWAS traits of human</article-title><source>Nucleic Acids Res</source><volume>53</volume><year>2024</year><fpage>D1151</fpage><lpage>D1161</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkae1008</pub-id><pub-id pub-id-type="pmcid">PMC11701642</pub-id><pub-id pub-id-type="pmid">39565208</pub-id></element-citation></ref><ref id="bib262"><label>262</label><element-citation publication-type="journal" id="sref262"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Du</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>B.</given-names></name></person-group><article-title>A semi-supervised approach for the integration of multi-omics data based on transformer multi-head self-attention mechanism and graph convolutional networks</article-title><source>BMC Genom</source><volume>25</volume><year>2024</year><fpage>86</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12864-024-09985-7</pub-id><pub-id pub-id-type="pmcid">PMC10802018</pub-id><pub-id pub-id-type="pmid">38254021</pub-id></element-citation></ref><ref id="bib263"><label>263</label><element-citation publication-type="journal" id="sref263"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name></person-group><article-title>Federated learning with multi-cohort real-world data for predicting the progression from mild cognitive impairment to Alzheimer's disease</article-title><source>Alzheimer's Dement</source><volume>21</volume><year>2025</year><object-id pub-id-type="publisher-id">e70128</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.70128</pub-id><pub-id pub-id-type="pmcid">PMC11992589</pub-id><pub-id pub-id-type="pmid">40219846</pub-id></element-citation></ref><ref id="bib264"><label>264</label><element-citation publication-type="journal" id="sref264"><person-group person-group-type="author"><name name-style="western"><surname>Machado Reyes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>P.</given-names></name></person-group><article-title>For the Alzheimer's disease neuroimaging I. Identifying progression-specific Alzheimer's subtypes using multimodal transformer</article-title><source>J Pers Med</source><volume>14</volume><year>2024</year><fpage>421</fpage><pub-id pub-id-type="pmid">38673048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm14040421</pub-id><pub-id pub-id-type="pmcid">PMC11051083</pub-id></element-citation></ref><ref id="bib265"><label>265</label><element-citation publication-type="journal" id="sref265"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>P.</given-names></name></person-group><article-title>scGraph2Vec: a deep generative model for gene embedding augmented by graph neural network and single-cell omics data</article-title><source>Gigascience</source><volume>13</volume><year>2024</year><object-id pub-id-type="publisher-id">giae108</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gigascience/giae108</pub-id><pub-id pub-id-type="pmcid">PMC11659981</pub-id><pub-id pub-id-type="pmid">39704704</pub-id></element-citation></ref><ref id="bib266"><label>266</label><element-citation publication-type="journal" id="sref266"><person-group person-group-type="author"><name name-style="western"><surname>Golovanevsky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eickhoff</surname><given-names>C.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name></person-group><article-title>Multimodal attention-based deep learning for Alzheimer's disease diagnosis</article-title><source>J Am Med Inform Assoc</source><volume>29</volume><year>2022</year><fpage>2014</fpage><lpage>2022</lpage><pub-id pub-id-type="pmid">36149257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jamia/ocac168</pub-id><pub-id pub-id-type="pmcid">PMC9667156</pub-id></element-citation></ref><ref id="bib267"><label>267</label><element-citation publication-type="journal" id="sref267"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Caselli</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Integrating transcriptomics, genomics, and imaging in Alzheimer's disease: a federated model</article-title><source>Front Radiol</source><volume>1</volume><year>2021</year><object-id pub-id-type="publisher-id">777030</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fradi.2021.777030</pub-id><pub-id pub-id-type="pmcid">PMC10365097</pub-id><pub-id pub-id-type="pmid">37492173</pub-id></element-citation></ref><ref id="bib268"><label>268</label><element-citation publication-type="journal" id="sref268"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tachimori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sekiguchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>Y.</given-names></name></person-group><article-title>A multimodal deep learning approach for the prediction of cognitive decline and its effectiveness in clinical trials for Alzheimer's disease</article-title><source>Transl Psychiatry</source><volume>14</volume><year>2024</year><fpage>105</fpage><pub-id pub-id-type="pmid">38383536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-024-02819-w</pub-id><pub-id pub-id-type="pmcid">PMC10882004</pub-id></element-citation></ref><ref id="bib269"><label>269</label><element-citation publication-type="journal" id="sref269"><person-group person-group-type="author"><name name-style="western"><surname>Iturria-Medina</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Carbonell</surname><given-names>F.</given-names></name><name name-style="western"><surname>Assadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Adewale</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Baumeister</surname><given-names>T.R.</given-names></name><etal/></person-group><article-title>Integrating molecular, histopathological, neuroimaging and clinical neuroscience data with NeuroPM-box</article-title><source>Commun Biol</source><volume>4</volume><year>2021</year><fpage>614</fpage><pub-id pub-id-type="pmid">34021244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-021-02133-x</pub-id><pub-id pub-id-type="pmcid">PMC8140107</pub-id></element-citation></ref><ref id="bib270"><label>270</label><element-citation publication-type="journal" id="sref270"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Timsina</surname><given-names>J.</given-names></name><name name-style="western"><surname>Western</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beric</surname><given-names>A.</given-names></name><name name-style="western"><surname>Budde</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuum</article-title><source>Neuron</source><volume>113</volume><year>2025</year><fpage>1363</fpage><lpage>1379</lpage><comment>e9</comment><pub-id pub-id-type="pmid">40088886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2025.02.014</pub-id><pub-id pub-id-type="pmcid">PMC12067247</pub-id></element-citation></ref><ref id="bib271"><label>271</label><element-citation publication-type="journal" id="sref271"><person-group person-group-type="author"><name name-style="western"><surname>Jahan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abu Taher</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Mahmud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Hosen</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Explainable AI-based Alzheimer's prediction and management using multimodal data</article-title><source>PLoS One</source><volume>18</volume><year>2023</year><object-id pub-id-type="publisher-id">e0294253</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0294253</pub-id><pub-id pub-id-type="pmcid">PMC10653516</pub-id><pub-id pub-id-type="pmid">37972072</pub-id></element-citation></ref><ref id="bib272"><label>272</label><element-citation publication-type="journal" id="sref272"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kowshik</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Lteif</surname><given-names>D.</given-names></name><name name-style="western"><surname>Puducheri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jasodanand</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>O.T.</given-names></name><etal/></person-group><article-title>AI-based differential diagnosis of dementia etiologies on multimodal data</article-title><source>Nat Med</source><volume>30</volume><year>2024</year><fpage>2977</fpage><lpage>2989</lpage><pub-id pub-id-type="pmid">38965435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03118-z</pub-id><pub-id pub-id-type="pmcid">PMC11485262</pub-id></element-citation></ref><ref id="bib273"><label>273</label><element-citation publication-type="journal" id="sref273"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S.X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Predicting conversion from MCI to AD combining multi-modality data and based on molecular subtype</article-title><source>Brain Sci</source><volume>11</volume><year>2021</year><fpage>674</fpage><pub-id pub-id-type="pmid">34064186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci11060674</pub-id><pub-id pub-id-type="pmcid">PMC8224289</pub-id></element-citation></ref><ref id="bib274"><label>274</label><element-citation publication-type="journal" id="sref274"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qing</surname><given-names>L.</given-names></name></person-group><article-title>Multi-modal cross-attention network for Alzheimer's disease diagnosis with multi-modality data</article-title><source>Comput Biol Med</source><volume>162</volume><year>2023</year><object-id pub-id-type="publisher-id">107050</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2023.107050</pub-id><pub-id pub-id-type="pmid">37269680</pub-id></element-citation></ref><ref id="bib275"><label>275</label><element-citation publication-type="journal" id="sref275"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>He</surname><given-names>B.</given-names></name><name name-style="western"><surname>Varathan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nho</surname><given-names>K.</given-names></name><name name-style="western"><surname>Risacher</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Saykin</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>Integrative-omics for discovery of network-level disease biomarkers: a case study in Alzheimer's disease</article-title><source>Brief Bioinform</source><volume>22</volume><year>2021</year><object-id pub-id-type="publisher-id">bbab121</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbab121</pub-id><pub-id pub-id-type="pmcid">PMC8574309</pub-id><pub-id pub-id-type="pmid">33971669</pub-id></element-citation></ref><ref id="bib276"><label>276</label><element-citation publication-type="journal" id="sref276"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez-Pascual</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naccache</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hooshmand</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wretlind</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gabrielli</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Multiomics machine learning identifies inflammation molecular pathways in prodromal Alzheimer's disease</article-title><source>medRxiv</source><year>2023</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2023.03.02.23286674</pub-id></element-citation></ref><ref id="bib277"><label>277</label><element-citation publication-type="journal" id="sref277"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name></person-group><article-title>Applied machine learning in Alzheimer's disease research: omics, imaging, and clinical data</article-title><source>Emerg Top Life Sci</source><volume>5</volume><year>2021</year><fpage>765</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">34881778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/ETLS20210249</pub-id><pub-id pub-id-type="pmcid">PMC8786302</pub-id></element-citation></ref><ref id="bib278"><label>278</label><element-citation publication-type="journal" id="sref278"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><etal/></person-group><article-title>SGUQ: staged graph convolution neural network for Alzheimer's disease diagnosis using multi-omics data</article-title><source>ArXiv</source><year>2024</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.2410.11046</pub-id></element-citation></ref><ref id="bib279"><label>279</label><element-citation publication-type="journal" id="sref279"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Identifying associations among genomic, proteomic and imaging biomarkers <italic toggle="yes">via</italic> adaptive sparse multi-view canonical correlation analysis</article-title><source>Med Image Anal</source><volume>70</volume><year>2021</year><object-id pub-id-type="publisher-id">102003</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.media.2021.102003</pub-id><pub-id pub-id-type="pmid">33735757</pub-id></element-citation></ref><ref id="bib280"><label>280</label><element-citation publication-type="journal" id="sref280"><person-group person-group-type="author"><name name-style="western"><surname>Eteleeb</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Novotny</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Perrin</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Karch</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Multi-omics data integration reveals clinically meaningful molecular profiles of Alzheimer disease</article-title><source>Alzheimer's Dement</source><volume>17</volume><year>2021</year><object-id pub-id-type="publisher-id">e052942</object-id></element-citation></ref><ref id="bib281"><label>281</label><element-citation publication-type="journal" id="sref281"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Saykin</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Long</surname><given-names>Q.</given-names></name></person-group><article-title>Integrative analysis of multi-omics and imaging data with incorporation of biological information <italic toggle="yes">via</italic> structural Bayesian factor analysis</article-title><source>Brief Bioinform</source><volume>24</volume><year>2023</year><object-id pub-id-type="publisher-id">bbad073</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbad073</pub-id><pub-id pub-id-type="pmcid">PMC10387302</pub-id><pub-id pub-id-type="pmid">36882008</pub-id></element-citation></ref><ref id="bib282"><label>282</label><element-citation publication-type="journal" id="sref282"><person-group person-group-type="author"><name name-style="western"><surname>Taiyeb Khosroshahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morsali</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gharakhanlou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Motamedi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hassanbaghlou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vahedi</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Explainable artificial intelligence in neuroimaging of Alzheimer's disease</article-title><source>Diagnostics (Basel)</source><volume>15</volume><year>2025</year><fpage>612</fpage><pub-id pub-id-type="pmid">40075859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics15050612</pub-id><pub-id pub-id-type="pmcid">PMC11899653</pub-id></element-citation></ref><ref id="bib283"><label>283</label><element-citation publication-type="journal" id="sref283"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z.Q.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Tung</surname><given-names>C.Y.</given-names></name><etal/></person-group><article-title>Transcriptomic predictors of rapid progression from mild cognitive impairment to Alzheimer's disease</article-title><source>Alzheimers Res Ther</source><volume>17</volume><year>2025</year><fpage>3</fpage><pub-id pub-id-type="pmid">39754267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01651-0</pub-id><pub-id pub-id-type="pmcid">PMC11697870</pub-id></element-citation></ref><ref id="bib284"><label>284</label><element-citation publication-type="journal" id="sref284"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Sequential proteomic analysis reveals the key APOE4-induced pathological and molecular features at the presymptomatic stage in Alzheimer's disease mice</article-title><source>CNS Neurosci Ther</source><volume>31</volume><year>2025</year><object-id pub-id-type="publisher-id">e70306</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cns.70306</pub-id><pub-id pub-id-type="pmcid">PMC11903334</pub-id><pub-id pub-id-type="pmid">40075551</pub-id></element-citation></ref><ref id="bib285"><label>285</label><element-citation publication-type="journal" id="sref285"><person-group person-group-type="author"><name name-style="western"><surname>Vivek</surname><given-names>S.</given-names></name></person-group><article-title>Using an integrated multi-omics approach to predict dementia: explainable variational autoencoder (E-VAE) classifier model</article-title><source>Alzheimer's Dement</source><volume>19</volume><year>2023</year><object-id pub-id-type="publisher-id">e075591</object-id></element-citation></ref><ref id="bib286"><label>286</label><element-citation publication-type="journal" id="sref286"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Varathan</surname><given-names>P.</given-names></name><name name-style="western"><surname>He</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nho</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Deep trans-omic network fusion for molecular mechanism of Alzheimer's disease</article-title><source>J Alzheimers Dis</source><volume>99</volume><year>2024</year><fpage>715</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">38728189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-240098</pub-id><pub-id pub-id-type="pmcid">PMC12090225</pub-id></element-citation></ref><ref id="bib287"><label>287</label><element-citation publication-type="journal" id="sref287"><person-group person-group-type="author"><name name-style="western"><surname>Bi</surname><given-names>X.A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>CE-GAN: community evolutionary generative adversarial network for Alzheimer's disease risk prediction</article-title><source>IEEE Trans Med Imag</source><volume>43</volume><year>2024</year><fpage>3663</fpage><lpage>3675</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TMI.2024.3385756</pub-id><pub-id pub-id-type="pmid">38587958</pub-id></element-citation></ref><ref id="bib288"><label>288</label><element-citation publication-type="journal" id="sref288"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name></person-group><article-title>SDGCCA: supervised deep generalized canonical correlation analysis for multi-omics integration</article-title><source>J Comput Biol</source><volume>29</volume><year>2022</year><fpage>892</fpage><lpage>907</lpage><pub-id pub-id-type="pmid">35951002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/cmb.2021.0598</pub-id><pub-id pub-id-type="pmcid">PMC9805883</pub-id></element-citation></ref><ref id="bib289"><label>289</label><element-citation publication-type="journal" id="sref289"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Patch-based interpretable deep learning framework for Alzheimer's disease diagnosis using multimodal data</article-title><source>Biomed Signal Process Control</source><volume>100</volume><year>2025</year><object-id pub-id-type="publisher-id">107085</object-id></element-citation></ref><ref id="bib290"><label>290</label><element-citation publication-type="journal" id="sref290"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maisto</surname><given-names>D.</given-names></name></person-group><article-title>Editorial: addressing large scale computing challenges in neuroscience: current advances and future directions</article-title><source>Front Neuroinform</source><volume>18</volume><year>2024</year><object-id pub-id-type="publisher-id">1534396</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fninf.2024.1534396</pub-id><pub-id pub-id-type="pmcid">PMC11685192</pub-id><pub-id pub-id-type="pmid">39741921</pub-id></element-citation></ref><ref id="bib291"><label>291</label><element-citation publication-type="journal" id="sref291"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>D.</given-names></name></person-group><article-title>On efficient training of large-scale deep learning models</article-title><source>ACM Comput Surv</source><volume>57</volume><year>2024</year><fpage>1</fpage><lpage>36</lpage></element-citation></ref><ref id="bib292"><label>292</label><element-citation publication-type="book" id="sref292"><person-group person-group-type="author"><name name-style="western"><surname>Musto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stamate</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Stahl</surname><given-names>D.</given-names></name></person-group><part-title>A machine learning approach for predicting deterioration in Alzheimer's disease</part-title><source>2021 20th IEEE International Conference on Machine Learning and Applications (ICMLA)</source><year>2021</year></element-citation></ref><ref id="bib293"><label>293</label><element-citation publication-type="journal" id="sref293"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kotowska</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kern</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Metabolomic and proteomic analysis of ApoE4-carrying H4 neuroglioma cells in Alzheimer's disease using OrbiSIMS and LC&#8211;MS/MS</article-title><source>Anal Chem</source><volume>96</volume><year>2024</year><fpage>11760</fpage><lpage>11770</lpage><pub-id pub-id-type="pmid">38989551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.analchem.4c01201</pub-id><pub-id pub-id-type="pmcid">PMC11270533</pub-id></element-citation></ref><ref id="bib294"><label>294</label><element-citation publication-type="journal" id="sref294"><person-group person-group-type="author"><name name-style="western"><surname>Ashford</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>G.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Okonkwo</surname><given-names>O.C.</given-names></name><name name-style="western"><surname>Mindt</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's disease Neuroimaging Initiative (ADNI)</article-title><source>Alzheimer's Dement</source><volume>18</volume><year>2022</year><fpage>2603</fpage><lpage>2613</lpage><pub-id pub-id-type="pmid">35213778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12640</pub-id><pub-id pub-id-type="pmcid">PMC9402812</pub-id></element-citation></ref><ref id="bib295"><label>295</label><element-citation publication-type="journal" id="sref295"><person-group person-group-type="author"><name name-style="western"><surname>Alatrany</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kolivand</surname><given-names>H.</given-names></name><name name-style="western"><surname>Al-Jumeily</surname><given-names>D.</given-names></name></person-group><article-title>An explainable machine learning approach for Alzheimer's disease classification</article-title><source>Sci Rep</source><volume>14</volume><year>2024</year><fpage>2637</fpage><pub-id pub-id-type="pmid">38302557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-51985-w</pub-id><pub-id pub-id-type="pmcid">PMC10834965</pub-id></element-citation></ref><ref id="bib296"><label>296</label><element-citation publication-type="journal" id="sref296"><person-group person-group-type="author"><name name-style="western"><surname>Barab&#225;si</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Oltvai</surname><given-names>Z.N.</given-names></name></person-group><article-title>Network biology: understanding the cell's functional organization</article-title><source>Nat Rev Genet</source><volume>5</volume><year>2004</year><fpage>101</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">14735121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrg1272</pub-id></element-citation></ref><ref id="bib297"><label>297</label><element-citation publication-type="journal" id="sref297"><person-group person-group-type="author"><name name-style="western"><surname>Menche</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kitsak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ghiassian</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Loscalzo</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Uncovering disease-disease relationships through the incomplete interactome</article-title><source>Science</source><volume>347</volume><year>2015</year><object-id pub-id-type="publisher-id">1257601</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1257601</pub-id><pub-id pub-id-type="pmcid">PMC4435741</pub-id><pub-id pub-id-type="pmid">25700523</pub-id></element-citation></ref><ref id="bib298"><label>298</label><element-citation publication-type="journal" id="sref298"><person-group person-group-type="author"><name name-style="western"><surname>Stuart</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Segal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Koller</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.K.</given-names></name></person-group><article-title>A gene-coexpression network for global discovery of conserved genetic modules</article-title><source>Science</source><volume>302</volume><year>2003</year><fpage>249</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">12934013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1087447</pub-id></element-citation></ref><ref id="bib299"><label>299</label><element-citation publication-type="journal" id="sref299"><person-group person-group-type="author"><name name-style="western"><surname>Langfelder</surname><given-names>P.</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>S.</given-names></name></person-group><article-title>WGCNA: an R package for weighted correlation network analysis</article-title><source>BMC Bioinf</source><volume>9</volume><year>2008</year><fpage>559</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-9-559</pub-id><pub-id pub-id-type="pmcid">PMC2631488</pub-id><pub-id pub-id-type="pmid">19114008</pub-id></element-citation></ref><ref id="bib300"><label>300</label><element-citation publication-type="journal" id="sref300"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>L.</given-names></name><name name-style="western"><surname>Langfelder</surname><given-names>P.</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>S.</given-names></name></person-group><article-title>Comparison of co-expression measures: mutual information, correlation, and model based indices</article-title><source>BMC Bioinf</source><volume>13</volume><year>2012</year><fpage>328</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-13-328</pub-id><pub-id pub-id-type="pmcid">PMC3586947</pub-id><pub-id pub-id-type="pmid">23217028</pub-id></element-citation></ref><ref id="bib301"><label>301</label><element-citation publication-type="journal" id="sref301"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Kontos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lafitte</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bontempi</surname><given-names>G.</given-names></name></person-group><article-title>Information-theoretic inference of large transcriptional regulatory networks</article-title><source>EURASIP J Bioinform Syst Biol</source><volume>2007</volume><year>2007</year><object-id pub-id-type="publisher-id">79879</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2007/79879</pub-id><pub-id pub-id-type="pmcid">PMC3171353</pub-id><pub-id pub-id-type="pmid">18354736</pub-id></element-citation></ref><ref id="bib302"><label>302</label><element-citation publication-type="journal" id="sref302"><person-group person-group-type="author"><name name-style="western"><surname>Huynh-Thu</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Irrthum</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wehenkel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Geurts</surname><given-names>P.</given-names></name></person-group><article-title>Inferring regulatory networks from expression data using tree-based methods</article-title><source>PLoS One</source><volume>5</volume><year>2010</year><object-id pub-id-type="publisher-id">e12776</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0012776</pub-id><pub-id pub-id-type="pmcid">PMC2946910</pub-id><pub-id pub-id-type="pmid">20927193</pub-id></element-citation></ref><ref id="bib303"><label>303</label><element-citation publication-type="journal" id="sref303"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Keszycki</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name></person-group><article-title>Protein&#8211;protein interactions underlying the behavioral and psychological symptoms of dementia (BPSD) and Alzheimer's disease</article-title><source>PLoS One</source><volume>15</volume><year>2020</year><object-id pub-id-type="publisher-id">e0226021</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0226021</pub-id><pub-id pub-id-type="pmcid">PMC6968845</pub-id><pub-id pub-id-type="pmid">31951614</pub-id></element-citation></ref><ref id="bib304"><label>304</label><element-citation publication-type="journal" id="sref304"><person-group person-group-type="author"><name name-style="western"><surname>Podder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pandit</surname><given-names>M.</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>L.</given-names></name></person-group><article-title>Drug target prioritization for Alzheimer's disease using protein interaction network analysis</article-title><source>Omics</source><volume>22</volume><year>2018</year><fpage>665</fpage><lpage>677</lpage><pub-id pub-id-type="pmid">30346884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/omi.2018.0131</pub-id></element-citation></ref><ref id="bib305"><label>305</label><element-citation publication-type="journal" id="sref305"><person-group person-group-type="author"><name name-style="western"><surname>Hein Marco</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hubner Nina</surname><given-names>C.</given-names></name><name name-style="western"><surname>Poser</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nagaraj</surname><given-names>N.</given-names></name><name name-style="western"><surname>Toyoda</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A human interactome in three quantitative dimensions organized by stoichiometries and abundances</article-title><source>Cell</source><volume>163</volume><year>2015</year><fpage>712</fpage><lpage>723</lpage><pub-id pub-id-type="pmid">26496610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.09.053</pub-id></element-citation></ref><ref id="bib306"><label>306</label><element-citation publication-type="journal" id="sref306"><person-group person-group-type="author"><name name-style="western"><surname>Needham</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Bradford</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Bulpitt</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Westhead</surname><given-names>D.R.</given-names></name></person-group><article-title>Inference in Bayesian networks</article-title><source>Nat Biotechnol</source><volume>24</volume><year>2006</year><fpage>51</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">16404397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt0106-51</pub-id></element-citation></ref><ref id="bib307"><label>307</label><element-citation publication-type="journal" id="sref307"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Conzen</surname><given-names>S.D.</given-names></name></person-group><article-title>A new dynamic Bayesian network (DBN) approach for identifying gene regulatory networks from time course microarray data</article-title><source>Bioinformatics</source><volume>21</volume><year>2005</year><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">15308537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bth463</pub-id></element-citation></ref><ref id="bib308"><label>308</label><element-citation publication-type="journal" id="sref308"><person-group person-group-type="author"><name name-style="western"><surname>De Domenico</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sol&#233;-Ribalta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Omodei</surname><given-names>E.</given-names></name><name name-style="western"><surname>G&#243;mez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arenas</surname><given-names>A.</given-names></name></person-group><article-title>Ranking in interconnected multilayer networks reveals versatile nodes</article-title><source>Nat Commun</source><volume>6</volume><year>2015</year><fpage>6868</fpage><pub-id pub-id-type="pmid">25904405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms7868</pub-id></element-citation></ref><ref id="bib309"><label>309</label><element-citation publication-type="book" id="sref309"><person-group person-group-type="author"><name name-style="western"><surname>Berlingerio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coscia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Giannotti</surname><given-names>F.</given-names></name></person-group><part-title>Finding and characterizing communities in multidimensional networks</part-title><source>2011 international conference on advances in social networks analysis and mining</source><year>2011</year></element-citation></ref><ref id="bib310"><label>310</label><element-citation publication-type="journal" id="sref310"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Segura</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Durainayagam</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Liggi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gra&#231;a</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dehghan</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pathway-based integration of multi-omics data reveals lipidomics alterations validated in an Alzheimer's disease mouse model and risk loci carriers</article-title><source>J Neurochem</source><volume>164</volume><year>2023</year><fpage>57</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">36326588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.15719</pub-id><pub-id pub-id-type="pmcid">PMC10107183</pub-id></element-citation></ref><ref id="bib311"><label>311</label><element-citation publication-type="journal" id="sref311"><person-group person-group-type="author"><name name-style="western"><surname>Argelaguet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Velten</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arnol</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zenz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Marioni</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Multi-omics factor analysis&#8212;a framework for unsupervised integration of multi-omics data sets</article-title><source>Mol Syst Biol</source><volume>14</volume><year>2018</year><object-id pub-id-type="publisher-id">e8124</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/msb.20178124</pub-id><pub-id pub-id-type="pmcid">PMC6010767</pub-id><pub-id pub-id-type="pmid">29925568</pub-id></element-citation></ref><ref id="bib312"><label>312</label><element-citation publication-type="journal" id="sref312"><person-group person-group-type="author"><name name-style="western"><surname>Kipf</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Welling</surname><given-names>M.</given-names></name></person-group><article-title>Semi-supervised classification with graph convolutional networks</article-title><source>arXiv</source><year>2017</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.1609.02907</pub-id></element-citation></ref><ref id="bib313"><label>313</label><element-citation publication-type="journal" id="sref313"><person-group person-group-type="author"><name name-style="western"><surname>Jimenez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hebert-Stevens</surname><given-names>L.</given-names></name><name name-style="western"><surname>Delatour</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stimmer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Racoceanu</surname><given-names>D.</given-names></name></person-group><article-title>Graph theory and GNNs to unravel the topographical organization of brain lesions in variants of Alzheimer's disease progression</article-title><source>arXiv</source><year>2024</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.2403.0063</pub-id></element-citation></ref><ref id="bib314"><label>314</label><element-citation publication-type="journal" id="sref314"><person-group person-group-type="author"><name name-style="western"><surname>Tripathy</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Frohock</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cary</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Keegan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>G.W.</given-names></name><etal/></person-group><article-title>An explainable graph neural network approach for effectively integrating multi-omics with prior knowledge to identify biomarkers from interacting biological domains</article-title><source>bioRxiv</source><year>2024</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2024.08.23.609465</pub-id></element-citation></ref><ref id="bib315"><label>315</label><element-citation publication-type="journal" id="sref315"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name></person-group><article-title>Graph neural networks for single-cell omics data: a review of approaches and applications</article-title><source>Brief Bioinform</source><volume>26</volume><year>2025</year><fpage>bbaf109</fpage><pub-id pub-id-type="pmid">40091193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbaf109</pub-id><pub-id pub-id-type="pmcid">PMC11911123</pub-id></element-citation></ref><ref id="bib316"><label>316</label><element-citation publication-type="journal" id="sref316"><person-group person-group-type="author"><name name-style="western"><surname>Hayes</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Nakahara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ono</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tsuge</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oka</surname><given-names>S.</given-names></name></person-group><article-title>From omics to multi-omics: a review of advantages and tradeoffs</article-title><source>Genes</source><volume>15</volume><year>2024</year><fpage>1551</fpage><pub-id pub-id-type="pmid">39766818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/genes15121551</pub-id><pub-id pub-id-type="pmcid">PMC11675490</pub-id></element-citation></ref><ref id="bib317"><label>317</label><element-citation publication-type="journal" id="sref317"><person-group person-group-type="author"><name name-style="western"><surname>Jahanshad</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lenzini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bijsterbosch</surname><given-names>J.</given-names></name></person-group><article-title>Current best practices and future opportunities for reproducible findings using large-scale neuroimaging in psychiatry</article-title><source>Neuropsychopharmacology</source><volume>50</volume><year>2025</year><fpage>37</fpage><lpage>51</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41386-024-01938-8</pub-id><pub-id pub-id-type="pmcid">PMC11526024</pub-id><pub-id pub-id-type="pmid">39117903</pub-id></element-citation></ref><ref id="bib318"><label>318</label><element-citation publication-type="journal" id="sref318"><person-group person-group-type="author"><name name-style="western"><surname>Mathys</surname><given-names>H.</given-names></name><name name-style="western"><surname>Boix</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Akay</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Davila-Velderrain</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>A.P.</given-names></name><etal/></person-group><article-title>Single-cell multiregion dissection of Alzheimer's disease</article-title><source>Nature</source><volume>632</volume><year>2024</year><fpage>858</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">39048816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-07606-7</pub-id><pub-id pub-id-type="pmcid">PMC11338834</pub-id></element-citation></ref><ref id="bib319"><label>319</label><element-citation publication-type="journal" id="sref319"><person-group person-group-type="author"><name name-style="western"><surname>Gamache</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gingerich</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shwab</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Barrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garrett</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Hume</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Integrative single-nucleus multi-omics analysis prioritizes candidate cis and trans regulatory networks and their target genes in Alzheimer's disease brains</article-title><source>Cell Biosci</source><volume>13</volume><year>2023</year><fpage>185</fpage><pub-id pub-id-type="pmid">37789374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13578-023-01120-5</pub-id><pub-id pub-id-type="pmcid">PMC10546724</pub-id></element-citation></ref><ref id="bib320"><label>320</label><element-citation publication-type="journal" id="sref320"><person-group person-group-type="author"><name name-style="western"><surname>Souchet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Micha&#239;l</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heuillet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dupuy-Gayral</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haudebourg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pech</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Multiomics blood-based biomarkers predict Alzheimer's predementia with high specificity in a multicentric cohort study</article-title><source>J Prev Alzheimers Dis</source><volume>11</volume><year>2024</year><fpage>567</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">38706273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2024.34</pub-id><pub-id pub-id-type="pmcid">PMC11061038</pub-id></element-citation></ref><ref id="bib321"><label>321</label><element-citation publication-type="journal" id="sref321"><person-group person-group-type="author"><name name-style="western"><surname>Burnham</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Faux</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>W.</given-names></name><name name-style="western"><surname>Laws</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ames</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bedo</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A blood-based predictor for neocortical A<italic toggle="yes">&#946;</italic> burden in Alzheimer's disease: results from the AIBL study</article-title><source>Mol Psychiatr</source><volume>19</volume><year>2014</year><fpage>519</fpage><lpage>526</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mp.2013.40</pub-id><pub-id pub-id-type="pmid">23628985</pub-id></element-citation></ref><ref id="bib322"><label>322</label><element-citation publication-type="journal" id="sref322"><person-group person-group-type="author"><name name-style="western"><surname>Binder</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ursu</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bologa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maphis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dadras</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Machine learning prediction and tau-based screening identifies potential Alzheimer's disease genes relevant to immunity</article-title><source>Commun Biol</source><volume>5</volume><year>2022</year><fpage>125</fpage><pub-id pub-id-type="pmid">35149761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-022-03068-7</pub-id><pub-id pub-id-type="pmcid">PMC8837797</pub-id></element-citation></ref><ref id="bib323"><label>323</label><element-citation publication-type="journal" id="sref323"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer's disease</article-title><source>Cell Rep</source><volume>41</volume><year>2022</year><object-id pub-id-type="publisher-id">111717</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2022.111717</pub-id><pub-id pub-id-type="pmcid">PMC9837836</pub-id><pub-id pub-id-type="pmid">36450252</pub-id></element-citation></ref><ref id="bib324"><label>324</label><element-citation publication-type="journal" id="sref324"><person-group person-group-type="author"><name name-style="western"><surname>Panizza</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cerione</surname><given-names>R.A.</given-names></name></person-group><article-title>An interpretable deep learning framework identifies proteomic drivers of Alzheimer's disease</article-title><source>Front Cell Dev Biol</source><volume>12</volume><year>2024</year><object-id pub-id-type="publisher-id">1379984</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2024.1379984</pub-id><pub-id pub-id-type="pmcid">PMC11442384</pub-id><pub-id pub-id-type="pmid">39355118</pub-id></element-citation></ref><ref id="bib325"><label>325</label><element-citation publication-type="journal" id="sref325"><person-group person-group-type="author"><name name-style="western"><surname>Ball</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Proctor</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Brubaker</surname><given-names>D.K.</given-names></name></person-group><article-title>Cross-species modeling identifies gene signatures in type 2 diabetes mouse models predictive of inflammatory and estrogen signaling pathways associated with Alzheimer's disease outcomes in humans</article-title><source>Pac Symp Biocomput</source><volume>30</volume><year>2025</year><fpage>426</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">39670387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1142/9789819807024_0031</pub-id></element-citation></ref><ref id="bib326"><label>326</label><element-citation publication-type="journal" id="sref326"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Reiman</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Readhead</surname><given-names>B.</given-names></name></person-group><article-title>Deep learning-based brain transcriptomic signatures associated with the neuropathological and clinical severity of Alzheimer's disease</article-title><source>Brain Commun</source><volume>4</volume><year>2022</year><object-id pub-id-type="publisher-id">fcab293</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcab293</pub-id><pub-id pub-id-type="pmcid">PMC8728025</pub-id><pub-id pub-id-type="pmid">34993477</pub-id></element-citation></ref><ref id="bib327"><label>327</label><element-citation publication-type="journal" id="sref327"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Province</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Payne</surname><given-names>P.R.O.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>PathFinder: a novel graph transformer model to infer multi-cell intra- and inter-cellular signaling pathways and communications</article-title><source>Front Cell Neurosci</source><volume>18</volume><year>2024</year><object-id pub-id-type="publisher-id">1369242</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2024.1369242</pub-id><pub-id pub-id-type="pmcid">PMC11155453</pub-id><pub-id pub-id-type="pmid">38846640</pub-id></element-citation></ref><ref id="bib328"><label>328</label><element-citation publication-type="journal" id="sref328"><person-group person-group-type="author"><name name-style="western"><surname>Vacher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Canovas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Laws</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Doecke</surname><given-names>J.D.</given-names></name></person-group><article-title>A comprehensive multi-omics analysis reveals unique signatures to predict Alzheimer's disease</article-title><source>Front Bioinform</source><volume>4</volume><year>2024</year><object-id pub-id-type="publisher-id">1390607</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fbinf.2024.1390607</pub-id><pub-id pub-id-type="pmcid">PMC11219798</pub-id><pub-id pub-id-type="pmid">38962175</pub-id></element-citation></ref><ref id="bib329"><label>329</label><element-citation publication-type="journal" id="sref329"><person-group person-group-type="author"><name name-style="western"><surname>Karaglani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gourlia</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsamardinos</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chatzaki</surname><given-names>E.</given-names></name></person-group><article-title>Accurate blood-based diagnostic biosignatures for Alzheimer's disease <italic toggle="yes">via</italic> automated machine learning</article-title><source>J Clin Med</source><volume>9</volume><year>2020</year><fpage>3016</fpage><pub-id pub-id-type="pmid">32962113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm9093016</pub-id><pub-id pub-id-type="pmcid">PMC7563988</pub-id></element-citation></ref><ref id="bib330"><label>330</label><element-citation publication-type="journal" id="sref330"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Minassie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nho</surname><given-names>K.</given-names></name><etal/></person-group><article-title>ADAS-viewer: web-based application for integrative analysis of multi-omics data in Alzheimer's disease</article-title><source>NPJ Syst Biol Appl</source><volume>7</volume><year>2021</year><fpage>18</fpage><pub-id pub-id-type="pmid">33741983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41540-021-00177-7</pub-id><pub-id pub-id-type="pmcid">PMC7979890</pub-id></element-citation></ref><ref id="bib331"><label>331</label><element-citation publication-type="journal" id="sref331"><person-group person-group-type="author"><name name-style="western"><surname>Soleimani Zakeri</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Pashazadeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>MotieGhader</surname><given-names>H.</given-names></name></person-group><article-title>Gene biomarker discovery at different stages of Alzheimer using gene co-expression network approach</article-title><source>Sci Rep</source><volume>10</volume><year>2020</year><object-id pub-id-type="publisher-id">12210</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-69249-8</pub-id><pub-id pub-id-type="pmcid">PMC7376049</pub-id><pub-id pub-id-type="pmid">32699331</pub-id></element-citation></ref><ref id="bib332"><label>332</label><element-citation publication-type="journal" id="sref332"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Varathan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nho</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saykin</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Salama</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name></person-group><article-title>Identification of functionally connected multi-omic biomarkers for Alzheimer's disease using modularity-constrained Lasso</article-title><source>PLoS One</source><volume>15</volume><year>2020</year><object-id pub-id-type="publisher-id">e0234748</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0234748</pub-id><pub-id pub-id-type="pmcid">PMC7299377</pub-id><pub-id pub-id-type="pmid">32555747</pub-id></element-citation></ref><ref id="bib333"><label>333</label><element-citation publication-type="journal" id="sref333"><person-group person-group-type="author"><name name-style="western"><surname>Fran&#231;ois</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karpe</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Beale</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hecker</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Multi-omics, an integrated approach to identify novel blood biomarkers of Alzheimer's disease</article-title><source>Metabolites</source><volume>12</volume><year>2022</year><fpage>949</fpage><pub-id pub-id-type="pmid">36295851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/metabo12100949</pub-id><pub-id pub-id-type="pmcid">PMC9610280</pub-id></element-citation></ref><ref id="bib334"><label>334</label><element-citation publication-type="journal" id="sref334"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>G.</given-names></name></person-group><article-title>Uncovering neuroinflammation-related modules and potential repurposing drugs for Alzheimer's disease through multi-omics data integrative analysis</article-title><source>Front Aging Neurosci</source><volume>15</volume><year>2023</year><object-id pub-id-type="publisher-id">1161405</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2023.1161405</pub-id><pub-id pub-id-type="pmcid">PMC10272561</pub-id><pub-id pub-id-type="pmid">37333458</pub-id></element-citation></ref><ref id="bib335"><label>335</label><element-citation publication-type="journal" id="sref335"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bekris</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leverenz</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Pieper</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>The Alzheimer's Cell Atlas (TACA): a single-cell molecular map for translational therapeutics accelerator in Alzheimer's disease</article-title><source>Alzheimers Dement (N Y)</source><volume>8</volume><year>2022</year><object-id pub-id-type="publisher-id">e12350</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.12350</pub-id><pub-id pub-id-type="pmcid">PMC9558163</pub-id><pub-id pub-id-type="pmid">36254161</pub-id></element-citation></ref><ref id="bib336"><label>336</label><element-citation publication-type="journal" id="sref336"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Khullar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Alatkar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Single-cell network biology characterizes cell type gene regulation for drug repurposing and phenotype prediction in Alzheimer's disease</article-title><source>PLoS Comput Biol</source><volume>18</volume><year>2022</year><object-id pub-id-type="publisher-id">e1010287</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pcbi.1010287</pub-id><pub-id pub-id-type="pmcid">PMC9333448</pub-id><pub-id pub-id-type="pmid">35849618</pub-id></element-citation></ref><ref id="bib337"><label>337</label><element-citation publication-type="journal" id="sref337"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hug</surname><given-names>C.</given-names></name><name name-style="western"><surname>Todorov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moret</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boswell</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Machine learning identifies candidates for drug repurposing in Alzheimer's disease</article-title><source>Nat Commun</source><volume>12</volume><year>2021</year><fpage>1033</fpage><pub-id pub-id-type="pmid">33589615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-21330-0</pub-id><pub-id pub-id-type="pmcid">PMC7884393</pub-id></element-citation></ref><ref id="bib338"><label>338</label><element-citation publication-type="journal" id="sref338"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name></person-group><article-title>Deep learning prediction of chemical-induced dose-dependent and context-specific multiplex phenotype responses and its application to personalized Alzheimer's disease drug repurposing</article-title><source>PLoS Comput Biol</source><volume>18</volume><year>2022</year><object-id pub-id-type="publisher-id">e1010367</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pcbi.1010367</pub-id><pub-id pub-id-type="pmcid">PMC9398009</pub-id><pub-id pub-id-type="pmid">35951653</pub-id></element-citation></ref><ref id="bib339"><label>339</label><element-citation publication-type="journal" id="sref339"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease</article-title><source>Alzheimers Res Ther</source><volume>14</volume><year>2022</year><fpage>7</fpage><pub-id pub-id-type="pmid">35012639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-021-00951-z</pub-id><pub-id pub-id-type="pmcid">PMC8751379</pub-id></element-citation></ref><ref id="bib340"><label>340</label><element-citation publication-type="journal" id="sref340"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bekris</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Pieper</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Leverenz</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer's drug discovery</article-title><source>Alzheimers Res Ther</source><volume>13</volume><year>2021</year><fpage>24</fpage><pub-id pub-id-type="pmid">33441136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-020-00760-w</pub-id><pub-id pub-id-type="pmcid">PMC7804907</pub-id></element-citation></ref><ref id="bib341"><label>341</label><element-citation publication-type="journal" id="sref341"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.</given-names></name><name name-style="western"><surname>Park</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.G.</given-names></name><etal/></person-group><article-title>A proteotranscriptomic-based computational drug-repositioning method for Alzheimer's disease</article-title><source>Front Pharmacol</source><volume>10</volume><year>2019</year><fpage>1653</fpage><pub-id pub-id-type="pmid">32063857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2019.01653</pub-id><pub-id pub-id-type="pmcid">PMC7000455</pub-id></element-citation></ref><ref id="bib342"><label>342</label><element-citation publication-type="journal" id="sref342"><person-group person-group-type="author"><name name-style="western"><surname>Cary</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Wiley</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Gockley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Keegan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amirtha Ganesh</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Heath</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Genetic and multi-omic risk assessment of Alzheimer's disease implicates core associated biological domains</article-title><source>Alzheimers Dement (N Y)</source><volume>10</volume><year>2024</year><object-id pub-id-type="publisher-id">e12461</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.12461</pub-id><pub-id pub-id-type="pmcid">PMC11033838</pub-id><pub-id pub-id-type="pmid">38650747</pub-id></element-citation></ref><ref id="bib343"><label>343</label><element-citation publication-type="journal" id="sref343"><person-group person-group-type="author"><name name-style="western"><surname>Barsh</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Milind</surname><given-names>N.</given-names></name><name name-style="western"><surname>Preuss</surname><given-names>C.</given-names></name><name name-style="western"><surname>Haber</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ananda</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Transcriptomic stratification of late-onset Alzheimer's cases reveals novel genetic modifiers of disease pathology</article-title><source>PLoS Genet</source><volume>16</volume><year>2020</year><object-id pub-id-type="publisher-id">e1008775</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1008775</pub-id><pub-id pub-id-type="pmcid">PMC7295244</pub-id><pub-id pub-id-type="pmid">32492070</pub-id></element-citation></ref><ref id="bib344"><label>344</label><element-citation publication-type="journal" id="sref344"><person-group person-group-type="author"><name name-style="western"><surname>Qorri</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tsay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Au</surname><given-names>R.</given-names></name><name name-style="western"><surname>Geraci</surname><given-names>J.</given-names></name></person-group><article-title>Using machine intelligence to uncover Alzheimer's disease progression heterogeneity</article-title><source>Explor Med</source><volume>1</volume><year>2020</year><fpage>377</fpage><lpage>395</lpage></element-citation></ref><ref id="bib345"><label>345</label><element-citation publication-type="journal" id="sref345"><person-group person-group-type="author"><name name-style="western"><surname>Lian</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Identification of metabolism-related subtypes and feature genes in Alzheimer's disease</article-title><source>J Transl Med</source><volume>21</volume><year>2023</year><fpage>628</fpage><pub-id pub-id-type="pmid">37715200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-023-04324-y</pub-id><pub-id pub-id-type="pmcid">PMC10504766</pub-id></element-citation></ref><ref id="bib346"><label>346</label><element-citation publication-type="journal" id="sref346"><person-group person-group-type="author"><name name-style="western"><surname>Landi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Glicksberg</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.-C.</given-names></name><name name-style="western"><surname>Cherng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Landi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Danieletto</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Deep representation learning of electronic health records to unlock patient stratification at scale</article-title><source>NPJ Digit Med</source><volume>3</volume><year>2020</year><fpage>96</fpage><pub-id pub-id-type="pmid">32699826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-020-0301-z</pub-id><pub-id pub-id-type="pmcid">PMC7367859</pub-id></element-citation></ref><ref id="bib347"><label>347</label><element-citation publication-type="journal" id="sref347"><person-group person-group-type="author"><name name-style="western"><surname>Wisch</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Butt</surname><given-names>O.H.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Schindler</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Fagan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Henson</surname><given-names>R.L.</given-names></name><etal/></person-group><article-title>Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression</article-title><source>Brain</source><volume>146</volume><year>2023</year><fpage>2944</fpage><lpage>2956</lpage><pub-id pub-id-type="pmid">36542469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awac484</pub-id><pub-id pub-id-type="pmcid">PMC10316757</pub-id></element-citation></ref><ref id="bib348"><label>348</label><element-citation publication-type="journal" id="sref348"><person-group person-group-type="author"><name name-style="western"><surname>Tijms</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Gobom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reus</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dobricic</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics</article-title><source>Brain</source><volume>143</volume><year>2020</year><fpage>3776</fpage><lpage>3792</lpage><pub-id pub-id-type="pmid">33439986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awaa325</pub-id><pub-id pub-id-type="pmcid">PMC7805814</pub-id></element-citation></ref><ref id="bib349"><label>349</label><element-citation publication-type="journal" id="sref349"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Uhm</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Using blood transcriptome analysis for Alzheimer's disease diagnosis and patient stratification</article-title><source>Alzheimer's Dement</source><volume>20</volume><year>2024</year><fpage>2469</fpage><lpage>2484</lpage><pub-id pub-id-type="pmid">38323937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13691</pub-id><pub-id pub-id-type="pmcid">PMC11032555</pub-id></element-citation></ref><ref id="bib350"><label>350</label><element-citation publication-type="journal" id="sref350"><person-group person-group-type="author"><name name-style="western"><surname>Elman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Schork</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Rangan</surname><given-names>A.V.</given-names></name></person-group><article-title>Exploring the genetic heterogeneity of Alzheimer's disease: evidence for genetic subtypes</article-title><source>J Alzheimers Dis</source><volume>100</volume><year>2024</year><fpage>1209</fpage><lpage>1226</lpage><pub-id pub-id-type="pmid">38995775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-231252</pub-id><pub-id pub-id-type="pmcid">PMC11636402</pub-id></element-citation></ref><ref id="bib351"><label>351</label><element-citation publication-type="journal" id="sref351"><person-group person-group-type="author"><name name-style="western"><surname>Xicota</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ichou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lejeune</surname><given-names>F.X.</given-names></name><name name-style="western"><surname>Colsch</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tenenhaus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leroy</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Multi-omics signature of brain amyloid deposition in asymptomatic individuals at-risk for Alzheimer's disease: the INSIGHT-preAD study</article-title><source>EBioMedicine</source><volume>47</volume><year>2019</year><fpage>518</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">31492558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2019.08.051</pub-id><pub-id pub-id-type="pmcid">PMC6796577</pub-id></element-citation></ref><ref id="bib352"><label>352</label><element-citation publication-type="journal" id="sref352"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matan-Lithwick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>De Jager</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Felsky</surname><given-names>D.</given-names></name></person-group><article-title>Multi-omic integration <italic toggle="yes">via</italic> similarity network fusion to detect molecular subtypes of ageing</article-title><source>Brain Commun</source><volume>5</volume><year>2023</year><object-id pub-id-type="publisher-id">fcad110</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcad110</pub-id><pub-id pub-id-type="pmcid">PMC10110975</pub-id><pub-id pub-id-type="pmid">37082508</pub-id></element-citation></ref><ref id="bib353"><label>353</label><element-citation publication-type="journal" id="sref353"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beckmann</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Roussos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease</article-title><source>Sci Data</source><volume>5</volume><year>2018</year><object-id pub-id-type="publisher-id">180185</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sdata.2018.185</pub-id><pub-id pub-id-type="pmcid">PMC6132187</pub-id><pub-id pub-id-type="pmid">30204156</pub-id></element-citation></ref><ref id="bib354"><label>354</label><element-citation publication-type="journal" id="sref354"><person-group person-group-type="author"><name name-style="western"><surname>Gabitto</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Travaglini</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Rachleff</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Long</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ariza</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Integrated multimodal cell atlas of Alzheimer's disease</article-title><source>Nat Neurosci</source><volume>27</volume><year>2024</year><fpage>2366</fpage><lpage>2383</lpage><pub-id pub-id-type="pmid">39402379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-024-01774-5</pub-id><pub-id pub-id-type="pmcid">PMC11614693</pub-id></element-citation></ref><ref id="bib355"><label>355</label><element-citation publication-type="journal" id="sref355"><person-group person-group-type="author"><name name-style="western"><surname>Bos</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vandenberghe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Engelborghs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.</given-names></name><etal/></person-group><article-title>The EMIF-AD multimodal biomarker discovery study: design, methods and cohort characteristics</article-title><source>Alzheimers Res Ther</source><volume>10</volume><year>2018</year><fpage>64</fpage><pub-id pub-id-type="pmid">29980228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-018-0396-5</pub-id><pub-id pub-id-type="pmcid">PMC6035398</pub-id></element-citation></ref><ref id="bib356"><label>356</label><element-citation publication-type="journal" id="sref356"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Multi-omics analyses identify gut microbiota&#8211;fecal metabolites&#8211;brain&#8211;cognition pathways in the Alzheimer's disease continuum</article-title><source>Alzheimers Res Ther</source><volume>17</volume><year>2025</year><fpage>36</fpage><pub-id pub-id-type="pmid">39893498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-025-01683-0</pub-id><pub-id pub-id-type="pmcid">PMC11786436</pub-id></element-citation></ref><ref id="bib357"><label>357</label><element-citation publication-type="journal" id="sref357"><person-group person-group-type="author"><name name-style="western"><surname>Iturria-Medina</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sotero</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Toussaint</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Mateos-P&#233;rez</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>A.C.</given-names></name></person-group><article-title>Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis</article-title><source>Nat Commun</source><volume>7</volume><year>2016</year><object-id pub-id-type="publisher-id">11934</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms11934</pub-id><pub-id pub-id-type="pmcid">PMC4919512</pub-id><pub-id pub-id-type="pmid">27327500</pub-id></element-citation></ref><ref id="bib358"><label>358</label><element-citation publication-type="journal" id="sref358"><person-group person-group-type="author"><name name-style="western"><surname>Mielke</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Haughey</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Bandaru</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Schech</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carrick</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss</article-title><source>Alzheimer's Dement</source><volume>6</volume><year>2010</year><fpage>378</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">20813340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2010.03.014</pub-id><pub-id pub-id-type="pmcid">PMC2933928</pub-id></element-citation></ref><ref id="bib359"><label>359</label><element-citation publication-type="journal" id="sref359"><person-group person-group-type="author"><name name-style="western"><surname>Bo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Brain-wide and cell-specific transcriptomic insights into MRI-derived cortical morphology in macaque monkeys</article-title><source>Nat Commun</source><volume>14</volume><year>2023</year><fpage>1499</fpage><pub-id pub-id-type="pmid">36932104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-37246-w</pub-id><pub-id pub-id-type="pmcid">PMC10023667</pub-id></element-citation></ref><ref id="bib360"><label>360</label><element-citation publication-type="journal" id="sref360"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Grabowska</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Roden</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer's disease with real-world clinical validation</article-title><source>NPJ Digit Med</source><volume>7</volume><year>2024</year><fpage>46</fpage><pub-id pub-id-type="pmid">38409350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-024-01038-3</pub-id><pub-id pub-id-type="pmcid">PMC10897392</pub-id></element-citation></ref><ref id="bib361"><label>361</label><element-citation publication-type="journal" id="sref361"><person-group person-group-type="author"><name name-style="western"><surname>Badhwar</surname><given-names>A.</given-names></name><name name-style="western"><surname>McFall</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Sapkota</surname><given-names>S.</given-names></name><name name-style="western"><surname>Black</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Chertkow</surname><given-names>H.</given-names></name><name name-style="western"><surname>Duchesne</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A multiomics approach to heterogeneity in Alzheimer's disease: focused review and roadmap</article-title><source>Brain</source><volume>143</volume><year>2020</year><fpage>1315</fpage><lpage>1331</lpage><pub-id pub-id-type="pmid">31891371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awz384</pub-id><pub-id pub-id-type="pmcid">PMC7241959</pub-id></element-citation></ref><ref id="bib362"><label>362</label><element-citation publication-type="journal" id="sref362"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Doody</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S.</given-names></name></person-group><article-title>Prediction of conversion to Alzheimer's disease with longitudinal measures and time-to-event data</article-title><source>J Alzheimers Dis</source><volume>58</volume><year>2017</year><fpage>361</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">28436391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-161201</pub-id><pub-id pub-id-type="pmcid">PMC5477671</pub-id></element-citation></ref><ref id="bib363"><label>363</label><element-citation publication-type="journal" id="sref363"><person-group person-group-type="author"><name name-style="western"><surname>B&#246;hle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eitel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Weygandt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ritter</surname><given-names>K.</given-names></name></person-group><article-title>Layer-wise relevance propagation for explaining deep neural network decisions in MRI-based Alzheimer's disease classification</article-title><source>Front Aging Neurosci</source><volume>11</volume><year>2019</year><fpage>194</fpage><pub-id pub-id-type="pmid">31417397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2019.00194</pub-id><pub-id pub-id-type="pmcid">PMC6685087</pub-id></element-citation></ref><ref id="bib364"><label>364</label><element-citation publication-type="journal" id="sref364"><person-group person-group-type="author"><name name-style="western"><surname>Borys</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Nauta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kr&#228;mer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Friedrich</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Explainable AI in medical imaging: an overview for clinical practitioners&#8212;beyond saliency-based XAI approaches</article-title><source>Eur J Radiol</source><volume>162</volume><year>2023</year><object-id pub-id-type="publisher-id">110786</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejrad.2023.110786</pub-id><pub-id pub-id-type="pmid">36990051</pub-id></element-citation></ref><ref id="bib365"><label>365</label><element-citation publication-type="journal" id="sref365"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Breteler</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>de Strooper</surname><given-names>B.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Alzheimer's disease</article-title><source>Lancet</source><volume>388</volume><year>2016</year><fpage>505</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">26921134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(15)01124-1</pub-id></element-citation></ref><ref id="bib366"><label>366</label><element-citation publication-type="journal" id="sref366"><person-group person-group-type="author"><name name-style="western"><surname>Villemagne</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Dor&#233;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Burnham</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Masters</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>C.C.</given-names></name></person-group><article-title>Imaging tau and amyloid-<italic toggle="yes">&#946;</italic> proteinopathies in Alzheimer disease and other conditions</article-title><source>Nat Rev Neurol</source><volume>14</volume><year>2018</year><fpage>225</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">29449700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2018.9</pub-id></element-citation></ref><ref id="bib367"><label>367</label><element-citation publication-type="journal" id="sref367"><person-group person-group-type="author"><name name-style="western"><surname>Kiddle</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Thambisetty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>A.</given-names></name><name name-style="western"><surname>Riddoch-Contreras</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hye</surname><given-names>A.</given-names></name><name name-style="western"><surname>Westman</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Plasma based markers of [<sup>11</sup>C] PiB-PET brain amyloid burden</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e44260</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0044260</pub-id><pub-id pub-id-type="pmcid">PMC3454385</pub-id><pub-id pub-id-type="pmid">23028511</pub-id></element-citation></ref><ref id="bib368"><label>368</label><element-citation publication-type="journal" id="sref368"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>E.C.B.</given-names></name><name name-style="western"><surname>Dammer</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Duong</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Ping</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation</article-title><source>Nat Med</source><volume>26</volume><year>2020</year><fpage>769</fpage><lpage>780</lpage><pub-id pub-id-type="pmid">32284590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0815-6</pub-id><pub-id pub-id-type="pmcid">PMC7405761</pub-id></element-citation></ref><ref id="bib369"><label>369</label><element-citation publication-type="journal" id="sref369"><person-group person-group-type="author"><name name-style="western"><surname>Mirabnahrazam</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Popuri</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Machine learning based multimodal neuroimaging genomics dementia score for predicting future conversion to Alzheimer's disease</article-title><source>J Alzheimers Dis</source><volume>87</volume><year>2022</year><fpage>1345</fpage><lpage>1365</lpage><pub-id pub-id-type="pmid">35466939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-220021</pub-id><pub-id pub-id-type="pmcid">PMC9195128</pub-id></element-citation></ref><ref id="bib370"><label>370</label><element-citation publication-type="journal" id="sref370"><person-group person-group-type="author"><name name-style="western"><surname>Moradi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pepe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gaser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huttunen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tohka</surname><given-names>J.</given-names></name></person-group><article-title>Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects</article-title><source>Neuroimage</source><volume>104</volume><year>2015</year><fpage>398</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">25312773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2014.10.002</pub-id><pub-id pub-id-type="pmcid">PMC5957071</pub-id></element-citation></ref><ref id="bib371"><label>371</label><element-citation publication-type="journal" id="sref371"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D.</given-names></name></person-group><article-title>Multimodal classification of Alzheimer's disease and mild cognitive impairment</article-title><source>Neuroimage</source><volume>55</volume><year>2011</year><fpage>856</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">21236349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2011.01.008</pub-id><pub-id pub-id-type="pmcid">PMC3057360</pub-id></element-citation></ref><ref id="bib372"><label>372</label><element-citation publication-type="journal" id="sref372"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Byun</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>Y.M.</given-names></name><etal/></person-group><article-title>Chemically treated plasma A<italic toggle="yes">&#946;</italic> is a potential blood-based biomarker for screening cerebral amyloid deposition</article-title><source>Alzheimers Res Ther</source><volume>9</volume><year>2017</year><fpage>20</fpage><pub-id pub-id-type="pmid">28330509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-017-0248-8</pub-id><pub-id pub-id-type="pmcid">PMC5361707</pub-id></element-citation></ref><ref id="bib373"><label>373</label><element-citation publication-type="journal" id="sref373"><person-group person-group-type="author"><name name-style="western"><surname>Lista</surname><given-names>S.</given-names></name><name name-style="western"><surname>O'Bryant</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hugon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Biomarkers in sporadic and familial Alzheimer's disease</article-title><source>J Alzheimers Dis</source><volume>47</volume><year>2015</year><fpage>291</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">26401553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-143006</pub-id></element-citation></ref><ref id="bib374"><label>374</label><element-citation publication-type="journal" id="sref374"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>N.</given-names></name><name name-style="western"><surname>Villemagne</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T.</given-names></name><name name-style="western"><surname>Doecke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dor&#233;</surname><given-names>V.</given-names></name><etal/></person-group><article-title>High performance plasma amyloid-<italic toggle="yes">&#946;</italic> biomarkers for Alzheimer's disease</article-title><source>Nature</source><volume>554</volume><year>2018</year><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">29420472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature25456</pub-id></element-citation></ref><ref id="bib375"><label>375</label><element-citation publication-type="journal" id="sref375"><person-group person-group-type="author"><name name-style="western"><surname>Jo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bice</surname><given-names>P.</given-names></name><name name-style="western"><surname>Huynh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Circular-SWAT for deep learning based diagnostic classification of Alzheimer's disease: application to metabolome data</article-title><source>EBioMedicine</source><volume>97</volume><year>2023</year><object-id pub-id-type="publisher-id">104820</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2023.104820</pub-id><pub-id pub-id-type="pmcid">PMC10579282</pub-id><pub-id pub-id-type="pmid">37806288</pub-id></element-citation></ref><ref id="bib376"><label>376</label><element-citation publication-type="journal" id="sref376"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hamel</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Melkonyan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>T.F.A.</given-names></name><name name-style="western"><surname>Au</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Prediction of progression from mild cognitive impairment to Alzheimer's disease with longitudinal and multimodal data</article-title><source>Front Dement</source><volume>2</volume><year>2023</year><object-id pub-id-type="publisher-id">1271680</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/frdem.2023.1271680</pub-id><pub-id pub-id-type="pmcid">PMC11185839</pub-id><pub-id pub-id-type="pmid">38895707</pub-id></element-citation></ref><ref id="bib377"><label>377</label><element-citation publication-type="journal" id="sref377"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Amouyel</surname><given-names>P.</given-names></name></person-group><article-title>Genetics of Alzheimer's disease: new evidences for an old hypothesis?.</article-title><source>Curr Opin Genet Dev</source><volume>21</volume><year>2011</year><fpage>295</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">21371880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gde.2011.02.002</pub-id></element-citation></ref><ref id="bib378"><label>378</label><element-citation publication-type="journal" id="sref378"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Das</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sobreira</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Igartua</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Genome-wide association and multi-omics studies identify MGMT as a novel risk gene for Alzheimer's disease among women</article-title><source>Alzheimer's Dement</source><volume>19</volume><year>2023</year><fpage>896</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">35770850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12719</pub-id><pub-id pub-id-type="pmcid">PMC9800643</pub-id></element-citation></ref><ref id="bib379"><label>379</label><element-citation publication-type="journal" id="sref379"><person-group person-group-type="author"><name name-style="western"><surname>van der Net</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Eijkemans</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kastelein</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Sijbrands</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Steyerberg</surname><given-names>E.W.</given-names></name></person-group><article-title>Cox proportional hazards models have more statistical power than logistic regression models in cross-sectional genetic association studies</article-title><source>Eur J Hum Genet</source><volume>16</volume><year>2008</year><fpage>1111</fpage><lpage>1116</lpage><pub-id pub-id-type="pmid">18382476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ejhg.2008.59</pub-id></element-citation></ref><ref id="bib380"><label>380</label><element-citation publication-type="book" id="sref380"><person-group person-group-type="author"><name name-style="western"><surname>Lundberg</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.-I.</given-names></name></person-group><part-title>A unified approach to interpreting model predictions</part-title><source>31st conference on Neural Information Processing Systems (NIPS 2017), Long Beach, CA, USA</source><year>2017</year></element-citation></ref><ref id="bib381"><label>381</label><element-citation publication-type="journal" id="sref381"><person-group person-group-type="author"><name name-style="western"><surname>Bhatia</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>&#214;zt&#252;rk</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Mai</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Spatial proteomics in three-dimensional intact specimens</article-title><source>Cell</source><volume>185</volume><year>2022</year><fpage>5040</fpage><lpage>5058</lpage><comment>e19</comment><pub-id pub-id-type="pmid">36563667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2022.11.021</pub-id></element-citation></ref><ref id="bib382"><label>382</label><element-citation publication-type="journal" id="sref382"><person-group person-group-type="author"><name name-style="western"><surname>Mo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vannucci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Hilsenbeck</surname><given-names>S.G.</given-names></name></person-group><article-title>A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data</article-title><source>Biostatistics</source><volume>19</volume><year>2017</year><fpage>71</fpage><lpage>86</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/biostatistics/kxx017</pub-id><pub-id pub-id-type="pmcid">PMC6455926</pub-id><pub-id pub-id-type="pmid">28541380</pub-id></element-citation></ref><ref id="bib383"><label>383</label><element-citation publication-type="journal" id="sref383"><person-group person-group-type="author"><name name-style="western"><surname>Moran</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Duke</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Turkheimer</surname><given-names>F.E.</given-names></name><name name-style="western"><surname>Banati</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Graeber</surname><given-names>M.B.</given-names></name></person-group><article-title>Towards a transcriptome definition of microglial cells</article-title><source>Neurogenetics</source><volume>5</volume><year>2004</year><fpage>95</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">15042428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10048-004-0172-5</pub-id></element-citation></ref><ref id="bib384"><label>384</label><element-citation publication-type="journal" id="sref384"><person-group person-group-type="author"><name name-style="western"><surname>Noble</surname><given-names>W.S.</given-names></name></person-group><article-title>What is a support vector machine?.</article-title><source>Nat Biotechnol</source><volume>24</volume><year>2006</year><fpage>1565</fpage><lpage>1567</lpage><pub-id pub-id-type="pmid">17160063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt1206-1565</pub-id></element-citation></ref><ref id="bib385"><label>385</label><element-citation publication-type="journal" id="sref385"><person-group person-group-type="author"><name name-style="western"><surname>Kauppi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>McEvoy</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>Combining polygenic hazard score with volumetric MRI and cognitive measures improves prediction of progression from mild cognitive impairment to Alzheimer's disease</article-title><source>Front Neurosci</source><volume>12</volume><year>2018</year><fpage>260</fpage><pub-id pub-id-type="pmid">29760643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2018.00260</pub-id><pub-id pub-id-type="pmcid">PMC5937163</pub-id></element-citation></ref><ref id="bib386"><label>386</label><element-citation publication-type="journal" id="sref386"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Brain-wide genome-wide colocalization study for integrating genetics, transcriptomics and brain morphometry in Alzheimer's disease</article-title><source>Neuroimage</source><volume>280</volume><year>2023</year><object-id pub-id-type="publisher-id">120346</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2023.120346</pub-id><pub-id pub-id-type="pmcid">PMC10552907</pub-id><pub-id pub-id-type="pmid">37634885</pub-id></element-citation></ref><ref id="bib387"><label>387</label><element-citation publication-type="journal" id="sref387"><person-group person-group-type="author"><name name-style="western"><surname>Reitz</surname><given-names>C.</given-names></name></person-group><article-title>Toward precision medicine in Alzheimer's disease</article-title><source>Ann Transl Med</source><volume>4</volume><year>2016</year><fpage>107</fpage><pub-id pub-id-type="pmid">27127760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm.2016.03.05</pub-id><pub-id pub-id-type="pmcid">PMC4828743</pub-id></element-citation></ref><ref id="bib388"><label>388</label><element-citation publication-type="journal" id="sref388"><person-group person-group-type="author"><name name-style="western"><surname>Deivasigamani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thekkan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vergara</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Conolly</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cosden</surname><given-names>M.</given-names></name><name name-style="western"><surname>Phan</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Multimodal blood-based biomarker panel reveals altered lysosomal ionic content in Alzheimer's disease</article-title><source>ACS Chem Biol</source><volume>20</volume><year>2024</year><fpage>137</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">39699875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschembio.4c00602</pub-id></element-citation></ref><ref id="bib389"><label>389</label><element-citation publication-type="journal" id="sref389"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Knopman</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>M.W.</given-names></name><etal/></person-group><article-title>Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade</article-title><source>Lancet Neurol</source><volume>9</volume><year>2010</year><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">20083042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(09)70299-6</pub-id><pub-id pub-id-type="pmcid">PMC2819840</pub-id></element-citation></ref><ref id="bib390"><label>390</label><element-citation publication-type="journal" id="sref390"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>V.O.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kaistha</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Downey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gozes</surname><given-names>I.</given-names></name><etal/></person-group><article-title>DeepDrug: an expert-led domain-specific AI-driven drug-repurposing mechanism for selecting the lead combination of drugs for Alzheimer's disease</article-title><source>medRxiv</source><year>2024</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2024.07.06.24309990</pub-id><pub-id pub-id-type="pmcid">PMC11735786</pub-id><pub-id pub-id-type="pmid">39814937</pub-id></element-citation></ref><ref id="bib391"><label>391</label><element-citation publication-type="journal" id="sref391"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S.T.</given-names></name></person-group><article-title>Converging multi-modality datasets to build efficient drug repositioning pipelines against Alzheimer's disease and related dementias</article-title><source>Med Rev (2021)</source><volume>2</volume><year>2022</year><fpage>110</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">35658114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/mr-2021-0017</pub-id><pub-id pub-id-type="pmcid">PMC9047641</pub-id></element-citation></ref><ref id="bib392"><label>392</label><element-citation publication-type="journal" id="sref392"><person-group person-group-type="author"><name name-style="western"><surname>Climacosa</surname><given-names>F.M.M.</given-names></name><name name-style="western"><surname>Anlacan</surname><given-names>V.M.M.</given-names></name><name name-style="western"><surname>Gordovez</surname><given-names>F.J.A.</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>J.C.B.</given-names></name><name name-style="western"><surname>Tabios</surname><given-names>I.K.B.</given-names></name><name name-style="western"><surname>Manalo</surname><given-names>R.V.M.</given-names></name><etal/></person-group><article-title>Monitoring drug efficacy through multi-omics research initiative in Alzheimer's disease (MEMORI-AD): a protocol for a multisite exploratory prospective cohort study on the drug response-related clinical, genetic, microbial and metabolomic signatures in Filipino patients with Alzheimer's disease</article-title><source>BMJ Open</source><volume>14</volume><year>2024</year><object-id pub-id-type="publisher-id">e078660</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2023-078660</pub-id><pub-id pub-id-type="pmcid">PMC11603684</pub-id><pub-id pub-id-type="pmid">39608999</pub-id></element-citation></ref><ref id="bib393"><label>393</label><element-citation publication-type="journal" id="sref393"><person-group person-group-type="author"><name name-style="western"><surname>Kouper</surname><given-names>I.</given-names></name></person-group><article-title>Data curation in interdisciplinary and highly collaborative research</article-title><source>Int J Digit Curation</source><volume>17</volume><year>2023</year><fpage>1</fpage><lpage>20</lpage></element-citation></ref><ref id="bib394"><label>394</label><element-citation publication-type="journal" id="sref394"><person-group person-group-type="author"><name name-style="western"><surname>Cuende</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ciccocioppo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Forte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Galipeau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ikonomou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>B.L.</given-names></name><etal/></person-group><article-title>Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products</article-title><source>Cytotherapy</source><volume>24</volume><year>2022</year><fpage>686</fpage><lpage>690</lpage><pub-id pub-id-type="pmid">35545453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcyt.2022.03.007</pub-id></element-citation></ref><ref id="bib395"><label>395</label><element-citation publication-type="journal" id="sref395"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name></person-group><article-title>Microglial APOE4 promotes neuron degeneration in Alzheimer's disease through inhibition of lipid droplet autophagy</article-title><source>Acta Pharm Sin B</source><volume>15</volume><year>2025</year><fpage>657</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">40041924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2024.10.009</pub-id><pub-id pub-id-type="pmcid">PMC11873644</pub-id></element-citation></ref><ref id="bib396"><label>396</label><element-citation publication-type="journal" id="sref396"><person-group person-group-type="author"><name name-style="western"><surname>Ertekin-Taner</surname><given-names>N.</given-names></name></person-group><article-title>Integrative gene expression studies on the path to precision medicine in Alzheimer's and related disorders</article-title><source>Alzheimer's Dement</source><volume>19</volume><year>2023</year><object-id pub-id-type="publisher-id">e081527</object-id></element-citation></ref><ref id="bib397"><label>397</label><element-citation publication-type="journal" id="sref397"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Heath</surname><given-names>L.</given-names></name><name name-style="western"><surname>Linden</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Seifar</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Bridging the gap: multi-omics profiling of brain tissue in Alzheimer's disease and older controls in multi-ethnic populations</article-title><source>Alzheimer's Dement</source><volume>20</volume><year>2024</year><fpage>7174</fpage><lpage>7192</lpage><pub-id pub-id-type="pmid">39215503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14208</pub-id><pub-id pub-id-type="pmcid">PMC11485084</pub-id></element-citation></ref><ref id="bib398"><label>398</label><element-citation publication-type="journal" id="sref398"><person-group person-group-type="author"><name name-style="western"><surname>Kikuchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miyashita</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hirota</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sakakibara</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Omics analysis of Alzheimer's disease stratified by the microglial polygenic effect</article-title><source>Alzheimer's Dement</source><volume>19</volume><year>2023</year><object-id pub-id-type="publisher-id">e075550</object-id></element-citation></ref><ref id="bib399"><label>399</label><element-citation publication-type="journal" id="sref399"><person-group person-group-type="author"><name name-style="western"><surname>Tijms</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Vromen</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Mjaavatten</surname><given-names>O.</given-names></name><name name-style="western"><surname>Holstege</surname><given-names>H.</given-names></name><name name-style="western"><surname>Reus</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>van der Lee</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Large-scale cerebrospinal fluid proteomic analysis in Alzheimer's disease patients reveals five molecular subtypes with distinct genetic risk profiles</article-title><source>medRxiv</source><year>2023</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2023.05.10.23289793</pub-id><pub-id pub-id-type="pmcid">PMC10798889</pub-id><pub-id pub-id-type="pmid">38195725</pub-id></element-citation></ref><ref id="bib400"><label>400</label><element-citation publication-type="journal" id="sref400"><person-group person-group-type="author"><name name-style="western"><surname>Iturria-Medina</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Adewale</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Ducharme</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rosa-Neto</surname><given-names>P.</given-names></name><name name-style="western"><surname>O'Donnell</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Unified epigenomic, transcriptomic, proteomic, and metabolomic taxonomy of Alzheimer's disease progression and heterogeneity</article-title><source>Sci Adv</source><volume>8</volume><year>2022</year><object-id pub-id-type="publisher-id">eabo6764</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abo6764</pub-id><pub-id pub-id-type="pmcid">PMC9674284</pub-id><pub-id pub-id-type="pmid">36399579</pub-id></element-citation></ref><ref id="bib401"><label>401</label><element-citation publication-type="journal" id="sref401"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Su</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name></person-group><article-title>Integrative analyses of neuroimaging, clinical, and multi-omics data identified meaningful Alzheimer's disease progression subtypes</article-title><source>medRxiv</source><year>2022</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2022.11.01.22281820</pub-id></element-citation></ref><ref id="bib402"><label>402</label><element-citation publication-type="journal" id="sref402"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Human brain aging heterogeneity observed from multi-region omics data reveals a subtype closely related to Alzheimer's disease</article-title><source>bioRxiv</source><year>2024</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2024.03.01.582970</pub-id></element-citation></ref><ref id="bib403"><label>403</label><element-citation publication-type="journal" id="sref403"><person-group person-group-type="author"><name name-style="western"><surname>Giang</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>D.H.</given-names></name></person-group><article-title>Stratifying patients using fast multiple kernel learning framework: case studies of Alzheimer's disease and cancers</article-title><source>BMC Med Inform Decis Mak</source><volume>20</volume><year>2020</year><fpage>108</fpage><pub-id pub-id-type="pmid">32546157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12911-020-01140-y</pub-id><pub-id pub-id-type="pmcid">PMC7296686</pub-id></element-citation></ref><ref id="bib404"><label>404</label><element-citation publication-type="journal" id="sref404"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>You</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name></person-group><article-title>Towards artificial intelligence to multi-omics characterization of tumor heterogeneity in esophageal cancer</article-title><source>Semin Cancer Biol</source><volume>91</volume><year>2023</year><fpage>35</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">36868394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2023.02.009</pub-id></element-citation></ref><ref id="bib405"><label>405</label><element-citation publication-type="journal" id="sref405"><person-group person-group-type="author"><name name-style="western"><surname>Mohr</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Ortega-Santos</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Whisner</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Klein-Seetharaman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jasbi</surname><given-names>P.</given-names></name></person-group><article-title>Navigating challenges and opportunities in multi-omics integration for personalized healthcare</article-title><source>Biomedicines</source><volume>12</volume><year>2024</year><fpage>1496</fpage><pub-id pub-id-type="pmid">39062068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines12071496</pub-id><pub-id pub-id-type="pmcid">PMC11274472</pub-id></element-citation></ref><ref id="bib406"><label>406</label><element-citation publication-type="journal" id="sref406"><person-group person-group-type="author"><name name-style="western"><surname>Chua</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Pfeifer</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Sekera</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Hummon</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Desaire</surname><given-names>H.</given-names></name></person-group><article-title>Workflow for evaluating normalization tools for omics data using supervised and unsupervised machine learning</article-title><source>J Am Soc Mass Spectrom</source><volume>34</volume><year>2023</year><fpage>2775</fpage><lpage>2784</lpage><pub-id pub-id-type="pmid">37897440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jasms.3c00295</pub-id><pub-id pub-id-type="pmcid">PMC10919320</pub-id></element-citation></ref><ref id="bib407"><label>407</label><element-citation publication-type="journal" id="sref407"><person-group person-group-type="author"><name name-style="western"><surname>Tarazona</surname><given-names>S.</given-names></name><name name-style="western"><surname>Balzano-Nogueira</surname><given-names>L.</given-names></name><name name-style="western"><surname>G&#243;mez-Cabrero</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Imhof</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hankemeier</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Harmonization of quality metrics and power calculation in multi-omic studies</article-title><source>Nat Commun</source><volume>11</volume><year>2020</year><fpage>3092</fpage><pub-id pub-id-type="pmid">32555183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-16937-8</pub-id><pub-id pub-id-type="pmcid">PMC7303201</pub-id></element-citation></ref><ref id="bib408"><label>408</label><element-citation publication-type="journal" id="sref408"><person-group person-group-type="author"><name name-style="western"><surname>Marinescu</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Oxtoby</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Young</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Bron</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Toga</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>M.W.</given-names></name><etal/></person-group><article-title>The Alzheimer's disease prediction of longitudinal evolution (TADPOLE) challenge: results after 1 year follow-up</article-title><source>J Mach Learn Biomed Imaging</source><volume>1</volume><year>2021</year><fpage>19</fpage></element-citation></ref><ref id="bib409"><label>409</label><element-citation publication-type="journal" id="sref409"><person-group person-group-type="author"><name name-style="western"><surname>Kapoor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>A.</given-names></name></person-group><article-title>Leakage and the reproducibility crisis in machine-learning-based science</article-title><source>Patterns (N Y)</source><volume>4</volume><year>2023</year><object-id pub-id-type="publisher-id">100804</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.patter.2023.100804</pub-id><pub-id pub-id-type="pmcid">PMC10499856</pub-id><pub-id pub-id-type="pmid">37720327</pub-id></element-citation></ref><ref id="bib410"><label>410</label><element-citation publication-type="journal" id="sref410"><person-group person-group-type="author"><name name-style="western"><surname>Picard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scott-Boyer</surname><given-names>M.-P.</given-names></name><name name-style="western"><surname>Bodein</surname><given-names>A.</given-names></name><name name-style="western"><surname>P&#233;rin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Droit</surname><given-names>A.</given-names></name></person-group><article-title>Integration strategies of multi-omics data for machine learning analysis</article-title><source>Comput Struct Biotechnol J</source><volume>19</volume><year>2021</year><fpage>3735</fpage><lpage>3746</lpage><pub-id pub-id-type="pmid">34285775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.csbj.2021.06.030</pub-id><pub-id pub-id-type="pmcid">PMC8258788</pub-id></element-citation></ref><ref id="bib411"><label>411</label><element-citation publication-type="book" id="sref411"><person-group person-group-type="author"><name name-style="western"><surname>Aliferis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>G.</given-names></name></person-group><part-title>Overfitting, underfitting and general model overconfidence and under-performance pitfalls and best practices in machine learning and AI</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Simon</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Aliferis</surname><given-names>C.</given-names></name></person-group><source>Artificial intelligence and machine learning in health care and medical sciences: best practices and pitfalls</source><year>2024</year><publisher-name>Springer Nature</publisher-name><publisher-loc>Cham</publisher-loc><fpage>477</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">39836821</pub-id></element-citation></ref><ref id="bib412"><label>412</label><element-citation publication-type="journal" id="sref412"><person-group person-group-type="author"><name name-style="western"><surname>Ueda</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kakinuma</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kamagata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fushimi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Fairness of artificial intelligence in healthcare: review and recommendations</article-title><source>Jpn J Radiol</source><volume>42</volume><year>2024</year><fpage>3</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">37540463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11604-023-01474-3</pub-id><pub-id pub-id-type="pmcid">PMC10764412</pub-id></element-citation></ref><ref id="bib413"><label>413</label><element-citation publication-type="journal" id="sref413"><person-group person-group-type="author"><name name-style="western"><surname>Nohara</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Soejima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakashima</surname><given-names>N.</given-names></name></person-group><article-title>Explanation of machine learning models using shapley additive explanation and application for real data in hospital</article-title><source>Comput Methods Progr Biomed</source><volume>214</volume><year>2022</year><object-id pub-id-type="publisher-id">106584</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmpb.2021.106584</pub-id><pub-id pub-id-type="pmid">34942412</pub-id></element-citation></ref><ref id="bib414"><label>414</label><element-citation publication-type="book" id="sref414"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bahadori</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Kulas</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name></person-group><part-title>RETAIN: an interpretable predictive model for healthcare using reverse time attention mechanism</part-title><source>29th conference on Neural Information Processing Systems (NIPS 2016)</source><year>2016</year><publisher-name>Curran Associates Inc.</publisher-name><publisher-loc>Barcelona, Spain</publisher-loc></element-citation></ref><ref id="bib415"><label>415</label><element-citation publication-type="journal" id="sref415"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kaymak</surname><given-names>U.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name></person-group><article-title>Interpretable clinical prediction <italic toggle="yes">via</italic> attention-based neural network</article-title><source>BMC Med Inform Decis Mak</source><volume>20</volume><year>2020</year><fpage>131</fpage><pub-id pub-id-type="pmid">32646437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12911-020-1110-7</pub-id><pub-id pub-id-type="pmcid">PMC7346336</pub-id></element-citation></ref><ref id="bib416"><label>416</label><element-citation publication-type="journal" id="sref416"><person-group person-group-type="author"><name name-style="western"><surname>Rehman</surname><given-names>M.U.</given-names></name><name name-style="western"><surname>Sehar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dar</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arafah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Mitochondrial dysfunctions, oxidative stress and neuroinflammation as therapeutic targets for neurodegenerative diseases: an update on current advances and impediments</article-title><source>Neurosci Biobehav Rev</source><volume>144</volume><year>2023</year><object-id pub-id-type="publisher-id">104961</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2022.104961</pub-id><pub-id pub-id-type="pmid">36395982</pub-id></element-citation></ref><ref id="bib417"><label>417</label><element-citation publication-type="journal" id="sref417"><person-group person-group-type="author"><name name-style="western"><surname>Preische</surname><given-names>O.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Apel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuhle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaeser</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Barro</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease</article-title><source>Nat Med</source><volume>25</volume><year>2019</year><fpage>277</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">30664784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0304-3</pub-id><pub-id pub-id-type="pmcid">PMC6367005</pub-id></element-citation></ref><ref id="bib418"><label>418</label><element-citation publication-type="journal" id="sref418"><person-group person-group-type="author"><name name-style="western"><surname>Duara</surname><given-names>R.</given-names></name><name name-style="western"><surname>Barker</surname><given-names>W.</given-names></name></person-group><article-title>Heterogeneity in Alzheimer's disease diagnosis and progression rates: implications for therapeutic trials</article-title><source>Neurotherapeutics</source><volume>19</volume><year>2022</year><fpage>8</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">35084721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13311-022-01185-z</pub-id><pub-id pub-id-type="pmcid">PMC9130395</pub-id></element-citation></ref><ref id="bib419"><label>419</label><element-citation publication-type="journal" id="sref419"><person-group person-group-type="author"><name name-style="western"><surname>Merta&#351;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bo&#351;gelmez</surname><given-names>&#304;.&#304;.</given-names></name></person-group><article-title>The role of genetic, environmental, and dietary factors in Alzheimer's disease: a narrative review</article-title><source>Int J Mol Sci</source><volume>26</volume><year>2025</year><fpage>1222</fpage><pub-id pub-id-type="pmid">39940989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms26031222</pub-id><pub-id pub-id-type="pmcid">PMC11818526</pub-id></element-citation></ref><ref id="bib420"><label>420</label><element-citation publication-type="journal" id="sref420"><person-group person-group-type="author"><name name-style="western"><surname>Min</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wenger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Walling</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Blaum</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cigolle</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ganz</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>When comorbidity, aging, and complexity of primary care meet: development and validation of the Geriatric CompleXity of Care Index</article-title><source>J Am Geriatr Soc</source><volume>61</volume><year>2013</year><fpage>542</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">23581912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgs.12160</pub-id><pub-id pub-id-type="pmcid">PMC3698956</pub-id></element-citation></ref><ref id="bib421"><label>421</label><element-citation publication-type="journal" id="sref421"><person-group person-group-type="author"><name name-style="western"><surname>Shvetcov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Spathos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>A.-N.</given-names></name><name name-style="western"><surname>Wilkins</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>Blood-based transcriptomic biomarkers are predictive of neurodegeneration rather than Alzheimer's disease</article-title><source>Int J Mol Sci</source><volume>24</volume><year>2023</year><object-id pub-id-type="publisher-id">15011</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms241915011</pub-id><pub-id pub-id-type="pmcid">PMC10573468</pub-id><pub-id pub-id-type="pmid">37834458</pub-id></element-citation></ref><ref id="bib422"><label>422</label><element-citation publication-type="journal" id="sref422"><person-group person-group-type="author"><name name-style="western"><surname>Esteva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Robicquet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramsundar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kuleshov</surname><given-names>V.</given-names></name><name name-style="western"><surname>DePristo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A guide to deep learning in healthcare</article-title><source>Nat Med</source><volume>25</volume><year>2019</year><fpage>24</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">30617335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0316-z</pub-id></element-citation></ref><ref id="bib423"><label>423</label><element-citation publication-type="journal" id="sref423"><person-group person-group-type="author"><name name-style="western"><surname>Riley</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Snell</surname><given-names>K.I.</given-names></name><name name-style="western"><surname>Ensor</surname><given-names>J.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Harrell</surname><given-names>F.E.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Moons</surname><given-names>K.G.</given-names></name><etal/></person-group><article-title>Minimum sample size for developing a multivariable prediction model: PART II&#8212;binary and time-to-event outcomes</article-title><source>Stat Med</source><volume>38</volume><year>2019</year><fpage>1276</fpage><lpage>1296</lpage><pub-id pub-id-type="pmid">30357870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.7992</pub-id><pub-id pub-id-type="pmcid">PMC6519266</pub-id></element-citation></ref><ref id="bib424"><label>424</label><element-citation publication-type="journal" id="sref424"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>S.</given-names></name></person-group><article-title>Generative AI in healthcare: an implementation science informed translational path on application, integration and governance</article-title><source>Implement Sci</source><volume>19</volume><year>2024</year><fpage>27</fpage><pub-id pub-id-type="pmid">38491544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13012-024-01357-9</pub-id><pub-id pub-id-type="pmcid">PMC10941464</pub-id></element-citation></ref><ref id="bib425"><label>425</label><element-citation publication-type="journal" id="sref425"><person-group person-group-type="author"><name name-style="western"><surname>Van Dort</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Engelsma</surname><given-names>T.</given-names></name><name name-style="western"><surname>Medlock</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dusseljee-Peute</surname><given-names>L.</given-names></name></person-group><article-title>User-centered methods in explainable AI development for hospital clinical decision support: a scoping review</article-title><source>Stud Health Technol Inform</source><volume>326</volume><year>2025</year><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">40357594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/SHTI250228</pub-id></element-citation></ref><ref id="bib426"><label>426</label><element-citation publication-type="journal" id="sref426"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>van der Vegt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>P.</given-names></name><name name-style="western"><surname>McPhail</surname><given-names>S.</given-names></name><name name-style="western"><surname>Magrabi</surname><given-names>F.</given-names></name></person-group><article-title>Achieving large-scale clinician adoption of AI-enabled decision support</article-title><source>BMJ Health Care Inform</source><volume>31</volume><year>2024</year><object-id pub-id-type="publisher-id">e100971</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjhci-2023-100971</pub-id><pub-id pub-id-type="pmcid">PMC11141172</pub-id><pub-id pub-id-type="pmid">38816209</pub-id></element-citation></ref><ref id="bib427"><label>427</label><element-citation publication-type="journal" id="sref427"><person-group person-group-type="author"><name name-style="western"><surname>Lauritsen</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kristensen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lauritsen</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>J&#248;rgensen</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Explainable artificial intelligence model to predict acute critical illness from electronic health records</article-title><source>Nat Commun</source><volume>11</volume><year>2020</year><fpage>3852</fpage><pub-id pub-id-type="pmid">32737308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-17431-x</pub-id><pub-id pub-id-type="pmcid">PMC7395744</pub-id></element-citation></ref><ref id="bib428"><label>428</label><element-citation publication-type="journal" id="sref428"><person-group person-group-type="author"><name name-style="western"><surname>Gomez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Zayas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Unberath</surname><given-names>M.</given-names></name><name name-style="western"><surname>Canares</surname><given-names>T.</given-names></name></person-group><article-title>Explainable AI decision support improves accuracy during telehealth strep throat screening</article-title><source>Commun Med (Lond)</source><volume>4</volume><year>2024</year><fpage>149</fpage><pub-id pub-id-type="pmid">39048726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43856-024-00568-x</pub-id><pub-id pub-id-type="pmcid">PMC11269612</pub-id></element-citation></ref><ref id="bib429"><label>429</label><element-citation publication-type="journal" id="sref429"><person-group person-group-type="author"><name name-style="western"><surname>Amann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vetter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Blomberg</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Coffee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gerke</surname><given-names>S.</given-names></name><etal/></person-group><article-title>To explain or not to explain?&#8212;artificial intelligence explainability in clinical decision support systems</article-title><source>PLoS Digit Health</source><volume>1</volume><year>2022</year><object-id pub-id-type="publisher-id">e0000016</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pdig.0000016</pub-id><pub-id pub-id-type="pmcid">PMC9931364</pub-id><pub-id pub-id-type="pmid">36812545</pub-id></element-citation></ref><ref id="bib430"><label>430</label><element-citation publication-type="journal" id="sref430"><person-group person-group-type="author"><name name-style="western"><surname>Aziz</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Manzoor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mazhar Qureshi</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Rashwan</surname><given-names>W.</given-names></name></person-group><article-title>Explainable AI in healthcare: systematic review of clinical decision support systems</article-title><source>medRxiv</source><year>2024</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2024.08.10.24311735</pub-id></element-citation></ref><ref id="bib431"><label>431</label><element-citation publication-type="journal" id="sref431"><person-group person-group-type="author"><name name-style="western"><surname>McKee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>O.J.</given-names></name></person-group><article-title>The challenges of regulating artificial intelligence in healthcare comment on &#8220;clinical decision support and new regulatory frameworks for medical devices: are we ready for it?&#8212;a viewpoint paper&#8221;</article-title><source>Int J Health Policy Manag</source><volume>12</volume><year>2023</year><fpage>7261</fpage><pub-id pub-id-type="pmid">36243948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.34172/ijhpm.2022.7261</pub-id><pub-id pub-id-type="pmcid">PMC10125205</pub-id></element-citation></ref><ref id="bib432"><label>432</label><element-citation publication-type="journal" id="sref432"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cruz Rivera</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Calvert</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Denniston</surname><given-names>A.K.</given-names></name></person-group><article-title>Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension</article-title><source>Nat Med</source><volume>26</volume><year>2020</year><fpage>1364</fpage><lpage>1374</lpage><pub-id pub-id-type="pmid">32908283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-1034-x</pub-id><pub-id pub-id-type="pmcid">PMC7598943</pub-id></element-citation></ref><ref id="bib433"><label>433</label><element-citation publication-type="journal" id="sref433"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>Y.-M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.-S.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Defining medical AI competencies for medical school graduates: outcomes of a Delphi survey and medical student/educator questionnaire of South Korean medical schools</article-title><source>Acad Med</source><volume>99</volume><year>2024</year><fpage>524</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">38207056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ACM.0000000000005618</pub-id></element-citation></ref><ref id="bib434"><label>434</label><element-citation publication-type="journal" id="sref434"><person-group person-group-type="author"><name name-style="western"><surname>Labkoff</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oladimeji</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kannry</surname><given-names>J.</given-names></name><name name-style="western"><surname>Solomonides</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leftwich</surname><given-names>R.</given-names></name><name name-style="western"><surname>Koski</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Toward a responsible future: recommendations for AI-enabled clinical decision support</article-title><source>J Am Med Inform Assoc</source><volume>31</volume><year>2024</year><fpage>2730</fpage><lpage>2739</lpage><pub-id pub-id-type="pmid">39325508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jamia/ocae209</pub-id><pub-id pub-id-type="pmcid">PMC11491642</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgements</title><p id="p0545">We would like to thank AJE (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.aje.cn" id="intref0010">www.aje.cn</ext-link>) for English language editing. This work was supported by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>Natural Science Foundation of China</institution></institution-wrap></funding-source> (Nos. 81903829, 82304994), the Open Project from the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100012829</institution-id><institution>State Key Laboratory of Traditional Chinese Medicine Syndrome</institution></institution-wrap></funding-source> (No. SKLKY2024B0006, China), the Sichuan <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100012551</institution-id><institution>Science and Technology Program</institution></institution-wrap></funding-source> (No. 2024YFHZ0361, China), the Science and Technology Strategic Cooperation Programs of Luzhou Municipal People's Government and <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100014895</institution-id><institution>Southwest Medical University</institution></institution-wrap></funding-source> (No. 2024LZXNYDJ026, China), and Chongqing Natural Science Foundation (CSTB2022NSGQ-MSX1560, China).</p></ack><fn-group><fn id="d36e3665"><p id="ntpara0010">This article is part of a special issue entitled: AI, computational and systems biology-guided translational research in Alzheimer's disease published in Acta Pharmaceutica Sinica B.</p></fn><fn id="d36e3668"><p id="ntpara0015">Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin Med J (Engl)</journal-id><journal-id journal-id-type="iso-abbrev">Chin Med J (Engl)</journal-id><journal-id journal-id-type="pmc-domain-id">2337</journal-id><journal-id journal-id-type="pmc-domain">chinesemj</journal-id><journal-id journal-id-type="publisher-id">CM9</journal-id><journal-title-group><journal-title>Chinese Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">0366-6999</issn><issn pub-type="epub">2542-5641</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12487924</article-id><article-id pub-id-type="pmcid-ver">PMC12487924.1</article-id><article-id pub-id-type="pmcaid">12487924</article-id><article-id pub-id-type="pmcaiid">12487924</article-id><article-id pub-id-type="pmid">40851365</article-id><article-id pub-id-type="doi">10.1097/CM9.0000000000003737</article-id><article-id pub-id-type="publisher-id">CMJ-2025-106</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Z-DNA-binding protein 1-mediated programmed cell death: Mechanisms and therapeutic implications</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="Y">Yuwei</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fna1" ref-type="fn"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="L">Lian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fna1" ref-type="fn"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="Y">Yanghui</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="X">Xiaoxue</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dai</surname><given-names initials="Y">Yingying</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>He</surname><given-names initials="G">Gu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Jiang</surname><given-names initials="X">Xian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor2" ref-type="corresp"/></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Guo</surname><given-names initials="L">Lishao</given-names></name></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label>Department of Dermatology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China</aff><aff id="aff2"><label><sup>2</sup></label>Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Gu He, Department of Dermatology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China E-Mail: hegu@scu.edu.cn;</corresp><corresp id="cor2">Xian Jiang, Department of Dermatology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China E-Mail: jiangxian@scu.edu.cn</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="ppub"><day>05</day><month>10</month><year>2025</year></pub-date><volume>138</volume><issue>19</issue><issue-id pub-id-type="pmc-issue-id">498114</issue-id><fpage>2421</fpage><lpage>2451</lpage><history><date date-type="received"><day>08</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-released-under-embargo"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-05 00:26:29.067"><day>05</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cm9-138-2421.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cm9-138-2421.pdf"/><abstract><title>Abstract</title><p>Programmed cell death (PCD) is characterized as a cell death pathway governed by specific gene-encoding requirements, plays crucial roles in the homeostasis and innate immunity of organisms, and serves as both a pathogenic mechanism and a therapeutic target for a variety of human diseases. Z-DNA-binding protein 1 (ZBP1) functions as a cytosolic nucleic acid sensor, utilizing its unique Z&#945; domains to detect endogenous or exogenous nucleic acids and its receptor-interacting protein homotypic interaction motif (RHIM) domains to sense or bind specific signaling molecules, thereby exerting regulatory effects on various forms of PCD. ZBP1 is involved in apoptosis, necroptosis, pyroptosis, and PANoptosis and interacts with molecules, such as receptor-interacting protein kinase 3 (RIPK3), to influence cell fate under various pathological conditions. It plays a crucial role in regulating PCD during infections, inflammatory and neurological diseases, cancers, and other conditions, affecting disease onset and progression. Targeting ZBP1-associated PCD may represent a viable therapeutic strategy for related pathological conditions. This review comprehensively summarizes the regulatory functions of ZBP1 in PCD and its interactions with several closely associated signaling molecules and delineates the diseases linked to ZBP1-mediated PCD, along with the potential therapeutic implications of ZBP1 in these contexts. Ongoing research on ZBP1 is being refined across various disease models, and these advancements may provide novel insights for studies focusing on PCD, potentially leading to new therapeutic options for related diseases.</p></abstract><kwd-group><title>Keywords:</title><kwd>Programmed cell death</kwd><kwd>Z-DNA-binding protein 1</kwd><kwd>PANoptosis</kwd><kwd>Receptor-interacting protein kinase 3 (RIPK3)</kwd><kwd>Pyroptosis</kwd><kwd>Apoptosis</kwd><kwd>Necroptosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Cell death plays a crucial role in organismal development, homeostasis, and the host response to infection, which differs from unregulated cell death resulting from physical, chemical, or biological damage. To date, multiple cell death pathways, each characterized by distinct genetically encoded mechanisms, have been identified and are collectively termed programmed cell death (PCD).<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> The identified PCD pathways mainly include apoptosis, necroptosis, pyroptosis, PANoptosis, autophagy, ferroptosis, and NETosis. Apoptosis is characterized by cellular shrinkage, chromatin condensation, apoptosome formation, and subsequent phagocytosis<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup> and is induced by the activation of cysteine protease caspase family members, particularly caspase-8 (CASP8), which in turn activates executioner caspases, such as CASP3 and CASP7.<sup>[<xref rid="R3" ref-type="bibr">3</xref><xref rid="R4" ref-type="bibr">4</xref><xref rid="R5" ref-type="bibr">5</xref>]</sup> Necroptosis is a type of inflammatory cell death characterized by the detection of pathogens and the facilitation of tissue repair, as evidenced by plasma membrane rupture and the release of damage-associated molecular patterns (DAMPs), which subsequently elicit an inflammatory response mediated by the host immune system.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> Pyroptosis is a CASP1-dependent inflammatory cell death process.<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> Recent studies have revealed a new definition of PCD, termed PANoptosis, which encompasses the hallmark features of apoptosis, pyroptosis, and necroptosis.<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> This integrated form of cell death is regulated by a multiprotein complex known as the PANoptosome.<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]</sup> Autophagy is a process in eukaryotic cells that involves the regulation of autophagy-related genes (ATGs), and cells degrade their cytoplasmic proteins and damaged organelles in lysosomes. Autophagy is divided into microautophagy, macroautophagy, and chaperone-mediated autophagy.<sup>[<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref>]</sup> In addition, when glutathione peroxidase 4 (GPX4) activity is impaired, divalent ions oxidize lipids to produce reactive oxygen species (ROS), triggering ferroptosis. NETosis is a specialized mechanism of cell death primarily mediated by neutrophils, which can release structures known as NETs (neutrophil extracellular traps). NETosis can be categorized into classical NETosis and autophagy-mediated NETosis. Classical NETosis occurs through the nicotinamide adenine dinucleotide phosphate oxidase pathway, resulting in the production of ROS that promote the formation of NETs, thereby activating the downstream nuclear factor kappa-B (NF-&#954;B) pathway and mediating inflammatory cell death.<sup>[<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref>]</sup> During the growth and development of living organisms, as well as the occurrence and progression of diseases, various types of PCD function individually or in combination to precisely regulate physiological and pathological processes in the body.</p><p>Z-DNA-binding protein 1 (ZBP1) is a cytosolic nucleic acid sensor and a pattern recognition receptor (PRR) induced by interferons (IFNs), playing a vital role in antiviral immune responses. Initially identified as an IFN-induced tumor-associated protein involved in host responses to tumors, ZBP1 has subsequently been found to be widely involved in the process of PCD and related diseases. ZBP1 primarily senses and binds viral nucleic acids through its nucleic acid-binding domain, participating in innate immune responses, and the RIP homotypic interaction motif (RHIM) domain of ZBP1 interacts with homologous proteins, regulating cell death and inflammatory responses.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> For example, during pyroptosis, the inflammasomes composed of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) and CASP1 are regulated by ZBP1 upstream.<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> Moreover, ZBP1 can bind and phosphorylate receptor-interacting protein kinase 3 (RIPK3), leading to the phosphorylation of mixed lineage kinase domain-like (MLKL) to form MLKL pores and induce necroptosis.<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> In addition to the independent PCD pathways, studies on ZBP1 have also found its regulatory role in the crosstalk of different PCD pathways and its involvement in the regulation of various key molecules in PCD.</p><p>The occurrence and development of various diseases are closely related to PCD. As a significant regulatory molecule in PCD, ZBP1 has been identified as having relevance and therapeutic potential in cancers, autoimmune diseases, inflammatory diseases, neurological disorders, and a range of other conditions. Some literatures have reviewed the role of ZBP1 in specific types of PCD and elucidated its regulatory mechanisms in diseases.<sup>[<xref rid="R18" ref-type="bibr">18</xref><xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref>]</sup> However, there is currently no comprehensive review system that describes the regulatory mechanisms of ZBP1 across all types of PCD, its associated diseases, and potential therapeutic value, as well as its interactions with relevant signaling molecules. Through searching public databases, such as PubMed, Embase, and Web of Science, we collected relevant research on ZBP1 from the time the concept was proposed in 1999 up until 2025. In this review, we comprehensively describe the current research advancements on ZBP1, including the structure and function of ZBP1, its regulatory roles and mechanisms in PCD, the molecules related to ZBP1&#8217;s regulatory network, the roles it plays in various diseases and potential therapeutic strategies, as well as the future potential for using artificial intelligence in the design of small molecule targeted drugs related to ZBP1.</p></sec><sec><title>Structure and Function of ZBP1</title><sec><title>Discovery and structural composition of ZBP1</title><p><italic toggle="yes">ZBP1</italic>, namely Z-DNA-binding protein 1, was originally called <italic toggle="yes">DLM-1</italic>, the name of the gene it was originally identified.<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> ZBP1 was initially identified and found to be highly expressed in mouse tumor stromal cells.<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> Studies have also shown that the expression of ZBP1 in mouse macrophages is significantly upregulated after treatment with IFN-&#947; or lipopolysaccharides (LPS), suggesting its potential involvement in the anti-tumor immune response. Additionally, ZBP1 expression is enhanced following IFN1 signaling, further indicating its crucial role in the innate immune response. In 2007, Takaoka <italic toggle="yes">et al</italic><sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup> proposed the alternative name DNA-dependent activator of IFN-regulatory factors (DAI) to refer to ZBP1, highlighting its primary biological function in mediating the activation of the innate immune response. The role of ZBP1 in DNA-associated antibacterial immunity makes it an important molecule for studying the signaling mechanisms of autoimmune diseases. This discovery provides the scientific community with a new perspective, revealing ZBP1&#8217;s dual role in regulating anti-infection immune responses and its potential contribution to autoimmune responses under pathological conditions. As research on ZBP1 deepens, accumulating evidence suggests that its roles in cellular immune responses, inflammation regulation, and tumor immunity are indispensable, offering critical theoretical foundations and research directions for understanding the complex mechanisms of innate immunity and the development of diseases. Thus, ZBP1 is not only a hotspot for academic research but could also emerge as a significant therapeutic target for related diseases in the future.</p><p>Structurally, ZBP1 comprises two N-terminal Z-nucleic acid binding domains (Z&#945;1 and Z&#945;2), two RIP homotypic interaction motifs (RHIM1 and RHIM2), and a C-terminal signaling domain (SD) that is crucial for signal transduction.<sup>[<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R23" ref-type="bibr">23</xref>]</sup> Functionally, early studies demonstrated that ZBP1 serves as a B-DNA sensor, initiating IFN1 responses and playing a pivotal role in the DNA-mediated activation of the innate immune system.<sup>[<xref rid="R23" ref-type="bibr">23</xref><xref rid="R24" ref-type="bibr">24</xref><xref rid="R25" ref-type="bibr">25</xref>]</sup> Subsequent research revealed that ZBP1 is significantly induced by IFN-&#947; and lipopolysaccharide (LPS), as well as by other types of IFNs, further enhancing the DNA-mediated expression of <italic toggle="yes">IFN1</italic> and other genes associated with innate immunity.<sup>[<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref>]</sup> As an innate sensor for various pathogenic infections, ZBP1 plays a critical role in regulating host defense and inflammatory diseases by coordinating cell death and inflammation.<sup>[<xref rid="R28" ref-type="bibr">28</xref><xref rid="R29" ref-type="bibr">29</xref><xref rid="R30" ref-type="bibr">30</xref><xref rid="R31" ref-type="bibr">31</xref><xref rid="R32" ref-type="bibr">32</xref><xref rid="R33" ref-type="bibr">33</xref>]</sup> For instance, during influenza A virus (IAV) infection, ZBP1 activates cell death and inflammatory responses through the RIPK1&#8211;RIPK3&#8211;CASP8 signaling axis. It also regulates the activation of the NLRP3 inflammasome, inducing apoptosis, necroptosis, and pyroptosis in IAV-infected cells.<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup> Notably, ZBP1 deficiency results in diminished inflammatory responses, reduced epithelial damage, and increased survival of mice following IAV infection.<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> The activation of ZBP1 orchestrates a variety of inflammatory and PCD pathways, including pyroptosis, necroptosis, apoptosis, and PANoptosis. These diverse PCD pathways collectively influence cell fate and play significant roles in disease progression, highlighting the importance of ZBP1 in the context of infectious diseases and the immune response.</p></sec><sec><title>Normal expression of ZBP1 and physiological/pathological activation</title><p>DNA can fold into the nonclassical left-handed Z-DNA conformation alongside the right-handed B-DNA conformation. Z-DNA, identified <italic toggle="yes">in vitro</italic> for the first time through X-ray crystallography 9, is present in nuclear and mitochondrial DNA (mtDNA) and has significant biological implications, characterized by alternating syn-anti conformations of its base pairs.<sup>[<xref rid="R34" ref-type="bibr">34</xref>]</sup> Since the discovery of proteins, such as ZBP1, which contain the Z&#945; domain/Z-DNA binding domain (ZBD) that specifically binds to Z-DNA/Z-RNA (Z-NA) conformations, the biological functions of Z-DNA have been widely studied. Under physiological conditions, the formation of Z-DNA is associated with various normal physiological processes; in mitochondria (mt), genomic instability promotes Z-DNA formation and its release into the cytoplasm. In the cell nucleus, Z-DNA is related to various cellular processes, including transcriptional regulation, and may influence gene expression.<sup>[<xref rid="R35" ref-type="bibr">35</xref>]</sup> In pathological states, Z-DNA is often found in individuals with repeat expansion diseases, such as myotonic dystrophy type 2 (DM2). In the <italic toggle="yes">DM2</italic> gene, Z-DNA sequences may play a protective role by reducing the potential for slipped-strand DNA formation in the (CCTG)(<italic toggle="yes">n</italic>) &#215; (CAGG)(<italic toggle="yes">n</italic>) repeat sequences.<sup>[<xref rid="R36" ref-type="bibr">36</xref>]</sup> Furthermore, the generation of Z-DNA has also been observed in the remodeling of cognitive functions, as alterations in the DNA conformation in the hippocampal region of Alzheimer&#8217;s disease (AD) brains revealed that severely affected AD DNA exhibits the typical left-handed Z-DNA conformation, whereas normal and young to aged brain DNA displays the B-DNA conformation.<sup>[<xref rid="R37" ref-type="bibr">37</xref>]</sup> Z-DNA also plays an important role in infections; for example, the exogenous DNA (eDNA) of bacterial biofilms comprises a rare <italic toggle="yes">Z</italic>-type structure as a component of the biofilm matrix, which helps bacteria evade the effects of stressors.<sup>[<xref rid="R38" ref-type="bibr">38</xref>]</sup></p><p>mtDNA in the cytoplasm and extracellular compartments exhibits partial formation of Z-DNA during transcription and replication mechanisms. The induced immune response is primarily mediated by the recognition of the Z nucleic acid sensor ZBP1.<sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup> The <italic toggle="yes">ZBP1</italic> gene is 1969 bp in length, with an open reading frame of 411 amino acids, encoding a protein with an approximate molecular weight of 44,000.<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> Under baseline physiological conditions, ZBP1 expression shows species and tissue specificity. In humans, ZBP1 exhibits higher expression levels in the small intestine and various lymphoid tissues, including lymph nodes, leukocytes, tonsils, bone marrow, and spleen, while showing relatively lower levels in the thymus, lungs, liver, and pancreas. In contrast, in mice, ZBP1 is primarily expressed in the lungs, spleen, and liver, with only minimal levels detected in the heart, kidneys, and testes.<sup>[<xref rid="R40" ref-type="bibr">40</xref>]</sup> At the subcellular level, under physiological conditions, full-length ZBP1 is distributed as discrete punctate structures in the cytoplasm, whereas the variant lacking the first Z&#945;1 structural domain (DeltaZ&#945;) shows markedly different intracellular localization. DeltaZ&#945; aggregates in large cytoplasmic granules that dynamically interact with stress granules,<sup>[<xref rid="R41" ref-type="bibr">41</xref>]</sup> a change that is not observed in variants lacking Z&#945;2, indicating that Z&#945;1 determines the subcellular localization of ZBP1.</p><p>In a state of stress (such as external trauma or inflammatory conditions, such as infections), ZBP1 is activated and may exhibit significantly upregulated expression. For example, in a heat stroke model, the ZBP1 promoter region was analyzed using bioinformatics tools, such as JASPAR, which identified predicted binding sites for heat shock transcription factor 1 (HSF1). The deletion of the presumed HSF1 binding sequence following heat stress resulted in the loss of ZBP1 transcriptional activation. Furthermore, the activation of ZBP1 promotes cell death caused by heatstroke through the activation of RIPK3-dependent necroptosis, similar to IFN1-induced activation.<sup>[<xref rid="R42" ref-type="bibr">42</xref>]</sup> Double-stranded RNA derived from retrotransposons may act as ligands for the Z&#945; domain of ZBP1, triggering its activation. Adenosine deaminase acting on RNA 1 (ADAR1) plays a critical role in preventing the abnormal activation of ZBP1 and the resulting harmful IFN response by inhibiting the formation of endogenous Z-RNA. ADAR1-dependent RNA editing primarily occurs within short interspersed nuclear elements (SINEs), and damage to these elements can lead to the accumulation of Z-RNA ligands, thereby activating ZBP1.<sup>[<xref rid="R43" ref-type="bibr">43</xref>]</sup> In the case of doxorubicin-induced cardiotoxicity, the accumulation of mitochondrial Z-DNA induces ZBP1 activation. ZBP1 stabilizes Z-mtDNA and forms complexes with cGAS, RIPK1, and RIPK3, maintaining the phosphorylation of signal transducer and activator of transcription 1 (STAT1) and the IFN1 signaling pathway.<sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup> Upon activation, ZBP1 activates NF-&#954;B, promoting the expression of inflammatory cytokines. During this process, endogenous RIPK1 binds to ZBP1 and colocalizes within characteristic cytoplasmic granules. The subsequent interaction through the RHIM domain facilitates the activation of NF-&#954;B. RNA interference techniques indicate that inhibiting the expression of RIPK1 reduces the level of NF-&#954;B activation, thereby decreasing the levels of IFNB1 induced by immune-stimulating DNA. Additionally, ZBP1 interacts with RIPK3, and this interaction further enhances ZBP1-mediated NF-&#954;B activation, suggesting that RIPK3 plays an important role in regulating this RHIM-dependent pathway.<sup>[<xref rid="R44" ref-type="bibr">44</xref>]</sup></p><p>As an innate immune sensor of viral infections, ZBP1 can bind to the viral ribonucleoprotein (RNP) complex and viral genomic RNA during the viral infection process.<sup>[<xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R45" ref-type="bibr">45</xref>]</sup> However, relying solely on viral genomic RNA does not replicate the cell death observed in fibroblasts stimulated with IFN&#946;, suggesting that ZBP1 may not be able to distinguish viral RNA on its own.<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup> It remains unclear whether endogenous Z-RNA is induced during viral infection and whether it influences ZBP1-mediated cell death. Previous studies have proposed that RNA expressed from endogenous retroviral-like elements may be sensed by ZBP1 in a Z-RNA conformation, thereby inducing cell death in the absence of RIPK1.<sup>[<xref rid="R46" ref-type="bibr">46</xref>]</sup> Further research is needed to clarify the distinct roles of viral RNA and endogenous RNA in the activation of ZBP1 during viral infections.</p><p>In summary, as a Z nucleic acid sensor present in the cytoplasm, ZBP1 exists under normal cellular physiological conditions and carries out its physiological functions. It is activated under stress conditions and mediates cell death. The functions of ZBP1 are mainly attributed to its several unique structural domains, and we will next elaborate on the functionalities of its Z&#945; domains and RHIM domains.</p></sec><sec><title>Z&#945; domains and RHIM domains</title><p>ZBP1 relies mainly on its Z&#945; domains to recognize ligands for the function of innate immunoreceptors. ZBP1 belongs to the Z-DNA binding Z&#945; protein family, and its N-terminus contains two Z&#945; domains (Z&#945;1 and Z&#945;2). These domains include conserved key Z-DNA binding residues, which confer specific nucleic acid recognition capabilities to ZBP1. The structure of the Z&#945; domains exhibits a winged-helix-turn-helix formation, further enhancing their binding ability to Z-DNA. Specifically, the Z&#945; domain consists of three alpha helices and three anti-parallel beta strands, which align to form a typical &#945;/&#946; structure.<sup>[<xref rid="R47" ref-type="bibr">47</xref>]</sup> In the Z&#945; domain of ZBP1, the protein-Z-DNA interface is composed of a conserved Asn-Tyr-Trp triad, which is crucial for its binding function. Experimental studies have shown that mutations in the Asn-122 and Tyr-126 residues of the Z&#945;2 domain significantly disrupt Z-DNA binding and diminish its downstream functional activities.<sup>[<xref rid="R45" ref-type="bibr">45</xref>]</sup> Nucleic acids are effective triggers of innate immunity.<sup>[<xref rid="R48" ref-type="bibr">48</xref>]</sup> Double-stranded DNA and RNA adopt different helical conformations, including the unusual Z conformation. The Z&#945; domain of ZBP1 exhibits a high affinity for double-stranded nucleic acids in the Z conformation, and the Z&#945;1 and Z&#945;2 domains, located at the N-terminal end of ZBP1, bind nucleic acids in the Z conformation.<sup>[<xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R48" ref-type="bibr">48</xref>]</sup> Z-binding domains (ZBDs) recognize Z-DNA/RNA, and mutations in key amino acids constituting ZBDs prevent necrotic apoptosis after infection with mouse cytomegalovirus.<sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup> In particular, Z&#945;2 is required for ZBP1 to sense virus and trigger PCD, and deletion of Z&#945;2 eliminates IAV-induced PANoptosis and NLRP3 inflammasome activation.<sup>[<xref rid="R49" ref-type="bibr">49</xref>]</sup></p><p>In addition, the absence of Z&#945;2 leads to a lack of ZBP1&#8217;s role in driving cell death and inflammation, and this absence allows RIPK1 (<italic toggle="yes">Ripk1</italic><sup>mRHIM/mRHIM</sup>) mutant mice, which have mutations in the RHIM domain, to escape perinatal mortality.<sup>[<xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R51" ref-type="bibr">51</xref>]</sup></p><p>The above results suggest that Z-RNAs may constitute a molecular pattern that induces inflammatory cell death through the sensing of ZBDs by ZBP1. Furthermore, ZBP1 induction of endogenous Z-DNA triggered RIPK3-dependent necroptosis and inflammation, which may underlie inflammatory diseases. Z&#945;-dependent induction of endogenous ligands induced skin inflammation in epidermal-specific RIPK1-deficient mice (RIPK1[E-KO]), as well as colitis in intestinal epithelial-specific Fas-associated death domain (FADD)-deficient mice (FADD[IEC-KO]).<sup>[<xref rid="R48" ref-type="bibr">48</xref>]</sup> The Z&#945; domains are also the target for ZBP1 inhibitors. For example, vaccinia virus (VACV) protein E3 competes with Z-RNA through the Z&#945;, thereby preventing ZBP1/RIPK3/MLKL-dependent necroptosis.<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup> ADAR1 interacts with the Z&#945;2 of ZBP1 to inhibit the interaction between ZBP1 and RIPK3, thereby restricting PANoptosis activated by the combination of IFNs and nuclear export inhibitors (NEIs). This inhibitory effect was significant in the ADAR1-P150 isoform, which contains the Z&#945; domain, but could not be observed in the ADAR1-P110 isoform, which lacks the Z&#945; domain.<sup>[<xref rid="R43" ref-type="bibr">43</xref>,<xref rid="R51" ref-type="bibr">51</xref>,<xref rid="R52" ref-type="bibr">52</xref>]</sup></p><p>ZBP1 mediates PCD through its RHIM structures (RHIM1, RHIM2). Four proteins, RIPK1, RIPK3, ZBP1, and TIR domain-containing adaptor-inducing INF &#946; (TRIF), containing RHIM, are key components of inflammatory signaling and PCD. Through the RHIM structural domains, ZBP1 can bind to them and mediate downstream.<sup>[<xref rid="R53" ref-type="bibr">53</xref>,<xref rid="R54" ref-type="bibr">54</xref>]</sup> RHIM is a highly conserved sequence, and its core tetrapeptide (I/V-Q-I/V/L/C-G) is crucial for stacking &#946;-sheet structures to form fibrous amyloid protein signaling complexes, ultimately leading to cell death and inflammatory signaling. Z-RNA sensing activates ZBP1 to enable its RHIM-mediated effector functions.<sup>[<xref rid="R55" ref-type="bibr">55</xref>,<xref rid="R56" ref-type="bibr">56</xref>]</sup> For example, ZBP1 can promote the autophosphorylation of RIPK3, inducing necroptosis, while RIPK1 can compete with RIPK3 for binding to ZBP1, thereby inhibiting necroptosis.<sup>[<xref rid="R57" ref-type="bibr">57</xref>]</sup> Activation of RHIMs is mediated by their oligomerization, and autophagy is essential for the turnover of all RHIM-domain proteins. Macrophages lacking the autophagy gene <italic toggle="yes">Atg16l</italic> accumulate highly insoluble RIPK1, RIPK3, TRIF, and ZBP1. Mutual recognition of RHIM affects cell death outcome, and ZBP1 drives necroptosis in the absence of RIPK1-RHIM, but ZBP1 inhibits necroptosis when multiple RHIM-domain-containing proteins accumulate in this process.<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup></p><p>The RHIM domains can also be targets for ZBP1 inhibition. The mouse cytomegalovirus protein M45 contains RHIM at the N-terminal 90 residues, which protects infected cells from necroptosis by interacting with the endogenous RHIM domains of RIPK1, RIPK3, and ZBP1. Mutation of residues in M45 RHIM attenuates homologous and heterologous amyloid assembly of M45, suggesting that the amyloidogenic properties of M45 RHIM underlie its biological activity.<sup>[<xref rid="R58" ref-type="bibr">58</xref>,<xref rid="R59" ref-type="bibr">59</xref>]</sup> Kolbrink <italic toggle="yes">et al</italic><sup>[<xref rid="R60" ref-type="bibr">60</xref>]</sup> developed a synthetic peptide containing only the RHIM domain of M45. The transcription-activating protein transduction domain of human immunodeficiency virus 1 was fused to the N-terminus of the peptide and introduced into target cells. The fused peptide caused necrosis by disrupting biofilms in all tested cancer cell lines and primary cells.<sup>[<xref rid="R58" ref-type="bibr">58</xref>]</sup> When ZBP1 encodes only the Z&#945; domain and not the RHIM domain, as in the case of the short isoform of mouse ZBP1 (ZBP1-S), it can negatively regulate the activation and signaling of normal ZBP1 by competing for Z-NA binding.<sup>[<xref rid="R59" ref-type="bibr">59</xref>]</sup></p><p>The structure of ZBP1 and the functions of its Z&#945; domain and RHIM domain are shown in Figure <xref rid="F1" ref-type="fig">1</xref>.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>Structure of ZBP1 and its interaction with the Z&#945; domains and RHIM domains. ZBP1 relies on its Z&#945; structural domains to recognize ligands, thereby fulfilling the role of an innate immune receptor. The Z&#945;1 and Z&#945;2 domains located at the N-terminus of ZBP1 are able to identify viral or ligand nucleic acids that adopt a Z conformation. The RHIM domain interacts with proteins that possess the same domain, which can either activate or inhibit ZBP1 functions, participating in PCD. ADAR1: Adenosine deaminase acting on RNA 1; CMVs: Cytomegaloviruses; DD: Death domain; HSV: Herpes simplex virus; IAV: Influenza A virus; ID: Intermediate domain; KD: Kinase domain; M45: Mouse cytomegalovirus protein M45; MRV: Mammalian orthoreovirus; RHIM: RIP homotypic interaction motif; RIPK: receptor-interacting protein kinase; RNR-LIKE: Ribonucleotide reductase-like domain; SD: Signal domain; TIR: Toll/interleukin receptor domain; TRIF: TIR domain-containing adaptor-inducing interferon-beta; VACV: Vaccinia virus; ZBP1: Z-DNA-binding protein 1.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cm9-138-2421-g001.jpg"/></fig></sec><sec><title>ZBP1 exercises functions in multiple PCD pathways</title><p>PRRs are a class of key innate immune receptors that can identify pathogen-associated molecular patterns (PAMPs), thereby initiating a series of specific signaling pathways closely related to inflammatory responses and cell fate decisions. This process is a crucial factor in maintaining homeostasis within living organisms. PRRs play a central role in regulating PCD and pro-inflammatory signaling to ensure that organisms can effectively respond to pathogen invasion while maintaining internal environmental balance. In this context, endogenous or pathogen-derived nucleic acids (including DNA and RNA) are regarded as specific PAMPs, recognized by specialized nucleic acid-sensing PRRs. ZBP1, as an important mammalian protein, not only possesses the ability to recognize the Z-alpha domain of Z-NA but is also the only protein, aside from adenosine deaminase ADAR1, with this capability. Once activated by Z-NA, ZBP1 triggers various forms of PCD and associated inflammatory responses by activating the NF-&#954;B signaling pathway. The interplay of these biological processes is essential for responding to foreign pathogens and regulating immune responses, thereby ensuring that organisms can maintain homeostasis in a changing environment. Additionally, ZBP1 contains a RHIM, which promotes homotypic interactions with proteins related to cell death, activating or transmitting PCD signals, and regulating the process of cell death. In this section, we will discuss in detail the role of ZBP1 in various forms of PCD, summarizing research progress on ZBP1 in apoptosis, necroptosis, pyroptosis, PANoptosis, ferroptosis, autophagy, and NETosis.</p><sec><title>Necroptosis</title><p>Necroptosis, as a form of regulated necrosis driven by receptor-interacting protein kinases (RIPKs), can lead to membrane permeabilization and necrotic cell death through signaling pathways and hierarchical responses, thereby regulating the innate immune response and host defense mechanisms. Stimuli that can induce necroptosis include death receptor,<sup>[<xref rid="R60" ref-type="bibr">60</xref>]</sup> which is a subset of the tumor necrosis factor receptor (TNFR) family, Toll-like receptors (TLRs), especially TLR3 and TLR4,<sup>[<xref rid="R61" ref-type="bibr">61</xref>]</sup> IFNs,<sup>[<xref rid="R62" ref-type="bibr">62</xref>]</sup> and the intracellular viral sensor ZBP1.<sup>[<xref rid="R63" ref-type="bibr">63</xref>,<xref rid="R64" ref-type="bibr">64</xref>]</sup> The classical necroptotic pathway involves the TNF&#945;-induced phosphorylation of RIPK3, which activates the phosphorylation of MLKL, leading to membrane rupture and cell death. In the classical pathway, ZBP1, as an upstream molecule in necroptosis, has been shown to recognize endogenous or exogenous Z-DNA/Z-RNA, interacting and binding with RIPK3 to mediate the regulation of necroptosis. For instance, in oxalate-induced acute kidney injury, ZBP1 recognizes mitochondrial Z-DNA and initiates the necroptotic pathway. In mice, knockout of ZBP1, RIPK3, or MLKL results in reduced inflammation.<sup>[<xref rid="R65" ref-type="bibr">65</xref>]</sup> Compared to the classical pathway, ZBP1 has been found to recognize Z-DNA or Z-RNA in humans infected with viruses, working alongside RIPK1 to regulate necroptotic cell death. ZBP1&#8217;s role in necroptosis is structurally based on its two RHIM domains, which may facilitate recognition and binding with the RHIM domains of RIPK3 and RIPK1. In this regard, ZBP1 shares a structural basis with the classical TRIF adapter, which recognizes RIPK3 in the context of Toll-like receptors 3/4 (TLR3/4).<sup>[<xref rid="R66" ref-type="bibr">66</xref>]</sup></p><p>In the necroptosis pathway involving ZBP1, RIPK1 often acts as a negative regulatory factor. The interactions among ZBP1, RIPK1, and RIPK3 determine the extent of necroptosis following infection, thereby influencing the outcome of the infection.<sup>[<xref rid="R67" ref-type="bibr">67</xref>]</sup> The RHIM domain of RIPK1 inhibits ZBP1-mediated necroptosis, and in the absence of RIPK1, the initiation of necroptosis may lead to embryonic death during growth and development.<sup>[<xref rid="R68" ref-type="bibr">68</xref>]</sup> However, the inhibitory effect of RIPK1 on ZBP1 is not absolute. Recently, Amusan <italic toggle="yes">et al</italic> found that ZBP1-driven necroptosis in human cells depends on the presence of RIPK1; the recognition and stable binding of ZBP1 and RIPK3 in necroptosis require RIPK1, whereas this process does not require RIPK1 in mouse cells. This discrepancy arises from differences in the RHIM domain of RIPK3 between human and mouse cells. When the mouse-derived RHIM domain replaces the RHIM domain of RIPK3 in human cells, ZBP1 no longer requires RIPK1 for recognition and binding to RIPK3.<sup>[<xref rid="R69" ref-type="bibr">69</xref>]</sup> These findings indicate that ZBP1, a critical molecule in the process of necroptosis in human diseases, may operate via mechanisms distinct from those commonly studied in mouse models. Current basic research on disease mechanisms should place greater emphasis on the potential differences between animal model mechanisms and those in human diseases.</p><p>In necroptosis, another important concept is necrosomes, which were first proposed in the classical pathway of necroptosis induced by TNF. In addition to act as a switch for necroptosis, ZBP1 can also interact with RIPK3, forming the key component necrosomes of necroptosis.<sup>[<xref rid="R70" ref-type="bibr">70</xref>]</sup> Necrosome is a cytoplasmic amyloid complex composed mainly of activated RIPK3 and MLKL.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> The binding of ZBP1 to RIPK3 promotes recruitment and phosphorylation of RIPK3 and MLKL, and active MLKL executes necroptosis by disrupting plasma membrane integrity and forming plasma membrane-damaging ion channels.<sup>[<xref rid="R71" ref-type="bibr">71</xref>]</sup> In necrosomes, if necroptosis is triggered by exogenous factors like TNF, the phosphorylation of RIPK3 can be activated by the activated RIPK1. However, when ZBP1 recognizes Z-DNA/Z-RNA caused by endogenous factors or viral infections, ZBP1 mediates the activation of necroptosis, exerting the function of driving RIPK3 phosphorylation while RIPK1 remains inactivated, serving as an inhibitory signal. When ZBP1 functions in the cell while RIPK1 is absent, the inflammation produced by necroptosis is intensified. The function of ZBP1 was initially defined in the context of necroptosis, where its interaction with the core molecules RIPK3 and RIPK1 activates downstream molecules of this pathway. This activation can determine the fate of cells and the progression of diseases, depending on the severity of inflammation.</p></sec><sec><title>Apoptosis</title><p>Unlike necroptosis commonly associated with diseases, apoptosis is a process of active PCD that occurs widely in normal tissues and plays a crucial role in maintaining tissue homeostasis. Apoptosis involves two classical pathways: the intrinsic pathway and the extrinsic pathway, both of which are highly associated with caspases, a group of cysteine proteases. In the intrinsic pathway, once apoptosis is initiated, members of the B-cell lymphoma 2 (Bcl-2) protein family trigger mitochondrial outer membrane permeabilization (MOMP),<sup>[<xref rid="R56" ref-type="bibr">56</xref>,<xref rid="R72" ref-type="bibr">72</xref>]</sup> leading to the release of cytochrome c from the mitochondria into the cytoplasm, where it binds to APAF-1. This results in the activation of CASP9, CASP3, and CASP7, forming a wheel-like apoptosome, thereby initiating cell death via the intrinsic pathway.<sup>[<xref rid="R73" ref-type="bibr">73</xref>]</sup> In contrast, the extrinsic pathway of apoptosis occurs when cells encounter extracellular death ligands (such as TNF), leading to the activation of CASP8 and subsequently triggering cell death.</p><p>Apoptosis induced by viral infections allows ZBP1 to recognize Z-DNA/Z-RNA, thereby participating in PCD. Additionally, the structural basis for ZBP1&#8217;s involvement in apoptosis is the RHIM domain, which relies on the recognition and binding of the RHIM domain to RIPK3, a process that primarily occurs in extrinsic apoptosis. Research has shown that the mutual recognition between ZBP1 and RIPK3 can also activate the assembly of the RIPK1/FADD/CASP8 complex, driving extrinsic apoptosis to combat viral infections.<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> Exogenous apoptosis is initiated through the involvement of the death-inducing receptor Fas and TNFR, where the Fas-associated protein with [DD] interacts with the receptor&#8217;s [DD], and recruits CASP8 through isoform interactions between its death effector domains (DED).<sup>[<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R74" ref-type="bibr">74</xref>]</sup></p><p>In addition to recognizing RIPK3, ZBP1 can also interact with RIPK1 through its RHIM domain, thereby mediating apoptosis. During bacterial infections, ZBP1 facilitates LPS-induced cell death and interleukin (IL)-1&#946; release through its interaction with RIPK1. Following LPS exposure or doublestranded RNA (dsRNA) infection, ZBP1 promotes the inflammatory response via the TLR3/4 signaling pathway through the timely transfer of RIPK1 to TRIF.<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup> The TRIF1-dependent complex (TRIFosome), formed by the binding of FADD, CASP8, and RIPK1 in continuous interaction with ZBP1, positively regulates CASP8-mediated extrinsic apoptosis and inflammasome activation, helping to sustain the inflammatory response. ZBP1&#8722;/&#8722; mice are resistant to lipopolysaccharide-induced septic shock and exhibit prolonged survival, a reduced inflammatory response, and decreased cell death.<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> As a protein traditionally thought to recognize viruses, ZBP1 can also initiate extrinsic apoptosis during bacterial infections, indicating a connection between bacterial and viral response pathways, as well as the potential for signaling crosstalk or conversion between apoptosis and necroptosis. This finding was corroborated by Solon <italic toggle="yes">et al</italic>,<sup>[<xref rid="R75" ref-type="bibr">75</xref>]</sup> who demonstrated that in the absence of CASP8 and TNFR1, ZBP1 triggers RIPK1-dependent lethal necroptosis. Notably, apoptosis and necroptosis are not mutually exclusive; in the presence of ZBP1, these two pathways may occur independently or separately.</p></sec><sec><title>Pyroptosis</title><p>Pyroptosis is a form of inflammatory cell death that triggers a PCD response due to cellular inflammation. When cells are assaulted, this form of cell death is regulated and induced by inflammasomes. Inflammasomes act as innate immune sensors; upon the detection of cellular disturbances or membrane perturbations, they become activated, leading to the cleavage of the inflammatory mediators pro-IL-1&#946; into their mature forms by downstream CASP1/CASP. Concurrently, gasdermin D (GSDMD) is cleaved, and its N-terminal domain forms pores in the cell membrane, disrupting the normal permeability barrier and inducing cell death and the release of inflammatory factors, thus resulting in an inflammatory response in the body.<sup>[<xref rid="R76" ref-type="bibr">76</xref>]</sup> Previous studies have shown that during IAV infection, the Z&#945; domain of ZBP1 can recognize IFN1, triggering the NF-&#954;B pathway and pyroptosis via the RIPK1&#8211;RIPK3&#8211;CASP-8 axis.<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup> In addition to recognizing IFN1 produced by IAV infection, ZBP1 can also detect type III IFNs in individuals with inflammatory bowel disease, leading to the upregulation of ZBP1, which induces pyroptosis and delays the regeneration of intestinal epithelial cells, thereby affecting intestinal repair.<sup>[<xref rid="R77" ref-type="bibr">77</xref>]</sup></p><p>The execution of pyroptosis relies on the assembly and activation of inflammasomes. The most classical inflammasome is known as the NLRP3 inflammasome, which comprises components such as the NLRP3, NAIP-NLRC4, NLRP1, absent in melanoma 2 (AIM2), and Pyrin inflammasomes. In addition, other identified inflammasomes include the CASP, NLRP6, and NLRP7 inflammasomes.<sup>[<xref rid="R78" ref-type="bibr">78</xref>]</sup> Through the mutual recognition of RHIM domains dependent on RIPK1 and RIPK3, ZBP1 can regulate the activation of the NLRP3 inflammasome, thereby controlling the pyroptotic process. In cases of viral or cellular infection, ZBP1 not only regulates the NLRP3 inflammasome during the well-studied IAV infection but also modulates the PGAM5 pathway in LPS-induced acute liver injury, leading to an increase in ROS production and promoting hepatocyte pyroptosis.<sup>[<xref rid="R79" ref-type="bibr">79</xref>]</sup> Recent research has revealed that ZBP1 regulates pyroptosis in neuronal cells. For example, during ischemic stroke, ZBP1 activates the NLRP3 inflammasome, promoting neuronal pyroptosis and mitochondrial fission. Inhibiting ZBP1 significantly reduces the cerebral infarct area in mice and ameliorates neurological deficits and anxiety symptoms.<sup>[<xref rid="R80" ref-type="bibr">80</xref>]</sup> The upregulation of ZBP1 expression in neurons has been noted in studies of AD, and silencing ZBP1 significantly reduces neuronal cell damage, oxidative stress, and inflammatory responses, resulting in improved cognitive function in AD rats through the modulation of IRF3-mediated pyroptosis.<sup>[<xref rid="R81" ref-type="bibr">81</xref>]</sup> These findings indicate that when ZBP1 functions in neuronal cells, it may tend to mediate PCD through pyroptosis.</p></sec><sec><title>PANoptosis</title><p>Research on necroptosis, apoptosis, and pyroptosis has been ongoing for decades, as these forms of PCD play roles in organism growth, development, and disease progression. However, they are not mutually exclusive; increasing evidence suggests that any two or even all three pathways can be simultaneously activated, substituted for one another, or even transformed. This interrelation between pathways is termed PCD crosstalk. PCD crosstalk was first identified in the context of the functions of specific signaling molecules. For example, CASP8 is often regarded as a signaling factor that mediates apoptosis; however, treatment with inflammasome-activating stimuli in the absence of CASP1 or GSDMD leads to the recruitment of the inflammasome complex and CASP8 activation, resulting in CASP8-mediated necroptosis. In addition, the apoptosis-associated CASP3 and CASP7 proteins inactivate GSDMD in the pyroptosis pathway through N-terminal cleavage. Orning <italic toggle="yes">et al</italic><sup>[<xref rid="R82" ref-type="bibr">82</xref>]</sup> also found that CASP8 can directly cleave GSDMD and induce the maturation of IL-1&#946;, leading to pyroptosis. Similarly, in the absence of the key apoptosis factor GSDMD, CASP1 activation leads to mitochondrial damage that activates CASP3, CASP9, and CASP8, resulting in apoptosis.<sup>[<xref rid="R83" ref-type="bibr">83</xref>]</sup> In addition to CASP8, RIPK1 acts as a key molecule in the regulation of cell survival, apoptosis, and necroptosis. In macrophages, necroptosis can also trigger the activation of the NLRP3 inflammasome through intracellular potassium efflux mediated by MLKL pores, leading to pyroptosis. ZBP1 is also a critical signaling factor in the additional molecular crosstalk between cell death pathways. In the previous discussion of apoptosis, pyroptosis, and necroptosis presented in this chapter, we noted that upon sensing external stimuli or viral infection, the Z&#945; domain of ZBP1 may activate any of the three PCD pathways. Indeed, as a sensor of innate immunity, ZBP1 can initiate one or multiple PCD processes to determine cell fate.<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> In some cases, cell death does not stem solely from a specific PCD pathway; rather, these pathways interact, activate each other, and collectively determine the state of the cell.</p><p>The discovery of crosstalk between different forms of PCD indicates that, in certain cases, no single pathway can fully explain the occurrence of PCD. For example, during IAV infection, macrophages exhibit the activation of CASP1, CASP8, and CASP3 and phosphorylation of MLKL, suggesting that apoptosis, pyroptosis, and necroptosis are all initiated within infected cells. Furthermore, with the discovery of PANoptosis, the interplay between pyroptosis, apoptosis, and necroptosis positions ZBP1 as a key molecule. Inhibiting a single molecule in a specific pathway does not prevent cell death, whereas inhibiting ZBP1 can promote cell survival, indicating the existence of a shared pathway mediated by ZBP1. In the context of sterile inflammation, the DED domain of CASP8 interacts with ASC in mouse cells with an inactivated CASP8 enzyme, triggering cell pyroptosis and severe intestinal inflammation. The resulting cell death can be rescued only through the combined deletion of the necroptotic and pyroptotic proteins CASP1 or ASC. Against this backdrop, the concept of PANoptosis was proposed to fill the gap in understanding the mechanisms of interaction between the molecular components of innate immune cell death. PANoptosis is a form of inflammatory cell death that integrates the features of pyroptosis, apoptosis, and necroptosis and can regulate multiple pathways.<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup> When one or more forms of cell death are hindered, PANoptosis provides the host with a means to activate alternative cell death defense mechanisms to modulate cell fate.</p><p>PANoptosis was first observed in macrophages infected with IAV,<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup> and this concept was proposed in 2019. Depending on the induction conditions, the morphological characteristics of apoptosis, necroptosis, or pyroptosis may be observed in cells undergoing PANoptosis, and all key signaling molecules related to these three PCD pathways can be detected. The integrated signaling molecules form a strong inflammatory response within the cell, leading to cell death. The CASP and RIPK families are extensively involved in the process of PANoptosis. The CASP family can be divided into proinflammatory and proapoptotic signaling molecules; for example, CASP-1, CASP-4, CASP-5, and CASP-11 can induce inflammatory cell death, whereas CASP-2, CASP-8, CASP-9, and CASP-11 can induce apoptosis, and CASP-3, CASP-6, and CASP-7 can execute apoptosis.<sup>[<xref rid="R84" ref-type="bibr">84</xref>]</sup> However, because PANoptosis initiates multiple cell death pathways simultaneously, the functions of CASP family members are diverse and can be mutually regulated, potentially acting as inhibitors of certain pathways. For example, in addition to the key regulatory factor CASP8 discussed above, CASP-3 has also been found to switch from activation-induced apoptosis to activation-induced pyroptosis under DFNA5 induction,<sup>[<xref rid="R85" ref-type="bibr">85</xref>]</sup> as well as to cleave GSDMD at sites that inactivate proteins, potentially blocking pyroptosis.<sup>[<xref rid="R86" ref-type="bibr">86</xref>]</sup> In nonclassical pathways of pyroptosis, CASP4 has been found to induce pyroptosis mediated by DSDME through the cleavage of CASP3.<sup>[<xref rid="R87" ref-type="bibr">87</xref>]</sup> RIPK1 and RIPK3 from the RIPK family are also important proteins in the PANoptosis process. RIPK3, a signaling molecule that binds to sensors, such as ZBP1, and stimulates downstream PCD, can induce various PCD processes and contribute to the integration of signaling pathways. Moreover, RIPK1 can exert both inhibitory and promotive effects, depending on its concentration within the cell. When the concentration of RIPK1 is moderate, both CASP-8 and RIPK3 are recruited, leading to the simultaneous initiation of apoptosis and necroptosis; however, when the concentration of RIPK1 is excessively high, apoptosis is inhibited, and only the RIPK3&#8211;MLKL axis leads to necroptosis.<sup>[<xref rid="R88" ref-type="bibr">88</xref>]</sup> In summary, various signaling molecules are involved in the regulation of PANoptosis, interacting with one another and potentially assembling together, integrating cell death signals, and promoting coordinated immune responses. Consequently, a molecular platform concept called the PANoptosome, which is considered to exercise core regulatory functions over PANoptosis, has been proposed.</p><p>With the widespread discovery and acceptance of the concept of PANoptosis, a concept similar to apoptosomes, necrosomes, and inflammasomes has emerged, known as the PANoptosome complex, which plays a crucial role in PANoptosis. The earliest discovered PANoptosome is mediated by ZBP1, which recognizes exogenous or endogenous stimuli, leading to the assembly of the ZBP1-PANoptosome. Its main components include ZBP1, the NLRP3 inflammasome, CASP-8, RIPK1, RIPK3, and an adapter protein containing a caspase activation and recruitment domain (ASC) known as apoptosis-associated speck-like protein.<sup>[<xref rid="R89" ref-type="bibr">89</xref>]</sup> Subsequently, CASP6 has also been considered a component of the ZBP1-PANoptosome, mainly functioning to promote the binding of ZBP1 and RIPK3.<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> As a sensor of viral components, ZBP1 has been found to activate the NLRP3 inflammasome during IAV infection, subsequently mediating the assembly of the ZBP1-PANoptosome with RIPK1 and RIPK3, triggering PANoptosis and driving inflammatory cell death. In the context of the ZBP1-PANoptosome&#8217;s role, IAV induces IFN1 signaling, activating the IFN regulatory factor (IRF) family, where IRF1 upregulates ZBP1 to form the ZBP1-PANoptosome and drives PANoptotic cell death during IAV infection.<sup>[<xref rid="R90" ref-type="bibr">90</xref>]</sup> When IFN1 receptor 1 is absent, cells exhibit resistance to IAV-induced cell death, as ZBP1 does not become upregulated in these cells.<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup> This indicates that ZBP1 is a key molecule in inducing PANoptosis during IAV infection. Beyond the initially discovered IAV infection, ZBP1 has been found to regulate PANoptosis in a wide range of viral infections. This will be summarized in detail in subsequent chapters discussing infectious diseases. Notably, in the infections of viruses, such as MCMV, HSV1, and varicella-zoster virus&#8212;viruses that encode proteins containing RHIM sequences&#8212;these sequences can interact with ZBP1 to inhibit cell death, potentially leading to host mortality in cases of severe infection when the virus cannot be cleared.<sup>[<xref rid="R91" ref-type="bibr">91</xref>,<xref rid="R92" ref-type="bibr">92</xref>]</sup></p><p>The ZBP1-PANoptosome was the first to be discovered, but it is not the only defined PANoptosome. Different types of pathogenic and sterile cell damage can lead to the assembly of various PANoptosome cell death complexes. The more common PANoptosomes identified to date include the ZBP1-PANoptosome, AIM2-PANoptosome, RIPK1-PANoptosome, and NLRP-PANoptosome.<sup>[<xref rid="R93" ref-type="bibr">93</xref>]</sup> Currently, several molecules that participate in the formation of the PANoptosome simultaneously have been identified. In fact, the components of PANoptosomes can be classified into sensors, adapters, and effectors. Key molecules involved in pyroptosis and necroptosis (including ASC, FADD, and RIPK3) are conserved components of the PANoptosome and act as adapters, as confirmed by single-cell analyses using expansion microscopy. The main distinction between various PANoptosomes lies in their sensors, primarily due to different stimuli. For example, HSV1 or Francisella infections are recognized by the AIM2 sensor, leading to the assembly of the AIM2-PANoptosome,<sup>[<xref rid="R94" ref-type="bibr">94</xref>]</sup> whereas infection with Yersinia, triggered by LPS, results in the assembly of the RIPK1-PANoptosome.<sup>[<xref rid="R90" ref-type="bibr">90</xref>]</sup> NLRP drives the activation of inflammasomes and PANoptosomes in response to heme and PAMPs.<sup>[<xref rid="R95" ref-type="bibr">95</xref>]</sup> Although the composition and functional roles of some PANoptosome components have not yet been fully elucidated, a key step in PANoptosis and PANoptosome assembly is the formation of the ZBP1-NLRP3 inflammasome. MLKL-dependent necroptosis, CASP8-dependent apoptosis, and CASP1-dependent pyroptosis share a common upstream regulator, ZBP1. In the ZBP1-PANoptosome, ZBP1 functions as a sensor; recent studies have also revealed that ZBP1 is an important component in the assembly of the AIM2-PANoptosome, potentially mediating RIPK3 involvement. In bacterial infections, mice lacking both ZBP1 and Pyrin presented increased bacterial titers, resembling the phenomenon observed in <italic toggle="yes">Aim2</italic><sup>&#8722;/&#8722;</sup> mice, indicating that ZBP1 is also deeply involved in the construction and function of the AIM2-PANoptosome.<sup>[<xref rid="R96" ref-type="bibr">96</xref>]</sup></p><p>Downstream of the PANoptosome, the executors of pyroptosis, apoptosis, and/or necroptosis may all be activated individually or concurrently, which may depend on the cell type and the occurrence of different stimuli. Each PANoptosome complex integrates key components, such as ASC, CASP-1, CASP-8, RIPK1, and RIPK3 as effectors of PANoptosis, acting as executors to ensure a robust and multifaceted cellular death response. When the assembly of the PANoptosome is disrupted (primarily due to dysfunction of receptors and adapters), it can lead to impaired downstream cell death pathways, contributing to the onset and progression of various diseases. This includes exacerbated infections due to inadequate pathogen clearance.<sup>[<xref rid="R93" ref-type="bibr">93</xref>]</sup> Conversely, if the PANoptosome is excessively activated, it may result in tissue damage and subsequent chronic inflammatory responses.<sup>[<xref rid="R97" ref-type="bibr">97</xref>]</sup> However, while PANoptosis has been widely employed to explain disease mechanisms and even for treatment strategies, the composition of the PANoptosome and its functions, along with the precise triggering conditions and pathways of PANoptosis, have not yet been fully validated. For example, when ZBP1 recognizes DAMPs or PAMPs, is the difference in the initiation of PCD pathways related to the type of cell or the stimuli it receives? Furthermore, what determines which pathways are activated and which are inhibited, and is there a correlation with the activity or concentration of certain key signaling molecules? Are there differences in the outcomes for cells after the initiation of different pathways? These are all questions that future research may explore. The role of ZBP1 in pyroptosis, apoptosis, necroptosis, and PANoptosis is illustrated in Figure <xref rid="F2" ref-type="fig">2</xref>.</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><p>ZBP1 is involved in processes of pyroptosis, apoptosis, necroptosis, and PANoptosis. ZBP1 can detect Z-nucleic acid or endogenous ligands, binding with associated proteins to initiate PCD pathways, mediating downstream signal molecules to complete one or more pathways of pyroptosis, apoptosis, or necroptosis in determining cell fate. When more than one type of PCD is activated simultaneously, there is crosstalk between the pathways. In PANoptosis, in addition to sensing and initiation functions, ZBP1 is also involved in the construction of various PANoptosomes to facilitate the process of PANoptosis. The specific pathways of these types of PCD are presented. AIM2: Absent in melanoma 2; ASC: Apoptosis-as-sociated speck-like protein containing CARD; Bcl 2: B-cell lymphoma 2; CASP: Caspase; Cyt c: Cytochrome c; FADD: FAS-associated protein with death domain; FAS: Fas ligand; GSDMD: Gasdermin D; IFNs: Interferons; IL: Interleukin; IRF1: Interferon regulatory factor 1; MLKL: Mixed lineage kinase domain-like; MOMP: Mitochondrial outer membrane permeabilization; NLRC4: The NLR family caspase activation and recruitment domain-containing 4; NLRP: NOD-, LRR-, and pyrin domain-containing protein; RIPK: Receptor-interacting protein kinase; TNF: Tumor necrosis factor; TRIF: TIR domain-containing adaptor-inducing IFN-beta.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cm9-138-2421-g002.jpg"/></fig></sec><sec><title>Autophagy</title><p>In addition to being broadly involved in PANoptosis, apoptosis, pyroptosis, and necroptosis, ZBP1 has been shown to play a regulatory role in other forms of PCD in recent studies. Autophagy is the primary endogenous degradation system in cells and plays a crucial role in metabolic adaptation, intracellular quality control, and developmental differentiation by delivering cytoplasmic material to lysosomes for degradation. Classical autophagy is a multistep process that involves the continuous and selective recruitment of ATG (autophagy-related) proteins. In recent years, the complex molecular networks underlying these different autophagy pathways have gradually attracted increasing interest from researchers. While ZBP1 does not directly regulate the autophagy process, it can alter or modulate cell death before and after the initiation of autophagy in cells where autophagic activity is present. ZBP1-mediated necroptosis, as a cellular inflammatory state, can also coexist with other types of PCD or act via alternative pathways. Autophagy-dependent replicative crises are regulated by ZBP1. With the activation of the cGAS&#8211;STING DNA-sensing pathway, the crisis-associated isoform of ZBP1 binds to telomeric repeat-containing RNA (TERRA) and then oligomerizes into filaments on the outer mitochondrial membrane, where it activates the innate immune adaptor protein mitochondrial antiviral signaling protein (MAVS), which is involved in telomere-mediated tumor suppression.<sup>[<xref rid="R98" ref-type="bibr">98</xref>]</sup> Regulating the cGAS&#8211;STING pathway and autophagy signaling pathway can significantly reduce the expression of ZBP1, STING1, DDX, and miR-6, thereby improving insulin resistance in rats fed a high-fat diet.<sup>[<xref rid="R99" ref-type="bibr">99</xref>]</sup> Autophagy can be controlled by proteins containing RHIM domains. In macrophages lacking the autophagy gene <italic toggle="yes">Atgl1</italic>, highly insoluble RIPK1, RIPK3, TRIF, and ZBP1 accumulate, and the combined deletion of Atgl1 and ZBP1 accelerates LPS-mediated necroptosis, suggesting that ZBP1 drives necroptosis in the absence of the RIPK1-RHIM but that when multiple RHIM domain-containing proteins aggregate, ZBP1 inhibits this process.<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup> Although no additional studies have explored the relationship between ZBP 1 and autophagy, in the future, this crosstalk may also be extensively studied in the disease process.</p></sec><sec><title>Ferroptosis</title><p>ZBP1 is involved in the process of ferroptosis, a form of PCD. Ferroptosis is regulated by various cellular metabolic events, including redox homeostasis, iron handling, mitochondrial activity, and the metabolism of amino acids, lipids, and sugars. Intracellular and intercellular signaling events, along with environmental stressors, can influence ferroptosis by modulating cellular metabolism and ROS levels.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> Studies have found that Diquat induces mitochondrial genomic instability in endothelial cells, resulting in the accumulation of Z-DNA. ZBP1 recognizes Z-DNA and then interacts with RIPK3, which phosphorylates MLKL to induce necroptosis and also phosphorylates FSP1 to inhibit its enzyme activity, thereby promoting ferroptosis. Specific deletion of ZBP1 or RIPK3 in endothelial cells inhibits both necroptosis and ferroptosis.<sup>[<xref rid="R74" ref-type="bibr">74</xref>]</sup> This suggests that RIPK3 and ZBP1 may act as mediators in necroptosis and ferroptosis, indicating that there might be certain conversion conditions or common pathways between these two forms of cell death. In summary, the pathways of cell death are not isolated, and more interactions may be discovered in the future.</p></sec><sec><title>NETosis</title><p>NETosis is a regulatory form of neutrophil death that involves defense against pathogens and has complex interactions with the complement and coagulation systems. NETs can capture and kill pathogens while promoting complement activation and thrombosis. NETosis refers to the formation of neutrophil extracellular traps (NETs) during this process, where neutrophils expel their chromatin, which is modified with antimicrobial proteins, resulting in sticky NETs that capture and kill pathogens.<sup>[<xref rid="R100" ref-type="bibr">100</xref>]</sup> Studies have found that in acute respiratory distress syndrome (ARDS) induced by Gram-negative bacterial pneumonia, NETs can activate the AIM2 inflammasome and induce pyroptosis in alveolar macrophages, with levels of NETs and CASP-1 being correlated with the severity of ARDS.<sup>[<xref rid="R101" ref-type="bibr">101</xref>]</sup> This indicates a possible common pathway or at least concurrent presence between NETosis and the pyroptotic pathway. Another study found that activation of the STING pathway induces ARDS, resulting not only in NETosis but also in PANoptosis, involving downstream regulation by cGAS, DDX41, IFI204, ZBP1, and AIM2 inflammasomes.<sup>[<xref rid="R102" ref-type="bibr">102</xref>]</sup> However, there is currently no evidence indicating that ZBP1 directly participates in the regulation of NETosis.</p><p>In this section, we focus on the role of ZBP1 in various forms of PCD and its research advancements. ZBP1 is an important PRRs that mainly mediates intracellular immune responses and cell death by recognizing structural changes in nucleic acids. As a multifunctional protein, ZBP1 plays a role in various forms of PCD, including apoptosis, necroptosis, pyroptosis, PANoptosis, ferroptosis, autophagy, and NETosis. In summary, ZBP1 plays an indispensable role in regulating multiple mechanisms of PCD. It is not only crucial in cellular responses to infection and injury but also provides new insights into the interplay between immune responses and cell death. These findings enrich our understanding of ZBP1&#8217;s functions and offer potential targets and strategies for the treatment of related diseases in the future. Next, we will discuss several molecules that interact with ZBP1 to achieve a more comprehensive understanding of ZBP1&#8217;s role in PCD.</p></sec></sec></sec><sec><title>Molecules Related to ZBP1</title><p>As mentioned in the previous section, ZBP1 is a key molecule in PCD, extensively involved in apoptosis, necroptosis, pyroptosis, the PANoptotic process, and other forms of PCD that are formed through their crosstalk. The functionality of ZBP1 relies on a complex regulatory network of molecules; some can regulate the activation or inhibition of ZBP1 upstream, while others interact with ZBP1 to regulate the downstream processes of PCD. In this section, we will select some popular research molecules related to ZBP1 and summarize their mechanisms of action and physiological and pathological roles and briefly describe how the regulation of these molecules affects the PCD process and disease outcome performed by ZBP1 [Table <xref rid="T1" ref-type="table">1</xref>].</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Molecules related to ZBP1 that affects the PCD process and disease outcome.</p></caption><table frame="hsides" rules="groups" border="0"><thead><tr><th align="left" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Molecules</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Relationship with ZBP1</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">PCD involved</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Diseases mediated by interactions with ZBP1</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">RIPK3</td><td align="left" valign="top" rowspan="1" colspan="1">RHIM-RHIM binding to ZBP1; A member of PANoptosome</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis; PANoptosis</td><td rowspan="2" align="left" valign="top" colspan="1">SARS-CoV-2; IAV infection; HSV infection; Alzheimer&#8217;s Disease; Heatstroke; Myocardial Inflammation; Airway inflammation; ARDS; HSV Encephalitis; Tumors; Biliary atresia; IBD; Apical periodontitis; Skin inflammation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MLKL</td><td align="left" valign="top" rowspan="1" colspan="1">Downstream molecule following ZBP1-RIPK3 activation</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis; PANoptosis</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RIPK1</td><td align="left" valign="top" rowspan="1" colspan="1">RHIM-RHIM binding to ZBP1; Inhibiting RIPK3 activation; Initiating TRIFosome interactions; A member of PANoptosome</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis; Pyroptosis; PANoptosis</td><td align="left" valign="top" rowspan="1" colspan="1">IAV infection; HSV infection; Breast cancer; Yersinia pseudotuberculosis infection; IBD; Skin inflammation; Ventilator-induced lung injury; Injury-induced colitis; Mycobacterium tuberculosis infection</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Caspase-8 and FADD</td><td align="left" valign="top" rowspan="1" colspan="1">Preventing spontaneous ZBP1 expression; Members of PANoptosome; Members of TRIFosome; Activating the ZBP1-NLRP3 inflammasome</td><td align="left" valign="top" rowspan="1" colspan="1">Apoptosis; PANoptosis</td><td align="left" valign="top" rowspan="1" colspan="1">Alzheimer&#8217;s disease; Acute lung injury; Yersinia pseudotuberculosis infection; IAV infection; Fungi infection; Colitis; Heatstroke; Mycobacterium tuberculosis infection</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Caspase-6</td><td align="left" valign="top" rowspan="1" colspan="1">Facilitating the RHIM-RHIM binding of RIPK3 to ZBP1 via its interaction with RIPK3</td><td align="left" valign="top" rowspan="1" colspan="1">Pyroptosis; Apoptosis; Necroptosis; PANoptosis</td><td align="left" valign="top" rowspan="1" colspan="1">IAV infection; Inflammatory diseases; Tumors</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NLRP3</td><td align="left" valign="top" rowspan="1" colspan="1">ZBP1 regulating NLRP3 inflammasome activation; Participating ZBP1-NLRP3 inflammasome forming; A member of PANoptosome</td><td align="left" valign="top" rowspan="1" colspan="1">Pyroptosis; Apoptosis; Necroptosis; PANoptosis</td><td align="left" valign="top" rowspan="1" colspan="1">ARDS; Sj&#246;gren&#8217;s syndrome; IAV infection; IBD; Tumors</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AIM2</td><td align="left" valign="top" rowspan="1" colspan="1">A member of PANoptosome</td><td align="left" valign="top" rowspan="1" colspan="1">Pyroptosis; PANoptosis</td><td align="left" valign="top" rowspan="1" colspan="1">ARDS; SARS-CoV-2 infection; Ovarian cancer; Colonic organoids; Breast cancer; Beh&#231;et disease</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ADAR1</td><td align="left" valign="top" rowspan="1" colspan="1">Z&#945;-Z&#945; binding to ZBP1; Suppressing spontaneous ZBP1 activation; Blocking ZBP1 binding to RIPK3</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis; PANoptosis</td><td align="left" valign="top" rowspan="1" colspan="1">Aicardi-Gouti&#232;res syndrome; Embryonic mortality (mice)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IRF1</td><td align="left" valign="top" rowspan="1" colspan="1">Upstream molecule of ZBP1; Activating ZBP1-NLRP3 inflammasome; Promoting PANoptosome forming</td><td align="left" valign="top" rowspan="1" colspan="1">PANoptosis</td><td align="left" valign="top" rowspan="1" colspan="1">BaP/BPDE exposure (mice); IAV infection.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TRIM34</td><td align="left" valign="top" rowspan="1" colspan="1">Binding to ZBP1 as an upstream molecule</td><td align="left" valign="top" rowspan="1" colspan="1">PANoptosis</td><td align="left" valign="top" rowspan="1" colspan="1">IAV infection</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RPA1</td><td align="left" valign="top" rowspan="1" colspan="1">Inhibiting the ZBP1 signaling pathway as an upstream molecule</td><td align="left" valign="top" rowspan="1" colspan="1">PANoptosis</td><td align="left" valign="top" rowspan="1" colspan="1">Lymphopenia (mice); Colitis (mice); Hepatitis (mice)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TAK1</td><td align="left" valign="top" rowspan="1" colspan="1">Inhibiting the activation of the PANoptosome as an upstream molecule</td><td align="left" valign="top" rowspan="1" colspan="1">PANoptosis</td><td align="left" valign="top" rowspan="1" colspan="1">SARS-CoV-2 infection</td></tr><tr><td align="left" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">PUMA</td><td align="left" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">Promoting mtDNA release and activating ZBP1</td><td align="left" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">Apoptosis; Necroptosis; PANoptosis</td><td align="left" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">Colorectal cancer</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>ADAR1: Adenosine deaminase acting on RNA 1; AIM2: Absent in melanoma 2; ARDS: Acute respiratory distress syndrome; BaP: Benzo[a]pyrene; BPDE: 7,8-diol-9,10-epoxides of BaP; FADD: Fas-associated death domain; HSV: Herpes simplex virus; IAV: Influenza A virus; IBD: Inflammatory bowel disease; IRF1: Interferon regulatory factor 1; MLKL: Mixed lineage kinase domain-like; NLRP3, NOD-, LRR-, and pyrin domain-containing protein 3; PCD: Programmed cell death; PUMA: p53 Upregulated modulator of apoptosis; RHIM: RIP homotypic interaction motif; RIPK1/3: Receptor-interacting protein kinase 1/3; RPA1: Replication protein A1; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; TAK1: Transforming growth factor &#946;-activated kinase 1; TRIM34: Tripartite motif containing 34; ZBP1: Z-DNA-binding protein 1.</p></fn></table-wrap-foot></table-wrap><sec><title>RIPK3 and MLKL</title><p>As one of the molecules with RHIM domains, RIPK3 interacts with the RHIM domain of ZBP1, forming the ZBP1&#8211;RIPK3 pathway, a classic process for initiating necroptosis. This programmed necroptosis is induced by MCMV infection or death receptor activation and can be inhibited by the MCMV-encoded RIP-activated viral inhibitor (vIRA).<sup>[<xref rid="R64" ref-type="bibr">64</xref>]</sup> RIPK3 and its substrate MLKL are key regulators of necroptosis, and the activation of RIPK3 depends on autophosphorylation and can mediate the phosphorylation of MLKL, which migrates and oligomerizes at the cell membrane, leading to cell lysis.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> RIPK3 promotes apoptosis and NLRP3&#8211;CASP1 activation by activating CASP8 even in the absence of MLKL.<sup>[<xref rid="R103" ref-type="bibr">103</xref>]</sup> In addition to acting as a downstream regulatory molecule following ZBP1&#8211;RIPK3 activation, MLKL also promotes inflammasome activation and IL-1&#946; maturation in IAV-infected macrophages. MLKL drives ZBP1&#8211;NLRP3 inflammasome activation via potassium efflux. In the absence of the MLKL&#8211;inflammasome axis, CASP8 orchestrates IL-1&#946; maturation and secretion. MLKL itself is essential in the <italic toggle="yes">in vivo</italic> host inflammatory response to IAV.<sup>[<xref rid="R34" ref-type="bibr">34</xref>]</sup> MLKL is an executioner of necrosis that promotes inflammasome activation and pyroptosis. When the MLKL&#8211;inflammasome axis is inhibited, cells shift to CASP8-dependent pyroptosis. Indeed, current research indicates that the mutual recognition between ZBP1 and RIPK3 may lead to the pathways of pyroptosis, apoptosis, or necroptosis and may or may not trigger the assembly of PANoptosomes. In summary, RIPK3 is an indispensable interacting molecule for ZBP1 in executing its functions, indicating that ZBP1 plays both an activating role and a mediating role in PCD. Targeting RIPK3 may provide protection against a broader range of necroptotic stimuli. Studies have shown that RIPK3 expression is often silenced in cancer cells and that its loss is actively selected during tumorigenesis and development. For example, in 85% of breast cancer patients, the expression of RIPK3 in tumor tissue is significantly lower than that in normal tissue. Using hypomethylating agents to restore RIPK3 expression, the sensitivity of cancer cells to chemotherapy can be increased in a RIPK3-dependent manner and the antitumor efficacy of certain chemotherapeutic agents can be improved. Therefore, for cancer patients with RIPK3 deficiency, the use of hypomethylating agents to induce RIPK3 expression before patients undergo standard chemotherapy would be a more favorable strategy.<sup>[<xref rid="R104" ref-type="bibr">104</xref>]</sup></p></sec><sec><title>RIPK1</title><p>Like RIPK3, RIPK1 can also interact directly with ZBP1 through its RHIM domain. As previously described, RIPK1 has a dual role in PCD and is able to both inhibit and promote the progression of PCD. Mice genetically lacking RIPK1 die perinatally and exhibit aberrant CASP8-dependent apoptosis and MLKL-dependent necroptosis, but mice expressing catalytically inactive RIPK1 survive.<sup>[<xref rid="R105" ref-type="bibr">105</xref>,<xref rid="R106" ref-type="bibr">106</xref>]</sup> Mechanistically, in cells expressing RIPK1 (mRHIM), ZBP1 strongly interacts with phosphorylated RIPK3. These findings suggest that RHIM&#8211;RHIM binding of RIPK1 to ZBP1 or RIPK3 prevents the phosphorylation of RIPK3, thereby blocking the ZBP1&#8211;RIPK3 complex from triggering RIPK3-driven CASP8-mediated apoptosis and MLKL-driven necroptosis pathways. RIPK1 has also been shown to prevent perinatal mortality and skin inflammation in adult mice.<sup>[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R106" ref-type="bibr">106</xref>]</sup> ZBP1 is a major activator of IFN-driven RIPK3 activation and perinatal lethality in RIPK1 deficiency. However, RIPK1 exerts an inhibitory effect on PCD. The interaction between ZBP1 and RIPK1 can also activate the NF-&#954;B pathway, leading to the activation of pyroptosis, and when induced by LPS, TLR4 can recruit RIPK1 via TRIF bound to ZBP1, leading to the assembly of the TRIFosome and subsequent activation of CASP8, leading to apoptosis activated by the exogenous pathway. Furthermore, in the formation of PANoptosomes, RIPK1 interacts with FADD and CASP8 and can trigger NLRP3-dependent and CASP8-mediated cleavage of GSDMD and the execution of pyroptosis.<sup>[<xref rid="R107" ref-type="bibr">107</xref>]</sup> For example, inducing RIPK1/RIPK3-mediated necroptosis in tumors has the potential to eliminate cancer cells, but the overexpression of RIPK1 may lead to carcinogenesis. To date, most of the RIPK1/3 kinase inhibitors designed have been type II or type III kinase inhibitors, including specific RIPK1 inhibitors, such as Nec-1s, GSK&#8242;772, GSK&#8242;547, and compound 22. Currently, some RIPK1 inhibitors have entered clinical trials for the treatment of rheumatoid arthritis, ulcerative colitis, and psoriasis.<sup>[<xref rid="R108" ref-type="bibr">108</xref>]</sup> Although no clear efficacy has been achieved in clinical trials involving human solid tumors, RIPK1 kinase inhibitors could become alternative treatments for patients who are unresponsive to antitumor necrosis factor therapy or who experience adverse reactions.</p></sec><sec><title>Caspase protein family</title><p>The caspase protein family is widely involved in various processes of PCD and is particularly indispensable in apoptosis and pyroptosis. Caspase family proteins, such as CASP8, CASP6, CASP3, CASP1, and ZBP1 are closely linked to the regulation of PCD. CASP3 is a key initiator of classical intrinsic apoptosis. Studies have shown that, in addition to its role in apoptosis, CASP3 can also participate in the pyroptotic pathway, inducing cell death through the nonclassical CASP3&#8211;GSMDE pyroptotic pathway. In the context of tumor cell killing, cytotoxic drugs can induce tumor cell death via CASP-3-dependent pyroptosis or apoptosis, depending on high or low levels of GSDME expression, which undoubtedly provides new insights into cancer treatment.<sup>[<xref rid="R109" ref-type="bibr">109</xref>]</sup> In apoptosis, CASP8 is a crucial protein activated by the extrinsic pathway. In addition to its involvement in CASP8-dependent apoptosis, which is involved in the upstream regulation of pyroptosis, CASP8, or its adapter FADD, also acts as an anti-necroptosis factor in ZBP1-mediated PCD.<sup>[<xref rid="R110" ref-type="bibr">110</xref>]</sup> In cells lacking FADD or CASP8, ZBP1 expression is increased, which is inhibited by the recombination of CASP8 or FADD. CASP8 or FADD deficiency leads to the activation of RIPK3&#8211;MLKL-dependent necrotic apoptosis, and its antinecroptotic function is likely executed through the CASP8-mediated cleavage of RIPK3.<sup>[<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R111" ref-type="bibr">111</xref>]</sup> In cells lacking CASP8 or FADD, ZBP1 expression and downstream activation of RIPK3 and MLKL rely on a positive feedback mechanism that requires the nucleic acid sensor loop cGMP&#8211;AMP synthase (cGAS), stimulator of IFN genes (STING), and the TANK-binding kinase 1 (TBK1) signaling pathway.<sup>[<xref rid="R112" ref-type="bibr">112</xref>]</sup> Additionally, the ZBP1&#8211;RIPK3&#8211;FADD&#8211;CASP8 complex is part of the main scaffold of the PANoptosome. CASP6 is a molecule required for innate immunity and activation of the ZBP1&#8211;NLRP3 inflammasome and has been shown to promote RIPK3 binding to ZBP1 through an interaction with RIPK3. During IAV infection, CASP6 is involved in the composition and regulation of the PANoptosome and can promote PANoptosis.<sup>[<xref rid="R113" ref-type="bibr">113</xref>]</sup> In addition, CASP6 promotes the differentiation of alternatively activated macrophages (AAMs).<sup>[<xref rid="R114" ref-type="bibr">114</xref>]</sup></p><p>Inhibition or activation of the caspase family proteins can play a role in certain cancer therapies. Studies indicate that the use of the caspase inhibitor zVAD-fmk to modulate the death of B16 melanoma cells can enhance anti-tumor immunity. <italic toggle="yes">In vivo</italic> experimental results show that in multi-modal cancer treatments combining radiotherapy (RT), dacarbazine (DTIC), and hyperthermia (HT), the use of broad-spectrum caspase inhibitors, such as Zvad-fmk and IDN-6556 (F-03491390) can induce apoptosis and necroptosis. These treatments significantly enhanced anti-tumor immune responses, evidenced by a marked increase in the infiltration of dendritic cells (DCs) and CD8<sup>+</sup> T cells, an elevation in the expression level of IFN-&#947; in CD8<sup>+</sup> T cells, while the tumor infiltration of regulatory T cells decreased. These changes collectively contributed to the inhibition of tumor growth.<sup>[<xref rid="R115" ref-type="bibr">115</xref>]</sup> Additionally, the chemotherapeutic agent cisplatin (DDP) has been found to effectively combat triple-negative breast cancer (TNBC), with its mechanism involving the upregulation of maternally expressed gene 3 (MEG3) and activation of the NLRP3/CASP-1/GSDMD signaling pathway, thereby inducing pyroptosis. This effect has demonstrated anti-tumor efficacy both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>, significantly increasing the pathological complete response rate in TNBC patients.<sup>[<xref rid="R116" ref-type="bibr">116</xref>]</sup> Given the close relationship between ZBP1 and the caspase family, the inhibition or activation of specific caspase family members may represent a potential strategy for the precise regulation of various PCD pathways mediated by ZBP1.</p></sec><sec><title>NLRP3 and AIM2: Assembly and regulation of the PANoptosome</title><p>Inflammasomes have multiple sensors, each of which detects and responds to a specific pathogen or damage-associated molecular pattern (PAMP or DAMP). Currently, five well-defined inflammasome sensors have been identified: NOD-like receptor (NLR) family pyrin domain-containing 1 (NLRP1), NLRP3, NLR family caspase recruitment domain-containing 4 (NLRC4), absent in melanoma 2 (AIM2), and PYRIN.<sup>[<xref rid="R117" ref-type="bibr">117</xref>]</sup> During infection, pathogens can induce the release of a variety of PAMPs and DAMPs, which can stimulate multiple inflammasome sensors simultaneously. NLRP3 is a typical inflammasome sensor, which is upstream regulated by the ZBP1-mediated RIPK1-RIPK3-CASP8 axis and can bind to ZBP1 to form ZBP1- NLRP3 inflammasome, which mediates CASP-1 activation and induces pyroptosis during IAV infection.<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup> In addition, the ZBP1-NLRP3 inflammasome can assemble with the ZBP1-RIPK3-FADD-CASP8 complex to form large multiprotein complexes that constitute PANoptosome and participate in PANoptosis. NLRP3, as a crucial component of the ZBP1-PANoptosome, regulates NLRP3&#8217;s involvement in diseases linked to PANoptosis. It has been suggested that targeting NLRP3 may help initiate immune responses against tumor cells.<sup>[<xref rid="R118" ref-type="bibr">118</xref>]</sup> However, these studies have so far been limited to animal experiments and have not yet been validated in humans.</p><p>In addition to the classical ZBP1-PANoptosome, the PANoptosome that uses AIM2 as a sensor also requires the participation of ZBP1.<sup>[<xref rid="R119" ref-type="bibr">119</xref>]</sup> The AIM2 inflammasome senses dsDNA and plays a mediating role in pyroptosis. A study showed that AIM2 can also modulate the innate immune sensors pyrin and ZBP1 to drive inflammatory signaling and PANoptosis and provide protection to the host during infection with HSV1 and <italic toggle="yes">Francisella sp</italic>. AIM2, pyrin, and ZBP1 are closely associated with ASC, and CASP1, CASP8, RIPK3, RIPK1, and FADD are all involved in the construction of the PANoptosome. Molecular interactions between AIM2, pyrin, and ZBP1 drive the assembly of AIM2-mediated multiprotein complexes.<sup>[<xref rid="R95" ref-type="bibr">95</xref>]</sup> The PANoptosome necessary for the initiation of PANoptosis varies across different disease models, indicating that regulating the PANoptosome may influence the process of cell death. When ZBP1 is a component of the PANoptosome, inhibiting ZBP1 may block both types of PANoptosomes simultaneously.</p><sec><title>Adenosine deaminase acting on RNA 1 (ADAR1)</title><p>ADAR1 is an adenosine deaminase that binds to dsRNA and has the ability to hydrolyze adenosine and convert it into inosine. In addition to ZBP1, ADAR1 is the only other mammalian protein that contains a Z&#945; domain.<sup>[<xref rid="R120" ref-type="bibr">120</xref>]</sup> ADAR1 acts as an innate immune mediator capable of self/nonself recognition. dsRNA is a common feature among pathogenic and endogenous triggers that can activate cytoplasmic dsRNA sensors, specifically melanoma differentiation-associated protein 5 (MDA5), which leads to a IFN1 response through MAVS-dependent signaling.<sup>[<xref rid="R121" ref-type="bibr">121</xref>]</sup> ADAR1 is an important ZBP1 regulatory hub. Mutations in ADAR1 cause serious disorders associated with chronic activation of the IFN response, including Aicardi&#8211;Gouti&#232;res syndrome (AGS) and bilateral striatal necrosis (BSN). In mammals, ADAR1 consists of two isoforms: a nuclear short p isoform and a cytoplasmic long p isoform. Both isoforms contain right-handed dsRNA-binding and deaminase domains, whereas ADAR1 p contains a Z&#945; domain that binds Z-RNA.<sup>[<xref rid="R122" ref-type="bibr">122</xref>]</sup> ADAR1 inhibits PANoptosis by the combination of IFNs and nuclear export inhibitors (NEIs) by limiting the interaction of ZBP1 and RIPK3 through interaction with the Z&#945;2 structural domain of ZBP1.<sup>[<xref rid="R43" ref-type="bibr">43</xref>]</sup> In addition, ADAR1 inhibits the spontaneous activation of ZBP1, which induces CASP8-dependent apoptosis and MLKL-mediated necroptosis in ADAR1-deficient cells. The Z&#945; domain of ADAR1 promotes the A-to-I editing of endogenous Alu elements, preventing the formation of dsRNA through the pairing of inverted Alu repeats and inhibiting ZBP1 activation.<sup>[<xref rid="R123" ref-type="bibr">123</xref>]</sup> ADAR1 p also prevents ZBP1 from sensing endogenous Z-RNA through the Z&#945; domain and its RNA editing activity and prevents protein kinase R (PKR) from sensing endogenous right-handed dsRNAs, leading to translational inhibition and growth arrest.<sup>[<xref rid="R122" ref-type="bibr">122</xref>]</sup></p><p>ADAR1 is an important protein that regulates the generation of immunogenic endogenous dsRNA, which may activate ZBP1. As a negative regulatory factor of ZBP1, ADAR1 downregulates ZBP1-mediated self-inflammation and tumor rejection, and the interplay between ZBP1 and ADAR1 is crucial for maintaining cellular homeostasis and mitigating the onset and progression of diseases. There is ample evidence demonstrating that ADAR1, as a negative regulator, can inhibit the function of ZBP1. ZBP1 promotes IFN1 activation in mouse models with impaired ADAR1 function, leading to lethal pathology. The deletion of ZBP1 or mutations in its Z&#945; domain can reduce the expression of IFN-stimulated genes and significantly decrease early postnatal mortality in ADAR1 mutant mice, suggesting that ADAR1 prevents pathological occurrences by inhibiting ZBP1-mediated IFN1 activation.<sup>[<xref rid="R43" ref-type="bibr">43</xref>]</sup> Furthermore, ADAR1 conceals ZBP1-mediated necroptosis by suppressing endogenous Z-type double-stranded RNA (Z-RNAs), thereby influencing tumor responses to immune checkpoint inhibitors (ICB),<sup>[<xref rid="R124" ref-type="bibr">124</xref>]</sup> making the regulation of ADAR1 a target for combating tumor resistance.</p></sec><sec><title>IRF1</title><p>IRF1 is the first member of the IRF transcription factor family and was initially thought to be a regulator of IFN and IFN-stimulated genes (ISGs).<sup>[<xref rid="R125" ref-type="bibr">125</xref>]</sup> IRF1 is an upstream regulator of NLRP3 inflammasome and cell death during IAV infection and acts to promote NLRP3 inflammasome activation and cell death during IAV infection. IRF1 is a transcriptional regulator of ZBP1, and cells deficient in IRF1 have reduced ZBP1 formation following IAV infection.<sup>[<xref rid="R126" ref-type="bibr">126</xref>]</sup> Furthermore, in PANoptosis, IRF1 induces the activation of the PANoptosome and promotes PANoptosis.<sup>[<xref rid="R90" ref-type="bibr">90</xref>]</sup> Research has revealed the critical role of IRF1 in the activation of inflammasomes and cell death during IAV infection. This finding further underscores the complex interactions among key molecules that regulate inflammatory responses and cell death during viral infections. As a transcriptional regulator of ZBP1, IRF1 may enhance antiviral host defenses by mediating inflammatory responses and mechanisms of cell death. Therefore, further exploration of whether IRF1 plays a similar role in other viral infections is necessary. Moreover, as a large family, other IRF family members might also have transcriptional regulatory effects on ZBP1 and subsequent PCD, warranting further research to identify these potential interactions.</p></sec><sec><title>Tripartite motif containing 34 (TRIM34)</title><p>Tripartite motif (TRIM) family includes over 70 highly conserved proteins. TRIM34, a member of TRIM family, interacts with ZBP1 as an upstream signaling pathway and promotes its polyubiquitination with the K63 linkage. Through <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> experiments, it has been shown that the interaction between TRIM34 and ZBP1 depends on cell death and inflammatory responses induced by the IAV, and that the expression and interaction of TRIM34 with ZBP1 can protect mice from death caused by IAV infection. Analysis of clinical samples indicates that the levels of pro-inflammatory cytokines in IAV-infected patients correlate with the levels of ZBP1. Therefore, TRIM34 has been identified as an important regulatory factor in virus-induced PCD.<sup>[<xref rid="R127" ref-type="bibr">127</xref>]</sup> However, aside from this isolated study, there are no other studies that have confirmed an association between members of the TRIM family and ZBP1.</p></sec><sec><title>Replication protein A1 (RPA1)</title><p>RPA1 is a highly conserved protein found in eukaryotic organisms that plays a crucial role in the processes of DNA replication, recombination, and repair. As a protein that binds single-stranded DNA (ssDNA), RPA1 detects the accumulation of ssDNA that occurs during lagging strand synthesis. This detection helps mitigate the fragility of the replication fork and activates signaling pathways mediated by ataxia telangiectasia and Rad3-related protein (ATR).<sup>[<xref rid="R128" ref-type="bibr">128</xref>]</sup> The depletion of RPA1 leads to lymphopenia by suppressing peripheral T-cell populations and limiting TCR repertoire diversity, thereby increasing susceptibility to inflammatory diseases, such as colitis and hepatitis. The loss of RPA1, which is upstream of ZBP1, induces severe DNA damage during T-cell expansion and activates ZBP1&#8211;RIPK3 signaling by triggering the leakage of genomic DNA to the cell membrane. T-cell necrosis increases the release of DAMPs, thereby amplifying the host&#8217;s innate immune response and exacerbating inflammatory damage. RPA1 expression is reduced in patients with ulcerative colitis or other autoinflammatory diseases.<sup>[<xref rid="R129" ref-type="bibr">129</xref>]</sup> RPA1 restricts DNA replication stress and promotes the self-replication of peripheral T cells.</p></sec><sec><title>Transforming growth factor &#946;-activated kinase 1 (TAK1)</title><p>TRIF is an adaptor protein associated with the Toll-like receptor (TLR) signaling pathway. In addition to playing a crucial role in the activation of TLR-mediated innate immunity, TRIF is also involved in the assembly of a multiprotein complex known as the &#8220;TRIFosome.&#8221; TAK1 serves as a downstream serine/threonine kinase of TRIF, playing a key role, as it can activate various kinases, such as IKK, JNK, and p38. These kinases not only regulate the expression of inflammatory cytokines but also help resist cell death in multiple scenarios.<sup>[<xref rid="R130" ref-type="bibr">130</xref>]</sup> TAK1 inactivation can be regarded as a master switch for ZBP1-mediated PANoptosis.<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> TAK1 deficiency triggers the RIPK1-dependent assembly of the PANoptosome. TAK1 inhibits phosphorylation and limits the activation of RIPK1, thereby blocking the assembly of PANoptosomes and the onset of PANoptosis. The inactivation of TAK1 leads to the formation of a cytosolic ripoptosome-like complex, which has the potential to initiate a diverse cell death process known as PANoptosis. TAK1 plays a pivotal role by inhibiting the phosphorylation of RIPK1, which is essential for preventing its activation and inhibiting the spontaneous onset of PANoptosis.<sup>[<xref rid="R131" ref-type="bibr">131</xref>]</sup> IAV infection can induce GSDME-mediated pyroptosis in respiratory epithelial cells. The activities of ZBP1 and RIPK1 are crucial for the activation of CASP8 and 3 and GSDMD/E, as well as for pyroptosis, while the activation of TAK1 inhibits these pathways through the TRIF adaptor protein.<sup>[<xref rid="R132" ref-type="bibr">132</xref>]</sup> Research shows that IAV infection activates TAK1, inhibiting RIPK1-dependent apoptosis and RIPK3-independent necroptosis in mouse alveolar epithelial cell line (LET1) and mouse fibrosarcoma cell line (L929). The TAK1 inhibitor <italic toggle="yes">5Z</italic> and <italic toggle="yes">TAK1</italic> gene knockout significantly enhance cell death caused by the influenza virus, indicating a protective role of TAK1 in this process. TAK1 activates the IKK and p38 pathways, inhibiting the activation of RIPK1, and while RIPK3 is critical for influenza virus-induced necroptosis, it is not essential for apoptosis.<sup>[<xref rid="R133" ref-type="bibr">133</xref>]</sup> In addition, a study of baicalin found that after the use of TAK1 inhibitors (such as OXO), BMDMs exhibited significant ZBP1-mediated PANoptosis.<sup>[<xref rid="R134" ref-type="bibr">134</xref>]</sup> In summary, the activation of TAK1 can partially block the PCD pathway mediated by ZBP1, thereby preventing cell death and tissue damage. The relationship between the two has been partially elucidated in some studies, but a more detailed mechanism remains to be further explored in subsequent studies.</p></sec><sec><title>p53 Upregulated modulator of apoptosis (PUMA)</title><p>ZBP1 expression and the downstream activation of RIPK3 and MLKL depend on a positive feedback mechanism. PUMA is a BH3-only member of the Bcl-2 family identified as a downstream target of the tumor suppressor p that effectively induces apoptosis in various tissues and cell types. PUMA induces mitochondrial dysfunction and initiates cell death signaling by binding to antiapoptotic members of the Bcl-2 family, which activates the proapoptotic proteins Bax and Bak. Additionally, PUMA enhances RIP3/MLKL-mediated necroptotic cell death by activating cytosolic DNA sensors. In cells expressing RIP3, the transcriptional activation of PUMA is promoted by autocrine TNF-&#945; and NF-&#954;B activity, further driving the release of mtDNA and the activation of the DNA sensors ZBP1 and STING, which increases the phosphorylation of RIP3 and MLKL. Notably, the deletion of PUMA partially rescues the developmental defects caused by necrotic cell death in FADD-deficient embryos. In certain colorectal cancer cells that express RIP3, necroptosis reliant on RIP3, rather than RIP1, has been identified as a major mechanism of cell death, particularly when these cells are treated with antimetabolites, such as 5-fluorouracil (5-FU). We identified a novel 5-FU-induced necrotic pathway that relies on the induction of the p53-mediated proapoptotic protein PUMA, facilitating the release of mtDNA and the activation of RIP3. <italic toggle="yes">In vitro</italic> and <italic toggle="yes">in vivo</italic> experiments demonstrated that PUMA/RIP3-dependent necrosis has significant antitumor effects and promotes a robust antitumor immune response, providing new insights for improving the treatment of colorectal cancer.<sup>[<xref rid="R135" ref-type="bibr">135</xref>,<xref rid="R136" ref-type="bibr">136</xref>]</sup> PUMA promotes the cytosolic release of mtDNA and the activation of ZBP1/RIPK3 and STING, which leads to increased phosphorylation of RIP3 and MLKL in a positive feedback loop.</p><p>In this section, we selected molecules that are currently related to the study of the ZBP1 mechanism and have relatively clear mechanisms. It should be noted that the ZBP1 and its regulated PCD signaling pathway network is quite complex, and not all molecules are included in this chapter; there are still many unexplained mechanisms that require further research for clarification.</p></sec></sec></sec><sec><title>Role of ZBP1 in Related Diseases and Therapeutic Implications</title><p>Given its ability to regulate a wide range of PCDs, ZBP1 is encompassed in the pathogenesis and progression of a wide range of infectious and non-infectious diseases and may have potential applications in the treatment of disease [Figure <xref rid="F3" ref-type="fig">3</xref>]. In this section, we will discuss in detail the research progress of ZBP1 in infectious and non-infectious diseases, as well as the possible therapeutic applications at present.</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3</label><caption><p>Diseases associated with ZBP1 in human systems. ZBP1 is involved in the development of both infectious and non-infectious diseases, playing a role with potential therapeutic value in respiratory diseases, skin and mucosal diseases, haematolymphatic diseases, neurological disorders, gastrointestinal diseases, cardiovascular diseases, and genitourinary diseases. CMV: Cytomegaloviruse; EPEC: Enteropathogenic <italic toggle="yes">Escherichia coli</italic> enteritis; HIV: Human immunodeficiency virus; HSV: Her-pes simplex virus; IAV: Influenza A virus; MRV: Mammalian orthoreovirus; Mtb: <italic toggle="yes">Mycobacterium tuberculosis</italic>; VACV: Vaccinia virus.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cm9-138-2421-g003.jpg"/></fig><sec><title>Virus infections</title><p>Infectious diseases are significant factors affecting human health, and among these, viral infectious diseases represent a common burden of transmissible diseases.<sup>[<xref rid="R137" ref-type="bibr">137</xref>]</sup> ZBP1 was initially identified as an innate sensor of viruses that senses viral ligands and stimulates host defenses by promoting inflammatory signal transduction and adaptive immune responses, thereby regulating the body&#8217;s response to viral infections. ZBP1 has been extensively studied in the context of infections caused by both DNA and RNA viruses. Under physiological conditions, ZBP1 specifically binds to the Z conformation, exhibiting relatively stable binding to dsRNA and dsDNA. When dsRNA and dsDNA are affected by certain external conditions (such as high-salt environments), they can transition to the Z conformation, which is recognized by ZBP1. Under physiological conditions, the transition of dsDNA requires the action of DNA unwinding enzymes (such as helicases and polymerases) to induce the transition in a negative supercoiling manner.<sup>[<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R138" ref-type="bibr">138</xref>]</sup> In infectious diseases caused by viruses, certain viral infections produce Z-RNA during replication, and ZBP1 senses these Z-RNA to activate cellular death and inflammation. ZBP1 is widely presented in virus-mediated PCD as an important mechanism of the body&#8217;s resistance to viral infections, including IAV,<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> herpes simplex virus (HSV),<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> mammalian orthoreovirus&#8217;s (MRVs),<sup>[<xref rid="R139" ref-type="bibr">139</xref>]</sup> cytomegaloviruses (CMVs),<sup>[<xref rid="R49" ref-type="bibr">49</xref>,<xref rid="R64" ref-type="bibr">64</xref>]</sup> vaccinia virus (VACVs),<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup> severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),<sup>[<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R140" ref-type="bibr">140</xref>]</sup> and human immunodeficiency virus type 1 (HIV-1).<sup>[<xref rid="R141" ref-type="bibr">141</xref>]</sup> IFN-induced 2&#8242;-5&#8242;-Oligoadenylate Synthetase Like (OASL) does not function as an enzyme. Nevertheless, OASL displays potent antiviral activity, and OASL promotes necroptosis-mediated antiviral immunity by providing a scaffold for the assembly of RIPK3&#8211;ZBP1 through its phase-separated droplets.<sup>[<xref rid="R142" ref-type="bibr">142</xref>]</sup> Moreover, when SET domain-bound histone lysine methyltransferase 1 (SETDB1) is knocked down, its RIPK3 neighboring members increase RIPK3 expression, and reactivated endogenous retroviruses produce excessive viral mimicry that promotes necroptosis via ZBP1.<sup>[<xref rid="R143" ref-type="bibr">143</xref>]</sup></p><p>As the first virus discovered to be recognized by ZBP1, IAV infection is essential in all studies of ZBP1. IAV has different subtypes, such as the seasonal IAV H1N1 and H3N2 subtypes that commonly lead to influenza illness. The most frequent symptom of infection is significant inflammation of the lower respiratory tract.<sup>[<xref rid="R144" ref-type="bibr">144</xref>]</sup> Human infection with IAV can range from asymptomatic cases to severe influenza requiring hospitalization, even resulting in death, depending on the subtype and the strength of the host&#8217;s defenses. Following IAV infection, the host rapidly initiates an inflammatory response, resulting in a cytokine storm. When this response is excessive or dysregulated, it can cause substantial tissue damage or even death.<sup>[<xref rid="R145" ref-type="bibr">145</xref>,<xref rid="R146" ref-type="bibr">146</xref>]</sup> Mechanistically, IAV induces PCD through both intrinsic pathways, which involve the recognition of PAMPs by host PRRs, and extrinsic pathways induced by effector molecules produced by immune cells, leading to the programmed death of target cells.<sup>[<xref rid="R147" ref-type="bibr">147</xref>]</sup> IAV is a negative-sense RNA virus that is cytotoxic to most cell types in which it replicates. During the active replication of the virus, the major product is defective viral genomes (DVGs) of Z-RNA, including the DVG RNA of Z-RNA, which are often poorly encapsidated, making them easily detectable by the host&#8217;s innate immune system.<sup>[<xref rid="R148" ref-type="bibr">148</xref>]</sup> The viral ribonucleoprotein (vRNP) complex and the polymerase subunit PB1 of IAV are recognized by ZBP1, and the induction of IAV RNA by retinoic acid-inducible gene I (RIG-I) initiates ZBP1-mediated cell death via the RIG-I&#8211;MAVS&#8211;IFN-&#946; signaling axis. Mediators involved in the pathogenesis of IAV infection, including IFNs, TNF&#945;, and agonists of TLRs 3 and 4, are also involved.<sup>[<xref rid="R149" ref-type="bibr">149</xref>]</sup> Studies have shown that ZBP1 activates RIPK3 to promote NLRP3 inflammasome activation and proinflammatory cytokine production, thus leading to pyroptosis.<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup> At the same time, IAV activates apoptosis, as well as necroptosis, of which necroptosis is often considered to be a fail-safe mechanism for apoptosis, but in fact, both cell death pathways compensate for each other, and both independently lead to the death of the cell, clearing the infected cell and thus protecting the host.<sup>[<xref rid="R150" ref-type="bibr">150</xref>]</sup> In fact, apoptosis driven by FADD and CASP-8 accounts for the majority of cell death following IAV infection. Apoptosis can limit the spread of the virus within lung tissue, thereby preventing collateral damage to other parts of the tissue. Moreover, RIPK3 activated by ZBP1 can mediate both necroptotic apoptosis and the occurrence of apoptosis itself. This finding may indicate that during IAV infection, cells essentially activate a PANoptotic pathway, regulating the production of the inflammatory cytokine storm from multiple angles. However, current research often shows only a single mode of cell death at the single-cell level, with cells exhibiting features of two or more death modalities being rare. This phenomenon may arise after ZBP1 recognizes and initiates PCD, potentially choosing to selectively activate a preferred PCD pathway or suppress the occurrence of others based on random chance, the cell type, or the nature of the insult. For example, in myeloid cells, IAV infection typically leads to ZBP1-mediated activation of NLRP3, which results in pyroptosis, differing from the necroptotic apoptosis or apoptosis commonly induced in macrophages. The reason for this pattern, where multiple PCD pathways can be activated simultaneously but ultimately result in the activation of only one specific pathway, as well as how this selection occurs, remain unclear. Future studies need to focus more on single-cell investigations to address this unresolved question.</p><p>Although the cell death induced by IAV ultimately manifests as the initiation of a single programmed death pathway, simply inhibiting one pathway of cell death is insufficient to halt the downstream responses elicited by IAV. For instance, preventing necroptosis by blocking RIPK3 kinase activity or eliminating MLKL expression does not significantly alter the extent or timing of cell death in mice, as apoptosis is still triggered.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> Similarly, inhibiting apoptosis can lead to the alternative initiation of necroptosis. Only by simultaneously inhibiting both pathways can cells evade the fate of death. IAV produces Z-RNA, which activates ZBP1 in the nucleus of infected cells through its Za2 domain, perhaps a new pathogen-associated molecular pattern. During IAV infection, ZBP1 function is regulated by many mediators. For example, ZBP1 activation is regulated by IRF1, RIPK1 prevents ZBP1 from binding to and activating RIPK3, and FADD and CASP8 act as anti-necroptotic agents through CSAP8-mediated cleavage of RIPK3.<sup>[<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R151" ref-type="bibr">151</xref>]</sup> Activation of ZBP1 initiates RIPK3-mediated MLKL activation in the nucleus, leading to nuclear membrane disruption, DNA leakage into the cytoplasm, and ultimately necroptosis. The initiation of necroptosis can eliminate the virus from the body during IAV infections; however, in severe cases of IAV infection, it may lead to the host&#8217;s death. Whether to activate this pathway, or to choose to activate a specific pathway at a certain stage of the disease, may represent a method for treating influenza.<sup>[<xref rid="R152" ref-type="bibr">152</xref>]</sup> From this perspective, modulating ZBP1 may become a new strategy for the future treatment of influenza caused by IAV.</p><p>In addition to being widely studied in IAV infections, the regulatory role of ZBP1 has also been extensively reported in other DNA and RNA viruses. HSV1 is a dsDNA virus that predominantly infects human epithelial cells and can be latent in the nervous system for long periods, also triggering necroptosis.<sup>[<xref rid="R153" ref-type="bibr">153</xref>]</sup> ZBP1 is required for the recognition of HSV-1 and HSV-2. Infected cell protein 6 (ICP6) of HSV-1 and ICP of HSV-2 are large subunits (R1) of a ribonucleotide reductase, which possesses a viral RHIM that competes with ZBP1 for binding to RIPK3, thereby blocking RIPK3-mediated necroptosis. Studies have revealed an increase in the ZBP1 concentration in human cells following ICP6 intervention. In addition to direct activation of RIPK3 by ICP6, HSV-1 infection in mice and mouse cells triggers virus-induced necroptosis via ZBP1.<sup>[<xref rid="R83" ref-type="bibr">83</xref>]</sup> Viruses associated with RHIM domain interactions include varicella-zoster virus (VZV) and mouse cytomegalovirus (MCMV). VZV utilizes the viral RHIM found within the capsid protein open reading frame (ORF) to form decoy assemblies that inhibit RHIM signal transduction, thereby suppressing ZBP1-driven apoptosis.<sup>[<xref rid="R91" ref-type="bibr">91</xref>]</sup> CMVs belong to the herpesvirus family and are dsDNA viruses. ZBP1 is a key sensor for mouse cytomegalovirus (MCMV)-induced necrotic apoptosis in its natural host, and the Za2 and RHIM structural domains are required for MCMV-mediated necrotic apoptosis in both murine and human cells.<sup>[<xref rid="R49" ref-type="bibr">49</xref>,<xref rid="R154" ref-type="bibr">154</xref>]</sup> Protein 45 of MCMV (M45) was identified as an RHIM-containing protein that can bind to ZBP1 through its functional RHIM, and M45 inhibits RIP3 phosphorylation and potentially disrupts the ZBP1-RIP interaction.<sup>[<xref rid="R58" ref-type="bibr">58</xref>]</sup> Meanwhile, RHIM-dependent necroptosis can be inhibited by the MCMV-encoded viral inhibitor of RIP activation (vIRA) to necroptosis.<sup>[<xref rid="R48" ref-type="bibr">48</xref>]</sup> MCMV-induced ZBP1-dependent necroptosis requires viral vesicle translocation to the nucleus and subsequent viral IE3-dependent early transcription, but is not dependent on input viral DNA or newly synthesized virus.<sup>[<xref rid="R70" ref-type="bibr">70</xref>]</sup> The viruses mentioned above are all DNA viruses. In fact, many RNA viruses derived from bats also contain viral RHIM domains. However, aside from SARS-CoV-2, which caused the pandemic in 2019, the regulatory role of ZBP1 concerning these RNA viruses is currently unknown. Cells infected with SARS-CoV-2 produce Z-RNA, which upon recognition by ZBP1 activates the necroptotic pathway involving RIPK3-MLKL. Unlike the inhibitory effects of DNA virus RHIM, the RNA virus RHIM of SARS-CoV-2 promotes cell death. When the expression of ZBP1 or RIPK3 is absent, the immune cell infiltration and lung damage caused during SARS-CoV-2 infection are reduced. Furthermore, in cells infected with SARS-CoV-2 treated with IFN1, ZBP1 drives the activation of PANoptosis, at which point the RHIM domain of DNA viruses inhibits cell death. This suggests that it may represent a potential therapeutic strategy, in conjunction with ZBP1 inhibitors, for treating COVID-19 caused by SARS-CoV-2. MRVs are enveloped viruses with a segmented double-stranded RNA genome. In humans, members of this virus family have been shown to cause mild gastroenteritis in infants and may contribute to the development of inflammatory diseases. MRV also activates several PCD pathways, such as apoptosis, autophagy, pyroptosis, and necroptosis.<sup>[<xref rid="R155" ref-type="bibr">155</xref>]</sup> ZBP1 activates RIPK3-dependent cell death during lysogenic infection of Mammalian orthoreoviruses (ReoV), orthomyxoviruses, herpesviruses, and members of the poxvirus family. Orthomyxovirus Z-RNA is sensed by ZBP1 in the nucleus of infected cells, leading to RIPK3 nuclear activation and subsequent rupture of the nucleus.<sup>[<xref rid="R156" ref-type="bibr">156</xref>]</sup> Among them, Vaccinia virus (VACV) does not contain the RHIM structural domain; however, its E3 protein&#8217;s N-terminal contains a Z&#945; structural domain that can bind to and sequester Z-RNA, thereby evading the activation of ZBP1 and the subsequent cell death.</p><p>Considering the association of ZBP1 with various viruses, its potential therapeutic value in improving adverse outcomes of viral infections is also being studied. For example, ZBP1-deficient mice were significantly protected in TNF + IFN-&#947;-induced acute systemic inflammatory response syndrome (SIRS).<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> The body activates multiple PCDs controlled by ZBP1 in response to adverse infection outcomes. MLKL-induced cell death effectively activates neutrophils. MLKL-deficient mice have reduced nuclear disruption of lung epithelial cells, reduced neutrophil entry into infected lungs, and increased survival after infection with lethal doses of IAV.<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> In addition, the form of cell death after IAV infection encompasses pyroptosis, suggesting that ZBP1 is likely to lead to the realization of PANoptosis.<sup>[<xref rid="R155" ref-type="bibr">155</xref>]</sup> HSV-1 ICP6 was identified as an RHIM-containing viral inhibitor that targets RIPK3 and acts as an inhibitor of ZBP1-RIPK3 signaling, acting as an anti-necroptotic agent to block viral-induced necroptosis in its natural host. Since necroptosis is highly inflammatory, MRV-induced necroptosis not only promotes necroptosis in infected cells but also inflames the surrounding tumor microenvironment, provoking a beneficial anti-tumor immune response.<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> This suggests that PCD mediated by ZBP1 could serve as a typical point of regulation in the treatment of viral infectious diseases. In non-lethal virus infection loads, the initiation of ZBP1-mediated PCDs can assist the body in clearing the virus. However, in lethal virus infections, it is necessary to inhibit ZBP1 to prevent death caused by intense inflammation. In summary, ZBP1 has been identified as a virus sensor, and its significant role in viral infectious diseases is undeniable. Currently, research targeting ZBP1 in viral infections is increasing. Although there are currently no inhibitors or other regulatory drugs aimed at ZBP1, it may become a noteworthy therapeutic target in the future, whether in DNA or RNA virus infections.</p></sec><sec><title>Bacterial, fungal, and other pathogen infections</title><p>In addition to being extensively studied in viral infectious diseases, the role of ZBP1 in other infectious diseases, such as those caused by bacteria, fungi, and parasites, has also attracted the attention of researchers in recent years. In bacterial infections, fungal infections, and infections caused by other pathogens, ZBP1 recognizes LPS, which mediates necroptosis, and increased expression of ZBP1 is associated with the activation of RIPK1/RIPK3 and NF-&#954;B.<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup> LPS induces lung inflammation and injury through the activation of ZBP1-mediated necroptosis and the release of proinflammatory cytokines from macrophages, and this activation and associated lung inflammatory injury are strongly attenuated by silencing ZBP1 in bone marrow-derived macrophages (BMDMs).<sup>[<xref rid="R157" ref-type="bibr">157</xref>]</sup> In the inflammatory response to LPS or dsRNA, ZBP1 mediates the delivery of RIPK1 to the TLR3/4 aptamer TRIF, promotes M1 ubiquitination of RIPK1, and regulates the formation of proinflammatory TRIFosome complexes to maintain the activation of the RIPK1 downstream inflammatory signaling cascade.<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup> The TRIFosome consists of TRIF, ZBP1, RIPK1, FADD, CASP-8, and GSDMD, with ZBP1 serving not as a sensor but rather as a scaffold for the nucleation of the TRIFosome complex, mediating the interaction of the core components TRIF and RIPK1. In addition to the TRIFosome, the AIM2-PANoptosome has also been found to form during bacterial infections, facilitating the occurrence of downstream PANoptosis. Current research results favor the view of ZBP1 as a component of a scaffold or complex involved in PCD triggered by bacterial infections rather than having a sensor function. However, given the well-described role of ZBP1 as a viral sensor, this finding suggests potential crosstalk between pathways that regulate host responses to bacteria and viruses, with ZBP1 acting as a crucial bridge. Perhaps this role can be observed in future research.</p><p>Currently, studies targeting several bacteria have identified the regulatory role of ZBP1. <italic toggle="yes">Mycobacterium tuberculosis</italic> (Mtb) infection of macrophages leads to upregulation of MLKL, TNFR1, and ZBP1 and downregulation of cIAP1, which establishes a robust pro-necrotic environment.<sup>[<xref rid="R158" ref-type="bibr">158</xref>]</sup> Deletion of MLKL or inhibition of RIPK1 does not affect the survival of human or mouse macrophages. Therefore, although the necroptotic pathway is activated during Mtb lung infection, it does not impact disease outcomes and only marginally affects bacterial proliferation. Cisatracurium Besylate is highly protective against macrophage survival during Mycobacterium tuberculosis infection by inhibiting necroptosis. It does not interfere with the association of RIPK3 with its upstream kinases RIPK1 or ZBP1 but prevents RIPK3 from binding to the execution molecule MLKL to form a necroptosis complex, which significantly inhibits intracellular Mycobacterium tuberculosis amplification. And it has an auxiliary bacteriostatic effect.<sup>[<xref rid="R159" ref-type="bibr">159</xref>]</sup> In addition, the role of ZBP1 in other bacterial infections has been investigated. A. baumannii triggers TRIF-dependent production of IFN1, which in turn leads to activation of the NLRP3 inflammasome and may promote focal death and necrotic apoptosis through the expression of ZBP11, MLKL, CASP11, and GSDMD.<sup>[<xref rid="R160" ref-type="bibr">160</xref>]</sup> The enteropathogenic <italic toggle="yes">Escherichia coli</italic> enteritis (EPEC) degrades the RHIM-containing proteins RIPK1, RIPK3, TRIF, and ZBP1 during infection using the type III secretion system (T3SS) effector EspL, suggesting the possibility that gastrointestinal pathogens directly target RHIM-dependent inflammatory and necrotic signaling pathways,<sup>[<xref rid="R54" ref-type="bibr">54</xref>]</sup> results in a downregulation of the innate immune pathway, achieving a viral-like evasion effect. It is worth mentioning that, compared to viral infections, the PCD pathways mediated or participated in by ZBP1 do not fully determine the outcomes of bacterial infections. However, this does not imply that ZBP1 is uninvolved in bacterial infections. The specific positive or negative roles of ZBP1 in bacterial infections remain to be elucidated in future studies involving a broader range of bacterial species.</p><p>ZBP1 is involved in both PCD resulting from infections with fungi and other pathogens. As an apical sensor of fungal infections, ZBP1 is responsible for the activation of pyroptosis, apoptosis, and necroptosis. Inflammasomes, which are usually formed upstream of pyroptotic cells, have been characterized as key mediators of fungal sensing and drivers of proinflammatory responses. Candida albicans and Aspergillus infections induce ZBP1-dependent PANoptosis in BMDMs.<sup>[<xref rid="R161" ref-type="bibr">161</xref>]</sup> When ZBP1 expression is lost or when there is a deletion in the coding region of its Z&#945;2 domain, the activation of the PANoptosome is reduced, leading to decreased release of proinflammatory cytokines and alleviating inflammation caused by pathogen infection. In parasitic infections, ZBP1 has been found to limit the replication of parasites and plays a key role in the degradation pathways of parasites while also protecting the host from parasite-induced inflammation. Toxoplasma gondii infection activates the PRR pathway, which drives innate inflammatory responses to control the infection, whereas ZBP1&#8211;RIKP3 mediates host control of and resistance to Toxoplasma gondii infection.<sup>[<xref rid="R162" ref-type="bibr">162</xref>,<xref rid="R163" ref-type="bibr">163</xref>]</sup> The survival of ZBP1-deficient mice is reduced after Toxoplasma gondii infection, and RIPK3-deficient mice have significantly increased survival after Toxoplasma gondii infection, suggesting that Toxoplasma gondii infection depends on ZBP1 but ZBP1 does not induce necroptotic pathways in response to this infection.<sup>[<xref rid="R162" ref-type="bibr">162</xref>]</sup></p><p>ZBP1-associated infectious diseases and the PCD processes they involve are displayed in Table <xref rid="T2" ref-type="table">2</xref>. ZBP1 was initially discovered for its function in infectious diseases. In these diseases, ZBP1 acts as a sensor that detects the assault of foreign pathogens and transmits signals to mediate PCD, while also serving as a support protein within the pathways of PCD. Many studies have reported various roles of ZBP1 in regulating host responses during pathogen infections; however, there remain significant research gaps. For example, it is unclear what factors determine the differing roles of ZBP1 in infections by different pathogens, what influences the initiation of various forms of PCD, and the detailed molecular mechanisms and regulatory networks during infections have yet to be clarified. The regulatory role of ZBP1 in infectious diseases cannot be overlooked and it holds promise as a new therapeutic target for treating these conditions.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>ZBP1-associated infectious diseases and involved PCD pathways.</p></caption><table frame="hsides" rules="groups" border="0"><thead><tr><th align="left" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Infections</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Major finding of ZBP1</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">PCD involved</th></tr></thead><tbody><tr><td colspan="3" align="left" valign="top" rowspan="1">Viral infections</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">IAV</td><td align="left" valign="top" rowspan="1" colspan="1">Recognize IAV&#8217;s Z-RNA, vRNP complex, and polymerase subunit PB1, mediate cell death.</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis, pyroptosis, apoptosis, PANoptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">HSV</td><td align="left" valign="top" rowspan="1" colspan="1">Direct recognition of HSV-1 and HSV-2 without the need for ICP6 to activate RIPK3.</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">MRV</td><td align="left" valign="top" rowspan="1" colspan="1">Identify Z-DNA of MRV to activate RIPK3.</td><td align="left" valign="top" rowspan="1" colspan="1">Apoptosis, autophagy, pyroptosis, necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Cytomegaloviruses</td><td align="left" valign="top" rowspan="1" colspan="1">Identify Z-DNA mediates RHIM-dependent necroptosis; or inhibits necroptosis by binding to M45.</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">HIV-1</td><td align="left" valign="top" rowspan="1" colspan="1">Activation of ZBP1 enhances HIV-1 replication through the NF-&#954;B pathway.</td><td align="left" valign="top" rowspan="1" colspan="1">/</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">SARS-CoV-2</td><td align="left" valign="top" rowspan="1" colspan="1">Cells infected with SARS-CoV-2 produce Z-RNA, which upon recognition by ZBP1 activates the necroptotic pathway involving RIPK3-MLKL. </td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">VACV</td><td align="left" valign="top" rowspan="1" colspan="1">Identify Z-RNA, which mediates RHIM-dependent necroptosis, or binds to VACV protein E3 to halt the transmission of death signals.</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Bacterial infections</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">
<italic toggle="yes">Mycobacterium tuberculosis</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">Identify lipopolysaccharides, upregulate and engage RIPK1 and RIPK3 to establish a robust pro-necrotic environment.</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">
<italic toggle="yes">A. baumannii</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">Interaction of NLRP3 with IFN1 activation.</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis, pyroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Enteropathogenic <italic toggle="yes">Escherichia coli</italic> enteritis</td><td align="left" valign="top" rowspan="1" colspan="1">Participate in RHIM dependency inflammation and necrosis signaling pathway.</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Fungal and other pathogen infections</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">
<italic toggle="yes">Candida albicans/Aspergillus</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">Participate the activation of pyroptosis, apoptosis, and necroptosis.</td><td align="left" valign="top" rowspan="1" colspan="1">Pyroptosis, apoptosis, necroptosis, PANoptosis</td></tr><tr><td align="left" valign="top" style="border-bottom:solid;padding-left:1em;" rowspan="1" colspan="1">
<italic toggle="yes">Toxoplasma gondii</italic>
</td><td align="left" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">Mediate host control of <italic toggle="yes">Toxoplasma gondii</italic> infection and promote host resistance to <italic toggle="yes">Toxoplasma gondii</italic> infection.</td><td align="left" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">Necroptosis</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>HIV-1: Human immunodeficiency virus type 1; HSV: Herpes simplex virus; IAV: Influenza A virus; ICP6: Infected cell protein 6; IFN: Interferons; M45: Mouse cytomegalovirus protein M45; MRV: Mammalian orthoreovirus; NF-&#954;B: Nuclear factor kappa-B; NLRP3: NOD-, LRR-, and pyrin domain-containing protein 3; PB1: P hox and B em 1 domain; PCD: Programmed cell death; RHIM: RIP homotypic interaction motif; RIPK1/3: Receptor-interacting protein kinase 1/3; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; VACV: Vaccinia virus; vRNP: Viral ribonucleoprotein; ZBP1: Z-DNA-binding protein 1. /: Not available.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Nervous system diseases</title><p>The central nervous system (CNS) is a complex structure composed of the brain and spinal cord, and its development relies primarily on the mechanism of PCD. During normal nervous system development, apoptosis is the most significant manifestation of PCD, particularly during the stages of neural embryonic development and postnatal neural development. Apoptosis affects various cell types, including neural progenitor cells (NPCs), mature neurons after division, and glial cells. This process of selective cell death is crucial, as it ensures that only cells of the appropriate size and morphology can survive. Furthermore, the surviving cells establish appropriate connections with their respective axons and dendrites, thereby performing essential functions within the neural network. Through stringent temporal and spatial regulation, apoptosis lays the foundation for the correct function and structure of the central nervous system, ensuring that the nervous system can conduct signal transmission and information processing in the most effective manner. PCD plays an important role in the pathogenesis of the central nervous system, with specific roles in brain development, homeostasis, and the clearance of infected/transformed cells.<sup>[<xref rid="R164" ref-type="bibr">164</xref>]</sup> Apoptosis is considered to be the predominant form of PCD in the nervous system.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup> Apoptosis is considered the predominant form of PCD in the nervous system. In contrast, other PCD pathways also play important roles in neurodegeneration, such as pyroptosis, which is associated with AD, multiple sclerosis, and traumatic brain injury, and are related to the pathology of the disease.<sup>[<xref rid="R165" ref-type="bibr">165</xref><xref rid="R166" ref-type="bibr">166</xref><xref rid="R167" ref-type="bibr">167</xref>]</sup> Necroptosis has also been shown to be related to the pathophysiology of neurological disorders, such as amyotrophic lateral sclerosis (ALS),<sup>[<xref rid="R168" ref-type="bibr">168</xref>]</sup> schizophrenia,<sup>[<xref rid="R169" ref-type="bibr">169</xref>]</sup> and ischemia.<sup>[<xref rid="R170" ref-type="bibr">170</xref>]</sup> AD is a complex neurodegenerative disorder characterized primarily by the formation of &#946;-amyloid (A&#946;) plaques and the abnormal aggregation of the tau protein. Research has shown that various immune cells in the brain, particularly microglia and astrocytes, play key roles in the pathogenesis of this disease. The cells of the innate immune system are not only crucial for clearing pathogens, such as bacteria and viruses but also essential for maintaining homeostasis of the internal environment of the brain and regulating the progression of AD. When these immune cells are activated, they can induce PCD through various mechanisms, including pyroptosis, apoptosis, necroptosis, and PANoptosis. Cell death may lead to chronic neuroinflammation, which is associated with neurodegenerative diseases and may worsen attention deficit disorder. These processes of cell death are typically accompanied by the release of proinflammatory cytokines, which help to enhance the innate immune response and promote the clearance of A&#946; plaques and the aggregated tau protein. However, sustained cell death and the resulting chronic neuroinflammation are closely associated with neurodegenerative diseases and may further exacerbate the progression of AD. Among the possible therapeutic mechanisms for AD is the propagation of the innate immune response due to the release of proinflammatory cytokines as a result of cell death, which usually leads to the elimination of A&#946; plaques and aggregated Tau proteins.<sup>[<xref rid="R171" ref-type="bibr">171</xref>]</sup> The AIM2 defect has been shown to reduce A&#946; deposition and microglial activation in AD mouse models, suggesting that the AIM2-PANoptosome may play a role in AD.<sup>[<xref rid="R172" ref-type="bibr">172</xref>]</sup> Additionally, ZBP1, as a key molecule in the formation of this structure, may also contribute to the regulation of AD mechanisms. Furthermore, AD may be related to the inflammatory factors released by microglia and astrocytes, with viral infections exacerbating neuroinflammation, leading to ZBP1 or AIM2-mediated PANoptosis, which could influence the pathogenesis of AD.<sup>[<xref rid="R53" ref-type="bibr">53</xref>]</sup> Currently, therapeutic targets for AD concerning PCD pathways and neuroinflammation include NLRP3, RIPK1, CASP1, and GSDMD.<sup>[<xref rid="R118" ref-type="bibr">118</xref>,<xref rid="R173" ref-type="bibr">173</xref>]</sup> Given the interconnected roles of ZBP1 in various PCD processes, ZBP1 may also be a potential therapeutic target for AD in the future.</p><p>In the neuroinflammation caused by the invasion of pathogens into the nervous system, ZBP1 can serve as a significant regulatory target. Neuroglial cells in the brain, such as microglia and astrocytes, are involved in inflammatory responses within the central nervous system. In the central nervous system, Zika virus (ZIKV) can infect various cell types, and ZBP1 exhibits a cell type-specific role in this process. Research indicates that in human astrocytes infected with Zika virus, the expression of ZBP1 is significantly upregulated; moreover, the levels of phosphorylation of RIPK3 and MLKL in the cells also increase correspondingly. ZIKV-induced necroptosis is RIPK1-dependent in astrocytes, and in ZIKV-infected astrocytes stimulates upregulation of the ZBP1-RIPK3.<sup>[<xref rid="R174" ref-type="bibr">174</xref>,<xref rid="R175" ref-type="bibr">175</xref>]</sup> However, in neurons, the activation of ZBP1 limits the replication of the Zika virus through a mechanism that is independent of cell death. During this process, ZBP1 works in conjunction with the RIPK1/3 signaling pathway to promote the upregulation of immune response gene 1 (IRG1) enzymatic activity, thereby altering the metabolic state of neurons and enhancing their antiviral capacity. Similarly, in HSV-1-infected astrocytes, deletion of ZBP1 in astrocytes leads to an increase in the number of viral particles released after HSV-1 infection.<sup>[<xref rid="R174" ref-type="bibr">174</xref>]</sup> ZBP1 promotes virus-induced apoptosis of glial cells and may reduce the morbidity and mortality associated with HSV encephalitis.</p><p>In addition to diseases related to the central nervous system, research has also identified the role of ZBP1 in peripheral neuropathy. In the pathogenesis of peripheral neuropathies, Seh1 (also known as SEH1L in mammals) safeguards genomic stability by mediating the interaction between SETDB1 and KAP1. Upon ablation of Seh1, the disruption of the interaction rescinds the inhibition of endogenous retroviruses and triggers ZBP1-dependent necroptosis in Schwann cells. Seh1 is required for Schwann cell homeostasis through the maintenance of genome integrity, and a reduction in the nuclear protein may be involved in the pathogenesis of peripheral neuropathies.<sup>[<xref rid="R176" ref-type="bibr">176</xref>]</sup></p></sec><sec><title>Inflammatory diseases</title><p>In addition to ZBP1 activation caused by exogenous infections, ZBP1 has been implicated in the development of inflammatory diseases, such as periodontitis.<sup>[<xref rid="R88" ref-type="bibr">88</xref>,<xref rid="R177" ref-type="bibr">177</xref>]</sup> The immune system recognizes endogenous danger signals, and the resulting inflammatory response is referred to as sterile inflammation. ZBP1 plays a crucial role in regulating sterile inflammation, particularly in the development of various noninfectious chronic diseases. IFN1 has become a core component of the immunopathology of systemic autoimmune diseases, with systemic lupus erythematosus being one of the most representative examples. Studies have shown that patients with systemic lupus erythematosus and other systemic autoimmune diseases, such as rheumatoid arthritis, systemic sclerosis, and Sj&#246;gren&#8217;s syndrome, present elevated levels of IFN1 in their serum. The sustained production of IFN1 drives almost all components of the immune system toward pathological functions, leading to tissue damage and disease onset. Dysregulation of the ability of ZBP1 to sense endogenous nucleic acids can drive inflammation, leading to the development of IL-driven inflammatory skin diseases, such as psoriasis.<sup>[<xref rid="R178" ref-type="bibr">178</xref>]</sup> Systemic lupus erythematosus is an autoimmune inflammatory connective tissue disease, and PANoptosis may mediate immune dysregulation in patients with this disease. Additionally, predictive models established using key PRGs, such as ZBP1, have shown good diagnostic performance for systemic lupus erythematosus.<sup>[<xref rid="R179" ref-type="bibr">179</xref>]</sup> Recent studies have revealed the critical role of the Z&#945; domain of ZBP1 in autoinflammatory diseases, including the sensing of endogenous Z-DNA and the induction of downstream necroptosis, including conditions, such as development, intestinal inflammation, and dermatitis. The sensing of endogenous Z-DNA elements mediated by the Z&#945; domain, along with the functions regulated by the RHIM of ZBP1, together form the physiological basis for ZBP1&#8211;RIPK3&#8211;MLKL-dependent necroptosis and related activation of inflammation. Notably, when the Z&#945; domain within the Z&#945;2 domain is deleted or when functional Z-DNA-binding residues are mutated, RIPK1-mediated skin inflammation is abolished. Additionally, when the RHIM function of RIPK1 is compromised, the Z&#945;2 domain of ZBP1 can independently induce necroptosis, which may lead to perinatal lethality. Similarly, in intestinal epithelial cells (IECs) with a nonfunctional FADD&#8211;CASP8 axis, the occurrence of necroptosis and inflammation also depends on the Z&#945; domain of ZBP1. Dysregulated immune mediators and abnormal immune responses can lead to inflammatory bowel diseases. In inflammatory bowel disease, SETDB1 can inhibit ZBP1 activation to control intestinal inflammation. Endogenous retroviruses elicited by reduced levels of SETDB1 in inflammatory bowel disease (IBD) patients trigger ZBP1-dependent necroptosis, which irreversibly disrupts epithelial barrier homeostasis, resulting in intestinal epithelial damage and increased inflammation.<sup>[<xref rid="R179" ref-type="bibr">179</xref><xref rid="R180" ref-type="bibr">180</xref><xref rid="R181" ref-type="bibr">181</xref>]</sup> Pathways controlling intestinal epithelial cell (IEC) death modulate intestinal immune homeostasis and contribute to the treatment of inflammatory bowel disease. FADD prevents enteritis downstream of ZBP1 and TNFR1 by simultaneously inhibiting MLKL-induced necroptosis and CASP8-GSDMD-dependent epithelial cell charring.<sup>[<xref rid="R182" ref-type="bibr">182</xref>]</sup></p><p>The inhibition of ZBP1 expression for the control of inflammatory diseases may involve pervasive inflammation-based regulation. In addition to the aforementioned IBD, in the control of skin inflammation, ZBP1-mediated RIPK3&#8211;MLKL-dependent necroptosis can be inhibited by RIPK1 to attenuate skin inflammatory responses, as the scaffolding function of RIPK1 restricts the spontaneous activation of ZBP1, and the lack of ZBP1 inhibits keratinocyte necroptosis and skin inflammation in epidermis-specific RIPK1 knockout mice.<sup>[<xref rid="R183" ref-type="bibr">183</xref>]</sup> This finding is consistent with the inhibitory effect of RIPK1 that we discussed earlier, which has also been observed in models of inflammatory bowel disease and perinatal lethality. In addition to RIPK1, recent studies have revealed a truncated form of mouse ZBP1, known as &#8220;ZBP1ca,&#8221; which contains only the Z&#945; domain and RHIM-A, is missing amino acid residues, and exhibits persistent activity. Full-length ZBP1 requires caspase inhibition to induce cell death in mouse fibroblasts, whereas ZBP1ca can induce cell death independently of caspase inhibitors. These findings indicate that the expression of ZBP1ca is sufficient to cause the death of keratinocytes and quickly leads to severe skin damage in mice. Furthermore, the kinase activity of RIPK1 is not essential for ZBP1ca-induced RIPK1&#8211;CASP8-mediated apoptosis, whereas the RIPK1&#8211;CASP8 axis plays an opposing role in regulating the signaling processes mediated by full-length ZBP1 and ZBP1ca.<sup>[<xref rid="R184" ref-type="bibr">184</xref>]</sup></p><p>In addition to the aforementioned diseases, the occurrence and progression of other types of sterile inflammation have also been found to be regulated by ZBP1 through PCD. A house dust mite (HDM)-induced asthma mouse model and macrophages presented significantly elevated levels of ZBP1, p-RIPK3, and p-MLKL, and the transcript release factor PTRF mediated ZBP1-induced necroptosis and airway inflammation, effects that were potentiated by bronchial epithelial cell-derived LL-33.<sup>[<xref rid="R177" ref-type="bibr">177</xref>]</sup> In individuals with acute pancreatitis (AP), tsRNAs suppress ZBP1 expression, thereby inhibiting NLRP3-mediated apoptosis and inflammation.<sup>[<xref rid="R185" ref-type="bibr">185</xref>]</sup> ZBP1 modulates the inflammatory response of inflammatory cells, fibroblasts, and endothelial cells to mtDNA and acts as an endogenous suppressor of mtDNA-induced myocardial inflammation during cardiac remodeling, exerting a protective effect.<sup>[<xref rid="R186" ref-type="bibr">186</xref>]</sup> Given the important role of ZBP1 in regulating inflammation and autoimmunity in infectious diseases, its role in sterile diseases and autoimmune diseases in the body also requires future investigation. As a class of common human diseases with common features, the clarification of ZBP1 function may provide new targets for the treatment of inflammatory diseases.</p></sec><sec><title>Tumors</title><p>A large number of studies indicate that different forms of PCD, such as apoptosis, pyroptosis, necroptosis, and ferroptosis, play significant roles in tumorigenesis. If any single or combination of PCD processes lose regulation, it may promote cancer development. Abnormal expression and significant mutations of PANoptosis-related genes (PRGs), including <italic toggle="yes">NLRP3, CASP8</italic>, and <italic toggle="yes">TNFAIP3</italic>, have been observed in various cancer types. As an important PRG, ZBP1 has been shown to be a crucial factor in regulating the death of various cancer cells. When ZBP1 is overexpressed intracellularly, it can effectively activate DNA-sensing innate immune responses as an adjuvant for DNA vaccines and create a sustained pro-inflammatory tumor microenvironment, resulting in the continuous production of cytotoxic CD8<sup>+</sup> T lymphocytes (CTLs). ZBP1 is involved in neoplasm development, necrosis, metastasis and prognosis. Its pro- or anti-tumorigenic function depends on the type of tumors and provides new methods for the treatment of tumors. Currently, research on the functions of ZBP1 has covered multiple tumor systems, demonstrating broad potential. ZBP1 is involved in the development and progression of a variety of tumors, including breast cancer,<sup>[<xref rid="R187" ref-type="bibr">187</xref>,<xref rid="R188" ref-type="bibr">188</xref>]</sup> melanoma,<sup>[<xref rid="R189" ref-type="bibr">189</xref>]</sup> colorectal cancer,<sup>[<xref rid="R52" ref-type="bibr">52</xref>]</sup> multiple myeloma,<sup>[<xref rid="R190" ref-type="bibr">190</xref>]</sup> ovarian cancer,<sup>[<xref rid="R191" ref-type="bibr">191</xref>]</sup> uroepithelial carcinoma,<sup>[<xref rid="R192" ref-type="bibr">192</xref>]</sup> hepatocellular carcinoma,<sup>[<xref rid="R193" ref-type="bibr">193</xref>]</sup> fibrosarcoma,<sup>[<xref rid="R194" ref-type="bibr">194</xref>]</sup> and renal clear cell carcinoma.<sup>[<xref rid="R55" ref-type="bibr">55</xref>]</sup> The role of ZBP1 in the occurrence and treatment of tumors is dual-directional. In this section, we will provide an overview of the current research findings regarding ZBP1 in tumors and discuss its potential roles or challenges in tumor treatment.</p><p>The activation of ZBP1 may inhibit tumor growth or play a regulatory role in antitumor therapy. Tumors arise through the accumulation of genetic and epigenetic alterations that enable cells to bypass telomeric barriers, proliferate, and achieve immortality. One such barrier is replicative crisis, an autophagy-dependent program that eliminates checkpoint-deficient cells with telomere instability and other cancer-associated chromosomal aberrations.<sup>[<xref rid="R98" ref-type="bibr">98</xref>]</sup> Research indicates that ZBP1 is crucial in the early stages of replication stress, acting as a key factor promoting the innate immune response and eliminating damaged cells. ZBP1 can act as a regulator by binding to and activating telomeric repeat-containing RNA (TERRA) transcripts synthesized from dysfunctional telomeres after induction by the cGAS&#8211;STING DNA induction pathway.<sup>[<xref rid="R55" ref-type="bibr">55</xref>]</sup> TERRA and ZBP1 interact to activate the innate immune adaptor mitochondrial antiviral signaling protein (MAVS), initiating a deleterious IFN response that depends on MAVS.<sup>[<xref rid="R98" ref-type="bibr">98</xref>]</sup> From this perspective, the activation of ZBP1 executes autophagy-dependent cell death through the autophagy pathway, inhibiting the tumorigenic transformation of these cells. The activation of the cGAS&#8211;STING1 signaling pathway can subsequently trigger ZBP1&#8211;RIPK3&#8211;MLKL-dependent necrotic apoptosis to regulate tumor cell proliferation. Moreover, ZBP1 plays a key role in radiation-induced antitumor immunity by forming a necrotic signal through its interaction with MLKL. This signal can activate the STING pathway within tumor cells, thereby enhancing the antitumor response. Research has shown that ZBP1-dependent MLKL activation can trigger an IFN response following radiation, with mechanisms involving the accumulation of DNA in the cytoplasm that subsequently activate the cGAS&#8211;STING signaling pathway, creating a positive feedback loop that continuously induces an inflammatory response. By removing CASP8, the activation of the STING pathway is increased, further enhancing the antitumor effects of radiation. During chemotherapy, the oxidative stress induced by sodium arsenite and the chemotherapeutic agent cisplatin significantly promotes the formation of endogenous Z-RNA in host cells. Z-RNA is localized to stress granules by ZBP1, triggering necrotic apoptosis in tumor cells and significantly enhancing the effects of tumor chemotherapy.<sup>[<xref rid="R195" ref-type="bibr">195</xref>]</sup> A recent study indicated that an HSV-1-based oncolytic virus (oHSV) enhances antitumor immune effects by triggering ZBP1-mediated PANoptosis; in combination with Fusobacterium nucleatum outer membrane vesicles (Fn-OMVs), it further activates PANoptosis executors, demonstrating robust antitumor immunogenicity.<sup>[<xref rid="R196" ref-type="bibr">196</xref>]</sup> Fisetin inhibits cell growth in a dose-dependent manner, inducing both apoptosis and necrotic apoptosis, in which ZBP1 regulates necrotic apoptosis through the RIP3/MLKL pathway.<sup>[<xref rid="R197" ref-type="bibr">197</xref>]</sup> This evidence suggests that activating ZBP1 is an effective antitumor strategy for certain types of tumors and represents a potential therapeutic approach.</p><p>However, the activation of ZBP1 is not always associated with tumor suppression. In some cases, ZBP1 is significantly related to the occurrence and development of tumors, playing a negative role in tumor therapy. ZBP1 promotes the phosphorylation of IRF3 by interacting with TBK1 and IRF3 in multiple myeloma, thereby activating cell cycle genes and promoting the proliferation of myeloma cells.<sup>[<xref rid="R190" ref-type="bibr">190</xref>]</sup> ZBP1-mediated dysregulation of PCD leads to aberrant cell growth, causing tumor growth, which is a hallmark feature of cancer pathologies and a potential therapeutic tool at this time. ZBP1 in combination with ADAR1 in mouse BMDMs using NEIs sequesters ADAR1 in the nucleus and increases the incidence of cell death. Induction of PANoptosis using a combination of NEIs and IFN may rapidly reduce tumor size and tumor growth.<sup>[<xref rid="R198" ref-type="bibr">198</xref>]</sup> In the context of cancer, the increased expression of ADAR1-p150 has been shown to limit the binding of ZBP1 and RIPK3, thereby inhibiting ZBP1-mediated PANoptosis to promote tumor growth. Similarly, in adrenocortical carcinoma (ACC), cyclin dependent kinase 1 (CDK1) regulates PANoptosis in ACC cells in a ZBP1-dependent manner by binding to the PANoptosome, whereas CurE is a potential candidate for ACC through the modulation of the EMT, G2/M checkpoints and PANoptosis.<sup>[<xref rid="R199" ref-type="bibr">199</xref>]</sup> Knockdown of ZBP1 in ovarian cancer (OC) cell lines attenuated the strong expression of RIPK3 and MLKL, and apoptosis and necroptosis were concurrently involved in fisetin-induced cell death in OC cells, demonstrating the inhibitory effect of fisetin on ovarian cancer.<sup>[<xref rid="R197" ref-type="bibr">197</xref>]</sup> The apoptosis regulator Bcl-2 family member inhibitor ABT-737 can inhibit the proliferation and invasion of bladder cancer cells by inducing cell death, and ZBP1 and RIPK3 play a major role in ABT-737-induced cell death.<sup>[<xref rid="R191" ref-type="bibr">191</xref>]</sup> Arrowtoxin CBL0137 activates ZBP1 by triggering the formation of Z-DNA in cells, induces ZBP1-dependent necroptosis in cancer-associated fibroblasts, and reverses unresponsiveness to immune-checkpoint blockade (ICB)-based monotherapy in a mouse melanoma model.<sup>[<xref rid="R124" ref-type="bibr">124</xref>]</sup> In a study of patients with colorectal cancer, somatic copy number alterations were identified in 19 PCD-related genes (PRG), with the most significant copy number variations observed in ZBP1, GSDMD, AIM2, and NLRP3. Additionally, many genes exhibited an upregulation trend in tumor samples, including <italic toggle="yes">CASP8, MLKL, FADD</italic>, and <italic toggle="yes">TRADD</italic>, while the expression of <italic toggle="yes">CASP7, NLRP3, RIPK1</italic>, and <italic toggle="yes">RIRP3</italic> was found to be decreased. The combined use of IFN and nuclear export inhibitors (such as KPT-330) can induce ZBP1-dependent PANoptosis by regulating the interaction between ADAR1 and ZBP1, effectively inhibiting the occurrence and progression of colorectal cancer.<sup>[<xref rid="R200" ref-type="bibr">200</xref>]</sup> The above research indicates that in the development of certain specific tumors, there is often an accompanying activation and functional regulation of ZBP1. This seems contradictory to the previously mentioned potential therapeutic role of ZBP1. However, the role of ZBP1 and its mediated PCD in tumors is complex, and it is even related to tumor metastasis and patient prognostic outcomes. Currently, these studies are limited to descriptive associations and have not yet fully clarified the underlying molecular mechanisms.</p><p>Tumor necrosis is common in advanced solid tumors, and necroptosis plays an important role in tumor necrosis and is associated with metastasis. ZBP1 deficiency blocks necroptosis during tumorigenesis and inhibits metastasis, providing a potential pharmacological target for controlling metastasis. Glucose deprivation of tumor cells leads to the release of mtDNA into the cytoplasm. mtDNA binds to ZBP1 and activates MLKL to induce necrosis in a Bcl-2 family protein, NOXA-dependent manner.<sup>[<xref rid="R186" ref-type="bibr">186</xref>]</sup> Cancer-associated fibroblasts (CAFs) can be divided into myofibroblast CAFs, which promote immune rejection and limit tumor spread, and iCAFs (inflammatory CAFs), which respond to IFN and Janus kinase/signal transducer and activator of transcription, which promote seeding of distant metastatic foci but also represent tumor vulnerability. ZBP1 senses Z-DNA or Z-RNA when it triggers CAF death. Triggering ZBP1-dependent necrosis in iCAFs inhibits tumor growth and metastasis by exploiting the tumor vulnerability caused by the expression of ZBP1-dependent immune cell death pathways in iCAFs.<sup>[<xref rid="R201" ref-type="bibr">201</xref>]</sup> As a downstream of ZBP1, MLKL deficiency in mouse mammary tumors had a modest effect on advanced tumor growth, whereas blockade of necroptosis by MLKL ablation significantly reduced lung metastasis of breast cancer cells.<sup>[<xref rid="R188" ref-type="bibr">188</xref>]</sup></p><p>The expression of PCD-related genes is expected to become a prognostic factor for cancer patients. In a study by Song <italic toggle="yes">et al</italic>,<sup>[<xref rid="R202" ref-type="bibr">202</xref>]</sup> the PANoptotic score was identified as an independent prognostic indicator for gliomas. The authors constructed this score based on the molecular subtypes of PANoptosome-related genes in gliomas, combined with various clinical characteristics of antitumor immunity. The results showed significant changes in the expression of five genes in glioma samples, further suggesting a deep intrinsic association between PANoptosis and gliomas. ZBP1 is also associated with the tumor prognosis, and PCD-related biomarkers, including ZBP1, have been found to be valuable in predicting the survival outcomes of breast cancer patients.<sup>[<xref rid="R203" ref-type="bibr">203</xref>]</sup> The <italic toggle="yes">ZBP1</italic> gene in patients with acute myeloid leukemia has been identified as an independent risk factor for patient prognosis.<sup>[<xref rid="R204" ref-type="bibr">204</xref>,<xref rid="R205" ref-type="bibr">205</xref>]</sup> In a highly immunogenic cancer type, renal clear cell carcinoma (KIRC), necroptosis-related genes (NRGs), including ZBP1, were associated with treatment response,<sup>[<xref rid="R206" ref-type="bibr">206</xref>]</sup> and the NRGs-related features could be used as a novel prognostic predictor of the immune microenvironment and therapeutic response in KIRC. High expression of PANoptotic genes is deleterious in low-grade gliomas (LGG). Expression of ZBP1, ADAR, CASP2, CASP3, CASP4, CASP8, and GSDMD negatively affects the prognosis of LGG. In contrast, expression of ZBP1, NLRP1, CASP8, and GSDMD positively affected the prognosis of cutaneous dermatomal melanoma (SKCM) and treatment of melanoma cells with a combination of therapies activating ZBP1 induced PANoptosis, the prognostic value of which allowed the construction of a prognostic model of SKCM.<sup>[<xref rid="R207" ref-type="bibr">207</xref>]</sup> In the study of prostate adenocarcinoma (PRAD), various interfering factors and interactions related to PANoptosis have been identified, including gene mutations, transcriptional changes, methylation status, and clinical characteristics.<sup>[<xref rid="R208" ref-type="bibr">208</xref>]</sup> Researchers, including Yi and colleagues, revealed several enriched PANoptosis pathways by comparing differences between tumors and adjacent normal tissues, focusing on genes, such as <italic toggle="yes">ZBP1, RIPK1, CASP1, CASP6, CASP8</italic>, and <italic toggle="yes">FADD</italic>. These genes demonstrate a close relationship between apoptosis, pyroptosis, and necroptosis. By constructing the characteristics of PANoptosis, the study provides a reliable basis for prognostic assessment and prediction of immune therapy response in patients with PRAD.<sup>[<xref rid="R209" ref-type="bibr">209</xref>]</sup></p><p>ZBP1 acts as an innate immune receptor in influenza virus (IAV) infection, playing a crucial role not only as an important regulatory factor in PANoptosis but also as a key node in the signaling pathways of cell death. It is involved in the processes of pyroptosis, apoptosis, and necroptosis. Current studies have confirmed that in necroptotic tumors, the expression of ZBP1 is significantly elevated, and its absence hinders the necrosis and apoptosis processes within tumor cells, thereby suppressing the proliferation of tumor cells. This makes ZBP1 a potential drug target for controlling tumor metastasis. Currently, research exploring the therapeutic role of targeting ZBP1 in cancer has introduced a small molecule drug, curaxin CBL0137, which successfully activates ZBP1-dependent nuclear necroptosis by promoting the formation of Z-DNA by fibroblasts in the tumor microenvironment. This approach has significantly reversed the non-responsive state to immune checkpoint blockade (ICB) therapy in a melanoma mouse model.<sup>[<xref rid="R124" ref-type="bibr">124</xref>]</sup> ZBP1-mediated PCD is a new determinant of tumor immunogenicity; however, this effect may be masked by ZBP1 inhibitory factors, such as ADAR1, thereby diminishing ZBP1&#8217;s potential in driving cancer immunity. Thus, the importance of ZBP1 as a signaling target in tumor treatment strategies is increasingly emphasized. In the future of tumor therapy, ZBP1 remains a promising therapeutic target. However, as previously mentioned in this chapter, ZBP1 has both positive inhibitory effects and negative promotional effects in tumor regulation. Therefore, when discussing the therapeutic functions of ZBP1, it is also essential to consider its potential risks and possible adverse consequences. Currently, the specific molecular mechanisms by which ZBP1 regulates tumor progression or intervenes in therapeutic outcomes remain unclear, and its functionality varies significantly across different types of tumors in various systems. If ZBP1 is to be targeted for cancer treatment, further research into more specific mechanisms related to particular tumors is required.</p></sec><sec><title>Other related diseases</title><p>In the previous section, we mentioned that oxidative stress caused by the use of sodium arsenite and the chemotherapeutic drug cisplatin significantly induces host cells to trigger ZBP1-mediated necroptosis in tumor cells. Under physiological conditions, oxidative stress leads to damage to mtDNA and its release into the cytoplasm, thereby disrupting cellular homeostasis. Research has shown that mtDNA-specific damage and activation of the ZBP1 pathway are mechanisms that connect low-level oxidative stress to inflammation. Damaged mtDNA enters the cytoplasm, binds to ZBP1, and triggers an inflammatory response through the TANK-binding kinase 1/IFN regulatory factor 3 signaling pathway, resulting in the upregulation of inflammatory factors.<sup>[<xref rid="R210" ref-type="bibr">210</xref>]</sup> Mechanistically, after mtDNA enters the cytoplasm, a small portion is believed to be converted to the Z-form. The Z&#945; domain of ZBP1 binds to Z-form of mtDNA, stabilizing its Z conformation. This binding allows the cytosolic DNA sensor cGAS to recognize Z-form mtDNA and subsequently activate the IFN1 response. Following the sensing of mtDNA, the RHIM motif of ZBP1 facilitates its interaction with cGAS, forming a cytosolic complex that includes ZBP1, cGAS, RIPK1, and RIPK3. This complex upregulates the expression of ISGs through the phosphorylation of signal transducer and activator of transcription 1 (STAT1), thereby promoting the occurrence of the IFN1 response.<sup>[<xref rid="R211" ref-type="bibr">211</xref>]</sup> In addition to oxidative stress, cell death may also occur due to external noninfectious insults, such as physical or mechanical injury. ZBP1-mediated cell death is associated with exogenous strikes. Lung injury from mechanical ventilation is caused by RIPK1/ZBP1 pathway-dependent CASP1 pyroptosis. The RIPK1 inhibitor necrostatin-1 reduces the expression of pyroptosis-related proteins and inhibits the release of inflammatory cytokines in lung tissues exposed to mechanical ventilation.<sup>[<xref rid="R212" ref-type="bibr">212</xref>]</sup> In a heat shock mouse model and <italic toggle="yes">in vitro</italic> cultured cells, ZBP1 activated RIPK3&#8211;MLKL-dependent necroptosis and CASP8-dependent apoptosis. Heat stress increases ZBP1 expression through HSF1 and promotes ZBP1 aggregation, followed by RIPK3 recruitment, MLKL phosphorylation, and CASP8 cleavage, resulting in heat shock in organisms.<sup>[<xref rid="R213" ref-type="bibr">213</xref>]</sup> Although the specific mechanism of heat shock has not yet been fully elucidated, this study indicates that upon heat stimulation, ZBP1 mediates the body&#8217;s immune response, leading to damage. In addition, congenital biliary atresia (BA) has been found to cause hepatic fibrotic injury, with necroptosis present in BA livers and occurring in hepatic macrophages. This process is also mediated by ZBP1/p-MLKL.<sup>[<xref rid="R214" ref-type="bibr">214</xref>]</sup></p><p>In addition to mechanical damage, ZBP1 also initiates PCD in response to chemical injury or stimulation by toxic substances. ZBP1 is activated after the exposure of cells or tissues to exogenous toxins. Nonylphenol (NP) is one of the most toxic and ubiquitous endocrine-disrupting compounds, and upon NP exposure, the long non-coding RNA plasmacytoma variant translocation 1 mediates hepatic necroptosis via ZBP1 promoter methylation to cause liver injury.<sup>[<xref rid="R215" ref-type="bibr">215</xref>]</sup> Developmental exposure to sevoflurane results in extensive neuronal cell death, which is known as sevoflurane-induced neurotoxicity (SIN). During SIN, mtDNA is released into the cytoplasm, and the expression levels of RIPK1, RIPK3, ZBP1, and the membrane protein pMLKL are significantly elevated, with ZBP1 sensing cytosolic mtDNA to induce RIPK3/MLKL-driven necroptosis.<sup>[<xref rid="R216" ref-type="bibr">216</xref>]</sup> Environmental benzo(a)pyrene (BaP) is an organic pollutant, and BaP exposure in a mouse model induced placental tissue pyroptosis and abortion through upregulation of the mouse ZBP1/Nlrp3 axis, whereas the knockdown of Nlrp3 effectively decreased placental pyroptosis and attenuated BaP-induced abortion in mice.<sup>[<xref rid="R217" ref-type="bibr">217</xref>]</sup> Under arsenite stress, ZBP1 induces necroptosis. Arsenite stress leads to the formation of nonmembrane-bound regions known as stress granules, which are primarily composed of the stalled translation machinery and RNA-binding proteins. In cells stimulated by IFN, arsenite treatment prompts ZBP1 to accumulate at stress granules associated with classic Ras GTPase-activating protein 1 (G3BP1). ZBP1 colocalizes within stress granules with other components, further recruiting RIPK3 and mediating necrosome assembly.<sup>[<xref rid="R218" ref-type="bibr">218</xref>]</sup> Chemical damage may also occur with the improper use of certain drugs. For example, ZBP1 and cGAS jointly sense mtDNA, promoting cardiac toxicity. In cardiomyocytes treated with doxorubicin, an increase in the level of Z-type mtDNA, elevated expression of ZBP1, and increased IFN1 signaling were observed. Mice lacking ZBP1 or IFN1 signaling were protected against doxorubicin-induced cardiac toxicity.<sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup></p><p>In summary, ZBP1 may be activated in response to systemic stress, leading to cell death. Excessive physiological stress resulting from external attacks may cause severe tissue damage or even death. The above disease-related mechanisms make ZBP1 a potential therapeutic site for cells in the event of a blow, and blocking ZBP1 or its associated regulatory proteins may reverse or attenuate the outcome of cell death. Inhibiting ZBP1 could serve as a strategy to avert lethal outcomes under conditions of extreme stress.</p><p>In this chapter, we elaborate on the current research related to ZBP1 in the context of both infectious and non-infectious diseases, as well as the potential therapeutic strategies targeting ZBP1. It should be noted that most of the existing studies on ZBP1 have primarily been limited to <italic toggle="yes">in vitro</italic> cellular levels or <italic toggle="yes">in vivo</italic> experiments in experimental animals, and the mechanisms and applications in humans still require further validation through additional research. ZBP1-associated non-infectious diseases and the PCD processes they involve are displayed in Table <xref rid="T3" ref-type="table">3</xref>.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>ZBP1-associated non-infectious diseases and involved PCD pathways.</p></caption><table frame="hsides" rules="groups" border="0"><thead><tr><th align="left" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Diseases</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Major finding of ZBP1</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">PCD involved</th></tr></thead><tbody><tr><td colspan="3" align="left" valign="top" rowspan="1">Nervous system diseases</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Alzheimer&#8217;s disease</td><td align="left" valign="top" rowspan="1" colspan="1">Mediate neuronal cell damage, oxidative stress, and inflammation in collaboration with IRF3</td><td align="left" valign="top" rowspan="1" colspan="1">Pyroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Zika virus/HSV-related encephalitis</td><td align="left" valign="top" rowspan="1" colspan="1">Inhibit virus replication, promote virus-induced apoptosis, and necroptosis of glial cells</td><td align="left" valign="top" rowspan="1" colspan="1">Apoptosis, necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Peripheral neuropathies</td><td align="left" valign="top" rowspan="1" colspan="1">After reducing Seh1, it triggers ZBP1-dependent necroptosis in XPC cells</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Inflammatory and autoimmune diseases</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Periodontitis</td><td align="left" valign="top" rowspan="1" colspan="1">Simultaneously involved in apoptosis, necroptosis, and pyroptosis, to form PANoptosomes</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis, pyroptosis apoptosis, PANoptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Psoriasis</td><td align="left" valign="top" rowspan="1" colspan="1">Perceive endogenous nucleic acids drive antiviral and interleukin-17 immune responses</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Inflammatory bowel disease</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis mediated by ZBP1 dependency leads to irreversible disruption of the delicate epithelial barrier balance</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Systemic lupus erythematosus</td><td align="left" valign="top" rowspan="1" colspan="1">Form PANoptosomes</td><td align="left" valign="top" rowspan="1" colspan="1">PANoptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Sj&#246;gren&#8217;s syndrome</td><td align="left" valign="top" rowspan="1" colspan="1">Interaction with NLRP3 mediates chronic inflammation</td><td align="left" valign="top" rowspan="1" colspan="1">Pyroptosis, apoptosis, PANoptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Ulcerative colitis</td><td align="left" valign="top" rowspan="1" colspan="1">Promote infestans 1 production, mediate the death of inflammatory cells</td><td align="left" valign="top" rowspan="1" colspan="1">Pyroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Acute pancreatitis</td><td align="left" valign="top" rowspan="1" colspan="1">Identified as tRF3-Thr-AGT downstream target, mediating inflammatory cell death</td><td align="left" valign="top" rowspan="1" colspan="1">Pyroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Myocardial inflammation</td><td align="left" valign="top" rowspan="1" colspan="1">Inhibit myocardial inflammation and apoptosis, protecting cardiac remodeling as an endogenous inhibitory factor</td><td align="left" valign="top" rowspan="1" colspan="1">Apoptosis, pyroptosis</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Tumors</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Breast cancer</td><td align="left" valign="top" rowspan="1" colspan="1">Reestablishment of normal &#946;-actin mRNA targeting patterns and inhibition of primary tumor chemotaxis and invasion, inhibition of tumor metastasis; mediation of necroptosis in tumor cells</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="top" rowspan="1" colspan="1">Treatment of melanoma cells as a combination therapy induces PANoptosis</td><td align="left" valign="top" rowspan="1" colspan="1">PANoptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Multiple myeloma</td><td align="left" valign="top" rowspan="1" colspan="1">In myeloma plasma cells, constitutively expressed ZBP1 interacts with TBK1 and IRF3, leading to IRF3 phosphorylation</td><td align="left" valign="top" rowspan="1" colspan="1">Pyroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Ovarian cancer</td><td align="left" valign="top" rowspan="1" colspan="1">Role in tumor growth, regulation of necrotic processes through the RIPK3/MLKL pathway leads to OC cell death</td><td align="left" valign="top" rowspan="1" colspan="1">Apoptosis, PANoptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Uroepithelial carcinoma</td><td align="left" valign="top" rowspan="1" colspan="1">Induced cell necroptosis and inhibited proliferation and invasion</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Hepatocellular carcinoma</td><td align="left" valign="top" rowspan="1" colspan="1">Predicted the prognosis of hepatocellular carcinoma</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Fibrosarcoma</td><td align="left" valign="top" rowspan="1" colspan="1">Involvement in immunotherapy through RNA sensing effects</td><td align="left" valign="top" rowspan="1" colspan="1">/</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Renal clear cell carcinoma</td><td align="left" valign="top" rowspan="1" colspan="1">Predicted the prognosis of renal clear cell carcinoma</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Adrenocortical carcinoma</td><td align="left" valign="top" rowspan="1" colspan="1">Form PANoptosomes</td><td align="left" valign="top" rowspan="1" colspan="1">PANoptosis</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Other related diseases</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Acute lung injury</td><td align="left" valign="top" rowspan="1" colspan="1">RIPK1/ZBP1 pathway-dependent caspase-1 induces lung injury and causes inflammatory factor release</td><td align="left" valign="top" rowspan="1" colspan="1">Pyroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Heat shock</td><td align="left" valign="top" rowspan="1" colspan="1">Aggregation of ZBP1 recruited RIPK3</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis + C48</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Biliary atresia</td><td align="left" valign="top" rowspan="1" colspan="1">Induction of necroptosis in hepatic macrophages</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Nonylphenol poisoning</td><td align="left" valign="top" rowspan="1" colspan="1">The lncRNA PVT1 mediates hepatic necroptosis via ZBP1 promoter methylation to cause liver injury</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Sevoflurane-induced neurotoxicity</td><td align="left" valign="top" rowspan="1" colspan="1">Sense mtDNA in the cytoplasm induces RIPK3/MLKL-driven necrosis</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td align="left" valign="top" style="padding-left:1em;" rowspan="1" colspan="1">Benzo(a)pyrene poisoning</td><td align="left" valign="top" rowspan="1" colspan="1">Induction of placental tissue precipitation and abortion</td><td align="left" valign="top" rowspan="1" colspan="1">Necroptosis</td></tr><tr><td align="left" valign="top" style="border-bottom:solid;padding-left:1em;" rowspan="1" colspan="1">Arsenite poisoning</td><td align="left" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">Induction of RIPK3/MLKL-driven necroptosis</td><td align="left" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">Necroptosis</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>HSV: Herpes simplex virus; IRF3: Interferon regulatory factor 3; lncRNA: Long non-coding RNA; MLKL: Mixed lineage kinase domain-like; NLRP3: NOD-, LRR-, and pyrin domain-containing protein 3; PCD: Programmed cell death; PVT1: Plasmacytoma variant translocation 1; RIPK1/3: Receptor-interacting protein kinase 1/3; TBK1: TANK-binding kinase 1; XPC: Xeroderma pigmentosum group C; ZBP1: Z-DNA-binding protein 1; /: Not available.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec><title>Design for ZBP1 and Other PCD-Related Targets for Related Drugs</title><p>As mentioned earlier, ZBP1 has potential value in treatment strategies for both infectious and noninfectious diseases because of its unique mechanisms. However, to our knowledge, no small-molecule drugs designed to target ZBP1 are currently available. The complexity and uniqueness of targeted drug design present significant challenges for disease treatment. With the application of computational biology/chemistry techniques in drug design, numerous computer-aided drug design and artificial intelligence (AI)-driven drug design (CADD/AIDD) methods have recently emerged to facilitate the development of chemical drugs.<sup>[<xref rid="R219" ref-type="bibr">219</xref>,<xref rid="R220" ref-type="bibr">220</xref>]</sup> AI presents promising performance in compound validation, target identification, drug discovery, dosage design, and drug repositioning, with the rapid design and optimization of various chemical contents.<sup>[<xref rid="R221" ref-type="bibr">221</xref><xref rid="R222" ref-type="bibr">222</xref><xref rid="R223" ref-type="bibr">223</xref>]</sup> Traditional drug synthesis relies mainly on chemical and biological experimental methods to discover and screen effective drug components through experimentation and trial and error. Thus, traditional drug synthesis is time-consuming and expensive, ranging from target identification to preclinical research and clinical trials, the entire process is long, and the success rate is relatively low.<sup>[<xref rid="R224" ref-type="bibr">224</xref>]</sup> AI addresses these challenges by accelerating target selection through sophisticated algorithms, such as natural language processing, deep learning models, and generative adversarial networks.<sup>[<xref rid="R219" ref-type="bibr">219</xref>]</sup> Importantly, AI solves the central challenge of evaluating and predicting the biological effects of chemicals based on the pattern recognition approach.<sup>[<xref rid="R225" ref-type="bibr">225</xref>,<xref rid="R226" ref-type="bibr">226</xref>]</sup> In addition, AI can also be used to predict the drug response. The developed AI model not only accurately predicts the drug response within cell lines but also stratifies clinical outcomes. It designs synergistic drug combinations through mechanistic analyses and allows researchers to conduct systematic validation using a combination of CRISPR, <italic toggle="yes">in vitro</italic> drug screening, and patient-derived xenografts.<sup>[<xref rid="R227" ref-type="bibr">227</xref>]</sup></p><p>Since diverse PCD pathways are highly complex processes that involve multiple molecules, AI has great potential to identify accurate therapeutic targets for drug development. In fact, some studies have focused on PCD targeting via AI. For example, Liu <italic toggle="yes">et al</italic><sup>[<xref rid="R228" ref-type="bibr">228</xref>]</sup> revealed that deep neural networks can automatically locate fish ventricles and perform a multiplex cardiac functional analysis, and they identified cyanidin chloride (CyCl) as a potent inhibitor of doxorubicin-induced cardiotoxicity with the help of a deep learning-based phenotypic screen in zebrafish. Mechanistic studies showed CyCl potently prevents ferroptosis and apoptosis-related cell deaths. Moreover, Ouyang <italic toggle="yes">et al</italic><sup>[<xref rid="R229" ref-type="bibr">229</xref>]</sup> systematically identified target omics of TNBC pyroptosis based on the genetic profile and characteristics of TNBC patients and established a collection of potential pyroptosis inducers. With integrated bioinformatics analyses, AI, dosage form development, and experimental validation, the targeted omics-based intelligent drug discovery framework repurposes existing drugs and enables the precise treatment of refractory diseases. Li <italic toggle="yes">et al</italic><sup>[<xref rid="R230" ref-type="bibr">230</xref>]</sup> also found that machine learning and radiomics can be used to predict the efficacy of PCD protein 1 inhibitor for small cell lung cancer. In addition, by integrating approaches with enhanced data infrastructure, explainable AI, computational advances, and machine learning potentials, researchers can develop innovative nanomedicine solutions, ultimately improving therapeutic outcomes.<sup>[<xref rid="R231" ref-type="bibr">231</xref>]</sup> Although no AI technology is currently used to design drugs targeting ZBP1, combining the functionality of AI will enable the design and synthesis of ZBP1 inhibitors in the future.</p></sec><sec sec-type="conclusions"><title>Prospects and Conclusions</title><p>PCD is a crucial component in the development of organisms, playing a significant role in host defenses against pathogens and maintaining internal balance. In recent years, many new concepts related to PCD have emerged, and various signaling pathways and regulatory mechanisms related to PCD have gradually been discovered and refined. The excessive activation or inhibition of the PCD pathway can lead to various diseases, representing a potential mechanism for the onset of multiple illnesses. Activating, inhibiting, or otherwise regulating PCD-related transcription factors and effector proteins, including ZBP1, may become a new trend in the treatment of various infectious and noninfectious diseases, with various small-molecule drugs currently under development. Therefore, regulating PCD has significant therapeutic potential. ZBP1, with its unique RHIM and Z&#945; domains, is widely involved in PCD, showing potential therapeutic value in processes related to cell apoptosis, pyroptosis, necroptosis, PANoptosis, autophagy, ferroptosis, and NETosis.</p><p>In this article, we started by describing the structure and function of ZBP1 to discuss its regulatory role in various PCD pathways and the upstream and downstream molecules associated with ZBP1. Furthermore, we thoroughly investigated the implications of ZBP1 in various diseases and treatment strategies based on its regulatory role in PCD, and we propose possible adjunct measures for the future design of ZBP1-related drugs. In fact, numerous related molecules bind to ZBP1 or regulate it upstream and downstream, indirectly or directly modulating cell death pathways and outcomes. However, this article does not provide a complete summary; some mechanisms of interaction or regulation between ZBP1 and other molecules remain unclear. Current research on ZBP1-related molecules has focused mainly on RIPK3 or RIPK, which share the same RHIM domain, as well as classical regulatory factors of cell death, such as CASP8 and FADD. Additionally, emerging studies are detailing the functions of CASP6 and AIM2, and the molecular regulation of the Z&#945; domain of ZBP1 is also gradually being clarified. ZBP1 is well known for its roles in sensing and mediating IAV infections, as well as infections with bacteria, fungi, and other pathogens. As a key molecule involved in pathogen recognition, ZBP1 regulates the immune response to diverse infections to eliminate pathogens. However, severe infections can lead to fatal inflammatory cytokine storms, which are critical factors to consider in treatment. Moreover, ZBP1 plays a unique role in inflammation, autoimmune conditions, neurological diseases, and tumor occurrence and development. Given the potential value of ZBP1 in treating various human diseases, the contributions of ZBP1-related molecules to PCD remain a hot topic for future research. From a treatment strategy perspective, whether related to infectious diseases or not, the activation of PCD has a dual nature. It may eliminate pathogens or harmful factors to achieve better clinical outcomes, but it can also result in severe inflammatory cytokine storms, causing bodily harm or even death. Therefore, research on ZBP1 and other PCD-related molecules can contribute to a deeper understanding of disease diagnosis and treatment, leading to more informed diagnostic decisions. Although drugs specifically targeting ZBP1 are currently unavailable, the emergence of novel tools, such as AI may fill this gap in the future. The potential therapeutic value of ZBP1 may provide new perspectives for drug development in the future, holding promise for clinical applications. We hope that further studies can elucidate the mechanisms by which ZBP1 regulates various types of PCD, thereby contributing to disease diagnosis and treatment.</p></sec><sec><title>Funding</title><p>This work was supported by grants from the National Natural Science Foundation of China (Nos. 82273559, 82103757, and 82073473), the Department of Science and Technology of Sichuan Province (No. 2022YFQ0054), and Sichuan Natural Science Foundation Project (No. 2023NSFSC1554).</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p>None.</p></sec></body><back><fn-group><fn fn-type="equal" id="fna1"><p>Yuwei Huang and Lian Wang contributed equally to this work.</p></fn><fn fn-type="other"><p><bold>How to cite this article:</bold> Huang YW, Wang L, Zhu YH, Li XX, Dai YY, He G, Jiang X. Z-DNA-binding protein 1-mediated programmed cell death: Mechanisms and therapeutic implications. Chin Med J 2025;138:2421&#8211;2451. doi: 10.1097/CM9.0000000000003737</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woodle</surname><given-names>ES</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>S</given-names></name></person-group>. <article-title>Programmed cell death</article-title>. <source>Transplantation</source><year>1998</year>;<volume>66</volume>:<fpage>681</fpage>&#8211;<lpage>691</lpage>. <comment>doi: 10.1097/00007890-199809270-00001</comment>.<pub-id pub-id-type="pmid">9771830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-199809270-00001</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bredesen</surname><given-names>DE</given-names></name></person-group>. <article-title>Neural apoptosis</article-title>. <source>Ann Neurol</source><year>1995</year>;<volume>38</volume>:<fpage>839</fpage>&#8211;<lpage>851</lpage>. <comment>doi: 10.1002/ana.410380604</comment>.<pub-id pub-id-type="pmid">8526456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.410380604</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name></person-group>. <article-title>Inflammasomes and their roles in autoimmune diseases</article-title>. <source>Rheumatol Autoimmun</source><year>2024</year>;<volume>4</volume>:<fpage>197</fpage>&#8211;<lpage>217</lpage>. <comment>doi: 10.1002/rai2.12155</comment>.</mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name></person-group>. <article-title>Unveiling the nexus: decoding interactions between regulated cell death and systemic lupus erythematosus pathogenesis for innovative therapeutic avenues</article-title>. <source>Rheumatol Autoimmun</source><year>2024</year>;<volume>4</volume>:<fpage>1</fpage>&#8211;<lpage>10</lpage>. <comment>doi: 10.1002/rai2.12104</comment>.</mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurung</surname><given-names>P</given-names></name><name name-style="western"><surname>Anand</surname><given-names>PK</given-names></name><name name-style="western"><surname>Malireddi</surname><given-names>RKS</given-names></name><name name-style="western"><surname>Vande Walle</surname><given-names>L</given-names></name><name name-style="western"><surname>Van Opdenbosch</surname><given-names>N</given-names></name><name name-style="western"><surname>Dillon</surname><given-names>CP</given-names></name>, <etal/></person-group>. <article-title>FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes</article-title>. <source>J Immunol</source><year>2014</year>;<volume>192</volume>:<fpage>1835</fpage>&#8211;<lpage>1846</lpage>. <comment>doi: 10.4049/jimmunol.1302839</comment>.<pub-id pub-id-type="pmid">24453255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1302839</pub-id><pub-id pub-id-type="pmcid">PMC3933570</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shubina</surname><given-names>M</given-names></name><name name-style="western"><surname>Tummers</surname><given-names>B</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>DF</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C</given-names></name><name name-style="western"><surname>Gautam</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>Necroptosis restricts influenza A virus as a stand-alone cell death mechanism</article-title>. <source>J Exp Med</source><year>2020</year>;<volume>217</volume>:<fpage>e20191259</fpage>. <comment>doi: 10.1084/jem.20191259</comment>.<pub-id pub-id-type="pmid">32797196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20191259</pub-id><pub-id pub-id-type="pmcid">PMC7596817</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>JM</given-names></name><name name-style="western"><surname>Czabotar</surname><given-names>PE</given-names></name><name name-style="western"><surname>Hildebrand</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lucet</surname><given-names>IS</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>JG</given-names></name><name name-style="western"><surname>Alvarez-Diaz</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism</article-title>. <source>Immunity</source><year>2013</year>;<volume>39</volume>:<fpage>443</fpage>&#8211;<lpage>453</lpage>. <comment>doi: 10.1016/j.immuni.2013.06.018</comment>.<pub-id pub-id-type="pmid">24012422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2013.06.018</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broz</surname><given-names>P</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>VM</given-names></name></person-group>. <article-title>Inflammasomes: Mechanism of assembly, regulation and signalling</article-title>. <source>Nat Rev Immunol</source><year>2016</year>;<volume>16</volume>:<fpage>407</fpage>&#8211;<lpage>420</lpage>. <comment>doi: 10.1038/nri.2016.58</comment>.<pub-id pub-id-type="pmid">27291964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri.2016.58</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malireddi</surname><given-names>RKS</given-names></name><name name-style="western"><surname>Kesavardhana</surname><given-names>S</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group>. <article-title>ZBP1 and TAK1: Master regulators of NLRP3 inflammasome/pyroptosis, apoptosis, and necroptosis</article-title>. <source>Front Cell Infect Microbiol</source><year>2019</year>;<volume>9</volume>:<fpage>406</fpage>. <comment>doi: 10.3389/fcimb.2019.00406</comment>.<pub-id pub-id-type="pmid">31850239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2019.00406</pub-id><pub-id pub-id-type="pmcid">PMC6902032</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samir</surname><given-names>P</given-names></name><name name-style="western"><surname>Malireddi</surname><given-names>RKS</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group>. <article-title>The panoptosome: A deadly protein complex driving pyroptosis, apoptosis, and necroptosis (panoptosis)</article-title>. <source>Front Cell Infect Microbiol</source><year>2020</year>;<volume>10</volume>:<fpage>238</fpage>. <comment>doi: 10.3389/fcimb.2020.00238</comment>.<pub-id pub-id-type="pmid">32582562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2020.00238</pub-id><pub-id pub-id-type="pmcid">PMC7283380</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name></person-group>. <article-title>A comprehensive analysis of PANoptosome to prognosis and immunotherapy response in pan-cancer</article-title>. <source>Sci Rep</source><year>2023</year>;<volume>13</volume>:<fpage>3877</fpage>. <comment>doi: 10.1038/s41598-023-30934-z</comment>.<pub-id pub-id-type="pmid">36890219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-30934-z</pub-id><pub-id pub-id-type="pmcid">PMC9995449</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghavami</surname><given-names>S</given-names></name><name name-style="western"><surname>Shojaei</surname><given-names>S</given-names></name><name name-style="western"><surname>Yeganeh</surname><given-names>B</given-names></name><name name-style="western"><surname>Ande</surname><given-names>SR</given-names></name><name name-style="western"><surname>Jangamreddy</surname><given-names>JR</given-names></name><name name-style="western"><surname>Mehrpour</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Autophagy and apoptosis dysfunction in neurodegenerative disorders</article-title>. <source>Prog Neurobiol</source><year>2014</year>;<volume>112</volume>:<fpage>24</fpage>&#8211;<lpage>49</lpage>. <comment>doi: 10.1016/j.pneurobio.2013.10.004</comment>.<pub-id pub-id-type="pmid">24211851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2013.10.004</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>J</given-names></name><name name-style="western"><surname>Park</surname><given-names>H</given-names></name><name name-style="western"><surname>Heisler</surname><given-names>J</given-names></name><name name-style="western"><surname>Maculins</surname><given-names>T</given-names></name><name name-style="western"><surname>Roose-Girma</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Autophagy regulates inflammatory programmed cell death via turnover of RHIM-domain proteins</article-title>. <source>eLife</source><year>2019</year>;<volume>8</volume>:<fpage>e44452</fpage>. <comment>doi: 10.7554/eLife.44452</comment>.<pub-id pub-id-type="pmid">31287416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.44452</pub-id><pub-id pub-id-type="pmcid">PMC6615860</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yipp</surname><given-names>BG</given-names></name><name name-style="western"><surname>Kubes</surname><given-names>P</given-names></name></person-group>. <article-title>NETosis: how vital is it?</article-title><source>Blood</source><year>2013</year>;<volume>122</volume>:<fpage>2784</fpage>&#8211;<lpage>2794</lpage>. <comment>doi: 10.1182/blood-2013-04-457671</comment>.<pub-id pub-id-type="pmid">24009232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2013-04-457671</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Stockwell</surname><given-names>BR</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>M</given-names></name></person-group>. <article-title>Ferroptosis: Mechanisms, biology and role in disease</article-title>. <source>Nat Rev Mol Cell Biol</source><year>2021</year>;<volume>22</volume>:<fpage>266</fpage>&#8211;<lpage>282</lpage>. <comment>doi: 10.1038/s41580-020-00324-8</comment>.<pub-id pub-id-type="pmid">33495651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-020-00324-8</pub-id><pub-id pub-id-type="pmcid">PMC8142022</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>DF</given-names></name><name name-style="western"><surname>Quarato</surname><given-names>G</given-names></name><name name-style="western"><surname>Ingram</surname><given-names>JP</given-names></name><name name-style="western"><surname>Shubina</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Influenza virus Z-RNAs induce ZBP1-mediated necroptosis</article-title>. <source>Cell</source><year>2020</year>;<volume>180</volume>:<fpage>1115</fpage>&#8211;<lpage>1129</lpage>. <comment>doi: 10.1016/j.cell.2020.02.050</comment>.<pub-id pub-id-type="pmid">32200799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.02.050</pub-id><pub-id pub-id-type="pmcid">PMC7153753</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>M</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group>. <article-title>The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis)</article-title>. <source>Immunol Rev</source><year>2020</year>;<volume>297</volume>:<fpage>26</fpage>&#8211;<lpage>38</lpage>. <comment>doi: 10.1111/imr.12909</comment>.<pub-id pub-id-type="pmid">32729116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.12909</pub-id><pub-id pub-id-type="pmcid">PMC7811275</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>D</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Q</given-names></name>, <etal/></person-group>. <article-title>ZBP1 mediates interferon-induced necroptosis</article-title>. <source>Cell Mol Immunol</source><year>2020</year>;<volume>17</volume>:<fpage>356</fpage>&#8211;<lpage>368</lpage>. <comment>doi: 10.1038/s41423-019-0237-x</comment>.<pub-id pub-id-type="pmid">31076724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-019-0237-x</pub-id><pub-id pub-id-type="pmcid">PMC7109092</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>XY</given-names></name><name name-style="western"><surname>Dai</surname><given-names>YH</given-names></name><name name-style="western"><surname>Wan</surname><given-names>XX</given-names></name><name name-style="western"><surname>Hu</surname><given-names>XM</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Ban</surname><given-names>XX</given-names></name>, <etal/></person-group>. <article-title>ZBP1-mediated necroptosis: Mechanisms and therapeutic implications</article-title>. <source>Mol Basel Switz</source><year>2022</year>;<volume>28</volume>:<fpage>52</fpage>. <comment>doi: 10.3390/molecules28010052</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules28010052</pub-id><pub-id pub-id-type="pmcid">PMC9822119</pub-id><pub-id pub-id-type="pmid">36615244</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeffries</surname><given-names>AM</given-names></name><name name-style="western"><surname>Suptela</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>I</given-names></name></person-group>. <article-title>Z-DNA binding protein 1 mediates necroptotic and apoptotic cell death pathways in murine astrocytes following herpes simplex virus-1 infection</article-title>. <source>J Neuroinflammation</source><year>2022</year>;<volume>19</volume>:<fpage>109</fpage>. <comment>doi: 10.1186/s12974-022-02469-z</comment>.<pub-id pub-id-type="pmid">35549723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-022-02469-z</pub-id><pub-id pub-id-type="pmcid">PMC9103380</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muendlein</surname><given-names>HI</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>WM</given-names></name><name name-style="western"><surname>Magri</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jetton</surname><given-names>D</given-names></name><name name-style="western"><surname>Smirnova</surname><given-names>I</given-names></name><name name-style="western"><surname>Degterev</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>ZBP1 promotes inflammatory responses downstream of TLR3/TLR4 via timely delivery of RIPK1 to TRIF</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2022</year>;<volume>119</volume>:<fpage>e2113872119</fpage>. <comment>doi: 10.1073/pnas.2113872119</comment>.<pub-id pub-id-type="pmid">35666872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2113872119</pub-id><pub-id pub-id-type="pmcid">PMC9214535</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Comella</surname><given-names>N</given-names></name><name name-style="western"><surname>Tognazzi</surname><given-names>K</given-names></name><name name-style="western"><surname>Brown</surname><given-names>LF</given-names></name><name name-style="western"><surname>Dvorak</surname><given-names>HF</given-names></name><name name-style="western"><surname>Kocher</surname><given-names>O</given-names></name></person-group>. <article-title>Cloning of DLM-1, a novel gene that is up-regulated in activated macrophages, using RNA differential display</article-title>. <source>Gene</source><year>1999</year>;<volume>240</volume>:<fpage>157</fpage>&#8211;<lpage>163</lpage>. <comment>doi: 10.1016/s0378-1119(99)00419-9</comment>.<pub-id pub-id-type="pmid">10564822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-1119(99)00419-9</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takaoka</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Choi</surname><given-names>MK</given-names></name><name name-style="western"><surname>Yanai</surname><given-names>H</given-names></name><name name-style="western"><surname>Negishi</surname><given-names>H</given-names></name><name name-style="western"><surname>Ban</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response</article-title>. <source>Nature</source><year>2007</year>;<volume>448</volume>:<fpage>501</fpage>&#8211;<lpage>505</lpage>. <comment>doi: 10.1038/nature06013</comment>.<pub-id pub-id-type="pmid">17618271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature06013</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name>, <etal/></person-group>. <article-title>ZBP1: a powerful innate immune sensor and double-edged sword in host immunity</article-title>. <source>Int J Mol Sci</source><year>2022</year>;<volume>23</volume>:<fpage>10224</fpage>. <comment>doi: 10.3390/ijms231810224</comment>.<pub-id pub-id-type="pmid">36142136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms231810224</pub-id><pub-id pub-id-type="pmcid">PMC9499459</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kesavardhana</surname><given-names>S</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group>. <article-title>ZBP1: A STARG&#5168;TE to decode the biology of Z-nucleic acids in disease</article-title>. <source>J Exp Med</source><year>2020</year>;<volume>217</volume>:<fpage>e20200885</fpage>. <comment>doi: 10.1084/jem.20200885</comment>.<pub-id pub-id-type="pmid">32584411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20200885</pub-id><pub-id pub-id-type="pmcid">PMC7336316</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishii</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Kawagoe</surname><given-names>T</given-names></name><name name-style="western"><surname>Koyama</surname><given-names>S</given-names></name><name name-style="western"><surname>Matsui</surname><given-names>K</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>H</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines</article-title>. <source>Nature</source><year>2008</year>;<volume>451</volume>:<fpage>725</fpage>&#8211;<lpage>729</lpage>. <comment>doi: 10.1038/nature06537</comment>.<pub-id pub-id-type="pmid">18256672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature06537</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muendlein</surname><given-names>HI</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>WM</given-names></name><name name-style="western"><surname>Magri</surname><given-names>Z</given-names></name><name name-style="western"><surname>Smirnova</surname><given-names>I</given-names></name><name name-style="western"><surname>Ilyukha</surname><given-names>V</given-names></name><name name-style="western"><surname>Gautam</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>ZBP1 promotes LPS-induced cell death and IL-1&#946; release via RHIM-mediated interactions with ripk1</article-title>. <source>Nat Commun</source><year>2021</year>;<volume>12</volume>:<fpage>86</fpage>. <comment>doi: 10.1038/s41467-020-20357-z</comment>.<pub-id pub-id-type="pmid">33397971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-20357-z</pub-id><pub-id pub-id-type="pmcid">PMC7782486</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balachandran</surname><given-names>S</given-names></name><name name-style="western"><surname>Rall</surname><given-names>GF</given-names></name></person-group>. <article-title>Benefits and perils of necroptosis in influenza virus infection</article-title>. <source>J Virol</source><year>2020</year>;<volume>94</volume>:<fpage>10</fpage>&#8211;<lpage>1128</lpage>. <comment>doi: 10.1128/JVI.01101-19</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01101-19</pub-id><pub-id pub-id-type="pmcid">PMC7163144</pub-id><pub-id pub-id-type="pmid">32051270</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuriakose</surname><given-names>T</given-names></name><name name-style="western"><surname>Man</surname><given-names>SM</given-names></name><name name-style="western"><surname>Malireddi</surname><given-names>RKS</given-names></name><name name-style="western"><surname>Karki</surname><given-names>R</given-names></name><name name-style="western"><surname>Kesavardhana</surname><given-names>S</given-names></name><name name-style="western"><surname>Place</surname><given-names>DE</given-names></name>, <etal/></person-group>. <article-title>ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways</article-title>. <source>Sci Immunol</source><year>2016</year>;<volume>1</volume>:<elocation-id>aag2045</elocation-id>. <comment>doi: 10.1126/sciimmunol.aag2045</comment>.<pub-id pub-id-type="pmid">27917412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.aag2045</pub-id><pub-id pub-id-type="pmcid">PMC5131924</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kesavardhana</surname><given-names>S</given-names></name><name name-style="western"><surname>Kuriakose</surname><given-names>T</given-names></name><name name-style="western"><surname>Guy</surname><given-names>CS</given-names></name><name name-style="western"><surname>Samir</surname><given-names>P</given-names></name><name name-style="western"><surname>Malireddi</surname><given-names>RKS</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>ZBP1/DAI ubiquitination and sensing of influenza vRNPs activate programmed cell death</article-title>. <source>J Exp Med</source><year>2017</year>;<volume>214</volume>:<fpage>2217</fpage>&#8211;<lpage>2229</lpage>. <comment>doi: 10.1084/jem.20170550</comment>.<pub-id pub-id-type="pmid">28634194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20170550</pub-id><pub-id pub-id-type="pmcid">PMC5551577</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koehler</surname><given-names>H</given-names></name><name name-style="western"><surname>Cotsmire</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>S</given-names></name><name name-style="western"><surname>Upton</surname><given-names>JW</given-names></name><name name-style="western"><surname>Langland</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>Vaccinia virus E3 prevents sensing of Z-RNA to block ZBP1-dependent necroptosis</article-title>. <source>Cell Host Microbe</source><year>2021</year>;<volume>29</volume>:<fpage>1266</fpage>&#8211;<lpage>1276</lpage>. <comment>doi: 10.1016/j.chom.2021.05.009</comment>.<pub-id pub-id-type="pmid">34192517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2021.05.009</pub-id><pub-id pub-id-type="pmcid">PMC9333947</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>H</given-names></name><name name-style="western"><surname>Omoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Harris</surname><given-names>PA</given-names></name><name name-style="western"><surname>Finger</surname><given-names>JN</given-names></name><name name-style="western"><surname>Bertin</surname><given-names>J</given-names></name><name name-style="western"><surname>Gough</surname><given-names>PJ</given-names></name>, <etal/></person-group>. <article-title>Herpes simplex virus suppresses necroptosis in human cells</article-title>. <source>Cell Host Microbe</source><year>2015</year>;<volume>17</volume>:<fpage>243</fpage>&#8211;<lpage>251</lpage>. <comment>doi: 10.1016/j.chom.2015.01.003</comment>.<pub-id pub-id-type="pmid">25674983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2015.01.003</pub-id><pub-id pub-id-type="pmcid">PMC4382104</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ye</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>You</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>SARS-CoV-2 Z-RNA activates the ZBP1-RIPK3 pathway to promote virus-induced inflammatory responses</article-title>. <source>Cell Res</source><year>2023</year>;<volume>33</volume>:<fpage>201</fpage>&#8211;<lpage>214</lpage>. <comment>doi: 10.1038/s41422-022-00775-y</comment>.<pub-id pub-id-type="pmid">36650286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-022-00775-y</pub-id><pub-id pub-id-type="pmcid">PMC9844202</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>AH</given-names></name><name name-style="western"><surname>Quigley</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Kolpak</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>JL</given-names></name><name name-style="western"><surname>van Boom</surname><given-names>JH</given-names></name><name name-style="western"><surname>van der Marel</surname><given-names>G</given-names></name>, <etal/></person-group>. <article-title>Molecular structure of a left-handed double helical DNA fragment at atomic resolution</article-title>. <source>Nature</source><year>1979</year>;<volume>282</volume>:<fpage>680</fpage>&#8211;<lpage>686</lpage>. <comment>doi: 10.1038/282680a0</comment>.<pub-id pub-id-type="pmid">514347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/282680a0</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahayasheela</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Ooga</surname><given-names>M</given-names></name><name name-style="western"><surname>Kumagai</surname><given-names>T</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>H</given-names></name></person-group>. <article-title>Z-DNA at the crossroads: Untangling its role in genome dynamics</article-title>. <source>Trends Biochem Sci</source><year>2025</year>;<volume>50</volume>:<fpage>267</fpage>&#8211;<lpage>279</lpage>. <comment>doi: 10.1016/j.tibs.2025.01.001</comment>.<pub-id pub-id-type="pmid">39875265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibs.2025.01.001</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>SF</given-names></name><name name-style="western"><surname>Sirito</surname><given-names>M</given-names></name><name name-style="western"><surname>Krahe</surname><given-names>R</given-names></name><name name-style="western"><surname>Sinden</surname><given-names>RR</given-names></name></person-group>. <article-title>A Z-DNA sequence reduces slipped-strand structure formation in the myotonic dystrophy type 2 (CCTG) x (CAGG) repeat</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2009</year>;<volume>106</volume>:<fpage>3270</fpage>&#8211;<lpage>3275</lpage>. <comment>doi: 10.1073/pnas.0807699106</comment>.<pub-id pub-id-type="pmid">19218442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0807699106</pub-id><pub-id pub-id-type="pmcid">PMC2651351</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suram</surname><given-names>A</given-names></name><name name-style="western"><surname>Rao</surname><given-names>KSJ</given-names></name><name name-style="western"><surname>Latha</surname><given-names>KS</given-names></name><name name-style="western"><surname>Viswamitra</surname><given-names>MA</given-names></name></person-group>. <article-title>First evidence to show the topological change of dna from B-DNA to Z-DNA conformation in the hippocampus of Alzheimer&#8217;s brain</article-title>. <source>Neuromolecular Med</source><year>2002</year>;<volume>2</volume>:<fpage>289</fpage>&#8211;<lpage>297</lpage>. <comment>doi: 10.1385/nmm:2:3:289</comment>.<pub-id pub-id-type="pmid">12622407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1385/nmm:2:3:289</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buzzo</surname><given-names>JR</given-names></name><name name-style="western"><surname>Devaraj</surname><given-names>A</given-names></name><name name-style="western"><surname>Gloag</surname><given-names>ES</given-names></name><name name-style="western"><surname>Jurcisek</surname><given-names>JA</given-names></name><name name-style="western"><surname>Robledo-Avila</surname><given-names>F</given-names></name><name name-style="western"><surname>Kesler</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>Z-Form extracellular DNA is a structural component of the bacterial biofilm matrix</article-title>. <source>Cell</source><year>2021</year>;<volume>184</volume>:<fpage>5740</fpage>&#8211;<lpage>5758</lpage>. <comment>doi: 10.1016/j.cell.2021.10.010</comment>.<pub-id pub-id-type="pmid">34735796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.10.010</pub-id><pub-id pub-id-type="pmcid">PMC8595767</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>Y</given-names></name><name name-style="western"><surname>VanPortfliet</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YF</given-names></name><name name-style="western"><surname>Bryant</surname><given-names>JD</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fails</surname><given-names>D</given-names></name>, <etal/></person-group>. <article-title>Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity</article-title>. <source>Cell</source><year>2023</year>;<volume>186</volume>:<fpage>3013</fpage>&#8211;<lpage>3032</lpage>. <comment>doi: 10.1016/j.cell.2023.05.039</comment>.<pub-id pub-id-type="pmid">37352855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.05.039</pub-id><pub-id pub-id-type="pmcid">PMC10330843</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothenburg</surname><given-names>S</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>T</given-names></name><name name-style="western"><surname>Koch-Nolte</surname><given-names>F</given-names></name><name name-style="western"><surname>Haag</surname><given-names>F</given-names></name></person-group>. <article-title>Complex regulation of the human gene for the Z-DNA binding protein DLM-1</article-title>. <source>Nucleic Acids Res</source><year>2002</year>;<volume>30</volume>:<fpage>993</fpage>&#8211;<lpage>1000</lpage>. <comment>doi: 10.1093/nar/30.4.993</comment>.<pub-id pub-id-type="pmid">11842111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/30.4.993</pub-id><pub-id pub-id-type="pmcid">PMC100341</pub-id></mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deigendesch</surname><given-names>N</given-names></name><name name-style="western"><surname>Koch-Nolte</surname><given-names>F</given-names></name><name name-style="western"><surname>Rothenburg</surname><given-names>S</given-names></name></person-group>. <article-title>ZBP1 subcellular localization and association with stress granules is controlled by its Z-DNA binding domains</article-title>. <source>Nucleic Acids Res</source><year>2006</year>;<volume>34</volume>:<fpage>5007</fpage>&#8211;<lpage>5020</lpage>. <comment>doi: 10.1093/nar/gkl575</comment>.<pub-id pub-id-type="pmid">16990255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkl575</pub-id><pub-id pub-id-type="pmcid">PMC1636418</pub-id></mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>F</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K</given-names></name><name name-style="western"><surname>Liang</surname><given-names>F</given-names></name>, <etal/></person-group>. <article-title>Z-DNA binding protein 1 promotes heatstroke-induced cell death</article-title>. <source>Science</source><year>2022</year>;<volume>376</volume>:<fpage>609</fpage>&#8211;<lpage>615</lpage>. <comment>doi: 10.1126/science.abg5251</comment>.<pub-id pub-id-type="pmid">35511979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abg5251</pub-id></mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wachsmuth</surname><given-names>L</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>S</given-names></name><name name-style="western"><surname>Lohmann</surname><given-names>J</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>M</given-names></name><name name-style="western"><surname>Kaya</surname><given-names>GG</given-names></name>, <etal/></person-group>. <article-title>ADAR1 averts fatal type I interferon induction by ZBP1</article-title>. <source>Nature</source><year>2022</year>;<volume>607</volume>:<fpage>776</fpage>&#8211;<lpage>783</lpage>. <comment>doi: 10.1038/s41586-022-04878-9</comment>.<pub-id pub-id-type="pmid">35859176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-04878-9</pub-id><pub-id pub-id-type="pmcid">PMC9329096</pub-id></mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaiser</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Upton</surname><given-names>JW</given-names></name><name name-style="western"><surname>Mocarski</surname><given-names>ES</given-names></name></person-group>. <article-title>Receptor-interacting protein homotypic interaction motif-dependent control of NF-Kappa B activation via the DNA-dependent activator of IFN regulatory factors</article-title>. <source>J Immunol</source><year>2008</year>;<volume>181</volume>:<fpage>6427</fpage>&#8211;<lpage>6434</lpage>. <comment>doi: 10.4049/jimmunol.181.9.6427</comment>.<pub-id pub-id-type="pmid">18941233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.181.9.6427</pub-id><pub-id pub-id-type="pmcid">PMC3104927</pub-id></mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thapa</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Ingram</surname><given-names>JP</given-names></name><name name-style="western"><surname>Ragan</surname><given-names>KB</given-names></name><name name-style="western"><surname>Nogusa</surname><given-names>S</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>DF</given-names></name><name name-style="western"><surname>Benitez</surname><given-names>AA</given-names></name>, <etal/></person-group>. <article-title>DAI senses influenza A virus genomic RNA and activates RIPK3-dependent cell death</article-title>. <source>Cell Host Microbe</source><year>2016</year>;<volume>20</volume>:<fpage>674</fpage>&#8211;<lpage>681</lpage>. <comment>doi: 10.1016/j.chom.2016.09.014</comment>.<pub-id pub-id-type="pmid">27746097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2016.09.014</pub-id><pub-id pub-id-type="pmcid">PMC5687825</pub-id></mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wachsmuth</surname><given-names>L</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>S</given-names></name><name name-style="western"><surname>Schwarzer</surname><given-names>R</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Eren</surname><given-names>RO</given-names></name>, <etal/></person-group>. <article-title>Z-nucleic-acid sensing triggers ZBP1-dependent necroptosis and inflammation</article-title>. <source>Nature</source><year>2020</year>;<volume>580</volume>:<fpage>391</fpage>&#8211;<lpage>395</lpage>. <comment>doi: 10.1038/s41586-020-2129-8</comment>.<pub-id pub-id-type="pmid">32296175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2129-8</pub-id><pub-id pub-id-type="pmcid">PMC7279955</pub-id></mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ha</surname><given-names>SC</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>HY</given-names></name><name name-style="western"><surname>Rich</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YG</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KK</given-names></name></person-group>. <article-title>The crystal structure of the second Z-DNA binding domain of human DAI (ZBP1) in complex with Z-DNA reveals an unusual binding mode to Z-DNA</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2008</year>;<volume>105</volume>:<fpage>20671</fpage>&#8211;<lpage>20676</lpage>. <comment>doi: 10.1073/pnas.0810463106</comment>.<pub-id pub-id-type="pmid">19095800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0810463106</pub-id><pub-id pub-id-type="pmcid">PMC2634953</pub-id></mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Miao</surname><given-names>R</given-names></name><name name-style="western"><surname>Mei</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name>, <etal/></person-group>. <article-title>The lysosomal Rag-ragulator complex licenses RIPK1 and caspase-8-mediated pyroptosis by Yersinia</article-title>. <source>Science</source><year>2021</year>;<volume>372</volume>:<elocation-id>eabg0269</elocation-id>. <comment>doi: 10.1126/science.abg0269</comment>.<pub-id pub-id-type="pmid">35058659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abg0269</pub-id><pub-id pub-id-type="pmcid">PMC8769499</pub-id></mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maelfait</surname><given-names>J</given-names></name><name name-style="western"><surname>Liverpool</surname><given-names>L</given-names></name><name name-style="western"><surname>Bridgeman</surname><given-names>A</given-names></name><name name-style="western"><surname>Ragan</surname><given-names>KB</given-names></name><name name-style="western"><surname>Upton</surname><given-names>JW</given-names></name><name name-style="western"><surname>Rehwinkel</surname><given-names>J</given-names></name></person-group>. <article-title>Sensing of viral and endogenous RNA by ZBP1/DAI induces necroptosis</article-title>. <source>EMBO J</source><year>2017</year>;<volume>36</volume>:<fpage>2529</fpage>&#8211;<lpage>2543</lpage>. <comment>doi: 10.15252/embj.201796476</comment>.<pub-id pub-id-type="pmid">28716805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.201796476</pub-id><pub-id pub-id-type="pmcid">PMC5579359</pub-id></mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sridharan</surname><given-names>H</given-names></name><name name-style="western"><surname>Ragan</surname><given-names>KB</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H</given-names></name><name name-style="western"><surname>Gilley</surname><given-names>RP</given-names></name><name name-style="western"><surname>Landsteiner</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>WJ</given-names></name>, <etal/></person-group>. <article-title>Murine cytomegalovirus IE3-dependent transcription is required for DAI/ZBP1-mediated necroptosis</article-title>. <source>EMBO Rep</source><year>2017</year>;<volume>18</volume>:<fpage>1429</fpage>&#8211;<lpage>1441</lpage>. <comment>doi: 10.15252/embr.201743947</comment>.<pub-id pub-id-type="pmid">28607035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embr.201743947</pub-id><pub-id pub-id-type="pmcid">PMC5538628</pub-id></mixed-citation></ref><ref id="R51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kesavardhana</surname><given-names>S</given-names></name><name name-style="western"><surname>Malireddi</surname><given-names>RKS</given-names></name><name name-style="western"><surname>Burton</surname><given-names>AR</given-names></name><name name-style="western"><surname>Porter</surname><given-names>SN</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>P</given-names></name><name name-style="western"><surname>Pruett-Miller</surname><given-names>SM</given-names></name>, <etal/></person-group>. <article-title>The Z&#945;2 domain of ZBP1 is a molecular switch regulating influenza-induced PANoptosis and perinatal lethality during development</article-title>. <source>J Biol Chem</source><year>2020</year>;<volume>295</volume>:<fpage>8325</fpage>&#8211;<lpage>8330</lpage>. <comment>doi: 10.1074/jbc.RA120.013752</comment>.<pub-id pub-id-type="pmid">32350114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.RA120.013752</pub-id><pub-id pub-id-type="pmcid">PMC7294087</pub-id></mixed-citation></ref><ref id="R52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>SK</given-names></name><name name-style="western"><surname>Weissbach</surname><given-names>R</given-names></name><name name-style="western"><surname>Ronson</surname><given-names>GE</given-names></name><name name-style="western"><surname>Scadden</surname><given-names>ADJ</given-names></name></person-group>. <article-title>Proteins that contain a functional Z-DNA-binding domain localize to cytoplasmic stress granules</article-title>. <source>Nucleic Acids Res</source><year>2013</year>;<volume>41</volume>:<fpage>9786</fpage>&#8211;<lpage>9799</lpage>. <comment>doi: 10.1093/nar/gkt750</comment>.<pub-id pub-id-type="pmid">23982513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkt750</pub-id><pub-id pub-id-type="pmcid">PMC3834823</pub-id></mixed-citation></ref><ref id="R53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karki</surname><given-names>R</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>B</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>BR</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Malireddi</surname><given-names>RKS</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>LN</given-names></name>, <etal/></person-group>. <article-title>ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis</article-title>. <source>Cell Rep</source><year>2021</year>;<volume>37</volume>:<fpage>109858</fpage>. <comment>doi: 10.1016/j.celrep.2021.109858</comment>.<pub-id pub-id-type="pmid">34686350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2021.109858</pub-id><pub-id pub-id-type="pmcid">PMC8853634</pub-id></mixed-citation></ref><ref id="R54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pearson</surname><given-names>JS</given-names></name><name name-style="western"><surname>Giogha</surname><given-names>C</given-names></name><name name-style="western"><surname>M&#252;hlen</surname><given-names>S</given-names></name><name name-style="western"><surname>Nachbur</surname><given-names>U</given-names></name><name name-style="western"><surname>Pham</surname><given-names>CLL</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <etal/></person-group>. <article-title>EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation</article-title>. <source>Nat Microbiol</source><year>2017</year>;<volume>2</volume>:<fpage>16258</fpage>. <comment>doi: 10.1038/nmicrobiol.2016.258</comment>.<pub-id pub-id-type="pmid">28085133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmicrobiol.2016.258</pub-id><pub-id pub-id-type="pmcid">PMC7613272</pub-id></mixed-citation></ref><ref id="R55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>A</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name></person-group>. <article-title>A novel prognostic predictor of immune microenvironment and therapeutic response in kidney renal clear cell carcinoma based on necroptosis-related gene signature</article-title>. <source>Int J Med Sci</source><year>2022</year>;<volume>19</volume>:<fpage>377</fpage>&#8211;<lpage>392</lpage>. <comment>doi: 10.7150/ijms.69060</comment>.<pub-id pub-id-type="pmid">35165523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijms.69060</pub-id><pub-id pub-id-type="pmcid">PMC8795799</pub-id></mixed-citation></ref><ref id="R56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>J</given-names></name><name name-style="western"><surname>Ying</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name>, <etal/></person-group>. <article-title>Mosaic composition of RIP1-RIP3 signalling hub and its role in regulating cell death</article-title>. <source>Nat Cell Biol</source><year>2022</year>;<volume>24</volume>:<fpage>471</fpage>&#8211;<lpage>482</lpage>. <comment>doi: 10.1038/s41556-022-00854-7</comment>.<pub-id pub-id-type="pmid">35256774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41556-022-00854-7</pub-id></mixed-citation></ref><ref id="R57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Komine</surname><given-names>O</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>H</given-names></name><name name-style="western"><surname>Fujimori-Tonou</surname><given-names>N</given-names></name><name name-style="western"><surname>Koike</surname><given-names>M</given-names></name><name name-style="western"><surname>Jin</surname><given-names>S</given-names></name><name name-style="western"><surname>Moriwaki</surname><given-names>Y</given-names></name>, <etal/></person-group>. <article-title>Innate immune adaptor TRIF deficiency accelerates disease progression of ALS mice with accumulation of aberrantly activated astrocytes</article-title>. <source>Cell Death Differ</source><year>2018</year>;<volume>25</volume>:<fpage>2130</fpage>&#8211;<lpage>2146</lpage>. <comment>doi: 10.1038/s41418-018-0098-3</comment>.<pub-id pub-id-type="pmid">29568058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-018-0098-3</pub-id><pub-id pub-id-type="pmcid">PMC6261996</pub-id></mixed-citation></ref><ref id="R58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pham</surname><given-names>CL</given-names></name><name name-style="western"><surname>Shanmugam</surname><given-names>N</given-names></name><name name-style="western"><surname>Strange</surname><given-names>M</given-names></name><name name-style="western"><surname>O&#8217;Carroll</surname><given-names>A</given-names></name><name name-style="western"><surname>Brown</surname><given-names>JW</given-names></name><name name-style="western"><surname>Sierecki</surname><given-names>E</given-names></name>, <etal/></person-group>. <article-title>Viral M45 and necroptosis-associated proteins form heteromeric amyloid assemblies</article-title>. <source>EMBO Rep</source><year>2019</year>;<volume>20</volume>:<fpage>e46518</fpage>. <comment>doi: 10.15252/embr.201846518</comment>.<pub-id pub-id-type="pmid">30498077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embr.201846518</pub-id><pub-id pub-id-type="pmcid">PMC6362354</pub-id></mixed-citation></ref><ref id="R59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagata</surname><given-names>M</given-names></name><name name-style="western"><surname>Carvalho Sch&#228;fer</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wachsmuth</surname><given-names>L</given-names></name><name name-style="western"><surname>Pasparakis</surname><given-names>M</given-names></name></person-group>. <article-title>A shorter splicing isoform antagonizes ZBP1 to modulate cell death and inflammatory responses</article-title>. <source>EMBO J</source><year>2024</year>;<volume>43</volume>:<fpage>5037</fpage>&#8211;<lpage>5056</lpage>. <comment>doi: 10.1038/s44318-024-00238-7</comment>.<pub-id pub-id-type="pmid">39300211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s44318-024-00238-7</pub-id><pub-id pub-id-type="pmcid">PMC11535224</pub-id></mixed-citation></ref><ref id="R60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolbrink</surname><given-names>B</given-names></name><name name-style="western"><surname>Riebeling</surname><given-names>T</given-names></name><name name-style="western"><surname>Teiwes</surname><given-names>NK</given-names></name><name name-style="western"><surname>Steinem</surname><given-names>C</given-names></name><name name-style="western"><surname>Kalbacher</surname><given-names>H</given-names></name><name name-style="western"><surname>Kunzendorf</surname><given-names>U</given-names></name>, <etal/></person-group>. <article-title>TAT-RHIM: a more complex issue than expected</article-title>. <source>Biochem J</source><year>2022</year>;<volume>479</volume>:<fpage>259</fpage>&#8211;<lpage>272</lpage>. <comment>doi: 10.1042/BCJ20210677</comment>.<pub-id pub-id-type="pmid">35015082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BCJ20210677</pub-id><pub-id pub-id-type="pmcid">PMC8883498</pub-id></mixed-citation></ref><ref id="R61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fan</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>, <etal/></person-group>. <article-title>RIP1 kinase activity-dependent roles in embryonic development of Fadd-deficient mice</article-title>. <source>Cell Death Differ</source><year>2017</year>;<volume>24</volume>:<fpage>1459</fpage>&#8211;<lpage>1469</lpage>. <comment>doi: 10.1038/cdd.2017.78</comment>.<pub-id pub-id-type="pmid">28574501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cdd.2017.78</pub-id><pub-id pub-id-type="pmcid">PMC5520462</pub-id></mixed-citation></ref><ref id="R62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gitlin</surname><given-names>AD</given-names></name><name name-style="western"><surname>Heger</surname><given-names>K</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>AF</given-names></name><name name-style="western"><surname>Reja</surname><given-names>R</given-names></name><name name-style="western"><surname>Yan</surname><given-names>D</given-names></name><name name-style="western"><surname>Pham</surname><given-names>VC</given-names></name>, <etal/></person-group>. <article-title>Integration of innate immune signalling by Caspase-8 cleavage of N4BP1</article-title>. <source>Nature</source><year>2020</year>;<volume>587</volume>:<fpage>275</fpage>&#8211;<lpage>280</lpage>. <comment>doi: 10.1038/s41586-020-2796-5</comment>.<pub-id pub-id-type="pmid">32971525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2796-5</pub-id></mixed-citation></ref><ref id="R63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boehm</surname><given-names>U</given-names></name><name name-style="western"><surname>Klamp</surname><given-names>T</given-names></name><name name-style="western"><surname>Groot</surname><given-names>M</given-names></name><name name-style="western"><surname>Howard</surname><given-names>JC</given-names></name></person-group>. <article-title>Cellular responses to interferon-gamma</article-title>. <source>Annu Rev Immunol</source><year>1997</year>;<volume>15</volume>:<fpage>749</fpage>&#8211;<lpage>795</lpage>. <comment>doi: 10.1146/annurev.immunol.15.1.749</comment>.<pub-id pub-id-type="pmid">9143706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.immunol.15.1.749</pub-id></mixed-citation></ref><ref id="R64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assil</surname><given-names>S</given-names></name><name name-style="western"><surname>Paludan</surname><given-names>SR</given-names></name></person-group>. <article-title>Live and let die: ZBP1 senses viral and cellular RNAs to trigger necroptosis</article-title>. <source>EMBO J</source><year>2017</year>;<volume>36</volume>:<fpage>2470</fpage>&#8211;<lpage>2472</lpage>. <comment>doi: 10.15252/embj.201797845</comment>.<pub-id pub-id-type="pmid">28821535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.201797845</pub-id><pub-id pub-id-type="pmcid">PMC5579367</pub-id></mixed-citation></ref><ref id="R65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ye</surname><given-names>K</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Dai</surname><given-names>X</given-names></name>, <etal/></person-group>. <article-title>Role of Z-DNA binding protein 1 sensing mitochondrial Z-DNA and triggering necroptosis in oxalate-induced acute kidney injury</article-title>. <source>J Am Soc Nephrol</source><year>2025</year>;<volume>36</volume>:<fpage>361</fpage>&#8211;<lpage>377</lpage>. <comment>doi: 10.1681/ASN.0000000516</comment>.<pub-id pub-id-type="pmid">39374087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.0000000516</pub-id><pub-id pub-id-type="pmcid">PMC11888962</pub-id></mixed-citation></ref><ref id="R66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seya</surname><given-names>T</given-names></name><name name-style="western"><surname>Shime</surname><given-names>H</given-names></name><name name-style="western"><surname>Takaki</surname><given-names>H</given-names></name><name name-style="western"><surname>Azuma</surname><given-names>M</given-names></name><name name-style="western"><surname>Oshiumi</surname><given-names>H</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>M</given-names></name></person-group>. <article-title>TLR3/TICAM-1 signaling in tumor cell RIP3-dependent necroptosis</article-title>. <source>Oncoimmunology</source><year>2012</year>;<volume>1</volume>:<fpage>917</fpage>&#8211;<lpage>923</lpage>. <comment>doi: 10.4161/onci.21244</comment>.<pub-id pub-id-type="pmid">23162759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/onci.21244</pub-id><pub-id pub-id-type="pmcid">PMC3489747</pub-id></mixed-citation></ref><ref id="R67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ingram</surname><given-names>JP</given-names></name><name name-style="western"><surname>Thapa</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>A</given-names></name><name name-style="western"><surname>Tummers</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C</given-names></name>, <etal/></person-group>. <article-title>ZBP1/DAI drives RIPK3-mediated cell death induced by IFNs in the absence of RIPK1</article-title>. <source>J Immunol Baltim Md 1950</source><year>2019</year>;<volume>203</volume>:<fpage>1348</fpage>&#8211;<lpage>1355</lpage>. <comment>doi: 10.4049/jimmunol.1900216</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1900216</pub-id><pub-id pub-id-type="pmcid">PMC6702065</pub-id><pub-id pub-id-type="pmid">31358656</pub-id></mixed-citation></ref><ref id="R68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newton</surname><given-names>K</given-names></name><name name-style="western"><surname>Wickliffe</surname><given-names>KE</given-names></name><name name-style="western"><surname>Maltzman</surname><given-names>A</given-names></name><name name-style="western"><surname>Dugger</surname><given-names>DL</given-names></name><name name-style="western"><surname>Strasser</surname><given-names>A</given-names></name><name name-style="western"><surname>Pham</surname><given-names>VC</given-names></name>, <etal/></person-group>. <article-title>RIPK1 inhibits ZBP1-driven necroptosis during development</article-title>. <source>Nature</source><year>2016</year>;<volume>540</volume>:<fpage>129</fpage>&#8211;<lpage>133</lpage>. <comment>doi: 10.1038/nature20559</comment>.<pub-id pub-id-type="pmid">27819682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature20559</pub-id></mixed-citation></ref><ref id="R69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amusan</surname><given-names>OT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C</given-names></name><name name-style="western"><surname>Koehler</surname><given-names>HS</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tenev</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>RIPK1 is required for ZBP1-driven necroptosis in human cells</article-title>. <source>PLoS Biol</source><year>2025</year>;<volume>23</volume>:<fpage>e3002845</fpage>. <comment>doi: 10.1371/journal.pbio.3002845</comment>.<pub-id pub-id-type="pmid">39982916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pbio.3002845</pub-id><pub-id pub-id-type="pmcid">PMC11844899</pub-id></mixed-citation></ref><ref id="R70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Upton</surname><given-names>JW</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Mocarski</surname><given-names>ES</given-names></name></person-group>. <article-title>DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vira</article-title>. <source>Cell Host Microbe</source><year>2019</year>;<volume>26</volume>:<fpage>564</fpage>. <comment>doi: 10.1016/j.chom.2019.09.004</comment>.<pub-id pub-id-type="pmid">31600504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2019.09.004</pub-id></mixed-citation></ref><ref id="R71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>W</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name></person-group>. <article-title>RIPK1 and RIPK3 form mosaic necrosomes</article-title>. <source>Nat Cell Biol</source><year>2022</year>;<volume>24</volume>:<fpage>406</fpage>&#8211;<lpage>407</lpage>. <comment>doi: 10.1038/s41556-022-00879-y</comment>.<pub-id pub-id-type="pmid">35315435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41556-022-00879-y</pub-id></mixed-citation></ref><ref id="R72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grunert</surname><given-names>M</given-names></name><name name-style="western"><surname>Gottschalk</surname><given-names>K</given-names></name><name name-style="western"><surname>Kapahnke</surname><given-names>J</given-names></name><name name-style="western"><surname>G&#252;ndisch</surname><given-names>S</given-names></name><name name-style="western"><surname>Kieser</surname><given-names>A</given-names></name><name name-style="western"><surname>Jeremias</surname><given-names>I</given-names></name></person-group>. <article-title>The adaptor protein FADD and the initiator Caspase-8 mediate activation of NF-&#954;B by TRAIL</article-title>. <source>Cell Death Dis</source><year>2012</year>;<volume>3</volume>:<fpage>e414</fpage>. <comment>doi: 10.1038/cddis.2012.154</comment>.<pub-id pub-id-type="pmid">23096115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cddis.2012.154</pub-id><pub-id pub-id-type="pmcid">PMC3481141</pub-id></mixed-citation></ref><ref id="R73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tait</surname><given-names>SWG</given-names></name><name name-style="western"><surname>Green</surname><given-names>DR</given-names></name></person-group>. <article-title>Mitochondria and cell death: Outer membrane permeabilization and beyond</article-title>. <source>Nat Rev Mol Cell Biol</source><year>2010</year>;<volume>11</volume>:<fpage>621</fpage>&#8211;<lpage>632</lpage>. <comment>doi: 10.1038/nrm2952</comment>.<pub-id pub-id-type="pmid">20683470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm2952</pub-id></mixed-citation></ref><ref id="R74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nassour</surname><given-names>J</given-names></name><name name-style="western"><surname>Aguiar</surname><given-names>LG</given-names></name><name name-style="western"><surname>Correia</surname><given-names>A</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>TT</given-names></name><name name-style="western"><surname>Mainz</surname><given-names>L</given-names></name><name name-style="western"><surname>Przetocka</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>Telomere-to-Mitochondria signalling by ZBP1 mediates replicative crisis</article-title>. <source>Nature</source><year>2023</year>;<volume>614</volume>:<fpage>767</fpage>&#8211;<lpage>773</lpage>. <comment>doi: 10.1038/s41586-023-05710-8</comment>.<pub-id pub-id-type="pmid">36755096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-05710-8</pub-id><pub-id pub-id-type="pmcid">PMC9946831</pub-id></mixed-citation></ref><ref id="R75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solon</surname><given-names>M</given-names></name><name name-style="western"><surname>Ge</surname><given-names>N</given-names></name><name name-style="western"><surname>Hambro</surname><given-names>S</given-names></name><name name-style="western"><surname>Haller</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Baca</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>ZBP1 and TRIF trigger lethal necroptosis in mice lacking Caspase-8 and TNFR1</article-title>. <source>Cell Death Differ</source><year>2024</year>;<volume>31</volume>:<fpage>672</fpage>&#8211;<lpage>682</lpage>. <comment>doi: 10.1038/s41418-024-01286-6</comment>.<pub-id pub-id-type="pmid">38548850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-024-01286-6</pub-id><pub-id pub-id-type="pmcid">PMC11093969</pub-id></mixed-citation></ref><ref id="R76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovacs</surname><given-names>SB</given-names></name><name name-style="western"><surname>Miao</surname><given-names>EA</given-names></name></person-group>. <article-title>Gasdermins: Effectors of pyroptosis</article-title>. <source>Trends Cell Biol</source><year>2017</year>;<volume>27</volume>:<fpage>673</fpage>&#8211;<lpage>684</lpage>. <comment>doi: 10.1016/j.tcb.2017.05.005</comment>.<pub-id pub-id-type="pmid">28619472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcb.2017.05.005</pub-id><pub-id pub-id-type="pmcid">PMC5565696</pub-id></mixed-citation></ref><ref id="R77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jena</surname><given-names>KK</given-names></name><name name-style="western"><surname>Mambu</surname><given-names>J</given-names></name><name name-style="western"><surname>Boehmer</surname><given-names>D</given-names></name><name name-style="western"><surname>Sposito</surname><given-names>B</given-names></name><name name-style="western"><surname>Millet</surname><given-names>V</given-names></name><name name-style="western"><surname>de Sousa Casal</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>Type III interferons induce pyroptosis in gut epithelial cells and impair mucosal repair</article-title>. <source>Cell</source><year>2024</year>;<volume>187</volume>:<fpage>7533</fpage>&#8211;<lpage>7550</lpage>. <comment>doi: 10.1016/j.cell.2024.10.010</comment>.<pub-id pub-id-type="pmid">39500322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2024.10.010</pub-id><pub-id pub-id-type="pmcid">PMC11682936</pub-id></mixed-citation></ref><ref id="R78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandey</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gautam</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>A</given-names></name><name name-style="western"><surname>Man</surname><given-names>SM</given-names></name></person-group>. <article-title>Molecular mechanisms of emerging inflammasome complexes and their activation and signaling in inflammation and pyroptosis</article-title>. <source>Immunol Rev</source><year>2025</year>;<volume>329</volume>:<fpage>e13406</fpage>. <comment>doi: 10.1111/imr.13406</comment>.<pub-id pub-id-type="pmid">39351983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.13406</pub-id><pub-id pub-id-type="pmcid">PMC11742652</pub-id></mixed-citation></ref><ref id="R79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xie</surname><given-names>D</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>S</given-names></name></person-group>. <article-title>ZBP1 promotes hepatocyte pyroptosis in acute liver injury by regulating the PGAM5/ROS pathway</article-title>. <source>Ann Hepatol</source><year>2024</year>;<volume>29</volume>:<fpage>101475</fpage>. <comment>doi: 10.1016/j.aohep.2024.101475</comment>.<pub-id pub-id-type="pmid">38331384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.aohep.2024.101475</pub-id></mixed-citation></ref><ref id="R80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>N</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Tao</surname><given-names>C</given-names></name>, <etal/></person-group>. <article-title>Elabela ameliorates neuronal pyroptosis and mitochondrial fission via APJ/ZBP1 signaling in ischemic stroke</article-title>. <source>Exp Neurol</source><year>2024</year>;<volume>378</volume>:<fpage>114802</fpage>. <comment>doi: 10.1016/j.expneurol.2024.114802</comment>.<pub-id pub-id-type="pmid">38679280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2024.114802</pub-id></mixed-citation></ref><ref id="R81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name></person-group>. <article-title>ZBP1 mediates the progression of Alzheimer&#8217;s disease via pyroptosis by regulating IRF3</article-title>. <source>Mol Cell Biochem</source><year>2023</year>;<volume>478</volume>:<fpage>2849</fpage>&#8211;<lpage>2860</lpage>. <comment>doi: 10.1007/s11010-023-04702-6</comment>.<pub-id pub-id-type="pmid">36964897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11010-023-04702-6</pub-id></mixed-citation></ref><ref id="R82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orning</surname><given-names>P</given-names></name><name name-style="western"><surname>Weng</surname><given-names>D</given-names></name><name name-style="western"><surname>Starheim</surname><given-names>K</given-names></name><name name-style="western"><surname>Ratner</surname><given-names>D</given-names></name><name name-style="western"><surname>Best</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B</given-names></name>, <etal/></person-group>. <article-title>Pathogen blockade of TAK1 triggers Caspase-8-dependent cleavage of gasdermin D and cell death</article-title>. <source>Science</source><year>2018</year>;<volume>362</volume>:<fpage>1064</fpage>&#8211;<lpage>1069</lpage>. <comment>doi: 10.1126/science.aau2818</comment>.<pub-id pub-id-type="pmid">30361383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aau2818</pub-id><pub-id pub-id-type="pmcid">PMC6522129</pub-id></mixed-citation></ref><ref id="R83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heilig</surname><given-names>R</given-names></name><name name-style="western"><surname>Dilucca</surname><given-names>M</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>KW</given-names></name><name name-style="western"><surname>Hancz</surname><given-names>D</given-names></name><name name-style="western"><surname>Demarco</surname><given-names>B</given-names></name>, <etal/></person-group>. <article-title>Caspase-1 cleaves bid to release mitochondrial SMAC and drive secondary necrosis in the absence of GSDMD</article-title>. <source>Life Sci Alliance</source><year>2020</year>;<volume>3</volume>:<fpage>e202000735</fpage>. <comment>doi: 10.26508/lsa.202000735</comment>.<pub-id pub-id-type="pmid">32345661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26508/lsa.202000735</pub-id><pub-id pub-id-type="pmcid">PMC7190276</pub-id></mixed-citation></ref><ref id="R84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>K</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S</given-names></name></person-group>. <article-title>Caspases in panoptosis</article-title>. <source>Curr Res Transl Med</source><year>2025</year>;<volume>73</volume>:<fpage>103502</fpage>. <comment>doi: 10.1016/j.retram.2025.103502</comment>.<pub-id pub-id-type="pmid">39985853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.retram.2025.103502</pub-id></mixed-citation></ref><ref id="R85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>C</given-names></name><name name-style="western"><surname>Fernandes-Alnemri</surname><given-names>T</given-names></name><name name-style="western"><surname>Mayes</surname><given-names>L</given-names></name><name name-style="western"><surname>Alnemri</surname><given-names>D</given-names></name><name name-style="western"><surname>Cingolani</surname><given-names>G</given-names></name><name name-style="western"><surname>Alnemri</surname><given-names>ES</given-names></name></person-group>. <article-title>Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death</article-title>. <source>Nat Commun</source><year>2017</year>;<volume>8</volume>:<fpage>14128</fpage>. <comment>doi: 10.1038/ncomms14128</comment>.<pub-id pub-id-type="pmid">28045099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms14128</pub-id><pub-id pub-id-type="pmcid">PMC5216131</pub-id></mixed-citation></ref><ref id="R86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okondo</surname><given-names>MC</given-names></name><name name-style="western"><surname>Bachovchin</surname><given-names>DA</given-names></name></person-group>. <article-title>Pyroptosis and apoptosis pathways engage in bidirectional crosstalk in monocytes and macrophages</article-title>. <source>Cell Chem Biol</source><year>2017</year>;<volume>24</volume>:<fpage>507</fpage>&#8211;<lpage>514</lpage>. <comment>doi: 10.1016/j.chembiol.2017.03.009</comment>.<pub-id pub-id-type="pmid">28392147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2017.03.009</pub-id><pub-id pub-id-type="pmcid">PMC5467448</pub-id></mixed-citation></ref><ref id="R87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S</given-names></name><name name-style="western"><surname>Foldi</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B</given-names></name><name name-style="western"><surname>Chung</surname><given-names>AY</given-names></name>, <etal/></person-group>. <article-title>Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization</article-title>. <source>Nat Immunol</source><year>2012</year>;<volume>13</volume>:<fpage>642</fpage>&#8211;<lpage>650</lpage>. <comment>doi: 10.1038/ni.2304</comment>.<pub-id pub-id-type="pmid">22610140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.2304</pub-id><pub-id pub-id-type="pmcid">PMC3513378</pub-id></mixed-citation></ref><ref id="R88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Inhibition of receptor-interacting protein kinase-3 in the necroptosis pathway attenuates inflammatory bone loss in experimental apical periodontitis in Balb/c mice</article-title>. <source>Int Endod J</source><year>2021</year>;<volume>54</volume>:<fpage>1538</fpage>&#8211;<lpage>1547</lpage>. <comment>doi: 10.1111/iej.13534</comment>.<pub-id pub-id-type="pmid">33896018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/iej.13534</pub-id></mixed-citation></ref><ref id="R89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christgen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M</given-names></name><name name-style="western"><surname>Kesavardhana</surname><given-names>S</given-names></name><name name-style="western"><surname>Karki</surname><given-names>R</given-names></name><name name-style="western"><surname>Malireddi</surname><given-names>RKS</given-names></name><name name-style="western"><surname>Banoth</surname><given-names>B</given-names></name>, <etal/></person-group>. <article-title>Identification of the PANoptosome: A molecular platform triggering pyroptosis, apoptosis, and necroptosis (PANoptosis)</article-title>. <source>Front Cell Infect Microbiol</source><year>2020</year>;<volume>10</volume>:<fpage>237</fpage>. <comment>doi: 10.3389/fcimb.2020.00237</comment>.<pub-id pub-id-type="pmid">32547960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2020.00237</pub-id><pub-id pub-id-type="pmcid">PMC7274033</pub-id></mixed-citation></ref><ref id="R90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>BR</given-names></name><name name-style="western"><surname>Karki</surname><given-names>R</given-names></name><name name-style="western"><surname>Rajesh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group>. <article-title>Immune regulator IRF1 contributes to ZBP1-, AIM2-, RIPK1-, and NLRP12-PANoptosome activation and inflammatory cell death (PANoptosis)</article-title>. <source>J Biol Chem</source><year>2023</year>;<volume>299</volume>:<fpage>105141</fpage>. <comment>doi: 10.1016/j.jbc.2023.105141</comment>.<pub-id pub-id-type="pmid">37557956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2023.105141</pub-id><pub-id pub-id-type="pmcid">PMC10494469</pub-id></mixed-citation></ref><ref id="R91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steain</surname><given-names>M</given-names></name><name name-style="western"><surname>Baker</surname><given-names>MODG</given-names></name><name name-style="western"><surname>Pham</surname><given-names>CLL</given-names></name><name name-style="western"><surname>Shanmugam</surname><given-names>N</given-names></name><name name-style="western"><surname>Gambin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sierecki</surname><given-names>E</given-names></name>, <etal/></person-group>. <article-title>Varicella zoster virus encodes a viral decoy RHIM to inhibit cell death</article-title>. <source>PLoS Pathog</source><year>2020</year>;<volume>16</volume>:<fpage>e1008473</fpage>. <comment>doi: 10.1371/journal.ppat.1008473</comment>.<pub-id pub-id-type="pmid">32649716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1008473</pub-id><pub-id pub-id-type="pmcid">PMC7375649</pub-id></mixed-citation></ref><ref id="R92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothan</surname><given-names>HA</given-names></name><name name-style="western"><surname>Arora</surname><given-names>K</given-names></name><name name-style="western"><surname>Natekar</surname><given-names>JP</given-names></name><name name-style="western"><surname>Strate</surname><given-names>PG</given-names></name><name name-style="western"><surname>Brinton</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>M</given-names></name></person-group>. <article-title>Z-DNA-Binding protein 1 is critical for controlling virus replication and survival in west nile virus encephalitis</article-title>. <source>Front Microbiol</source><year>2019</year>;<volume>10</volume>:<fpage>2089</fpage>. <comment>doi: 10.3389/fmicb.2019.02089</comment>.<pub-id pub-id-type="pmid">31572318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2019.02089</pub-id><pub-id pub-id-type="pmcid">PMC6749019</pub-id></mixed-citation></ref><ref id="R93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandeya</surname><given-names>A</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group>. <article-title>Therapeutic potential of PANoptosis: Innate sensors, inflammasomes, and RIPKs in PANoptosomes</article-title>. <source>Trends Mol Med</source><year>2024</year>;<volume>30</volume>:<fpage>74</fpage>&#8211;<lpage>88</lpage>. <comment>doi: 10.1016/j.molmed.2023.10.001</comment>.<pub-id pub-id-type="pmid">37977994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2023.10.001</pub-id><pub-id pub-id-type="pmcid">PMC10842719</pub-id></mixed-citation></ref><ref id="R94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sagulenko</surname><given-names>V</given-names></name><name name-style="western"><surname>Thygesen</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Sester</surname><given-names>DP</given-names></name><name name-style="western"><surname>Idris</surname><given-names>A</given-names></name><name name-style="western"><surname>Cridland</surname><given-names>JA</given-names></name><name name-style="western"><surname>Vajjhala</surname><given-names>PR</given-names></name>, <etal/></person-group>. <article-title>AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC</article-title>. <source>Cell Death Differ</source><year>2013</year>;<volume>20</volume>:<fpage>1149</fpage>&#8211;<lpage>1160</lpage>. <comment>doi: 10.1038/cdd.2013.37</comment>.<pub-id pub-id-type="pmid">23645208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cdd.2013.37</pub-id><pub-id pub-id-type="pmcid">PMC3741496</pub-id></mixed-citation></ref><ref id="R95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sundaram</surname><given-names>B</given-names></name><name name-style="western"><surname>Pandian</surname><given-names>N</given-names></name><name name-style="western"><surname>Mall</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>R</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name>, <etal/></person-group>. <article-title>NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs</article-title>. <source>Cell</source><year>2023</year>;<volume>186</volume>:<fpage>2783</fpage>&#8211;<lpage>2801</lpage>. <comment>doi: 10.1016/j.cell.2023.05.005</comment>.<pub-id pub-id-type="pmid">37267949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.05.005</pub-id><pub-id pub-id-type="pmcid">PMC10330523</pub-id></mixed-citation></ref><ref id="R96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Karki</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>LN</given-names></name><name name-style="western"><surname>Kalathur</surname><given-names>RC</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group>. <article-title>AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence</article-title>. <source>Nature</source><year>2021</year>;<volume>597</volume>:<fpage>415</fpage>&#8211;<lpage>419</lpage>. <comment>doi: 10.1038/s41586-021-03875-8</comment>.<pub-id pub-id-type="pmid">34471287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03875-8</pub-id><pub-id pub-id-type="pmcid">PMC8603942</pub-id></mixed-citation></ref><ref id="R97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sundaram</surname><given-names>B</given-names></name><name name-style="western"><surname>Pandian</surname><given-names>N</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Abdelaal</surname><given-names>HM</given-names></name><name name-style="western"><surname>Mall</surname><given-names>R</given-names></name><name name-style="western"><surname>Indari</surname><given-names>O</given-names></name>, <etal/></person-group>. <article-title>NLRC5 senses NAD+ depletion to form a PANoptosome driving PANoptosis and inflammation</article-title>. <source>Cell</source><year>2024</year>;<volume>187</volume>:<fpage>4061</fpage>&#8211;<lpage>4077</lpage>. <comment>doi: 10.1016/j.cell.2024.05.034</comment>.<pub-id pub-id-type="pmid">38878777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2024.05.034</pub-id><pub-id pub-id-type="pmcid">PMC11283362</pub-id></mixed-citation></ref><ref id="R98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>HK</given-names></name><name name-style="western"><surname>Chung</surname><given-names>KM</given-names></name><name name-style="western"><surname>Park</surname><given-names>H</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J</given-names></name><name name-style="western"><surname>Gim</surname><given-names>JE</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H</given-names></name>, <etal/></person-group>. <article-title>CASP9 (Caspase 9) is essential for autophagosome maturation through regulation of mitochondrial homeostasis</article-title>. <source>Autophagy</source><year>2020</year>;<volume>16</volume>:<fpage>1598</fpage>&#8211;<lpage>1617</lpage>. <comment>doi: 10.1080/15548627.2019.1695398</comment>.<pub-id pub-id-type="pmid">31818185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2019.1695398</pub-id><pub-id pub-id-type="pmcid">PMC8386608</pub-id></mixed-citation></ref><ref id="R99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>HS</given-names></name><name name-style="western"><surname>Al-Amodi</surname><given-names>HS</given-names></name><name name-style="western"><surname>Hamady</surname><given-names>S</given-names></name><name name-style="western"><surname>Roushdy</surname><given-names>MMS</given-names></name><name name-style="western"><surname>Helmy Hasanin</surname><given-names>A</given-names></name><name name-style="western"><surname>Ellithy</surname><given-names>G</given-names></name>, <etal/></person-group>. <article-title>Rosavin improves insulin resistance and alleviates hepatic and kidney damage via modulating the cGAS-STING pathway and autophagy signaling in HFD/STZ-induced T2DM animals</article-title>. <source>RSC Med Chem</source><year>2024</year>;<volume>15</volume>:<fpage>2098</fpage>&#8211;<lpage>2113</lpage>. <comment>doi: 10.1039/d4md00023d</comment>.<pub-id pub-id-type="pmid">38911169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d4md00023d</pub-id><pub-id pub-id-type="pmcid">PMC11187545</pub-id></mixed-citation></ref><ref id="R100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Bont</surname><given-names>CM</given-names></name><name name-style="western"><surname>Boelens</surname><given-names>WC</given-names></name><name name-style="western"><surname>Pruijn</surname><given-names>GJM</given-names></name></person-group>. <article-title>NETosis, complement, and coagulation: A triangular relationship</article-title>. <source>Cell Mol Immunol</source><year>2019</year>;<volume>16</volume>:<fpage>19</fpage>&#8211;<lpage>27</lpage>. <comment>doi: 10.1038/s41423-018-0024-0</comment>.<pub-id pub-id-type="pmid">29572545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-018-0024-0</pub-id><pub-id pub-id-type="pmcid">PMC6318284</pub-id></mixed-citation></ref><ref id="R101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>C</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dai</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name>, <etal/></person-group>. <article-title>Neutrophil extracellular traps augmented alveolar macrophage pyroptosis via AIM2 inflammasome activation in LPS-induced ALI/ARDS</article-title>. <source>J Inflamm Res</source><year>2021</year>;<volume>14</volume>:<fpage>4839</fpage>&#8211;<lpage>4858</lpage>. <comment>doi: 10.2147/JIR.S321513</comment>.<pub-id pub-id-type="pmid">34588792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JIR.S321513</pub-id><pub-id pub-id-type="pmcid">PMC8473117</pub-id></mixed-citation></ref><ref id="R102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Messaoud-Nacer</surname><given-names>Y</given-names></name><name name-style="western"><surname>Culerier</surname><given-names>E</given-names></name><name name-style="western"><surname>Rose</surname><given-names>S</given-names></name><name name-style="western"><surname>Maillet</surname><given-names>I</given-names></name><name name-style="western"><surname>Rouxel</surname><given-names>N</given-names></name><name name-style="western"><surname>Briault</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS)</article-title>. <source>Cell Death Dis</source><year>2022</year>;<volume>13</volume>:<fpage>269</fpage>. <comment>doi: 10.1038/s41419-022-04664-5</comment>.<pub-id pub-id-type="pmid">35338116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-022-04664-5</pub-id><pub-id pub-id-type="pmcid">PMC8953969</pub-id></mixed-citation></ref><ref id="R103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lin</surname><given-names>G</given-names></name><name name-style="western"><surname>Ye</surname><given-names>K</given-names></name>, <etal/></person-group>. <article-title>Sensing of mitochondrial DNA by ZBP1 promotes RIPK3-mediated necroptosis and ferroptosis in response to diquat poisoning</article-title>. <source>Cell Death Differ</source><year>2024</year>;<volume>31</volume>:<fpage>635</fpage>&#8211;<lpage>650</lpage>. <comment>doi: 10.1038/s41418-024-01279-5</comment>.<pub-id pub-id-type="pmid">38493248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-024-01279-5</pub-id><pub-id pub-id-type="pmcid">PMC11094118</pub-id></mixed-citation></ref><ref id="R104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koo</surname><given-names>GB</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DG</given-names></name><name name-style="western"><surname>Kim</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>JH</given-names></name><name name-style="western"><surname>Koo</surname><given-names>JS</given-names></name>, <etal/></person-group>. <article-title>Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics</article-title>. <source>Cell Res</source><year>2015</year>;<volume>25</volume>:<fpage>707</fpage>&#8211;<lpage>725</lpage>. <comment>doi: 10.1038/cr.2015.56</comment>.<pub-id pub-id-type="pmid">25952668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cr.2015.56</pub-id><pub-id pub-id-type="pmcid">PMC4456623</pub-id></mixed-citation></ref><ref id="R105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>D</given-names></name><name name-style="western"><surname>Liwinski</surname><given-names>T</given-names></name><name name-style="western"><surname>Elinav</surname><given-names>E</given-names></name></person-group>. <article-title>Inflammasome activation and regulation: Toward a better understanding of complex mechanisms</article-title>. <source>Cell Discov</source><year>2020</year>;<volume>6</volume>:<fpage>36</fpage>. <comment>doi: 10.1038/s41421-020-0167-x</comment>.<pub-id pub-id-type="pmid">32550001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41421-020-0167-x</pub-id><pub-id pub-id-type="pmcid">PMC7280307</pub-id></mixed-citation></ref><ref id="R106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>C</given-names></name><name name-style="western"><surname>Erkes</surname><given-names>DA</given-names></name><name name-style="western"><surname>Nardone</surname><given-names>A</given-names></name><name name-style="western"><surname>Aplin</surname><given-names>AE</given-names></name><name name-style="western"><surname>Fernandes-Alnemri</surname><given-names>T</given-names></name><name name-style="western"><surname>Alnemri</surname><given-names>ES</given-names></name></person-group>. <article-title>Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation</article-title>. <source>Nat Commun</source><year>2019</year>;<volume>10</volume>:<fpage>1689</fpage>. <comment>doi: 10.1038/s41467-019-09397-2</comment>.<pub-id pub-id-type="pmid">30976076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-09397-2</pub-id><pub-id pub-id-type="pmcid">PMC6459836</pub-id></mixed-citation></ref><ref id="R107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muscolino</surname><given-names>E</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>R</given-names></name><name name-style="western"><surname>Loroch</surname><given-names>S</given-names></name><name name-style="western"><surname>Caragliano</surname><given-names>E</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>C</given-names></name><name name-style="western"><surname>Rizzato</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Herpesviruses induce aggregation and selective autophagy of host signalling proteins NEMO and RIPK1 as an immune-evasion mechanism</article-title>. <source>Nat Microbiol</source><year>2020</year>;<volume>5</volume>:<fpage>331</fpage>&#8211;<lpage>342</lpage>. <comment>doi: 10.1038/s41564-019-0624-1</comment>.<pub-id pub-id-type="pmid">31844296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-019-0624-1</pub-id></mixed-citation></ref><ref id="R108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martens</surname><given-names>S</given-names></name><name name-style="western"><surname>Hofmans</surname><given-names>S</given-names></name><name name-style="western"><surname>Declercq</surname><given-names>W</given-names></name><name name-style="western"><surname>Augustyns</surname><given-names>K</given-names></name><name name-style="western"><surname>Vandenabeele</surname><given-names>P</given-names></name></person-group>. <article-title>Inhibitors targeting RIPK1/RIPK3: Old and new drugs</article-title>. <source>Trends Pharmacol Sci</source><year>2020</year>;<volume>41</volume>:<fpage>209</fpage>&#8211;<lpage>224</lpage>. <comment>doi: 10.1016/j.tips.2020.01.002</comment>.<pub-id pub-id-type="pmid">32035657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2020.01.002</pub-id></mixed-citation></ref><ref id="R109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>M</given-names></name><name name-style="western"><surname>Qi</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group>. <article-title>The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer</article-title>. <source>Cell Death Discov</source><year>2020</year>;<volume>6</volume>:<fpage>112</fpage>. <comment>doi: 10.1038/s41420-020-00349-0</comment>.<pub-id pub-id-type="pmid">33133646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-020-00349-0</pub-id><pub-id pub-id-type="pmcid">PMC7595122</pub-id></mixed-citation></ref><ref id="R110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fritsch</surname><given-names>M</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>SD</given-names></name><name name-style="western"><surname>Schwarzer</surname><given-names>R</given-names></name><name name-style="western"><surname>Albert</surname><given-names>MC</given-names></name><name name-style="western"><surname>Schorn</surname><given-names>F</given-names></name><name name-style="western"><surname>Werthenbach</surname><given-names>JP</given-names></name>, <etal/></person-group>. <article-title>Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis</article-title>. <source>Nature</source><year>2019</year>;<volume>575</volume>:<fpage>683</fpage>&#8211;<lpage>687</lpage>. <comment>doi: 10.1038/s41586-019-1770-6</comment>.<pub-id pub-id-type="pmid">31748744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1770-6</pub-id></mixed-citation></ref><ref id="R111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weisel</surname><given-names>K</given-names></name><name name-style="western"><surname>Berger</surname><given-names>S</given-names></name><name name-style="western"><surname>Thorn</surname><given-names>K</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>P</given-names></name><name name-style="western"><surname>Peterfy</surname><given-names>C</given-names></name><name name-style="western"><surname>Siddall</surname><given-names>H</given-names></name>, <etal/></person-group>. <article-title>A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis</article-title>. <source>Arthritis Res Ther</source><year>2021</year>;<volume>23</volume>:<fpage>85</fpage>. <comment>doi: 10.1186/s13075-021-02468-0</comment>.<pub-id pub-id-type="pmid">33726834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-021-02468-0</pub-id><pub-id pub-id-type="pmcid">PMC7962407</pub-id></mixed-citation></ref><ref id="R112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Z</given-names></name>, <etal/></person-group>. <article-title>Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases</article-title>. <source>Cell Death Dis</source><year>2023</year>;<volume>14</volume>:<fpage>851</fpage>. <comment>doi: 10.1038/s41419-023-06370-2</comment>.<pub-id pub-id-type="pmid">38129399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-023-06370-2</pub-id><pub-id pub-id-type="pmcid">PMC10739961</pub-id></mixed-citation></ref><ref id="R113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>M</given-names></name><name name-style="western"><surname>Karki</surname><given-names>R</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>P</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group>. <article-title>Caspase-6 is a key regulator of innate immunity, inflammasome activation, and host defense</article-title>. <source>Cell</source><year>2020</year>;<volume>181</volume>:<fpage>674</fpage>&#8211;<lpage>687</lpage>. <comment>doi: 10.1016/j.cell.2020.03.040</comment>.<pub-id pub-id-type="pmid">32298652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.03.040</pub-id><pub-id pub-id-type="pmcid">PMC7425208</pub-id></mixed-citation></ref><ref id="R114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gutierrez</surname><given-names>KD</given-names></name><name name-style="western"><surname>Davis</surname><given-names>MA</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>BP</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>TM</given-names></name><name name-style="western"><surname>Ralli-Jain</surname><given-names>P</given-names></name><name name-style="western"><surname>Tait</surname><given-names>SWG</given-names></name>, <etal/></person-group>. <article-title>MLKL activation triggers NLRP3-mediated processing and release of IL-1&#946; independently of gasdermin-D</article-title>. <source>J Immunol</source><year>2017</year>;<volume>198</volume>:<fpage>2156</fpage>&#8211;<lpage>2164</lpage>. <comment>doi: 10.4049/jimmunol.1601757</comment>.<pub-id pub-id-type="pmid">28130493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1601757</pub-id><pub-id pub-id-type="pmcid">PMC5321867</pub-id></mixed-citation></ref><ref id="R115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Werthm&#246;ller</surname><given-names>N</given-names></name><name name-style="western"><surname>Frey</surname><given-names>B</given-names></name><name name-style="western"><surname>Wunderlich</surname><given-names>R</given-names></name><name name-style="western"><surname>Fietkau</surname><given-names>R</given-names></name><name name-style="western"><surname>Gaipl</surname><given-names>US</given-names></name></person-group>. <article-title>Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-Fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner</article-title>. <source>Cell Death Dis</source><year>2015</year>;<volume>6</volume>:<fpage>e1761</fpage>. <comment>doi: 10.1038/cddis.2015.129</comment>.<pub-id pub-id-type="pmid">25973681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cddis.2015.129</pub-id><pub-id pub-id-type="pmcid">PMC4669707</pub-id></mixed-citation></ref><ref id="R116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>H</given-names></name><name name-style="western"><surname>Luo</surname><given-names>B</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Guan</surname><given-names>F</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name>, <etal/></person-group>. <article-title>Cisplatin induces pyroptosis via activation of MEG3/NLRP3/Caspase-1/GSDMD pathway in triple-negative breast cancer</article-title>. <source>Int J Biol Sci</source><year>2021</year>;<volume>17</volume>:<fpage>2606</fpage>&#8211;<lpage>2621</lpage>. <comment>doi: 10.7150/ijbs.60292</comment>.<pub-id pub-id-type="pmid">34326697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijbs.60292</pub-id><pub-id pub-id-type="pmcid">PMC8315016</pub-id></mixed-citation></ref><ref id="R117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name><name name-style="western"><surname>Oz&#246;ren</surname><given-names>N</given-names></name><name name-style="western"><surname>Body-Malapel</surname><given-names>M</given-names></name><name name-style="western"><surname>Amer</surname><given-names>A</given-names></name><name name-style="western"><surname>Park</surname><given-names>JH</given-names></name><name name-style="western"><surname>Franchi</surname><given-names>L</given-names></name>, <etal/></person-group>. <article-title>Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3</article-title>. <source>Nature</source><year>2006</year>;<volume>440</volume>:<fpage>233</fpage>&#8211;<lpage>236</lpage>. <comment>doi: 10.1038/nature04517</comment>.<pub-id pub-id-type="pmid">16407888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature04517</pub-id></mixed-citation></ref><ref id="R118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mangan</surname><given-names>MSJ</given-names></name><name name-style="western"><surname>Olhava</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Roush</surname><given-names>WR</given-names></name><name name-style="western"><surname>Seidel</surname><given-names>HM</given-names></name><name name-style="western"><surname>Glick</surname><given-names>GD</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E</given-names></name></person-group>. <article-title>Targeting the NLRP3 inflammasome in inflammatory diseases</article-title>. <source>Nat Rev Drug Discov</source><year>2018</year>;<volume>17</volume>:<fpage>588</fpage>&#8211;<lpage>606</lpage>. <comment>doi: 10.1038/nrd.2018.97</comment>.<pub-id pub-id-type="pmid">30026524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2018.97</pub-id></mixed-citation></ref><ref id="R119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>IF</given-names></name><name name-style="western"><surname>Ou-Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Hung</surname><given-names>JY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>JC</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SC</given-names></name>, <etal/></person-group>. <article-title>AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model</article-title>. <source>Mol Cancer Ther</source><year>2006</year>;<volume>5</volume>:<fpage>1</fpage>&#8211;<lpage>7</lpage>. <comment>doi: 10.1158/1535-7163.MCT-05-0310</comment>.<pub-id pub-id-type="pmid">16432157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1535-7163.MCT-05-0310</pub-id></mixed-citation></ref><ref id="R120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Reuver</surname><given-names>R</given-names></name><name name-style="western"><surname>Dierick</surname><given-names>E</given-names></name><name name-style="western"><surname>Wiernicki</surname><given-names>B</given-names></name><name name-style="western"><surname>Staes</surname><given-names>K</given-names></name><name name-style="western"><surname>Seys</surname><given-names>L</given-names></name><name name-style="western"><surname>De Meester</surname><given-names>E</given-names></name>, <etal/></person-group>. <article-title>ADAR1 interaction with Z-RNA promotes editing of endogenous double-stranded RNA and prevents MDA5-dependent immune activation</article-title>. <source>Cell Rep</source><year>2021</year>;<volume>36</volume>:<fpage>109500</fpage>. <comment>doi: 10.1016/j.celrep.2021.109500</comment>.<pub-id pub-id-type="pmid">34380029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2021.109500</pub-id></mixed-citation></ref><ref id="R121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dias Junior</surname><given-names>AG</given-names></name><name name-style="western"><surname>Sampaio</surname><given-names>NG</given-names></name><name name-style="western"><surname>Rehwinkel</surname><given-names>J</given-names></name></person-group>. <article-title>A balancing act: MDA5 in antiviral immunity and autoinflammation</article-title>. <source>Trends Microbiol</source><year>2019</year>;<volume>27</volume>:<fpage>75</fpage>&#8211;<lpage>85</lpage>. <comment>doi: 10.1016/j.tim.2018.08.007</comment>.<pub-id pub-id-type="pmid">30201512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tim.2018.08.007</pub-id><pub-id pub-id-type="pmcid">PMC6319154</pub-id></mixed-citation></ref><ref id="R122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakahama</surname><given-names>T</given-names></name><name name-style="western"><surname>Kawahara</surname><given-names>Y</given-names></name></person-group>. <article-title>The RNA-editing enzyme ADAR1: A regulatory hub that tunes multiple dsRNA-sensing pathways</article-title>. <source>Int Immunol</source><year>2023</year>;<volume>35</volume>:<fpage>123</fpage>&#8211;<lpage>133</lpage>. <comment>doi: 10.1093/intimm/dxac056</comment>.<pub-id pub-id-type="pmid">36469491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/intimm/dxac056</pub-id></mixed-citation></ref><ref id="R123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Reuver</surname><given-names>R</given-names></name><name name-style="western"><surname>Verdonck</surname><given-names>S</given-names></name><name name-style="western"><surname>Dierick</surname><given-names>E</given-names></name><name name-style="western"><surname>Nemegeer</surname><given-names>J</given-names></name><name name-style="western"><surname>Hessmann</surname><given-names>E</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>ADAR1 prevents autoinflammation by suppressing spontaneous ZBP1 activation</article-title>. <source>Nature</source><year>2022</year>;<volume>607</volume>:<fpage>784</fpage>&#8211;<lpage>789</lpage>. <comment>doi: 10.1038/s41586-022-04974-w</comment>.<pub-id pub-id-type="pmid">35859175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-04974-w</pub-id></mixed-citation></ref><ref id="R124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C</given-names></name><name name-style="western"><surname>Fedorov</surname><given-names>A</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>L</given-names></name><name name-style="western"><surname>Bao</surname><given-names>H</given-names></name><name name-style="western"><surname>Beknazarov</surname><given-names>N</given-names></name>, <etal/></person-group>. <article-title>ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis</article-title>. <source>Nature</source><year>2022</year>;<volume>606</volume>:<fpage>594</fpage>&#8211;<lpage>602</lpage>. <comment>doi: 10.1038/s41586-022-04753-7</comment>.<pub-id pub-id-type="pmid">35614224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-04753-7</pub-id><pub-id pub-id-type="pmcid">PMC9373927</pub-id></mixed-citation></ref><ref id="R125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ikushima</surname><given-names>H</given-names></name><name name-style="western"><surname>Negishi</surname><given-names>H</given-names></name><name name-style="western"><surname>Taniguchi</surname><given-names>T</given-names></name></person-group>. <article-title>The IRF family transcription factors at the interface of innate and adaptive immune responses</article-title>. <source>Cold Spring Harb Symp Quant Biol</source><year>2013</year>;<volume>78</volume>:<fpage>105</fpage>&#8211;<lpage>116</lpage>. <comment>doi: 10.1101/sqb.2013.78.020321</comment>.<pub-id pub-id-type="pmid">24092468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/sqb.2013.78.020321</pub-id></mixed-citation></ref><ref id="R126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuriakose</surname><given-names>T</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M</given-names></name><name name-style="western"><surname>Neale</surname><given-names>G</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group>. <article-title>IRF1 is a transcriptional regulator of ZBP1 promoting NLRP3 inflammasome activation and cell death during influenza virus infection</article-title>. <source>J Immunol</source><year>2018</year>;<volume>200</volume>:<fpage>1489</fpage>&#8211;<lpage>1495</lpage>. <comment>doi: 10.4049/jimmunol.1701538</comment>.<pub-id pub-id-type="pmid">29321274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1701538</pub-id><pub-id pub-id-type="pmcid">PMC6483084</pub-id></mixed-citation></ref><ref id="R127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Q</given-names></name>, <etal/></person-group>. <article-title>TRIM34 modulates influenza virus-activated programmed cell death by targeting Z-DNA-binding protein 1 for K63-linked polyubiquitination</article-title>. <source>J Biol Chem</source><year>2022</year>;<volume>298</volume>:<fpage>101611</fpage>. <comment>doi: 10.1016/j.jbc.2022.101611</comment>.<pub-id pub-id-type="pmid">35065966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2022.101611</pub-id><pub-id pub-id-type="pmcid">PMC8867111</pub-id></mixed-citation></ref><ref id="R128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>BM</given-names></name><name name-style="western"><surname>Oakley</surname><given-names>GG</given-names></name></person-group>. <article-title>Replication protein a, the laxative that keeps DNA regular: The importance of RPA phosphorylation in maintaining genome stability</article-title>. <source>Semin Cell Dev Biol</source><year>2019</year>;<volume>86</volume>:<fpage>112</fpage>&#8211;<lpage>120</lpage>. <comment>doi: 10.1016/j.semcdb.2018.04.005</comment>.<pub-id pub-id-type="pmid">29665433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcdb.2018.04.005</pub-id></mixed-citation></ref><ref id="R129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <etal/></person-group>. <article-title>Loss of RPA1 impairs peripheral T cell homeostasis and exacerbates inflammatory damage through triggering T cell necroptosis</article-title>. <source>Adv Sci Weinh Baden-Wurtt Ger</source><year>2023</year>;<volume>10</volume>:<fpage>e2206344</fpage>. <comment>doi: 10.1002/advs.202206344</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202206344</pub-id><pub-id pub-id-type="pmcid">PMC10104672</pub-id><pub-id pub-id-type="pmid">36721037</pub-id></mixed-citation></ref><ref id="R130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dondelinger</surname><given-names>Y</given-names></name><name name-style="western"><surname>Delanghe</surname><given-names>T</given-names></name><name name-style="western"><surname>Priem</surname><given-names>D</given-names></name><name name-style="western"><surname>Wynosky-Dolfi</surname><given-names>MA</given-names></name><name name-style="western"><surname>Sorobetea</surname><given-names>D</given-names></name><name name-style="western"><surname>Rojas-Rivera</surname><given-names>D</given-names></name>, <etal/></person-group>. <article-title>Serine 25 phosphorylation inhibits RIPK1 kinase-dependent cell death in models of infection and inflammation</article-title>. <source>Nat Commun</source><year>2019</year>;<volume>10</volume>:<fpage>1729</fpage>. <comment>doi: 10.1038/s41467-019-09690-0</comment>.<pub-id pub-id-type="pmid">30988283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-09690-0</pub-id><pub-id pub-id-type="pmcid">PMC6465317</pub-id></mixed-citation></ref><ref id="R131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>CK</given-names></name><name name-style="western"><surname>Wang-Kan</surname><given-names>X</given-names></name><name name-style="western"><surname>Idorn</surname><given-names>M</given-names></name><name name-style="western"><surname>Kjaer</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>FY</given-names></name>, <etal/></person-group>. <article-title>Human ZBP1 induces cell death-independent inflammatory signaling via RIPK3 and RIPK1</article-title>. <source>EMBO Rep</source><year>2022</year>;<volume>23</volume>:<fpage>e55839</fpage>. <comment>doi: 10.15252/embr.202255839</comment>.<pub-id pub-id-type="pmid">36268590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embr.202255839</pub-id><pub-id pub-id-type="pmcid">PMC9724671</pub-id></mixed-citation></ref><ref id="R132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>TRIF-TAK1 signaling suppresses caspase-8/3-mediated GSDMD/E activation and pyroptosis in influenza A virus-infected airway epithelial cells</article-title>. <source>iScience</source><year>2025</year>;<volume>28</volume>:<fpage>111581</fpage>. <comment>doi: 10.1016/j.isci.2024.111581</comment>.<pub-id pub-id-type="pmid">39811662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2024.111581</pub-id><pub-id pub-id-type="pmcid">PMC11732511</pub-id></mixed-citation></ref><ref id="R133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ji</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <etal/></person-group>. <article-title>Influenza virus infection activates TAK1 to suppress RIPK3-independent apoptosis and RIPK1-dependent necroptosis</article-title>. <source>Cell Commun Signal</source><year>2024</year>;<volume>22</volume>:<fpage>372</fpage>. <comment>doi: 10.1186/s12964-024-01727-2</comment>.<pub-id pub-id-type="pmid">39044278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-024-01727-2</pub-id><pub-id pub-id-type="pmcid">PMC11264382</pub-id></mixed-citation></ref><ref id="R134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>YP</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L</given-names></name><name name-style="western"><surname>Ke</surname><given-names>HY</given-names></name><name name-style="western"><surname>Li</surname><given-names>YP</given-names></name><name name-style="western"><surname>Shi</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>ZY</given-names></name>, <etal/></person-group>. <article-title>Baicalin inhibits PANoptosis by blocking mitochondrial Z-DNA formation and ZBP1-PANoptosome assembly in macrophages</article-title>. <source>Acta Pharmacol Sin</source><year>2025</year>;<volume>46</volume>:<fpage>430</fpage>&#8211;<lpage>447</lpage>. <comment>doi: 10.1038/s41401-024-01376-8</comment>.<pub-id pub-id-type="pmid">39223367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41401-024-01376-8</pub-id><pub-id pub-id-type="pmcid">PMC11747177</pub-id></mixed-citation></ref><ref id="R135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name><name name-style="western"><surname>Tong</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L</given-names></name><name name-style="western"><surname>Stolz</surname><given-names>DB</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2018</year>;<volume>115</volume>:<fpage>3930</fpage>&#8211;<lpage>3935</lpage>. <comment>doi: 10.1073/pnas.1717190115</comment>.<pub-id pub-id-type="pmid">29581256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1717190115</pub-id><pub-id pub-id-type="pmcid">PMC5899441</pub-id></mixed-citation></ref><ref id="R136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name><name name-style="western"><surname>Ermine</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name>, <etal/></person-group>. <article-title>PUMA/RIP3 mediates chemotherapy response via necroptosis and local immune activation in colorectal cancer</article-title>. <source>Mol Cancer Ther</source><year>2023</year>;<volume>23</volume>:<fpage>354</fpage>&#8211;<lpage>367</lpage>. <comment>doi: 10.1158/1535-7163.MCT-23-0162</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1535-7163.MCT-23-0162</pub-id><pub-id pub-id-type="pmcid">PMC10932881</pub-id><pub-id pub-id-type="pmid">37992761</pub-id></mixed-citation></ref><ref id="R137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xia</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Cao</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name>, <etal/></person-group>. <article-title>Survey of hepatitis B virus infection for liver cancer screening in China: A population-based, cross-sectional study</article-title>. <source>Chin Med J</source><year>2024</year>;<volume>137</volume>:<fpage>1414</fpage>&#8211;<lpage>1420</lpage>. <comment>doi: 10.1097/CM9.0000000000003171</comment>.<pub-id pub-id-type="pmid">38766992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000003171</pub-id><pub-id pub-id-type="pmcid">PMC11188860</pub-id></mixed-citation></ref><ref id="R138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peck</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JC</given-names></name></person-group>. <article-title>Energetics of B-to-Z transition in DNA</article-title>. <source>Proc Natl Acad Sci U S A</source><year>1983</year>;<volume>80</volume>:<fpage>6206</fpage>&#8211;<lpage>6210</lpage>. <comment>doi: 10.1073/pnas.80.20.6206</comment>.<pub-id pub-id-type="pmid">6578505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.80.20.6206</pub-id><pub-id pub-id-type="pmcid">PMC394264</pub-id></mixed-citation></ref><ref id="R139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeAntoneo</surname><given-names>C</given-names></name><name name-style="western"><surname>Danthi</surname><given-names>P</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>S</given-names></name></person-group>. <article-title>Reovirus activated cell death pathways</article-title>. <source>Cells</source><year>2022</year>;<volume>11</volume>:<fpage>1757</fpage>. <comment>doi: 10.3390/cells11111757</comment>.<pub-id pub-id-type="pmid">35681452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells11111757</pub-id><pub-id pub-id-type="pmcid">PMC9179526</pub-id></mixed-citation></ref><ref id="R140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>C</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>S</given-names></name></person-group>. <article-title>ZBP1 inflames the SARS-CoV-2-infected lung</article-title>. <source>Cell Res</source><year>2023</year>;<volume>33</volume>:<fpage>333</fpage>&#8211;<lpage>334</lpage>. <comment>doi: 10.1038/s41422-023-00784-5</comment>.<pub-id pub-id-type="pmid">36792808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-023-00784-5</pub-id><pub-id pub-id-type="pmcid">PMC9930697</pub-id></mixed-citation></ref><ref id="R141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Nishitsuji</surname><given-names>H</given-names></name><name name-style="western"><surname>Takamori</surname><given-names>A</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>A</given-names></name><name name-style="western"><surname>Masuda</surname><given-names>T</given-names></name><name name-style="western"><surname>Kannagi</surname><given-names>M</given-names></name></person-group>. <article-title>DNA-Dependent activator of IFN-regulatory factors enhances the transcription of HIV-1 through NF-&#954;B</article-title>. <source>Microbes Infect</source><year>2010</year>;<volume>12</volume>:<fpage>937</fpage>&#8211;<lpage>947</lpage>. <comment>doi: 10.1016/j.micinf.2010.06.003</comment>.<pub-id pub-id-type="pmid">20599623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micinf.2010.06.003</pub-id></mixed-citation></ref><ref id="R142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SA</given-names></name><name name-style="western"><surname>Chang</surname><given-names>LC</given-names></name><name name-style="western"><surname>Jung</surname><given-names>W</given-names></name><name name-style="western"><surname>Bowman</surname><given-names>JW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name>, <etal/></person-group>. <article-title>OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis</article-title>. <source>Nat Cell Biol</source><year>2023</year>;<volume>25</volume>:<fpage>92</fpage>&#8211;<lpage>107</lpage>. <comment>doi: 10.1038/s41556-022-01039-y</comment>.<pub-id pub-id-type="pmid">36604592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41556-022-01039-y</pub-id><pub-id pub-id-type="pmcid">PMC9859756</pub-id></mixed-citation></ref><ref id="R143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Feng</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H</given-names></name>, <etal/></person-group>. <article-title>Transposable elements activation triggers necroptosis in mouse embryonic stem cells</article-title>. <source>Cell Death Dis</source><year>2023</year>;<volume>14</volume>:<fpage>184</fpage>. <comment>doi: 10.1038/s41419-023-05705-3</comment>.<pub-id pub-id-type="pmid">36882393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-023-05705-3</pub-id><pub-id pub-id-type="pmcid">PMC9992707</pub-id></mixed-citation></ref><ref id="R144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalil</surname><given-names>AC</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>PG</given-names></name></person-group>. <article-title>Influenza virus-related critical illness: Pathophysiology and epidemiology</article-title>. <source>Crit Care</source><year>2019</year>;<volume>23</volume>:<fpage>258</fpage>. <comment>doi: 10.1186/s13054-019-2539-x</comment>.<pub-id pub-id-type="pmid">31324202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-019-2539-x</pub-id><pub-id pub-id-type="pmcid">PMC6642581</pub-id></mixed-citation></ref><ref id="R145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marty</surname><given-names>FM</given-names></name><name name-style="western"><surname>Vidal-Puigserver</surname><given-names>J</given-names></name><name name-style="western"><surname>Clark</surname><given-names>C</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>SK</given-names></name><name name-style="western"><surname>Merino</surname><given-names>E</given-names></name><name name-style="western"><surname>Garot</surname><given-names>D</given-names></name>, <etal/></person-group>. <article-title>Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: An international, randomised, double-blind, double-dummy, phase 3 trial</article-title>. <source>Lancet Respir Med</source><year>2017</year>;<volume>5</volume>:<fpage>135</fpage>&#8211;<lpage>146</lpage>. <comment>doi: 10.1016/S2213-2600(16)30435-0</comment>.<pub-id pub-id-type="pmid">28094141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-2600(16)30435-0</pub-id></mixed-citation></ref><ref id="R146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Sui</surname><given-names>T</given-names></name><name name-style="western"><surname>Wu</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>Regulation of early host immune responses shapes the pathogenicity of avian influenza A virus</article-title>. <source>Front Microbiol</source><year>2019</year>;<volume>10</volume>:<fpage>2007</fpage>. <comment>doi: 10.3389/fmicb.2019.02007</comment>.<pub-id pub-id-type="pmid">31572308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2019.02007</pub-id><pub-id pub-id-type="pmcid">PMC6749051</pub-id></mixed-citation></ref><ref id="R147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yatim</surname><given-names>N</given-names></name><name name-style="western"><surname>Albert</surname><given-names>ML</given-names></name></person-group>. <article-title>Dying to replicate: The orchestration of the viral life cycle, cell death pathways, and immunity</article-title>. <source>Immunity</source><year>2011</year>;<volume>35</volume>:<fpage>478</fpage>&#8211;<lpage>490</lpage>. <comment>doi: 10.1016/j.immuni.2011.10.010</comment>.<pub-id pub-id-type="pmid">22035840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2011.10.010</pub-id></mixed-citation></ref><ref id="R148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saira</surname><given-names>K</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name><name name-style="western"><surname>DePasse</surname><given-names>JV</given-names></name><name name-style="western"><surname>Halpin</surname><given-names>R</given-names></name><name name-style="western"><surname>Twaddle</surname><given-names>A</given-names></name><name name-style="western"><surname>Stockwell</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>Sequence analysis of in vivo defective interfering-like RNA of influenza a H1N1 pandemic virus</article-title>. <source>J Virol</source><year>2013</year>;<volume>87</volume>:<fpage>8064</fpage>&#8211;<lpage>8074</lpage>. <comment>doi: 10.1128/JVI.00240-13</comment>.<pub-id pub-id-type="pmid">23678180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00240-13</pub-id><pub-id pub-id-type="pmcid">PMC3700204</pub-id></mixed-citation></ref><ref id="R149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Florence</surname><given-names>JM</given-names></name><name name-style="western"><surname>Jung</surname><given-names>BG</given-names></name><name name-style="western"><surname>Kurdowska</surname><given-names>AK</given-names></name><name name-style="western"><surname>Samten</surname><given-names>B</given-names></name>, <etal/></person-group>. <article-title>Influenza virus infection induces ZBP1 expression and necroptosis in mouse lungs</article-title>. <source>Front Cell Infect Microbiol</source><year>2019</year>;<volume>9</volume>:<fpage>286</fpage>. <comment>doi: 10.3389/fcimb.2019.00286</comment>.<pub-id pub-id-type="pmid">31440477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2019.00286</pub-id><pub-id pub-id-type="pmcid">PMC6694206</pub-id></mixed-citation></ref><ref id="R150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lien</surname><given-names>E</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>KA</given-names></name></person-group>. <article-title>MLKL-Driven inflammasome activation and caspase-8 mediate inflammatory cell death in influenza A virus infection</article-title>. <source>mBio</source><year>2023</year>;<volume>14</volume>:<fpage>e0011023</fpage>. <comment>doi: 10.1128/mbio.00110-23</comment>.<pub-id pub-id-type="pmid">36852999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mbio.00110-23</pub-id><pub-id pub-id-type="pmcid">PMC10127685</pub-id></mixed-citation></ref><ref id="R151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pham</surname><given-names>TH</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>KM</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YE</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KK</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>JH</given-names></name></person-group>. <article-title>DNA sensing-independent inhibition of herpes simplex virus 1 replication by DAI/ZBP1</article-title>. <source>J Virol</source><year>2013</year>;<volume>87</volume>:<fpage>3076</fpage>&#8211;<lpage>3086</lpage>. <comment>doi: 10.1128/JVI.02860-12</comment>.<pub-id pub-id-type="pmid">23283962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02860-12</pub-id><pub-id pub-id-type="pmcid">PMC3592125</pub-id></mixed-citation></ref><ref id="R152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyd</surname><given-names>DF</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>SV</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>S</given-names></name></person-group>. <article-title>ZBP1-Driven cell death in severe influenza</article-title>. <source>Trends Microbiol</source><year>2025</year>;<volume>33</volume>:<fpage>521</fpage>&#8211;<lpage>532</lpage>. <comment>doi: 10.1016/j.tim.2024.12.008</comment>.<pub-id pub-id-type="pmid">39809680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tim.2024.12.008</pub-id><pub-id pub-id-type="pmcid">PMC12369450</pub-id></mixed-citation></ref><ref id="R153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>H</given-names></name><name name-style="western"><surname>Gilley</surname><given-names>RP</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>A</given-names></name><name name-style="western"><surname>Lane</surname><given-names>R</given-names></name><name name-style="western"><surname>Landsteiner</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Ragan</surname><given-names>KB</given-names></name>, <etal/></person-group>. <article-title>Species-Independent contribution of ZBP1/DAI/DLM-1-triggered necroptosis in host defense against HSV1</article-title>. <source>Cell Death Dis</source><year>2018</year>;<volume>9</volume>:<fpage>816</fpage>. <comment>doi: 10.1038/s41419-018-0868-3</comment>.<pub-id pub-id-type="pmid">30050136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-018-0868-3</pub-id><pub-id pub-id-type="pmcid">PMC6062522</pub-id></mixed-citation></ref><ref id="R154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Wollenberg</surname><given-names>DJM</given-names></name><name name-style="western"><surname>Kemp</surname><given-names>V</given-names></name><name name-style="western"><surname>Rabelink</surname><given-names>MJWE</given-names></name><name name-style="western"><surname>Hoeben</surname><given-names>RC</given-names></name></person-group>. <article-title>Reovirus type 3 dearing variants do not induce necroptosis in RIPK3-expressing human tumor cell lines</article-title>. <source>Int J Mol Sci</source><year>2023</year>;<volume>24</volume>:<fpage>2320</fpage>. <comment>doi: 10.3390/ijms24032320</comment>.<pub-id pub-id-type="pmid">36768641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24032320</pub-id><pub-id pub-id-type="pmcid">PMC9916669</pub-id></mixed-citation></ref><ref id="R155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balachandran</surname><given-names>S</given-names></name><name name-style="western"><surname>Mocarski</surname><given-names>ES</given-names></name></person-group>. <article-title>Viral Z-RNA triggers ZBP1-dependent cell death</article-title>. <source>Curr Opin Virol</source><year>2021</year>;<volume>51</volume>:<fpage>134</fpage>&#8211;<lpage>140</lpage>. <comment>doi: 10.1016/j.coviro.2021.10.004</comment>.<pub-id pub-id-type="pmid">34688984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coviro.2021.10.004</pub-id><pub-id pub-id-type="pmcid">PMC8643332</pub-id></mixed-citation></ref><ref id="R156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rebsamen</surname><given-names>M</given-names></name><name name-style="western"><surname>Heinz</surname><given-names>LX</given-names></name><name name-style="western"><surname>Meylan</surname><given-names>E</given-names></name><name name-style="western"><surname>Michallet</surname><given-names>MC</given-names></name><name name-style="western"><surname>Schroder</surname><given-names>K</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>K</given-names></name>, <etal/></person-group>. <article-title>DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-kappaB</article-title>. <source>EMBO Rep</source><year>2009</year>;<volume>10</volume>:<fpage>916</fpage>&#8211;<lpage>922</lpage>. <comment>doi: 10.1038/embor.2009.109</comment>.<pub-id pub-id-type="pmid">19590578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/embor.2009.109</pub-id><pub-id pub-id-type="pmcid">PMC2726668</pub-id></mixed-citation></ref><ref id="R157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>XK</given-names></name><name name-style="western"><surname>Ge</surname><given-names>WY</given-names></name><name name-style="western"><surname>Jing</surname><given-names>R</given-names></name><name name-style="western"><surname>Pan</surname><given-names>LH</given-names></name></person-group>. <article-title>Necroptosis in pulmonary macrophages mediates lipopolysaccharide-induced lung inflammatory injury by activating ZBP-1</article-title>. <source>Int Immunopharmacol</source><year>2019</year>;<volume>77</volume>:<fpage>105944</fpage>. <comment>doi: 10.1016/j.intimp.2019.105944</comment>.<pub-id pub-id-type="pmid">31655343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2019.105944</pub-id></mixed-citation></ref><ref id="R158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stutz</surname><given-names>MD</given-names></name><name name-style="western"><surname>Ojaimi</surname><given-names>S</given-names></name><name name-style="western"><surname>Allison</surname><given-names>C</given-names></name><name name-style="western"><surname>Preston</surname><given-names>S</given-names></name><name name-style="western"><surname>Arandjelovic</surname><given-names>P</given-names></name><name name-style="western"><surname>Hildebrand</surname><given-names>JM</given-names></name>, <etal/></person-group>. <article-title>Necroptotic signaling is primed in Mycobacterium Tuberculosis-infected macrophages, but its pathophysiological consequence in disease is restricted</article-title>. <source>Cell Death Differ</source><year>2018</year>;<volume>25</volume>:<fpage>951</fpage>&#8211;<lpage>965</lpage>. <comment>doi: 10.1038/s41418-017-0031-1</comment>.<pub-id pub-id-type="pmid">29229989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-017-0031-1</pub-id><pub-id pub-id-type="pmcid">PMC5943269</pub-id></mixed-citation></ref><ref id="R159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Han</surname><given-names>Z</given-names></name>, <etal/></person-group>. <article-title>Cisatracurium besylate rescues Mycobacterium Tuberculosis-infected macrophages from necroptosis and enhances the bactericidal effect of isoniazid</article-title>. <source>Int Immunopharmacol</source><year>2023</year>;<volume>120</volume>:<fpage>110291</fpage>. <comment>doi: 10.1016/j.intimp.2023.110291</comment>.<pub-id pub-id-type="pmid">37182451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2023.110291</pub-id></mixed-citation></ref><ref id="R160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name>, <etal/></person-group>. <article-title>Type I IFN operates pyroptosis and necroptosis during multidrug-resistant A. Baumannii infection</article-title>. <source>Cell Death Differ</source><year>2018</year>;<volume>25</volume>:<fpage>1304</fpage>&#8211;<lpage>1318</lpage>. <comment>doi: 10.1038/s41418-017-0041-z</comment>.<pub-id pub-id-type="pmid">29352265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-017-0041-z</pub-id><pub-id pub-id-type="pmcid">PMC6030212</pub-id></mixed-citation></ref><ref id="R161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banoth</surname><given-names>B</given-names></name><name name-style="western"><surname>Tuladhar</surname><given-names>S</given-names></name><name name-style="western"><surname>Karki</surname><given-names>R</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>BR</given-names></name><name name-style="western"><surname>Briard</surname><given-names>B</given-names></name><name name-style="western"><surname>Kesavardhana</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>ZBP1 promotes fungi-induced inflammasome activation and pyroptosis, apoptosis, and necroptosis (PANoptosis)</article-title>. <source>J Biol Chem</source><year>2020</year>;<volume>295</volume>:<fpage>18276</fpage>&#8211;<lpage>18283</lpage>. <comment>doi: 10.1074/jbc.RA120.015924</comment>.<pub-id pub-id-type="pmid">33109609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.RA120.015924</pub-id><pub-id pub-id-type="pmcid">PMC7939383</pub-id></mixed-citation></ref><ref id="R162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cervantes</surname><given-names>PW</given-names></name><name name-style="western"><surname>Martorelli Di Genova</surname><given-names>B</given-names></name><name name-style="western"><surname>Erazo Flores</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Knoll</surname><given-names>LJ</given-names></name></person-group>. <article-title>RIPK3 Facilitates host resistance to oral Toxoplasma Gondii infection</article-title>. <source>Infect Immun</source><year>2021</year>;<volume>89</volume>:<fpage>e00021</fpage>-<lpage>21</lpage>. <comment>doi: 10.1128/IAI.00021-21</comment>.<pub-id pub-id-type="pmid">33526566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.00021-21</pub-id><pub-id pub-id-type="pmcid">PMC8091083</pub-id></mixed-citation></ref><ref id="R163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pittman</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Cervantes</surname><given-names>PW</given-names></name><name name-style="western"><surname>Knoll</surname><given-names>LJ</given-names></name></person-group>. <article-title>Z-DNA binding protein mediates host control of Toxoplasma Gondii infection</article-title>. <source>Infect Immun</source><year>2016</year>;<volume>84</volume>:<fpage>3063</fpage>&#8211;<lpage>3070</lpage>. <comment>doi: 10.1128/IAI.00511-16</comment>.<pub-id pub-id-type="pmid">27481249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.00511-16</pub-id><pub-id pub-id-type="pmcid">PMC5038082</pub-id></mixed-citation></ref><ref id="R164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moujalled</surname><given-names>D</given-names></name><name name-style="western"><surname>Strasser</surname><given-names>A</given-names></name><name name-style="western"><surname>Liddell</surname><given-names>JR</given-names></name></person-group>. <article-title>Molecular mechanisms of cell death in neurological diseases</article-title>. <source>Cell Death Differ</source><year>2021</year>;<volume>28</volume>:<fpage>2029</fpage>&#8211;<lpage>2044</lpage>. <comment>doi: 10.1038/s41418-021-00814-y</comment>.<pub-id pub-id-type="pmid">34099897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-021-00814-y</pub-id><pub-id pub-id-type="pmcid">PMC8257776</pub-id></mixed-citation></ref><ref id="R165"><label>165.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moonen</surname><given-names>S</given-names></name><name name-style="western"><surname>Koper</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Van Schoor</surname><given-names>E</given-names></name><name name-style="western"><surname>Schaeverbeke</surname><given-names>JM</given-names></name><name name-style="western"><surname>Vandenberghe</surname><given-names>R</given-names></name><name name-style="western"><surname>von Arnim</surname><given-names>CAF</given-names></name>, <etal/></person-group>. <article-title>Pyroptosis in Alzheimer&#8217;s disease: Cell type-specific activation in microglia, astrocytes and neurons</article-title>. <source>Acta Neuropathol</source><year>2023</year>;<volume>145</volume>:<fpage>175</fpage>&#8211;<lpage>195</lpage>. <comment>doi: 10.1007/s00401-022-02528-y</comment>.<pub-id pub-id-type="pmid">36481964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-022-02528-y</pub-id></mixed-citation></ref><ref id="R166"><label>166.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humphries</surname><given-names>F</given-names></name><name name-style="western"><surname>Shmuel-Galia</surname><given-names>L</given-names></name><name name-style="western"><surname>Ketelut-Carneiro</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Nemmara</surname><given-names>VV</given-names></name>, <etal/></person-group>. <article-title>Succination inactivates gasdermin D and blocks pyroptosis</article-title>. <source>Science</source><year>2020</year>;<volume>369</volume>:<fpage>1633</fpage>&#8211;<lpage>1637</lpage>. <comment>doi: 10.1126/science.abb9818</comment>.<pub-id pub-id-type="pmid">32820063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb9818</pub-id><pub-id pub-id-type="pmcid">PMC8744141</pub-id></mixed-citation></ref><ref id="R167"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X</given-names></name><name name-style="western"><surname>Ni</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>K</given-names></name></person-group>. <article-title>Emerging role of STING signalling in CNS injury: Inflammation, autophagy, necroptosis, ferroptosis and pyroptosis</article-title>. <source>J Neuroinflammation</source><year>2022</year>;<volume>19</volume>:<fpage>242</fpage>. <comment>doi: 10.1186/s12974-022-02602-y</comment>.<pub-id pub-id-type="pmid">36195926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-022-02602-y</pub-id><pub-id pub-id-type="pmcid">PMC9531511</pub-id></mixed-citation></ref><ref id="R168"><label>168.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ofengeim</surname><given-names>D</given-names></name><name name-style="western"><surname>Najafov</surname><given-names>A</given-names></name><name name-style="western"><surname>Das</surname><given-names>S</given-names></name><name name-style="western"><surname>Saberi</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <etal/></person-group>. <article-title>RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS</article-title>. <source>Science</source><year>2016</year>;<volume>353</volume>:<fpage>603</fpage>&#8211;<lpage>608</lpage>. <comment>doi: 10.1126/science.aaf6803</comment>.<pub-id pub-id-type="pmid">27493188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaf6803</pub-id><pub-id pub-id-type="pmcid">PMC5444917</pub-id></mixed-citation></ref><ref id="R169"><label>169.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X</given-names></name>, <etal/></person-group>. <article-title>Quetiapine induces myocardial necroptotic cell death through bidirectional regulation of cannabinoid receptors</article-title>. <source>Toxicol Lett</source><year>2019</year>;<volume>313</volume>:<fpage>77</fpage>&#8211;<lpage>90</lpage>. <comment>doi: 10.1016/j.toxlet.2019.06.005</comment>.<pub-id pub-id-type="pmid">31220554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.toxlet.2019.06.005</pub-id></mixed-citation></ref><ref id="R170"><label>170.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>ME</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>Prolonged cold ischemia induces necroptotic cell death in ischemia-reperfusion injury and contributes to primary graft dysfunction after lung transplantation</article-title>. <source>Am J Respir Cell Mol Biol</source><year>2019</year>;<volume>61</volume>:<fpage>244</fpage>&#8211;<lpage>256</lpage>. <comment>doi: 10.1165/rcmb.2018-0207OC</comment>.<pub-id pub-id-type="pmid">30742487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1165/rcmb.2018-0207OC</pub-id><pub-id pub-id-type="pmcid">PMC6670033</pub-id></mixed-citation></ref><ref id="R171"><label>171.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C</given-names></name><name name-style="western"><surname>Qi</surname><given-names>X</given-names></name><name name-style="western"><surname>Cardona</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Z</given-names></name></person-group>. <article-title>RIPK3-dependent necroptosis is induced and restricts viral replication in human astrocytes infected with zika virus</article-title>. <source>Front Cell Infect Microbiol</source><year>2021</year>;<volume>11</volume>:<fpage>637710</fpage>. <comment>doi: 10.3389/fcimb.2021.637710</comment>.<pub-id pub-id-type="pmid">33796483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2021.637710</pub-id><pub-id pub-id-type="pmcid">PMC8007970</pub-id></mixed-citation></ref><ref id="R172"><label>172.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Hung</surname><given-names>YF</given-names></name><name name-style="western"><surname>Liu</surname><given-names>HY</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>YP</given-names></name></person-group>. <article-title>Deletion of the inflammasome sensor Aim2 mitigates A&#946; deposition and microglial activation but increases inflammatory cytokine expression in an Alzheimer disease mouse model</article-title>. <source>Neuroimmunomodulation</source><year>2017</year>;<volume>24</volume>:<fpage>29</fpage>&#8211;<lpage>39</lpage>. <comment>doi: 10.1159/000477092</comment>.<pub-id pub-id-type="pmid">28618410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000477092</pub-id></mixed-citation></ref><ref id="R173"><label>173.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flores</surname><given-names>J</given-names></name><name name-style="western"><surname>No&#235;l</surname><given-names>A</given-names></name><name name-style="western"><surname>Foveau</surname><given-names>B</given-names></name><name name-style="western"><surname>Lynham</surname><given-names>J</given-names></name><name name-style="western"><surname>Lecrux</surname><given-names>C</given-names></name><name name-style="western"><surname>LeBlanc</surname><given-names>AC</given-names></name></person-group>. <article-title>Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer&#8217;s disease mouse model</article-title>. <source>Nat Commun</source><year>2018</year>;<volume>9</volume>:<fpage>3916</fpage>. <comment>doi: 10.1038/s41467-018-06449-x</comment>.<pub-id pub-id-type="pmid">30254377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-06449-x</pub-id><pub-id pub-id-type="pmcid">PMC6156230</pub-id></mixed-citation></ref><ref id="R174"><label>174.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniels</surname><given-names>BP</given-names></name><name name-style="western"><surname>Kofman</surname><given-names>SB</given-names></name><name name-style="western"><surname>Smith</surname><given-names>JR</given-names></name><name name-style="western"><surname>Norris</surname><given-names>GT</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>AG</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>JP</given-names></name>, <etal/></person-group>. <article-title>The nucleotide sensor ZBP1 and kinase RIPK3 induce the enzyme IRG1 to promote an antiviral metabolic state in neurons</article-title>. <source>Immunity</source><year>2019</year>;<volume>50</volume>:<fpage>64</fpage>&#8211;<lpage>76</lpage>. <comment>doi: 10.1016/j.immuni.2018.11.017</comment>.<pub-id pub-id-type="pmid">30635240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2018.11.017</pub-id><pub-id pub-id-type="pmcid">PMC6342485</pub-id></mixed-citation></ref><ref id="R175"><label>175.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajesh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group>. <article-title>Innate immune cell death in neuroinflammation and Alzheimer&#8217;s disease</article-title>. <source>Cells</source><year>2022</year>;<volume>11</volume>:<fpage>1885</fpage>. <comment>doi: 10.3390/cells11121885</comment>.<pub-id pub-id-type="pmid">35741014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells11121885</pub-id><pub-id pub-id-type="pmcid">PMC9221514</pub-id></mixed-citation></ref><ref id="R176"><label>176.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Yan</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Ding</surname><given-names>W</given-names></name>, <etal/></person-group>. <article-title>Nucleoporin Seh1 maintains Schwann cell homeostasis by regulating genome stability and necroptosis</article-title>. <source>Cell Rep</source><year>2023</year>;<volume>42</volume>:<fpage>112802</fpage>. <comment>doi: 10.1016/j.celrep.2023.112802</comment>.<pub-id pub-id-type="pmid">37453065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2023.112802</pub-id></mixed-citation></ref><ref id="R177"><label>177.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lan</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liao</surname><given-names>K</given-names></name>, <etal/></person-group>. <article-title>PTRF-IL33-ZBP1 signaling mediating macrophage necroptosis contributes to HDM-induced airway inflammation</article-title>. <source>Cell Death Dis</source><year>2023</year>;<volume>14</volume>:<fpage>432</fpage>. <comment>doi: 10.1038/s41419-023-05971-1</comment>.<pub-id pub-id-type="pmid">37454215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-023-05971-1</pub-id><pub-id pub-id-type="pmcid">PMC10349813</pub-id></mixed-citation></ref><ref id="R178"><label>178.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devos</surname><given-names>M</given-names></name><name name-style="western"><surname>Tanghe</surname><given-names>G</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>B</given-names></name><name name-style="western"><surname>Dierick</surname><given-names>E</given-names></name><name name-style="western"><surname>Verheirstraeten</surname><given-names>M</given-names></name><name name-style="western"><surname>Nemegeer</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>Sensing of endogenous nucleic acids by ZBP1 induces keratinocyte necroptosis and skin inflammation</article-title>. <source>J Exp Med</source><year>2020</year>;<volume>217</volume>:<fpage>e20191913</fpage>. <comment>doi: 10.1084/jem.20191913</comment>.<pub-id pub-id-type="pmid">32315377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20191913</pub-id><pub-id pub-id-type="pmcid">PMC7336309</pub-id></mixed-citation></ref><ref id="R179"><label>179.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Cai</surname><given-names>ZY</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Ni</surname><given-names>H</given-names></name>, <etal/></person-group>. <article-title>Gut stem cell necroptosis by genome instability triggers bowel inflammation</article-title>. <source>Nature</source><year>2020</year>;<volume>580</volume>:<fpage>386</fpage>&#8211;<lpage>390</lpage>. <comment>doi: 10.1038/s41586-020-2127-x</comment>.<pub-id pub-id-type="pmid">32296174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2127-x</pub-id></mixed-citation></ref><ref id="R180"><label>180.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarzer</surname><given-names>R</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wachsmuth</surname><given-names>L</given-names></name><name name-style="western"><surname>Tresch</surname><given-names>A</given-names></name><name name-style="western"><surname>Pasparakis</surname><given-names>M</given-names></name></person-group>. <article-title>FADD and caspase-8 regulate gut homeostasis and inflammation by controlling MLKL- and GSDMD-mediated death of intestinal epithelial cells</article-title>. <source>Immunity</source><year>2020</year>;<volume>52</volume>:<fpage>978</fpage>&#8211;<lpage>993</lpage>. <comment>doi: 10.1016/j.immuni.2020.04.002</comment>.<pub-id pub-id-type="pmid">32362323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2020.04.002</pub-id></mixed-citation></ref><ref id="R181"><label>181.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>G</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J</given-names></name></person-group>. <article-title>Growing burden of inflammatory bowel disease in china: Findings from the global burden of disease study 2021 and predictions to 2035</article-title>. <source>Chin Med J</source><year>2024</year>;<volume>137</volume>:<fpage>2851</fpage>&#8211;<lpage>2859</lpage>. <comment>doi: 10.1097/CM9.0000000000003345</comment>.<pub-id pub-id-type="pmid">39501850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000003345</pub-id><pub-id pub-id-type="pmcid">PMC11649283</pub-id></mixed-citation></ref><ref id="R182"><label>182.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>, <etal/></person-group>. <article-title>Molecular characterization of PANoptosis-related genes with features of immune dysregulation in systemic lupus erythematosus</article-title>. <source>Clin Immunol</source><year>2023</year>;<volume>253</volume>:<fpage>109660</fpage>. <comment>doi: 10.1016/j.clim.2023.109660</comment>.<pub-id pub-id-type="pmid">37295541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2023.109660</pub-id></mixed-citation></ref><ref id="R183"><label>183.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C</given-names></name><name name-style="western"><surname>Van</surname><given-names>TM</given-names></name><name name-style="western"><surname>Wachsmuth</surname><given-names>L</given-names></name><name name-style="western"><surname>Polykratis</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>RIPK1 counteracts ZBP1-mediated necroptosis to inhibit inflammation</article-title>. <source>Nature</source><year>2016</year>;<volume>540</volume>:<fpage>124</fpage>&#8211;<lpage>128</lpage>. <comment>doi: 10.1038/nature20558</comment>.<pub-id pub-id-type="pmid">27819681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature20558</pub-id><pub-id pub-id-type="pmcid">PMC5755685</pub-id></mixed-citation></ref><ref id="R184"><label>184.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koerner</surname><given-names>L</given-names></name><name name-style="western"><surname>Wachsmuth</surname><given-names>L</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>S</given-names></name><name name-style="western"><surname>Schwarzer</surname><given-names>R</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>T</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>H</given-names></name>, <etal/></person-group>. <article-title>ZBP1 causes inflammation by inducing RIPK3-mediated necroptosis and RIPK1 kinase activity-independent apoptosis</article-title>. <source>Cell Death Differ</source><year>2024</year>;<volume>31</volume>:<fpage>938</fpage>&#8211;<lpage>953</lpage>. <comment>doi: 10.1038/s41418-024-01321-6</comment>.<pub-id pub-id-type="pmid">38849574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-024-01321-6</pub-id><pub-id pub-id-type="pmcid">PMC11239871</pub-id></mixed-citation></ref><ref id="R185"><label>185.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chi</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>B</given-names></name></person-group>. <article-title>Endogenous tRNA-derived small RNA (tRF3-Thr-AGT) inhibits ZBP1/NLRP3 pathway-mediated cell pyroptosis to attenuate acute pancreatitis (AP)</article-title>. <source>J Cell Mol Med</source><year>2021</year>;<volume>25</volume>:<fpage>10441</fpage>&#8211;<lpage>10453</lpage>. <comment>doi: 10.1111/jcmm.16972</comment>.<pub-id pub-id-type="pmid">34643045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.16972</pub-id><pub-id pub-id-type="pmcid">PMC8581331</pub-id></mixed-citation></ref><ref id="R186"><label>186.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enzan</surname><given-names>N</given-names></name><name name-style="western"><surname>Matsushima</surname><given-names>S</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>S</given-names></name><name name-style="western"><surname>Okabe</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishikita</surname><given-names>A</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>ZBP1 protects against mtDNA-induced myocardial inflammation in failing hearts</article-title>. <source>Circ Res</source><year>2023</year>;<volume>132</volume>:<fpage>1110</fpage>&#8211;<lpage>1126</lpage>. <comment>doi: 10.1161/CIRCRESAHA.122.322227</comment>.<pub-id pub-id-type="pmid">36974722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.122.322227</pub-id><pub-id pub-id-type="pmcid">PMC10144299</pub-id></mixed-citation></ref><ref id="R187"><label>187.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaela</surname><given-names>VM</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LY</given-names></name></person-group>. <article-title>Ends end it via mitochondria: A telomere-dependent tumor suppressive mechanism acts during replicative crisis</article-title>. <source>Mol Cell</source><year>2023</year>;<volume>83</volume>:<fpage>1027</fpage>&#8211;<lpage>1029</lpage>. <comment>doi: 10.1016/j.molcel.2023.03.012</comment>.<pub-id pub-id-type="pmid">37028414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2023.03.012</pub-id></mixed-citation></ref><ref id="R188"><label>188.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baik</surname><given-names>JY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>D</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Kadigamuwa</surname><given-names>C</given-names></name>, <etal/></person-group>. <article-title>ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer</article-title>. <source>Nat Commun</source><year>2021</year>;<volume>12</volume>:<fpage>2666</fpage>. <comment>doi: 10.1038/s41467-021-23004-3</comment>.<pub-id pub-id-type="pmid">33976222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-23004-3</pub-id><pub-id pub-id-type="pmcid">PMC8113527</pub-id></mixed-citation></ref><ref id="R189"><label>189.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Goswami</surname><given-names>S</given-names></name><name name-style="western"><surname>Lapidus</surname><given-names>K</given-names></name><name name-style="western"><surname>Wells</surname><given-names>AL</given-names></name><name name-style="western"><surname>Wyckoff</surname><given-names>JB</given-names></name><name name-style="western"><surname>Sahai</surname><given-names>E</given-names></name>, <etal/></person-group>. <article-title>Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors</article-title>. <source>Cancer Res</source><year>2004</year>;<volume>64</volume>:<fpage>8585</fpage>&#8211;<lpage>8594</lpage>. <comment>doi: 10.1158/0008-5472.CAN-04-1136</comment>.<pub-id pub-id-type="pmid">15574765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-04-1136</pub-id></mixed-citation></ref><ref id="R190"><label>190.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ponnusamy</surname><given-names>K</given-names></name><name name-style="western"><surname>Tzioni</surname><given-names>MM</given-names></name><name name-style="western"><surname>Begum</surname><given-names>M</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>ME</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>VS</given-names></name><name name-style="western"><surname>Katsarou</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma</article-title>. <source>Haematologica</source><year>2022</year>;<volume>107</volume>:<fpage>721</fpage>&#8211;<lpage>732</lpage>. <comment>doi: 10.3324/haematol.2020.274480</comment>.<pub-id pub-id-type="pmid">33596642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3324/haematol.2020.274480</pub-id><pub-id pub-id-type="pmcid">PMC8883568</pub-id></mixed-citation></ref><ref id="R191"><label>191.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Duan</surname><given-names>M</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Q</given-names></name>, <etal/></person-group>. <article-title>Exploration of pyroptosis-associated prognostic gene signature and lncRNA regulatory network in ovarian cancer</article-title>. <source>Comput Biol Med</source><year>2023</year>;<volume>164</volume>:<fpage>107343</fpage>. <comment>doi: 10.1016/j.compbiomed.2023.107343</comment>.<pub-id pub-id-type="pmid">37566932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2023.107343</pub-id></mixed-citation></ref><ref id="R192"><label>192.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tang</surname><given-names>K</given-names></name></person-group>. <article-title>ABT&#8209;737, a Bcl&#8209;2 family inhibitor, has a synergistic effect with apoptosis by inducing urothelial carcinoma cell necroptosis</article-title>. <source>Mol Med Rep</source><year>2021</year>;<volume>23</volume>:<fpage>412</fpage>. <comment>doi: 10.3892/mmr.2021.12051</comment>.<pub-id pub-id-type="pmid">33786632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2021.12051</pub-id><pub-id pub-id-type="pmcid">PMC8025475</pub-id></mixed-citation></ref><ref id="R193"><label>193.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>C</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Geng</surname><given-names>R</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <etal/></person-group>. <article-title>Necroptosis-related signatures identify two distinct hepatocellular carcinoma subtypes: Implications for predicting drug sensitivity and prognosis</article-title>. <source>Heliyon</source><year>2023</year>;<volume>9</volume>:<fpage>e18136</fpage>. <comment>doi: 10.1016/j.heliyon.2023.e18136</comment>.<pub-id pub-id-type="pmid">37519654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2023.e18136</pub-id><pub-id pub-id-type="pmcid">PMC10372238</pub-id></mixed-citation></ref><ref id="R194"><label>194.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sales Conniff</surname><given-names>A</given-names></name><name name-style="western"><surname>Encalada</surname><given-names>G</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S</given-names></name><name name-style="western"><surname>Bhandary</surname><given-names>M</given-names></name><name name-style="western"><surname>Al-Takrouri</surname><given-names>F</given-names></name><name name-style="western"><surname>Heller</surname><given-names>L</given-names></name></person-group>. <article-title>Poly(I:C) transfection induces a pro-inflammatory cascade in murine mammary carcinoma and fibrosarcoma cells</article-title>. <source>RNA Biol</source><year>2022</year>;<volume>19</volume>:<fpage>841</fpage>&#8211;<lpage>851</lpage>. <comment>doi: 10.1080/15476286.2022.2084861</comment>.<pub-id pub-id-type="pmid">35737804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15476286.2022.2084861</pub-id><pub-id pub-id-type="pmcid">PMC9235898</pub-id></mixed-citation></ref><ref id="R195"><label>195.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yun</surname><given-names>F</given-names></name>, <etal/></person-group>. <article-title>Triggering endogenous Z-RNA sensing for anti-tumor therapy through ZBP1-dependent necroptosis</article-title>. <source>Cell Rep</source><year>2023</year>;<volume>42</volume>:<fpage>113377</fpage>. <comment>doi: 10.1016/j.celrep.2023.113377</comment>.<pub-id pub-id-type="pmid">37922310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2023.113377</pub-id></mixed-citation></ref><ref id="R196"><label>196.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Song</surname><given-names>A</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>WD</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>MJ</given-names></name>, <etal/></person-group>. <article-title>Fn-OMV potentiates ZBP1-mediated PANoptosis triggered by oncolytic HSV-1 to fuel antitumor immunity</article-title>. <source>Nat Commun</source><year>2024</year>;<volume>15</volume>:<fpage>3669</fpage>. <comment>doi: 10.1038/s41467-024-48032-7</comment>.<pub-id pub-id-type="pmid">38693119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-48032-7</pub-id><pub-id pub-id-type="pmcid">PMC11063137</pub-id></mixed-citation></ref><ref id="R197"><label>197.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cao</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shan</surname><given-names>L</given-names></name><name name-style="western"><surname>Lan</surname><given-names>S</given-names></name></person-group>. <article-title>Fisetin-induced cell death in human ovarian cancer cell lines via Zbp1-mediated necroptosis</article-title>. <source>J Ovarian Res</source><year>2022</year>;<volume>15</volume>:<fpage>57</fpage>. <comment>doi: 10.1186/s13048-022-00984-4</comment>.<pub-id pub-id-type="pmid">35538559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13048-022-00984-4</pub-id><pub-id pub-id-type="pmcid">PMC9092675</pub-id></mixed-citation></ref><ref id="R198"><label>198.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camilli</surname><given-names>S</given-names></name><name name-style="western"><surname>Lockey</surname><given-names>R</given-names></name><name name-style="western"><surname>Kolliputi</surname><given-names>N</given-names></name></person-group>. <article-title>Nuclear export inhibitors selinexor (KPT-330) and Eltanexor (KPT-8602) provide a novel therapy to reduce tumor growth by induction of PANoptosis</article-title>. <source>Cell Biochem Biophys</source><year>2023</year>;<volume>81</volume>:<fpage>421</fpage>&#8211;<lpage>426</lpage>. <comment>doi: 10.1007/s12013-023-01135-2</comment>.<pub-id pub-id-type="pmid">37126200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12013-023-01135-2</pub-id></mixed-citation></ref><ref id="R199"><label>199.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis</article-title>. <source>J Transl Med</source><year>2022</year>;<volume>20</volume>:<fpage>444</fpage>. <comment>doi: 10.1186/s12967-022-03641-y</comment>.<pub-id pub-id-type="pmid">36184616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-022-03641-y</pub-id><pub-id pub-id-type="pmcid">PMC9528181</pub-id></mixed-citation></ref><ref id="R200"><label>200.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>BR</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group>. <article-title>Inflammasome signaling in colorectal cancer</article-title>. <source>Transl Res J Lab Clin Med</source><year>2023</year>;<volume>252</volume>:<fpage>45</fpage>&#8211;<lpage>52</lpage>. <comment>doi: 10.1016/j.trsl.2022.09.002</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trsl.2022.09.002</pub-id><pub-id pub-id-type="pmcid">PMC9839553</pub-id><pub-id pub-id-type="pmid">36150688</pub-id></mixed-citation></ref><ref id="R201"><label>201.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbert</surname><given-names>A</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>S</given-names></name></person-group>. <article-title>Z-DNA enhances immunotherapy by triggering death of inflammatory cancer-associated fibroblasts</article-title>. <source>J Immunother Cancer</source><year>2022</year>;<volume>10</volume>:<fpage>e005704</fpage>. <comment>doi: 10.1136/jitc-2022-005704</comment>.<pub-id pub-id-type="pmid">36450382</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2022-005704</pub-id><pub-id pub-id-type="pmcid">PMC9716847</pub-id></mixed-citation></ref><ref id="R202"><label>202.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name></person-group>. <article-title>The PANoptosis-related signature indicates the prognosis and tumor immune infiltration features of gliomas</article-title>. <source>Front Mol Neurosci</source><year>2023</year>;<volume>16</volume>:<fpage>1198713</fpage>. <comment>doi: 10.3389/fnmol.2023.1198713</comment>.<pub-id pub-id-type="pmid">37501725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnmol.2023.1198713</pub-id><pub-id pub-id-type="pmcid">PMC10369193</pub-id></mixed-citation></ref><ref id="R203"><label>203.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>T</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Y</given-names></name>, <etal/></person-group>. <article-title>Identification of a PANoptosis-related gene signature for predicting the prognosis, tumor microenvironment and therapy response in breast cancer</article-title>. <source>J Cancer</source><year>2024</year>;<volume>15</volume>:<fpage>428</fpage>&#8211;<lpage>443</lpage>. <comment>doi: 10.7150/jca.90113</comment>.<pub-id pub-id-type="pmid">38169571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/jca.90113</pub-id><pub-id pub-id-type="pmcid">PMC10758028</pub-id></mixed-citation></ref><ref id="R204"><label>204.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name></person-group>. <article-title>A novel identified necroptosis-related risk signature for prognosis prediction and immune infiltration indication in acute myeloid leukemia patients</article-title>. <source>Genes</source><year>2022</year>;<volume>13</volume>:<fpage>1837</fpage>. <comment>doi: 10.3390/genes13101837</comment>.<pub-id pub-id-type="pmid">36292722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/genes13101837</pub-id><pub-id pub-id-type="pmcid">PMC9602382</pub-id></mixed-citation></ref><ref id="R205"><label>205.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>W</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W</given-names></name></person-group>. <article-title>A novel necroptosis-related gene signature in acute myeloid leukemia</article-title>. <source>Hematol Amst Neth</source><year>2023</year>;<volume>28</volume>:<fpage>2227491</fpage>. <comment>doi: 10.1080/16078454.2023.2227491</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/16078454.2023.2227491</pub-id><pub-id pub-id-type="pmid">37367830</pub-id></mixed-citation></ref><ref id="R206"><label>206.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pan</surname><given-names>KH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name></person-group>. <article-title>Necroptosis-Related genes are associated with prognostic features of kidney renal clear cell carcinoma</article-title>. <source>Discov Oncol</source><year>2023</year>;<volume>14</volume>:<fpage>192</fpage>. <comment>doi: 10.1007/s12672-023-00794-0</comment>.<pub-id pub-id-type="pmid">37878133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12672-023-00794-0</pub-id><pub-id pub-id-type="pmcid">PMC10600093</pub-id></mixed-citation></ref><ref id="R207"><label>207.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>B</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <etal/></person-group>. <article-title>A novel necroptosis-related gene signature in skin cutaneous melanoma prognosis and tumor microenvironment</article-title>. <source>Front Genet</source><year>2022</year>;<volume>13</volume>:<fpage>917007</fpage>. <comment>doi: 10.3389/fgene.2022.917007</comment>.<pub-id pub-id-type="pmid">35899194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.917007</pub-id><pub-id pub-id-type="pmcid">PMC9309482</pub-id></mixed-citation></ref><ref id="R208"><label>208.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>You</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name></person-group>. <article-title>Pancreatic ductal adenocarcinoma chemoresistance: From metabolism reprogramming to novel treatment</article-title>. <source>Chin Med J</source><year>2024</year>;<volume>137</volume>:<fpage>408</fpage>&#8211;<lpage>420</lpage>. <comment>doi: 10.1097/CM9.0000000000002758</comment>.<pub-id pub-id-type="pmid">37545027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000002758</pub-id><pub-id pub-id-type="pmcid">PMC10876258</pub-id></mixed-citation></ref><ref id="R209"><label>209.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Liao</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>Construction of PANoptosis signature: Novel target discovery for prostate cancer immunotherapy</article-title>. <source>Mol Ther Nucleic Acids</source><year>2023</year>;<volume>33</volume>:<fpage>376</fpage>&#8211;<lpage>390</lpage>. <comment>doi: 10.1016/j.omtn.2023.07.010</comment>.<pub-id pub-id-type="pmid">37547288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2023.07.010</pub-id><pub-id pub-id-type="pmcid">PMC10400972</pub-id></mixed-citation></ref><ref id="R210"><label>210.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szczesny</surname><given-names>B</given-names></name><name name-style="western"><surname>Marcatti</surname><given-names>M</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>A</given-names></name><name name-style="western"><surname>Montalbano</surname><given-names>M</given-names></name><name name-style="western"><surname>Bruny&#225;nszki</surname><given-names>A</given-names></name><name name-style="western"><surname>Bibli</surname><given-names>SI</given-names></name>, <etal/></person-group>. <article-title>Mitochondrial DNA damage and subsequent activation of Z-DNA binding protein 1 links oxidative stress to inflammation in epithelial cells</article-title>. <source>Sci Rep</source><year>2018</year>;<volume>8</volume>:<fpage>914</fpage>. <comment>doi: 10.1038/s41598-018-19216-1</comment>.<pub-id pub-id-type="pmid">29343810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-19216-1</pub-id><pub-id pub-id-type="pmcid">PMC5772643</pub-id></mixed-citation></ref><ref id="R211"><label>211.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group>. <article-title>Heartbreakers: Innate sensors&#160;ZBP1 and cGAS linked to cardiotoxicity</article-title>. <source>Cell Res</source><year>2023</year>;<volume>33</volume>:<fpage>902</fpage>&#8211;<lpage>903</lpage>. <comment>doi: 10.1038/s41422-023-00861-9</comment>.<pub-id pub-id-type="pmid">37587292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-023-00861-9</pub-id><pub-id pub-id-type="pmcid">PMC10709570</pub-id></mixed-citation></ref><ref id="R212"><label>212.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>RG</given-names></name><name name-style="western"><surname>Xie</surname><given-names>QW</given-names></name><name name-style="western"><surname>Pan</surname><given-names>LH</given-names></name><name name-style="western"><surname>Lin</surname><given-names>F</given-names></name><name name-style="western"><surname>Qin</surname><given-names>K</given-names></name><name name-style="western"><surname>Ming</surname><given-names>SP</given-names></name>, <etal/></person-group>. <article-title>Necrostatin-1 attenuates caspase-1-dependent pyroptosis induced by the RIPK1/ZBP1 pathway in ventilator-induced lung injury</article-title>. <source>Cytokine</source><year>2022</year>;<volume>157</volume>:<fpage>155950</fpage>. <comment>doi: 10.1016/j.cyto.2022.155950</comment>.<pub-id pub-id-type="pmid">35780712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2022.155950</pub-id></mixed-citation></ref><ref id="R213"><label>213.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J</given-names></name><name name-style="western"><surname>He</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Y</given-names></name></person-group>. <article-title>ZBP1 and heatstroke</article-title>. <source>Front Immunol</source><year>2023</year>;<volume>14</volume>:<fpage>1091766</fpage>. <comment>doi: 10.3389/fimmu.2023.1091766</comment>.<pub-id pub-id-type="pmid">36845119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1091766</pub-id><pub-id pub-id-type="pmcid">PMC9950778</pub-id></mixed-citation></ref><ref id="R214"><label>214.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Chang</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><name name-style="western"><surname>Xue</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>Necroptosis of macrophage is a key pathological feature in biliary atresia via GDCA/S1PR2/ZBP1/p-MLKL axis</article-title>. <source>Cell Death Dis</source><year>2023</year>;<volume>14</volume>:<fpage>175</fpage>. <comment>doi: 10.1038/s41419-023-05615-4</comment>.<pub-id pub-id-type="pmid">36859525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-023-05615-4</pub-id><pub-id pub-id-type="pmcid">PMC9977961</pub-id></mixed-citation></ref><ref id="R215"><label>215.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di</surname><given-names>QN</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>QQ</given-names></name><name name-style="western"><surname>Sun</surname><given-names>JH</given-names></name><name name-style="western"><surname>Fu</surname><given-names>HW</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name></person-group>. <article-title>LncRNA PVT1 mediates the progression of liver necroptosis via ZBP1 promoter methylation under nonylphenol exposure</article-title>. <source>Sci Total Environ</source><year>2022</year>;<volume>844</volume>:<fpage>157185</fpage>. <comment>doi: 10.1016/j.scitotenv.2022.157185</comment>.<pub-id pub-id-type="pmid">35803419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scitotenv.2022.157185</pub-id></mixed-citation></ref><ref id="R216"><label>216.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>WY</given-names></name><name name-style="western"><surname>Yi</surname><given-names>WQ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YS</given-names></name><name name-style="western"><surname>Hu</surname><given-names>QY</given-names></name><name name-style="western"><surname>Qian</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>JT</given-names></name>, <etal/></person-group>. <article-title>Z-DNA/RNA binding protein 1 senses mitochondrial DNA to induce receptor-interacting protein kinase-3/mixed lineage kinase domain-like-driven necroptosis in developmental sevoflurane neurotoxicity</article-title>. <source>Neuroscience</source><year>2022</year>;<volume>507</volume>:<fpage>99</fpage>&#8211;<lpage>111</lpage>. <comment>doi: 10.1016/j.neuroscience.2022.11.005</comment>.<pub-id pub-id-type="pmid">36370933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2022.11.005</pub-id></mixed-citation></ref><ref id="R217"><label>217.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>BPDE exposure promotes trophoblast cell pyroptosis and induces miscarriage by up-regulating Lnc-HZ14/ZBP1/NLRP3 axis</article-title>. <source>J Hazard Mater</source><year>2023</year>;<volume>455</volume>:<fpage>131543</fpage>. <comment>doi: 10.1016/j.jhazmat.2023.131543</comment>.<pub-id pub-id-type="pmid">37167865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhazmat.2023.131543</pub-id></mixed-citation></ref><ref id="R218"><label>218.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szczerba</surname><given-names>M</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B</given-names></name><name name-style="western"><surname>Acciai</surname><given-names>F</given-names></name><name name-style="western"><surname>Gogerty</surname><given-names>C</given-names></name><name name-style="western"><surname>McCaughan</surname><given-names>M</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>Canonical cellular stress granules are required for arsenite-induced necroptosis mediated by Z-DNA-binding protein 1</article-title>. <source>Sci Signal</source><year>2023</year>;<volume>16</volume>:<elocation-id>eabq0837</elocation-id>. <comment>doi: 10.1126/scisignal.abq0837</comment>.<pub-id pub-id-type="pmid">36917643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scisignal.abq0837</pub-id><pub-id pub-id-type="pmcid">PMC10561663</pub-id></mixed-citation></ref><ref id="R219"><label>219.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>BHM</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Long</surname><given-names>X</given-names></name><name name-style="western"><surname>Hung</surname><given-names>SW</given-names></name><name name-style="western"><surname>Gaponova</surname><given-names>A</given-names></name><name name-style="western"><surname>Ren</surname><given-names>F</given-names></name>, <etal/></person-group>. <article-title>Utilizing ai for the identification and validation of novel therapeutic targets and repurposed drugs for endometriosis</article-title>. <source>Adv Sci Weinh Baden-Wurtt Ger</source><year>2025</year>;<volume>12</volume>:<fpage>e2406565</fpage>. <comment>doi: 10.1002/advs.202406565</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202406565</pub-id><pub-id pub-id-type="pmcid">PMC11792045</pub-id><pub-id pub-id-type="pmid">39666559</pub-id></mixed-citation></ref><ref id="R220"><label>220.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>J</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>CY</given-names></name><name name-style="western"><surname>Fang</surname><given-names>M</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Hou</surname><given-names>T</given-names></name></person-group>. <article-title>Development of protacs using computational approaches</article-title>. <source>Trends Pharmacol Sci</source><year>2024</year>;<volume>45</volume>:<fpage>1162</fpage>&#8211;<lpage>1174</lpage>. <comment>doi: 10.1016/j.tips.2024.10.006</comment>.<pub-id pub-id-type="pmid">39567313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2024.10.006</pub-id></mixed-citation></ref><ref id="R221"><label>221.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>E</given-names></name><name name-style="western"><surname>Spaeth</surname><given-names>J</given-names></name><name name-style="western"><surname>Shing</surname><given-names>L</given-names></name><name name-style="western"><surname>Jaimes</surname><given-names>R</given-names></name><name name-style="western"><surname>Engelhart</surname><given-names>E</given-names></name>, <etal/></person-group>. <article-title>Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries</article-title>. <source>Nat Commun</source><year>2023</year>;<volume>14</volume>:<fpage>3454</fpage>. <comment>doi: 10.1038/s41467-023-39022-2</comment>.<pub-id pub-id-type="pmid">37308471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-39022-2</pub-id><pub-id pub-id-type="pmcid">PMC10258481</pub-id></mixed-citation></ref><ref id="R222"><label>222.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Qian</surname><given-names>F</given-names></name><name name-style="western"><surname>Kurths</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>AI-guided few-shot inverse design of HDP-mimicking polymers against drug-resistant bacteria</article-title>. <source>Nat Commun</source><year>2024</year>;<volume>15</volume>:<fpage>6288</fpage>. <comment>doi: 10.1038/s41467-024-50533-4</comment>.<pub-id pub-id-type="pmid">39060236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-50533-4</pub-id><pub-id pub-id-type="pmcid">PMC11282099</pub-id></mixed-citation></ref><ref id="R223"><label>223.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutz</surname><given-names>ID</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Norn</surname><given-names>C</given-names></name><name name-style="western"><surname>Courbet</surname><given-names>A</given-names></name><name name-style="western"><surname>Borst</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>YT</given-names></name>, <etal/></person-group>. <article-title>Top-down design of protein architectures with reinforcement learning</article-title>. <source>Science</source><year>2023</year>;<volume>380</volume>:<fpage>266</fpage>&#8211;<lpage>273</lpage>. <comment>doi: 10.1126/science.adf6591</comment>.<pub-id pub-id-type="pmid">37079676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.adf6591</pub-id></mixed-citation></ref><ref id="R224"><label>224.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nosengo</surname><given-names>N</given-names></name></person-group>. <article-title>Can you teach old drugs new tricks?</article-title><source>Nature</source><year>2016</year>;<volume>534</volume>:<fpage>314</fpage>&#8211;<lpage>316</lpage>. <comment>doi: 10.1038/534314a</comment>.<pub-id pub-id-type="pmid">27306171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/534314a</pub-id></mixed-citation></ref><ref id="R225"><label>225.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abe</surname><given-names>H</given-names></name><name name-style="western"><surname>Kumazawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Taji</surname><given-names>T</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>S</given-names></name></person-group>. <article-title>Applications of computerized pattern recognition: A survey of correlations between pharmacological activities and mass spectra</article-title>. <source>Biomed Mass Spectrom</source><year>1976</year>;<volume>3</volume>:<fpage>151</fpage>&#8211;<lpage>154</lpage>. <comment>doi: 10.1002/bms.1200030402</comment>.<pub-id pub-id-type="pmid">963271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bms.1200030402</pub-id></mixed-citation></ref><ref id="R226"><label>226.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>R</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>G</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name></person-group>. <article-title>Concepts of artificial intelligence for computer-assisted drug discovery</article-title>. <source>Chem Rev</source><year>2019</year>;<volume>119</volume>:<fpage>10520</fpage>&#8211;<lpage>10594</lpage>. <comment>doi: 10.1021/acs.chemrev.8b00728</comment>.<pub-id pub-id-type="pmid">31294972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.chemrev.8b00728</pub-id></mixed-citation></ref><ref id="R227"><label>227.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuenzi</surname><given-names>BM</given-names></name><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Fong</surname><given-names>SH</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>KS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Kreisberg</surname><given-names>JF</given-names></name>, <etal/></person-group>. <article-title>Predicting drug response and synergy using a deep learning model of human cancer cells</article-title>. <source>Cancer Cell</source><year>2020</year>;<volume>38</volume>:<fpage>672</fpage>&#8211;<lpage>684</lpage>. <comment>doi: 10.1016/j.ccell.2020.09.014</comment>.<pub-id pub-id-type="pmid">33096023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2020.09.014</pub-id><pub-id pub-id-type="pmcid">PMC7737474</pub-id></mixed-citation></ref><ref id="R228"><label>228.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Qi</surname><given-names>K</given-names></name>, <etal/></person-group>. <article-title>Use of deep-learning assisted assessment of cardiac parameters in zebrafish to discover cyanidin chloride as a novel keap1 inhibitor against doxorubicin-induced cardiotoxicity</article-title>. <source>Adv Sci (Weinh)</source><year>2023</year>;<volume>10</volume>:<fpage>e2301136</fpage>. <comment>doi: 10.1002/advs.202301136</comment>.<pub-id pub-id-type="pmid">37679058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202301136</pub-id><pub-id pub-id-type="pmcid">PMC10602559</pub-id></mixed-citation></ref><ref id="R229"><label>229.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouyang</surname><given-names>B</given-names></name><name name-style="western"><surname>Shan</surname><given-names>C</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Dai</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Su</surname><given-names>X</given-names></name>, <etal/></person-group>. <article-title>AI-Powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer</article-title>. <source>Nat Commun</source><year>2024</year>;<volume>15</volume>:<fpage>7560</fpage>. <comment>doi: 10.1038/s41467-024-51980-9</comment>.<pub-id pub-id-type="pmid">39215014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-51980-9</pub-id><pub-id pub-id-type="pmcid">PMC11364624</pub-id></mixed-citation></ref><ref id="R230"><label>230.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Han</surname><given-names>R</given-names></name><name name-style="western"><surname>Tang</surname><given-names>M</given-names></name><name name-style="western"><surname>Fei</surname><given-names>G</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>D</given-names></name>, <etal/></person-group>. <article-title>Machine learning and radiomics for predicting efficacy of programmed cell death protein 1 inhibitor for small cell lung cancer: A multicenter cohort study</article-title>. <source>Clin Transl Med</source><year>2024</year>;<volume>14</volume>:<fpage>e1673</fpage>. <comment>doi: 10.1002/ctm2.1673</comment>.<pub-id pub-id-type="pmid">38840331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ctm2.1673</pub-id><pub-id pub-id-type="pmcid">PMC11154803</pub-id></mixed-citation></ref><ref id="R231"><label>231.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Ciura</surname><given-names>K</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mikolajczyk</surname><given-names>A</given-names></name><name name-style="western"><surname>Jagiello</surname><given-names>K</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y</given-names></name>, <etal/></person-group>. <article-title>Toward the integration of machine learning and molecular modeling for designing drug delivery nanocarriers</article-title>. <source>Adv Mater</source><year>2024</year>;<volume>36</volume>:<fpage>e2407793</fpage>. <comment>doi: 10.1002/adma.202407793</comment>.<pub-id pub-id-type="pmid">39252670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202407793</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">eBioMedicine</journal-id><journal-id journal-id-type="iso-abbrev">EBioMedicine</journal-id><journal-id journal-id-type="pmc-domain-id">2749</journal-id><journal-id journal-id-type="pmc-domain">ebiom</journal-id><journal-title-group><journal-title>eBioMedicine</journal-title></journal-title-group><issn pub-type="epub">2352-3964</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12489771</article-id><article-id pub-id-type="pmcid-ver">PMC12489771.1</article-id><article-id pub-id-type="pmcaid">12489771</article-id><article-id pub-id-type="pmcaiid">12489771</article-id><article-id pub-id-type="pmid">40975928</article-id><article-id pub-id-type="doi">10.1016/j.ebiom.2025.105925</article-id><article-id pub-id-type="pii">S2352-3964(25)00369-X</article-id><article-id pub-id-type="publisher-id">105925</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>&#945;-Synuclein seed amplification assay positivity beyond synucleinopathies</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Martinez-Valbuena</surname><given-names initials="I">Ivan</given-names></name><email>ivan.martinez@utoronto.ca</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Fullam</surname><given-names initials="S">Sarah</given-names></name><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>O&#8217;Dowd</surname><given-names initials="S">Sean</given-names></name><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Tartaglia</surname><given-names initials="MC">M. Carmela</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Kovacs</surname><given-names initials="GG">Gabor G.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff8" ref-type="aff">h</xref><xref rid="aff9" ref-type="aff">i</xref><xref rid="aff10" ref-type="aff">j</xref></contrib><aff id="aff1"><label>a</label>Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada</aff><aff id="aff2"><label>b</label>Krembil Brain Institute, University Health Network, Toronto, Ontario, M5T 0S8, Canada</aff><aff id="aff3"><label>c</label>Rossy Centre for PSP, Toronto Western Hospital, Toronto, Ontario, M5T 2S8, Canada</aff><aff id="aff4"><label>d</label>Department of Neurology, Tallaght University Hospital, Dublin 24, Ireland</aff><aff id="aff5"><label>e</label>Academic Unit of Neurology, Trinity College Dublin, Ireland</aff><aff id="aff6"><label>f</label>Tallaght University Hospital Institute of Memory and Cognition, Ireland</aff><aff id="aff7"><label>g</label>Department of Neurology, University of Toronto, Toronto, Ontario, M5T 1A8, Canada</aff><aff id="aff8"><label>h</label>Edmond J. Safra Programme in Parkinson&#8217;s Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, M5T 2S8, Canada</aff><aff id="aff9"><label>i</label>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada</aff><aff id="aff10"><label>j</label>Laboratory Medicine Programme, University Health Network, Toronto, Canada</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author. Tanz Centre for Research in Neurodegenerative Diseases (CRND), University of Toronto, Krembil Discovery Tower, 60 Leonard Ave, Toronto, ON, M5T 0S8, Canada. <email>ivan.martinez@utoronto.ca</email></corresp></author-notes><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>9</month><year>2025</year></pub-date><volume>120</volume><issue-id pub-id-type="pmc-issue-id">497285</issue-id><elocation-id>105925</elocation-id><history><date date-type="received"><day>29</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>15</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-03 11:25:16.713"><day>03</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><title>Summary</title><p>Neurodegenerative diseases are increasingly recognized as complex disorders involving multiple protein pathologies, with &#945;-synuclein frequently observed beyond classical synucleinopathies such as Parkinson&#8217;s disease and multiple system atrophy. Recent advances in seed amplification assays (SAAs) have enabled the highly sensitive and specific detection of misfolded &#945;-synuclein <italic toggle="yes">in vivo</italic>, particularly in cerebrospinal fluid (CSF). This review focuses on CSF-based &#945;-synuclein SAAs and their application in detecting co-pathology across non-synucleinopathies, including Alzheimer&#8217;s disease, progressive supranuclear palsy, corticobasal syndrome, idiopathic normal pressure hydrocephalus, and traumatic brain injury. Evidence indicates a role for &#945;-synuclein in clinical heterogeneity and disease progression. Emerging diagnostic frameworks increasingly support integrating co-pathologies into classification and therapeutic strategies. Addressing key knowledge gaps, such as &#945;-synuclein interactions with other protein pathologies, and current limitations of &#945;-syn SAA, such as the lack of quantification of misfolded &#945;-synuclein seeds, will refine precision medicine and improve outcomes for patients with neurodegenerative diseases.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>&#945;-Synuclein</kwd><kwd>Seed amplification assays</kwd><kwd>Co-pathology</kwd><kwd>Alzheimer&#8217;s disease</kwd><kwd>Progressive supranuclear palsy</kwd><kwd>Precision medicine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="p0010">
<boxed-text id="dtbox1" position="float" orientation="portrait"><caption><title>Search strategy and selection criteria</title></caption><p id="p0015">We searched PubMed for studies published from the database&#8217;s inception to May 2025. Our aim was to identify key publications on &#945;-synuclein seed amplification assays (&#945;-syn SAA) applied to cerebrospinal fluid (CSF) from patients with non-synucleinopathies. Studies were excluded if they involved non-synucleinopathy cases solely to assess assay sensitivity or specificity relative to classical synucleinopathies.</p><p id="p0020">The core search terms included: (&#8220;Alzheimer&#8217;s disease&#8221; OR &#8220;progressive supranuclear palsy&#8221; OR &#8220;corticobasal syndrome&#8221; OR &#8220;idiopathic normal pressure hydrocephalus&#8221; OR &#8220;traumatic brain injury&#8221;) AND (&#8220;seed amplification assays&#8221; OR &#8220;RT-QuIC&#8221;) AND biomarkers. Additional disease-specific terms were used to tailor searches for individual sections. No language restrictions were applied.</p><p id="p0025">This review is not intended as a systematic review, but rather as a narrative synthesis informed by a targeted literature search and expert appraisal. The final reference list was curated based on relevance to the review&#8217;s objectives and selected through author consensus, rather than via systematic screening protocols.</p></boxed-text>
</p><sec id="sec1"><title>Introduction</title><p id="p0030">&#945;-Synuclein seed amplification assays (&#945;-syn SAAs), such as real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA), have revolutionized the diagnosis of Parkinson&#8217;s disease (PD) by detecting misfolded &#945;-synuclein in living patients with exceptional sensitivity.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> These assays exploit the self-propagating nature of misfolded &#945;-synuclein, amplifying its signal through thioflavin T (ThT) fluorescence to achieve reliable detection.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> However, their specificity is reduced when applied to other neurodegenerative conditions such as in Alzheimer&#8217;s disease (AD), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS) that are associated with other proteinopathies but may show frequent presence of &#945;-synuclein as a co-pathology.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> This overlap, rather than diminishing the utility of SAAs, underscores the clinical relevance of detecting &#945;-synuclein seeding in non-synucleinopathies, influencing disease progression and phenotypic expression.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> This review highlights the significance of detecting &#945;-synuclein co-pathology <italic toggle="yes">in vivo</italic> using SAAs across a spectrum of neurodegenerative disorders, demonstrating its widespread clinical relevance beyond the diagnosis of synucleinopathies. The complex interplay of mixed proteinopathies underscores the urgent need for a multimodal approach that integrates fluid-based biomarkers with advanced neuroimaging techniques. This integrated approach promises to refine the biological classification of neurodegenerative diseases, ultimately advancing precision diagnostics and enabling the development of targeted therapeutic interventions.</p></sec><sec id="sec2"><title>Lessons from neuropathology</title><p id="p0035">Advances in detecting &#945;-synuclein pathology through <italic toggle="yes">in vivo</italic> &#945;-syn SAAs must be anchored in neuropathological studies, which define the biological basis of synucleinopathies, elucidate the role of co-pathologies, and reveal critical insights into the anatomical and structural diversity of &#945;-synuclein aggregates.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> This section summarizes the neuropathological understanding of &#945;-synucleinopathies, the prevalence and impact of co-pathologies, and the lessons learnt from postmortem analyses that inform the interpretation of <italic toggle="yes">in vivo</italic> findings.</p><p id="p0040">&#945;-Synucleinopathies are a subset of neurodegenerative diseases marked by the selective dysfunction and loss of neurons and synaptic connectivity, alongside the pathological accumulation of conformationally altered &#945;-synuclein in neurons and/or glial cells. The term proteinopathy is used when there are abundant filamentous aggregates of misfolded proteins that follow typical patterns of cellular involvement and correlate with clinical phenotypes and neurodegeneration. In contrast, protein pathology refers more broadly to the presence of assembled proteins, as detected by histochemical or molecular techniques&#8212;such as immunohistochemistry, silver staining, electron microscopy, immunoblotting, or SAAs&#8212;without necessarily inferring a distinct clinicopathologic entity.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref></p><p id="p0045">When interpreting &#945;-synuclein pathology in postmortem studies, several key factors must be considered: the clinical phenotype, the distribution and stage of neurodegeneration, the sequential anatomical involvement, the intracellular aggregation stage (i.e., pre-aggregates vs. fibrillar inclusions), and the presence of co-existing proteinopathies or vascular lesions. These must be contextualized within the framework of mixed pathologies, which are highly prevalent in ageing and neurodegeneration.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref></p><p id="p0050">Based on these concepts, current classification of synucleinopathies include clinical, morphological, and, most recently, structural aspects. Two major groups are distinguished: the neuron predominant forms showing Lewy body pathology (LBP) and those exhibiting predominant oligodendroglial inclusions (Papp-Lantos bodies) defining MSA. Lewy body diseases (LBD) are stratified based on the clinical phenotype as PD, PD with dementia (PDD), or Dementia with Lewy bodies (DLB). More recent studies have investigated structural aspects of &#945;-synuclein. Cryogenic electron microscopy (cryo-EM) studies revealed uniform folds in LBD (PD, PDD, and DLB)<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> that are distinct from the filament fold in typical MSA cases<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> and from that in juvenile onset synucleinopathy (JOS).<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> However, our recent study indicates that Lewy-MSA hybrid folds can also be generated leading to distinct neuronal synuclein pathology in atypical form of MSA.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Moreover, SAAs using post-mortem brain homogenates revealed that specific reaction buffer conditions can effectively differentiate the seeding profiles characteristic of MSA from those associated with Lewy body disorders.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref></p><p id="p0055">Regarding LBD, one neuropathological approach applies staging of &#945;-synuclein pathology according to Braak and colleagues,<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> while another approach identified brainstem, limbic, and neocortical types of Lewy body disease.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> Importantly, Lewy bodies can also be detected incidentally in the olfactory bulb, brainstem, or amygdala in the absence of clinical symptoms. Further updates for the neuropathology diagnostic practice have been described to integrate these observations.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> It should be emphasized that most studies focus only on Lewy bodies, however, less appreciated disease-associated &#945;-synuclein immunoreactivities in LBD in the brain, such as in astrocytes, oligodendrocytes, and ependyma, have been also described.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> Regarding MSA, the presence of &#945;-synuclein immunoreactive argyrophilic oligodendroglial inclusions (Papp-Lantos bodies) is sufficient for the diagnosis of MSA<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> and clinical subtypes such as MSA-P (parkinsonism dominant) and MSA-C (cerebellar symptom predominant) are defined with striatonigral or olivopontocerebellar predominance, respectively.</p><p id="p0060">LBD and MSA represent disease where &#945;-synuclein pathology is consistently identified, while there are many conditions where they are detected inconsistently.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> The association of &#945;-synuclein pathology with different neurodegenerative conditions can be discussed from two perspectives: when &#945;-synuclein appears as co-pathology and when other neurodegenerative protein pathologies are observed in LBD and MSA.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Indeed, a combination of pathological alterations is commonly observed in the brains of elderly individuals and in neurodegenerative diseases. However, due to the inconsistencies in the nomenclature and methodologies used (i.e., antibodies, criteria etc.) in various studies, and lack of a standardised classification of mixed pathologies it is difficult to decipher all details of the presence of &#945;-synuclein as co-pathology. While it is difficult to dissect when LBD is the primary disorder or the co-pathology, literature data suggests that cases diagnosed as LBD on a neuropathology level have mostly limbic TDP-43 pathology and AD neuropathologic change as co-pathology. On the other hand, wide range of prevalences of LBP as co-pathology have been reported in various neurodegenerative proteinopathies (<xref rid="fig1" ref-type="fig">Fig. 1</xref>).<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Unfortunately, MSA pathology is usually not sought in the diagnostic screening for concomitant pathologies, in particular, that early steps of the disease might involve only the cerebellum.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> Interestingly, asymptomatic MSA cases have been identified in post-mortem studies of elderly individuals through &#945;-synuclein immunostaining across multiple anatomical regions.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref><fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Range of prevalences of Lewy body (LB) pathology (Braak stage 3&#8805;) reported in autopsy studies that used a systematic approach and evaluation. Representative ranges are reported for Alzheimer&#8217;s disease (AD),<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> Pick&#8217;s disease (PiD),<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> corticobasal degeneration (CBD),<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> progressive supranuclear palsy (PSP),<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> for globular glial tauopathies (GGT),<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> frontotemporal lobar degeneration with tau or TDP-43 inclusions (FTLD-TDP, depending on whether sporadic or genetic),<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> motor neuron disease with TDP-43 pathology (MND-TDP),<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Creutzfeldt-Jakob disease (CJD),<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> multiple system atrophy (MSA),<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> and cognitively unimpaired.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> On the left side colour coding of major neurodegenerative proteins are indicated. NS: not specified. A cautionary note is that the age groups in the different reports are not matched and studies on cognitively unimpaired represent older age categories and do not necessarily report lack of movement disorder.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0065">Based on neuropathological studies, the following points need to be considered when we detect misfolded &#945;&#8722;synuclein:<list list-type="simple" id="olist0010"><list-item id="o0010"><label>1.</label><p id="p0070">Caution is needed to consider &#945;-synucleinopathy as a disease based on the mere detection of seeding of misfolded &#945;-synuclein and a descriptive (presence or absence) approach is recommended since it is not necessarily associated with neuronal degeneration and disease.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref></p></list-item><list-item id="o0015"><label>2.</label><p id="p0075">We need more observations whether distinct cytopathologies are associated with different protein structure and seeding.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr"><sup>33</sup></xref></p></list-item><list-item id="o0020"><label>3.</label><p id="p0080">The combination of &#945;-synuclein with any other misfolded protein pathology can be a foundation for disease diversity that might reflect distinct &#8220;biological&#8221; associations, warranting unique approaches to clinical diagnosis<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> and eventually the interpretation of SAAs.</p></list-item><list-item id="o0025"><label>4.</label><p id="p0085">The reported frequency of cases with LBD as co-pathology varies considerably across neuropathological studies, therefore, it is always important to focus on how the inclusion criteria of cohorts were defined, whether the methods to evaluate misfolded &#945;-synuclein were standardised, and whether all factors, that for example can influence SAAs, were excluded or considered for the interpretation. Some of these considerations might explain why SAA studies may report different prevalences.</p></list-item></list></p></sec><sec id="sec3"><title>&#945;-Synuclein biomarkers and their clinical relevance</title><p id="p0090">As previously mentioned, large-scale neuropathological studies have paved the way and highlighted the substantial prevalence of &#945;-synuclein protein pathology across non-synucleinopathies.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> However, the terminal neuropathological landscape may not fully depict the dynamic interplay of multiple proteinopathies throughout the disease course and the advent of <italic toggle="yes">in vivo</italic> biomarkers offers a transformative opportunity for real-time analysis of the misfolding of these proteins during life.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> In this section, we summarize recent advances in understanding the clinical significance of misfolded &#945;-synuclein detected in cerebrospinal fluid (CSF) - using &#945;-syn SAAs- across four distinct neurological conditions.</p><sec id="sec3.1"><title>Alzheimer&#8217;s disease (AD)</title><p id="p0095">Given that AD is the most prevalent neurodegenerative disease worldwide<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> and that a high rate of &#945;-synuclein protein pathology is observed in AD brains,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> numerous studies in recent years have aimed to determine the prevalence and impact of &#945;-synuclein co-pathology, as determined by &#945;-syn SAA, in patients with AD<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref> (<xref rid="tbl1" ref-type="table">Table 1</xref>). These studies have reported varying prevalence rates of &#945;-synuclein co-pathology, ranging from 12 to 45%,<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> which are often lower than those reported in analogous neuropathological studies.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> One critical aspect to consider when interpreting these percentages is the sensitivity of &#945;-syn SAA for different anatomical distributions of &#945;-synuclein protein pathology. In AD cohorts, the amygdala-predominant pattern is more common than diffuse neocortical or limbic patterns (&#8216;typical&#8217; &#945;-synuclein protein pathology).<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> Neuropathological validation studies of &#945;-syn SAA have shown near-perfect sensitivity (97&#8211;100%)<xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref> for &#8216;typical&#8217; &#945;-synuclein protein pathology involving diffuse neocortical and limbic brain regions but much lower sensitivities (14&#8211;60%) for the amygdala-predominant pattern.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref> Specifically in the AD clinical context, an overall sensitivity of 64&#8211;79%<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> has been reported, with sensitivities based on anatomical distribution at 100% for diffuse neocortical, 57% for transitional limbic and 60% amygdala-predominant.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> The specificity for pure AD is reported at 94&#8211;100%<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref><sup>,</sup><xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> with a small number of false positives identified. These findings underscore the importance of understanding the limitations of &#945;-syn SAA in the AD clinical context and how the anatomical distribution of &#945;-synuclein protein pathology may influence its detection.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Clinical associations of &#945;-syn SAA positivity. Populations not directly comparable due to differing study design.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Study</th><th colspan="1" rowspan="1">Quadalti, C. et al. Nature Medicine. 2023<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref></th><th colspan="1" rowspan="1">Bellomo, G. et al. Alzheimer&#8217;s and Dementia. 2024<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref></th><th colspan="1" rowspan="1">Pilotto, A. et al. Alzheimer&#8217;s &amp; Dementia. 2023<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref></th><th colspan="1" rowspan="1">Collij, L.E. et al. Nature Communications. 2024.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref></th><th colspan="1" rowspan="1">Tosun, D. et al. Alzheimer&#8217;s and Dementia. 2024<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref></th><th colspan="1" rowspan="1">Silva-Rodr&#237;guez, J. et al. Brain 2025<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Sample Size</td><td colspan="1" rowspan="1">883<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td colspan="1" rowspan="1">240<xref rid="tbl1fnc" ref-type="table-fn">c</xref></td><td colspan="1" rowspan="1">80<xref rid="tbl1fnd" ref-type="table-fn">d</xref></td><td colspan="1" rowspan="1">795<xref rid="tbl1fne" ref-type="table-fn">e</xref></td><td colspan="1" rowspan="1">1638<xref rid="tbl1fnf" ref-type="table-fn">f</xref></td><td colspan="1" rowspan="1">865<xref rid="tbl1fng" ref-type="table-fn">g</xref></td></tr><tr><td colspan="1" rowspan="1">Study Design (CS, L)</td><td colspan="1" rowspan="1">CS, L</td><td colspan="1" rowspan="1">CS, L</td><td colspan="1" rowspan="1">CS</td><td colspan="1" rowspan="1">CS, L</td><td colspan="1" rowspan="1">CS, L</td><td colspan="1" rowspan="1">CS, L</td></tr><tr><td colspan="1" rowspan="1">% SAA positivity</td><td colspan="1" rowspan="1">23%<xref rid="tbl1fnb" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1">30%</td><td colspan="1" rowspan="1">45%</td><td colspan="1" rowspan="1">27%<xref rid="tbl1fnb" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1">22%<xref rid="tbl1fnb" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1">32%<xref rid="tbl1fnh" ref-type="table-fn">h</xref></td></tr><tr><td colspan="7" rowspan="1"><bold>Clinical associations of &#945;-syn SAA positivity</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Global cognition</td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1">&#8595;</td></tr><tr><td colspan="1" rowspan="1">&#160;Memory</td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1">&#8595;</td></tr><tr><td colspan="1" rowspan="1">&#160;Executive function</td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1">&#8722;<xref rid="tbl1fnj" ref-type="table-fn">j</xref></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1">&#8595;</td></tr><tr><td colspan="1" rowspan="1">&#160;Language</td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic><xref rid="tbl1fnk" ref-type="table-fn">k</xref></td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td></tr><tr><td colspan="1" rowspan="1">&#160;Visuospatial</td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8595;</td></tr><tr><td colspan="1" rowspan="1">&#160;Cognitive fluctuations</td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td></tr><tr><td colspan="1" rowspan="1">&#160;Motor function</td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1">&#8595;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td></tr><tr><td colspan="1" rowspan="1">&#160;Hallucinations</td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">&#8722;<xref rid="tbl1fnj" ref-type="table-fn">j</xref></td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">&#160;RBD symptoms<xref rid="tbl1fni" ref-type="table-fn">i</xref></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1">&#8722;<xref rid="tbl1fnj" ref-type="table-fn">j</xref><sup>,</sup><xref rid="tbl1n1" ref-type="table-fn">m</xref></td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td></tr><tr><td colspan="1" rowspan="1">&#160;Dysautonomia</td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td></tr><tr><td colspan="1" rowspan="1">&#160;Hyposmia</td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">NR</italic></td></tr><tr><td colspan="1" rowspan="1">&#160;Progression</td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">&#8593;<xref rid="tbl1fnl" ref-type="table-fn">l</xref></td><td colspan="1" rowspan="1">&#8593;</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>Variations exist within studies with regards to cross-sectional (CS) and longitudinal (L) design, disease stage and kinetic analysis.</p></fn><fn id="tspara0020"><p>NR, Not Reported; &#8216;&#8211;&#8217;, No change.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0010">Memory clinic patients with MCI or dementia.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0015">Frequency of positivity across entire cohort.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnc"><label>c</label><p id="ntpara0020">AD patients, preclinical, prodromal and dementia stages, biomarker-supported.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnd"><label>d</label><p id="ntpara0025">AD patients, MCI and mild dementia, biomarker-supported.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fne"><label>e</label><p id="ntpara0030">Cognitively impaired individuals (MCI and dementia) derived from the ADNI database.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnf"><label>f</label><p id="ntpara0035">Participants included cognitively unimpaired individuals, individuals with MCI, and individuals with clinical diagnosis of dementia due to AD (derived from the ADNI database).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fng"><label>g</label><p id="ntpara0040">Individuals with clinical diagnosis of amnestic MCI or AD, derived from the ADNI database.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnh"><label>h</label><p id="ntpara0045">Excluding isolated LB pathology.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fni"><label>i</label><p id="ntpara0050">Not confirmed with polysomnography.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnj"><label>j</label><p id="ntpara0055">Reported difference on kinetic analysis.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnk"><label>k</label><p id="ntpara0060">Not reported as individual subdomain.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnl"><label>l</label><p id="ntpara0065">Cognitively unimpaired only.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1n1"><label>m</label><p id="ntparayDoA83w1C3">Night time behaviours on the NPI (Neuropsychiatric Inventory).</p></fn></table-wrap-foot></table-wrap></p><p id="p0100">Considering this, it is necessary to examine the influence of anatomic distribution of LBP on phenotypic expression. Disease progression modelling of LBD supports distinct spatio-temporal trajectories that associate clinicopathological features. Early limbic disposition is associated with a clinico-pathologic diagnosis of AD, while those with early brainstem/late olfactory bulb deposition demonstrate a greater degree of motor symptoms and hyposmia.<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> However, there are limited data examining the influence of regional distribution of LBP specifically in the AD clinical context. A small retrospective clinico-pathologic study (n = 33) revealed those harbouring classical (neocortical, limbic, brainstem) LBP were more likely to experience earlier cognitive fluctuations, which could represent an early clinical differentiator for classical LB co-pathology. Several non-significant associations were seen, such as greater frequency of parkinsonism and earlier hallucinations in classical LBP cases and higher frequency of anxiety and apathy in the amygdala-LBP cohort. However, the small sample size may have influenced the statistical power of the study.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref></p><p id="p0105">Neuropathological studies suggest that the prevalence of &#8216;typical&#8217; &#945;-synuclein protein pathology increases with age,<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> while younger cohorts are more likely to exhibit focal amygdala-predominant &#945;-synuclein protein pathology, potentially influencing antemortem CSF &#945;-syn SAA rates.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> This pattern appears to hold for &#945;-syn SAA, with two large studies, using data from BioFINDER<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> and ADNI<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> finding that &#945;-syn SAA positivity increases with age but to a lesser degree than it does with extent of AD pathology. Furthermore, these studies demonstrate an increase in &#945;-syn SAA with disease stage, in the ADNI cohort from 16% in cognitively unimpaired, to 19% in mild cognitive impairment (MCI) and 38% in dementia, with similarly increasing prevalence noted in the BioFINDER cohort (17% MCI, 21% AD). Taken together, these findings might implicate &#945;-syn SAA positivity as exerting a significant impact on phenotype and clinical trajectory beyond the extent of AD pathology alone.</p><p id="p0110">Clinical identification of &#945;-synuclein co-pathology in AD remains challenging, as characteristic clinical features of LBD are frequently absent in affected individuals. This limits the sensitivity of clinical suspicion for underlying &#945;-synuclein pathology. As such, the need for reliable &#945;-synuclein biomarkers becomes even more critical. Both neuropathological<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> and &#945;-syn SAA studies<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> emphasize this, as core clinical features of LBD are often absent in these cohorts. For example, applying clinical criteria for probable DLB (MCI<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> or dementia stage<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref>) and PD<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> to individuals with LB co-pathology showed that only 9% met clinical criteria at baseline, increasing to 16% during follow-up.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> Despite this, &#945;-syn SAA positivity in AD populations exerts significant effects on global cognition, attention, language, executive, visuospatial, and motor functions, with some studies reporting increased prevalence of visual hallucinations.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> Data examining the relationship between &#945;-syn SAA and more specific LBD clinical features in AD cohorts, such as anosmia, dysautonomia, and REM sleep behaviour disorder (RBD) remain sparse. Pilloto and colleagues found a slightly higher prevalence of symptomatic orthostatic hypotension (n = 3) in their &#945;-syn SAA positive AD group, with no differences in RBD between the &#945;-syn SAA positive and negative AD groups.<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> However, the clinical implications of &#945;-synuclein co-pathology extend beyond symptom profiles to disease trajectory. Neuropathologic studies have demonstrated that patients with AD harbouring &#945;-synuclein protein pathology have more severe clinical trajectories over time, with earlier disease onset, faster progression and shorter survival.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> A number of &#945;-syn SAA studies have also demonstrated this, with faster decline in global cognition and domain specific deficits over time.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref><sup>,</sup><xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> Data from the ADNI cohort demonstrate greater impairment in global and domain-specific cognitive function (memory, language, executive function) for &#945;-syn SAA positivity MCI-AD and early-AD as compared to their &#945;-syn SAA negative counterparts.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> Furthermore, longitudinal analysis of SAA status in AD, demonstrates more rapid decline in &#945;-syn SAA stable positive compared to &#945;-syn SAA stable negative individuals, particularly during the MCI stage.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> Collij and colleagues also demonstrated that patients with AD with &#945;-synuclein protein pathology performed worse on cognitive testing at baseline compared to those with isolated AD pathology and demonstrated faster decline in global cognition over time. Interestingly, cognitive decline was not domain-specific in this cohort, despite evidence of more pronounced posterior cortical hypometabolism in those with &#945;-synuclein protein pathology.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> Moreover, neuropathological studies in a subgroup of the cohort refuted more severe AD pathology as a feature in those harbouring co-pathology, implying LB pathology exerts an independent effect. The clinical impact of &#945;-synuclein protein pathology in the AD population is further exemplified by its negative impact on cognitive performance in those with low tau burden.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref> Taken together, these studies suggest that &#945;-syn SAA positivity is crucial to interpret prognostic aspects of cognitive decline, particularly in the earlier phases of the disease.</p><p id="p0115">Therefore, &#945;-syn SAA negative status seems to confer a more innocuous clinical trajectory in AD cohorts. With respect to risk of conversion to &#945;-syn SAA positive status over time, Tosun and colleagues demonstrated a relatively low rate of conversion from &#945;-syn SAA negative to &#945;-syn SAA positive status over time of 5%, with time from last &#945;-syn SAA negative sample to first &#945;-syn SAA positive sample of 2.5 &#177; 1.6 years on average. The rate of conversion according to baseline diagnostic group was greatest for MCI at 6.7% (cognitively unimpaired (CU) 3.7%, dementia 5.1%).<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> Supporting this trend, data from an autosomal dominant AD (ADAD) cohort showed no &#945;-syn SAA positivity in presymptomatic patients, with rates increasing to 11% in the symptomatic stage.<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> These findings highlight the need for longitudinal studies to clarify the temporal dynamics of &#945;-synuclein positivity in AD and future directions are likely to see move from the binary interpretation of the &#945;-syn SAA, to a more nuanced assessment of kinetic parameters<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> and aggregation status<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> as potential biomarkers for risk of progression in AD.</p><p id="p0120">While typical late-onset amnestic AD accounts for most clinical cases, the prevalence and characteristics of &#945;-synuclein protein pathology in atypical AD presentations warrant further discussion. As mentioned above, the low sensitivity of &#945;-syn SAA for the amygdala-predominant pattern seen in early-onset AD is reflected in studies of ADAD, where the positivity rate in symptomatic patients is only 11%, despite 83% harbouring &#945;-synuclein protein pathology at autopsy.<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> Furthermore, the absence of &#945;-syn SAA positivity in asymptomatic ADAD cohorts supports the hypothesis of secondary &#945;-synuclein accrual in AD, particularly in amygdala-predominant variants.<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> Studies of certain atypical AD presentations, such as posterior cortical atrophy (PCA) and behavioural-dysexecutive variant AD, report higher &#945;-synuclein positivity<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> whereas lower rates are observed in logopenic variant AD. However, recent neuropathological comparisons between typical and atypical AD presentations did not find a significant association between atypical presentation and &#945;-synuclein protein pathology.<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref> These findings highlight the need for additional research to clarify the role of &#945;-synuclein protein pathology across diverse AD phenotypes.</p><p id="p0125">As the field evolves, the ability of the &#945;-syn SAA to enhance phenotypic profiling and ultimately provide bespoke molecular characterisation of disease in the real-time clinical context is likely to expand, bringing with it significant prognostic and therapeutic implications for patients. As discussed, in its binary form, &#945;-syn SAA requires nuanced interpretation in the AD clinical setting. It also is worth noting the currently limited ability of the assay to distinguish between the synucleinopathies,<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> with the exception of MSA where conformational differences in the protein affect seeding ability.<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> However, distinct subtypes of &#945;-synuclein have been shown to exhibit varying morphological and biochemical traits that can influence clinical phenotype and may explain the clinical heterogeneity of this group of disorders.<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> The impact of cellular <italic toggle="yes">milieu</italic> on strain properties<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> supports the hypothesis proposed by Just and colleagues that differing cellular environments encountered during the course of spatiotemporal spread impacts the structure and function of the protein.<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref> The influence of cellular <italic toggle="yes">milieu</italic> is of particular interest in AD given the predominance of LBP restricted to the amygdala, which has been hypothesised as pivotal locus for protein misfolding and may play a key role in defining disease trajectory.<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> Sorrentino and colleagues demonstrated that LBP found in the amygdala of LBD brains is pathologically and biochemically distinct, and more prone to aggregation, than LBP found restricted to the amygdala in amygdala-predominant-AD which may account for the more innocuous trajectory of the latter.<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref></p><p id="p0130">Furthermore, the indisputable impact of co-pathology on disease trajectory requires attention and of relevance to this review, is the relationship between &#945;-synuclein, tau and amyloid &#946;. Differing associations of CSF-based biomarkers highlight the need for further studies in this area. In the ADNI cohort, higher CSF amyloid &#946; burden and lower p-tau181 was linked with higher &#945;-syn SAA positivity rates, particularly at dementia stage,<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> furthermore SAA conversion was associated with amyloid &#946; pathology and greater cognitive decline.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> However, Ding and colleagues found that both aggregated and non-aggregated &#945;-synuclein was more closely associated with both p-tau and t-tau than with amyloid &#946;.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> A recent study by Franzmeier and colleagues<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref> demonstrated that CSF &#945;-syn SAA positivity was associated with greater amyloid &#946;-related increases in p-tau181, higher tau-PET burden in AD-typical regions, and faster longitudinal tau accumulation. Additionally, &#945;-synuclein co-pathology was linked to accelerated amyloid &#946;-related cognitive decline, suggesting that &#945;-synuclein may exacerbate amyloid &#946;-driven tau pathology in AD.</p><p id="p0135">The recent addition of CSF &#945;-syn SAA to the criteria for diagnosis and staging of AD<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> buttresses its role in the diagnostic work-up of neurodegenerative disease. However, the increasing availability of pathologically based biomarkers demands a nuanced interpretation in the clinical setting. Clinical judgement must be exercised when discerning the leading clinical syndrome, notwithstanding the presence of co-pathology.<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> Furthermore, pertinent to the AD clinical context, is the reduced sensitivity of the &#945;-syn SAA for amygdala-predominant LBP in AD, although the phenotypic influence and therapeutic implications of this subtype remain to be fully elucidated. As the field continues to evolve, greater understanding of strain-specific clinical associations may bring about improved specificity for LBD subtypes and less invasive methods of detecting &#945;-synuclein pathology (such as skin<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref> and blood<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref>) could further increase the diagnostic utility of this test. Furthermore, variable morphological and seeding characteristics could see the influence of distinct pathological sites yielding more specific results.</p></sec><sec id="sec3.2"><title>Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS)</title><p id="p0140">Diagnosing PSP and CBS in the early stages is challenging due to their significant clinical overlap with other parkinsonian disorders, such as PD and MSA. Although &#945;-synuclein SAAs are highly sensitive and specific for diagnosing PD<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> and MSA,<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> neuropathological studies have found that patients with PSP and corticobasal degeneration (CBD) also exhibit &#945;-synuclein protein pathology,<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib67" ref-type="bibr"><sup>67</sup></xref><sup>,</sup><xref rid="bib68" ref-type="bibr"><sup>68</sup></xref> potentially limiting the specificity of &#945;-synuclein SAAs in the differential diagnosis of these diseases.</p><p id="p0145">In response to this, Anastassiadis and colleagues,<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref> Gomes and colleagues<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref> and Vaughan and colleagues<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref> have investigated the prevalence and clinical relevance of &#945;-synuclein co-pathology in atypical parkinsonisms (<xref rid="tbl2" ref-type="table">Table 2</xref>). All three research groups discovered that a substantial proportion of patients with PSP and CBS were &#945;-synuclein SAA positive. Anastassiadis and colleagues reported that misfolded &#945;-synuclein was detectable via SAAs in 36% of patients with CBS and 29% of patients with PSP.<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref> Gomes and colleagues reported &#945;-synuclein SAA positivity in 29% of CBD and 25% of PSP<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref> while Vaughan and colleagues identified &#945;-synuclein SAA positivity in 29.7% of patients with CBS and 10.2% of patients with PSP.<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref><table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Clinical associations of &#945;-syn SAA positivity in living patients with PSP and CBS.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Study</th><th colspan="1" rowspan="1">Sample size</th><th colspan="1" rowspan="1">Study design</th><th colspan="1" rowspan="1">% &#945;-Syn SAA positivity</th><th colspan="1" rowspan="1">Clinical associations of &#945;-Syn SAA positivity</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Anastassiadis et al. Neurology. 2024.<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref></td><td colspan="1" rowspan="1">67 (CBS: 39, PSP: 28)</td><td colspan="1" rowspan="1">Cross-sectional</td><td colspan="1" rowspan="1">CBS: 35.9% (14/39)<break/>PSP: 28.6% (8/28)</td><td colspan="1" rowspan="1"><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>-</label><p id="p0270">Lower CSF amyloid &#946; 42 in &#945;-Syn SAA+</p></list-item><list-item id="u0015"><label>-</label><p id="p0275">CSF AD biomarker positivity more frequent in &#945;-Syn SAA+</p></list-item><list-item id="u0020"><label>-</label><p id="p0280">Higher frequency of RBD symptoms</p></list-item><list-item id="u0025"><label>-</label><p id="p0285">No significant association with sex, APOE4, or MoCA scores</p></list-item></list></td></tr><tr><td colspan="1" rowspan="1">Vaughan et al., Movement Disorders. 2024.<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref></td><td colspan="1" rowspan="1">96 (CBS: 37, PSP: 59)</td><td colspan="1" rowspan="1">Longitudinal (PROSPECT-UK cohort)</td><td colspan="1" rowspan="1">CBS: 29.7% (11/37)<break/>PSP: 10.2% (6/59)</td><td colspan="1" rowspan="1"><list list-type="simple" id="ulist0015"><list-item id="u0030"><label>-</label><p id="p0290">In PSP: &#945;-Syn SAA + associated with older age, shorter disease duration, more severe motor/cognitive impairment, and higher hyposmia rates</p></list-item><list-item id="u0035"><label>-</label><p id="p0295">In CBS: &#945;-Syn SAA + SAA + associated with higher rate of AD biomarker positivity (6/9 &#945;-Syn SAA + cases were CBS-AD)</p></list-item></list></td></tr></tbody></table><table-wrap-foot><fn><p>AD, Alzheimer&#8217;s disease; APOE4, apolipoprotein E &#949;4 allele; CBS, corticobasal syndrome; CSF, cerebrospinal fluid; MoCA, Montreal Cognitive Assessment; PSP, progressive supranuclear palsy; RBD, REM sleep behaviour disorder; SAA, seed amplification assay; &#945;-syn, &#945;-synuclein.</p></fn></table-wrap-foot></table-wrap></p><p id="p0150">Anastassiadis and colleagues further demonstrated a strong association between &#945;-syn SAA positivity and younger disease onset in CBS, as well as a correlation with AD biomarkers, particularly decreased CSF amyloid &#946; levels&#8212;suggesting potential interactions among proteinopathies. Moreover, &#945;-synuclein pathology was linked to specific clinical features such as RBD, pointing to its nuanced role in shaping disease presentation. Despite observing lower &#945;-synuclein positivity rates, Vaughan and colleagues suggest that &#945;-synuclein protein pathology may be more common in older patients with PSP,<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref> consistent with the notion that age-related declines in proteostasis contribute to the accumulation of multiple co-pathologies.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> Additionally, the authors highlight that, unlike previous clinicopathological studies,<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref><sup>,</sup><xref rid="bib68" ref-type="bibr"><sup>68</sup></xref> their findings offer preliminary evidence suggesting that &#945;-synuclein co-pathology could exacerbate disease severity and accelerate progression.<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref></p><p id="p0155">Although larger, multicenter studies are needed to fully elucidate the role of &#945;-synuclein co-pathology in these conditions, the three studies converge on the view that a better understanding of &#945;-synuclein&#8217;s contribution could improve diagnostic accuracy&#8212;enabling distinctions between pure tauopathies and those influenced by &#945;-synuclein co-pathology&#8212;and inform personalized therapeutic strategies. They also highlight the population heterogeneity observed across cohorts, which aligns with the variable rates of co-pathologies reported in neuropathological studies of these disorders.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib67" ref-type="bibr"><sup>67</sup></xref><sup>,</sup><xref rid="bib68" ref-type="bibr"><sup>68</sup></xref> Importantly, these studies also reinforce the trend observed in postmortem analyses showing that &#945;-synuclein co-pathology is more common in patients with CBS who had underlying AD pathology, compared to those with CBD as the primary pathology.</p><p id="p0160">Recognizing &#945;-synuclein co-pathology is thus essential for refining the diagnostic classification of PSP and CBS, and it underscores the need for comprehensive biomarker assessments in atypical parkinsonisms&#8212;including 4R-Tau SAAs<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref><sup>,</sup><xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> &#8212;to optimize clinical care and accelerate the development of targeted therapies for these devastating conditions.</p></sec><sec id="sec3.3"><title>Idiopathic normal pressure hydrocephalus (iNPH)</title><p id="p0165">iNPH is characterised by gait disturbance, cognitive decline, and urinary incontinence, and its hallmark feature is ventriculomegaly, an enlargement of the brain&#8217;s ventricles without an apparent cause.<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref><sup>,</sup><xref rid="bib75" ref-type="bibr"><sup>75</sup></xref> It primarily affects the elderly<xref rid="bib76" ref-type="bibr"><sup>76</sup></xref> and CSF ventriculoperitoneal shunting often alleviates these symptoms.<xref rid="bib76" ref-type="bibr"><sup>76</sup></xref> However, diagnostic challenges arise due to clinical overlaps with neurodegenerative diseases such as AD, PD, and DLB. Studies have shown that co-existing AD-related pathologies, including amyloid &#946; and tau abnormalities, are associated with poorer cognitive outcomes following shunt procedures.<xref rid="bib77" ref-type="bibr">77</xref>, <xref rid="bib78" ref-type="bibr">78</xref>, <xref rid="bib79" ref-type="bibr">79</xref> Furthermore, progressive ventricular enlargement has also been observed in patients with PD<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref> and a handful of neuroimaging studies using dopamine transporter (DAT) imaging have identified striatal dopaminergic deficits in more than 60% of patients with iNPH, which are partially reversed by shunt surgery.<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref><sup>,</sup><xref rid="bib82" ref-type="bibr"><sup>82</sup></xref></p><p id="p0170">These studies prompted questions about the relationship between &#945;-synuclein protein pathology and iNPH, and the need to distinguish synucleinopathies with ventricular enlargement from iNPH itself. To address these, Giannini and colleagues<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref> Fasano and colleagues<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref> and Weber and colleagues<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref> explored the role of &#945;-synuclein protein pathology and other neurodegenerative biomarkers in iNPH (<xref rid="tbl3" ref-type="table">Table 3</xref>). Giannini and colleagues found that approximately 20% of their iNPH cases were positive for &#945;-syn SAA.<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref> This subset of patients exhibited increased parkinsonian signs, specifically greater axial and upper limb rigidity. Similarly, Fasano and colleagues reported the presence of misfolded &#945;-synuclein in 14% of iNPH cases.<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref> While &#945;-synuclein positive patients were clinically similar to &#945;-synuclein-negative patients, they exhibited a wider base of gait at baseline and greater responsiveness to levodopa. Interestingly, Giannini and colleagues also noted that &#945;-syn SAA positive patients more frequently used levodopa and demonstrated a subjective clinical benefit, despite patients with iNPH typically responding poorly to levodopa.<xref rid="bib86" ref-type="bibr"><sup>86</sup></xref><table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>Clinical associations of &#945;-syn SAA positivity in patients with idiopathic normal pressure hydrocephalus (iNPH).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Study</th><th colspan="1" rowspan="1">Sample size</th><th colspan="1" rowspan="1">Study design</th><th colspan="1" rowspan="1">% &#945;-Syn SAA positivity</th><th colspan="1" rowspan="1">Clinical associations of &#945;-Syn SAA positivity</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Fasano et al. Annals of Neurology. 2022.<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref></td><td colspan="1" rowspan="1">64 iNPH</td><td colspan="1" rowspan="1">Cross-sectional</td><td colspan="1" rowspan="1">14.0% (7/50 analysed)</td><td colspan="1" rowspan="1"><list list-type="simple" id="ulist0020"><list-item id="u0040"><label>-</label><p id="p0300">More frequent L-dopa responsiveness</p></list-item><list-item id="u0045"><label>-</label><p id="p0305">Wider base of support while walking</p></list-item><list-item id="u0050"><label>-</label><p id="p0310">No difference in MoCA, AD CSF biomarkers or shunt response</p></list-item></list></td></tr><tr><td colspan="1" rowspan="1">Giannini et al. Fluids Barriers CNS. 2022.<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref></td><td colspan="1" rowspan="1">293 iNPH</td><td colspan="1" rowspan="1">Cross-sectional</td><td colspan="1" rowspan="1">20.5% (60/293)</td><td colspan="1" rowspan="1"><list list-type="simple" id="ulist0025"><list-item id="u0055"><label>-</label><p id="p0315">Higher axial rigidity</p></list-item><list-item id="u0060"><label>-</label><p id="p0320">Higher upper limb rigidity</p></list-item><list-item id="u0065"><label>-</label><p id="p0325">Lower MMSE</p></list-item><list-item id="u0070"><label>-</label><p id="p0330">No differences in AD CSF biomarkers or shunt response</p></list-item></list></td></tr><tr><td colspan="1" rowspan="1">Weber et al. Movement Disorders. 2025.<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref></td><td colspan="1" rowspan="1">144 iNPH</td><td colspan="1" rowspan="1">Cross-sectional</td><td colspan="1" rowspan="1">30.1% (43/143)</td><td colspan="1" rowspan="1"><list list-type="simple" id="ulist0030"><list-item id="u0075"><label>-</label><p id="p0335">Worse olfactory performance (64% anosmic)</p></list-item><list-item id="u0080"><label>-</label><p id="p0340">No differences in AD CSF biomarkers</p></list-item></list></td></tr></tbody></table><table-wrap-foot><fn><p>AD, Alzheimer&#8217;s disease; CSF, cerebrospinal fluid; iNPH, idiopathic normal pressure hydrocephalus; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; p-tau, phosphorylated tau; SAA, seed amplification assay; &#945;-syn, &#945; -synuclein.</p></fn></table-wrap-foot></table-wrap></p><p id="p0175">Weber and colleagues<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref> expanded on these findings by analysing a cohort of 144 iNPH patients, identifying misfolded &#945;-synuclein in approximately 30% of cases using &#945;-syn SAA. These &#945;-syn SAA positive patients showed distinct clinical characteristics, including significant upper limb rigidity, a notably higher prevalence of anosmia (64% compared to 15.3% in &#945;-syn SAA negative patients), and increased hallucinations. Cognitive impairment was slightly more pronounced in &#945;-syn SAA positive individuals, particularly within the subgroup undergoing comprehensive olfactory assessment. Anosmia, a common early symptom of synucleinopathies, was highlighted as a potential clinical marker to identify underlying &#945;-synuclein pathology in iNPH.</p><p id="p0180">Because iNPH predominantly affects older adults - the group at highest risk for age-related changes (e.g., primary age-related tauopathy [PART]) and other protein pathologies<xref rid="bib87" ref-type="bibr"><sup>87</sup></xref><sup>,</sup><xref rid="bib88" ref-type="bibr"><sup>88</sup></xref> co-pathology is common. In one small cases series 9/9 of patients with clinical NPH had co-pathology with 8/9 having AD and 1/9 having PSP.<xref rid="bib87" ref-type="bibr"><sup>87</sup></xref> Another study in brain biopsies found over 60% had AD co-pathology.<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref> While iNPH remains a distinct clinical-radiological syndrome treatable with a ventriculoperitoneal shunt, emerging evidence underscores the need to screen for AD biomarkers and &#945;-synuclein protein pathology and tailor treatment based on co-pathology profiles, i.e., levodopa trials in &#945;-synuclein positive cases.<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref> Additionally, integrating biomarkers of co-pathology as in the ATN approach,<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref> which aims to provide a biological characterisation of disease may be useful in iNPH to better ascertain the heterogeneity of this disease and improve prognostication after intervention<xref rid="bib90" ref-type="bibr"><sup>90</sup></xref> as there is ample evidence that cognition deteriorates in patient with iNPH<xref rid="bib91" ref-type="bibr">91</xref>, <xref rid="bib92" ref-type="bibr">92</xref>, <xref rid="bib93" ref-type="bibr">93</xref>, <xref rid="bib94" ref-type="bibr">94</xref>, <xref rid="bib95" ref-type="bibr">95</xref> and AD co-pathology despite shunting.<xref rid="bib90" ref-type="bibr"><sup>90</sup></xref></p></sec><sec id="sec4"><title>Traumatic brain injuries (TBIs)</title><p id="p0185">TBIs, including mild TBIs (mTBI), have been reported as a risk factor for dementia.<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref> Although the link between repetitive mTBI and chronic traumatic encephalopathy (CTE) has received the most attention, numerous reports have linked a higher risk of neurodegenerative conditions such as AD, PD, and DLB with mTBI.<xref rid="bib97" ref-type="bibr">97</xref>, <xref rid="bib98" ref-type="bibr">98</xref>, <xref rid="bib99" ref-type="bibr">99</xref>, <xref rid="bib100" ref-type="bibr">100</xref>, <xref rid="bib101" ref-type="bibr">101</xref>, <xref rid="bib102" ref-type="bibr">102</xref>, <xref rid="bib103" ref-type="bibr">103</xref> Numerous studies have also reported the frequent co-pathology of AD, &#945;-synuclein and other proteinopathies with CTE.<xref rid="bib103" ref-type="bibr">103</xref>, <xref rid="bib104" ref-type="bibr">104</xref>, <xref rid="bib105" ref-type="bibr">105</xref>, <xref rid="bib106" ref-type="bibr">106</xref>, <xref rid="bib107" ref-type="bibr">107</xref>, <xref rid="bib108" ref-type="bibr">108</xref>, <xref rid="bib109" ref-type="bibr">109</xref> Prompted by this association, Vasilevskaya and colleagues used &#945;-syn SAA to investigate &#945;-synuclein protein pathology in former contact sport athletes, who may be at increased risk for &#945;-synuclein-related disorders due to repeated TBIs.<xref rid="bib110" ref-type="bibr"><sup>110</sup></xref> In their study, Vasilevskaya and colleagues examined the presence of misfolded &#945;-synuclein in a cohort of 30 retired athletes and compared the results with healthy controls. They found that six of the athletes (20%) were &#945;-synuclein-positive, including one individual diagnosed with PD. Although demographic and clinical features did not significantly differ between &#945;-synuclein positive and &#945;-synuclein negative athletes, the &#945;-synuclein positive group was, on average, younger and had played contact sports for a longer period.</p><p id="p0190">Further analysis revealed that &#945;-synuclein positive athletes without additional neurological conditions exhibited a significant decrease in grey matter volumes. The areas where this decrease in volume was more evident were right inferior orbitofrontal, right anterior insula, and right olfactory cortices. These findings highlight the importance of studying athletes as a unique cohort for early detection of &#945;-synuclein protein pathology. Furthermore, the presence of misfolded &#945;-synuclein in younger athletes with longer exposure to contact sports underscores the potential link between repetitive TBIs and the early onset of neurodegenerative processes.<xref rid="bib110" ref-type="bibr"><sup>110</sup></xref> However, longitudinal research is necessary to clarify the progression and clinical significance of &#945;-synuclein positivity in this population.</p></sec></sec><sec id="sec5"><title>Implications of co-pathology in disease modifying clinical trials</title><p id="p0195">As previously discussed in this review, while primary proteinopathies define neurodegenerative diseases, it is now well established that co-pathologies are the rule rather than the exception.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> This has major implications for disease-modifying clinical trials, which have traditionally focused on single proteins without accounting for additional or overlapping protein pathologies. The recognition that neurodegenerative diseases often involve complex combinations of protein pathologies&#8212;including tau, TDP-43, amyloid &#946;, and &#945;-synuclein&#8212;sometimes alongside cerebrovascular disease,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib111" ref-type="bibr"><sup>111</sup></xref> has driven a paradigm shift in their clinical characterisation.</p><p id="p0200">A biological staging framework, developed under the auspices of the National Institute on Ageing and Alzheimer&#8217;s Association, reconceptualizes AD as a biological process rather than relying solely on syndromic presentation.<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref> This framework addresses co-pathology by expanding the original biomarker classification of A (amyloid), T (tau), and N (neurodegeneration) to include V (vascular) and S (&#945;-synuclein). Similar to precision classification systems used in oncology, this approach is being envisioned for other neurodegenerative diseases.<xref rid="bib112" ref-type="bibr"><sup>112</sup></xref><sup>,</sup><xref rid="bib113" ref-type="bibr"><sup>113</sup></xref> By incorporating multiple biomarker-defined dimensions, integrated biological and clinical staging acknowledges that common protein pathologies influence the relationship between clinical and biological stages of AD, contributing to heterogeneity in clinical presentation and progression. However, this framework has yet to be translated into interventional clinical trials.</p><p id="p0205">Some reports have already demonstrated that mixed protein pathologies are present in clinical trial participants. A recently published clinicopathologic study identified cerebrovascular and &#945;-synuclein protein pathology in two patients who received AD disease-modifying therapies (DMTs).<xref rid="bib114" ref-type="bibr"><sup>114</sup></xref> Furthermore, CAA is highly prevalent in autopsy series (&#8764;48%).<xref rid="bib115" ref-type="bibr"><sup>115</sup></xref> However, imaging studies significantly underestimate CAA prevalence in patients with AD, detecting only severe cases (&#8764;22%),<xref rid="bib115" ref-type="bibr"><sup>115</sup></xref> as milder pathology remains undetectable <italic toggle="yes">in vivo</italic>. Importantly, amyloid-removing DMTs have been associated with amyloid-related imaging abnormalities (ARIA), which may be partially explained by undetected CAA, a known risk factor for ARIA.<xref rid="bib116" ref-type="bibr"><sup>116</sup></xref></p><p id="p0210">Thus, the recognition of co-existing protein pathologies has substantial implications for the design of DMTs in neurodegenerative diseases. The exact impact of co-pathologies on clinical features remains challenging to quantify, complicating efforts to determine the number of participants required to achieve sufficient statistical power for agents targeting only one pathology (i.e., amyloid &#946;). Stratifying patients by co-pathology could improve precision but would require larger cohorts, further increasing trial costs. Alternatively, precision trials targeting multiple pathologies simultaneously may offer a more effective approach.</p><p id="p0215">In AD, therapies targeting both amyloid &#946; and tau are already being explored in a familial AD trial (Tau NexGen trial). While recent AD trials have demonstrated slowed disease progression with amyloid &#946; removal, the disease continues to progress.<xref rid="bib117" ref-type="bibr"><sup>117</sup></xref><sup>,</sup><xref rid="bib118" ref-type="bibr"><sup>118</sup></xref> Tau-targeting drugs represent a critical missing link that could further decelerate progression. The Alzheimer&#8217;s Tau Platform (ATP) trial is expected to combine anti-amyloid &#946; and anti-tau therapies in prodromal AD.</p><p id="p0220">Considering the growing recognition of co-pathology prevalence in neurodegenerative diseases, it is increasingly clear that DMTs must move beyond single-target approaches. The high prevalence of &#945;-synuclein co-pathology in AD and its significant impact on clinical outcomes strongly support the future integration of anti-&#945;-synuclein therapies into AD treatment paradigms once such agents become available.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib119" ref-type="bibr">119</xref>, <xref rid="bib120" ref-type="bibr">120</xref>, <xref rid="bib121" ref-type="bibr">121</xref> There is growing evidence that &#945;-synuclein might interact with amyloid &#946; and tau, potentially promoting mutual aggregation and worsening neurodegeneration since experimental models have shown that &#945;-synuclein oligomers enhance amyloid &#946; toxicity and tau hyperphosphorylation, driving neuronal dysfunction.<xref rid="bib119" ref-type="bibr">119</xref>, <xref rid="bib120" ref-type="bibr">120</xref>, <xref rid="bib121" ref-type="bibr">121</xref> These findings, largely derived from basic research, suggest that misfolded proteins may facilitate cross-seeding and amplify neurotoxic cascades, however, whether these mechanisms occur in the human brain remains uncertain. Neuropathological studies will be essential to determine the <italic toggle="yes">in vivo</italic> relevance of these interactions and to disentangle the true impact of cross-seeding on disease severity and progression.</p><p id="p0225">In addition to the well-established relevance of &#945;-synuclein and amyloid &#946; pathologies, TDP-43 co-pathology is now recognized as both prevalent and clinically significant. Limbic-predominant TDP-43 pathology<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref> is found in approximately 19&#8211;57% of AD cases.<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref><sup>,</sup><xref rid="bib124" ref-type="bibr"><sup>124</sup></xref> Furthermore, neuroinflammation is now recognized as a central driver of neurodegenerative disease progression. Immune modulation, therefore, represents a rational therapeutic avenue, with the potential to slow or halt neurodegeneration.<xref rid="bib125" ref-type="bibr"><sup>125</sup></xref><sup>,</sup><xref rid="bib126" ref-type="bibr"><sup>126</sup></xref> Given the complex and overlapping pathologies in most neurodegenerative diseases, the logical next step in disease-modifying therapy is the adoption of combination approaches.<xref rid="bib127" ref-type="bibr">127</xref>, <xref rid="bib128" ref-type="bibr">128</xref>, <xref rid="bib129" ref-type="bibr">129</xref> Combination therapies can simultaneously target multiple pathological proteins (such as amyloid &#946;, tau, &#945;-synuclein, and TDP-43) and modulate neuroinflammation, addressing the multifactorial nature of these disorders.<xref rid="bib127" ref-type="bibr">127</xref>, <xref rid="bib128" ref-type="bibr">128</xref>, <xref rid="bib129" ref-type="bibr">129</xref></p></sec><sec id="sec6"><title>Outstanding questions</title><p id="p0230">As the field moves toward a biological classification of neurodegenerative diseases,<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref><sup>,</sup><xref rid="bib112" ref-type="bibr"><sup>112</sup></xref><sup>,</sup><xref rid="bib113" ref-type="bibr"><sup>113</sup></xref> several critical questions remain unanswered. The development of &#945;-syn SAA has transformed the <italic toggle="yes">ante</italic>-<italic toggle="yes">mortem</italic> detection of &#945;-synuclein pathology, however, while &#945;-syn SAA demonstrates high inter-laboratory concordance once standardised,<xref rid="bib130" ref-type="bibr"><sup>130</sup></xref> its implementation involves numerous procedural steps that require meticulous optimization to ensure consistent results across settings. For instance, the assay&#8217;s sensitivity to variations in sample preparation and laboratory conditions necessitates careful standardisation to maintain reliability and avoid false positive or negative results.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib131" ref-type="bibr"><sup>131</sup></xref> Additionally, &#945;-syn SAA has limitations in distinguishing disease subtypes, such as diffuse neocortical, limbic transitional, and amygdala-predominant LBD in AD cohorts, which can hinder precise diagnostic differentiation. The assay also lacks robust quantitative capabilities to measure the burden of pathological &#945;-synuclein seeds&#8212;meaning the ability to reliably assess the amount pathological protein aggregates in a standardised way&#8212;which is critical for tracking disease progression or therapeutic response. Although recent advances, such as the application of microfluidics to SAA platforms, have demonstrated the potential for quantitative readouts, these approaches are still in early stages and require further validation before they can be implemented in clinical settings.<xref rid="bib132" ref-type="bibr"><sup>132</sup></xref> Future research should focus on refining standardised protocols to streamline the assay&#8217;s complex workflow and developing quantitative methods to enhance its clinical utility.</p><p id="p0235">To address these challenges, multi-modal biomarker approaches offer significant promise. Skin-based biomarkers have emerged as a less-invasive tool for detecting protein pathologies outside the central nervous system, providing insights into systemic aspects of neurodegenerative diseases. For &#945;-synuclein, studies have identified pathological aggregates in skin biopsies from patients with PD, DLB, and MSA, with high sensitivity and specificity.<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref> These skin-based &#945;-synuclein assays can complement CSF-based &#945;-syn SAA by offering a less invasive diagnostic method, potentially improving early detection and patient stratification. Similarly, skin-based tau-SAAs have shown promise in detecting tau pathology in AD<xref rid="bib133" ref-type="bibr"><sup>133</sup></xref> and distinguishing tauopathies from synucleinopathies.<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref><sup>,</sup><xref rid="bib134" ref-type="bibr"><sup>134</sup></xref> However, further validation in larger cohorts is needed to establish their diagnostic and prognostic value across diverse neurodegenerative disorders.<xref rid="bib135" ref-type="bibr"><sup>135</sup></xref></p><p id="p0240">Complementary to skin biomarkers, positron emission tomography (PET) imaging with &#945;-synuclein-specific tracers, such as [18F]ACI-12589<xref rid="bib136" ref-type="bibr"><sup>136</sup></xref> and [18F]-F0502B,<xref rid="bib137" ref-type="bibr"><sup>137</sup></xref> could address in the future the limitation of subtype differentiation by visualizing regional differences in &#945;-synuclein deposition.</p><p id="p0245">The independent effects of &#945;-synuclein pathology on cognition also require further exploration. While studies have demonstrated its role in cognitive decline in AD cohorts,<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> longitudinal analyses are needed to elucidate the temporal dynamics of &#945;-syn SAA positivity and its interplay with co-pathologies like tau and amyloid &#946;, which is crucial for defining &#945;-synuclein&#8217;s role in the AD continuum and its impact on anti-amyloid disease-modifying therapies.</p><p id="p0250">Drawing on progress in AD, where &#945;-synuclein and vascular contributions are integrated into staging frameworks, these advancements provide a model for studying co-pathologies in other neurodegenerative diseases. As combination therapies targeting multiple proteinopathies become feasible, biomarkers like &#945;-synuclein and tau in skin and CSF, alongside neuroimaging and genetic analysis, will be essential for stratifying patients, monitoring disease progression, and evaluating therapeutic efficacy. Kovacs and colleagues emphasized the need for biomarkers of pathogenetic processes to complement protein modifications for personalized diagnostic profiles.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> By refining &#945;-syn SAA protocols, expanding the use of skin-based biomarkers, and integrating multi-modal approaches, researchers can advance our understanding of neurodegenerative diseases and drive meaningful improvements in patient care.</p></sec><sec id="sec7"><title>Contributors</title><p id="p0255">IMV, MCT, and GGK conceptualized the review. IMV coordinated the writing process by inviting co-authors to contribute sections aligned with their expertise and by collating and editing their input. IMV, SF, SOD, MCT, and GGK contributed to writing the manuscript and performed data curation. IMV prepared <xref rid="tbl2" ref-type="table">Tables 2</xref> and <xref rid="tbl3" ref-type="table">3</xref>; SF prepared <xref rid="tbl1" ref-type="table">Table 1</xref>; GGK prepared <xref rid="fig1" ref-type="fig">Fig. 1</xref>. All authors read, edited, and approved the final version of the manuscript.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of interests</title><p id="p0260">IMV has a pending patent for Diagnostic assays for movement disorders (18/537,455), reports personal fees from Ferrer and receives research funding from the Rossy Family Foundation, the Blidner family, Ajay Virmani and the Michael J. Fox Foundation. SF has received financial support for attending scientific meetings from the NCHD Training Supports Scheme and the Trinity College, School of Medicine. MCT reports funding from the Tanenbaum Institute of Science in Sport, National Institute of Ageing, Canadian Institutes of Health Research, University Health Network Foundation, Weston Brain Foundation and the Michael J. Fox Foundation. She has received consulting fees from Eisai and Eli Lilly and in-kind support from Roche (to institution). She participates as a clinical trial site for studies sponsored by Janssen, Biogen, Avanex, Green Valley, UCB, Novo Nordisk, GSK, BMS, and Passage Bio. She holds unpaid scientific advisory roles with the Women&#8217;s Brain Foundation, Brain Injury Canada, and PSP Canada. SOD reports no conflict of interest. GGK reports personal fees from Parexel and Mitsubishi-Tanabe, other funding from the Rossy Family Foundation and the Edmond Safra Foundation. Grants from Krembil Foundation, MSA Coalition, Michael J. Fox Foundation, Parkinson Canada, NIH, Canada Foundation for Innovation, and Ontario Research Fund outside the submitted work; in addition, GGK has a shared patent for 5G4 Synuclein antibody and a pending patent for Diagnostic assays for movement disorders (18/537,455). GGK has also received royalties from Wiley, Cambridge, Taylor Francis, and Elsevier publishers. None of these had influence on this study.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Concha-Marambio</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pritzkow</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shahnawaz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farris</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Soto</surname><given-names>C.</given-names></name></person-group><article-title>Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid</article-title><source>Nat Protoc</source><volume>18</volume><issue>4</issue><year>2023</year><fpage>1179</fpage><lpage>1196</lpage><pub-id pub-id-type="pmid">36653527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41596-022-00787-3</pub-id><pub-id pub-id-type="pmcid">PMC10561622</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Siderowf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Concha-Marambio</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lafontant</surname><given-names>D.E.</given-names></name><etal/></person-group><article-title>Assessment of heterogeneity among participants in the Parkinson&#8217;s progression markers initiative cohort using &#945;-synuclein seed amplification: a cross-sectional study</article-title><source>Lancet Neurol</source><volume>22</volume><issue>5</issue><year>2023</year><fpage>407</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">37059509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(23)00109-6</pub-id><pub-id pub-id-type="pmcid">PMC10627170</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Farris</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study</article-title><source>Lancet Neurol</source><volume>23</volume><issue>12</issue><year>2024</year><fpage>1225</fpage><lpage>1237</lpage><pub-id pub-id-type="pmid">39577923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(24)00395-8</pub-id><pub-id pub-id-type="pmcid">PMC12288831</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Forrest</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>G.G.</given-names></name></person-group><article-title>Current concepts and molecular pathology of neurodegenerative diseases</article-title><source>Pathology</source><volume>57</volume><issue>2</issue><year>2025</year><fpage>178</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">39672768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pathol.2024.10.006</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Forrest</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>G.G.</given-names></name></person-group><article-title>Current concepts of mixed pathologies in neurodegenerative diseases</article-title><source>Can J Neurol Sci</source><volume>50</volume><issue>3</issue><year>2023</year><fpage>329</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">35356856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/cjn.2022.34</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Bellomo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Toja</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paolini Paoletti</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Investigating alpha-synuclein co-pathology in Alzheimer&#8217;s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay</article-title><source>Alzheimers Dement</source><volume>20</volume><issue>4</issue><year>2024</year><fpage>2444</fpage><lpage>2452</lpage><pub-id pub-id-type="pmid">38323747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13658</pub-id><pub-id pub-id-type="pmcid">PMC11032521</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Quadalti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Palmqvist</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Clinical effects of Lewy body pathology in cognitively impaired individuals</article-title><source>Nat Med</source><volume>29</volume><issue>8</issue><year>2023</year><fpage>1964</fpage><lpage>1970</lpage><pub-id pub-id-type="pmid">37464058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-023-02449-7</pub-id><pub-id pub-id-type="pmcid">PMC10427416</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="book" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Kovacs</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>I.</given-names></name></person-group><part-title>Neurodegenerative diseases: classification</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Smith</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Jacques</surname><given-names>T.</given-names></name></person-group><source>Greenfield&#8217;s neuropathology</source><edition>1. 10 ed.</edition><year>2025</year><publisher-name>Taylor &amp; Francis</publisher-name><publisher-loc>Boca Raton, FL</publisher-loc><fpage>803</fpage><lpage>817</lpage></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Schweighauser</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Structures of &#945;-synuclein filaments from human brains with Lewy pathology</article-title><source>Nature</source><volume>610</volume><issue>7933</issue><year>2022</year><fpage>791</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">36108674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-05319-3</pub-id><pub-id pub-id-type="pmcid">PMC7613749</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Schweighauser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tarutani</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Structures of &#945;-synuclein filaments from multiple system atrophy</article-title><source>Nature</source><volume>585</volume><issue>7825</issue><year>2020</year><fpage>464</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">32461689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2317-6</pub-id><pub-id pub-id-type="pmcid">PMC7116528</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Garringer</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>New SNCA mutation and structures of &#945;-synuclein filaments from juvenile-onset synucleinopathy</article-title><source>Acta Neuropathol</source><volume>145</volume><issue>5</issue><year>2023</year><fpage>561</fpage><lpage>572</lpage><pub-id pub-id-type="pmid">36847833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-023-02550-8</pub-id><pub-id pub-id-type="pmcid">PMC10119069</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Enomoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinez-Valbuena</surname><given-names>I.</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>Lewy-MSA hybrid fold drives distinct neuronal &#945;-synuclein pathology</article-title><source>Commun Biol</source><volume>8</volume><issue>1</issue><year>2025</year><fpage>929</fpage><pub-id pub-id-type="pmid">40523906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-025-08355-7</pub-id><pub-id pub-id-type="pmcid">PMC12170825</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-Valbuena</surname><given-names>I.</given-names></name><name name-style="western"><surname>Visanji</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy</article-title><source>Transl Neurodegener</source><volume>11</volume><issue>1</issue><year>2022</year><fpage>7</fpage><pub-id pub-id-type="pmid">35125105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-022-00283-4</pub-id><pub-id pub-id-type="pmcid">PMC8819887</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Braak</surname><given-names>H.</given-names></name><name name-style="western"><surname>Del Tredici</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rub</surname><given-names>U.</given-names></name><name name-style="western"><surname>de Vos</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Jansen Steur</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Braak</surname><given-names>E.</given-names></name></person-group><article-title>Staging of brain pathology related to sporadic Parkinson&#8217;s disease</article-title><source>Neurobiol Aging</source><volume>24</volume><issue>2</issue><year>2003</year><fpage>197</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">12498954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0197-4580(02)00065-9</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>McKeith</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium</article-title><source>Neurology</source><volume>65</volume><issue>12</issue><year>2005</year><fpage>1863</fpage><lpage>1872</lpage><pub-id pub-id-type="pmid">16237129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000187889.17253.b1</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Attems</surname><given-names>J.</given-names></name><name name-style="western"><surname>Toledo</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study</article-title><source>Acta Neuropathol</source><volume>141</volume><issue>2</issue><year>2021</year><fpage>159</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">33399945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-020-02255-2</pub-id><pub-id pub-id-type="pmcid">PMC7847437</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Kovacs</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Breydo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Green</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Intracellular processing of disease-associated alpha-synuclein in the human brain suggests prion-like cell-to-cell spread</article-title><source>Neurobiol Dis</source><volume>69</volume><year>2014</year><fpage>76</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">24878508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2014.05.020</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Trojanowski</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Revesz</surname><given-names>T.</given-names></name><collab>Neuropathology Working Group on MSA</collab></person-group><article-title>Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy</article-title><source>Neuropathol Appl Neurobiol</source><volume>33</volume><issue>6</issue><year>2007</year><fpage>615</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">17990994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2990.2007.00907.x</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Kovacs</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Grinberg</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Halliday</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Biomarker-based approach to alpha-Synucleinopathies: lessons from neuropathology</article-title><source>Mov Disord</source><volume>39</volume><issue>12</issue><year>2024</year><fpage>2173</fpage><lpage>2179</lpage><pub-id pub-id-type="pmid">39360851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.30028</pub-id><pub-id pub-id-type="pmcid">PMC11657033</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Visanji</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>G.G.</given-names></name></person-group><article-title>Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities</article-title><source>Transl Neurodegener</source><volume>8</volume><year>2019</year><fpage>28</fpage><pub-id pub-id-type="pmid">31508228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-019-0172-x</pub-id><pub-id pub-id-type="pmcid">PMC6727368</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Kovacs</surname><given-names>G.G.</given-names></name></person-group><article-title>Are comorbidities compatible with a molecular pathological classification of neurodegenerative diseases?</article-title><source>Curr Opin Neurol</source><volume>32</volume><issue>2</issue><year>2019</year><fpage>279</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">30672825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WCO.0000000000000664</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Spina</surname><given-names>S.</given-names></name><name name-style="western"><surname>La Joie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Comorbid neuropathological diagnoses in early versus late-onset Alzheimer&#8217;s disease</article-title><source>Brain</source><volume>144</volume><issue>7</issue><year>2021</year><fpage>2186</fpage><lpage>2198</lpage><pub-id pub-id-type="pmid">33693619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awab099</pub-id><pub-id pub-id-type="pmcid">PMC8502474</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S.X.</given-names></name><etal/></person-group><article-title>Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated</article-title><source>Brain</source><volume>141</volume><issue>7</issue><year>2018</year><fpage>2181</fpage><lpage>2193</lpage><pub-id pub-id-type="pmid">29878075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awy146</pub-id><pub-id pub-id-type="pmcid">PMC6022546</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Forrest</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Crockford</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Sizemova</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration</article-title><source>Neurology</source><volume>92</volume><issue>21</issue><year>2019</year><fpage>e2472</fpage><lpage>e2482</lpage><pub-id pub-id-type="pmid">31019099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000007530</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Forrest</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Kril</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>G.G.</given-names></name></person-group><article-title>Association between globular glial tauopathies and frontotemporal dementia-expanding the spectrum of gliocentric disorders: a review</article-title><source>JAMA Neurol</source><volume>78</volume><issue>8</issue><year>2021</year><fpage>1004</fpage><lpage>1014</lpage><pub-id pub-id-type="pmid">34152367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2021.1813</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Grau-Rivera</surname><given-names>O.</given-names></name><name name-style="western"><surname>Gelpi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nos</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Clinicopathological correlations and concomitant pathologies in rapidly progressive dementia: a brain bank series</article-title><source>Neurodegener Dis</source><volume>15</volume><issue>6</issue><year>2015</year><fpage>350</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">26523804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000439251</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Vital</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fernagut</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Canron</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>The nigrostriatal pathway in Creutzfeldt-Jakob disease</article-title><source>J Neuropathol Exp Neurol</source><volume>68</volume><issue>7</issue><year>2009</year><fpage>809</fpage><lpage>815</lpage><pub-id pub-id-type="pmid">19535991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/NEN.0b013e3181abdae8</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Sekiya</surname><given-names>H.</given-names></name><name name-style="western"><surname>Koga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Frequency of comorbid pathologies and their clinical impact in multiple system atrophy</article-title><source>Mov Disord</source><volume>39</volume><issue>2</issue><year>2024</year><fpage>380</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">37986699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.29670</pub-id><pub-id pub-id-type="pmcid">PMC10922743</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Elobeid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Libard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Popova</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Alafuzoff</surname><given-names>I.</given-names></name></person-group><article-title>Altered proteins in the aging brain</article-title><source>J Neuropathol Exp Neurol</source><volume>75</volume><issue>4</issue><year>2016</year><fpage>316</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">26979082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/nlw002</pub-id><pub-id pub-id-type="pmcid">PMC4793886</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Markesbery</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Jicha</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>F.A.</given-names></name></person-group><article-title>Lewy body pathology in normal elderly subjects</article-title><source>J Neuropathol Exp Neurol</source><volume>68</volume><issue>7</issue><year>2009</year><fpage>816</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">19535990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/NEN.0b013e3181ac10a7</pub-id><pub-id pub-id-type="pmcid">PMC2704264</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Brettschneider</surname><given-names>J.</given-names></name><name name-style="western"><surname>Irwin</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Boluda</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type</article-title><source>Neuropathol Appl Neurobiol</source><volume>43</volume><issue>4</issue><year>2017</year><fpage>315</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">27716988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/nan.12362</pub-id><pub-id pub-id-type="pmcid">PMC5362365</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Kovacs</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Milenkovic</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wohrer</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series</article-title><source>Acta Neuropathol</source><volume>126</volume><issue>3</issue><year>2013</year><fpage>365</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">23900711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-013-1157-y</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martinez-Valbuena</surname><given-names>I.</given-names></name><name name-style="western"><surname>Danics</surname><given-names>K.</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>G.G.</given-names></name></person-group><article-title>Contribution of &#945;-synuclein cytopathologies to distinct seeding of misfolded &#945;-synuclein</article-title><source>Brain Pathol</source><year>2025</year><object-id pub-id-type="publisher-id">e70024</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bpa.70024</pub-id><pub-id pub-id-type="pmcid">PMC12488258</pub-id><pub-id pub-id-type="pmid">40524452</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Livingston</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.Y.</given-names></name><etal/></person-group><article-title>Dementia prevention, intervention, and care: 2024 report of the lancet standing commission</article-title><source>Lancet</source><volume>404</volume><issue>10452</issue><year>2024</year><fpage>572</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">39096926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(24)01296-0</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Pilotto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bongianni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tirloni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Galli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Padovani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zanusso</surname><given-names>G.</given-names></name></person-group><article-title>CSF alpha-synuclein aggregates by seed amplification and clinical presentation of AD</article-title><source>Alzheimers Dement</source><volume>19</volume><issue>8</issue><year>2023</year><fpage>3754</fpage><lpage>3759</lpage><pub-id pub-id-type="pmid">37102457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13109</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Collij</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Mastenbroek</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Mattsson-Carlgren</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer&#8217;s disease</article-title><source>Nat Commun</source><volume>15</volume><issue>1</issue><year>2024</year><fpage>8061</fpage><pub-id pub-id-type="pmid">39277604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-52299-1</pub-id><pub-id pub-id-type="pmcid">PMC11401923</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Tosun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hausle</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Iwaki</surname><given-names>H.</given-names></name><etal/></person-group><article-title>A cross-sectional study of &#945;-synuclein seed amplification assay in Alzheimer&#8217;s disease neuroimaging initiative: prevalence and associations with Alzheimer&#8217;s disease biomarkers and cognitive function</article-title><source>Alzheimers Dement</source><volume>20</volume><issue>8</issue><year>2024</year><fpage>5114</fpage><lpage>5131</lpage><pub-id pub-id-type="pmid">38770829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13858</pub-id><pub-id pub-id-type="pmcid">PMC11350010</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Silva-Rodr&#237;guez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Labrador-Espinosa</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>The effect of Lewy body (co-)pathology on the clinical and imaging phenotype of amnestic patients</article-title><source>Brain</source><volume>148</volume><issue>7</issue><year>2025</year><fpage>2441</fpage><lpage>2452</lpage><pub-id pub-id-type="pmid">39888600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awaf037</pub-id><pub-id pub-id-type="pmcid">PMC12233547</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>R.L.</given-names></name></person-group><article-title>Lewy bodies in Alzheimer&#8217;s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry</article-title><source>Brain Pathol</source><volume>10</volume><issue>3</issue><year>2000</year><fpage>378</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">10885656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1750-3639.2000.tb00269.x</pub-id><pub-id pub-id-type="pmcid">PMC8098522</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Babulal</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Monsell</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Cairns</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Roe</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J.C.</given-names></name></person-group><article-title>Clinical features of Alzheimer disease with and without Lewy bodies</article-title><source>JAMA Neurol</source><volume>72</volume><issue>7</issue><year>2015</year><fpage>789</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">25985321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2015.0606</pub-id><pub-id pub-id-type="pmcid">PMC4501861</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Samudra</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Lenio</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohort</article-title><source>Alzheimers Dement</source><volume>20</volume><issue>5</issue><year>2024</year><fpage>3334</fpage><lpage>3341</lpage><pub-id pub-id-type="pmid">38539061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13799</pub-id><pub-id pub-id-type="pmcid">PMC11095442</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Coughlin</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Brumbach</surname><given-names>B.H.</given-names></name><etal/></person-group><article-title>&#945;-Synuclein seed amplification in CSF and brain from patients with different brain distributions of pathological &#945;-Synuclein in the context of Co-Pathology and Non-LBD diagnoses</article-title><source>Ann Neurol</source><volume>92</volume><issue>4</issue><year>2022</year><fpage>650</fpage><lpage>662</lpage><pub-id pub-id-type="pmid">35808984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26453</pub-id><pub-id pub-id-type="pmcid">PMC9489647</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>S.</given-names></name><name name-style="western"><surname>Orr&#249;</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>G.E.</given-names></name><etal/></person-group><article-title>Performance of &#945;Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease</article-title><source>Acta Neuropathol Commun</source><volume>10</volume><issue>1</issue><year>2022</year><fpage>90</fpage><pub-id pub-id-type="pmid">35733234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-022-01388-7</pub-id><pub-id pub-id-type="pmcid">PMC9219141</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Candelise</surname><given-names>N.</given-names></name><name name-style="western"><surname>Baiardi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies</article-title><source>Acta Neuropathol</source><volume>140</volume><issue>1</issue><year>2020</year><fpage>49</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">32342188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-020-02160-8</pub-id><pub-id pub-id-type="pmcid">PMC7299922</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Fairfoul</surname><given-names>G.</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies</article-title><source>Ann Clin Transl Neurol</source><volume>3</volume><issue>10</issue><year>2016</year><fpage>812</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">27752516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.338</pub-id><pub-id pub-id-type="pmcid">PMC5048391</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Mastenbroek</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Collij</surname><given-names>L.E.</given-names></name><etal/></person-group><article-title>Disease progression modelling reveals heterogeneity in trajectories of Lewy-type &#945;-synuclein pathology</article-title><source>Nat Commun</source><volume>15</volume><issue>1</issue><year>2024</year><fpage>5133</fpage><pub-id pub-id-type="pmid">38879548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-49402-x</pub-id><pub-id pub-id-type="pmcid">PMC11180185</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Roudil</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deramecourt</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dufournet</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Influence of Lewy pathology on Alzheimer&#8217;s disease phenotype: a retrospective clinico-pathological study</article-title><source>J Alzheimers Dis</source><volume>63</volume><issue>4</issue><year>2018</year><fpage>1317</fpage><lpage>1323</lpage><pub-id pub-id-type="pmid">29758938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-170914</pub-id><pub-id pub-id-type="pmcid">PMC6218122</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>McKeith</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Boeve</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>D.W.</given-names></name><etal/></person-group><article-title>Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium</article-title><source>Neurology</source><volume>89</volume><issue>1</issue><year>2017</year><fpage>88</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">28592453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000004058</pub-id><pub-id pub-id-type="pmcid">PMC5496518</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>McKeith</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Ferman</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>Research criteria for the diagnosis of prodromal dementia with Lewy bodies</article-title><source>Neurology</source><volume>94</volume><issue>17</issue><year>2020</year><fpage>743</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">32241955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000009323</pub-id><pub-id pub-id-type="pmcid">PMC7274845</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Postuma</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>M.</given-names></name><etal/></person-group><article-title>MDS clinical diagnostic criteria for Parkinson&#8217;s disease</article-title><source>Mov Disord</source><volume>30</volume><issue>12</issue><year>2015</year><fpage>1591</fpage><lpage>1601</lpage><pub-id pub-id-type="pmid">26474316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.26424</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Tosun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hausle</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Thropp</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Association of CSF &#945;-synuclein seed amplification assay positivity with disease progression and cognitive decline: a longitudinal Alzheimer&#8217;s disease neuroimaging initiative study</article-title><source>Alzheimers Dement</source><volume>20</volume><issue>12</issue><year>2024</year><fpage>8444</fpage><lpage>8460</lpage><pub-id pub-id-type="pmid">39428831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14276</pub-id><pub-id pub-id-type="pmcid">PMC11667524</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Brenowitz</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Keene</surname><given-names>C.D.</given-names></name><etal/></person-group><article-title>Mixed neuropathologies and associations with domain-specific cognitive decline</article-title><source>Neurology</source><volume>89</volume><issue>17</issue><year>2017</year><fpage>1773</fpage><lpage>1781</lpage><pub-id pub-id-type="pmid">28939667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000004567</pub-id><pub-id pub-id-type="pmcid">PMC5664309</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Landau</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Individuals with Alzheimer&#8217;s disease and low tau burden: characteristics and implications</article-title><source>Alzheimers Dement</source><volume>20</volume><issue>3</issue><year>2024</year><fpage>2113</fpage><lpage>2127</lpage><pub-id pub-id-type="pmid">38241084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13609</pub-id><pub-id pub-id-type="pmcid">PMC10984443</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baiardi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Quadalti</surname><given-names>C.</given-names></name><etal/></person-group><article-title>&#945;-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer&#8217;s disease late in the disease course and dependent on Lewy pathology burden</article-title><source>Alzheimers Dement</source><volume>20</volume><issue>6</issue><year>2024</year><fpage>4351</fpage><lpage>4365</lpage><pub-id pub-id-type="pmid">38666355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13818</pub-id><pub-id pub-id-type="pmcid">PMC11180868</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>A.</given-names></name></person-group><article-title>Distinct CSF &#945;-synuclein aggregation profiles associated with Alzheimer&#8217;s disease phenotypes and MCI-to-AD conversion</article-title><source>J Prev Alzheimers Dis</source><volume>12</volume><issue>2</issue><year>2025</year><object-id pub-id-type="publisher-id">100040</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tjpad.2024.100040</pub-id><pub-id pub-id-type="pmcid">PMC12184058</pub-id><pub-id pub-id-type="pmid">39863324</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Pina-Escudero</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>La Joie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Spina</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Comorbid neuropathology and atypical presentation of Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement (Amst)</source><volume>16</volume><issue>3</issue><year>2024</year><object-id pub-id-type="publisher-id">e12602</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12602</pub-id><pub-id pub-id-type="pmcid">PMC11262028</pub-id><pub-id pub-id-type="pmid">39040464</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Shahnawaz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pritzkow</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Discriminating &#945;-synuclein strains in Parkinson&#8217;s disease and multiple system atrophy</article-title><source>Nature</source><volume>578</volume><issue>7794</issue><year>2020</year><fpage>273</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">32025029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-1984-7</pub-id><pub-id pub-id-type="pmcid">PMC7066875</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Malfertheiner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stefanova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Heras-Garvin</surname><given-names>A.</given-names></name></person-group><article-title>The concept of &#945;-Synuclein strains and how different conformations may explain distinct neurodegenerative disorders</article-title><source>Front Neurol</source><volume>12</volume><year>2021</year><object-id pub-id-type="publisher-id">737195</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2021.737195</pub-id><pub-id pub-id-type="pmcid">PMC8523670</pub-id><pub-id pub-id-type="pmid">34675870</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Holec</surname><given-names>S.A.M.</given-names></name><name name-style="western"><surname>Woerman</surname><given-names>A.L.</given-names></name></person-group><article-title>Evidence of distinct &#945;-synuclein strains underlying disease heterogeneity</article-title><source>Acta Neuropathol</source><volume>142</volume><issue>1</issue><year>2021</year><fpage>73</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">32440702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-020-02163-5</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Just</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Gram</surname><given-names>H.</given-names></name><name name-style="western"><surname>Theologidis</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Alpha-synuclein strain variability in body-first and brain-first synucleinopathies</article-title><source>Front Aging Neurosci</source><volume>14</volume><year>2022</year><object-id pub-id-type="publisher-id">907293</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.907293</pub-id><pub-id pub-id-type="pmcid">PMC9178288</pub-id><pub-id pub-id-type="pmid">35693346</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Abner</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>E.</given-names></name><etal/></person-group><article-title>The amygdala as a locus of pathologic misfolding in neurodegenerative diseases</article-title><source>J Neuropathol Exp Neurol</source><volume>77</volume><issue>1</issue><year>2018</year><fpage>2</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">29186501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/nlx099</pub-id><pub-id pub-id-type="pmcid">PMC5901077</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Sorrentino</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Riffe</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>Unique &#945;-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression</article-title><source>Acta Neuropathol Commun</source><volume>7</volume><issue>1</issue><year>2019</year><fpage>142</fpage><pub-id pub-id-type="pmid">31477175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-019-0787-2</pub-id><pub-id pub-id-type="pmcid">PMC6718048</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Franzmeier</surname><given-names>N.</given-names></name><name name-style="western"><surname>Roemer-Cassiano</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Bernhardt</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer&#8217;s disease</article-title><source>Mol Neurodegener</source><volume>20</volume><issue>1</issue><year>2025</year><fpage>31</fpage><pub-id pub-id-type="pmid">40098057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-025-00822-3</pub-id><pub-id pub-id-type="pmcid">PMC11916967</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Andrews</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T.G.</given-names></name><etal/></person-group><article-title>Revised criteria for the diagnosis and staging of Alzheimer&#8217;s disease</article-title><source>Nat Med</source><volume>30</volume><issue>8</issue><year>2024</year><fpage>2121</fpage><lpage>2124</lpage><pub-id pub-id-type="pmid">38942991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-02988-7</pub-id><pub-id pub-id-type="pmcid">PMC11630478</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Skin &#945;-synuclein assays in diagnosing Parkinson&#8217;s disease: a systematic review and meta-analysis</article-title><source>J Neurol</source><volume>272</volume><issue>5</issue><year>2025</year><fpage>326</fpage><pub-id pub-id-type="pmid">40205187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-025-12978-5</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Okuzumi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hatano</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Propagative &#945;-synuclein seeds as serum biomarkers for synucleinopathies</article-title><source>Nat Med</source><volume>29</volume><issue>6</issue><year>2023</year><fpage>1448</fpage><lpage>1455</lpage><pub-id pub-id-type="pmid">37248302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-023-02358-9</pub-id><pub-id pub-id-type="pmcid">PMC10287557</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Caswell</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Primary tau pathology, not copathology, correlates with clinical symptoms in PSP and CBD</article-title><source>J Neuropathol Exp Neurol</source><volume>79</volume><issue>3</issue><year>2020</year><fpage>296</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">31999351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/nlz141</pub-id><pub-id pub-id-type="pmcid">PMC7036659</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Jecmenica Lukic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kurz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Respondek</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Copathology in progressive supranuclear palsy: does it matter?</article-title><source>Mov Disord</source><volume>35</volume><issue>6</issue><year>2020</year><fpage>984</fpage><lpage>993</lpage><pub-id pub-id-type="pmid">32125724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.28011</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Anastassiadis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Martinez-Valbuena</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vasilevskaya</surname><given-names>A.</given-names></name><etal/></person-group><article-title>CSF &#945;-Synuclein seed amplification assay in patients with atypical parkinsonian disorders</article-title><source>Neurology</source><volume>103</volume><issue>6</issue><year>2024</year><object-id pub-id-type="publisher-id">e209818</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000209818</pub-id><pub-id pub-id-type="pmid">39208367</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Fernandes Gomes</surname><given-names>B.</given-names></name><name name-style="western"><surname>Farris</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>&#945;-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders</article-title><source>Parkinson Relat Disord</source><volume>117</volume><year>2023</year><object-id pub-id-type="publisher-id">105807</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2023.105807</pub-id><pub-id pub-id-type="pmid">37591709</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Vaughan</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Fumi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Theilmann Jensen</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Evaluation of cerebrospinal fluid &#945;-Synuclein seed amplification assay in progressive supranuclear palsy and corticobasal syndrome</article-title><source>Mov Disord</source><volume>39</volume><issue>12</issue><year>2024</year><fpage>2285</fpage><lpage>2291</lpage><pub-id pub-id-type="pmid">39301998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.30019</pub-id><pub-id pub-id-type="pmcid">PMC11657022</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Saijo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Metrick</surname><given-names>M.A.</given-names><suffix>2nd</suffix></name><name name-style="western"><surname>Koga</surname><given-names>S.</given-names></name><etal/></person-group><article-title>4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration</article-title><source>Acta Neuropathol</source><volume>139</volume><issue>1</issue><year>2020</year><fpage>63</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">31616982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-019-02080-2</pub-id><pub-id pub-id-type="pmcid">PMC7192393</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-Valbuena</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tartaglia</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>G.G.</given-names></name></person-group><article-title>Four-repeat tau seeding in the skin of patients with progressive supranuclear palsy</article-title><source>JAMA Neurol</source><volume>81</volume><issue>11</issue><year>2024</year><fpage>1228</fpage><lpage>1230</lpage><pub-id pub-id-type="pmid">39312261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2024.3162</pub-id><pub-id pub-id-type="pmcid">PMC11420818</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Hakim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>R.D.</given-names></name></person-group><article-title>The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics</article-title><source>J Neurol Sci</source><volume>2</volume><issue>4</issue><year>1965</year><fpage>307</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">5889177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0022-510x(65)90016-x</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Relkin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Marmarou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klinge</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bergsneider</surname><given-names>M.</given-names></name><name name-style="western"><surname>Black</surname><given-names>P.M.</given-names></name></person-group><article-title>Diagnosing idiopathic normal-pressure hydrocephalus</article-title><source>Neurosurgery</source><volume>57</volume><issue>3 Suppl</issue><year>2005</year><fpage>S4</fpage><lpage>S16</lpage><comment>discussion ii&#8211;v</comment><pub-id pub-id-type="pmid">16160425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1227/01.neu.0000168185.29659.c5</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Jaraj</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rabiei</surname><given-names>K.</given-names></name><name name-style="western"><surname>Marlow</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Skoog</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wikkels&#248;</surname><given-names>C.</given-names></name></person-group><article-title>Prevalence of idiopathic normal-pressure hydrocephalus</article-title><source>Neurology</source><volume>82</volume><issue>16</issue><year>2014</year><fpage>1449</fpage><lpage>1454</lpage><pub-id pub-id-type="pmid">24682964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000000342</pub-id><pub-id pub-id-type="pmcid">PMC4001197</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Abu-Rumeileh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Giannini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Polischi</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Revisiting the cerebrospinal fluid biomarker profile in idiopathic normal pressure hydrocephalus: the Bologna pro-hydro study</article-title><source>J Alzheimers Dis</source><volume>68</volume><issue>2</issue><year>2019</year><fpage>723</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">30883350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-181012</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bjurnemark</surname><given-names>C.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Higher levels of neurofilament light chain and total tau in CSF are associated with negative outcome after shunt surgery in patients with normal pressure hydrocephalus</article-title><source>Fluids Barriers CNS</source><volume>19</volume><issue>1</issue><year>2022</year><fpage>15</fpage><pub-id pub-id-type="pmid">35164790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12987-022-00306-2</pub-id><pub-id pub-id-type="pmcid">PMC8845290</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Lukkarinen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jeppsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wikkels&#246;</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients</article-title><source>Fluids Barriers CNS</source><volume>19</volume><issue>1</issue><year>2022</year><fpage>11</fpage><pub-id pub-id-type="pmid">35123528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12987-022-00309-z</pub-id><pub-id pub-id-type="pmcid">PMC8817565</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Mak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>G.B.</given-names></name><etal/></person-group><article-title>Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson&#8217;s disease</article-title><source>Neurobiol Aging</source><volume>55</volume><year>2017</year><fpage>78</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">28431288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2017.03.012</pub-id><pub-id pub-id-type="pmcid">PMC5454799</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Pozzi</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Brumberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Todisco</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Striatal dopamine deficit and motor impairment in idiopathic normal pressure hydrocephalus</article-title><source>Mov Disord</source><volume>36</volume><issue>1</issue><year>2021</year><fpage>124</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">33151012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.28366</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Todisco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zangaglia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Minafra</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Clinical outcome and striatal dopaminergic function after shunt surgery in patients with idiopathic normal pressure hydrocephalus</article-title><source>Neurology</source><volume>96</volume><issue>23</issue><year>2021</year><fpage>e2861</fpage><lpage>e2873</lpage><pub-id pub-id-type="pmid">33893195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000012064</pub-id><pub-id pub-id-type="pmcid">PMC8205459</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Giannini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baiardi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dellavalle</surname><given-names>S.</given-names></name><etal/></person-group><article-title>In vivo assessment of Lewy body and beta-amyloid copathologies in idiopathic normal pressure hydrocephalus: prevalence and associations with clinical features and surgery outcome</article-title><source>Fluids Barriers CNS</source><volume>19</volume><issue>1</issue><year>2022</year><fpage>71</fpage><pub-id pub-id-type="pmid">36071460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12987-022-00368-2</pub-id><pub-id pub-id-type="pmcid">PMC9454182</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Fasano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martinez-Valbuena</surname><given-names>I.</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Alpha-synuclein RT-QuIC in idiopathic normal pressure hydrocephalus</article-title><source>Ann Neurol</source><volume>92</volume><issue>6</issue><year>2022</year><fpage>985</fpage><lpage>991</lpage><pub-id pub-id-type="pmid">36094107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26505</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Farris</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Anosmia and upper limb Rigidity-A potential phenotype of idiopathic normal pressure hydrocephalus with cerebrospinal fluid &#945;-Synuclein seeds</article-title><source>Mov Disord</source><volume>40</volume><issue>6</issue><year>2025</year><fpage>1206</fpage><lpage>1213</lpage><pub-id pub-id-type="pmid">40200913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.30184</pub-id><pub-id pub-id-type="pmcid">PMC12160991</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Molde</surname><given-names>K.</given-names></name><name name-style="western"><surname>S&#246;derstr&#246;m</surname><given-names>L.</given-names></name><name name-style="western"><surname>Laurell</surname><given-names>K.</given-names></name></person-group><article-title>Parkinsonian symptoms in normal pressure hydrocephalus: a population-based study</article-title><source>J Neurol</source><volume>264</volume><issue>10</issue><year>2017</year><fpage>2141</fpage><lpage>2148</lpage><pub-id pub-id-type="pmid">28879446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-017-8598-5</pub-id><pub-id pub-id-type="pmcid">PMC5617872</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Cabral</surname><given-names>D.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Vedders</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Frequency of Alzheimer&#8217;s disease pathology at autopsy in patients with clinical normal pressure hydrocephalus</article-title><source>Alzheimers Dement</source><volume>7</volume><issue>5</issue><year>2011</year><fpage>509</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">21723206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2010.12.008</pub-id><pub-id pub-id-type="pmcid">PMC3166980</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Libard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alafuzoff</surname><given-names>I.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease neuropathological change and loss of matrix/neuropil in patients with idiopathic normal pressure hydrocephalus, a model of Alzheimer&#8217;s disease</article-title><source>Acta Neuropathol Commun</source><volume>7</volume><issue>1</issue><year>2019</year><fpage>98</fpage><pub-id pub-id-type="pmid">31142354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-019-0748-9</pub-id><pub-id pub-id-type="pmcid">PMC6540414</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Andrews</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T.G.</given-names></name><etal/></person-group><article-title>Revised criteria for diagnosis and staging of Alzheimer&#8217;s disease: Alzheimer&#8217;s association workgroup</article-title><source>Alzheimers Dement</source><volume>20</volume><issue>8</issue><year>2024</year><fpage>5143</fpage><lpage>5169</lpage><pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Malm</surname><given-names>J.</given-names></name><name name-style="western"><surname>Graff-Radford</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Influence of comorbidities in idiopathic normal pressure hydrocephalus - research and clinical care. A report of the ISHCSF task force on comorbidities in INPH</article-title><source>Fluids Barriers CNS</source><volume>10</volume><issue>1</issue><year>2013</year><fpage>22</fpage><pub-id pub-id-type="pmid">23758953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/2045-8118-10-22</pub-id><pub-id pub-id-type="pmcid">PMC3689166</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Bech-Azeddine</surname><given-names>R.</given-names></name><name name-style="western"><surname>H&#248;gh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Juhler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gjerris</surname><given-names>F.</given-names></name><name name-style="western"><surname>Waldemar</surname><given-names>G.</given-names></name></person-group><article-title>Idiopathic normal-pressure hydrocephalus: clinical comorbidity correlated with cerebral biopsy findings and outcome of cerebrospinal fluid shunting</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>78</volume><issue>2</issue><year>2007</year><fpage>157</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">17012342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.2006.095117</pub-id><pub-id pub-id-type="pmcid">PMC2077673</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Golomb</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wisoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>D.C.</given-names></name><etal/></person-group><article-title>Alzheimer&#8217;s disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>68</volume><issue>6</issue><year>2000</year><fpage>778</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">10811706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.68.6.778</pub-id><pub-id pub-id-type="pmcid">PMC1736969</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Leinonen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Koivisto</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Alafuzoff</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Cortical brain biopsy in long-term prognostication of 468 patients with possible normal pressure hydrocephalus</article-title><source>Neurodegener Dis</source><volume>10</volume><issue>1&#8211;4</issue><year>2012</year><fpage>166</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">22343771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000335155</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.B.</given-names></name><etal/></person-group><article-title>Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology</article-title><source>Ann Neurol</source><volume>68</volume><issue>4</issue><year>2010</year><fpage>535</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">20687117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.22015</pub-id><pub-id pub-id-type="pmcid">PMC2964442</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Leinonen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Koivisto</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Savolainen</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Amyloid and tau proteins in cortical brain biopsy and Alzheimer&#8217;s disease</article-title><source>Ann Neurol</source><volume>68</volume><issue>4</issue><year>2010</year><fpage>446</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">20976765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.22100</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Livingston</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sommerlad</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Dementia prevention, intervention, and care: 2020 report of the lancet commission</article-title><source>Lancet</source><volume>396</volume><issue>10248</issue><year>2020</year><fpage>413</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">32738937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30367-6</pub-id><pub-id pub-id-type="pmcid">PMC7392084</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>V.E.</given-names></name><name name-style="western"><surname>Mez</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Lewy body pathology and chronic traumatic encephalopathy associated with contact sports</article-title><source>J Neuropathol Exp Neurol</source><volume>77</volume><issue>9</issue><year>2018</year><fpage>757</fpage><lpage>768</lpage><pub-id pub-id-type="pmid">30053297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/nly065</pub-id><pub-id pub-id-type="pmcid">PMC6097837</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Morissette</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Prior</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Tate</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Wade</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leiter</surname><given-names>J.R.S.</given-names></name></person-group><article-title>Associations between concussion and risk of diagnosis of psychological and neurological disorders: a retrospective population-based cohort study</article-title><source>Fam Med Community Health</source><volume>8</volume><issue>3</issue><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/fmch-2020-000390</pub-id><pub-id pub-id-type="pmcid">PMC7388873</pub-id><pub-id pub-id-type="pmid">32719017</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Crane</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Dams-O&#8217;Connor</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Association of traumatic brain injury with late-life neurodegenerative conditions and neuropathologic findings</article-title><source>JAMA Neurol</source><volume>73</volume><issue>9</issue><year>2016</year><fpage>1062</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">27400367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2016.1948</pub-id><pub-id pub-id-type="pmcid">PMC5319642</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Mackay</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>K.</given-names></name><name name-style="western"><surname>MacLean</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Pell</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>W.</given-names></name></person-group><article-title>Neurodegenerative disease mortality among former professional soccer players</article-title><source>N Engl J Med</source><volume>381</volume><issue>19</issue><year>2019</year><fpage>1801</fpage><lpage>1808</lpage><pub-id pub-id-type="pmid">31633894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1908483</pub-id><pub-id pub-id-type="pmcid">PMC8747032</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leurgans</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>James</surname><given-names>B.D.</given-names></name><etal/></person-group><article-title>Association of traumatic brain injury with and without loss of consciousness with neuropathologic outcomes in community-dwelling older persons</article-title><source>JAMA Netw Open</source><volume>5</volume><issue>4</issue><year>2022</year><object-id pub-id-type="publisher-id">e229311</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.9311</pub-id><pub-id pub-id-type="pmcid">PMC9047640</pub-id><pub-id pub-id-type="pmid">35476062</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Deutsch</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Mendez</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>E.</given-names></name></person-group><article-title>Interactions between traumatic brain injury and frontotemporal degeneration</article-title><source>Dement Geriatr Cogn Disord</source><volume>39</volume><issue>3&#8211;4</issue><year>2015</year><fpage>143</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">25531628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000369787</pub-id><pub-id pub-id-type="pmcid">PMC4427348</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Taghdiri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Khodadadi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sadia</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Unusual combinations of neurodegenerative pathologies with chronic traumatic encephalopathy (CTE) complicates clinical prediction of CTE</article-title><source>Eur J Neurol</source><volume>31</volume><issue>6</issue><year>2024</year><object-id pub-id-type="publisher-id">e16259</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.16259</pub-id><pub-id pub-id-type="pmcid">PMC11235773</pub-id><pub-id pub-id-type="pmid">38404144</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Bieniek</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Cairns</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Crary</surname><given-names>J.F.</given-names></name><etal/></person-group><article-title>The second NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy</article-title><source>J Neuropathol Exp Neurol</source><volume>80</volume><issue>3</issue><year>2021</year><fpage>210</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">33611507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/nlab001</pub-id><pub-id pub-id-type="pmcid">PMC7899277</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Asken</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>VandeVrede</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Multi-modal biomarkers of repetitive head impacts and traumatic encephalopathy syndrome: a clinicopathological case series</article-title><source>J Neurotrauma</source><volume>39</volume><issue>17&#8211;18</issue><year>2022</year><fpage>1195</fpage><lpage>1213</lpage><pub-id pub-id-type="pmid">35481808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/neu.2022.0060</pub-id><pub-id pub-id-type="pmcid">PMC9422800</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>H.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players</article-title><source>Acta Neuropathol</source><volume>133</volume><issue>3</issue><year>2017</year><fpage>337</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">28205009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-017-1680-3</pub-id><pub-id pub-id-type="pmcid">PMC5325836</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Mez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Daneshvar</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Kiernan</surname><given-names>P.T.</given-names></name><etal/></person-group><article-title>Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football</article-title><source>Jama</source><volume>318</volume><issue>4</issue><year>2017</year><fpage>360</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">28742910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2017.8334</pub-id><pub-id pub-id-type="pmcid">PMC5807097</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nag</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J.A.</given-names></name></person-group><article-title>A clinicopathological report of a 93-Year-Old former street boxer with coexistence of chronic traumatic encephalopathy, Alzheimer&#8217;s disease, dementia with Lewy bodies, and hippocampal sclerosis with TDP-43 pathology</article-title><source>Front Neurol</source><volume>11</volume><year>2020</year><fpage>42</fpage><pub-id pub-id-type="pmid">32117011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2020.00042</pub-id><pub-id pub-id-type="pmcid">PMC7028767</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Forrest</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Sadia</surname><given-names>N.</given-names></name><name name-style="western"><surname>Khodadadi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Unprecedented combination of rare degenerative pathologies in an octogenarian Ex-Football player</article-title><source>Neuropathology</source><volume>45</volume><issue>4</issue><year>2025</year><object-id pub-id-type="publisher-id">e70004</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/neup.70004</pub-id><pub-id pub-id-type="pmcid">PMC12309147</pub-id><pub-id pub-id-type="pmid">40079251</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>Vasilevskaya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martinez-Valbuena</surname><given-names>I.</given-names></name><name name-style="western"><surname>Anastassiadis</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Misfolded &#945;-Synuclein in cerebrospinal fluid of contact sport athletes</article-title><source>Mov Disord</source><volume>38</volume><issue>11</issue><year>2023</year><fpage>2125</fpage><lpage>2131</lpage><pub-id pub-id-type="pmid">37792643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.29621</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S.X.</given-names></name><etal/></person-group><article-title>The development and convergence of co-pathologies in Alzheimer&#8217;s disease</article-title><source>Brain</source><volume>144</volume><issue>3</issue><year>2021</year><fpage>953</fpage><lpage>962</lpage><pub-id pub-id-type="pmid">33449993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awaa438</pub-id><pub-id pub-id-type="pmcid">PMC8041349</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Hoglinger</surname><given-names>G.U.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A biological classification of Parkinson&#8217;s disease: the SynNeurGe research diagnostic criteria</article-title><source>Lancet Neurol</source><volume>23</volume><issue>2</issue><year>2024</year><fpage>191</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">38267191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(23)00404-0</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Simuni</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chahine</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Poston</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A biological definition of neuronal &#945;-synuclein disease: towards an integrated staging system for research</article-title><source>Lancet Neurol</source><volume>23</volume><issue>2</issue><year>2024</year><fpage>178</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">38267190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(23)00405-2</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>VandeVrede</surname><given-names>L.</given-names></name><name name-style="western"><surname>La Joie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Horiki</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab</article-title><source>Acta Neuropathol</source><volume>146</volume><issue>5</issue><year>2023</year><fpage>777</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">37725166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-023-02631-8</pub-id><pub-id pub-id-type="pmcid">PMC10564667</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>J&#228;kel</surname><given-names>L.</given-names></name><name name-style="western"><surname>De Kort</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Klijn</surname><given-names>C.J.M.</given-names></name><name name-style="western"><surname>Schreuder</surname><given-names>F.</given-names></name><name name-style="western"><surname>Verbeek</surname><given-names>M.M.</given-names></name></person-group><article-title>Prevalence of cerebral amyloid angiopathy: a systematic review and meta-analysis</article-title><source>Alzheimers Dement</source><volume>18</volume><issue>1</issue><year>2022</year><fpage>10</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">34057813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12366</pub-id><pub-id pub-id-type="pmcid">PMC9290643</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Sveikata</surname><given-names>L.</given-names></name><name name-style="western"><surname>Charidimou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Viswanathan</surname><given-names>A.</given-names></name></person-group><article-title>Vessels sing their ARIAs: the role of vascular amyloid in the age of aducanumab</article-title><source>Stroke</source><volume>53</volume><issue>1</issue><year>2022</year><fpage>298</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">34905943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.121.036873</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Lecanemab in early Alzheimer&#8217;s disease</article-title><source>N Engl J Med</source><volume>388</volume><issue>1</issue><year>2023</year><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">36449413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2212948</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Sims</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>C.D.</given-names></name><etal/></person-group><article-title>Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial</article-title><source>JAMA</source><volume>330</volume><issue>6</issue><year>2023</year><fpage>512</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">37459141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.13239</pub-id><pub-id pub-id-type="pmcid">PMC10352931</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>Shim</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Youn</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>An</surname><given-names>S.S.A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name></person-group><article-title>Alpha-synuclein: a pathological factor with A&#946; and tau and biomarker in Alzheimer&#8217;s disease</article-title><source>Alzheimers Res Ther</source><volume>14</volume><issue>1</issue><year>2022</year><fpage>201</fpage><pub-id pub-id-type="pmid">36587215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-022-01150-0</pub-id><pub-id pub-id-type="pmcid">PMC9805257</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Fouka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mavroeidi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tsaka</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xilouri</surname><given-names>M.</given-names></name></person-group><article-title>In search of effective treatments targeting &#945;-Synuclein toxicity in synucleinopathies: pros and cons</article-title><source>Front Cell Dev Biol</source><volume>8</volume><year>2020</year><object-id pub-id-type="publisher-id">559791</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2020.559791</pub-id><pub-id pub-id-type="pmcid">PMC7500083</pub-id><pub-id pub-id-type="pmid">33015057</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Twohig</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>H.M.</given-names></name></person-group><article-title>&#945;-synuclein in the pathophysiology of Alzheimer&#8217;s disease</article-title><source>Mol Neurodegener</source><volume>14</volume><issue>1</issue><year>2019</year><fpage>23</fpage><pub-id pub-id-type="pmid">31186026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-019-0320-x</pub-id><pub-id pub-id-type="pmcid">PMC6558879</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>J.Q.</given-names></name><etal/></person-group><article-title>Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report</article-title><source>Brain</source><volume>142</volume><issue>6</issue><year>2019</year><fpage>1503</fpage><lpage>1527</lpage><pub-id pub-id-type="pmid">31039256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awz099</pub-id><pub-id pub-id-type="pmcid">PMC6536849</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Jo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name></person-group><article-title>The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies</article-title><source>Exp Mol Med</source><volume>52</volume><issue>10</issue><year>2020</year><fpage>1652</fpage><lpage>1662</lpage><pub-id pub-id-type="pmid">33051572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-020-00513-7</pub-id><pub-id pub-id-type="pmcid">PMC8080625</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>Meneses</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koga</surname><given-names>S.</given-names></name><name name-style="western"><surname>O&#8217;Leary</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>N.</given-names></name></person-group><article-title>TDP-43 pathology in Alzheimer&#8217;s disease</article-title><source>Mol Neurodegener</source><volume>16</volume><issue>1</issue><year>2021</year><fpage>84</fpage><pub-id pub-id-type="pmid">34930382</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-021-00503-x</pub-id><pub-id pub-id-type="pmcid">PMC8691026</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Deczkowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>M.</given-names></name></person-group><article-title>Targeting neuro-immune communication in neurodegeneration: challenges and opportunities</article-title><source>J Exp Med</source><volume>215</volume><issue>11</issue><year>2018</year><fpage>2702</fpage><lpage>2704</lpage><pub-id pub-id-type="pmid">30301785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20181737</pub-id><pub-id pub-id-type="pmcid">PMC6219738</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Adamu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>G.</given-names></name></person-group><article-title>The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets</article-title><source>Front Aging Neurosci</source><volume>16</volume><year>2024</year><object-id pub-id-type="publisher-id">1347987</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2024.1347987</pub-id><pub-id pub-id-type="pmcid">PMC11045904</pub-id><pub-id pub-id-type="pmid">38681666</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Valera</surname><given-names>E.</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E.</given-names></name></person-group><article-title>Combination therapies: the next logical step for the treatment of synucleinopathies?</article-title><source>Mov Disord</source><volume>31</volume><issue>2</issue><year>2016</year><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">26388203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.26428</pub-id><pub-id pub-id-type="pmcid">PMC4747680</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ballard</surname><given-names>C.</given-names></name></person-group><article-title>Treatment combinations for Alzheimer&#8217;s disease: current and future pharmacotherapy options</article-title><source>J Alzheimers Dis</source><volume>67</volume><issue>3</issue><year>2019</year><fpage>779</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">30689575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-180766</pub-id><pub-id pub-id-type="pmcid">PMC6398562</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Del Giudice</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Cosgaya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zaro</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Anti-alpha synuclein and anti-tau immunotherapies: can a cocktail approach work?</article-title><source>Parkinsonism Relat Disord</source><volume>122</volume><year>2024</year><object-id pub-id-type="publisher-id">106080</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2024.106080</pub-id><pub-id pub-id-type="pmid">38508903</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Br&#228;uer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deuschle</surname><given-names>C.</given-names></name><etal/></person-group><article-title>High agreement across laboratories between different alpha-synuclein seed amplification protocols</article-title><source>Eur J Neurol</source><volume>32</volume><issue>4</issue><year>2025</year><object-id pub-id-type="publisher-id">e70165</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.70165</pub-id><pub-id pub-id-type="pmcid">PMC12000918</pub-id><pub-id pub-id-type="pmid">40237217</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Fort-Aznar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Molina-Porcel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ramos-Campoy</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Misfolded &#945;-Synuclein in autosomal dominant Alzheimer&#8217;s disease</article-title><source>J Alzheimers Dis</source><volume>97</volume><issue>3</issue><year>2024</year><fpage>1091</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">38250774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-230919</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Gilboa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Swank</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Thakur</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Toward the quantification of &#945;-synuclein aggregates with digital seed amplification assays</article-title><source>Proc Natl Acad Sci USA</source><volume>121</volume><issue>3</issue><year>2024</year><object-id pub-id-type="publisher-id">e2312031121</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2312031121</pub-id><pub-id pub-id-type="pmcid">PMC10801878</pub-id><pub-id pub-id-type="pmid">38194461</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gerasimenko</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Seeding activity of skin misfolded tau as a biomarker for tauopathies</article-title><source>Mol Neurodegener</source><volume>19</volume><issue>1</issue><year>2024</year><fpage>92</fpage><pub-id pub-id-type="pmid">39609917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-024-00781-1</pub-id><pub-id pub-id-type="pmcid">PMC11606191</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Dellarole</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>Vacchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ruiz-Barrio</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Tau seeding activity in skin biopsy differentiates tauopathies from synucleinopathies</article-title><source>NPJ Parkinsons Dis</source><volume>10</volume><issue>1</issue><year>2024</year><fpage>116</fpage><pub-id pub-id-type="pmid">38879633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-024-00728-9</pub-id><pub-id pub-id-type="pmcid">PMC11180195</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-Valbuena</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tartaglia</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>A.E.</given-names></name></person-group><article-title>Copathology in atypical parkinsonism-the rule rather than the exception?</article-title><source>JAMA Neurol</source><year>2025</year><pub-id pub-id-type="doi">10.1001/jamaneurol.2025.1630</pub-id><pub-id pub-id-type="pmid">40489089</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>R.</given-names></name><name name-style="western"><surname>Capotosti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schain</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The &#945;-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases</article-title><source>Nat Commun</source><volume>14</volume><issue>1</issue><year>2023</year><fpage>6750</fpage><pub-id pub-id-type="pmid">37891183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-42305-3</pub-id><pub-id pub-id-type="pmcid">PMC10611796</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Development of an &#945;-synuclein positron emission tomography tracer for imaging synucleinopathies</article-title><source>Cell</source><volume>186</volume><issue>16</issue><year>2023</year><fpage>3350</fpage><lpage>3367.e19</lpage><pub-id pub-id-type="pmid">37421950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.06.004</pub-id><pub-id pub-id-type="pmcid">PMC10527432</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgements</title><p id="p0265">This review was funded in part by the <funding-source id="gs1">Michael J. Fox Foundation for Parkinson&#8217;s Research</funding-source> [MJFF-025618]. The authors especially acknowledge all the patients and their families who participate in research studies. No funders had any role in the paper design, data collection, data analysis, interpretation, or writing of the paper.</p></ack></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin Med J (Engl)</journal-id><journal-id journal-id-type="iso-abbrev">Chin Med J (Engl)</journal-id><journal-id journal-id-type="pmc-domain-id">2337</journal-id><journal-id journal-id-type="pmc-domain">chinesemj</journal-id><journal-id journal-id-type="publisher-id">CM9</journal-id><journal-title-group><journal-title>Chinese Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">0366-6999</issn><issn pub-type="epub">2542-5641</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12487944</article-id><article-id pub-id-type="pmcid-ver">PMC12487944.1</article-id><article-id pub-id-type="pmcaid">12487944</article-id><article-id pub-id-type="pmcaiid">12487944</article-id><article-id pub-id-type="pmid">40879279</article-id><article-id pub-id-type="doi">10.1097/CM9.0000000000003745</article-id><article-id pub-id-type="publisher-id">CMJ-2025-057</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Biomarkers and neuroimaging markers in Parkinson&#8217;s disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Su</surname><given-names initials="D">Dongning</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fna1" ref-type="fn"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zheng</surname><given-names initials="Y">Yuanchu</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fna1" ref-type="fn"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Feng</surname><given-names initials="T">Tao</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp"/></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Gao</surname><given-names initials="T">Ting</given-names></name></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label>Center for Movement Disorders, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China</aff><aff id="aff2"><label><sup>2</sup></label>China National Clinical Research Center for Neurological Diseases, Beijing 100070, China</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Tao Feng, MD, Professor, Center for Movement Disorders, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China E-Mail: <email>bxbkyjs@sina.com</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="ppub"><day>05</day><month>10</month><year>2025</year></pub-date><volume>138</volume><issue>19</issue><issue-id pub-id-type="pmc-issue-id">498114</issue-id><fpage>2365</fpage><lpage>2380</lpage><history><date date-type="received"><day>04</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-released-under-embargo"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-05 00:26:29.067"><day>05</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cm9-138-2365.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cm9-138-2365.pdf"/><abstract><title>Abstract</title><p>Parkinson&#8217;s disease (PD) is the second most common neurodegenerative disorder worldwide, highlighting the urgent need for improved diagnostic and therapeutic strategies. Biomarkers from cerebrospinal fluid (CSF), blood, and peripheral tissue hold promise for early PD detection. In addition, neuroimaging techniques, including magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), and positron emission tomography (PET), allow for detailed visualization of neurodegeneration and associated structural and functional brain changes. This review summarizes recent advances in PD biomarkers and neuroimaging, highlighting their diagnostic potential and implications for future research.</p></abstract><kwd-group><title>Keywords:</title><kwd>Parkinson&#8217;s disease</kwd><kwd>Biomarker</kwd><kwd>Neuroimaging</kwd><kwd>&#945;-synuclein</kwd><kwd>MRI</kwd><kwd>PET</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Parkinson&#8217;s disease (PD) is the second most common neurodegenerative disorder worldwide, affecting millions of individuals. Its prevalence increases sharply with age, making it a major public health concern, particularly in rapidly aging populations.<sup>[<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>]</sup> The clinical diagnosis of PD relies primarily on a detailed patient history and physical examination, with motor symptoms being a necessary criterion for diagnosis.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> However, by the time a patient is diagnosed, PD has often progressed to Braak stage 3,<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> as early symptoms are frequently masked by the body&#8217;s compensatory mechanisms.<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup> Pathology studies from 1991 and 1992 reported an early diagnostic accuracy rate of only 76%,<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> which improved to only 84.2% in 2023.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> This growing burden, coupled with the suboptimal early diagnostic accuracy, underscores the urgent need for improved diagnostic and therapeutic strategies to address this escalating health challenge.</p><p>Biomarkers have emerged as a valuable tool for assisting in the early diagnosis of PD. They include biochemical markers, such as &#945;-synuclein (&#945;-syn) and neurofilament light chain (NfL), genetic markers, and extracellular vesicle (EV) components. Additionally, neuroimaging modalities, including positron emission tomography (PET) and neuromelanin-sensitive magnetic resonance imaging (MRI), play pivotal roles in PD diagnosis by enabling the visualization of neurodegeneration and the detection of structural and functional brain changes. In this review, we discuss recent advances in PD biomarkers and neuroimaging, highlighting their diagnostic potential and future research directions.</p></sec><sec><title>Biomarkers in PD</title><p>Biomarkers of PD can be categorized into cerebrospinal fluid (CSF), blood, peripheral tissue, and cellular biomarkers [Figure <xref rid="F1" ref-type="fig">1</xref>].</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>Biomarkers in PD. &#8593;: Increased; &#8595;: Decreased; =: Equivalent; A&#946;42: Amyloid &#946; peptide 1-42; CSF: Cerebrospinal fluid; GI: Gastrointestinal tract; NfL: Neurofilament light chain; P: Phosphorylation; RBC: Red blood cell; SAAs: &#945;-synuclein seeding amplification assays.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cm9-138-2365-g001.jpg"/></fig><sec><title>CSF biomarkers</title><p>CSF is intimately connected to the central nervous system (CNS), offering a valuable window into the CNS and serving as a widely explored source of PD biomarkers. Key CSF biomarkers for PD include &#945;-syn species, NfL, and microRNAs (miRNAs).</p><p>The abnormal aggregation of &#945;-syn and the spread of pathology among the gut, brainstem, and higher brain regions may be the underlying cause of the development and progression of PD.<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> The &#945;-syn species in CSF have been extensively explored as potential biomarkers for PD, with investigations focusing on both total &#945;-syn and its oligomeric and phosphorylated forms. Wang <italic toggle="yes">et al</italic><sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> reported that the levels of CSF phosphorylated &#945;-syn at Ser129 (pS129) were significantly elevated in PD patients compared with healthy controls, as well as compared with those with multiple system atrophy (MSA) or progressive supranuclear palsy (PSP). Additionally, the pS129/total &#945;-syn ratio was notably greater in PD patients than in controls.<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> Stewart <italic toggle="yes">et al</italic><sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup> using longitudinal data from the DATATOP cohort, demonstrated that both pS129 levels and the pS129/total &#945;-syn ratio increased over two years in early PD patients. These findings suggest that the relationship between pS129 levels and clinical measures of disease severity may vary with PD disease stage. Furthermore, Majbour <italic toggle="yes">et al</italic><sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> confirmed earlier findings that PD patients exhibit reduced total &#945;-syn but elevated &#945;-syn oligomers and pS129 levels in CSF compared with controls. Their study also revealed that combining &#945;-syn oligomers, pS129, and total &#945;-syn significantly improves the differentiation between PD patients and healthy controls or individuals with other neurodegenerative diseases. Despite their potential, CSF &#945;-syn species have shown considerable variability in sensitivity and specificity across different studies, limiting their widespread clinical application.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup> The heterogeneity in the diagnostic performance of CSF &#945;-syn species can be attributed to three key factors. The first is variability in sample collection and processing. CSF sampling protocols and centrifugation conditions critically affect &#945;-syn quantification.<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup> The second is a lack of assay standardization. Platform-dependent discrepancies (enzyme linked immunosorbent assay [ELISA], single-molecule array [Simoa], and mass spectrometry) in the detection of specific &#945;-syn species lead to significant variability.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup> The third is cohort heterogeneity. Early PD patients often show milder CSF &#945;-syn reduction than typical PD patients do, whereas advanced PD patients with Alzheimer&#8217;s copathology may confound &#945;-syn levels via A&#946; or tau protein interactions.<sup>[<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref>]</sup></p><p>Misfolded &#945;-syn in CSF, which has prion-like seeding activity, represents another key target for PD diagnostics. &#945;-syn seeding amplification assays (SAAs) have demonstrated high sensitivity and specificity in differentiating PD patients from healthy controls.<sup>[<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>]</sup> The ability of &#945;-syn to seed and propagate misfolded aggregates is a hallmark of its pathological role in PD, and SAAs capitalize on this property to detect trace amounts of misfolded &#945;-syn. A systematic review reported that the pooled sensitivity and specificity of CSF &#945;-syn SAAs for distinguishing PD patients from healthy or nonneurodegenerative controls were 0.91 and 0.95, respectively, indicating excellent diagnostic accuracy.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> Additionally, Siderowf <italic toggle="yes">et al</italic><sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> demonstrated that CSF &#945;-syn SAAs achieved 87.7% sensitivity and 96.3% specificity in diagnosing PD, further underscoring their potential as effective diagnostic tools for PD and other synucleinopathies. This method has also shown promise in detecting early-stage PD and distinguishing PD subtypes on the basis of the presence of synuclein pathology.</p><p>NfL in CSF has emerged as a particularly important biomarker for differentiating PD from atypical Parkinsonian syndromes. NfL is a structural protein found in myelinated axons, and its CSF levels increase in response to axonal damage.<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> Elevated CSF NfL levels are observed in atypical Parkinsonian syndromes, such as MSA and PSP, which are characterized by more widespread neurodegeneration than PD is.<sup>[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref><xref rid="R23" ref-type="bibr">23</xref><xref rid="R24" ref-type="bibr">24</xref>]</sup> This makes NfL a valuable marker for distinguishing PD from atypical Parkinsonian syndromes.</p><p>Certain CSF miRNAs have shown strong potential as diagnostic biomarkers for PD. Dos Santos <italic toggle="yes">et al</italic><sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> identified a panel comprising Let-7f-5p, miR-27a-3p, miR-125a-5p, miR-151a-3p, and miR-423-5p, which achieved 90% sensitivity and 80% specificity in distinguishing PD patients from healthy controls. The diagnostic accuracy further improved when these miRNA profiles were combined with hallmark PD proteins, such as &#945;-syn, with one panel reaching 97% sensitivity and 90% specificity. These results indicate that miRNAs could serve as promising tools for early PD diagnosis, although their clinical use may be hindered by the complexity of the required analytical techniques.</p><p>Several CSF biomarkers have been investigated for their potential in diagnosing PD; however, their diagnostic efficacy has often been assessed in single studies. Among these proteins, the autophagy-related proteins LC3B and Beclin1 have shown promising diagnostic efficacy. LC3B demonstrated a sensitivity of 96.9% and a specificity of 86.3% in distinguishing early-stage PD patients from healthy controls, whereas Beclin1 showed similar sensitivity (96.9%) but lower specificity (71.4%). Both markers are also associated with the clinical features of PD, such as dopamine transporter (DAT) imaging and motor symptom severity.<sup>[<xref rid="R26" ref-type="bibr">26</xref>]</sup> Additionally, the dopamine metabolite dihydroxyphenylacetic acid (DOPAC) exhibited 100% sensitivity and 89% specificity in differentiating <italic toggle="yes">de novo</italic> PD patients from healthy controls, although it was unable to distinguish PD patients from patients with atypical Parkinsonian syndromes, such as MSA.<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup></p><p>While CSF biomarkers hold promise for PD diagnosis, their clinical utility is constrained by the invasive nature of sample collection and variability in diagnostic accuracy. Meta-analyses indicate that although &#945;-syn species in CSF can distinguish between PD patients and healthy controls, most &#945;-syn-related CSF biomarkers have shown limited diagnostic accuracy and significant heterogeneity across studies, making their reliability suboptimal.<sup>[<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref>]</sup> An exception to this is &#945;-syn SAAs in CSF, as this biomarker not only has strong diagnostic efficacy but also has low heterogeneity across meta-analyses.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup></p></sec><sec><title>Blood biomarkers</title><p>Blood-based biomarkers represent a more accessible and patient-friendly alternative to CSF biomarkers for PD diagnosis. Extensive research has been conducted on plasma, serum, erythrocytes, and plasma- or serum-derived extracellular vesicles (EVs).</p><p>The potential of &#945;-syn species in plasma or serum as reliable biomarkers for PD remains uncertain. Despite numerous studies, findings to date have been highly heterogeneous, making it challenging to draw definitive conclusions.<sup>[<xref rid="R30" ref-type="bibr">30</xref><xref rid="R31" ref-type="bibr">31</xref><xref rid="R32" ref-type="bibr">32</xref><xref rid="R33" ref-type="bibr">33</xref><xref rid="R34" ref-type="bibr">34</xref><xref rid="R35" ref-type="bibr">35</xref><xref rid="R36" ref-type="bibr">36</xref>]</sup> These inconsistencies may be attributed to factors, such as hemolysis, sample size, detection methods, and experimental conditions. Given that more than 99% of peripheral &#945;-syn is derived from erythrocytes, &#945;-syn levels in plasma and serum are particularly vulnerable to interference from red blood cells. However, this also makes erythrocytes a key source for biomarker research. Several studies have reported elevated erythrocytic &#945;-syn species in PD patients, with &#945;-syn oligomers showing particularly strong diagnostic potential.<sup>[<xref rid="R37" ref-type="bibr">37</xref><xref rid="R38" ref-type="bibr">38</xref><xref rid="R39" ref-type="bibr">39</xref>]</sup></p><p>EVs are membrane-bound vesicles secreted by many cell types, and they can cross the blood&#8211;brain barrier, making them a valuable source of CNS-derived biomarkers that can be accessed through the peripheral blood.<sup>[<xref rid="R40" ref-type="bibr">40</xref>,<xref rid="R41" ref-type="bibr">41</xref>]</sup> &#945;-syn in neuron-derived EVs (NDEV-derived &#945;-syn) has shown considerable potential for PD diagnosis. Multiple studies have explored the differences in plasma or serum levels of NDEV-derived &#945;-syn between individuals with PD and healthy controls.<sup>[<xref rid="R42" ref-type="bibr">42</xref>]</sup> A meta-analysis revealed a significantly greater level of total &#945;-syn in the plasma NDEVs of PD patients than in those of healthy controls.<sup>[<xref rid="R42" ref-type="bibr">42</xref>]</sup> The identification of NDEV-associated &#945;-syn in peripheral blood represents an emerging diagnostic strategy for PD. One recent multicenter study highlighted the utility of NDEV-associated &#945;-syn in identifying individuals at risk of developing PD, such as those with isolated rapid eye movement sleep behavior disorder (iRBD) or individuals carrying <italic toggle="yes">GBA1</italic> mutations.<sup>[<xref rid="R43" ref-type="bibr">43</xref>]</sup> This study revealed that NDEV-derived &#945;-syn could differentiate individuals with more than an 80% probability of prodromal PD from controls, with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.90. Moreover, NDEV-derived &#945;-syn was elevated in 80% of patients who later converted to PD or related dementia, suggesting its potential as a screening tool for identifying individuals at high risk of phenoconversion and improving early PD diagnostic strategies.</p><p>A recently developed immunoprecipitation-based real-time quaking-induced conversion (IP/RT-QuIC) assay has significantly advanced blood biomarker diagnostics. Okuzumi <italic toggle="yes">et al</italic><sup>[<xref rid="R44" ref-type="bibr">44</xref>]</sup> reported that this assay could effectively detect pathogenic &#945;-syn seeds in serum, offering a promising diagnostic tool for distinguishing PD patients from healthy controls. The IP/RT-QuIC assay achieved an AUC of 0.96 in differentiating PD patients from controls, with external validation confirming its high sensitivity and specificity.</p><p>In addition to &#945;-syn, blood miRNAs represent another potentially valuable category of biomarkers for PD.<sup>[<xref rid="R45" ref-type="bibr">45</xref>]</sup> MiRNAs are small noncoding RNAs that regulate gene expression and influence metabolic pathways. They serve as modulators and potential biomarkers for a range of diseases, including &#945;-synucleinopathies.<sup>[<xref rid="R46" ref-type="bibr">46</xref>]</sup> Alterations in specific miRNA profiles have been linked to PD pathology, as these miRNAs play roles in neuroinflammation, autophagy, and synaptic function. Most studies employ real-time quantitative polymerase chain reaction (RT-qPCR) methods to detect panels of multiple miRNAs for diagnostic purposes.<sup>[<xref rid="R47" ref-type="bibr">47</xref>,<xref rid="R48" ref-type="bibr">48</xref>]</sup> One study employed machine learning (ML) methods to identify a panel of biomarkers for diagnosing PD, including miR-10b-5p, miR-22-3p, miR-151a-3p, and &#945;-syn. This panel of biomarkers demonstrated excellent diagnostic performance, achieving a sensitivity of 97% and a specificity of 90%. Specifically, the role of ML in integrating multiomics data (e.g., CSF proteomics, imaging, and genetic risk scores) to identify combinatorial biomarkers (e.g., &#945;-syn + GCase activity + miR-30c) with superior diagnostic accuracy (AUC 0.92 <italic toggle="yes">vs</italic>. 0.78 for single markers) must be highlighted.<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> Compared with traditional RT-qPCR methods for detecting miRNAs, a multicenter cross-sectional study employed nanocage molecular beacon-based detection of circulating miRNA-44438-containing EVs in plasma.<sup>[<xref rid="R49" ref-type="bibr">49</xref>]</sup> The results demonstrated high diagnostic efficacy, highlighting the potential of plasma miRNA-44438-containing EVs as biomarkers for early detection and disease monitoring in PD patients. However, this nanocage molecular beacon probe detection method still requires further validation.</p><p>Blood NfL levels are strongly correlated with CSF NfL concentrations. Postmortem studies of human brains have revealed that axonal degeneration is a prominent characteristic in the early stages of PD and that NfL may play a role in the formation of Lewy bodies.<sup>[<xref rid="R50" ref-type="bibr">50</xref>]</sup> Similar to changes observed in the CSF, blood NfL levels are elevated in patients with atypical Parkinsonian syndromes but are comparatively lower in those with typical PD, underscoring its utility in distinguishing PD from atypical Parkinsonian syndromes.<sup>[<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R51" ref-type="bibr">51</xref>,<xref rid="R52" ref-type="bibr">52</xref>]</sup> Additionally, blood NfL levels correlate with disease progression, suggesting their potential use in monitoring the course of PD.<sup>[<xref rid="R52" ref-type="bibr">52</xref>]</sup> Other blood biomarkers under investigation include tau proteins, amyloid-beta, glycoprotein non-metastatic melanoma protein B, DJ-1, and apoA-I, although their diagnostic utility for PD remains to be fully validated.<sup>[<xref rid="R53" ref-type="bibr">53</xref><xref rid="R54" ref-type="bibr">54</xref><xref rid="R55" ref-type="bibr">55</xref><xref rid="R56" ref-type="bibr">56</xref><xref rid="R57" ref-type="bibr">57</xref>]</sup></p></sec><sec><title>Peripheral tissue and cellular biomarkers</title><p>Postmortem studies have revealed abnormal &#945;-syn aggregates in both the brain and peripheral tissues of PD patients, prompting investigations into abnormal &#945;-syn deposits in <italic toggle="yes">in vivo</italic> peripheral tissue samples.<sup>[<xref rid="R58" ref-type="bibr">58</xref>]</sup> Previous research has explored the potential of detecting &#945;-syn deposits in tissues, such as the gastrointestinal tract, skin, salivary glands, and olfactory and oral mucosa as biomarkers for PD.<sup>[<xref rid="R59" ref-type="bibr">59</xref>,<xref rid="R60" ref-type="bibr">60</xref>]</sup></p><p>The salivary glands, gastrointestinal tract, and skin, which are accessible via minimally invasive biopsies, have been frequently studied. However, their diagnostic performance has been inconsistent. Anti-phosphorylated &#945;-syn antibodies consistently demonstrate higher specificity than anti-native &#945;-syn antibodies do, with skin biopsy using anti-phosphorylated &#945;-syn achieving the highest diagnostic accuracy.<sup>[<xref rid="R61" ref-type="bibr">61</xref>,<xref rid="R62" ref-type="bibr">62</xref>]</sup> A recent large-scale multicenter study demonstrated that phosphorylated &#945;-syn detection in skin biopsies is a promising diagnostic marker for synucleinopathies, with 92.7% sensitivity in PD patients and only 3.3% positivity in nonsynucleinopathy controls, indicating high sensitivity and specificity.<sup>[<xref rid="R62" ref-type="bibr">62</xref>]</sup> Compared with immunohistochemistry, SAAs have been increasingly applied to peripheral tissues, such as the salivary glands,<sup>[<xref rid="R63" ref-type="bibr">63</xref>,<xref rid="R64" ref-type="bibr">64</xref>]</sup> gastrointestinal tract,<sup>[<xref rid="R65" ref-type="bibr">65</xref>,<xref rid="R66" ref-type="bibr">66</xref>]</sup> and skin<sup>[<xref rid="R67" ref-type="bibr">67</xref><xref rid="R68" ref-type="bibr">68</xref><xref rid="R69" ref-type="bibr">69</xref><xref rid="R70" ref-type="bibr">70</xref><xref rid="R71" ref-type="bibr">71</xref><xref rid="R72" ref-type="bibr">72</xref>]</sup> in recent years. Skin &#945;-syn SAAs demonstrated a pooled sensitivity of 0.91 and a pooled specificity of 0.92. In contrast, gastrointestinal tract &#945;-syn SAAs showed lower diagnostic performance, with a pooled sensitivity of 0.44 and a pooled specificity of 0.92.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> For submandibular gland samples, the pooled sensitivity and specificity were 0.80 and 0.87, respectively.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup></p><p>Several studies have also investigated &#945;-syn SAAs in noninvasive peripheral cellular samples, such as those from the olfactory and oral mucosa, as potential biomarkers for PD. Olfactory mucosa &#945;-syn SAA demonstrated a sensitivity ranging from 46% to 69% and a specificity ranging from 90% to 91%,<sup>[<xref rid="R73" ref-type="bibr">73</xref><xref rid="R74" ref-type="bibr">74</xref><xref rid="R75" ref-type="bibr">75</xref><xref rid="R76" ref-type="bibr">76</xref><xref rid="R77" ref-type="bibr">77</xref>]</sup> whereas oral mucosa cells showed 67.3% sensitivity and 90% specificity.<sup>[<xref rid="R78" ref-type="bibr">78</xref>]</sup> Although these methods have lower sensitivity than skin and submandibular gland samples do, their high specificity makes them valuable adjuncts for clinical diagnosis. Importantly, their noninvasive nature offers a more convenient and patient-accepted option for diagnostic testing.</p><p>While peripheral tissue and cellular biomarkers hold promise, their diagnostic accuracy varies depending on both the tissue type and detection method. This highlights the need for further optimization and standardization across different peripheral tissues to ensure reliable PD diagnosis.</p><p>The current landscape of diagnostic biomarkers for PD has advanced significantly, yet challenges remain regarding diagnostic consistency and accessibility. Many biomarkers have shown potential for the early diagnosis of PD, but variability in sensitivity and specificity across studies limits their widespread clinical utility. The invasive nature of CSF collection also poses a barrier to its routine use. Blood-based biomarkers, including &#945;-syn species in NDEVs, NfL, and miRNAs, provide a more accessible alternative, although issues, such as hemolysis-related contamination, particularly, have contributed to inconsistencies in diagnostic accuracy. Similarly, while peripheral tissue and cellular samples have shown potential, their diagnostic performance remains inconsistent, necessitating further refinement of these methods.</p><p>Heterogeneity in PD biomarker studies arises from three interrelated factors: variability in sample collection timepoints, divergent patient inclusion criteria, and methodological discrepancies in assay protocols. First, biomarker levels (e.g., &#945;-syn) fluctuate dynamically across disease stages and may critically influence sensitivity and specificity. Second, inconsistent definitions of disease severity and comorbidity exclusion (e.g., cognitive impairment) introduce biological heterogeneity across study cohorts. Third, the lack of standardization in sample collection and analysis contributes to variability in results across studies. Therefore, further validation is needed to ensure reproducibility and diagnostic accuracy across different laboratories and patient populations.</p><p>A critical issue in PD biomarker research is the lack of standardization in sample collection and analysis, leading to variability in results across studies. For example, the &#945;-syn SAA has demonstrated strong diagnostic potential, but further validation is needed to ensure reproducibility across different laboratories and patient populations. Similarly, standardizing protocols for blood-based biomarkers could mitigate factors affecting their accuracy, such as hemolysis and variability in detection techniques. Addressing these methodological inconsistencies will be essential for their successful clinical implementation.</p><p>Future research should prioritize the development of noninvasive or minimally invasive diagnostic methods that can be easily integrated into clinical practice. Blood-based biomarkers and noninvasive peripheral samples hold great potential, but their diagnostic efficacy must be validated in large, multicenter studies with diverse patient populations. Combining multiple biomarkers, such as &#945;-syn, NfL, and miRNA panels, may increase diagnostic accuracy and improve differentiation between PD and other neurodegenerative disorders. Furthermore, the utility of these biomarkers in monitoring disease progression and response to treatment should be explored. Ultimately, the goal is to develop a reliable, accessible, and cost-effective biomarker panel that enables earlier diagnosis and personalized treatment strategies for PD.</p></sec></sec><sec><title>Neuroimaging Markers in PD</title><p>The latest advances in brain imaging provide valuable insights for diagnosing, monitoring progression, and predicting the prognosis of PD patients within both clinical and research settings. Neuroimaging tools, such as MRI, PET, and single-photon emission computed tomography (SPECT) enhance our understanding of PD-related pathologies by revealing the underlying pathological processes during the course of the&#160;disease.</p><sec><title>MRI</title><p>PD is caused primarily by pathological changes in the substantia nigra. Certain sequences that target the substantia nigra via 3.0 Tesla (T) MRI have been developed, making it possible for researchers to observe changes in both the substantia nigra and the nigrosome.<sup>[<xref rid="R79" ref-type="bibr">79</xref>]</sup> Ultrahigh-field-strength MRI technologies, such as 7.0 T MRI, enable in-depth visualization of the nigrosome,<sup>[<xref rid="R80" ref-type="bibr">80</xref>]</sup> revealing lesions in the substantia nigra.<sup>[<xref rid="R81" ref-type="bibr">81</xref>]</sup> Furthermore, PD patients exhibit distinct MRI characteristics in the globus pallidus, putamen, locus coeruleus, and red nucleus, aiding in diagnosis and differential diagnosis [Table <xref rid="T1" ref-type="table">1</xref>].</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Current MRl biomarkers for PD.</p></caption><table frame="hsides" rules="groups" border="0"><thead><tr><th align="left" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Image&#160;modality</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">&#160;Field&#160;strength</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Sequence</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Region</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Imaging&#160;marker</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Sample</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Differentiation</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="10" align="left" valign="top" colspan="1">Susceptibility-sensitive MRI sequence</td><td align="center" valign="top" rowspan="1" colspan="1">3T</td><td align="center" valign="top" rowspan="1" colspan="1">SWI</td><td align="center" valign="top" rowspan="1" colspan="1">Substantia&#160;nigra</td><td align="center" valign="top" rowspan="1" colspan="1">Swallow&#160;tail&#160;sign</td><td align="center" valign="top" rowspan="1" colspan="1">60&#160;Early&#160;PD<break/>12&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD&#160;<italic toggle="yes">vs</italic>.&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">Meijer <italic toggle="yes">et al</italic><sup>[<xref rid="R148" ref-type="bibr">148</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3T</td><td align="center" valign="top" rowspan="1" colspan="1">SWI</td><td align="center" valign="top" rowspan="1" colspan="1">Putamen</td><td align="center" valign="top" rowspan="1" colspan="1"> Signal&#160;intensity</td><td align="center" valign="top" rowspan="1" colspan="1">39&#160;MSA;<break/>18&#160;PD;<break/>31&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD&#160;<italic toggle="yes">vs</italic>.&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">Wang <italic toggle="yes">et al</italic><sup>[<xref rid="R84" ref-type="bibr">84</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3T</td><td align="center" valign="top" rowspan="1" colspan="1">SMwI</td><td align="center" valign="top" rowspan="1" colspan="1">Substantia&#160;nigra</td><td align="center" valign="top" rowspan="1" colspan="1">Swallow&#160;tail&#160;sign</td><td align="center" valign="top" rowspan="1" colspan="1">128 PD;<break/>15&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD&#160;<italic toggle="yes">vs</italic>.&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">Sung <italic toggle="yes">et al</italic><sup>[<xref rid="R149" ref-type="bibr">149</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3T</td><td align="center" valign="top" rowspan="1" colspan="1">QSM</td><td align="center" valign="top" rowspan="1" colspan="1">Nigrosome-1</td><td align="center" valign="top" rowspan="1" colspan="1">Iron&#160;deposition</td><td align="center" valign="top" rowspan="1" colspan="1">87&#160;PD;<break/>77&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD&#160;<italic toggle="yes">vs</italic>.&#160;HC;<break/>Early&#160;PD&#160;<italic toggle="yes">vs</italic>.&#160;Advanced&#160;PD</td><td align="center" valign="top" rowspan="1" colspan="1">Cheng <italic toggle="yes">et al</italic><sup>[<xref rid="R82" ref-type="bibr">82</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3T</td><td align="center" valign="top" rowspan="1" colspan="1">T2*&#160;WI</td><td align="center" valign="top" rowspan="1" colspan="1">Globus&#160;pallidus</td><td align="center" valign="top" rowspan="1" colspan="1">Iron&#160;deposition</td><td align="center" valign="top" rowspan="1" colspan="1">12&#160;PD;<break/>13&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">Early&#160;PD&#160;<italic toggle="yes">vs</italic>.&#160;Advanced&#160;PD</td><td align="center" valign="top" rowspan="1" colspan="1">Ye <italic toggle="yes">et al</italic><sup>[<xref rid="R150" ref-type="bibr">150</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3T</td><td align="center" valign="top" rowspan="1" colspan="1">GRE</td><td align="center" valign="top" rowspan="1" colspan="1">Dentate&#160;nucleus</td><td align="center" valign="top" rowspan="1" colspan="1">Iron&#160;deposition</td><td align="center" valign="top" rowspan="1" colspan="1">19&#160;TD;<break/>24 AR;<break/>48&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">AR&#160;<italic toggle="yes">vs</italic>.&#160;TD</td><td align="center" valign="top" rowspan="1" colspan="1">He <italic toggle="yes">et al</italic><sup>[<xref rid="R89" ref-type="bibr">89</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">7T</td><td align="center" valign="top" rowspan="1" colspan="1">T2*&#160;WI</td><td align="center" valign="top" rowspan="1" colspan="1">SNpc</td><td align="center" valign="top" rowspan="1" colspan="1">Nigrosome&#160;1</td><td align="center" valign="top" rowspan="1" colspan="1">10&#160;PD;<break/>8&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD&#160;<italic toggle="yes">vs</italic>.&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">Blazejewska <italic toggle="yes">et al</italic><sup>[<xref rid="R151" ref-type="bibr">151</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">7T</td><td align="center" valign="top" rowspan="1" colspan="1">T2*&#160;WI</td><td align="center" valign="top" rowspan="1" colspan="1">SNpc</td><td align="center" valign="top" rowspan="1" colspan="1">Nigrosomes&#160;1&#8211;5</td><td align="center" valign="top" rowspan="1" colspan="1">26&#160;PD;<break/>15&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">Early&#160;PD&#160;<italic toggle="yes">vs</italic>.&#160;Advanced&#160;PD</td><td align="center" valign="top" rowspan="1" colspan="1">Schwarz <italic toggle="yes">et al</italic><sup>[<xref rid="R87" ref-type="bibr">87</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">7T</td><td align="center" valign="top" rowspan="1" colspan="1">R2*&#160;map/QSM</td><td align="center" valign="top" rowspan="1" colspan="1">Oculomotor&#160;nerve;<break/>Red&#160;nucleus</td><td align="center" valign="top" rowspan="1" colspan="1">R2*&#160;value;<break/>QSM&#160;value</td><td align="center" valign="top" rowspan="1" colspan="1">5&#160;PD;<break/>5&#160;PSP;<break/>5HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD&#160;<italic toggle="yes">vs</italic>.&#160;PSP</td><td align="center" valign="top" rowspan="1" colspan="1">Lee <italic toggle="yes">et al</italic><sup>[<xref rid="R152" ref-type="bibr">152</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">7T</td><td align="center" valign="top" rowspan="1" colspan="1">QSM</td><td align="center" valign="top" rowspan="1" colspan="1">Gray&#160;matter&#160;nucleus</td><td align="center" valign="top" rowspan="1" colspan="1">QSM&#160;value</td><td align="center" valign="top" rowspan="1" colspan="1">9&#160;MSA-P;<break/>13&#160;MSA-C;<break/>16&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">MSA-P&#160;<italic toggle="yes">vs</italic>.&#160;MSA-C</td><td align="center" valign="top" rowspan="1" colspan="1">Lancione <italic toggle="yes">et al</italic><sup>[<xref rid="R153" ref-type="bibr">153</xref>]</sup></td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">Neuromelanin-sensitive Sequencing</td><td align="center" valign="top" rowspan="1" colspan="1">3T</td><td align="center" valign="top" rowspan="1" colspan="1">T1*WI</td><td align="center" valign="top" rowspan="1" colspan="1">Substantia&#160;nigra</td><td align="center" valign="top" rowspan="1" colspan="1">Substantia&#160;nigra&#160;volume</td><td align="center" valign="top" rowspan="1" colspan="1">29&#160;Early&#160;PD;<break/>31 Advanced&#160;PD;<break/>20&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD&#160;<italic toggle="yes">vs</italic>.&#160;HC;<break/>Early&#160;PD&#160;<italic toggle="yes">vs</italic>.&#160;Advanced&#160;PD</td><td align="center" valign="top" rowspan="1" colspan="1">Vitali <italic toggle="yes">et al</italic><sup>[<xref rid="R92" ref-type="bibr">92</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3T</td><td align="center" valign="top" rowspan="1" colspan="1">T1*WI</td><td align="center" valign="top" rowspan="1" colspan="1">Locus coeruleus</td><td align="center" valign="top" rowspan="1" colspan="1">Signal intensity</td><td align="center" valign="top" rowspan="1" colspan="1">21 iRBD;<break/>21 HC</td><td align="center" valign="top" rowspan="1" colspan="1">iRBD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Ehrminger <italic toggle="yes">et al</italic><sup>[<xref rid="R94" ref-type="bibr">94</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">7T</td><td align="center" valign="top" rowspan="1" colspan="1">GRE</td><td align="center" valign="top" rowspan="1" colspan="1">Substantia nigra</td><td align="center" valign="top" rowspan="1" colspan="1">SNpc volume;<break/>average contrast ratio;<break/>asymmetry index</td><td align="center" valign="top" rowspan="1" colspan="1">21 PD;<break/>13 ET;<break/>18 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. ET;<break/>PD <italic toggle="yes">vs</italic>. HC;<break/>AR <italic toggle="yes">vs</italic>. TD</td><td align="center" valign="top" rowspan="1" colspan="1">Lakhani <italic toggle="yes">et al</italic><sup>[<xref rid="R154" ref-type="bibr">154</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">7T</td><td align="center" valign="top" rowspan="1" colspan="1">MT-TFL</td><td align="center" valign="top" rowspan="1" colspan="1">Locus coeruleus</td><td align="center" valign="top" rowspan="1" colspan="1">Signal intensity</td><td align="center" valign="top" rowspan="1" colspan="1">78 PD;<break/>36 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Wolters <italic toggle="yes">et al</italic><sup>[<xref rid="R155" ref-type="bibr">155</xref>]</sup></td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Diffusion tensor imaging</td><td align="center" valign="top" rowspan="1" colspan="1">3T</td><td align="center" valign="top" rowspan="1" colspan="1">DTI</td><td align="center" valign="top" rowspan="1" colspan="1">Substantia nigra</td><td align="center" valign="top" rowspan="1" colspan="1">Free water</td><td align="center" valign="top" rowspan="1" colspan="1">34 iRBD;<break/>38 PD;<break/>32 HC</td><td align="center" valign="top" rowspan="1" colspan="1">iRBD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Zhou <italic toggle="yes">et al</italic><sup>[<xref rid="R156" ref-type="bibr">156</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3T</td><td align="center" valign="top" rowspan="1" colspan="1">DTI</td><td align="center" valign="top" rowspan="1" colspan="1">Basal ganglia;<break/>Midbrain;<break/>Cerebellum</td><td align="center" valign="top" rowspan="1" colspan="1">Free water</td><td align="center" valign="top" rowspan="1" colspan="1">511 PD;<break/>84 MSA;<break/>129 PSP</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. AP;<break/>MSA <italic toggle="yes">vs</italic>. PSP</td><td align="center" valign="top" rowspan="1" colspan="1">Archer <italic toggle="yes">et al</italic><sup>[<xref rid="R157" ref-type="bibr">157</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3T</td><td align="center" valign="top" rowspan="1" colspan="1">DTI</td><td align="center" valign="top" rowspan="1" colspan="1">Putamen/caudate complex</td><td align="center" valign="top" rowspan="1" colspan="1">Fractional anisotropy</td><td align="center" valign="top" rowspan="1" colspan="1">12 PD;<break/>8 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Yoshikawa <italic toggle="yes">et al</italic><sup>[<xref rid="R97" ref-type="bibr">97</xref>]</sup></td></tr><tr><td rowspan="4" align="left" valign="top" style="border-bottom:solid;" colspan="1">Glymphatic imaging</td><td align="center" valign="top" rowspan="1" colspan="1">3T</td><td align="center" valign="top" rowspan="1" colspan="1">DCE-MRI</td><td align="center" valign="top" rowspan="1" colspan="1">Cervical lymph node;<break/>Mlvs</td><td align="center" valign="top" rowspan="1" colspan="1">Blood flow and perfusion</td><td align="center" valign="top" rowspan="1" colspan="1">375 PD;<break/>152 MSA;<break/>136 PSP;<break/>8 DLB;<break/>19 VP;<break/>371 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD&#160;<italic toggle="yes">vs</italic>.&#160;AP</td><td align="center" valign="top" rowspan="1" colspan="1">Ding <italic toggle="yes">et al</italic><sup>[<xref rid="R98" ref-type="bibr">98</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3T</td><td align="center" valign="top" rowspan="1" colspan="1">DTI</td><td align="center" valign="top" rowspan="1" colspan="1">PVS</td><td align="center" valign="top" rowspan="1" colspan="1">DTI-ALPS index</td><td align="center" valign="top" rowspan="1" colspan="1">181 PD/ET</td><td align="center" valign="top" rowspan="1" colspan="1">PD&#160;<italic toggle="yes">vs</italic>.&#160;ET</td><td align="center" valign="top" rowspan="1" colspan="1">McKnight <italic toggle="yes">et al</italic><sup>[<xref rid="R99" ref-type="bibr">99</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3T</td><td align="center" valign="top" rowspan="1" colspan="1">DTI</td><td align="center" valign="top" rowspan="1" colspan="1">PVS</td><td align="center" valign="top" rowspan="1" colspan="1">DTI-ALPS index</td><td align="center" valign="top" rowspan="1" colspan="1">20 iRBD;<break/>20 PD;<break/>20 HC</td><td align="center" valign="top" rowspan="1" colspan="1">iRBD&#160;<italic toggle="yes">vs</italic>.&#160;HC</td><td align="center" valign="top" rowspan="1" colspan="1">Bae <italic toggle="yes">et al</italic><sup>[<xref rid="R158" ref-type="bibr">158</xref>]</sup></td></tr><tr><td align="center" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">7T</td><td align="center" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">DTI</td><td align="center" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">PVS</td><td align="center" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">DTI-ALPS index;<break/>PVS burden</td><td align="center" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">76 PD;<break/>48 HC</td><td align="center" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">PD&#160;<italic toggle="yes">vs</italic>.&#160;HC</td><td align="center" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">Shen <italic toggle="yes">et al</italic><sup>[<xref rid="R159" ref-type="bibr">159</xref>]</sup></td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>3T: 3 Tesla; 7T: 7 Tesla; AP: Atypical Parkinsonian; AR: Akinetic-rigid subtype of PD; DCE-MRI: Dynamic contrast-enhanced magnetic resonance imagingl; DLB: Dementia with Lewy bodies; DTI: Diffusion tensor imaging; DTI-ALPS: DTI analysis along the peripheral space; ET: Essential tremor; GRE: Gradient recalled echo; HC: Healthy controls; iRBD: Isolated REM sleep behavior disorder; mLVs: Meningeal lymphatic vessels; MSA: Multiple system atrophy; MSA-C: MSA-cerebellar type; MSA-P: MSA-Parkinsonian type; MT-TFL: Magnetization transfer turbo fast low-angle shot; PD: Parkinson&#8217;s disease; PVS: Perivascular space; PSP: Progressive supranuclear palsy; QSM: Quantitative susceptibility mapping; REM: Rapid eye movement stage; SMwI: Susceptibility map-weighted imaging; SNpc: Substantia nigra pars compacta; SWI: Susceptibility-weighted imaging; T1*WI: T1*-Weighted images; T2*WI: T2*-Weighted images; TD: Tremor dominant subtype of PD; VP: Vascular Parkinsonism.</p></fn></table-wrap-foot></table-wrap><sec><title>Susceptibility-sensitive MRI sequencing</title><p>A key pathological characteristic of PD is iron deposition in the substantia nigra, which disrupts cellular autophagy and leads to increased levels of &#945;-syn in the substantia nigra, serving as a potential biomarker for PD. Iron binds to ferritin to form a diamagnetic material that appears as a low signal on T2*-weighted images (T2*WIs) and susceptibility-weighted imaging (SWI).<sup>[<xref rid="R82" ref-type="bibr">82</xref>,<xref rid="R83" ref-type="bibr">83</xref>]</sup> Iron deposition in the substantia nigra is unevenly distributed, with lower levels in the substantia nigra pars compacta (SNpc) and higher levels in the reticular portion and matrix area. On susceptibility-sensitive sequences, this distribution creates a high signal for the iron-poor pars compacta, which contrasts with the low signal in the surrounding matrix&#8212;an appearance known as the &#8220;swallow tail sign&#8221;. In PD and various Parkinson-plus syndromes, degenerative changes in the pars compacta lead to increased iron deposition, resulting in the disappearance of this sign.<sup>[<xref rid="R79" ref-type="bibr">79</xref>]</sup></p><p>According to a 2020 meta-analysis of 19 studies using 3.0 T MRI, the sensitivity and specificity for distinguishing PD patients from healthy controls on the basis of the disappearance of the &#8220;swallow tail sign&#8221; were 94% and 90%, respectively, with 0&#8211;33% of healthy individuals also showing this sign.<sup>[<xref rid="R81" ref-type="bibr">81</xref>]</sup> With an AUC of only 0.56 to 0.68, the diagnostic accuracy of the &#8220;swallow tail sign&#8221; in distinguishing PD from Parkinson-plus syndromes on 3.0 T MRI was relatively low. To improve diagnostic accuracy, researchers suggest that combining the &#8220;swallow tail sign&#8221; with low signal intensity in the putamen could increase the AUC to 0.93.<sup>[<xref rid="R84" ref-type="bibr">84</xref>]</sup></p><p>Ultrahigh-field MRI is a magnetic resonance technology with a&#160;field strength of 7 T or higher. The advancement of 7 T MRI offers a higher signal&#8211;to&#8211;noise ratio (SNR), enabling images with exceptional anatomical details.<sup>[<xref rid="R85" ref-type="bibr">85</xref>]</sup> Kwon <italic toggle="yes">et al</italic><sup>[<xref rid="R86" ref-type="bibr">86</xref>]</sup> first reported hyperintensity in the dorsal lateral substantia nigra on 7 T T2*WIs. Subsequent pathological studies confirmed that the hyperintensity in the dorsal lateral substantia nigra in healthy individuals was the nigrosome.<sup>[<xref rid="R86" ref-type="bibr">86</xref>]</sup> A meta-analysis, including five 7 T MRI studies reported that the disappearance of this hyperintensity distinguished PD patients from healthy controls, with a sensitivity and specificity of 99% and 92%, respectively.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> Additionally, high-resolution 7 T T2*WI can identify all five substantia nigra bodies,<sup>[<xref rid="R87" ref-type="bibr">87</xref>]</sup> visualize the 3D structure of the substantia nigra, and quantify differences in its shape and boundaries between PD patients and healthy controls. Notably, previous studies have shown that the normally smooth and well-defined arch boundaries between the substantia nigra and the cerebral peduncle become irregular and less distinct in PD patients.<sup>[<xref rid="R88" ref-type="bibr">88</xref>]</sup></p><p>In addition to the substantia nigra, iron is also plentiful in the dentate nucleus. For tremor-dominant PD patients, increased iron deposition in the dentate nucleus is correlated with the severity of tremor, making the structure a potential marker for this PD subtype.<sup>[<xref rid="R89" ref-type="bibr">89</xref>]</sup></p></sec><sec><title>Neuromelanin-sensitive sequencing</title><p>The paramagnetic properties of the neuromelanin-iron complex shorten T1 relaxation times and enhance magnetization transfer (MT) effects, allowing neuromelanin-sensitive imaging on T1-weighted fast spin echo sequences. These sequences reveal high signals in neuromelanin-rich dopaminergic neurons in the substantia nigra of the midbrain.<sup>[<xref rid="R90" ref-type="bibr">90</xref>]</sup> Compared with healthy controls, PD patients show a reduction in neuromelanin-rich neurons, leading to decreased signal intensity and shrinkage of the substantia nigra. A 2019 meta-analysis reported that neuromelanin-sensitive MRI differentiates PD patients from healthy controls with 82% sensitivity and 82% specificity, with substantia nigra volume measurements further improving diagnostic accuracy.<sup>[<xref rid="R91" ref-type="bibr">91</xref>,<xref rid="R92" ref-type="bibr">92</xref>]</sup> Longitudinal studies have revealed a progressive reduction in the substantia nigra volume in PD patients, beginning in the posterolateral region and gradually affecting the medial areas. This pattern aids in distinguishing early-stage PD from advanced-stage PD and differentiating PD patients from healthy controls.<sup>[<xref rid="R92" ref-type="bibr">92</xref>,<xref rid="R93" ref-type="bibr">93</xref>]</sup></p><p>While nigrosome imaging is sensitive to changes in early-stage PD, its utility may diminish after initial neurodegeneration.<sup>[<xref rid="R87" ref-type="bibr">87</xref>]</sup> Neuromelanin sequences also show potential in identifying the prodromal phase of PD, as they have demonstrated reduced signal intensity in the locus coeruleus in patients with RBD, with a diagnostic sensitivity and specificity of 82.5% and 81.0%, respectively.<sup>[<xref rid="R94" ref-type="bibr">94</xref>]</sup> These findings suggest a role for neuromelanin imaging in early PD detection, warranting further longitudinal validation.</p><p>Neuromelanin-sensitive MRI sequences offer a promising tool for monitoring PD progression. Studies suggest that the loss of neuromelanin is correlated with disease severity and motor symptoms.<sup>[<xref rid="R95" ref-type="bibr">95</xref>]</sup> Quantifying the loss of neuromelanin using neuromelanin-sensitive MRI has been proposed as a potential biomarker for tracking the progression of dopaminergic cell loss over time. The degree of neuromelanin loss has been shown to be correlated with motor impairment and disease duration.<sup>[<xref rid="R96" ref-type="bibr">96</xref>]</sup></p></sec><sec><title>Diffusion tensor imaging (DTI)</title><p>DTI maps the anisotropic motion of water molecules and can be applied to determine the extent of white matter damage in various diseases. Two main parameters derived from DTI are mean diffusivity and fractional anisotropy. Mean diffusivity represents the average magnitude of molecular displacement by diffusion and is independent of the diffusion direction, whereas fractional anisotropy reflects the directionality of molecular displacement by diffusion and is related to the direction of dispersion. Studies have shown that, compared with those in healthy controls, fractional anisotropy values along a line between the substantia nigra and the lower part of the putamen/caudate complex are significantly lower in PD patients, in which nigrostriatal dopaminergic neurons are concentrated, indicating that the change in fractional anisotropy may be related to the loss of neurons.<sup>[<xref rid="R97" ref-type="bibr">97</xref>]</sup></p></sec><sec><title>Glymphatic imaging</title><p>The glymphatic system plays a crucial role in clearing metabolic waste from the brain, primarily through the perivascular space (PVS), arachnoid granules, and dural venous sinuses. Ding <italic toggle="yes">et al</italic><sup>[<xref rid="R98" ref-type="bibr">98</xref>]</sup> applied dynamic contrast-enhanced MRI and reported that, compared with that in atypical parkinsonism patients, the flow of the superior sagittal sinus and sigmoid sinus through the meningeal lymphatic vessels in PD patients was significantly reduced, and the perfusion of deep cervical lymph nodes was significantly delayed. These findings indicate impaired meningeal lymphatic drainage in PD patients. The DTI analysis along the peripheral space (DTI-ALPS) index is widely used to evaluate glymphatic function and measures the diffusion rate along the PVS. Compared with healthy controls and patients with essential tremors, PD patients had lower DTI-ALPS indices. A lower DTI-ALPS index has been shown to be correlated with more severe disease, poorer cognitive function, greater age, and lower sleep quality in PD patients.<sup>[<xref rid="R99" ref-type="bibr">99</xref>]</sup> A cohort study revealed that the DTI-ALPS index of RBD patients was also lower than that of healthy controls. Importantly, RBD patients with a lower DTI-ALPS index had a greater risk of converting to &#945;-synucleinopathy, suggesting that glymphatic dysfunction may serve as an early biomarker for neurodegeneration in at-risk individuals.<sup>[<xref rid="R100" ref-type="bibr">100</xref>]</sup></p><p>Other MRI techniques can also assist in the diagnosis of PD. For example, 7 T functional magnetic resonance imaging (fMRI) with echo planar imaging (EPI) sequences provides high-resolution, noninvasive identification of subcortical structures. One study utilizing resting-state fMRI (rs-fMRI) with gradient EPI sequences applied single-subject independent component analysis to assess thalamic&#8211;basal ganglia functional connectivity within the sensorimotor network.<sup>[<xref rid="R100" ref-type="bibr">100</xref>]</sup> The results indicated increased connectivity in Huntington&#8217;s disease (HD) patients but reduced connectivity in PD patients, suggesting that these network alterations could serve as imaging biomarkers for differentiating early-stage HD from PD.<sup>[<xref rid="R101" ref-type="bibr">101</xref>]</sup> Additionally, T1-weighted structural sequences can detect volume changes and atrophy patterns in gray matter, subcortical regions, and the basal ganglia. A 7 T T1-weighted study comparing 31 brain regions in patients with essential tremor and PD revealed a significant reduction in parietal lobe volume in PD patients.<sup>[<xref rid="R102" ref-type="bibr">102</xref>]</sup> These findings suggest that structural differences could aid in distinguishing PD from essential tremor.</p></sec></sec><sec><title>Molecular imaging</title><p>SPECT and PET imaging agents significantly enhance the clinical diagnosis of PD by enabling the visualization of cellular functions and molecular processes within living humans [Supplementary Figure 1, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/CM9/C549" ext-link-type="uri">http://links.lww.com/CM9/C549</ext-link> and Table <xref rid="T2" ref-type="table">2</xref>].</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Current molecular imaging biomarkers for PD.</p></caption><table frame="hsides" rules="groups" border="0"><thead><tr><th align="left" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Image modality</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Tracer</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Target</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Sample</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Differentiation</th><th align="center" valign="bottom" style="border-top:solid;border-bottom:solid;" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="4" align="left" valign="top" colspan="1">SPECT</td><td align="center" valign="top" rowspan="1" colspan="1">123I-&#946;-CIT</td><td align="center" valign="top" rowspan="1" colspan="1">Dopamine precursor</td><td align="center" valign="top" rowspan="1" colspan="1">15 MSA-P<break/>15 PD<break/>13 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. MSA-P<break/>HC <italic toggle="yes">vs</italic>. PD<break/>HC <italic toggle="yes">vs</italic>. MSA-P</td><td align="center" valign="top" rowspan="1" colspan="1">Scherfler <italic toggle="yes">et al</italic><sup>[<xref rid="R160" ref-type="bibr">160</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">123I-FP-CIT</td><td align="center" valign="top" rowspan="1" colspan="1">Dopamine precursor</td><td align="center" valign="top" rowspan="1" colspan="1">6 Early PD<break/>12 Advanced PD<break/>6 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC<break/>Early PD <italic toggle="yes">vs</italic>. Advanced PD</td><td align="center" valign="top" rowspan="1" colspan="1">Booij <italic toggle="yes">et al</italic><sup>[<xref rid="R161" ref-type="bibr">161</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">123I-altropane</td><td align="center" valign="top" rowspan="1" colspan="1">Dopamine transporter</td><td align="center" valign="top" rowspan="1" colspan="1">19 PD<break/>10 DLB<break/>17 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC<break/>DLB <italic toggle="yes">vs</italic>. HC<break/>PD <italic toggle="yes">vs</italic>. DLB</td><td align="center" valign="top" rowspan="1" colspan="1">Marquie <italic toggle="yes">et al</italic><sup>[<xref rid="R162" ref-type="bibr">162</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">99mTc-TRODAT-1</td><td align="center" valign="top" rowspan="1" colspan="1">Dopamine precursor</td><td align="center" valign="top" rowspan="1" colspan="1">48 PD<break/>19 PPS<break/>36 ET</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. PPS<break/>PD <italic toggle="yes">vs</italic>. ET</td><td align="center" valign="top" rowspan="1" colspan="1">Sood <italic toggle="yes">et al</italic><sup>[<xref rid="R163" ref-type="bibr">163</xref>]</sup></td></tr><tr><td rowspan="17" align="left" valign="top" colspan="1">PET</td><td align="center" valign="top" rowspan="1" colspan="1">18F-FDOPA</td><td align="center" valign="top" rowspan="1" colspan="1">Dopamine precursor</td><td align="center" valign="top" rowspan="1" colspan="1">9 MSA-P<break/>24 PD<break/>7 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC<break/>MSA-P <italic toggle="yes">vs</italic>. HC<break/>PD <italic toggle="yes">vs</italic>. MSA-P</td><td align="center" valign="top" rowspan="1" colspan="1">Ghaemi <italic toggle="yes">et al</italic><sup>[<xref rid="R164" ref-type="bibr">164</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">11C-RTI 32</td><td align="center" valign="top" rowspan="1" colspan="1">DAT</td><td align="center" valign="top" rowspan="1" colspan="1">11 Early PD<break/>10 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Guttman <italic toggle="yes">et al</italic><sup>[<xref rid="R165" ref-type="bibr">165</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18F-FP-CIT</td><td align="center" valign="top" rowspan="1" colspan="1">DAT</td><td align="center" valign="top" rowspan="1" colspan="1">23 PD<break/>27 MSA-C<break/>12 MSA-P<break/>5 PSP</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. MSA-P<break/>PD <italic toggle="yes">vs</italic>. MSA-C<break/>PD <italic toggle="yes">vs</italic>. PSP</td><td align="center" valign="top" rowspan="1" colspan="1">Jin <italic toggle="yes">et al</italic><sup>[<xref rid="R166" ref-type="bibr">166</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">11C-WIN 35428</td><td align="center" valign="top" rowspan="1" colspan="1">DAT</td><td align="center" valign="top" rowspan="1" colspan="1">6 PD<break/>6 PSP<break/>6 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC<break/>PSP <italic toggle="yes">vs</italic>. HC<break/>PD <italic toggle="yes">vs</italic>. PSP</td><td align="center" valign="top" rowspan="1" colspan="1">Ilgin <italic toggle="yes">et al</italic><sup>[<xref rid="R167" ref-type="bibr">167</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18F-CFT</td><td align="center" valign="top" rowspan="1" colspan="1">DAT</td><td align="center" valign="top" rowspan="1" colspan="1">8 Early PD<break/>7 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Nurmi <italic toggle="yes">et al</italic><sup>[<xref rid="R168" ref-type="bibr">168</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18F-FE-PE2I</td><td align="center" valign="top" rowspan="1" colspan="1">DAT</td><td align="center" valign="top" rowspan="1" colspan="1">9 PD<break/>34 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Delva <italic toggle="yes">et al</italic><sup>[<xref rid="R169" ref-type="bibr">169</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">11C-DTBZ</td><td align="center" valign="top" rowspan="1" colspan="1">VMAT-2</td><td align="center" valign="top" rowspan="1" colspan="1">30 PD<break/>30 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Sanchez-Catasus <italic toggle="yes">et al</italic><sup>[<xref rid="R170" ref-type="bibr">170</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18F-DTBZ</td><td align="center" valign="top" rowspan="1" colspan="1">VMAT-2</td><td align="center" valign="top" rowspan="1" colspan="1">30 Early PD<break/>17 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Lin <italic toggle="yes">et al</italic><sup>[<xref rid="R119" ref-type="bibr">119</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18F-DMFP</td><td align="center" valign="top" rowspan="1" colspan="1">D2</td><td align="center" valign="top" rowspan="1" colspan="1">16 HC<break/>16 PD<break/>19 APS</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. APS<break/>HC <italic toggle="yes">vs</italic>. APS<break/>PD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Schreckenberger <italic toggle="yes">et al</italic><sup>[<xref rid="R171" ref-type="bibr">171</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">11C-raclopride</td><td align="center" valign="top" rowspan="1" colspan="1">D2</td><td align="center" valign="top" rowspan="1" colspan="1">9 MSA<break/>10 PD<break/>10 HC</td><td align="center" valign="top" rowspan="1" colspan="1">MSA <italic toggle="yes">vs</italic>. PD<break/>MSA <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Antonini <italic toggle="yes">et al</italic><sup>[<xref rid="R172" ref-type="bibr">172</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18F-FDG</td><td align="center" valign="top" rowspan="1" colspan="1">GLU</td><td align="center" valign="top" rowspan="1" colspan="1">8 PD<break/>24 MSA-P</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. MSA-P</td><td align="center" valign="top" rowspan="1" colspan="1">Kwon <italic toggle="yes">et al</italic><sup>[<xref rid="R173" ref-type="bibr">173</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18F ACI-12589</td><td align="center" valign="top" rowspan="1" colspan="1">a-syn</td><td align="center" valign="top" rowspan="1" colspan="1">8 HC<break/>8 PD<break/>2 MSA<break/>13 DLB<break/>3 PSP<break/>5 AD<break/>3 Ataxia</td><td align="center" valign="top" rowspan="1" colspan="1">MSA-C <italic toggle="yes">vs</italic>. HC<break/>MSA-C <italic toggle="yes">vs</italic>. MSA-P<break/>MSA-C <italic toggle="yes">vs</italic>. LDB(PD+DLB)<break/>MSA-P <italic toggle="yes">vs</italic>. HC<break/>MSA-P <italic toggle="yes">vs</italic>. LDB(PD+DLB)<break/>MSA <italic toggle="yes">vs</italic>. PSP<break/>MSA <italic toggle="yes">vs</italic>. AD<break/>MSA <italic toggle="yes">vs</italic>. Ataxia</td><td align="center" valign="top" rowspan="1" colspan="1">Smith <italic toggle="yes">et al</italic><sup>[<xref rid="R174" ref-type="bibr">174</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18F-SPAL-T-06</td><td align="center" valign="top" rowspan="1" colspan="1">a-syn</td><td align="center" valign="top" rowspan="1" colspan="1">2 MSA-P<break/>1 MSA-C<break/>1 HC</td><td align="center" valign="top" rowspan="1" colspan="1">MSA-C <italic toggle="yes">vs</italic>. HC<break/>MSA-P <italic toggle="yes">vs</italic>. HC<break/>MSA-C <italic toggle="yes">vs</italic>. MSA-P</td><td align="center" valign="top" rowspan="1" colspan="1">Matsuoka <italic toggle="yes">et al</italic><sup>[<xref rid="R135" ref-type="bibr">135</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18F-AV1451</td><td align="center" valign="top" rowspan="1" colspan="1">Tau</td><td align="center" valign="top" rowspan="1" colspan="1">17 PD<break/>16 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Hansen <italic toggle="yes">et al</italic><sup>[<xref rid="R175" ref-type="bibr">175</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18F-THK5351</td><td align="center" valign="top" rowspan="1" colspan="1">Tau</td><td align="center" valign="top" rowspan="1" colspan="1">6 PD<break/>6 MSA-C<break/>9 MSA-P<break/>13 PSP</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. MSA-P<break/>PD <italic toggle="yes">vs</italic>. MSA-C<break/>PD <italic toggle="yes">vs</italic>. PSP<break/>PSP <italic toggle="yes">vs</italic>. MSA-C<break/>PSP <italic toggle="yes">vs</italic>. MSA-P</td><td align="center" valign="top" rowspan="1" colspan="1">Sch&#246;necker <italic toggle="yes">et al</italic><sup>[<xref rid="R138" ref-type="bibr">138</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18F-APN-1607</td><td align="center" valign="top" rowspan="1" colspan="1">Tau</td><td align="center" valign="top" rowspan="1" colspan="1">20 PSP<break/>7 MSA-P<break/>10 PD<break/>13 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PSP <italic toggle="yes">vs</italic>. MSA-P<break/>PSP <italic toggle="yes">vs</italic>. PD<break/>PSP <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Li <italic toggle="yes">et al</italic><sup>[<xref rid="R139" ref-type="bibr">139</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">11C-DPA714</td><td align="center" valign="top" rowspan="1" colspan="1">TSPO</td><td align="center" valign="top" rowspan="1" colspan="1">24 PD<break/>28 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Lavisse <italic toggle="yes">et al</italic><sup>[<xref rid="R142" ref-type="bibr">142</xref>]</sup></td></tr><tr><td rowspan="4" align="left" valign="top" style="border-bottom:solid;" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">11C-PK11195</td><td align="center" valign="top" rowspan="1" colspan="1">TSPO</td><td align="center" valign="top" rowspan="1" colspan="1">18 PD<break/>11 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Gerhard <italic toggle="yes">et al</italic><sup>[<xref rid="R176" ref-type="bibr">176</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">11C-PBR28</td><td align="center" valign="top" rowspan="1" colspan="1">TSPO</td><td align="center" valign="top" rowspan="1" colspan="1">20 PD<break/>51 HC</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Al-Abdulrasul <italic toggle="yes">et al</italic><sup>[<xref rid="R177" ref-type="bibr">177</xref>]</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">18F-FEPPA</td><td align="center" valign="top" rowspan="1" colspan="1">TSPO</td><td align="center" valign="top" rowspan="1" colspan="1">30 PD(14MAB;16HAB)<break/>22 HC(11MAB;11HAB)</td><td align="center" valign="top" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" rowspan="1" colspan="1">Ghadery <italic toggle="yes">et al</italic><sup>[<xref rid="R178" ref-type="bibr">178</xref>]</sup></td></tr><tr><td align="center" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">11C-BU99008</td><td align="center" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">Imidazoline 2</td><td align="center" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">22 PD<break/>14 HC</td><td align="center" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">PD <italic toggle="yes">vs</italic>. HC</td><td align="center" valign="top" style="border-bottom:solid;" rowspan="1" colspan="1">Wilson <italic toggle="yes">et al</italic><sup>[<xref rid="R146" ref-type="bibr">146</xref>]</sup></td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>11C-DTBZ: 11C-Dihydrotetrabenazine; 11C-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="WIN35428">WIN35428</ext-link>: [11C]2Beta-carbomethoxy-3beta-(4-fluorophenyl)-tropane; 123I-&#946;-CIT: Iodine-123-labeled-2-beta-carboxymethoxy-3-beta-(4-iodophenyl)tropane; 18F-CFT: 2Beta-carbomethoxy-3beta-(4-[18F]fluorophenyl)tropane; 18F-DMFP: 18F-desmethoxyfallypride; 18F-FDOPA: 6-18F-Fluoro-levodopa; 18F-FE-PE2I: 18F-(E)-N-(3-Iodoprop-2-enyl)-2&#946;-carbofluoroethoxy-3&#946;-(4&#8242;methylphenyl)nortropane; 18F-FP-CIT: F-18-Fluorinated-N-3-fluoropropyl-2&#946;-carboxymethoxy-3&#946;-(4-iodophenyl)-nortropane; DLB: Dementia with Lewy bodies; DTBZ: Dihydrotetrabenazine; HC: Healthy controls; MSA: Multiple system atrophy; MSA-C: MSA-Cerebellar type; MSA-P: MSA-Parkinsonian type; PD: Parkinson&#8217;s disease; PET: Positron emission tomography; PSP: Progressive supranuclear palsy; SPECT: Single-photon emission computed tomography.</p></fn></table-wrap-foot></table-wrap><sec><title>Dopamine system</title><p>The primary pathological change in PD is the loss of neurons in the substantia nigra, leading to a deficiency of striatal dopamine. PET and SPECT investigate striatal dopamine terminal function by measuring the distribution concentration of presynaptic dopamine transporters (DATs), the bioactivity of striatal aromatic amino acid decarboxylase (AADC), the presence of vesicular monoamine transporter 2 (VMAT2), and the number and function of dopamine receptors.</p><p>DAT is a presynaptic membrane protein responsible for dopamine reuptake from the synaptic cleft back into neurons, thereby terminating neurotransmission. A reduction in DAT tracer uptake in the striatum usually indicates dopamine neuron loss. PET and SPECT tracers are commonly used for DAT imaging. PET tracers include tropane derivatives, such as 11C-RTI 32, 11C-CFT, and 18F-FP-carbomethoxy-3 beta-(4-iodophenyltropane) (CIT), as well as non-tropane radioligands, including 11C-methylphenidate and 11C-nomifensine. SPECT tropane tracers include 123I-&#946;-CIT, 123I-labeled 2&#946;-carbomethoxy-3&#946;-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT), 123I-altropane, and [Tc-99m]technetium, [2-[[2-[[[3(4-chlorophenyl)-8-methyl-8-azabicyclo [3.2.1]oct-2-yl]methyl](2-mercap-toethyl)amino]ethyl]amino]ethanethiolato(3-)-N2,N2,S2,S2] oxo-[1R-(exo-exo)]-, (mol. wt. 540) (99mTc-TRODAT-1).<sup>[<xref rid="R103" ref-type="bibr">103</xref>,<xref rid="R104" ref-type="bibr">104</xref>]</sup> Compared with healthy controls, PD patients present significantly lower 18F-FP-CIT/123I-FP-CIT uptake in the caudate region, anterior putamen, and posterior putamen.<sup>[<xref rid="R105" ref-type="bibr">105</xref>]</sup> Furthermore, the use of the striatum/occipital cortex, putamen/occipital cortex, and contralateral putamen/caudate ratio in 99mTc-TRODAT-1 uptake demonstrates 100% sensitivity and specificity in distinguishing early-stage PD patients from healthy subjects aged 50&#8211;59 years and 60&#8211;69 years.<sup>[<xref rid="R106" ref-type="bibr">106</xref>]</sup> DAT imaging can be used for the differential diagnosis of PD and essential tremor. The sensitivity and specificity of FP-CIT SPECT for distinguishing clinically diagnosed PD patients from those with essential tremor were 91% and 100%, respectively.<sup>[<xref rid="R107" ref-type="bibr">107</xref>]</sup> However, its utility is more limited in differentiating PD from atypical parkinsonian syndromes. A study utilizing a 3D deep convolutional neural network (CNN) to analyze DAT imaging features demonstrated promising accuracy in the differential diagnosis of parkinsonism. The model achieved a sensitivity of 90.7% and specificity of 88.4% for PD, a sensitivity of 84.1% and a specificity of 97.5% for MSA, and a sensitivity of 78.6% and a specificity of 93.3% for PSP.<sup>[<xref rid="R108" ref-type="bibr">108</xref>]</sup> Additionally, DAT imaging can be used to monitor the progression of PD. A longitudinal study using 123I-CIT DAT imaging reported an 11% annual reduction in striatal DAT uptake from baseline in a PD cohort.<sup>[<xref rid="R109" ref-type="bibr">109</xref>]</sup> There were also follow-up studies demonstrating that the loss of DAT binding in early-to-moderate PD follows a single exponential decline.<sup>[<xref rid="R110" ref-type="bibr">110</xref>]</sup></p><p>6-18F-Fluoro-levodopa (18F-DOPA), an analog of L-DOPA, can be converted to dopamine by AADC in monoaminergic neurons. The update of 18F-DOPA in the basal ganglia reflects AADC bioactivity, which is closely linked to disease progression and weakly inversely correlates with clinical severity in mild-to-moderate PD.<sup>[<xref rid="R111" ref-type="bibr">111</xref>]</sup> Striatal 18F-DOPA uptake levels correlate well with declining substantia nigra cell counts.<sup>[<xref rid="R112" ref-type="bibr">112</xref>]</sup> In PD patients, 18F-DOPA metabolism in the dorsal putamen has been shown to decrease by nearly 50% during the early stages of the disease, whereas the ventral putamen remains relatively unaffected. However, DOPA metabolism in the ventral putamen also decreases as symptoms progress.<sup>[<xref rid="R113" ref-type="bibr">113</xref>]</sup> In addition, PD patients exhibit a significant reduction in the mean uptake of 18F-DOPA in the posterior part of the putamen, whereas patients with PSP show equally severe impairment in the anterior and posterior putamen. A study using 18F-DOPA PET revealed that the influx rate constant kocc and the effective distribution volume ratio (EDVR, its inverse is an indicator of dopamine turnover) in the putamen could effectively differentiate PD patients from healthy controls (sensitivity &gt;97%, specificity 100%).<sup>[<xref rid="R114" ref-type="bibr">114</xref>]</sup> For discriminating PD from atypical parkinsonian syndromes, the highest AUC was found for the caudate nucleus-to-anterior putamen ratio of 18F-DOPA uptake (AUC = 0.824; <italic toggle="yes">P</italic> &lt;0.001).<sup>[<xref rid="R115" ref-type="bibr">115</xref>]</sup> In a study of patients in the early stages of PD, fluorodopa uptake declined more rapidly in the first two years but slowed in the following three years.<sup>[<xref rid="R116" ref-type="bibr">116</xref>]</sup> Similar findings were observed in the Parkinson disease progression markers initiative (PPMI) cohort, where striatal DAT binding declined more sharply in the first year, followed by a slower decline.<sup>[<xref rid="R117" ref-type="bibr">117</xref>]</sup> Taken together, these findings suggest that, in addition to DAT imaging, fluorodopa uptake could be used to monitor presynaptic striatal dopaminergic denervation in individuals with early PD.</p><p>VMAT2 is responsible for packaging monoamines into their appropriate synaptic vesicles and is a valid imaging target for determining PD severity.<sup>[<xref rid="R118" ref-type="bibr">118</xref>]</sup> VMAT2 binding is typically studied with 11C-dihydrotetrabenazine (DTBZ) and 18F-FP-(+)-DTBZ. The specific uptake ratios of the bilateral posterior putamen and contralateral anterior putamen provided 100% sensitivity and specificity in differentiating PD patients from healthy subjects.<sup>[<xref rid="R119" ref-type="bibr">119</xref>]</sup> Compared with older PD patients, younger PD patients have been reported to have a markedly greater loss of putamen DTBZ binding at symptom onset. However, the rate of DTBZ binding loss significantly slows considerably over time in younger patients. It has also been shown that isolated RBD in elderly nonparkinsonian individuals is associated with reduced striatal uptake of DTBZ.<sup>[<xref rid="R120" ref-type="bibr">120</xref>]</sup></p><p>Postsynaptic dopamine receptors comprise two major families: the D1 family (D1 and D5) and the D2 family (D2, D3, and D4). Research on D1 receptors is limited, but some studies suggest that early PD is characterized by abnormal D2 receptor binding, whereas D1 receptor binding remains unaffected.<sup>[<xref rid="R121" ref-type="bibr">121</xref>]</sup> At the onset of PD, there is an increase in the activity of DOPA decarboxylase within the nigrostriatal dopaminergic pathways, leading to an initial upregulation of D2 receptors in the striatum of PD patients. However, this upregulation reverses to downregulation approximately 4.4 years after motor symptom onset. Additionally, patients with PSP and MSA exhibit lower striatal D2 receptor binding than PD patients do, which may aid in differential diagnosis.<sup>[<xref rid="R122" ref-type="bibr">122</xref>]</sup></p></sec><sec><title>Cerebral glucose metabolism and blood flow</title><p>18F-Fluorodeoxyglucose PET (18F-FDG PET) measures intracellular levels of glucose metabolism and has been used to localize and quantify abnormal brain energy metabolism <italic toggle="yes">in vivo</italic>, facilitating early PD diagnosis. The PD-related pattern (PDRP)<sup>[<xref rid="R123" ref-type="bibr">123</xref>]</sup> of cerebral glucose metabolism has been identified and validated in several independent populations.<sup>[<xref rid="R124" ref-type="bibr">124</xref><xref rid="R125" ref-type="bibr">125</xref><xref rid="R126" ref-type="bibr">126</xref><xref rid="R127" ref-type="bibr">127</xref>]</sup> PDRP is characterized by a relative increase in glucose metabolism in the globus pallidum, putamen, thalamus, cerebellum, pons, and sensorimotor cortex, alongside a relative decrease in the lateral frontal and parieto-occipital regions in PD patients compared with healthy controls.<sup>[<xref rid="R123" ref-type="bibr">123</xref>]</sup> The clinical correlates of the PDRP have also been extensively investigated. A prospective study of 15 early-stage PD patients<sup>[<xref rid="R128" ref-type="bibr">128</xref>]</sup> revealed that, as the disease progresses, glucose metabolism is increased in the subthalamic nucleus, in an internal globus pallidus region that is associated with motor functions, as well as in the dorsolateral pons and primary motor cortex. PDRP expression is linearly associated with disease progression and significantly correlated with UPDRS scores. In addition, the sensitivity and specificity of the PDRP for discriminating between PD and non-PD parkinsonism have been reported to be 83% and 94%, 79% and 90% for MSA, and 100% and 94% for PSP, respectively.<sup>[<xref rid="R129" ref-type="bibr">129</xref>]</sup> These studies show that the PDRP can serve as an imaging biomarker for effectively diagnosing PD and distinguishing PD from parkinsonism.</p><p>iRBD is considered a prodromal stage of PD. A serial 18F-FDG PET imaging follow-up study demonstrated that patients with iRBD exhibit progressive abnormalities in brain metabolism over time,<sup>[<xref rid="R130" ref-type="bibr">130</xref>]</sup> suggesting that PDRP expression can be used as an early imaging marker for predicting PD. A large multicenter study confirmed that the PDRP can detect PD in its early stages, even when dopaminergic treatment is initiated.<sup>[<xref rid="R131" ref-type="bibr">131</xref>]</sup> Additionally, the PDRP progresses within 24 months of early PD, making it a valuable marker for tracking early disease progression.<sup>[<xref rid="R128" ref-type="bibr">128</xref>]</sup> However, the PDRP does not correlate with tremor. To address this, Mure <italic toggle="yes">et al</italic><sup>[<xref rid="R132" ref-type="bibr">132</xref>]</sup> proposed the PD tremor-related pattern (PDTP), characterized by increased metabolism in the cerebellum/dentate nucleus and primary motor cortex. PDTP expression scores are significantly correlated with clinical tremor scores but not with bradykinesia/rigidity scores. Despite limited research on the PDTP, its potential for accurately diagnosing PD in patients with predominant tremor symptoms has emerged. Furthermore, network studies have revealed a PD cognition-related pattern (PDCP), which is characterized by decreased metabolism in frontal and parietal-related regions and increased metabolism in the cerebellar vermis and dentate nuclei.<sup>[<xref rid="R133" ref-type="bibr">133</xref>]</sup> The expression of the PDCP is correlated with executive and memory performance but not with the motor symptom score. PD-associated cognitive patterns also progress over time, with the PDRP usually progressing several years before PD-associated cognitive patterns.<sup>[<xref rid="R134" ref-type="bibr">134</xref>]</sup> Therefore, the PDRP is particularly important in patients with advanced PD and helps to track disease progression.</p></sec><sec><title>&#945;-synuclein PET</title><p>The abnormal aggregation of &#945;-syn in the SNpc-striatum region is a typical pathological feature of PD. As such, the ability to image &#945;-syn is highly important for early diagnosis and gaining insight into the pathophysiology of PD. Matsuoka <italic toggle="yes">et al</italic><sup>[<xref rid="R135" ref-type="bibr">135</xref>]</sup> developed a novel small-molecule ligand that targets &#945;-syn fibrils called 18F-SPAL-T-06 (PCT/JP2021/030899), representing the first human <italic toggle="yes">in vivo</italic> imaging of &#945;-syn PET. They found that, compared with healthy controls, MSA-P and MSA-C patients presented significantly increased signals of 18F-SPAL-T-06 retention in the putamen, pons, cerebellar white matter, and cerebellar peduncle. Notably, the distribution pattern of this radioligand corresponded with the predominant localization of glial cytoplasmic inclusions in these MSA subtypes.<sup>[<xref rid="R135" ref-type="bibr">135</xref>]</sup></p></sec><sec><title>Tau PET</title><p>Increasing evidence suggests that the tau protein is also involved in the pathophysiology of PD, highlighting the need for <italic toggle="yes">in vivo</italic> visualization of tau protein deposition in PD patients. Several relatively selective tau radiotracers, including 18F-THK523, 18F-THK5117, 18F-THK5105, 18F-THK5351, 18F-AV1451(T807), and 11C-PBB3, have been developed and have demonstrated utility in differentiating idiopathic PD from PSP and cortico-basal degeneration.<sup>[<xref rid="R136" ref-type="bibr">136</xref>,<xref rid="R137" ref-type="bibr">137</xref>]</sup> A study using [18F]-THK5351 revealed lower tau tracer uptake in the thalamus and midbrain of PD patients compared with PSP patients and in the pons compared with MSA-C patients.<sup>[<xref rid="R138" ref-type="bibr">138</xref>]</sup> Similarly, an 18F-APN-1607 imaging study revealed that tau tracer uptake in the striatum, pallidum, thalamic nuclei, midbrain, tegmentum, substantia nigra, red nucleus, and pons was lower in PD patients than in PSP patients, suggesting that tau PET imaging could aid in distinguishing PD from PSP.<sup>[<xref rid="R139" ref-type="bibr">139</xref>]</sup></p></sec><sec><title>Neuroinflammation PET</title><p>Neuroinflammation plays a significant role in the pathogenesis of PD. Translocator protein (TSPO) is a potential marker of neuroinflammation<sup>[<xref rid="R140" ref-type="bibr">140</xref>]</sup> and can be imaged and quantified by 11CPK11195, 11C-PBR28, and 18F-FEPPA.<sup>[<xref rid="R141" ref-type="bibr">141</xref>]</sup> However, findings on neuroinflammation in PD remain inconsistent, with some studies reporting increased inflammation in the midbrain or other brain regions,<sup>[<xref rid="R142" ref-type="bibr">142</xref>,<xref rid="R143" ref-type="bibr">143</xref>]</sup> whereas others reported no significant changes.<sup>[<xref rid="R144" ref-type="bibr">144</xref>]</sup> In addition to microglial activation, accumulating evidence suggests that activated astroglia may contribute to early PD pathophysiology.<sup>[<xref rid="R145" ref-type="bibr">145</xref>]</sup> Wilson <italic toggle="yes">et al</italic><sup>[<xref rid="R146" ref-type="bibr">146</xref>]</sup> employed 11C-BU99008 PET imaging, which targets the imidazoline 2 binding site (I2BS), to assess astroglial pathology in PD patients. Their study revealed increased expression of the I2BS in cortical and brainstem regions in early-stage PD, whereas in mid- to late-stage PD, I2BS expression decreased in cortical and subcortical areas, indicating a loss of astroglial function as the disease burden increases. A better understanding of neuroinflammation and its role in PD progression could improve early diagnosis and inform the development of targeted therapies.<sup>[<xref rid="R147" ref-type="bibr">147</xref>]</sup></p></sec></sec></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Recent advancements in fluid biomarkers and neuroimaging have greatly enhanced our understanding of PD, providing new opportunities for early diagnosis, disease monitoring, and prognostic assessment. Fluid biomarkers, such as &#945;-syn and NfL, are closely linked to PD pathology. While many studies have focused on the middle to late stages of PD, further validation of biomarkers indicative of early- and premotor-stage PD is needed. Longitudinal studies are essential to assess their diagnostic and prognostic significance. The development of novel imaging sequences has enhanced the visualization of PD pathology from multiple dimensions. Ultrahigh-field MRI offers high-resolution imaging for clearer, more detailed lesion detection. Moreover, SPECT and PET imaging, which target dopamine system molecules (e.g., DAT, AADC, and VMAT2), provide critical insights into functional and molecular changes in the dopaminergic pathways. Together, these imaging modalities are essential for the early detection and monitoring of PD. Integrating fluid biomarkers with neuroimaging has substantial potential to enhance early PD diagnosis and advance precision medicine&#8212;ultimately paving the way for more effective treatments and disease-modifying therapies in the future.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p>None.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><caption><title>SUPPLEMENTARY MATERIAL</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cm9-138-2365-s001.pdf" id="d67e2622" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><fn-group><fn fn-type="equal" id="fna1"><p>Dongning Su and Yuanchu Zheng contributed equally to this work.</p></fn><fn fn-type="other"><p><bold>How to cite this article:</bold> Su DN, Zheng YC, Feng T. Biomarkers and neuroimaging markers in Parkinson&#8217;s disease. Chin Med J 2025;138:2365&#8211;2380. doi: 10.1097/CM9.0000000000003745</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yan</surname><given-names>R</given-names></name><name name-style="western"><surname>Su</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D</given-names></name>, <etal/></person-group>. <article-title>Temporal trends in the prevalence of Parkinson&#8217;s disease from 1980 to 2023: a systematic review and meta-analysis</article-title>. <source>Lancet Healthy Longev</source><year>2024</year>;<volume>5</volume>:<fpage>e464</fpage>&#8211;<lpage>e479</lpage>. <comment>doi: 10.1016/S2666-7568(24)00094-1</comment>.<pub-id pub-id-type="pmid">38945129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-7568(24)00094-1</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>GBD 2016 Parkinson&#8217;s Disease Collaborators</collab></person-group>. <article-title>Global, regional, and national burden of Parkinson&#8217;s disease, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016</article-title>. <source>Lancet Neurol</source><year>2018</year>;<volume>17</volume>:<fpage>939</fpage>&#8211;<lpage>953</lpage>. <comment>doi: 10.1016/S1474-4422(18)30295-3</comment>.<pub-id pub-id-type="pmid">30287051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(18)30295-3</pub-id><pub-id pub-id-type="pmcid">PMC6191528</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Postuma</surname><given-names>RB</given-names></name><name name-style="western"><surname>Berg</surname><given-names>D</given-names></name><name name-style="western"><surname>Stern</surname><given-names>M</given-names></name><name name-style="western"><surname>Poewe</surname><given-names>W</given-names></name><name name-style="western"><surname>Olanow</surname><given-names>CW</given-names></name><name name-style="western"><surname>Oertel</surname><given-names>W</given-names></name>, <etal/></person-group>. <article-title>MDS clinical diagnostic criteria for Parkinson&#8217;s disease</article-title>. <source>Mov Disord</source><year>2015</year>;<volume>30</volume>:<fpage>1591</fpage>&#8211;<lpage>1601</lpage>. <comment>doi: 10.1002/mds.26424</comment>.<pub-id pub-id-type="pmid">26474316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.26424</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braak</surname><given-names>H</given-names></name><name name-style="western"><surname>Del Tredici</surname><given-names>K</given-names></name><name name-style="western"><surname>R&#252;b</surname><given-names>U</given-names></name><name name-style="western"><surname>de Vos</surname><given-names>RA</given-names></name><name name-style="western"><surname>Jansen Steur</surname><given-names>EN</given-names></name><name name-style="western"><surname>Braak</surname><given-names>E</given-names></name></person-group>. <article-title>Staging of brain pathology related to sporadic Parkinson&#8217;s disease</article-title>. <source>Neurobiol Aging</source><year>2003</year>;<volume>24</volume>:<fpage>197</fpage>&#8211;<lpage>211</lpage>. <comment>doi: 10.1016/s0197-4580(02)00065-9</comment>.<pub-id pub-id-type="pmid">12498954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0197-4580(02)00065-9</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>SE</given-names></name><name name-style="western"><surname>Kilford</surname><given-names>L</given-names></name><name name-style="western"><surname>Lees</surname><given-names>AJ</given-names></name></person-group>. <article-title>Accuracy of clinical diagnosis of idiopathic Parkinson&#8217;s disease: a clinico-pathological study of 100 cases</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>1992</year>;<volume>55</volume>:<fpage>181</fpage>&#8211;<lpage>184</lpage>. <comment>doi: 10.1136/jnnp.55.3.181</comment>.<pub-id pub-id-type="pmid">1564476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.55.3.181</pub-id><pub-id pub-id-type="pmcid">PMC1014720</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Virameteekul</surname><given-names>S</given-names></name><name name-style="western"><surname>Revesz</surname><given-names>T</given-names></name><name name-style="western"><surname>Jaunmuktane</surname><given-names>Z</given-names></name><name name-style="western"><surname>Warner</surname><given-names>TT</given-names></name><name name-style="western"><surname>De Pablo-Fern&#225;ndez</surname><given-names>E</given-names></name></person-group>. <article-title>Clinical Diagnostic Accuracy of Parkinson&#8217;s Disease: Where Do We Stand</article-title>. <source>Mov Disord</source><year>2023</year>;<volume>38</volume>:<fpage>558</fpage>&#8211;<lpage>566</lpage>. <comment>doi: 10.1002/mds.29317</comment>.<pub-id pub-id-type="pmid">36602274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.29317</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>HR</given-names></name><name name-style="western"><surname>Spillantini</surname><given-names>MG</given-names></name><name name-style="western"><surname>Sue</surname><given-names>CM</given-names></name><name name-style="western"><surname>Williams-Gray</surname><given-names>CH</given-names></name></person-group>. <article-title>The pathogenesis of Parkinson&#8217;s disease</article-title>. <source>Lancet</source><year>2024</year>;<volume>403</volume>:<fpage>293</fpage>&#8211;<lpage>304</lpage>. <comment>doi: 10.1016/S0140-6736(23)01478-2</comment>.<pub-id pub-id-type="pmid">38245249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)01478-2</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>M</given-names></name><name name-style="western"><surname>Chung</surname><given-names>KA</given-names></name><name name-style="western"><surname>Zabetian</surname><given-names>CP</given-names></name><name name-style="western"><surname>Leverenz</surname><given-names>JB</given-names></name><name name-style="western"><surname>Berg</surname><given-names>D</given-names></name>, <etal/></person-group>. <article-title>Phosphorylated &#945;-synuclein in Parkinson&#8217;s disease</article-title>. <source>Sci Transl Med</source><year>2012</year>;<volume>4</volume>:<fpage>121ra20</fpage>. <comment>doi: 10.1126/scitranslmed.3002566</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3002566</pub-id><pub-id pub-id-type="pmcid">PMC3302662</pub-id><pub-id pub-id-type="pmid">22344688</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>T</given-names></name><name name-style="western"><surname>Sossi</surname><given-names>V</given-names></name><name name-style="western"><surname>Aasly</surname><given-names>JO</given-names></name><name name-style="western"><surname>Wszolek</surname><given-names>ZK</given-names></name><name name-style="western"><surname>Uitti</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>K</given-names></name>, <etal/></person-group>. <article-title>Phosphorylated &#945;-synuclein in Parkinson&#8217;s disease: correlation depends on disease severity</article-title>. <source>Acta Neuropathol Commun</source><year>2015</year>;<volume>3</volume>:<fpage>7</fpage>. <comment>doi: 10.1186/s40478-015-0185-3</comment>.<pub-id pub-id-type="pmid">25637461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-015-0185-3</pub-id><pub-id pub-id-type="pmcid">PMC4362824</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majbour</surname><given-names>NK</given-names></name><name name-style="western"><surname>Vaikath</surname><given-names>NN</given-names></name><name name-style="western"><surname>van Dijk</surname><given-names>KD</given-names></name><name name-style="western"><surname>Ardah</surname><given-names>MT</given-names></name><name name-style="western"><surname>Varghese</surname><given-names>S</given-names></name><name name-style="western"><surname>Vesterager</surname><given-names>LB</given-names></name>, <etal/></person-group>. <article-title>Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson&#8217;s disease</article-title>. <source>Mol Neurodegener</source><year>2016</year>;<volume>11</volume>:<fpage>7</fpage>. <comment>doi: 10.1186/s13024-016-0072-9</comment>.<pub-id pub-id-type="pmid">26782965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-016-0072-9</pub-id><pub-id pub-id-type="pmcid">PMC4717559</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eusebi</surname><given-names>P</given-names></name><name name-style="western"><surname>Giannandrea</surname><given-names>D</given-names></name><name name-style="western"><surname>Biscetti</surname><given-names>L</given-names></name><name name-style="western"><surname>Abraha</surname><given-names>I</given-names></name><name name-style="western"><surname>Chiasserini</surname><given-names>D</given-names></name><name name-style="western"><surname>Orso</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Diagnostic utility of cerebrospinal fluid &#945;-synuclein in Parkinson&#8217;s disease: A systematic review and meta-analysis</article-title>. <source>Mov Disord</source><year>2017</year>;<volume>32</volume>:<fpage>1389</fpage>&#8211;<lpage>1400</lpage>. <comment>doi: 10.1002/mds.27110</comment>.<pub-id pub-id-type="pmid">28880418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.27110</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mollenhauer</surname><given-names>B</given-names></name><name name-style="western"><surname>Batrla</surname><given-names>R</given-names></name><name name-style="western"><surname>El-Agnaf</surname><given-names>O</given-names></name><name name-style="western"><surname>Galasko</surname><given-names>DR</given-names></name><name name-style="western"><surname>Lashuel</surname><given-names>HA</given-names></name><name name-style="western"><surname>Merchant</surname><given-names>KM</given-names></name>, <etal/></person-group>. <article-title>A user&#8217;s guide for &#945;-synuclein biomarker studies in biological fluids: Perianalytical considerations</article-title>. <source>Mov Disord</source><year>2017</year>;<volume>32</volume>:<fpage>1117</fpage>&#8211;<lpage>1130</lpage>. <comment>doi: 10.1002/mds.27090</comment>.<pub-id pub-id-type="pmid">28734051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.27090</pub-id><pub-id pub-id-type="pmcid">PMC5638072</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mollenhauer</surname><given-names>B</given-names></name><name name-style="western"><surname>Caspell-Garcia</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Coffey</surname><given-names>CS</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>P</given-names></name><name name-style="western"><surname>Singleton</surname><given-names>A</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>LM</given-names></name>, <etal/></person-group>. <article-title>Longitudinal analyses of cerebrospinal fluid &#945;-Synuclein in prodromal and early Parkinson&#8217;s disease</article-title>. <source>Mov Disord</source><year>2019</year>;<volume>34</volume>:<fpage>1354</fpage>&#8211;<lpage>1364</lpage>. <comment>doi: 10.1002/mds.27806</comment>.<pub-id pub-id-type="pmid">31361367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.27806</pub-id><pub-id pub-id-type="pmcid">PMC7098385</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irwin</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Grossman</surname><given-names>M</given-names></name><name name-style="western"><surname>Weintraub</surname><given-names>D</given-names></name><name name-style="western"><surname>Hurtig</surname><given-names>HI</given-names></name><name name-style="western"><surname>Duda</surname><given-names>JE</given-names></name><name name-style="western"><surname>Xie</surname><given-names>SX</given-names></name>, <etal/></person-group>. <article-title>Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis</article-title>. <source>Lancet Neurol</source><year>2017</year>;<volume>16</volume>:<fpage>55</fpage>&#8211;<lpage>65</lpage>. <comment>doi: 10.1016/S1474-4422(16)30291-5</comment>.<pub-id pub-id-type="pmid">27979356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(16)30291-5</pub-id><pub-id pub-id-type="pmcid">PMC5181646</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Feng</surname><given-names>T</given-names></name></person-group>. <article-title>Comparison of biospecimens for &#945;-synuclein seed amplification assays in Parkinson&#8217;s disease: A systematic review and network meta-analysis</article-title>. <source>Eur J Neurol</source><year>2023</year>;<volume>30</volume>:<fpage>3949</fpage>&#8211;<lpage>3967</lpage>. <comment>doi: 10.1111/ene.16041</comment>.<pub-id pub-id-type="pmid">37573472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.16041</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>D</given-names></name><name name-style="western"><surname>Bang</surname><given-names>JI</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>C</given-names></name><name name-style="western"><surname>Nyaga</surname><given-names>VN</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YE</given-names></name><name name-style="western"><surname>Kang</surname><given-names>MJ</given-names></name>, <etal/></person-group>. <article-title>Diagnostic value of &#945;-synuclein seeding amplification assays in &#945;-synucleinopathies: A systematic review and meta-analysis</article-title>. <source>Parkinsonism Relat Disord</source><year>2022</year>;<volume>104</volume>:<fpage>99</fpage>&#8211;<lpage>109</lpage>. <comment>doi: 10.1016/j.parkreldis.2022.10.007</comment>.<pub-id pub-id-type="pmid">36289019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2022.10.007</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siderowf</surname><given-names>A</given-names></name><name name-style="western"><surname>Concha-Marambio</surname><given-names>L</given-names></name><name name-style="western"><surname>Lafontant</surname><given-names>DE</given-names></name><name name-style="western"><surname>Farris</surname><given-names>CM</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Urenia</surname><given-names>PA</given-names></name>, <etal/></person-group>. <article-title>Assessment of heterogeneity among participants in the Parkinson&#8217;s Progression Markers Initiative cohort using &#945;-synuclein seed amplification: A cross-sectional study</article-title>. <source>Lancet Neurol</source><year>2023</year>;<volume>22</volume>:<fpage>407</fpage>&#8211;<lpage>417</lpage>. <comment>doi: 10.1016/S1474-4422(23)00109-6</comment>.<pub-id pub-id-type="pmid">37059509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(23)00109-6</pub-id><pub-id pub-id-type="pmcid">PMC10627170</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalil</surname><given-names>M</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>S</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M</given-names></name><name name-style="western"><surname>Piehl</surname><given-names>F</given-names></name><name name-style="western"><surname>Ziemssen</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>Neurofilaments as biomarkers in neurological disorders-towards clinical application</article-title>. <source>Nat Rev Neurol</source><year>2024</year>;<volume>20</volume>:<fpage>269</fpage>&#8211;<lpage>287</lpage>. <comment>doi: 10.1038/s41582-024-00955-x</comment>.<pub-id pub-id-type="pmid">38609644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-024-00955-x</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katzdobler</surname><given-names>S</given-names></name><name name-style="western"><surname>N&#252;bling</surname><given-names>G</given-names></name><name name-style="western"><surname>Klietz</surname><given-names>M</given-names></name><name name-style="western"><surname>Fietzek</surname><given-names>UM</given-names></name><name name-style="western"><surname>Palleis</surname><given-names>C</given-names></name><name name-style="western"><surname>Bernhardt</surname><given-names>AM</given-names></name>, <etal/></person-group>. <article-title>GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)</article-title>. <source>J Neurol</source><year>2024</year>;<volume>271</volume>:<fpage>6991</fpage>&#8211;<lpage>6999</lpage>. <comment>doi: 10.1007/s00415-024-12647-z</comment>.<pub-id pub-id-type="pmid">39254698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-024-12647-z</pub-id><pub-id pub-id-type="pmcid">PMC11447157</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singer</surname><given-names>W</given-names></name><name name-style="western"><surname>Schmeichel</surname><given-names>AM</given-names></name><name name-style="western"><surname>Shahnawaz</surname><given-names>M</given-names></name><name name-style="western"><surname>Schmelzer</surname><given-names>JD</given-names></name><name name-style="western"><surname>Boeve</surname><given-names>BF</given-names></name><name name-style="western"><surname>Sletten</surname><given-names>DM</given-names></name>, <etal/></person-group>. <article-title>Alpha-Synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from lewy body synucleinopathies</article-title>. <source>Ann Neurol</source><year>2020</year>;<volume>88</volume>:<fpage>503</fpage>&#8211;<lpage>512</lpage>. <comment>doi: 10.1002/ana.25824</comment>.<pub-id pub-id-type="pmid">32557811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25824</pub-id><pub-id pub-id-type="pmcid">PMC7719613</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdo</surname><given-names>WF</given-names></name><name name-style="western"><surname>Bloem</surname><given-names>BR</given-names></name><name name-style="western"><surname>Van Geel</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Esselink</surname><given-names>RA</given-names></name><name name-style="western"><surname>Verbeek</surname><given-names>MM</given-names></name></person-group>. <article-title>CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson&#8217;s disease</article-title>. <source>Neurobiol Aging</source><year>2007</year>;<volume>28</volume>:<fpage>742</fpage>&#8211;<lpage>747</lpage>. <comment>doi: 10.1016/j.neurobiolaging.2006.03.010</comment>.<pub-id pub-id-type="pmid">16678934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2006.03.010</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canaslan</surname><given-names>S</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>M</given-names></name><name name-style="western"><surname>Villar-Piqu&#233;</surname><given-names>A</given-names></name><name name-style="western"><surname>Maass</surname><given-names>F</given-names></name><name name-style="western"><surname>Gmitterov&#225;</surname><given-names>K</given-names></name><name name-style="western"><surname>Varges</surname><given-names>D</given-names></name>, <etal/></person-group>. <article-title>Detection of cerebrospinal fluid neurofilament light chain as a marker for alpha-synucleinopathies</article-title>. <source>Front Aging Neurosci</source><year>2021</year>;<volume>13</volume>:<fpage>717930</fpage>. <comment>doi: 10.3389/fnagi.2021.717930</comment>.<pub-id pub-id-type="pmid">34630068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2021.717930</pub-id><pub-id pub-id-type="pmcid">PMC8493247</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbert</surname><given-names>MK</given-names></name><name name-style="western"><surname>Aerts</surname><given-names>MB</given-names></name><name name-style="western"><surname>Beenes</surname><given-names>M</given-names></name><name name-style="western"><surname>Norgren</surname><given-names>N</given-names></name><name name-style="western"><surname>Esselink</surname><given-names>RA</given-names></name><name name-style="western"><surname>Bloem</surname><given-names>BR</given-names></name>, <etal/></person-group>. <article-title>CSF neurofilament light chain but not FLT3 ligand discriminates parkinsonian disorders</article-title>. <source>Front Neurol</source><year>2015</year>;<volume>6</volume>:<fpage>91</fpage>. <comment>doi: 10.3389/fneur.2015.00091</comment>.<pub-id pub-id-type="pmid">25999911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2015.00091</pub-id><pub-id pub-id-type="pmcid">PMC4419719</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quadalti</surname><given-names>C</given-names></name><name name-style="western"><surname>Calandra-Buonaura</surname><given-names>G</given-names></name><name name-style="western"><surname>Baiardi</surname><given-names>S</given-names></name><name name-style="western"><surname>Mastrangelo</surname><given-names>A</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>M</given-names></name><name name-style="western"><surname>Zenesini</surname><given-names>C</given-names></name>, <etal/></person-group>. <article-title>Neurofilament light chain and &#945;-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes</article-title>. <source>NPJ Parkinsons Dis</source><year>2021</year>;<volume>7</volume>:<fpage>93</fpage>. <comment>doi: 10.1038/s41531-021-00232-4</comment>.<pub-id pub-id-type="pmid">34635674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-021-00232-4</pub-id><pub-id pub-id-type="pmcid">PMC8505434</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dos Santos</surname><given-names>M</given-names></name><name name-style="western"><surname>Barreto-Sanz</surname><given-names>MA</given-names></name><name name-style="western"><surname>Correia</surname><given-names>B</given-names></name><name name-style="western"><surname>Bell</surname><given-names>R</given-names></name><name name-style="western"><surname>Widnall</surname><given-names>C</given-names></name><name name-style="western"><surname>Perez</surname><given-names>LT</given-names></name>, <etal/></person-group>. <article-title>miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson&#8217;s disease</article-title>. <source>Oncotarget</source><year>2018</year>;<volume>9</volume>:<fpage>17455</fpage>&#8211;<lpage>17465</lpage>. <comment>doi: 10.18632/oncotarget.24736</comment>.<pub-id pub-id-type="pmid">29707120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.24736</pub-id><pub-id pub-id-type="pmcid">PMC5915128</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Youn</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SB</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HS</given-names></name><name name-style="western"><surname>Yang</surname><given-names>HO</given-names></name><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JS</given-names></name>, <etal/></person-group>. <article-title>Cerebrospinal Fluid Levels of Autophagy-related Proteins Represent Potentially Novel Biomarkers of Early-Stage Parkinson&#8217;s Disease</article-title>. <source>Sci Rep</source><year>2018</year>;<volume>8</volume>:<fpage>16866</fpage>. <comment>doi: 10.1038/s41598-018-35376-6</comment>.<pub-id pub-id-type="pmid">30442917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-35376-6</pub-id><pub-id pub-id-type="pmcid">PMC6237988</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldstein</surname><given-names>DS</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>C</given-names></name><name name-style="western"><surname>Sharabi</surname><given-names>Y</given-names></name></person-group>. <article-title>Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson&#8217;s disease and other synucleinopathies</article-title>. <source>Brain</source><year>2012</year>;<volume>135</volume>:<fpage>1900</fpage>&#8211;<lpage>1913</lpage>. <comment>doi: 10.1093/brain/aws055</comment>.<pub-id pub-id-type="pmid">22451506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aws055</pub-id><pub-id pub-id-type="pmcid">PMC3359749</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>C</given-names></name><name name-style="western"><surname>Cong</surname><given-names>S</given-names></name><name name-style="western"><surname>Tan</surname><given-names>X</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name>, <etal/></person-group>. <article-title>A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson&#8217;s disease</article-title>. <source>NPJ Parkinsons Dis</source><year>2022</year>;<volume>8</volume>:<fpage>165</fpage>. <comment>doi: 10.1038/s41531-022-00431-7</comment>. <comment>Erratum in: NPJ Parkinsons Dis 2023;9:39. doi: 10.1038/s41531-023-00483-3</comment>.<pub-id pub-id-type="pmid">36446820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-022-00431-7</pub-id><pub-id pub-id-type="pmcid">PMC9709054</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>L</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><name name-style="western"><surname>Nie</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Gan</surname><given-names>R</given-names></name>, <etal/></person-group>. <article-title>Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson&#8217;s disease diagnosis: A systematic review and meta-analysis</article-title>. <source>Int J Neurosci</source><year>2015</year>;<volume>125</volume>:<fpage>645</fpage>&#8211;<lpage>654</lpage>. <comment>doi: 10.3109/00207454.2014.961454</comment>.<pub-id pub-id-type="pmid">25202803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/00207454.2014.961454</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grossauer</surname><given-names>A</given-names></name><name name-style="western"><surname>Hemicker</surname><given-names>G</given-names></name><name name-style="western"><surname>Krismer</surname><given-names>F</given-names></name><name name-style="western"><surname>Peball</surname><given-names>M</given-names></name><name name-style="western"><surname>Djamshidian</surname><given-names>A</given-names></name><name name-style="western"><surname>Poewe</surname><given-names>W</given-names></name>, <etal/></person-group>. <article-title>&#945;-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid-a systematic review and meta-analysis</article-title>. <source>Mov Disord Clin Pract</source><year>2023</year>;<volume>10</volume>:<fpage>737</fpage>&#8211;<lpage>747</lpage>. <comment>doi: 10.1002/mdc3.13710</comment>.<pub-id pub-id-type="pmid">37205253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mdc3.13710</pub-id><pub-id pub-id-type="pmcid">PMC10187020</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>HL</given-names></name><name name-style="western"><surname>Lu</surname><given-names>CS</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>TH</given-names></name><name name-style="western"><surname>Shen</surname><given-names>YM</given-names></name><name name-style="western"><surname>Weng</surname><given-names>YH</given-names></name><name name-style="western"><surname>Huang</surname><given-names>YZ</given-names></name>, <etal/></person-group>. <article-title>Combined assessment of serum alpha-synuclein and Rab35 is a better biomarker for Parkinson&#8217;s disease</article-title>. <source>J Clin Neurol</source><year>2019</year>;<volume>15</volume>:<fpage>488</fpage>&#8211;<lpage>495</lpage>. <comment>doi: 10.3988/jcn.2019.15.4.488</comment>.<pub-id pub-id-type="pmid">31591837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3988/jcn.2019.15.4.488</pub-id><pub-id pub-id-type="pmcid">PMC6785464</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name>, <etal/></person-group>. <article-title>A comparative study of the diagnostic potential of plasma and erythrocytic &#945;-synuclein in Parkinson&#8217;s disease</article-title>. <source>Neurodegener Dis</source><year>2019</year>;<volume>19</volume>:<fpage>204</fpage>&#8211;<lpage>210</lpage>. <comment>doi: 10.1159/000506480</comment>.<pub-id pub-id-type="pmid">32485710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000506480</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chahine</surname><given-names>LM</given-names></name><name name-style="western"><surname>Beach</surname><given-names>TG</given-names></name><name name-style="western"><surname>Brumm</surname><given-names>MC</given-names></name><name name-style="western"><surname>Adler</surname><given-names>CH</given-names></name><name name-style="western"><surname>Coffey</surname><given-names>CS</given-names></name><name name-style="western"><surname>Mosovsky</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>In vivo distribution of &#945;-synuclein in multiple tissues and biofluids in Parkinson disease</article-title>. <source>Neurology</source><year>2020</year>;<volume>95</volume>:<fpage>e1267</fpage>&#8211;<lpage>e1284</lpage>. <comment>doi: 10.1212/WNL.0000000000010404</comment>.<pub-id pub-id-type="pmid">32747521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000010404</pub-id><pub-id pub-id-type="pmcid">PMC7538226</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldman</surname><given-names>JG</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>H</given-names></name><name name-style="western"><surname>Amara</surname><given-names>A</given-names></name><name name-style="western"><surname>Naito</surname><given-names>A</given-names></name><name name-style="western"><surname>Alcalay</surname><given-names>RN</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>LM</given-names></name>, <etal/></person-group>. <article-title>Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson&#8217;s disease Features</article-title>. <source>Mov Disord</source><year>2018</year>;<volume>33</volume>:<fpage>282</fpage>&#8211;<lpage>288</lpage>. <comment>doi: 10.1002/mds.27232</comment>.<pub-id pub-id-type="pmid">29205509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.27232</pub-id><pub-id pub-id-type="pmcid">PMC5836918</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorostidi</surname><given-names>A</given-names></name><name name-style="western"><surname>Bergareche</surname><given-names>A</given-names></name><name name-style="western"><surname>Ruiz-Mart&#237;nez</surname><given-names>J</given-names></name><name name-style="western"><surname>Mart&#237;-Mass&#243;</surname><given-names>JF</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>M</given-names></name><name name-style="western"><surname>Varghese</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>&#913;lpha-synuclein levels in blood plasma from LRRK2 mutation carriers</article-title>. <source>PLoS One</source><year>2012</year>;<volume>7</volume>:<fpage>e52312</fpage>. <comment>doi: 10.1371/journal.pone.0052312</comment>.<pub-id pub-id-type="pmid">23300640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0052312</pub-id><pub-id pub-id-type="pmcid">PMC3531490</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishii</surname><given-names>R</given-names></name><name name-style="western"><surname>Tokuda</surname><given-names>T</given-names></name><name name-style="western"><surname>Tatebe</surname><given-names>H</given-names></name><name name-style="western"><surname>Ohmichi</surname><given-names>T</given-names></name><name name-style="western"><surname>Kasai</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Decrease in plasma levels of &#945;-synuclein is evident in patients with Parkinson&#8217;s disease after elimination of heterophilic antibody interference</article-title>. <source>PLoS One</source><year>2015</year>;<volume>10</volume>:<fpage>e0123162</fpage>. <comment>doi: 10.1371/journal.pone.0123162</comment>.<pub-id pub-id-type="pmid">25849645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0123162</pub-id><pub-id pub-id-type="pmcid">PMC4388641</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Arkin</surname><given-names>E</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Feng</surname><given-names>T</given-names></name></person-group>. <article-title>Erythrocytic &#945;-Synuclein Species for Parkinson&#8217;s Disease Diagnosis and the Correlations With Clinical Characteristics</article-title>. <source>Front Aging Neurosci</source><year>2022</year>;<volume>14</volume>:<fpage>827493</fpage>. <comment>doi: 10.3389/fnagi.2022.827493</comment>.<pub-id pub-id-type="pmid">35185529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.827493</pub-id><pub-id pub-id-type="pmcid">PMC8850836</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Lv</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name>, <etal/></person-group>. <article-title>Erythrocytic &#945;-Synuclein Species as Biomarkers for Isolated Rapid Eye Movement Sleep Behavior Disorder</article-title>. <source>Mov Disord</source><year>2023</year>;<volume>38</volume>:<fpage>2315</fpage>&#8211;<lpage>2317</lpage>. <comment>doi: 10.1002/mds.29583</comment>.<pub-id pub-id-type="pmid">37594009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.29583</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L</given-names></name><name name-style="western"><surname>Soltys</surname><given-names>D</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>Erythrocytic &#945;-Synuclein as a potential biomarker for Parkinson&#8217;s disease</article-title>. <source>Transl Neurodegener</source><year>2019</year>;<volume>8</volume>:<fpage>15</fpage>. <comment>doi: 10.1186/s40035-019-0155-y</comment>.<pub-id pub-id-type="pmid">31123587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-019-0155-y</pub-id><pub-id pub-id-type="pmcid">PMC6521422</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Cook</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Bullock</surname><given-names>KM</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ginghina</surname><given-names>C</given-names></name>, <etal/></person-group>. <article-title>Plasma exosomal &#945;-synuclein is likely CNS-derived and increased in Parkinson&#8217;s disease</article-title>. <source>Acta Neuropathol</source><year>2014</year>;<volume>128</volume>:<fpage>639</fpage>&#8211;<lpage>650</lpage>. <comment>doi: 10.1007/s00401-014-1314-y</comment>.<pub-id pub-id-type="pmid">24997849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-014-1314-y</pub-id><pub-id pub-id-type="pmcid">PMC4201967</pub-id></mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ha</surname><given-names>D</given-names></name><name name-style="western"><surname>Yang</surname><given-names>N</given-names></name><name name-style="western"><surname>Nadithe</surname><given-names>V</given-names></name></person-group>. <article-title>Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges</article-title>. <source>Acta Pharm Sin B</source><year>2016</year>;<volume>6</volume>:<fpage>287</fpage>&#8211;<lpage>296</lpage>. <comment>doi: 10.1016/j.apsb.2016.02.001</comment>.<pub-id pub-id-type="pmid">27471669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2016.02.001</pub-id><pub-id pub-id-type="pmcid">PMC4951582</pub-id></mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xylaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>A</given-names></name><name name-style="western"><surname>Weber</surname><given-names>S</given-names></name><name name-style="western"><surname>Bartl</surname><given-names>M</given-names></name><name name-style="western"><surname>Outeiro</surname><given-names>TF</given-names></name><name name-style="western"><surname>Mollenhauer</surname><given-names>B</given-names></name></person-group>. <article-title>Extracellular vesicles for the diagnosis of parkinson&#8217;s disease: systematic review and meta-analysis</article-title>. <source>Mov Disord</source><year>2023</year>;<volume>38</volume>:<fpage>1585</fpage>&#8211;<lpage>1597</lpage>. <comment>doi: 10.1002/mds.29497</comment>.<pub-id pub-id-type="pmid">37449706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.29497</pub-id></mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C</given-names></name><name name-style="western"><surname>Janzen</surname><given-names>A</given-names></name><name name-style="western"><surname>Barber</surname><given-names>TR</given-names></name><name name-style="western"><surname>Seger</surname><given-names>A</given-names></name><name name-style="western"><surname>Sommerauer</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Neuronally Derived Extracellular Vesicle &#945;-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease</article-title>. <source>JAMA Neurol</source><year>2024</year>;<volume>81</volume>:<fpage>59</fpage>&#8211;<lpage>68</lpage>. <comment>doi: 10.1001/jamaneurol.2023.4398</comment>.<pub-id pub-id-type="pmid">38048087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2023.4398</pub-id><pub-id pub-id-type="pmcid">PMC10696516</pub-id></mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okuzumi</surname><given-names>A</given-names></name><name name-style="western"><surname>Hatano</surname><given-names>T</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>G</given-names></name><name name-style="western"><surname>Nojiri</surname><given-names>S</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>SI</given-names></name><name name-style="western"><surname>Imamichi-Tatano</surname><given-names>Y</given-names></name>, <etal/></person-group>. <article-title>Propagative &#945;-synuclein seeds as serum biomarkers for synucleinopathies</article-title>. <source>Nat Med</source><year>2023</year>;<volume>29</volume>:<fpage>1448</fpage>&#8211;<lpage>1455</lpage>. <comment>doi: 10.1038/s41591-023-02358-9</comment>.<pub-id pub-id-type="pmid">37248302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-023-02358-9</pub-id><pub-id pub-id-type="pmcid">PMC10287557</pub-id></mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>J</given-names></name><name name-style="western"><surname>Takousis</surname><given-names>P</given-names></name><name name-style="western"><surname>Wohlers</surname><given-names>I</given-names></name><name name-style="western"><surname>Itua</surname><given-names>I</given-names></name><name name-style="western"><surname>Dobricic</surname><given-names>V</given-names></name><name name-style="western"><surname>R&#252;cker</surname><given-names>G</given-names></name>, <etal/></person-group>. <article-title>Meta-analyses identify differentially expressed micrornas in Parkinson&#8217;s disease</article-title>. <source>Ann Neurol</source><year>2019</year>;<volume>85</volume>:<fpage>835</fpage>&#8211;<lpage>851</lpage>. <comment>doi: 10.1002/ana.25490</comment>.<pub-id pub-id-type="pmid">30990912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25490</pub-id></mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Kou</surname><given-names>W</given-names></name>, <etal/></person-group>. <article-title>Molecular beacon-based detection of circulating microRNA-containing extracellular vesicle as an &#945;-synucleinopathy biomarker</article-title>. <source>Sci Adv</source><year>2024</year>;<volume>10</volume>:<elocation-id>eadl6442</elocation-id>. <comment>doi: 10.1126/sciadv.adl6442</comment>.<pub-id pub-id-type="pmid">38748787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adl6442</pub-id><pub-id pub-id-type="pmcid">PMC11095448</pub-id></mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>MC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>SC</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>YF</given-names></name><name name-style="western"><surname>Wu</surname><given-names>RM</given-names></name></person-group>. <article-title>The role of noncoding RNAs in Parkinson&#8217;s disease: biomarkers and associations with pathogenic pathways</article-title>. <source>J Biomed Sci</source><year>2021</year>;<volume>28</volume>:<fpage>78</fpage>. <comment>doi: 10.1186/s12929-021-00775-x</comment>.<pub-id pub-id-type="pmid">34794432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12929-021-00775-x</pub-id><pub-id pub-id-type="pmcid">PMC8603508</pub-id></mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Koc</surname><given-names>S</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G</given-names></name></person-group>. <article-title>The Role of Non-Coding RNAs in the Pathogenesis of Parkinson&#8217;s Disease: Recent Advancement</article-title>. <source>Pharmaceuticals (Basel)</source><year>2022</year>;<volume>15</volume>.<comment>doi: 10.3390/ph15070811</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph15070811</pub-id><pub-id pub-id-type="pmcid">PMC9315906</pub-id><pub-id pub-id-type="pmid">35890110</pub-id></mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Kou</surname><given-names>W</given-names></name>, <etal/></person-group>. <article-title>Molecular beacon-based detection of circulating microRNA-containing extracellular vesicle as an &#945;-synucleinopathy biomarker</article-title>. <source>Sci Adv</source><year>2024</year>;<volume>10</volume>:<elocation-id>eadl6442</elocation-id>. <comment>doi: 10.1126/sciadv.adl6442</comment>.<pub-id pub-id-type="pmid">38748787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adl6442</pub-id><pub-id pub-id-type="pmcid">PMC11095448</pub-id></mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oosterveld</surname><given-names>LP</given-names></name><name name-style="western"><surname>Verberk</surname><given-names>I</given-names></name><name name-style="western"><surname>Majbour</surname><given-names>NK</given-names></name><name name-style="western"><surname>El-Agnaf</surname><given-names>OM</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>HC</given-names></name><name name-style="western"><surname>Berendse</surname><given-names>HW</given-names></name>, <etal/></person-group>. <article-title>CSF or serum neurofilament light added to &#945;-Synuclein panel discriminates Parkinson&#8217;s from controls</article-title>. <source>Mov Disord</source><year>2020</year>;<volume>35</volume>:<fpage>288</fpage>&#8211;<lpage>295</lpage>. <comment>doi: 10.1002/mds.27897</comment>.<pub-id pub-id-type="pmid">31737952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.27897</pub-id><pub-id pub-id-type="pmcid">PMC7027879</pub-id></mixed-citation></ref><ref id="R51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>CH</given-names></name><name name-style="western"><surname>Li</surname><given-names>CH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>KC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>CC</given-names></name><name name-style="western"><surname>Chieh</surname><given-names>JJ</given-names></name>, <etal/></person-group>. <article-title>Blood NfL: A biomarker for disease severity and progression in Parkinson disease</article-title>. <source>Neurology</source><year>2019</year>;<volume>93</volume>:<fpage>e1104</fpage>&#8211;<lpage>e1111</lpage>. <comment>doi: 10.1212/WNL.0000000000008088</comment>.<pub-id pub-id-type="pmid">31420461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000008088</pub-id></mixed-citation></ref><ref id="R52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansson</surname><given-names>O</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></name><name name-style="western"><surname>Hall</surname><given-names>S</given-names></name><name name-style="western"><surname>Magdalinou</surname><given-names>N</given-names></name><name name-style="western"><surname>Lees</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Andreasson</surname><given-names>U</given-names></name>, <etal/></person-group>. <article-title>Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder</article-title>. <source>Neurology</source><year>2017</year>;<volume>88</volume>:<fpage>930</fpage>&#8211;<lpage>937</lpage>. <comment>doi: 10.1212/WNL.0000000000003680</comment>.<pub-id pub-id-type="pmid">28179466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000003680</pub-id><pub-id pub-id-type="pmcid">PMC5333515</pub-id></mixed-citation></ref><ref id="R53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schirinzi</surname><given-names>T</given-names></name><name name-style="western"><surname>Zenuni</surname><given-names>H</given-names></name><name name-style="western"><surname>Grillo</surname><given-names>P</given-names></name><name name-style="western"><surname>Bovenzi</surname><given-names>R</given-names></name><name name-style="western"><surname>Guerrera</surname><given-names>G</given-names></name><name name-style="western"><surname>Gargano</surname><given-names>F</given-names></name>, <etal/></person-group>. <article-title>Tau and amyloid-&#946; peptides in serum of patients with Parkinson&#8217;s disease: Correlations with CSF levels and clinical parameters</article-title>. <source>Front Neurol</source><year>2022</year>;<volume>13</volume>:<fpage>748599</fpage>. <comment>doi: 10.3389/fneur.2022.748599</comment>.<pub-id pub-id-type="pmid">35280296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2022.748599</pub-id><pub-id pub-id-type="pmcid">PMC8914101</pub-id></mixed-citation></ref><ref id="R54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krawczuk</surname><given-names>D</given-names></name><name name-style="western"><surname>Kulczy&#324;ska-Przybik</surname><given-names>A</given-names></name><name name-style="western"><surname>Mroczko</surname><given-names>B</given-names></name></person-group>. <article-title>Clinical application of blood biomarkers in neurodegenerative diseases-present and future perspectives</article-title>. <source>Int J Mol Sci</source><year>2024</year>;<volume>25</volume>.<comment>doi: 10.3390/ijms25158132</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25158132</pub-id><pub-id pub-id-type="pmcid">PMC11311320</pub-id><pub-id pub-id-type="pmid">39125699</pub-id></mixed-citation></ref><ref id="R55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>X</given-names></name><name name-style="western"><surname>Saffari</surname><given-names>SE</given-names></name><name name-style="western"><surname>Ng</surname><given-names>S</given-names></name><name name-style="western"><surname>Chia</surname><given-names>N</given-names></name><name name-style="western"><surname>Tan</surname><given-names>JY</given-names></name><name name-style="western"><surname>Choi</surname><given-names>X</given-names></name>, <etal/></person-group>. <article-title>Blood lipid biomarkers in early Parkinson&#8217;s disease and Parkinson&#8217;s disease with mild cognitive impairment</article-title>. <source>J Parkinsons Dis</source><year>2022</year>;<volume>12</volume>:<fpage>1937</fpage>&#8211;<lpage>1943</lpage>. <comment>doi: 10.3233/JPD-213135</comment>.<pub-id pub-id-type="pmid">35723114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JPD-213135</pub-id></mixed-citation></ref><ref id="R56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fu</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name></person-group>. <article-title>Changes in serum uric acid, glutathione, and amyloid-&#946;1-42 levels in Parkinson&#8217;s disease patients and their association with disease progression and cognitive decline</article-title>. <source>Curr Med Res Opin</source><year>2025</year>;<volume>41</volume>:<fpage>105</fpage>&#8211;<lpage>113</lpage>. <comment>doi: 10.1080/03007995.2024.2422002</comment>.<pub-id pub-id-type="pmid">39465510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/03007995.2024.2422002</pub-id></mixed-citation></ref><ref id="R57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katunina</surname><given-names>EA</given-names></name><name name-style="western"><surname>Blokhin</surname><given-names>V</given-names></name><name name-style="western"><surname>Nodel</surname><given-names>MR</given-names></name><name name-style="western"><surname>Pavlova</surname><given-names>EN</given-names></name><name name-style="western"><surname>Kalinkin</surname><given-names>AL</given-names></name><name name-style="western"><surname>Kucheryanu</surname><given-names>VG</given-names></name>, <etal/></person-group>. <article-title>Searching for biomarkers in the blood of patients at risk of developing Parkinson&#8217;s disease at the prodromal stage</article-title>. <source>Int J Mol Sci</source><year>2023</year>;<volume>24</volume>:<fpage>1842</fpage>. <comment>doi: 10.3390/ijms24031842</comment>.<pub-id pub-id-type="pmid">36768161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24031842</pub-id><pub-id pub-id-type="pmcid">PMC9915927</pub-id></mixed-citation></ref><ref id="R58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beach</surname><given-names>TG</given-names></name><name name-style="western"><surname>Adler</surname><given-names>CH</given-names></name><name name-style="western"><surname>Sue</surname><given-names>LI</given-names></name><name name-style="western"><surname>Vedders</surname><given-names>L</given-names></name><name name-style="western"><surname>Lue</surname><given-names>L</given-names></name><name name-style="western"><surname>White Iii</surname><given-names>CL</given-names></name>, <etal/></person-group>. <article-title>Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders</article-title>. <source>Acta Neuropathol</source><year>2010</year>;<volume>119</volume>:<fpage>689</fpage>&#8211;<lpage>702</lpage>. <comment>doi: 10.1007/s00401-010-0664-3</comment>.<pub-id pub-id-type="pmid">20306269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-010-0664-3</pub-id><pub-id pub-id-type="pmcid">PMC2866090</pub-id></mixed-citation></ref><ref id="R59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>LY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>GL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>DX</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>MM</given-names></name><name name-style="western"><surname>Kou</surname><given-names>WY</given-names></name><name name-style="western"><surname>Feng</surname><given-names>T</given-names></name></person-group>. <article-title>Alpha-synuclein in peripheral tissues in Parkinson&#8217;s disease</article-title>. <source>ACS Chem Neurosci</source><year>2019</year>;<volume>10</volume>:<fpage>812</fpage>&#8211;<lpage>823</lpage>. <comment>doi: 10.1021/acschemneuro.8b00383</comment>.<pub-id pub-id-type="pmid">30714719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschemneuro.8b00383</pub-id></mixed-citation></ref><ref id="R60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <etal/></person-group>. <article-title>Oral mucosa derived &#945;-synuclein as a potential diagnostic biomarker for Parkinson&#8217;s disease</article-title>. <source>Front Aging Neurosci</source><year>2022</year>;<volume>14</volume>:<fpage>867528</fpage>. <comment>doi: 10.3389/fnagi.2022.867528</comment>.<pub-id pub-id-type="pmid">35418851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.867528</pub-id><pub-id pub-id-type="pmcid">PMC9000972</pub-id></mixed-citation></ref><ref id="R61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsukita</surname><given-names>K</given-names></name><name name-style="western"><surname>Sakamaki-Tsukita</surname><given-names>H</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>K</given-names></name><name name-style="western"><surname>Suenaga</surname><given-names>T</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>R</given-names></name></person-group>. <article-title>Value of in vivo &#945;-synuclein deposits in Parkinson&#8217;s disease: A systematic review and meta-analysis</article-title>. <source>Mov Disord</source><year>2019</year>;<volume>34</volume>:<fpage>1452</fpage>&#8211;<lpage>1463</lpage>. <comment>doi: 10.1002/mds.27794</comment>.<pub-id pub-id-type="pmid">31322768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.27794</pub-id></mixed-citation></ref><ref id="R62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibbons</surname><given-names>CH</given-names></name><name name-style="western"><surname>Levine</surname><given-names>T</given-names></name><name name-style="western"><surname>Adler</surname><given-names>C</given-names></name><name name-style="western"><surname>Bellaire</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Stohl</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>Skin biopsy detection of phosphorylated &#945;-synuclein in patients with synucleinopathies</article-title>. <source>JAMA</source><year>2024</year>;<volume>331</volume>:<fpage>1298</fpage>&#8211;<lpage>1306</lpage>. <comment>doi: 10.1001/jama.2024.0792</comment>.<pub-id pub-id-type="pmid">38506839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2024.0792</pub-id><pub-id pub-id-type="pmcid">PMC10955354</pub-id></mixed-citation></ref><ref id="R63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manne</surname><given-names>S</given-names></name><name name-style="western"><surname>Kondru</surname><given-names>N</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H</given-names></name><name name-style="western"><surname>Anantharam</surname><given-names>V</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Kanthasamy</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>&#945;-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson&#8217;s disease patients</article-title>. <source>Mov Disord</source><year>2020</year>;<volume>35</volume>:<fpage>268</fpage>&#8211;<lpage>278</lpage>. <comment>doi: 10.1002/mds.27907</comment>.<pub-id pub-id-type="pmid">31758740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.27907</pub-id><pub-id pub-id-type="pmcid">PMC7102508</pub-id></mixed-citation></ref><ref id="R64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chahine</surname><given-names>LM</given-names></name><name name-style="western"><surname>Beach</surname><given-names>TG</given-names></name><name name-style="western"><surname>Adler</surname><given-names>CH</given-names></name><name name-style="western"><surname>Hepker</surname><given-names>M</given-names></name><name name-style="western"><surname>Kanthasamy</surname><given-names>A</given-names></name><name name-style="western"><surname>Appel</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>Central and peripheral &#945;-synuclein in Parkinson disease detected by seed amplification assay</article-title>. <source>Ann Clin Transl Neurol</source><year>2023</year>;<volume>10</volume>:<fpage>696</fpage>&#8211;<lpage>705</lpage>. <comment>doi: 10.1002/acn3.51753</comment>.<pub-id pub-id-type="pmid">36972727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.51753</pub-id><pub-id pub-id-type="pmcid">PMC10187727</pub-id></mixed-citation></ref><ref id="R65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luan</surname><given-names>M</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L</given-names></name>, <etal/></person-group>. <article-title>Diagnostic value of salivary real-time quaking-induced conversion in Parkinson&#8217;s disease and multiple system atrophy</article-title>. <source>Mov Disord</source><year>2022</year>;<volume>37</volume>:<fpage>1059</fpage>&#8211;<lpage>1063</lpage>. <comment>doi: 10.1002/mds.28976</comment>.<pub-id pub-id-type="pmid">35278004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.28976</pub-id></mixed-citation></ref><ref id="R66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vivacqua</surname><given-names>G</given-names></name><name name-style="western"><surname>Mason</surname><given-names>M</given-names></name><name name-style="western"><surname>De Bartolo</surname><given-names>MI</given-names></name><name name-style="western"><surname>W&#281;grzynowicz</surname><given-names>M</given-names></name><name name-style="western"><surname>Cal&#242;</surname><given-names>L</given-names></name><name name-style="western"><surname>Belvisi</surname><given-names>D</given-names></name>, <etal/></person-group>. <article-title>Salivary &#945;-synuclein RT-QuIC correlates with disease severity in de novo Parkinson&#8217;s disease</article-title>. <source>Mov Disord</source><year>2023</year>;<volume>38</volume>:<fpage>153</fpage>&#8211;<lpage>155</lpage>. <comment>doi: 10.1002/mds.29246</comment>.<pub-id pub-id-type="pmid">36259554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.29246</pub-id><pub-id pub-id-type="pmcid">PMC10092811</pub-id></mixed-citation></ref><ref id="R67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manne</surname><given-names>S</given-names></name><name name-style="western"><surname>Kondru</surname><given-names>N</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>GE</given-names></name><name name-style="western"><surname>Anantharam</surname><given-names>V</given-names></name><name name-style="western"><surname>Kanthasamy</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>Blinded RT-QuIC Analysis of &#945;-Synuclein Biomarker in Skin Tissue From Parkinson&#8217;s Disease Patients</article-title>. <source>Mov Disord</source><year>2020</year>;<volume>35</volume>:<fpage>2230</fpage>&#8211;<lpage>2239</lpage>. <comment>doi: 10.1002/mds.28242</comment>.<pub-id pub-id-type="pmid">32960470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.28242</pub-id><pub-id pub-id-type="pmcid">PMC7749035</pub-id></mixed-citation></ref><ref id="R68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuzkina</surname><given-names>A</given-names></name><name name-style="western"><surname>Bargar</surname><given-names>C</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>D</given-names></name><name name-style="western"><surname>R&#246;&#223;le</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>AL</given-names></name>, <etal/></person-group>. <article-title>Diagnostic value of skin RT-QuIC in Parkinson&#8217;s disease: a two-laboratory study</article-title>. <source>NPJ Parkinsons Dis</source><year>2021</year>;<volume>7</volume>:<fpage>99</fpage>. <comment>doi: 10.1038/s41531-021-00242-2</comment>.<pub-id pub-id-type="pmid">34782640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-021-00242-2</pub-id><pub-id pub-id-type="pmcid">PMC8593128</pub-id></mixed-citation></ref><ref id="R69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shi</surname><given-names>M</given-names></name><name name-style="western"><surname>Chung</surname><given-names>KA</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>JF</given-names></name><name name-style="western"><surname>Peskind</surname><given-names>ER</given-names></name><name name-style="western"><surname>Galasko</surname><given-names>D</given-names></name>, <etal/></person-group>. <article-title>DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson&#8217;s disease</article-title>. <source>Brain</source><year>2010</year>;<volume>133</volume>:<fpage>713</fpage>&#8211;<lpage>726</lpage>. <comment>doi: 10.1093/brain/awq008</comment>.<pub-id pub-id-type="pmid">20157014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awq008</pub-id><pub-id pub-id-type="pmcid">PMC2842513</pub-id></mixed-citation></ref><ref id="R70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donadio</surname><given-names>V</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Incensi</surname><given-names>A</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>G</given-names></name><name name-style="western"><surname>Fileccia</surname><given-names>E</given-names></name><name name-style="western"><surname>Vacchiano</surname><given-names>V</given-names></name>, <etal/></person-group>. <article-title>In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC</article-title>. <source>Neurology</source><year>2021</year>;<volume>96</volume>:<fpage>e2513</fpage>&#8211;<lpage>e2524</lpage>. <comment>doi: 10.1212/WNL.0000000000011935</comment>.<pub-id pub-id-type="pmid">33837116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000011935</pub-id><pub-id pub-id-type="pmcid">PMC8205473</pub-id></mixed-citation></ref><ref id="R71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K</given-names></name><name name-style="western"><surname>Donadio</surname><given-names>V</given-names></name><name name-style="western"><surname>Siedlak</surname><given-names>S</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name><name name-style="western"><surname>Rezaee</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Skin &#945;-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease</article-title>. <source>JAMA Neurol</source><year>2020</year>;<volume>78</volume>:<fpage>1</fpage>&#8211;<lpage>11</lpage>. <comment>doi: 10.1001/jamaneurol.2020.3311</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2020.3311</pub-id><pub-id pub-id-type="pmcid">PMC7522783</pub-id><pub-id pub-id-type="pmid">32986090</pub-id></mixed-citation></ref><ref id="R72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuzkina</surname><given-names>A</given-names></name><name name-style="western"><surname>Panzer</surname><given-names>C</given-names></name><name name-style="western"><surname>Seger</surname><given-names>A</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>D</given-names></name><name name-style="western"><surname>R&#246;&#223;le</surname><given-names>J</given-names></name><name name-style="western"><surname>Schreglmann</surname><given-names>SR</given-names></name>, <etal/></person-group>. <article-title>Dermal real-time quaking-induced conversion is a sensitive marker to confirm isolated rapid eye movement sleep behavior disorder as an early &#945;-synucleinopathy</article-title>. <source>Mov Disord</source><year>2023</year>;<volume>38</volume>:<fpage>1077</fpage>&#8211;<lpage>1082</lpage>. <comment>doi: 10.1002/mds.29340</comment>.<pub-id pub-id-type="pmid">36750755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.29340</pub-id></mixed-citation></ref><ref id="R73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stefani</surname><given-names>A</given-names></name><name name-style="western"><surname>Iranzo</surname><given-names>A</given-names></name><name name-style="western"><surname>Holzknecht</surname><given-names>E</given-names></name><name name-style="western"><surname>Perra</surname><given-names>D</given-names></name><name name-style="western"><surname>Bongianni</surname><given-names>M</given-names></name><name name-style="western"><surname>Gaig</surname><given-names>C</given-names></name>, <etal/></person-group>. <article-title>Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder</article-title>. <source>Brain</source><year>2021</year>;<volume>144</volume>:<fpage>1118</fpage>&#8211;<lpage>1126</lpage>. <comment>doi: 10.1093/brain/awab005</comment>.<pub-id pub-id-type="pmid">33855335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awab005</pub-id></mixed-citation></ref><ref id="R74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Luca</surname><given-names>C</given-names></name><name name-style="western"><surname>Elia</surname><given-names>AE</given-names></name><name name-style="western"><surname>Portaleone</surname><given-names>SM</given-names></name><name name-style="western"><surname>Cazzaniga</surname><given-names>FA</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>M</given-names></name><name name-style="western"><surname>Bistaffa</surname><given-names>E</given-names></name>, <etal/></person-group>. <article-title>Efficient RT-QuIC seeding activity for &#945;-synuclein in olfactory mucosa samples of patients with Parkinson&#8217;s disease and multiple system atrophy</article-title>. <source>Transl Neurodegener</source><year>2019</year>;<volume>8</volume>:<fpage>24</fpage>. <comment>doi: 10.1186/s40035-019-0164-x</comment>.<pub-id pub-id-type="pmid">31406572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-019-0164-x</pub-id><pub-id pub-id-type="pmcid">PMC6686411</pub-id></mixed-citation></ref><ref id="R75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bargar</surname><given-names>C</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>C</given-names></name><name name-style="western"><surname>Devigili</surname><given-names>G</given-names></name><name name-style="western"><surname>Elia</surname><given-names>AE</given-names></name><name name-style="western"><surname>Cilia</surname><given-names>R</given-names></name><name name-style="western"><surname>Portaleone</surname><given-names>SM</given-names></name>, <etal/></person-group>. <article-title>Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories</article-title>. <source>Mol Neurodegener</source><year>2021</year>;<volume>16</volume>:<fpage>82</fpage>. <comment>doi: 10.1186/s13024-021-00491-y</comment>.<pub-id pub-id-type="pmid">34895275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-021-00491-y</pub-id><pub-id pub-id-type="pmcid">PMC8665327</pub-id></mixed-citation></ref><ref id="R76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bongianni</surname><given-names>M</given-names></name><name name-style="western"><surname>Catalan</surname><given-names>M</given-names></name><name name-style="western"><surname>Perra</surname><given-names>D</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>E</given-names></name><name name-style="western"><surname>Janes</surname><given-names>F</given-names></name><name name-style="western"><surname>Bertolotti</surname><given-names>C</given-names></name>, <etal/></person-group>. <article-title>Olfactory swab sampling optimization for &#945;-synuclein aggregate detection in patients with Parkinson&#8217;s disease</article-title>. <source>Transl Neurodegener</source><year>2022</year>;<volume>11</volume>:<fpage>37</fpage>. <comment>doi: 10.1186/s40035-022-00311-3</comment>.<pub-id pub-id-type="pmid">35902902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-022-00311-3</pub-id><pub-id pub-id-type="pmcid">PMC9330656</pub-id></mixed-citation></ref><ref id="R77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuzkina</surname><given-names>A</given-names></name><name name-style="western"><surname>R&#246;&#223;le</surname><given-names>J</given-names></name><name name-style="western"><surname>Seger</surname><given-names>A</given-names></name><name name-style="western"><surname>Panzer</surname><given-names>C</given-names></name><name name-style="western"><surname>Kohl</surname><given-names>A</given-names></name><name name-style="western"><surname>Maltese</surname><given-names>V</given-names></name>, <etal/></person-group>. <article-title>Combining skin and olfactory &#945;-synuclein seed amplification assays (SAA)-towards biomarker-driven phenotyping in synucleinopathies</article-title>. <source>NPJ Parkinsons Dis</source><year>2023</year>;<volume>9</volume>:<fpage>79</fpage>. <comment>doi: 10.1038/s41531-023-00519-8</comment>.<pub-id pub-id-type="pmid">37248217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-023-00519-8</pub-id><pub-id pub-id-type="pmcid">PMC10226020</pub-id></mixed-citation></ref><ref id="R78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Kou</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>Detection of &#945;-synuclein in oral mucosa by seed amplification assay in synucleinopathies and isolated REM sleep behavior disorder</article-title>. <source>Mov Disord</source><year>2024</year>;<volume>39</volume>:<fpage>1300</fpage>&#8211;<lpage>1309</lpage>. <comment>doi: 10.1002/mds.29828</comment>.<pub-id pub-id-type="pmid">38715177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.29828</pub-id></mixed-citation></ref><ref id="R79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chau</surname><given-names>MT</given-names></name><name name-style="western"><surname>Todd</surname><given-names>G</given-names></name><name name-style="western"><surname>Wilcox</surname><given-names>R</given-names></name><name name-style="western"><surname>Agzarian</surname><given-names>M</given-names></name><name name-style="western"><surname>Bezak</surname><given-names>E</given-names></name></person-group>. <article-title>Diagnostic accuracy of the appearance of Nigrosome-1 on magnetic resonance imaging in Parkinson&#8217;s disease: A systematic review and meta-analysis</article-title>. <source>Parkinsonism Relat Disord</source><year>2020</year>;<volume>78</volume>:<fpage>12</fpage>&#8211;<lpage>20</lpage>. <comment>doi: 10.1016/j.parkreldis.2020.07.002</comment>.<pub-id pub-id-type="pmid">32668370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2020.07.002</pub-id></mixed-citation></ref><ref id="R80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berg</surname><given-names>D</given-names></name><name name-style="western"><surname>Postuma</surname><given-names>RB</given-names></name><name name-style="western"><surname>Bloem</surname><given-names>B</given-names></name><name name-style="western"><surname>Chan</surname><given-names>P</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>B</given-names></name><name name-style="western"><surname>Gasser</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson&#8217;s disease</article-title>. <source>Mov Disord</source><year>2014</year>;<volume>29</volume>:<fpage>454</fpage>&#8211;<lpage>462</lpage>. <comment>doi: 10.1002/mds.25844</comment>.<pub-id pub-id-type="pmid">24619848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.25844</pub-id><pub-id pub-id-type="pmcid">PMC4204150</pub-id></mixed-citation></ref><ref id="R81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sacks</surname><given-names>D</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>B</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>BCV</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>JS</given-names></name><name name-style="western"><surname>Cognard</surname><given-names>C</given-names></name><name name-style="western"><surname>Dippel</surname><given-names>D</given-names></name>, <etal/></person-group>. <article-title>Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke</article-title>. <source>Int J Stroke</source><year>2018</year>;<volume>13</volume>:<fpage>612</fpage>&#8211;<lpage>632</lpage>. <comment>doi: 10.1177/1747493018778713</comment>.<pub-id pub-id-type="pmid">29786478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1747493018778713</pub-id></mixed-citation></ref><ref id="R82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>He</surname><given-names>N</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>R</given-names></name><name name-style="western"><surname>Sethi</surname><given-names>SK</given-names></name>, <etal/></person-group>. <article-title>Imaging the Nigrosome 1 in the substantia nigra using susceptibility weighted imaging and quantitative susceptibility mapping: An application to Parkinson&#8217;s disease</article-title>. <source>Neuroimage Clin</source><year>2020</year>;<volume>25</volume>:<fpage>102103</fpage>. <comment>doi: 10.1016/j.nicl.2019.102103</comment>.<pub-id pub-id-type="pmid">31869769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2019.102103</pub-id><pub-id pub-id-type="pmcid">PMC6933220</pub-id></mixed-citation></ref><ref id="R83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>J</given-names></name><name name-style="western"><surname>Su</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lam</surname><given-names>JST</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Feng</surname><given-names>T</given-names></name></person-group>. <article-title>Iron deposition in subcortical nuclei of Parkinson&#8217;s disease: A meta-analysis of quantitative iron-sensitive magnetic resonance imaging studies</article-title>. <source>Chin Med J</source><year>2025</year>;<volume>138</volume>:<fpage>678</fpage>&#8211;<lpage>692</lpage>. <comment>doi: 10.1097/CM9.0000000000003167</comment>.<pub-id pub-id-type="pmid">38809051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000003167</pub-id><pub-id pub-id-type="pmcid">PMC11925423</pub-id></mixed-citation></ref><ref id="R84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name></person-group>. <article-title>Using &#8216;swallow-tail&#8217; sign and putaminal hypointensity as biomarkers to distinguish multiple system atrophy from idiopathic Parkinson&#8217;s disease: A susceptibility-weighted imaging study</article-title>. <source>Eur Radiol</source><year>2017</year>;<volume>27</volume>:<fpage>3174</fpage>&#8211;<lpage>3180</lpage>. <comment>doi: 10.1007/s00330-017-4743-x</comment>.<pub-id pub-id-type="pmid">28105503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-017-4743-x</pub-id></mixed-citation></ref><ref id="R85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>BH</given-names></name><name name-style="western"><surname>Moon</surname><given-names>HC</given-names></name><name name-style="western"><surname>Kim</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Cheong</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Park</surname><given-names>YS</given-names></name></person-group>. <article-title>Prefrontal and hippocampal atrophy using 7-tesla magnetic resonance imaging in patients with Parkinson&#8217;s disease</article-title>. <source>Acta Radiol Open.</source><year>2021</year>;<volume>10</volume>:<fpage>2058460120988097</fpage>. <comment>doi: 10.1177/2058460120988097</comment>.<pub-id pub-id-type="pmid">33786201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2058460120988097</pub-id><pub-id pub-id-type="pmcid">PMC7958639</pub-id></mixed-citation></ref><ref id="R86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>DH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JM</given-names></name><name name-style="western"><surname>Oh</surname><given-names>SH</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Park</surname><given-names>SY</given-names></name><name name-style="western"><surname>Oh</surname><given-names>ES</given-names></name>, <etal/></person-group>. <article-title>Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease</article-title>. <source>Ann Neurol</source><year>2012</year>;<volume>71</volume>:<fpage>267</fpage>&#8211;<lpage>277</lpage>. <comment>doi: 10.1002/ana.22592</comment>.<pub-id pub-id-type="pmid">22367998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.22592</pub-id></mixed-citation></ref><ref id="R87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>ST</given-names></name><name name-style="western"><surname>Mougin</surname><given-names>O</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Y</given-names></name><name name-style="western"><surname>Blazejewska</surname><given-names>A</given-names></name><name name-style="western"><surname>Bajaj</surname><given-names>N</given-names></name><name name-style="western"><surname>Auer</surname><given-names>DP</given-names></name>, <etal/></person-group>. <article-title>Parkinson&#8217;s disease related signal change in the nigrosomes 1-5 and the substantia nigra using T2* weighted 7T MRI</article-title>. <source>Neuroimage Clin</source><year>2018</year>;<volume>19</volume>:<fpage>683</fpage>&#8211;<lpage>689</lpage>. <comment>doi: 10.1016/j.nicl.2018.05.027</comment>.<pub-id pub-id-type="pmid">29872633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2018.05.027</pub-id><pub-id pub-id-type="pmcid">PMC5986169</pub-id></mixed-citation></ref><ref id="R88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>ZH</given-names></name><name name-style="western"><surname>Oh</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JM</given-names></name><name name-style="western"><surname>Park</surname><given-names>SY</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>DH</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>HJ</given-names></name>, <etal/></person-group>. <article-title>Direct visualization of Parkinson&#8217;s disease by in vivo human brain imaging using 7.0T magnetic resonance imaging</article-title>. <source>Mov Disord</source><year>2011</year>;<volume>26</volume>:<fpage>713</fpage>&#8211;<lpage>718</lpage>. <comment>doi: 10.1002/mds.23465</comment>.<pub-id pub-id-type="pmid">21506148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.23465</pub-id></mixed-citation></ref><ref id="R89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>N</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name><name name-style="western"><surname>Ling</surname><given-names>H</given-names></name><name name-style="western"><surname>Langley</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Ding</surname><given-names>B</given-names></name>, <etal/></person-group>. <article-title>Dentate nucleus iron deposition is a potential biomarker for tremor-dominant Parkinson&#8217;s disease</article-title>. <source>NMR Biomed</source><year>2017</year>;<volume>30</volume>.<comment>doi: 10.1002/nbm.3554</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/nbm.3554</pub-id><pub-id pub-id-type="pmcid">PMC4906439</pub-id><pub-id pub-id-type="pmid">27192177</pub-id></mixed-citation></ref><ref id="R90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Baek</surname><given-names>SY</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>MP</given-names></name>, <etal/></person-group>. <article-title>The Neuromelanin-related T2* contrast in postmortem human substantia nigra with 7T MRI</article-title>. <source>Sci Rep</source><year>2016</year>;<volume>6</volume>:<fpage>32647</fpage>. <comment>doi: 10.1038/srep32647</comment>.<pub-id pub-id-type="pmid">27596274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep32647</pub-id><pub-id pub-id-type="pmcid">PMC5011647</pub-id></mixed-citation></ref><ref id="R91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name>, <etal/></person-group>. <article-title>The diagnostic value of SNpc using NM-MRI in Parkinson&#8217;s disease: meta-analysis</article-title>. <source>Neurol Sci</source><year>2019</year>;<volume>40</volume>:<fpage>2479</fpage>&#8211;<lpage>2489</lpage>. <comment>doi: 10.1007/s10072-019-04014-y</comment>.<pub-id pub-id-type="pmid">31392640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10072-019-04014-y</pub-id></mixed-citation></ref><ref id="R92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vitali</surname><given-names>P</given-names></name><name name-style="western"><surname>Pan</surname><given-names>MI</given-names></name><name name-style="western"><surname>Palesi</surname><given-names>F</given-names></name><name name-style="western"><surname>Germani</surname><given-names>G</given-names></name><name name-style="western"><surname>Faggioli</surname><given-names>A</given-names></name><name name-style="western"><surname>Anzalone</surname><given-names>N</given-names></name>, <etal/></person-group>. <article-title>Substantia nigra volumetry with 3-T MRI in <italic toggle="yes">de novo</italic> and advanced Parkinson disease</article-title>. <source>Radiology</source><year>2020</year>;<volume>296</volume>:<fpage>401</fpage>&#8211;<lpage>410</lpage>. <comment>doi: 10.1148/radiol.2020191235</comment>.<pub-id pub-id-type="pmid">32544035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.2020191235</pub-id></mixed-citation></ref><ref id="R93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biondetti</surname><given-names>E</given-names></name><name name-style="western"><surname>Gaurav</surname><given-names>R</given-names></name><name name-style="western"><surname>Yahia-Cherif</surname><given-names>L</given-names></name><name name-style="western"><surname>Mangone</surname><given-names>G</given-names></name><name name-style="western"><surname>Pyatigorskaya</surname><given-names>N</given-names></name><name name-style="western"><surname>Valabr&#232;gue</surname><given-names>R</given-names></name>, <etal/></person-group>. <article-title>Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson&#8217;s disease</article-title>. <source>Brain</source><year>2020</year>;<volume>143</volume>:<fpage>2757</fpage>&#8211;<lpage>2770</lpage>. <comment>doi: 10.1093/brain/awaa216</comment>.<pub-id pub-id-type="pmid">32856056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awaa216</pub-id></mixed-citation></ref><ref id="R94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ehrminger</surname><given-names>M</given-names></name><name name-style="western"><surname>Latimier</surname><given-names>A</given-names></name><name name-style="western"><surname>Pyatigorskaya</surname><given-names>N</given-names></name><name name-style="western"><surname>Garcia-Lorenzo</surname><given-names>D</given-names></name><name name-style="western"><surname>Leu-Semenescu</surname><given-names>S</given-names></name><name name-style="western"><surname>Vidailhet</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder</article-title>. <source>Brain</source><year>2016</year>;<volume>139</volume>:<fpage>1180</fpage>&#8211;<lpage>1188</lpage>. <comment>doi: 10.1093/brain/aww006</comment>.<pub-id pub-id-type="pmid">26920675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aww006</pub-id></mixed-citation></ref><ref id="R95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>T</given-names></name><name name-style="western"><surname>Leh&#233;ricy</surname><given-names>S</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>SY</given-names></name><name name-style="western"><surname>Strafella</surname><given-names>AP</given-names></name><name name-style="western"><surname>Stoessl</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Vaillancourt</surname><given-names>DE</given-names></name></person-group>. <article-title>Emerging neuroimaging biomarkers across disease stage in Parkinson disease: A review</article-title>. <source>JAMA Neurol</source><year>2021</year>;<volume>78</volume>:<fpage>1262</fpage>&#8211;<lpage>1272</lpage>. <comment>doi: 10.1001/jamaneurol.2021.1312</comment>.<pub-id pub-id-type="pmid">34459865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2021.1312</pub-id><pub-id pub-id-type="pmcid">PMC9017381</pub-id></mixed-citation></ref><ref id="R96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name><name name-style="western"><surname>Martin-Bastida</surname><given-names>A</given-names></name><name name-style="western"><surname>Murueta-Goyena</surname><given-names>A</given-names></name><name name-style="western"><surname>Gabilondo</surname><given-names>I</given-names></name><name name-style="western"><surname>Cuenca</surname><given-names>N</given-names></name><name name-style="western"><surname>Piccini</surname><given-names>P</given-names></name>, <etal/></person-group>. <article-title>Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease</article-title>. <source>Nat Rev Neurol</source><year>2022</year>;<volume>18</volume>:<fpage>203</fpage>&#8211;<lpage>220</lpage>. <comment>doi: 10.1038/s41582-022-00618-9</comment>.<pub-id pub-id-type="pmid">35177849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-022-00618-9</pub-id></mixed-citation></ref><ref id="R97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshikawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>M</given-names></name></person-group>. <article-title>Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2004</year>;<volume>75</volume>:<fpage>481</fpage>&#8211;<lpage>484</lpage>. <comment>doi: 10.1136/jnnp.2003.021873</comment>.<pub-id pub-id-type="pmid">14966170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.2003.021873</pub-id><pub-id pub-id-type="pmcid">PMC1738942</pub-id></mixed-citation></ref><ref id="R98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>XB</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XX</given-names></name><name name-style="western"><surname>Xia</surname><given-names>DH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Tian</surname><given-names>HY</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name>, <etal/></person-group>. <article-title>Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson&#8217;s disease</article-title>. <source>Nat Med</source><year>2021</year>;<volume>27</volume>:<fpage>411</fpage>&#8211;<lpage>418</lpage>. <comment>doi: 10.1038/s41591-020-01198-1</comment>.<pub-id pub-id-type="pmid">33462448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-01198-1</pub-id></mixed-citation></ref><ref id="R99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKnight</surname><given-names>CD</given-names></name><name name-style="western"><surname>Trujillo</surname><given-names>P</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>AM</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>K</given-names></name><name name-style="western"><surname>Considine</surname><given-names>C</given-names></name><name name-style="western"><surname>Lin</surname><given-names>YC</given-names></name>, <etal/></person-group>. <article-title>Diffusion along perivascular spaces reveals evidence supportive of glymphatic function impairment in Parkinson disease</article-title>. <source>Parkinsonism Relat Disord</source><year>2021</year>;<volume>89</volume>:<fpage>98</fpage>&#8211;<lpage>104</lpage>. <comment>doi: 10.1016/j.parkreldis.2021.06.004</comment>.<pub-id pub-id-type="pmid">34271425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2021.06.004</pub-id><pub-id pub-id-type="pmcid">PMC8429254</pub-id></mixed-citation></ref><ref id="R100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JM</given-names></name><name name-style="western"><surname>Choi</surname><given-names>BS</given-names></name><name name-style="western"><surname>Ryoo</surname><given-names>N</given-names></name><name name-style="western"><surname>Song</surname><given-names>YS</given-names></name><name name-style="western"><surname>Nam</surname><given-names>Y</given-names></name>, <etal/></person-group>. <article-title>Altered brain glymphatic flow at diffusion-tensor MRI in rapid eye movement sleep behavior disorder</article-title>. <source>Radiology</source><year>2023</year>;<volume>307</volume>:<fpage>e221848</fpage>. <comment>doi: 10.1148/radiol.221848</comment>.<pub-id pub-id-type="pmid">37158722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.221848</pub-id></mixed-citation></ref><ref id="R101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evangelisti</surname><given-names>S</given-names></name><name name-style="western"><surname>Boessenkool</surname><given-names>S</given-names></name><name name-style="western"><surname>Pflanz</surname><given-names>CP</given-names></name><name name-style="western"><surname>Basting</surname><given-names>R</given-names></name><name name-style="western"><surname>Betts</surname><given-names>JF</given-names></name><name name-style="western"><surname>Jenkinson</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Subthalamic nucleus shows opposite functional connectivity pattern in Huntington&#8217;s and Parkinson&#8217;s disease</article-title>. <source>Brain Commun</source><year>2023</year>;<volume>5</volume>:<elocation-id>fcad282</elocation-id>. <comment>doi: 10.1093/braincomms/fcad282</comment>.<pub-id pub-id-type="pmid">38075949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcad282</pub-id><pub-id pub-id-type="pmcid">PMC10699743</pub-id></mixed-citation></ref><ref id="R102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>HC</given-names></name><name name-style="western"><surname>Kim</surname><given-names>A</given-names></name><name name-style="western"><surname>Park</surname><given-names>YS</given-names></name></person-group>. <article-title>Brain structure comparison among Parkinson disease, essential tremor, and healthy controls using 7T MRI</article-title>. <source>Medicine (Baltimore)</source><year>2024</year>;<volume>103</volume>:<fpage>e38139</fpage>. <comment>doi: 10.1097/MD.0000000000038139</comment>.<pub-id pub-id-type="pmid">38728497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000038139</pub-id><pub-id pub-id-type="pmcid">PMC11081548</pub-id></mixed-citation></ref><ref id="R103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>DJ</given-names></name></person-group>. <article-title>Molecular imaging of dopamine transporters</article-title>. <source>Ageing Res Rev</source><year>2016</year>;<volume>30</volume>:<fpage>114</fpage>&#8211;<lpage>121</lpage>. <comment>doi: 10.1016/j.arr.2015.12.009</comment>.<pub-id pub-id-type="pmid">26802555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2015.12.009</pub-id></mixed-citation></ref><ref id="R104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>DJ</given-names></name></person-group>. <article-title>Technology insight: imaging neurodegeneration in Parkinson&#8217;s disease</article-title>. <source>Nat Clin Pract Neurol</source><year>2008</year>;<volume>4</volume>:<fpage>267</fpage>&#8211;<lpage>277</lpage>. <comment>doi: 10.1038/ncpneuro0773</comment>.<pub-id pub-id-type="pmid">18382437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncpneuro0773</pub-id></mixed-citation></ref><ref id="R105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K</given-names></name><name name-style="western"><surname>Wagle Shukla</surname><given-names>A</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y</given-names></name></person-group>. <article-title>Imaging of dopamine transporters in Parkinson disease: A meta-analysis of (18) F/(123) I-FP-CIT studies</article-title>. <source>Ann Clin Transl Neurol</source><year>2020</year>;<volume>7</volume>:<fpage>1524</fpage>&#8211;<lpage>1534</lpage>. <comment>doi: 10.1002/acn3.51122</comment>.<pub-id pub-id-type="pmid">32794655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.51122</pub-id><pub-id pub-id-type="pmcid">PMC7480930</pub-id></mixed-citation></ref><ref id="R106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>YH</given-names></name><name name-style="western"><surname>Yen</surname><given-names>TC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>MC</given-names></name><name name-style="western"><surname>Kao</surname><given-names>PF</given-names></name><name name-style="western"><surname>Tzen</surname><given-names>KY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>RS</given-names></name>, <etal/></person-group>. <article-title>Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson&#8217;s disease from healthy subjects</article-title>. <source>J Nucl Med</source><year>2004</year>;<volume>45</volume>:<fpage>393</fpage>&#8211;<lpage>401</lpage>.<pub-id pub-id-type="pmid">15001678</pub-id></mixed-citation></ref><ref id="R107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doepp</surname><given-names>F</given-names></name><name name-style="western"><surname>Plotkin</surname><given-names>M</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>L</given-names></name><name name-style="western"><surname>Kivi</surname><given-names>A</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>D</given-names></name><name name-style="western"><surname>Lobsien</surname><given-names>E</given-names></name>, <etal/></person-group>. <article-title>Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson&#8217;s disease and essential tremor</article-title>. <source>Mov Disord</source><year>2008</year>;<volume>23</volume>:<fpage>405</fpage>&#8211;<lpage>410</lpage>. <comment>doi: 10.1002/mds.21861</comment>.<pub-id pub-id-type="pmid">18067184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.21861</pub-id></mixed-citation></ref><ref id="R108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Brendel</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2022</year>;<volume>49</volume>:<fpage>2798</fpage>&#8211;<lpage>2811</lpage>. <comment>doi: 10.1007/s00259-022-05804-x</comment>.<pub-id pub-id-type="pmid">35588012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-022-05804-x</pub-id><pub-id pub-id-type="pmcid">PMC9206631</pub-id></mixed-citation></ref><ref id="R109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marek</surname><given-names>K</given-names></name><name name-style="western"><surname>Innis</surname><given-names>R</given-names></name><name name-style="western"><surname>van Dyck</surname><given-names>C</given-names></name><name name-style="western"><surname>Fussell</surname><given-names>B</given-names></name><name name-style="western"><surname>Early</surname><given-names>M</given-names></name><name name-style="western"><surname>Eberly</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson&#8217;s disease progression</article-title>. <source>Neurology</source><year>2001</year>;<volume>57</volume>:<fpage>2089</fpage>&#8211;<lpage>2094</lpage>. <comment>doi: 10.1212/wnl.57.11.2089</comment>.<pub-id pub-id-type="pmid">11739831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.57.11.2089</pub-id></mixed-citation></ref><ref id="R110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>J</given-names></name><name name-style="western"><surname>Storch</surname><given-names>A</given-names></name><name name-style="western"><surname>Koch</surname><given-names>W</given-names></name><name name-style="western"><surname>Pogarell</surname><given-names>O</given-names></name><name name-style="western"><surname>Radau</surname><given-names>PE</given-names></name><name name-style="western"><surname>Tatsch</surname><given-names>K</given-names></name></person-group>. <article-title>Loss of dopamine transporter binding in Parkinson&#8217;s disease follows a single exponential rather than linear decline</article-title>. <source>J Nucl Med</source><year>2004</year>;<volume>45</volume>:<fpage>1694</fpage>&#8211;<lpage>1697</lpage>.<pub-id pub-id-type="pmid">15471835</pub-id></mixed-citation></ref><ref id="R111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karimi</surname><given-names>M</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L</given-names></name><name name-style="western"><surname>Brown</surname><given-names>CA</given-names></name><name name-style="western"><surname>Flores</surname><given-names>HP</given-names></name><name name-style="western"><surname>Loftin</surname><given-names>SK</given-names></name><name name-style="western"><surname>Videen</surname><given-names>TO</given-names></name>, <etal/></person-group>. <article-title>Validation of nigrostriatal positron emission tomography measures: critical limits</article-title>. <source>Ann Neurol</source><year>2013</year>;<volume>73</volume>:<fpage>390</fpage>&#8211;<lpage>396</lpage>. <comment>doi: 10.1002/ana.23798</comment>.<pub-id pub-id-type="pmid">23423933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.23798</pub-id><pub-id pub-id-type="pmcid">PMC3631302</pub-id></mixed-citation></ref><ref id="R112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snow</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Tooyama</surname><given-names>I</given-names></name><name name-style="western"><surname>McGeer</surname><given-names>EG</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>T</given-names></name><name name-style="western"><surname>Calne</surname><given-names>DB</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></name>, <etal/></person-group>. <article-title>Human positron emission tomographic [18F] fluorodopa studies correlate with dopamine cell counts and levels</article-title>. <source>Ann Neurol</source><year>1993</year>;<volume>34</volume>:<fpage>324</fpage>&#8211;<lpage>330</lpage>. <comment>doi: 10.1002/ana.410340304</comment>.<pub-id pub-id-type="pmid">8363349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.410340304</pub-id></mixed-citation></ref><ref id="R113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morrish</surname><given-names>PK</given-names></name><name name-style="western"><surname>Sawle</surname><given-names>GV</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>DJ</given-names></name></person-group>. <article-title>Regional changes in [18F] dopa metabolism in the striatum in Parkinson&#8217;s disease</article-title>. <source>Brain</source><year>1996</year>;<volume>119</volume>(<issue> Pt 6</issue>):<fpage>2097</fpage>&#8211;<lpage>2103</lpage>. <comment>doi: 10.1093/brain/119.6.2097</comment>.<pub-id pub-id-type="pmid">9010013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/119.6.2097</pub-id></mixed-citation></ref><ref id="R114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oehme</surname><given-names>L</given-names></name><name name-style="western"><surname>Perick</surname><given-names>M</given-names></name><name name-style="western"><surname>Beuthien-Baumann</surname><given-names>B</given-names></name><name name-style="western"><surname>Wolz</surname><given-names>M</given-names></name><name name-style="western"><surname>Storch</surname><given-names>A</given-names></name><name name-style="western"><surname>L&#246;hle</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with <sup>18</sup>F-dopa brain PET in normal controls and patients with Parkinson&#8217;s disease</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2011</year>;<volume>38</volume>:<fpage>1550</fpage>&#8211;<lpage>1559</lpage>. <comment>doi: 10.1007/s00259-011-1819-8</comment>.<pub-id pub-id-type="pmid">21553090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-011-1819-8</pub-id></mixed-citation></ref><ref id="R115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stormezand</surname><given-names>GN</given-names></name><name name-style="western"><surname>Chaves</surname><given-names>LT</given-names></name><name name-style="western"><surname>V&#225;llez Garc&#237;a</surname><given-names>D</given-names></name><name name-style="western"><surname>Doorduin</surname><given-names>J</given-names></name><name name-style="western"><surname>De Jong</surname><given-names>BM</given-names></name><name name-style="western"><surname>Leenders</surname><given-names>KL</given-names></name>, <etal/></person-group>. <article-title>Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders</article-title>. <source>Neuroimage Clin</source><year>2020</year>;<volume>25</volume>:<fpage>102161</fpage>. <comment>doi: 10.1016/j.nicl.2019.102161</comment>.<pub-id pub-id-type="pmid">31981888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2019.102161</pub-id><pub-id pub-id-type="pmcid">PMC6976972</pub-id></mixed-citation></ref><ref id="R116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Br&#252;ck</surname><given-names>A</given-names></name><name name-style="western"><surname>Aalto</surname><given-names>S</given-names></name><name name-style="western"><surname>Rauhala</surname><given-names>E</given-names></name><name name-style="western"><surname>Bergman</surname><given-names>J</given-names></name><name name-style="western"><surname>Marttila</surname><given-names>R</given-names></name><name name-style="western"><surname>Rinne</surname><given-names>JO</given-names></name></person-group>. <article-title>A follow-up study on 6-[18F] fluoro-L-dopa uptake in early Parkinson&#8217;s disease shows nonlinear progression in the putamen</article-title>. <source>Mov Disord</source><year>2009</year>;<volume>24</volume>:<fpage>1009</fpage>&#8211;<lpage>1015</lpage>. <comment>doi: 10.1002/mds.22484</comment>.<pub-id pub-id-type="pmid">19260097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.22484</pub-id></mixed-citation></ref><ref id="R117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simuni</surname><given-names>T</given-names></name><name name-style="western"><surname>Siderowf</surname><given-names>A</given-names></name><name name-style="western"><surname>Lasch</surname><given-names>S</given-names></name><name name-style="western"><surname>Coffey</surname><given-names>CS</given-names></name><name name-style="western"><surname>Caspell-Garcia</surname><given-names>C</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>D</given-names></name>, <etal/></person-group>. <article-title>Longitudinal change of clinical and biological measures in early Parkinson&#8217;s disease: Parkinson&#8217;s progression markers initiative cohort</article-title>. <source>Mov Disord</source><year>2018</year>;<volume>33</volume>:<fpage>771</fpage>&#8211;<lpage>782</lpage>. <comment>doi: 10.1002/mds.27361</comment>.<pub-id pub-id-type="pmid">29572948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.27361</pub-id><pub-id pub-id-type="pmcid">PMC6001458</pub-id></mixed-citation></ref><ref id="R118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bohnen</surname><given-names>NI</given-names></name><name name-style="western"><surname>Albin</surname><given-names>RL</given-names></name><name name-style="western"><surname>Koeppe</surname><given-names>RA</given-names></name><name name-style="western"><surname>Wernette</surname><given-names>KA</given-names></name><name name-style="western"><surname>Kilbourn</surname><given-names>MR</given-names></name><name name-style="western"><surname>Minoshima</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease</article-title>. <source>J Cereb Blood Flow Metab</source><year>2006</year>;<volume>26</volume>:<fpage>1198</fpage>&#8211;<lpage>1212</lpage>. <comment>doi: 10.1038/sj.jcbfm.9600276</comment>.<pub-id pub-id-type="pmid">16421508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.jcbfm.9600276</pub-id></mixed-citation></ref><ref id="R119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>SC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>IT</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Lin</surname><given-names>WY</given-names></name><name name-style="western"><surname>Lu</surname><given-names>CS</given-names></name>, <etal/></person-group>. <article-title>In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET</article-title>. <source>J Nucl Med</source><year>2014</year>;<volume>55</volume>:<fpage>73</fpage>&#8211;<lpage>79</lpage>. <comment>doi: 10.2967/jnumed.113.121897</comment>.<pub-id pub-id-type="pmid">24287322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.113.121897</pub-id></mixed-citation></ref><ref id="R120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albin</surname><given-names>RL</given-names></name><name name-style="western"><surname>Koeppe</surname><given-names>RA</given-names></name><name name-style="western"><surname>Chervin</surname><given-names>RD</given-names></name><name name-style="western"><surname>Consens</surname><given-names>FB</given-names></name><name name-style="western"><surname>Wernette</surname><given-names>K</given-names></name><name name-style="western"><surname>Frey</surname><given-names>KA</given-names></name>, <etal/></person-group>. <article-title>Decreased striatal dopaminergic innervation in REM sleep behavior disorder</article-title>. <source>Neurology</source><year>2000</year>;<volume>55</volume>:<fpage>1410</fpage>&#8211;<lpage>1412</lpage>. <comment>doi: 10.1212/wnl.55.9.1410</comment>.<pub-id pub-id-type="pmid">11087796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.55.9.1410</pub-id></mixed-citation></ref><ref id="R121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varalta</surname><given-names>V</given-names></name><name name-style="western"><surname>Evangelista</surname><given-names>E</given-names></name><name name-style="western"><surname>Righetti</surname><given-names>A</given-names></name><name name-style="western"><surname>Morone</surname><given-names>G</given-names></name><name name-style="western"><surname>Tamburin</surname><given-names>S</given-names></name><name name-style="western"><surname>Picelli</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>Effect of Upper Limb Motor Rehabilitation on Cognition in Parkinson&#8217;s Disease: An Observational Study</article-title>. <source>Brain Sci</source><year>2022</year>;<volume>12</volume>:<fpage>1684</fpage>. <comment>doi: 10.3390/brainsci12121684</comment>.<pub-id pub-id-type="pmid">36552144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci12121684</pub-id><pub-id pub-id-type="pmcid">PMC9775162</pub-id></mixed-citation></ref><ref id="R122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaasinen</surname><given-names>V</given-names></name><name name-style="western"><surname>Vahlberg</surname><given-names>T</given-names></name><name name-style="western"><surname>Stoessl</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Strafella</surname><given-names>AP</given-names></name><name name-style="western"><surname>Antonini</surname><given-names>A</given-names></name></person-group>. <article-title>Dopamine receptors in Parkinson&#8217;s disease: A meta-analysis of imaging studies</article-title>. <source>Mov Disord</source><year>2021</year>;<volume>36</volume>:<fpage>1781</fpage>&#8211;<lpage>1791</lpage>. <comment>doi: 10.1002/mds.28632</comment>.<pub-id pub-id-type="pmid">33955044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.28632</pub-id></mixed-citation></ref><ref id="R123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eidelberg</surname><given-names>D</given-names></name><name name-style="western"><surname>Moeller</surname><given-names>JR</given-names></name><name name-style="western"><surname>Dhawan</surname><given-names>V</given-names></name><name name-style="western"><surname>Spetsieris</surname><given-names>P</given-names></name><name name-style="western"><surname>Takikawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>The metabolic topography of parkinsonism</article-title>. <source>J Cereb Blood Flow Metab</source><year>1994</year>;<volume>14</volume>:<fpage>783</fpage>&#8211;<lpage>801</lpage>. <comment>doi: 10.1038/jcbfm.1994.99</comment>.<pub-id pub-id-type="pmid">8063874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jcbfm.1994.99</pub-id></mixed-citation></ref><ref id="R124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teune</surname><given-names>LK</given-names></name><name name-style="western"><surname>Renken</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Mudali</surname><given-names>D</given-names></name><name name-style="western"><surname>De Jong</surname><given-names>BM</given-names></name><name name-style="western"><surname>Dierckx</surname><given-names>RA</given-names></name><name name-style="western"><surname>Roerdink</surname><given-names>JB</given-names></name>, <etal/></person-group>. <article-title>Validation of parkinsonian disease-related metabolic brain patterns</article-title>. <source>Mov Disord</source><year>2013</year>;<volume>28</volume>:<fpage>547</fpage>&#8211;<lpage>551</lpage>. <comment>doi: 10.1002/mds.25361</comment>.<pub-id pub-id-type="pmid">23483593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.25361</pub-id></mixed-citation></ref><ref id="R125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>S</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y</given-names></name>, <etal/></person-group>. <article-title>Metabolic brain network in the Chinese patients with Parkinson&#8217;s disease based on 18F-FDG PET imaging</article-title>. <source>Parkinsonism Relat Disord</source><year>2013</year>;<volume>19</volume>:<fpage>622</fpage>&#8211;<lpage>627</lpage>. <comment>doi: 10.1016/j.parkreldis.2013.02.013</comment>.<pub-id pub-id-type="pmid">23529021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2013.02.013</pub-id></mixed-citation></ref><ref id="R126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>R</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>Validation of abnormal glucose metabolism associated with Parkinson&#8217;s disease in Chinese participants based on 18F-fluorodeoxyglucose positron emission tomography imaging</article-title>. <source>Neuropsychiatr Dis Treat</source><year>2018</year>;<volume>14</volume>:<fpage>1981</fpage>&#8211;<lpage>1989</lpage>. <comment>doi: 10.2147/NDT.S167548</comment>.<pub-id pub-id-type="pmid">30122931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/NDT.S167548</pub-id><pub-id pub-id-type="pmcid">PMC6086566</pub-id></mixed-citation></ref><ref id="R127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meles</surname><given-names>SK</given-names></name><name name-style="western"><surname>Renken</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Pagani</surname><given-names>M</given-names></name><name name-style="western"><surname>Teune</surname><given-names>LK</given-names></name><name name-style="western"><surname>Arnaldi</surname><given-names>D</given-names></name><name name-style="western"><surname>Morbelli</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>Abnormal pattern of brain glucose metabolism in Parkinson&#8217;s disease: replication in three European cohorts</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2020</year>;<volume>47</volume>:<fpage>437</fpage>&#8211;<lpage>450</lpage>. <comment>doi: 10.1007/s00259-019-04570-7</comment>.<pub-id pub-id-type="pmid">31768600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-019-04570-7</pub-id><pub-id pub-id-type="pmcid">PMC6974499</pub-id></mixed-citation></ref><ref id="R128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C</given-names></name><name name-style="western"><surname>Feigin</surname><given-names>A</given-names></name><name name-style="western"><surname>Lesser</surname><given-names>M</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pourfar</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Changes in network activity with the progression of Parkinson&#8217;s disease</article-title>. <source>Brain</source><year>2007</year>;<volume>130</volume>:<fpage>1834</fpage>&#8211;<lpage>1846</lpage>. <comment>doi: 10.1093/brain/awm086</comment>.<pub-id pub-id-type="pmid">17470495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awm086</pub-id><pub-id pub-id-type="pmcid">PMC4454378</pub-id></mixed-citation></ref><ref id="R129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tripathi</surname><given-names>M</given-names></name><name name-style="western"><surname>Tang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Feigin</surname><given-names>A</given-names></name><name name-style="western"><surname>De Lucia</surname><given-names>I</given-names></name><name name-style="western"><surname>Nazem</surname><given-names>A</given-names></name><name name-style="western"><surname>Dhawan</surname><given-names>V</given-names></name>, <etal/></person-group>. <article-title>Automated differential diagnosis of early parkinsonism using metabolic brain networks: A validation study</article-title>. <source>J Nucl Med</source><year>2016</year>;<volume>57</volume>:<fpage>60</fpage>&#8211;<lpage>66</lpage>. <comment>doi: 10.2967/jnumed.115.161992</comment>.<pub-id pub-id-type="pmid">26449840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.115.161992</pub-id></mixed-citation></ref><ref id="R130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kogan</surname><given-names>RV</given-names></name><name name-style="western"><surname>Janzen</surname><given-names>A</given-names></name><name name-style="western"><surname>Meles</surname><given-names>SK</given-names></name><name name-style="western"><surname>Sittig</surname><given-names>E</given-names></name><name name-style="western"><surname>Renken</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Gurvits</surname><given-names>V</given-names></name>, <etal/></person-group>. <article-title>Four-year follow-up of [(18)F] fluorodeoxyglucose positron emission tomography-based Parkinson&#8217;s disease-related pattern expression in 20 patients with isolated rapid eye movement sleep behavior disorder shows prodromal progression</article-title>. <source>Mov Disord</source><year>2021</year>;<volume>36</volume>:<fpage>230</fpage>&#8211;<lpage>235</lpage>. <comment>doi: 10.1002/mds.28260</comment>.<pub-id pub-id-type="pmid">32909650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.28260</pub-id><pub-id pub-id-type="pmcid">PMC7891341</pub-id></mixed-citation></ref><ref id="R131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schindlbeck</surname><given-names>KA</given-names></name><name name-style="western"><surname>Lucas-Jim&#233;nez</surname><given-names>O</given-names></name><name name-style="western"><surname>Tang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Morbelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Arnaldi</surname><given-names>D</given-names></name><name name-style="western"><surname>Pardini</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Metabolic network abnormalities in drug-na&#239;ve Parkinson&#8217;s disease</article-title>. <source>Mov Disord</source><year>2020</year>;<volume>35</volume>:<fpage>587</fpage>&#8211;<lpage>594</lpage>. <comment>doi: 10.1002/mds.27960</comment>.<pub-id pub-id-type="pmid">31872507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.27960</pub-id></mixed-citation></ref><ref id="R132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mure</surname><given-names>H</given-names></name><name name-style="western"><surname>Hirano</surname><given-names>S</given-names></name><name name-style="western"><surname>Tang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Isaias</surname><given-names>IU</given-names></name><name name-style="western"><surname>Antonini</surname><given-names>A</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name>, <etal/></person-group>. <article-title>Parkinson&#8217;s disease tremor-related metabolic network: Characterization, progression, and treatment effects</article-title>. <source>Neuroimage</source><year>2011</year>;<volume>54</volume>:<fpage>1244</fpage>&#8211;<lpage>1253</lpage>. <comment>doi: 10.1016/j.neuroimage.2010.09.028</comment>.<pub-id pub-id-type="pmid">20851193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2010.09.028</pub-id><pub-id pub-id-type="pmcid">PMC2997135</pub-id></mixed-citation></ref><ref id="R133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><name name-style="western"><surname>Mattis</surname><given-names>P</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C</given-names></name><name name-style="western"><surname>Perrine</surname><given-names>K</given-names></name><name name-style="western"><surname>Carbon</surname><given-names>M</given-names></name><name name-style="western"><surname>Eidelberg</surname><given-names>D</given-names></name></person-group>. <article-title>Metabolic brain networks associated with cognitive function in Parkinson&#8217;s disease</article-title>. <source>Neuroimage</source><year>2007</year>;<volume>34</volume>:<fpage>714</fpage>&#8211;<lpage>723</lpage>. <comment>doi: 10.1016/j.neuroimage.2006.09.003</comment>.<pub-id pub-id-type="pmid">17113310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2006.09.003</pub-id><pub-id pub-id-type="pmcid">PMC4456012</pub-id></mixed-citation></ref><ref id="R134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattis</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Niethammer</surname><given-names>M</given-names></name><name name-style="western"><surname>Sako</surname><given-names>W</given-names></name><name name-style="western"><surname>Tang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Nazem</surname><given-names>A</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>ML</given-names></name>, <etal/></person-group>. <article-title>Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases</article-title>. <source>Neurology</source><year>2016</year>;<volume>87</volume>:<fpage>1925</fpage>&#8211;<lpage>1933</lpage>. <comment>doi: 10.1212/WNL.0000000000003285</comment>.<pub-id pub-id-type="pmid">27708130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000003285</pub-id><pub-id pub-id-type="pmcid">PMC5100716</pub-id></mixed-citation></ref><ref id="R135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuoka</surname><given-names>K</given-names></name><name name-style="western"><surname>Ono</surname><given-names>M</given-names></name><name name-style="western"><surname>Takado</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hirata</surname><given-names>K</given-names></name><name name-style="western"><surname>Endo</surname><given-names>H</given-names></name><name name-style="western"><surname>Ohfusa</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>High-contrast imaging of &#945;-synuclein pathologies in living patients with multiple system atrophy</article-title>. <source>Mov Disord</source><year>2022</year>;<volume>37</volume>:<fpage>2159</fpage>&#8211;<lpage>2161</lpage>. <comment>doi: 10.1002/mds.29186</comment>.<pub-id pub-id-type="pmid">36041211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.29186</pub-id><pub-id pub-id-type="pmcid">PMC9804399</pub-id></mixed-citation></ref><ref id="R136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villemagne</surname><given-names>VL</given-names></name><name name-style="western"><surname>Fodero-Tavoletti</surname><given-names>MT</given-names></name><name name-style="western"><surname>Masters</surname><given-names>CL</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>CC</given-names></name></person-group>. <article-title>Tau imaging: early progress and future directions</article-title>. <source>Lancet Neurol</source><year>2015</year>;<volume>14</volume>:<fpage>114</fpage>&#8211;<lpage>124</lpage>. <comment>doi: 10.1016/S1474-4422(14)70252-2</comment>.<pub-id pub-id-type="pmid">25496902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(14)70252-2</pub-id></mixed-citation></ref><ref id="R137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dani</surname><given-names>M</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Edison</surname><given-names>P</given-names></name></person-group>. <article-title>Tau imaging in neurodegenerative diseases</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2016</year>;<volume>43</volume>:<fpage>1139</fpage>&#8211;<lpage>1150</lpage>. <comment>doi: 10.1007/s00259-015-3231-2</comment>.<pub-id pub-id-type="pmid">26572762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-015-3231-2</pub-id><pub-id pub-id-type="pmcid">PMC4844651</pub-id></mixed-citation></ref><ref id="R138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#246;necker</surname><given-names>S</given-names></name><name name-style="western"><surname>Brendel</surname><given-names>M</given-names></name><name name-style="western"><surname>Palleis</surname><given-names>C</given-names></name><name name-style="western"><surname>Beyer</surname><given-names>L</given-names></name><name name-style="western"><surname>H&#246;glinger</surname><given-names>GU</given-names></name><name name-style="western"><surname>Schuh</surname><given-names>E</given-names></name>, <etal/></person-group>. <article-title>PET imaging of astrogliosis and tau facilitates diagnosis of parkinsonian syndromes</article-title>. <source>Front Aging Neurosci</source><year>2019</year>;<volume>11</volume>:<fpage>249</fpage>. <comment>doi: 10.3389/fnagi.2019.00249</comment>.<pub-id pub-id-type="pmid">31572166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2019.00249</pub-id><pub-id pub-id-type="pmcid">PMC6749151</pub-id></mixed-citation></ref><ref id="R139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>FT</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>JY</given-names></name><name name-style="western"><surname>Sun</surname><given-names>YM</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X</given-names></name>, <etal/></person-group>. <article-title>Clinical Utility of (18) F-APN-1607 tau PET imaging in patients with progressive supranuclear palsy</article-title>. <source>Mov Disord</source><year>2021</year>;<volume>36</volume>:<fpage>2314</fpage>&#8211;<lpage>2323</lpage>. <comment>doi: 10.1002/mds.28672</comment>.<pub-id pub-id-type="pmid">34089275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.28672</pub-id></mixed-citation></ref><ref id="R140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koshimori</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ko</surname><given-names>JH</given-names></name><name name-style="western"><surname>Mizrahi</surname><given-names>R</given-names></name><name name-style="western"><surname>Rusjan</surname><given-names>P</given-names></name><name name-style="western"><surname>Mabrouk</surname><given-names>R</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>MF</given-names></name>, <etal/></person-group>. <article-title>Imaging Striatal microglial activation in patients with Parkinson&#8217;s disease</article-title>. <source>PLoS One</source><year>2015</year>;<volume>10</volume>:<fpage>e0138721</fpage>. <comment>doi: 10.1371/journal.pone.0138721</comment>.<pub-id pub-id-type="pmid">26381267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0138721</pub-id><pub-id pub-id-type="pmcid">PMC4575151</pub-id></mixed-citation></ref><ref id="R141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haider</surname><given-names>A</given-names></name><name name-style="western"><surname>Elghazawy</surname><given-names>NH</given-names></name><name name-style="western"><surname>Dawoud</surname><given-names>A</given-names></name><name name-style="western"><surname>Gebhard</surname><given-names>C</given-names></name><name name-style="western"><surname>Wichmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Sippl</surname><given-names>W</given-names></name>, <etal/></person-group>. <article-title>Translational molecular imaging and drug development in Parkinson&#8217;s disease</article-title>. <source>Mol Neurodegener</source><year>2023</year>;<volume>18</volume>:<fpage>11</fpage>. <comment>doi: 10.1186/s13024-023-00600-z</comment>.<pub-id pub-id-type="pmid">36759912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-023-00600-z</pub-id><pub-id pub-id-type="pmcid">PMC9912681</pub-id></mixed-citation></ref><ref id="R142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lavisse</surname><given-names>S</given-names></name><name name-style="western"><surname>Goutal</surname><given-names>S</given-names></name><name name-style="western"><surname>Wimberley</surname><given-names>C</given-names></name><name name-style="western"><surname>Tonietto</surname><given-names>M</given-names></name><name name-style="western"><surname>Bottlaender</surname><given-names>M</given-names></name><name name-style="western"><surname>Gervais</surname><given-names>P</given-names></name>, <etal/></person-group>. <article-title>Increased microglial activation in patients with Parkinson disease using [(18)F]-DPA714 TSPO PET imaging</article-title>. <source>Parkinsonism Relat Disord</source><year>2021</year>;<volume>82</volume>:<fpage>29</fpage>&#8211;<lpage>36</lpage>. <comment>doi: 10.1016/j.parkreldis.2020.11.011</comment>.<pub-id pub-id-type="pmid">33242662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2020.11.011</pub-id></mixed-citation></ref><ref id="R143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edison</surname><given-names>P</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>I</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hinz</surname><given-names>R</given-names></name><name name-style="western"><surname>Gelosa</surname><given-names>G</given-names></name><name name-style="western"><surname>Ray Chaudhuri</surname><given-names>K</given-names></name>, <etal/></person-group>. <article-title>Microglia, amyloid, and glucose metabolism in Parkinson&#8217;s disease with and without dementia</article-title>. <source>Neuropsychopharmacology</source><year>2013</year>;<volume>38</volume>:<fpage>938</fpage>&#8211;<lpage>949</lpage>. <comment>doi: 10.1038/npp.2012.255</comment>.<pub-id pub-id-type="pmid">23303049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npp.2012.255</pub-id><pub-id pub-id-type="pmcid">PMC3629382</pub-id></mixed-citation></ref><ref id="R144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varn&#228;s</surname><given-names>K</given-names></name><name name-style="western"><surname>Csel&#233;nyi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jucaite</surname><given-names>A</given-names></name><name name-style="western"><surname>Halldin</surname><given-names>C</given-names></name><name name-style="western"><surname>Svenningsson</surname><given-names>P</given-names></name><name name-style="western"><surname>Farde</surname><given-names>L</given-names></name>, <etal/></person-group>. <article-title>PET imaging of [(11)C]PBR28 in Parkinson&#8217;s disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2019</year>;<volume>46</volume>:<fpage>367</fpage>&#8211;<lpage>375</lpage>. <comment>doi: 10.1007/s00259-018-4161-6</comment>.<pub-id pub-id-type="pmid">30270409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-018-4161-6</pub-id><pub-id pub-id-type="pmcid">PMC6333720</pub-id></mixed-citation></ref><ref id="R145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#252;ssmuth</surname><given-names>SD</given-names></name><name name-style="western"><surname>Uttner</surname><given-names>I</given-names></name><name name-style="western"><surname>Landwehrmeyer</surname><given-names>B</given-names></name><name name-style="western"><surname>Pinkhardt</surname><given-names>EH</given-names></name><name name-style="western"><surname>Brettschneider</surname><given-names>J</given-names></name><name name-style="western"><surname>Petzold</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>Differential pattern of brain-specific CSF proteins tau and amyloid-&#946; in Parkinsonian syndromes</article-title>. <source>Mov Disord</source><year>2010</year>;<volume>25</volume>:<fpage>1284</fpage>&#8211;<lpage>1288</lpage>. <comment>doi: 10.1002/mds.22895</comment>.<pub-id pub-id-type="pmid">20589870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.22895</pub-id></mixed-citation></ref><ref id="R146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>H</given-names></name><name name-style="western"><surname>Dervenoulas</surname><given-names>G</given-names></name><name name-style="western"><surname>Pagano</surname><given-names>G</given-names></name><name name-style="western"><surname>Tyacke</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Polychronis</surname><given-names>S</given-names></name><name name-style="western"><surname>Myers</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson&#8217;s disease: An in vivo11C-BU99008 PET study</article-title>. <source>Brain</source><year>2019</year>;<volume>142</volume>:<fpage>3116</fpage>&#8211;<lpage>3128</lpage>. <comment>doi: 10.1093/brain/awz260</comment>.<pub-id pub-id-type="pmid">31504212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awz260</pub-id></mixed-citation></ref><ref id="R147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>YX</given-names></name><name name-style="western"><surname>Su</surname><given-names>DN</given-names></name><name name-style="western"><surname>Lam</surname><given-names>JST</given-names></name><name name-style="western"><surname>Feng</surname><given-names>T</given-names></name></person-group>. <article-title>Advances in clinical neurorestorative treatments of Parkinson&#8217;s disease</article-title>. <source>J Neurorestoratology</source><year>2025</year>;<volume>13</volume>. <comment>doi: 10.1016/j.jnrt.2025.100204</comment>.</mixed-citation></ref><ref id="R148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meijer</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Steens</surname><given-names>SC</given-names></name><name name-style="western"><surname>van Rumund</surname><given-names>A</given-names></name><name name-style="western"><surname>van Cappellen van Walsum</surname><given-names>AM</given-names></name><name name-style="western"><surname>K&#252;sters</surname><given-names>B</given-names></name><name name-style="western"><surname>Esselink</surname><given-names>RA</given-names></name>, <etal/></person-group>. <article-title>Nigrosome-1 on susceptibility weighted imaging to differentiate Parkinson&#8217;s disease from atypical parkinsonism: An in vivo and ex vivo pilot study</article-title>. <source>Pol J Radiol</source><year>2016</year>;<volume>81</volume>:<fpage>363</fpage>&#8211;<lpage>369</lpage>. <comment>doi: 10.12659/PJR.897090</comment>.<pub-id pub-id-type="pmid">27559425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/PJR.897090</pub-id><pub-id pub-id-type="pmcid">PMC4975367</pub-id></mixed-citation></ref><ref id="R149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>YH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Nam</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shin</surname><given-names>HG</given-names></name><name name-style="western"><surname>Noh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shin</surname><given-names>DH</given-names></name>, <etal/></person-group>. <article-title>Differential involvement of nigral subregions in idiopathic parkinson&#8217;s disease</article-title>. <source>Hum Brain Mapp</source><year>2018</year>;<volume>39</volume>:<fpage>542</fpage>&#8211;<lpage>553</lpage>. <comment>doi: 10.1002/hbm.23863</comment>.<pub-id pub-id-type="pmid">29064601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.23863</pub-id><pub-id pub-id-type="pmcid">PMC6866465</pub-id></mixed-citation></ref><ref id="R150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>FQ</given-names></name><name name-style="western"><surname>Allen</surname><given-names>PS</given-names></name><name name-style="western"><surname>Martin</surname><given-names>WR</given-names></name></person-group>. <article-title>Basal ganglia iron content in Parkinson&#8217;s disease measured with magnetic resonance</article-title>. <source>Mov Disord</source><year>1996</year>;<volume>11</volume>:<fpage>243</fpage>&#8211;<lpage>249</lpage>. <comment>doi: 10.1002/mds.870110305</comment>.<pub-id pub-id-type="pmid">8723139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.870110305</pub-id></mixed-citation></ref><ref id="R151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blazejewska</surname><given-names>AI</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>ST</given-names></name><name name-style="western"><surname>Pitiot</surname><given-names>A</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>MC</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>J</given-names></name><name name-style="western"><surname>Bajaj</surname><given-names>N</given-names></name>, <etal/></person-group>. <article-title>Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI</article-title>. <source>Neurology</source><year>2013</year>;<volume>81</volume>:<fpage>534</fpage>&#8211;<lpage>540</lpage>. <comment>doi: 10.1212/WNL.0b013e31829e6fd2</comment>.<pub-id pub-id-type="pmid">23843466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e31829e6fd2</pub-id><pub-id pub-id-type="pmcid">PMC3775686</pub-id></mixed-citation></ref><ref id="R152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Huh</surname><given-names>GY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H</given-names></name></person-group>. <article-title>Iron accumulation in the oculomotor nerve of the progressive supranuclear palsy brain</article-title>. <source>Sci Rep</source><year>2021</year>;<volume>11</volume>:<fpage>2950</fpage>. <comment>doi: 10.1038/s41598-021-82469-w</comment>.<pub-id pub-id-type="pmid">33536537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-82469-w</pub-id><pub-id pub-id-type="pmcid">PMC7859181</pub-id></mixed-citation></ref><ref id="R153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lancione</surname><given-names>M</given-names></name><name name-style="western"><surname>Cencini</surname><given-names>M</given-names></name><name name-style="western"><surname>Costagli</surname><given-names>M</given-names></name><name name-style="western"><surname>Donatelli</surname><given-names>G</given-names></name><name name-style="western"><surname>Tosetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Giannini</surname><given-names>G</given-names></name>, <etal/></person-group>. <article-title>Diagnostic accuracy of quantitative susceptibility mapping in multiple system atrophy: The impact of echo time and the potential of histogram analysis</article-title>. <source>Neuroimage Clin</source><year>2022</year>;<volume>34</volume>:<fpage>102989</fpage>. <comment>doi: 10.1016/j.nicl.2022.102989</comment>.<pub-id pub-id-type="pmid">35303599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2022.102989</pub-id><pub-id pub-id-type="pmcid">PMC8927993</pub-id></mixed-citation></ref><ref id="R154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakhani</surname><given-names>DA</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Tao</surname><given-names>S</given-names></name><name name-style="western"><surname>Patel</surname><given-names>V</given-names></name><name name-style="western"><surname>Wen</surname><given-names>S</given-names></name><name name-style="western"><surname>Okromelidze</surname><given-names>L</given-names></name>, <etal/></person-group>. <article-title>Diagnostic utility of 7T neuromelanin imaging of the substantia nigra in Parkinson&#8217;s disease</article-title>. <source>NPJ Parkinsons Dis</source><year>2024</year>;<volume>10</volume>:<fpage>13</fpage>. <comment>doi: 10.1038/s41531-024-00631-3</comment>.<pub-id pub-id-type="pmid">38191546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-024-00631-3</pub-id><pub-id pub-id-type="pmcid">PMC10774294</pub-id></mixed-citation></ref><ref id="R155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolters</surname><given-names>AF</given-names></name><name name-style="western"><surname>Heijmans</surname><given-names>M</given-names></name><name name-style="western"><surname>Priovoulos</surname><given-names>N</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>H</given-names></name><name name-style="western"><surname>Postma</surname><given-names>AA</given-names></name><name name-style="western"><surname>Temel</surname><given-names>Y</given-names></name>, <etal/></person-group>. <article-title>Neuromelanin related ultra-high field signal intensity of the locus coeruleus differs between Parkinson&#8217;s disease and controls</article-title>. <source>Neuroimage Clin</source><year>2023</year>;<volume>39</volume>:<fpage>103479</fpage>. <comment>doi: 10.1016/j.nicl.2023.103479</comment>.<pub-id pub-id-type="pmid">37494758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2023.103479</pub-id><pub-id pub-id-type="pmcid">PMC10394012</pub-id></mixed-citation></ref><ref id="R156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <etal/></person-group>. <article-title>Increased free water in the substantia nigra in idiopathic REM sleep behaviour disorder</article-title>. <source>Brain</source><year>2021</year>;<volume>144</volume>:<fpage>1488</fpage>&#8211;<lpage>1497</lpage>. <comment>doi: 10.1093/brain/awab039</comment>.<pub-id pub-id-type="pmid">33880500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awab039</pub-id></mixed-citation></ref><ref id="R157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Archer</surname><given-names>DB</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>T</given-names></name><name name-style="western"><surname>Burciu</surname><given-names>RG</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Nigro</surname><given-names>S</given-names></name><name name-style="western"><surname>Quattrone</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>Magnetic resonance imaging and neurofilament light in the differentiation of parkinsonism</article-title>. <source>Mov Disord</source><year>2020</year>;<volume>35</volume>:<fpage>1388</fpage>&#8211;<lpage>1395</lpage>. <comment>doi: 10.1002/mds.28060</comment>.<pub-id pub-id-type="pmid">32357259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.28060</pub-id><pub-id pub-id-type="pmcid">PMC8316785</pub-id></mixed-citation></ref><ref id="R158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E</given-names></name><name name-style="western"><surname>Park</surname><given-names>HS</given-names></name><name name-style="western"><surname>Kang</surname><given-names>SY</given-names></name>, <etal/></person-group>. <article-title>Loss of substantia nigra hyperintensity at 3.0-T MR imaging in idiopathic REM sleep behavior disorder: Comparison with 123I-FP-CIT SPECT</article-title>. <source>Radiology</source><year>2018</year>;<volume>287</volume>:<fpage>285</fpage>&#8211;<lpage>293</lpage>. <comment>doi: 10.1148/radiol.2017162486</comment>.<pub-id pub-id-type="pmid">29232183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.2017162486</pub-id></mixed-citation></ref><ref id="R159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>T</given-names></name><name name-style="western"><surname>Yue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ba</surname><given-names>F</given-names></name><name name-style="western"><surname>He</surname><given-names>T</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name>, <etal/></person-group>. <article-title>Diffusion along perivascular spaces as marker for impairment of glymphatic system in Parkinson&#8217;s disease</article-title>. <source>NPJ Parkinsons Dis</source><year>2022</year>;<volume>8</volume>:<fpage>174</fpage>. <comment>doi: 10.1038/s41531-022-00437-1</comment>.<pub-id pub-id-type="pmid">36543809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-022-00437-1</pub-id><pub-id pub-id-type="pmcid">PMC9772196</pub-id></mixed-citation></ref><ref id="R160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scherfler</surname><given-names>C</given-names></name><name name-style="western"><surname>Seppi</surname><given-names>K</given-names></name><name name-style="western"><surname>Donnemiller</surname><given-names>E</given-names></name><name name-style="western"><surname>Goebel</surname><given-names>G</given-names></name><name name-style="western"><surname>Brenneis</surname><given-names>C</given-names></name><name name-style="western"><surname>Virgolini</surname><given-names>I</given-names></name>, <etal/></person-group>. <article-title>Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson&#8217;s disease</article-title>. <source>Brain</source><year>2005</year>;<volume>128</volume>:<fpage>1605</fpage>&#8211;<lpage>1612</lpage>. <comment>doi: 10.1093/brain/awh485</comment>.<pub-id pub-id-type="pmid">15817519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awh485</pub-id></mixed-citation></ref><ref id="R161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Booij</surname><given-names>J</given-names></name><name name-style="western"><surname>Tissingh</surname><given-names>G</given-names></name><name name-style="western"><surname>Winogrodzka</surname><given-names>A</given-names></name><name name-style="western"><surname>Boer</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Stoof</surname><given-names>JC</given-names></name><name name-style="western"><surname>Wolters</surname><given-names>EC</given-names></name>, <etal/></person-group>. <article-title>Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson&#8217;s disease</article-title>. <source>Eur J Nucl Med</source><year>1997</year>;<volume>24</volume>:<fpage>68</fpage>&#8211;<lpage>71</lpage>. <comment>doi: 10.1007/BF01728311</comment>.<pub-id pub-id-type="pmid">9044880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01728311</pub-id></mixed-citation></ref><ref id="R162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marquie</surname><given-names>M</given-names></name><name name-style="western"><surname>Locascio</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Rentz</surname><given-names>DM</given-names></name><name name-style="western"><surname>Becker</surname><given-names>JA</given-names></name><name name-style="western"><surname>Hedden</surname><given-names>T</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>KA</given-names></name>, <etal/></person-group>. <article-title>Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: An (11)C altropane positron emission tomography study</article-title>. <source>Alzheimers Res Ther</source><year>2014</year>;<volume>6</volume>:<fpage>52</fpage>. <comment>doi: 10.1186/s13195-014-0052-7</comment>.<pub-id pub-id-type="pmid">25429309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-014-0052-7</pub-id><pub-id pub-id-type="pmcid">PMC4245149</pub-id></mixed-citation></ref><ref id="R163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sood</surname><given-names>A</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>J</given-names></name><name name-style="western"><surname>Shree</surname><given-names>R</given-names></name><name name-style="western"><surname>Vatsa</surname><given-names>R</given-names></name><name name-style="western"><surname>Modi</surname><given-names>M</given-names></name><name name-style="western"><surname>Mittal</surname><given-names>BR</given-names></name></person-group>. <article-title>Comparative performance of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT imaging in patients with Parkinson&#8217;s disease, parkinson-plus syndrome, and essential tremor</article-title>. <source>Clin Nucl Med</source><year>2021</year>;<volume>46</volume>:<fpage>95</fpage>&#8211;<lpage>102</lpage>. <comment>doi: 10.1097/RLU.0000000000003409</comment>.<pub-id pub-id-type="pmid">33234920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/RLU.0000000000003409</pub-id></mixed-citation></ref><ref id="R164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghaemi</surname><given-names>M</given-names></name><name name-style="western"><surname>Hilker</surname><given-names>R</given-names></name><name name-style="western"><surname>Rudolf</surname><given-names>J</given-names></name><name name-style="western"><surname>Sobesky</surname><given-names>J</given-names></name><name name-style="western"><surname>Heiss</surname><given-names>WD</given-names></name></person-group>. <article-title>Differentiating multiple system atrophy from Parkinson&#8217;s disease: Contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2002</year>;<volume>73</volume>:<fpage>517</fpage>&#8211;<lpage>523</lpage>. <comment>doi: 10.1136/jnnp.73.5.517</comment>.<pub-id pub-id-type="pmid">12397143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.73.5.517</pub-id><pub-id pub-id-type="pmcid">PMC1738131</pub-id></mixed-citation></ref><ref id="R165"><label>165.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guttman</surname><given-names>M</given-names></name><name name-style="western"><surname>Burkholder</surname><given-names>J</given-names></name><name name-style="western"><surname>Kish</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Hussey</surname><given-names>D</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>A</given-names></name><name name-style="western"><surname>DaSilva</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>[11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson&#8217;s disease: Implications for the symptomatic threshold</article-title>. <source>Neurology</source><year>1997</year>;<volume>48</volume>:<fpage>1578</fpage>&#8211;<lpage>1583</lpage>. <comment>doi: 10.1212/wnl.48.6.1578</comment>.<pub-id pub-id-type="pmid">9191769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.48.6.1578</pub-id></mixed-citation></ref><ref id="R166"><label>166.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>S</given-names></name><name name-style="western"><surname>Oh</surname><given-names>M</given-names></name><name name-style="western"><surname>Oh</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Oh</surname><given-names>JS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Chung</surname><given-names>SJ</given-names></name>, <etal/></person-group>. <article-title>Additional Value of Early-Phase 18F-FP-CIT PET Image for Differential Diagnosis of Atypical Parkinsonism</article-title>. <source>Clin Nucl Med</source><year>2017</year>;<volume>42</volume>:<fpage>e80</fpage>&#8211;<lpage>e87</lpage>. <comment>doi: 10.1097/RLU.0000000000001474</comment>.<pub-id pub-id-type="pmid">27922865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/RLU.0000000000001474</pub-id></mixed-citation></ref><ref id="R167"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ilgin</surname><given-names>N</given-names></name><name name-style="western"><surname>Zubieta</surname><given-names>J</given-names></name><name name-style="western"><surname>Reich</surname><given-names>SG</given-names></name><name name-style="western"><surname>Dannals</surname><given-names>RF</given-names></name><name name-style="western"><surname>Ravert</surname><given-names>HT</given-names></name><name name-style="western"><surname>Frost</surname><given-names>JJ</given-names></name></person-group>. <article-title>PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson&#8217;s disease</article-title>. <source>Neurology</source><year>1999</year>;<volume>52</volume>:<fpage>1221</fpage>&#8211;<lpage>1226</lpage>. <comment>doi: 10.1212/wnl.52.6.1221</comment>.<pub-id pub-id-type="pmid">10214747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.52.6.1221</pub-id></mixed-citation></ref><ref id="R168"><label>168.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nurmi</surname><given-names>E</given-names></name><name name-style="western"><surname>Ruottinen</surname><given-names>HM</given-names></name><name name-style="western"><surname>Kaasinen</surname><given-names>V</given-names></name><name name-style="western"><surname>Bergman</surname><given-names>J</given-names></name><name name-style="western"><surname>Haaparanta</surname><given-names>M</given-names></name><name name-style="western"><surname>Solin</surname><given-names>O</given-names></name>, <etal/></person-group>. <article-title>Progression in Parkinson&#8217;s disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT</article-title>. <source>Ann Neurol</source><year>2000</year>;<volume>47</volume>:<fpage>804</fpage>&#8211;<lpage>808</lpage>.<pub-id pub-id-type="pmid">10852547</pub-id></mixed-citation></ref><ref id="R169"><label>169.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delva</surname><given-names>A</given-names></name><name name-style="western"><surname>Van Weehaeghe</surname><given-names>D</given-names></name><name name-style="western"><surname>van Aalst</surname><given-names>J</given-names></name><name name-style="western"><surname>Ceccarini</surname><given-names>J</given-names></name><name name-style="western"><surname>Koole</surname><given-names>M</given-names></name><name name-style="western"><surname>Baete</surname><given-names>K</given-names></name>, <etal/></person-group>. <article-title>Quantification and discriminative power of (18)F-FE-PE2I PET in patients with Parkinson&#8217;s disease</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2020</year>;<volume>47</volume>:<fpage>1913</fpage>&#8211;<lpage>1926</lpage>. <comment>doi: 10.1007/s00259-019-04587-y</comment>.<pub-id pub-id-type="pmid">31776633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-019-04587-y</pub-id></mixed-citation></ref><ref id="R170"><label>170.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez-Catasus</surname><given-names>CA</given-names></name><name name-style="western"><surname>Bohnen</surname><given-names>NI</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>FC</given-names></name><name name-style="western"><surname>D&#8217;Cruz</surname><given-names>N</given-names></name><name name-style="western"><surname>Kanel</surname><given-names>P</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M</given-names></name></person-group>. <article-title>Dopaminergic nigrostriatal connectivity in early Parkinson disease: In vivo neuroimaging study of 11C-DTBZ PET combined with correlational tractography</article-title>. <source>J Nucl Med</source><year>2021</year>;<volume>62</volume>:<fpage>545</fpage>&#8211;<lpage>552</lpage>. <comment>doi: 10.2967/jnumed.120.248500</comment>.<pub-id pub-id-type="pmid">32859707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.120.248500</pub-id><pub-id pub-id-type="pmcid">PMC8973250</pub-id></mixed-citation></ref><ref id="R171"><label>171.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schreckenberger</surname><given-names>M</given-names></name><name name-style="western"><surname>H&#228;gele</surname><given-names>S</given-names></name><name name-style="western"><surname>Siessmeier</surname><given-names>T</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>HG</given-names></name><name name-style="western"><surname>Armbrust-Henrich</surname><given-names>H</given-names></name><name name-style="western"><surname>R&#246;sch</surname><given-names>F</given-names></name>, <etal/></person-group>. <article-title>The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism</article-title>. <source>Eur J Nucl Med Mol Imaging</source><year>2004</year>;<volume>31</volume>:<fpage>1128</fpage>&#8211;<lpage>1135</lpage>. <comment>doi: 10.1007/s00259-004-1465-5</comment>.<pub-id pub-id-type="pmid">15042325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-004-1465-5</pub-id></mixed-citation></ref><ref id="R172"><label>172.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonini</surname><given-names>A</given-names></name><name name-style="western"><surname>Leenders</surname><given-names>KL</given-names></name><name name-style="western"><surname>Vontobel</surname><given-names>P</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>RP</given-names></name><name name-style="western"><surname>Missimer</surname><given-names>J</given-names></name><name name-style="western"><surname>Psylla</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson&#8217;s disease</article-title>. <source>Brain</source><year>1997</year>;<volume>120</volume>(<issue>Pt 12</issue>):<fpage>2187</fpage>&#8211;<lpage>2195</lpage>. <comment>doi: 10.1093/brain/120.12.2187</comment>.<pub-id pub-id-type="pmid">9448574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/120.12.2187</pub-id></mixed-citation></ref><ref id="R173"><label>173.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>KY</given-names></name><name name-style="western"><surname>Choi</surname><given-names>CG</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MC</given-names></name><name name-style="western"><surname>Chung</surname><given-names>SJ</given-names></name></person-group>. <article-title>Comparison of brain MRI and 18F-FDG PET in the differential diagnosis of multiple system atrophy from Parkinson&#8217;s disease</article-title>. <source>Mov Disord</source><year>2007</year>;<volume>22</volume>:<fpage>2352</fpage>&#8211;<lpage>2358</lpage>. <comment>doi: 10.1002/mds.21714</comment>.<pub-id pub-id-type="pmid">17894342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.21714</pub-id></mixed-citation></ref><ref id="R174"><label>174.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>R</given-names></name><name name-style="western"><surname>Capotosti</surname><given-names>F</given-names></name><name name-style="western"><surname>Schain</surname><given-names>M</given-names></name><name name-style="western"><surname>Ohlsson</surname><given-names>T</given-names></name><name name-style="western"><surname>Vokali</surname><given-names>E</given-names></name><name name-style="western"><surname>Molette</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>The &#945;-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases</article-title>. <source>Nat Commun</source><year>2023</year>;<volume>14</volume>:<fpage>6750</fpage>. <comment>doi: 10.1038/s41467-023-42305-3</comment>.<pub-id pub-id-type="pmid">37891183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-42305-3</pub-id><pub-id pub-id-type="pmcid">PMC10611796</pub-id></mixed-citation></ref><ref id="R175"><label>175.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>AK</given-names></name><name name-style="western"><surname>Parbo</surname><given-names>P</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>R</given-names></name><name name-style="western"><surname>&#216;stergaard</surname><given-names>K</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Borghammer</surname><given-names>P</given-names></name></person-group>. <article-title>Tau Tangles in Parkinson&#8217;s Disease: A 2-Year Follow-Up Flortaucipir PET Study</article-title>. <source>J Parkinsons Dis</source><year>2020</year>;<volume>10</volume>:<fpage>161</fpage>&#8211;<lpage>171</lpage>. <comment>doi: 10.3233/JPD-191774</comment>.<pub-id pub-id-type="pmid">31815700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JPD-191774</pub-id></mixed-citation></ref><ref id="R176"><label>176.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerhard</surname><given-names>A</given-names></name><name name-style="western"><surname>Pavese</surname><given-names>N</given-names></name><name name-style="western"><surname>Hotton</surname><given-names>G</given-names></name><name name-style="western"><surname>Turkheimer</surname><given-names>F</given-names></name><name name-style="western"><surname>Es</surname><given-names>M</given-names></name><name name-style="western"><surname>Hammers</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson&#8217;s disease</article-title>. <source>Neurobiol Dis</source><year>2006</year>;<volume>21</volume>:<fpage>404</fpage>&#8211;<lpage>412</lpage>. <comment>doi: 10.1016/j.nbd.2005.08.002</comment>.<pub-id pub-id-type="pmid">16182554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2005.08.002</pub-id></mixed-citation></ref><ref id="R177"><label>177.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Abdulrasul</surname><given-names>H</given-names></name><name name-style="western"><surname>Ajalin</surname><given-names>R</given-names></name><name name-style="western"><surname>Tuisku</surname><given-names>J</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><name name-style="western"><surname>Vahlberg</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>Neuroinflammation in Parkinson&#8217;s disease: A study with [11C]PBR28 PET and cerebrospinal fluid markers</article-title>. <source>Parkinsonism Relat Disord</source><year>2025</year>;<volume>130</volume>:<fpage>107177</fpage>. <comment>doi: 10.1016/j.parkreldis.2024.107177</comment>.<pub-id pub-id-type="pmid">39531949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2024.107177</pub-id></mixed-citation></ref><ref id="R178"><label>178.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghadery</surname><given-names>C</given-names></name><name name-style="western"><surname>Koshimori</surname><given-names>Y</given-names></name><name name-style="western"><surname>Coakeley</surname><given-names>S</given-names></name><name name-style="western"><surname>Harris</surname><given-names>M</given-names></name><name name-style="western"><surname>Rusjan</surname><given-names>P</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>Microglial activation in Parkinson&#8217;s disease using [18F]-FEPPA</article-title>. <source>J Neuroinflammation</source><year>2017</year>;<volume>14</volume>:<fpage>8</fpage>. <comment>doi: 10.1186/s12974-016-0778-1</comment>.<pub-id pub-id-type="pmid">28086916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-016-0778-1</pub-id><pub-id pub-id-type="pmcid">PMC5234135</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>